<SEC-DOCUMENT>0000896262-23-000017.txt : 20230216
<SEC-HEADER>0000896262-23-000017.hdr.sgml : 20230216
<ACCEPTANCE-DATETIME>20230216080048
ACCESSION NUMBER:		0000896262-23-000017
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		112
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230216
DATE AS OF CHANGE:		20230216

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMEDISYS INC
		CENTRAL INDEX KEY:			0000896262
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOME HEALTH CARE SERVICES [8082]
		IRS NUMBER:				113131700
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-24260
		FILM NUMBER:		23637173

	BUSINESS ADDRESS:	
		STREET 1:		3854 AMERICAN WAY
		STREET 2:		SUITE A
		CITY:			BATON ROUGE
		STATE:			LA
		ZIP:			70816
		BUSINESS PHONE:		2252922031

	MAIL ADDRESS:	
		STREET 1:		3854 AMERICAN WAY
		STREET 2:		SUITE A
		CITY:			BATON ROUGE
		STATE:			LA
		ZIP:			70816

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANALYTICAL NURSING MANAGEMENT CORP
		DATE OF NAME CHANGE:	19940819

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	M&N CAPITAL CORP
		DATE OF NAME CHANGE:	19930125
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>amed-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:c9bac751-1ef0-45f1-8208-1bc5d72ec892,g:1d8a20b2-a85c-4def-9d57-f7b6e7a974de,d:5c10b724a6674979bf3c35a339f29685--><html xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:srt="http://fasb.org/srt/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:amed="http://www.amedisys.com/20221231" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>amed-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV80L2ZyYWc6OTJhYTJmZGU1Yzg1NDgzMWI3NWZlOWNlZjE5ZTQwNjgvdGFibGU6OGY0OTViZDI4NDE0NDViNzgyN2EyYjU3MDIwOTYzZDcvdGFibGVyYW5nZTo4ZjQ5NWJkMjg0MTQ0NWI3ODI3YTJiNTcwMjA5NjNkN180LTEtMS0xLTUwNzI1_21ac5da5-9da0-4696-85f2-4b75924b8945">false</ix:nonNumeric><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV80L2ZyYWc6OTJhYTJmZGU1Yzg1NDgzMWI3NWZlOWNlZjE5ZTQwNjgvdGFibGU6OGY0OTViZDI4NDE0NDViNzgyN2EyYjU3MDIwOTYzZDcvdGFibGVyYW5nZTo4ZjQ5NWJkMjg0MTQ0NWI3ODI3YTJiNTcwMjA5NjNkN181LTEtMS0xLTUwNzI1_2a15092f-0699-4600-b4df-7f7e1f1e6206">true</ix:nonNumeric><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV80L2ZyYWc6OTJhYTJmZGU1Yzg1NDgzMWI3NWZlOWNlZjE5ZTQwNjgvdGFibGU6OGY0OTViZDI4NDE0NDViNzgyN2EyYjU3MDIwOTYzZDcvdGFibGVyYW5nZTo4ZjQ5NWJkMjg0MTQ0NWI3ODI3YTJiNTcwMjA5NjNkN183LTEtMS0xLTUwNzI1_91c8946d-b25b-41df-80ec-f48e797a08b6">2022</ix:nonNumeric><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV80L2ZyYWc6OTJhYTJmZGU1Yzg1NDgzMWI3NWZlOWNlZjE5ZTQwNjgvdGFibGU6OGY0OTViZDI4NDE0NDViNzgyN2EyYjU3MDIwOTYzZDcvdGFibGVyYW5nZTo4ZjQ5NWJkMjg0MTQ0NWI3ODI3YTJiNTcwMjA5NjNkN184LTEtMS0xLTUwNzI1_fb236a3c-f6cd-4361-958f-b99385c1b2b5">FY</ix:nonNumeric><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV80L2ZyYWc6OTJhYTJmZGU1Yzg1NDgzMWI3NWZlOWNlZjE5ZTQwNjgvdGFibGU6OGY0OTViZDI4NDE0NDViNzgyN2EyYjU3MDIwOTYzZDcvdGFibGVyYW5nZTo4ZjQ5NWJkMjg0MTQ0NWI3ODI3YTJiNTcwMjA5NjNkN18xMS0xLTEtMS01MDcyNQ_0e0af890-d6fe-4fe2-9cfc-d07ecd4200e3">0000896262</ix:nonNumeric><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV80L2ZyYWc6OTJhYTJmZGU1Yzg1NDgzMWI3NWZlOWNlZjE5ZTQwNjgvdGFibGU6OGY0OTViZDI4NDE0NDViNzgyN2EyYjU3MDIwOTYzZDcvdGFibGVyYW5nZTo4ZjQ5NWJkMjg0MTQ0NWI3ODI3YTJiNTcwMjA5NjNkN18xMi0xLTEtMS01MDcyNQ_77deb875-d8f8-4d7d-b64b-936f2be04ee2">12/31</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="i18a8ecfea90b46dea16770739b772958_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83Ni9mcmFnOmE2ZDU3OTMyZTg5YzQ3YjJiZTRjMmNhNzY5NzJiN2JkL3RleHRyZWdpb246YTZkNTc5MzJlODljNDdiMmJlNGMyY2E3Njk3MmI3YmRfNTU_3685d894-7fab-4712-8676-2a5241ef9106">3.0</ix:nonFraction><ix:nonNumeric contextRef="i5ebb0aba87354b6e94fa00495eb40c4c_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjg1OTA_1486623a-649a-4c91-b48e-f23d489bb99f">P2Y</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84Mi9mcmFnOmIxNzE2N2NiZDZkYjQxY2ZiNzQ4NzMzODEzNTQ0ZTBhL3RhYmxlOjZmYWNlZjNjZTBlMTQxYjg5OTI1ZWIyZGFjYTRjODc5L3RhYmxlcmFuZ2U6NmZhY2VmM2NlMGUxNDFiODk5MjVlYjJkYWNhNGM4NzlfNC0xLTEtMS01MDcyNQ_23b89b73-2db2-4a8d-a55f-643213e6b2dd">115,372</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i28853129c6904eb18dd32328ff6639b9_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV85MS9mcmFnOmMxZGY1NjBiOGNiMzQ3MWI4NzEzYTA3OWQ4NGRlNjAyL3RhYmxlOmQ4NTc4Mzg5YzAwOTRkZWVhMThlNWM2MzQxNjJjMmMzL3RhYmxlcmFuZ2U6ZDg1NzgzODljMDA5NGRlZWExOGU1YzYzNDE2MmMyYzNfNS0xLTEtMS01MDcyNQ_98df1124-e97b-480d-aa38-643c379eb40f">5.3</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i2df95a1c5f0f44979741b294afe8e34f_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV85MS9mcmFnOmMxZGY1NjBiOGNiMzQ3MWI4NzEzYTA3OWQ4NGRlNjAyL3RhYmxlOmQ4NTc4Mzg5YzAwOTRkZWVhMThlNWM2MzQxNjJjMmMzL3RhYmxlcmFuZ2U6ZDg1NzgzODljMDA5NGRlZWExOGU1YzYzNDE2MmMyYzNfNy0xLTEtMS01MDcyNQ_68812500-02b3-46d8-bc2b-da50b449ccc3">39.1</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i39143f0cd5e04faf9cb6b93e100ed3a7_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV85MS9mcmFnOmMxZGY1NjBiOGNiMzQ3MWI4NzEzYTA3OWQ4NGRlNjAyL3RhYmxlOmQ4NTc4Mzg5YzAwOTRkZWVhMThlNWM2MzQxNjJjMmMzL3RhYmxlcmFuZ2U6ZDg1NzgzODljMDA5NGRlZWExOGU1YzYzNDE2MmMyYzNfNy0yLTEtMS02MTU4NQ_170c62db-c59e-4e0f-842c-002f3e79d966">10.3</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i28853129c6904eb18dd32328ff6639b9_D20220101-20221231" decimals="-5" sign="-" name="amed:IncreaseDecreaseInAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV85MS9mcmFnOmMxZGY1NjBiOGNiMzQ3MWI4NzEzYTA3OWQ4NGRlNjAyL3RhYmxlOmQ4NTc4Mzg5YzAwOTRkZWVhMThlNWM2MzQxNjJjMmMzL3RhYmxlcmFuZ2U6ZDg1NzgzODljMDA5NGRlZWExOGU1YzYzNDE2MmMyYzNfMTEtMS0xLTEtNjE0Njk_5927a058-70ec-4679-a54e-720ccd0dbaa4">2.1</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i28853129c6904eb18dd32328ff6639b9_D20220101-20221231" decimals="-5" sign="-" name="amed:IncreaseDecreaseInLiabilitiesAssumed" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV85MS9mcmFnOmMxZGY1NjBiOGNiMzQ3MWI4NzEzYTA3OWQ4NGRlNjAyL3RhYmxlOmQ4NTc4Mzg5YzAwOTRkZWVhMThlNWM2MzQxNjJjMmMzL3RhYmxlcmFuZ2U6ZDg1NzgzODljMDA5NGRlZWExOGU1YzYzNDE2MmMyYzNfMTItMS0xLTEtNjE0NzE_8372a70a-1bdc-44d3-b341-a22e51043417">0.3</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i2df95a1c5f0f44979741b294afe8e34f_D20220101-20221231" decimals="-5" sign="-" name="amed:IncreaseDecreaseInLiabilitiesAssumed" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV85MS9mcmFnOmMxZGY1NjBiOGNiMzQ3MWI4NzEzYTA3OWQ4NGRlNjAyL3RhYmxlOmQ4NTc4Mzg5YzAwOTRkZWVhMThlNWM2MzQxNjJjMmMzL3RhYmxlcmFuZ2U6ZDg1NzgzODljMDA5NGRlZWExOGU1YzYzNDE2MmMyYzNfOS0xLTEtMS02MTc5Mg_f491d039-3e3a-4b40-bab0-a54f2f6a2275">2.8</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i2df95a1c5f0f44979741b294afe8e34f_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV85MS9mcmFnOmMxZGY1NjBiOGNiMzQ3MWI4NzEzYTA3OWQ4NGRlNjAyL3RhYmxlOmQ4NTc4Mzg5YzAwOTRkZWVhMThlNWM2MzQxNjJjMmMzL3RhYmxlcmFuZ2U6ZDg1NzgzODljMDA5NGRlZWExOGU1YzYzNDE2MmMyYzNfMTAtMS0xLTEtNjE3OTU_ae8b8cc7-29f8-4a75-b704-f04c3206a804">2.8</ix:nonFraction><ix:nonNumeric contextRef="i2d9433232b954207a3e4c9d8333d21a2_I20221231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90ZXh0cmVnaW9uOmJiNDEwNTZmMDg4MjQ1MTA5YTBlMWZmY2IxMGRiN2U2XzQyMw_4521311a-fbff-4d4f-a200-9de841dcd915">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i5b6ef7c6980a4e1db02f8ba15b55658c_I20221231" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzYtMS0xLTEtNTA3MjU_1eca02a9-f1dd-4c12-b3b8-0c54b6fd691a">http://fasb.org/us-gaap/2022#DebtCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i51a68f127e8d4d428c82dc489e61cc98_I20211231" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzYtMy0xLTEtNTA3MjU_8d1038d1-419b-4128-8314-0aa1a5467841">http://fasb.org/us-gaap/2022#DebtCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i57ced13309e04a01b09898e7b88dd6f0_I20221231" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzctMS0xLTEtNTA3MjU_a814e167-8383-4d45-81ca-86cc22f5c011">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations</ix:nonNumeric><ix:nonNumeric contextRef="i56be49fb71c4480598cef05e8ba9605a_I20211231" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzctMy0xLTEtNTA3MjU_89a632c7-217b-411e-a52c-c18cee261893">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations</ix:nonNumeric><ix:nonNumeric contextRef="iee6010de5eaf4258ad77ac9f7a65376e_I20221231" name="us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzgtMS0xLTEtNTA3MjU_12d2aa00-0042-4307-aa11-8f39561b8e9d">http://fasb.org/us-gaap/2022#OtherLiabilities</ix:nonNumeric><ix:nonNumeric contextRef="i11cb8a9911234299b66dee77ff4909b4_I20211231" name="us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzgtMy0xLTEtNTA3MjU_15a6bc06-843b-4c48-b58a-8be83b9c35ba">http://fasb.org/us-gaap/2022#OtherLiabilities</ix:nonNumeric><ix:nonNumeric contextRef="iee6010de5eaf4258ad77ac9f7a65376e_I20221231" name="us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzktMy0xLTEtNTA3MjU_99acfacd-090d-4833-8cd5-0990e12d974a">http://fasb.org/us-gaap/2022#OtherLiabilities</ix:nonNumeric><ix:nonNumeric contextRef="i1fafeebfd1ab4899a21ae02fae464c83_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseOptionToTerminate" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDkvZnJhZzplNWVkMTFhOTdlOGI0M2JiOWQ3YWEzNzhiYmE0NDEzZC90ZXh0cmVnaW9uOmU1ZWQxMWE5N2U4YjQzYmI5ZDdhYTM3OGJiYTQ0MTNkXzIwNQ_eb166711-d217-426c-8f01-2c83605f6ecf">Option for early termination of lease after one year</ix:nonNumeric><ix:nonNumeric contextRef="i03c7e40c5f95416f9b140b596a1f186a_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseOptionToTerminate" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDkvZnJhZzplNWVkMTFhOTdlOGI0M2JiOWQ3YWEzNzhiYmE0NDEzZC90ZXh0cmVnaW9uOmU1ZWQxMWE5N2U4YjQzYmI5ZDdhYTM3OGJiYTQ0MTNkXzIwNg_b3d34981-52a2-4207-a6e0-ac9456f7f5f8">Option for early termination of lease after three years</ix:nonNumeric><ix:nonNumeric contextRef="i7909f4de3b454ec89111061cf24a2773_I20221231" name="us-gaap:LesseeFinanceLeaseTermOfContract1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDkvZnJhZzplNWVkMTFhOTdlOGI0M2JiOWQ3YWEzNzhiYmE0NDEzZC90ZXh0cmVnaW9uOmU1ZWQxMWE5N2U4YjQzYmI5ZDdhYTM3OGJiYTQ0MTNkXzU0OTc1NTgxNDEwMA_c5b56727-f558-4a3c-92e9-8654dccd3958">1</ix:nonNumeric><ix:nonNumeric contextRef="id0706f579da046e79bf159bafde70b5e_D20210730-20210730" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTUvZnJhZzo0YTZiYTFmYzYxYzQ0YjhhYmFmNzE3ODI3ZmJiNGU2YS90ZXh0cmVnaW9uOjRhNmJhMWZjNjFjNDRiOGFiYWY3MTc4MjdmYmI0ZTZhXzQzOQ_c22fed69-f7b6-49ad-bf2a-22c5065ee2bb">Fluctuating rate per annum equal to the highest of (a)&#160;the federal funds rate plus 0.50% per annum, (b)&#160;the prime rate of interest established by the Administrative Agent, and (c)&#160;the Eurodollar Rate for an interest period of one month plus 1% per annum.</ix:nonNumeric><ix:nonNumeric contextRef="i4b1209d2737e48bd9bdbd36398d6f1ee_D20210730-20210730" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTUvZnJhZzo0YTZiYTFmYzYxYzQ0YjhhYmFmNzE3ODI3ZmJiNGU2YS90ZXh0cmVnaW9uOjRhNmJhMWZjNjFjNDRiOGFiYWY3MTc4MjdmYmI0ZTZhXzQ0MA_68ab4404-999e-4074-95fe-e03e89007eb4">Rate at which Eurodollar deposits in the London interbank market for an interest period of one, two, three or six months</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjEvZnJhZzozMzIyYWQ4MTU3OTc0M2QzOWFjMjAwZmVkMTBiZWY0Ny90YWJsZTo3NmFiYWVmN2JmMGE0MzU1OTFiNGIxODgzMmM4OWIyNC90YWJsZXJhbmdlOjc2YWJhZWY3YmYwYTQzNTU5MWI0YjE4ODMyYzg5YjI0XzItMS0xLTEtNjE2MjI_0b17f38b-e7a4-407a-a8e3-ed172a34890c">23,377</ix:nonFraction><ix:nonNumeric contextRef="i03c7e40c5f95416f9b140b596a1f186a_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzI5NTc_223df790-b680-48db-b730-c00d1beab04b">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="i24418f4a250c4f51b8e485261ec4b457_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4Xzc0MzA_f3f1355f-39bb-4d10-ac63-3dcf30959476">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i4248f5c857bb4a3dbdce56078e7b58f5_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4Xzc0MzY_d0064103-cecb-48d9-8073-473521ccb07a">P4Y</ix:nonNumeric><ix:nonNumeric contextRef="i1fafeebfd1ab4899a21ae02fae464c83_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjcvZnJhZzo4ODIyMDc4YWQxMDY0ZGRhODA5ZGJjYzg4MWI0MmQ5Zi90YWJsZTowNzliNjMzOGMwOTE0NDlhYjU4Y2ZjNzNmM2VkMGUzMi90YWJsZXJhbmdlOjA3OWI2MzM4YzA5MTQ0OWFiNThjZmM3M2YzZWQwZTMyXzItMS0xLTEtNTA3MjU_31f925f4-b205-4406-9c06-3caff312c27f">12</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="amed-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i266eb829b984448ebdfabbddfb0be360_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="icd730d7570504ba281605ef8099ea7ec_I20230210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b13a726ce4740309bdc481148b0ab43_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab144f7e34ce4a479683c59de399ff42_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a842a348ea54e2aa7af78df38c5e42a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i812c4f7fd6e8491d8a6c1f0f7f2f0c8a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1184798dbf244669a8ac664a6a3e701e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94b781b07d4d4409b8dcc3915918b994_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7347a5a29b245a290ea5780c2f8e972_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i883b9612a1ce4040993b8d0c85aa8244_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idaad48809b5744fabff0426f64590228_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbbf4b06ee8949419799fc4f109084c8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6914d90131e14c43a26dc97a98c426c8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76caa3bd393e42e2ba1a0e9df9033378_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7be9b19ba9f7478f8d633e2083f22149_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f85583bb3f049d3afa37b4d013dcf79_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42b1e865f1ed4b2e8363dfcc39186a91_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae6f76a71f3044fc83923db577d2d9bc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9fa2aa843ed46e5b472b3eebcb45775_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12929bbf3109412399f3172e7fddd206_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f961b554cbf4c35b1fa83b2cd487b4e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a5303400c1a425783f3183ad6fb484d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95978a83297249e088bf477ac218a6d8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83305f332a5848699f3e80d713ebcc32_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a2c2693b2ff45998961c13ebdcfd739_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95ad470da34d4eb9b8d8e685b7c60a58_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73ef0a6e63d24e92b674d33b19f2b5ee_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie172076182c0492ea35971de45486231_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a03e986997443978a0dd90f53d4f1dc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2079949881f8457b9711b22291635c52_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0475ea6bdae24921b04d181f1d8ee6d7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab17129f66c14badb8c3affdd50289b4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd498162f85e4b45bc79f00af8af6e6b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bb8f10d82464615b7fd2f7df5d5bd4e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18dba7744c814ab9907cd2868da0ddc6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2983eae666eb46e39d6a7d6ffe711703_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i964159f6265c4a9fa26afa837937e2a9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0d005a9091143199e4be44f3a337678_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ecdf11c833e48ba8909b67bec1dd8bc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0db7a80feb5475f810c67719ce36ad3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7f80dee79fe4ac684481f6cd7fd746b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83862c03aee5480f950115749f6f0551_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie386fbdef29444a7b1e34af6f9fe68b2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70cecdb6f3b04a83a501c7724ab21784_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f3f8f64156c4928a36902ecbfdb0cc5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib60ffa9c6822423ca9d59d283467feaa_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amed:MedicareRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i30a242e707714a1eab7e611922efcc2c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amed:MedicareRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66aac21e2a3b47cb9f000f260204e4ff_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amed:MedicareRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f7b8ece18824575809137727a001ab8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="care_center"><xbrli:measure>amed:care_center</xbrli:measure></xbrli:unit><xbrli:context id="i4fb0b4ede01d45a8ac9f87b995dfc5bd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i466c99d823de4e3da04d3e6d94ea4feb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc62063a43fb4e54a4eb1692d07bbee2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="numberofjointventures"><xbrli:measure>amed:numberOfJointVentures</xbrli:measure></xbrli:unit><xbrli:unit id="state"><xbrli:measure>amed:state</xbrli:measure></xbrli:unit><xbrli:context id="idaa8aedfe8c3470cbd124c76fae216cf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">amed:HomeHealthBenefitManagerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31897eeed2424fdabfb8a7277396df7f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">amed:ConnectRNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43a583e1be0e4362a0f5b5887d9c279a_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:TypeOfEquityMethodInvestmentAxis">amed:A49InterestSoldInTwoCareCentersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e9dcae6e6af40a2a3ad82452046bbbb_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:TypeOfEquityMethodInvestmentAxis">amed:A30InterestSoldInTwoCareCentersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9e57117e59349509aa17240e4b739bb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:TypeOfEquityMethodInvestmentAxis">amed:MedalogixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dc0472ea16a4281be6243dd9c20268f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7265ebd4cec34caa817f807dc1d6cbc1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b27a458690140b59e1f60faae27b54c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18a8ecfea90b46dea16770739b772958_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">amed:HeritageHealthcareInnovationFundLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i332e5cf83f704c55b25091d8aac22686_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc45e2e2cecf43c7a6bdb033a411f0dc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ef480ba6e114f2599922f6fecdb6adc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b7d185a3a5845299460ef91d19e3737_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20f7b2610db946b6b2c5a7131a2c6402_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i045954bc2da64e639f3d2657db45c8c6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie68834514d89475fa05705e2a104287c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3293bf9528d2455dbef45aa497f1802f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if428e0eafe734ae298c1d7e4fd10018f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i404ba799d43b4f9cbc11bd0f031fa84f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf2d05881bc84546bd58a3bfa9971f2a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife774e47b4e649bbb69a2233094f5f4b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bb3b80738f34bf39ce177e3aa4c2391_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3f54ce15271460d90fc908cd65314f0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8da51266d38e4113b6deb81ba671c1f4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i417cb5125535485c9ef0320496af5e26_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d4251ae99c943f193588862db0c1b69_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72cdabc594824ec3a9da4123e53b9fbb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8691440b2404ff496cc413ef83e5825_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic803d3d531314ae89f73add64e4be217_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2045ac339bf340c48bb59e921fe05def_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89bafb018d3a43eb8a3f1bbb4c93b71b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number_of_visits"><xbrli:measure>amed:Number_of_Visits</xbrli:measure></xbrli:unit><xbrli:context id="i1a4434e079494d01969542db2a51ebee_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8d7fbaae8144d01ae5b61ba948ca043_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d7eeb1ee5ac46b29435cfd337b5b8a7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d86e0102e724a01b5f8cbf75e5ad801_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id22ec472968f424eaedee0df2c1a6a6c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c715413d797438591b1cf5dd86e46fa_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd1a9219629443d5bd28be1543aad1fe_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie980f7f172dd4fc384952e9b8c0724f0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:VariousAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19a05af82bb1454eb68e81cc291cbc07_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:VariousAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a008987e83a4ada9f3b12cc812bd0a1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe86b23f247c43068f7f25f069252db2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic14d437ad5074709988cb2cca394f95f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amed:EquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i000722521f3240b491676997b1fb573f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amed:EquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21ca39c2911849ffa737ddd3e958f192_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9c24eced7104a4e97d673f1e2ca0501_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c4545751ceb443c93f828600b08a087_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a34fcd3e4ca44f997870b28af217929_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c1fcea9f947413daad53be6d9712b19_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i289606829e684a02a13b4c2d309ec6a3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amed:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd970c25fe194ee8bb233e64dbeeb49b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amed:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5efc684324124683b1a591012cf24d74_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amed:EquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75cc8e8f3048499ea5dff437d4511970_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amed:EquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b2a5e41e9ee4551ba7962246c513287_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetsHeldUnderCapitalLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9e60ab572054136b724859b7d07a982_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetsHeldUnderCapitalLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87145fca776747b8862566f844f11da8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i450c80a3586442a8bc78d59bb78f68ce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ebb0aba87354b6e94fa00495eb40c4c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ba082d05d43495b95f7c201e8451ff3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff5859d4cb064056a2a55fa3dc5feb6f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8990c36c1ca24b9b9986a1b57a6b70aa_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00b2929fc5c94edaa315a2c9b947f6d0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide5ecdbd8c87484b981d596040ebe425_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b4aa69adae3479e99bf23edae8da8b3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6711eaed3f0d4ee694ed7955ac3b1e03_I20200327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d7e910da92c42bc90993e8096f3b599_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5316c48403b245d7a32babf7c76d35ac_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfa6a89efdee40b3b7b70040f4cc830d_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b33f1ef384d4000bd6fb60c0d49e71d_D20200401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i144647094c4a4625802e08748d886f42_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if61757dea5844f219019c3a64a1972b4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">amed:COVID19DeferralOfSocialSecurityTaxesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0530cc1fa306423dba7c186bb6ab97cc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">amed:COVID19DeferralOfSocialSecurityTaxesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24fd071f2c354373829031fc28f4be1b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">amed:COVID19DeferralOfSocialSecurityTaxesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06f200e2df374ac19cb47bab63a56b3f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i329d3927fede4bdf9fab592d7ad5bbca_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:A2022NewJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34442d4c2cdd49e8ad3bacd82824cc9b_I20220323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:A2022NewJointVentureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedAndLicensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib16b4cdc559b48b48aaca7b7709eccf7_I20220323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:A2022NewJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ee24d260ef448cd85330a7919fef9a6_D20220401-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5a9c836f91a48a19480bcf0f161b5ea_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5385a5f630f492ca9a57b76acb56832_D20220401-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="amed:BusinessCombinationAdjustmentsAxis">amed:PotentialClosingPaymentAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5164993430b74c95b0e12d477628d1e3_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d98a7f596b54b549b3e1d6ace83797e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71d46c678b1f4800889099f17f5f7799_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28853129c6904eb18dd32328ff6639b9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ce5ed93672d4ebbba91deaaf07e6054_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:LicensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9515534e01de4100ba0629e25ec08585_D20220401-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2021555b705242a99ec6febf31d7a964_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb92529d6381424facef8b4b61830b50_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i599a4a53807b476383b1600b004d88dc_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:LicensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bf01ffe6b0244e5921dd50351b7b4e7_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43eafef87dff4c529ba66562fa0cf94e_I20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e2142a5ef784762a3c038048115d45d_D20220401-20220401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b54240bf3d2420990c7a9096aefde0b_D20210501-20210501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:RandolphCountyNorthCarolinaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie00945c9207e49129104d8327cdab5ac_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:RandolphCountyNorthCarolinaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b9388aa1085440fb4ae49552b5eac30_I20210501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificateOfNeedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:RandolphCountyNorthCarolinaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a6a5482d808478ca8d187e7994862e3_D20210701-20210701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthAndHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:VisitingNurseAssociationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iead9a275ae234dd58c7aa7d6084ed1a8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthAndHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:VisitingNurseAssociationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4e5e1d9f2c04c828295e9928469b871_I20210701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:LicensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthAndHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:VisitingNurseAssociationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id09c2a6d2e8c408fbdffeec1f5145603_D20210712-20210712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-12</xbrli:startDate><xbrli:endDate>2021-07-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4df44aa40d846c888dfefff67b0441e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52779ae3c4594b42bfa6a1f5c28042c3_I20210712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificateOfNeedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9ad18fcb7674a4ca8ca6600d605a491_D20210801-20210801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63526fb29695460daf7c8961c2d352cc_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2df95a1c5f0f44979741b294afe8e34f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0cb3457d3634ebab6e8f002cf82c20c_I20210801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0b5f88e95e24345a3cc0fc5516016cd_I20210801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i337a7e831425489abb80a0847c6f2a4b_I20210801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ab1ecd500d7495dae3df1070f41f7cb_D20210801-20210801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib97247344bf049d2bffeb43e431f858c_D20210801-20210801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39143f0cd5e04faf9cb6b93e100ed3a7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i361c6850de2f4f6caca843b2cad888d0_D20211018-20211018"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-18</xbrli:startDate><xbrli:endDate>2021-10-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ed696897d0041f897bb1b2722b9e756_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7063e6037ddf43518429b892fa7cc4a8_I20211018"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificateOfNeedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51977ad5557047dd858b744031685543_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b006d894f5b438ca664557b42c11392_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7751bbf329e84761a9116e25c1dcb3c3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i200744aa491542f088ed7c2507164bf0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17c7b35f5a01427b9c32a21c25a8f6c0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic26ea180cb834e98a9002bae772f59e2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if15a919ad56a4337a9e1425b3d811e04_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28bb5f40eceb4433925f35b9ac96a7d6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e7c7cfb405d44b8814669a0483f033c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i279e0b1e700047bf850eaae20ab0fa8f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53953caaedb34bb19c4ac51bc0d443fd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i306ee8d06e3d4ce9aedc1f8ceaa8c3a6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f5fa4f13a1b44e0bb2bbf24f19d98ee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedAndLicensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44541ba456f945819b774b06105dc6c8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:UnamortizableAcquiredNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00a4803566c64d9ab540401d7fabdd92_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AmortizableAcquiredNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d01709de86048228674a5671c0c2757_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07c90a9f4c064c94bff73ae8df530042_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib63a631603bd42f9baf706aaa6b526b0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedAndLicensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifff3b1dd516d4ca88196cc4ffb04052e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:UnamortizableAcquiredNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8422ab7dd1f4a4f8d174c43529c7198_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AmortizableAcquiredNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida06184838c44dd1bcfc0a1cfbb4fa09_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfe3ab0bd83e411e92a0dd230a06c08b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9523618072184796b42e15f02c400bf6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedAndLicensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ecf9ee75110493892617267abbac656_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:UnamortizableAcquiredNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b3d453ff35049aca81a81d5e4f888a8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AmortizableAcquiredNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f475dca4f124f1595292633d4e5f191_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b493d5524cf479ea3603709ff2740c8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied840af486324d3b938d05e97bc6b784_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedAndLicensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d8cd69d4e1c45f08f19939d27d4ae62_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:UnamortizableAcquiredNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b384340c0b449dc85760ae9232d9127_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AmortizableAcquiredNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i839a632511504949957616ab961bc135_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60bbec5fe5254517bcba03cfb32af2a8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedAndLicensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1fdd03a76db4dd099fcd6639124379e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:UnamortizableAcquiredNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60f209194f5e43898d6ddf2a2eef8d68_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AmortizableAcquiredNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e005cf326124f079141ed28e6ca38da_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89dfc092633c4ce0845425c7e17c37c3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21a308e1f5cd4afdbceafc5966fb3595_I20230210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d9433232b954207a3e4c9d8333d21a2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabc17e0bc0164f2ab68e1dacdbd3fa3a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i242800e8bae14013ad55b6c47fc0d95c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:LeaseTypeAxis">amed:FleetLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b6ef7c6980a4e1db02f8ba15b55658c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amed:CurrentPortionOfLongTermObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51a68f127e8d4d428c82dc489e61cc98_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amed:CurrentPortionOfLongTermObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57ced13309e04a01b09898e7b88dd6f0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amed:LongTermObligationsLessCurrentPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56be49fb71c4480598cef05e8ba9605a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amed:LongTermObligationsLessCurrentPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee6010de5eaf4258ad77ac9f7a65376e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amed:CurrentAndLongTermObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11cb8a9911234299b66dee77ff4909b4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amed:CurrentAndLongTermObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fafeebfd1ab4899a21ae02fae464c83_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03c7e40c5f95416f9b140b596a1f186a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7909f4de3b454ec89111061cf24a2773_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amed:TelehealthKitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f4fcaea6b154a0bbd917fba61d92e52_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i916f340079654056b2571fa1ce003955_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a8567395eba45968f1f59959fef3ffb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6c3d510a20748ce9ea87e61c6e92cc4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacc4528c818b4326ae050e255a5a7a3e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc761fea5e584f6080ec28aa409e26d2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b6a940fe41e4c4e9bd71fc532b5f27c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ebd597356dc40a6baa7eabf9da5fb56_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:PromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bb00aa3ab56488ea6e59211d0ec0f49_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:PromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id86557107c34492d8c132ad64570a3ed_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbdaead26d8b4e69b17a84ea4692f399_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i178263b3689c4dbeb4183a1b2a8f06f4_I20180629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i204f7f8314234638a578a2852af0430f_I20180629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76cb131f8a16465eb2fc15903e2b579d_D20180629-20180629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-29</xbrli:startDate><xbrli:endDate>2018-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1af0127cb3643d8b17864fcb195bfd5_I20190204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3178979288cb4514826472f72e5bfb60_I20190204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba0cc26b6786477a93c245c64b48976e_I20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bb8d308c9224e5b844d2c6db275e492_I20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3eb443904904bc78906ce21c0d215af_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07211fe9ad5d4482bd6b137633c2aa1d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida7bcb808f0e4c318ec059d9ceff470a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa67d7d55667443394ca159d57aa511b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice4835f824f5444f94f1ecd506168658_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie35e7d51c69e442a9aaed895a70d075f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife65de97c43c4ff38decb113044c4058_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f84542d7b53490e9e21f12a81a49347_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ca3fedd3e1b4c93a4622a8fb6dc1a1e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17742e3ab61d4196b516dfbe59d556fd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6d924aa96d649d1b106241f0f9d3dc6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf4da83d5cea4929a377d16e2a794965_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96a9d31440c94da5a965cfe8fea3f233_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e09b2632feb4e60a63f4f0811a7e6f8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6453a68ab024f0481790410c647ca02_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3fe9ab766bf4b6aac1a8ef448a228af_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fb8d922ed7840eba4d9f5c8439d8634_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6144bb4d6ba64536b8a021e88b94f277_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5b4115d16ee4985a95f2ba4f5411a8b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb4d003ebe754bc288a304ab991ccff7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i346c9bba84d040c583bc1c161bbc63a2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i492cad6b4f6d4dff915ecfdc41239333_D20210730-20260730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2026-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b1fdf13b14f42838235e12dc847d78f_D20210730-20230930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4e912d799f345eb811d0a45ef8aad22_D20231001-20260730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2026-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ac0dcfcf2f843d2ac033b98c430f309_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie72df9520c04416783c5c1351b95aa45_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7b0d6790e424eb28816c7faa3cbcaf5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31b64bb9856d4b7ab6ed7600628a1276_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5660c9b896a4ecaa1234048bbedeafa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41fd72dfb82543b4af87db7a75cd295a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if39b026dc9a34fbe996e7be93272debd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0706f579da046e79bf159bafde70b5e_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b1209d2737e48bd9bdbd36398d6f1ee_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7805668b7a84f7d95cb285d7db5a548_D20200810-20200810"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:ExecutiveStockOptionExerciseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-10</xbrli:startDate><xbrli:endDate>2020-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i287e698cf9eb4bdfb671be9b8b48fffc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:ExecutiveStockOptionExerciseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibace990f785a497b98867b384cd11b5f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:ExecutiveStockOptionExerciseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i039df82eb47c4820a0f22e9789c65e30_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:ExecutiveStockOptionExerciseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i956eb24e24e0444b86f101edaf26c1b4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:UnrecognizedTaxBenefitsAxis">amed:NetOperatingLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47060e74f1c24113966bf5b707b10e09_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:UnrecognizedTaxBenefitsAxis">amed:NetOperatingLossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cc7c6096a3746f28dfa0ec43e47b91a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">amed:StateTaxCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a6f6b5c67ab4519b50f44d3984d3460_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:ShareBasedAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29922553b57d4a4f913d8dc9ac058907_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:ShareBasedAwardsToMoreThanTenPercentOwnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f97dee560fa43f381b21ce637429d33_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaab2533120e743218b94d1ca1acd32ae_D20120607-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2012-06-07</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88f7ee58380e478992f80d0861c1607f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id59b7e2a3058490b9b7c36016e54fda5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ab351315e174023b86cc7cc10277227_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if75caf01fb8b4cf59e6837df49b4e315_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadba656fc0c44917b7651f7ad78cbd0c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib60868f2b1d84557b45341890a39d860_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5c669dea2424147a7e748e8a71c927c_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4df39100e7da46d49d9439da9cf924d8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i611f679bc0fc435c9e898dad11348fcf_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e118c828cfd44b387ff3fef4f4d36ec_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide0d67cdc1d84448bde7a943cb636abd_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b2fa1ac38fb4e9f99f2949b063d86c5_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39be0476e53e4678b7f5eebe2f65b0d1_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e2596f2753a45a9b4ddde231581db8b_D20120607-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2012-06-07</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06eb9ed545f04bdcbf647b341b4ab114_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8002223ee9342dbb6725f50e35539b6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15f9883719504dad940b79d91d5a68cf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14c451d987c9475fa3c8992bc94cbf8f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24418f4a250c4f51b8e485261ec4b457_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4248f5c857bb4a3dbdce56078e7b58f5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd5a663f1bb844bab57b874fbf18534e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52a228fca81e41d693cd6d81c49a90c4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11c1dc78db0e49b68f847e221371a443_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdd8f4e213094cc396d0fcbfc8c7cc13_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e87c3e7b1004ea799c3dc520a7f0a4e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i082da853b55e488ab9ef8c389ed4b49f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceBasedAndPerformanceBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5b0758fc5c841c69f0e3000600e3618_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceBasedAndPerformanceBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecabe05cd8be4b96a216b1a6513dcb34_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceBasedAndPerformanceBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5aa28b6040cd4209a28424a8ddb8c083_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceBasedAndPerformanceBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d8e565a484b4115a30a498efd2fead8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceBasedAndPerformanceBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72f8833e23b44a2ea0d2a7d9a3387fad_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic191fcc8192b4608959c14133dc12c5e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieba00eb7d405413d818c4971105613ee_D20150521-20150521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-05-21</xbrli:startDate><xbrli:endDate>2015-05-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="patient"><xbrli:measure>amed:patient</xbrli:measure></xbrli:unit><xbrli:context id="i8d55411f20e04d00a2eea8301fc2ae5a_D20151103-20151103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:MorgantownWestVirginiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-11-03</xbrli:startDate><xbrli:endDate>2015-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i011327a38e254fcaa937ffb2732985d4_D20160627-20160627"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ParkersburgWestVirginiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-27</xbrli:startDate><xbrli:endDate>2016-06-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic16a0c94f3004de7b7a900a946d92672_D20080101-20100331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2008-01-01</xbrli:startDate><xbrli:endDate>2010-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="beneficiary"><xbrli:measure>amed:beneficiary</xbrli:measure></xbrli:unit><xbrli:context id="if1bca261c0b946248dfe5cee858c643d_D20110606-20110606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:ExtrapolatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2011-06-06</xbrli:startDate><xbrli:endDate>2011-06-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d52cf787d4f4a21ba644c6537028eca_I20160118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-01-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd850077008b489db6c689d6678a854b_D20160118-20160118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-18</xbrli:startDate><xbrli:endDate>2016-01-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>amed:claim</xbrli:measure></xbrli:unit><xbrli:context id="if8e53a67d325418698e7dff0da8ae0f8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29b899adcb534d2fb11ae45ba13dffa5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38abfa2908c74f76a39c59f03f0a1f88_I20190110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ad4b2a4d1904246a60f312fe6e54a55_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d9c1bb997894061aeafb6aabddeffd5_D20170801-20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-01</xbrli:startDate><xbrli:endDate>2017-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id957a4e2cf624f1f8c0755fef660c4fc_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica936df2e1054ec1b0ff8eb6510dfbcb_D20170801-20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-01</xbrli:startDate><xbrli:endDate>2017-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d88d76487a74a848baa03e874a5eccd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieaeca3977d8a40ec9994588b4150109b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2c6967c53284f0ea2b6b8001c55cacd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c5014c365be4c5d90c38959f215dfb5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieefca07772a441c18ef7fd78ee354800_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic41315c634e841cc9d84abadce65303b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i868f83b3f18641769d70c97c93d30912_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib79f3470b4c9406fa918cc4fbe458ad1_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2ead6d6a5b24846a24cab167648cd41_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23cfc9c5f5334cb98796bce037009c13_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b610aa7397640f8a2fa1d7a074bd768_I20201223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:A2021ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0c9423c441c4978b769e4a86bc9188f_D20201223-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:A2021ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-23</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4261a3345d54d03886673d73969d061_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:A2021ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia01a4c270b254b66aa3015655785be61_I20210802"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:NewShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic922798f82384a0cb1c5e20555cd93c6_D20210802-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:NewShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-02</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fdb42e0a3874ea5a19076aa86bff340_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:NewShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92bd39f0d2544264b7d724dd1ae6eac3_I20230202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:A2023ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b423f65ef9c451d935438afdcfc2e15_D20230202-20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:A2023ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>amed:segment</xbrli:measure></xbrli:unit><xbrli:context id="icff92844bf7e45cf8941114000e0fa42_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i971b271744ea4a63aca16276f887bcb4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e623706c1354124a369dc7758938060_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47b68ba2f13e424bacfacf577053382b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i114e5c43f13843719a8a60aa9fd64db1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc3b9823141645e68eb892a3c076e69b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c8bd5c211c94e959f7bcc237d284961_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc02119e099f490a8a653314b18712d4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i722dd3d3be554fc1bcbc003ddc943c6a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a8daa3605c04f07bf026bdc825236d7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id362cc93e6cd48da8f96f15cbc8bed2e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6db8f1d2d01b4b87b43031a471f0a747_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad09634e54b64f4ab4f376450c10a9fe_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5e19c6308394df88a3ac225cead2412_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55522935511e4608b35d61ba4b0cb9d2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65690d26701e4e5ea588f0959375f58b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">amed:MedalogixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaf95b2f3ae241fa85a7edcd22950e29_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">amed:MedalogixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9c94f55e0204d55a40837adab0df9ec_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">amed:MedalogixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i5c10b724a6674979bf3c35a339f29685_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.409%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8zODM3_f32a86a9-34cb-499c-a4ba-036c145e4dab">10-K</ix:nonNumeric> </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.409%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="padding-left:31.5pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8zODM4_77aff5d6-d1ae-4b5b-9eab-bfc4684a580e">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:2pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended: <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8yMTk_749aad99-29e1-4351-8fc1-21c12f6723b3">December&#160;31, 2022</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="padding-left:31.5pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8zODI3_a0ad69d7-deae-48f8-b86a-aeed4d669344">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:2pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8zODM5_74eda771-48bb-4c24-bd36-dcbd5836410d">0-24260</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.409%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><img src="amed-20221231_g1.jpg" alt="amed-20221231_g1.jpg" style="height:98px;margin-bottom:5pt;vertical-align:text-bottom;width:156px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8zODI5_6e8910a1-75bf-45a9-9ea5-bdd304eac29b">AMEDISYS, INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.409%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.486%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGFibGU6YjhiZjc2MGVmMDBmNDBhZWEzYmQ4MDQyMjI4MjMzYzkvdGFibGVyYW5nZTpiOGJmNzYwZWYwMGY0MGFlYTNiZDgwNDIyMjgyMzNjOV8wLTAtMS0xLTUwNzI1_70ea33b3-4f34-469f-9762-7c853ec2387b">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGFibGU6YjhiZjc2MGVmMDBmNDBhZWEzYmQ4MDQyMjI4MjMzYzkvdGFibGVyYW5nZTpiOGJmNzYwZWYwMGY0MGFlYTNiZDgwNDIyMjgyMzNjOV8wLTItMS0xLTUwNzI1_8b0fdd01-f569-46fa-93d3-aeb2de23170a">11-3131700</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8zODQw_33308252-7015-4fc9-9dde-30c66e8082b8">3854 American Way, Suite A,</ix:nonNumeric> <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8zODMz_5a5ab52c-1f5a-4f2b-8c96-918f84a60324">Baton Rouge,</ix:nonNumeric> <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8zODQx_7af42365-6ea5-4ccd-b60a-bc3c598a6e80">LA</ix:nonNumeric> <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8zODI4_942a8c6e-6350-4528-850f-1ef55d3e403f">70816</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8zODQy_8028c5ef-1621-4c81-9e89-76e910def44e">225</ix:nonNumeric>) <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8zODMw_d2ab8b3b-0c7f-4698-8f02-8506f1b3f117">292-2031</ix:nonNumeric> or (800)&#160;467-2662</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.409%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:33.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.678%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.678%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.448%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of Each Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGFibGU6Y2M5OTdhMjNlYmMzNGZlN2ExMDNiMGY0ZjIwZjQxYTIvdGFibGVyYW5nZTpjYzk5N2EyM2ViYzM0ZmU3YTEwM2IwZjRmMjBmNDFhMl8xLTAtMS0xLTUwNzI1_d4747d8f-cadf-442a-91ce-52f8a5fb1844">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGFibGU6Y2M5OTdhMjNlYmMzNGZlN2ExMDNiMGY0ZjIwZjQxYTIvdGFibGVyYW5nZTpjYzk5N2EyM2ViYzM0ZmU3YTEwM2IwZjRmMjBmNDFhMl8xLTItMS0xLTUwNzI1_4adfba1a-d2fa-45b6-b3d5-4f0681800a46">AMED</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGFibGU6Y2M5OTdhMjNlYmMzNGZlN2ExMDNiMGY0ZjIwZjQxYTIvdGFibGVyYW5nZTpjYzk5N2EyM2ViYzM0ZmU3YTEwM2IwZjRmMjBmNDFhMl8xLTQtMS0xLTUwNzI1_3029b9ab-f228-4fce-8b41-792873b6b1f7">The NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act: None</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.409%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8zODM0_dfc19212-983c-4c7d-99ab-0037b0ac2c99">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8zODMx_708de81f-fd8f-4f5b-8782-8d6b4bfda90e">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8zODM1_644c9052-b87b-47bb-ab60-054752f352da">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;&#160;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8zODMy_36b4da9f-55e3-49e2-95eb-68582249c1ee">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.279%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.113%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.282%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGFibGU6MjczYzRhMmE4NmU1NGMzMzhiZjdlYTk3Y2ZkOGZkMmIvdGFibGVyYW5nZToyNzNjNGEyYTg2ZTU0YzMzOGJmN2VhOTdjZmQ4ZmQyYl8wLTAtMS0xLTUwNzI1_ab496ac6-8b4c-4c18-8af4-283eb2dfe238">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9745;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></div><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer<br/></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company<br/></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGFibGU6MjczYzRhMmE4NmU1NGMzMzhiZjdlYTk3Y2ZkOGZkMmIvdGFibGVyYW5nZToyNzNjNGEyYTg2ZTU0YzMzOGJmN2VhOTdjZmQ4ZmQyYl8xLTQtMS0xLTUwNzI1_f5579074-985f-4f3c-b5e1-45e4b8d8ece7">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company<br/></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGFibGU6MjczYzRhMmE4NmU1NGMzMzhiZjdlYTk3Y2ZkOGZkMmIvdGFibGVyYW5nZToyNzNjNGEyYTg2ZTU0YzMzOGJmN2VhOTdjZmQ4ZmQyYl8yLTQtMS0xLTUwNzI1_517d2e58-d12f-4fb8-8703-2757397d2727">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9745;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. &#9633;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167; 240.10D-1(b). &#9633;</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF81NDk3NTU4MTg1MDk_cf38efee-e26b-44ed-9f0c-2ad7aaf2ef13">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9745;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The aggregate market value of the voting and non-voting common stock held by non-affiliates of the registrant, based on the last sale price as quoted by the NASDAQ Global Select Market on June&#160;30, 2022 (the last business day of the registrant&#8217;s most recently completed second fiscal quarter) was $<ix:nonFraction unitRef="usd" contextRef="i266eb829b984448ebdfabbddfb0be360_I20220630" decimals="-8" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8zMTYw_4cf9cc18-b457-41d0-9cc9-7f34f6e934aa">3.0</ix:nonFraction> billion. For purposes of this determination, shares beneficially owned by executive officers, directors and ten percent stockholders have been excluded, which does not constitute a determination that such persons are affiliates.</span></div><div style="margin-bottom:9pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;10, 2023, the registrant had <ix:nonFraction unitRef="shares" contextRef="icd730d7570504ba281605ef8099ea7ec_I20230210" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8zNDEz_a123f52d-969c-418e-966b-444aa1ecaf39">32,550,602</ix:nonFraction>&#160;shares of Common Stock outstanding.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s definitive Proxy Statement for its 2023 Annual Meeting of Stockholders (the &#8220;2023 Proxy Statement&#8221;) to be filed pursuant to the Securities Exchange Act of 1934 with the Securities and Exchange Commission within 120 days of December&#160;31, 2022 are incorporated herein by reference into Part III of this Annual Report on Form&#160;10-K.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i5c10b724a6674979bf3c35a339f29685_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.755%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.102%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_10">SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_10">1</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_13">PART I.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_16">ITEM&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_16">BUSINESS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_16">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_19">ITEM&#160;1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_19">RISK FACTORS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_19">17</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_22">ITEM&#160;1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_22">UNRESOLVED STAFF COMMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_22">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_25">ITEM&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_25">PROPERTIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_25">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_28">ITEM&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_28">LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_28">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_31">ITEM&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_31">MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_31">32</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_34">PART II.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_37">ITEM&#160;5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_37">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_37">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_40">ITEM&#160;6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_40">[RESERVED]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_40">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_43">ITEM&#160;7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_43">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_43">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_46">ITEM&#160;7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_46">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_46">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_49">ITEM&#160;8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_49">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_49">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_175">ITEM&#160;9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_175">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_175">99</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_178">ITEM&#160;9A</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_178">CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_178">99</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_181">ITEM&#160;9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_181">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_181">103</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_184">ITEM 9C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_184">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_184">103</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_187">PART III.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_190">ITEM&#160;10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_190">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_190">103</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_193">ITEM&#160;11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_193">EXECUTIVE COMPENSATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_193">103</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_196">ITEM&#160;12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_196">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT&#160;AND RELATED STOCKHOLDER MATTERS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_196">103</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_199">ITEM&#160;13</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_199">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_199">103</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_202">ITEM&#160;14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_202">PRINCIPAL ACCOUNTANT FEES AND SERVICES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_202">103</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_205">PART IV.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_208">ITEM&#160;15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_208">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_208">104</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_211">ITEM&#160;16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_211">FORM 10-K SUMMARY</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_211">104</a></span></div></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_214">EXHIBIT INDEX</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_214">105</a></span></div></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_217">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c10b724a6674979bf3c35a339f29685_217">111</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i5c10b724a6674979bf3c35a339f29685_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">When included in this Annual Report on Form&#160;10-K, or in other documents that we file with the Securities and Exchange Commission (&#8220;SEC&#8221;) or in statements made by or on behalf of the Company, words like &#8220;believes,&#8221; &#8220;belief,&#8221; &#8220;expects,&#8221; &#8220;strategy,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;projects,&#8221; &#8220;estimates,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should&#8221; and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: changes in Medicare and other medical payment levels; changes in payments and covered services by federal and state governments; future cost containment initiatives undertaken by third-party payors; changes in the episodic versus non-episodic mix of our payors or payment methodologies; changes in the case mix of our patients; staffing shortages driven by the competitive labor market; our ability to attract and retain qualified personnel; competition in the healthcare industry; our ability to maintain or establish new patient referral sources; changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis; the impact of the novel coronavirus pandemic ("COVID-19"), including the measures that have been and may be taken by governmental authorities to mitigate it, on our business, financial condition and results of operations; changes in estimates and judgments associated with critical accounting policies; our ability to consistently provide high-quality care; our ability to keep our patients and employees safe; our access to financing; our ability to meet debt service requirements and comply with covenants in debt agreements; business disruptions due to natural or man-made disasters, climate change or acts of terrorism, widespread protests or civil unrest; our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively; our ability to realize the anticipated benefits of acquisitions, investments and joint ventures; our ability to integrate, manage and keep our information systems secure; the impact of inflation; and changes in laws or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control, and such other factors as discussed throughout Part I, Item 1A. "Risk Factors" of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events.&#160;We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as may be required by law.&#160;For a discussion of some of the factors discussed above as well as additional factors, see Part&#160;I, Item&#160;1A, &#8220;Risk Factors&#8221; and Part&#160;II, Item&#160;7, &#8220;Critical Accounting Estimates&#8221; within &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221;</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unless otherwise provided, &#8220;Amedisys,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and &#8220;the Company&#8221; refer to Amedisys, Inc. and our consolidated subsidiaries, and when we refer to 2022, 2021 and 2020, we mean the twelve month period then ended December&#160;31, unless otherwise provided.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">A copy of this Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022 as filed with the SEC, including all exhibits, is available on our internet website at http://www.amedisys.com on the &#8220;Investors&#8221; page under the &#8220;SEC Filings&#8221; link.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i5c10b724a6674979bf3c35a339f29685_13"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i5c10b724a6674979bf3c35a339f29685_16"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1.&#160;BUSINESS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amedisys, Inc. is a leading healthcare services company committed to helping our patients age in place by providing clinically excellent care and support in the home. Our operations involve serving patients across the United States through our four operating divisions: home health, hospice, personal care and high acuity care. We deliver clinically distinct care that best suits our patients' needs, whether that is home-based recovery and rehabilitation after an operation or injury or care that empowers patients to manage a chronic disease through our home health division, hospice care at the end of life, providing assistance with daily activities through our personal care division or delivering the essential elements of inpatient hospital, palliative and skilled nursing facility ("SNF") care to patients in their homes through our high acuity care division.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are among the largest providers of home health and hospice care in the United States, with approximately 20,000 employees in 532 care centers in 37&#160;states within the United States and the District of Columbia. Our&#160;employees deliver the highest quality care performing more than 11.2&#160;million visits for more than 465,000&#160;patients annually. Over 3,000&#160;hospitals and 102,000&#160;physicians nationwide have chosen us as a partner in post-acute care.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the age demographics of our patient base, our services are primarily paid for by Medicare which has represented approximately 74% to 75% of our net service revenue over the last three years. We also remain focused on maintaining a profitable and strategically important managed care contract portfolio. We continuously work with our payors to structure innovative contracts which reward us for providing quality care to our patients.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amedisys is headquartered in Baton Rouge, Louisiana, with an executive office in Nashville, Tennessee. Our common stock is currently traded on the NASDAQ Global Select Market under the trading symbol &#8220;AMED.&#8221; Founded and incorporated in Louisiana in 1982, Amedisys was reincorporated as a Delaware corporation prior to becoming a publicly traded company in August 1994.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy is to be the best choice for care wherever our patients call home. We accomplish this by providing clinically distinct care, being the employer of choice and delivering operational excellence and efficiency, which when combined, drive growth. Our mission is to provide best-in-class home health, hospice, personal care and high acuity care services allowing our patients to maintain a sense of independence, quality of life and dignity while delivering industry leading outcomes. We believe that our unwavering dedication to clinical quality and constant focus on both our patients and our employees differentiates us from our competitors.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Our Home Health Segment:</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our home health segment provides compassionate healthcare to help our patients recover from surgery or illness, live with chronic diseases and prevent avoidable hospital readmissions. Our home health footprint includes 347 care centers located in 34&#160;states within the United States and the District of Columbia. Within these care centers, we deploy our care teams which include skilled nurses who are trained, licensed and certified to administer medications, care for wounds, monitor vital signs and provide a wide range of other nursing services; rehabilitation therapists specialized in physical, speech and occupational therapy; and social workers and aides who assist our patients with completing important personal tasks.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We take an empowering approach to helping our patients and their families understand their medical conditions, how to manage them and how to maximize the quality of their lives while living with a chronic disease or other health condition. Our clinicians are trained to understand the whole patient &#8211; not just their medical diagnosis.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitment to clinical distinction is most evident in our clinical quality measures such as the Quality of Patient Care and Patient Satisfaction star ratings. In the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) reports for the April 2023 preview, the Quality of Patient Care star average across all Amedisys providers was 4.49 with 99% of our care centers at 4+ stars and 46 care centers rated at 5 stars. Our Patient Satisfaction star average for the January 2023 release was 3.57, outperforming the industry average by 1% (April 2023 preview data is not available for this metric). Our goal is to have all care centers achieve a 4.0 Quality of Patient Care star rating, and we have implemented targeted action plans to continue to improve the quality of care we deliver for our patients and further our culture of quality.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Our Hospice Segment:</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hospice care is designed to provide comfort and support for those who are dealing with a terminal illness. It is a benevolent form of care that promotes dignity and affirms quality of life for the patient, family members and other loved ones. Individuals with a terminal illness such as cancer, heart disease, pulmonary disease or Alzheimer&#8217;s may be eligible for hospice care if they have a life expectancy of six months or less. Our hospice care teams include nurse practitioners and other skilled nurses, social workers, aides, bereavement counselors and chaplains.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our focus is on building and retaining an exceptional team, delivering the highest quality care and service to our patients and their families and establishing Amedisys as the preferred and preeminent hospice provider in each community we serve. In order to realize these goals, we invest in tailored training and development for our employees which has led to our team&#8217;s consistent achievement at or above the national average in family satisfaction results and quality scores, as well as the trust of the healthcare community.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Another element of our approach is our outreach strategy to more fully engage the entire community of eligible patients.&#160;These outreach efforts have built our hospice patient population to more accurately represent the causes of death in the communities we serve, with a specific focus on heart disease, lung disease and dementia in order to address the historical underrepresentation of non-cancer diagnoses. By working to accept every eligible patient who seeks end-of-life care, we fulfill our hospice mission and strengthen our standing in the community. </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Our Personal Care Segment:</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personal care provides assistance with the essential activities of daily living. Amedisys acquired its first personal care company in 2016 and continued to expand the personal care segment with four additional acquisitions. We currently operate 11 personal-care care centers in Massachusetts and one personal-care care center in each Florida and Tennessee. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2023, we signed a definitive agreement to sell our personal care business (excluding the Florida operations). The divestment is expected to close during the second quarter of 2023. See Item 8, Note 6 - Assets Held For Sale for additional information. </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Our High Acuity Care Segment:</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of Contessa Health ("Contessa") on August 1, 2021 established our high acuity care segment. Our high acuity care segment has the capability to deliver the essential elements of inpatient hospital, SNF care and palliative care to patients in their homes. In connection with the acquisition of Contessa, we obtained interests in a professional corporation that employs clinicians and several joint ventures with health system partners. Additionally, the acquisition provided the Company with an advanced claims analytic platform, network management and additional capabilities to enter into risk-based arrangements with managed care organizations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our joint venture partners in the high acuity care segment represent national and large regional healthcare systems, each of which view the ability to provide inpatient level care in patients&#8217; homes as critical to relieving capacity constraints within their facilities, providing care in a more cost-effective setting and keeping patients engaged with their health system brand by providing a superior patient experience. The patients who utilize our home-based recovery services typically have one or more chronic conditions that have historically required frequent emergency department visits and inpatient hospital stays. Our patient satisfaction scores for these home-based programs have consistently exceeded 85%, and we have successfully reduced hospital and skilled nursing readmission rates compared to historical baselines for these episodes of care. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide management services to the joint ventures which include the development and implementation of clinical protocols to ensure the safe and efficient delivery of services in the home and high quality outcomes; an internally-developed technology platform that provides medical documentation, analytics and claims processing capabilities; provider network development services to ensure that all care resources are available to meet patient needs; and expertise in developing and negotiating contracts with third party health insurance payors to provide reimbursement for services in risk-based arrangements. Our expertise and capabilities in these areas deliver value to both the health system and the health insurance payor and give us the opportunity for future expansion within the healthcare continuum for chronically ill patients, including palliative care services, especially as the U.S. population ages and consumer preferences continue to shift to home-based care. Our joint venture partnership model with leading healthcare systems and our relationships with health plan insurers facilitate our ability to take and manage additional risk for this patient population in value-based arrangements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Network Partnerships:</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a Care Coordination Agreement with BrightStar Care to add its agencies to the Amedisys personal care network, which helps facilitate the coordination of care between our home health and hospice care centers and a network of personal care partners. We believe this agreement will further our efforts to provide patients with a true care continuum in the home. This relationship will also help us as we continue to have innovative payment conversations with Medicare Advantage plans who recognize the value that combined home health, hospice, personal care and high acuity care services bring to their members and care delivery infrastructure.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Responding to the Changing Regulatory and Reimbursement Environment:</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the government continues to seek opportunities to refine payment models, we believe that our strategy of becoming a leader in providing a range of services across the at-home continuum positions us well for the future. Our ability to provide quality home health, hospice, personal care and high acuity care allows us to partner with health systems and managed care organizations to improve care coordination, reduce hospitalizations and lower costs.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Innovations:</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the coming year, our core business innovations will consist of workforce optimization with a focus on new ways to engage, recruit and retain our clinical staff, clinical optimization and reorganization initiatives and continuing to differentiate our service offerings as we build out our aging-in-place capabilities. The acquisition of Contessa in 2021 will also be a platform for continued innovations as we expand Contessa&#8217;s lines of business, including palliative care at home.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Acquisitions:</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2022, we acquired 15 home health care centers from Evolution Health, LLC, a division of Envision Healthcare, doing business as Guardian Healthcare, Gem City, and Care Connection of Cincinnati ("Evolution") and two home health locations from AssistedCare Home Health, Inc. and RH Homecare Services, LLC, doing business as AssistedCare Home Health and AssistedCare of the Carolinas ("AssistedCare").</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Information:</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial information for our home health, hospice, personal care and high acuity care segments can be found in our consolidated financial statements included in this Annual Report on Form 10-K.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our employees are critical to our vision to be the leading aging-in-place company. Taking care of our people is our top priority. Our success is directly correlated with our ability to continue to attract, develop and retain the most qualified and passionate employees. Our work is not just a job but a calling. Our workforce strategy emanates from our core values of SPIRIT - Service, Passion, Integrity, Respect, Innovation and Talent. We know that by taking great care of our people, they can continue to provide industry leading patient care.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;10, 2023, we employed approximately 20,000 people throughout the United States. We also utilize contract employees in the normal course of our business.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Diversity and Inclusion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We endeavor to create a culture of caregiving where our employees feel as cared for every day as our patients. Success means all team members feel a sense of belonging, support and empowerment to be their best selves personally and professionally. We have committed to giving our employees a voice and have instituted numerous formal listening programs including quarterly pulse surveys, focus groups and town halls to routinely gather feedback from our employees and address any concerns. Our commitment to diversity and inclusion is also broadly reflected across our policies and people practices. Under the leadership of our employee-led Diversity and Inclusion Council, over 1,100 leaders participated in diversity and inclusion training designed to support a positive and inclusive work environment during 2022. Additionally, we have four Employee Resource Groups ("ERGs") which foster connection and community within our workforce: (1) Global Black Community, (2) LGBTQIA+, (3) disAbilities and (4) Military/Veterans. We are also committed to having a diverse Board of Directors. Women currently comprise over half of the directors on our Board.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Talent Acquisition, Retention and Development:</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to hire, develop and retain top talent. The core of our care delivery model is dependent upon attracting clinicians, predominately nurses. We compete for talent by offering a great culture, an opportunity to provide the highest quality clinical care and competitive market-based compensation. Our compensation plans are designed to deliver a competitive base pay as well as attractive incentive opportunities, primarily for leadership positions, but also to reward quality care. We provide significant opportunities for development and continuing education as we know that career development is a key component of attracting and retaining top talent. We continually monitor and assess employee metrics on hiring, retention and terminations to gain a deep understanding of our workforce and drive continuous improvement.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact of the novel coronavirus pandemic ("COVID-19") and demand for clinicians has generated continuing pressure on the labor markets. Clinicians have become harder to recruit and more costly to employ. Attracting the best people in healthcare and supporting our people with an unrivaled experience are key initiatives for the Company to ensure adequate clinical capacity for our patients.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Health and Safety</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The health and well-being of our employees is of utmost importance to us. We offer a comprehensive benefit package that provides employees and their families with access to a variety of innovative, flexible and convenient health and wellness programs that support their physical and mental health by providing tools and resources to help them improve or maintain their health status. </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Payment for Our Services</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues are derived in large part from governmental third-party payors. Governmental payment programs are subject to statutory and regulatory changes, retroactive rate adjustments, administrative or executive orders and government funding restrictions, all of which may materially increase or decrease the rate of program payments to us for our services. It is possible that future budget cuts in Medicare and Medicaid may be enacted by Congress and implemented by CMS. Therefore, we cannot assure you that payments from governmental or private payors will remain at levels comparable to present levels or will, in the future, be sufficient to cover the costs allocable to patients eligible for reimbursement pursuant to such programs. See Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations: Overview &#8211; CMS Payment Updates" for additional information on the most recent regulations from CMS.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Home Health Medicare</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare home health benefit is available both for patients who need home care following discharge from a hospital and patients who suffer from chronic conditions that require ongoing, but intermittent, care. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a condition of participation under Medicare, beneficiaries must be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during COVID-19, CMS has relaxed the definition of homebound status through the duration of the public health emergency. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their house because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Services under the Medicare home health benefit are bundled into 60-day episodes of care. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier. If a patient is still in treatment on the 60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day, a recertification assessment is undertaken to determine whether the patient needs additional care. If the patient&#8217;s physician determines that further care is necessary, another episode begins on the 61</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day (regardless of whether a billable visit is rendered on that day) and ends 60 days later.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2020, CMS implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"). PDGM uses a 30-day period of care rather than a 60-day episode of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information. Under PDGM, each 60-day episode includes two 30-day payment periods. The table below includes the base 30-day payment rates.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Base 30-Day Payment</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 1, 2020 through December 31, 2020 (only applies to episodes beginning on January 1, 2020 and thereafter)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,864&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 1, 2021 through December 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 1, 2022 through December 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 1, 2023 through December 31, 2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On October 31, 2022, CMS issued the Home Health Final Rule for Medicare home health providers for calendar year 2023. CMS estimates that the final rule will result in a 0.7% increase in payments to home health providers. This increase is the result of a 4.0% payment update (4.1% market basket adjustment less a 0.1% productivity adjustment) and an increase of 0.2% for the update to the fixed-dollar loss ratio used in determining outlier payments offset by a permanent adjustment of -3.5% based on the difference between assumed and actual behavioral changes resulting from the implementation of PDGM. The -3.5% permanent adjustment is derived from a -3.925% behavioral assumption adjustment. In the Calendar Year 2023 Preliminary Rule, CMS proposed a behavioral assumption adjustment of -7.69%. CMS revised the adjustment to -7.85% in the final rule and also reduced it by half (to -3.925%) in order to mitigate such a significant reduction to reimbursement in a single year. The remaining -3.925% behavioral assumption adjustment will be considered in future rulemaking. The final rule also finalizes a permanent 5% cap on negative wage index changes for home health agencies. Based on our analysis of the final rule, we expect our impact to be flat, which is less than the estimated 0.7% rate increase.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the permanent adjustments, CMS is also considering a temporary adjustment of approximately $2 billion to offset overpayments in calendar years 2020 and 2021. CMS has elected not to apply the temporary adjustment to calendar year 2023; however, CMS is still considering how to best apply the adjustment in future rulemaking. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables, including, but not limited to (a) an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#8220;LUPA&#8221;) if the number of visits provided was less than the established threshold, which ranges from two to six visits and varies for every case-mix group under PDGM; (c)&#160;a partial payment if a patient transferred to another provider or from another provider before completing the 30-day period of care; and (d)&#160;the applicable geographic wage index. Payments for routine and non-routine supplies are included in the 30-day payment rate.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a Medicare provider, we are subject to periodic audits by the Medicare program, and that program has various rights and remedies against us if they assert that we have overcharged the program or failed to comply with program requirements. Home health providers are subject to pre- and post-payment reviews for compliance with Medicare coverage guidelines and medical necessity. Adjustments on this basis may include individual claims adjustments or overpayment determinations based on an extrapolated sample of claims. Medical necessity reviews evaluate whether services are clinically appropriate in terms of frequency, type, extent, site and duration. Technical billing and documentation reviews focus on documentation of services. Medicare and other payors may reject or deny claims for payment if the underlying documentation does not support the medical necessity of services or fails to establish satisfaction of a coverage rule, such as if a provider is unable to perform periodic therapy assessments required by coverage criteria or cannot provide appropriate billing documentation, acceptable physician authorizations or face-to-face meeting documentation.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare can reopen previously filed and reviewed claims and deny coverage of the services and require us to repay any overcharges, as well as make deductions from future amounts due to us. In the ordinary course of business, we appeal the Medicare and Medicaid program's denial of claims that we believe are inappropriate in an effort to recover the denied claims.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Home Health Non-Medicare</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments from non-Medicare payors are either a percentage of Medicare rates, per-visit rates or case rates depending upon the terms and conditions established with such payors. Reimbursements from our non-Medicare payors that are based on Medicare rates are paid in a similar manner and subject to the same adjustments as discussed above for Medicare; however, these rates can vary based upon negotiated terms which generally range from 95% to 100% of Medicare rates. Approximately 30% of our managed care contract volume affords us the opportunity to receive additional payments if we achieve certain quality or process metrics as defined in each contract (e.g. star ratings and acute-care hospitalization rates).</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Medicare</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare hospice benefit is available when a physician and specific clinical findings support a diagnosis of a terminal condition where the patient has a terminal diagnosis of six months or less. Hospice care is evaluated in benefit periods: two 90-day benefit periods followed by an unlimited number of 60-day benefit periods. Payments are based on daily rates for each day a beneficiary is enrolled in the hospice benefit. Payments are made according to a fee schedule that has four different levels of care: routine home care, continuous home care, inpatient respite care and general inpatient care. The daily payment rates are intended to cover costs that hospices incur in furnishing services identified in patients' care plans, based on specific levels of care. Payments are adjusted by a wage index to reflect health care labor costs across the country and are established annually through federal legislation. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare payments include two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, Medicare also reimburses for a service intensity add-on (&#8220;SIA&#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments for eligibility and technical billing requirements may be made to Medicare revenue based on the same claims processing reviews described above for home health services when we find we are unable to obtain appropriate billing documentation, authorizations or face-to-face documentation and other reasons unrelated to credit risk.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Two caps limit the amount of payment that any individual hospice provider number can receive in a single year. Generally, each hospice care center has its own provider number; however, where we have created branch care centers to help our parent care centers serve a geographic location, the parent and branch have the same provider number. </span></div><div style="margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Inpatient Cap: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inpatient cap limits the number of days of inpatient care an agency may provide to not more than 20 percent of its total patient care days. The daily Medicare payment rate for any inpatient days of service that exceed the cap is set at the routine home care rate, and the provider is required to reimburse Medicare for any amounts it receives in excess of the cap.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Overall Payment Cap: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The overall payment cap is an absolute dollar limit on the average annual payment per beneficiary a hospice agency can receive. This cap is calculated by the Medicare Administrative Contractor at the end of each hospice cap period to determine the maximum allowable payments per provider number. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate our potential cap exposure using information available for both inpatient day limits as well as per beneficiary cap amounts. The total cap amount for each provider is calculated by multiplying the number of beneficiaries electing hospice care during the period by a statutory amount that is indexed for inflation.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment rates for hospice care, the hospice cap amount and the hospice wage index are updated annually according to Section 1814(i)(1)(C)(ii)(VII) of the Social Security Act ("SSA"), which requires CMS to use the inpatient hospital market basket, adjusted for multifactor productivity and other adjustments as specified in the SSA, to determine the hospice payment update percentage. The caps are subject to annual and retroactive adjustments, which can cause providers to be required to reimburse the Medicare program if such caps are exceeded. Our ability to stay within these caps depends on a number of factors, each determined on a provider number basis, including the average length of stay and mix in level of care.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Non-Medicare</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-Medicare payors pay at rates that differ from established Medicare rates for hospice services, and are based on separate, negotiated agreements. We bill and are paid by these non-Medicare payors based on such negotiated agreements.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Personal Care</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personal care payments are received from payor clients, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers, based on rates that are either contractual or fixed by legislation.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">High Acuity Care</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">High acuity care payments are derived from health insurance plans, health system partners and Medicare and non-Medicare home health payors. Contracts with health insurance plans provide for fixed payment rates for a 30-day or 60-day episode of care indexed to assigned patient diagnoses in return for our obligation to assume risk for the coordination and payment of required medical services necessary to treat the medical condition for which the patient was diagnosed in a home-based setting. Contracts with health system partners provide for payments on a per diem basis at the contracted rate for each day during the remainder of an inpatient acuity stay serviced at the patient's home. Payments for home health services are similar to those described above. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contracted payment rates with health insurance plans and health system partners are developed by our medical economics team using historical claims and inpatient admission data provided by the respective health insurance plan or health system partner. The data includes medical costs incurred outside of a patient&#8217;s historical inpatient stay that may be expected to continue under our program and an estimate of the cost of the medical services under our program which will replace the patient&#8217;s inpatient hospital stay. We mitigate the risk of excessive program medical costs by ensuring that we enroll eligible members into the plan, by effectuating clinically effective plans of care and by ensuring that all covered services are related to the condition for which the patient was admitted to the program. Additionally, we have purchased episodic stop-loss insurance for certain payor contracts. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Controls Over Our Business System Infrastructure</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We establish and maintain processes and controls over coding, clinical operations, billing, patient recertifications and compliance to help monitor and promote adherence with Medicare requirements.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Coding &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Specified international classification of disease ("ICD") diagnosis codes are assigned to each of our patients based on their particular health conditions (such as diabetes, coronary artery disease or congestive heart failure). Because coding regulations are complex and are subject to frequent change, we maintain controls surrounding our coding process. To reduce the associated risk of coding failures, we provide annual update training to clinical managers, as needed training to care center directors and clinical managers and training during orientation for new employees to ensure accurate information is gathered and provided to our coding team. In addition, our electronic medical records system (Homecare Homebase) includes automated edits for home health and hospice based on pre-defined compliance metrics. For home health, we also provide monthly specialized coding education, obtain outside expert coding instruction and have certified coders review all patient outcome and assessment information sets (&#8220;OASIS&#8221;) and assign the appropriate ICD code. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Clinical Operations &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We provide education on coverage criteria and conditions of participation and utilize outside expert regulatory services if necessary. Regulatory requirements allow patients to be eligible for home health care benefits if through a face-to-face visit with a physician or a qualified non-physician practitioner, they are considered homebound and it is determined that skilled nursing, physical therapy or speech therapy services are required. These clinical services may include: educating the patient about their disease, assessment and observation of disease status, delivery of clinical skills such as wound care, administration of injections or intravenous medications, management and evaluation of a patient&#8217;s plan of care, physical therapy services to assist patients with functional limitations and speech therapy services for speech or swallowing disorders. Patients eligible for hospice care are terminally ill (with a life expectancy of six months or less if the illness runs its normal course). Our hospice program provides care and support to our terminally ill patients with a 6-month prognosis and their families through services including medical care, counseling, spiritual care, pre-bereavement and bereavement support, medication management and needed equipment and supplies for the terminal illness and all related conditions. Our high acuity care clinical protocols include utilization of the Milliman Clinical Guidelines ("MCG") criteria to ensure that patients are eligible for inpatient level care, in-person evaluations by hospital-based physicians to determine the patient's clinical eligibility for home-based inpatient care, social and behavioral assessments to determine safety of the patient's home setting and an informed consent requirement to ensure that the patient and caregivers are comfortable with the delivery of inpatient level care in the home.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Billing &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We maintain controls over our billing processes to help promote accurate and complete billing. Processes and controls have been implemented to ensure that prior to the submission of any bills, the visit/occurrence was completed, documented sufficiently by an appropriate clinician and/or provider, and that the billed claim complies with all regulatory and payor requirements. Examples of process monitoring controls include conducting annual billing compliance testing, user access reviews for billing systems and use of automated daily billing operational indicators. We take prompt corrective action with employees who knowingly fail to follow our billing policies and procedures.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Patient Recertification &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In order to be recertified for an additional home health episode of care, a patient must continue to meet qualifying criteria and have a continuing medical need that requires the skills of a nurse or therapist. Changes in the patient&#8217;s condition may require changes to the patient&#8217;s medical regimen or modified care protocols within the episode of care. The patient&#8217;s progress towards established goals is evaluated prior to recertification. As with the initial episode of care, a recertification requires orders from the patient&#8217;s physician. Before any employee recommends recertification to a physician, we conduct a care center level, multidisciplinary care team conference. Specific tools are used to ensure that the patient continues to meet coverage criteria prior to recertifying. Hospice recertification for additional benefit periods of care requires continued demonstration of a terminal prognosis as determined by the hospice physician in collaboration with the attending physician and the interdisciplinary care team.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Compliance &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We develop, implement and maintain ethics and compliance programs as a component of the centralized corporate services provided to our home health, hospice, personal care and high acuity-care service lines. Our ethics and compliance program includes a Code of Conduct for our employees, officers, directors, contractors and affiliates and a disclosure program for reporting regulatory or ethical concerns to our compliance team through a confidential hotline, which is augmented by exit surveys of departing employees. We promote a culture of compliance within our company through educational presentations, regular newsletters and persistent messaging from our senior leadership to our employees stressing the importance of strict compliance with legal requirements and company policies and procedures.&#160;Additionally, we have mandatory compliance training and testing for all new employees upon hire and annually for all staff thereafter. We also maintain a robust compliance audit program focusing on key risk areas.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Regulatory Environment</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly regulated by federal, state and local authorities. The healthcare industry is subject to numerous laws, regulations and rules including, among others, those related to government healthcare participation requirements, various licensure and accreditations, reimbursement for patient services, health information privacy and security rules and Medicare and Medicaid fraud and abuse prohibitions (including, but not limited to, federal statutes and regulations prohibiting kickbacks and other illegal inducements to potential referral sources, self-referrals by physicians and false claims submitted to federal health care programs). Regulations and policies frequently change, and we monitor changes through our internal government affairs department, as well as multiple trade and governmental publications and associations. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our home health and hospice subsidiaries are certified by CMS and therefore are subject to the rules and regulations of the Medicare system. Additionally, all of our business lines are subject to federal, state and local laws and regulations dealing with issues such as occupational safety, employment, medical leave, insurance, civil rights, discrimination, building codes, data privacy, data security and recordkeeping. We have set forth below a discussion of the regulations that we believe most significantly affect our businesses.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensure, Certificates of Need ("CON") and Permits of Approval ("POA")</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Home health and hospice care centers operate under licenses granted by the health authorities of their respective states. Some states require health care providers (including hospice and home health agencies) to obtain prior state approval for the purchase, construction or expansion of health care locations, capital expenditures exceeding a prescribed amount, or changes in services. Additionally, certain states, including a number in which we operate, carefully restrict new entrants into the market based on demographic and/or demonstrative usage of additional providers. These states limit the entry of new providers or services and the expansion of existing providers or services in their markets through a CON or POA process, which is periodically evaluated and updated as required by applicable state law. For those states that require a CON or POA, the provider must complete a separate application process establishing a location and must receive required approvals.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent a CON, POA or other similar approvals are required to expand our operations, our expansion could be adversely affected by the inability to obtain the necessary approvals, changes in the standards applicable to those approvals and possible delays and expenses associated with obtaining those approvals. In some instances, other providers in the market may file opposition to a CON or POA application and this could further delay an approval.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In every state where required, our care centers possess a license and/or a CON or POA issued by the state health authority that determines the local service area for the home health or hospice care centers. Currently, state health authorities in 17 states and the District of Columbia require a CON or, in the State of Arkansas, a POA, in order to establish and operate a home health care center, and state health authorities in 12 states and the District of Columbia require a CON to operate a hospice care center.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate 231 home health care centers and 47 hospice care centers in the following CON/POA states as listed below.</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.976%"><tr><td style="width:1.0%"></td><td style="width:42.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.183%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.183%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Home Health</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hospice</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alabama</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arkansas (POA)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Georgia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kentucky</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maryland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mississippi</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Jersey</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North Carolina</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Carolina</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tennessee</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Washington</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">West Virginia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Washington, DC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Care Centers in CON/POA States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47</span></td></tr></table></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medicare Participation: Licensing, Certification and Accreditation</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our care centers must comply with regulations promulgated by the United States Department of Health and Human Services ("HHS") and CMS in order to participate in the Medicare program and receive Medicare payments. Sections 1861(o) and 1891 of the SSA, 42 CFR 484.1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">et seq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., establish the conditions that a home health agency ("HHA") must meet in order to participate in the Medicare program. Section 1861(dd) of the SSA, 42 CFR 418.1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">et seq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., establishes the conditions that a hospice provider must meet in order to participate in the Medicare program. Among other things, these regulations, applicable to HHAs and hospices, respectively, known as conditions of participation and/or conditions of payment (&#8220;COPs&#8221;), relate to the type of facility, its personnel and its standards of medical care, as well as its compliance with federal, state and local laws and regulations. Additional COPs applicable to HHAs focus on the safe delivery of quality care provided to patients and the impact of that care on patient outcomes through the protection and promotion of patients' rights, care planning, delivery and coordination of services and streamlining of regulatory requirements. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS has adopted alternative sanction enforcement options which allow CMS (i) to impose temporary management, direct plans of correction or direct training and (ii) to impose payment suspensions and civil monetary penalties in each case on providers out of compliance with the COPs. CMS engages or has engaged a number of third party contractors, including Recovery Audit Contractors (&#8220;RACs&#8221;), Program Safeguard Contractors (&#8220;PSCs&#8221;), Zone Program Integrity Contractors (&#8220;ZPICs&#8221;), Uniform Program Integrity Contractors ("UPICs"), Medicaid Integrity Contractors (&#8220;MICs&#8221;) and Supplemental Medical Review Contractors (&#8220;SMRCs&#8221;), to conduct extensive reviews of claims data and state and federal government health care program laws and regulations applicable to healthcare providers. These audits evaluate the appropriateness of billings submitted for payment. In addition to identifying overpayments, audit contractors can refer suspected violations of law to government enforcement authorities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All providers are subject to compliance with various federal, state and local statutes and regulations in the United States and receive periodic inspection by state licensing agencies to review standards of medical care, equipment and safety. We have dedicated internal resources and utilize external parties when necessary to monitor and ensure compliance with the various applicable federal, state and local laws, rules and regulations, as well as requirements of applicable accrediting organizations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with applicable laws and regulations, we could be subjected to liabilities, including criminal penalties, civil penalties (including the loss of our licenses to operate one or more of our businesses) and/or exclusion of a facility from participation in the Medicare, Medicaid and other federal and state health care programs. If any of our facilities were to lose its accreditation or otherwise lose its certification under the Medicare and Medicaid programs, the facility would be unable to receive reimbursement from the Medicare and Medicaid programs and other payors until it gains recertification or accreditation. We believe our facilities are in substantial compliance with current applicable federal, state, local and independent review body regulations and standards. The requirements for licensure, certification and accreditation are subject to change and, in order to </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">remain qualified, it may become necessary for us to make changes in our facilities, equipment, personnel and services in the future, which could have a material adverse impact on our operations.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Federal and State Anti-Fraud and Abuse Laws and Regulations</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a provider under the Medicare and Medicaid programs, we are subject to various anti-fraud and abuse laws, including the Anti-Kickback Statute, the Stark or Physician Self-Referral Law, the False Claims Act, Civil Monetary Penalties Law and various state anti-fraud and abuse laws. These laws govern any health care plans or programs that are funded by the United States government (other than certain federal employee health insurance benefits/programs), as well as certain state health care programs that receive federal funds, such as Medicaid. Our compliance and ethics program is designed to ensure Amedisys meets all applicable federal and state laws and regulations as well as industry standards. </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Federal Anti-Kickback Statute ("AKS")</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions, the federal AKS prohibits any offer, payment, solicitation or receipt of any form of remuneration to induce or reward the referral of business payable under a government health care program or in return for the purchase, lease, order, arranging for, or recommendation of items or services covered under a government health care program. The law also forbids the offer or transfer of anything of value, including certain waivers of co-payment obligations and deductible amounts, to a beneficiary of Medicare or Medicaid that is likely to influence the beneficiary&#8217;s selection of health care providers, again, subject to certain safe harbor exceptions. Violations of the federal AKS can trigger the False Claims Act and Civil Monetary Penalties Law, potentially resulting in civil fines up to $25,076 for each violation, penalties of up to $112,131 (last updated 2022) plus three times the amount of the improper remuneration, imprisonment and potentially, exclusion from furnishing services under any government health care program. There are also criminal penalties under the AKS, and providers found to be in violation of the federal AKS can be excluded from participation in the federal health care programs.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stark or Physician Self-Referral Law</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Stark Law, also known as the Physician Self-Referral Law, prohibits physicians from referring Medicare and Medicaid patients to entities for the provision of designated health services with which they or any of their immediate family members have a direct or indirect financial relationship, unless an exception to the law's prohibition is met. Sanctions for violating the Stark Law include penalties of up to $27,750 for each violation and up to $185,009 (last updated 2022) for schemes to circumvent the Stark Law restrictions. There are a number of exceptions to the self-referral prohibition, including employment contracts and leases, that may be used so long as the arrangement adheres to certain enumerated requirements. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of the Stark Law may also result in payment denials, False Claims Act scrutiny, additional civil monetary penalties and federal program exclusion.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The False Claims Act</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal False Claims Act ("FCA") prohibits false claims or requests for payment for health care services. Under the FCA, the government may penalize any person who knowingly submits, or participates in submitting, claims for payment to the Federal Government which are false or fraudulent, or which contain false or misleading information. Any person who knowingly makes or uses a false record or statement to avoid paying the Federal Government, or knowingly conceals or avoids an obligation to pay money to the Federal Government, may also be subject to fines under the FCA. Under the FCA, the term &#8220;person&#8221; means an individual, company or corporation. The term "knowingly" means the person (i) has actual knowledge of the information; (ii) acts in deliberate ignorance of the truth or falsity of the information; or (iii) acts in reckless disregard of the truth or falsity of the information.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Federal Government has used the FCA to prosecute Medicare and other governmental program fraud in areas such as violations of the federal Anti-Kickback Statute or the Stark Laws, coding errors, billing for services not provided and submitting false cost reports. The FCA has also been used to prosecute people or entities that bill services at a higher reimbursement rate than is allowed and that bill for care that is not medically necessary. In addition to government enforcement, the FCA authorizes private citizens to bring qui tam or &#8220;whistleblower&#8221; lawsuits, greatly extending the practical reach of the FCA. The per-claim penalty range is between $23,607 and $25,076 (last updated 2022).</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Fraud Enforcement and Recovery Act of 2009 (&#8220;FERA&#8221;) amended the FCA with the intent of enhancing the powers of government enforcement authorities and whistleblowers to bring FCA cases. In particular, FERA attempts to clarify that liability may be established not only for false claims submitted directly to the government, but also for claims submitted to government contractors and grantees. FERA also seeks to clarify that liability exists for attempts to avoid repayment of overpayments, including improper retention of federal funds. FERA also included amendments to FCA procedures, expanding </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the government&#8217;s ability to use the Civil Investigative Demand process to investigate defendants, and permitting government complaints and intervention to relate back to the filing of the whistleblower&#8217;s original complaint. FERA is likely to increase both the volume and liability exposure of FCA cases brought against health care providers.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Patient Protection and Affordable Care Act (enacted in 2010), Congress enacted requirements related to identifying and returning overpayments made under Medicare and Medicaid. CMS finalized regulations regarding this so-called &#8220;60-day rule,&#8221; which requires providers to report and return Medicare and Medicaid overpayments within 60 days of identifying the overpayment. A provider who retains identified overpayments beyond 60 days may be liable under the FCA. &#8220;Identification&#8221; occurs when a person &#8220;has, or should have through the exercise of reasonable diligence,&#8221; identified and quantified the amount of an overpayment. The final rule also established a six-year lookback period, meaning overpayments must be reported and returned if a person identifies the overpayment within six years of the date the overpayment was received. Providers must report and return overpayments even if they did not cause the overpayment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the FCA, the Federal Government may use several criminal statutes to prosecute the submission of false or fraudulent claims for payment to the Federal Government. Many states have similar false claims statutes that impose liability for the types of acts prohibited by the False Claims Act. As part of the Deficit Reduction Act of 2005 (the &#8220;DRA&#8221;), Congress provides states an incentive to adopt state false claims acts consistent with the federal FCA. Additionally, the DRA requires providers who receive $5&#160;million or more annually from Medicaid to include information on federal and state false claims acts, whistleblower protections and the providers&#8217; own policies on detecting and preventing fraud in their written employee policies.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Civil Monetary Penalties Law</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HHS may impose civil monetary penalties ("CMP") for a variety of civil offenses related to federal health care programs. They may be imposed upon any person or entity who presents, or causes to be presented, certain ineligible claims for medical items or services, for providing improper inducements to beneficiaries to obtain services, for payments to limit services to patients, and for offenses related to relationships with excluded individuals, among other things. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maximum CMP amounts increased in 2022. For example, the penalty for knowing and willful solicitation, receipt, offer or payment of remuneration for referring an individual for a service or for purchasing, leasing or ordering an item to be paid for by a federal health care program increased from $105,563 to $112,131, and the CMP for beneficiary inducement increased from $21,113 to $22,427 per occurrence. </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">State Laws</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to federal laws, some states in which we operate generally have laws that prohibit kickbacks in exchange for referrals, certain direct or indirect payments or fee-splitting arrangements between health care providers, improper physician referrals, beneficiary inducements and false or improperly billed claims. The available guidance and enforcement activity associated with such state laws vary considerably, but in some cases may be stricter than federal law.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Federal and State Privacy and Security Laws</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Insurance Portability and Accountability Act of 1996 ("HIPAA") requires us to comply with standards for the exchange of health information within our company and with third parties, such as payors, business associates and patients. These include standards for common health care transactions, such as claims information, plan eligibility, payment information and the use of electronic signatures; unique identifiers for providers, employers, health plans and individuals; and security, privacy, breach notification and enforcement.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The HIPAA transaction regulations establish form, format and data content requirements for most electronic health care transactions, such as health care claims that are submitted electronically. The HIPAA privacy regulations establish comprehensive requirements relating to the use and disclosure of protected health information. The HIPAA security regulations establish minimum standards for the protection of protected health information that is stored or transmitted electronically. The HIPAA breach notification regulations establish the applicable requirements for notifying individuals, HHS and the media in the event of a data breach affecting protected health information. Violations of the privacy, security and breach notification regulations are punishable by civil and criminal penalties.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, civil monetary penalties for HIPAA violations can range from $127 per violation to a maximum fine of $1.919 million for multiple violations of the same provision during a calendar year. To date, the largest penalty imposed by HHS following a data breach is $16 million. State attorneys general may also bring civil enforcement actions under HIPAA, and attorneys general are actively engaged in enforcement. These penalties could be in addition to other penalties assessed by a state for a breach which would be considered reportable under a particular state&#8217;s data breach notification laws.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recent changes to HIPAA have stimulated increased enforcement activity and enhanced the potential that health care providers will be subject to financial penalties for violations of HIPAA. In addition, the Secretary of HHS is required to perform periodic audits to ensure covered entities (and their business associates, as that term is defined under HIPAA) comply with the applicable HIPAA requirements, increasing the likelihood that a HIPAA violation will result in an enforcement action. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the federal HIPAA regulations, most states also have laws that protect the confidentiality of health information and other personally identifiable information, and these laws may be broader in scope with respect to protected health information and other personal information than HIPAA. Some of these laws grant individuals rights with respect to personal information. We may be required to expend significant resources to comply with these laws. Further, all 50 states and the District of Columbia have adopted data breach notification laws that impose, in varying degrees, an obligation to notify affected persons and/or state regulators in the event of a data breach or compromise, including when their personal information has or may have been accessed by an unauthorized person. Some state breach notification laws may also impose physical and electronic security requirements regarding the safeguarding of personal information, such as social security numbers and bank and credit card account numbers. Violation of state privacy, security and breach notification laws can trigger significant monetary penalties. In addition, certain states&#8217; privacy, security and data breach laws, including, for example, the California Consumer Privacy Act, as amended by the California Privacy Rights Act, include private rights of action that may expose us to private litigation regarding our privacy practices and significant damages awards or settlements in civil litigation.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Food and Drug Administration ("FDA") Regulation</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA regulates medical device user facilities, which include home health care providers. FDA regulations require user facilities to report patient deaths and serious injuries to the FDA and/or the manufacturer of a device used by the facility if the device may have caused or contributed to the death or serious injury of any patient. FDA regulations also require user facilities to maintain files related to adverse events and to establish and implement appropriate procedures to ensure compliance with the above reporting and recordkeeping requirements. User facilities are subject to FDA inspection, and noncompliance with applicable requirements may result in warning letters or sanctions including civil monetary penalties, injunction, product seizure, criminal fines and/or imprisonment.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Improving Medicare Post-Acute Care Transformation Act</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2014, the Improving Medicare Post-Acute Care Transformation Act (&#8220;IMPACT Act&#8221;)&#160;was signed into law requiring the reporting of standardized patient assessment data for quality improvement, payment and discharge planning purposes across the spectrum of post-acute care providers (&#8220;PACs&#8221;), including skilled nursing facilities and home health agencies. The IMPACT Act requires PACs to report: (1)&#160;standardized patient assessment data at admission and discharge; (2) quality measures, including functional status, skin integrity, medication reconciliation, incidence of major falls and patient preference regarding treatment and discharge; and (3)&#160;resource use measures, including Medicare spending per beneficiary, discharge to community and hospitalization rates of potentially preventable readmissions. Failure to report such data when required would subject a facility to a two percent reduction in market basket prices then in effect.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IMPACT Act further requires HHS and the Medicare Payment Advisory Commission (&#8220;MedPAC&#8221;), a commission chartered by Congress to advise it on Medicare payment issues, to study alternative PAC payment models, including payment based upon individual patient characteristics and not care setting, with corresponding Congressional reports required based on such analysis. The IMPACT Act also includes provisions impacting Medicare-certified hospices, including: (1)&#160;increasing survey frequency for Medicare-certified hospices to once every 36 months; (2)&#160;imposing a medical review process for facilities with a high percentage of stays in excess of 180 days; and (3)&#160;updating the annual aggregate Medicare payment cap.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Review Choice Demonstration for Home Health Services</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS's Review Choice Demonstration for Home Health Services ("RCD") gives HHAs in the demonstration states three options: pre-claim review of all claims, post-payment review of all claims, or minimal post-payment review with a 25% payment reduction for all home health services. Under the pre-claim review and post-payment review options, provider claims are reviewed for every episode of care until the appropriate claim approval rate (90% based on a minimum of ten pre-claim requests or claims submitted) is reached. Further, once the appropriate claim approval rate is reached, a provider can elect to opt-out of claim reviews except for a spot check of 5% of its claims to ensure continued compliance. Amedisys has elected the pre-claim review option. The demonstration initially applies to HHA providers in Florida, Illinois, North Carolina, Ohio and Texas, with the option to expand after five years to other states in the Medicare Administrative Contractor Jurisdiction M (Palmetto). After several delays, RCD has been fully implemented in all five states as of April 1, 2022.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Home Health Value-Based Purchasing</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2016, CMS implemented Home Health Value-Based Purchasing ("HHVBP"). The HHVBP model was designed to give Medicare-certified home health agencies incentives or penalties, through payment bonuses, to provide higher quality and more efficient care. HHVBP was rolled out to nine pilot states: Arizona, Florida, Iowa, Maryland, Massachusetts, Nebraska, North Carolina, Tennessee and Washington, eight of which Amedisys currently has home health operations.&#160;Bonuses and penalties began in 2018 with the maximum of plus or minus 3% growing to plus or minus 8% by 2022.&#160;Payment adjustments were calculated based on performance in a variety of measures which included Quality of Patient Care and Patient Satisfaction star measures, as well as measures based on submission of data to a CMS web portal. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the demonstration, agencies with higher performance received bonuses, while those with lower scores received lower payments relative to current levels. Agency performance was evaluated against separate improvement and attainment scores, with payment tied to the higher of these two scores. CMS used 2015 as the baseline year for performance, with 2016 as the first year for performance measurement. The first payment adjustment began January 1, 2018, based on 2016 performance data. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, CMS and the Center for Medicare and Medicaid Innovation announced its intention, through rulemaking, to expand HHVBP with an implementation date no earlier than January 2022. In November 2021, CMS issued the Calendar Year 2022 Home Health Final Rule for Medicare home health providers which provided for the expansion of the HHVBP model to all 50 states beginning January 1, 2023 with calendar year 2023 being the first performance year and calendar year 2025 being the first payment year with a proposed maximum payment adjustment, up or down, of 5%. In doing so, the final payment year of the HHVBP demonstration (2022) was cancelled.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Home Health Payment Reform</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 9, 2018, Congress passed the Bipartisan Budget Act of 2018 ("BBA of 2018"), which provided for a targeted extension of the home health rural add-on payment, a reduction of the 2020 market basket update, modification of eligibility documentation requirements and reform to the Home Health Prospective Payment System ("HHPPS"). The HHPPS reform included the following parameters: for home health units of service beginning on January 1, 2020, a 30-day payment system was to be applied; the transition to the 30-day payment system was to be budget neutral; and CMS was to conduct at least one Technical Expert Panel during 2018, prior to any notice and comment rulemaking process, related to the design of any new case-mix adjustment model.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Calendar Year 2019 Home Health Final Rule updated the Medicare HHPPS and finalized the implementation of an alternative case-mix adjustment methodology, PDGM, which became effective on January 1, 2020. PDGM adjusted payments to home health agencies based on patient characteristics for 30-day periods of care and also eliminated the use of therapy visits in the determination of payments. While the changes were to be implemented in a budget neutral manner to the industry, the ultimate impact varied by provider based on factors including patient mix and admission source. Additionally, CMS made assumptions about behavioral changes which were finalized in the Calendar Year 2020 Home Health Final Rule released on October 31, 2019 and resulted in a 4.36% reduction to reimbursement. The behavioral changes were related to coding practices, low utilization payment adjustment ("LUPA") management and co-morbidities. CMS is required by law to analyze data for calendar years 2020-2026, retrospectively, to determine the impact of the difference between assumed and actual behavior changes and to make any such payment changes as are necessary to offset or supplement the adjustments based on anticipated behavior. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in an effort to eliminate fraud risks, CMS reduced the upfront payment associated with requests for anticipated payment ("RAPs") to 20% in 2020 with the full elimination of RAPs in 2021. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2022, CMS issued the Home Health Final Rule for Medicare home health providers for calendar year 2023. CMS estimates that the final rule will result in a 0.7% increase in payments to home health providers. This increase is the result of a 4.0% payment update (4.1% market basket adjustment less a 0.1% productivity adjustment) and an increase of 0.2% for the update to the fixed-dollar loss ratio used in determining outlier payments offset by a permanent adjustment of -3.5% based on the difference between assumed and actual behavioral changes resulting from the implementation of PDGM. The -3.5% permanent adjustment is derived from a -3.925% behavioral assumption adjustment. In the Calendar Year 2023 Preliminary Rule, CMS proposed a behavioral assumption adjustment of -7.69%. CMS revised the adjustment to -7.85% in the final rule and also reduced it by half (to -3.925%) in order to mitigate such a significant reduction to reimbursement in a single year. The remaining -3.925% behavioral assumption adjustment will be considered in future rulemaking. The final rule also finalizes a permanent 5% cap on negative wage index changes for home health agencies. Based on our analysis of the final rule, we expect our impact to be flat, which is less than the estimated 0.7% rate increase.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the permanent adjustments, CMS is also considering a temporary adjustment of approximately $2 billion to offset overpayments in calendar years 2020 and 2021. CMS has elected not to apply the temporary adjustment to calendar year 2023; however, CMS is still considering how to best apply the adjustment in future rulemaking. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase-Out of the Rural Add-On</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BBA of 2018 also mandated the implementation of a new methodology for applying rural add-on payments for home health services (&#8220;rural add-on&#8221;). Unlike previous rural add-ons, which were applied to all rural areas uniformly, the extension provided varying add-on amounts depending on the rural county (or equivalent area) classification by classifying each rural county (or equivalent area) into one of three distinct categories: (1) rural counties and equivalent areas in the highest quartile of all counties and equivalent areas based on the number of Medicare home health episodes furnished per 100 individuals who are entitled to, or enrolled for, benefits under Part A of Medicare or enrolled for benefits under Part B of Medicare only, but not enrolled in a Medicare Advantage plan under Part C of Medicare (the "high utilization" category); (2) rural counties and equivalent areas with a population density of 6 individuals or fewer per square mile of land area that are not included in the "high utilization" category (the "low population density" category); and (3) rural counties and equivalent areas not in either the "high utilization" or "low population density" categories (the "all other" category).</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Calendar Year ("CY") 2019 Home Health Final Rule, CMS finalized policies for the rural add-on payments for CY 2019 through CY 2022, in accordance with section 50208 of the BBA of 2018. The CY 2019 through CY 2022 rural add-on percentages outlined in the rule are shown in the table below.</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rural Add-On Percentages, CYs 2019-2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Category</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CY 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CY 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CY 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CY 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">High utilization</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Low population density</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td></tr></table></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental and Climate Change Matters</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to transparency around our environmental footprint and climate-related risks and opportunities. We have adopted an integrated approach to address the impacts of climate change on our business, with cross-disciplinary teams responsible for managing climate-related activities, initiatives and policies. Strategies and progress toward our goals are reviewed with senior leadership and the Nominating and Corporate Governance Committee of our Board of Directors. During 2022, we engaged a third party expert to conduct our inaugural greenhouse gas (&#8220;GHG&#8221;) emissions inventory. We will establish interim GHG targets covering Scope 1 and 2 emissions in line with the Paris Agreement&#8217;s 1.5&#176;C emissions reduction goal and report all relevant Scope 3 emissions and a timeline for establishing Scope 3 GHG reduction targets by December 31, 2023. Additional information about our environmental and climate activities can be found in our annual Environmental, Social and Governance Report, which is available on our website. For more information regarding climate change and its possible adverse impact on us, see &#8220;Item 1A. Risk Factors &#8212; Risks Related to Our Operations &#8212; Our operations could be impacted by war, terrorism, natural or man-made disasters and climate change&#8221; in this Annual Report on Form 10-K.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Competitors</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are few barriers to entry in the home health and hospice jurisdictions that do not require a CON or POA.&#160;Our primary competition in these jurisdictions comes from local privately and publicly-owned and hospital-owned health care providers.&#160;We compete based on the quality of services, the availability of personnel, expertise of visiting staff, and, in certain instances, on the price of our services.&#160;In addition, we compete with a number of non-profit organizations that finance acquisitions and capital expenditures on a tax-exempt basis or receive charitable contributions that are unavailable to us.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our company website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.amedisys.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We use our website as a channel of distribution for important company information. Important information, including press releases, analyst presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled &#8220;Investors&#8221; on our website home page. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website. In addition, we make available on the Investor Relations subpage of our website (under the link &#8220;SEC Filings&#8221;), free of charge, our annual reports on Form&#160;10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, ownership reports on Forms 3, 4 and 5 and any amendments to those reports as soon as reasonably practicable after we electronically file or furnish such reports with the Securities and Exchange Commission ("SEC"). Further, copies of our Certificate of Incorporation and Bylaws, our Code of Ethical Business Conduct, our Corporate Governance Guidelines and the charters for the Audit, Compensation, Quality of Care, Compliance and Ethics and Nominating and Corporate Governance Committees of our Board are also available on the Investor Relations subpage of our website (under the link &#8220;Governance&#8221;). Reference to our website does not constitute incorporation by reference of the information contained on the website and should not be considered part of this document.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our electronically filed reports can also be obtained on the SEC&#8217;s internet site at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">http://www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i5c10b724a6674979bf3c35a339f29685_19"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.  RISK FACTORS</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The risks described below, and risks described elsewhere in this Form 10-K, could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows and the actual outcome of matters as to which forward-looking statements are made in this Form&#160;10-K. The risk factors described below and elsewhere in this Form 10-K are not the only risks faced by Amedisys. Our business and consolidated financial condition, results of operations and cash flows may also be materially adversely affected by factors that are not currently known to us, by factors that we currently consider immaterial or by factors that are not specific to us, such as general economic conditions.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If any of the following risks are actually realized, our business and consolidated financial condition, results of operations and cash flows could be materially adversely affected. In that case, the trading price of our common stock could decline.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should refer to the explanation of the qualifications and limitations on forward-looking statements under &#8220;Special Caution Concerning Forward-Looking Statements.&#8221; All forward-looking statements made by us are qualified by the risk factors described below.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Reimbursement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Federal and state changes to reimbursement and other aspects of Medicare and Medicaid could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net service revenue is primarily derived from Medicare, which accounted for 74%, 75% and 75% of our consolidated net service revenue during 2022, 2021 and 2020, respectively. Payments received from Medicare are subject to changes made through federal legislation. When such changes are implemented, we must also modify our internal billing processes and procedures accordingly, which can require significant time and expense. These changes, as further detailed in Part I, Item 1, &#8220;Business: Payment for Our Services,&#8221; can include changes to base payments and adjustments for home health services, changes to cap limits and per diem rates for hospice services and changes to Medicare eligibility and documentation requirements or changes designed to restrict utilization. Any such changes, including retroactive adjustments, adopted in the future by CMS could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 6407 of the Affordable Care Act, as implemented by 42 CFR &#167; 424.22,&#160;added Medicare requirements for face-to-face encounters to support claims for home health services.&#160;The requirements for face-to-face encounters continue to be one of the most complex issues in the industry and can be the source of claims denials if not fulfilled. Section 6407(d) of the Affordable Care Act also provided that the requirements for face-to-face encounters in the provisions described above shall apply in the case of physicians making certifications for home health services under title XIX of the Act (Medicaid) in the same manner and to the same extent as such requirements apply&#160;under title XVIII&#160;(Medicare). </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are continuing efforts to reform governmental health care programs that could result in major changes in the health care delivery and reimbursement system on a national and state level, including changes directly impacting the reimbursement systems for our home health and hospice care centers. The U.S. federal budget is subject to change, and the Medicare program is frequently mentioned as a target for spending cuts. Within the Medicare program, the hospice benefit is often specifically targeted for cuts. The full impact on our business of any future cuts in Medicare or other programs is uncertain. Though we cannot predict what, if any, reform proposals will be adopted, health care reform and legislation may have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows through decreasing payments made for our services.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also be affected adversely by the continuing efforts of governmental payors to contain health care costs. We cannot assure you that reimbursement payments under governmental payor programs, including Medicare supplemental insurance policies, will remain at levels comparable to present levels or will be sufficient to cover the costs allocable to patients eligible for reimbursement pursuant to these programs. Any such changes could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future cost containment initiatives undertaken by private third party payors may limit our future revenue and profitability.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our non-Medicare revenue and profitability are affected by continuing efforts of third party payors to maintain or reduce costs of health care by lowering payment rates, narrowing the scope of covered services, increasing case management review of services and negotiating pricing. There can be no assurance that third party payors will make timely payments for our services, and there is no assurance that we will continue to maintain our current payor or revenue mix. We are continuing our efforts to develop our non-Medicare sources of revenue. Any changes in payment levels from current or future third party payors could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Possible changes in the case mix of patients, as well as payor mix and payment methodologies, could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is determined by a number of factors, including our mix of patients and the rates of payment among payors. Changes in the case mix of our patients, payment methodologies or the payor mix among Medicare, Medicaid and private payors could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to negotiate favorable managed care contracts, or our loss of existing favorable managed care contracts, could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of our strategies is to diversify our payor sources by increasing the business we do with managed care companies. We strive to put in place favorable contracts with managed care payors; however, we may not be successful in these efforts. Additionally, there is a risk that the favorable managed care contracts that we put in place may be terminated. Managed care contracts typically permit the payor to terminate the contract without cause, on very short notice, typically 60 days, which can provide payors leverage to reduce volume or obtain favorable pricing. Our failure to negotiate and put in place favorable managed care contracts, or our failure to maintain in place favorable managed care contracts, could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Quality reporting requirements may negatively impact Medicare reimbursement.</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hospice quality reporting was mandated by the Patient Protection and Affordable Health Care Act and the Health Care and Education Reconciliation Act ("PPACA"), which directs the Secretary to establish quality reporting requirements for hospice programs. Failure to submit required quality data will result in a 2% reduction to the market basket percentage increase for that fiscal year. This quality reporting program is currently &#8220;pay-for-reporting,&#8221; meaning it is the act of submitting data that determines compliance with program requirements.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 1895(b)(3)(B)(v) of the Social Security Act requires the submission of quality data by home health agencies. Failure to submit quality data will result in a 2% reduction in the home health agency's annual home health payment update percentage. This pay-for-reporting requirement was implemented on January 1, 2007. In the Calendar Year 2015 Home Health Final Rule, CMS defined a more explicit &#8220;Pay-for-Reporting Performance Requirement&#8221; by which provider compliance with quality reporting requirements can be measured. In the Calendar Year 2016 Home Health Final Rule, CMS required home health agencies to report prescribed quality assessment data for a minimum of 90% of all patients.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Improving Medicare Post-Acute Care Transformation Act of 2014 (the &#8220;IMPACT Act&#8221;) requires the submission of standardized data by home health agencies and other providers. Specifically, the IMPACT Act requires, among other significant activities, the reporting of standardized patient assessment data with regard to quality measures, resource use and other measures. Failure to report data as required will subject providers to a 2% reduction in market basket prices then in effect.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that all of our agencies will continue to meet quality reporting requirements in the future which may result in one or more of our agencies seeing a reduction in its Medicare reimbursements. Regardless, we, like other healthcare providers, are likely to incur additional expenses in an effort to comply with additional and changing quality reporting requirements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Value-based purchasing may negatively impact Medicare reimbursement.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both government and private payors are increasingly looking to value-based purchasing to contain costs. Value-based purchasing focuses on quality of outcomes and efficiency of care, rather than quantity of care. The first performance year of the expanded value-based purchasing model begins on January 1, 2023, and the model has been expanded to all 50 states. Under the expanded model, home health agencies receive adjustments to their Medicare fee-for-service payments based on their performance against a set of quality measures, relative to their peers' performance. Performance on these quality measures in a specified year (performance year) impacts payment adjustments in a later year (payment year). CMS may also create a similar plan for hospices in the future. Government and private payors&#8217; implementation of value-based purchasing requirements could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any economic downturn, deepening of an economic downturn, continued deficit spending by the Federal Government or state budget pressures may result in a reduction in payments and covered services.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse developments in the United States could lead to a reduction in Federal Government expenditures, including governmentally funded programs in which we participate, such as Medicare and Medicaid. In addition, if at any time the Federal Government is not able to meet its debt payments unless the federal debt ceiling is raised, and legislation increasing the debt ceiling is not enacted, the Federal Government may stop or delay making payments on its obligations, including funding for government programs in which we participate, such as Medicare and Medicaid. Failure of the government to make payments under these programs could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. Further, any failure by the United States Congress to complete the federal budget process and fund government operations may result in a Federal Government shutdown, potentially causing us to incur substantial costs without reimbursement under the Medicare program, which could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. As an example, the failure of the 2011 Joint Select Committee to meet its Deficit Reduction goal resulted in an automatic reduction in Medicare home health and hospice payments of 2% beginning April&#160;1, 2013 ("sequestration" - suspended from May 1, 2020 through March 31, 2022; reinstated at 1% for the period April 1, 2022 through June 30, 2022 and at 2% thereafter).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, state budget pressures have resulted in reductions in state spending. Given that Medicaid outlays are a significant component of state budgets, we can expect continuing cost containment pressures on Medicaid outlays for our services.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, sustained unfavorable economic conditions may affect the number of patients enrolled in managed care programs and the profitability of managed care companies, which could result in reduced payment rates and could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Operations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A shortage of qualified nursing staff and other clinicians, such as therapists and nurse practitioners, could materially impact our ability to attract, train and retain qualified personnel and could increase operating costs.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete for qualified personnel with other healthcare providers. Our ability to attract and retain clinicians depends on several factors, including our ability to provide these personnel with attractive assignments and competitive salaries and benefits. We cannot be assured we will succeed in any of these areas. In addition, there are shortages of qualified health care personnel in some of our markets. As a result, we may face higher costs of attracting clinicians and providing them with more attractive benefit packages than we originally anticipated or we may have to utilize contract clinicians, both of which could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. In addition, if we expand our operations into geographic areas where health care providers historically have been unionized, or if any of our care center employees become unionized, being subject to a collective bargaining agreement may have a negative impact on our ability to timely and successfully recruit qualified personnel and may increase our operating costs. In some circumstances, we may have to hire contract clinicians to fulfill staffing needs, which could increase the risk of an adverse patient event. Generally, if we are unable to attract and retain clinicians, the quality of our services may decline and we could lose patients and referral sources, which could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business may be materially adversely affected by the ongoing COVID-19 pandemic.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outbreak of the COVID-19 pandemic has resulted in a general economic downturn and volatility in the stock market and has also caused and may continue to cause a decrease in our patient volumes and revenues, an increase in our costs, an inability to access our patients and referral sources, staffing shortages and medical supply shortages, any of which, or a combination of which, could have a material adverse effect on our business and financial results. The ultimate impact of COVID-19, including the impact on our liquidity, financial condition and results of operations, is uncertain and will depend on many factors and future developments, which are highly uncertain and cannot be predicted at this time, such as the severity, scope and length of time that the pandemic continues, including regional surges in COVID-19 cases at various times. In addition, the COVID-19 pandemic has resulted in widespread global supply chain disruptions to vendors including critical supply shortages, significant material cost inflation and extended lead times for items that are required for our operations. Continued disruptions could increase our costs and could limit the availability of products critical to our operations. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be more vulnerable to the effects of a public health emergency than other businesses due to the nature of our patient population and the physical proximity required by our operations, which could harm our business disproportionately to other businesses.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our patients are older individuals and/or individuals with complex medical challenges or multiple ongoing diseases, many of whom may be more vulnerable than the general public during a pandemic or in a public health emergency. Our employees are also at greater risk of contracting contagious diseases due to their increased exposure to vulnerable individuals. Our employees could also have difficulty attending to our patients if a program of social distancing or quarantine is instituted in response to a public health emergency. In addition, we may expand existing internal policies in a manner that may have a similar effect. If the virus that causes COVID-19 and its potentially more contagious variants cause an additional resurgence of infections of COVID-19, if new variants that are resistant to government approved COVID-19 vaccinations continue to emerge, or if an influenza or other pandemic were to occur, we could suffer significant losses to our patient population or a reduction in the availability of our employees and caregivers, and we could be required to hire replacements for affected workers at an inflated cost. Accordingly, public health emergencies could have a disproportionate material adverse effect on our financial condition and results of operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we are limited in our ability to control rates received for our services, our business and consolidated financial condition, results of operations and cash flows could be materially adversely affected if we are not able to maintain or reduce our costs to provide such services.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As Medicare is our primary payor and rates are established through federal legislation, we have to manage our costs of providing care to achieve a desired level of profitability. Additionally, non-Medicare rates are difficult for us to negotiate as such payors are under pressure to reduce their own costs. As a result, we manage our costs in order to achieve a desired level of profitability including, but not limited to, centralization of various processes, the use of technology and management of the number of employees utilized. If we are not able to continue to streamline our processes and reduce our costs, our business and consolidated financial condition, results of operations and cash flows could be materially adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to consistently provide high quality of care, our business will be adversely impacted.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Providing quality patient care is the cornerstone of our business. We believe that hospitals, physicians and other referral sources refer patients to us in large part because of our reputation for delivering quality care. Clinical quality is becoming increasingly important within our industry. Medicare imposes a financial penalty upon hospitals that have excessive rates of patient readmissions within 30 days from hospital discharge. We believe this regulation provides a competitive advantage to home health providers who can differentiate themselves based upon quality, particularly by achieving low patient acute care hospitalization readmission rates and by implementing disease management programs designed to be responsive to the needs of patients served by referring hospitals. We are focused intently upon improving our patient outcomes, particularly our patient acute care hospitalization readmission rates. If we should fail to attain our goals regarding acute care hospitalization readmission rates and other quality metrics, we expect our ability to generate referrals would be adversely impacted, which could have a material adverse effect upon our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Medicare has established consumer-facing websites, Home Health Compare and Hospice Compare, that present data regarding our performance on certain quality measures compared to state and national averages. Failure to achieve or exceed these averages may negatively affect our rates of reimbursement and our ability to generate referrals, which could have a material adverse effect upon our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to maintain relationships with existing patient referral sources, our business and consolidated financial condition, results of operations and cash flows could be materially adversely affected.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends on referrals from physicians, hospitals and other sources in the communities we serve and on our ability to maintain good relationships with existing referral sources. Our referral sources are not (and cannot be) contractually obligated to refer patients to us and may refer their patients to other providers. Our growth and profitability depend, in part, on our ability to establish and maintain close working relationships with these patient referral sources and to increase awareness and acceptance of the benefits of home health and hospice care by our referral sources and their patients. Our loss of, or failure to maintain, existing relationships or our failure to develop new referral relationships could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our industry is highly competitive, with few barriers to entry in certain states.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are few barriers to entry in home health and hospice markets that do not require a CON or POA. Our primary competition comes from local privately-owned, publicly-owned and hospital-owned health care providers. We compete based on the availability of personnel, the quality of services, expertise of visiting staff, and in certain instances, on the price of our services. In addition, we compete with a number of non-profit organizations and tax-supported governmental agencies that finance acquisitions and capital expenditures on a tax-exempt or tax-favorable basis or receive charitable contributions that are unavailable to us. Increased competition in the future may limit our ability to maintain or increase our market share.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the introduction of new and enhanced service offerings by others, in combination with industry consolidation and the development of strategic relationships by our competitors (including mergers of competitors with each other and with insurers), could cause a decline in revenue or loss of market acceptance of our services or make our services less attractive. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed care organizations and other third party payors continue to consolidate, which enhances their ability to influence the delivery of health care services. Consequently, the health care needs of patients in the United States are increasingly served by a smaller number of managed care organizations. These organizations generally enter into service agreements with a limited number of providers. Our business and consolidated financial condition, results of operations and cash flows could be materially adversely affected if these organizations terminate us as a provider and/or engage our competitors as a preferred or exclusive provider. In addition, should private payors, including managed care payors, seek to negotiate additional discounted fee structures or the assumption by health care providers of all or a portion of the financial risk through prepaid capitation arrangements, our business and consolidated financial condition, results of operations and cash flows could be materially adversely affected.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to react competitively to new developments, our operating results may suffer. State CON or POA laws often limit the ability of competitors to enter into a given market, are not uniform throughout the United States and are frequently the subject of efforts to limit or repeal such laws. If states remove existing CONs or POAs, we could face increased competition in these states. There can be no assurances that other states will not seek to eliminate or limit their existing CON or POA programs, which could lead to increased competition in these states. Further, we cannot assure you that we will be able to compete successfully against current or future competitors, which could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The success of our high acuity care segment depends on our ability to enter into capitation and other forms of risk-based contracts with managed care health plans. If we are unsuccessful in obtaining these contracts or if we are unsuccessful in managing costs associated with risk-based contracts, our business and consolidated financial condition, results of operations and cash flows could be materially adversely affected.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our acquisition of Contessa not only established the foundation for our high acuity care segment, but it also added key infrastructure to enable us to more quickly and effectively enter into risk-based contracts with managed care health plans. Should our high acuity care joint venture partnerships not deliver sufficient perceived value to managed care health plans, those health plans may limit or forego opportunities to partner with us in expanded risk-based contracts. Additionally, assuming risk from managed care health plans requires that the appropriate clinical and operating protocols be in place to actuarially assess eligible members and determine historical baseline healthcare expenditures, enroll eligible members into the program, effectuate a clinically effective plan of care to treat those patients primarily in a home-based setting and coordinate care throughout various phases of the member&#8217;s treatment including proactive primary care and palliative care services. Should we be ineffective in identifying and enrolling members into the program or should the clinical treatment plans we implement for enrolled members not result in reduced healthcare costs during the period in which those members are enrolled, we could incur significant additional costs under these contracts that exceed the revenues we receive. These negative outcomes could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business depends on our information systems. A cyber-attack, security breach or our inability to effectively integrate, manage and keep our information systems secure and operational could disrupt our operations.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers and health insurance plans must comply with the HIPAA regulations regarding the privacy and security of protected health information. The HIPAA regulations impose significant requirements on providers with regard to how such protected health information may be used and disclosed. Further, the regulations include extensive and complex requirements for providers to establish reasonable and appropriate administrative, technical and physical safeguards to ensure the confidentiality, integrity and availability of protected health information. In the event the provider experiences a "breach" and the personal information is compromised, providers are obligated under HIPAA to notify individuals, the government, and in the event the breach involves 500 or more individuals, the media. HIPAA directs the Secretary of HHS to provide for periodic audits to ensure covered entities (and their business associates, as that term is defined under HIPAA) comply with the applicable HIPAA requirements. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to federal regulators, state attorneys general are also enforcing information security breaches. All 50 states have breach notification laws; some of these laws also include proactive data security requirements. In addition to state laws regarding confidentiality of medical information, several states are now focused on expanding state privacy laws regarding personal information which is more broadly defined than medical information.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our networks, systems and devices store sensitive information, including intellectual property, proprietary business information and personal information of our patients, partners and employees. We have installed privacy protection systems and devices on our network, systems and point of care tablets in an attempt to prevent unauthorized access to information created, received, transmitted and maintained by us. However, in the event of a sophisticated ransomware attack, malware, viruses, phishing, or social engineering, our technology may fail to adequately secure the protected health information and personal information we create, receive, transmit and maintain in our databases. In such circumstances, we may be held liable to our patients and regulators, which could result in fines, litigation or adverse publicity that could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. Even if we are not held liable, any resulting negative publicity could harm our business and distract the attention of management.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business depends on effective, secure and operational information systems which include systems provided by or hosted by external contractors, partners and other service providers. For example, our care centers depend upon our information systems and software for patient care, accounting, billing, collections, risk management, quality assurance, human resources, payroll and other information considered to be sensitive and/or confidential. These third party vendors, or "business associates," comply with substantially the same HIPAA requirements as the healthcare provider. This is accomplished through the use of "Business Associate Agreements" with vendors. We believe that our subcontractors and vendors take precautionary measures to prevent problems that could affect our business operations as a result of failure or disruption to their information systems or networks. However, there is no guarantee such efforts will be successful in preventing a system disruption or security incident. The occurrence of any information system failure, breach or security incident, or a vendor's breach of the Business Associate Agreement could result in interruptions, delays, breaches of protected health information and personal information, loss or corruption of data and cessations or interruptions in the availability of these systems and the information they create, receive, transmit or maintain. All of these events or circumstances, among others, could have an adverse effect on our business and consolidated financial condition, results of operations and cash flows, and they could harm our business reputation.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, all information systems, including those we host or have hosted by third parties, are vulnerable to damage or interruption from fire, flood, power loss, telecommunications failure, human error or malicious acts, break-ins and other intentional or unintentional events. Our business is also at risk from and may be materially impacted and/or disrupted by information security incidents, such as ransomware, malware, viruses, phishing, social engineering and other security events. Such incidents can range from individual attempts to gain unauthorized access to information technology systems to more sophisticated security threats. These events can also result from internal compromises, such as human error or a rogue employee or contractor, and can occur on our systems or on the systems of our partners and subcontractors. Additionally, our current information systems are subject to other non-environmental risks, including technological obsolescence, in some instances, which may create increased security and/or operational risk.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Problems with, or the failure of, our technology and systems or any system upgrades or programming changes associated with such technology and systems could have a material adverse effect on our operations, patient care, data capture and integrity, medical documentation, billing, collections, assessment of internal controls and management and reporting capabilities. If we experience a reduction in the performance, reliability or availability of our information systems, our operations and ability to produce timely and accurate reports could be materially adversely affected.  </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our information systems and applications also require continual maintenance, upgrading and enhancement to meet our operational and security needs. Our acquisition activity requires transitions and integration of various information systems. We regularly upgrade and expand our information systems&#8217; capabilities. If we experience difficulties with the transition and integration of information systems or are unable to implement, maintain or expand our systems properly, we could suffer from, among other things, operational disruptions, regulatory investigations or audits and increases in administrative expenses.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As cyber threats continue to evolve, we may be required to expend significant capital and other resources to protect against the threat of security breaches or to mitigate and alleviate problems caused by security incidents, including unauthorized access to protected health information and personal information stored in our information systems and the introduction of computer viruses or other malicious software programs to our systems. If we don't expend capital and other resources to continually enhance our security systems, our security measures may be inadequate to prevent security breaches and our business operations and reputation could be materially adversely affected by federal and state fines and penalties, legal claims or proceedings, cancellation of contracts and loss of patients if security breaches are not prevented. The healthcare industry is currently a target for cyber criminals and is therefore experiencing increased scrutiny from federal and state regulators with </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respect to compliance with regulations designed to safeguard protected health information and mitigate cyber-attacks. There are significant costs associated with a breach, including investigation costs, remediation and mitigation costs, notification costs, attorney fees, litigation and the potential for reputational harm and lost revenues due to a loss in confidence in the provider. We cannot predict the costs to comply with these laws or the costs associated with a potential breach of protected health information, which could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows, and our business reputation.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are subject to cyber-attacks or security breaches in the future, this could result in harm to patients; business interruptions and delays; the loss, misappropriation, corruption or unauthorized access of data; litigation and potential liability under privacy, security and consumer protection laws or other applicable laws; reputational damage and federal and state governmental inquiries. Any such problems or failures and the costs incurred in correcting any such problems or failures, could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. Further, to the extent our external information technology contractors or other service providers have their own cyber-attack, security event or information technology failure, become insolvent or fail to support the software or systems we have licensed from them, our operations could be materially adversely affected. A failure to restore our information systems after the occurrence of any of these events could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. Because of the protected health information we store and transmit, loss of electronically stored information for any reason could expose us to risk of regulatory action and litigation and possible liability and loss.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have all the necessary licenses from third parties to use technology and software that we do not own. A third party could, however, allege that we are infringing its rights, which may deter our ability to obtain licenses on commercially reasonable terms from the third party, if at all, or cause the third party to commence litigation against us. In addition, we may find it necessary to initiate litigation to protect our trade secrets, to enforce our intellectual property rights and to determine the scope and validity of any proprietary rights of others. Any such litigation, or the failure to obtain any necessary licenses or other rights, could materially and adversely affect our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our insurance liability coverage may not be sufficient for our business needs.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of operating in the home health industry, our business entails an inherent risk of claims, losses and potential lawsuits alleging incidents involving our employees that may occur in a patient&#8217;s home. We maintain professional liability insurance to provide coverage to us and our subsidiaries against these risks. However, we cannot assure you claims will not be made in the future in excess of the limits of our insurance, nor can we assure you that any such claims, if successful and in excess of such limits, will not have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. In some states, state law may prohibit or limit insurance coverage for the risk of punitive damages arising from professional liability and general liability claims and/or litigation. As a result, we may be liable for punitive damage awards in these states that either are not covered or are in excess of our insurance policy limits. Our insurance coverage also includes fire, property damage, cyber security and general liability with varying limits. We cannot assure you that the insurance we maintain will satisfy claims made against us or that insurance coverage will continue to be available to us at commercially reasonable rates, in adequate amounts or on satisfactory terms. Any claims made against us, regardless of their merit or eventual outcome, could damage our reputation and business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to substantial malpractice or other similar claims.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The services we offer involve an inherent risk of professional liability and related substantial damage awards. As of February&#160;10, 2023, we have approximately 20,000&#160;employees (11,200 home health, 5,900 hospice, 1,900 personal care, 200 high acuity care and 1,000 corporate employees). In addition, we employ direct care workers on a contractual basis to support our existing workforce. Due to the nature of our business, we, through our employees and caregivers who provide services on our behalf, may be the subject of medical malpractice claims. A court could find these individuals should be considered our agents, and, as a result, we could be held liable for their acts or omissions. We cannot predict the effect that any claims of this nature, regardless of&#160;their ultimate outcome, could have on our business or reputation or on our ability to attract and retain patients and employees. While we maintain malpractice liability coverage that we believe is appropriate given the nature and breadth of our operations, any claims against us in excess of insurance limits, or multiple claims requiring us to pay deductibles, could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to maintain our corporate reputation, our business may suffer.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends on our ability to maintain our corporate reputation, including our reputation for providing quality patient care and for compliance with Medicare requirements and the other laws to which we are subject. Adverse publicity surrounding any aspect of our business, including the death or disability of any of our patients due to our failure to provide proper care, or due to any failure on our part to comply with Medicare requirements, HIPAA requirements, or other laws to which we are </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subject, could negatively affect our Company&#8217;s overall reputation and the willingness of referral sources to refer patients to us. Further, the poor performance, reputation or negative conduct of competitors may have spillover effects that adversely affect the industry and our brand.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A write off of a significant amount of intangible assets or long-lived assets could have a material adverse effect on our consolidated financial condition and results of operations.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant and sustained decline in our stock price and market capitalization, a significant decline in our expected future cash flows, a significant adverse change in the business climate or slower growth rates could result in the need to perform an impairment analysis under Accounting Standards Codification (&#8220;ASC&#8221;) Topic 350 &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles &#8211; Goodwill and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in future periods in addition to our annual impairment test. If we were to conclude that a write down of goodwill is necessary, then we would record the appropriate charge, which could result in material charges that are adverse to our consolidated financial condition and results of operations. See Part II, Item&#160;8, Note 5 &#8211; Goodwill and Other Intangible Assets, Net to our consolidated financial statements for additional information.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have grown in part through acquisitions, goodwill and other acquired intangible assets represent a substantial portion of our assets. Goodwill was $1.3 billion as of December&#160;31, 2022 and if we make additional acquisitions, it is likely that we will record additional goodwill and intangible assets in our consolidated financial statements. We also have long-lived assets consisting of property and equipment and other identifiable intangible assets of $117.2 million as of December&#160;31, 2022, which we review on a periodic basis as well as when events or circumstances indicate that the carrying amount of an asset may not be recoverable. If a determination that a significant impairment in value of our unamortized intangible assets or long-lived assets occurs, such determination could require us to write off a substantial portion of our assets. A write off of these assets could have a material adverse effect on our consolidated financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations could be impacted by war, terrorism, natural or man-made disasters and climate change.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's business may be adversely affected by instability, disruption or destruction in a geographic region in which it operates, regardless of cause, including war, terrorism, riot, civil insurrection or social unrest, climate change, natural or man-made disasters and extreme weather conditions, such as hurricanes, tornadoes, wildfires, earthquakes and floods. Any such event in the markets in which we operate could not only impact the day-to-day operations of our care centers, but could also disrupt our relationships with patients, employees and referral sources located in the affected areas and, in the case of our corporate office, our ability to provide administrative support services, including billing and collection services. In addition, any episode of care that is not completed due to such an event will generally result in lower revenue for the episode. Our corporate office and a number of our care centers are located in the southeastern United States and the Gulf Coast Region, increasing our exposure to hurricanes and flooding. Moreover, global climate change could increase the intensity of individual hurricanes or the number of hurricanes that occur each year. Even if our facilities are not directly damaged, we may experience considerable disruptions in our operations due to property damage or electrical outages experienced in storm-affected areas by our care givers, payors, vendors and others. Additionally, long-term adverse weather conditions, whether caused by global climate change or otherwise, could cause an outmigration of people from the communities where our care centers are located. If any of the circumstances described above occur, there could be a harmful effect on our business and our results of operations could be adversely affected.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the current Russia-Ukraine conflict has created extreme volatility in the global financial markets and is expected to have further global economic consequences, including disruptions of the global supply chain and energy markets. Any such volatility or disruptions may have adverse consequences on us or the third parties on whom we rely. If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive. Our business, financial condition and results of operations may be materially and adversely affected by any negative impact on the global economy resulting from the conflict in Ukraine or any other geopolitical tensions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inflation in the economy could negatively impact our business and results of operations.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently, inflation has increased throughout the United States economy. Our operations have been materially impacted by the current inflationary environment as we have experienced higher labor costs and increases in supply costs, fuel costs and mileage reimbursements. Additionally, cost increases may outpace our expectations, causing us to use our cash and other liquid assets faster than forecasted. If we are unable to successfully manage the effects of inflation, our business, operating results, cash flows and financial condition may be adversely affected.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Growth Strategies</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our growth strategy depends on our ability to acquire additional care centers and integrate and operate these care centers effectively, make investments and enter into joint ventures and other strategic relationships. If our growth strategy is unsuccessful or we are not able to successfully integrate newly acquired care centers into our existing operations, our business and consolidated financial condition, results of operations and cash flows could be materially adversely affected.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to fully integrate the operations of our acquired businesses with our current business structure in an efficient and cost-effective manner. Acquisitions, investments, joint ventures or strategic relationships involve significant risks and uncertainties, including:</span></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Difficulties in recouping partial episode payments and other types of misdirected payments for services from the previous owners in an acquisition; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Difficulties integrating acquired personnel and business practices into our business; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The potential loss of key employees, referral sources or patients of acquired care centers; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The delay in payments associated with change in ownership, control and the internal processes of the Medicare Administrative Contractors; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The assumption of liabilities and exposure to unforeseen liabilities of acquired care centers; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The incurrence or assumption of significant debt, which could also cause a deterioration of our credit ratings, result in increased borrowing costs and interest expense and diminish our future access to the capital markets;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Diverging interests from those of our joint venture partners or other strategic partners - we may not be able to direct the management and operations of the joint venture or other strategic relationship in the manner we believe is most appropriate, exposing us to additional risk; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Variability in operating results which could cause our financial results to differ from our own expectations or the investment community&#8217;s expectations in any given period, or over the long-term; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pre-closing and post-closing earnings charges which could adversely impact operating results in any given period.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisitions and investments, we have recorded significant goodwill and other assets on our balance sheet. If we are not able to realize the value of these assets, or if the fair value of our investments declines, we may be required to record impairment charges which could have a material adverse effect on our consolidated financial condition and results of operations. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the financial benefits we expect to realize from many of our acquisitions are largely dependent upon our ability to improve clinical performance, overcome regulatory deficiencies, improve the reputation of the acquired business in the community and control costs. As we expand our markets, our growth could strain our resources, including our management, information and accounting systems, regulatory compliance, logistics and other internal controls. The failure to accomplish any of these objectives, to effectively integrate any of these businesses or to maintain a sufficient level of resources to match our growth could have material adverse effects on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The indemnification provisions of acquisition agreements by which we have acquired companies may not fully protect us, and as a result, we may face unexpected liabilities.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the acquisition agreements by which we have acquired companies require the former owners to indemnify us against certain liabilities related to the operation of the acquired company before we acquired it. In most of these agreements, however, the liability of the former owners is limited, and certain former owners may be unable to meet their indemnification responsibilities. We cannot assure you that these indemnification provisions will protect us fully or at all, and as a result, we may face unexpected liabilities that could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">State efforts to regulate the establishment or expansion of health care providers could impair our ability to expand our operations.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some states require health care providers (including skilled nursing facilities, hospice care centers, home health care centers and assisted living facilities) to obtain prior approval, known as a CON or POA, in order to commence operations (see Part I, Item 1, &#8220;Our Regulatory Environment&#8221; for additional information on CONs and POAs). If we are not able to obtain such approvals, our ability to expand our operations could be impaired, which could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Federal regulation may impair our ability to consummate acquisitions or open new care centers.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in federal laws or regulations may materially adversely impact our ability to acquire care centers or open new start-up care centers. For example, the Social Security Act provides the Secretary with the authority to impose temporary moratoria on the enrollment of new Medicare providers, if deemed necessary to combat fraud, waste or abuse under government programs.&#160;While there are no active Medicare moratoria, there can be no assurance that CMS will not adopt a moratorium on new providers in the future.&#160;Additionally, in 2010, CMS implemented and amended a regulation known as the &#8220;36 Month Rule&#8221; that is applicable to home health care center acquisitions.&#160;Subject to certain exceptions, the 36 Month Rule prohibits buyers of certain home health care centers - those that either enrolled in Medicare or underwent a change in majority ownership fewer than 36 months prior to the acquisition - from assuming the Medicare billing privileges of the acquired care center. The 36 Month Rule may restrict bona fide transactions and potentially block new investments in home health agencies. These changes in federal laws and regulations, and similar future changes, may further increase competition for acquisition targets and could have a material detrimental impact on our acquisition strategy.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestitures or other dispositions could negatively impact our business, and contingent liabilities from businesses that we have sold could adversely affect our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually assess the strategic fit of our existing businesses and may divest, spin-off or otherwise dispose of businesses that are deemed not to fit with our strategic plan or are not achieving the desired return on investment. These transactions pose risks and challenges that could negatively impact our business and financial statements. For example, when we decide to sell or otherwise dispose of a business or assets, we may be unable to do so on satisfactory terms within our anticipated timeframe or at all, and even after reaching a definitive agreement to sell or dispose a business, the sale is typically subject to satisfaction of pre-closing conditions which may not become satisfied. In addition, divestitures or other dispositions may dilute our earnings per share, have other adverse tax, financial and accounting impacts and distract management, and disputes may arise with buyers. In addition, we may retain responsibility for and/or agree to indemnify buyers against some known and unknown contingent liabilities related to certain businesses or assets we sell or dispose. Any of these conditions or liabilities may negatively impact our results of operations and cash flows.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Laws and Government Regulations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to extensive government regulation. Any changes to the laws and regulations governing our business, or to the interpretation and enforcement of those laws or regulations, could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our industry is subject to extensive federal and state laws and regulations. See Part I, Item 1, &#8220;Our Regulatory Environment&#8221; for additional information on such laws and regulations. Federal and state laws and regulations impact how we conduct our business, the services we offer and our interactions with patients, our employees and the public and impose certain requirements on us such as:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">licensure and certification;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adequacy and quality of health care services;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">qualifications of health care and support personnel;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">quality and safety of medical equipment;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">confidentiality, maintenance and security associated with medical records and claims processing;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relationships with physicians and other referral sources;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operating policies and procedures;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">emergency preparedness risk assessments and policies and procedures;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">policies and procedures regarding employee relations;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addition of facilities and services;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">billing for services;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirements for utilization of services;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">documentation required for billing and patient care; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reporting and maintaining records regarding adverse events.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These laws and regulations, and their interpretations, are subject to change. Changes in existing laws and regulations, or their interpretations, or the enactment of new laws or regulations could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows by:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increasing our administrative and other costs;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increasing or decreasing mandated services;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">causing us to abandon business opportunities we might have otherwise pursued;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreasing utilization of services;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">forcing us to restructure our relationships with referral sources and providers; or</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requiring us to implement additional or different programs and systems.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we are subject to various routine and non-routine reviews, audits and investigations by the Medicare and Medicaid programs and other federal and state governmental agencies, which have various rights and remedies against us if they establish that we have overcharged the programs or failed to comply with program requirements. We are also subject to potential lawsuits under the federal False Claims Act and other federal and state whistleblower statutes designed to combat fraud and abuse in our industry. Violation of the laws governing our operations, or changes in interpretations of those laws, could result in the imposition of fines, civil or criminal penalties, the termination of our rights to participate in federal and state-sponsored programs and/or the suspension or revocation of our licenses. If we become subject to material fines, or if other sanctions or other corrective actions are imposed on us, our business and consolidated financial condition, results of operations and cash flows could be materially adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face periodic and routine reviews, audits and investigations under our contracts with federal and state government agencies and private payors, and these audits could have adverse findings that may negatively impact our business.</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our participation in the Medicare and Medicaid programs, we are subject to various governmental reviews, audits and investigations to verify our compliance with these programs and applicable laws and regulations. We also are subject to audits under various federal and state government programs in which third party firms engaged by CMS, including Recovery Audit Contractors (&#8220;RACs&#8221;), Zone Program Integrity Contractors (&#8220;ZPICs&#8221;), Uniform Program Integrity Contractors ("UPICs"), Program Safeguard Contractors (&#8220;PSCs&#8221;), Medicaid Integrity Contractors (&#8220;MICs&#8221;) and Supplemental Medical Review Contractors (&#8220;SMRCs&#8221;), conduct extensive reviews of claims data and medical and other records to identify potential improper payments under the Medicare program. Additionally, private pay sources reserve the right to conduct audits. If billing errors are identified in the sample of reviewed claims, the billing error can be extrapolated to all claims filed which could result in a larger overpayment than originally identified in the sample of reviewed claims. Our costs to respond to and defend reviews, audits and investigations may be significant and could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. Moreover, an adverse review, audit or investigation could result in:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">required refunding or retroactive adjustment of amounts we have been paid pursuant to the federal or state programs or from private payors;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state or federal agencies imposing fines, penalties and other sanctions on us;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of our right to participate in the Medicare program, state programs or one or more private payor networks;&#160;or</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">damage to our business and reputation in various markets.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These results could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If a care center fails to comply with the conditions of participation in the Medicare program, that care center could be subjected to sanctions or terminated from the Medicare program.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of our care centers must comply with required conditions of participation in the Medicare program. If we fail to meet the conditions of participation at a care center, we may receive a notice of deficiency from the applicable state surveyor. If that care center then fails to institute an acceptable plan of correction to remediate the deficiency within the correction period provided by the state surveyor, that care center could be terminated from the Medicare program or subjected to alternative sanctions. CMS may impose temporary management, direct a plan of correction, direct training or impose payment suspensions and civil monetary penalties, in each case, upon providers who fail to comply with the conditions of participation. Termination of one or more of our care centers from the Medicare program for failure to satisfy the program&#8217;s conditions of participation, or the imposition of alternative sanctions, could disrupt operations, require significant attention by management or have a material adverse effect on our business and reputation and consolidated financial condition, results of operations and cash flows. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to federal and state laws that govern our financial relationships with physicians and other health care providers, including potential or current referral sources.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As stated in Part I, Item 1, "Our Regulatory Environment" of this document pertaining to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Federal and State Anti-Fraud and Abuse Laws and Regulations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we are required to comply with various federal anti-fraud and abuse laws, including the Anti-Kickback Statute, the Stark or Physician Self-Referral Law, the False Claims Act and Civil Monetary Penalties Law, as well as state laws and regulations. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe we have structured our relationships with physicians and other actual or potential referral sources to comply with these laws where applicable, the laws are complex, and the Stark Law contains a number of strict liability provisions under which no intent to violate the law is required for a violation to be found. It is possible that courts or regulatory agencies may interpret state and federal anti-kickback laws and/or the Stark Law and similar state laws regulating relationships between health care providers and physicians in ways that will adversely implicate our practices or that isolated instances of noncompliance may occur. Violations of federal or state Stark or anti-kickback laws could lead to criminal or civil fines or other sanctions, including repayment of federal health care program payments related to these arrangements, denials of government program reimbursement or even exclusion from participation in governmental health care programs, which could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. It is possible that a claim that results from a kickback or is made in violation of the Stark Law also may render it false or fraudulent, creating further potential liability under the federal False Claims Act, discussed above.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The No Surprises Act and similar price transparency initiatives could impact our relationships with patients and insurers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2022, the No Surprises Act, enacted as part of the Consolidated Appropriations Act, 2021, creates price transparency requirements, including (i) requiring providers to send to patients or their health plan a good faith estimate of the expected charges and diagnostic codes prior to furnishing scheduled items or services and (ii) prohibiting providers from charging patients an amount beyond the in-network cost sharing amount for services rendered by out-of network providers, subject to limited exceptions. Price transparency initiatives such as the No Surprises Act may impact our ability to obtain or maintain favorable contract terms, and may impact our competitive position and our relationships with patients and insurers.</span></div><div style="margin-bottom:9pt;margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Liquidity</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delays in payment may cause liquidity problems.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is characterized by delays from the time we provide services to the time we receive payment for these services. Timing delays in billings and collections may cause working capital shortages. Working capital management, including prompt and diligent billing and collection, is an important factor in achieving our financial results and maintaining liquidity. It is possible that delays in obtaining documentation support such as physician orders, system problems, Medicare or other payor issues or industry trends may extend our collection period, which may materially adversely affect our working capital, and our working capital management procedures may not successfully mitigate this risk.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 29, 2018, CMS issued a notice indicating its intention to re-launch a home health agency pre-claim review demonstration project. Now called the Review Choice Demonstration for Home Health Services ("RCD") and fully implemented in five states as of April 1, 2022 (Florida, Illinois, North Carolina, Ohio and Texas), the revised demonstration gives home health agencies in the demonstration states three initial options: pre-claim review of all claims, post-payment review of all claims, or minimal post-payment review with a 25% payment reduction for all home health services. Reduced review options are available for home health agencies that demonstrate compliance. Compliance with this process has resulted in increased administrative costs and delays in reimbursement for home health services in the states subject to the demonstration. These delays could materially adversely affect our working capital.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our hospice operations may experience payment delays. We have experienced payment delays when attempting to collect funds from state Medicaid programs in certain instances. Delays in receiving payments from these programs may also materially adversely affect our working capital.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in units of payment for home health agencies could reduce our Medicare home health reimbursement levels.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2020, CMS implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"). Although this change was to be implemented in an overall budget neutral manner, the ultimate impact varied by provider based on factors including patient mix and admission source. Additionally, CMS made assumptions about behavioral changes which resulted in a 4.36% reduction to reimbursement. Accordingly, the adoption of PDGM had a negative impact on our Medicare revenue per episode in 2020. Additionally, in the Calendar Year 2023 Home Health Final Rule, CMS finalized a 3.5% permanent reduction in reimbursement based on the difference between assumed and actual behavioral changes resulting from the implementation of PDGM. The -3.5% permanent adjustment is derived from a -3.925% behavioral assumption adjustment which is half of the full proposed adjustment of 7.85%. The remaining -3.925% behavioral assumption adjustment will be considered in future rulemaking. In addition to the permanent adjustments, CMS is also considering a temporary adjustment of $2 billion to offset overpayments in calendar years 2020 and 2021. Payment updates could continue to negatively impact our rates of reimbursement in future years and have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows. See Part I, Item 1, &#8220;Our Regulatory Environment &#8211; Home Health Payment Reform&#8221; for additional information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The volatility and disruption of the capital and credit markets and adverse changes in the United States and global economies could impact our ability to access both available and affordable financing, and without such financing, we may be unable to achieve our objectives for strategic acquisitions and internal growth.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we intend to finance strategic acquisitions and internal growth with cash flows from operations and borrowings under our revolving credit facility, we may require sources of capital in addition to those presently available to us. Uncertainty in the capital and credit markets may impact our ability to access capital on terms acceptable to us (i.e. at attractive/affordable rates) or at all, and this may result in our inability to achieve present objectives for strategic acquisitions and internal growth. Further, in the event we need additional funds, and we are unable to raise the necessary funds on acceptable terms, our business and consolidated financial condition, results of operations and cash flows could be materially adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our indebtedness could impact our financial condition and impair our ability to fulfill other obligations.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had total outstanding indebtedness, excluding finance leases, of approximately $436.1 million.&#160;Our level of indebtedness could have a material adverse effect on our business and consolidated financial position, results of operations and cash flows and could impair our ability to fulfill other obligations in several ways, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it could require us to dedicate a portion of our cash flow from operations to payments on our indebtedness, which could reduce the availability of cash flow to fund acquisitions, start-ups, working capital, capital expenditures and other general corporate purposes;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it could limit our ability to borrow money or sell stock for working capital, capital expenditures, debt service requirements and other purposes;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it could limit our flexibility in planning for, and reacting to, changes in our industry or business;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it could make us more vulnerable to unfavorable economic or business conditions;&#160;and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it could limit our ability to make acquisitions or take advantage of other business opportunities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event we incur additional indebtedness, the risks described above could increase.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The agreements governing our indebtedness contain various covenants that limit our discretion in the operation of our business and our failure to satisfy requirements in these agreements could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreements governing our indebtedness (the &#8220;Debt Agreements&#8221;) contain certain obligations, including restrictive covenants that require us to comply with or maintain certain financial covenants and ratios and restrict our ability to:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur additional debt;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">redeem or repurchase stock, pay dividends or make other distributions;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make certain investments;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">create liens;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enter into transactions with affiliates;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make acquisitions;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enter into joint ventures;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">merge or consolidate;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">invest in foreign subsidiaries;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">amend acquisition documents;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enter into certain swap agreements;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make certain restricted payments;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">transfer, sell or leaseback assets; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make fundamental changes in our corporate existence and principal business.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Debt Agreements also limit our ability to reinvest the net cash proceeds from asset sales or subordinated debt issuances in certain circumstances. For example, in the event we or any of our subsidiaries receive more than $5 million in net cash proceeds from an asset sale, disposition or involuntary disposition, our Debt Agreements require us to prepay our term loan facility and revolving credit facility with all of such net cash proceeds, unless we elect to reinvest the net cash proceeds in fixed or capital assets related to our business.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, events beyond our control could affect our ability to comply with the Debt Agreements. Any failure by us to comply with or maintain all applicable financial covenants and ratios and to comply with all other applicable covenants could result in an event of default with respect to the Debt Agreements.&#160;If we are unable to obtain a waiver from our lenders in the event of any non-compliance, our lenders could accelerate the maturity of any outstanding indebtedness and terminate the commitments to make further extensions of credit (including our ability to borrow under our revolving credit facility).&#160;Any failure to comply with these covenants could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock has been and may continue to be volatile, which could lead to securities litigation brought against us or cause investors to lose the value of their investment.</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The price at which our common stock trades has experienced significant volatility and may continue to be volatile. During 2022, the closing price of our common stock ranged from a high of $178.09 per share to a low of $80.12 per share. Various factors have impacted, and may continue to impact, the price of our common stock, including among others:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variances in our quarterly financial results compared to research analyst expectations;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in financial estimates and recommendations by securities analysts;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in our estimates, guidance or business plans;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in management;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes or proposed changes in health care laws or regulations or enforcement of these laws and regulations, or announcements relating to these matters;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the Medicare, Medicaid and private insurance payment rates for home health and hospice;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the operating and stock price performance of other comparable companies;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us or our competitors of significant contracts, acquisitions, strategic partnerships, joint ventures or capital commitments; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market and business conditions related to COVID-19;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic and stock market conditions; or</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other factors described in this "Risk Factors" section and elsewhere in this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock market in general, and the NASDAQ Global Select Market (&#8220;NASDAQ&#8221;) in particular, has experienced price and volume fluctuations that we believe have often been unrelated or disproportionate to the operating performance of </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">health care provider companies. These broad market and industry factors may materially reduce the market price of our common stock, regardless of our operating performance. As a result, investors may not be able to sell their common stock at or above the purchase price. In addition, securities class-action cases have often been brought against companies following periods of volatility in the market price of their securities. Such litigation, if instituted against us, could result in substantial costs and a diversion of management's attention and resources.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities of short sellers could reduce the price or prevent increases in the price of our common stock. &#8220;Short sale&#8221; is defined as the sale of stock by an investor that the investor does not own. Typically, investors who sell short believe the price of the stock will fall, and anticipate selling shares at a higher price than the purchase price at which they will buy the stock. As of December&#160;31, 2022, investors held a short position of approximately 1.6 million&#160;shares of our common stock which represented 5% of our outstanding common stock. The anticipated downward pressure on our stock price due to actual or anticipated sales of our stock by some institutions or individuals who engage in short sales of our common stock could cause our stock price to decline.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Board of Directors may use anti-takeover provisions or issue stock to discourage a change of control.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation currently authorizes us to issue up to 60,000,000&#160;shares of common stock and 5,000,000 shares of undesignated preferred stock. Our Board of Directors may cause us to issue additional stock to discourage an attempt to obtain control of our company. For example, shares of stock could be sold to purchasers who might support our Board of Directors in a control contest or to dilute the voting or other rights of a person seeking to obtain control. In addition, our Board of Directors could cause us to issue preferred stock entitling holders to vote separately on any proposed transaction, convert preferred stock into common stock, demand redemption at a specified price in connection with a change in control or exercise other rights designed to impede a takeover.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of additional shares may, among other things, dilute the earnings and equity per share of our common stock and the voting rights of common stockholders.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have implemented other anti-takeover provisions or provisions that could have an anti-takeover effect, including advance notice requirements for director nominations and stockholder proposals, no cumulative voting for directors, a requirement that director vacancies are filled by remaining directors (including vacancies resulting from removal), the number of directors is fixed by the Board of Directors, and the Board of Directors can increase or decrease the size of the Board of Directors without stockholder approval (within the range set forth in our Certificate of Incorporation and Bylaws). These provisions, and others that our Board of Directors may adopt hereafter, may discourage offers to acquire us and may permit our Board of Directors to choose not to entertain offers to purchase us, even if such offers include a substantial premium to the market price of our stock. Therefore, our stockholders may be deprived of opportunities to profit from a change of control.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Bylaws designate the Court of Chancery of the State of Delaware or, if the Court of Chancery does not have jurisdiction, the federal court for the District of Delaware, as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could discourage lawsuits against us and our directors, officers, employees and stockholders.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Bylaws provide that unless we otherwise consent to the selection of an alternative forum, the Court of Chancery of the State of Delaware or, if the Court of Chancery does not have jurisdiction, the federal court for the District of Delaware, will be the sole and exclusive forum for any derivative action or proceeding brought on behalf of us, any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or agents to us or our stockholders, any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law or our Certificate of Incorporation or Bylaws or any action asserting a claim governed by the internal affairs doctrine. This provision would not apply to claims brought to enforce a duty or liability created by the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) or any other claim for which the federal courts have exclusive jurisdiction.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our Bylaws provide that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), unless we consent in writing to the selection of an alternative forum.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These exclusive forum provisions may limit the ability of our stockholders to bring a claim in a judicial forum that such stockholders find favorable for disputes with us or our directors or officers, which may discourage such lawsuits against us and our directors, officers, employees and agents. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="i5c10b724a6674979bf3c35a339f29685_22"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B.  UNRESOLVED STAFF COMMENTS</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div id="i5c10b724a6674979bf3c35a339f29685_25"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.  PROPERTIES</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive office is located in Nashville, Tennessee in a leased property consisting of 20,759 square feet; our corporate headquarters is located in Baton Rouge, Louisiana in a leased property consisting of 85,955 square feet. We believe we have adequate space to accommodate our corporate staff located in these locations for the foreseeable future.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our executive office and corporate headquarters, we also lease facilities for our home health, hospice and personal-care care centers and our high acuity care joint ventures.&#160;Generally, our leases have an initial term of five years, but range from one to ten years.&#160;Most of our leases also contain early termination options and renewal options. The following table shows the location of our 347 Medicare-certified home health care centers, 164 Medicare-certified hospice care centers, 13 personal-care care centers and 8 admitting high acuity care joint ventures at December&#160;31, 2022:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home&#160;Health</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal&#160;Care</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home&#160;Health</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal&#160;Care</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alabama</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nebraska</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Arizona</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">New Hampshire</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Arkansas</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">New Jersey</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">California</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">New York</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Connecticut</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">North Carolina</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Delaware</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ohio</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Florida</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Oklahoma</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Georgia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Oregon</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Illinois</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pennsylvania</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indiana</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rhode Island</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Iowa</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">South Carolina</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Kansas</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">South Dakota</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Kentucky</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tennessee</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Louisiana</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Texas</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maine</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Virginia</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maryland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Washington</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Massachusetts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">West Virginia</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Michigan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Wisconsin</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mississippi</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Washington, D.C.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Missouri</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 25.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div id="i5c10b724a6674979bf3c35a339f29685_28"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.  LEGAL PROCEEDINGS</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Part II, Item&#160;8, Note 12 &#8211; Commitments and Contingencies for information concerning our legal proceedings.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i5c10b724a6674979bf3c35a339f29685_31"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.  MINE SAFETY DISCLOSURES</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i5c10b724a6674979bf3c35a339f29685_34"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i5c10b724a6674979bf3c35a339f29685_37"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information and Holders</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock trades on the NASDAQ Global Select Market under the trading symbol &#8220;AMED.&#8221; As of February&#160;10, 2023, there were approximately 478&#160;holders of record of our common stock. This number of holders of record does not represent the actual number of beneficial owners of our common stock because shares are frequently held in &#8220;street name&#8221; by securities dealers and others for the benefit of individual owners who have the right to vote their shares.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not declared or paid any cash dividends on our common stock or any other of our securities and do not expect to pay cash dividends for the foreseeable future. We currently intend to retain our future earnings, if any, to fund the development and growth of our business. Future decisions concerning the payment of dividends will depend upon our results of operations, financial condition, capital expenditure plans and debt service requirements, as well as such other factors that our Board of Directors, in its sole discretion, may consider relevant. In addition, our outstanding indebtedness restricts, and we anticipate any additional future indebtedness may restrict, our ability to pay cash dividends; provided, however, that we may pay dividends (i) payable solely in our equity securities or (ii) cash dividends if (1) no default or event of default under the Second Amended Credit Agreement shall have occurred and be continuing at the time of such dividend or would result therefrom, and (2) we demonstrate that, upon giving pro forma effect to such dividend, our consolidated leverage ratio (as defined in the Second Amended Credit Agreement) is less than 2.75 to 1.0.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information with respect to purchases made by us of shares of our common stock during each of the months during the three-month period ended December&#160;31, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(a)<br/>Total&#160;Number<br/>of&#160; Shares&#160;(or&#160;Units)<br/>Purchased</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(b)<br/>Average&#160;Price<br/>Paid&#160; per&#160;Share&#160;(or&#160;Unit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(c)<br/>Total&#160;Number&#160; of<br/>Shares&#160;(or&#160;Units)<br/>Purchased&#160;as&#160;Part&#160;of<br/>Publicly Announced<br/>Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(d) Maximum&#160;Number&#160; (or<br/>Approximate Dollar<br/>Value) of Shares (or<br/>Units)&#160;That&#160;May&#160;Yet&#160;Be<br/>Purchased Under the<br/>Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 1, 2022 to October 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,648,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 1, 2022 to November 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,648,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 1, 2022 to December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,648,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.98&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,648,900&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:24.75pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes shares of common stock surrendered to us by certain employees to satisfy tax withholding and/or strike price obligations in connection with the vesting of non-vested stock and the exercise of stock options previously awarded to such employees under our 2008 and 2018 Omnibus Incentive Compensation Plans.</span></div><div style="padding-left:24.75pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Represents amounts remaining as of December 31, 2022 under the $100 million New Share Repurchase Program, which was authorized by our Board of Directors on August 2, 2021 and expired on December 31, 2022. Effective as of February 2, 2023, we are authorized to repurchase up to $100 million of our common stock through December 31, 2023 under the 2023 Share Repurchase Program. See Item 8, Note 17 &#8211; Subsequent Events for additional information on the 2023 Share Repurchase Program.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Performance Graph</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Performance Graph below compares the cumulative total stockholder return on our common stock, $0.001 par value per share, for the five-year period ended December&#160;31, 2022 with the cumulative total return on the NASDAQ composite index and an industry peer group over the same period (assuming the investment of $100 in our common stock, the NASDAQ composite index and the industry peer group on December&#160;31, 2017 and the reinvestment of dividends). The peer group we selected is comprised of: Addus Homecare Corporation ("ADUS"), Chemed Corporation ("CHE"), Encompass Health Corporation ("EHC"), LHC Group, Inc. (&#8220;LHCG&#8221;) and National Healthcare Corporation (&#8220;NHC&#8221;). The cumulative total stockholder return on the following graph is historical and is not necessarily indicative of future stock price performance. No cash dividends have been paid on our common stock.</span></div><div style="margin-top:5pt;text-align:justify"><img src="amed-20221231_g2.jpg" alt="amed-20221231_g2.jpg" style="height:467px;margin-bottom:5pt;vertical-align:text-bottom;width:664px"/></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.058%"><tr><td style="width:1.0%"></td><td style="width:24.711%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.594%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amedisys, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">222.18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">316.68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">556.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">307.11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NASDAQ Composite</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">235.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Peer Group</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This stock performance information is &#8220;furnished&#8221; and shall not be deemed to be &#8220;soliciting material&#8221; or subject to Regulation 14A under the Exchange Act, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, whether made before or after the date of this report and irrespective of any general incorporation by reference language in any such filing, except to the extent we specifically incorporate the information by reference.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i5c10b724a6674979bf3c35a339f29685_40"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;6. [RESERVED]</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="i5c10b724a6674979bf3c35a339f29685_43"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis provides information we believe is relevant to an assessment and understanding of our results of operations and financial condition for 2022, 2021 and 2020. This discussion should be read in conjunction with our audited financial statements included in Item 8, "Financial Statements and Supplementary Data&#8221; and Part I, Item 1, &#8220;Business&#8221; of this Annual Report on Form 10-K. The following analysis contains forward-looking statements about our future revenues, operating results and expectations. See &#8220;Special Caution Concerning Forward-Looking Statements&#8221; for a discussion of the risks, assumptions and uncertainties affecting these statements as well as Part I, Item 1A, &#8220;Risk Factors.&#8221;</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">For a discussion of a comparison of the years ended December 31, 2021 and December 31, 2020, please refer to "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on February 24, 2022.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a provider of high-quality in-home healthcare and related services to the chronic, co-morbid, aging American population, with approximately 74%, 75% and 75% of our consolidated net service revenue derived from Medicare for 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations involve servicing patients through our four reportable business segments: home health, hospice, personal care and high acuity care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from an illness, injury or surgery. Our hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. Our personal care segment provides patients with assistance with the essential activities of daily living. Our high acuity care segment, which was established with the acquisition of Contessa Health ("Contessa") on August 1, 2021, delivers the essential elements of inpatient hospital and skilled nursing facility ("SNF") care to patients in their homes. As of December&#160;31, 2022, we owned and operated 347 Medicare-certified home health care centers, 164 Medicare-certified hospice care centers, 13 personal-care care centers and 8 admitting high acuity care joint ventures in 37 states within the United States and the District of Columbia.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Care Centers Summary (Includes Unconsolidated Joint Ventures)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home&#160;Health</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal&#160;Care</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care (1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">At December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions/Expansions/Denovos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closed/Consolidated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">At December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions/Expansions/Denovos</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closed/Consolidated</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">At December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions/Expansions/Denovos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closed/Consolidated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">At December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Prior year count has been recast to include admitting joint ventures only.</span></div><div style="margin-bottom:6pt;margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Developments</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Maintained the highest Quality of Patient Care star rating in the home health industry of 4.49 with 99% of our care centers at 4+ Stars</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Outperformed the industry on all Hospice Item Set ("HIS") measures as well as the newly reported Hospice Care Index ("HCI") metric</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Released our inaugural Environmental, Social and Governance ("ESG") Report</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Performed 11.2 million visits</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expanded our usage and relationship with Medalogix, a predictive data and analytics company, helping to further optimize our current business and positioning us to work more closely with Medicare Advantage payors</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Executed an innovative case rate contract with a large national payor</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued to grow our Contessa partnerships ending the year with 11 signed joint ventures</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Grew our home health footprint via the Evolution and AssistedCare acquisitions</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Generated $133 million in cash flow from operations</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Began to execute on a clinical optimization plan to gain efficiencies and clinical capacity</span></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2023 Strategy</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Further advance our industry leading Quality of Patient Care star scores in home health and drive best-in-class hospice quality as measured by the Hospice Care Index</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continue to better the communities and patients we serve by further incorporating ESG practices into our business operations</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Advance our culture and sense of belonging through diversity and inclusion initiatives</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Build a learning culture through world class leadership development</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reduce turnover in all roles, especially focused on critical clinician positions</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Further expand our analytics capabilities internally and through our Medalogix investment</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Consistently grow all lines of business organically and inorganically</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Execute new hospital at home joint venture agreements and expand Contessa's service offering into new lines of business such as palliative care at home</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continue to execute clinical optimization and reorganization initiatives</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Performance</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a consolidated basis, operating income decreased $71 million on a $9 million increase in net service revenue. Significant drivers of the $71 million decrease in operating income were the return of sequestration ($23 million) and acquisitions ($34 million). Additionally, wage inflation and a shift in our home health volumes from episodic to non-episodic negatively impacted performance.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our home health segment's revenue and volume were impacted by COVID-19 early in the year, staffing shortages driven by the competitive labor market and a shift from episodic volumes which generate higher revenue to non-episodic volumes which, combined with the return of sequestration and labor pressures, led to a $38 million decrease in operating income for the segment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our hospice segment experienced declines in both our same store admissions and average daily census, which is the main driver of hospice revenue, primarily due to a decline in our length of stay resulting from a delay in the timing of patients coming onto service and an increase in the discharge rate of our patients.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our personal care segment continued to be impacted by staffing shortages during 2022.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our high acuity care segment expanded its joint venture footprint and made significant investments to build the clinical, operational and technological infrastructure necessary to support the development and future growth of home recovery care programs on a national scale.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Economic and Industry Factors</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our segments operate in a highly fragmented and highly competitive industry. The degree of competitiveness for our home health and hospice care centers varies based upon whether our care centers operate in states that require a certificate of need ("CON") or permit of approval ("POA"). In such states, expansion by existing providers or entry into the market by new providers is permitted only where determination is made by state health authorities that a given amount of unmet healthcare need exists. Currently, 67% and 29% of our home health and hospice care centers, respectively, operate in CON/POA states.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Federal government continues to debate a reduction in expenditures and a reform of the Medicare system, our industry continues to face reimbursement pressures. These reform efforts could result in major changes in the health care delivery and reimbursement system on a national and state level, including changes directly impacting the reimbursement systems for our home health and hospice care centers. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wages and other expenses increase during periods of inflation and when labor shortages occur in the marketplace. The impact of inflation on the Company is primarily in the area of labor costs, supply costs, fuel costs and mileage reimbursements. The healthcare industry is labor intensive. We have experienced, and expect to continue to experience, increases in wage costs. In addition, increases in healthcare costs are typically higher than inflation and impact our costs under our employee benefit plans.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Centers for Medicare and Medicaid ("CMS") Payment Updates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Hospice</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 27, 2022, CMS issued the final rule to update hospice payment rates and the wage index for fiscal year 2023, effective for services provided beginning October 1, 2022. CMS estimates hospices serving Medicare beneficiaries will see a 3.8% increase in payments. This increase is the result of a 4.1% market basket adjustment as required under the Patient Protection and Affordable Health Care Act and the Health Care and Education Reconciliation Act ("PPACA") less a 0.3% productivity adjustment. Additionally, CMS increased the aggregate cap amount by 3.8% to $32,487. Based on our analysis of the final rule, we expect our impact to be in line with the 3.8% increase.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Home Health</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 31, 2022, CMS issued the Home Health Final Rule for Medicare home health providers for calendar year 2023. CMS estimates that the final rule will result in a 0.7% increase in payments to home health providers. This increase is the result of a 4.0% payment update (4.1% market basket adjustment less a 0.1% productivity adjustment) and an increase of 0.2% for the update to the fixed-dollar loss ratio used in determining outlier payments offset by a permanent adjustment of -3.5% based on the difference between assumed and actual behavioral changes resulting from the implementation of PDGM. The -3.5% permanent adjustment is derived from a -3.925% behavioral assumption adjustment. In the Calendar Year 2023 Preliminary Rule, CMS proposed a behavioral assumption adjustment of -7.69%. CMS revised the adjustment to -7.85% in the final rule and also reduced it by half (to -3.925%) in order to mitigate such a significant reduction to reimbursement in a single year. The remaining -3.925% behavioral adjustment will be considered in future rulemaking. The final rule also finalizes a permanent 5% cap on negative wage index changes for home health agencies. Based on our analysis of the final rule, we expect our impact to be flat, which is less than the estimated 0.7% rate increase.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the permanent adjustments, CMS is also considering a temporary adjustment of approximately $2 billion to offset overpayments in calendar years 2020 and 2021. CMS has elected not to apply the temporary adjustment to calendar year 2023; however, CMS is still considering how to best apply the adjustment in future rulemaking. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amedisys submitted formal comments to the Calendar Year 2023 Home Health Proposed Rule in mid-August and joined industry stakeholders in requesting that CMS use an alternative methodology to determine budget neutrality.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following payment adjustments are effective for each of the years indicated based on CMS&#8217;s final rules:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home Health</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023 (1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market Basket Update</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rural Add-On Adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Productivity Adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Behavioral Adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed-Dollar Loss Ratio Adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Industry Impact</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Company-Specific Impact </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Effective for services provided from October&#160;1, 2022 to September&#160;30, 2023.</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Our company-specific impact of the home health final rule could differ depending on differences in the wage index, our patient case mix and other factors, such as low utilization payment adjustments ("LUPAs") or outliers, which are described in more detail under Critical Accounting Estimates below. Our company-specific impact of the hospice final rule could differ based on our mix of patients and differences in the wage index.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Sequestration</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2020, Congress passed the bipartisan Coronavirus Aid, Relief and Economic Security Act ("CARES Act") which provided for the suspension of the automatic 2% reduction of Medicare claim reimbursements ("sequestration") for the period May 1, 2020 through December 31, 2020. During 2020 and 2021, Congress passed additional COVID-19 relief legislation which extended the 2% suspension of sequestration through March 31, 2022; sequestration was reinstated as a 1% reduction to Medicare claim reimbursements for the period April 1, 2022 through June 30, 2022 and was fully reinstated as a 2% reduction to Medicare claim reimbursements effective July 1, 2022. The reinstatement of sequestration has resulted in a reduction of our net service revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Novel Coronavirus Pandemic ("COVID-19")</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and financial performance have been impacted by COVID-19. The financial impacts of COVID-19 are discussed in further detail under "Results of Operations" below. While we currently believe that we have a reasonable view of operations, the ultimate impact of COVID-19, including the impact on our liquidity, financial condition and results of operations is uncertain and will depend on many factors and future developments, which are highly uncertain and cannot be predicted at this time, such as the severity, scope and length of time that the pandemic continues, including regional surges in COVID-19 cases at various times. In addition, the COVID-19 pandemic has resulted in widespread global supply chain disruptions to vendors including critical supply shortages, significant material cost inflation and extended lead times for items that are required for our operations. Potential impacts of COVID-19 on our results include lower revenue; higher salary and wage expense related to quarantine pay, contract clinicians, wage inflation, increased costs to hire and retain employees and training; and increased supply costs related to supply chain constraints, personal protective equipment ("PPE") and COVID-19 testing. The impacts to net service revenue include the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lower volumes due to interruption of the operations of our referral sources, patients' unwillingness to accept services and restrictions on access to facilities for hospice services;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lower reimbursement due to missed visits resulting in an increase in LUPAs and lost billing periods; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lower hospice average daily census due to a decline in our average length of stay.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 8, Note 3 &#8211; Novel Coronavirus Pandemic ("COVID-19") to our consolidated financial statements for additional information regarding COVID-19 and the CARES Act.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Network Developments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a Care Coordination Agreement with BrightStar Care to add its agencies to the Amedisys personal care network, which helps facilitate the coordination of care between our home health and hospice care centers and a network of personal care partners. Long term, we believe this agreement will allow us to build a nation-wide network of personal care agencies and further our efforts to provide patients with a true care continuum in the home. This relationship will also help us as we continue to have innovative payment conversations with Medicare Advantage plans who recognize the value that combined home health, hospice, personal care and high acuity care services bring to their members and care delivery infrastructure.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Governmental Inquiries and Investigations and Other Litigation</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 8, Note 12 &#8211; Commitments and Contingencies to our consolidated financial statements for a discussion of and updates regarding legal proceedings and investigations we are involved in. No assurances can be given as to the timing or outcome of these items.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Consolidated</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our consolidated results of operations (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,223.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,214.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,233.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,185.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">962.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">% of net service revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">43.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">44.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">44.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses, excluding depreciation and amortization and impairment charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">711.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">% of net service revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">32.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">26.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss (income) attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Amedisys, Inc.</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Year Ended December&#160;31, 2022 Compared to the Year Ended December&#160;31, 2021 </span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a consolidated basis, our operating income decreased approximately $71 million on a net service revenue increase of $9 million. The year over year decrease in operating income is primarily due to the acquisitions of Contessa on August 1, 2021 and Evolution and AssistedCare on April 1, 2022 (which combined contributed $54 million in net service revenue and an operating loss of $44 million in the current year and $4 million in net service revenue and an operating loss of $10 million in the prior year), a $9 million reduction to net service revenue related to our Infinity Zone Program Integrity Contractors ("ZPIC") audits, a $7 million favorable adjustment recorded in the prior year related to our U.S. Department of Justice ("DOJ") matters (see Item 8, Note 12 &#8211; Commitments and Contingencies to our consolidated financial statements for additional information regarding both the ZPIC and DOJ matters), a $3 million impairment charge recorded in connection with the wind down of operations of one of our high acuity care joint ventures and a greater benefit recognized in the prior year totaling $23 million associated with the suspension of sequestration. </span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding our acquisitions, the Infinity ZPIC audits, the DOJ matters, the impairment charge and the incremental sequestration benefit recognized in the prior year, our operating income increased $5 million while net service revenue decreased $2 million. Our results were positively impacted by rate increases, improvements in clinician utilization, reductions in hospice staffing levels and lower depreciation and amortization. These items were offset by a decrease in our episodic home health revenue as a percentage of total net service revenue, a decline in our hospice average daily census, which is the main driver of hospice revenue, a decrease in our other operating income due to the expiration of the CARES Act Provider Relief Fund ("PRF") funds, an increase in our cost of service resulting from planned wage increases and wage inflation and an increase in our general and administrative expenses. Additionally, our volumes have been and continue to be impacted by staffing shortages resulting from the competitive labor market. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, we received CARES Act PRF funds in 2020 which were used to cover COVID-19 expenses incurred by our home health and hospice segments through June 30, 2021. We recorded income related to these funds totaling $13 million in </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other operating income within our consolidated statements of operations during the year ended December 31, 2021. This income fully offset the COVID-19 costs incurred during the six-month period ended June 30, 2021, which totaled $13 million; however, we were not able to recognize any operating income during the six-month period ended December 31, 2021 to offset the $8 million of COVID-19 costs incurred during this period. Additionally, we were not able to recognize any operating income to offset the $9 million of COVID-19 costs incurred during the year ended December 31, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results reflect a $43 million increase in our general and administrative expenses compared to prior year. Excluding our acquisitions, our general and administrative expenses increased $8 million (1%) due to the addition of resources to support growth, planned wage increases, higher travel and training spend, higher acquisition and integration costs, severance, lease termination and other costs related to clinical optimization and reorganization initiatives and increased information technology fees partially offset by higher gains on the sale of fleet vehicles, a favorable legal settlement and lower incentive compensation costs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other (expense) income, net includes the following items (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For&#160;the&#160;Years&#160;Ended<br/>December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in (loss) earnings from equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miscellaneous, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other (expense) income, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense increased $13&#160;million year over year as a result of interest accrued in conjunction with the Inifnity ZPIC audits discussed above and increased borrowings and higher interest rates under our Second Amended Credit Agreement (see Item 8, Note 9 &#8211; Long-Term Obligations to our consolidated financial statements for additional information regarding our Second Amended Credit Agreement). Gain on equity method investments for the prior year includes a $31 million gain related to our investment in Medalogix (see Item 8, Note 1 &#8211; Nature of Operations, Consolidation and Presentation of Financial Statements to our consolidated financial statements for additional information).</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:14pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Home Health Segment</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our home health segment results of operations:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,249.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">769.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Same Store Growth (1):</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total admissions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total volume (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Statistical Data - Total (3):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Admissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374,631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331,354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recertifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total volume</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552,732&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536,209&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508,985&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare completed episodes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average Medicare revenue per completed episode (4)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare visits per completed episode (5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Visiting clinician cost per visit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical manager cost per visit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost per visit</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.98&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.19&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.79&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Visits</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,929,137&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,331,935&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,388,549&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Same store information represents the percent change in our Medicare, Non-Medicare and Total revenue, admissions or volume for the period as a percent of the Medicare, Non-Medicare and Total revenue, admissions or volume of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Total volume includes all admissions and recertifications.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Total includes acquisitions, start-ups and denovos.</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care. Average Medicare revenue per completed episode reflects the suspension of sequestration for the period May 1, 2020 through March 31, 2022 and the reinstatement of sequestration at 1% effective April 1, 2022 and at 2% effective July 1, 2022. </span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Year Ended December&#160;31, 2022 Compared to the Year Ended December&#160;31, 2021 </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, our operating income decreased $38 million on a $2 million increase in net service revenue. The year over year results were impacted by the April 1, 2022 acquisitions of Evolution and AssistedCare (which contributed net service revenue of $35 million and an operating loss of $3 million to the year ended December 31, 2022), a $9 million reduction in net service revenue related to our Infinity ZPIC audits and a greater benefit recognized in the prior year totaling $14 million associated with the suspension of sequestration. Excluding these items, our operating income decreased $12 million on a $10 million decrease in net service revenue primarily due to a decrease in episodic revenue as a percentage of total net service revenue, higher revenue adjustments, the expiration of the CARES Act PRF funds, planned wage increases, wage inflation and an increase in our other general and administrative expenses. These items were partially offset by the increase in reimbursement and improvement in our operating performance driven by improvements in clinician utilization.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Service Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net service revenue increased $2 million. Excluding our April 1, 2022 acquisitions of Evolution and AssistedCare, the Infinity ZPIC audits and the incremental sequestration benefit recognized in the prior year, our net service revenue decreased $10 million. We have experienced a year over year decline in our episodic volumes, which generate higher revenue than our non-episodic volumes. Additionally, our volumes have been impacted by staffing shortages driven by the competitive labor market. These items, as well as an increase in revenue adjustments, have resulted in a year over year decline in our net service revenue which was partially offset by the 3.2% increase in reimbursement effective January 1, 2022. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Income</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating income consists of the recognition of funds received from the CARES Act PRF which were available for use through June 30, 2021. We recorded income related to these funds totaling $7 million during the year ended December 31, 2021. This income fully offset the COVID-19 costs incurred during the six-month period ended June 30, 2021, which totaled $7 million; however, we were not able to recognize any operating income during the six-month period ended December 31, 2021 to offset the $6 million of COVID-19 costs incurred during this period. Additionally, we were not able to recognize any operating income to offset the $7 million of COVID-19 costs incurred during the year ended December 31, 2022. The COVID-19 costs were associated with the purchase of PPE, quarantine pay and COVID-19 testing and have been recorded to cost of service within our consolidated statements of operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Service, Excluding Depreciation and Amortization</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cost of service consists of costs associated with direct clinician care in the homes of our patients as well as the cost of clinical managers who monitor the overall delivery of care. Overall, our total cost of service increased 2% primarily due to an 8% increase in our total cost per visit partially offset by a 6% decrease in total visits resulting from improvements in clinician utilization as evidenced by a decline of 1.0 visit per Medicare completed episode year over year. The 2% increase in our total cost per visit is primarily due to planned wage increases, an increase in salaried employees (partially due to our recent acquisitions), wage inflation, increased costs to hire and retain employees, visit mix, higher fuel prices and mileage reimbursement partially offset by a decrease in COVID-19 costs. In addition, while we compensate our clinicians on a per visit basis, there is a fixed cost component of our cost structure which also resulted in an increase in our cost per visit due to the significant decline in visits year over year.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other general and administrative expenses increased $20 million. Excluding our acquisitions, other general and administrative expenses increased $10 million primarily due to planned wage increases, the addition of resources to support volume growth, higher travel and training spend and higher information technology fees partially offset by lower incentive compensation costs.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Segment</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our hospice segment results of operations:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:55.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Same Store Growth (1):</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospice admissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average daily census</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Statistical Data - Total (2):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospice admissions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,656&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average daily census</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per day, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service per day</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average discharge length of stay</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Same store information represents the percent change in our Medicare revenue, Hospice admissions or average daily census for the period as a percent of the Medicare revenue, Hospice admissions or average daily census of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Total includes acquisitions and denovos.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Year Ended December&#160;31, 2022 Compared to the Year Ended December&#160;31, 2021 </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, our operating income decreased $16 million on a $4&#160;million decrease in net service revenue. Excluding a $7 million favorable adjustment recorded in the prior year related to our DOJ matters (see Item 8, Note 12 &#8211; Commitments and Contingencies to our consolidated financial statements for additional information) and a $9 million greater benefit recognized in the prior year associated with the suspension of sequestration, operating income was flat as the increases in reimbursement effective October 1, 2021 and 2022, lower revenue adjustments, savings associated with clinical optimization and reorganization initiatives and reductions in staffing levels were offset by a decline in our hospice average daily census, which is the main driver of hospice revenue, planned wage increases, wage inflation and an increase in our other general and administrative expenses. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Service Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding the DOJ matters and incremental sequestration benefit recognized in the prior year, our net service revenue increased $12&#160;million primarily due to the increases in reimbursement effective October 1, 2021 and 2022 as well as lower revenue adjustments partially offset by a decline in our same store average daily census, which is the main driver of hospice revenue. Our same store average daily census was down 1% year over year primarily due to a decline in our length of stay resulting from a delay in the timing of patients coming onto service, an increase in the discharge rate of our patients and a decline in our hospice admissions throughout the year.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Income</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating income consists of the recognition of funds received from the CARES Act PRF which were available for use through June 30, 2021. We recorded income related to these funds totaling $6 million during the year ended December 31, 2021. This income fully offset the COVID-19 costs incurred during the six-month period ended June 30, 2021, which totaled $6 million; however, we were not able to recognize any operating income during the six-month period ended December 31, 2021 to offset the $2 million of COVID-19 costs incurred during this period. Additionally, we were not able to recognize any operating income to offset the $2 million of COVID-19 costs incurred during the year ended December 31, 2022. The COVID-19 costs were associated with the purchase of PPE, quarantine pay and COVID-19 testing and have been recorded to cost of service within our consolidated statements of operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Service, Excluding Depreciation and Amortization</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our hospice cost of service increased less than 1% as a 2% increase in our cost of service per day was offset by a 1% decline in our average daily census. The increase in our cost of service per day is due to planned wage increases, wage inflation, increased costs to hire and retain employees and higher fuel prices and mileage reimbursements partially offset by lower COVID-19 costs, reductions in staffing levels and savings associated with clinical optimization and reorganization initiatives.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other general and administrative expenses increased $5&#160;million, primarily due to planned wage increases, higher travel and training spend, higher information technology fees and severance and lease termination costs associated with clinical optimization and reorganization initiatives.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Personal Care Segment</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our personal care segment results of operations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Statistical Data - Total:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Billable hours</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,851,563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,275,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,730,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clients served</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,074&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shifts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791,596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974,409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,177,586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per hour</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per shift</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hours per shift</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Year Ended December&#160;31, 2022 Compared to the Year Ended December&#160;31, 2021 </span></div><div style="margin-bottom:9pt;margin-top:5pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income related to our personal care segment increased $1 million on a $4 million decrease in net service revenue. The decrease in net service revenue is due to lower billable hours resulting from staffing shortages partially offset by rate increases. These impacts have been mitigated by a reduction in our cost of service as most of our personal care employees are paid on an hourly basis as well as a reduction in our other general and administrative expenses.</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2023, we signed a definitive agreement to sell our personal care business (excluding the Florida operations). The divestment is expected to close during the second quarter of 2023. See Item 8, Note 6 - Assets Held For Sale for additional information.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">High Acuity Care Segment</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our high acuity care segment results of operations:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Statistical Data - Total:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Full risk admissions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Limited risk admissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total admissions</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,590&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Full risk revenue per episode</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Limited risk revenue per episode</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of admitting joint ventures (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Prior year count has been recast to include admitting joint ventures only.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Year Ended December&#160;31, 2022 Compared to the Year Ended December&#160;31, 2021 </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our high acuity care segment results include a full year of operations in the current year compared to five months of operations in the prior year. Our year over year results reflect revenue growth which was offset by an increase in our cost of service and other general and administrative expenses driven by additional investments in the business. We also recorded an impairment charge in connection with the wind down of the operations of one of our joint ventures. Although we expect our high acuity care segment to continue to generate operating losses, we also expect improvement in our operating income as we leverage our operating structure through growth in current and future joint ventures and expansion into new lines of business such as palliative care at home.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Service Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our high acuity care segment provides home recovery care services for high acuity patients on either a full risk or limited risk basis, each with different reimbursement arrangements. Full risk admissions are admissions for which we assume the financial risk for all related healthcare services during a 30-day or 60-day episodic period in exchange for a fixed contracted bundled rate. Limited risk admissions are admissions for which we assume the risk for certain healthcare services during a shorter acute phase period (equivalent to an inpatient hospital stay) in exchange for a contracted per diem payment. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on March 23, 2022, our high acuity care segment entered into a transaction in which one of our health system partners contributed its home health operations to one of our existing joint ventures. As a result, our high acuity care segment includes revenue totaling approximately $6 million related to this joint venture's home health operations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Service, Excluding Depreciation and Amortization</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cost of service consists primarily of medical costs associated with direct clinician care provided to our patients during the applicable episode period, costs associated with our virtual care unit ("VCU") which enables us to provide monitoring services and facilitates virtual patient rounding visits via telehealth and costs associated with resources to support future palliative care at home programs. We continue to invest in the infrastructure of our VCU in anticipation of future growth.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other general and administrative expenses primarily consist of salaries and benefits. We have made significant investments to build the clinical, operational and technological infrastructure necessary to support the development and future growth of home recovery care programs on a national scale. We have employees at both the local market level and at our corporate offices. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Corporate</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our corporate results of operations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other general and administrative expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate expenses consist of costs related to our executive management and corporate and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Year Ended December&#160;31, 2022 Compared to the Year Ended December&#160;31, 2021 </span></div><div style="margin-bottom:9pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate other general and administrative expenses decreased approximately $3 million during the year ended December 31, 2022. Excluding our acquisitions, corporate other general and administrative expenses decreased $4 million year over year primarily due to higher gains on the sale of fleet vehicles, lower incentive compensation costs and a favorable legal settlement; these items were partially offset by planned wage increases, costs associated with our clinical optimization and reorganization initiatives and higher acquisition and integration costs.</span></div><div style="margin-bottom:9pt;margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(287.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities for 2022, 2021 and 2020 has provided sufficient liquidity to finance our capital expenditures, both routine and non-routine, and acquisitions. Changes in our cash provided by operating activities during the past three years were primarily the result of fluctuations in our net income, the collections of our accounts receivable and the timing of payments of accrued expenses. Cash provided by operating activities decreased $55.6 million during 2022 compared to 2021 primarily due to the payment of a full year of operating expenses for our high acuity care segment compared to only </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">five months in the prior year, the repayment of $38.0 million in connection with our Infinity ZPIC audits (see Item 8, Note 12 - Commitments and Contingencies to our consolidated financial statements for additional information), lower collections due to the reinstatement of sequestration and an increase in days revenue outstanding. Cash provided by operating activities decreased $100.1 million during 2021 compared to 2020 primarily due to the deferral of payroll taxes and the receipts of CARES Act PRF funds in 2020 and an increase in days revenue outstanding in 2021 partially offset by an increase in operating income.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in investing activities primarily consists of the purchase of property and equipment, investments and acquisitions. Cash used in investing activities decreased $187.1 million during 2022 primarily due to reductions in acquisition spend. Our 2020 cash flows from investing activities included proceeds from the sale of our investment in the Heritage Healthcare Innovation Fund, LP (see Item 8, Note 1 - Nature of Operations, Consolidation and Presentation of Financial Statements to our consolidated financial statements for additional information). Excluding these proceeds, cash used in investing activities decreased $23.4 million during 2021 primarily due to reductions in acquisition spend.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financing activities primarily consist of borrowings under our term loan and/or revolving credit facility, repayments of borrowings, the remittance of taxes associated with shares withheld on non-cash compensation, proceeds related to the exercise of stock options, proceeds related to the purchase of stock under our employee stock purchase plan and the purchase of company stock under our stock repurchase programs. Cash used in financing activities totaled $30.4 million during 2022; cash provided by financing activities totaled $55.1 million during 2021. The $85.5 million change is primarily due to higher borrowings under our Second Amended Credit Agreement to fund acquisitions in 2021.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, our principal source of liquidity is the collection of our patient accounts receivable, primarily through the Medicare program. In addition to our collection of patient accounts receivable, from time to time, we can and do obtain additional sources of liquidity by the incurrence of additional indebtedness.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, we spent $6.2&#160;million in capital expenditures compared to $6.3&#160;million and $5.3&#160;million during 2021 and 2020, respectively. Our capital expenditures for 2023 are expected to be approximately $13.0 million to $15.0&#160;million, excluding the impact of any future acquisitions.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, during 2022, pursuant to our authorized stock repurchase program, we repurchased 150,000 shares of our common stock at a weighted average price of $115.64 per share and a total cost of approximately $17 million. The repurchased shares are classified as treasury shares. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had $40.5 million in cash and cash equivalents and $520.4 million in availability under our $550.0&#160;million Revolving Credit Facility.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our operating forecasts and our debt service requirements, we believe we will have sufficient liquidity to fund our operations, capital requirements and debt service requirements for the next twelve months and beyond.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Outstanding Patient Accounts Receivable</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patient accounts receivable increased $21.8&#160;million from December 31, 2021. Our Medicare patient accounts receivable increased $9.8 million primarily due to billing issues related to the Notice of Admissions ("NOAs") process and billing delays resulting from the pre-claim review process in the five Review Choice Demonstration ("RCD") states. Our non-Medicare patient accounts receivable increased $12.0 million as a result of the transition of episodic payor reimbursement models to per visit reimbursement methods. Our cash collection as a percentage of revenue was 100% for the twelve-month periods ended December&#160;31, 2022 and 2021. Our days revenue outstanding, net at December&#160;31, 2022 was 46.1 days which is an increase of 2.9 days from December&#160;31, 2021. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patient accounts receivable includes unbilled receivables and are aged based upon the initial service date. We monitor unbilled receivables on a care center by care center basis to ensure that all efforts are made to bill claims within timely filing deadlines. Our unbilled patient accounts receivable may be impacted by pre-claim reviews required by the Medicare Administrative Contractors in the five RCD states, voluntary pre-bill edits and review, efforts to secure needed documentation to bill (orders, consents, etc.), integrations of recent acquisitions, changes of ownership and any regulatory and procedural updates impacting claim submission. The timely filing deadline for Medicare is one year from the date of the last billable service in the 30-day billing period and varies by state for Medicaid-reimburseable services and among insurance companies and other private payors.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following schedules detail our patient accounts receivable, by payor class, aged based upon initial date of service (amounts in millions, except days revenue outstanding):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0-90</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">91-180</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">181-365</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Over&#160;365</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">At December 31, 2022:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare patient accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other patient accounts receivable:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total patient accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296.8&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Days revenue outstanding (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0-90</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">91-180</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">181-365</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Over&#160;365</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">At December 31, 2021:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare patient accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other patient accounts receivable:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total patient accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275.0&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Days revenue outstanding (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Our calculation of days revenue outstanding is derived by dividing our ending patient accounts receivable at December&#160;31, 2022 and 2021 by our average daily net service revenue for the three-month periods ended December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indebtedness</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Second Amendment to the Credit Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 30, 2021, we entered into the Second Amendment to our Credit Agreement (as amended by the Second Amendment, the "Second Amended Credit Agreement"). The Second Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $1.0&#160;billion, which includes a $550.0&#160;million Revolving Credit Facility and a term loan facility with a principal amount of up to $450.0&#160;million (the "Amended Term Loan Facility" and collectively with the Revolving Credit Facility, the "Amended Credit Facility").</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net proceeds from the $450.0&#160;million Amended Term Loan Facility were used to fund the Contessa acquisition. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our weighted average interest rate for borrowings under our Amended Term Loan Facility was 3.2% for the year ended December 31, 2022 and 1.6% for the year ended December&#160;31, 2021. Our weighted average interest rate for borrowings under our $550.0 million Revolving Credit Facility was 3.4% for the year ended December 31, 2022 and 1.9% for the year ended December 31, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, our consolidated leverage ratio was 1.7, our consolidated interest coverage ratio was 11.6 and we are in compliance with our covenants under the Second Amended Credit Agreement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, our availability under our $550.0 million Revolving Credit Facility was $520.4 million as we have no outstanding borrowings and $29.6 million outstanding in letters of credit.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 8, Note 9 &#8211; Long Term Obligations to our consolidated financial statements for additional details on our outstanding long-term obligations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Repurchase Programs</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 23, 2020, we announced that our Board of Directors authorized a stock repurchase program, under which we could repurchase up to $100&#160;million of our outstanding common stock through December&#160;31, 2021 (the "2021 Share Repurchase Program"). Pursuant to this program, we repurchased 446,832 shares of our common stock at a weighted average price of $223.49 per share and a total cost of approximately $100&#160;million during the year ended December 31, 2021. We did not repurchase any shares pursuant to this stock repurchase program during the year ended December 31, 2020. The repurchased shares were classified as treasury shares. The 2021 Share Repurchase Program expired on December 31, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2021, our Board of Directors authorized a share repurchase program, under which we could repurchase up to $100&#160;million of our outstanding common stock through December&#160;31, 2022 to commence upon the completion of the Company's 2021 Share Repurchase Program (the "New Share Repurchase Program"). Pursuant to this program, we repurchased 150,000 shares of our common stock at a weighted average price of $115.64 per share and a total cost of approximately $17 million during the year ended December 31, 2022. The repurchased shares were classified as treasury shares. The New Share Repurchase Program expired on December 31, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2021 Share Repurchase Program and the New Share Repurchase Program, we were allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases were determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2023, our Board of Directors authorized a share repurchase program, under which we may repurchase up to $100 million of our outstanding common stock through December 31, 2023 (the "2023 Share Repurchase Program"). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2023 Share Repurchase Program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual Obligations</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future contractual obligations at December&#160;31, 2022 were as follows (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments Due by Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less&#160;than<br/>1&#160;Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2-3<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4-5<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">After<br/>5&#160;Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on long-term obligations (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase obligations (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Interest on debt with variable rates was calculated using the current rate for that particular debt instrument at December&#160;31, 2022.</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Purchase obligations are primarily related to information technology contracts and software licenses. We have a significant information technology contract that will be renewed in 2023. The table above does not reflect any amounts related to this contract.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inflation</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have been materially impacted by the current inflationary environment as we have experienced higher labor costs and increases in supply costs, fuel costs and mileage reimbursements. We expect inflation to continue to impact our operations in 2023. As of December 31, 2022, the impacts of inflation on our results of operations have been partially mitigated by rate increases, improvements in clinician utilization and reductions in hospice staffing levels. No assurance can be given as to our ability to offset the impacts of inflation in the future.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with U.S. Generally Accepted Accounting Principles (&#8220;U.S. GAAP&#8221;). The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses and related disclosures of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to revenue recognition, collectability of accounts receivable, reserves related to insurance and litigation, business combinations, goodwill, intangible assets, income taxes and contingencies. We base these estimates on our historical experience and various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results experienced may vary materially and adversely from our estimates. To the extent there are material differences between our estimates and the actual results, our future results of operations may be affected.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the following critical accounting policies represent our most significant judgments and estimates used in the preparation of our consolidated financial statements.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for revenue from contracts with customers in accordance with Accounting Standards Codification ("ASC") 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. Our cost of obtaining contracts is not material. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligations relate to contracts with a duration of less than one year; therefore, we have elected to apply the optional exemption provided by ASC 606 and are not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third-party payors and others for services provided. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current industry conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. We assess our ability to collect for the healthcare services provided at the time of patient admission based on our verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represents approximately 74% of our consolidated net service revenue.  </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation based on our historical experience which primarily includes a historical collection rate of over 99% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home Health Revenue Recognition</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"). PDGM uses 30-day periods of care rather than 60-day episodes of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, we account for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed. Each 60-day episode includes two 30-day payment periods.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net service revenue is recorded based on the established Federal Medicare home health payment rate for a 30-day period of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#8217;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice" practical expedient, and therefore, our revenue recognition is based on the reimbursement we are entitled to for each 30-day period of care. We utilize our historical average length of stay for each 30-day period of care as the measure of progress towards the satisfaction of our performance obligation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables, including, but not limited to (a) an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#8220;LUPA&#8221;) if the number of visits provided was less than the established threshold, which ranges from two to six visits and varies for every case-mix group; (c)&#160;a partial payment if a patient is transferred to another provider or from another provider before completing the 30-day period of care; and (d)&#160;the applicable geographic wage index. Payments for routine and non-routine supplies are included in the 30-day payment rate.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered to revenue with a corresponding reduction to patient accounts receivable. A 0.1% change in our Medicare collection rate would impact our annual Medicare revenue by approximately $0.9 million.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during the novel coronavirus pandemic ("COVID-19"), CMS relaxed the definition of homebound status through the duration of the public health emergency. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their home because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, 20% of the reimbursement from each Medicare 30-day payment rate was billed near the start of each 30-day period of care, referred to as a request for anticipated payment ("RAP"), and cash was typically received before all services were rendered. Any cash received from Medicare for a RAP for a 30-day period of care that exceeded the associated revenue earned was recorded to accrued expenses within our consolidated balance sheets. CMS fully eliminated all upfront payments associated with RAPs effective January 1, 2021. Effective January 1, 2022, CMS implemented a new one-time Notice of Admission ("NOA") process. The NOA process requires a one-time submission that establishes the home health period of care and covers all contiguous 30-day periods of care until the patient is discharged from Medicare home health services. If the NOA is not submitted timely, a payment reduction will be applied equal to 1/30 of the payment amount for each day from the home health start of care date until the date the NOA is submitted.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments from non-Medicare payors are either a percentage of Medicare rates, per-visit rates or case rates depending upon the terms and conditions established with such payors. Approximately 30% of our managed care contract volume affords us the opportunity to receive additional payments if we achieve certain quality or process metrics as defined in each contract (e.g. star ratings and acute-care hospitalization rates).</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Episodic-based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms which generally range from 95% to 100% of Medicare rates.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-episodic based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For our per visit contracts, gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. For our case rate contracts, gross revenue is recorded over our historical average length of stay using the established case rate for each admission. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on our historical experience to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our case rate contracts, we may receive reimbursement before all services are rendered. Any cash received that exceeds the associated revenue earned is recorded to deferred revenue in accrued expenses within our consolidated balance sheets.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospice Revenue Recognition</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Medicare Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for 97% of our total Medicare hospice service revenue for each of 2022, 2021 and 2020, respectively. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#8220;SIA&#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record it during the period services are rendered. A 0.1% change in our Medicare collection rate would impact our annual Medicare revenue by approximately $0.7 million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our consolidated balance sheets. Providers are required to self-report and pay their estimated cap liability by February 28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the following year. As of December&#160;31, 2022, we have recorded $4.3 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2023. As of December&#160;31, 2021, we had recorded $4.5 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2022.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Non-Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third-party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on our historical experience to reflect the estimated transaction price.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Personal Care Revenue Recognition</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Personal Care Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate net service revenue by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points ("ASAPs"), Senior Care Options ("SCOs"), Program of All-Inclusive Care for the Elderly ("PACE") and the Veterans Administration ("VA"). </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">High Acuity Care Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">High Acuity Care Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues are derived from contracts with (1) health insurance plans for the coordination and provision of home recovery care services to clinically-eligible patients who are enrolled members in those insurance plans, (2) health system partners for the coordination and provision of home recovery care services to clinically-eligible patients who are discharged early from a health system facility to complete their inpatient stay at home and (3) Medicare and other payors for the provision of home health services. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our health insurance plan contracts, we provide home recovery care services, which include hospital-equivalent ("H@H") and skilled nursing facility ("SNF") equivalent services ("SNF@H"), for high acuity care patients on a full risk basis whereby we assume the financial risk for the coordination and payment of all hospital or SNF replacement medical services necessary to treat the medical condition for which the patient was diagnosed in a home-based setting for a 30-day (H@H) or 60-</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">day (SNF@H) episode of care in exchange for a fixed contracted bundled rate. For H@H programs, the fixed rate is based on the assigned diagnosis related group ("DRG") and the 30-day post-discharge related spend. For SNF@H programs, the fixed rate is based on the 60-day post-discharge related spend. Our performance obligation is the coordination and provision of patient care in accordance with physicians&#8217; orders over either a 30-day or 60-day episode of care. The majority of our care coordination services and direct patient care is provided in the first five to seven days of the episode period (the "acute phase"). Monitoring services and follow-up direct patient care, as deemed necessary by the treating physician, are provided throughout the remainder of the episode. Since the majority of our services are provided during the acute phase, we recognize net service revenue over the acute phase based on gross charges for the services provided per the applicable managed care contract rates, reduced by estimates for revenue adjustments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our contracts with health system partners, we provide home recovery care services for high acuity patients on a limited risk basis whereby we assume the risk for certain healthcare services during the remainder of an inpatient acute stay serviced at the patient&#8217;s home in exchange for a contracted per diem rate. The performance obligation is the coordination and provision of required medical services, as determined by the treating physician, for each day the patient receives inpatient-equivalent care at home. As such, revenues are recognized as services are administered and as our performance obligations are satisfied on a per diem basis, reduced by estimates for revenue adjustments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize adjustments to revenue during the period in which changes to estimates of assigned patient diagnoses or episode terminations become known, in accordance with the applicable managed care contracts. For certain health insurance plans, revenue is reduced by amounts owed by enrollees to healthcare providers under deductible, coinsurance or copay provisions of health insurance plan policies, since those amounts are repaid to the health insurance plans by us as part of a retrospective reconciliation process.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, our high acuity care segment entered into a transaction in which one of our health system partners contributed its home health operations to one of our existing high acuity care joint ventures. We recognize Medicare and non-Medicare revenue in a manner that is consistent with our home health segment revenue recognition policy described above.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Acquisitions are accounted for as purchases and are included in our consolidated financial statements from their respective acquisition dates. Assets acquired, liabilities assumed and noncontrolling interests, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets. In determining the fair value of identifiable intangible assets and any noncontrolling interests, we use various valuation techniques including the income approach, the cost approach and the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">market approach. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, growth rates and discount rates.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Other Intangible Assets</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had a goodwill balance of $1,287.4 million. Goodwill represents the amount of the purchase price in excess of the fair values assigned to the underlying identifiable net assets of acquired businesses. Goodwill is not amortized, but is subject to an annual impairment test. Tests are performed more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount. These events or circumstances include, but are not limited to, a significant adverse change in the business environment, regulatory environment or legal factors, or a substantial decline in the market capitalization of our stock. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. GAAP allows for impairment testing to be done on either a quantitative or qualitative basis. During 2022, we performed a qualitative assessment to determine if it is more likely than not that the fair value of our reporting units are less than their carrying values by evaluating relevant events and circumstances including financial performance, market conditions and share price. Based on this assessment, we concluded that the goodwill associated with our home health, hospice and high acuity care reporting units was not considered at risk of impairment as of October 31, 2022. In addition to the qualitative assessment, we also performed a quantitative analysis for our personal care reporting unit due to the decline in revenues resulting from staffing shortages using an income and market approach. Based on this analysis, we concluded that the goodwill associated with our personal care reporting unit was not considered at risk of impairment as of October 31, 2022. Since the date of our last goodwill impairment test, there have been no material developments, events, changes in operating performance or other circumstances that would cause management to believe it is more likely than not that the fair value of any of our reporting units would be less than their carrying amounts. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had an other intangible assets balance of $101.2 million. Intangible assets consist of certificates of need, licenses, acquired names, non-compete agreements and technology. We amortize non-compete agreements and acquired names that we do not intend to use indefinitely on a straight-line basis over their estimated useful lives, which are generally two to three years for non-compete agreements and up to three years for acquired names. We amortize technology over its estimated useful service life, which is generally up to seven years. Our indefinite-lived intangible assets are reviewed for impairment annually or more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the intangible asset below its carrying amount. We performed a qualitative assessment of our indefinite-lived intangible assets during 2022 and determined that there have been no material developments, events, changes in operating performance or other circumstances that would cause management to believe it is more likely than not that the fair value of any of our indefinite-lived intangible assets would be less than their carrying amounts.</span></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div id="i5c10b724a6674979bf3c35a339f29685_46"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk from fluctuations in interest rates. Our Term Loan and Revolving Credit Facility carry a floating interest rate which is tied to the Eurodollar rate (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> LIBOR) and the Prime Rate, and therefore, our consolidated statements of operations and our consolidated statements of cash flows are exposed to changes in interest rates. Our Second Amended Credit Agreement provides for the replacement of LIBOR with the daily or term secured overnight financing rate ("SOFR") whenever LIBOR is discontinued. As of December&#160;31, 2022, the total amount of outstanding debt subject to interest rate fluctuations was $435.9&#160;million. A 1.0% interest rate change would cause interest expense to change by approximately $4.4&#160;million annually, assuming the Company makes no principal repayments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="i5c10b724a6674979bf3c35a339f29685_49"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and Board of Directors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amedisys, Inc.:</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Opinion on the Consolidated Financial Statements</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Amedisys, Inc. and subsidiaries (the Company) as of December 31, 2022 and 2021, the related consolidated statements of operations, comprehensive income, stockholders&#8217; equity, and cash flows for each of the years in the three-year period ended December 31, 2022, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2022, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated February 16, 2023 expressed an unqualified opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis for Opinion</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Audit Matter</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of the non-contractual revenue adjustment estimates for Home Health and Hospice</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 2 to the consolidated financial statements, the Company determines the transaction price for revenue contracts based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from the Company&#8217;s inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Non-contractual revenue adjustments are recorded based on the Company&#8217;s historical collection experience, aged accounts receivable by payor and current industry conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts the Company expects to collect based on its collection history with similar payors.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified the evaluation of the non-contractual revenue adjustment estimates noted above for the Home Health and Hospice segments as a critical audit matter. Subjective and complex auditor judgment was required to evaluate the method and historical collection experience used by the Company when developing the non-contractual revenue adjustment estimate. Specifically, the significant judgments related to evaluating the relevance of historical collection experience to the determination of the estimate, which included evaluation of current conditions, trends, historical adjustment experience, and other factors.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls related to the Company&#8217;s revenue process, including controls over the method and significant judgments for estimating non-contractual revenue adjustments noted above. We assessed the outcome of the estimation of non-contractual revenue adjustments in the prior period to identify circumstances or conditions that are relevant to the determination of the current year estimate. To assess the current year method and the relevance of the historical collection experience, we also evaluated current conditions, trends, historical adjustment experience, and other factors relevant to the estimation of non-contractual revenue adjustments.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ KPMG LLP</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 2002.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Baton Rouge, Louisiana</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;16, 2023 </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="i5c10b724a6674979bf3c35a339f29685_52"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share data)</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfNC0xLTEtMS01MDcyNQ_6f8b2a28-6143-476d-81cb-75a622fef5ee">40,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfNC0zLTEtMS01MDcyNQ_891ce023-3b48-4297-86bb-209f84968d41">42,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfNS0xLTEtMS01MDcyNQ_c840153d-d1b8-44f7-b4e8-be47d9b0c1d6">13,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfNS0zLTEtMS01MDcyNQ_6c4113d5-03d4-4ed8-a63a-e734e8fe3b32">3,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfNi0xLTEtMS01MDcyNQ_c71c5a72-3675-4b3f-80f9-6e18a2379751">296,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfNi0zLTEtMS01MDcyNQ_7a66ed7d-a668-4d78-90f4-168d717424b1">274,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfNy0xLTEtMS01MDcyNQ_645c6e15-3044-4624-a7f0-cc5f52bf7d4c">11,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfNy0zLTEtMS01MDcyNQ_3c43aaf9-c0ff-4b70-9b80-3818b289610d">10,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfOC0xLTEtMS01MDcyNQ_03c1e340-6f28-4b0b-b3f8-4aad82b95efb">26,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfOC0zLTEtMS01MDcyNQ_a7237be7-e2e8-4106-a5f0-6579e4582343">25,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfOS0xLTEtMS01MDcyNQ_c6a23010-275b-498a-9149-d815b526a0ae">388,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfOS0zLTEtMS01MDcyNQ_db2f56bc-8b8b-4ffe-a981-5c9575c87704">356,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation of $<ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTAtMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjo2OTg5YzMyY2JmZWQ0ZmQ5YmUwZmM4ZTg1ZGY4MGJlMF82Mw_4e6550d1-4e28-4417-91d4-3be0a5c1d4d1">101,364</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTAtMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjo2OTg5YzMyY2JmZWQ0ZmQ5YmUwZmM4ZTg1ZGY4MGJlMF83MA_292ad74b-57a1-4ae1-846d-0829792ca0e5">96,937</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTAtMS0xLTEtNTA3MjU_131ea69e-2a47-455c-832b-ad68877e3e1e">16,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTAtMy0xLTEtNTA3MjU_8cead186-856a-46d3-8a87-5a7e8bd7ee01">18,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTEtMS0xLTEtNTA3MjU_998279fe-5330-4bd8-bb85-c0ded6da213a">102,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTEtMy0xLTEtNTA3MjU_43487ffb-98c9-4a3d-925f-3ad4fa5d7598">101,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTItMS0xLTEtNTA3MjU_c909fdd7-6075-4310-8034-674588aa80b6">1,287,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTItMy0xLTEtNTA3MjU_fb869bf7-0468-466a-97c6-711bb7927956">1,196,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets, net of accumulated amortization of $<ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTMtMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjpjYWQ0NDYyNGZjYTM0M2YzOGNiYmZlZGIzNGNiZDA1Y181OA_6a04dbe6-02d9-4d74-88b5-7586dcec441c">14,604</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTMtMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjpjYWQ0NDYyNGZjYTM0M2YzOGNiYmZlZGIzNGNiZDA1Y182NQ_b96361e9-b8f0-4ef2-bca0-92b141a47de1">19,900</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTMtMS0xLTEtNTA3MjU_22b3900d-0c41-49b5-b5c3-ca84278fc452">101,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTMtMy0xLTEtNTA3MjU_34409f6e-a789-447e-9eb1-fa899efcd56a">111,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTQtMS0xLTEtNTA3MjU_653345e3-6c4a-4cd9-abab-ecce038639f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTQtMy0xLTEtNTA3MjU_b0bad924-63ca-4c6d-bfc0-ef3285ce2b68">289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTUtMS0xLTEtNTA3MjU_ec80db31-b01b-4a16-bcc4-40192e2c59a4">79,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTUtMy0xLTEtNTA3MjU_bed5561a-2e58-405c-af1c-82f2f1ac9631">73,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTYtMS0xLTEtNTA3MjU_9e7aaca5-8188-451d-995f-9a324c5e5535">1,976,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTYtMy0xLTEtNTA3MjU_0c6c7806-b198-4f52-a475-de95ebb24ff4">1,856,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTktMS0xLTEtNTA3MjU_970a17c7-efab-4a30-83fb-08429ed00e2d">43,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTktMy0xLTEtNTA3MjU_ade55d32-cd5f-4c88-b209-c4856751d2f0">38,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjAtMS0xLTEtNTA3MjU_886578d9-3bb7-4d08-ae8a-069a81258508">125,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjAtMy0xLTEtNTA3MjU_3a3bb214-89ec-43eb-b68e-86c9943c90c0">141,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjEtMS0xLTEtNTA3MjU_fad362e9-8eae-4bf4-8297-12a6b39b47e8">137,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjEtMy0xLTEtNTA3MjU_7cc0a0af-8835-4f14-a77d-cf95a18b7920">150,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjMtMS0xLTEtNTA3MjU_a595aca5-6473-4c8a-ac93-e73133832d0e">15,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjMtMy0xLTEtNTA3MjU_34454e96-e15a-418a-9cec-a8f1a8101ee8">12,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjQtMS0xLTEtNTA3MjU_1224af15-10d2-4987-993a-a58c97adcae3">33,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjQtMy0xLTEtNTA3MjU_4efa6450-d7fc-4820-8d58-b8432eb7a464">31,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjUtMS0xLTEtNTA3MjU_1d3a422f-9f4e-47f1-bbbc-c83aec24e86e">355,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjUtMy0xLTEtNTA3MjU_8069e90e-19a7-41ff-9e12-231b215a1089">374,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term obligations, less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjYtMS0xLTEtNTA3MjU_28b3fcc2-9314-4dae-b39d-b4162fcb6243">419,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjYtMy0xLTEtNTA3MjU_bbda2953-2a4e-4499-8866-bfe1918d8618">432,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities, less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjctMS0xLTEtNTA3MjU_212fe27f-5a7b-495d-a68f-50f237111d5b">69,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjctMy0xLTEtNTA3MjU_da38734d-6aba-4753-879c-484a61b89a7e">69,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjctMS0xLTEtNTExMjI_9a611df7-5a5a-4365-9ff1-4f976a8da3f3">20,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjctMy0xLTEtNTExMjI_86e992f1-0139-4406-b712-00657aea49be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjgtMS0xLTEtNTA3MjU_8bf8d9ab-047f-41a3-9ed4-163ca6521661">4,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjgtMy0xLTEtNTA3MjU_00821ce2-af3d-48c9-9aaf-3ccdac19b58d">4,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjktMS0xLTEtNTA3MjU_3b587846-1ae6-4193-aa25-891b42968ce2">869,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjktMy0xLTEtNTA3MjU_9daf0817-3fca-44bc-a816-c03ac82dd840">880,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and Contingencies &#8211; Note 12</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzAtMS0xLTEtNTA3MjU_05885eb5-865c-4335-9034-0cae949b87e2"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzAtMy0xLTEtNTA3MjU_f410415d-5669-4383-a3c7-e05b9eb31c19"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzItMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjplY2U4MDFjNGI2Yzg0M2NmOTI1MjU0YmNiYzIzZjRhZF8yMQ_0da36e70-6eec-4604-9915-69f595558bae"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzItMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjplY2U4MDFjNGI2Yzg0M2NmOTI1MjU0YmNiYzIzZjRhZF8yMQ_6ef0ea87-680e-4799-8c62-dd614e1efcf5">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzItMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjplY2U4MDFjNGI2Yzg0M2NmOTI1MjU0YmNiYzIzZjRhZF8zNQ_5079b752-0589-4d58-8178-2c2da8650431"><ix:nonFraction unitRef="shares" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzItMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjplY2U4MDFjNGI2Yzg0M2NmOTI1MjU0YmNiYzIzZjRhZF8zNQ_c5b9ebbd-6547-463b-b680-f15e184428c7">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzItMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjplY2U4MDFjNGI2Yzg0M2NmOTI1MjU0YmNiYzIzZjRhZF81Nw_19f9206f-abbf-4bfe-a37c-5442acf52b27"><ix:nonFraction unitRef="shares" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzItMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjplY2U4MDFjNGI2Yzg0M2NmOTI1MjU0YmNiYzIzZjRhZF81Nw_353c62cb-52e8-464b-8e0a-cde2d63daa18"><ix:nonFraction unitRef="shares" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzItMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjplY2U4MDFjNGI2Yzg0M2NmOTI1MjU0YmNiYzIzZjRhZF81Nw_65d78b23-3ae1-4f47-87b2-139ddcb3f1a8"><ix:nonFraction unitRef="shares" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzItMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjplY2U4MDFjNGI2Yzg0M2NmOTI1MjU0YmNiYzIzZjRhZF81Nw_802ff55d-9717-4a48-b338-7e0e43328366">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued or outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:PreferredStockValueOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzItMS0xLTEtNTA3MjU_28bf9e25-9425-46d8-9b26-e82e23dc9c3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:PreferredStockValueOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzItMy0xLTEtNTA3MjU_d9567e2a-aea7-40d8-8005-38a739cb37a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzMtMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjozN2NmM2JhOGY3YzM0ZThjOTNkZmIwNzM1YjdhYjg0NV8xOA_1dc95f66-fc47-4349-82ee-984871a46796"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzMtMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjozN2NmM2JhOGY3YzM0ZThjOTNkZmIwNzM1YjdhYjg0NV8xOA_de9ba54e-599d-4465-92c6-7043baf56329">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzMtMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjozN2NmM2JhOGY3YzM0ZThjOTNkZmIwNzM1YjdhYjg0NV8zMg_67cfa59e-1233-4139-a39a-dafb034ab1dc"><ix:nonFraction unitRef="shares" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzMtMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjozN2NmM2JhOGY3YzM0ZThjOTNkZmIwNzM1YjdhYjg0NV8zMg_91307ad1-b11e-4bce-b71f-a92b5beb517e">60,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzMtMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjozN2NmM2JhOGY3YzM0ZThjOTNkZmIwNzM1YjdhYjg0NV81NA_cb9699bd-06a3-43e0-a2ac-143fa8109c46">37,891,186</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzMtMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjozN2NmM2JhOGY3YzM0ZThjOTNkZmIwNzM1YjdhYjg0NV82MQ_f5b352ca-8923-48a5-8d0b-ac7b4dfa030f">37,674,868</ix:nonFraction> shares issued; and <ix:nonFraction unitRef="shares" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzMtMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjozN2NmM2JhOGY3YzM0ZThjOTNkZmIwNzM1YjdhYjg0NV84Mw_eaade403-1975-4e38-861c-875f7f5526a7">32,518,278</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzMtMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjozN2NmM2JhOGY3YzM0ZThjOTNkZmIwNzM1YjdhYjg0NV85MA_5653a9f8-98c0-4777-9d9a-3c5b9f5e91de">32,509,969</ix:nonFraction> shares outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzMtMS0xLTEtNTA3MjU_6a7c3d33-e6b3-43d0-9e33-21f7c5444a66">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzMtMy0xLTEtNTA3MjU_0eeb59cf-9f90-4f85-8e61-ea65afc273da">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzQtMS0xLTEtNTA3MjU_9d353e0d-55d4-4c46-a60e-e89dbbbdd5bc">755,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzQtMy0xLTEtNTA3MjU_f42e7619-b134-4667-9e59-501a403cde63">728,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock at cost, <ix:nonFraction unitRef="shares" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzUtMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjplNmNjOWI3OTQ0ZTI0M2YzODMwOTc1YjI5NGQwNTk1ZV8yOA_c1e8901d-0f27-4cb3-bf8f-95d58d9b6d66">5,372,908</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzUtMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjplNmNjOWI3OTQ0ZTI0M2YzODMwOTc1YjI5NGQwNTk1ZV8zNQ_fec8e94d-0228-4bdc-a726-e90bc0fe2e9c">5,164,899</ix:nonFraction> shares of common stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzUtMS0xLTEtNTA3MjU_22a300da-96b4-4557-8563-8e56e645d0be">461,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzUtMy0xLTEtNTA3MjU_e05b173a-a4e9-473a-bddd-4b20e109c807">435,868</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzYtMS0xLTEtNTA3MjU_1fdb871d-9a13-48ff-a94d-c8b606606b47">757,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzYtMy0xLTEtNTA3MjU_0d28dfa3-07ef-4d92-b00c-7fc0a35245e6">639,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Amedisys, Inc. stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzctMS0xLTEtNTA3MjU_682a11bc-9b99-4143-8d42-51dbf4d31743">1,051,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzctMy0xLTEtNTA3MjU_0f35b6dd-f3f3-48b1-8785-c67d7d99884b">931,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzgtMS0xLTEtNTA3MjU_f123335f-6357-4f70-833e-49e184676039">55,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzgtMy0xLTEtNTA3MjU_3a8a6ff0-a7e3-445f-b988-e6bc751215ae">44,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzktMS0xLTEtNTA3MjU_77646148-adfe-4572-82c6-f394ef6822af">1,106,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzktMy0xLTEtNTA3MjU_c1c3cebb-ba5a-45a4-a38b-4a8de1835f6d">976,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfNDAtMS0xLTEtNTA3MjU_8ddcd12c-d6d7-4b4c-a51b-2c9640b6acf5">1,976,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfNDAtMy0xLTEtNTA3MjU_ad9a2267-c71e-4439-aae8-6c4effdb5c89">1,856,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="i5c10b724a6674979bf3c35a339f29685_58"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except per share data)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMi0xLTEtMS01MDcyNQ_8bf5ad3a-1522-44f3-b274-19aa4acb5035">2,223,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMi0zLTEtMS01MDcyNQ_cfc82291-4e8d-4eb4-976e-e3fcc0b54587">2,214,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMi01LTEtMS01MDcyNQ_f59a2a88-c0ef-4b12-b659-786847f08c3a">2,071,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:OtherOperatingIncome" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMy0xLTEtMS01MDcyNQ_ee3574eb-c31d-43d3-8e87-2d0cb46a7ed1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:OtherOperatingIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMy0zLTEtMS01MDcyNQ_5093c418-358c-41cf-96b4-7c2d8a04fe50">13,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:OtherOperatingIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMy01LTEtMS01MDcyNQ_fa63eade-c98f-42da-9008-722a97834507">34,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfNC0xLTEtMS01MDcyNQ_fc49e86f-e678-485f-95fe-019ba0791ba2">1,260,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfNC0zLTEtMS01MDcyNQ_5f88bf83-dbeb-424d-b548-dd7336ae151d">1,233,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfNC01LTEtMS01MDcyNQ_d842ec48-dfda-4eb8-84ff-73e902f46b89">1,185,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Salaries and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfNi0xLTEtMS01MDcyNQ_0c2af7d6-bd3a-49fe-b003-ceadf8b5279a">508,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfNi0zLTEtMS01MDcyNQ_38db668c-6b1a-43f4-b4a8-e16fe981ca9b">474,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfNi01LTEtMS01MDcyNQ_afdf0e24-698b-41ec-a2be-1a4a3bd21959">449,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Non-cash compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfNy0xLTEtMS01MDcyNQ_bd3eece0-95c2-4889-a0cf-2f2b4320d625">16,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfNy0zLTEtMS01MDcyNQ_3d6a3d57-264c-4b6b-b5a6-918bf81f9d57">23,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfNy01LTEtMS01MDcyNQ_12c660fe-3811-46b8-88b2-03c2f582e868">26,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:OtherGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfOC0xLTEtMS01MDcyNQ_f5df5eb7-2c95-40b3-b3f7-2996aebdfcce">228,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:OtherGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfOC0zLTEtMS01MDcyNQ_1ffdf80b-054f-4dd0-b7a3-e4a634534a3b">212,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:OtherGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfOC01LTEtMS01MDcyNQ_3597be2e-7901-45c1-bb8e-908eaa3a2b21">192,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="amed:DepreciationAndAmortizationForContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfOS0xLTEtMS01MDcyNQ_7fdda89a-2072-4b95-a0b0-cade3ddfe242">24,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="amed:DepreciationAndAmortizationForContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfOS0zLTEtMS01MDcyNQ_0fe30948-3140-46dc-a767-3c49d331b93c">30,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="amed:DepreciationAndAmortizationForContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfOS01LTEtMS01MDcyNQ_5172eaf9-5b0f-403d-8ae7-e9c9d03dc9ba">28,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTAtMS0xLTEtNTA3MjU_802af9ce-0a16-499a-9fd2-af2e6b2b10c9">3,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTAtMy0xLTEtNTA3MjU_d5431d21-9192-4238-a7f0-23fb59da0a98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTAtNS0xLTEtNTA3MjU_c200f855-d79a-474a-bead-cdc927f8a6c6">4,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTEtMS0xLTEtNTA3MjU_59198ab9-fbcd-4d74-a292-61dedb62424b">2,042,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTEtMy0xLTEtNTA3MjU_5510850c-474b-485c-a876-bc9a7a3ba7b4">1,975,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTEtNS0xLTEtNTA3MjU_76536723-d356-4eb4-b9e4-f6f47d14b672">1,886,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTItMS0xLTEtNTA3MjU_1b912c8f-7b64-4401-b85e-7c8292596e3b">180,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTItMy0xLTEtNTA3MjU_3953b48f-1b37-4a7e-8d33-e61dba4b1232">251,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTItNS0xLTEtNTA3MjU_35190b30-c120-490c-ac13-5fb2a98e9d01">219,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTQtMS0xLTEtNTA3MjU_dbac5121-6475-41ff-b2e9-1b801d78495b">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTQtMy0xLTEtNTA3MjU_f880c4c9-1099-4eee-ba65-36e335e01c34">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTQtNS0xLTEtNTA3MjU_2ada4277-065c-4ff1-ab10-1392a8f984e2">292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTUtMS0xLTEtNTA3MjU_3bed6e0a-9327-4bcf-9993-08adbf282b46">22,228</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTUtMy0xLTEtNTA3MjU_c113ced6-b8e9-4275-bf78-0387703b9015">9,525</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTUtNS0xLTEtNTA3MjU_f60e6efe-2eab-4b41-a78f-461edf005890">11,038</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity in (loss) earnings from equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTYtMS0xLTEtNTA3MjU_9100d8b4-2d12-4819-8bd1-6d50e179530c">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTYtMy0xLTEtNTA3MjU_96fd99f6-003c-47d2-94ba-b7cbb36a7607">4,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTYtNS0xLTEtNTA3MjU_432e75ee-f3cb-4a75-aedc-2cc0f1d6b2b3">3,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) on equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:GainLossOnInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTctMS0xLTEtNTA3MjU_83805ff3-9181-4c3c-9a5d-02aec335a45e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTctMy0xLTEtNTA3MjU_9298f8c4-28f9-481c-87f7-800ec4fc70a9">31,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTctNS0xLTEtNTA3MjU_ec9ad0c2-7625-49e4-91ce-162fa21adbcf">2,980</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Miscellaneous, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTgtMS0xLTEtNTA3MjU_bfeaf1b4-127c-4bf3-abdf-09e2bf0580cb">1,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTgtMy0xLTEtNTA3MjU_74867bf6-1243-408e-8953-cfb126a533a0">1,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTgtNS0xLTEtNTA3MjU_45aebde6-0d7a-42ae-ae85-1f00a394dc6e">1,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other (expense) income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTktMS0xLTEtNTA3MjU_f9cc5c90-dfff-42ce-89c7-b420a1214b4e">20,528</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTktMy0xLTEtNTA3MjU_25a29592-6821-40f9-a337-95f529a385bf">28,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTktNS0xLTEtNTA3MjU_2a28008e-7662-4a47-9fbf-f7285701c187">8,449</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjAtMS0xLTEtNTA3MjU_cc7efc3c-c91b-486b-995c-33bffc7360c3">160,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjAtMy0xLTEtNTA3MjU_54f3c0dc-64bb-4b39-87d5-fb889d22796f">280,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjAtNS0xLTEtNTA3MjU_b939b3a5-10b8-4503-acc8-8ca0cd65479e">210,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjEtMS0xLTEtNTA3MjU_9bdd278e-dadc-4be7-9a26-69e7b2a710c7">42,545</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjEtMy0xLTEtNTA3MjU_3b9ff771-ce42-4b73-a6e3-04b83fa6a849">70,065</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjEtNS0xLTEtNTA3MjU_741f0d51-507b-43fd-a6e7-c91c8417b848">25,635</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjItMS0xLTEtNTA3MjU_0a6c1995-4df1-4ff4-9abf-a507f5920019">117,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjItMy0xLTEtNTA3MjU_fa34a7c1-ab53-44e1-ad07-a796093d57a0">210,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjItNS0xLTEtNTA3MjU_1e98b1da-59f4-4a6e-b748-c5e189dae34e">185,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss (income) attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjMtMS0xLTEtNTA3MjU_a8d495fe-64d2-44a6-bcf7-a193feed41b9">910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjMtMy0xLTEtNTA3MjU_aa92651b-8db5-44a2-894e-51d5a0f5792e">1,094</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjMtNS0xLTEtNTA3MjU_f9a54ea5-4aee-4b2c-9bba-0319ce013072">1,576</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Amedisys, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjQtMS0xLTEtNTA3MjU_dca2a6c6-3d54-401a-946a-0cd412e61e14">118,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjQtMy0xLTEtNTA3MjU_f42b8cea-f7b2-42a1-b814-3793c4b46b90">209,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjQtNS0xLTEtNTA3MjU_67c43d7c-dc62-4f89-adeb-be1201f4c0e2">183,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic earnings per common share:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Amedisys, Inc. common stockholders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjYtMS0xLTEtNTA3MjU_6aa723cf-fda6-4c11-8559-0e935f9009d8">3.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjYtMy0xLTEtNTA3MjU_6334dd9c-c5a9-4cd1-8d6d-4433e355e44a">6.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjYtNS0xLTEtNTA3MjU_7d876d0e-a803-4c65-a414-d643cef9508d">5.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjctMS0xLTEtNTA3MjU_9a41f619-0df5-48d3-a62d-1603ff021afd">32,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjctMy0xLTEtNTA3MjU_0321ec41-3936-4628-a2a4-d5534b673f62">32,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjctNS0xLTEtNTA3MjU_0fb87633-aec9-4632-ad0a-3014a98aa05d">32,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings per common share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Amedisys, Inc. common stockholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjktMS0xLTEtNTA3MjU_9a0081af-0624-4f76-9e1b-91b8396ec81f">3.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjktMy0xLTEtNTA3MjU_5711ea04-4e7d-4ded-bfce-6846ea737eaa">6.34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjktNS0xLTEtNTA3MjU_ac82a575-4342-420a-9998-754b26bf3b50">5.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMzAtMS0xLTEtNTA3MjU_d08bc5fb-ed43-4e48-a126-03df3455b35c">32,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMzAtMy0xLTEtNTA3MjU_54927090-5722-4e2e-850b-bd92016d2763">32,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMzAtNS0xLTEtNTA3MjU_0e1a4993-758f-41d0-82cd-15aeaa218065">33,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="i5c10b724a6674979bf3c35a339f29685_61"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82MS9mcmFnOmZmNmMxY2JlYzg2NjRkNTY4ZjU3ZDM1MWZiYTE3Mjc4L3RhYmxlOjI1NWZiMzZiYTNiMTQ0NjY5MjEzNmExYmU1ZjA3YTI5L3RhYmxlcmFuZ2U6MjU1ZmIzNmJhM2IxNDQ2NjkyMTM2YTFiZTVmMDdhMjlfMi0xLTEtMS01MDcyNQ_1e3a60e5-2a1b-402a-b240-a6addcd06e07">117,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82MS9mcmFnOmZmNmMxY2JlYzg2NjRkNTY4ZjU3ZDM1MWZiYTE3Mjc4L3RhYmxlOjI1NWZiMzZiYTNiMTQ0NjY5MjEzNmExYmU1ZjA3YTI5L3RhYmxlcmFuZ2U6MjU1ZmIzNmJhM2IxNDQ2NjkyMTM2YTFiZTVmMDdhMjlfMi0zLTEtMS01MDcyNQ_38eb71d3-a5e4-4ea2-b526-117d34cfa618">210,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82MS9mcmFnOmZmNmMxY2JlYzg2NjRkNTY4ZjU3ZDM1MWZiYTE3Mjc4L3RhYmxlOjI1NWZiMzZiYTNiMTQ0NjY5MjEzNmExYmU1ZjA3YTI5L3RhYmxlcmFuZ2U6MjU1ZmIzNmJhM2IxNDQ2NjkyMTM2YTFiZTVmMDdhMjlfMi01LTEtMS01MDcyNQ_63d008bb-1494-4641-8b32-ebb4652dce79">185,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82MS9mcmFnOmZmNmMxY2JlYzg2NjRkNTY4ZjU3ZDM1MWZiYTE3Mjc4L3RhYmxlOjI1NWZiMzZiYTNiMTQ0NjY5MjEzNmExYmU1ZjA3YTI5L3RhYmxlcmFuZ2U6MjU1ZmIzNmJhM2IxNDQ2NjkyMTM2YTFiZTVmMDdhMjlfMy0xLTEtMS01MDcyNQ_2ad648f9-7769-48f3-83cc-69918dc7f3f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82MS9mcmFnOmZmNmMxY2JlYzg2NjRkNTY4ZjU3ZDM1MWZiYTE3Mjc4L3RhYmxlOjI1NWZiMzZiYTNiMTQ0NjY5MjEzNmExYmU1ZjA3YTI5L3RhYmxlcmFuZ2U6MjU1ZmIzNmJhM2IxNDQ2NjkyMTM2YTFiZTVmMDdhMjlfMy0zLTEtMS01MDcyNQ_6c6498e2-bf07-4117-920c-6a23599ba378">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82MS9mcmFnOmZmNmMxY2JlYzg2NjRkNTY4ZjU3ZDM1MWZiYTE3Mjc4L3RhYmxlOjI1NWZiMzZiYTNiMTQ0NjY5MjEzNmExYmU1ZjA3YTI5L3RhYmxlcmFuZ2U6MjU1ZmIzNmJhM2IxNDQ2NjkyMTM2YTFiZTVmMDdhMjlfMy01LTEtMS01MDcyNQ_61e95ed7-2fb8-4e3c-a01e-f19988fa1f69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82MS9mcmFnOmZmNmMxY2JlYzg2NjRkNTY4ZjU3ZDM1MWZiYTE3Mjc4L3RhYmxlOjI1NWZiMzZiYTNiMTQ0NjY5MjEzNmExYmU1ZjA3YTI5L3RhYmxlcmFuZ2U6MjU1ZmIzNmJhM2IxNDQ2NjkyMTM2YTFiZTVmMDdhMjlfNC0xLTEtMS01MDcyNQ_97689403-c24b-444f-9d47-58b465a4cbd6">117,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82MS9mcmFnOmZmNmMxY2JlYzg2NjRkNTY4ZjU3ZDM1MWZiYTE3Mjc4L3RhYmxlOjI1NWZiMzZiYTNiMTQ0NjY5MjEzNmExYmU1ZjA3YTI5L3RhYmxlcmFuZ2U6MjU1ZmIzNmJhM2IxNDQ2NjkyMTM2YTFiZTVmMDdhMjlfNC0zLTEtMS01MDcyNQ_b0853582-6b63-4dbd-ae1d-33b9dfb9ec2e">210,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82MS9mcmFnOmZmNmMxY2JlYzg2NjRkNTY4ZjU3ZDM1MWZiYTE3Mjc4L3RhYmxlOjI1NWZiMzZiYTNiMTQ0NjY5MjEzNmExYmU1ZjA3YTI5L3RhYmxlcmFuZ2U6MjU1ZmIzNmJhM2IxNDQ2NjkyMTM2YTFiZTVmMDdhMjlfNC01LTEtMS01MDcyNQ_54ec4b6e-b875-4858-bb81-47784cfd163e">185,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Comprehensive loss (income) attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82MS9mcmFnOmZmNmMxY2JlYzg2NjRkNTY4ZjU3ZDM1MWZiYTE3Mjc4L3RhYmxlOjI1NWZiMzZiYTNiMTQ0NjY5MjEzNmExYmU1ZjA3YTI5L3RhYmxlcmFuZ2U6MjU1ZmIzNmJhM2IxNDQ2NjkyMTM2YTFiZTVmMDdhMjlfNS0xLTEtMS01MDcyNQ_b1a553d4-8a4f-49dc-ae16-f9006a26023d">910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82MS9mcmFnOmZmNmMxY2JlYzg2NjRkNTY4ZjU3ZDM1MWZiYTE3Mjc4L3RhYmxlOjI1NWZiMzZiYTNiMTQ0NjY5MjEzNmExYmU1ZjA3YTI5L3RhYmxlcmFuZ2U6MjU1ZmIzNmJhM2IxNDQ2NjkyMTM2YTFiZTVmMDdhMjlfNS0zLTEtMS01MDcyNQ_7d7437bf-7d47-478c-b50a-d7c0fcf39343">1,094</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82MS9mcmFnOmZmNmMxY2JlYzg2NjRkNTY4ZjU3ZDM1MWZiYTE3Mjc4L3RhYmxlOjI1NWZiMzZiYTNiMTQ0NjY5MjEzNmExYmU1ZjA3YTI5L3RhYmxlcmFuZ2U6MjU1ZmIzNmJhM2IxNDQ2NjkyMTM2YTFiZTVmMDdhMjlfNS01LTEtMS01MDcyNQ_929d0838-8bb1-4581-a82b-c9d44dd6417a">1,576</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Comprehensive income attributable to Amedisys, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82MS9mcmFnOmZmNmMxY2JlYzg2NjRkNTY4ZjU3ZDM1MWZiYTE3Mjc4L3RhYmxlOjI1NWZiMzZiYTNiMTQ0NjY5MjEzNmExYmU1ZjA3YTI5L3RhYmxlcmFuZ2U6MjU1ZmIzNmJhM2IxNDQ2NjkyMTM2YTFiZTVmMDdhMjlfNi0xLTEtMS01MDcyNQ_9fcdc65a-097b-4a31-9cb2-6c1828b011af">118,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82MS9mcmFnOmZmNmMxY2JlYzg2NjRkNTY4ZjU3ZDM1MWZiYTE3Mjc4L3RhYmxlOjI1NWZiMzZiYTNiMTQ0NjY5MjEzNmExYmU1ZjA3YTI5L3RhYmxlcmFuZ2U6MjU1ZmIzNmJhM2IxNDQ2NjkyMTM2YTFiZTVmMDdhMjlfNi0zLTEtMS01MDcyNQ_50e6af5d-c302-4136-b5ba-65b8d83b033f">209,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82MS9mcmFnOmZmNmMxY2JlYzg2NjRkNTY4ZjU3ZDM1MWZiYTE3Mjc4L3RhYmxlOjI1NWZiMzZiYTNiMTQ0NjY5MjEzNmExYmU1ZjA3YTI5L3RhYmxlcmFuZ2U6MjU1ZmIzNmJhM2IxNDQ2NjkyMTM2YTFiZTVmMDdhMjlfNi01LTEtMS01MDcyNQ_c7ed5aed-6bde-4cb0-969a-918a36fb4e97">183,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:341pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><div id="i5c10b724a6674979bf3c35a339f29685_64"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except common stock shares)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:23.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.270%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.213%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interests</span></td></tr><tr style="height:23pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab144f7e34ce4a479683c59de399ff42_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMi0xLTEtMS01MDcyNQ_752fc10f-d732-4065-ae6c-0318977ae909">641,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a842a348ea54e2aa7af78df38c5e42a_I20191231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMi0zLTEtMS01MDcyNQ_2f4570c7-6f39-4d76-952e-8d113890f4da">36,638,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a842a348ea54e2aa7af78df38c5e42a_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMi01LTEtMS01MDcyNQ_32c486a4-7239-447b-b87d-ded7be7bf1df">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i812c4f7fd6e8491d8a6c1f0f7f2f0c8a_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMi03LTEtMS01MDcyNQ_4c26f27a-018c-4803-808e-75bbf2c65a09">645,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1184798dbf244669a8ac664a6a3e701e_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMi05LTEtMS01MDcyNQ_38635a9a-9189-404c-8925-5928da1ac096">251,241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94b781b07d4d4409b8dcc3915918b994_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMi0xMS0xLTEtNTA3MjU_551a4f65-0f21-4ac4-aaa6-0e586300104e">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7347a5a29b245a290ea5780c2f8e972_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMi0xMy0xLTEtNTA3MjU_a098ac79-4368-4cf6-ba89-9eacbbaf9cef">246,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i883b9612a1ce4040993b8d0c85aa8244_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMi0xNS0xLTEtNTA3MjU_a8f34a6f-1d62-43f0-a013-ab1d6caa59b0">1,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock &#8211; employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMy0xLTEtMS01MDcyNQ_c0a66930-77ed-4e6b-b2f5-5fb4e813deed">3,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idaad48809b5744fabff0426f64590228_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMy0zLTEtMS01MDcyNQ_809c9b59-f1a7-4c5e-8875-743bc9320afe">21,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbbf4b06ee8949419799fc4f109084c8_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMy03LTEtMS01MDcyNQ_58080249-1def-4675-94ab-ac8a6209d72c">3,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock &#8211; 401(k) plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfNC0xLTEtMS01MDcyNQ_6f9aa1a2-ed54-4e5b-adb5-acb271271fe1">3,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idaad48809b5744fabff0426f64590228_D20200101-20201231" decimals="INF" name="amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfNC0zLTEtMS01MDcyNQ_71656623-1523-42c8-b861-105de191e7d2">18,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbbf4b06ee8949419799fc4f109084c8_D20200101-20201231" decimals="-3" name="amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfNC03LTEtMS01MDcyNQ_9586d797-8b55-47f1-9f74-54bc155489f5">3,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance/(cancellation) of non-vested stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfNS0xLTEtMS01MDcyNQ_bf7491a2-3878-4e22-9261-f4dc04891aa0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idaad48809b5744fabff0426f64590228_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfNS0zLTEtMS01MDcyNQ_ead75d7f-d84f-461c-95bd-ec30c00b4960">169,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbbf4b06ee8949419799fc4f109084c8_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfNS03LTEtMS01MDcyNQ_2b5d7621-e4d8-4fa0-881d-1f81a2cfbd1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfNi0xLTEtMS01MDcyNQ_20a5843b-99dd-42fe-ba07-e151c39ccd00">6,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idaad48809b5744fabff0426f64590228_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfNi0zLTEtMS01MDcyNQ_eca0dea0-f972-47d9-bd19-8cf9db3882ea">622,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaad48809b5744fabff0426f64590228_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfNi01LTEtMS01MDcyNQ_5bc46777-e479-468a-b6ac-896b47129c50">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbbf4b06ee8949419799fc4f109084c8_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfNi03LTEtMS01MDcyNQ_05ec89fd-b947-42a4-aa8d-ab3b084d8fc8">6,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfNy0xLTEtMS01MDcyNQ_5d678602-0494-48b2-913c-1191a52331db">26,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbbf4b06ee8949419799fc4f109084c8_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfNy03LTEtMS01MDcyNQ_a46c0102-0e1a-4bdc-a530-0923751e7042">26,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surrendered shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" sign="-" name="amed:SurrenderedShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfOC0xLTEtMS01MDcyNQ_b007ca08-855f-4314-b588-d0c599821958">54,493</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbbf4b06ee8949419799fc4f109084c8_D20200101-20201231" decimals="-3" name="amed:SurrenderedShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfOC03LTEtMS01MDcyNQ_a33ecf4e-d79e-4eb8-9700-0a089ab4963f">13,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6914d90131e14c43a26dc97a98c426c8_D20200101-20201231" decimals="-3" sign="-" name="amed:SurrenderedShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfOC05LTEtMS01MDcyNQ_f2b7b2f8-3e3b-42eb-ab31-69b359fbdcd8">67,851</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interest distributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfOS0xLTEtMS01MDcyNQ_da60e754-415a-453e-949f-151824b915a0">1,122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76caa3bd393e42e2ba1a0e9df9033378_D20200101-20201231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfOS0xNS0xLTEtNTA3MjU_c96d9753-873b-4cb0-9555-0131cb11e183">1,122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Write-off of other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="amed:EquityImpactOfWriteOffOfOtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTAtMS0xLTEtNTE0MTQ_21f3dbbf-c76b-4259-96eb-52164207b024">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7be9b19ba9f7478f8d633e2083f22149_D20200101-20201231" decimals="-3" name="amed:EquityImpactOfWriteOffOfOtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTAtMTEtMS0xLTUxNDE0_e7c6bedf-f40e-4484-b11d-dd7549da1b70">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTAtMS0xLTEtNTA3MjU_ff581590-d3b6-4dd9-b459-a657660cb1ce">185,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f85583bb3f049d3afa37b4d013dcf79_D20200101-20201231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTAtMTMtMS0xLTUwNzI1_e1e06426-0b44-48be-b28d-ba30cd9d7fec">183,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76caa3bd393e42e2ba1a0e9df9033378_D20200101-20201231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTAtMTUtMS0xLTUwNzI1_a5242c47-2bb2-48ca-970b-a463d9022751">1,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42b1e865f1ed4b2e8363dfcc39186a91_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTEtMS0xLTEtNTA3MjU_bba6de73-2669-439f-8b12-143f49d0ee08">810,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae6f76a71f3044fc83923db577d2d9bc_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTEtMy0xLTEtNTA3MjU_5ae4ab2e-e391-4855-bdc3-a7ab8ad48c3f">37,470,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae6f76a71f3044fc83923db577d2d9bc_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTEtNS0xLTEtNTA3MjU_77f84c59-1e8d-44bd-8be1-67b57e05f7f6">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9fa2aa843ed46e5b472b3eebcb45775_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTEtNy0xLTEtNTA3MjU_9045baff-168e-42aa-b385-dfa364f6066c">698,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12929bbf3109412399f3172e7fddd206_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTEtOS0xLTEtNTA3MjU_01bdc5bf-c740-4a54-b7f2-6751bf118551">319,092</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f961b554cbf4c35b1fa83b2cd487b4e_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTEtMTEtMS0xLTUwNzI1_084fe91d-06f7-4942-a6fc-d21cafb20c45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a5303400c1a425783f3183ad6fb484d_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTEtMTMtMS0xLTUwNzI1_a67e8fde-74e1-45c7-a279-a710fda9ea8d">429,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95978a83297249e088bf477ac218a6d8_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTEtMTUtMS0xLTUwNzI1_29614d89-832b-4cb5-b207-e10db88d8889">1,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock &#8211; employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTItMS0xLTEtNTA3MjU_8b469b07-e82c-4cae-8813-df987a66f5dd">3,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i83305f332a5848699f3e80d713ebcc32_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTItMy0xLTEtNTA3MjU_35347246-31b6-4544-9e9c-1082ecc455d0">20,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a2c2693b2ff45998961c13ebdcfd739_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTItNy0xLTEtNTA3MjU_eb6f7825-1a84-4399-946a-720846a1e8ac">3,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance/(cancellation) of non-vested stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTQtMS0xLTEtNTA3MjU_aadc2e31-8db2-4925-b9c0-ab9b631993cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i83305f332a5848699f3e80d713ebcc32_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTQtMy0xLTEtNTA3MjU_acc0ba2b-4983-4841-8e67-9ccd94c588a4">151,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a2c2693b2ff45998961c13ebdcfd739_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTQtNy0xLTEtNTA3MjU_30af0a20-3bcd-47fe-9e2a-a12bc6049375">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTUtMS0xLTEtNTA3MjU_02c77b26-633d-4960-ab87-d07e45a3c59f">2,054</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i83305f332a5848699f3e80d713ebcc32_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTUtMy0xLTEtNTA3MjU_ce7c962b-88ad-4d39-8fba-633a7dce3e03">32,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a2c2693b2ff45998961c13ebdcfd739_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTUtNy0xLTEtNTA3MjU_6a88bc2e-7d8b-4eb0-9a24-ea5ac26fdf64">2,054</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTYtMS0xLTEtNTA3MjU_12de6b67-5c18-4146-b00f-e5623bbcee11">23,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a2c2693b2ff45998961c13ebdcfd739_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTYtNy0xLTEtNTA3MjU_5d559494-5fcd-4a7b-9b04-798e367c3711">23,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surrendered shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" sign="-" name="amed:SurrenderedShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTctMS0xLTEtNTA3MjU_dd6dbe50-eb80-4253-948e-461109106408">16,898</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95ad470da34d4eb9b8d8e685b7c60a58_D20210101-20211231" decimals="-3" sign="-" name="amed:SurrenderedShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTctOS0xLTEtNTA3MjU_d10fb02d-2374-4e87-b01d-f9ed7e546995">16,898</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares repurchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTgtMS0xLTEtNTE0MjM_60e2331d-4ce1-4b32-bb04-584f41dd9e74">99,878</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95ad470da34d4eb9b8d8e685b7c60a58_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTgtOS0xLTEtNTE0MjM_72d93f15-fa2d-4102-9e74-d2ed21015e90">99,878</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interest contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="amed:ContributionsAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTktMS0xLTEtNTE0MjM_0388bda4-2ca2-470e-acc6-5fd3ae8eabf4">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73ef0a6e63d24e92b674d33b19f2b5ee_D20210101-20211231" decimals="-3" name="amed:ContributionsAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTktMTUtMS0xLTUxNDIz_a551a580-4206-4651-9d77-fdb23dcd3bcb">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interest distributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTgtMS0xLTEtNTA3MjU_6f048e21-04e4-438c-b223-14e54399560c">1,747</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73ef0a6e63d24e92b674d33b19f2b5ee_D20210101-20211231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTgtMTUtMS0xLTUwNzI1_4f714211-0190-4080-a2f7-1a594e2f1c40">1,747</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTktMS0xLTEtNTA3MjU_88a767da-58b7-4888-bf61-3cc96df6c589">43,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73ef0a6e63d24e92b674d33b19f2b5ee_D20210101-20211231" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTktMTUtMS0xLTUwNzI1_50b41475-6f77-4632-a8aa-183db92080ec">43,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjAtMS0xLTEtNTA3MjU_f67611fd-abd9-4e0d-86ef-9cb57ac0d294">210,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie172076182c0492ea35971de45486231_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjAtMTMtMS0xLTUwNzI1_300825c7-7ef6-4d2b-bd52-355160e91a27">209,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73ef0a6e63d24e92b674d33b19f2b5ee_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjAtMTUtMS0xLTUwNzI1_0fff34cd-a190-464a-a77f-64057e502d58">1,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjEtMS0xLTEtNTA3MjU_662968eb-24ea-450c-a73e-e021bc974f48">976,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3a03e986997443978a0dd90f53d4f1dc_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjEtMy0xLTEtNTA3MjU_2d8e1bce-5fb5-42f7-bea7-4ea7cfdebc2a">37,674,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a03e986997443978a0dd90f53d4f1dc_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjEtNS0xLTEtNTA3MjU_aed87a7c-7ffa-42ea-b357-f2d2ec81c5cc">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2079949881f8457b9711b22291635c52_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjEtNy0xLTEtNTA3MjU_b4a61a37-8a9c-43f5-b7ff-54cdf988788c">728,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0475ea6bdae24921b04d181f1d8ee6d7_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjEtOS0xLTEtNTA3MjU_fd509d9e-32b8-4225-a5cc-1242b95f4314">435,868</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab17129f66c14badb8c3affdd50289b4_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjEtMTEtMS0xLTUwNzI1_9eb06979-6661-470e-b6ad-5c8f899c2b77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd498162f85e4b45bc79f00af8af6e6b_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjEtMTMtMS0xLTUwNzI1_de551cc6-9fa6-40ff-834c-62fe4460c24f">639,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bb8f10d82464615b7fd2f7df5d5bd4e_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjEtMTUtMS0xLTUwNzI1_19a0f02a-ce48-4d9a-8c54-b654b7846243">44,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock &#8211; employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjItMS0xLTEtNTA3MjU_9f29b9f1-888b-40f0-9c48-46eac48dda78">3,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18dba7744c814ab9907cd2868da0ddc6_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjItMy0xLTEtNTA3MjU_3fd27364-cc34-468e-a73c-2d79cf40b10d">36,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2983eae666eb46e39d6a7d6ffe711703_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjItNy0xLTEtNTA3MjU_b69b5533-51b0-43c2-a9e3-b0d06e103249">3,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance/(cancellation) of non-vested stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjMtMS0xLTEtNTA3MjU_3b0bc60a-93c0-4d12-b410-514c6628970d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18dba7744c814ab9907cd2868da0ddc6_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjMtMy0xLTEtNTA3MjU_150df73b-86e6-4d37-a053-c2b0745de7de">142,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2983eae666eb46e39d6a7d6ffe711703_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjMtNy0xLTEtNTA3MjU_88bdc8b7-95f6-4dbf-a4cb-9683be0c0688">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjQtMS0xLTEtNTA3MjU_8556fac2-7b3a-489f-905b-02e16447a00c">2,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18dba7744c814ab9907cd2868da0ddc6_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjQtMy0xLTEtNTA3MjU_41e22c91-f2ec-4763-953e-ef17274097ab">37,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2983eae666eb46e39d6a7d6ffe711703_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjQtNy0xLTEtNTA3MjU_92c100b5-ff8a-4d72-9cf6-1d046e1897ee">2,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjUtMS0xLTEtNTA3MjU_dada54b6-ae45-4f5f-b81b-d87c26322b6d">16,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2983eae666eb46e39d6a7d6ffe711703_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjUtNy0xLTEtNTA3MjU_783eff72-74dc-4180-a8e3-b6ee4806fa9a">16,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surrendered shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" sign="-" name="amed:SurrenderedShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjYtMS0xLTEtNTA3MjU_5761b0b9-9123-4a38-bbc4-65d90bf6f7b6">7,981</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i964159f6265c4a9fa26afa837937e2a9_D20220101-20221231" decimals="-3" sign="-" name="amed:SurrenderedShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjYtOS0xLTEtNTA3MjU_43d74058-e53d-4025-a2e7-daa65e1caa6e">7,981</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares repurchased</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjctMS0xLTEtNTA3MjU_d352faeb-512b-4f1b-922b-57619c25eaf0">17,351</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i964159f6265c4a9fa26afa837937e2a9_D20220101-20221231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjctOS0xLTEtNTA3MjU_76391d5f-5f3e-4811-bead-afaeb6e9db99">17,351</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interest contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="amed:ContributionsAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjgtMS0xLTEtNTA3MjU_7ab7ef17-d916-495e-8994-7d47bb4aafd9">12,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0d005a9091143199e4be44f3a337678_D20220101-20221231" decimals="-3" name="amed:ContributionsAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjgtMTUtMS0xLTUwNzI1_8af9cf7e-faf1-46ac-89f1-6d3ab5c63ea7">12,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interest distributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjktMS0xLTEtNTA3MjU_4ebdc8e0-5b05-4895-a230-b5eec0dd7a00">1,561</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0d005a9091143199e4be44f3a337678_D20220101-20221231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjktMTUtMS0xLTUwNzI1_30df70f5-1223-4bc2-8f3b-246f93436d94">1,561</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sale of noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMzAtMS0xLTEtNTA3MjU_29edec74-18d7-4b48-8c98-03857191412b">4,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2983eae666eb46e39d6a7d6ffe711703_D20220101-20221231" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMzAtNy0xLTEtNTA3MjU_8857bd0c-d9a0-4258-bb84-c32e82f4f6ae">4,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0d005a9091143199e4be44f3a337678_D20220101-20221231" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMzAtMTUtMS0xLTUwNzI1_14ee8248-ed7f-4d55-a01d-eae88b496241">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMzEtMS0xLTEtNTA3MjU_7195b38e-6bc0-4f96-b07d-057b49dc2cbc">117,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ecdf11c833e48ba8909b67bec1dd8bc_D20220101-20221231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMzEtMTMtMS0xLTUwNzI1_d2bd1c40-6a49-4760-8763-32deb6d09df4">118,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0d005a9091143199e4be44f3a337678_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMzEtMTUtMS0xLTUwNzI1_28e8ff36-5327-4911-9f67-6a74eecab115">910</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMzItMS0xLTEtNTA3MjU_b2a3bbaf-66e7-4c03-a399-8560875585aa">1,106,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0db7a80feb5475f810c67719ce36ad3_I20221231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMzItMy0xLTEtNTA3MjU_86f9c937-94e5-420d-8da9-e464b94fac8b">37,891,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0db7a80feb5475f810c67719ce36ad3_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMzItNS0xLTEtNTA3MjU_12817433-e7f8-4047-9822-532228c03035">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7f80dee79fe4ac684481f6cd7fd746b_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMzItNy0xLTEtNTA3MjU_5ed5a8ba-1057-4c6a-9adc-5da507ea4eb4">755,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i83862c03aee5480f950115749f6f0551_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMzItOS0xLTEtNTA3MjU_0a11f9c1-2fc8-4a59-a0e2-5813383f6516">461,200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie386fbdef29444a7b1e34af6f9fe68b2_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMzItMTEtMS0xLTUwNzI1_6d8073da-0a5c-4611-b154-46f7b94e0b4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70cecdb6f3b04a83a501c7724ab21784_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMzItMTMtMS0xLTUwNzI1_5c71a25a-a3d7-4b7d-8fee-f0495f6c46b0">757,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f3f8f64156c4928a36902ecbfdb0cc5_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMzItMTUtMS0xLTUwNzI1_6daae69a-eae2-478b-ab81-ba816f5b1d13">55,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="i5c10b724a6674979bf3c35a339f29685_67"></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMy0xLTEtMS01MDcyNQ_b87ea963-adca-4674-81e0-b6fb8f7a4bc8">117,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMy0zLTEtMS01MDcyNQ_52e9e4e1-6088-47a8-a3f4-3534de417fa3">210,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMy01LTEtMS01MDcyNQ_7aecdc09-d35f-41a6-bdd5-8ecb9be49a48">185,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNS0xLTEtMS01MDcyNQ_fe4d1621-390a-438c-80db-b16542f54883">24,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNS0zLTEtMS01MDcyNQ_5a906c13-fc10-44e3-af20-923c960329a8">30,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNS01LTEtMS01MDcyNQ_ea15f114-553d-4e09-9026-5bbec48cc9e0">28,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNi0xLTEtMS01MDcyNQ_954f10ad-ffd8-4f55-8e82-b96bc3a80fce">16,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNi0zLTEtMS01MDcyNQ_98682c9c-9261-4f6a-830f-55af728a17f8">23,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNi01LTEtMS01MDcyNQ_04e7e61b-942c-469c-b47d-9d85feb38406">26,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and impairment of operating lease right of use assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="amed:AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfOC0xLTEtMS01MDcyNQ_c811b8eb-f27d-4a64-8576-6023b90608e3">46,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="amed:AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfOC0zLTEtMS01MDcyNQ_31dc7990-f0b6-4686-bb2c-5f7726438132">40,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="amed:AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfOC01LTEtMS01MDcyNQ_f4bd7bfb-10f5-4ef9-8e18-6ea34f804fb9">39,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss (gain) on disposal of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfOS0xLTEtMS01MDcyNQ_a654bdd5-fa57-4919-abff-81f9daa0ecef">519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfOS0zLTEtMS01MDcyNQ_443257e8-2e5d-43d3-b590-e151c98aa6d1">124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfOS01LTEtMS01MDcyNQ_cb58a187-b32b-4021-abf4-72604a735eae">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTAtMS0xLTEtNTA3MjU_4d4109f8-f0f8-4b27-bb6f-ef90c139827e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTAtMy0xLTEtNTA3MjU_29d72665-50da-4090-8dc5-8d6f8111f422">31,098</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTAtNS0xLTEtNTA3MjU_730438c9-4fe5-4473-bb85-835f1863dd8b">2,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Write-off of other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="amed:WriteOffOfOtherComprehensiveIncome" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTEtMS0xLTEtNTA3MjU_c06741e9-eead-4b68-b254-35900c84d9d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="amed:WriteOffOfOtherComprehensiveIncome" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTEtMy0xLTEtNTA3MjU_c7052eb6-5a51-422d-a28c-bc92e6a74cb0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="amed:WriteOffOfOtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTEtNS0xLTEtNTA3MjU_5e8de6e4-6a86-4e60-8979-6507f810e72a">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTItMS0xLTEtNTA3MjU_04106508-c0ec-4f2f-a8df-1b77d042ba69">23,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTItMy0xLTEtNTA3MjU_5d9d21d0-5f14-4add-92a4-62bfc4b97d5e">44,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTItNS0xLTEtNTA3MjU_66772a19-e0a7-4e58-aa98-5fbdcf703bb0">26,560</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity in loss (earnings) from equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTMtMS0xLTEtNTA3MjU_b1ed1acb-b9f3-4d7c-bbe1-fde95c3f3a02">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTMtMy0xLTEtNTA3MjU_3e20d6a9-716f-4c27-8717-91cf2ee60570">4,949</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTMtNS0xLTEtNTA3MjU_2dcf92f2-9a70-4caf-baef-a3a0047df378">3,966</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of deferred debt issuance costs/debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTQtMS0xLTEtNTA3MjU_8bed9b13-e364-4c52-863a-405a6719ddc3">991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTQtMy0xLTEtNTA3MjU_9f58c7e5-2e6f-4269-9999-a8dc0475e36d">917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTQtNS0xLTEtNTA3MjU_504a553d-6b27-4897-8f88-fb32e7ace6c0">869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Return on equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTUtMS0xLTEtNTA3MjU_9a83139a-20ba-4c13-afab-f13e8a966132">5,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTUtMy0xLTEtNTA3MjU_e3cecaa0-6a3e-4dd0-b3f2-6be25cdface4">5,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTUtNS0xLTEtNTA3MjU_324b7bb7-4027-4667-842c-9a30485ff825">5,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTYtMS0xLTEtNTA3MjU_bde1d822-acae-4418-9078-27518e848b59">3,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTYtMy0xLTEtNTA3MjU_b2e330c5-ced1-461c-b78b-bca97118a4c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTYtNS0xLTEtNTA3MjU_f8d00388-ca5a-49b1-aa0b-321b21044483">4,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of impact of acquisitions:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTgtMS0xLTEtNTA3MjU_a668b41d-7c56-4298-a89c-0e87d160e2ae">14,230</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTgtMy0xLTEtNTA3MjU_a047180a-497c-4c48-a37b-e2c630cf42f3">18,030</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTgtNS0xLTEtNTA3MjU_67250fb5-efa9-4fa3-9203-07b83771f948">2,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTktMS0xLTEtNTA3MjU_e472af02-8e76-4e5b-9419-2be8eda8a72f">3,525</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTktMy0xLTEtNTA3MjU_cde72e20-e4a3-4222-ba76-5d9b060728d0">12,202</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTktNS0xLTEtNTA3MjU_ca847a5a-9fd4-427a-9c17-b44b9a5a4c6b">7,181</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjAtMS0xLTEtNTA3MjU_de1687d0-eb01-47e7-bbce-c925e347c75c">438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjAtMy0xLTEtNTA3MjU_f35b194e-816d-4ea3-acfa-6b66ffdb7e4b">1,017</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjAtNS0xLTEtNTA3MjU_59d751e6-5348-49c1-bac9-dc0d00de45dc">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjEtMS0xLTEtNTA3MjU_bb693b5e-67fa-4178-a444-40706fb6a189">4,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjEtMy0xLTEtNTA3MjU_6c51db24-e0ee-437b-aeb5-9fed1957f28e">4,353</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjEtNS0xLTEtNTA3MjU_cee00b30-4cb6-4257-8b5b-11b2f052e7d4">1,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjItMS0xLTEtNTA3MjU_9868411f-be56-47b2-b5d6-0e165316fd71">39,382</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjItMy0xLTEtNTA3MjU_b39a4114-00a8-4aef-95a6-64cb342e35dd">26,915</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjItNS0xLTEtNTA3MjU_02b05ea5-7db7-4ac1-a35d-e600a39647b7">39,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjMtMS0xLTEtNTA3MjU_4d2f7c9c-5d90-43cd-9bca-d1b75bda9723">8,822</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjMtMy0xLTEtNTA3MjU_af0d56bd-4698-4df8-becb-c89dde78cf41">28,796</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjMtNS0xLTEtNTA3MjU_dce3c7de-104a-45c5-896b-dd315cf3bc76">27,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjQtMS0xLTEtNTA3MjU_aad984f7-a8d9-463e-98ac-ba5dbf852a78">41,175</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjQtMy0xLTEtNTA3MjU_71213a90-1a74-420b-b6a5-73c908736438">36,645</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjQtNS0xLTEtNTA3MjU_cbcd1840-d4ff-48c6-b099-6f8b038caea4">34,695</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" sign="-" name="amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjUtMS0xLTEtNTA3MjU_23dbe513-b262-402e-a115-8b2f58e43159">3,242</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" sign="-" name="amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjUtMy0xLTEtNTA3MjU_ddbde2b4-0bce-48f6-b2a8-f46013ec43d6">3,060</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" sign="-" name="amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjUtNS0xLTEtNTA3MjU_6f3f1c24-336a-4491-bcc7-2f807c1f56b2">3,544</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjYtMS0xLTEtNTA3MjU_ded5d2fb-7adc-4cf6-8fef-b9658ea59300">133,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjYtMy0xLTEtNTA3MjU_5dfda47d-d14f-4434-a44b-23707f85157e">188,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjYtNS0xLTEtNTA3MjU_bbadf5d5-0d6a-4296-82e6-634457a2333a">288,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from the sale of deferred compensation plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleOfRestrictedInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjgtMS0xLTEtNTA3MjU_311a048c-9c62-41ac-81dd-f88a5e12d58e">252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfRestrictedInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjgtMy0xLTEtNTA3MjU_36dde604-9e98-4f94-b565-625c6777d019">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleOfRestrictedInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjgtNS0xLTEtNTA3MjU_cf046c71-d2fa-4ac5-bbb8-bcfbf82fabbc">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from the sale of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjktMS0xLTEtNTA3MjU_25dbd17f-295e-4da9-8545-b34036dbf494">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjktMy0xLTEtNTA3MjU_5f7a9f44-0c59-42c4-b0ab-7dee863dc888">144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjktNS0xLTEtNTA3MjU_c4ae835e-b693-4e2b-9ddb-2ff7f4176b83">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzAtMS0xLTEtNTA3MjU_0d117e92-4917-4642-b749-1c98adb7375c">6,165</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzAtMy0xLTEtNTA3MjU_59f52e13-7c1b-4b28-b2b5-5a5f24dd0e5b">6,302</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzAtNS0xLTEtNTA3MjU_1eac7c50-f24b-44f6-9dc7-ac12143dc296">5,332</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments in technology assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToDevelopSoftware" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzEtMS0xLTEtNTA3MjU_3a4332cb-0d6c-49ff-ae3d-459138c59ca9">1,050</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToDevelopSoftware" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzEtMy0xLTEtNTA3MjU_820520e0-b74e-453e-97ae-e57848fa59f9">419</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToDevelopSoftware" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzEtNS0xLTEtNTA3MjU_ed25c793-0b2a-4ebb-8a4c-78e42c455612">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investment in equity method investee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzItMS0xLTEtNTA3MjU_b1bf03b3-9472-402c-a0e1-064c29e78b13">637</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzItMy0xLTEtNTA3MjU_df3e9fa2-430f-47db-8194-213349a11d29">200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzItNS0xLTEtNTA3MjU_32ad30d3-fbd6-4cd4-885a-173ff1e26523">875</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of equity method investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzMtMS0xLTEtNTA3MjU_ed23dbe4-38ab-4c13-ae25-974c33ee34ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzMtMy0xLTEtNTA3MjU_215d7a5c-b7a3-460e-8ad1-ce7d068dbb8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzMtNS0xLTEtNTA3MjU_2189df8b-f97e-4732-84f7-e93922a8b6f5">17,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of cost method investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzMtMS0xLTEtNTY5MTI_aa0757c4-1b39-4e8e-9f35-c0d2c5505140">15,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzMtMy0xLTEtNTY5MTI_cdba32f5-ff05-4dc5-be23-0bf55fadfc4e">5,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireOtherInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzMtNS0xLTEtNTY5MTI_9d95dabb-8b19-45bf-aa72-6de47ff1e734">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions of businesses, net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzQtMS0xLTEtNTA3MjU_9512d324-feab-4e59-b7a9-8e1527e42267">71,952</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzQtMy0xLTEtNTA3MjU_26a36fa6-b05d-432d-8abe-5cd5bc867c62">269,965</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzQtNS0xLTEtNTA3MjU_f829d3fa-de8e-4fba-832e-1cb5816ac76a">298,958</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzUtMS0xLTEtNTA3MjU_0bafed4d-aa53-4f39-bc1e-d5dde3ef162c">94,486</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzUtMy0xLTEtNTA3MjU_9030369e-a33f-4713-a573-df8eb3f23206">281,607</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzUtNS0xLTEtNTA3MjU_16f564f3-f21a-450c-a376-2a3a5dcb8705">287,108</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of stock upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzctMS0xLTEtNTA3MjU_5d28993d-5132-4405-888f-c23f871cf196">2,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzctMy0xLTEtNTA3MjU_981f385f-383a-4763-b858-a36fd1ff9de5">2,054</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzctNS0xLTEtNTA3MjU_cb196d48-f79a-473c-b60c-40b846b25a27">6,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of stock to employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzgtMS0xLTEtNTA3MjU_44d2f9bd-dc66-416e-931b-13335e8fddf0">3,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzgtMy0xLTEtNTA3MjU_5f834227-9643-4fff-b5a6-619e98b24479">3,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzgtNS0xLTEtNTA3MjU_1fbd4d1e-18d5-42d8-922a-26cdc8ae1fe8">3,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares withheld to pay taxes on non-cash compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzktMS0xLTEtNTA3MjU_8543df66-9ed4-4a0f-a6a3-472bcfc54190">7,981</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzktMy0xLTEtNTA3MjU_e13949a2-1282-43e6-9056-c50ec2413135">16,898</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzktNS0xLTEtNTA3MjU_c2145af1-10b1-4ea1-867e-3fe8d03e7aec">54,493</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interest contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="amed:CashContributionToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDAtMS0xLTEtNTA3MjU_cf9d81ea-91aa-4d17-92a0-697a35806732">3,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="amed:CashContributionToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDAtMy0xLTEtNTA3MjU_af21a168-64cc-4f1d-9a5f-b25b20a9268b">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="amed:CashContributionToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDAtNS0xLTEtNTA3MjU_d9ed2c1d-6530-405e-a625-542b2a6d45be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interest distributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="amed:CashDistributionToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDEtMS0xLTEtNTA3MjU_80c7f4c5-b1f3-4ef7-9ff6-605cfad28517">1,561</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="amed:CashDistributionToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDEtMy0xLTEtNTA3MjU_d2aefcba-50bb-4108-b926-70c151762228">1,747</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="amed:CashDistributionToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDEtNS0xLTEtNTA3MjU_a08af458-3544-4536-a621-5689be112051">1,122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDEtMS0xLTEtNTY4NjU_0e4234fd-f7b9-4333-9939-640e3bad41c0">5,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromMinorityShareholders" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDEtMy0xLTEtNTY4NjU_9a30a514-0b3e-40ce-82bc-1a16f4ad089c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromMinorityShareholders" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDEtNS0xLTEtNTY4NjU_22e90aee-bc04-4c09-8b7a-465a0573c762">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from borrowings under term loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="amed:ProceedsFromBorrowingsUnderTermLoan" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDItMS0xLTEtNTA3MjU_e2e45d88-87ed-435a-ab11-d6289347c64c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="amed:ProceedsFromBorrowingsUnderTermLoan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDItMy0xLTEtNTA3MjU_f45729c2-03f8-4f71-a579-d6874bfe4b3e">290,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="amed:ProceedsFromBorrowingsUnderTermLoan" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDItNS0xLTEtNTA3MjU_b5dd1b7e-abd5-42c0-952f-1bc5f7d5215d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from borrowings under revolving line of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDMtMS0xLTEtNTA3MjU_bd5c6dff-39ec-43c4-9c16-51b243887118">534,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDMtMy0xLTEtNTA3MjU_ad00f0d8-4224-4b7a-8ede-e0261279b5f0">500,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDMtNS0xLTEtNTA3MjU_34f21edc-9fde-4fd6-9c89-4f3a9153a799">684,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayments of borrowings under revolving line of credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDQtMS0xLTEtNTA3MjU_4997d0cd-bf58-44ef-b9b2-8243e0a110cf">534,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDQtMy0xLTEtNTA3MjU_221013c0-c43e-4f5e-ad2f-3b1f97b69dec">551,700</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDQtNS0xLTEtNTA3MjU_4e6b7e87-b5e2-432a-921b-96982bf9f0cb">703,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal payments of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDUtMS0xLTEtNTA3MjU_93380aaf-9188-4a2b-a4a0-d2a1b5208cf4">13,296</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDUtMy0xLTEtNTA3MjU_e2fae318-4947-4d33-a5c4-4e57fa40f113">9,143</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDUtNS0xLTEtNTA3MjU_61c82a25-06ba-4abe-b8cb-19671711c4d8">10,249</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsOfFinancingCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDYtMS0xLTEtNTA3MjU_17325b70-75ca-4950-a068-d0942d86b9c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDYtMy0xLTEtNTA3MjU_3a67d3a2-ff6b-4d95-8f8e-1919a299408e">2,792</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsOfFinancingCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDYtNS0xLTEtNTA3MjU_12ae4176-fd8e-4327-b8ad-e31c1c682a73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provider relief fund advance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="amed:FundsReceivedFromProviderReliefFundAdvance" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDctMS0xLTEtNTA3MjU_cfc0025c-7214-4ef3-b298-7f9958f576d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" sign="-" name="amed:FundsReceivedFromProviderReliefFundAdvance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDctMy0xLTEtNTA3MjU_3ae3eaf1-09ab-41f4-ac7a-6f78d68d7fd0">60,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="amed:FundsReceivedFromProviderReliefFundAdvance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDctNS0xLTEtNTA3MjU_f1f87f55-459c-444a-9f91-98815af23ede">60,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of company stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDgtMS0xLTEtNTA3MjU_cef4f27e-cd43-4fe8-9626-7eca9dd496b0">17,351</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDgtMy0xLTEtNTA3MjU_b9b1092d-df26-4ec6-9077-822c28efe287">99,878</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDgtNS0xLTEtNTA3MjU_7acc0721-009b-4ba6-bed9-92f25f31429e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment of accrued contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDgtMS0xLTEtNTE2NTg_309d9ce5-eac4-4dcd-96dd-f1dad2b39e2d">5,714</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDgtMy0xLTEtNTE2NTg_25f9ebe0-adeb-4394-a5cc-1461aee3cf5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDgtNS0xLTEtNTE2NTg_e95bb464-1d03-474e-a35a-8e52570c7cbe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDktMS0xLTEtNTA3MjU_eecfab13-62a6-49f6-bd6f-52fb22fc93b9">30,433</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDktMy0xLTEtNTA3MjU_0d18161c-5070-4ad5-b6c4-a7fbfa033244">55,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDktNS0xLTEtNTA3MjU_cca31aa2-0e3e-45b1-8c12-4655d63ca017">14,977</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTAtMS0xLTEtNTA3MjU_31672a5f-4efb-473a-8a5c-c4c7eca98f30">8,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTAtMy0xLTEtNTA3MjU_08c07d42-6e4b-4ff8-bf25-82f81e11c723">37,588</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTAtNS0xLTEtNTA3MjU_cbe6f7e4-5562-4aae-99ca-bdc5cfc32de2">13,133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTEtMS0xLTEtNTA3MjU_19392b76-2928-479e-9518-5a872d155328">45,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42b1e865f1ed4b2e8363dfcc39186a91_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTEtMy0xLTEtNTA3MjU_8c556b6e-bef2-490d-8058-7242fd5b8066">83,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab144f7e34ce4a479683c59de399ff42_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTEtNS0xLTEtNTA3MjU_643c333c-914a-4d88-a7da-258d1947822c">96,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTItMS0xLTEtNTA3MjU_b8acc60f-30c9-499d-bb94-af558467ed2b">54,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTItMy0xLTEtNTA3MjU_6afb6d52-0d11-4292-84fa-3598e032387f">45,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42b1e865f1ed4b2e8363dfcc39186a91_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTItNS0xLTEtNTA3MjU_fa412156-7c2f-4aa6-887c-410fba926a05">83,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental Disclosures of Cash Flow Information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTQtMS0xLTEtNTA3MjU_be164efe-1602-4495-b241-595b70f78ceb">14,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTQtMy0xLTEtNTA3MjU_7544296c-f580-4e95-b8c8-3abd62a65462">5,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTQtNS0xLTEtNTA3MjU_dae34cf8-0953-414a-a5ef-ab6d196946d5">6,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for Infinity ZPIC interest</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="amed:CashPaidForInfinityZPICInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTYtMS0xLTEtNTY4NTg_ad81886f-c3a7-40b6-aa9f-a93424ac3516">12,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="amed:CashPaidForInfinityZPICInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTYtMy0xLTEtNTY4NTg_151815be-5ec6-46d3-acaf-cc43cad713cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="amed:CashPaidForInfinityZPICInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTYtNS0xLTEtNTY4NTg_e82daa6c-fee8-4fe8-bf9f-c61187e5bfb2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for income taxes, net of refunds received</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTUtMS0xLTEtNTA3MjU_8c854f5d-22cb-49af-8d9e-91c5a3e0b7a2">24,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTUtMy0xLTEtNTA3MjU_98e434a7-8e10-41fd-a7cb-a9ffbca7ae97">34,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTUtNS0xLTEtNTA3MjU_507f04ac-692d-4b8e-a1e1-64dc2aeb4a7b">50,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental Disclosures of Non-Cash Activity:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="amed:NonCashAccruedContingentConsideration" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNjEtMS0xLTEtNTk5MzM_884090b8-450b-4e4d-8430-1bf45f1e0e16">19,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="amed:NonCashAccruedContingentConsideration" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNjEtMy0xLTEtNTk5MzM_bf4f1f48-53f9-4750-ac80-76cd72bae963">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="amed:NonCashAccruedContingentConsideration" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNjEtNS0xLTEtNjA4MjQ_135a6bae-5b6a-475d-a926-15a7304518d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interest contribution</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="amed:NonCashNoncontrollingInterestContribution" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNjItMS0xLTEtNTk5MzM_7948e71b-606c-4b63-b0a2-0e6c4d1eae24">8,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="amed:NonCashNoncontrollingInterestContribution" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNjItMy0xLTEtNTk5MzM_6a9d1307-4b8d-4652-9433-252a58743405">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="amed:NonCashNoncontrollingInterestContribution" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNjItNS0xLTEtNjA4MzA_2ca203e4-3d59-471a-8488-c71281e14de4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="i5c10b724a6674979bf3c35a339f29685_70"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></div><div><span><br/></span></div><div id="i5c10b724a6674979bf3c35a339f29685_73"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfMTEzNzM_e5cb1ff6-4103-4920-94c4-b9e2d8192e4c" continuedAt="i07fc44ea968f4dd9b07fe7db0d0fd90a" escape="true">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</ix:nonNumeric></span></div><ix:continuation id="i07fc44ea968f4dd9b07fe7db0d0fd90a" continuedAt="i9120ac5377154f4f8ab62fa2a2ccfc68"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amedisys, Inc., a Delaware corporation (together with its consolidated subsidiaries, referred to herein as &#8220;Amedisys,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;), is a multi-state provider of home health, hospice, personal care and high acuity care services with approximately <ix:nonFraction unitRef="number" contextRef="ib60ffa9c6822423ca9d59d283467feaa_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfMzQy_9ffd9ec7-d761-4a15-8ac3-093e22c35dd7">74</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i30a242e707714a1eab7e611922efcc2c_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfMzQ2_a1b20370-f314-4392-8d4d-2209b4bcdac5">75</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i66aac21e2a3b47cb9f000f260204e4ff_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfMzUz_1fdf8ad8-aa35-4f62-b99d-781b9fd5313c">75</ix:nonFraction>% of our consolidated net service revenue derived from Medicare for 2022, 2021 and 2020, respectively. As of December&#160;31, 2022, we owned and operated <ix:nonFraction unitRef="care_center" contextRef="i2f7b8ece18824575809137727a001ab8_I20221231" decimals="INF" name="amed:OperatingCareCenters" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfNDU4_9fc8e937-b9c4-4203-90bc-f0c04967f9d6">347</ix:nonFraction> Medicare-certified home health care centers, <ix:nonFraction unitRef="care_center" contextRef="i4fb0b4ede01d45a8ac9f87b995dfc5bd_I20221231" decimals="INF" name="amed:OperatingCareCenters" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfNTA2_f193d505-f96e-45da-8133-6e5462c28206">164</ix:nonFraction> Medicare-certified hospice care centers, <ix:nonFraction unitRef="care_center" contextRef="i466c99d823de4e3da04d3e6d94ea4feb_I20221231" decimals="INF" name="amed:OperatingCareCenters" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfNTUw_a7bf3541-5fab-47fa-aabb-b4ba8ba406b2">13</ix:nonFraction> personal-care care centers and <ix:nonFraction unitRef="numberofjointventures" contextRef="ibc62063a43fb4e54a4eb1692d07bbee2_I20221231" decimals="INF" name="amed:NumberOfAdmittingJointVentures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfNTg0_ec07058f-e8ce-4779-9755-ee6c600ecf16">8</ix:nonFraction> admitting high acuity care joint ventures in <ix:nonFraction unitRef="state" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="INF" name="us-gaap:NumberOfStatesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfNjIy_ebb2b6b5-d70f-4556-badd-a5038ce1dce6">37</ix:nonFraction> states within the United States and the District of Columbia.</span></div><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfMTEzNTk_85308d9f-0a68-41d2-8847-3c3ceab1da82" continuedAt="i84d4c041826b46ce9ebe3f50b02d081c" escape="true"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the Company adopted Accounting Standards Update ("ASU") 2020-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which included minor technical corrections and clarifications to improve consistency and clarify the application of various provisions of the codification by amending the codification to include all disclosure guidance in the appropriate disclosure sections and by amending and adding new headings, cross referencing to other guidance and refining or correcting terminology. Our adoption of this standard did not have a material effect on our consolidated financial statements.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the Company adopted ASU 2021-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was intended to increase transparency around financial reporting regarding government assistance by requiring disclosure of information about (1) the types of government assistance received, (2) an entity's accounting for the government assistance received and (3) the effect of the assistance on an entity's financial statements. The ASU was effective for annual periods beginning after December 15, 2021, with early adoption permitted. See Note 3 &#8211; Novel Coronavirus Pandemic ("COVID-19") for the disclosures associated with this standard. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, the Company adopted ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provided guidance for measuring credit losses on financial instruments. Our adoption of this standard did not have a material effect on our consolidated financial statements. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, the Company adopted ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which eliminated certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating taxes during the interim periods and the recognition of deferred tax liabilities for outside basis differences. This guidance also simplified aspects of the accounting for franchise taxes, enacted changes in tax laws or rates and clarified the accounting for transactions that result in a step-up in the tax basis of goodwill. The guidance was effective for interim and annual periods beginning after December 15, 2020, with early adoption permitted. Our adoption of this standard on a prospective basis was not material to the Company&#8217;s consolidated financial statements.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><ix:continuation id="i84d4c041826b46ce9ebe3f50b02d081c" continuedAt="ib7ba8e3324524737a8965d1c07e058e4"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Financial Accounting Standards Board ("FASB") issued ASU 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides optional expedients and exceptions for applying U.S. Generally Accepted Accounting Principles ("U.S. GAAP") to contract modifications and hedging relationships that reference the London Inter-Bank Offered Rate ("LIBOR") or another reference rate expected to be discontinued, subject to meeting certain criteria. In January 2021, the FASB issued ASU 2021-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Scope</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which adds implementation guidance to ASU 2020-04 to clarify certain optional expedients in Topic 848. The guidance in ASU 2020-04 and ASU 2021-01 was effective upon issuance and may generally be applied prospectively through December 31, 2022. In December 2022, the FASB issued ASU 2022-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848,</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib7ba8e3324524737a8965d1c07e058e4"> which deferred the sunset date of Topic 848 from December 31, 2022 to December 31, 2024. These standards did not have an effect on our consolidated financial statements.</ix:continuation> </span></div><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfMTEzNzU_b9ae40ac-a91d-437f-a36f-4b9e8ae7f8fc" escape="true"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting and reporting policies conform with U.S. GAAP. In preparing the consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfMTEzNjg_d46de7e5-381b-40df-bdf0-f4ee626c0b81" continuedAt="i016a1d97acf148139b2e5daa5b4bc812" escape="true"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements include the accounts of Amedisys, Inc. and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying consolidated financial </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></div><ix:continuation id="i9120ac5377154f4f8ab62fa2a2ccfc68" continuedAt="i126636697ad04ea6a404857e3e432bd0"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i016a1d97acf148139b2e5daa5b4bc812">statements, and business combinations accounted for as purchases have been included in our consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.</ix:continuation></span></div><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:EquityMethodInvestmentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfMTEzNzI_16d1d022-91e2-4a7b-9a22-b7c90864327b" continuedAt="ida432061514e4a97a0aeeaca13c3c4df" escape="true"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consolidate investments when the entity is a variable interest entity ("VIE") and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of <ix:nonFraction unitRef="number" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="INF" name="amed:MinimumPercentOwnershipForControllingInterestPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfNzU2Mg_f65a512a-573a-427e-8957-abc762459bd3">50</ix:nonFraction>%. Third party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our consolidated financial statements. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold <ix:nonFraction unitRef="number" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="INF" name="amed:MaximumPercentOwnershipForEquityMethodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfNzg1Mg_f55b2e5d-4ffe-4c8f-8ad8-8c0d91b49769">50</ix:nonFraction>% or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary. The book value of investments that we account for under the equity method of accounting totaled $<ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:EquityMethodInvestmentAggregateCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfODA0OA_4e7d4cc0-e4e7-4624-8cfb-aa8a754759c2">40.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:EquityMethodInvestmentAggregateCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfODA1NQ_d05cb6c3-bb7d-448e-bf1a-34596425284d">48.1</ix:nonFraction> million as of December&#160;31, 2022 and 2021, respectively, and is reflected in other assets within our consolidated balance sheets. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for investments in entities in which we have less than <ix:nonFraction unitRef="number" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="INF" name="amed:MaximumPercentOwnershipForCostMethodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfODIyOQ_dd2f0187-0426-4703-ac11-1abf38019454">20</ix:nonFraction>% ownership interest under the cost method of accounting if we do not have the ability to exercise significant influence over the investee. During 2022, we made a $<ix:nonFraction unitRef="usd" contextRef="idaa8aedfe8c3470cbd124c76fae216cf_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfNTQ5NzU1ODMyMTM1_99fa2d28-5753-4423-ae2d-c51dcbcb5a0f">15.0</ix:nonFraction>&#160;million investment in a home health benefit manager, which is accounted for under the cost method. During 2021, we made a $<ix:nonFraction unitRef="usd" contextRef="i31897eeed2424fdabfb8a7277396df7f_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfODM5Mw_399c7bc8-3fd8-4d6a-89ef-f1ebe2f13a70">5.0</ix:nonFraction>&#160;million investment in ConnectRN, a workforce optimization company, which is accounted for under the cost method. The book value of investments that we account for under the cost method of accounting was $<ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:InvestmentOwnedAtCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfNTQ5NzU1ODMyMTUw_fbe7316e-0bbd-469e-90e1-48dff81edc9c">20.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:InvestmentOwnedAtCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfNTQ5NzU1ODMyMTY1_195fbc6d-2d3e-4f9f-85d7-87ea4c166fac">5.0</ix:nonFraction>&#160;million as of December 31, 2022 and 2021, respectively, and is reflected in other assets within our consolidated balance sheets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three-month period ended December 31, 2022, we sold a 49% interest in two of our home health care centers while maintaining a controlling interest in the newly formed joint venture. We are consolidating this joint venture. The total cash consideration received for the 49% noncontrolling interest was $<ix:nonFraction unitRef="usd" contextRef="i43a583e1be0e4362a0f5b5887d9c279a_D20221001-20221231" decimals="-5" name="us-gaap:ProceedsFromMinorityShareholders" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfNTQ5NzU1ODMyMTc5_f87cd859-d271-4411-bcba-0da06fc4e07f">1.9</ix:nonFraction>&#160;million. In connection with the transaction, we recorded an after-tax gain of $<ix:nonFraction unitRef="usd" contextRef="i43a583e1be0e4362a0f5b5887d9c279a_D20221001-20221231" decimals="-5" name="amed:GainRelatedToSaleOfNoncontrollingInterestNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfNTQ5NzU1ODMyMTkz_98107b0e-27a2-4684-ac91-245b5be6768f">1.4</ix:nonFraction>&#160;million; this gain was recorded to additional paid-in capital within our consolidated balance sheet. During the three-month period ended September 30, 2022, we sold a 30% interest in two of our home health care centers while maintaining a controlling interest in the newly formed joint venture. We are consolidating this joint venture. The total cash consideration received for the 30% noncontrolling interest was $<ix:nonFraction unitRef="usd" contextRef="i0e9dcae6e6af40a2a3ad82452046bbbb_D20220701-20220930" decimals="-5" name="us-gaap:ProceedsFromMinorityShareholders" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfNTQ5NzU1ODMyMjA3_0f578b9f-b8e7-4c2d-bc70-628a2aa39b20">3.9</ix:nonFraction>&#160;million. In connection with the transaction, we recorded an after-tax gain of $<ix:nonFraction unitRef="usd" contextRef="i0e9dcae6e6af40a2a3ad82452046bbbb_D20220701-20220930" decimals="-5" name="amed:GainRelatedToSaleOfNoncontrollingInterestNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfNTQ5NzU1ODMyMjIx_78fa9b96-4043-4d87-91c8-e83496903cc5">2.9</ix:nonFraction>&#160;million; this gain was recorded to additional paid-in capital within our consolidated balance sheet.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, a third-party acquired a majority of the issued and outstanding membership interests of one of our equity method investments, Medalogix, for cash, with the remaining membership interests rolling over into a newly formed entity that includes Medalogix as well as another healthcare predictive data and analytics company. We rolled over 100% of our ownership interest in Medalogix to the newly formed entity, and in connection with this transaction, we recognized a $<ix:nonFraction unitRef="usd" contextRef="id9e57117e59349509aa17240e4b739bb_D20210101-20211231" decimals="-5" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfNTQ5NzU1ODMyMjM1_4eed71fe-4802-45e2-9113-26057b6e073b">31.1</ix:nonFraction>&#160;million gain based on the purchase price of Medalogix, which is reflected in gain on equity method investments within our consolidated statements of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Contessa Health ("Contessa") on August 1, 2021, we obtained interests in several joint ventures with health system partners and a professional corporation that employs clinicians. Each of these entities meets the criteria to be classified as a VIE. As of December 31, 2022, we are consolidating all of our admitting joint ventures with health system partners as well as the professional corporation as we have concluded that we are the primary beneficiary of these VIEs. We have management agreements in place with each of these entities whereby we manage the entities and run the day-to-day operations. As such, we possess the power to direct the activities that most significantly impact the economic performance of the VIEs. The significant activities include, but are not limited to, negotiating provider and payor contracts, establishing patient care policies and protocols, making employment and compensation decisions, developing the operating and capital budgets, performing marketing activities and providing accounting support. We also have the obligation to absorb any expected losses and the right to receive benefits. Additionally, from time to time we may be required to provide joint venture funding. Our high acuity care segment also includes two non-admitting joint ventures with health system partners that are accounted for under the equity method of accounting. Operations of one of these joint ventures have ceased, and we are currently awaiting claims runout to complete financial reconciliations with our health plan partner; we recorded a $<ix:nonFraction unitRef="usd" contextRef="i9dc0472ea16a4281be6243dd9c20268f_D20220701-20220930" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfNTQ5NzU1ODMyMjUw_6a696926-50ad-472f-b415-95c20aaa9472">3.0</ix:nonFraction>&#160;million impairment charge related to our investment in this joint venture during the three-month period ended September 30, 2022.  </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></div><ix:continuation id="i126636697ad04ea6a404857e3e432bd0"><ix:continuation id="ida432061514e4a97a0aeeaca13c3c4df"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the agreements with each VIE prohibit us from using the assets of the VIE to satisfy the obligations of other entities. <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:ScheduleOfVariableInterestEntitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfMTEzNjI_319b53c9-3452-4940-b785-6c717a04b903" continuedAt="i92f0b129bed14b069e36cb658b7d5ec4" escape="true">The carrying amount of the VIEs&#8217; assets and liabilities included in our consolidated balance sheets are as follows (amounts in millions):</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><ix:continuation id="i92f0b129bed14b069e36cb658b7d5ec4"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.667%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.669%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7265ebd4cec34caa817f807dc1d6cbc1_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMy0xLTEtMS02MTA5MA_3f051ce5-3b72-4f2d-8213-c062422d916d">15.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b27a458690140b59e1f60faae27b54c_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMy0xLTEtMS01MDcyNQ_e6c356ca-aa2a-44bd-959c-9119bcca6039">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Patient accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7265ebd4cec34caa817f807dc1d6cbc1_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfNC0xLTEtMS02MTA5MA_8ec1bb2b-b1a4-4a02-8f49-a077b6c0d580">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b27a458690140b59e1f60faae27b54c_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfNC0xLTEtMS01MDcyNQ_07e52500-58c2-4d18-a64a-31b7a6c51b6c">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7265ebd4cec34caa817f807dc1d6cbc1_I20221231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfNS0xLTEtMS02MTA5MA_f2851766-cf7c-4bcd-bba7-20e755e01a35">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b27a458690140b59e1f60faae27b54c_I20211231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfNS0xLTEtMS01MDcyNQ_307f324a-fa50-40e5-8227-46460b8e1682">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7265ebd4cec34caa817f807dc1d6cbc1_I20221231" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfNi0xLTEtMS02MTA5MA_31d31cdc-e1b9-4695-a4d4-415e830b5394">22.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b27a458690140b59e1f60faae27b54c_I20211231" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfNi0xLTEtMS01MDcyNQ_19257744-235f-4ec7-bc15-febfb20013b0">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7265ebd4cec34caa817f807dc1d6cbc1_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfNy0xLTEtMS02MTA5MA_9f26a882-5863-41d3-9d5f-b8e8939960e9">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b27a458690140b59e1f60faae27b54c_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfNy0xLTEtMS01MDcyNQ_f46fe9ba-76d5-48a7-a609-076b8a783824">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7265ebd4cec34caa817f807dc1d6cbc1_I20221231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfOC0xLTEtMS02MTA5Ng_3c664c20-590f-483d-9e8d-5de2a17240bc">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b27a458690140b59e1f60faae27b54c_I20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfOC0zLTEtMS02MTEwMA_8226f049-5ce4-4f35-ba0b-deb723a13d62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7265ebd4cec34caa817f807dc1d6cbc1_I20221231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfOS0xLTEtMS02MTA5OA_993afa69-edb4-4d80-8ca3-bab8eb9bc0a1">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b27a458690140b59e1f60faae27b54c_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfOS0zLTEtMS02MTEwMA_26d4656b-52f8-4fe0-be4c-938f11650502">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7265ebd4cec34caa817f807dc1d6cbc1_I20221231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMTAtMS0xLTEtNjEwOTg_7f4e852b-4174-4e2c-96e4-1200b56999f4">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b27a458690140b59e1f60faae27b54c_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMTAtMy0xLTEtNjExMDA_110a2b30-6124-497a-952a-cf918e11ac8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7265ebd4cec34caa817f807dc1d6cbc1_I20221231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMTEtMS0xLTEtNjEwOTg_afe060c8-8530-414b-8f60-047bb7d6fcb5">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b27a458690140b59e1f60faae27b54c_I20211231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMTEtMy0xLTEtNjExMDA_c7ceb840-0b7e-48db-8cc6-c1444b0d4b43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7265ebd4cec34caa817f807dc1d6cbc1_I20221231" decimals="-5" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMTItMS0xLTEtNjEwOTI_6c179717-48ce-41f0-8f83-0fc8e81026eb">31.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b27a458690140b59e1f60faae27b54c_I20211231" decimals="-5" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfOC0xLTEtMS01MDcyNQ_04da706f-8f9d-4ad0-b9b3-36938181fbca">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7265ebd4cec34caa817f807dc1d6cbc1_I20221231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMTUtMS0xLTEtNjExMDI_914cc469-e22f-4868-952a-93d4b602c271">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b27a458690140b59e1f60faae27b54c_I20211231" decimals="-5" name="us-gaap:AccountsPayableCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMTUtMy0xLTEtNjExMDQ_3fe29da7-d6f4-4ad9-b2ed-2ffd30a8b839">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Payroll and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7265ebd4cec34caa817f807dc1d6cbc1_I20221231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMTYtMS0xLTEtNjEwOTQ_4e1deab7-4fb7-44b1-bb45-3ef56f9ef6a6">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b27a458690140b59e1f60faae27b54c_I20211231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMTEtMS0xLTEtNTA3MjU_1705f3f1-d225-4f3e-8c1b-d6901078d959">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7265ebd4cec34caa817f807dc1d6cbc1_I20221231" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMTctMS0xLTEtNjEwOTQ_1273cf9a-9f84-4761-a433-16a990237206">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b27a458690140b59e1f60faae27b54c_I20211231" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMTItMS0xLTEtNTA3MjU_ba98a6d8-51fa-4b73-bdf7-0500444e5449">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7265ebd4cec34caa817f807dc1d6cbc1_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMTgtMS0xLTEtNjE1NTA_8a5ec1a2-03cb-48fc-abb1-60754870c0eb">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b27a458690140b59e1f60faae27b54c_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMTgtMy0xLTEtNjE1NTI_fe922089-19a2-49fd-834c-af006c81d017">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7265ebd4cec34caa817f807dc1d6cbc1_I20221231" decimals="-5" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMTgtMS0xLTEtNjEwOTQ_1fadd1fb-fc56-4ed4-b636-8f1192c863a3">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b27a458690140b59e1f60faae27b54c_I20211231" decimals="-5" name="us-gaap:DebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMTMtMS0xLTEtNTA3MjU_39b5b6be-75c2-45a4-af15-3268735d30c2">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7265ebd4cec34caa817f807dc1d6cbc1_I20221231" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMjEtMS0xLTEtNjEwOTQ_4268ebe3-9161-4abf-8dd0-fbbcd70eb89f">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b27a458690140b59e1f60faae27b54c_I20211231" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMTYtMS0xLTEtNTA3MjU_ef60b358-09d8-49da-87cb-012b3a39151a">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we sold our investment in the Heritage Healthcare Innovation Fund, LP via a secondary transaction for $<ix:nonFraction unitRef="usd" contextRef="i18a8ecfea90b46dea16770739b772958_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfMTA5OTg_26c694f7-64b1-4915-b7a4-0013d6b1adeb">17.9</ix:nonFraction>&#160;million which resulted in a $3.0&#160;million loss which is reflected in gain (loss) on equity method investments within our consolidated statement of operations for the year ended December 31, 2020. The Company's original investment was made in 2010 and no longer fit within our strategic areas of focus. Proceeds from the sale were used to pay down debt and fund capital needs.</span></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i5c10b724a6674979bf3c35a339f29685_79"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwMzQ_e9fa762b-0adf-4a46-9432-bdbccda3679a" continuedAt="ia11b862ebb164d24a1846c0dab042145" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="ia11b862ebb164d24a1846c0dab042145" continuedAt="i00991c20703d4cd79054b8f3f93a23cf"><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwNTA_e3eb1cfe-99d1-4914-9c56-eaa44e39ef41" continuedAt="idd05ac1152cc49c99a58a0c2e29bcb59" escape="true"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for revenue from contracts with customers in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. Our cost of obtaining contracts is not material. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligations relate to contracts with a duration of less than one year; therefore, we have elected to apply the optional exemption provided by ASC 606 and are not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></div><ix:continuation id="i00991c20703d4cd79054b8f3f93a23cf" continuedAt="i2fdaf8789bac42a7909c7a00b1f8624c"><ix:continuation id="idd05ac1152cc49c99a58a0c2e29bcb59" continuedAt="ie85c987090814b87bb1d2b0e7bf0b332"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third-party payors and others for services provided. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current industry conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. We assess our ability to collect for the healthcare services provided at the time of patient admission based on our verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represents approximately <ix:nonFraction unitRef="number" contextRef="ib60ffa9c6822423ca9d59d283467feaa_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjk5Nw_e712797e-8207-41ad-88e8-ad2bd29e60de">74</ix:nonFraction>% of our consolidated net service revenue.  </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation based on our historical experience which primarily includes a historical collection rate of over <ix:nonFraction unitRef="number" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="2" name="amed:HistoricalCollectionRateFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzc2OA_b402b9c4-6940-45a5-9f57-995f44df5e60">99</ix:nonFraction>% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided. </span></div><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwMDE_883f993e-dd80-4e7d-afa6-33f37b77fa35" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by payor class as a percentage of total net service revenue is as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"></td><td style="width:59.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.522%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.855%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Home Health:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i332e5cf83f704c55b25091d8aac22686_D20220101-20221231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfMy0xLTEtMS01MDcyNQ_5ad47067-b44f-4419-8f66-8dc56e2c2f1d">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icc45e2e2cecf43c7a6bdb033a411f0dc_D20210101-20211231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfMy0zLTEtMS01MDcyNQ_e002a4b5-9382-4a23-8dd8-74fe2877b4f2">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0ef480ba6e114f2599922f6fecdb6adc_D20200101-20201231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfMy01LTEtMS01MDcyNQ_c290bc19-6a0f-49f0-a335-b50fdfde4afa">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare - Episodic-based</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b7d185a3a5845299460ef91d19e3737_D20220101-20221231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfNC0xLTEtMS01MDcyNQ_fd75d430-7f4e-4413-8775-955edc191735">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20f7b2610db946b6b2c5a7131a2c6402_D20210101-20211231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfNC0zLTEtMS01MDcyNQ_6269f89a-a9a7-45a6-bcc2-d19d501a5d35">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i045954bc2da64e639f3d2657db45c8c6_D20200101-20201231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfNC01LTEtMS01MDcyNQ_c58ffd27-52e3-4c4f-abed-0ad1b9774375">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare - Non-episodic based</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie68834514d89475fa05705e2a104287c_D20220101-20221231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfNS0xLTEtMS01MDcyNQ_223d4f9f-6c88-4c8c-aee8-1ba704b87749">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3293bf9528d2455dbef45aa497f1802f_D20210101-20211231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfNS0zLTEtMS01MDcyNQ_79888cf2-66f8-43e2-98a3-c03dd2583686">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if428e0eafe734ae298c1d7e4fd10018f_D20200101-20201231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfNS01LTEtMS01MDcyNQ_546bd5f7-60a5-413d-af25-2fd4165a62a6">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Hospice:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i404ba799d43b4f9cbc11bd0f031fa84f_D20220101-20221231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfNy0xLTEtMS01MDcyNQ_823d0ddb-bbaf-489c-850b-fbd66f2973dc">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaf2d05881bc84546bd58a3bfa9971f2a_D20210101-20211231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfNy0zLTEtMS01MDcyNQ_030557f9-2827-41e5-a8a9-afe7d0fd6f8b">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ife774e47b4e649bbb69a2233094f5f4b_D20200101-20201231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfNy01LTEtMS01MDcyNQ_c15c61a8-d16c-4930-8ffc-5f71b8ad0c74">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9bb3b80738f34bf39ce177e3aa4c2391_D20220101-20221231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfOC0xLTEtMS01MDcyNQ_56112d79-85bb-48df-a4b7-60a980d1873e">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id3f54ce15271460d90fc908cd65314f0_D20210101-20211231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfOC0zLTEtMS01MDcyNQ_df3647d2-6e71-4c00-adba-bbe72b82fb48">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8da51266d38e4113b6deb81ba671c1f4_D20200101-20201231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfOC01LTEtMS01MDcyNQ_7682715a-cf63-4f05-a453-6e1fe63ed1c8">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i417cb5125535485c9ef0320496af5e26_D20220101-20221231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfOS0xLTEtMS01MDcyNQ_6362c605-ae89-42c8-83c0-107851c96aaf">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9d4251ae99c943f193588862db0c1b69_D20210101-20211231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfOS0zLTEtMS01MDcyNQ_5226cf90-d40e-42e7-a9e3-f6ec45f33e94">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i72cdabc594824ec3a9da4123e53b9fbb_D20200101-20201231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfOS01LTEtMS01MDcyNQ_51526dd0-116a-425f-bf13-a2a98d335744">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">High Acuity Care (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia8691440b2404ff496cc413ef83e5825_D20220101-20221231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfMTAtMS0xLTEtNTA3MjU_fd81e8d1-5ae6-42db-a96a-abd01f70731b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic803d3d531314ae89f73add64e4be217_D20210101-20211231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfMTAtMy0xLTEtNTA3MjU_336748ed-8f86-45bc-811c-2f45fe257be2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2045ac339bf340c48bb59e921fe05def_D20200101-20201231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfMTAtNS0xLTEtNTA3MjU_faf3535c-0a4e-4ab2-96bb-b297f11125f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfMTEtMS0xLTEtNTA3MjU_04d9880d-6631-448c-87bc-c705af7fcae7">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfMTEtMy0xLTEtNTA3MjU_05072825-d600-40b8-ac83-251a6256f2ed">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfMTEtNS0xLTEtNTA3MjU_ddae85dc-b190-4093-b539-8d897d25adc7">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Acquired Contessa Health on August 1, 2021.</span></div></ix:nonNumeric><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home Health Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"). PDGM uses <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfNDU3MQ_7ec76e96-0e16-472a-a2d5-b10d880ccd02">30</ix:nonNumeric>-day periods of care rather than <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="amed:NetServiceRevenueEpisodePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfNDYwNg_fda9264d-9f37-4b33-818f-fd5bdf8247c5">60</ix:nonNumeric>-day episodes of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, we account for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed. Each <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="amed:NetServiceRevenueEpisodePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfNTQ4MA_5d789297-fa19-4a2b-b487-906a0c4f87a4">60</ix:nonNumeric>-day episode includes two <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfNTUwOA_461bf875-8299-41de-83a2-c5a488a93033">30</ix:nonNumeric>-day payment periods.</span></div></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></div><ix:continuation id="i2fdaf8789bac42a7909c7a00b1f8624c" continuedAt="ied2b44463ef341c283a73a9d3945b632"><ix:continuation id="ie85c987090814b87bb1d2b0e7bf0b332" continuedAt="ibdc9f50ba64245fabf07bae57b5fe84c"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net service revenue is recorded based on the established Federal Medicare home health payment rate for a <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfNTYzNw_0ef2e161-3df6-452b-a262-14dc165f1e03">30</ix:nonNumeric>-day period of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#8217;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice" practical expedient, and therefore, our revenue recognition is based on the reimbursement we are entitled to for each 30-day period of care. We utilize our historical average length of stay for each <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfNjE3NQ_62d1cb77-83b8-4b94-a671-e73a6c8ebcee">30</ix:nonNumeric>-day period of care as the measure of progress towards the satisfaction of our performance obligation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfNjQ0NA_65f8868d-af42-48e1-8eb5-4206c1e36ef4">30</ix:nonNumeric>-day period of care is subject to additional adjustments based on certain variables, including, but not limited to (a) an outlier payment if our patient's care was unusually costly (capped at <ix:nonFraction unitRef="number" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="INF" name="amed:PercentageOfTotalReimbursementOfOutlierPayment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfNjYzOA_4570545f-969e-473a-af47-7264d426c8eb">10</ix:nonFraction>% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#8220;LUPA&#8221;) if the number of visits provided was less than the established threshold, which ranges from <ix:nonFraction unitRef="number_of_visits" contextRef="i89bafb018d3a43eb8a3f1bbb4c93b71b_D20220101-20221231" decimals="0" name="amed:LowUtilizationPaymentAdjustmentNumberOfVisits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfNjgyOA_098d14f8-b79d-4652-befe-e2287e5d9f66">two</ix:nonFraction> to <ix:nonFraction unitRef="number_of_visits" contextRef="i1a4434e079494d01969542db2a51ebee_D20220101-20221231" decimals="0" name="amed:LowUtilizationPaymentAdjustmentNumberOfVisits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfNjgzNA_ee21a25d-1039-44f5-b525-e56c1bd2ed6c">six</ix:nonFraction> visits and varies for every case-mix group; (c)&#160;a partial payment if a patient transferred to another provider or from another provider before completing the <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfNzAwNg_020f53fb-0965-4b94-8481-6705f2d9229d">30</ix:nonNumeric>-day period of care; and (d)&#160;the applicable geographic wage index. Payments for routine and non-routine supplies are included in the 30-day payment rate.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over <ix:nonFraction unitRef="number" contextRef="ie8d7fbaae8144d01ae5b61ba948ca043_D20220101-20221231" decimals="2" name="amed:HistoricalCollectionRateFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfNzQ1OQ_dfd60a43-d8d2-4a3a-9ea0-d8ad6dcde498">99</ix:nonFraction>% on Medicare claims, and record this estimate during the period in which services are rendered to revenue with a corresponding reduction to patient accounts receivable. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during the novel coronavirus pandemic ("COVID-19"), CMS relaxed the definition of homebound status through the duration of the public health emergency. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their home because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19.  </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, <ix:nonFraction unitRef="number" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="2" name="amed:RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfODk3NA_e2e7ce14-680d-4452-a57f-d2ad0b7e62d9">20</ix:nonFraction>% of the reimbursement from each Medicare 30-day payment period was billed near the start of each <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfOTA3Mw_93a176a3-586b-45f1-a08d-0d40d8a34a19">30</ix:nonNumeric>-day period of care, referred to as a request for anticipated payment ("RAP"), and cash was typically received before all services were rendered. Any cash received from Medicare for a RAP for a <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfOTI2OQ_1413b669-389c-43a2-aa94-dc9d56ade8d8">30</ix:nonNumeric>-day period of care that exceeded the associated revenue earned was recorded to accrued expenses within our consolidated balance sheets. CMS fully eliminated all upfront payments associated with RAPs effective January 1, 2021. Effective January 1, 2022, CMS implemented a new one-time Notice of Admission ("NOA") process. The NOA process requires a one-time submission that establishes the home health period of care and covers all contiguous 30-day periods of care until the patient is discharged from Medicare home health services. If the NOA is not submitted timely, a payment reduction will be applied equal to 1/30 of the payment amount for each day from the home health start of care date until the date the NOA is submitted.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments from non-Medicare payors are either a percentage of Medicare rates, per-visit rates or case rates depending upon the terms and conditions established with such payors. Approximately <ix:nonFraction unitRef="number" contextRef="ie8d7fbaae8144d01ae5b61ba948ca043_D20220101-20221231" decimals="INF" name="amed:PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfNTQ5NzU1ODYzMjI3_7762e98b-2e77-4f7a-8a41-45dfdb62a7c3">30</ix:nonFraction>% of our managed care contract volume affords us the opportunity to receive additional payments if we achieve certain quality or process metrics as defined in each contract (e.g. star ratings and acute-care hospitalization rates).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Episodic-based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms, the majority of which range from <ix:nonFraction unitRef="number" contextRef="i89bafb018d3a43eb8a3f1bbb4c93b71b_D20220101-20221231" decimals="INF" name="amed:NonMedicareRevenueTermRates" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfOTgwOQ_e8900d31-2367-4b24-b240-c7488c499915">95</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i1a4434e079494d01969542db2a51ebee_D20220101-20221231" decimals="INF" name="amed:NonMedicareRevenueTermRates" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfOTgxNQ_3ed4766e-c000-4cbd-97d9-c60f9ca3b9f9">100</ix:nonFraction>% of Medicare rates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-episodic based Revenue. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our per visit contracts, gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. For our case rate contracts, gross revenue is recorded over our historical average length of stay using the established case rate for each admission. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on our historical experience to reflect the estimated transaction </span></div></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></div><ix:continuation id="ied2b44463ef341c283a73a9d3945b632" continuedAt="i02addcca6acd48debfa762baaca61a4f"><ix:continuation id="ibdc9f50ba64245fabf07bae57b5fe84c" continuedAt="i901f4a4beb614197a3df1993624a8097"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our case rate contracts, we may receive reimbursement before all services are rendered. Any cash received that exceeds the associated revenue earned is recorded to deferred revenue in accrued expenses within our consolidated balance sheets.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospice Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Medicare Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for <ix:nonFraction unitRef="number" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="2" name="amed:HospiceMedicareRevenueRateAccountedForRoutineCare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMTA5OTM_2216e347-7cbe-41ac-9e71-e2a12fc01c7d"><ix:nonFraction unitRef="number" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="2" name="amed:HospiceMedicareRevenueRateAccountedForRoutineCare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMTA5OTM_33299017-52e3-443c-a95a-6548becaaa6e"><ix:nonFraction unitRef="number" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="2" name="amed:HospiceMedicareRevenueRateAccountedForRoutineCare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMTA5OTM_c3cdb8b5-62b7-44db-a26f-9358d3f1c541">97</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of our total Medicare hospice service revenue for each of 2022, 2021 and 2020, respectively. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#8220;SIA&#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over <ix:nonFraction unitRef="number" contextRef="i6d7eeb1ee5ac46b29435cfd337b5b8a7_D20220101-20221231" decimals="2" name="amed:HistoricalCollectionRateFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMTE5ODk_abcbd6fe-2521-43eb-b7d8-cd1fd25fbb6b">99</ix:nonFraction>% on Medicare claims, and record it during the period services are rendered. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our consolidated balance sheets. Providers are required to self-report and pay their estimated cap liability by February 28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the following year. As of December&#160;31, 2022, we have recorded $<ix:nonFraction unitRef="usd" contextRef="i3d86e0102e724a01b5f8cbf75e5ad801_I20221231" decimals="-5" name="amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMTI4MzY_25cd86bc-1ef2-496d-b6cc-439ca526238b">4.3</ix:nonFraction> million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2023. As of December&#160;31, 2021, we had recorded $<ix:nonFraction unitRef="usd" contextRef="id22ec472968f424eaedee0df2c1a6a6c_I20211231" decimals="-5" name="amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMTMwMDU_7c253e60-25cd-42a6-bf39-04a6114d92fc">4.5</ix:nonFraction> million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2022.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Non-Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third-party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on our historical experience to reflect the estimated transaction price.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Personal Care Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Personal Care Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points ("ASAPs"), Senior Care Options ("SCOs"), Program of All-Inclusive Care for the Elderly ("PACE") and the Veterans Administration ("VA"). </span></div></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></div><ix:continuation id="i02addcca6acd48debfa762baaca61a4f" continuedAt="i2cedf91d471742f9bd75ae228adc5848"><ix:continuation id="i901f4a4beb614197a3df1993624a8097"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">High Acuity Care Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">High Acuity Care Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues are derived from contracts with (1) health insurance plans for the coordination and provision of home recovery care services to clinically-eligible patients who are enrolled members in those insurance plans, (2) health system partners for the coordination and provision of home recovery care services to clinically-eligible patients who are discharged early from a health system facility to complete their inpatient stay at home and (3) Medicare and other payors for the provision of home health services. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our health insurance plan contracts, we provide home recovery care services, which include hospital-equivalent ("H@H") and skilled nursing facility ("SNF") equivalent services ("SNF@H"), for high acuity care patients on a full risk basis whereby we assume the financial risk for the coordination and payment of all hospital or SNF replacement medical services necessary to treat the medical condition for which the patient was diagnosed in a home-based setting for a <ix:nonNumeric contextRef="i2c715413d797438591b1cf5dd86e46fa_D20220101-20221231" name="amed:NetServiceRevenueEpisodePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMTU0MzA_1d582605-43d5-4e4c-b560-9362d4e238cf">30</ix:nonNumeric>-day (H@H) or <ix:nonNumeric contextRef="ifd1a9219629443d5bd28be1543aad1fe_D20220101-20221231" name="amed:NetServiceRevenueEpisodePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMTU0NDA_44bb158e-210e-4091-ac41-fb6e560b032d">60</ix:nonNumeric>-day (SNF@H) episode of care in exchange for a fixed contracted bundled rate. For H@H programs, the fixed rate is based on the assigned diagnosis related group ("DRG") and the <ix:nonNumeric contextRef="i2c715413d797438591b1cf5dd86e46fa_D20220101-20221231" name="amed:NetServiceRevenueEpisodePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMTU2OTc_0f1c7caf-f9f2-4267-9b00-6e834279204b">30</ix:nonNumeric>-day post-discharge related spend. For SNF@H programs, the fixed rate is based on the <ix:nonNumeric contextRef="ifd1a9219629443d5bd28be1543aad1fe_D20220101-20221231" name="amed:NetServiceRevenueEpisodePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMTU3MDc_47564e4d-b07d-40a5-b177-44e4c1996d82">60</ix:nonNumeric>-day post-discharge related spend. Our performance obligation is the coordination and provision of patient care in accordance with physicians&#8217; orders over either a 30-day or 60-day episode of care. The majority of our care coordination services and direct patient care is provided in the first five to seven days of the episode period (the "acute phase"). Monitoring services and follow-up direct patient care, as deemed necessary by the treating physician, are provided throughout the remainder of the episode. Since the majority of our services are provided during the acute phase, we recognize net service revenues over the acute phase based on gross charges for the services provided per the applicable managed care contract rates, reduced by estimates for revenue adjustments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our contracts with health system partners, we provide home recovery care services for high acuity patients on a limited risk basis whereby we assume the risk for certain healthcare services during the remainder of an inpatient acute stay serviced at the patient&#8217;s home in exchange for a contracted per diem rate. The performance obligation is the coordination and provision of required medical services, as determined by the treating physician, for each day the patient receives inpatient-equivalent care at home. As such, revenues are recognized as services are administered and as our performance obligations are satisfied on a per diem basis, reduced by estimates for revenue adjustments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize adjustments to revenue during the period in which changes to estimates of assigned patient diagnoses or episode terminations become known, in accordance with the applicable managed care contracts. For certain health insurance plans, revenue is reduced by amounts owed by enrollees to healthcare providers under deductible, coinsurance or copay provisions of health insurance plan policies, since those amounts are repaid to the health insurance plans by us as part of a retrospective reconciliation process.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, our high acuity care segment entered into a transaction in which one of our health system partners contributed its home health operations to one of our existing high acuity care joint ventures. We recognize Medicare and non-Medicare revenue in a manner that is consistent with our home health segment revenue recognition policy described above.</span></div></ix:continuation><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="amed:GovernmentGrantsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwMTA_05dc17b0-ba9c-4a20-8bb4-d5f230f0a3b3" escape="true"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Grants</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for government grants in accordance with ASU 2021-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance (Topic 832), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by applying the grant model in accordance with International Accounting Standard ("IAS") 20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Government Grants and Disclosure of Government Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and as such, we recognize grant income on a systematic basis in line with the recognition of expenses or the loss of revenues for which the grants are intended to compensate. We recognize grants once both of the following conditions are met: (1) we are able to comply with the relevant conditions of the grant and (2) the grant will be received. See Note 3 &#8211; Novel Coronavirus Pandemic ("COVID-19") for additional information on our accounting for government funds received under the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") and the Mass Home Care ASAP COVID-19 Provider Sustainability Program.</span></div></ix:nonNumeric><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwMTY_d4a811b7-4c47-4df5-99bf-a5ec2a087068" continuedAt="i5f55b41fdf3447438abf8ac1dfe7615a" escape="true">Cash, Cash Equivalents and Restricted Cash</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5f55b41fdf3447438abf8ac1dfe7615a">Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased. Restricted cash includes cash that is not available for ordinary business use.</ix:continuation> As of December 31, 2022 and 2021, we had $<ix:nonFraction unitRef="usd" contextRef="ie980f7f172dd4fc384952e9b8c0724f0_I20221231" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMTg5MDA_22bc7a6b-b957-49cf-bd08-32f42f5e944c"><ix:nonFraction unitRef="usd" contextRef="ie980f7f172dd4fc384952e9b8c0724f0_I20221231" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMTg5MDA_7fb034d9-4c3d-43c7-bd16-35ae44efb165">13.6</ix:nonFraction></ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i19a05af82bb1454eb68e81cc291cbc07_I20211231" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMTkxMTc_3a6c60cb-1162-482e-b2e1-870a0f0987b7"><ix:nonFraction unitRef="usd" contextRef="i19a05af82bb1454eb68e81cc291cbc07_I20211231" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMTkxMTc_bc9ff8a4-5b9e-43a8-afc0-955a437b0c94">3.1</ix:nonFraction></ix:nonFraction>&#160;million, respectively, classified as restricted cash related to funds placed into escrow accounts in connection with the indemnity, closing payment and other provisions within the purchase agreements of our acquisitions. The increase in restricted cash from December 31, 2021 to December 31, 2022 is related to our acquisitions of Evolution Health, LLC ("Evolution") and Assisted Care Home Health, Inc. and RH Homecare Services, LLC ("Assisted Care") on April 1, 2022. See Note 4 &#8211; Acquisitions for additional information.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></div><ix:continuation id="i2cedf91d471742f9bd75ae228adc5848" continuedAt="icbea6175c23349b6b4f0b540ee819e23"><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="amed:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwMTc_a69314b0-2c13-4331-8057-ed3a79fe03e6" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmNjOWZmZjE2ZjU5ZjQ1MjNhNTFhZWY3NDgzODA4Mjg5L3RhYmxlcmFuZ2U6Y2M5ZmZmMTZmNTlmNDUyM2E1MWFlZjc0ODM4MDgyODlfMi0xLTEtMS01MDcyNQ_f5e075f4-e292-4252-bee9-9b98508cc124">40.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmNjOWZmZjE2ZjU5ZjQ1MjNhNTFhZWY3NDgzODA4Mjg5L3RhYmxlcmFuZ2U6Y2M5ZmZmMTZmNTlmNDUyM2E1MWFlZjc0ODM4MDgyODlfMi0zLTEtMS01MDcyNQ_d1d45e0e-21b5-490f-960b-3cb79c19c000">42.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmNjOWZmZjE2ZjU5ZjQ1MjNhNTFhZWY3NDgzODA4Mjg5L3RhYmxlcmFuZ2U6Y2M5ZmZmMTZmNTlmNDUyM2E1MWFlZjc0ODM4MDgyODlfMy0xLTEtMS01MDcyNQ_25d71d73-fad6-4f1e-a87e-618daafff061">13.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmNjOWZmZjE2ZjU5ZjQ1MjNhNTFhZWY3NDgzODA4Mjg5L3RhYmxlcmFuZ2U6Y2M5ZmZmMTZmNTlmNDUyM2E1MWFlZjc0ODM4MDgyODlfMy0zLTEtMS01MDcyNQ_ea2f4407-e1dd-4cde-b98b-131dd0479ec3">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmNjOWZmZjE2ZjU5ZjQ1MjNhNTFhZWY3NDgzODA4Mjg5L3RhYmxlcmFuZ2U6Y2M5ZmZmMTZmNTlmNDUyM2E1MWFlZjc0ODM4MDgyODlfNC0xLTEtMS01MDcyNQ_8d6ee321-a4ca-4e2e-8d70-c57e9702c515">54.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmNjOWZmZjE2ZjU5ZjQ1MjNhNTFhZWY3NDgzODA4Mjg5L3RhYmxlcmFuZ2U6Y2M5ZmZmMTZmNTlmNDUyM2E1MWFlZjc0ODM4MDgyODlfNC0zLTEtMS02MTEyMA_19b1f978-2bab-4327-97e9-e1614f12e2ba">45.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwMjY_e68b9e73-dcf2-4aae-a59d-d771f3d079e6" escape="true"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patient Accounts Receivable</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. Our non-Medicare third-party payor base is comprised of a diverse group of payors that are geographically dispersed across the country. As of December&#160;31, 2022, there is no single payor, other than Medicare, that accounts for more than <ix:nonFraction unitRef="number" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="INF" name="amed:PercentageOfPatientReceivablesOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMTk5OTE_48bd3af0-22a5-4c4f-a28b-b113ddeff0ca">10</ix:nonFraction>% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectability risk associated with our Medicare accounts, which represented <ix:nonFraction unitRef="number" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="2" name="amed:PortionOfPatientAccountsReceivableDerivedFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjA0NDM_4930fd42-4f12-4746-bf80-cd450f7f0301">67</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="2" name="amed:PortionOfPatientAccountsReceivableDerivedFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjA0NTA_9a0894a0-6a3e-4922-9c3e-e1df510d7b65">68</ix:nonFraction>% of our net patient accounts receivable at December&#160;31, 2022 and 2021, respectively, is limited due to our historical collection rate of over <ix:nonFraction unitRef="number" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="2" name="amed:HistoricalCollectionRateFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjA1Nzk_c0fcdc23-f257-4ab2-9f1e-aee493f1142e">99</ix:nonFraction>% from Medicare and the fact that Medicare is a U.S. government payor. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Home Health</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our home health patients (within both our home health and high acuity care segments), our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare following the end of each <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfNTQ5NzU1ODYxMjI3_65f8868d-af42-48e1-8eb5-4206c1e36ef4">30</ix:nonNumeric>-day period of care or upon discharge, if earlier, for the services provided to the patient.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Hospice</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Medicare Home Health, Hospice, Personal Care and High Acuity Care</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#8217;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwNDY_40efb9d4-cab9-4409-8d0c-6a5429340169" continuedAt="i3178ec795cc540df8ab8e8a6d506a9e6" escape="true"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets or life of the lease, if shorter. Additionally, we have internally developed computer software for our own use. Additions and improvements (including interest costs for construction of qualifying long-lived assets) are capitalized. Maintenance and repair expenses are charged to expense as incurred. The cost of property and equipment sold or disposed of and the related accumulated depreciation are eliminated from the property and equipment and related accumulated depreciation accounts, and any gain or loss is credited or charged to other general and administrative expenses.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></div><ix:continuation id="icbea6175c23349b6b4f0b540ee819e23" continuedAt="i4a0992208dfa4b5ea40765003b39b49e"><ix:continuation id="i3178ec795cc540df8ab8e8a6d506a9e6"><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the impairment of a long-lived asset group whenever events or changes in circumstances indicate that the asset&#8217;s carrying value may not be recoverable. Factors we consider important that could trigger an impairment review include but are not limited to the following:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A significant change in the extent or manner in which the long-lived asset group is being used.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A significant change in the business climate that could affect the value of the long-lived asset group.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A significant change in the market value of the assets included in the asset group.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we determine that the carrying value of long-lived assets may not be recoverable, we compare the carrying value of the asset group to the undiscounted cash flows expected to be generated by the asset group. If the carrying value exceeds the undiscounted cash flows, an impairment charge is indicated. An impairment charge is recognized to the extent that the carrying value of the asset group exceeds its fair value.</span></div><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="amed:EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwNjU_34f937e9-669e-4195-a7dd-1267e464906e" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally provide for depreciation over the following estimated useful service lives.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9a008987e83a4ada9f3b12cc812bd0a1_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmQ0YjcwZmYzY2U4NDRmMDFhNTZiYTBkMGVhM2U2OWRmL3RhYmxlcmFuZ2U6ZDRiNzBmZjNjZTg0NGYwMWE1NmJhMGQwZWEzZTY5ZGZfMS0xLTEtMS01MDcyNQ_4c3ecf7c-53e7-45cb-bd0b-d924b9813d56">39</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibe86b23f247c43068f7f25f069252db2_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmQ0YjcwZmYzY2U4NDRmMDFhNTZiYTBkMGVhM2U2OWRmL3RhYmxlcmFuZ2U6ZDRiNzBmZjNjZTg0NGYwMWE1NmJhMGQwZWEzZTY5ZGZfMi0xLTEtMS01MDcyNQ_4abdc7f6-5fa2-4b39-b002-d6be444c0def">Lesser&#160;of&#160;lease term&#160;or&#160;expected&#160;useful&#160;life</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment and furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic14d437ad5074709988cb2cca394f95f_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmQ0YjcwZmYzY2U4NDRmMDFhNTZiYTBkMGVhM2U2OWRmL3RhYmxlcmFuZ2U6ZDRiNzBmZjNjZTg0NGYwMWE1NmJhMGQwZWEzZTY5ZGZfMy0xLTEtMS01MDcyNS90ZXh0cmVnaW9uOjAwZTM1NWNhOTBhMDQ2OGE5MjNmN2M4ZTU1NzYzYWZkXzQ_2301621f-a392-49a8-adf5-67b7df9306aa">3</ix:nonNumeric> to <ix:nonNumeric contextRef="i000722521f3240b491676997b1fb573f_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmQ0YjcwZmYzY2U4NDRmMDFhNTZiYTBkMGVhM2U2OWRmL3RhYmxlcmFuZ2U6ZDRiNzBmZjNjZTg0NGYwMWE1NmJhMGQwZWEzZTY5ZGZfMy0xLTEtMS01MDcyNS90ZXh0cmVnaW9uOjAwZTM1NWNhOTBhMDQ2OGE5MjNmN2M4ZTU1NzYzYWZkXzEw_e5bb2d4a-081a-49b3-9d50-eb9a596dfb25">7</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i21ca39c2911849ffa737ddd3e958f192_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmQ0YjcwZmYzY2U4NDRmMDFhNTZiYTBkMGVhM2U2OWRmL3RhYmxlcmFuZ2U6ZDRiNzBmZjNjZTg0NGYwMWE1NmJhMGQwZWEzZTY5ZGZfNC0xLTEtMS01MDcyNS90ZXh0cmVnaW9uOjYwNjhhYzBkMGFmYjRjNjlhMjY1MzA1MzExZjFmOTljXzU0OTc1NTgxMzg5Mg_b37c398b-ba25-4fa1-9253-62e8871bdf67">3</ix:nonNumeric> to <ix:nonNumeric contextRef="if9c24eced7104a4e97d673f1e2ca0501_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmQ0YjcwZmYzY2U4NDRmMDFhNTZiYTBkMGVhM2U2OWRmL3RhYmxlcmFuZ2U6ZDRiNzBmZjNjZTg0NGYwMWE1NmJhMGQwZWEzZTY5ZGZfNC0xLTEtMS01MDcyNS90ZXh0cmVnaW9uOjYwNjhhYzBkMGFmYjRjNjlhMjY1MzA1MzExZjFmOTljXzU0OTc1NTgxMzg5OQ_679659a5-85e1-486f-b0f2-c3cbaf740c32">5</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6c4545751ceb443c93f828600b08a087_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmQ0YjcwZmYzY2U4NDRmMDFhNTZiYTBkMGVhM2U2OWRmL3RhYmxlcmFuZ2U6ZDRiNzBmZjNjZTg0NGYwMWE1NmJhMGQwZWEzZTY5ZGZfNS0xLTEtMS01MDcyNS90ZXh0cmVnaW9uOmU0MjlhYTE4MTRiZjRlNDM5Nzg3NjUzYTYyYmVjNGRkXzQ_b2693e20-419c-417e-8934-96d564dbdbc3">2</ix:nonNumeric> to <ix:nonNumeric contextRef="i4a34fcd3e4ca44f997870b28af217929_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmQ0YjcwZmYzY2U4NDRmMDFhNTZiYTBkMGVhM2U2OWRmL3RhYmxlcmFuZ2U6ZDRiNzBmZjNjZTg0NGYwMWE1NmJhMGQwZWEzZTY5ZGZfNS0xLTEtMS01MDcyNS90ZXh0cmVnaW9uOmU0MjlhYTE4MTRiZjRlNDM5Nzg3NjUzYTYyYmVjNGRkXzEw_25bd95d4-f800-46d6-a48b-64a0b4a8d3f8">7</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1c1fcea9f947413daad53be6d9712b19_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmQ0YjcwZmYzY2U4NDRmMDFhNTZiYTBkMGVhM2U2OWRmL3RhYmxlcmFuZ2U6ZDRiNzBmZjNjZTg0NGYwMWE1NmJhMGQwZWEzZTY5ZGZfNi0xLTEtMS01MDcyNQ_aacf1313-e309-42c8-bc02-f8f05e0f299a">3</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwMjA_1456c619-b639-4acc-ae20-416fe4d1a945" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balances related to our property and equipment for 2022 and 2021 (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i289606829e684a02a13b4c2d309ec6a3_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjQ1ODg0N2JjMTdkNDRlOWQ5NTViNGU2ZjBiYjJkZmIwL3RhYmxlcmFuZ2U6NDU4ODQ3YmMxN2Q0NGU5ZDk1NWI0ZTZmMGJiMmRmYjBfMi0xLTEtMS01MDcyNQ_913f62c4-aade-4c5a-9967-04aae86431d5">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd970c25fe194ee8bb233e64dbeeb49b_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjQ1ODg0N2JjMTdkNDRlOWQ5NTViNGU2ZjBiYjJkZmIwL3RhYmxlcmFuZ2U6NDU4ODQ3YmMxN2Q0NGU5ZDk1NWI0ZTZmMGJiMmRmYjBfMi0zLTEtMS01MDcyNQ_3bf8a59b-c3d7-4d75-8ff3-af993e0f2176">9.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment and furniture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5efc684324124683b1a591012cf24d74_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjQ1ODg0N2JjMTdkNDRlOWQ5NTViNGU2ZjBiYjJkZmIwL3RhYmxlcmFuZ2U6NDU4ODQ3YmMxN2Q0NGU5ZDk1NWI0ZTZmMGJiMmRmYjBfMy0xLTEtMS01MDcyNQ_1f656a16-4514-4c6a-86f5-f0ab2bd83385">56.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75cc8e8f3048499ea5dff437d4511970_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjQ1ODg0N2JjMTdkNDRlOWQ5NTViNGU2ZjBiYjJkZmIwL3RhYmxlcmFuZ2U6NDU4ODQ3YmMxN2Q0NGU5ZDk1NWI0ZTZmMGJiMmRmYjBfMy0zLTEtMS01MDcyNQ_262b8f7b-7dc3-4c69-accf-b2714d395168">54.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b2a5e41e9ee4551ba7962246c513287_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjQ1ODg0N2JjMTdkNDRlOWQ5NTViNGU2ZjBiYjJkZmIwL3RhYmxlcmFuZ2U6NDU4ODQ3YmMxN2Q0NGU5ZDk1NWI0ZTZmMGJiMmRmYjBfNC0xLTEtMS01MDcyNQ_b354bd44-870d-4088-9baa-5b0cc9b3c05b">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9e60ab572054136b724859b7d07a982_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjQ1ODg0N2JjMTdkNDRlOWQ5NTViNGU2ZjBiYjJkZmIwL3RhYmxlcmFuZ2U6NDU4ODQ3YmMxN2Q0NGU5ZDk1NWI0ZTZmMGJiMmRmYjBfNC0zLTEtMS01MDcyNQ_ac0c96a6-723f-4610-9598-8920f6c8accd">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87145fca776747b8862566f844f11da8_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjQ1ODg0N2JjMTdkNDRlOWQ5NTViNGU2ZjBiYjJkZmIwL3RhYmxlcmFuZ2U6NDU4ODQ3YmMxN2Q0NGU5ZDk1NWI0ZTZmMGJiMmRmYjBfNS0xLTEtMS01MDcyNQ_e28297ce-32ec-4600-907e-23dfa8090c0a">46.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i450c80a3586442a8bc78d59bb78f68ce_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjQ1ODg0N2JjMTdkNDRlOWQ5NTViNGU2ZjBiYjJkZmIwL3RhYmxlcmFuZ2U6NDU4ODQ3YmMxN2Q0NGU5ZDk1NWI0ZTZmMGJiMmRmYjBfNS0zLTEtMS01MDcyNQ_bf9369b9-cff4-4d8a-8741-e249b1e84d44">47.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjQ1ODg0N2JjMTdkNDRlOWQ5NTViNGU2ZjBiYjJkZmIwL3RhYmxlcmFuZ2U6NDU4ODQ3YmMxN2Q0NGU5ZDk1NWI0ZTZmMGJiMmRmYjBfNi0xLTEtMS01MDcyNQ_1a4c6241-b697-4832-a970-95828d2af81a">117.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjQ1ODg0N2JjMTdkNDRlOWQ5NTViNGU2ZjBiYjJkZmIwL3RhYmxlcmFuZ2U6NDU4ODQ3YmMxN2Q0NGU5ZDk1NWI0ZTZmMGJiMmRmYjBfNy0xLTEtMS01MDcyNQ_892067a1-1d80-4674-a3ed-e317a7f9f320">101.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjQ1ODg0N2JjMTdkNDRlOWQ5NTViNGU2ZjBiYjJkZmIwL3RhYmxlcmFuZ2U6NDU4ODQ3YmMxN2Q0NGU5ZDk1NWI0ZTZmMGJiMmRmYjBfNy0zLTEtMS01MDcyNQ_1c3048bf-5481-4839-9489-b7e78afd0ec1">96.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjQ1ODg0N2JjMTdkNDRlOWQ5NTViNGU2ZjBiYjJkZmIwL3RhYmxlcmFuZ2U6NDU4ODQ3YmMxN2Q0NGU5ZDk1NWI0ZTZmMGJiMmRmYjBfOC0xLTEtMS01MDcyNQ_a5d5f6d2-2e77-4aec-bea8-55869aa2a7fc">16.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjQ1ODg0N2JjMTdkNDRlOWQ5NTViNGU2ZjBiYjJkZmIwL3RhYmxlcmFuZ2U6NDU4ODQ3YmMxN2Q0NGU5ZDk1NWI0ZTZmMGJiMmRmYjBfOC0zLTEtMS01MDcyNQ_ba63daac-ef90-403a-82c9-ddfc43e8a9a7">18.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjQ0Mzk_9136898a-293e-4f63-b5b8-18d39fbb3163">11.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjQ0NDM_487bef3a-39a4-43ea-8260-f50361532278">12.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjQ0NTA_50916972-9a19-41a8-80e2-8c1c429c8833">12.1</ix:nonFraction> million, respectively.</span></div></ix:continuation><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwNTk_c61f45d8-ee75-49c8-b3ef-0cc5327814b1" escape="true"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Acquisitions are accounted for as purchases and are included in our consolidated financial statements from their respective acquisition dates. Assets acquired, liabilities assumed and noncontrolling interests, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets. In determining the fair value of identifiable intangible assets and any noncontrolling interests, we use various valuation techniques including the income approach, the cost approach and the market approach. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, growth rates and discount rates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwMDM_5972b940-a5cb-42b7-9782-8dd4256f6022" continuedAt="i4ddf1aad81974bbb86876cefdb51a078" escape="true"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Other Intangible Assets</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had a goodwill balance of $<ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjU1MDI_55755e84-fbbf-4d1e-b484-7ae37a22825f">1,287.4</ix:nonFraction>&#160;million. Goodwill represents the amount of the purchase price in excess of the fair values assigned to the underlying identifiable net assets of acquired businesses. Goodwill is not amortized, but is subject to an annual impairment test. Tests are performed more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount. These events or circumstances include, but are not limited to, a significant adverse change in the business environment, regulatory environment or legal factors, or a substantial decline in the market capitalization of our stock. </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></div><ix:continuation id="i4a0992208dfa4b5ea40765003b39b49e" continuedAt="i6f60f4e82ed2493aa106f6bdfdd85384"><ix:continuation id="i4ddf1aad81974bbb86876cefdb51a078" continuedAt="ie31616fa5241408bbaac3a78d8b67b83"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of our operating segments described in Note 15 &#8211; Segment Information is considered to represent an individual reporting unit for goodwill impairment testing purposes. We consider each of our home health care centers to constitute an individual business for which discrete financial information is available. However, since these care centers have substantially similar operating and economic characteristics and resource allocations and since significant investment decisions concerning these businesses are centralized and the benefits broadly distributed, we have aggregated these care centers and deemed them to constitute a single reporting unit. We have applied this same aggregation principle to our hospice and personal-care care centers and high acuity care joint ventures and have also deemed each of them to be a single reporting unit.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, we performed a qualitative assessment to determine if it is more likely than not that the fair value of our reporting units are less than their carrying values by evaluating relevant events and circumstances including financial performance, market conditions and share price. Based on this assessment, we concluded that the goodwill associated with our home health, hospice and high acuity care reporting units was not considered at risk of impairment as of October&#160;31, 2022. In addition to the qualitative assessment, we also performed a quantitative analysis for our personal care reporting unit due to the decline in revenues resulting from staffing shortages using an income and market approach. Based on this analysis, we concluded that the goodwill associated with our personal care reporting unit was not considered at risk of impairment as of October 31, 2022. Since the date of our last goodwill impairment analysis, there have been no material developments, events, changes in operating performance or other circumstances that would cause management to believe it is more likely than not that the fair value of any of our reporting units would be less than their carrying amounts.</span></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie31616fa5241408bbaac3a78d8b67b83">As of December 31, 2022, we had an other intangibles assets balance of $<ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjgyOTQ_ea380d63-7147-44f3-9a14-5cba456cd60f">101.2</ix:nonFraction>&#160;million. Intangible assets consist of certificates of need, licenses, acquired names, non-compete agreements and technology. We amortize non-compete agreements and acquired names that we do not intend to use indefinitely on a straight-line basis over their estimated useful lives, which are generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjg1OTA_1486623a-649a-4c91-b48e-f23d489bb99f">two</span> to <ix:nonNumeric contextRef="i7ba082d05d43495b95f7c201e8451ff3_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjg1OTY_9febcac8-62bf-4eaf-ba19-3f9d2977cfdc">three years</ix:nonNumeric> for non-compete agreements and up to <ix:nonNumeric contextRef="iff5859d4cb064056a2a55fa3dc5feb6f_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjg2MzY_0bf38d02-cdcf-4143-87bf-010efa9cf712">three years</ix:nonNumeric> for acquired names. We amortize technology over its estimated useful service life, which is generally up to <ix:nonNumeric contextRef="i8990c36c1ca24b9b9986a1b57a6b70aa_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjg3NDc_0895515b-cab6-4fd6-9e4e-ebc732b28066">seven years</ix:nonNumeric>. Our indefinite-lived intangible assets are reviewed for impairment annually or more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the intangible asset below its carrying amount. We performed a qualitative assessment of our indefinite-lived intangible assets during 2022 and determined that there have been no material developments, events, changes in operating performance or other circumstances that would cause management to believe it is more likely than not that the fair value of any of our indefinite-lived intangible assets would be less than their carrying amounts.</ix:continuation> </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="amed:DebtIssuanceCostsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwNDE_37b60e16-2e2e-4b87-891d-d576d12109b9" continuedAt="i5e68f38135c048608cc21d7589b8810a" escape="true">Debt Issuance Costs</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5e68f38135c048608cc21d7589b8810a">During 2021, we recorded $<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjk2Mzg_bf601284-a1da-4af5-9ce3-4e67eb22509c">2.8</ix:nonFraction>&#160;million in deferred debt issuance costs as a reduction to long-term obligations, less current portion in our consolidated balance sheet in connection with our entry into the Second Amended Credit Agreement (See Note 9 - Long-Term Obligations). As of December&#160;31, 2022 and 2021, we had unamortized debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:UnamortizedDebtIssuanceExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjk5Mzc_ec77d7ea-b68e-48a0-94c1-299e18f9bcee">3.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:UnamortizedDebtIssuanceExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjk5NDQ_61cf16b1-2dbd-4503-a4b3-b3a290063fa0">4.5</ix:nonFraction> million, respectively, recorded as a reduction to long-term obligations, less current portion in our accompanying consolidated balance sheets. We amortize deferred debt issuance costs related to our long-term obligations over the term of the obligation through interest expense, unless the debt is extinguished, in which case unamortized balances are immediately expensed.</ix:continuation> The unamortized debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:UnamortizedDebtIssuanceExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzAzNTE_937b3747-dbe7-4f01-a6c0-5c61a0f39e2f">3.5</ix:nonFraction> million at December&#160;31, 2022 will be amortized over a weighted-average amortization period of <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="amed:UnamortizedDebtIssuanceCostAmortizationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzA0MjU_f0d5b327-82a3-4b8f-89f5-8ffb1093d8a9">3.6</ix:nonNumeric> years.</span></div><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwMTM_cb9d0bec-74df-40e9-b18a-826dd0c84e92" continuedAt="i5c4378d246894ee1b3039d6dfb8b2ab9" escape="true"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="amed:FinancialInstrumentDetailsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwNDI_dda42196-dccc-4eb1-af7a-da0ed6dfc815" escape="true"><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</span></div><div style="margin-bottom:9pt;margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"></td><td style="width:24.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Financial Instrument</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value as of<br/>December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Items<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="amed:DebtInstrumentCarryingAmountExcludingFinanceLeases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjdlNWE2Yjg5ODVlNTRkMjhhZGY1ZWI5MDFhZmNhOGJiL3RhYmxlcmFuZ2U6N2U1YTZiODk4NWU1NGQyOGFkZjVlYjkwMWFmY2E4YmJfMi0xLTEtMS01MDcyNQ_319e78f3-11db-4a55-b802-c2b7bf8bfb79">436.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00b2929fc5c94edaa315a2c9b947f6d0_I20221231" decimals="-5" name="us-gaap:LongTermDebtFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjdlNWE2Yjg5ODVlNTRkMjhhZGY1ZWI5MDFhZmNhOGJiL3RhYmxlcmFuZ2U6N2U1YTZiODk4NWU1NGQyOGFkZjVlYjkwMWFmY2E4YmJfMi0zLTEtMS01MDcyNQ_552f9919-8040-427b-8e4a-723e646c2c22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5ecdbd8c87484b981d596040ebe425_I20221231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjdlNWE2Yjg5ODVlNTRkMjhhZGY1ZWI5MDFhZmNhOGJiL3RhYmxlcmFuZ2U6N2U1YTZiODk4NWU1NGQyOGFkZjVlYjkwMWFmY2E4YmJfMi01LTEtMS01MDcyNQ_cabd6c6b-5ebd-47a8-90a3-bee3bbe57500">428.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b4aa69adae3479e99bf23edae8da8b3_I20221231" decimals="-5" name="us-gaap:LongTermDebtFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjdlNWE2Yjg5ODVlNTRkMjhhZGY1ZWI5MDFhZmNhOGJiL3RhYmxlcmFuZ2U6N2U1YTZiODk4NWU1NGQyOGFkZjVlYjkwMWFmY2E4YmJfMi03LTEtMS01MDcyNQ_cf3ec500-25c0-414a-a96a-e6a5e8978c02">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1 &#8211; Quoted prices in active markets for identical assets and liabilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></div><ix:continuation id="i6f60f4e82ed2493aa106f6bdfdd85384"><ix:continuation id="i5c4378d246894ee1b3039d6dfb8b2ab9" continuedAt="i004d386a6ed84e978fe6f95c1586f602"><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2 &#8211; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3 &#8211; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.</span></div></ix:continuation><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i004d386a6ed84e978fe6f95c1586f602">Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value.</ix:continuation> </span></div><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwNDc_ddfdd1a5-139a-4e0a-a46b-86f4fc53b693" escape="true"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the asset and liability approach for measuring deferred tax assets and liabilities based on temporary differences existing at each balance sheet date using currently enacted tax rates. Our deferred tax calculation requires us to make certain estimates about future operations. Deferred tax assets are reduced by a valuation allowance when we believe it is more likely than not that some portion or all of the deferred tax assets will not be realized. The effect of a change in tax rate is recognized as income or expense in the period that includes the enactment date. As of December&#160;31, 2022, we had net deferred tax liabilities of $<ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzIzNjU_a172fe6b-b702-464c-b8ce-cafcb69fa003">20.4</ix:nonFraction> million. As of December 31, 2021, we had net deferred tax assets of $<ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzIzNzI_db97e10b-64c4-4266-a7e2-44e069d28031">0.3</ix:nonFraction> million. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management regularly assesses the ability to realize deferred tax assets recorded in the Company&#8217;s entities based upon the weight of available evidence, including such factors as the recent earnings history and expected future taxable income. In the event future taxable income is below management&#8217;s estimates or is generated in tax jurisdictions different than projected, we could be required to increase the valuation allowance for deferred tax assets. This would result in an increase in our effective tax rate.</span></div></ix:nonNumeric><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwMjc_f1e24050-26f2-4454-a0ab-2fd037a54a1f" continuedAt="ib5cd740ba8b74c2d984489f0bf09a9b8" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib5cd740ba8b74c2d984489f0bf09a9b8">We record all share-based compensation as expense in the financial statements measured at the fair value of the award. We recognize compensation cost on a straight-line basis over the requisite service period for each separately vesting portion of the award.</ix:continuation> Share-based compensation expense for 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzMyNDU_18b87dfb-03cd-4643-9b12-ee25ee767a62">16.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzMyNDk_96f7fb56-d001-4ca4-a313-31dcdaa983a5">23.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzMyNTY_075bc440-db69-4e31-9f44-f66fb9dffaec">26.7</ix:nonFraction> million, respectively, and the total income tax benefit recognized for these expenses was $<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzMzNDE_a15885c9-2ffe-422b-b89f-9bd951abca6d">4.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzMzNDU_be6cc3f7-2621-4b4e-8553-1bd982ae02b7">6.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzMzNTI_0c2952f1-bbc4-4976-922f-60297760b99a">4.7</ix:nonFraction> million, respectively, prior to the application of the income tax compensation rules under Internal Revenue Code section 162(m) ("162(m)"). As of December 31, 2022, the income tax benefit recognized for the three-year period was reduced by a cumulative $<ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="amed:RecognizedTaxBenefitThatImpactsEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfNTQ5NzU1ODYxMTk1_b958efd9-c917-4359-83fe-91a9a512ebe5">2.7</ix:nonFraction>&#160;million, pursuant to 162(m).</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwNDk_b08fe801-7f6c-44cf-a6d7-eb8bab937c9b" continuedAt="ifa8d4d4562da40b0a9b0ce4b0bfd382f" escape="true">Weighted-Average Shares Outstanding.</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifa8d4d4562da40b0a9b0ce4b0bfd382f">Net income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period.</ix:continuation> <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwNjE_8447d127-5e08-4cdf-92c0-9768d990ec0b" continuedAt="i26ef518ad6db4ad496c69c8281d69cd9" escape="true">The following table sets forth, for the periods indicated, shares used in our computation of weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="i26ef518ad6db4ad496c69c8281d69cd9"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding &#8211; basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjI1MDNhNjY4NzY1NTRiMTNiYWUwZjUwNWZlNzIyYjY0L3RhYmxlcmFuZ2U6MjUwM2E2Njg3NjU1NGIxM2JhZTBmNTA1ZmU3MjJiNjRfMi0xLTEtMS01MDcyNQ_30c215a0-82a9-47c4-ab3d-058d6233f796">32,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjI1MDNhNjY4NzY1NTRiMTNiYWUwZjUwNWZlNzIyYjY0L3RhYmxlcmFuZ2U6MjUwM2E2Njg3NjU1NGIxM2JhZTBmNTA1ZmU3MjJiNjRfMi0zLTEtMS01MDcyNQ_95ed5ad8-db7c-4627-97f4-d33232b28eeb">32,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjI1MDNhNjY4NzY1NTRiMTNiYWUwZjUwNWZlNzIyYjY0L3RhYmxlcmFuZ2U6MjUwM2E2Njg3NjU1NGIxM2JhZTBmNTA1ZmU3MjJiNjRfMi01LTEtMS01MDcyNQ_65353c4a-51f8-4a61-ab25-2dc18f43375e">32,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjI1MDNhNjY4NzY1NTRiMTNiYWUwZjUwNWZlNzIyYjY0L3RhYmxlcmFuZ2U6MjUwM2E2Njg3NjU1NGIxM2JhZTBmNTA1ZmU3MjJiNjRfNC0xLTEtMS01MDcyNQ_f555d96a-ca4f-4008-afac-50c65c7fc4da">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjI1MDNhNjY4NzY1NTRiMTNiYWUwZjUwNWZlNzIyYjY0L3RhYmxlcmFuZ2U6MjUwM2E2Njg3NjU1NGIxM2JhZTBmNTA1ZmU3MjJiNjRfNC0zLTEtMS01MDcyNQ_deaf1f8f-68b6-4b43-8aea-8366cee2dc42">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjI1MDNhNjY4NzY1NTRiMTNiYWUwZjUwNWZlNzIyYjY0L3RhYmxlcmFuZ2U6MjUwM2E2Njg3NjU1NGIxM2JhZTBmNTA1ZmU3MjJiNjRfNC01LTEtMS01MDcyNQ_1dc7f13d-3b8a-40f5-bb23-0a5db1f04d7c">420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested stock and stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="amed:NonVestedStockAndStockUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjI1MDNhNjY4NzY1NTRiMTNiYWUwZjUwNWZlNzIyYjY0L3RhYmxlcmFuZ2U6MjUwM2E2Njg3NjU1NGIxM2JhZTBmNTA1ZmU3MjJiNjRfNS0xLTEtMS01MDcyNQ_81a6744f-87bf-473e-94ff-e7c536f5dddd">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="amed:NonVestedStockAndStockUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjI1MDNhNjY4NzY1NTRiMTNiYWUwZjUwNWZlNzIyYjY0L3RhYmxlcmFuZ2U6MjUwM2E2Njg3NjU1NGIxM2JhZTBmNTA1ZmU3MjJiNjRfNS0zLTEtMS01MDcyNQ_25c16613-7c99-4329-9240-635e588056aa">208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="amed:NonVestedStockAndStockUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjI1MDNhNjY4NzY1NTRiMTNiYWUwZjUwNWZlNzIyYjY0L3RhYmxlcmFuZ2U6MjUwM2E2Njg3NjU1NGIxM2JhZTBmNTA1ZmU3MjJiNjRfNS01LTEtMS01MDcyNQ_f9313da4-6729-41be-a1e9-416cfb751181">289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding &#8211; diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjI1MDNhNjY4NzY1NTRiMTNiYWUwZjUwNWZlNzIyYjY0L3RhYmxlcmFuZ2U6MjUwM2E2Njg3NjU1NGIxM2JhZTBmNTA1ZmU3MjJiNjRfNi0xLTEtMS01MDcyNQ_eb5fbf83-cc7b-43cb-9c2a-1a5e679c843e">32,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjI1MDNhNjY4NzY1NTRiMTNiYWUwZjUwNWZlNzIyYjY0L3RhYmxlcmFuZ2U6MjUwM2E2Njg3NjU1NGIxM2JhZTBmNTA1ZmU3MjJiNjRfNi0zLTEtMS01MDcyNQ_4f6aabb1-a72d-4d9c-aece-60854de54c9f">32,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjI1MDNhNjY4NzY1NTRiMTNiYWUwZjUwNWZlNzIyYjY0L3RhYmxlcmFuZ2U6MjUwM2E2Njg3NjU1NGIxM2JhZTBmNTA1ZmU3MjJiNjRfNi01LTEtMS01MDcyNQ_6e3fc8cd-9ec8-4da1-8eaf-795f3a16eafd">33,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjI1MDNhNjY4NzY1NTRiMTNiYWUwZjUwNWZlNzIyYjY0L3RhYmxlcmFuZ2U6MjUwM2E2Njg3NjU1NGIxM2JhZTBmNTA1ZmU3MjJiNjRfNy0xLTEtMS01MDcyNQ_6a6ab2ca-78d3-4bdc-9554-0d001d4acfef">303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjI1MDNhNjY4NzY1NTRiMTNiYWUwZjUwNWZlNzIyYjY0L3RhYmxlcmFuZ2U6MjUwM2E2Njg3NjU1NGIxM2JhZTBmNTA1ZmU3MjJiNjRfNy0zLTEtMS01MDcyNQ_420e45b3-aede-4429-b82b-61f7ac9f3f26">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjI1MDNhNjY4NzY1NTRiMTNiYWUwZjUwNWZlNzIyYjY0L3RhYmxlcmFuZ2U6MjUwM2E2Njg3NjU1NGIxM2JhZTBmNTA1ZmU3MjJiNjRfNy01LTEtMS01MDcyNQ_9c03c2c3-cf40-4692-9e45-df58a47b7571">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwNjI_f34f7b3e-d9d0-4e28-9f4e-ddc124a3f67d" continuedAt="iffa81566e9744b7780e4d8179354eb82" escape="true">Advertising Costs</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iffa81566e9744b7780e4d8179354eb82">We expense advertising costs as incurred.</ix:continuation> Advertising expense for 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzM5NzE_3a5e6768-97de-42ec-8404-008501e7b5ee">7.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzM5NzU_6af43949-722a-4adc-99a4-f79a6612b9f0">7.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-5" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzM5ODI_04d01348-21ba-4056-9ec6-dd1b21e5af3d">6.5</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i5c10b724a6674979bf3c35a339f29685_85"></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="amed:COVID19TextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RleHRyZWdpb246Y2E3NmY1NWJjMDUxNDQxNjhiY2I3OGM5MGNkOWJkMDlfNDQxMw_6cc2fe97-e63c-4f05-9c03-0f7668f5bb02" continuedAt="i4daa3c8c3cff48f8856102d5d9dc7e7c" escape="true">NOVEL CORONAVIRUS PANDEMIC ("COVID-19")</ix:nonNumeric></span></div><ix:continuation id="i4daa3c8c3cff48f8856102d5d9dc7e7c"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared COVID-19 a pandemic. As a healthcare at home company, we have been and will continue to be impacted by the effects of COVID-19; however, we remain committed to carrying out our mission of caring for our patients. We will continue to closely monitor the impact of COVID-19 on all aspects of our business, including the impacts to our employees, patients and suppliers; however, at this time, we are unable to estimate the ultimate impact the pandemic will have on our consolidated financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the CARES Act was signed into legislation. The CARES Act provided for $<ix:nonFraction unitRef="usd" contextRef="i6711eaed3f0d4ee694ed7955ac3b1e03_I20200327" decimals="-9" name="amed:FundingForHealthcareProvidersIncludingHospitals" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RleHRyZWdpb246Y2E3NmY1NWJjMDUxNDQxNjhiY2I3OGM5MGNkOWJkMDlfNzMx_8d1366bb-d0dd-43c7-ac2b-f919e30b3156">175</ix:nonFraction>&#160;billion to healthcare providers, including hospitals on the front lines of the COVID-19 pandemic. Of this total allocated amount, $<ix:nonFraction unitRef="usd" contextRef="i6711eaed3f0d4ee694ed7955ac3b1e03_I20200327" decimals="-9" name="amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RleHRyZWdpb246Y2E3NmY1NWJjMDUxNDQxNjhiY2I3OGM5MGNkOWJkMDlfODU2_3ebe8971-8bf4-482e-95c2-3cd9cc218b11">30</ix:nonFraction>&#160;billion was distributed immediately to providers based on their proportionate share of Medicare fee-for-service reimbursements in 2019. Healthcare providers were required to sign an attestation confirming receipt of the Provider Relief Fund ("PRF") funds and agree to the terms and conditions of payment. Our home health and hospice segments received approximately $<ix:nonFraction unitRef="usd" contextRef="i6d7e910da92c42bc90993e8096f3b599_D20200401-20200430" decimals="-6" name="amed:FundingReceivedFromCARESAct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RleHRyZWdpb246Y2E3NmY1NWJjMDUxNDQxNjhiY2I3OGM5MGNkOWJkMDlfMTIxNg_e8a8a8d6-4e83-431f-9aa2-ec734c053fff">100</ix:nonFraction>&#160;million from the first $<ix:nonFraction unitRef="usd" contextRef="i6711eaed3f0d4ee694ed7955ac3b1e03_I20200327" decimals="-9" name="amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RleHRyZWdpb246Y2E3NmY1NWJjMDUxNDQxNjhiY2I3OGM5MGNkOWJkMDlfMTIzNA_036d3e3a-8af3-49a0-bcb0-6ff1bc736dbd">30</ix:nonFraction>&#160;billion of funds distributed to healthcare providers in April 2020, which is inclusive of $<ix:nonFraction unitRef="usd" contextRef="i5316c48403b245d7a32babf7c76d35ac_D20200401-20200430" decimals="-6" name="amed:FundingReceivedFromCARESAct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RleHRyZWdpb246Y2E3NmY1NWJjMDUxNDQxNjhiY2I3OGM5MGNkOWJkMDlfMTMxOQ_f495ffe1-13de-4812-a952-44350ec1c8ad">2</ix:nonFraction>&#160;million related to our joint venture care centers (equity method investments). We also acquired approximately $<ix:nonFraction unitRef="usd" contextRef="idfa6a89efdee40b3b7b70040f4cc830d_D20200401-20200430" decimals="-6" name="amed:FundingReceivedFromCARESAct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RleHRyZWdpb246Y2E3NmY1NWJjMDUxNDQxNjhiY2I3OGM5MGNkOWJkMDlfMTQyNA_df4c6419-93aa-42c9-91e7-9be147da85cd">6</ix:nonFraction>&#160;million of PRF funds in connection with the acquisition of AseraCare Hospice ("AseraCare"). Under the terms and conditions for receipt of the payment, we were allowed to use the funds to cover lost revenues and health care costs related to COVID-19 through June 30, 2021, and we were required to properly and fully document the use of these funds in reports to the U.S. Department of Health and Human Services ("HHS"). All required reporting was completed during the three-month period ended September 30, 2021, and our audit report was submitted to HHS on September 26, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our wholly-owned subsidiaries, we utilized PRF funds to the extent we had qualifying COVID-19 expenses; we did not use PRF funds to cover lost revenues resulting from COVID-19. The grant income associated with the COVID-19 expenses incurred through June 30, 2021 is reflected in other operating income within our consolidated statements of operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not fully utilize the funds received; all unutilized funds were repaid in October 2021. <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="amed:ScheduleOfCaresActProviderReliefFundsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RleHRyZWdpb246Y2E3NmY1NWJjMDUxNDQxNjhiY2I3OGM5MGNkOWJkMDlfNDQxNA_b8e2520e-ac10-49e8-a2cc-ff89fa82333d" continuedAt="i2aa708e5c4784cfeb085ba27166bbad5" escape="true">In summary, the total funds that we received from the CARES Act PRF were accounted for as follows (amounts in millions):</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><ix:continuation id="i2aa708e5c4784cfeb085ba27166bbad5"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"></td><td style="width:74.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds utilized through June 30, 2021 by consolidated entities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b33f1ef384d4000bd6fb60c0d49e71d_D20200401-20210630" decimals="-5" name="amed:CARESActProviderReliefFundsUtilized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RhYmxlOjM0MGNmYjg1ZDVmMTQzMWZiNTE3M2MzNzcxODBhYzgwL3RhYmxlcmFuZ2U6MzQwY2ZiODVkNWYxNDMxZmI1MTczYzM3NzE4MGFjODBfMS0xLTEtMS01MDcyNQ_a2b41041-573c-484a-a11e-b1565b0392ef">46.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds repaid to the government by consolidated entities (excludes $<ix:nonFraction unitRef="usd" contextRef="i144647094c4a4625802e08748d886f42_I20211031" decimals="-5" name="amed:CARESActInterestRepaidToGovernment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RhYmxlOjM0MGNmYjg1ZDVmMTQzMWZiNTE3M2MzNzcxODBhYzgwL3RhYmxlcmFuZ2U6MzQwY2ZiODVkNWYxNDMxZmI1MTczYzM3NzE4MGFjODBfMi0wLTEtMS01MDcyNS90ZXh0cmVnaW9uOjExYTNjMjY1MTlkZDRiY2ZiMzZiMmEyMGU5NTYwZWI0Xzcw_f543021d-8b65-4897-83f2-d1ed662d7b6d">0.2</ix:nonFraction> million of interest repaid)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144647094c4a4625802e08748d886f42_I20211031" decimals="-5" name="amed:CARESActProviderReliefFundsRepaidToTheGovernment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RhYmxlOjM0MGNmYjg1ZDVmMTQzMWZiNTE3M2MzNzcxODBhYzgwL3RhYmxlcmFuZ2U6MzQwY2ZiODVkNWYxNDMxZmI1MTczYzM3NzE4MGFjODBfMi0xLTEtMS01MDcyNQ_78921f3c-34bd-4523-b810-6e1ce0600c47">58.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds utilized through June 30, 2021 by unconsolidated joint ventures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b33f1ef384d4000bd6fb60c0d49e71d_D20200401-20210630" decimals="-5" name="amed:CARESActProviderReliefFundUtilizedByUnconsolidatedJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RhYmxlOjM0MGNmYjg1ZDVmMTQzMWZiNTE3M2MzNzcxODBhYzgwL3RhYmxlcmFuZ2U6MzQwY2ZiODVkNWYxNDMxZmI1MTczYzM3NzE4MGFjODBfMy0xLTEtMS01MDcyNQ_c017f320-2c04-4425-9d5e-70b0291e2a30">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds repaid to the government by unconsolidated joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144647094c4a4625802e08748d886f42_I20211031" decimals="-5" name="amed:CARESActProviderReliefFundsRepaidByUnconsolidatedJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RhYmxlOjM0MGNmYjg1ZDVmMTQzMWZiNTE3M2MzNzcxODBhYzgwL3RhYmxlcmFuZ2U6MzQwY2ZiODVkNWYxNDMxZmI1MTczYzM3NzE4MGFjODBfNC0xLTEtMS01MDcyNQ_c9aa5bab-c299-431e-bad7-822506f2b16c">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="amed:TotalCARESActProviderReliefFundsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RhYmxlOjM0MGNmYjg1ZDVmMTQzMWZiNTE3M2MzNzcxODBhYzgwL3RhYmxlcmFuZ2U6MzQwY2ZiODVkNWYxNDMxZmI1MTczYzM3NzE4MGFjODBfNS0xLTEtMS01MDcyNQ_58a0e986-8141-4ec2-b9fc-d748d1a81987">106.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CARES Act also provided for the temporary suspension of the automatic 2% reduction of Medicare claim reimbursements ("sequestration") for the period May 1, 2020 through December 31, 2020. During 2020 and 2021, Congress passed additional COVID-19 relief legislation which extended the 2% suspension of sequestration through March 31, 2022; sequestration was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reinstated as a 1% reduction to Medicare claim reimbursements effective April 1, 2022 and a 2% reduction to Medicare claim reimbursements effective July 1, 2022. We recognized benefits to net service revenue totalin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g $<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="amed:ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RleHRyZWdpb246Y2E3NmY1NWJjMDUxNDQxNjhiY2I3OGM5MGNkOWJkMDlfNTQ5NzU1ODIwOTY3_50e52be8-c4a6-4456-851e-39210828f9ff">13</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="amed:ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RleHRyZWdpb246Y2E3NmY1NWJjMDUxNDQxNjhiY2I3OGM5MGNkOWJkMDlfNTQ5NzU1ODIwOTgw_31fd4ba1-e3de-4fb2-a2e1-0cebf08c75d9">36</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-5" name="amed:ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RleHRyZWdpb246Y2E3NmY1NWJjMDUxNDQxNjhiY2I3OGM5MGNkOWJkMDlfNTQ5NzU1ODIwOTkz_fdcfd07d-8840-44cd-b581-232598717808">23</ix:nonFraction>&#160;million during 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the CARES Act provided for the deferral of the employer share of social security tax (6.2%), effective for payments due after the enactment date through December 31, 2020. During 2020, we deferred approximately $<ix:nonFraction unitRef="usd" contextRef="if61757dea5844f219019c3a64a1972b4_I20201231" decimals="-5" name="amed:CARESActDeferralOfEmployerShareSocialSecurityTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RleHRyZWdpb246Y2E3NmY1NWJjMDUxNDQxNjhiY2I3OGM5MGNkOWJkMDlfMzgxMA_43d20f2c-357e-403a-b2d6-36e3d4d2fdbd">55</ix:nonFraction>&#160;million of social security taxes. Approximately $<ix:nonFraction unitRef="usd" contextRef="i0530cc1fa306423dba7c186bb6ab97cc_D20220101-20221231" decimals="-5" name="amed:PaymentOfDeferredSocialSecurityTaxUnderCARESAct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RleHRyZWdpb246Y2E3NmY1NWJjMDUxNDQxNjhiY2I3OGM5MGNkOWJkMDlfMzg1Mw_cad47e93-3b80-4114-8ba3-5b026306b2b0"><ix:nonFraction unitRef="usd" contextRef="i24fd071f2c354373829031fc28f4be1b_D20210101-20211231" decimals="-5" name="amed:PaymentOfDeferredSocialSecurityTaxUnderCARESAct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RleHRyZWdpb246Y2E3NmY1NWJjMDUxNDQxNjhiY2I3OGM5MGNkOWJkMDlfMzg1Mw_f9ade2cf-f272-49dd-91c3-fe76ee0f79c5">27</ix:nonFraction></ix:nonFraction>&#160;million was paid during December 2021; the remaining balance was paid during December 2022. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our personal care segment did not receive funds under the CARES Act; however, it did receive funds totaling $<ix:nonFraction unitRef="usd" contextRef="i06f200e2df374ac19cb47bab63a56b3f_D20200101-20201231" decimals="-6" name="us-gaap:OtherOperatingIncome" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RleHRyZWdpb246Y2E3NmY1NWJjMDUxNDQxNjhiY2I3OGM5MGNkOWJkMDlfNDEzNQ_288c898b-9a0a-4bbd-97c1-610ec14f76da"><ix:nonFraction unitRef="usd" contextRef="i06f200e2df374ac19cb47bab63a56b3f_D20200101-20201231" decimals="-5" name="amed:FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RleHRyZWdpb246Y2E3NmY1NWJjMDUxNDQxNjhiY2I3OGM5MGNkOWJkMDlfNDEzNQ_5d79a1bd-b81f-47f1-81c9-566d50db049d">1</ix:nonFraction></ix:nonFraction>&#160;million from the Mass Home Care ASAP COVID-19 Provider Sustainability Program, which were used during 2020 to cover costs related to COVID-19. The grant income associated with the funds received is reflected in other operating income within our consolidated statements of operations.</span></div></ix:continuation><div><span><br/></span></div><div id="i5c10b724a6674979bf3c35a339f29685_88"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfOTU5Ng_e90312f4-e505-4f5b-8fae-841fbcfe8355" continuedAt="i1d59052383304037bf78e1bdbbf6c1b8" escape="true">ACQUISITIONS</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1d59052383304037bf78e1bdbbf6c1b8" continuedAt="i42fc6aee2ab54a57aaca1dce52894e71">We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health, hospice, personal care and high acuity care services. The purchase price paid for acquisitions is negotiated through arm&#8217;s length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows. Acquisitions are </ix:continuation></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></div><ix:continuation id="i42fc6aee2ab54a57aaca1dce52894e71" continuedAt="i5aeffae74b5b4d2a8d975dbf0018f126"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accounted for as purchases and are included in our consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy. We typically engage outside appraisal firms to assist in the fair value determination of identifiable intangible assets and noncontrolling interests, if any, for significant acquisitions. The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuation and liabilities assumed.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Acquisitions </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2022, we entered into a transaction with one of our high acuity care health system partners in which we contributed cash and our health system partner contributed its home health operations to one of our existing high acuity care joint ventures. As a result of this transaction, we recorded goodwill of $<ix:nonFraction unitRef="usd" contextRef="i329d3927fede4bdf9fab592d7ad5bbca_D20220101-20221231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMDkz_54335891-1b0a-46f0-ab45-39f6834466fb">8.5</ix:nonFraction>&#160;million, other intangibles of $<ix:nonFraction unitRef="usd" contextRef="i34442d4c2cdd49e8ad3bacd82824cc9b_I20220323" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMTA3_8e05b177-702c-46d5-8012-e3492789de33">0.4</ix:nonFraction>&#160;million (certificate of need and licenses) and noncontrolling interest of $<ix:nonFraction unitRef="usd" contextRef="ib16b4cdc559b48b48aaca7b7709eccf7_I20220323" decimals="-5" name="amed:BusinessCombinationAcquiredNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMTIx_04393496-c69b-436b-b450-730c748c169b">8.9</ix:nonFraction>&#160;million within our consolidated balance sheet. The fair value of noncontrolling interest was determined using an income approach and a market approach.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2022, we acquired <ix:nonFraction unitRef="care_center" contextRef="i3ee24d260ef448cd85330a7919fef9a6_D20220401-20220401" decimals="INF" name="us-gaap:NumberOfBusinessesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMTM1_922300b7-0f58-4b4c-8aad-f06d83ef7494">15</ix:nonFraction> home health care centers from Evolution Health, LLC, a division of Envision Healthcare, doing business as Guardian Healthcare, Gem City, and Care Connection of Cincinnati ("Evolution"), for an estimated purchase price of $<ix:nonFraction unitRef="usd" contextRef="i3ee24d260ef448cd85330a7919fef9a6_D20220401-20220401" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMTM5_711db88a-218f-4ecb-a950-eef986c05793">67.8</ix:nonFraction>&#160;million. A portion of the purchase price ($<ix:nonFraction unitRef="usd" contextRef="i3ee24d260ef448cd85330a7919fef9a6_D20220401-20220401" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMTU0_f770ff7e-0438-47b4-9ecb-3dfc0f2bf29b">51.1</ix:nonFraction>&#160;million) was paid to the seller with cash on hand and proceeds from borrowings under our Revolving Credit Facility. The remainder ($<ix:nonFraction unitRef="usd" contextRef="ib5a9c836f91a48a19480bcf0f161b5ea_I20220401" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMTY5_f978f0d3-49f3-41a7-9719-b4333e9906be">16.7</ix:nonFraction>&#160;million) was placed into an escrow account in accordance with the closing payment, indemnity and other provisions within the purchase agreement and recorded as restricted cash within our consolidated balance sheet. Corresponding liabilities were also recorded to accrued expenses and other long-term obligations within our consolidated balance sheet related to these contingent consideration arrangements. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the total $<ix:nonFraction unitRef="usd" contextRef="ib5a9c836f91a48a19480bcf0f161b5ea_I20220401" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMTg0_2af2ca20-6fdd-4e67-be73-f35a75cd97f1">16.7</ix:nonFraction>&#160;million placed into escrow, $<ix:nonFraction unitRef="usd" contextRef="ie5385a5f630f492ca9a57b76acb56832_D20220401-20220401" decimals="-5" name="amed:NonCashAccruedContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMTk5_b2749947-4b3c-46e2-b6e0-ccdcab6000cd">1.0</ix:nonFraction>&#160;million was set aside for the closing payment adjustment. The closing payment calculated on the acquisition date included estimates for cash, working capital and various other items. Under the purchase agreement, the purchase price was subject to an adjustment for any differences between estimated amounts included in the closing payment and actual amounts at close. The closing payment adjustment, which was finalized during the three-month period ended September 30, 2022, decreased the purchase price by $<ix:nonFraction unitRef="usd" contextRef="i5164993430b74c95b0e12d477628d1e3_D20220701-20220930" decimals="-5" name="amed:BusinessAcquisitionClosingPaymentAdjustment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMjEz_96ad92ae-a25b-487f-810c-b96226290f8b">1.3</ix:nonFraction>&#160;million from $<ix:nonFraction unitRef="usd" contextRef="i3ee24d260ef448cd85330a7919fef9a6_D20220401-20220401" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMjI3_fef17a63-e2d5-4b43-9068-3168f4856a72">67.8</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="i7d98a7f596b54b549b3e1d6ace83797e_I20220930" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMjQy_30b6003c-c2fb-4c66-969e-c63770f03cd6">66.5</ix:nonFraction>&#160;million. The remaining $<ix:nonFraction unitRef="usd" contextRef="i3ee24d260ef448cd85330a7919fef9a6_D20220401-20220401" decimals="-5" name="amed:NonCashAccruedContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMjU3_cbf2557e-3700-49da-84b4-1678d81ca568">15.7</ix:nonFraction>&#160;million placed into escrow relates to certain outstanding matters existing as of the acquisition date as well as potential losses the Company may incur for which the seller has an obligation to indemnify the Company. This amount will either be paid to third parties as outstanding matters are resolved or to the seller at certain intervals in the future. As of December 31, 2022, $<ix:nonFraction unitRef="usd" contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231" decimals="-5" name="amed:AmountReleasedFromEscrow" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMjcy_f9adf8f4-5180-43e9-bd62-308e388a8c97">5.7</ix:nonFraction>&#160;million of the $<ix:nonFraction unitRef="usd" contextRef="ib5a9c836f91a48a19480bcf0f161b5ea_I20220401" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMjg2_ee93bf80-301e-40bd-bb88-fd76348aa909">16.7</ix:nonFraction>&#160;million has been released from escrow.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect $<ix:nonFraction unitRef="usd" contextRef="ib5a9c836f91a48a19480bcf0f161b5ea_I20220401" decimals="-5" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMzAx_1738573a-d84d-41fb-8d03-34b11939c7b2">15</ix:nonFraction>&#160;million of goodwill recorded for this acquisition to be deductible for income tax purposes over approximately <ix:nonNumeric contextRef="i3ee24d260ef448cd85330a7919fef9a6_D20220401-20220401" name="amed:GoodwillDeductibleForIncomeTaxPurposesPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMzM0_b3a0aa84-3162-4282-8885-9550d9b137dc">15</ix:nonNumeric> years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolution contributed $<ix:nonFraction unitRef="usd" contextRef="i28853129c6904eb18dd32328ff6639b9_D20220101-20221231" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMzE0_c7a189b9-af11-4060-afad-99304038577f">29.4</ix:nonFraction>&#160;million in net service revenue and an operating loss of $5.3 million during the year ended December 31, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is in the process of reviewing the fair value of the assets acquired and liabilities assumed. During the post-acquisition period ended December 31, 2022, total assets acquired decreased by $2.1&#160;million (primarily patient accounts receivable and property and equipment) and total liabilities assumed (specifically, the deferred income tax liability) decreased by $0.3&#160;million as a result of our review. These adjustments, combined with the closing payment adjustment of $<ix:nonFraction unitRef="usd" contextRef="i5164993430b74c95b0e12d477628d1e3_D20220701-20220930" decimals="-5" name="amed:BusinessAcquisitionClosingPaymentAdjustment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMzc4_3f41f8d1-c1ce-44d7-8cb1-d2665825c7ca">1.3</ix:nonFraction>&#160;million described above, resulted in a $<ix:nonFraction unitRef="usd" contextRef="i28853129c6904eb18dd32328ff6639b9_D20220101-20221231" decimals="-5" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMzky_5740a2b9-4162-4fec-88ed-5223f63b1c9d">0.5</ix:nonFraction>&#160;million increase in goodwill. <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="amed:ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwODkw_058d63d3-da01-424c-9c04-5e359e4f05ae" continuedAt="i7e4e42d973c0421d8a1e64abcfb7e25e" escape="true">Based on the Company's preliminary valuation, which may be revised as additional information becomes available during the measurement period, the total consideration of $<ix:nonFraction unitRef="usd" contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNDA2_8d885e29-d48d-475e-a603-8f482bb5dbeb">66.5</ix:nonFraction>&#160;million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):</ix:nonNumeric></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></div><ix:continuation id="i5aeffae74b5b4d2a8d975dbf0018f126" continuedAt="id60ec571cdd04592bac84ea82c97732e"><div style="margin-top:6pt;text-align:center"><ix:continuation id="i7e4e42d973c0421d8a1e64abcfb7e25e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"></td><td style="width:74.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfMi0xLTEtMS02MTQ3NA_6395b2e0-eb41-45cd-b472-61f2c7d006e1">7.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfMy0xLTEtMS02MTQ3Nw_b7c67c11-b139-43a0-b1f5-16caa2bb7f9d">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfNC0xLTEtMS02MTQ3Nw_912bc4dd-dc73-457a-a85d-731b2173b891">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfNS0xLTEtMS02MTQ3Nw_52b5eac7-0c39-47f9-827a-27cc242257c5">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfNi0xLTEtMS02MTQ3Nw_1450c187-b29f-4924-b712-92eb86e29d6a">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets (licenses)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce5ed93672d4ebbba91deaaf07e6054_I20221231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfNy0xLTEtMS02MTQ3Nw_0fad9887-b6ad-4fd9-b73e-43883f6a549f">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfOC0xLTEtMS02MTQ3Nw_bb3a91cd-ea24-4011-93dd-8c9363aff101">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfOS0xLTEtMS02MTQ3Nw_1e8a6336-825d-4317-b672-2494be9fa30b">14.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfMTEtMS0xLTEtNjE0ODA_c662fe67-7031-42c0-8a29-a0f094af4445">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfMTItMS0xLTEtNjE0ODA_1d07ade4-def2-4003-88b7-23e7d806b556">2.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfMTMtMS0xLTEtNjE0ODA_76b5f6ef-3651-4109-a7a6-6688cb949a13">2.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfMTQtMS0xLTEtNjE0ODA_9f60bf90-8241-48c7-8f07-9a65de1efa4c">2.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfMTUtMS0xLTEtNjE0ODA_629fd031-bc73-4436-9cd4-42b4959be393">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfMTYtMS0xLTEtNjE0ODA_4f61ddfd-7187-423b-90b0-63bdb5ee5b2f">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities assumed</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfMTctMS0xLTEtNjE0ODA_55dcfa80-453c-4171-912c-2123a8dd9efe">9.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net identifiable assets acquired</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfMTgtMS0xLTEtNjE0ODA_1a5bee49-78a8-465d-93c4-93fef3bbd615">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28853129c6904eb18dd32328ff6639b9_D20220101-20221231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfMTktMS0xLTEtNjE0ODA_2633a194-2168-42e7-aafb-dbd1714d3187">61.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfMjAtMS0xLTEtNjE0ODA_12d6f701-b861-4e9f-8737-b4eb591f4059">66.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2022, we acquired <ix:nonFraction unitRef="care_center" contextRef="i9515534e01de4100ba0629e25ec08585_D20220401-20220401" decimals="INF" name="us-gaap:NumberOfBusinessesAcquired" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwODgx_e8ab8682-05dc-40e6-b986-55a9715c2475">two</ix:nonFraction> home health locations from AssistedCare Home Health, Inc. and RH Homecare Services, LLC, doing business as AssistedCare Home Health and AssistedCare of the Carolinas ("AssistedCare"), respectively, for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="i9515534e01de4100ba0629e25ec08585_D20220401-20220401" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNDIx_d43e3de4-85ec-492a-b6f1-9c51bba6353d">24.7</ix:nonFraction>&#160;million. A portion of the purchase price ($<ix:nonFraction unitRef="usd" contextRef="i9515534e01de4100ba0629e25ec08585_D20220401-20220401" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNDM2_707b9635-d0b5-4984-bf51-77e4310d4026">22.2</ix:nonFraction>&#160;million) was paid to the seller with cash on hand and proceeds from borrowings under our Revolving Credit Facility. The remainder ($<ix:nonFraction unitRef="usd" contextRef="i2021555b705242a99ec6febf31d7a964_I20220401" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNDUx_984e18e4-c3f8-43f4-88c1-92773c10fa2e">2.5</ix:nonFraction>&#160;million) was placed into an escrow account in accordance with the indemnity provisions within the purchase agreement and is reflected in restricted cash within our consolidated balance sheet. A corresponding liability was also recorded to other long-term obligations within our consolidated balance sheet related to this contingent consideration arrangement. The $<ix:nonFraction unitRef="usd" contextRef="i2021555b705242a99ec6febf31d7a964_I20220401" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNDY1_b144d26f-06bb-4af3-9845-5c59c0312b58">2.5</ix:nonFraction>&#160;million will either be paid to third parties or to the seller at certain intervals in the future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company's preliminary valuation, we recorded goodwill of $<ix:nonFraction unitRef="usd" contextRef="i2021555b705242a99ec6febf31d7a964_I20220401" decimals="-6" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNDc5_4cf55b1e-6e8e-45a1-8417-01463f7628f6"><ix:nonFraction unitRef="usd" contextRef="icb92529d6381424facef8b4b61830b50_D20220101-20221231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNDc5_a27c1098-d33e-4b76-840e-6df6621194f6">24.0</ix:nonFraction></ix:nonFraction>&#160;million and other intangibles of $<ix:nonFraction unitRef="usd" contextRef="i2021555b705242a99ec6febf31d7a964_I20220401" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNDk0_f8a95f8f-eaf9-4f58-a21c-b59cd6d9825a">0.7</ix:nonFraction>&#160;million in connection with the acquisition. Intangible assets acquired include licenses ($<ix:nonFraction unitRef="usd" contextRef="i599a4a53807b476383b1600b004d88dc_I20220401" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNTA4_a7e79dbe-a589-4d77-aba9-a0566f964cb5">0.5</ix:nonFraction>&#160;million), certificates of need ($<ix:nonFraction unitRef="usd" contextRef="i1bf01ffe6b0244e5921dd50351b7b4e7_I20220401" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNTIy_70d81a54-1202-4b1d-8576-3418b12eb6c8">0.2</ix:nonFraction>&#160;million) and acquired names (less than $<ix:nonFraction unitRef="usd" contextRef="i43eafef87dff4c529ba66562fa0cf94e_I20220401" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNTM2_c6e6cb0d-369a-446e-846a-9f4dd2acdc00">0.1</ix:nonFraction>&#160;million). The acquired names will be amortized over a weighted average period of <ix:nonNumeric contextRef="i8e2142a5ef784762a3c038048115d45d_D20220401-20220401" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNTU0_240ddd94-1c4c-4ca6-9889-b884d91c6557">one year</ix:nonNumeric>.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the entire amount of goodwill recorded for this acquisition to be deductible for income tax purposes over approximately <ix:nonNumeric contextRef="i9515534e01de4100ba0629e25ec08585_D20220401-20220401" name="amed:GoodwillDeductibleForIncomeTaxPurposesPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNTc0_ae0105d6-700b-4c42-833b-ed1f4b49f2fc">15</ix:nonNumeric> years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AssistedCare contributed $<ix:nonFraction unitRef="usd" contextRef="icb92529d6381424facef8b4b61830b50_D20220101-20221231" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNTkw_050312da-6ec1-4100-8060-a3f714055482">6.1</ix:nonFraction>&#160;million in net service revenue and operating income of $<ix:nonFraction unitRef="usd" contextRef="icb92529d6381424facef8b4b61830b50_D20220101-20221231" decimals="-5" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNjA0_9efd71bb-686d-4059-b65e-132a7337a97f">0.8</ix:nonFraction>&#160;million during the year ended December 31, 2022.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></div><ix:continuation id="id60ec571cdd04592bac84ea82c97732e" continuedAt="i86cb58b8bbb0449291958affd24c63c1"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Acquisitions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 1, 2021, we acquired the regulatory assets of a home health provider in Randolph County, North Carolina for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="i9b54240bf3d2420990c7a9096aefde0b_D20210501-20210501" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfMTQzNQ_a5c641c9-18ab-47b7-8215-c69ee4bd89a2">2.5</ix:nonFraction>&#160;million. The purchase price was paid with cash on hand on the date of the transaction. We recorded goodwill of $<ix:nonFraction unitRef="usd" contextRef="ie00945c9207e49129104d8327cdab5ac_D20210101-20211231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfMTU4Nw_8a1581cc-a770-41ae-a4e6-cedd8f4c6fdd">2.4</ix:nonFraction>&#160;million and other intangibles (certificate of need) of $<ix:nonFraction unitRef="usd" contextRef="i6b9388aa1085440fb4ae49552b5eac30_I20210501" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfMTYzNw_8a131438-29dc-4cd5-87c7-201c25783b03">0.1</ix:nonFraction>&#160;million in connection with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2021, we acquired Visiting Nurse Association ("VNA"), a home health and hospice provider with locations in Nebraska and Iowa for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="i3a6a5482d808478ca8d187e7994862e3_D20210701-20210701" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfMTgzNg_1b883021-b424-4562-b7be-0c9c392fe3a7">20.1</ix:nonFraction>&#160;million. The purchase price was paid with cash on hand on the date of the transaction. We recorded goodwill of $<ix:nonFraction unitRef="usd" contextRef="iead9a275ae234dd58c7aa7d6084ed1a8_D20210101-20211231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfMTk4OA_573c7044-e198-4e32-b59d-a5cac47a141b">19.7</ix:nonFraction>&#160;million and other intangibles (licenses) of $<ix:nonFraction unitRef="usd" contextRef="ie4e5e1d9f2c04c828295e9928469b871_I20210701" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfMjAyNw_41d1c210-d620-4d31-979e-99cd1bb3a770">0.4</ix:nonFraction>&#160;million in connection with the acquisition. We expect the entire amount of goodwill for this acquisition to be deductible for income tax purposes over approximately <ix:nonNumeric contextRef="i3a6a5482d808478ca8d187e7994862e3_D20210701-20210701" name="amed:GoodwillDeductibleForIncomeTaxPurposesPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfMjE4Nw_06f1c46b-80b3-4bec-8de6-a761b9103bcf">15</ix:nonNumeric> years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 12, 2021, we acquired the regulatory assets of a home health provider in New York for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="id09c2a6d2e8c408fbdffeec1f5145603_D20210712-20210712" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfMjMwNQ_6f8ced4d-f024-4aa6-a29a-d1750a9cf62a">1.5</ix:nonFraction>&#160;million. The purchase price was paid with cash on hand on the date of the transaction. We recorded goodwill of $<ix:nonFraction unitRef="usd" contextRef="id4df44aa40d846c888dfefff67b0441e_D20210101-20211231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfMjQ1Nw_099a43b6-9c07-404b-b9f5-aa300c70d062">1.4</ix:nonFraction>&#160;million and other intangibles (certificate of need) of $<ix:nonFraction unitRef="usd" contextRef="i52779ae3c4594b42bfa6a1f5c28042c3_I20210712" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfMjUwNw_60d8eeef-ee32-4a60-bc56-da8c546cc381">0.1</ix:nonFraction>&#160;million in connection with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2021, we acquired Contessa, a leader in hospital-at-home and skilled nursing facility at-home services for an estimated purchase price of $<ix:nonFraction unitRef="usd" contextRef="ia9ad18fcb7674a4ca8ca6600d605a491_D20210801-20210801" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNjE4_376eadd3-b5ef-4b4f-a1da-eabbd915e4b6">240.7</ix:nonFraction>&#160;million, net of cash acquired. The Contessa purchase price included estimates for cash, working capital and other items. Under the purchase agreement, the purchase price was subject to a closing payment adjustment for any differences between estimated amounts included in the closing payment and actual amounts at close. The closing payment adjustment, which was finalized during the three-month period ended December 31, 2021, increased the purchase price by $<ix:nonFraction unitRef="usd" contextRef="i63526fb29695460daf7c8961c2d352cc_D20211001-20211231" decimals="-5" name="amed:BusinessAcquisitionClosingPaymentAdjustment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNjM0_f49a85dc-4ed2-4fa1-a809-88574d6e8cc2">0.6</ix:nonFraction>&#160;million from $<ix:nonFraction unitRef="usd" contextRef="ia9ad18fcb7674a4ca8ca6600d605a491_D20210801-20210801" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNjQ4_359d38af-cd29-4ad6-ab43-9c38a0ebcd18">240.7</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNjY0_5b621d20-fb46-4c8a-b035-62f0ce1851a7">241.3</ix:nonFraction>&#160;million. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></div><ix:continuation id="i86cb58b8bbb0449291958affd24c63c1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has finalized its valuation of the assets acquired, liabilities assumed and noncontrolling interests. During the year ended December 31, 2022, the deferred income tax liability was adjusted downward by $2.8&#160;million resulting in a $2.8&#160;million decrease in goodwill. <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="amed:ScheduleOfBusinessAcquisitionsContessaHealthTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwODg3_f3f8768c-04b5-4824-a1f5-0d15171c0d23" continuedAt="i16201077ed1148f8945033c64fa123c8" escape="true">The total consideration of $<ix:nonFraction unitRef="usd" contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNjgw_25f8a9af-5924-42aa-b5d6-40fe8b91715a">241.3</ix:nonFraction>&#160;million has been allocated to assets acquired, liabilities assumed and noncontrolling interests as of the acquisition date as follows (amounts in millions):</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><ix:continuation id="i16201077ed1148f8945033c64fa123c8"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"></td><td style="width:74.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfMi0xLTEtMS02MTU1OQ_86ddebb4-5ed2-4ab7-88f5-a2921499a8a8">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfMy0xLTEtMS02MTU1OQ_28d3c27c-9122-4331-99a3-4e76bdba2cd1">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfNC0xLTEtMS02MTU1OQ_bba6ab11-af17-4b01-adb5-4969c957886c">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfNS0xLTEtMS02MTU1OQ_13eb5555-5fee-49b3-b859-f1d2c326af80">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfNi0xLTEtMS02MTU1OQ_883b95c9-9ff6-43c2-9aef-605beceefaca">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfNy0xLTEtMS02MTU1OQ_2a27da1b-7ca2-4a98-807d-badfa9210c59">54.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfOC0xLTEtMS02MTU1OQ_07e72b24-0da2-4435-87a4-3bb44b926802">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfOS0xLTEtMS02MTU1OQ_f623e634-6b4a-45e7-baa7-4414404d2029">60.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfMTEtMS0xLTEtNjE1NjI_34045cc8-8fa9-48e9-8a9a-666fd0c101d7">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfMTItMS0xLTEtNjE1NjI_269c68d3-7c98-4176-9448-e0093330c8f8">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfMTMtMS0xLTEtNjE1NjI_1e0db14f-2244-48cb-bb48-84bb5e48d241">3.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfMTQtMS0xLTEtNjE1NjI_922060e1-1785-4bc6-af10-97fca6e94ca3">0.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfMTUtMS0xLTEtNjE1NjI_9b97957d-c41c-439d-9d17-0700573ff2dc">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfMTYtMS0xLTEtNjE1NjI_4cbfb7f7-fea3-48ba-821a-bc33e39a0ca0">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfMTctMS0xLTEtNjE1NzI_2ab4a90a-bc8d-451d-9874-2bbcaa3e582f">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities assumed</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfMTgtMS0xLTEtNjE1NjQ_f9e82ef9-3f4b-4074-9373-a025958fac2f">6.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfMTktMS0xLTEtNjE1NzQ_37b25562-cb8d-46db-81bd-52329dd06cbc">43.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfMjAtMS0xLTEtNjE1Nzc_95a5f3de-c6b3-46e6-a656-126500a85503">43.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and equity assumed</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfMjEtMS0xLTEtNjE1Nzc_f5f1bd70-46ed-4d42-b91f-14948d9571bd">50.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net identifiable assets acquired</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfMjItMS0xLTEtNjE1NjY_7f4c6db1-a42a-4ad1-9804-43bc12583f8e">10.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df95a1c5f0f44979741b294afe8e34f_D20220101-20221231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfMjMtMS0xLTEtNjE1NjY_d6c1f489-cf0f-46ef-87d1-801d4fc72cc3">231.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfMjQtMS0xLTEtNjE1NjY_b4f03814-a057-4864-b3b1-c6baf5195688">241.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired include acquired names ($<ix:nonFraction unitRef="usd" contextRef="ia0cb3457d3634ebab6e8f002cf82c20c_I20210801" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNzI0_62ea8540-6528-4223-9b94-77b018031cd3">28.3</ix:nonFraction>&#160;million), technology ($<ix:nonFraction unitRef="usd" contextRef="id0b5f88e95e24345a3cc0fc5516016cd_I20210801" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNzM5_0fffa9e4-4fff-4498-a635-de6ca93c64c2">19.8</ix:nonFraction>&#160;million) and non-compete agreements ($<ix:nonFraction unitRef="usd" contextRef="i337a7e831425489abb80a0847c6f2a4b_I20210801" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNzU0_d336b993-a915-41a5-ba61-6c0cb75eee3f">6.2</ix:nonFraction>&#160;million). The non-compete agreements will be amortized over a weighted-average period of <ix:nonNumeric contextRef="i3ab1ecd500d7495dae3df1070f41f7cb_D20210801-20210801" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNzcz_b98768cd-adaa-4791-8660-256404fc394d">2.0</ix:nonNumeric> years, and the technology will be amortized over a weighted-average period of <ix:nonNumeric contextRef="ib97247344bf049d2bffeb43e431f858c_D20210801-20210801" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNzkx_c1529efc-5ae8-4ef2-b857-d76976de69f1">7.0</ix:nonNumeric> years. The fair value of noncontrolling interest ($43.9&#160;million) was determined using an income approach.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect any of the goodwill recorded for this acquisition to be deductible for income tax purposes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contessa contributed $<ix:nonFraction unitRef="usd" contextRef="i2df95a1c5f0f44979741b294afe8e34f_D20220101-20221231" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwODIx_666a50f5-b373-438d-9de5-8ae9c8284984">18.5</ix:nonFraction>&#160;million in net service revenue and an operating loss of $39.1&#160;million (inclusive of technology intangibles amortization totaling $<ix:nonFraction unitRef="usd" contextRef="i2df95a1c5f0f44979741b294afe8e34f_D20220101-20221231" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwODM2_f3548a67-a94a-412a-9d09-87447d322da3">3.0</ix:nonFraction>&#160;million) during the year ended December 31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i39143f0cd5e04faf9cb6b93e100ed3a7_D20210101-20211231" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwODUw_bf059b46-af06-4f16-bec8-f6b36ff6b3ca">3.5</ix:nonFraction>&#160;million in net service revenue and an operating loss of $10.3 million (inclusive of technology intangibles amortization totaling $<ix:nonFraction unitRef="usd" contextRef="i39143f0cd5e04faf9cb6b93e100ed3a7_D20210101-20211231" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwODY0_dd209ec2-f888-4d70-9ecc-8f59d07f8923">1.2</ix:nonFraction>&#160;million) during the year ended December 31, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 18, 2021, we acquired the regulatory assets of a home health provider in North Carolina for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="i361c6850de2f4f6caca843b2cad888d0_D20211018-20211018" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNDc1Mg_8b03bd63-dea5-46a7-9cf8-a685317124de">4.5</ix:nonFraction>&#160;million. The purchase price was paid with cash on hand on the date of the transaction. We recorded goodwill of $<ix:nonFraction unitRef="usd" contextRef="i2ed696897d0041f897bb1b2722b9e756_D20210101-20211231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNDkwNA_1f18ec0e-1713-42a4-bd01-7ac2f0c2c03a">4.3</ix:nonFraction>&#160;million and other intangibles (certificate of need) of $<ix:nonFraction unitRef="usd" contextRef="i7063e6037ddf43518429b892fa7cc4a8_I20211018" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNDk1NA_157f6cfa-ad66-4c57-ade3-a36f0ace5b9a">0.2</ix:nonFraction>&#160;million in connection with the acquisition.</span></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><div id="i5c10b724a6674979bf3c35a339f29685_100"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90ZXh0cmVnaW9uOjdkM2VmNDhlNTQzZjQ4N2NhMWI2MTA1ODI5ZTZmNDY1XzIwNTY_83c0abd1-1cf8-4c95-892a-26fde01a404a" continuedAt="i3d690c8efa5143a9b7c29e9cd37641d6" escape="true">GOODWILL AND OTHER INTANGIBLE ASSETS, NET</ix:nonNumeric></span></div><ix:continuation id="i3d690c8efa5143a9b7c29e9cd37641d6" continuedAt="ifa8cf8519b8044208ad164097d932374"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, 2021 and 2020, we did not record any goodwill impairment charges as a result of our annual impairment test and none of the goodwill associated with our reporting units was considered impaired as of October 31st of each respective year (the date of our annual goodwill impairment test). Since the date of our last annual goodwill impairment test, there have been no material developments, events, changes in operating performance or other circumstances that would cause management to believe it is more likely than not that the fair value of any of our reporting units would be less than their carrying amounts. </span></div><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90ZXh0cmVnaW9uOjdkM2VmNDhlNTQzZjQ4N2NhMWI2MTA1ODI5ZTZmNDY1XzIwNTg_282300b8-f1c6-44fc-a27a-d1a649e7d876" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to our goodwill for 2022 and 2021 (amounts in millions):</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Goodwill</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home&#160;Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal&#160;Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High  Acuity Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2020 (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51977ad5557047dd858b744031685543_I20201231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzItMS0xLTEtNTA3MjU_83b7ed52-3fb8-467c-b50c-b24476d9dccd">90.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b006d894f5b438ca664557b42c11392_I20201231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzItMy0xLTEtNTA3MjU_5ffefbbc-9258-48c0-a0ea-3c310af3cbad">799.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7751bbf329e84761a9116e25c1dcb3c3_I20201231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzItNS0xLTEtNTA3MjU_a5a2ee01-ca2b-4f7a-b369-d27e2a5cf7a5">43.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i200744aa491542f088ed7c2507164bf0_I20201231" decimals="-5" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzItNy0xLTEtNTA3MjU_514057fe-10a0-4c20-bbd4-5faf9fa7e528">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42b1e865f1ed4b2e8363dfcc39186a91_I20201231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzItOS0xLTEtNTA3MjU_38cb32e0-6f45-49d4-aab2-aed671368e12">932.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17c7b35f5a01427b9c32a21c25a8f6c0_D20210101-20211231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzMtMS0xLTEtNTA3MjU_9c10e4fa-7968-4aa3-8b2e-1dff13b48500">27.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic26ea180cb834e98a9002bae772f59e2_D20210101-20211231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzMtMy0xLTEtNTA3MjU_4e7016e9-57a7-4731-abc3-8194382cf746">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if15a919ad56a4337a9e1425b3d811e04_D20210101-20211231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzMtNS0xLTEtNTA3MjU_1d79682c-d552-4624-b51d-7c76a9426187">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic803d3d531314ae89f73add64e4be217_D20210101-20211231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzMtNy0xLTEtNTA3MjU_7dee1b50-8385-4523-8e27-96aa9df07d83">233.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzMtOS0xLTEtNTA3MjU_03c0d48d-e13e-4d76-bb9b-f955f8576383">263.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28bb5f40eceb4433925f35b9ac96a7d6_I20211231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzQtMS0xLTEtNTA3MjU_227b6990-1647-43ea-ba9c-aa10eb6b56b5">118.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e7c7cfb405d44b8814669a0483f033c_I20211231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzQtMy0xLTEtNTA3MjU_6a9ed97c-5f08-40e1-8050-1513eed88b42">800.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i279e0b1e700047bf850eaae20ab0fa8f_I20211231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzQtNS0xLTEtNTA3MjU_0d4dd396-6554-44e3-9a82-3543071a1941">43.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53953caaedb34bb19c4ac51bc0d443fd_I20211231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzQtNy0xLTEtNTA3MjU_a6058967-37ce-46c4-a122-f5b40951ed0e">233.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzQtOS0xLTEtNTA3MjU_2dfb87b9-0824-4a2f-a372-1da468a197a5">1,196.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8d7fbaae8144d01ae5b61ba948ca043_D20220101-20221231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzUtMS0xLTEtNTA3MjU_bc13da6d-b355-4425-b555-fa9e857dde30">85.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d7eeb1ee5ac46b29435cfd337b5b8a7_D20220101-20221231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzUtMy0xLTEtNTA3MjU_679258b2-2f48-4f8e-be4e-2ad0cee80e34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306ee8d06e3d4ce9aedc1f8ceaa8c3a6_D20220101-20221231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzUtNS0xLTEtNTA3MjU_afe90ab0-6503-4c8f-9e46-7dc9c18a504f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8691440b2404ff496cc413ef83e5825_D20220101-20221231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzUtNy0xLTEtNTA3MjU_974befc3-460d-4ed3-9b30-23045a87b653">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzUtOS0xLTEtNTA3MjU_8b6d0ad7-2e3e-487d-a1c6-792e518d4edc">94.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8d7fbaae8144d01ae5b61ba948ca043_D20220101-20221231" decimals="-5" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzYtMS0xLTEtNTYxOTY_adf275a1-41f0-4e71-add0-0569d64533e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d7eeb1ee5ac46b29435cfd337b5b8a7_D20220101-20221231" decimals="-5" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzYtMy0xLTEtNTYxOTY_66c76cde-2912-4d5d-bbc4-58bb3b3e3d3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306ee8d06e3d4ce9aedc1f8ceaa8c3a6_D20220101-20221231" decimals="-5" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzYtNS0xLTEtNTYxOTY_5454f53d-aadd-4a0f-9f14-f5cb104ddf15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8691440b2404ff496cc413ef83e5825_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:GoodwillPurchaseAccountingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzYtNy0xLTEtNTYxOTY_8fb2601b-6606-4fe2-82d7-af72fd6971d9">2.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:GoodwillPurchaseAccountingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzYtOS0xLTEtNTYxOTY_c6b5ea76-049f-44a3-a14b-e1d039429255">2.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f7b8ece18824575809137727a001ab8_I20221231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzYtMS0xLTEtNTA3MjU_aa8940c8-2c7a-4cc4-8d23-e7923eda5797">203.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fb0b4ede01d45a8ac9f87b995dfc5bd_I20221231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzYtMy0xLTEtNTA3MjU_71d53045-df42-4844-9e57-b130933cddcd">800.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i466c99d823de4e3da04d3e6d94ea4feb_I20221231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzYtNS0xLTEtNTA3MjU_a993545b-847e-4f6e-abe9-c2c810253edb">43.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc62063a43fb4e54a4eb1692d07bbee2_I20221231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzYtNy0xLTEtNTA3MjU_957e331e-f1db-4a1a-a20e-88c71fd1ee84">239.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzYtOS0xLTEtNTA3MjU_259676fb-c938-42e4-8d38-6f0bec4a784f">1,287.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Net of prior years' accumulated impairment losses of $<ix:nonFraction unitRef="usd" contextRef="i42b1e865f1ed4b2e8363dfcc39186a91_I20201231" decimals="-5" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90ZXh0cmVnaW9uOjdkM2VmNDhlNTQzZjQ4N2NhMWI2MTA1ODI5ZTZmNDY1XzgzOA_b109c993-79ca-41d9-bc6a-384ef1b9ec8a">733.7</ix:nonFraction> million, which is inclusive of write-offs related to the sale and closure of care centers.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Company finalized its valuation of the assets acquired, liabilities assumed and noncontrolling interests in connection with the acquisition of Contessa on August 1, 2021. See Note 4 &#8211; Acquisitions for additional information.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Intangible Assets, Net</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022 and 2021, we did not record any impairment charges related to our other intangible assets.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to our other intangible assets, net for 2022 and 2021 (amounts in millions):</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Intangible Assets, Net</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Certificates of Need and Licenses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired<br/>Names -Unamortizable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired<br/>Names -Amortizable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-Compete<br/>Agreements (3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Technology (3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2020 (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f5fa4f13a1b44e0bb2bbf24f19d98ee_I20201231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzItMS0xLTEtNTA3MjU_e6d1a031-0e80-49c4-b883-5f9e73b6d540">47.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44541ba456f945819b774b06105dc6c8_I20201231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzItMy0xLTEtNTA3MjU_c6bec8e2-2652-4ab3-84ee-6deb3c8e82c2">13.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a4803566c64d9ab540401d7fabdd92_I20201231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzItNS0xLTEtNTA3MjU_9c72b3de-b3d8-4601-9c26-83aaa5a1173b">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d01709de86048228674a5671c0c2757_I20201231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzItNy0xLTEtNTA3MjU_d10e74c3-86ae-4de4-b9c4-157aaff4f8fa">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07c90a9f4c064c94bff73ae8df530042_I20201231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzItOS0xLTEtNTA3MjU_06b400db-d0d5-47c3-89f2-c12cd41bf766">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42b1e865f1ed4b2e8363dfcc39186a91_I20201231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzItMTEtMS0xLTUwNzI1_aacb2ac7-f0c6-4ff6-8f34-db502f259c03">74.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63a631603bd42f9baf706aaa6b526b0_D20210101-20211231" decimals="-5" name="amed:OtherIntangibleAssetsAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzMtMS0xLTEtNTA3MjU_d2a8be55-204c-4be5-865c-222e7dce440a">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifff3b1dd516d4ca88196cc4ffb04052e_D20210101-20211231" decimals="-5" name="amed:OtherIntangibleAssetsAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzMtMy0xLTEtNTA3MjU_d6d8f681-b571-473b-aa5b-3a00934391d2">28.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8422ab7dd1f4a4f8d174c43529c7198_D20210101-20211231" decimals="-5" name="amed:OtherIntangibleAssetsAdditions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzMtNS0xLTEtNTA3MjU_41ca6b0b-b9c8-47cc-9d18-b31a6417d727">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida06184838c44dd1bcfc0a1cfbb4fa09_D20210101-20211231" decimals="-5" name="amed:OtherIntangibleAssetsAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzMtNy0xLTEtNTA3MjU_157f2b97-1f9a-4ba8-977d-d7d11830d42f">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfe3ab0bd83e411e92a0dd230a06c08b_D20210101-20211231" decimals="-5" name="amed:OtherIntangibleAssetsAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzMtOS0xLTEtNTA3MjU_19a96725-0dc9-4da4-ba84-e41944ac9a7e">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="amed:OtherIntangibleAssetsAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzMtMTEtMS0xLTUwNzI1_ae84c463-ba2b-43f7-b793-44ab017338f8">55.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclass to amortizable intangible</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63a631603bd42f9baf706aaa6b526b0_D20210101-20211231" decimals="-5" name="amed:ReclassToAmortizableIntangible" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzQtMS0xLTEtNTA3MjU_a659f5c8-25fb-478a-9f73-8717993c7160">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifff3b1dd516d4ca88196cc4ffb04052e_D20210101-20211231" decimals="-5" sign="-" name="amed:ReclassToAmortizableIntangible" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzQtMy0xLTEtNTA3MjU_354aa50b-4456-4723-b611-7660a1dfe361">6.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8422ab7dd1f4a4f8d174c43529c7198_D20210101-20211231" decimals="-5" name="amed:ReclassToAmortizableIntangible" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzQtNS0xLTEtNTA3MjU_54568d0e-49bc-4035-9c99-000fb3e93ba8">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida06184838c44dd1bcfc0a1cfbb4fa09_D20210101-20211231" decimals="-5" name="amed:ReclassToAmortizableIntangible" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzQtNy0xLTEtNTA3MjU_1058f206-eb3d-4854-9505-db5f4585086a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfe3ab0bd83e411e92a0dd230a06c08b_D20210101-20211231" decimals="-5" name="amed:ReclassToAmortizableIntangible" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzQtOS0xLTEtNTA3MjU_3a4b7d78-7e23-41df-b60f-8e4fc42f9a77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="amed:ReclassToAmortizableIntangible" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzQtMTEtMS0xLTUwNzI1_2341d407-fbdd-410c-8312-d17dc8b044c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63a631603bd42f9baf706aaa6b526b0_D20210101-20211231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzUtMS0xLTEtNTA3MjU_d3f0c714-0565-41e4-99bb-3ea7b4ed94cc">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifff3b1dd516d4ca88196cc4ffb04052e_D20210101-20211231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzUtMy0xLTEtNTA3MjU_a8b91859-2213-4691-bbb5-b5c7ce91b445">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8422ab7dd1f4a4f8d174c43529c7198_D20210101-20211231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzUtNS0xLTEtNTA3MjU_72ac8c98-557f-4a95-8fe1-b26253f00538">9.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida06184838c44dd1bcfc0a1cfbb4fa09_D20210101-20211231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzUtNy0xLTEtNTA3MjU_81c6f793-5573-4318-a20c-1ddf53476a68">7.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfe3ab0bd83e411e92a0dd230a06c08b_D20210101-20211231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzUtOS0xLTEtNTA3MjU_456e88b2-43c4-46d1-a41c-40b7c3252b22">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzUtMTEtMS0xLTUwNzI1_18602160-da70-4276-a687-9315a1512625">18.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9523618072184796b42e15f02c400bf6_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzYtMS0xLTEtNTA3MjU_2470b8db-bef5-4dc8-af32-1cd82bbfa9e2">47.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ecf9ee75110493892617267abbac656_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzYtMy0xLTEtNTA3MjU_d625904a-94cc-4330-809d-040c29a3fae1">35.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b3d453ff35049aca81a81d5e4f888a8_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzYtNS0xLTEtNTA3MjU_6fcc1ac6-732e-4c4b-b43b-852fcf612ca6">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f475dca4f124f1595292633d4e5f191_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzYtNy0xLTEtNTA3MjU_1a47c1f9-99f8-49fc-92ef-ccc86f3a5263">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b493d5524cf479ea3603709ff2740c8_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzYtOS0xLTEtNTA3MjU_4fb4aead-3029-4b1c-89ee-e61fc6f68e62">19.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzYtMTEtMS0xLTUwNzI1_4f34eed4-4313-4b22-b5ea-e235487d4b02">111.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied840af486324d3b938d05e97bc6b784_D20220101-20221231" decimals="-5" name="amed:OtherIntangibleAssetsAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzctMS0xLTEtNTA3MjU_ec7a3211-3fb5-4e36-a437-a8a2d8b4eeac">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d8cd69d4e1c45f08f19939d27d4ae62_D20220101-20221231" decimals="-5" name="amed:OtherIntangibleAssetsAdditions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzctMy0xLTEtNTA3MjU_63b0f7da-5a66-4d19-a2b5-0deba85fc548">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b384340c0b449dc85760ae9232d9127_D20220101-20221231" decimals="-5" name="amed:OtherIntangibleAssetsAdditions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzctNS0xLTEtNTA3MjU_baba5448-4436-4222-9966-ae2921047f37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i839a632511504949957616ab961bc135_D20220101-20221231" decimals="-5" name="amed:OtherIntangibleAssetsAdditions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzctNy0xLTEtNTA3MjU_2f29d927-33bd-48d1-b59c-f84f7d69dee8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8990c36c1ca24b9b9986a1b57a6b70aa_D20220101-20221231" decimals="-5" name="amed:OtherIntangibleAssetsAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzctOS0xLTEtNTA3MjU_963160c5-2817-4dbe-8358-cd6b553a3147">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="amed:OtherIntangibleAssetsAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzctMTEtMS0xLTUwNzI1_f8947d7b-ee84-4a33-ad20-9d5183920119">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied840af486324d3b938d05e97bc6b784_D20220101-20221231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzktMS0xLTEtNTA3MjU_4d870798-4700-4e08-88f5-600ba306c514">2.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d8cd69d4e1c45f08f19939d27d4ae62_D20220101-20221231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzktMy0xLTEtNTA3MjU_2922cd35-9b43-4f74-98c6-b854df8c328f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b384340c0b449dc85760ae9232d9127_D20220101-20221231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzktNS0xLTEtNTA3MjU_7be99a1e-535c-4995-8f06-fb0c7908cd2a">3.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i839a632511504949957616ab961bc135_D20220101-20221231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzktNy0xLTEtNTA3MjU_2d133fe1-264e-4b24-9777-639dd6f7e2ca">4.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8990c36c1ca24b9b9986a1b57a6b70aa_D20220101-20221231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzktOS0xLTEtNTA3MjU_7295bad3-a026-4797-9610-62e863a42acf">3.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzktMTEtMS0xLTUwNzI1_860752bd-ba6a-418e-bf9d-10321d4bd9a2">13.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60bbec5fe5254517bcba03cfb32af2a8_I20221231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzEwLTEtMS0xLTUwNzI1_6edac428-f0a8-4971-aa87-40f048dfec2c">46.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1fdd03a76db4dd099fcd6639124379e_I20221231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzEwLTMtMS0xLTUwNzI1_d83f846b-43e7-46ed-a07e-f584d95025a3">35.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60f209194f5e43898d6ddf2a2eef8d68_I20221231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzEwLTUtMS0xLTUwNzI1_8cde3960-4594-4ef3-b075-40ac50333628">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e005cf326124f079141ed28e6ca38da_I20221231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzEwLTctMS0xLTUwNzI1_21f6721c-14ee-4618-9dbb-81cd0fb1f98a">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89dfc092633c4ce0845425c7e17c37c3_I20221231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzEwLTktMS0xLTUwNzI1_b29b2155-d57c-4012-b663-54c21fd6f8bd">17.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzEwLTExLTEtMS01MDcyNQ_ba75553d-237c-4560-a95d-02e171af01ea">101.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Net of prior years' accumulated amortization of $<ix:nonFraction unitRef="usd" contextRef="i00a4803566c64d9ab540401d7fabdd92_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90ZXh0cmVnaW9uOjdkM2VmNDhlNTQzZjQ4N2NhMWI2MTA1ODI5ZTZmNDY1XzEzMzQ_3c0e57c9-45c8-42de-bf21-3d8f2b47ed74">11.5</ix:nonFraction>&#160;million for acquired names and $<ix:nonFraction unitRef="usd" contextRef="i6d01709de86048228674a5671c0c2757_I20201231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90ZXh0cmVnaW9uOjdkM2VmNDhlNTQzZjQ4N2NhMWI2MTA1ODI5ZTZmNDY1XzEzNjA_abdd45ba-54f1-4563-875b-176d5c52edb5">9.0</ix:nonFraction> million for non-compete agreements. </span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Amortization of certificates of need and licenses is related to care centers that were closed during 2021 and 2022.</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The weighted average remaining amortization period of our amortizable non-compete agreements and technology is <ix:nonNumeric contextRef="i839a632511504949957616ab961bc135_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90ZXh0cmVnaW9uOjdkM2VmNDhlNTQzZjQ4N2NhMWI2MTA1ODI5ZTZmNDY1XzE3Njk_1a97e161-dc50-4137-9442-2422e67fdc10">0.6</ix:nonNumeric> years and <ix:nonNumeric contextRef="i8990c36c1ca24b9b9986a1b57a6b70aa_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90ZXh0cmVnaW9uOjdkM2VmNDhlNTQzZjQ4N2NhMWI2MTA1ODI5ZTZmNDY1XzE3NzY_f978f665-a534-48f8-94ec-756a75e6e8eb">5.6</ix:nonNumeric> years, respectively.</span></div></ix:nonNumeric></ix:continuation><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></div><ix:continuation id="ifa8cf8519b8044208ad164097d932374"><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90ZXh0cmVnaW9uOjdkM2VmNDhlNTQzZjQ4N2NhMWI2MTA1ODI5ZTZmNDY1XzIwNjQ_8b306140-d8ea-4172-9986-b2b89606a142" escape="true"><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated aggregate amortization expense related to intangible assets for each of the five succeeding years is as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.356%"><tr><td style="width:1.0%"></td><td style="width:72.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.255%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intangible Asset Amortization</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZToyMjI1NTVjZmUxN2Q0NDhhOTE4NDAxMjJmNWUyZjZjOC90YWJsZXJhbmdlOjIyMjU1NWNmZTE3ZDQ0OGE5MTg0MDEyMmY1ZTJmNmM4XzEtMS0xLTEtNTA3MjU_9b22a163-d789-41b0-b5d0-d9e0928fd91f">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZToyMjI1NTVjZmUxN2Q0NDhhOTE4NDAxMjJmNWUyZjZjOC90YWJsZXJhbmdlOjIyMjU1NWNmZTE3ZDQ0OGE5MTg0MDEyMmY1ZTJmNmM4XzItMS0xLTEtNTA3MjU_778b5da6-0c3e-4511-9f4f-5686ef0d2458">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZToyMjI1NTVjZmUxN2Q0NDhhOTE4NDAxMjJmNWUyZjZjOC90YWJsZXJhbmdlOjIyMjU1NWNmZTE3ZDQ0OGE5MTg0MDEyMmY1ZTJmNmM4XzMtMS0xLTEtNTA3MjU_bc8ae05c-1636-4496-b30b-77dee72086a4">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZToyMjI1NTVjZmUxN2Q0NDhhOTE4NDAxMjJmNWUyZjZjOC90YWJsZXJhbmdlOjIyMjU1NWNmZTE3ZDQ0OGE5MTg0MDEyMmY1ZTJmNmM4XzQtMS0xLTEtNTA3MjU_ab27d3d5-afd4-404c-9b57-aae362822067">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZToyMjI1NTVjZmUxN2Q0NDhhOTE4NDAxMjJmNWUyZjZjOC90YWJsZXJhbmdlOjIyMjU1NWNmZTE3ZDQ0OGE5MTg0MDEyMmY1ZTJmNmM4XzUtMS0xLTEtNTA3MjU_7f40f172-416d-4ca8-b27b-5ce5c7c767de">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZToyMjI1NTVjZmUxN2Q0NDhhOTE4NDAxMjJmNWUyZjZjOC90YWJsZXJhbmdlOjIyMjU1NWNmZTE3ZDQ0OGE5MTg0MDEyMmY1ZTJmNmM4XzYtMS0xLTEtNTA3MjU_38adf0b5-ab7c-41d9-b99e-a929d5f88bd8">16.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 4 &#8211; Acquisitions for further details on additions to goodwill and other intangible assets, net.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i5c10b724a6674979bf3c35a339f29685_1774"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGV4dHJlZ2lvbjozN2MxYzkzNjRkYjU0MmZjYTgzYmMxN2JiODYyOWFhMl81NDk3NTU4MTQ1MTc_97b69e73-b982-4b9f-baf1-fd9778ae4b18" continuedAt="i27bc56900f5840e0b06f4de1886ad560" escape="true">ASSETS HELD FOR SALE</ix:nonNumeric></span></div><ix:continuation id="i27bc56900f5840e0b06f4de1886ad560" continuedAt="i8e0c238c4b7f44aebe414d72795f7150"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2023, we signed a definitive agreement to sell our personal care business (excluding the Florida operations) for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="i21a308e1f5cd4afdbceafc5966fb3595_I20230210" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGV4dHJlZ2lvbjozN2MxYzkzNjRkYjU0MmZjYTgzYmMxN2JiODYyOWFhMl81NDk3NTU4MTQ1MjA_3a430021-93d0-4964-805c-e9c1563f3f96">50</ix:nonFraction>&#160;million. The divestment is expected to close during the second quarter of 2023.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGV4dHJlZ2lvbjozN2MxYzkzNjRkYjU0MmZjYTgzYmMxN2JiODYyOWFhMl81NDk3NTU4MTQ1MTg_01ae8929-d8b6-43ba-a630-5dd69f5126e9" continuedAt="i345cc35cb8434aaca5c8796091732495" escape="true">The carrying amount of the assets and liabilities associated with our personal care reporting unit (which approximate fair value) included in our consolidated balance sheets are as follows (amounts in millions):</ix:nonNumeric></span></div></ix:continuation><div style="margin-top:6pt;text-align:center"><ix:continuation id="i8e0c238c4b7f44aebe414d72795f7150"><ix:continuation id="i345cc35cb8434aaca5c8796091732495"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.725%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.696%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.697%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i466c99d823de4e3da04d3e6d94ea4feb_I20221231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8zLTEtMS0xLTYyMTYx_f0748a3e-6942-4544-a058-368ea9bec7c9">9.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i279e0b1e700047bf850eaae20ab0fa8f_I20211231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8zLTMtMS0xLTYyMTg4_458b7416-a326-4b32-af73-8c64ae20f664">8.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i466c99d823de4e3da04d3e6d94ea4feb_I20221231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV80LTEtMS0xLTYyMTY2_309f6b18-7512-439d-a5ab-e1e43fd5dc96">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i279e0b1e700047bf850eaae20ab0fa8f_I20211231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV80LTMtMS0xLTYyMTg4_9bec1390-492a-4ce3-9996-934fd5c5cc86">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i466c99d823de4e3da04d3e6d94ea4feb_I20221231" decimals="-5" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV81LTEtMS0xLTYyMTY2_4ed7c14c-da5c-4659-ae46-a3a43fa34968">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i279e0b1e700047bf850eaae20ab0fa8f_I20211231" decimals="-5" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV81LTMtMS0xLTYyMTg4_5fd2fe89-2bf7-48aa-9ad3-7d061fe23043">8.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i466c99d823de4e3da04d3e6d94ea4feb_I20221231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV82LTEtMS0xLTYyMTY2_c633498f-ab76-45f2-9944-e00c50f27e08">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i279e0b1e700047bf850eaae20ab0fa8f_I20211231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV82LTMtMS0xLTYyMTg4_bf7556ec-1eac-42e6-89f7-30d8af00922f">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i466c99d823de4e3da04d3e6d94ea4feb_I20221231" decimals="-5" name="amed:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV83LTEtMS0xLTYyMTY2_85fc16b6-31cf-4c61-b501-19002953be18">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i279e0b1e700047bf850eaae20ab0fa8f_I20211231" decimals="-5" name="amed:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV83LTMtMS0xLTYyMTg4_445717dc-b966-445b-b82a-d03bb647ba05">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i466c99d823de4e3da04d3e6d94ea4feb_I20221231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV84LTEtMS0xLTYyMTY2_d3a60b1d-4bb0-4cce-91e0-8164a3b19bcc">43.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i279e0b1e700047bf850eaae20ab0fa8f_I20211231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV84LTMtMS0xLTYyMTg4_52c909a7-5d42-4b3f-99ea-8a7d7a948726">43.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i466c99d823de4e3da04d3e6d94ea4feb_I20221231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV85LTEtMS0xLTYyMTY2_c914ad6d-f9de-4a6c-8372-f971c591b43f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i279e0b1e700047bf850eaae20ab0fa8f_I20211231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV85LTMtMS0xLTYyMTg4_997590ea-cd14-4479-8ca2-8acf346cb38c">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i466c99d823de4e3da04d3e6d94ea4feb_I20221231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8xMS0xLTEtMS02MjE2Ng_222434e1-3079-45b9-b8cb-6dfb3c161627">55.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i279e0b1e700047bf850eaae20ab0fa8f_I20211231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8xMS0zLTEtMS02MjE4OA_05e8e791-5649-4c48-bb8f-2bb1ce08bc11">56.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i466c99d823de4e3da04d3e6d94ea4feb_I20221231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8xNC0xLTEtMS02MjE2OA_3938cc52-e84f-425f-9bbf-b776c86bec32">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i279e0b1e700047bf850eaae20ab0fa8f_I20211231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8xNC0zLTEtMS02MjE4OA_4ee2081d-24b0-47d2-954e-8c1fe84163d3">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i466c99d823de4e3da04d3e6d94ea4feb_I20221231" decimals="-5" name="amed:DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8xNS0xLTEtMS02MjE2OA_1f96a838-2841-4f0c-bab4-81e52d72f91a">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i279e0b1e700047bf850eaae20ab0fa8f_I20211231" decimals="-5" name="amed:DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8xNS0zLTEtMS02MjE4OA_a24db23c-7df7-488e-8aa1-e60490ae4535">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i466c99d823de4e3da04d3e6d94ea4feb_I20221231" decimals="-5" name="amed:DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8xNi0xLTEtMS02MjE2OA_1b32c71c-8926-4143-93b2-d25f5fafa1a1">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i279e0b1e700047bf850eaae20ab0fa8f_I20211231" decimals="-5" name="amed:DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8xNi0zLTEtMS02MjE4OA_71eb62c6-e73e-4165-9f43-e3044c3baab1">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i466c99d823de4e3da04d3e6d94ea4feb_I20221231" decimals="-5" name="amed:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8xOC0xLTEtMS02MjE2OA_e5035e71-33be-4909-8425-6f194b59faa7">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i279e0b1e700047bf850eaae20ab0fa8f_I20211231" decimals="-5" name="amed:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8xOC0zLTEtMS02MjE4OA_8d026fe2-dd23-4b3d-b802-bf7e60a42d53">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i466c99d823de4e3da04d3e6d94ea4feb_I20221231" decimals="-5" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8xOS0xLTEtMS02MjE2OA_1b3ff10b-a4ae-4ba5-acb7-3684de5b5c76">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i279e0b1e700047bf850eaae20ab0fa8f_I20211231" decimals="-5" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8xOS0zLTEtMS02MjE4OA_b2629056-1408-446b-80cf-33e1fa35d66c">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i466c99d823de4e3da04d3e6d94ea4feb_I20221231" decimals="-5" name="amed:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8yMS0xLTEtMS02MjE2OA_010e83b6-7ee4-43bc-ae3e-436a541c37d6">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i279e0b1e700047bf850eaae20ab0fa8f_I20211231" decimals="-5" name="amed:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8yMS0zLTEtMS02MjE4OA_5d347a27-fc2e-424a-8a16-1e7ef4cc6748">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i466c99d823de4e3da04d3e6d94ea4feb_I20221231" decimals="-5" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8yMi0xLTEtMS02MjE2OA_ec4d7f7e-1b9d-4c5f-ab6b-6acd34b3bb87">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i279e0b1e700047bf850eaae20ab0fa8f_I20211231" decimals="-5" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8yMi0zLTEtMS02MjE4OA_92803c4a-8fb1-4262-941e-b3260a9aedad">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="i5c10b724a6674979bf3c35a339f29685_103"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="amed:DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90ZXh0cmVnaW9uOjMwZjc4NTc2MjZkNTQxYmJhZTg2OTFmMmM0ZWVmNjQ3XzE3NA_78b0ca87-b39b-4548-942b-127f342b5763" continuedAt="i6696389723a24cc4a11581accb8df4e9" escape="true">DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS</ix:nonNumeric></span></div><ix:continuation id="i6696389723a24cc4a11581accb8df4e9"><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90ZXh0cmVnaW9uOjMwZjc4NTc2MjZkNTQxYmJhZTg2OTFmMmM0ZWVmNjQ3XzE2MA_decd02bc-5fff-4e10-ab83-5b7d944d930e" escape="true"><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90ZXh0cmVnaW9uOjMwZjc4NTc2MjZkNTQxYmJhZTg2OTFmMmM0ZWVmNjQ3XzE2Mg_ee6f1818-c60b-4215-8c13-71039cbae4c8" escape="true"><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90ZXh0cmVnaW9uOjMwZjc4NTc2MjZkNTQxYmJhZTg2OTFmMmM0ZWVmNjQ3XzE2Mw_c373b5be-0ce4-473e-a795-7eca7f67781a" escape="true"><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:ScheduleOfOtherAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90ZXh0cmVnaW9uOjMwZjc4NTc2MjZkNTQxYmJhZTg2OTFmMmM0ZWVmNjQ3XzE3NQ_f8668efe-eeec-4dfc-94b5-f667858a3cd1" escape="true"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information regarding certain balance sheet accounts is presented below (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payroll tax escrow</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="amed:PayrollTaxEscrow" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzMtMS0xLTEtNTA3MjU_e2cc6b05-ea06-4b4f-af40-c08085d58cd2">7.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="amed:PayrollTaxEscrow" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzMtMy0xLTEtNTA3MjU_0520a091-8482-47db-8d16-b63b818b93a8">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:IncomeTaxesReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzQtMS0xLTEtNTA3MjU_8c7941df-db79-4af2-b12f-7d5bcb27392e">8.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:IncomeTaxesReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzQtMy0xLTEtNTA3MjU_36caa656-e8ae-4cd1-a101-105be273579b">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due from joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:DueFromJointVenturesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzUtMS0xLTEtNTA3MjU_699f833c-cc3d-405f-9a15-e4baa2db05e3">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:DueFromJointVenturesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzUtMy0xLTEtNTA3MjU_d9874756-b221-44b5-b968-0c1e3441db29">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:OtherAssetsMiscellaneousCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzYtMS0xLTEtNTA3MjU_49401d64-49f3-4264-b984-5e5f3353b17a">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:OtherAssetsMiscellaneousCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzYtMy0xLTEtNTA3MjU_14decf36-bda9-4214-a3a4-26248ee51afb">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzctMS0xLTEtNTA3MjU_e1c2daa0-acb2-4824-8d2f-16873bb1f0e8">26.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzctMy0xLTEtNTA3MjU_196edc4e-f8f1-40d6-a55b-b81de44eb20b">25.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Workers&#8217; compensation deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="amed:WorkersCompensationDeposits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzktMS0xLTEtNTA3MjU_90e1d755-6976-4d0b-8263-a62289182220">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="amed:WorkersCompensationDeposits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzktMy0xLTEtNTA3MjU_c38d3933-7427-442f-8d38-93b4f67ff96d">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Health insurance deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="amed:HealthInsuranceDeposits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzEwLTEtMS0xLTUwNzI1_8b96ae49-9f2b-440b-8ec3-33154730a819">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="amed:HealthInsuranceDeposits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzEwLTMtMS0xLTUwNzI1_178385b7-b9f4-44dd-b266-e35e3c02ac98">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other miscellaneous deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="amed:OtherMiscellaneousDeposits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzExLTEtMS0xLTUwNzI1_179e0877-921b-486c-b180-22ef67bcbd3f">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="amed:OtherMiscellaneousDeposits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzExLTMtMS0xLTUwNzI1_b99ed426-c4e1-4584-8c6f-04e719bd9cb7">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indemnity receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:LossContingencyReceivableNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzEyLTEtMS0xLTUwNzI1_2218b6bb-ab4b-4e03-bc0f-568c26ff75a8">13.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:LossContingencyReceivableNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzEyLTMtMS0xLTUwNzI1_242ddc5c-6073-4179-a987-c4982af320de">13.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzEzLTEtMS0xLTUwNzI1_ee63ef27-958f-4cc5-9e75-17d63228d1a2">40.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzEzLTMtMS0xLTUwNzI1_c434d4bf-487f-43f5-8452-ad078f7305f3">48.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:InvestmentOwnedAtCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzE0LTEtMS0xLTYxNjQ4_edc72b29-bc40-423a-9afa-259ae3d58448">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:InvestmentOwnedAtCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzE0LTMtMS0xLTYxNjQ4_0fd9b778-1163-4e0b-bd2a-386c766aaea5">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:OtherAssetsMiscellaneousNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzE0LTEtMS0xLTUwNzI1_72927b8d-449b-4fc0-a5a7-261ae1d1d233">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:OtherAssetsMiscellaneousNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzE0LTMtMS0xLTUwNzI1_a2d9dd45-4b5e-4f5d-ad11-6971f74d38ed">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzE1LTEtMS0xLTUwNzI1_99bac1a2-1594-4ee4-bc83-7f0a61f2db3f">79.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzE1LTMtMS0xLTUwNzI1_08aec01f-d969-4147-99b3-48bc0350f929">73.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Health insurance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:AccruedInsuranceCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzE3LTEtMS0xLTUwNzI1_f6552c82-d5b5-4c13-afb5-bf1ca7a66114">16.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:AccruedInsuranceCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzE3LTMtMS0xLTUwNzI1_43f1b3e4-f586-4817-9f18-ca1b0ac905eb">16.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:WorkersCompensationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzE4LTEtMS0xLTUwNzI1_45085d0b-191b-4179-b144-ce138d44e906">40.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:WorkersCompensationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzE4LTMtMS0xLTUwNzI1_9e724986-8e21-4c2a-9a9a-c4952eb8fe1b">40.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Florida ZPIC audit, gross liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="amed:ProvisionForLiabilityOnRegulatoryAudit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzE5LTEtMS0xLTUwNzI1_b226eaf1-f337-46ef-91c1-49df4624b9d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="amed:ProvisionForLiabilityOnRegulatoryAudit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzE5LTMtMS0xLTUwNzI1_4fda7704-4c20-4b9c-bbdb-08cfa0c715cc">17.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Legal settlements and other audits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="amed:LegalAndOtherSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzIwLTEtMS0xLTUwNzI1_f9cc3367-1efb-475c-b743-dc31c3f0da03">32.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="amed:LegalAndOtherSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzIwLTMtMS0xLTUwNzI1_2e1d9a8f-28d8-40be-9100-4624c6f31ece">27.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charity care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="amed:CharityCare" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzIxLTEtMS0xLTUwNzI1_621d043d-b4b0-45ec-b4bd-4498e89cbd0c">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="amed:CharityCare" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzIxLTMtMS0xLTUwNzI1_ec3c0f84-959a-4fbb-a056-9c41ad61b085">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated Medicare cap liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="amed:EstimatedMedicareCapLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzIyLTEtMS0xLTUwNzI1_d7144eb5-501d-4c2c-a50b-21224367c9b7">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="amed:EstimatedMedicareCapLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzIyLTMtMS0xLTUwNzI1_272e2cb8-97ed-4804-a520-03b31736779a">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hospice accruals (room and board, general in-patient and other)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="amed:HospiceAccruals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzIzLTEtMS0xLTUwNzI1_14491b9d-c39e-4064-a495-03321aa6a98a">19.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="amed:HospiceAccruals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzIzLTMtMS0xLTUwNzI1_209f754e-7c16-4500-9836-739757a582a6">23.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patient and payor liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="amed:PatientLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzI1LTEtMS0xLTUwNzI1_6f90a3bf-5153-4340-9af1-f3c72f1f5de2">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="amed:PatientLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzI1LTMtMS0xLTUwNzI1_6dd8b36c-92d6-4aaa-8bbf-00675c3b8465">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzI3LTEtMS0xLTYxNjc1_06b3e83b-9da9-44ce-840b-8d1cfd4fcdd6">10.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzI3LTMtMS0xLTYxNjc1_554a9407-a2f2-4a63-b742-6d6c002042bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="amed:AccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzI4LTEtMS0xLTYxNjc1_69390625-d8f4-4115-b8ba-dee4c332ecd2">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="amed:AccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzI4LTMtMS0xLTYxNjc1_e465a3b4-4f8c-4f84-87d2-4ad0c5f723f0">8.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzI3LTEtMS0xLTUwNzI1_01c986c2-4ebf-43e7-b3ca-442decb831ea">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzI3LTMtMS0xLTUwNzI1_46f1f2f4-d77c-4f4f-aa2d-337e1da57db4">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzI4LTEtMS0xLTUwNzI1_6809b42d-d883-453d-95be-94c1192aa889">137.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzI4LTMtMS0xLTUwNzI1_2b50eb8d-6da5-44fb-9c85-e116e2b2e528">150.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term obligations:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reserve for uncertain tax positions</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="amed:UncertainTaxBenefitsInLongTermObligations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzMwLTEtMS0xLTUwNzI1_7164092a-9ab6-47ca-82b1-73b19fc30742">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="amed:UncertainTaxBenefitsInLongTermObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzMwLTMtMS0xLTUwNzI1_2c31df23-1a5e-45c8-8b25-d0b81f419a0b">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="amed:DeferredCompensationPlanLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzMxLTEtMS0xLTUwNzI1_6f9d3a21-cca0-4797-a56e-db42e410bed9">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="amed:DeferredCompensationPlanLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzMxLTMtMS0xLTUwNzI1_27e7468c-eb43-4067-8cb4-63b5ec093bf2">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzMxLTEtMS0xLTYwMTA5_a2e2ee52-5ae2-4689-bed1-4ccf6a82cb64">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzMxLTMtMS0xLTYwMTA5_d9e91417-c3f3-4978-98e9-3b1ff4d53054">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:OtherSundryLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzMzLTEtMS0xLTUwNzI1_bcf3c89b-9c65-492d-a278-6159ae913b02">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:OtherSundryLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzMzLTMtMS0xLTUwNzI1_c466ab8e-eac2-4a98-9d7b-040f655ea1d9">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzM0LTEtMS0xLTUwNzI1_a6d4d442-62a9-4da0-883c-47e7dfa1a310">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzM0LTMtMS0xLTUwNzI1_23e49173-27ca-4d31-b640-21525f910f84">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i5c10b724a6674979bf3c35a339f29685_106"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="amed:LesseeLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90ZXh0cmVnaW9uOmJiNDEwNTZmMDg4MjQ1MTA5YTBlMWZmY2IxMGRiN2U2XzM5Mzg_e8a91122-b0fc-43b7-a4c8-3ebe0a91b65a" continuedAt="i4d9867e7e07d4c72b830bab39ffd35a2" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="i4d9867e7e07d4c72b830bab39ffd35a2" continuedAt="icef9619f54fe4dbe8847bf47351f9d16"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine whether an arrangement is a lease at inception. We have operating leases, primarily for offices and fleet, that expire at various dates over the next <ix:nonNumeric contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90ZXh0cmVnaW9uOmJiNDEwNTZmMDg4MjQ1MTA5YTBlMWZmY2IxMGRiN2U2XzE3OQ_218982f2-799d-42d6-b0e2-521b80b271fe">seven years</ix:nonNumeric>. We have finance leases covering certain office equipment that expire at various dates over the next <ix:nonNumeric contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" name="us-gaap:LesseeFinanceLeaseTermOfContract1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90ZXh0cmVnaW9uOmJiNDEwNTZmMDg4MjQ1MTA5YTBlMWZmY2IxMGRiN2U2XzI4OA_e569afb7-baff-4646-bf95-bc2873273209">three years</ix:nonNumeric>. Our leases do not contain any restrictive covenants.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our office leases generally contain renewal options for periods ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90ZXh0cmVnaW9uOmJiNDEwNTZmMDg4MjQ1MTA5YTBlMWZmY2IxMGRiN2U2XzQyMw_4521311a-fbff-4d4f-a200-9de841dcd915">one</span> to <ix:nonNumeric contextRef="iabc17e0bc0164f2ab68e1dacdbd3fa3a_I20221231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90ZXh0cmVnaW9uOmJiNDEwNTZmMDg4MjQ1MTA5YTBlMWZmY2IxMGRiN2U2XzQyOQ_caeaf1b2-d76e-4584-99de-f7c8f76ab3ca">five years</ix:nonNumeric>. Because we are not reasonably certain to exercise these renewal options, the options are not considered in determining the lease term, and payments associated with the option years are excluded from lease payments. Our office leases also generally include termination options, which allow for early termination of the lease after the first one to three years. Because we are not reasonably certain to exercise these termination options, the options are not considered in determining the lease term; payments for the full lease term are included in lease payments. Our office leases do not contain any material residual value guarantees.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fleet leases include a term of <ix:nonNumeric contextRef="i242800e8bae14013ad55b6c47fc0d95c_I20221231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90ZXh0cmVnaW9uOmJiNDEwNTZmMDg4MjQ1MTA5YTBlMWZmY2IxMGRiN2U2XzExMDY_92709c4b-99dd-481f-b119-67823d5420f4">367</ix:nonNumeric> days with monthly renewal options thereafter. Our fleet leases also include terminal rental adjustment clauses (&#8220;TRAC&#8221;), which provide for a final rental payment adjustment at the end of the lease, typically based on </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></div><ix:continuation id="icef9619f54fe4dbe8847bf47351f9d16" continuedAt="if261803224b940999b8fc291feba5a55"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the amount realized from the sale of the vehicle. The TRAC is structured such that it will almost always result in a significant payment by us to the lessor if the renewal option is not exercised. Based on the significance of the TRAC adjustment at the initial lease expiration, we believe that it is reasonably certain that we will exercise the monthly renewal options; therefore, the renewal options are considered in determining the lease term, and payments associated with the renewal options are included in lease payments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our fleet and office equipment leases, we use the implicit rate in the lease as the discount rate. For our office leases, the implicit rate is typically not available, so we use our incremental borrowing rate as the discount rate. Our lease agreements include both lease and non-lease components. We have elected the practical expedient that allows us to not separate lease and non-lease components for all of our leases.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments due under our operating and finance leases include fixed payments as well as variable payments. For our office leases, variable payments include amounts for our proportionate share of operating expenses, utilities, property taxes, insurance, common area maintenance and other facility-related expenses. For our vehicle and equipment leases, variable payments consist of sales tax. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90ZXh0cmVnaW9uOmJiNDEwNTZmMDg4MjQ1MTA5YTBlMWZmY2IxMGRiN2U2XzM5NDU_442dd02c-1064-47e3-b733-7e4281de1efc" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost for the years ended December 31, 2022 and 2021 are as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:56.316%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.794%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzMtMS0xLTEtNTA3MjU_63a66bcc-e595-4e56-bf3c-906adc25b4e4">43.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzMtMy0xLTEtNTA3MjU_599ca56a-3bd3-434e-a40f-201105ee3f53">40.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of operating lease ROU assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzQtMS0xLTEtNTA3MjU_6ee6c723-846f-47ce-9ad6-9769f42001c8">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzQtMy0xLTEtNTA3MjU_43584910-2557-4abf-b709-5093e59d39e2">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease cost</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzUtMS0xLTEtNTA3MjU_ddfde720-eeac-423d-84fe-11d445e7ffd6">46.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzUtMy0xLTEtNTA3MjU_cd65656f-962c-4db6-9360-d8ec71f65ae7">40.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on termination</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:GainLossOnTerminationOfLease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzgtMS0xLTEtNTU2NTk_cb6a75cd-c348-4b94-ba08-42ff684758e8">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:GainLossOnTerminationOfLease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzgtMy0xLTEtNTU2NTk_05987a37-216d-40a9-8826-eb94c64d1bb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of ROU assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzgtMS0xLTEtNTA3MjU_4b2be9db-91c0-4167-a470-11ec11f4ca79">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzgtMy0xLTEtNTA3MjU_d0495cf5-0cfa-43cb-b6b7-54b33dce3d68">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzktMS0xLTEtNTA3MjU_12eeea2d-d3b7-48b2-93d8-101bce463611">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzktMy0xLTEtNTA3MjU_369b5849-908a-4200-b43a-be787fb2dea4">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease cost</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="amed:FinanceLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzEwLTEtMS0xLTUwNzI1_d4b35f24-1b20-4e75-9c14-63b733681d13">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="amed:FinanceLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzEwLTMtMS0xLTUwNzI1_f6f77c81-c1b3-4a75-bebb-3cb7e396fdd5">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzEyLTEtMS0xLTUwNzI1_f685e4aa-55f1-4c13-9633-50ed3c553562">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzEyLTMtMS0xLTUwNzI1_dbbe9b9d-6d20-4662-ae89-4b33a37cbe9a">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:ShortTermLeaseCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzEzLTEtMS0xLTUwNzI1_db36f0ea-1712-4e6b-ad5b-6a05140034f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:ShortTermLeaseCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzEzLTMtMS0xLTUwNzI1_42cd9adb-1a88-4488-9774-a92857705c3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzE0LTEtMS0xLTUwNzI1_72768ca1-9e4e-4af9-80ec-58700c51370a">51.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzE0LTMtMS0xLTUwNzI1_68d38424-68cc-42f2-9b9c-074b13c47825">45.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="amed:OperatingLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90ZXh0cmVnaW9uOmJiNDEwNTZmMDg4MjQ1MTA5YTBlMWZmY2IxMGRiN2U2XzM5NDA_9a8a9d1c-324f-4832-ba7e-21daae72e3cb" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reported in the consolidated balance sheets as of December 31, 2022 and 2021 for our operating leases are as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:56.316%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.794%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0NTU3NzBiMTQ2OGU0MGVjOGY3NWY1ZDQwYTU4YmVmMC90YWJsZXJhbmdlOjQ1NTc3MGIxNDY4ZTQwZWM4Zjc1ZjVkNDBhNThiZWYwXzItMS0xLTEtNTA3MjU_324d4d05-2cdf-4855-b33d-75e213150c9e">102.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0NTU3NzBiMTQ2OGU0MGVjOGY3NWY1ZDQwYTU4YmVmMC90YWJsZXJhbmdlOjQ1NTc3MGIxNDY4ZTQwZWM4Zjc1ZjVkNDBhNThiZWYwXzItMy0xLTEtNTA3MjU_97aec2bb-9214-4515-a1ba-a0951f5fe553">101.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0NTU3NzBiMTQ2OGU0MGVjOGY3NWY1ZDQwYTU4YmVmMC90YWJsZXJhbmdlOjQ1NTc3MGIxNDY4ZTQwZWM4Zjc1ZjVkNDBhNThiZWYwXzQtMS0xLTEtNTA3MjU_1fb38fe6-19ce-4e82-8fdb-49f3346e3775">33.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0NTU3NzBiMTQ2OGU0MGVjOGY3NWY1ZDQwYTU4YmVmMC90YWJsZXJhbmdlOjQ1NTc3MGIxNDY4ZTQwZWM4Zjc1ZjVkNDBhNThiZWYwXzQtMy0xLTEtNTA3MjU_f0076f85-926f-4d05-9365-8b2fe794168c">31.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, less current portion</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0NTU3NzBiMTQ2OGU0MGVjOGY3NWY1ZDQwYTU4YmVmMC90YWJsZXJhbmdlOjQ1NTc3MGIxNDY4ZTQwZWM4Zjc1ZjVkNDBhNThiZWYwXzUtMS0xLTEtNTA3MjU_49d8625a-75ed-4a8c-9562-7652596a1027">69.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0NTU3NzBiMTQ2OGU0MGVjOGY3NWY1ZDQwYTU4YmVmMC90YWJsZXJhbmdlOjQ1NTc3MGIxNDY4ZTQwZWM4Zjc1ZjVkNDBhNThiZWYwXzUtMy0xLTEtNTA3MjU_c22654e8-839e-4dbb-b13c-c449d6e20112">69.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0NTU3NzBiMTQ2OGU0MGVjOGY3NWY1ZDQwYTU4YmVmMC90YWJsZXJhbmdlOjQ1NTc3MGIxNDY4ZTQwZWM4Zjc1ZjVkNDBhNThiZWYwXzYtMS0xLTEtNTA3MjU_0414fe15-ac27-4b0f-aa25-8bbc104bc366">103.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0NTU3NzBiMTQ2OGU0MGVjOGY3NWY1ZDQwYTU4YmVmMC90YWJsZXJhbmdlOjQ1NTc3MGIxNDY4ZTQwZWM4Zjc1ZjVkNDBhNThiZWYwXzYtMy0xLTEtNTA3MjU_90936908-f73d-4aca-b588-24da3d5033e3">100.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="amed:FinanceLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90ZXh0cmVnaW9uOmJiNDEwNTZmMDg4MjQ1MTA5YTBlMWZmY2IxMGRiN2U2XzM5MzY_88fac82e-35a8-405e-9735-8ce869ddb361" continuedAt="i304f2bc80b484152915d6bc9fd61b47c" escape="true">Amounts reported in the consolidated balance sheets as of December 31, 2022 and 2021 for finance leases are included in the table below. The finance lease ROU assets are recorded within property and equipment, net of accumulated depreciation within our consolidated balance sheets. The finance lease liabilities are recorded within current portion of long-term obligations and long-term obligations, less current portion within our consolidated balance sheets.</ix:nonNumeric></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></div><ix:continuation id="if261803224b940999b8fc291feba5a55" continuedAt="i7fdb1653264d48ada64edacb7529f18f"><div style="margin-top:5pt;text-align:center"><ix:continuation id="i304f2bc80b484152915d6bc9fd61b47c"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:56.316%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.794%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease ROU assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzItMS0xLTEtNTA3MjU_b7709235-813a-461b-846e-4887a5040c3f">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzItMy0xLTEtNTA3MjU_24793e17-a02e-4581-870a-8fa43d205c9f">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzMtMS0xLTEtNTA3MjU_6f3351e5-08ef-4474-b55c-801ef148ce87">1.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzMtMy0xLTEtNTA3MjU_e2bb4c9f-2f0e-49f2-9487-833e1e068ef4">2.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease ROU assets, net</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b2a5e41e9ee4551ba7962246c513287_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzQtMS0xLTEtNTA3MjU_e4b2546b-909d-4b24-8ce3-732b41eb7c2d">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9e60ab572054136b724859b7d07a982_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzQtMy0xLTEtNTA3MjU_10377fc6-f9ee-4ba8-bc93-fa7e3e0abf7e">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current installments of obligations under finance leases</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzYtMS0xLTEtNTA3MjU_1eca02a9-f1dd-4c12-b3b8-0c54b6fd691a">1.2</span>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzYtMy0xLTEtNTA3MjU_8d1038d1-419b-4128-8314-0aa1a5467841">0.9</span>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of obligations under finance leases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzctMS0xLTEtNTA3MjU_a814e167-8383-4d45-81ca-86cc22f5c011">1.1</span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzctMy0xLTEtNTA3MjU_89a632c7-217b-411e-a52c-c18cee261893">0.7</span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzgtMS0xLTEtNTA3MjU_12d2aa00-0042-4307-aa11-8f39561b8e9d">2.3</span>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzgtMy0xLTEtNTA3MjU_15a6bc06-843b-4c48-b58a-8be83b9c35ba">1.6</span>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:center"><span><br/></span></div><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="amed:SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90ZXh0cmVnaW9uOmJiNDEwNTZmMDg4MjQ1MTA5YTBlMWZmY2IxMGRiN2U2XzM5Mzk_a01c2d25-7537-4f7f-96db-53966dbb09d4" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information and non-cash activity related to our leases are as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:56.316%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.794%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities and ROU assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flow from operating leases</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpkYjM2YjkyOWNmMzc0MWIwYmI4YjIzYmJiMWQ1N2E4OC90YWJsZXJhbmdlOmRiMzZiOTI5Y2YzNzQxYjBiYjhiMjNiYmIxZDU3YTg4XzMtMS0xLTEtNTA3MjU_c047cc3d-2f6c-47bf-8b20-278b2f86e562">44.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpkYjM2YjkyOWNmMzc0MWIwYmI4YjIzYmJiMWQ1N2E4OC90YWJsZXJhbmdlOmRiMzZiOTI5Y2YzNzQxYjBiYjhiMjNiYmIxZDU3YTg4XzMtMy0xLTEtNTA3MjU_14173d38-fe00-4695-9753-bb01158a2337">39.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flow from finance leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpkYjM2YjkyOWNmMzc0MWIwYmI4YjIzYmJiMWQ1N2E4OC90YWJsZXJhbmdlOmRiMzZiOTI5Y2YzNzQxYjBiYjhiMjNiYmIxZDU3YTg4XzQtMS0xLTEtNTA3MjU_65300dc6-5732-4f43-b83a-b6a93938bd16">1.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpkYjM2YjkyOWNmMzc0MWIwYmI4YjIzYmJiMWQ1N2E4OC90YWJsZXJhbmdlOmRiMzZiOTI5Y2YzNzQxYjBiYjhiMjNiYmIxZDU3YTg4XzQtMy0xLTEtNTA3MjU_cfc4fe37-4d5c-4830-9e64-cba8fa6b8129">2.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpkYjM2YjkyOWNmMzc0MWIwYmI4YjIzYmJiMWQ1N2E4OC90YWJsZXJhbmdlOmRiMzZiOTI5Y2YzNzQxYjBiYjhiMjNiYmIxZDU3YTg4XzctMS0xLTEtNTA3MjU_dcf88387-50c0-4299-8783-f59ada2b4b74">45.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpkYjM2YjkyOWNmMzc0MWIwYmI4YjIzYmJiMWQ1N2E4OC90YWJsZXJhbmdlOmRiMzZiOTI5Y2YzNzQxYjBiYjhiMjNiYmIxZDU3YTg4XzctMy0xLTEtNTA3MjU_dca49409-11fa-41f9-a53c-275952f9cc9e">46.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpkYjM2YjkyOWNmMzc0MWIwYmI4YjIzYmJiMWQ1N2E4OC90YWJsZXJhbmdlOmRiMzZiOTI5Y2YzNzQxYjBiYjhiMjNiYmIxZDU3YTg4XzgtMS0xLTEtNTA3MjU_1243616d-bc0c-49e0-96c9-bec99c298dcc">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpkYjM2YjkyOWNmMzc0MWIwYmI4YjIzYmJiMWQ1N2E4OC90YWJsZXJhbmdlOmRiMzZiOTI5Y2YzNzQxYjBiYjhiMjNiYmIxZDU3YTg4XzgtMy0xLTEtNTA3MjU_1fc410c0-1f83-478d-98b6-02e2c86dc9ec">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions to ROU assets resulting from reductions to lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" sign="-" name="amed:LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpkYjM2YjkyOWNmMzc0MWIwYmI4YjIzYmJiMWQ1N2E4OC90YWJsZXJhbmdlOmRiMzZiOTI5Y2YzNzQxYjBiYjhiMjNiYmIxZDU3YTg4XzExLTEtMS0xLTUwNzI1_00305bb1-07c5-4bc3-97e1-35cc18393663">4.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" sign="-" name="amed:LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpkYjM2YjkyOWNmMzc0MWIwYmI4YjIzYmJiMWQ1N2E4OC90YWJsZXJhbmdlOmRiMzZiOTI5Y2YzNzQxYjBiYjhiMjNiYmIxZDU3YTg4XzExLTMtMS0xLTUwNzI1_74a185df-e81e-46fa-845e-8f6a2a4eecf2">1.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" sign="-" name="amed:LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpkYjM2YjkyOWNmMzc0MWIwYmI4YjIzYmJiMWQ1N2E4OC90YWJsZXJhbmdlOmRiMzZiOTI5Y2YzNzQxYjBiYjhiMjNiYmIxZDU3YTg4XzEyLTEtMS0xLTUwNzI1_ba255dd0-6f4d-497a-95a1-b11da1da58c2">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="amed:LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpkYjM2YjkyOWNmMzc0MWIwYmI4YjIzYmJiMWQ1N2E4OC90YWJsZXJhbmdlOmRiMzZiOTI5Y2YzNzQxYjBiYjhiMjNiYmIxZDU3YTg4XzEyLTMtMS0xLTUwNzI1_5959351a-a78d-4b1d-9056-5a617d45e55c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts disclosed for ROU assets obtained in exchange for lease obligations include amounts added to the carrying amount of ROU assets resulting from lease modifications and reassessments.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="amed:WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90ZXh0cmVnaW9uOmJiNDEwNTZmMDg4MjQ1MTA5YTBlMWZmY2IxMGRiN2U2XzM5NDM_388f9f78-c6db-44a4-9885-b85e391e42ae" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease terms and discount rates for our leases as of December 31, 2022 and 2021 are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:56.316%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.794%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (years):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo2NTZkNjk3NGE3ZTg0ZTEzODlmMWEyY2RhMzhmMDc0NS90YWJsZXJhbmdlOjY1NmQ2OTc0YTdlODRlMTM4OWYxYTJjZGEzOGYwNzQ1XzMtMS0xLTEtNTA3MjU_04d172bb-e764-4503-bcce-604eb135ccf1">3.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo2NTZkNjk3NGE3ZTg0ZTEzODlmMWEyY2RhMzhmMDc0NS90YWJsZXJhbmdlOjY1NmQ2OTc0YTdlODRlMTM4OWYxYTJjZGEzOGYwNzQ1XzMtMy0xLTEtNTA3MjU_b863ef31-a29f-484d-9058-0dc8222e4913">3.7</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo2NTZkNjk3NGE3ZTg0ZTEzODlmMWEyY2RhMzhmMDc0NS90YWJsZXJhbmdlOjY1NmQ2OTc0YTdlODRlMTM4OWYxYTJjZGEzOGYwNzQ1XzQtMS0xLTEtNTA3MjU_b101a6ee-3def-41be-9f80-e3b80612a101">2.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo2NTZkNjk3NGE3ZTg0ZTEzODlmMWEyY2RhMzhmMDc0NS90YWJsZXJhbmdlOjY1NmQ2OTc0YTdlODRlMTM4OWYxYTJjZGEzOGYwNzQ1XzQtMy0xLTEtNTA3MjU_a0b6ecd5-f240-4270-ad07-4118571f26c6">1.7</ix:nonNumeric></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo2NTZkNjk3NGE3ZTg0ZTEzODlmMWEyY2RhMzhmMDc0NS90YWJsZXJhbmdlOjY1NmQ2OTc0YTdlODRlMTM4OWYxYTJjZGEzOGYwNzQ1XzctMS0xLTEtNTA3MjU_218312bd-24ba-4e13-b583-099b20bc06f9">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo2NTZkNjk3NGE3ZTg0ZTEzODlmMWEyY2RhMzhmMDc0NS90YWJsZXJhbmdlOjY1NmQ2OTc0YTdlODRlMTM4OWYxYTJjZGEzOGYwNzQ1XzctMy0xLTEtNTA3MjU_a287969c-c17b-4081-9ea8-44ea4d85fedd">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo2NTZkNjk3NGE3ZTg0ZTEzODlmMWEyY2RhMzhmMDc0NS90YWJsZXJhbmdlOjY1NmQ2OTc0YTdlODRlMTM4OWYxYTJjZGEzOGYwNzQ1XzgtMS0xLTEtNTA3MjU_a23da77e-6e4b-47f2-bd66-95b5a73a2cbf">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo2NTZkNjk3NGE3ZTg0ZTEzODlmMWEyY2RhMzhmMDc0NS90YWJsZXJhbmdlOjY1NmQ2OTc0YTdlODRlMTM4OWYxYTJjZGEzOGYwNzQ1XzgtMy0xLTEtNTA3MjU_8603ea6c-ff05-4adc-9a03-5436fb82d103">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></div><ix:continuation id="i7fdb1653264d48ada64edacb7529f18f"><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="amed:LeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90ZXh0cmVnaW9uOmJiNDEwNTZmMDg4MjQ1MTA5YTBlMWZmY2IxMGRiN2U2XzM5Mzc_f9e6a921-f348-4424-a988-f34da96a1466" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December 31, 2022 are as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"><tr><td style="width:1.0%"></td><td style="width:64.154%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.850%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating <br/>Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance <br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzEtMS0xLTEtNTA3MjU_e3364727-cf40-4a77-80f0-86fcf0493822">36.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzEtMy0xLTEtNTA3MjU_1ed7f591-d2ee-440d-839d-cb8622bfe34c">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzItMS0xLTEtNTA3MjU_1e5efa1a-e04c-4f03-ad80-bda4c91ffd48">30.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzItMy0xLTEtNTA3MjU_79eb7d2f-0ba1-4d03-b558-6654364d1838">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzMtMS0xLTEtNTA3MjU_158d1774-5577-48dd-92e2-a1ad29933345">20.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzMtMy0xLTEtNTA3MjU_59716f1c-10cc-489e-8c51-2d2409d47005">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzQtMS0xLTEtNTA3MjU_d1098cd7-51c9-4e4e-8e0a-d22f3a8c9907">12.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzQtMy0xLTEtNTA3MjU_94a759de-d88a-472e-9637-04ffabcbb12f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzUtMS0xLTEtNTA3MjU_faa260e1-679c-4a49-9749-f0afd9be1bd5">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzUtMy0xLTEtNTA3MjU_93a20cc4-64a1-47cf-b49e-fdb8ce69b274">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzYtMS0xLTEtNTA3MjU_690d632e-cd83-4e38-98b5-d5ce9cf7df6e">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzYtMy0xLTEtNTA3MjU_7a94734b-c720-4b31-b7e5-7bdde57c24ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzctMS0xLTEtNTA3MjU_c03bca8f-a020-43fd-9133-499f391c74a8">109.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzctMy0xLTEtNTA3MjU_17cc2cb0-fa1c-413f-8b67-00d09a3de8bf">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzgtMS0xLTEtNTA3MjU_3cc1daa4-3467-4901-9eb3-d00d188802b6">6.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzgtMy0xLTEtNTA3MjU_a1da0392-80ef-4c55-8a3b-fd0e675ba8ee">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzktMS0xLTEtNTA3MjU_4792e780-c5e2-4302-8e3a-8307e1801353">103.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzktMy0xLTEtNTA3MjU_99acfacd-090d-4833-8cd5-0990e12d974a">2.3</span>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="padding-left:94.5pt;text-indent:-58.5pt"><span><br/></span></div><div><span><br/></span></div><div id="i5c10b724a6674979bf3c35a339f29685_112"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzEwMzMw_0b9a52df-87c3-4020-91fb-df6116b093d1" continuedAt="i7eeda40940ab46e19676ab1d87b3ba30" escape="true">LONG-TERM OBLIGATIONS</ix:nonNumeric></span></div><ix:continuation id="i7eeda40940ab46e19676ab1d87b3ba30" continuedAt="i280e4fa04abb4e40968ec4a6e87adbff"><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzEwMzQ1_7aeb7389-04f8-42bc-85c2-9949a0740ec1" escape="true"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consists of the following for the periods indicated (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i8f4fcaea6b154a0bbd917fba61d92e52_I20221231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzItMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjo5ODc1YWY4ZTM4Njk0M2MxOWNhOTJkMjdkMTQyZjBmMF80_b5aff638-aef7-4735-94f8-59a40c80c53c">450.0</ix:nonFraction> million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (<ix:nonFraction unitRef="number" contextRef="i916f340079654056b2571fa1ce003955_I20221231" decimals="3" name="amed:DebtInstrumentInterestRateatPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzItMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjo5ODc1YWY4ZTM4Njk0M2MxOWNhOTJkMjdkMTQyZjBmMF8xMDc_30ecc35f-43e6-4d4a-9b11-c618b3711d1d">5.9</ix:nonFraction>% at December 31, 2022); due <ix:nonNumeric contextRef="i3a8567395eba45968f1f59959fef3ffb_D20220101-20221231" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzItMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjo5ODc1YWY4ZTM4Njk0M2MxOWNhOTJkMjdkMTQyZjBmMF8xMzc_3f6e0cc4-3e3f-469d-b7c1-cc2d19e1cbd7">July&#160;30, 2026</ix:nonNumeric></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f4fcaea6b154a0bbd917fba61d92e52_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzItMS0xLTEtNTA3MjU_85e9978d-1075-4f46-b0a0-446d65811911">435.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6c3d510a20748ce9ea87e61c6e92cc4_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzItMy0xLTEtNTA3MjU_75eb04fa-cc09-44a1-a6e9-a9ccff90f763">447.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="iacc4528c818b4326ae050e255a5a7a3e_I20221231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzMtMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjpjMTMxNzdmODZmOTM0NTZiYjRhMjZmNWEzZjQxZjUzNV80_a7fbab19-8102-4d7d-8251-ac1b7e248d32">550.0</ix:nonFraction> million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate; due <ix:nonNumeric contextRef="idc761fea5e584f6080ec28aa409e26d2_D20220101-20221231" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzMtMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjpjMTMxNzdmODZmOTM0NTZiYjRhMjZmNWEzZjQxZjUzNV8xNTE_5cabf2f8-87ab-4bc4-b119-ba4f94d1ac91">July&#160;30, 2026</ix:nonNumeric></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacc4528c818b4326ae050e255a5a7a3e_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzMtMS0xLTEtNTA3MjU_634c6356-2fd3-4869-a4d1-47b10a448c22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b6a940fe41e4c4e9bd71fc532b5f27c_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzMtMy0xLTEtNTA3MjU_1b49b624-ca46-4b88-864e-899c14ac297f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Promissory notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ebd597356dc40a6baa7eabf9da5fb56_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzQtMS0xLTEtNTA3MjU_8c949f9e-d34e-467a-bb54-2d93eafa1ae0">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bb00aa3ab56488ea6e59211d0ec0f49_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzQtMy0xLTEtNTA3MjU_e70c2811-d061-43de-9c7b-c10c0c9a4912">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id86557107c34492d8c132ad64570a3ed_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzUtMS0xLTEtNTA3MjU_9ed7270d-f5e0-4346-9cc1-8d3797875d88">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbdaead26d8b4e69b17a84ea4692f399_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzUtMy0xLTEtNTA3MjU_4a9cfbbe-07a1-42c0-9c8f-5dd4ec858fb9">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzYtMS0xLTEtNTA3MjU_569ef6c5-8348-48ca-84ca-08182c519e8e">438.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzYtMy0xLTEtNTA3MjU_75ec4add-9657-4e90-964c-7b730ec27e20">449.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzctMS0xLTEtNTA3MjU_5795987d-440c-4fc9-8d7a-3f7ffb0bdaf3">3.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzctMy0xLTEtNTA3MjU_0a0d5dba-bd3e-4f4b-84c2-eb4358614a2f">4.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzgtMS0xLTEtNTA3MjU_02d5ab3a-c804-4c5e-9831-838d13286391">434.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzgtMy0xLTEtNTA3MjU_ba297cda-8f51-4506-bc68-0ef22f7b1140">445.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzktMS0xLTEtNTA3MjU_428fe96a-4815-4ac6-b964-ae7e8467651a">15.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzktMy0xLTEtNTA3MjU_f0e939c9-7ff7-427c-bf71-93580331688d">13.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations, less current portion</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzEwLTEtMS0xLTUwNzI1_ac26483c-5ada-4c30-8816-dce191ac1431">419.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzEwLTMtMS0xLTUwNzI1_352248d6-e2f3-48b6-a27b-d32ee0f11b27">432.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzEwMzI4_a5a42c8b-b8cb-4f24-a16f-e5c0ec9c8703" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of debt as of December&#160;31, 2022 are as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.783%"><tr><td style="width:1.0%"></td><td style="width:72.219%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.581%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term<br/>obligations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToyNTI1NWMwZmU2MmI0NTI1OTg3NjBlMGQ0OGZmMjNkMC90YWJsZXJhbmdlOjI1MjU1YzBmZTYyYjQ1MjU5ODc2MGUwZDQ4ZmYyM2QwXzItMS0xLTEtNTA3MjU_07d102e1-4b7b-4c4f-9a98-edb1a59e689e">15.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToyNTI1NWMwZmU2MmI0NTI1OTg3NjBlMGQ0OGZmMjNkMC90YWJsZXJhbmdlOjI1MjU1YzBmZTYyYjQ1MjU5ODc2MGUwZDQ4ZmYyM2QwXzMtMS0xLTEtNTA3MjU_761dc80b-9bc2-4175-ad27-2b53e2a3e6e3">23.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToyNTI1NWMwZmU2MmI0NTI1OTg3NjBlMGQ0OGZmMjNkMC90YWJsZXJhbmdlOjI1MjU1YzBmZTYyYjQ1MjU5ODc2MGUwZDQ4ZmYyM2QwXzQtMS0xLTEtNTA3MjU_6abab13e-f7ff-4741-8a76-78dbca29d9e9">22.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToyNTI1NWMwZmU2MmI0NTI1OTg3NjBlMGQ0OGZmMjNkMC90YWJsZXJhbmdlOjI1MjU1YzBmZTYyYjQ1MjU5ODc2MGUwZDQ4ZmYyM2QwXzUtMS0xLTEtNTA3MjU_f39a4ebd-20df-4f7d-8b6b-deff213c466c">376.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToyNTI1NWMwZmU2MmI0NTI1OTg3NjBlMGQ0OGZmMjNkMC90YWJsZXJhbmdlOjI1MjU1YzBmZTYyYjQ1MjU5ODc2MGUwZDQ4ZmYyM2QwXzYtMS0xLTEtNTA3MjU_0edabb4f-b620-4b82-a92f-743cc9367b1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToyNTI1NWMwZmU2MmI0NTI1OTg3NjBlMGQ0OGZmMjNkMC90YWJsZXJhbmdlOjI1MjU1YzBmZTYyYjQ1MjU5ODc2MGUwZDQ4ZmYyM2QwXzctMS0xLTEtNTA3MjU_d1df1a4e-96e2-43c0-8cdb-6131287075fc">438.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Agreement</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 29, 2018, we entered into our Amended and Restated Credit Agreement (the "Credit Agreement") which provided for a senior secured revolving credit facility in an initial aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="i178263b3689c4dbeb4183a1b2a8f06f4_I20180629" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzQyMQ_57909d38-6ee1-46ec-b342-951a7852c89f">550.0</ix:nonFraction> million (the "Revolving Credit Facility"). The Revolving Credit Facility provided for and included within its $<ix:nonFraction unitRef="usd" contextRef="i178263b3689c4dbeb4183a1b2a8f06f4_I20180629" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzUyNg_8326705a-6c90-4bae-8dde-e6b68b13a5dc">550.0</ix:nonFraction> million limit a $<ix:nonFraction unitRef="usd" contextRef="i204f7f8314234638a578a2852af0430f_I20180629" decimals="-5" name="amed:SwingLineFacility" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzUzNw_26b74d87-74cd-4b31-8088-fa2dcb90ce0a">25.0</ix:nonFraction> million swingline facility and commitments for up to $<ix:nonFraction unitRef="usd" contextRef="i204f7f8314234638a578a2852af0430f_I20180629" decimals="-5" name="amed:LettersofCreditmaximumcommitment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzU4NQ_1259dd31-0205-42eb-bf09-4ea3a6100a02">60.0</ix:nonFraction> million in letters of credit. Upon lender approval, we could increase the aggregate loan amount under the Revolving Credit Facility by $<ix:nonFraction unitRef="usd" contextRef="i178263b3689c4dbeb4183a1b2a8f06f4_I20180629" decimals="-5" name="amed:LineOfCreditFacilityAdditionalBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzcxNQ_db4bc905-3db1-40dd-9214-9a6e7d422c38">125.0</ix:nonFraction> million plus an unlimited amount subject to a leverage limit of <ix:nonFraction unitRef="number" contextRef="i178263b3689c4dbeb4183a1b2a8f06f4_I20180629" decimals="INF" name="amed:CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzc3NA_93c39499-2fcc-4869-b1bf-4119612139d2">0.5</ix:nonFraction>x under the maximum allowable consolidated leverage ratio which was <ix:nonFraction unitRef="number" contextRef="i178263b3689c4dbeb4183a1b2a8f06f4_I20180629" decimals="0" name="amed:Creditfacilitymaximumallowableconsolidatedleverageratio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzg0NA_412685a2-98a8-4bf2-a8e1-5a79aa1c14f8">3.0</ix:nonFraction>x per the Credit Agreement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final maturity of the Revolving Credit Facility was <ix:nonNumeric contextRef="i76cb131f8a16465eb2fc15903e2b579d_D20180629-20180629" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzkzMA_3cc4526f-c730-4648-8748-253d9831a0e8">June 29, 2023</ix:nonNumeric>, and there was no mandatory amortization on the outstanding principal balances which were payable in full upon maturity. The Revolving Credit Facility was used to provide </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></div><ix:continuation id="i280e4fa04abb4e40968ec4a6e87adbff" continuedAt="id9933e69ef6f4f6ba3f4b410f51362af"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ongoing working capital needs and for general corporate purposes of the Company and our subsidiaries, including permitted acquisitions, as defined in the Credit Agreement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">First Amendment to the Credit Agreement</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 4, 2019, we entered into the First Amendment to the Credit Agreement (as amended by the First Amendment, the &#8220;Amended Credit Agreement&#8221;). The Amended Credit Agreement provided for a senior secured credit facility in an initial aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="ic1af0127cb3643d8b17864fcb195bfd5_I20190204" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzE1OTE_e909783f-6dfb-4ccf-8d13-11e7979fad81">725.0</ix:nonFraction> million, which included the $<ix:nonFraction unitRef="usd" contextRef="ic1af0127cb3643d8b17864fcb195bfd5_I20190204" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzE2MTQ_e3488dce-ad77-4da3-8d70-931393c5aa10">550.0</ix:nonFraction> million Revolving Credit Facility under the Credit Agreement, and a term loan facility with a principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="i3178979288cb4514826472f72e5bfb60_I20190204" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzE3Mjk_68b60548-ca58-40d3-a3eb-6a6bf1f6b938">175.0</ix:nonFraction> million (the &#8220;Term Loan Facility&#8221; and collectively with the Revolving Credit Facility, the &#8220;Credit Facility&#8221;), which was added by the First Amendment.  </span></div><div style="margin-top:5pt;padding-right:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We borrowed the entire principal amount of the Term Loan Facility on February&#160;4, 2019 in order to fund a portion of the purchase price of the Compassionate Care Hospice ("CCH") acquisition, with the remainder of the purchase price and associated transactional fees and expenses funded by proceeds from the Revolving Credit Facility. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Second Amendment to the Credit Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 30, 2021, we entered into the Second Amendment to our Credit Agreement (as amended by the Second Amendment, the "Second Amended Credit Agreement"). The Second Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="iba0cc26b6786477a93c245c64b48976e_I20210730" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzI1NDA_24ac59bd-c7cc-4d7c-9453-e4ba41ffb73b">1.0</ix:nonFraction>&#160;billion, which includes the $<ix:nonFraction unitRef="usd" contextRef="iba0cc26b6786477a93c245c64b48976e_I20210730" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzI1NjM_a9333e02-274b-4fbe-a250-80e17149b262">550.0</ix:nonFraction>&#160;million Revolving Credit Facility and a term loan facility with a principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="i1bb8d308c9224e5b844d2c6db275e492_I20210730" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzI2NTA_2fc31aa8-1c59-459f-a009-0814712e8fd3">450.0</ix:nonFraction>&#160;million (the "Amended Term Loan Facility" and collectively with the Revolving Credit Facility, the "Amended Credit Facility").</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net proceeds from the $<ix:nonFraction unitRef="usd" contextRef="i1bb8d308c9224e5b844d2c6db275e492_I20210730" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzI3OTQ_51b5bbd1-16d2-4252-b486-cdc20c4e76fa">450.0</ix:nonFraction>&#160;million Amended Term Loan Facility were used to fund the Contessa acquisition. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The loans issued under the Amended Credit Facility bear interest on a per annum basis, at our election, at either: (i) the Base Rate plus the Applicable Rate or (ii) the Eurodollar Rate plus the Applicable Rate. The &#8220;Base Rate&#8221; means a fluctuating rate per annum equal to the highest of (a) the federal funds rate plus <ix:nonFraction unitRef="number" contextRef="ia3eb443904904bc78906ce21c0d215af_D20210730-20210730" decimals="INF" name="amed:DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzMxODg_cae4e17f-a083-44dc-8e27-225703f6099a">0.50</ix:nonFraction>% per annum, (b)&#160;the prime rate of interest established by the Administrative Agent, and (c)&#160;the Eurodollar Rate plus <ix:nonFraction unitRef="number" contextRef="ia3eb443904904bc78906ce21c0d215af_D20210730-20210730" decimals="INF" name="amed:DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzMzMDc_9c41b9ae-ea96-4de8-b01f-80fa4337f20a">1</ix:nonFraction>% per annum. The &#8220;Eurodollar Rate&#8221; means the quoted rate per annum equal to the London Interbank Offered Rate ("LIBOR") or a comparable successor rate approved by the Administrative Agent for an interest period of one, three or six months (as selected by us). <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzEwMzQx_3fef4def-69a3-4975-854b-e13562ab41cc" continuedAt="i07db2adc6c3d4d56804d3c7d4d0727ef" escape="true">The &#8220;Applicable Rate&#8221; is based on the consolidated leverage ratio and is presented in the table below. As of December&#160;31, 2022, the Applicable Rate is <ix:nonFraction unitRef="number" contextRef="i07211fe9ad5d4482bd6b137633c2aa1d_D20220101-20221231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzM2OTk_e630da29-2351-45c0-b67b-9eb0d7937d4c">0.50</ix:nonFraction>% per annum for Base Rate Loans and <ix:nonFraction unitRef="number" contextRef="ida7bcb808f0e4c318ec059d9ceff470a_D20220101-20221231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzM3MzY_a979c016-179b-453c-9363-82e357538f73">1.50</ix:nonFraction>% per annum for Eurodollar Rate Loans. Our Second Amended Credit Agreement provides for the replacement of LIBOR with the daily or term secured overnight financing rate ("SOFR") whenever LIBOR is discontinued. We are also subject to a commitment fee and letter of credit fee under the terms of the Second Amended Credit Agreement, as presented in the table below.</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="i07db2adc6c3d4d56804d3c7d4d0727ef"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pricing Tier</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Leverage Ratio</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Base Rate Loans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eurodollar Rate Loans and Daily Floating LIBOR Rate Loans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commitment<br/>Fee</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Letter&#160;of<br/>Credit&#160;Fee</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">I</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&gt;  <ix:nonFraction unitRef="number" contextRef="iaa67d7d55667443394ca159d57aa511b_D20220101-20221231" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzEtMS0xLTEtNTA3MjUvdGV4dHJlZ2lvbjo1NTlkY2ZjMGM2Njk0NGQzYjQwZDdiOGY5MTU3NzNhOV83_59c520fb-d129-4d3f-a1e2-1d45aaa78eb0">3.00</ix:nonFraction> to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ice4835f824f5444f94f1ecd506168658_D20220101-20221231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzEtMy0xLTEtNTA3MjU_bd39f2af-cb1d-474c-b70a-90beff89fdbf">1.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie35e7d51c69e442a9aaed895a70d075f_D20220101-20221231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzEtNS0xLTEtNTA3MjU_68b1d1de-8fff-441a-bb1b-01f327d53c53">2.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ife65de97c43c4ff38decb113044c4058_D20220101-20221231" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzEtNy0xLTEtNTA3MjU_3d426991-3762-452e-a277-1cbb0d4b8e7a">0.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ife65de97c43c4ff38decb113044c4058_D20220101-20221231" decimals="INF" name="amed:LetterOfCreditFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzEtOS0xLTEtNTA3MjU_f4e32285-64ca-4983-bfff-c6a4f26b0958">1.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">II</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> <ix:nonFraction unitRef="number" contextRef="i3f84542d7b53490e9e21f12a81a49347_D20220101-20221231" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzItMS0xLTEtNTA3MjUvdGV4dHJlZ2lvbjo3M2ZjOTA0MTE4Mzk0NjllYWVjMTIwYTI2M2Q0MTlkZV82_f5c8a9a9-f3cc-41f7-8c13-acda42f96769">3.00</ix:nonFraction> to 1.0 but &gt;&#160;<ix:nonFraction unitRef="number" contextRef="i5ca3fedd3e1b4c93a4622a8fb6dc1a1e_D20220101-20221231" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzItMS0xLTEtNTA3MjUvdGV4dHJlZ2lvbjo3M2ZjOTA0MTE4Mzk0NjllYWVjMTIwYTI2M2Q0MTlkZV8yMg_e7f8ba83-5fe7-4955-aa75-83eb8517d38b">2.00</ix:nonFraction> to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i17742e3ab61d4196b516dfbe59d556fd_D20220101-20221231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzItMy0xLTEtNTA3MjU_5d1810cf-6bbf-46c9-8aed-696928f14d0c">0.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib6d924aa96d649d1b106241f0f9d3dc6_D20220101-20221231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzItNS0xLTEtNTA3MjU_81661eee-acab-4ef0-a657-19d1c0789763">1.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibf4da83d5cea4929a377d16e2a794965_D20220101-20221231" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzItNy0xLTEtNTA3MjU_996aab97-33c7-4204-8ae2-06740fc720a2">0.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibf4da83d5cea4929a377d16e2a794965_D20220101-20221231" decimals="INF" name="amed:LetterOfCreditFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzItOS0xLTEtNTA3MjU_56485003-e412-42ab-b611-031761023e7b">1.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">III</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> <ix:nonFraction unitRef="number" contextRef="i96a9d31440c94da5a965cfe8fea3f233_D20220101-20221231" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzMtMS0xLTEtNTA3MjUvdGV4dHJlZ2lvbjphZDVlMDhmYmQzMzc0ZmI1ODAyNWU2ZGQ4NDhkZWQyMV82_098954f3-c756-4b12-b646-ed0f31b541ba">2.00</ix:nonFraction> to 1.0 but &gt;&#160;<ix:nonFraction unitRef="number" contextRef="i0e09b2632feb4e60a63f4f0811a7e6f8_D20220101-20221231" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzMtMS0xLTEtNTA3MjUvdGV4dHJlZ2lvbjphZDVlMDhmYmQzMzc0ZmI1ODAyNWU2ZGQ4NDhkZWQyMV8yMg_dc954696-f6ed-40cc-ad23-c7f3d2b401d6">0.75</ix:nonFraction> to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie6453a68ab024f0481790410c647ca02_D20220101-20221231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzMtMy0xLTEtNTA3MjU_003cf89b-81fb-4c35-a8ed-572e4c07b0f0">0.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia3fe9ab766bf4b6aac1a8ef448a228af_D20220101-20221231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzMtNS0xLTEtNTA3MjU_c775e579-3aa6-44f4-aed7-dc0719df072d">1.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0fb8d922ed7840eba4d9f5c8439d8634_D20220101-20221231" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzMtNy0xLTEtNTA3MjU_64a40c12-b015-4ba8-93a1-910593d47607">0.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0fb8d922ed7840eba4d9f5c8439d8634_D20220101-20221231" decimals="INF" name="amed:LetterOfCreditFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzMtOS0xLTEtNTA3MjU_97403a81-b38e-4c7c-813d-2f0b33101875">1.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IV</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  <ix:nonFraction unitRef="number" contextRef="i6144bb4d6ba64536b8a021e88b94f277_D20220101-20221231" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzQtMS0xLTEtNTA3MjUvdGV4dHJlZ2lvbjozMTE5ZDI4ZWRjOGQ0ZTViYTg3YmIzZWI3MWU3N2UyZF83_01490d3a-d660-44e5-9dbd-e1c20fc19c1f">0.75</ix:nonFraction> to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia5b4115d16ee4985a95f2ba4f5411a8b_D20220101-20221231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzQtMy0xLTEtNTA3MjU_4453e99f-08ed-4fd1-b0cd-160bd8a5aab6">0.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icb4d003ebe754bc288a304ab991ccff7_D20220101-20221231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzQtNS0xLTEtNTA3MjU_a90808f3-9147-4118-94ae-65e40dec1c32">1.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i346c9bba84d040c583bc1c161bbc63a2_D20220101-20221231" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzQtNy0xLTEtNTA3MjU_c4335a87-adc0-4670-a173-918fc853d87f">0.15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i346c9bba84d040c583bc1c161bbc63a2_D20220101-20221231" decimals="INF" name="amed:LetterOfCreditFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzQtOS0xLTEtNTA3MjU_17e892f5-18e4-408b-80ad-52129262e6b2">1.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final maturity date of the Amended Credit Facility is <ix:nonNumeric contextRef="i492cad6b4f6d4dff915ecfdc41239333_D20210730-20260730" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzM5OTE_f133c67c-241d-420b-b521-8a39cad3231b">July 30, 2026</ix:nonNumeric>. The Revolving Credit Facility will terminate and be due and payable as of the final maturity date. The Amended Term Loan Facility, however, is subject to quarterly amortization of principal in the amount of (i) <ix:nonFraction unitRef="number" contextRef="i0b1fdf13b14f42838235e12dc847d78f_D20210730-20230930" decimals="5" name="amed:DebtInstrumentPeriodicPaymentPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzQyMDY_ebdc4430-065b-4555-b15f-7662dc77f707">0.625</ix:nonFraction>% for the period commencing on July 30, 2021 and ending on September 30, 2023, and (ii) <ix:nonFraction unitRef="number" contextRef="ia4e912d799f345eb811d0a45ef8aad22_D20231001-20260730" decimals="5" name="amed:DebtInstrumentPeriodicPaymentPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzQyOTU_c9593dab-de40-425f-92f3-d22fc038a7ad">1.250</ix:nonFraction>% for the period commencing on October 1, 2023 and ending on July 30, 2026. The remaining balance of the Amended Term Loan Facility must be paid upon the final maturity date. In addition to the scheduled amortization of the Amended Term Loan Facility, and subject to customary exceptions and reinvestment rights, we are required to prepay the Amended Term Loan Facility first and the Revolving Credit Facility second with 100% of all net cash proceeds received by any loan party or any subsidiary thereof in connection with (a) any asset sale or disposition where such loan party receives net cash proceeds in excess of $<ix:nonFraction unitRef="usd" contextRef="i7ac0dcfcf2f843d2ac033b98c430f309_D20210730-20210730" decimals="-6" name="amed:ProceedsReceivedFromLoanPartyOfSubsidiary" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzQ5MTY_8760e6a1-cc2c-4cdb-afab-7a1cc65f47ce">5</ix:nonFraction> million or (b) any debt issuance that is not permitted under the Second Amended Credit Agreement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Second Amended Credit Agreement requires maintenance of two financial covenants: (i) a consolidated leverage ratio of funded indebtedness to Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA"), as defined in the Second Amended Credit Agreement, and (ii) a consolidated interest coverage ratio of EBITDA to cash interest charges, as defined in the Second Amended Credit Agreement. Each of these covenants is calculated over rolling four-quarter periods and also is subject to certain exceptions and baskets. The Second Amended Credit Agreement also contains customary covenants, </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></div><ix:continuation id="id9933e69ef6f4f6ba3f4b410f51362af"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including, but not limited to, restrictions on: incurrence of liens, incurrence of additional debt, sales of assets and other fundamental corporate changes, investments and declarations of dividends. These covenants contain customary exclusions and baskets as detailed in the Second Amended Credit Agreement. In connection with our entry into the Second Amended Credit Agreement during the year ended December 31, 2021, we recorded $<ix:nonFraction unitRef="usd" contextRef="ie72df9520c04416783c5c1351b95aa45_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzYwMDU_2f8895e2-bb87-416f-8268-2e9fde4e1c89">2.8</ix:nonFraction> million in deferred debt issuance costs as long-term obligations, less current portion within our consolidated balance sheet.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Credit Facility is guaranteed by substantially all of our wholly-owned direct and indirect subsidiaries. The Second Amended Credit Agreement requires at all times that we (i) provide guarantees from wholly-owned subsidiaries that in the aggregate represent not less than <ix:nonFraction unitRef="number" contextRef="ia3eb443904904bc78906ce21c0d215af_D20210730-20210730" decimals="2" name="amed:PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzY0NTE_b72e2c08-e0f2-44a0-8583-230d52388577">95</ix:nonFraction>% of our consolidated net revenues and adjusted EBITDA from all wholly-owned subsidiaries and (ii)&#160;provide guarantees from subsidiaries that in the aggregate represent not less than <ix:nonFraction unitRef="number" contextRef="ia3eb443904904bc78906ce21c0d215af_D20210730-20210730" decimals="2" name="amed:PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzY2MzQ_27fe7ea3-fe11-4678-b2e7-3275310a58b7">70</ix:nonFraction>% of consolidated adjusted EBITDA, subject to certain exceptions.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our weighted average interest rate for borrowings under our Amended Term Loan Facility was <ix:nonFraction unitRef="number" contextRef="i3a8567395eba45968f1f59959fef3ffb_D20220101-20221231" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzY3OTU_a8a219fe-bdfa-4409-919f-956d677e37d0">3.2</ix:nonFraction>% for the year ended December 31, 2022 and <ix:nonFraction unitRef="number" contextRef="if7b0d6790e424eb28816c7faa3cbcaf5_D20210101-20211231" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzY4Mzk_f5313785-5d94-4525-9f92-7fd21d301e8b">1.6</ix:nonFraction>% for the year ended December&#160;31, 2021. Our weighted average interest rate for borrowings under our $<ix:nonFraction unitRef="usd" contextRef="iacc4528c818b4326ae050e255a5a7a3e_I20221231" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzY5NDA_a00ebbb7-62c0-403b-8033-59054eacb8a0">550.0</ix:nonFraction> million Revolving Credit Facility was <ix:nonFraction unitRef="number" contextRef="idc761fea5e584f6080ec28aa409e26d2_D20220101-20221231" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzY5NzM_8d1a3a84-22df-4efe-9477-c34d47a9bf69">3.4</ix:nonFraction>% for the year ended December 31, 2022 and <ix:nonFraction unitRef="number" contextRef="i31b64bb9856d4b7ab6ed7600628a1276_D20210101-20211231" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzcwMTc_dbbf6ca9-f5a0-4e05-abd5-561dd11cb71e">1.9</ix:nonFraction>% for the year ended December 31, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, our consolidated leverage ratio was <ix:nonFraction unitRef="number" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="INF" name="amed:TotalLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzcxMDQ_f97234c6-92fe-4456-a8b3-1ec79ce856ad">1.7</ix:nonFraction>, our consolidated interest coverage ratio was <ix:nonFraction unitRef="number" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="1" name="amed:ConsolidatedInterestCoverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzcxNTM_bffdadfc-cb11-489f-9c03-ef3474ed91ae">11.6</ix:nonFraction> and we are in compliance with our covenants under the Second Amended Credit Agreement. In the event we are not in compliance with our debt covenants in the future, we would pursue various alternatives in an attempt to successfully resolve the non-compliance, which might include, among other things, seeking debt covenant waivers or amendments.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, our availability under our $<ix:nonFraction unitRef="usd" contextRef="iacc4528c818b4326ae050e255a5a7a3e_I20221231" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzc1Mzg_2adbcc0a-44d5-4681-8180-e37e7764a852">550.0</ix:nonFraction> million Revolving Credit Facility was $<ix:nonFraction unitRef="usd" contextRef="iacc4528c818b4326ae050e255a5a7a3e_I20221231" decimals="-5" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzc1NzE_ab99e8e9-1efb-4b11-87ff-b91b73579634">520.4</ix:nonFraction> million as we have no outstanding borrowings and $<ix:nonFraction unitRef="usd" contextRef="ib5660c9b896a4ecaa1234048bbedeafa_I20221231" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzc2MTU_247e82bd-7699-489c-9285-71ac74c7d7a9">29.6</ix:nonFraction> million outstanding in letters of credit.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Joinder Agreements</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the CCH acquisition, we entered into a Joinder Agreement, dated as of February 4, 2019 (the &#8220;CCH Joinder&#8221;), pursuant to which CCH and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement (now the Second Amended Credit Agreement), the Amended and Restated Security Agreement, dated as of June 29, 2018 (the &#8220;Amended and Restated Security Agreement&#8221;), and the Amended and Restated Pledge Agreement, dated as of June 29, 2018 (the &#8220;Amended and Restated Pledge Agreement&#8221;). In connection with the AseraCare acquisition, we entered into a Joinder Agreement, dated as of June 12, 2020, pursuant to which the AseraCare entities were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement (now the Second Amended Credit Agreement), the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement (the &#8220;AseraCare Joinder"). In connection with the Contessa acquisition and the Second Amendment, we entered into a Joinder Agreement, dated as of September 3, 2021, pursuant to which Contessa and its subsidiaries and Asana, which we acquired on January 1, 2020, and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Second Amended Credit Agreement, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement (the &#8220;Contessa and Asana Joinder,&#8221; and together with the CCH Joinder and the AseraCare Joinder, the &#8220;Joinders&#8221;). </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the Joinders, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement, CCH and its subsidiaries, the AseraCare entities, Contessa and its subsidiaries and Asana and its subsidiaries granted in favor of the Administrative Agent a first lien security interest in substantially all of their personal property assets and pledged to the Administrative Agent each of their respective subsidiaries' issued and outstanding equity interests. CCH and its subsidiaries, the AseraCare entities, Contessa and its subsidiaries and Asana and its subsidiaries also guaranteed our obligations, whether now existing or arising after the respective effective dates of the Joinders, under the Second Amended Credit Agreement pursuant to the terms of the Joinders and the Second Amended Credit Agreement.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Promissory Notes</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our outstanding promissory note totaling $<ix:nonFraction unitRef="usd" contextRef="i2ebd597356dc40a6baa7eabf9da5fb56_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzEwMDky_4caed8d3-fc12-49a3-966e-ccdc7a765535">0.2</ix:nonFraction>&#160;million, obtained through the acquisition of Contessa on August 1, 2021, bears an interest rate of <ix:nonFraction unitRef="number" contextRef="i2ebd597356dc40a6baa7eabf9da5fb56_I20221231" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzEwMTk5_8c161f97-8abe-4370-8b93-9085e0a2f35a">6.5</ix:nonFraction>%.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finance Leases</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our outstanding finance leases totaling $<ix:nonFraction unitRef="usd" contextRef="id86557107c34492d8c132ad64570a3ed_I20221231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzEwMjUy_10e36389-eb08-4a79-b57c-f6df36405602">2.3</ix:nonFraction> million relate to leased equipment and bear interest rates ranging from <ix:nonFraction unitRef="number" contextRef="i41fd72dfb82543b4af87db7a75cd295a_I20221231" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzEwMzE5_67644588-3fdc-4184-ab4b-04a91d2dfa0c">2.1</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="if39b026dc9a34fbe996e7be93272debd_I20221231" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzEwMzI1_74292f5a-5f52-4281-a38a-c75fc1413ca3">5.3</ix:nonFraction>%.</span></div></ix:continuation><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><div id="i5c10b724a6674979bf3c35a339f29685_118"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzgyMzA_5cf298cd-3672-4d35-9935-802907962b8b" continuedAt="i8d4c05515b9341bfaf63f696e83538c8" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="i8d4c05515b9341bfaf63f696e83538c8" continuedAt="ic36489df294e4c47b88e63833dd2c77f"><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="amed:ProvisionforIncomeTaxesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzgyNDE_cb37171b-dc73-4fc5-aaf8-1f0b84ef5835" escape="true"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes attributable to continuing operations consist of the following (amounts in millions):</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income tax expense/(benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzMtMS0xLTEtNTA3MjU_3c9bf7da-1b2c-43bf-a397-71fd9b743687">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzMtMy0xLTEtNTA3MjU_047861e4-918d-47e3-87bf-87095bba23fc">20.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzMtNS0xLTEtNTA3MjU_bf828ecd-8d05-431f-b787-169c925199a3">41.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzQtMS0xLTEtNTA3MjU_1ee3d975-6a37-499a-8d97-b87961794401">7.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzQtMy0xLTEtNTA3MjU_c71890f3-aa78-4cf7-b74d-7c0d9d3d6c4f">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzQtNS0xLTEtNTA3MjU_0433b15a-a284-433f-8730-8ee769a95ced">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzUtMS0xLTEtNTA3MjU_f1b331a7-a73b-4e2b-aa5a-77594e15d311">19.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzUtMy0xLTEtNTA3MjU_0a4d1676-6170-45f1-b9a7-d12ac86a52e2">25.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzUtNS0xLTEtNTA3MjU_a618055d-79bc-4ca3-be93-9c8fd54e450b">52.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax expense/(benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzctMS0xLTEtNTA3MjU_567e5191-96ae-41dc-9b87-53bec15cd305">20.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzctMy0xLTEtNTA3MjU_764651a7-4829-46b8-8421-13bf0eb6ce92">35.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzctNS0xLTEtNTA3MjU_a855cc3f-54c3-4b49-90f9-1cfe6c4b1248">22.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzgtMS0xLTEtNTA3MjU_366f8d05-934c-4fb8-b3be-f229cde66bad">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzgtMy0xLTEtNTA3MjU_c0cf6842-16cb-4820-bb5a-53f0d84f6dea">8.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzgtNS0xLTEtNTA3MjU_25283f3c-bf2c-4afb-940c-49cebab05976">4.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzktMy0xLTEtNTA3MjU_8abe1d4d-2b16-4806-8b94-b711fab95a57">44.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzktNS0xLTEtNTA3MjU_350cdeb5-1be6-4986-af6f-7bc6de7588f4">26.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzEwLTEtMS0xLTUwNzI1_0f76f8f4-0c7b-407c-938d-3b84df643f62">42.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzEwLTMtMS0xLTUwNzI1_4869e820-2367-4090-bb09-07a4d3450416">70.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzEwLTUtMS0xLTUwNzI1_cb21f9c4-ce1c-4126-9bf1-9904d666c04e">25.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total income tax expense for the years ended December&#160;31, 2022, 2021 and 2020 was allocated as follows (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo0NmQyMjg0NzVmZjc0MWQ5OGVhMWQyZmRiZWM4MTY1Yi90YWJsZXJhbmdlOjQ2ZDIyODQ3NWZmNzQxZDk4ZWExZDJmZGJlYzgxNjViXzItMS0xLTEtNTA3MjU_3338b8c1-fa63-45f2-9ca8-47693cea4a53">42.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo0NmQyMjg0NzVmZjc0MWQ5OGVhMWQyZmRiZWM4MTY1Yi90YWJsZXJhbmdlOjQ2ZDIyODQ3NWZmNzQxZDk4ZWExZDJmZGJlYzgxNjViXzItMy0xLTEtNTA3MjU_fa963ab5-e800-4777-af56-b63f3852ec4d">70.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo0NmQyMjg0NzVmZjc0MWQ5OGVhMWQyZmRiZWM4MTY1Yi90YWJsZXJhbmdlOjQ2ZDIyODQ3NWZmNzQxZDk4ZWExZDJmZGJlYzgxNjViXzItNS0xLTEtNTA3MjU_92da1f83-4161-4d7a-99de-ddf62b4db7dc">25.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" sign="-" name="amed:IncomeTaxEffectsAllocatedToInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo0NmQyMjg0NzVmZjc0MWQ5OGVhMWQyZmRiZWM4MTY1Yi90YWJsZXJhbmdlOjQ2ZDIyODQ3NWZmNzQxZDk4ZWExZDJmZGJlYzgxNjViXzMtMS0xLTEtNTA3MjU_e9e58d5b-5648-4791-82cf-8853ecaaabe1">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="amed:IncomeTaxEffectsAllocatedToInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo0NmQyMjg0NzVmZjc0MWQ5OGVhMWQyZmRiZWM4MTY1Yi90YWJsZXJhbmdlOjQ2ZDIyODQ3NWZmNzQxZDk4ZWExZDJmZGJlYzgxNjViXzMtMy0xLTEtNTA3MjU_58d28634-e697-41a7-ab20-a822daffb554">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-5" name="amed:IncomeTaxEffectsAllocatedToInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo0NmQyMjg0NzVmZjc0MWQ5OGVhMWQyZmRiZWM4MTY1Yi90YWJsZXJhbmdlOjQ2ZDIyODQ3NWZmNzQxZDk4ZWExZDJmZGJlYzgxNjViXzMtNS0xLTEtNTA3MjU_d6a0e4e4-9f5a-48ba-ae42-8f8c93db78fe">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" sign="-" name="amed:IncomeTaxEffectsAllocatedToGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo0NmQyMjg0NzVmZjc0MWQ5OGVhMWQyZmRiZWM4MTY1Yi90YWJsZXJhbmdlOjQ2ZDIyODQ3NWZmNzQxZDk4ZWExZDJmZGJlYzgxNjViXzQtMS0xLTEtNTA3MjU_41d58ed5-80ea-47ea-b0b1-c5320d2ac29a">2.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="amed:IncomeTaxEffectsAllocatedToGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo0NmQyMjg0NzVmZjc0MWQ5OGVhMWQyZmRiZWM4MTY1Yi90YWJsZXJhbmdlOjQ2ZDIyODQ3NWZmNzQxZDk4ZWExZDJmZGJlYzgxNjViXzQtMy0xLTEtNTA3MjU_821ad2bc-764e-4b1c-b7a4-72a73e3ac9ec">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-5" name="amed:IncomeTaxEffectsAllocatedToGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo0NmQyMjg0NzVmZjc0MWQ5OGVhMWQyZmRiZWM4MTY1Yi90YWJsZXJhbmdlOjQ2ZDIyODQ3NWZmNzQxZDk4ZWExZDJmZGJlYzgxNjViXzQtNS0xLTEtNTA3MjU_4ddbafb6-f543-4260-94e0-cb9869199cbe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax expense recorded to additional paid-in-capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="amed:TaxExpenseRecordedToAdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo0NmQyMjg0NzVmZjc0MWQ5OGVhMWQyZmRiZWM4MTY1Yi90YWJsZXJhbmdlOjQ2ZDIyODQ3NWZmNzQxZDk4ZWExZDJmZGJlYzgxNjViXzUtMS0xLTEtNTczNTY_dc85fd88-4d9f-468f-a2a7-a58b571c694b">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="amed:TaxExpenseRecordedToAdditionalPaidInCapital" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo0NmQyMjg0NzVmZjc0MWQ5OGVhMWQyZmRiZWM4MTY1Yi90YWJsZXJhbmdlOjQ2ZDIyODQ3NWZmNzQxZDk4ZWExZDJmZGJlYzgxNjViXzUtMy0xLTEtNTczNTY_b9a4fdac-533b-4f05-ba3e-5c0ad937447b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-5" name="amed:TaxExpenseRecordedToAdditionalPaidInCapital" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo0NmQyMjg0NzVmZjc0MWQ5OGVhMWQyZmRiZWM4MTY1Yi90YWJsZXJhbmdlOjQ2ZDIyODQ3NWZmNzQxZDk4ZWExZDJmZGJlYzgxNjViXzUtNS0xLTEtNTczNTY_83518b34-85ba-4576-992b-1a61025776ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo0NmQyMjg0NzVmZjc0MWQ5OGVhMWQyZmRiZWM4MTY1Yi90YWJsZXJhbmdlOjQ2ZDIyODQ3NWZmNzQxZDk4ZWExZDJmZGJlYzgxNjViXzUtMS0xLTEtNTA3MjU_792dd0e2-8e9a-4981-8005-2fa184707683">40.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo0NmQyMjg0NzVmZjc0MWQ5OGVhMWQyZmRiZWM4MTY1Yi90YWJsZXJhbmdlOjQ2ZDIyODQ3NWZmNzQxZDk4ZWExZDJmZGJlYzgxNjViXzUtMy0xLTEtNTA3MjU_8d3e248c-d1e9-4b75-a7e1-5aae759d2378">73.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo0NmQyMjg0NzVmZjc0MWQ5OGVhMWQyZmRiZWM4MTY1Yi90YWJsZXJhbmdlOjQ2ZDIyODQ3NWZmNzQxZDk4ZWExZDJmZGJlYzgxNjViXzUtNS0xLTEtNTA3MjU_e74bc42f-545a-4595-9227-2966a16ba958">25.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzgyMjQ_4db665e2-6b35-4ee7-8183-6274589cb766" continuedAt="ib341f60861ec42acbac80cdff01084bf" escape="true"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of significant differences between the reported amount of income tax expense and the expected amount of income tax expense that would result from applying the U.S. federal statutory income tax rate of 21% to income before income taxes is as follows:</span></div><div style="margin-bottom:6pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense at U.S. federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzItMS0xLTEtNTA3MjU_d56eb69a-8990-41e6-aa35-ddef8246ec0b">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzItMy0xLTEtNTA3MjU_f03294d0-348b-4d12-be5d-bdd32165ca91">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzItNS0xLTEtNTA3MjU_638626ad-0d23-4127-8d75-135ebe61392c">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local income taxes, net of federal income tax benefit (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzMtMS0xLTEtNTA3MjU_72a9f8a3-aa3a-4d21-b066-c35f2e624e0b">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzMtMy0xLTEtNTA3MjU_42625313-e9be-4ac3-842f-658406f4f33e">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzMtNS0xLTEtNTA3MjU_97a588d5-c1fa-43b1-860d-a89031c1d220">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess tax benefits from share-based compensation (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="3" sign="-" name="amed:EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzQtMS0xLTEtNTA3MjU_b58b5450-228c-489c-be08-44c78843ccf0">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="3" name="amed:EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzQtMy0xLTEtNTA3MjU_c85e8f77-0467-4f26-8b24-eb3ef2afb859">2.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="3" name="amed:EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzQtNS0xLTEtNTA3MjU_d542ac48-ad5c-4b59-97de-e6cb4958637c">12.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible executive compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="3" name="amed:EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzUtMS0xLTEtNTA3MjU_fbc275f1-4718-43f4-a9c5-7d11a947df33">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="3" name="amed:EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzUtMy0xLTEtNTA3MjU_74acfedf-9d2c-4087-859a-a1a2c6f95600">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="3" name="amed:EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzUtNS0xLTEtNTA3MjU_7fbf700b-0de2-486a-a341-9eb37235eb69">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="3" sign="-" name="amed:EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzYtMS0xLTEtNTczODQ_9ce4e54d-7bd1-4523-9494-f90622b03dc9">1.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="INF" name="amed:EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzYtMy0xLTEtNTczODQ_38b776d1-394f-47cd-8b4b-51c9f109ba32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="INF" name="amed:EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzYtNS0xLTEtNTczODQ_5a229fbd-71a4-459a-9d39-a31961faa34a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items, net (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzYtMS0xLTEtNTA3MjU_409d7f31-209a-402f-9e62-c91dbcfebd97">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzYtMy0xLTEtNTA3MjU_503eefbf-b610-49f4-812a-47f7b7d900bd">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzYtNS0xLTEtNTA3MjU_f37c988f-ccf0-4fe1-9e50-2cdfeeb3f0b8">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzctMS0xLTEtNTA3MjU_f065029d-571c-44ae-8d1d-34d9a236996f">26.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzctMy0xLTEtNTA3MjU_b4609367-06c9-4259-9350-ee76ecb9725a">25.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzctNS0xLTEtNTA3MjU_e76fbfc6-428f-4f42-ad22-463e2a886e1c">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">On August 10, 2020, Paul B. Kusserow, Chief Executive Officer and Chairman of the Board of Amedisys, exercised <ix:nonFraction unitRef="shares" contextRef="if7805668b7a84f7d95cb285d7db5a548_D20200810-20200810" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzYxNA_9e82c5b9-7774-496a-a5be-1f6dee848490">500,000</ix:nonFraction> stock options previously awarded to him under our 2008 Omnibus Incentive Compensation Plan. We recognize compensation expense for stock option awards on a straight-line basis over the requisite service period for each separately vesting portion of the award in accordance with ASC 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Compensation: Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">; however, the income tax deduction related to stock options is not recognized until the stock option exercise date. As a result, for awards that are expected to result in a tax deduction, a deferred tax asset is created as the entity recognizes compensation expense for U.S. GAAP purposes. If the tax deduction exceeds the cumulative U.S. GAAP compensation expense for the award, the tax benefit associated with any excess deduction is recognized as an income tax benefit in the statement of operations, resulting in a reduction of the effective tax rate. Mr. Kusserow's stock option exercise produced a $<ix:nonFraction unitRef="usd" contextRef="i287e698cf9eb4bdfb671be9b8b48fffc_D20200101-20201231" decimals="-5" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzE1NDA_1e744815-c6da-42b3-8e09-5fb1f81d3b02">92.1</ix:nonFraction>&#160;million tax deduction in excess of U.S. GAAP compensation expense, resulting in a $<ix:nonFraction unitRef="usd" contextRef="ibace990f785a497b98867b384cd11b5f_D20200101-20201231" decimals="-5" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzE2MTc_5642e8d4-4774-44e4-b752-74caf85d818a">19.4</ix:nonFraction>&#160;million federal income tax benefit and a $<ix:nonFraction unitRef="usd" contextRef="i039df82eb47c4820a0f22e9789c65e30_D20200101-20201231" decimals="-5" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzE2NTM_2aedc580-50d5-4f4e-8d06-ba44fcf79cee">4.6</ix:nonFraction>&#160;million state and local income tax benefit for the year ended December 31, 2020.</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">For the year ended December 31, 2022, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzU0OTc1NTgyNTczNQ_79a212c0-8198-43a8-98e8-02ac3f6aad8e">2.7</ix:nonFraction>&#160;million of federal uncertain tax positions due to a lapse of the statute of limitations.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></div><ix:continuation id="ic36489df294e4c47b88e63833dd2c77f" continuedAt="i278738d191cc4649bbe983c438e28574"><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><ix:continuation id="ib341f60861ec42acbac80cdff01084bf"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Includes various items such as non-deductible expenses, non-taxable income, tax credits, valuation allowance, uncertain tax positions and return-to-accrual adjustments.</span></ix:continuation></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, the Company had income taxes receivable of $<ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzE5NTg_8b3ccb13-4682-4a94-93c5-92ceb839fded">8.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzE5NjU_359ebf5a-d1cb-46db-9306-b71e9baef8ca">8.2</ix:nonFraction> million, respectively, included in other current assets within our consolidated balance sheets. </span></div><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzgyMjk_79fe7056-ebdd-4048-9ddc-6ae082c6df4c" continuedAt="id01a8dbde87f4eb09ee2eff65650768c" escape="true"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets (liabilities) consist of the following components (amounts in millions):</span></div><div style="margin-bottom:9pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll&#160;&amp; employee benefits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzMtMS0xLTEtNTA3MjU_a1e3afc0-4395-4e00-84ad-b33ca95489c0">14.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzMtMy0xLTEtNTA3MjU_e8061607-b6e0-479c-9541-5cb28326ef51">13.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="amed:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzQtMS0xLTEtNTA3MjU_845b3f62-15b3-4af7-badd-79e6df6b67ef">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="amed:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzQtMy0xLTEtNTA3MjU_ace811a6-1dce-4056-b070-0d7d3166aced">10.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzUtMS0xLTEtNTA3MjU_53a57cc9-8ef9-4e28-8f53-ddd3ffcb0f42">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzUtMy0xLTEtNTA3MjU_1d5bc8e1-4840-4c2c-a433-8b60b395f659">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal &amp; compliance matters</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="amed:DeferredTaxAssetsLegalAndComplianceMatters" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzYtMS0xLTEtNTA3MjU_e446d865-7ee2-4f3c-953e-d0b61c191632">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="amed:DeferredTaxAssetsLegalAndComplianceMatters" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzYtMy0xLTEtNTA3MjU_bc11d3d3-3b26-4273-8f91-fd02d8bd9057">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="amed:DeferredTaxAssetsLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzctMS0xLTEtNTA3MjU_1e05f185-6075-488c-9144-8d255a753e1f">27.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="amed:DeferredTaxAssetsLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzctMy0xLTEtNTA3MjU_b5ea4ee4-3b12-413d-9fc8-fb0d7e1bf1cb">27.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred social security taxes (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="amed:DeferredTaxAssetDeferredSocialSecurityTaxes" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzktMS0xLTEtNTA3MjU_772f6682-f71c-482f-a30f-72eabfe1903b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="amed:DeferredTaxAssetDeferredSocialSecurityTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzktMy0xLTEtNTA3MjU_cc5e9c11-5f64-42cc-b5c8-de02ee478265">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsOtherLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzEwLTEtMS0xLTUwNzI1_43ec9a18-b04e-4997-a764-baaea10fba97">11.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOtherLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzEwLTMtMS0xLTUwNzI1_f454016b-bee9-45a6-baee-de81da40705b">13.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzExLTEtMS0xLTUwNzI1_d1a9093b-9f66-4a69-b289-bad9aa1bc228">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzExLTMtMS0xLTUwNzI1_5ba16ed9-8581-4df3-a94e-b7935da65b0c">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzEyLTEtMS0xLTUwNzI1_1f9453f8-1b5e-473e-852c-730d18b92353">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzEyLTMtMS0xLTUwNzI1_a117e200-1203-4866-9dde-c4083251281e">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzEzLTEtMS0xLTUwNzI1_eaaa7b4d-60d6-412e-bbfd-7c48c8a1ed9e">77.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzEzLTMtMS0xLTUwNzI1_9fa0022c-e5f8-4c7e-bf2f-ba60427e0cf3">86.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzE0LTEtMS0xLTUwNzI1_84d2abbe-750a-470d-b932-6284c3c0637f">5.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzE0LTMtMS0xLTUwNzI1_5971f631-74f0-4afd-be8a-26356a024b26">3.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzE1LTEtMS0xLTUwNzI1_85ab5afe-9390-4424-9efb-824451a75e1c">72.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzE1LTMtMS0xLTUwNzI1_dc500680-0a07-4b7e-8c9d-897b150054a9">83.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzE3LTEtMS0xLTUwNzI1_e500becd-bcc6-458a-93ac-ee4655f6e866">6.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzE3LTMtMS0xLTUwNzI1_b3df8f63-69a1-4598-b514-7052eff0dd8a">8.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="amed:DeferredTaxLiabilitiesAmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzE4LTEtMS0xLTUwNzI1_4c8b6650-f3d9-4393-b557-6de3b2a3287c">48.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="amed:DeferredTaxLiabilitiesAmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzE4LTMtMS0xLTUwNzI1_6b24db93-3520-4d66-a462-cce7619d6a43">32.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzE5LTEtMS0xLTUwNzI1_c9a1674f-bcdf-4c6d-8df2-1892eed0b6fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzE5LTMtMS0xLTUwNzI1_28897efa-4b04-42fa-8eae-1950781d2d30">4.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in partnerships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzIwLTEtMS0xLTUwNzI1_06b13f8f-fe17-46e4-aac9-2f5dc89a4350">10.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzIwLTMtMS0xLTUwNzI1_95bbc7f9-83eb-4c37-aeb1-f499eb2a78c5">10.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="amed:DeferredTaxLiabilitiesRightOfUseAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzIxLTEtMS0xLTUwNzI1_103500a7-074e-4f37-a930-a869089171bd">27.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="amed:DeferredTaxLiabilitiesRightOfUseAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzIxLTMtMS0xLTUwNzI1_0c33ab22-7641-4115-b471-aa54627fb4d2">26.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzIyLTEtMS0xLTUwNzI1_353fbf70-1ed5-4b9d-a536-9e2e1d4cd0a0">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzIyLTMtMS0xLTUwNzI1_ef393146-c9d2-4b8a-97af-e8f60ab0d11d">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:DeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzIzLTEtMS0xLTUwNzI1_bd197593-a32a-442a-8adc-582bacb87d0d">92.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzIzLTMtMS0xLTUwNzI1_3856af32-830a-45ba-839f-8c7d420bbe89">83.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzI0LTEtMS0xLTUwNzI1_ec14ab20-f5f3-4391-8f0b-66bf5a6e88d8">20.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzI0LTMtMS0xLTUwNzI1_b5496480-708f-4f75-a51a-4b81a5325324">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:14pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="id01a8dbde87f4eb09ee2eff65650768c" continuedAt="i9cb16c6a2dd24fe69591f0da38dbd95c">(1)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt"><ix:continuation id="i9cb16c6a2dd24fe69591f0da38dbd95c">The CARES Act provided for the deferral of the employer share of social security tax (6.2%), effective for payments due after the enactment date through December 31, 2020. Fifty percent of the deferred payroll taxes were due on December 31, 2021 with the remaining amounts due on December 31, 2022. As of December 31, 2021, the Company had a remaining balance of deferred social security taxes of $<ix:nonFraction unitRef="usd" contextRef="i0530cc1fa306423dba7c186bb6ab97cc_D20220101-20221231" decimals="-5" name="amed:PaymentOfDeferredSocialSecurityTaxUnderCARESAct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzMyMDY_361752d2-80dd-4df9-a86c-f0d8a0adb725"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="amed:CARESActDeferralOfEmployerShareSocialSecurityTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzMyMDY_a271d445-5ac0-4b47-8088-3dfbe72f9fa7">27</ix:nonFraction></ix:nonFraction>&#160;million, reflected within our consolidated balance sheets, which was paid in December 2022. For income tax purposes, the deferred social security taxes are deductible when paid, leaving no remaining deferred tax asset as of December 31, 2022.</ix:continuation> </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we have U.S. net operating loss (&#8220;NOL&#8221;) carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i956eb24e24e0444b86f101edaf26c1b4_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzM2MDI_2cd8ceb6-d5b6-4d94-befb-674e41ca5a17">20.9</ix:nonFraction>&#160;million that are available to reduce future taxable income and may be carried forward indefinitely. While the NOL carryforwards are not subject to expiration, the annual NOL amount that is available to offset future taxable income is subject to limitation. The NOL carryforwards were acquired as part of the stock purchase of Contessa on August 1, 2021. Under Section 382 of the Internal Revenue Code of 1986, as amended ("Section 382"), substantial changes in a Company&#8217;s ownership may limit the amount of NOL carryforwards that can be utilized annually to offset future taxable income. As a result of the ownership change, the Company determined that there is an annual limitation, pursuant to Section 382, on the amount of NOL carryforwards that may be utilized to offset future taxable income. </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we have state NOL carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i47060e74f1c24113966bf5b707b10e09_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzQ1MzM_f60c5fb0-ba4a-4bc2-a89a-72e4cbf5c876">144.7</ix:nonFraction> million that are available to reduce future taxable income and various state tax credits totaling $<ix:nonFraction unitRef="usd" contextRef="i3cc7c6096a3746f28dfa0ec43e47b91a_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxCreditsAndAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzQ1OTE_0f8a49d8-ddef-4689-a1f7-5815bd07c207">3.7</ix:nonFraction> million available to reduce future state income taxes. The state NOL and tax credit carryforwards expire at various times.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></div><ix:continuation id="i278738d191cc4649bbe983c438e28574"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, the valuation allowance for deferred tax assets, which is related to certain state NOLs, was $<ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzQ4NjU_a605dfdc-ab14-4850-bc46-6e743fd3669d">5.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzQ4NzI_17e42d78-184f-401e-b7e0-6569fa5272ae">3.3</ix:nonFraction> million, respectively. The net change in the total valuation allowance for the years ended December 31, 2022 and 2021 was an increase of $<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzUwMDQ_b608e1ff-6e1c-4d26-890a-f1e027a0f097">1.9</ix:nonFraction>&#160;million and an increase of $<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzUwMjU_609ee894-3263-4186-bb4b-e67f8da4a172">3.2</ix:nonFraction> million, respectively. The $<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzUwNDc_a7bc8912-f386-4d7e-9791-d50d2d3b5b0c">1.9</ix:nonFraction>&#160;million increase in the valuation allowance for the year ended December 31, 2022 is due to Contessa's creation of state NOL carryforwards in jurisdictions that require separate company reporting and where the Company does not expect to have sufficient separate company future taxable income available to offset the state NOL carryforwards. </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in those jurisdictions during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities (including the impact of available carryback and carryforward periods), projected future taxable income and tax-planning strategies in making this assessment. In order to fully realize the deferred tax assets, the Company will need to generate future taxable income before the expiration of the carryforwards governed by the tax code. Based on the current level of pre-tax earnings, the Company will generate the minimum amount of future taxable income needed to support the realization of the deferred tax assets. As a result, as of December 31, 2022, management believes that it is more likely than not that we will realize the benefits of these deferred tax assets, net of the existing valuation allowances. The amount of the deferred tax asset considered realizable, however, could be reduced in the near term if estimates of future taxable income during the carryforward period are reduced.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Uncertain Tax Positions</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for uncertain tax positions in accordance with the authoritative guidance for uncertain tax positions. <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzgyMjc_560ae8f6-bcce-4203-a426-01b95f1c4e3b" continuedAt="ieee079f7679a4960ad5753abe93fbade" escape="true">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (amounts in millions):</ix:nonNumeric></span></div><div style="margin-top:14pt;text-align:center"><ix:continuation id="ieee079f7679a4960ad5753abe93fbade"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzItMS0xLTEtNTA3MjU_dfe9edf9-bceb-4c37-9332-becccc91228a">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42b1e865f1ed4b2e8363dfcc39186a91_I20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzItMy0xLTEtNTA3MjU_7d81efe6-6cba-4c58-952f-89c0b9fa552f">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab144f7e34ce4a479683c59de399ff42_I20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzItNS0xLTEtNTA3MjU_abb7fce4-8fed-4eee-8352-096fd7acc676">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions for tax positions related to current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzMtMS0xLTEtNTA3MjU_9dabbf5d-7427-4021-ae24-8d917e77cbd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzMtMy0xLTEtNTA3MjU_3404922b-fb02-4c37-8a27-3e97d0825153">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzMtNS0xLTEtNTA3MjU_bfcdf2c1-e133-4cdd-bc40-9c80ff435a7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions for tax positions related to prior year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzQtMS0xLTEtNTA3MjU_477f61e6-dd65-4b34-841d-b5c19ad432e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzQtMy0xLTEtNTA3MjU_ba8ae235-e3c9-4ca7-aedf-6aea1ed76be8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzQtNS0xLTEtNTA3MjU_95baf012-2743-480e-be99-e305a2839a7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reductions for tax positions related to prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzUtMS0xLTEtNTA3MjU_2493b8ad-33e2-47b4-827a-49957b6c473e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzUtMy0xLTEtNTA3MjU_b6c3b8db-8ea0-40ec-b54f-3197862cad88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzUtNS0xLTEtNTA3MjU_7d48a60d-8a17-4d88-9bc8-879f527d35d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzYtMS0xLTEtNTA3MjU_afa36244-3fd2-4620-9bc9-5b2d2fc97905">2.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzYtMy0xLTEtNTA3MjU_d5d154bd-ec94-4667-a2ba-1e384a8b0eb5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzYtNS0xLTEtNTA3MjU_b5a39cc3-44cc-4567-9473-169446cdb97a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzctMS0xLTEtNTA3MjU_16146dcf-b323-4aa4-a33b-db66d9e84684">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzctMy0xLTEtNTA3MjU_7cd77c39-e1e0-4c35-ae01-ca606a8ced29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzctNS0xLTEtNTA3MjU_e445dbdb-125f-4697-990f-97bf2210723a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzgtMS0xLTEtNTA3MjU_98c5cb9f-519f-40a2-9cf6-bd7f35c054c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzgtMy0xLTEtNTA3MjU_6b17dd62-2082-478c-baf6-ec582c1f1d20">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42b1e865f1ed4b2e8363dfcc39186a91_I20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzgtNS0xLTEtNTA3MjU_ea84a080-a16c-4ba1-8564-a26ca9829394">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzcwMzk_9da2b196-527b-470d-ba54-b3aeb99deac7">2.7</ix:nonFraction> million of unrecognized tax benefits recorded in other long-term obligations within the consolidated balance sheets. During 2022, the statute of limitations lapsed, ultimately removing the uncertainty surrounding the Company's ability to recognize the tax positions, if challenged under audit. As a result, the Company recognized a $<ix:nonFraction unitRef="usd" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="amed:RecognizedTaxBenefitThatImpactsEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzU0OTc1NTgyNTcyMQ_7451dfc3-9bac-4a7b-9e6a-717844368bf4">2.7</ix:nonFraction>&#160;million income tax benefit and corresponding reduction in our effective tax rate for the period ended December 31, 2022.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized $<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzcyNDA_96ca500c-5c38-4d6c-9f84-05c8c31a48b4">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzcyNTE_799078a5-6bf9-4338-99a2-804cebc4866c">0.2</ix:nonFraction> million of interest as components of interest expense in connection with our reserve for uncertain tax positions during the years ended December 31, 2021 and 2020, respectively. For the period ended December 31, 2022, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="amed:BenefitAsComponentOfInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzU0OTc1NTgyNTcwNw_5d38c37c-a3d7-4808-b368-f2bd81b34cab">0.7</ix:nonFraction>&#160;million benefit as a component of interest expense, as a result of the lapse of the statute of limitations and corresponding release of the reserve for uncertain tax positions. Accrued interest related to uncertain tax positions included in the consolidated balance sheet at December 31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzc1NTk_d0a06ff0-ccba-412c-8080-4fb57d2cac99">0.7</ix:nonFraction> million. There was no accrued interest related to uncertain tax positions included in the consolidated balance sheet at December 31, 2022.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes in the U.S. and in many individual states, with significant operations in Louisiana, South Carolina, Alabama, Georgia, Massachusetts and Tennessee. We are open to examination in the U.S. and in various individual states for the tax years ended December&#160;31, 2014 through December&#160;31, 2022. We are also open to examination in various states for the years ended <ix:nonNumeric contextRef="i1fafeebfd1ab4899a21ae02fae464c83_D20220101-20221231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzgxMzA_caee6b06-d5aa-44b0-a85f-715634aef8ce">2007</ix:nonNumeric> through <ix:nonNumeric contextRef="i03c7e40c5f95416f9b140b596a1f186a_D20220101-20221231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzgxNDE_1ad1592b-ea7b-4a56-a119-b07806e32f2d">2022</ix:nonNumeric> resulting from NOLs generated and available for carryforward from those years.</span></div></ix:continuation><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><div id="i5c10b724a6674979bf3c35a339f29685_124"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzEwMTM0_a3c3d42a-ab65-4b9e-8d93-c4c4ced62484" continuedAt="i933bcbe2b0d143e99b124d4b0e5e8588" escape="true">CAPITAL STOCK AND SHARE-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="i933bcbe2b0d143e99b124d4b0e5e8588" continuedAt="i7b0b1476fffa4710aeb12d695db874a6"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are authorized by our Certificate of Incorporation to issue <ix:nonFraction unitRef="shares" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzExNQ_ef85fab0-c051-4221-a92c-da871507f45a">60,000,000</ix:nonFraction> shares of common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzE0Mg_7f61d458-365c-46b5-9d1b-e0eab095b57c">0.001</ix:nonFraction> par value and <ix:nonFraction unitRef="shares" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzE1OQ_f8650c20-8e3f-4222-a451-c3d83c24abae">5,000,000</ix:nonFraction> shares of preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzE4OQ_795e1f16-fd0c-4124-82f8-ffabf6ef4cce">0.001</ix:nonFraction> par value. As of December&#160;31, 2022, there were <ix:nonFraction unitRef="shares" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzIyNA_8f31540c-75ad-4537-8d8d-5c42eeee8531">37,891,186</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzIzMQ_3369d22c-0eca-4781-8058-887e70941fd4">32,518,278</ix:nonFraction> shares of common stock issued and outstanding, respectively, and <ix:nonFraction unitRef="shares" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzI5OQ_8c438204-5801-43b7-b2b2-fadbaf344b70">no</ix:nonFraction> shares of preferred stock issued or outstanding. Our Board of Directors is authorized to fix the dividend rights and terms, conversion and voting rights, redemption rights and other privileges and restrictions applicable to our preferred stock.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Awards</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 29, 2018, our Board of Directors and the Compensation Committee approved, subject to stockholder approval, the Amedisys, Inc. 2018 Omnibus Incentive Compensation Plan (the &#8220;2018 Plan&#8221;). On June 6, 2018, our stockholders approved the 2018 Plan at the Company's annual meeting of stockholders. The 2018 Plan replaces our 2008 Omnibus Incentive Compensation Plan (the &#8220;2008 Plan&#8221;), which terminated on June 6, 2018 when the stockholders approved the 2018 Plan. The 2018 Plan, as amended to date, authorizes the grant of various types of equity-based awards, such as stock awards, restricted stock units, stock appreciation rights and stock options to eligible participants, which include all of our employees and all employees of our <ix:nonFraction unitRef="number" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="INF" name="amed:Percentageofownershipinsubsidiaries" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzEzMDY_3306f861-0c61-413c-9419-5288e6fb06f0">50</ix:nonFraction>% or more owned subsidiaries, our non-employee directors and certain consultants. The vesting terms of the awards may be tied to continued employment (or, for our non-employee directors, continued service on the Board of Directors) and/or achievement of certain pre-determined performance goals. We refer to restricted stock units subject to service-based or a combination of service-based and performance-based vesting conditions as &#8220;non-vested stock units.&#8221; The 2018 Plan is administered by the Compensation Committee of our Board of Directors, which determines, within the provisions of the 2018 Plan, those eligible participants to whom, and the times at which, awards shall be granted. The Compensation Committee, in its discretion, may delegate its authority and duties under the 2018 Plan to specified officers; however, only the Compensation Committee may approve the terms of awards to our executive officers.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity-based awards may be granted for a number of shares not to exceed, in the aggregate, approximately <ix:nonFraction unitRef="shares" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzIzMzE_0b550b8f-b0e8-4938-ae97-fa7f6845fdcc">2.5</ix:nonFraction> million shares of common stock. We had approximately <ix:nonFraction unitRef="shares" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzIzNzk_299b467d-517d-41d8-939a-d19f7efc3b8f">1.7</ix:nonFraction> million shares available at December&#160;31, 2022. The price per share for stock options shall be no less than the greater of (a) <ix:nonFraction unitRef="number" contextRef="i9a6f6b5c67ab4519b50f44d3984d3460_D20220101-20221231" decimals="INF" name="amed:Fairvalueofshareofcommonstockpercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzI0ODU_ed639610-7d69-43eb-896c-4f4e4c37e4fd">100</ix:nonFraction>% of the fair value of a share of common stock on the date the option is granted or (b)&#160;the aggregate par value of the shares of our common stock on the date the option is granted. If a stock option is granted to any owner of <ix:nonFraction unitRef="number" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="INF" name="amed:Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzI3MTI_bb82d683-ae19-4b8f-84a5-f42a470ae63c">10</ix:nonFraction>% or more of the total combined voting power of us and our subsidiaries, the price is to be at least <ix:nonFraction unitRef="number" contextRef="i29922553b57d4a4f913d8dc9ac058907_D20220101-20221231" decimals="INF" name="amed:Fairvalueofshareofcommonstockpercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzI4MTQ_b7883d35-dde3-440a-b4ea-76adbdf24d3e">110</ix:nonFraction>% of the fair value of a share of our common stock on the date the award is granted. Each equity-based award vests ratably over a one year to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzI5NTc_223df790-b680-48db-b730-c00d1beab04b">four</span> year period, with the exception of those issued under contractual arrangements that specify otherwise, and may be exercised during a period as determined by our Compensation Committee or as otherwise approved by our Compensation Committee. The contractual terms of stock options exercised shall not exceed <ix:nonNumeric contextRef="i8f97dee560fa43f381b21ce637429d33_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzMyNjY_cfe7f456-1df9-4b34-9800-8cb21290372a">ten years</ix:nonNumeric> from the date such option is granted. The Company analyzes historical data of forfeited awards to develop an estimated forfeiture rate that is applied to the Company's non-cash compensation expense; however, all non-cash compensation expense is adjusted to reflect actual vestings and forfeitures.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan (&#8220;ESPP&#8221;)                                                                                                                                                                        </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a plan whereby our eligible employees may purchase our common stock at <ix:nonFraction unitRef="number" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzM4NTI_707fb8e8-cc52-4f4e-a14c-e7f6b141491d">85</ix:nonFraction>% of the market price at the time of purchase. The total number of shares of our common stock authorized for issuance under our ESPP is <ix:nonFraction unitRef="shares" contextRef="iabc17e0bc0164f2ab68e1dacdbd3fa3a_I20221231" decimals="-3" name="amed:CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzQxMDY_92ed2530-c724-4e06-9972-9d4a658ed879">4,500,000</ix:nonFraction>, and as of December&#160;31, 2022, there were <ix:nonFraction unitRef="shares" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="INF" name="amed:CommonStockSharesAvailableForIssuanceToEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzQxNDI_285079de-8b7e-433e-9985-cec579998610">1,264,302</ix:nonFraction> shares available for future issuance. <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzEwMTM4_5a3813c8-3ca8-4e39-ace9-48382c28d478" continuedAt="i71679451f9ff407fa82626bc6ff237be" escape="true">The following is a detail of the purchases that have been made under the plan:</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="i71679451f9ff407fa82626bc6ff237be"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employee Stock Purchase Plan Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares&#160;Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 and Prior</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaab2533120e743218b94d1ca1acd32ae_D20120607-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzEtMS0xLTEtNTA3MjU_3c8f5627-e6bb-4d98-9b81-54d4de5bbc8a">3,171,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i42b1e865f1ed4b2e8363dfcc39186a91_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzEtMy0xLTEtNTA3MjU_b1042c73-8a1b-4f7a-99a1-38b865b3295d">17.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January&#160;1, 2021 to March&#160;31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88f7ee58380e478992f80d0861c1607f_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzItMS0xLTEtNTA3MjU_adf2ca22-4a74-4b8d-a42d-bba2fbb83853">4,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id59b7e2a3058490b9b7c36016e54fda5_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzItMy0xLTEtNTA3MjU_f9b8b617-0453-467c-814b-48b6aca62110">225.07</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April&#160;1, 2021 to June&#160;30, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ab351315e174023b86cc7cc10277227_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzMtMS0xLTEtNTA3MjU_839cd8d6-9217-4854-a53b-d3202b7c79f2">5,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if75caf01fb8b4cf59e6837df49b4e315_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzMtMy0xLTEtNTA3MjU_70686f47-a51c-44fc-aa0a-7a344c99950a">208.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July&#160;1, 2021 to September&#160;30, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iadba656fc0c44917b7651f7ad78cbd0c_D20210701-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzQtMS0xLTEtNTA3MjU_00031189-f1cc-4a60-a94a-01cd95e6b807">7,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib60868f2b1d84557b45341890a39d860_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzQtMy0xLTEtNTA3MjU_be199516-d0a9-45cc-8a57-d8938095ed38">126.74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October&#160;1, 2021 to December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic5c669dea2424147a7e748e8a71c927c_D20211001-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzUtMS0xLTEtNTA3MjU_b28e7fa9-60ed-4095-aa77-2d41a5802c07">7,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzUtMy0xLTEtNTA3MjU_0703b281-e6ba-453c-a276-2ebecc8e9e50">137.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January&#160;1, 2022 to March&#160;31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4df39100e7da46d49d9439da9cf924d8_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzYtMS0xLTEtNTA3MjU_bf315c17-200e-443b-8171-fdbae778a4ab">6,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i611f679bc0fc435c9e898dad11348fcf_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzYtMy0xLTEtNTA3MjU_161cb5ae-bb7d-4c9b-a899-cd1a3cc5444e">146.45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April&#160;1, 2022 to June&#160;30, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e118c828cfd44b387ff3fef4f4d36ec_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzctMS0xLTEtNTA3MjU_e3068595-a1fa-43e6-bc2a-03a4d3eb9893">10,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i266eb829b984448ebdfabbddfb0be360_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzctMy0xLTEtNTA3MjU_50a9f05c-ee87-4f2c-8719-894e1cab6ab0">89.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July&#160;1, 2022 to September&#160;30, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide0d67cdc1d84448bde7a943cb636abd_D20220701-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzgtMS0xLTEtNTA3MjU_590ef688-5959-4fba-92c6-6707d778eeea">12,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7b2fa1ac38fb4e9f99f2949b063d86c5_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzgtMy0xLTEtNTA3MjU_6a49f249-30c5-4821-a09e-37cae68c11b9">82.27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October&#160;1, 2022 to December&#160;31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i39be0476e53e4678b7f5eebe2f65b0d1_D20221001-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzktMS0xLTEtNTA3MjU_9b51fdac-0969-4986-abc4-9a6f452c421c">11,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzktMy0xLTEtNTA3MjU_a364faf6-5fbe-4157-8ecd-29b6b7c36297">71.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7e2596f2753a45a9b4ddde231581db8b_D20120607-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzEwLTEtMS0xLTUwNzI1_fe62a704-3493-41cc-8528-45827d1841d0">3,235,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></div><ix:continuation id="i7b0b1476fffa4710aeb12d695db874a6" continuedAt="iba6edece74f44744b45ee74afe9eed73"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ESPP expense included in general and administrative expense in our accompanying consolidated statements of operations was $<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzQzODE_1531a7d9-f9ec-4932-bb0f-d313ba64b579">0.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzQzODU_d8936329-03a6-4821-91ef-4f817cc07354">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-5" name="us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzQzOTI_df7f6c74-45c3-437f-9d57-074ccf0a5732">0.6</ix:nonFraction> million for 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 10, 2020, Paul B. Kusserow, Chief Executive Officer and Chairman of the Board of Amedisys, exercised <ix:nonFraction unitRef="shares" contextRef="if7805668b7a84f7d95cb285d7db5a548_D20200810-20200810" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzQ1NTM_02728efc-1cf7-4347-8f0d-75191cacb7af">500,000</ix:nonFraction> stock options previously awarded to him under the 2008 Plan. In connection with the exercise, Mr. Kusserow surrendered <ix:nonFraction unitRef="shares" contextRef="if7805668b7a84f7d95cb285d7db5a548_D20200810-20200810" decimals="INF" name="amed:SurrenderedSharesInShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzQ2NzU_80fe980b-6a45-4aa2-90ca-74228a0e7182">231,683</ix:nonFraction> shares of common stock to us to satisfy tax withholding and strike price obligations and elected to hold the net <ix:nonFraction unitRef="shares" contextRef="if7805668b7a84f7d95cb285d7db5a548_D20200810-20200810" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzQ3OTE_c93a5a74-dca0-4a03-8291-05abddd3852f">268,317</ix:nonFraction> shares issued to him. The surrendered shares are classified as treasury shares. This transaction resulted in a cash outflow of $<ix:nonFraction unitRef="usd" contextRef="i287e698cf9eb4bdfb671be9b8b48fffc_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzQ5MjE_3c964460-50f2-427d-9afc-0848470d0b12">40.4</ix:nonFraction>&#160;million, reflected within financing activities in our consolidated statement of cash flows, related to the remittance of tax withholding obligations. In addition, Mr. Kusserow's stock option exercise resulted in a $<ix:nonFraction unitRef="usd" contextRef="i287e698cf9eb4bdfb671be9b8b48fffc_D20200101-20201231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzUxMzA_6a2f5dcb-8704-40df-bc60-4dcb8b7f7317">24.0</ix:nonFraction>&#160;million income tax benefit that was recorded in our consolidated statement of operations during the year ended December 31, 2020. See Note 10 &#8211; Income Taxes for additional details.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes option pricing model to estimate the fair value of our stock options. There were <ix:nonFraction unitRef="shares" contextRef="i06eb9ed545f04bdcbf647b341b4ab114_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzYwOTI_3827a44a-f6d7-4d65-b3df-7aca6dbe2212">33,656</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="ic8002223ee9342dbb6725f50e35539b6_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzYwOTY_ecc7f639-b972-4497-8145-36ef8048850e">40,788</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i15f9883719504dad940b79d91d5a68cf_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzYxMDM_76027059-03a3-44be-b2bb-fdd5b7e8447e">43,249</ix:nonFraction> options granted during 2022, 2021 and 2020, respectively. Stock option compensation expense included in general and administrative expense in our accompanying consolidated statements of operations was $<ix:nonFraction unitRef="usd" contextRef="i06eb9ed545f04bdcbf647b341b4ab114_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzYzMDE_0a154a01-3b6e-41ae-853b-7d5aa4f31bcd">1.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ic8002223ee9342dbb6725f50e35539b6_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzYzMDU_35feb633-5701-4a38-868a-d324304e2a9d">3.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i15f9883719504dad940b79d91d5a68cf_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzYzMTI_69c1504b-acca-439f-bcc8-a6c480157890">4.3</ix:nonFraction> million for 2022, 2021 and 2020, respectively.</span></div><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzEwMTI0_5fa37eb2-0ce2-499c-bbf5-d241a9fc9fb1" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the stock option awards were estimated using the following assumptions for 2022, 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.038%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk Free Rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i06eb9ed545f04bdcbf647b341b4ab114_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzItMS0xLTEtNTA3MjUvdGV4dHJlZ2lvbjpiNGRiODFmOWFhZDc0MWRlYTBjMTM5ODRmYWY5YjE1MF80_6c4605c7-d1c4-4259-b6aa-e512d954ad98">1.91</ix:nonFraction>% </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic8002223ee9342dbb6725f50e35539b6_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzItMy0xLTEtNTA3MjUvdGV4dHJlZ2lvbjoyNGU2ZjMyNGE0Nzc0ZTM1ODIxN2RlNDM1MDI2MTQ5MV80_d064731b-089d-4589-948d-c1ebbf53f92f">0.80</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ic8002223ee9342dbb6725f50e35539b6_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzItMy0xLTEtNTA3MjUvdGV4dHJlZ2lvbjoyNGU2ZjMyNGE0Nzc0ZTM1ODIxN2RlNDM1MDI2MTQ5MV85_c75685c6-5e13-49e9-a15e-ea8f2b2b8375">1.35</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i15f9883719504dad940b79d91d5a68cf_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzItNS0xLTEtNTA3MjUvdGV4dHJlZ2lvbjpmNDY3MDcyMDdlZWQ0YWI0YTc2NDU1ZDZhY2VlMTkyOF80_092f8f71-8f26-4989-92ad-c4e99de8fe7b">0.38</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i15f9883719504dad940b79d91d5a68cf_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzItNS0xLTEtNTA3MjUvdGV4dHJlZ2lvbjpmNDY3MDcyMDdlZWQ0YWI0YTc2NDU1ZDZhY2VlMTkyOF85_160d87bf-8137-4849-a94d-71249d7dcd2f">1.51</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i06eb9ed545f04bdcbf647b341b4ab114_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzMtMS0xLTEtNTA3MjUvdGV4dHJlZ2lvbjpjM2Y2YjhiOTEwNTM0MzZlYWE0MWJhYzNmOWQ3NzNkMl80_f16044b5-f7b0-4c63-9ded-97c0636d70bb">40.97</ix:nonFraction>% </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic8002223ee9342dbb6725f50e35539b6_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzMtMy0xLTEtNTA3MjUvdGV4dHJlZ2lvbjpkZjhiMzk0YmFhMjk0MjM1OTBjM2U4OGIxOGZiMTIwOF80_fefae255-7678-4013-9962-db156fc9a9fb">39.84</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ic8002223ee9342dbb6725f50e35539b6_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzMtMy0xLTEtNTA3MjUvdGV4dHJlZ2lvbjpkZjhiMzk0YmFhMjk0MjM1OTBjM2U4OGIxOGZiMTIwOF85_c6df0e26-247e-4cb5-9d11-3f56cfdb1272">41.40</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i15f9883719504dad940b79d91d5a68cf_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzMtNS0xLTEtNTA3MjUvdGV4dHJlZ2lvbjpjNTBiNmI2MWY1OGI0ODY2ODZjMzQ4NTE4MWZiNTI3Yl80_b0447965-1f08-42aa-a00e-92fd40e0e34b">40.15</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i15f9883719504dad940b79d91d5a68cf_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzMtNS0xLTEtNTA3MjUvdGV4dHJlZ2lvbjpjNTBiNmI2MWY1OGI0ODY2ODZjMzQ4NTE4MWZiNTI3Yl85_993d9870-8e61-4969-b647-d90d2e33e3eb">42.80</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected Term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i06eb9ed545f04bdcbf647b341b4ab114_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzQtMS0xLTEtNTA3MjU_c016387d-2d1d-4310-bd68-f4966e333509">6.25</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic8002223ee9342dbb6725f50e35539b6_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzQtMy0xLTEtNTA3MjUvdGV4dHJlZ2lvbjowOWU3MzAxYWJkZjY0MjkzOTI1NjQ1ODY5ZTZmMzNiZV80_5665c32e-941e-4334-9ad6-577133315625">6.25</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i15f9883719504dad940b79d91d5a68cf_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzQtNS0xLTEtNTA3MjUvdGV4dHJlZ2lvbjo3N2E2YzMwMzVmZDQ0MjYxYmY2YWJjNzA2MzExYTUwYV80_31211b7f-52c5-4aad-a7d4-d177d2d08702">6.25</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Fair Value</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i06eb9ed545f04bdcbf647b341b4ab114_D20220101-20221231" decimals="2" name="amed:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzUtMS0xLTEtNTA3MjU_1b6bae82-f430-474c-a7dd-a9b6a1225c94">61.31</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ic8002223ee9342dbb6725f50e35539b6_D20210101-20211231" decimals="2" name="amed:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzUtMy0xLTEtNTA3MjU_ba3c22af-8702-4ede-9c7d-1893ec30605e">107.45</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i15f9883719504dad940b79d91d5a68cf_D20200101-20201231" decimals="2" name="amed:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzUtNS0xLTEtNTA3MjU_e079b757-8017-4097-8f8a-3b42810f5b03">86.72</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend Yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i06eb9ed545f04bdcbf647b341b4ab114_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzYtMS0xLTEtNTA3MjU_ae9c62cf-142d-4ce7-a58e-b2dda8036ab9">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic8002223ee9342dbb6725f50e35539b6_D20210101-20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzYtMy0xLTEtNTA3MjU_5e360f60-f298-46f1-8b06-8d2bee67ba13">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i15f9883719504dad940b79d91d5a68cf_D20200101-20201231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzYtNS0xLTEtNTA3MjU_fe4d98c3-6400-443c-be27-75e613b0b5a7">&#8212;</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We used the simplified method to estimate the expected term for the stock options granted during 2022, 2021 and 2020 as adequate historical experience is not available to provide a reasonable estimate.</span></div><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzEwMTQz_d5c1d705-1f6c-48d7-85fa-2e177ad64c0c" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our stock option activity for 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:54.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.297%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average&#160;Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average&#160;Contractual<br/>Life&#160;(Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding options at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo1YzcxNGQ1OTcwNTY0ZTk3YTg2OTVhMjMxNTE4YWJlMi90YWJsZXJhbmdlOjVjNzE0ZDU5NzA1NjRlOTdhODY5NWEyMzE1MThhYmUyXzEtMS0xLTEtNTA3MjU_ff1d905e-942b-4e1a-943e-f684afe0a373">273,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo1YzcxNGQ1OTcwNTY0ZTk3YTg2OTVhMjMxNTE4YWJlMi90YWJsZXJhbmdlOjVjNzE0ZDU5NzA1NjRlOTdhODY5NWEyMzE1MThhYmUyXzEtMy0xLTEtNTA3MjU_c975ba88-c512-4060-b9bd-bd9f5d1b9061">137.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo1YzcxNGQ1OTcwNTY0ZTk3YTg2OTVhMjMxNTE4YWJlMi90YWJsZXJhbmdlOjVjNzE0ZDU5NzA1NjRlOTdhODY5NWEyMzE1MThhYmUyXzEtNS0xLTEtNTA3MjU_2b8955b3-c568-48ab-87d2-a95a10bda660">7.21</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo1YzcxNGQ1OTcwNTY0ZTk3YTg2OTVhMjMxNTE4YWJlMi90YWJsZXJhbmdlOjVjNzE0ZDU5NzA1NjRlOTdhODY5NWEyMzE1MThhYmUyXzItMS0xLTEtNTA3MjU_109af690-cba1-4c79-a1cb-d54d0a630b25">33,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo1YzcxNGQ1OTcwNTY0ZTk3YTg2OTVhMjMxNTE4YWJlMi90YWJsZXJhbmdlOjVjNzE0ZDU5NzA1NjRlOTdhODY5NWEyMzE1MThhYmUyXzItMy0xLTEtNTA3MjU_3750a641-8a40-45c4-b1aa-db9088a4418c">143.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo1YzcxNGQ1OTcwNTY0ZTk3YTg2OTVhMjMxNTE4YWJlMi90YWJsZXJhbmdlOjVjNzE0ZDU5NzA1NjRlOTdhODY5NWEyMzE1MThhYmUyXzMtMS0xLTEtNTA3MjU_00fac2ed-fb6a-4e11-bd82-9a99c305dada">37,635</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo1YzcxNGQ1OTcwNTY0ZTk3YTg2OTVhMjMxNTE4YWJlMi90YWJsZXJhbmdlOjVjNzE0ZDU5NzA1NjRlOTdhODY5NWEyMzE1MThhYmUyXzMtMy0xLTEtNTA3MjU_29d1e22b-6ca3-46ac-8960-f394e958a2e6">61.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled, forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo1YzcxNGQ1OTcwNTY0ZTk3YTg2OTVhMjMxNTE4YWJlMi90YWJsZXJhbmdlOjVjNzE0ZDU5NzA1NjRlOTdhODY5NWEyMzE1MThhYmUyXzQtMS0xLTEtNTA3MjU_75520116-666c-4010-9e6a-c127db297ec1">51,382</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo1YzcxNGQ1OTcwNTY0ZTk3YTg2OTVhMjMxNTE4YWJlMi90YWJsZXJhbmdlOjVjNzE0ZDU5NzA1NjRlOTdhODY5NWEyMzE1MThhYmUyXzQtMy0xLTEtNTA3MjU_8244fc49-3ec0-481e-bba6-8bb9500913c7">174.57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding options at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo1YzcxNGQ1OTcwNTY0ZTk3YTg2OTVhMjMxNTE4YWJlMi90YWJsZXJhbmdlOjVjNzE0ZDU5NzA1NjRlOTdhODY5NWEyMzE1MThhYmUyXzUtMS0xLTEtNTA3MjU_a89e4a13-1434-46f7-a901-a5bb47b991e9">218,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo1YzcxNGQ1OTcwNTY0ZTk3YTg2OTVhMjMxNTE4YWJlMi90YWJsZXJhbmdlOjVjNzE0ZDU5NzA1NjRlOTdhODY5NWEyMzE1MThhYmUyXzUtMy0xLTEtNTA3MjU_d0e7d9d7-19f6-484b-aded-41ffff91fe94">142.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo1YzcxNGQ1OTcwNTY0ZTk3YTg2OTVhMjMxNTE4YWJlMi90YWJsZXJhbmdlOjVjNzE0ZDU5NzA1NjRlOTdhODY5NWEyMzE1MThhYmUyXzUtNS0xLTEtNTA3MjU_b2db7a41-af5d-4386-847c-8f0c8850489e">6.56</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercisable options at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo1YzcxNGQ1OTcwNTY0ZTk3YTg2OTVhMjMxNTE4YWJlMi90YWJsZXJhbmdlOjVjNzE0ZDU5NzA1NjRlOTdhODY5NWEyMzE1MThhYmUyXzYtMS0xLTEtNTA3MjU_95748358-0963-4e46-b7af-88666970317c">163,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo1YzcxNGQ1OTcwNTY0ZTk3YTg2OTVhMjMxNTE4YWJlMi90YWJsZXJhbmdlOjVjNzE0ZDU5NzA1NjRlOTdhODY5NWEyMzE1MThhYmUyXzYtMy0xLTEtNTA3MjU_c2f5893a-52d4-4129-a005-64cce3d12be2">122.54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo1YzcxNGQ1OTcwNTY0ZTk3YTg2OTVhMjMxNTE4YWJlMi90YWJsZXJhbmdlOjVjNzE0ZDU5NzA1NjRlOTdhODY5NWEyMzE1MThhYmUyXzYtNS0xLTEtNTA3MjU_dfe42436-31d2-4964-a529-4c99c9a76aaa">6.04</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of our outstanding options and exercisable options at December&#160;31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i14c451d987c9475fa3c8992bc94cbf8f_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzY3OTg_5e15d27c-c0f1-4d45-8a8b-21a2cd0c2ba1">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i14c451d987c9475fa3c8992bc94cbf8f_I20221231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzY4MDU_b0822b99-77f1-4981-8a82-3de9cbf7f3e6">0.7</ix:nonFraction> million, respectively. Total intrinsic value of options exercised was $<ix:nonFraction unitRef="usd" contextRef="i06eb9ed545f04bdcbf647b341b4ab114_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzY4NzA_cb6157bf-74a6-46b4-a8e0-ecfcc469e5d1">1.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ic8002223ee9342dbb6725f50e35539b6_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzY4NzQ_aa377f4a-4913-4348-a6c2-828cf1efaa13">5.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i15f9883719504dad940b79d91d5a68cf_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzY4ODE_789a73bd-04b6-4387-a419-2e32d43f3e3a">121.1</ix:nonFraction> million for 2022, 2021 and 2020, respectively. The tax benefit from stock options exercised during the period amounted to $<ix:nonFraction unitRef="usd" contextRef="i06eb9ed545f04bdcbf647b341b4ab114_D20220101-20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzY5OTI_d7f242c5-09a1-4304-8cb8-fdb8a460de3c">0.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ic8002223ee9342dbb6725f50e35539b6_D20210101-20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzY5OTY_646103d9-0066-4fea-a8eb-505527c6c237">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i15f9883719504dad940b79d91d5a68cf_D20200101-20201231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzcwMDM_f701659e-0139-4063-97c9-65ea16258457">27.9</ix:nonFraction> million for 2022, 2021 and 2020, respectively.</span></div><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="amed:SharedBasedPaymentArrangementNonVestedOptionActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzEwMTQ2_ef5d8f56-1b45-4330-a59d-e5f89b661ff5" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our non-vested stock option activity for 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;Average<br/>Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock options at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTozNWUzZGFhZmEzZWM0NjZlODhmODNlYTBiZjEzMWE1Yi90YWJsZXJhbmdlOjM1ZTNkYWFmYTNlYzQ2NmU4OGY4M2VhMGJmMTMxYTViXzEtMS0xLTEtNTA3MjU_809c547c-0c18-4826-9c08-33ac96d6e2bf">129,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTozNWUzZGFhZmEzZWM0NjZlODhmODNlYTBiZjEzMWE1Yi90YWJsZXJhbmdlOjM1ZTNkYWFmYTNlYzQ2NmU4OGY4M2VhMGJmMTMxYTViXzEtMy0xLTEtNTA3MjU_82bb4be3-7fe9-4210-bc40-3269e52a52c4">182.45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTozNWUzZGFhZmEzZWM0NjZlODhmODNlYTBiZjEzMWE1Yi90YWJsZXJhbmdlOjM1ZTNkYWFmYTNlYzQ2NmU4OGY4M2VhMGJmMTMxYTViXzItMS0xLTEtNTA3MjU_ddc258fc-613f-4571-8a15-5df44d3c26bd">33,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTozNWUzZGFhZmEzZWM0NjZlODhmODNlYTBiZjEzMWE1Yi90YWJsZXJhbmdlOjM1ZTNkYWFmYTNlYzQ2NmU4OGY4M2VhMGJmMTMxYTViXzItMy0xLTEtNTA3MjU_d2486796-f5fa-4925-8c93-938b20e4b8cf">143.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTozNWUzZGFhZmEzZWM0NjZlODhmODNlYTBiZjEzMWE1Yi90YWJsZXJhbmdlOjM1ZTNkYWFmYTNlYzQ2NmU4OGY4M2VhMGJmMTMxYTViXzMtMS0xLTEtNTA3MjU_84ef8c43-f6ba-435e-8f89-39160d817f4c">64,496</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTozNWUzZGFhZmEzZWM0NjZlODhmODNlYTBiZjEzMWE1Yi90YWJsZXJhbmdlOjM1ZTNkYWFmYTNlYzQ2NmU4OGY4M2VhMGJmMTMxYTViXzMtMy0xLTEtNTA3MjU_2b3e22d7-b3d0-47bb-93fe-38f94b53463b">150.79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTozNWUzZGFhZmEzZWM0NjZlODhmODNlYTBiZjEzMWE1Yi90YWJsZXJhbmdlOjM1ZTNkYWFmYTNlYzQ2NmU4OGY4M2VhMGJmMTMxYTViXzQtMS0xLTEtNTA3MjU_689ac8cd-9e49-44b5-bb39-83435bf05e5f">43,273</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTozNWUzZGFhZmEzZWM0NjZlODhmODNlYTBiZjEzMWE1Yi90YWJsZXJhbmdlOjM1ZTNkYWFmYTNlYzQ2NmU4OGY4M2VhMGJmMTMxYTViXzQtMy0xLTEtNTA3MjU_dcc58f3d-df2c-4949-95c3-9b48ec98b2f5">173.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock options at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTozNWUzZGFhZmEzZWM0NjZlODhmODNlYTBiZjEzMWE1Yi90YWJsZXJhbmdlOjM1ZTNkYWFmYTNlYzQ2NmU4OGY4M2VhMGJmMTMxYTViXzUtMS0xLTEtNTA3MjU_780a130d-e170-4617-b4ab-09d0300189c3">55,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTozNWUzZGFhZmEzZWM0NjZlODhmODNlYTBiZjEzMWE1Yi90YWJsZXJhbmdlOjM1ZTNkYWFmYTNlYzQ2NmU4OGY4M2VhMGJmMTMxYTViXzUtMy0xLTEtNTA3MjU_f33363f4-4cd4-4729-9cb1-e4b01cd5abd3">202.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></div><ix:continuation id="iba6edece74f44744b45ee74afe9eed73" continuedAt="i6cf4fad88021437782f0905d8b5f3c30"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i14c451d987c9475fa3c8992bc94cbf8f_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzcxMzI_846f79f1-de55-4c4b-868f-7715e39b7e6e">2.0</ix:nonFraction> million of unrecognized compensation cost related to stock options that we expect to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i06eb9ed545f04bdcbf647b341b4ab114_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzcyNjA_985b6a63-4836-4dc4-9706-b345c9590167">1.8</ix:nonNumeric> years.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Vested Stock Units</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issue non-vested stock unit awards that are service-based, performance-based or a combination of both with vesting terms ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4Xzc0MzA_f3f1355f-39bb-4d10-ac63-3dcf30959476">one</span> to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4Xzc0MzY_d0064103-cecb-48d9-8073-473521ccb07a">four</span> years. Based on the terms and conditions of these awards, we determine if the awards should be recorded as either equity or liability instruments. The compensation expense is determined based on the market price of our common stock at the date of grant, applied to the total number of units that are anticipated to vest, unless the award specifies differently. Shares of stock are not issued to the recipient until the stock unit awards have vested and after the pre-determined delivery date has occurred.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Vested Stock Units &#8211; Service-Based ("Service-Based Non-Vested Stock Units")</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service-based non-vested stock unit compensation expense included in general and administrative expenses in our accompanying consolidated statements of operations was $<ix:nonFraction unitRef="usd" contextRef="icd5a663f1bb844bab57b874fbf18534e_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzgxOTI_f5c53bb6-803c-46c2-96f9-e1106395eed5">12.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i52a228fca81e41d693cd6d81c49a90c4_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzgxOTY_064befd9-b396-44ec-bb27-1f7817b5c1ca">9.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i11c1dc78db0e49b68f847e221371a443_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzgyMDM_5512e455-3444-48b0-8102-8663d16c901f">7.5</ix:nonFraction> million for 2022, 2021 and 2020, respectively.</span></div><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzEwMTMz_035dc0c8-1cbb-4c46-87f7-0a9e097d4883" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our service-based non-vested stock units activity for 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of&#160;<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;Average<br/>Grant Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock units at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifdd8f4e213094cc396d0fcbfc8c7cc13_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo3NDQyODI3YTA0ZDU0MDg1YmFhZmFjMjliODllNjYzZS90YWJsZXJhbmdlOjc0NDI4MjdhMDRkNTQwODViYWFmYWMyOWI4OWU2NjNlXzEtMS0xLTEtNTA3MjU_d66f80cb-efcb-4a0b-8d12-b2276880b3d5">180,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifdd8f4e213094cc396d0fcbfc8c7cc13_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo3NDQyODI3YTA0ZDU0MDg1YmFhZmFjMjliODllNjYzZS90YWJsZXJhbmdlOjc0NDI4MjdhMDRkNTQwODViYWFmYWMyOWI4OWU2NjNlXzEtMy0xLTEtNTA3MjU_df629705-0075-48c0-8266-273802f6a310">195.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd5a663f1bb844bab57b874fbf18534e_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo3NDQyODI3YTA0ZDU0MDg1YmFhZmFjMjliODllNjYzZS90YWJsZXJhbmdlOjc0NDI4MjdhMDRkNTQwODViYWFmYWMyOWI4OWU2NjNlXzItMS0xLTEtNTA3MjU_1441b37c-3fd4-4e90-94aa-2caca853719a">211,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icd5a663f1bb844bab57b874fbf18534e_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo3NDQyODI3YTA0ZDU0MDg1YmFhZmFjMjliODllNjYzZS90YWJsZXJhbmdlOjc0NDI4MjdhMDRkNTQwODViYWFmYWMyOWI4OWU2NjNlXzItMy0xLTEtNTA3MjU_74f484cb-ae66-46f1-ac26-14468cb0ccc3">115.07</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icd5a663f1bb844bab57b874fbf18534e_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo3NDQyODI3YTA0ZDU0MDg1YmFhZmFjMjliODllNjYzZS90YWJsZXJhbmdlOjc0NDI4MjdhMDRkNTQwODViYWFmYWMyOWI4OWU2NjNlXzMtMS0xLTEtNTA3MjU_f5733574-b19b-4642-8787-93fb1a2f57dd">59,006</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icd5a663f1bb844bab57b874fbf18534e_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo3NDQyODI3YTA0ZDU0MDg1YmFhZmFjMjliODllNjYzZS90YWJsZXJhbmdlOjc0NDI4MjdhMDRkNTQwODViYWFmYWMyOWI4OWU2NjNlXzMtMy0xLTEtNTA3MjU_635479cc-9bc7-49b3-a1dd-fb6f72621ffc">146.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled, forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icd5a663f1bb844bab57b874fbf18534e_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo3NDQyODI3YTA0ZDU0MDg1YmFhZmFjMjliODllNjYzZS90YWJsZXJhbmdlOjc0NDI4MjdhMDRkNTQwODViYWFmYWMyOWI4OWU2NjNlXzQtMS0xLTEtNTA3MjU_bd4ce8f6-1f3f-4664-92ea-94ac4d7a614e">70,025</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icd5a663f1bb844bab57b874fbf18534e_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo3NDQyODI3YTA0ZDU0MDg1YmFhZmFjMjliODllNjYzZS90YWJsZXJhbmdlOjc0NDI4MjdhMDRkNTQwODViYWFmYWMyOWI4OWU2NjNlXzQtMy0xLTEtNTA3MjU_b3927131-b243-4a7f-be1c-485d4bec7d05">194.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock units at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e87c3e7b1004ea799c3dc520a7f0a4e_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo3NDQyODI3YTA0ZDU0MDg1YmFhZmFjMjliODllNjYzZS90YWJsZXJhbmdlOjc0NDI4MjdhMDRkNTQwODViYWFmYWMyOWI4OWU2NjNlXzUtMS0xLTEtNTA3MjU_65949770-9276-46fe-8bc8-771adbdbdf2e">263,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1e87c3e7b1004ea799c3dc520a7f0a4e_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo3NDQyODI3YTA0ZDU0MDg1YmFhZmFjMjliODllNjYzZS90YWJsZXJhbmdlOjc0NDI4MjdhMDRkNTQwODViYWFmYWMyOWI4OWU2NjNlXzUtMy0xLTEtNTA3MjU_4f54776b-30a3-47b1-a3bf-810879eb398e">141.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value of service-based non-vested stock units granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="icd5a663f1bb844bab57b874fbf18534e_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4Xzg0MjM_aab19ca9-b50c-4fcb-97f1-0cb691bc2442">115.07</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i52a228fca81e41d693cd6d81c49a90c4_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4Xzg0Mjc_6d731d12-ebe6-4f87-b177-334f6b21633f">234.42</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i11c1dc78db0e49b68f847e221371a443_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4Xzg0MzQ_55fda94e-a3da-42d0-8832-e2cfe9d494fa">206.10</ix:nonFraction> in 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i1e87c3e7b1004ea799c3dc520a7f0a4e_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4Xzg0ODY_e0a65e52-8f8c-4dce-b63b-5cee7313c8ae">22.6</ix:nonFraction> million of unrecognized compensation cost related to our service-based non-vested stock units that we expect to be recognized over a weighted average period of <ix:nonNumeric contextRef="icd5a663f1bb844bab57b874fbf18534e_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4Xzg2NDE_4df8cbd1-9cb5-413d-8358-920ced97a76f">2.2</ix:nonNumeric> years.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Vested Stock Units &#8211; Service-Based and Performance-Based Awards ("Performance-Based Non-Vested Stock Units")</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, we awarded performance-based awards to certain employees. The target level established by the award, which is based on the Company&#8217;s 2022 adjusted earnings before interest, taxes, depreciation and amortization (&#8220;Adjusted EBITDA&#8221;), provided for the recipients to receive an aggregate of <ix:nonFraction unitRef="shares" contextRef="i082da853b55e488ab9ef8c389ed4b49f_D20220101-20221231" decimals="INF" name="amed:Performancebasedawardtargetshareamount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzkwNTk_0c359ec4-d062-4ff6-b30a-f3364ea8ec40">71,349</ix:nonFraction> non-vested stock units if the target was achieved. For a select group of employees, if the target objective was surpassed to the point of achieving the projected maximum payout, the recipients would receive an additional aggregate of <ix:nonFraction unitRef="shares" contextRef="i082da853b55e488ab9ef8c389ed4b49f_D20220101-20221231" decimals="INF" name="amed:AdditionalPerformanceBasedAwardTargetShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzkyOTY_739a2f17-e467-4930-8c6a-16b5f2bdbf98">32,048</ix:nonFraction> non-vested stock units during 2023. The target number of shares to be potentially awarded was reduced by forfeitures as indicated in the table below. On February 1, 2023, the Compensation Committee determined that the 2022 performance-based objective established by the award was not satisfied, and as a result, the target number of non-vested stock units will be forfeited. Performance-based non-vested stock units compensation expense included in general and administrative expenses in our consolidated statements of operations was $<ix:nonFraction unitRef="usd" contextRef="i082da853b55e488ab9ef8c389ed4b49f_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4Xzk2NTM_b6af5307-0e02-4bd0-aaab-8bf22ef82a2c">2.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ia5b0758fc5c841c69f0e3000600e3618_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4Xzk2NTc_c7135539-5a69-4d14-85a4-ac4556196493">10.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iecabe05cd8be4b96a216b1a6513dcb34_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4Xzk2NjQ_fd37aab0-eced-4213-b670-0416cf21713c">13.5</ix:nonFraction> million for 2022, 2021 and 2020, respectively.</span></div><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzEwMTI4_c95a5fbd-4647-417d-ba32-defd02799475" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our performance-based non-vested stock units activity for 2022:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of&#160;<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;Average<br/>Grant Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock units at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5aa28b6040cd4209a28424a8ddb8c083_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTphYmRjZDZkMjliMDk0MTNiYWUxZmQ0YzVlYzNkMmVhYS90YWJsZXJhbmdlOmFiZGNkNmQyOWIwOTQxM2JhZTFmZDRjNWVjM2QyZWFhXzEtMS0xLTEtNTA3MjU_8628ace9-918f-4cba-ab72-cd1cb8917743">186,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5aa28b6040cd4209a28424a8ddb8c083_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTphYmRjZDZkMjliMDk0MTNiYWUxZmQ0YzVlYzNkMmVhYS90YWJsZXJhbmdlOmFiZGNkNmQyOWIwOTQxM2JhZTFmZDRjNWVjM2QyZWFhXzEtMy0xLTEtNTA3MjU_15659e33-e49a-4254-ba3e-fe3abe033661">206.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i082da853b55e488ab9ef8c389ed4b49f_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTphYmRjZDZkMjliMDk0MTNiYWUxZmQ0YzVlYzNkMmVhYS90YWJsZXJhbmdlOmFiZGNkNmQyOWIwOTQxM2JhZTFmZDRjNWVjM2QyZWFhXzItMS0xLTEtNTA3MjU_28de8a81-488a-417b-bb42-1ae1566bdd6a">71,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i082da853b55e488ab9ef8c389ed4b49f_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTphYmRjZDZkMjliMDk0MTNiYWUxZmQ0YzVlYzNkMmVhYS90YWJsZXJhbmdlOmFiZGNkNmQyOWIwOTQxM2JhZTFmZDRjNWVjM2QyZWFhXzItMy0xLTEtNTA3MjU_96d22bd5-c103-4a69-9379-1091938a4715">133.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i082da853b55e488ab9ef8c389ed4b49f_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTphYmRjZDZkMjliMDk0MTNiYWUxZmQ0YzVlYzNkMmVhYS90YWJsZXJhbmdlOmFiZGNkNmQyOWIwOTQxM2JhZTFmZDRjNWVjM2QyZWFhXzMtMS0xLTEtNTA3MjU_41b9770c-cc13-446f-8f99-45e8aa2d9e14">85,767</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i082da853b55e488ab9ef8c389ed4b49f_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTphYmRjZDZkMjliMDk0MTNiYWUxZmQ0YzVlYzNkMmVhYS90YWJsZXJhbmdlOmFiZGNkNmQyOWIwOTQxM2JhZTFmZDRjNWVjM2QyZWFhXzMtMy0xLTEtNTA3MjU_96b426e7-df66-47db-b913-cbdb50df71eb">156.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled, forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i082da853b55e488ab9ef8c389ed4b49f_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTphYmRjZDZkMjliMDk0MTNiYWUxZmQ0YzVlYzNkMmVhYS90YWJsZXJhbmdlOmFiZGNkNmQyOWIwOTQxM2JhZTFmZDRjNWVjM2QyZWFhXzQtMS0xLTEtNTA3MjU_e8bf5e0e-3116-41b7-b261-863e7476d675">104,486</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i082da853b55e488ab9ef8c389ed4b49f_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTphYmRjZDZkMjliMDk0MTNiYWUxZmQ0YzVlYzNkMmVhYS90YWJsZXJhbmdlOmFiZGNkNmQyOWIwOTQxM2JhZTFmZDRjNWVjM2QyZWFhXzQtMy0xLTEtNTA3MjU_52b15943-c3f1-4a69-85b7-22658e42a790">237.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock units at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2d8e565a484b4115a30a498efd2fead8_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTphYmRjZDZkMjliMDk0MTNiYWUxZmQ0YzVlYzNkMmVhYS90YWJsZXJhbmdlOmFiZGNkNmQyOWIwOTQxM2JhZTFmZDRjNWVjM2QyZWFhXzUtMS0xLTEtNTA3MjU_317af6e6-b212-4830-8ae8-54039efdf5a8">68,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2d8e565a484b4115a30a498efd2fead8_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTphYmRjZDZkMjliMDk0MTNiYWUxZmQ0YzVlYzNkMmVhYS90YWJsZXJhbmdlOmFiZGNkNmQyOWIwOTQxM2JhZTFmZDRjNWVjM2QyZWFhXzUtMy0xLTEtNTA3MjU_0a203911-da95-4e83-8091-581ee75334a0">144.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></div><ix:continuation id="i6cf4fad88021437782f0905d8b5f3c30"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value of performance-based non-vested stock units granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="i082da853b55e488ab9ef8c389ed4b49f_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4Xzk4OTI_96681dbb-e37a-49ab-b327-bc7a14898cfa">133.70</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="ia5b0758fc5c841c69f0e3000600e3618_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4Xzk4OTY_4125353f-f0c5-430d-81fc-274fe1f997b6">262.67</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="iecabe05cd8be4b96a216b1a6513dcb34_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4Xzk5MDM_bb1d2e6e-197b-4803-9784-204d54a64d44">201.90</ix:nonFraction> in 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i2d8e565a484b4115a30a498efd2fead8_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4Xzk5NTU_eec2f5bd-f84b-42fa-9388-4a4f3ca6cf4c">1.1</ix:nonFraction> million in unrecognized compensation costs related to our performance-based non-vested stock units that we expect to be recognized over a weighted average period of <ix:nonNumeric contextRef="i082da853b55e488ab9ef8c389ed4b49f_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzEwMTE1_1a691d2d-59aa-4a02-84c6-ba02e4f23cc6">1.1</ix:nonNumeric> years.</span></div></ix:continuation><div><span><br/></span></div><div id="i5c10b724a6674979bf3c35a339f29685_130"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzE0MjQ1_ac8e1eb1-c025-4294-a1e6-546536ee5319" continuedAt="iea69fc0435764ef1b2bcfa15ce4d6075" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="iea69fc0435764ef1b2bcfa15ce4d6075" continuedAt="i147047ef864c44058deb098ddf44473e"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings &#8211; Ongoing</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. Based on information available to us as of the date of this filing, we do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal fees related to all legal matters are expensed as incurred.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings - Completed</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subpoena Duces Tecum and Civil Investigative Demands Issued by the U.S. Department of Justice</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 7, 2021, the U.S. Department of Justice notified the Company that they were closing their investigation into the below-referenced Subpoena Duces Tecum ("Subpoena") and civil investigative demands ("CIDs"). At the time, we had $<ix:nonFraction unitRef="usd" contextRef="i72f8833e23b44a2ea0d2a7d9a3387fad_I20210331" decimals="-5" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3Xzg5OA_336ec972-779f-41eb-9790-d737a453aee4"><ix:nonFraction unitRef="usd" contextRef="ic191fcc8192b4608959c14133dc12c5e_I20210630" decimals="-5" name="amed:ReversalOfLossContingencyAccrual" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3Xzg5OA_c3a69ad9-c222-4c8a-b4bb-984abb1b7398">6.5</ix:nonFraction></ix:nonFraction>&#160;million recorded to accrued expenses in our consolidated balance sheets related to these matters. We reversed this accrual during the three-month period ended June 30, 2021.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;21, 2015, we received a Subpoena issued by the U.S. Department of Justice. The Subpoena requested the delivery of information regarding <ix:nonFraction unitRef="patient" contextRef="ieba00eb7d405413d818c4971105613ee_D20150521-20150521" decimals="INF" name="amed:Numberofpatients" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzEyMTA_23bc3bc1-99d3-4196-8f1a-c00fb48d5246">53</ix:nonFraction> identified hospice patients to the United States Attorney&#8217;s Office for the District of Massachusetts. It also requested the delivery of documents relating to our hospice clinical and business operations and related compliance activities. The Subpoena generally covered the period from January&#160;1, 2011 through May 21, 2015. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;3, 2015, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Morgantown, West Virginia area. The CID requested the delivery of information to the United States Attorney&#8217;s Office for the Northern District of West Virginia regarding <ix:nonFraction unitRef="patient" contextRef="i8d55411f20e04d00a2eea8301fc2ae5a_D20151103-20151103" decimals="INF" name="amed:Numberofpatients" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzE5NTI_b76784e4-6e5c-4068-904a-c05a9441077e">66</ix:nonFraction> identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Morgantown area. The CID generally covered the period from January&#160;1, 2009 through August&#160;31, 2015.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;27, 2016, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Parkersburg, West Virginia area. The CID requested the delivery of information to the United States Attorney&#8217;s Office for the Southern District of West Virginia regarding <ix:nonFraction unitRef="patient" contextRef="i011327a38e254fcaa937ffb2732985d4_D20160627-20160627" decimals="INF" name="amed:Numberofpatients" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzI1ODI_1593d42b-e81d-4353-b3df-c5511a644627">68</ix:nonFraction> identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Parkersburg area. The CID generally covered the period from January&#160;1, 2011 through June&#160;20, 2016. </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third Party Audits &#8211; Ongoing</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, in the ordinary course of business, we are subject to audits under various governmental programs in which third party firms engaged by CMS, including Recovery Audit Contractors (&#8220;RACs&#8221;), Zone Program Integrity Contractors (&#8220;ZPICs&#8221;), Uniform Program Integrity Contractors (&#8220;UPICs&#8221;), Program Safeguard Contractors (&#8220;PSCs&#8221;), Medicaid Integrity Contractors (&#8220;MICs&#8221;), Supplemental Medical Review Contractors (&#8220;SMRCs&#8221;) and the Office of the Inspector General ("OIG"), conduct extensive reviews of claims data to identify potential improper payments. We cannot predict the ultimate outcome of any regulatory reviews or other governmental audits and investigations.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a ZPIC a request for records regarding a sample of <ix:nonFraction unitRef="beneficiary" contextRef="ic16a0c94f3004de7b7a900a946d92672_D20080101-20100331" decimals="INF" name="amed:NumberOfBeneficiaries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzY4ODU_89df6d15-523e-4a17-a1ae-ab1ab9e3a4d7">30</ix:nonFraction> beneficiaries who received services from the subsidiary during the period of January&#160;1, 2008 through March&#160;31, 2010 (the &#8220;Review Period&#8221;) to determine whether the underlying services met pertinent Medicare payment requirements.&#160;We acquired the hospice operations subject to this review on August&#160;1, 2009; the Review Period covers time periods both before and after our ownership of these hospice operations.&#160;Based on the ZPIC&#8217;s findings for <ix:nonFraction unitRef="beneficiary" contextRef="if1bca261c0b946248dfe5cee858c643d_D20110606-20110606" decimals="INF" name="amed:NumberOfBeneficiaries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzczMjk_73c541aa-7ac5-4b35-84c7-b99fdd9c3b7a">16</ix:nonFraction> beneficiaries, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June&#160;6, 2011, the Medicare Administrative Contractor ("MAC") for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment. We dispute these findings, and our Florence subsidiary has filed appeals through the Original Medicare Standard Appeals Process, in which we are seeking to have those findings overturned. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></div><ix:continuation id="i147047ef864c44058deb098ddf44473e" continuedAt="i8c0dc38c4a094b7b8c3ca23375efbc87"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An administrative law judge ("ALJ") hearing was held in early January 2015. On January&#160;18, 2016, we received a letter dated January&#160;6, 2016 referencing the ALJ hearing decision for the overpayment issued on June&#160;6, 2011. The decision was partially favorable with a new overpayment amount of $<ix:nonFraction unitRef="usd" contextRef="i5d52cf787d4f4a21ba644c6537028eca_I20160118" decimals="-5" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzgxMzI_615d6aab-1681-4ec5-a38b-7d7d8eb3b976">3.7</ix:nonFraction> million with a balance owed of $<ix:nonFraction unitRef="usd" contextRef="i5d52cf787d4f4a21ba644c6537028eca_I20160118" decimals="-5" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzgxNTg_6316e065-82b3-4548-9dba-ff0dcfb3452f">5.6</ix:nonFraction> million including interest based on <ix:nonFraction unitRef="claim" contextRef="ibd850077008b489db6c689d6678a854b_D20160118-20160118" decimals="INF" name="amed:NumberOfClaimsSubmittedBySubsidiary" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzgxODk_e59ca91e-056d-453e-a69a-12b13f8826d1">9</ix:nonFraction> disputed claims (originally <ix:nonFraction unitRef="beneficiary" contextRef="if1bca261c0b946248dfe5cee858c643d_D20110606-20110606" decimals="INF" name="amed:NumberOfBeneficiaries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzgyMjA_73c541aa-7ac5-4b35-84c7-b99fdd9c3b7a">16</ix:nonFraction>). We filed an appeal to the Medicare Appeals Council on the remaining <ix:nonFraction unitRef="claim" contextRef="ibd850077008b489db6c689d6678a854b_D20160118-20160118" decimals="INF" name="amed:NumberOfClaimsSubmittedBySubsidiary" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzgyOTM_e59ca91e-056d-453e-a69a-12b13f8826d1">9</ix:nonFraction> disputed claims and also argued that the statistical method used to select the sample was not valid.&#160;No assurances can be given as to the timing or outcome of the Medicare Appeals Council decision. As of December 31, 2022, Medicare has withheld payments of $<ix:nonFraction unitRef="usd" contextRef="if8e53a67d325418698e7dff0da8ae0f8_I20221231" decimals="-5" name="amed:Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3Xzg1NTM_eda25102-6908-4e98-a63a-6dae0d7cbaba">5.7</ix:nonFraction> million (including additional interest) as part of their standard procedures once this level of the appeal process has been reached. In the event we are not able to recoup this alleged overpayment, we are entitled to be indemnified by the prior owners of the hospice operations for amounts relating to the period prior to August&#160;1, 2009. On January 10, 2019, an arbitration panel from the American Health Lawyers Association determined that the prior owners' liability for their indemnification obligation was $<ix:nonFraction unitRef="usd" contextRef="i29b899adcb534d2fb11ae45ba13dffa5_I20221231" decimals="-5" name="us-gaap:LossContingencyReceivableNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzkwNTg_09ce0ef8-f484-445f-be12-469b7b35de86"><ix:nonFraction unitRef="usd" contextRef="i38abfa2908c74f76a39c59f03f0a1f88_I20190110" decimals="-5" name="amed:IndemnificationAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzkwNTg_6fdb0027-50bf-4210-bf83-f47f2e0c7fac">2.8</ix:nonFraction></ix:nonFraction> million. This amount is recorded as an indemnity receivable within other assets in our consolidated balance sheets.</span></div><div style="margin-top:5pt;padding-left:2.25pt;padding-right:11.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2016, the Company received a request for medical records from SafeGuard Services, L.L.C (&#8220;SafeGuard&#8221;), a ZPIC, related to services provided by some of the care centers that the Company acquired from Infinity Home Care, L.L.C. The review period covered time periods both before and after our ownership of the care centers, which were acquired on December 31, 2015. In August 2017, the Company received Requests for Repayment from Palmetto GBA, LLC (&#8220;Palmetto&#8221;) regarding Infinity Home Care of Lakeland, LLC, (&#8220;Lakeland Care Centers&#8221;) and Infinity Home Care of Pinellas, LLC, (&#8220;Clearwater Care Center&#8221;). The Palmetto letters were based on a statistical extrapolation performed by SafeGuard which alleged an overpayment of $<ix:nonFraction unitRef="usd" contextRef="i5ad4b2a4d1904246a60f312fe6e54a55_I20170831" decimals="-5" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3Xzk4OTU_c61da3d7-2e04-45b8-9c41-e48cf48c45f3">34.0</ix:nonFraction> million for the Lakeland Care Centers on a universe of <ix:nonFraction unitRef="claim" contextRef="i5d9c1bb997894061aeafb6aabddeffd5_D20170801-20170831" decimals="INF" name="amed:NumberOfClaimsSubmittedBySubsidiary" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3Xzk5NDU_36466948-1fdd-4da8-a45a-c70a9901150f">72</ix:nonFraction> Medicare claims totaling $<ix:nonFraction unitRef="usd" contextRef="i5ad4b2a4d1904246a60f312fe6e54a55_I20170831" decimals="-5" name="amed:ActualClaimsPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3Xzk5NzM_0fa1bc78-5466-4d95-98ec-e4f521badb97">0.2</ix:nonFraction> million in actual claims payments using a <ix:nonFraction unitRef="number" contextRef="i5ad4b2a4d1904246a60f312fe6e54a55_I20170831" decimals="INF" name="amed:ErrorRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzEwMDEw_7a1203fe-307c-4b17-b7a6-4bff59e8cd5e">100</ix:nonFraction>% error rate and an overpayment of $<ix:nonFraction unitRef="usd" contextRef="id957a4e2cf624f1f8c0755fef660c4fc_I20170831" decimals="-5" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzEwMDQ2_a07aa546-8f98-4924-8efd-6b0e242d865b">4.8</ix:nonFraction> million for the Clearwater Care Center on a universe of <ix:nonFraction unitRef="claim" contextRef="ica936df2e1054ec1b0ff8eb6510dfbcb_D20170801-20170831" decimals="INF" name="amed:NumberOfClaimsSubmittedBySubsidiary" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzEwMDk3_a0e3b443-ab27-4eee-8b4a-8c984824ef31">70</ix:nonFraction> Medicare claims totaling $<ix:nonFraction unitRef="usd" contextRef="id957a4e2cf624f1f8c0755fef660c4fc_I20170831" decimals="-5" name="amed:ActualClaimsPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzEwMTI1_e50612d1-ffd4-407d-82ec-49719281f73e">0.2</ix:nonFraction> million in actual claims payments using a <ix:nonFraction unitRef="number" contextRef="id957a4e2cf624f1f8c0755fef660c4fc_I20170831" decimals="INF" name="amed:ErrorRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzEwMTYy_61d3129f-bbcd-4fb6-be87-ec6f357dff43">100</ix:nonFraction>% error rate. </span></div><div style="margin-top:5pt;padding-left:2.25pt;padding-right:11.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lakeland Request for Repayment covered claims between January 2, 2014 and September 13, 2016. The Clearwater Request for Repayment covered claims between January 2, 2015 and December 9, 2016. As a result of partially successful Level I and Level II Administrative Appeals, the alleged overpayment for the Lakeland Care Centers was reduced to $<ix:nonFraction unitRef="usd" contextRef="i7d88d76487a74a848baa03e874a5eccd_I20221231" decimals="-5" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzEwNTI4_557a48e6-7545-48b8-afbd-61568458375f">26.0</ix:nonFraction> million and the alleged overpayment for the Clearwater Care Center was reduced to $<ix:nonFraction unitRef="usd" contextRef="ieaeca3977d8a40ec9994588b4150109b_I20221231" decimals="-5" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzEwNjEw_2b11bf8d-f387-4bf3-ad27-b6aab49bd56f">3.3</ix:nonFraction> million. The Company filed Level III Administrative Appeals, and the ALJ hearings regarding the Lakeland Request for Repayment and the Clearwater Request for Repayment were held in April 2022.</span></div><div style="margin-top:10pt;padding-left:2.25pt;padding-right:11.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received the results of the ALJ hearings for the Clearwater Care Center and the Lakeland Care Centers on June 23, 2022 and June 30, 2022, respectively. The ALJ decisions for both the Clearwater Care Center and the Lakeland Care Centers were partially favorable for the claims that were reviewed, but the extrapolations were upheld. As a result, we increased our total accrual related to these matters from $<ix:nonFraction unitRef="usd" contextRef="id2c6967c53284f0ea2b6b8001c55cacd_I20220331" decimals="-5" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzU0OTc1NTgzODU3Nw_b9853a7d-edd8-4412-9b6e-5677c4bdab3a">17.4</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="i7c5014c365be4c5d90c38959f215dfb5_I20220630" decimals="-5" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzU0OTc1NTgzODU5Mg_94531069-6008-4696-8f43-73905bfd9679">25.8</ix:nonFraction>&#160;million during the three-month period ended June 30, 2022. The net of these two amounts, $<ix:nonFraction unitRef="usd" contextRef="ieefca07772a441c18ef7fd78ee354800_D20220401-20220630" decimals="-5" name="amed:ReductionToNetServiceRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzU0OTc1NTgzODYwNw_e8488a68-1946-4707-83df-968881b215bf">8.4</ix:nonFraction>&#160;million, was recorded as a reduction to net service revenue in our consolidated statement of operations during the three-month period ended June 30, 2022. We received demands for repayment from Palmetto for both the Clearwater Care Center and the Lakeland Care Centers during the three-month period ended September 30, 2022. The demands were slightly less than our estimated accrual of $<ix:nonFraction unitRef="usd" contextRef="i7c5014c365be4c5d90c38959f215dfb5_I20220630" decimals="-5" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzU0OTc1NTgzODYyMQ_f5e94adb-1052-4855-9872-42a03484cd1a">25.8</ix:nonFraction>&#160;million. During the three-month period ended September 30, 2022, we adjusted our accrual to $<ix:nonFraction unitRef="usd" contextRef="ic41315c634e841cc9d84abadce65303b_I20220930" decimals="-5" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzU0OTc1NTgzODYzNg_9378be21-a6fb-4ba6-a067-74f7f5641652">25.2</ix:nonFraction>&#160;million to reflect the final amounts owed, excluding interest. The repayment for the Lakeland Care Centers totaling $<ix:nonFraction unitRef="usd" contextRef="i868f83b3f18641769d70c97c93d30912_D20220701-20220930" decimals="-5" name="amed:TotalLegalSettlementPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzU0OTc1NTgzODY1MQ_ba8821bd-d4de-4f40-b245-20abb7ae87d2">34.3</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usd" contextRef="i868f83b3f18641769d70c97c93d30912_D20220701-20220930" decimals="-5" name="amed:LegalSettlementPaymentLessInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzU0OTc1NTgzODY2Ng_1efa04cb-50fd-4747-b322-9ef01672a6a8">22.8</ix:nonFraction>&#160;million extrapolated repayment plus $<ix:nonFraction unitRef="usd" contextRef="i868f83b3f18641769d70c97c93d30912_D20220701-20220930" decimals="-5" name="us-gaap:LitigationSettlementInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzU0OTc1NTgzODY4MQ_af49e68f-36de-4f94-b1d4-4832b54087fe">11.5</ix:nonFraction>&#160;million accrued interest) was made during the three-month period ended September 30, 2022. The repayment for the Clearwater Care Center totaling $<ix:nonFraction unitRef="usd" contextRef="ib79f3470b4c9406fa918cc4fbe458ad1_D20221001-20221231" decimals="-5" name="amed:TotalLegalSettlementPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzU0OTc1NTgzODY5Ng_22661d0b-d757-4a61-ae04-949ee76e8a57">3.7</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usd" contextRef="ib79f3470b4c9406fa918cc4fbe458ad1_D20221001-20221231" decimals="-5" name="amed:LegalSettlementPaymentLessInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzU0OTc1NTgzODcxMA_9873fff9-5348-42a7-a935-c83d799b6eed">2.4</ix:nonFraction>&#160;million extrapolated repayment plus $<ix:nonFraction unitRef="usd" contextRef="ib79f3470b4c9406fa918cc4fbe458ad1_D20221001-20221231" decimals="-5" name="us-gaap:LitigationSettlementInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzU0OTc1NTgzODcyNA_707ad797-0dbd-412b-a6b3-12530d29d88c">1.2</ix:nonFraction>&#160;million accrued interest) was made during the three-month period ended December 31, 2022. Additionally, we wrote off $<ix:nonFraction unitRef="usd" contextRef="ie2ead6d6a5b24846a24cab167648cd41_D20220701-20220930" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzU0OTc1NTgzODczOA_53965471-326a-41d3-9e5c-d2baae36d687">1.5</ix:nonFraction>&#160;million of receivables that were impacted by these matters. We expect to be indemnified by the prior owners, upon exhaustion of the parties' appeal rights, for approximately $<ix:nonFraction unitRef="usd" contextRef="i23cfc9c5f5334cb98796bce037009c13_I20221231" decimals="-5" name="us-gaap:LossContingencyReceivableNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzU0OTc1NTgzODc1Mg_679d615f-8ef0-4162-ae50-9da92f0ee6fb">10.9</ix:nonFraction>&#160;million and have recorded this amount within other assets in our consolidated balance sheets. </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Insurance</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated for certain costs associated with our insurance programs, including employee health, workers&#8217; compensation and professional liability. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs, up to specified deductible limits in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="amed:InsuranceProgramsTableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzE0MjQw_c46f308e-5e3b-4e29-9404-30dcc1792881" continuedAt="i42bb047ef9b1448ab2f993b073c92153" escape="true">The following table presents details of our insurance programs, including amounts recorded, for the periods indicated within accrued expenses in our consolidated balance sheets. The amounts below represent our total estimated liability for individual </ix:nonNumeric></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></div><ix:continuation id="i8c0dc38c4a094b7b8c3ca23375efbc87"><ix:continuation id="i42bb047ef9b1448ab2f993b073c92153"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">claims that are less than our noted insurance coverage amounts, which can include outstanding claims and claims incurred but not reported (amounts in millions).</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.035%"><tr><td style="width:1.0%"></td><td style="width:67.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.196%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.199%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Type of Insurance</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health insurance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="amed:HealthInsurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90YWJsZTo0YjIzNzM3ZjY4NmM0YWI1OTYzMzVhMjE5ZDg2MmMyZi90YWJsZXJhbmdlOjRiMjM3MzdmNjg2YzRhYjU5NjMzNWEyMTlkODYyYzJmXzItMS0xLTEtNTA3MjU_3ad6e5c1-e14c-4fc2-8843-cd1e4aa77061">16.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="amed:HealthInsurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90YWJsZTo0YjIzNzM3ZjY4NmM0YWI1OTYzMzVhMjE5ZDg2MmMyZi90YWJsZXJhbmdlOjRiMjM3MzdmNjg2YzRhYjU5NjMzNWEyMTlkODYyYzJmXzItMy0xLTEtNTA3MjU_62004978-6120-40f2-883d-0ad8ac7d069d">16.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="amed:WokersCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90YWJsZTo0YjIzNzM3ZjY4NmM0YWI1OTYzMzVhMjE5ZDg2MmMyZi90YWJsZXJhbmdlOjRiMjM3MzdmNjg2YzRhYjU5NjMzNWEyMTlkODYyYzJmXzMtMS0xLTEtNTA3MjU_eb95ba79-d907-43b7-8a87-c8611a72147f">40.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="amed:WokersCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90YWJsZTo0YjIzNzM3ZjY4NmM0YWI1OTYzMzVhMjE5ZDg2MmMyZi90YWJsZXJhbmdlOjRiMjM3MzdmNjg2YzRhYjU5NjMzNWEyMTlkODYyYzJmXzMtMy0xLTEtNTA3MjU_831f9801-b5d7-46e9-94cb-e2565cd8979d">40.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="amed:ProfessionalLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90YWJsZTo0YjIzNzM3ZjY4NmM0YWI1OTYzMzVhMjE5ZDg2MmMyZi90YWJsZXJhbmdlOjRiMjM3MzdmNjg2YzRhYjU5NjMzNWEyMTlkODYyYzJmXzQtMS0xLTEtNTA3MjU_2f812967-a579-4ee1-a8c5-5889eb91d14b">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="amed:ProfessionalLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90YWJsZTo0YjIzNzM3ZjY4NmM0YWI1OTYzMzVhMjE5ZDg2MmMyZi90YWJsZXJhbmdlOjRiMjM3MzdmNjg2YzRhYjU5NjMzNWEyMTlkODYyYzJmXzQtMy0xLTEtNTA3MjU_87d89f25-f432-435a-a543-d263100ca75f">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="amed:EstimatedInsuranceTotal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90YWJsZTo0YjIzNzM3ZjY4NmM0YWI1OTYzMzVhMjE5ZDg2MmMyZi90YWJsZXJhbmdlOjRiMjM3MzdmNjg2YzRhYjU5NjMzNWEyMTlkODYyYzJmXzUtMS0xLTEtNTA3MjU_dccba1d5-4ad2-4b53-8997-fb801253ac35">62.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="amed:EstimatedInsuranceTotal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90YWJsZTo0YjIzNzM3ZjY4NmM0YWI1OTYzMzVhMjE5ZDg2MmMyZi90YWJsZXJhbmdlOjRiMjM3MzdmNjg2YzRhYjU5NjMzNWEyMTlkODYyYzJmXzUtMy0xLTEtNTA3MjU_1fb5d68a-04e1-40b1-8154-af99968eaf6c">61.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: long-term portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="amed:EstimatedInsuranceLongTermPortion" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90YWJsZTo0YjIzNzM3ZjY4NmM0YWI1OTYzMzVhMjE5ZDg2MmMyZi90YWJsZXJhbmdlOjRiMjM3MzdmNjg2YzRhYjU5NjMzNWEyMTlkODYyYzJmXzYtMS0xLTEtNjI4MzE_338a0f50-80a0-4dd2-a03c-c7e2d320fe5e">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="amed:EstimatedInsuranceLongTermPortion" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90YWJsZTo0YjIzNzM3ZjY4NmM0YWI1OTYzMzVhMjE5ZDg2MmMyZi90YWJsZXJhbmdlOjRiMjM3MzdmNjg2YzRhYjU5NjMzNWEyMTlkODYyYzJmXzYtMy0xLTEtNjI4MzE_f4d0f4f5-6baa-43fb-8935-2a52cccc355f">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="amed:EstimatedInsuranceExcludingLongTermPortion" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90YWJsZTo0YjIzNzM3ZjY4NmM0YWI1OTYzMzVhMjE5ZDg2MmMyZi90YWJsZXJhbmdlOjRiMjM3MzdmNjg2YzRhYjU5NjMzNWEyMTlkODYyYzJmXzctMS0xLTEtNjI4MzE_1a7bfdf3-ccc8-4d62-9f8c-63ce8d8cee8a">61.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="amed:EstimatedInsuranceExcludingLongTermPortion" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90YWJsZTo0YjIzNzM3ZjY4NmM0YWI1OTYzMzVhMjE5ZDg2MmMyZi90YWJsZXJhbmdlOjRiMjM3MzdmNjg2YzRhYjU5NjMzNWEyMTlkODYyYzJmXzctMy0xLTEtNjI4MzE_ac176f1b-7fe0-4671-8ebb-e50681606acb">61.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our health insurance has an exposure limit of $<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="amed:HealthInsuranceRetentionLimit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzEzNDgx_bf2b375a-8e96-4456-9637-f4d8eefaf70e">1.3</ix:nonFraction> million for any individual covered life. Our workers compensation insurance has a retention limit of $<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="amed:WorkersCompensationInsuranceRetentionLimit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzEzNTc3_2d94eb5e-b78f-43b3-8df4-93247372fe43">2.0</ix:nonFraction> million per incident, and our professional liability insurance has a retention limit of $<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="amed:ProfessionalLiabilityInsuranceRetentionLimit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzEzNjU5_a8fe32a9-16f3-4a0c-a74b-2fb48f1677bf">0.3</ix:nonFraction> million per incident. </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Severance</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have commitments related to our severance plans applicable to a number of our senior executives and senior management, which generally commit us to pay severance benefits under certain circumstances.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various other types of claims and disputes arising in the ordinary course of our business. While the resolution of such issues is not presently determinable, we believe that the ultimate resolution of such matters will not have a significant effect on our consolidated financial condition, results of operations or cash flows.</span></div></ix:continuation><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div id="i5c10b724a6674979bf3c35a339f29685_136"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzYvZnJhZzo0YmE2YWI5Nzk0OGQ0OGY3YmFhMTE1OWE0MzBhMDhmOS90ZXh0cmVnaW9uOjRiYTZhYjk3OTQ4ZDQ4ZjdiYWExMTU5YTQzMGEwOGY5XzE2NDk_fb267374-cecb-48e1-8c9b-a2a14f8a7f97" continuedAt="i44a64b40d3234276b960ae097c0d3f46" escape="true">EMPLOYEE BENEFIT PLANS</ix:nonNumeric></span></div><ix:continuation id="i44a64b40d3234276b960ae097c0d3f46"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">401(k) Benefit Plan</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a plan qualified under Section 401(k) of the Internal Revenue Code for all employees who have reached 21 years of age, effective the first month after their hire date. Under the plan, eligible employees may elect to defer a portion of their compensation, subject to Internal Revenue Service limits.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our match of contributions to be made to each eligible employee contribution is $<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="INF" name="amed:DefinedContributionPlanEmployerMatchingContribution" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzYvZnJhZzo0YmE2YWI5Nzk0OGQ0OGY3YmFhMTE1OWE0MzBhMDhmOS90ZXh0cmVnaW9uOjRiYTZhYjk3OTQ4ZDQ4ZjdiYWExMTU5YTQzMGEwOGY5XzQ0Mw_a98cdd23-ea56-4a2a-8df8-20ecbc820c1b">0.44</ix:nonFraction> for every $<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="INF" name="amed:DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzYvZnJhZzo0YmE2YWI5Nzk0OGQ0OGY3YmFhMTE1OWE0MzBhMDhmOS90ZXh0cmVnaW9uOjRiYTZhYjk3OTQ4ZDQ4ZjdiYWExMTU5YTQzMGEwOGY5XzQ1Ng_a43f96a1-263d-4328-bf1a-d72dcada08bb">1.00</ix:nonFraction> contributed up to the first <ix:nonFraction unitRef="number" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="INF" name="amed:DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzYvZnJhZzo0YmE2YWI5Nzk0OGQ0OGY3YmFhMTE1OWE0MzBhMDhmOS90ZXh0cmVnaW9uOjRiYTZhYjk3OTQ4ZDQ4ZjdiYWExMTU5YTQzMGEwOGY5XzQ4Nw_c9661498-ac0c-49f5-a167-9e7976173506">6</ix:nonFraction>% of the employee's salary. The match is discretionary and thus is subject to change at the discretion of management. Our match of contributions is made in the form of cash. We expensed approximately $<ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzYvZnJhZzo0YmE2YWI5Nzk0OGQ0OGY3YmFhMTE1OWE0MzBhMDhmOS90ZXh0cmVnaW9uOjRiYTZhYjk3OTQ4ZDQ4ZjdiYWExMTU5YTQzMGEwOGY5Xzg3NQ_42e414f3-89f2-4271-803e-474bddc52345">18.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzYvZnJhZzo0YmE2YWI5Nzk0OGQ0OGY3YmFhMTE1OWE0MzBhMDhmOS90ZXh0cmVnaW9uOjRiYTZhYjk3OTQ4ZDQ4ZjdiYWExMTU5YTQzMGEwOGY5Xzg3OQ_031adb43-bdfc-4e0d-ad1d-78ca08f091bf">17.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzYvZnJhZzo0YmE2YWI5Nzk0OGQ0OGY3YmFhMTE1OWE0MzBhMDhmOS90ZXh0cmVnaW9uOjRiYTZhYjk3OTQ4ZDQ4ZjdiYWExMTU5YTQzMGEwOGY5Xzg4Ng_45d48851-d36a-44e1-b640-798643a97b49">12.9</ix:nonFraction> million related to our 401(k) benefit plan for 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Compensation Plan</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had a Deferred Compensation Plan for additional tax-deferred savings for a select group of management or highly compensated employees. Amounts credited under the Deferred Compensation Plan were funded into a rabbi trust, which is managed by a trustee. The trustee has the discretion to manage the assets of the Deferred Compensation Plan as deemed fit, thus, the assets are not necessarily reflective of the same investment choices that would have been made by the participants.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January&#160;1, 2015, all prospective salary deferrals ceased. Participants are allowed to make transactions with any remaining account balances as they wish per plan guidelines.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i5c10b724a6674979bf3c35a339f29685_142"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:TreasuryStockTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNDIvZnJhZzozNzJhMTAxNzc4NWE0NWVmYTNmNDk1ZDI1YjQwYjY2My90ZXh0cmVnaW9uOjM3MmExMDE3Nzg1YTQ1ZWZhM2Y0OTVkMjViNDBiNjYzXzI1OTA_b4afff2a-d31d-4e5e-9f7c-40dd1e0a34bb" continuedAt="ia1778331bdc24ea196862c8a3602d01a" escape="true">SHARE REPURCHASES </ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia1778331bdc24ea196862c8a3602d01a" continuedAt="i68775cc953c24ad9b7260441d6e2d404">On December 23, 2020, we announced that our Board of Directors authorized a stock repurchase program, under which we could repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i6b610aa7397640f8a2fa1d7a074bd768_I20201223" decimals="-5" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNDIvZnJhZzozNzJhMTAxNzc4NWE0NWVmYTNmNDk1ZDI1YjQwYjY2My90ZXh0cmVnaW9uOjM3MmExMDE3Nzg1YTQ1ZWZhM2Y0OTVkMjViNDBiNjYzXzE5OA_59a9b0e3-32fb-4408-be92-7a680999f9ec">100</ix:nonFraction>&#160;million of our outstanding common stock through <ix:nonNumeric contextRef="if0c9423c441c4978b769e4a86bc9188f_D20201223-20211231" name="us-gaap:StockRepurchaseProgramExpirationDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNDIvZnJhZzozNzJhMTAxNzc4NWE0NWVmYTNmNDk1ZDI1YjQwYjY2My90ZXh0cmVnaW9uOjM3MmExMDE3Nzg1YTQ1ZWZhM2Y0OTVkMjViNDBiNjYzXzI0MQ_80917f09-7429-44d4-ad58-cb948e114c74">December 31, 2021</ix:nonNumeric> (the "2021 Share Repurchase Program"). Pursuant to this program, we repurchased <ix:nonFraction unitRef="shares" contextRef="ib4261a3345d54d03886673d73969d061_D20210101-20211231" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNDIvZnJhZzozNzJhMTAxNzc4NWE0NWVmYTNmNDk1ZDI1YjQwYjY2My90ZXh0cmVnaW9uOjM3MmExMDE3Nzg1YTQ1ZWZhM2Y0OTVkMjViNDBiNjYzXzkxNg_65712b17-b919-4991-ab7c-8a5bcbd34858">446,832</ix:nonFraction> shares of our common stock at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib4261a3345d54d03886673d73969d061_D20210101-20211231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNDIvZnJhZzozNzJhMTAxNzc4NWE0NWVmYTNmNDk1ZDI1YjQwYjY2My90ZXh0cmVnaW9uOjM3MmExMDE3Nzg1YTQ1ZWZhM2Y0OTVkMjViNDBiNjYzXzk3Nw_d47e30fd-aef6-49f3-bbe9-e7f2afc10086">223.49</ix:nonFraction> per share and a total cost of approximately $<ix:nonFraction unitRef="usd" contextRef="ib4261a3345d54d03886673d73969d061_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNDIvZnJhZzozNzJhMTAxNzc4NWE0NWVmYTNmNDk1ZDI1YjQwYjY2My90ZXh0cmVnaW9uOjM3MmExMDE3Nzg1YTQ1ZWZhM2Y0OTVkMjViNDBiNjYzXzEwMjQ_3ff1415c-5023-4c3f-9b04-ee5d7eb7d594">100</ix:nonFraction>&#160;million during the year ended December 31, 2021. We did not repurchase any shares pursuant to this stock repurchase program during the year ended December 31, 2020. The repurchased shares were classified as treasury shares. The 2021 Share Repurchase Program expired on December 31, 2021.</ix:continuation></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></div><ix:continuation id="i68775cc953c24ad9b7260441d6e2d404" continuedAt="ia3bc697a5bff49f4999168f87430d78e"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2021, our Board of Directors authorized a share repurchase program, under which we could repurchase up to $<ix:nonFraction unitRef="usd" contextRef="ia01a4c270b254b66aa3015655785be61_I20210802" decimals="-5" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNDIvZnJhZzozNzJhMTAxNzc4NWE0NWVmYTNmNDk1ZDI1YjQwYjY2My90ZXh0cmVnaW9uOjM3MmExMDE3Nzg1YTQ1ZWZhM2Y0OTVkMjViNDBiNjYzXzEzNjA_fbd21231-48ec-416b-946b-b101c47409f5">100</ix:nonFraction>&#160;million of our outstanding common stock through <ix:nonNumeric contextRef="ic922798f82384a0cb1c5e20555cd93c6_D20210802-20221231" name="us-gaap:StockRepurchaseProgramExpirationDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNDIvZnJhZzozNzJhMTAxNzc4NWE0NWVmYTNmNDk1ZDI1YjQwYjY2My90ZXh0cmVnaW9uOjM3MmExMDE3Nzg1YTQ1ZWZhM2Y0OTVkMjViNDBiNjYzXzE0MDM_7b1fdb24-cc0e-4171-a5a1-514002492165">December 31, 2022</ix:nonNumeric> to commence upon the completion of the Company's 2021 Share Repurchase Program (the "New Share Repurchase Program"). Pursuant to this program, we repurchased <ix:nonFraction unitRef="shares" contextRef="i9fdb42e0a3874ea5a19076aa86bff340_D20220101-20221231" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNDIvZnJhZzozNzJhMTAxNzc4NWE0NWVmYTNmNDk1ZDI1YjQwYjY2My90ZXh0cmVnaW9uOjM3MmExMDE3Nzg1YTQ1ZWZhM2Y0OTVkMjViNDBiNjYzXzU0OTc1NTgxODI4Mw_afd78306-7c54-4128-a36e-0ea28b4fa7b9">150,000</ix:nonFraction> shares of our common stock at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9fdb42e0a3874ea5a19076aa86bff340_D20220101-20221231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNDIvZnJhZzozNzJhMTAxNzc4NWE0NWVmYTNmNDk1ZDI1YjQwYjY2My90ZXh0cmVnaW9uOjM3MmExMDE3Nzg1YTQ1ZWZhM2Y0OTVkMjViNDBiNjYzXzU0OTc1NTgxODI5Mg_cb0fb73b-32ab-423e-9dfe-4126ec4af775">115.64</ix:nonFraction> per share and a total cost of approximately $<ix:nonFraction unitRef="usd" contextRef="i9fdb42e0a3874ea5a19076aa86bff340_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNDIvZnJhZzozNzJhMTAxNzc4NWE0NWVmYTNmNDk1ZDI1YjQwYjY2My90ZXh0cmVnaW9uOjM3MmExMDE3Nzg1YTQ1ZWZhM2Y0OTVkMjViNDBiNjYzXzU0OTc1NTgxODMwMQ_fafcf368-e75a-40eb-afc8-86d28e7ac53c">17</ix:nonFraction>&#160;million during the year ended December 31, 2022. The repurchased shares were classified as treasury shares. The New Share Repurchase Program expired on December 31, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2021 Share Repurchase Program and the New Share Repurchase Program, we were allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases were determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2023, our Board of Directors authorized a share repurchase program, under which we may repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i92bd39f0d2544264b7d724dd1ae6eac3_I20230202" decimals="-5" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNDIvZnJhZzozNzJhMTAxNzc4NWE0NWVmYTNmNDk1ZDI1YjQwYjY2My90ZXh0cmVnaW9uOjM3MmExMDE3Nzg1YTQ1ZWZhM2Y0OTVkMjViNDBiNjYzXzU0OTc1NTgxODY2OQ_ddcd0c92-bca9-40db-9ae7-fbb0c6fc8412">100</ix:nonFraction>&#160;million of our outstanding common stock through <ix:nonNumeric contextRef="i4b423f65ef9c451d935438afdcfc2e15_D20230202-20231231" name="us-gaap:StockRepurchaseProgramExpirationDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNDIvZnJhZzozNzJhMTAxNzc4NWE0NWVmYTNmNDk1ZDI1YjQwYjY2My90ZXh0cmVnaW9uOjM3MmExMDE3Nzg1YTQ1ZWZhM2Y0OTVkMjViNDBiNjYzXzU0OTc1NTgxODY4Mw_f6447fc3-3ddf-4d77-ae77-aa64ee3e166e">December 31, 2023</ix:nonNumeric> ("the 2023 Share Repurchase Program"). See Note 17 - Subsequent Events for additional information on the newly authorized share repurchase program.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia3bc697a5bff49f4999168f87430d78e">Under the terms of the 2023 Share Repurchase Program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors.</ix:continuation> </span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div id="i5c10b724a6674979bf3c35a339f29685_154"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90ZXh0cmVnaW9uOjg3Yjk2YTkwMjNkODRlMjZiNjJkNTBkN2IxYzA4ZjNkXzE1ODQ_ea145558-e1e4-42c7-94f3-fbc0b55a9d73" continuedAt="i139246d89579460f9e1d6c17f43fb395" escape="true">SEGMENT INFORMATION</ix:nonNumeric></span></div><ix:continuation id="i139246d89579460f9e1d6c17f43fb395" continuedAt="i081e1691d4634aa482adaeddb7046d90"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations involve servicing patients through our <ix:nonFraction unitRef="segment" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90ZXh0cmVnaW9uOjg3Yjk2YTkwMjNkODRlMjZiNjJkNTBkN2IxYzA4ZjNkXzgz_d2e7fb2b-fd54-4ec6-b996-ab271f7e03b6">four</ix:nonFraction> reportable business segments: home health, hospice, personal care and high acuity care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from an illness, injury or surgery. Our hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. Our personal care segment provides patients with assistance with the essential activities of daily living. Our high acuity care segment, which was established with the acquisition of Contessa on August 1, 2021, delivers the essential elements of inpatient hospital and SNF care to patients in their homes. The &#8220;other&#8221; column in the following tables consists of costs relating to executive management and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration.</span></div><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90ZXh0cmVnaW9uOjg3Yjk2YTkwMjNkODRlMjZiNjJkNTBkN2IxYzA4ZjNkXzE1ODY_376fedda-277d-4166-b114-67a0bd5f10ca" continuedAt="i1ae223968e4941e9932d111855567666" escape="true"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management evaluates performance and allocates resources based on the operating income of the reportable segments, which includes an allocation of corporate expenses attributable to the specific segment and includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company&#8217;s chief operating decision maker and therefore are not disclosed below (amounts in millions).</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:35.117%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.017%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.554%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home&#160;Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal&#160;Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icff92844bf7e45cf8941114000e0fa42_D20220101-20221231" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzItMS0xLTEtNTA3MjU_98025dbb-a685-4ea2-8993-dcebf855098a">1,355.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971b271744ea4a63aca16276f887bcb4_D20220101-20221231" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzItMy0xLTEtNTA3MjU_8a6a173f-a943-4209-b4db-13aa3c8df6c5">787.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e623706c1354124a369dc7758938060_D20220101-20221231" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzItNS0xLTEtNTA3MjU_96021338-5eeb-43eb-9854-cdb44a6c0eb3">61.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47b68ba2f13e424bacfacf577053382b_D20220101-20221231" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzItNy0xLTEtNTA3MjU_9b51fdd4-82e9-4ccd-b2b3-00a63f0fc917">18.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i114e5c43f13843719a8a60aa9fd64db1_D20220101-20221231" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzItOS0xLTEtNTA3MjU_2c7aa015-301c-4011-b163-9501ea8459c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzItMTEtMS0xLTUwNzI1_73135754-663b-4e77-9813-f33a6a310311">2,223.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icff92844bf7e45cf8941114000e0fa42_D20220101-20221231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzQtMS0xLTEtNTA3MjU_be1cbbb1-5b24-4e11-a0ea-76737ce47a24">769.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971b271744ea4a63aca16276f887bcb4_D20220101-20221231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzQtMy0xLTEtNTA3MjU_965847a5-7003-4754-b69f-b33713736ab2">426.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e623706c1354124a369dc7758938060_D20220101-20221231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzQtNS0xLTEtNTA3MjU_50a8c434-6e46-422e-b5c3-a76a9d814af5">46.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47b68ba2f13e424bacfacf577053382b_D20220101-20221231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzQtNy0xLTEtNTA3MjU_b295a207-e23d-4a6d-aa62-3e459a94b28b">18.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i114e5c43f13843719a8a60aa9fd64db1_D20220101-20221231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzQtOS0xLTEtNTA3MjU_d2ed78a6-dfe1-4dc4-a124-ce102069bb40">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzQtMTEtMS0xLTUwNzI1_83df0b2d-17c4-440b-b52d-0922fde265af">1,260.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses, excluding depreciation and amortization and impairment charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icff92844bf7e45cf8941114000e0fa42_D20220101-20221231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzUtMS0xLTEtNTA3MjU_ce22a97f-0b52-43a8-8b86-13992e87fee4">348.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971b271744ea4a63aca16276f887bcb4_D20220101-20221231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzUtMy0xLTEtNTA3MjU_85d1c7d1-4ded-4e81-9881-32f9be4e9c07">203.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e623706c1354124a369dc7758938060_D20220101-20221231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzUtNS0xLTEtNTA3MjU_dbbe3ded-cfa1-4f7f-a527-90d22549f2c7">9.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47b68ba2f13e424bacfacf577053382b_D20220101-20221231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzUtNy0xLTEtNTA3MjU_a97702ec-146d-49ff-a467-001a35d06036">33.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i114e5c43f13843719a8a60aa9fd64db1_D20220101-20221231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzUtOS0xLTEtNTA3MjU_0d56f87c-9115-4dd1-bbd9-19e39ba71640">160.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzUtMTEtMS0xLTUwNzI1_de82981d-4444-49f3-a27c-8d02d4b29570">754.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icff92844bf7e45cf8941114000e0fa42_D20220101-20221231" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzYtMS0xLTEtNTA3MjU_8fa9a5fd-0fac-4fad-9d20-80b80b5a192d">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971b271744ea4a63aca16276f887bcb4_D20220101-20221231" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzYtMy0xLTEtNTA3MjU_faee45f7-22f5-4cc1-b503-2f7303b6187a">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e623706c1354124a369dc7758938060_D20220101-20221231" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzYtNS0xLTEtNTA3MjU_3f83f096-7ca2-40a8-b0ff-848236d0430d">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47b68ba2f13e424bacfacf577053382b_D20220101-20221231" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzYtNy0xLTEtNTA3MjU_1adefd9f-ab9c-42e8-a511-259d86ce2857">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i114e5c43f13843719a8a60aa9fd64db1_D20220101-20221231" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzYtOS0xLTEtNTA3MjU_dc253fd5-ec64-4ad1-bd79-abc4fc293b09">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzYtMTEtMS0xLTUwNzI1_b854d0ce-fbb9-4b83-9b1c-2545e75d02fb">24.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icff92844bf7e45cf8941114000e0fa42_D20220101-20221231" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzYtMS0xLTEtNTY0Nzk_377d866c-dd85-43ce-9a00-ac7993d16829">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971b271744ea4a63aca16276f887bcb4_D20220101-20221231" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzYtMy0xLTEtNTY0Nzk_210c4889-c9cf-421d-80b5-e94d8b6afb1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e623706c1354124a369dc7758938060_D20220101-20221231" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzYtNS0xLTEtNTY0Nzk_7d1b5ddf-1688-4ab7-ab22-c6330048a3d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47b68ba2f13e424bacfacf577053382b_D20220101-20221231" decimals="-5" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzYtNy0xLTEtNTY0Nzk_6c6d0201-8f12-4d20-a6ec-ae740dcb713c">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i114e5c43f13843719a8a60aa9fd64db1_D20220101-20221231" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzYtOS0xLTEtNTY0Nzk_3e4292b7-a4ef-4b9a-b6bd-5d413a521f7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzYtMTEtMS0xLTU2NDc5_83a6c521-2ade-44a1-8a79-edc9d73c4b3b">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icff92844bf7e45cf8941114000e0fa42_D20220101-20221231" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzctMS0xLTEtNTA3MjU_7d06a697-3b64-48de-91f1-0649c2f4f95c">1,121.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971b271744ea4a63aca16276f887bcb4_D20220101-20221231" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzctMy0xLTEtNTA3MjU_e3f20629-2bf0-4700-8b2b-02a0131d5118">632.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e623706c1354124a369dc7758938060_D20220101-20221231" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzctNS0xLTEtNTA3MjU_15b54cb0-bacf-49e4-b7c4-a7b9e227ba14">56.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47b68ba2f13e424bacfacf577053382b_D20220101-20221231" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzctNy0xLTEtNTA3MjU_8b45d9c7-30e6-4674-9582-199030937b07">57.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i114e5c43f13843719a8a60aa9fd64db1_D20220101-20221231" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzctOS0xLTEtNTA3MjU_1d00c491-e8a7-43e0-a54b-cf43669e467c">175.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzctMTEtMS0xLTUwNzI1_3404920c-b5a3-469c-987c-f9836eb6489c">2,042.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icff92844bf7e45cf8941114000e0fa42_D20220101-20221231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzgtMS0xLTEtNTA3MjU_80f831a5-2645-46cb-96b5-e590f43c46e8">234.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971b271744ea4a63aca16276f887bcb4_D20220101-20221231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzgtMy0xLTEtNTA3MjU_be7008bf-172d-4266-9d19-03b6e16a8087">155.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e623706c1354124a369dc7758938060_D20220101-20221231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzgtNS0xLTEtNTA3MjU_e57f37a5-6ff1-4310-966c-64ef35a61917">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47b68ba2f13e424bacfacf577053382b_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzgtNy0xLTEtNTA3MjU_494a93af-31f8-475d-a0b0-00877815c378">39.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i114e5c43f13843719a8a60aa9fd64db1_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzgtOS0xLTEtNTA3MjU_ecaa5b28-dcd5-45d7-be02-6eb14258e0e2">175.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzgtMTEtMS0xLTUwNzI1_abc93e10-302e-4a3f-80ab-03d3fd629054">180.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022</span></div></div><ix:continuation id="i081e1691d4634aa482adaeddb7046d90"><ix:continuation id="i1ae223968e4941e9932d111855567666"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:35.117%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.017%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.554%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home&#160;Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal&#160;Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc3b9823141645e68eb892a3c076e69b_D20210101-20211231" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzItMS0xLTEtNTA3MjU_46ad90c5-3e70-46bc-8cd0-8f8b6e994b65">1,353.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8bd5c211c94e959f7bcc237d284961_D20210101-20211231" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzItMy0xLTEtNTA3MjU_8c20d5fd-aaef-45ea-b1db-5cd10db89376">791.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc02119e099f490a8a653314b18712d4_D20210101-20211231" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzItNS0xLTEtNTA3MjU_55478176-ca46-43a9-bfc7-aee7a443e042">65.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i722dd3d3be554fc1bcbc003ddc943c6a_D20210101-20211231" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzItNy0xLTEtNTA3MjU_4c5eb07f-4160-4536-af40-a4698b3dea0b">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a8daa3605c04f07bf026bdc825236d7_D20210101-20211231" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzItOS0xLTEtNTA3MjU_aef038da-7d85-4787-a6b5-24e5da6c1e7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzItMTEtMS0xLTUwNzI1_8c2f36ad-5e22-40b1-b4df-ff40d2ccc387">2,214.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc3b9823141645e68eb892a3c076e69b_D20210101-20211231" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzMtMS0xLTEtNTA3MjU_00d06b3c-f113-4cc9-bb5a-7de932712880">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8bd5c211c94e959f7bcc237d284961_D20210101-20211231" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzMtMy0xLTEtNTA3MjU_15615dd3-7685-4fdb-ba97-b7d10085af95">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc02119e099f490a8a653314b18712d4_D20210101-20211231" decimals="-5" name="us-gaap:OtherOperatingIncome" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzMtNS0xLTEtNTA3MjU_ffe0c1f0-c5be-4096-8707-b9a85715c016">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i722dd3d3be554fc1bcbc003ddc943c6a_D20210101-20211231" decimals="-5" name="us-gaap:OtherOperatingIncome" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzMtNy0xLTEtNTA3MjU_2c84430c-9b47-4dfb-a89e-740f07e9c4e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a8daa3605c04f07bf026bdc825236d7_D20210101-20211231" decimals="-5" name="us-gaap:OtherOperatingIncome" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzMtOS0xLTEtNTA3MjU_2c3c19d8-328e-4116-8a3c-f326769c06bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzMtMTEtMS0xLTUwNzI1_28c2e876-e87f-4ad0-b990-f76a06e898ed">13.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc3b9823141645e68eb892a3c076e69b_D20210101-20211231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzQtMS0xLTEtNTA3MjU_c5a33982-acf1-4b2c-91dc-0fd5030c31f2">756.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8bd5c211c94e959f7bcc237d284961_D20210101-20211231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzQtMy0xLTEtNTA3MjU_82f66892-1461-49d8-a727-9bb5f23f9d26">425.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc02119e099f490a8a653314b18712d4_D20210101-20211231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzQtNS0xLTEtNTA3MjU_fb1ea16a-66cd-40ee-a39a-9694d2c321b0">49.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i722dd3d3be554fc1bcbc003ddc943c6a_D20210101-20211231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzQtNy0xLTEtNTA3MjU_6170fc46-9903-4653-8f22-e7f533f6588b">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a8daa3605c04f07bf026bdc825236d7_D20210101-20211231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzQtOS0xLTEtNTA3MjU_fddd1b04-d191-4dc3-bb9e-6a511ff373d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzQtMTEtMS0xLTUwNzI1_71cd6a68-8637-4849-82ab-001296e7bf1c">1,233.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses, excluding depreciation and amortization and impairment charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc3b9823141645e68eb892a3c076e69b_D20210101-20211231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzUtMS0xLTEtNTA3MjU_8a7d363c-b426-4789-b6e9-13edee953960">328.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8bd5c211c94e959f7bcc237d284961_D20210101-20211231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzUtMy0xLTEtNTA3MjU_148eb65b-e24f-4c65-b37e-0102434e45ff">198.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc02119e099f490a8a653314b18712d4_D20210101-20211231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzUtNS0xLTEtNTA3MjU_540beeb6-2e57-41de-8be6-644fd57c7b33">11.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i722dd3d3be554fc1bcbc003ddc943c6a_D20210101-20211231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzUtNy0xLTEtNTA3MjU_9766ec94-d716-425f-aa54-812c62ceddf0">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a8daa3605c04f07bf026bdc825236d7_D20210101-20211231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzUtOS0xLTEtNTA3MjU_e467e846-ef81-42cd-a1d3-2be1eba20020">163.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzUtMTEtMS0xLTUwNzI1_59927506-4331-4fe2-810f-2d5b5932f1eb">711.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc3b9823141645e68eb892a3c076e69b_D20210101-20211231" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzYtMS0xLTEtNTA3MjU_3b09d31e-e35a-4ebd-97df-2e25057dd7a0">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8bd5c211c94e959f7bcc237d284961_D20210101-20211231" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzYtMy0xLTEtNTA3MjU_af6a1c87-332b-489d-a230-cd3406effa56">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc02119e099f490a8a653314b18712d4_D20210101-20211231" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzYtNS0xLTEtNTA3MjU_fdc0e99e-36ff-4834-919d-82bd397225f9">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i722dd3d3be554fc1bcbc003ddc943c6a_D20210101-20211231" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzYtNy0xLTEtNTA3MjU_a0c93d10-efaa-4bbf-9b4a-700e73bb5690">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a8daa3605c04f07bf026bdc825236d7_D20210101-20211231" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzYtOS0xLTEtNTA3MjU_9e7f39f1-0288-4aa3-91bc-e5273291d6ce">22.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzYtMTEtMS0xLTUwNzI1_4dd07547-70dc-4389-ae11-93721411f769">30.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc3b9823141645e68eb892a3c076e69b_D20210101-20211231" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzgtMS0xLTEtNTA3MjU_5ef7cf8e-3361-49c2-9722-0f470d3b27d3">1,089.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8bd5c211c94e959f7bcc237d284961_D20210101-20211231" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzgtMy0xLTEtNTA3MjU_b0764537-ecf7-44c4-8ff6-c759d02e9734">626.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc02119e099f490a8a653314b18712d4_D20210101-20211231" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzgtNS0xLTEtNTA3MjU_618d3e50-dd92-48b2-aa03-fae53f4b4b39">60.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i722dd3d3be554fc1bcbc003ddc943c6a_D20210101-20211231" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzgtNy0xLTEtNTA3MjU_6746224b-0a46-4e7d-b38a-53a1848685f8">13.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a8daa3605c04f07bf026bdc825236d7_D20210101-20211231" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzgtOS0xLTEtNTA3MjU_919d776c-ce2d-4f18-9737-21eb3dd8cc53">185.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzgtMTEtMS0xLTUwNzI1_fa3e2308-4ec2-4e0d-9a83-70b818c18dc4">1,975.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc3b9823141645e68eb892a3c076e69b_D20210101-20211231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzktMS0xLTEtNTA3MjU_c5f75d9d-c0fe-4cfe-aef2-69e3fd42b391">271.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c8bd5c211c94e959f7bcc237d284961_D20210101-20211231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzktMy0xLTEtNTA3MjU_bf30f273-4308-4ccc-9cd6-5417588d17a8">171.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc02119e099f490a8a653314b18712d4_D20210101-20211231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzktNS0xLTEtNTA3MjU_b62db2e4-c6e4-48dd-ab8d-e8c7e613ffd2">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i722dd3d3be554fc1bcbc003ddc943c6a_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzktNy0xLTEtNTA3MjU_faa8abc2-b4d6-42e8-92d6-49bae40035e8">10.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a8daa3605c04f07bf026bdc825236d7_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzktOS0xLTEtNTA3MjU_e67646e8-bdf9-4fb5-a632-184c544dfbe5">185.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzktMTEtMS0xLTUwNzI1_6dae06b4-9d9e-4998-bdae-038e92418385">251.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:35.117%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.017%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.554%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home&#160;Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal&#160;Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id362cc93e6cd48da8f96f15cbc8bed2e_D20200101-20201231" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzItMS0xLTEtNTA3MjU_edeec692-1355-48fb-b067-29f3e1554dc7">1,249.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6db8f1d2d01b4b87b43031a471f0a747_D20200101-20201231" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzItMy0xLTEtNTA3MjU_0d840389-f577-44d4-9394-11c118517e2f">750.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad09634e54b64f4ab4f376450c10a9fe_D20200101-20201231" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzItNS0xLTEtNTA3MjU_4657c20c-af35-43d2-849a-34821cf7d8fb">72.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5e19c6308394df88a3ac225cead2412_D20200101-20201231" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzItNy0xLTEtNTA3MjU_4d1e52fd-159a-4fe5-8060-7c865fd45bac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55522935511e4608b35d61ba4b0cb9d2_D20200101-20201231" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzItOS0xLTEtNTA3MjU_06af6548-c20e-4e51-beb4-fcec9ac09435">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzItMTEtMS0xLTUwNzI1_9ccc61a6-fa05-4ef8-8247-afb411888ed4">2,071.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id362cc93e6cd48da8f96f15cbc8bed2e_D20200101-20201231" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzMtMS0xLTEtNTMwMTE_43055798-1c53-419a-bf7e-618de9217a3b">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6db8f1d2d01b4b87b43031a471f0a747_D20200101-20201231" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzMtMy0xLTEtNTMwMTE_6c1e0d65-be8b-4e54-abeb-226c92ca2ace">13.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad09634e54b64f4ab4f376450c10a9fe_D20200101-20201231" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzMtNS0xLTEtNTMwMTE_62384bbe-73db-4db0-86be-45f1d2af145d">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5e19c6308394df88a3ac225cead2412_D20200101-20201231" decimals="-5" name="us-gaap:OtherOperatingIncome" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzMtNy0xLTEtNTMwMTE_192b7c6a-d2c3-417d-abc5-8032d9505400">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55522935511e4608b35d61ba4b0cb9d2_D20200101-20201231" decimals="-5" name="us-gaap:OtherOperatingIncome" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzMtOS0xLTEtNTMwMTE_1eb0914f-f979-46be-bb7c-8cedc5382e80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-5" name="us-gaap:OtherOperatingIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzMtMTEtMS0xLTUzMDEx_ad27f933-47ef-45eb-ac11-1101a250a951">34.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id362cc93e6cd48da8f96f15cbc8bed2e_D20200101-20201231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzMtMS0xLTEtNTA3MjU_14efe36f-c06a-4ff2-a525-081ac92d7d2b">729.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6db8f1d2d01b4b87b43031a471f0a747_D20200101-20201231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzMtMy0xLTEtNTA3MjU_dc5d5377-8d12-420b-8aec-d9f72fee9689">400.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad09634e54b64f4ab4f376450c10a9fe_D20200101-20201231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzMtNS0xLTEtNTA3MjU_5fede8cc-e22b-4045-ac53-6eaad3f70722">54.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5e19c6308394df88a3ac225cead2412_D20200101-20201231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzMtNy0xLTEtNTA3MjU_29c8b7fd-93c1-440d-9b12-e057be70a30f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55522935511e4608b35d61ba4b0cb9d2_D20200101-20201231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzMtOS0xLTEtNTA3MjU_faa0dfb8-37e9-48e0-80e7-3515cce6cad4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzMtMTEtMS0xLTUwNzI1_24a77adb-3054-413d-b4fe-7dc9db5ab584">1,185.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses, excluding depreciation and amortization and impairment charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id362cc93e6cd48da8f96f15cbc8bed2e_D20200101-20201231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzQtMS0xLTEtNTA3MjU_7b8fe721-00f6-45b6-8133-03387dd6b169">307.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6db8f1d2d01b4b87b43031a471f0a747_D20200101-20201231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzQtMy0xLTEtNTA3MjU_1f606750-9b60-4cde-a8f9-5e68359faa45">175.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad09634e54b64f4ab4f376450c10a9fe_D20200101-20201231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzQtNS0xLTEtNTA3MjU_b0c40367-4c1e-4e55-a6c6-b40ce05b435f">12.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5e19c6308394df88a3ac225cead2412_D20200101-20201231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzQtNy0xLTEtNTA3MjU_21ba025d-1b83-493c-8f00-6b464ab269f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55522935511e4608b35d61ba4b0cb9d2_D20200101-20201231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzQtOS0xLTEtNTA3MjU_ddf475a2-a7b2-44bd-a00b-361af2edd302">173.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzQtMTEtMS0xLTUwNzI1_0f5656be-a3ce-47bf-a5b5-5cc166fac754">668.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id362cc93e6cd48da8f96f15cbc8bed2e_D20200101-20201231" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzUtMS0xLTEtNTA3MjU_c80f08fd-7550-48b2-a2e8-d163467ccc2d">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6db8f1d2d01b4b87b43031a471f0a747_D20200101-20201231" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzUtMy0xLTEtNTA3MjU_04ebb8b2-912c-49db-8f2f-230bfae46ea5">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad09634e54b64f4ab4f376450c10a9fe_D20200101-20201231" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzUtNS0xLTEtNTA3MjU_f323bb55-c1ab-47de-8062-1a545ae6bcc3">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5e19c6308394df88a3ac225cead2412_D20200101-20201231" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzUtNy0xLTEtNTA3MjU_4693b5c5-d125-4bd4-a2a4-6bc3de6a4774">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55522935511e4608b35d61ba4b0cb9d2_D20200101-20201231" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzUtOS0xLTEtNTA3MjU_b0b97e8d-2db0-45e9-99e2-d21680bca7c5">22.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-5" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzUtMTEtMS0xLTUwNzI1_ceea6e92-736f-465b-bc2f-b32ba1b6491f">28.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id362cc93e6cd48da8f96f15cbc8bed2e_D20200101-20201231" decimals="-5" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzYtMS0xLTEtNTA3MjU_3eed6425-ec35-4859-b753-e3e3166d9087">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6db8f1d2d01b4b87b43031a471f0a747_D20200101-20201231" decimals="-5" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzYtMy0xLTEtNTA3MjU_7ce45c53-2888-402d-bcf5-08babc4985c2">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad09634e54b64f4ab4f376450c10a9fe_D20200101-20201231" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzYtNS0xLTEtNTA3MjU_116378d8-e83d-427c-9675-0bfe4d2ae2ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5e19c6308394df88a3ac225cead2412_D20200101-20201231" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzYtNy0xLTEtNTA3MjU_4ae6fc2c-b32e-4c13-8ce8-5c3e9ce2b9a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55522935511e4608b35d61ba4b0cb9d2_D20200101-20201231" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzYtOS0xLTEtNTA3MjU_fdf8de06-66a3-43e5-9a4a-09bafd402fab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-5" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzYtMTEtMS0xLTUwNzI1_f33175d9-105e-4009-8600-f5e2e5e497ba">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id362cc93e6cd48da8f96f15cbc8bed2e_D20200101-20201231" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzctMS0xLTEtNTA3MjU_c0dd1bd9-54c2-4371-85a8-8ae82e391940">1,044.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6db8f1d2d01b4b87b43031a471f0a747_D20200101-20201231" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzctMy0xLTEtNTA3MjU_33ecbbd5-072f-4bd1-bbbc-22ecfe70da32">579.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad09634e54b64f4ab4f376450c10a9fe_D20200101-20201231" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzctNS0xLTEtNTA3MjU_a132a627-a570-4f2e-8f64-6deb7dd6b3c1">67.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5e19c6308394df88a3ac225cead2412_D20200101-20201231" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzctNy0xLTEtNTA3MjU_cefec6aa-93d8-4699-a967-dcef877cc4c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55522935511e4608b35d61ba4b0cb9d2_D20200101-20201231" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzctOS0xLTEtNTA3MjU_05efa34d-d55a-4a6d-9e28-05c3b6207e5d">195.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzctMTEtMS0xLTUwNzI1_aa977a8d-033c-4dc6-bd82-cf02ae161249">1,886.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id362cc93e6cd48da8f96f15cbc8bed2e_D20200101-20201231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzgtMS0xLTEtNTA3MjU_47682c55-e89e-4e8a-ba8b-cf1e8f0c4db2">225.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6db8f1d2d01b4b87b43031a471f0a747_D20200101-20201231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzgtMy0xLTEtNTA3MjU_d440d613-b7be-438d-b9cf-cfe7f969bef0">184.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad09634e54b64f4ab4f376450c10a9fe_D20200101-20201231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzgtNS0xLTEtNTA3MjU_8a3af758-7862-4e98-a742-d43f91e37a9b">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5e19c6308394df88a3ac225cead2412_D20200101-20201231" decimals="-5" name="us-gaap:OperatingIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzgtNy0xLTEtNTA3MjU_f06873b9-186f-436a-bb2d-c73b67f39892">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55522935511e4608b35d61ba4b0cb9d2_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzgtOS0xLTEtNTA3MjU_5baf03e5-6979-4ab4-8902-38526bea33ee">195.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzgtMTEtMS0xLTUwNzI1_dee51e80-c325-46c9-b636-cdf5892ada04">219.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="i5c10b724a6674979bf3c35a339f29685_163"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.&#160;<ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNjMvZnJhZzoyNzYxYjgxNjVhZTY0Mzg0YjRmYzBjOTdhZmY5OTdiMC90ZXh0cmVnaW9uOjI3NjFiODE2NWFlNjQzODRiNGZjMGM5N2FmZjk5N2IwXzQ2MA_fd94ada7-fbd6-4e7f-9459-760b11f8776b" continuedAt="i20be092c20b141ed890c7ab9ff905479" escape="true">RELATED PARTY TRANSACTIONS</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i20be092c20b141ed890c7ab9ff905479">We have an investment in Medalogix, a healthcare predictive data and analytics company, which is accounted for under the equity method. During the years ended December 31, 2022, 2021 and 2020, we incurred costs of approximately $<ix:nonFraction unitRef="usd" contextRef="i65690d26701e4e5ea588f0959375f58b_D20220101-20221231" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNjMvZnJhZzoyNzYxYjgxNjVhZTY0Mzg0YjRmYzBjOTdhZmY5OTdiMC90ZXh0cmVnaW9uOjI3NjFiODE2NWFlNjQzODRiNGZjMGM5N2FmZjk5N2IwXzI2NA_8fce2aa3-a6c1-4f63-803d-80dcf4cc3d9c">9.4</ix:nonFraction>&#160;million,$<ix:nonFraction unitRef="usd" contextRef="idaf95b2f3ae241fa85a7edcd22950e29_D20210101-20211231" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNjMvZnJhZzoyNzYxYjgxNjVhZTY0Mzg0YjRmYzBjOTdhZmY5OTdiMC90ZXh0cmVnaW9uOjI3NjFiODE2NWFlNjQzODRiNGZjMGM5N2FmZjk5N2IwXzI2Nw_a3dd26f2-4242-483c-99b8-cbaef92240fb">5.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ib9c94f55e0204d55a40837adab0df9ec_D20200101-20201231" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNjMvZnJhZzoyNzYxYjgxNjVhZTY0Mzg0YjRmYzBjOTdhZmY5OTdiMC90ZXh0cmVnaW9uOjI3NjFiODE2NWFlNjQzODRiNGZjMGM5N2FmZjk5N2IwXzI3NA_cb8afad9-801f-48a4-bf1d-3c230300b08d">3.9</ix:nonFraction> million, respectively, in connection with our usage of Medalogix's analytics platforms. We believe that the terms of these transactions are consistent with those negotiated at arm&#8217;s length.</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div id="i5c10b724a6674979bf3c35a339f29685_169"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.&#160;SUBSEQUENT EVENTS</span></div><ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNjkvZnJhZzo4MDhiNzc5Y2Y1OWY0MmY2ODkxYjZmNzM5MDdmZGZiNi90ZXh0cmVnaW9uOjgwOGI3NzljZjU5ZjQyZjY4OTFiNmY3MzkwN2ZkZmI2XzU0OTc1NTgxNjAxMg_eb28e6da-dda8-4c64-b947-7bdb61407045" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2023 Share Repurchase Program</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2023, our Board of Directors authorized a share repurchase program, under which we may repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i92bd39f0d2544264b7d724dd1ae6eac3_I20230202" decimals="-5" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNjkvZnJhZzo4MDhiNzc5Y2Y1OWY0MmY2ODkxYjZmNzM5MDdmZGZiNi90ZXh0cmVnaW9uOjgwOGI3NzljZjU5ZjQyZjY4OTFiNmY3MzkwN2ZkZmI2XzU0OTc1NTgxNTExMA_ddcd0c92-bca9-40db-9ae7-fbb0c6fc8412">100</ix:nonFraction>&#160;million of our outstanding common stock through <ix:nonNumeric contextRef="i4b423f65ef9c451d935438afdcfc2e15_D20230202-20231231" name="us-gaap:StockRepurchaseProgramExpirationDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNjkvZnJhZzo4MDhiNzc5Y2Y1OWY0MmY2ODkxYjZmNzM5MDdmZGZiNi90ZXh0cmVnaW9uOjgwOGI3NzljZjU5ZjQyZjY4OTFiNmY3MzkwN2ZkZmI2XzU0OTc1NTgxNTE1NA_f6447fc3-3ddf-4d77-ae77-aa64ee3e166e">December&#160;31, 2023</ix:nonNumeric> (the "2023 Share Repurchase Program"). Under the terms of the 2023 Share Repurchase Program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. Effective January 1, 2023, repurchases are subject to a 1% excise tax under the Inflation Reduction Act.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets Held For Sale</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2023, we signed a definitive agreement to sell our personal care business (excluding the Florida operations). The divestment is expected to close during the second quarter of 2023. See Note 6 - Assets Held For Sale for additional information.</span></div></ix:nonNumeric><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><div id="i5c10b724a6674979bf3c35a339f29685_175"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9.&#160;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i5c10b724a6674979bf3c35a339f29685_178"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9A.&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established disclosure controls and procedures which are designed to provide reasonable assurance of achieving their objectives and to ensure that information required to be disclosed in our reports filed under the Exchange Act is recorded, processed, summarized, disclosed and reported within the time periods specified in the SEC&#8217;s rules and forms. This information is also accumulated and communicated to our management, including our principal executive officer and principal financial officer, and Board of Directors to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the preparation of this Annual Report on Form 10-K, as of December&#160;31, 2022, under the supervision and with the participation of our principal executive officer and principal financial officer, our management conducted an evaluation of the effectiveness of our disclosure controls and procedures, as such term is defined under Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of December&#160;31, 2022, the end of the period covered by this Annual Report on Form 10-K.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over our financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act. Under the supervision and with the participation of our principal executive officer and our principal financial officer, our management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation under the framework in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our management concluded our internal control over financial reporting was effective as of December&#160;31, 2022.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under guidelines established by the SEC, companies are allowed to exclude acquisitions from their assessment of internal control over financial reporting during the first year of an acquisition while integrating the acquired company. Accordingly, our assessment of internal controls excluded our acquisitions of Evolution Health, LLC, a division of Envision Healthcare, doing business as Guardian Healthcare, Gem City, and Care Connection of Cincinnati ("Evolution") and Assisted Care Home Health, Inc. and RH Homecare Services, LLC doing business as AssistedCare Home Health and AssistedCare of the Carolinas ("AssistedCare"), completed on April 1, 2022. See Item 8, Note 4 - Acquisitions to our consolidated financial statements for additional information on our acquisitions of Evolution and AssistedCare. Operations from these acquisitions represented approximately 1% of total assets and approximately 2% of total revenue as of and for the year ended December 31, 2022.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KPMG LLP, the independent registered public accounting firm that audited our consolidated financial statements included in this Form 10-K, has issued a report on our internal control over financial reporting, which is included herein.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Controls</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f)) that occurred during the quarter ended December&#160;31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inherent Limitations on Effectiveness of Controls</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls or our internal controls over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls&#8217; effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives and, based on an evaluation of our controls and procedures, our principal executive officer and our principal financial officer concluded our disclosure controls and procedures were effective at a reasonable assurance level as of December 31, 2022, the end of the period covered by this Annual Report.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and Board of Directors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amedisys, Inc.:</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Amedisys, Inc. and subsidiaries' (the Company) internal control over financial reporting as of December 31, 2022, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2022 and 2021, the related consolidated statements of operations, comprehensive income, stockholders&#8217; equity, and cash flows for each of the years in the three-year period ended December 31, 2022, and the related notes (collectively, the consolidated financial statements), and our report dated February 16, 2023 expressed an unqualified opinion on those consolidated financial statements.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acquired Evolution Health, LLC, a division of Envision Healthcare, doing business as Guardian Healthcare, Gem City, and Care Connection of Cincinnati (Evolution) and Assisted Care Home Health, Inc. and RH Homecare Services, LLC doing business as AssistedCare Home Health and AssistedCare of the Carolinas (AssistedCare) during 2022, and management excluded from its assessment of the effectiveness of the Company&#8217;s internal control over financial reporting as of December 31, 2022, Evolution Health, LLC, a division of Envision Healthcare, doing business as Guardian Healthcare, Gem City, and Care Connection of Cincinnati (Evolution) and Assisted Care Home Health, Inc. and RH Homecare Services, LLC doing business as AssistedCare Home Health and AssistedCare of the Carolinas (AssistedCare)&#8217;s internal control over financial reporting associated with approximately 1% of total assets and approximately 2% of total revenue included in the consolidated financial statements of the Company as of and for the year ended December 31, 2022. Our audit of internal control over financial reporting of the Company also excluded an evaluation of the internal control over financial reporting of Evolution Health, LLC, a division of Envision Healthcare, doing business as Guardian Healthcare, Gem City, and Care Connection of Cincinnati (Evolution) and Assisted Care Home Health, Inc. and RH Homecare Services, LLC doing business as AssistedCare Home Health and AssistedCare of the Carolinas (AssistedCare).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis for Opinion</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ KPMG LLP</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Baton Rouge, Louisiana</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;16, 2023 </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><div id="i5c10b724a6674979bf3c35a339f29685_181"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9B. OTHER INFORMATION</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div id="i5c10b724a6674979bf3c35a339f29685_184"></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div id="i5c10b724a6674979bf3c35a339f29685_187"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div style="text-align:center"><span><br/></span></div><div id="i5c10b724a6674979bf3c35a339f29685_190"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to the 2023 Proxy Statement to be filed with the SEC within 120 days after the end of the year ended December&#160;31, 2022.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Conduct and Ethics</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a code of ethics that applies to all of our directors, officers and employees, including our principal executive officer, principal financial officer and principal accounting officer. This code of ethics is posted at our internet website, http://www.amedisys.com. Any amendments to, or waivers of, the code of ethics will be disclosed on our website promptly following the date of such amendment or waiver.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i5c10b724a6674979bf3c35a339f29685_193"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;11. EXECUTIVE COMPENSATION</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to the 2023 Proxy Statement to be filed with the SEC within 120 days after the end of the year ended December&#160;31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i5c10b724a6674979bf3c35a339f29685_196"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to the 2023 Proxy Statement to be filed with the SEC within 120 days after the end of the year ended December&#160;31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i5c10b724a6674979bf3c35a339f29685_199"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to the 2023 Proxy Statement to be filed with the SEC within 120 days after the end of the year ended December&#160;31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i5c10b724a6674979bf3c35a339f29685_202"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our independent registered public accounting firm is <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8yMDIvZnJhZzpiZTJiNDQ1YjBiZGU0ZmE0OTYyMWM0YmQ3Y2Y1MWQzYi90ZXh0cmVnaW9uOmJlMmI0NDViMGJkZTRmYTQ5NjIxYzRiZDdjZjUxZDNiXzMyOA_5e5a2744-303f-4c02-8d6b-6c799daf2b8e">KPMG LLP</ix:nonNumeric>, <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8yMDIvZnJhZzpiZTJiNDQ1YjBiZGU0ZmE0OTYyMWM0YmQ3Y2Y1MWQzYi90ZXh0cmVnaW9uOmJlMmI0NDViMGJkZTRmYTQ5NjIxYzRiZDdjZjUxZDNiXzMyOQ_e02937f1-ab9e-43f3-84cf-4e26525f3043">Baton Rouge, Louisiana</ix:nonNumeric>, Auditor Firm ID: <ix:nonNumeric contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8yMDIvZnJhZzpiZTJiNDQ1YjBiZGU0ZmE0OTYyMWM0YmQ3Y2Y1MWQzYi90ZXh0cmVnaW9uOmJlMmI0NDViMGJkZTRmYTQ5NjIxYzRiZDdjZjUxZDNiXzE1Nw_90a60668-65b7-4834-a6f0-afb242aee3c6">185</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference to the 2023 Proxy Statement to be filed with the SEC within 120 days after the end of the year ended December&#160;31, 2022.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><div id="i5c10b724a6674979bf3c35a339f29685_205"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div style="text-align:center"><span><br/></span></div><div id="i5c10b724a6674979bf3c35a339f29685_208"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.815%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Statements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All financial statements are set forth under Part II, Item 8 of this report.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Statement Schedules</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">There are no financial statement schedules included in this report as they are either not applicable or included in the financial statements.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibits</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Exhibits are listed in the Exhibit Index required by Item&#160;601 of Regulation&#160;S-K preceding the signature page of this report.</span></td></tr></table></div><div><span><br/></span></div><div id="i5c10b724a6674979bf3c35a339f29685_211"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;16. FORM 10-K SUMMARY</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><div id="i5c10b724a6674979bf3c35a339f29685_214"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits marked with the cross symbol (&#8224;) are filed and the exhibits marked with a double cross (&#8224;&#8224;) are furnished with this Form 10-K. Any exhibits marked with the asterisk symbol (*) are management contracts or compensatory plans or arrangements filed pursuant to Item&#160;601(b)(10)(iii) of Regulation S-K. The registrant agrees to furnish to the Commission supplementally upon request a copy of any schedules or exhibits omitted pursuant to Item&#160;601(a)(5) of Regulation S-K of any exhibit set forth below.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.450%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.101%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Document Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Report&#160;or&#160;Registration&#160;Statement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SEC&#160;File&#160;or<br/>Registration<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>or&#160;Other<br/>Reference</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312516577422/d173200dex21.htm">Equity Purchase Agreement dated February 5, 2016, by and between the Company, as Purchaser, and Michael Trigilio, as Seller</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000089626218000008/amed-20183006xexx101.htm">First Amendment to Equity Purchase Agreement, dated May 18, 2018, by and among the Company, Amedisys Personal Care, LLC, Associated Home Care, LLC, Elder Home Options, LLC and Michael Trigilio</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312518183451/d600655dex21.htm">Share Repurchase Agreement, dated as of June 4, 2018, by and among the Company and the selling stockholders set forth on Schedule I thereto</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company's current Report on Form 8-K filed on June 4, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000089626218000010/amed-20183009xexx21.htm">Stock Purchase Agreement, dated as of October 9, 2018, by and among Milton Heching, the Heching 2012 Exempt Irrevocable Trust, Amedisys Hospice, L.L.C., Compassionate Care Hospice Group, Inc., and solely for purposes of Sections 3.4, 4.3(a), 4.15 and Article VIII thereof, Amedisys, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312520119950/d882548dex21.htm">Securities Purchase Agreement, dated as of April 23, 2020, by and between Amedisys Hospice, L.L.C. and Golden Gate Ancillary LLC (Immaterial schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company will furnish a copy of any omitted schedule or exhibit to the Securities and Exchange Commission upon request.)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company's Current Report on Form 8-K filed on April 27, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312521236286/d196437dex21.htm">Agreement and Plan of Merger, dated as of June 27, 2021, by and among Amedisys Holding, L.L.C., Amedisys Commodore, L.L.C., Contessa Health, Inc., Shareholder Representative Services LLC, and, solely for purposes of Section 10.17, Amedisys, Inc. (Immaterial schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant agrees to furnish supplementally a copy of any omitted schedule or exhibit to the U.S. Securities and Exchange Commission upon request)</a></span></div><div><span><br/></span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Current Report on Form 8-K filed on August 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312507166703/dex31.htm">Composite of Certificate of Incorporation of the Company inclusive of all amendments through June&#160;14, 2007</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2007</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312522307494/d407394dex31.htm">Amended and Restated By-Laws</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Current Report on Form 8-K filed on December 16, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312507186003/dex48.htm">Common Stock Specimen</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Registration Statement on Form S-3 filed August&#160;20, 2007</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-145582</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000089626222000020/a202110-kexhibit42.htm">Description of Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company's Annual Report on Form 10-K for the year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:6.513%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.481%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.450%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.101%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Document Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Report&#160;or&#160;Registration&#160;Statement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SEC&#160;File&#160;or<br/>Registration<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>or&#160;Other<br/>Reference</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312509031143/dex101.htm">Form of Director Indemnification Agreement dated February&#160;12, 2009</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2008</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312512264590/d366568dex101.htm">Amended and Restated Amedisys, Inc. Employee Stock Purchase Plan dated June&#160;7, 2012</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Current Report on Form 8-K filed June&#160;8, 2012</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000089626220000006/a201910-kexhibit103.htm">Composite Amedisys, Inc. 2008 Omnibus Incentive Compensation Plan (inclusive of Plan amendments dated June&#160;7, 2012, October&#160;25, 2012, April&#160;23, 2015 and June&#160;4, 2015, January&#160;20, 2017,  February&#160;22, 2017 and September 25, 2018 and the full text of the Amedisys, Inc. 2008 Omnibus Incentive Compensation Plan)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company's Annual Report on Form 10-K for the year ended December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312515076564/d861886dex106.htm">Form of Stock Option Award Agreement Issued under the Amedisys, Inc. 2008 Omnibus Incentive Compensation Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312515076564/d861886dex107.htm">Form of Performance Stock Option Award Agreement Issued under the Amedisys, Inc. 2008 Omnibus Incentive Compensation Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000089626219000004/a201810-kexhibit1010.htm">Form of Stock Option Award Agreement Issued under the Amedisys, Inc. 2018 Omnibus Incentive Compensation Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company's Annual Report on Form 10-K for the year ended December 31, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000089626219000004/a201810-kexhibit1011.htm">Form of Restricted Stock Unit Award Agreement Issued under the Amedisys, Inc. 2018 Omnibus Incentive Compensation Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company's Annual Report on Form 10-K for the year ended December 31, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000089626219000004/a201810-kexhibit1012.htm">Form of Performance Restricted Stock Unit Award Agreement Issued under the Amedisys, Inc. 2018 Omnibus Incentive Compensation Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company's Annual Report on Form 10-K for the year ended December 31, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312518292066/d624008dex101.htm">Amended and Restated Employment Agreement dated as of September 27, 2018,  by and  among Amedisys, Inc., Amedisys Holding, L.L.C. and Paul B. Kusserow</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Current Report on Form 8-K filed on October 3, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000089626219000014/amed-20193009xexx101.htm">Amedisys Holding, L.L.C. Amended and Restated Severance Plan for Executive Officers dated as of July 25, 2019</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000089626218000005/amed-20183103xexx101.htm">Confidential Separation Agreement and General Release between the Company and Stephen E. Seim</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000089626221000045/a202010-kexhibit1016.htm">Composite Amedisys, Inc. 2018 Omnibus Incentive Compensation Plan (inclusive of Plan amendments dated September 25, 2018 and October 21, 2020 and the full text of the Amedisys, Inc. 2018 Omnibus Incentive Compensation Plan)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:6.524%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.688%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.434%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Document Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Report&#160;or&#160;Registration&#160;Statement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SEC&#160;File&#160;or<br/>Registration<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>or&#160;Other<br/>Reference</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312518210472/d676917dex101.htm">Amended and Restated Credit Agreement dated as of June 29, 2018, among the Company and Amedisys Holding, L.L.C., as borrowers, certain subsidiaries of the Company party thereto as guarantors, Bank of America, N.A., as Administrative Agent, Swingline Lender and L/C Issuer, JPMorgan Chase Bank, N.A., as Syndication Agent, Capital One Bank National Association, Citizens Bank, N.A., Compass Bank, Fifth Third Bank, Hancock Whitney Bank, Regions Bank, and Wells Fargo Bank, National Association, as Co-Documentation Agents, the lenders party thereto, Merrill Lynch, Pierce Fenner&#160;&amp; Smith Incorporated, Citizens Bank N.A., Fifth Third Bank and JPMorgan Chase Bank, N.A., as Joint Lead Arrangers, and Merrill Lynch, Pierce, Fenner&#160;&amp; Smith Incorporated and JPMorgan Chase Bank, N.A., as Joint Bookrunners</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s current Report on Form 8-K filed on July 2, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312518210472/d676917dex102.htm">Amended and Restated Security Agreement, dated as of June 29, 2018, among the Company and Amedisys Holding, L.L.C., as borrowers, certain other parties identified as &#8220;grantors&#8221; on the signature pages thereto and Bank of America, N.A., in its capacity as Administrative Agent</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s current Report on Form 8-K filed on July 2, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312518210472/d676917dex103.htm">Amended and Restated Pledge Agreement dated as of June 29, 2018, among the Company and Amedisys Holding, L.L.C., as borrowers, certain other parties identified as &#8220;pledgors&#8221; on the signature pages thereto, and Bank of America, N.A., in its capacity as Administrative Agent</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s current Report on Form 8-K filed on July 2, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312516498856/d38348dex1027.htm">Agreement and Plan of Merger dated October&#160;31, 2015 by and among Amedisys Health Care West, L.L.C., IHC Acquisitions, L.L.C., Infinity Home Care, L.L.C., Axiom HealthEquity Holdings Management, LLC, Infinity Healthcare Holdings, LLC, and Amedisys, Inc.</a></span></div><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312516498856/d38348dex1028.htm">Agreement of Purchase and Sale dated as of November&#160;25, 2015, between Amedisys, Inc., through its wholly-owned subsidiary, Amedisys Property, L.L.C., as seller and Franciscan Missionaries of Our Lady of the Lake Heath System, Inc., as purchaser.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.450%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.101%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Document Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Report&#160;or&#160;Registration&#160;Statement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SEC&#160;File&#160;or<br/>Registration<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>or&#160;Other<br/>Reference</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312519026458/d699024dex101.htm">First Amendment to Amended and Restated Credit Agreement, dated as of February 4, 2019, by and among the Amedisys, Inc. and Amedisys Holding, L.L.C., as the borrowers, certain subsidiaries of the Company party thereto as guarantors, Bank of America, N.A., as the administrative agent, swingline lender and letter of credit issuer, JPMorganChase Bank, N.A., as syndication agent, Capital One Bank, National Association, Citizens Bank, N.A., Compass Bank, Fifth Third Bank, Hancock Whitney Bank, Regions Bank, and Wells Fargo Bank, National Association, as co-documentation agents, the lenders party thereto, Merrill Lynch, Pierce, Fenner &amp; Smith Incorporated, Citizens Bank, N.A., Fifth Third Bank and JPMorgan Chase Bank, N.A., as joint lead arrangers, and Merrill Lynch, Pierce, Fenner &amp; Smith Incorporated and JPMorgan Chase Bank, N.A., as joint bookrunners </a></span></div><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Current Report on Form 8-K filed on February 4, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312519026458/d699024dex102.htm">Joinder Agreement, dated as of February 4, 2019, by and among Amedisys, Inc. and Amedisys Holding, L.L.C., as the borrowers, each of the new subsidiary guarantors party thereto, and Bank of America, N.A., as the administrative agent  </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Current Report on Form 8-K filed on February 4, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312519043484/d709399dex101.htm">Retirement and Consulting Agreement, dated as of February 13, 2019, by and between Amedisys, Inc. and Linda J. Hall</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Current Report on Form 8-K filed on February 19, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312520169361/d944425dex101.htm">Joinder Agreement, dated as of June 12, 2020, by and among Amedisys, Inc. and Amedisys Holding, L.L.C., as the borrowers, each of the new subsidiary guarantors party thereto, and Bank of America, N.A., as the administrative agent (The schedules to the Joinder have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company will furnish copies of the omitted schedules to the Securities and Exchange Commission upon request.)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company's Current Report on Form 8-K filed on June 15, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000089626221000045/a202010-kexhibit1026.htm">Second Amendment to the Amedisys, Inc. 2018 Omnibus Incentive Compensation Plan, dated October 21, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company's Annual Report on Form 10-K for the year ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312521054618/d104306dex101.htm">Amendment to Amended and Restated Employment Agreement, dated as of February 18, 2021, by and between Amedisys, Inc. and Paul B. Kusserow</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s Current Report on Form 8-K filed on February</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">24, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312521236286/d196437dex101.htm">Second Amendment to Amended and Restated Credit Agreement, dated as of July 30, 2021, by and among Amedisys, Inc. and Amedisys Holding, L.L.C., as the borrowers, the Guarantors party thereto, the Lenders party thereto, Bank of America, N.A., as Administrative Agent, Swingline Lender and L/C Issuer, and the other L/C Issuers party thereto (Immaterial schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule or exhibit to the U.S. Securities and Exchange Commission upon request.)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s Current Report on Form 8-K filed on August 4, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:147pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.531%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.093%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Document Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Report&#160;or&#160;Registration&#160;Statement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SEC&#160;File&#160;or<br/>Registration<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>or&#160;Other<br/>Reference</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312522005108/d261098dex101.htm">Amedisys Holding, L.L.C. Severance Plan for Chief Executive Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s Current Report on Form 8-K filed on January 10, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000089626222000066/amed-20223009xexhibit101.htm">Mutual Separation Agreement and General Release, by and between Amedisys, Inc. and David L. Kemmerly (including the Consulting Services Agreement attached as Exhibit A thereto)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;The Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;10.27*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amedexamendmentno1toexecut.htm">Amendment No. 1 to Amedisys Holding, L.L.C. Amended and Restated Severance Plan for Executive Officers, dated as of November 21, 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a202210-kexhibit211.htm">Subsidiaries of the Registrant</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a202210-kexhibit231.htm">Consent of KPMG LLP</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a202210-kexhibit311.htm">Certification of Paul B. Kusserow, Chief Executive Officer (principal executive officer), pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a202210-kexhibit312.htm">Certification of Scott G. Ginn, Acting Chief Operating Officer, Executive Vice President and Chief Financial Officer (principal financial officer), pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a202210-kexhibit321.htm">Certification of Paul B. Kusserow, Chief Executive Officer (principal executive officer), pursuant to 18&#160;U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;32.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a202210-kexhibit322.htm">Certification of Scott G. Ginn, Acting Chief Operating Officer, Executive Vice President and Chief Financial Officer (principal financial officer), pursuant to 18&#160;U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.450%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.101%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Document Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Report&#160;or&#160;Registration&#160;Statement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SEC&#160;File&#160;or<br/>Registration<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>or&#160;Other<br/>Reference</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><div id="i5c10b724a6674979bf3c35a339f29685_217"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.222%"><tr><td style="width:1.0%"></td><td style="width:8.497%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.756%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MEDISYS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AUL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> B. K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">USSEROW&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Paul B. Kusserow,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chief Executive Officer and</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chairman of the Board</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: February&#160;16, 2023 </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the date indicated:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:42.013%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.615%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AUL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> B. K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">USSEROW</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer<br/>and Chairman of the Board (Principal<br/>Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 16, 2023</span></td></tr><tr style="height:18pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Paul B. Kusserow</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/S/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">COTT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> G. G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">INN</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acting Chief Operating Officer, Executive Vice President and Chief Financial Officer (Principal<br/>Financial Officer and Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 16, 2023</span></td></tr><tr style="height:29pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Scott G. Ginn</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/S/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;V</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ICKIE </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">APPS</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 16, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Vickie L. Capps</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/S/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OLLY </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OYE, MD</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 16, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Molly Coye, MD</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ULIE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> D. K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">LAPSTEIN</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lead Independent Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 16, 2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Julie D. Klapstein</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ERESA </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">LINE</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 16, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Teresa L. Kline</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RUCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> D. P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ERKINS</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 16, 2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bruce D. Perkins</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">EFFREY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> A. R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IDEOUT, MD</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 16, 2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jeffrey A. Rideout, MD</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;IVANETTA D. SAMUELS</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 16, 2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ivanetta D. Samuels</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.27
<SEQUENCE>2
<FILENAME>amedexamendmentno1toexecut.htm
<DESCRIPTION>EX-10.27
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i35af87ab63cf42309667cfee7c160550_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 10.27</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDMENT NO. 1 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMEDISYS HOLDING, L.L.C. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDED AND RESTATED SEVERANCE PLAN FOR EXECUTIVE OFFICERS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;THIS AMENDMENT NO. 1 TO AMEDISYS HOLDING, L.L.C. AMENDED AND RESTATED SEVERANCE PLAN FOR EXECUTIVE OFFICERS (this &#8220;Amendment&#8221;) is made as of the 21st day of November, 2022 (the &#8220;Effective Date&#8221;), by Amedisys Holding, L.L.C., a Louisiana limited liability company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(the &#8220;Company&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">W I T N E S S E T H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;WHEREAS, the Company established the Amedisys Holding, L.L.C. Amended and Restated Severance Plan for Executive Officers (the &#8220;Plan&#8221;) effective July 25, 2019&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;WHEREAS, the Company wishes to amend the Plan, as permitted pursuant to Section 12 of the Plan, in certain respects as set forth below&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;WHEREAS, the Compensation Committee of the Board of Directors of Amedisys, Inc., the ultimate parent company of the Company, has approved the amendments set forth herein.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;NOW THEREFORE, the Plan is hereby amended as follows, effective as of the Effective Date&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Amendments to the Plan</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;Capitalized terms used in this Amendment and not otherwise defined herein have the respective meanings assigned to such terms in the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4 of the Plan is hereby amended by adding a new subsection (c) as follows&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(c)  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">Temporary Expansion of Cash Severance (Salary and Bonus).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">    Notwithstanding Section 4(a) above and in lieu of any payment thereunder, should the Company terminate a Covered Executive&#8217;s employment without Cause or should a Covered Executive terminate Covered Executive&#8217;s employment with Good Reason in either case on or before December 31, 2023, then the Company shall pay to Covered Executive (i) an amount equal to two (2) times the sum of (A) the Covered Executive&#8217;s base salary, as in effect on the date of Employment Termination (or in the event a reduction in base salary is a basis for a termination with Good Reason, then the base salary in effect immediately prior to such reduction) and (B) the greater of (x) an amount equal to the cash bonus earned by the Covered Executive for the previous fiscal year or (y) an amount equal to the Covered Executive&#8217;s short-term incentive bonus target percentage for the fiscal year of the Employment Termination times the Covered Executive&#8217;s base salary, as in effect on the date of the Employment Termination (or, in the event a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#123;06726100.1&#125;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;1 of 4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">reduction in base salary is a basis for termination for Good Reason, then the base salary in effect immediately prior to such reduction), which amount shall be payable in substantially equal monthly installments in accordance with the Company&#8217;s normal payroll practices for a period of 12 months and which payments shall commence in accordance with the provisions of Section 6, herein (unless otherwise required to be paid in accordance with Section 7 below).  For the avoidance of doubt, should the Company terminate a Covered Executive&#8217;s employment without Cause or should a Covered Executive terminate Covered Executive&#8217;s employment with Good Reason on or after January 1, 2024, this Section 4(c) shall no longer be in effect, and Section 4(a) shall govern the Covered Executive&#8217;s rights to cash severance for such termination events prior to a Change in Control. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;Section 6 of the Plan is hereby deleted and replaced in its entirety with the following&#58; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">6.&#160;&#160;&#160;&#160;Release of Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">. The Company&#8217;s obligations under this Plan are contingent upon Covered Executive&#8217;s executing (and not revoking during any applicable revocation period) a separation agreement containing (and reaffirming) certain post-employment covenants Covered Executive has to the Company and a valid, enforceable, full and unconditional release of all claims Covered Executive may have against the Company, Amedisys, Inc. and their respective directors, officers, employees, subsidiaries, stockholders, successors, assigns, agents, representatives subsidiaries and affiliates (whether known or unknown) as of the date of Employment Termination, in the form attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> hereto (the &#8220;Release&#8221;), no later than 60 days after the date of Employment Termination (such 60-day period, the &#8220;Release Execution Period&#8221;). If the Release is executed and delivered and no longer subject to revocation within 60 days after the date of Employment Termination, then the following shall apply&#58;</font></div><div style="padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(a)&#160;&#160;&#160;&#160;To the extent any payments due to Covered Executive under this Plan are not &#8220;deferred compensation&#8221; for purposes of Section&#160;409A of the Code then such payments shall commence upon the first regularly-scheduled payroll date immediately following the date the Release is executed and no longer subject to revocation (the &#8220;Release Effective Date&#8221;)&#59; provided, however, if the Release Execution Period begins in one taxable year and ends in another taxable year, payment shall not be made until first payroll date that (i) occurs in the second taxable year, and (ii) follows the Release Effective Date. The first such cash payment shall include payment of all amounts that otherwise would have been due prior to the Release Effective Date under the terms of this Plan had such payments commenced after the date of Employment Termination, and any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#123;06726100.1&#125;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2 of 4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">payments to be made thereafter shall continue as provided herein. The delayed payments shall in any event expire at the time such payments would have expired had such payments commenced after the date of Employment Termination.</font></div><div style="padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">(b)&#160;&#160;&#160;&#160;To the extent any payments due to Covered Executive under this Plan above are &#8220;deferred compensation&#8221; for purposes of Section&#160;409A, then such payments shall commence upon the first payroll date immediately following the expiration of the Release Execution Period. The first such cash payment shall include payment of all amounts that otherwise would have been due prior thereto under the terms of this Plan had such payments commenced after the date of Employment Termination, and any payments to be made thereafter shall continue as provided herein. The delayed payments shall in any event expire at the time such payments would have expired had such payments commenced immediately following the date of Employment Termination.</font></div><div style="padding-right:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;The fifth (5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) paragraph of Section 10 of the Plan is hereby deleted and replaced in its entirety with the following&#58; </font></div><div style="padding-right:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">The Plan is intended to provide benefits for a select group of management or highly compensated employees of the Company within the meaning of Sections 201(2), 301(a)(3), and 401(a)(1) of ERISA as an employee welfare benefit plan providing severance pay and benefits as described in this Plan document under the Amedisys Employees Welfare Benefit Plan (the &#8220;Benefit Plan&#8221;), except for any period during which the Plan is determined to be a top-hat pension plan for such group under ERISA. All Severance Benefits under the Benefit Plan shall be paid directly by the Company from its general assets, and the rights of an eligible employee to any benefits hereunder shall not be superior to those of an unsecured general creditor of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;The Plan is hereby amended to add the form of Release as Exhibit A to the Plan, which Release is attached to this Amendment as Attachment 1. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.&#160;&#160;&#160;&#160;Except as amended hereby, all terms and provisions of the Plan shall remain in full force and effect. In the event of a conflict between the provisions of the Plan and this Amendment, the provisions of this Amendment shall control.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(signature page follows)</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#123;06726100.1&#125;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3 of 4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the Company has caused this Amendment to be executed as of the Effective Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="padding-left:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMEDISYS HOLDING, L.L.C.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;_&#47;s&#47; Adam Y. Holton_________</font></div><div style="padding-left:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Adam Y. Holton</font></div><div style="padding-left:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; &#160;&#160;&#160;&#160;Chief People Officer</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#123;06726100.1&#125;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;4 of 4</font></div><div><font><br></font></div></div></div><div id="i35af87ab63cf42309667cfee7c160550_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ATTACHMENT 1 TO AMENDMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><br>Form of Release</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#123;06726100.1&#125;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AGREEMENT AND RELEASE TEMPLATE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">UNDER SECTION 6 OF SEVERANCE PLAN FOR EXECUTIVE OFFICERS &#91;Masculine Form&#93;</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SEPARATION AGREEMENT AND GENERAL RELEASE</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This SEPARATION AGREEMENT AND GENERAL RELEASE (&#8220;Agreement&#8221;) hereby is made and entered into by and between ____________ (&#8220;Executive&#8221;) and Amedisys, Inc. (the &#8220;Company&#8221; or &#8220;Amedisys&#8221; and together with Executive, collectively the &#8220;Parties&#8221; and individually a &#8220;Party&#8221;), and to and for the benefit of the stockholders, directors, officers, successors, subsidiaries, employees, supervisors, advisors, attorneys, affiliates, lenders, heirs, assigns, agents, parents, employee retirement benefit plans, and non-retirement employee benefit plans of the Company and of Amedisys Holding, L.L.C. (collectively, &#8220;Releasees&#8221;).  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;WHEREAS, Executive&#8217;s employment with the Company will terminate for reasons covered by Section 4 of the Amedisys Holding, L.L.C. Amended and Restated Severance Plan for Executive Officers, as amended (the &#8220;Severance Plan&#8221;)&#59;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Parties desire to end their employment relationship amicably and forever resolve all employment-related issues, if there are any, which have arisen or may arise up to the Effective Date (as defined below) of this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;WHEREAS, Executive, as a senior executive of Amedisys, has provided business and professional covenants to the Company and had access to &#8220;Confidential Information&#8221; (defined below and in documents incorporated herein by reference) of the Company&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;WHEREAS, the Company desires that Executive reaffirm all of his existing, post-employment covenants to the Company and protect its Confidential Information, and Executive reaffirms his ongoing, post-employment contractual covenants to the Company including but not limited to the Amedisys, Inc. Dispute Resolution Agreement (&#8220;DRA&#8221;), his Executive Protective Covenants Agreement (&#8220;EPCA&#8221;), his obligations to refrain from using or disclosing the Company&#8217;s Confidential Information, privileged communications, and attorney-work product and to provide a prospective covenant not to disparage the Company for a reasonable period of time as specified herein.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In consideration of the premises, promises and other items contained herein, the receipt and sufficiency of which are hereby acknowledged, Executive and the Company agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Separation of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive&#8217;s employment as ______________ with the Company is hereby terminated as of _________ __, ____ (the &#8220;Separation Date&#8221; or the &#8220;date of Employment Termination&#8221;), on which date he will relinquish all rights, privileges, duties, responsibilities, and authority of his position with the Company except for Executive&#8217;s contractual and professional covenants and obligations that survive his employment with the Company. The &#8220;Effective Date&#8221; of this Agreement is the eighth day after the date on which it is signed timely by Executive if not revoked in accordance with Section 12 below. The Parties agree that Executive will not sign the Agreement before the Separation Date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#123;06726100.1&#125;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Non-Contingent Payments and Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Regardless of whether Executive signs and does not revoke this Agreement, Amedisys (a) has paid or will pay his regular base salary through_________ __, ____, and (b) has or will reimburse all reasonable, necessary and preauthorized business expenses incurred prior to_________ __, ____. Executive shall submit all requests to the Company for expense reimbursements on or before the Separation Date. Any requests submitted thereafter shall not be eligible for reimbursement, unless required by applicable law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Compensation under Agreement and Related Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to Executive&#8217;s execution and non-revocation of this Agreement and his performance of his covenants and obligations under this Agreement and to reconcile and forever resolve all differences among the Parties relating to Executive&#8217;s employment and the period thereof, the Company hereby agrees to pay or provide Executive the compensation and&#47;or benefits outlined below.  The specific terms of the &#8220;Severance Payment&#8221; to be paid to Executive hereunder are as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Salary and Bonus.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The Company shall pay to Executive an amount equal to one (1) times the sum of (A) the Executive&#8217;s base salary, as in effect on the date of Employment Termination (or in the event a reduction in base salary is a basis for a termination with Good Reason, then the base salary in effect immediately prior to such reduction) and (B) the greater of (x) an amount equal to the cash bonus earned by the Executive for the previous fiscal year or (y) an amount equal to the Executive&#8217;s short-term incentive bonus target percentage for the fiscal year of the Employment Termination times the Executive&#8217;s base salary as in effect on the date of the Employment Termination (or, in the event a reduction in base salary is a basis for termination for Good Reason, then the base salary in effect immediately prior to such reduction), which amount shall be payable in substantially equal monthly installments in accordance with the Company&#8217;s normal payroll practices for a period of 12 months and which payment shall commence in accordance with the provisions of Section 6 of the Severance Plan (unless otherwise required to be paid in accordance with Section 7 of the Severance Plan).</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">                    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> &#91;Alternative (a) for Employment Termination on or before December 31, 2023&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company shall pay to Executive (i) an amount equal to two (2) times the sum of (A) the Executive&#8217;s base salary, as in effect on the date of Employment Termination (or in the event a reduction in base salary is a basis for a termination with Good Reason, then the base salary in effect immediately prior to such reduction) and (B) the greater of (x) an amount equal to the cash bonus earned by the Executive for the previous fiscal year or (y) an amount equal to the Executive&#8217;s short-term incentive bonus target percentage for the fiscal year of the Employment Termination times the Executive&#8217;s base salary, as in effect on the date of the Employment Termination (or, in the event a reduction in base salary is a basis for termination for Good Reason, then the base salary in effect immediately prior to such reduction), which amount shall be payable in substantially equal monthly installments in accordance with the Company&#8217;s normal payroll practices for a period of 12 months and which payments shall commence in accordance with the provisions of Section 6 of the Severance Plan (unless otherwise required to be paid in accordance with Section 7 of the Severance Plan). </font></div><div style="margin-bottom:6pt;padding-left:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Stock Vesting. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any unvested equity awards issued in the name of Executive as of the date of termination will vest in accordance with the terms contained in the applicable Award Agreement for such awards.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Employee Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except as set forth in this Agreement or as otherwise required by applicable law (including without limitation the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended), the Employee&#8217;s participation in and rights under any Company employee benefit plans and programs will be governed by the terms and conditions of those plans and programs, which plans, programs, terms and conditions may be amended, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#123;06726100.1&#125;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">modified, suspended or terminated by the Company at any time for any or no reason to the extent permitted by law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Executive Bears the Tax Liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Other than withholdings from his &#8220;Non-Contingent Payments and Benefits&#8221; set forth in Section 2 and the Severance Payment provided in Section 3, Executive agrees that to the extent that any federal, state, or local taxes, interest or penalties of any kind may be due or payable as a result of (i) payments made hereunder to Executive or on his behalf and&#47;or (ii) benefits of any kind made available hereunder to Executive or on his behalf, Executive will be solely responsible for the payment of such taxes and will hold Company harmless, and will indemnify Company, from and against all claims, penalties, fees, assessments, fines or other costs arising from said payments.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Surrender of Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Executive warrants and guarantees that he has returned to the Company on or before ___________ __, ____ all originals, duplicates and images of all Company property and information, including but not limited to Company documents, disks, computers, files, software and credit cards that Executive received in connection with his employment with the Company.  The &#8220;property and information&#8221; surrendered hereunder shall include all emails, text messages, photographs, written communications, images, collected records and other materials of any kind that relate in any way to, or have as their subject, any current or former director, officer and&#47;or employee of the Company that is in the possession, access or control of Executive. Executive agrees that he will not retain any copies, duplicates, reproductions or excerpts thereof.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Release of Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For all of the purposes of this Section 7, the term &#8220;Company&#8221; shall be deemed to include the Releasees defined above.  Executive hereby unconditionally agrees to release, discharge, and hold harmless Company from any and all claims that may arise out of Executive&#8217;s employment, relationship and affiliation with Company and its directors, executive officers and agents and&#47;or the termination of said employment.  In consideration of the above described promises and payments, Executive agrees on behalf of himself and all persons who may claim through him to hereby irrevocably and unconditionally release, acquit and forever discharge the Company from any and all charges, complaints, claims, liabilities, obligations, promises, agreements, controversies, damages, actions, causes of actions, suits, rights, demands, costs, losses, wages, salary, benefits, compensation, debts or expenses of any kind whatsoever, known or unknown, suspected or unsuspected, which Executive now has, owns or holds or which Executive at any time heretofore had, owned, or held, including but not limited to (i) all claims based on alleged or actual rights arising under any federal, state, or local laws prohibiting race, sex, religion, age, disability or other forms of discrimination or retaliation, including without limitation, (A) the Age Discrimination in Employment Act of 1967, as amended (&#8220;ADEA&#8221;) and the Older Workers Benefits Protection Act (&#8220;OWBPA&#8221;), (B) the Tennessee Human Rights Act (Tenn. Code Ann. &#167; 4-21-101 et seq.) (&#8220;THRA&#8221;), (C) Tennessee Disability Act (&#8220;TDA&#8221;) (Tenn. Code Ann. &#167; 8-5-103 et seq.), (D) Tennessee Public Protection Act (&#8220;TPPA&#8221;) (Tenn. Code Ann. &#167; 50-1-304), (E) Title VII of the Civil Rights Act of 1964, as amended, (F) the Occupational Safety and Health Act, (G) the Americans With Disabilities Act, as amended (H) the Family and Medical Leave Act, (I) all written Employment Agreements, (J) the Employee Retirement Income Security Act of 1974, as amended, and&#47;or (K) any other federal, state or local laws relating to or otherwise regulating Executive&#8217;s employment with Company, (ii) any claims of any nature based on or arising out of (A) Executive&#8217;s employment with Company or the cessation of such employment, including but not limited to whistleblower and unlawful retaliation claims, and&#47;or (B) any alleged oral or written employment agreement or contract, or (iii) any claims based on fraud, tort, contract, negligence, recklessness or intent of any nature whatsoever. Except as specifically provided herein, Executive hereby releases any and all rights, claims, entitlements, compensation, equity or other privileges under the Severance Plan and the Amedisys, Inc. 2018 Omnibus Incentive Compensation Plan, as amended to date. It is the intention of Executive and Company that this Agreement constitute a complete and general </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#123;06726100.1&#125;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">release of all of Executive&#8217;s claims of every nature arising on or before the Effective Date and shall be effective as an affirmative defense to any and all such claims or potential claims of any kind whatsoever, whether known or unknown.  Executive represents and warrants that he has not filed any civil action, suit, arbitration, administrative civil action, or legal proceeding against Company, that he has not assigned, pledged, or hypothecated his claims to any person, and that no other person has an interest in the claims that Executive is releasing herein.  Nothing in this Section 7 or in any other part of this Agreement shall be construed to release either party from obligations under this Agreement, the Consulting Agreement or under any applicable terms and provisions of the Company&#8217;s 401(k) Plan.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Nothing in this Agreement limits or terminates Executive&#8217;s right to file a charge or complaint with or participate in an investigation conducted by the Equal Employment Opportunity Commission (&#8220;EEOC&#8221;), the National Labor Relations Board (&#8220;NLRB&#8221;), or any other federal, state, or local governmental agency (collectively, the &#8220;Governmental Agencies&#8221;). However, by signing this Agreement, Executive is waiving the right to any monetary recovery or other relief (other than monetary awards from the Securities and Exchange Commission&#8217;s whistleblower program) should the Governmental Agencies pursue any claims on Executive&#8217;s behalf and assigns any such recovery to the Company.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Executive&#8217;s Covenants to the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt;text-decoration:underline">Executive&#8217;s Covenants and Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive acknowledges and agrees that pursuant to his employment with the Company as ________________ he has accepted several professional, contractual and other binding covenants and obligations that inured to the benefit of the Company both during his employment and following the termination of his employment. Executive recognizes that his fulfillment of all such covenants and obligations is a significant and material factor in the Company&#8217;s desire to enter into this Agreement. Executive, in recognition of the reasonableness of the scope and terms of all such covenants that survive the termination of his employment, hereby reaffirms and agrees following the Effective Date to perform and fulfill all covenants and obligations to the Company that are contained in the EPCA, the DRA, the Amedisys Policy Manual (including the Company&#8217;s Information Security Policy (&#8220;ISP&#8221;)) (&#8220;Policy Manual&#8221;), and all other legal, professional and contractual covenants and obligations that he has to the Company. The EPCA and its definitions, terms, conditions, covenants, remedies, and other provisions are incorporated herein by reference as if set forth fully herein. To the extent that the post-employment temporal duration of any such covenant in the EPCA to which Executive has been subject prior to the Effective Date of this Agreement are different from the covenant&#8217;s temporal duration stated in this Agreement, the longer temporal duration stated in this Agreement shall apply and govern the covenant(s). </font><font style="color:#15232b;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">It is expressly understood and agreed by Executive that although Executive considers the restrictions in this Agreement to be reasonable, if a final determination is made by a court of competent jurisdiction or an arbitrator that the time or territory or any other restriction contained in the Agreement is an unenforceable restriction against Executive, the provisions of this Agreement shall not be rendered void but shall be deemed amended to apply as to such maximum time and territory and to such maximum extent as such court or arbitrator may determine or indicate to be enforceable.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limiting the generality of the foregoing promises, Executive reaffirms, accepts and&#47;or promises to fulfill the following specific covenants and obligations&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">Confidentiality and Non-Disclosure of Information&#58; those non-disclosure and confidentiality covenants (as more fully articulated in Paragraph 2 of the Company&#8217;s EPCA) will survive in perpetuity. The duty to maintain the confidentiality of any particular information will end when such information is in the public domain by means other than a breach of confidentiality or non-disclosure by Executive.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">Non-Competition with Company (as more fully articulated in Paragraph 3.a of the EPCA) for the duration stated in Paragraph 3.a of the EPCA.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#123;06726100.1&#125;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">Non-Solicitation of Business (as more fully articulated in Paragraph 3.b of the EPCA) for the duration stated in Paragraph 3.b of the EPCA.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">Non-Solicitation of Employees (as more fully articulated in Paragraph 3.c of the EPCA) for the duration stated in Paragraph 3.c of the EPCA.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Non-Disparagement&#58; Executive will not make any disparaging statements to current, former or prospective Company customers, contractors, vendors, stockholders, directors or executive officers, or to any media representatives or any other person about the Company, its affiliates or subsidiaries, or their current or former officers, directors or employees. This covenant continues for three (3) years from the Effective Date.  This additional covenant is stated more completely in Section 11 below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">Any and all other covenants of the Executive that are currently in place and, by their terms, survive Executive&#8217;s term of employment will continue in accordance with their stated terms. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt;text-decoration:underline">Company&#8217;s Neutral Reference</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Executive shall direct all third parties inquiring or reasonably likely to inquire about Executive&#8217;s employment with the Company to The Work Number at 800-367-2884 or www.theworknumber.com (Employer Code&#58; 15071). In response to such inquiries received by such person, the Company will communicate only the Employee&#8217;s dates of employment and last position held with the Company.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Executive agrees that any and all discussions and requests leading up to this Agreement are strictly confidential.  Executive agrees to take all reasonable efforts to preserve the confidentiality of all discussions and requests leading to the Parties&#8217; entry into this Agreement.  The attorneys who have been in these discussions are understood and agreed to be bound to confidentiality of the discussions of the terms of the Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Without the prior written consent of Company, and subject to the exception in Section 9(c) below, Executive agrees not to disclose, discuss or reveal any &#8220;Confidential Information&#8221; (as defined or described in the EPCA, the Amedisys Policy Manual and the ISP), in the absence of a subpoena, summons, or court order. Without limiting the generality or breadth of the scope of Executive&#8217;s obligations to preserve in perpetuity the absolute privacy and confidentiality of Confidential Information, Executive is obligated to maintain the complete confidentiality of all matters in which, during the term of his employment at the Company, he has collected information, emails, texts, and attachments thereto that involve or relate in any way to the board of directors, stockholders, executives, and&#47;or employees of Amedisys.  In order to allow the Company to preserve the confidentiality of attorney-client communications or attorney work product or any other legally protected Confidential Information as defined or described in the EPCA, the Amedisys Policy Manual and&#47;or the ISP, such as trade secrets, Executive further agrees that, if he receives any subpoena, summons or court order requiring him to testify in a proceeding involving the Company, he will use commercially reasonable efforts to inform the Company within five (5) business days of receipt of such request or demand, or at least three (3) days before the date requested for such testimony, whichever is earlier.  In the event a subpoena, summons or court order is served on Executive requiring him to testify without at least three (3) days&#8217; notice, he will use commercially reasonable efforts to inform the Company as soon as reasonably practicable (e.g., by email or telephone, if that is the most expedient manner under the circumstances), and Executive shall cooperate with the Company in any proceeding at the Company&#8217;s expense.  Executive shall not disclose any attorney-client communications or attorney work product information to which the Company has a good faith claim of privilege without first complying with the procedure set forth </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#123;06726100.1&#125;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in this Section 9(b).  Executive shall have no authority to waive the Company&#8217;s attorney-client or attorney work product privileges.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Nothing in this Section 9 or otherwise in this Agreement prevents Executive from complying with any applicable laws, cooperating fully in any investigation by any governmental agency or providing any information to any governmental agency or governmental investigator acting lawfully in an official capacity.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Consultation and Assistance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Executive agrees that for the Term during which Severance Payments are made to him, he will remain reasonably accessible and available to the Company for consultation as the Company may request or desire from time to time, and provide all reasonable assistance to the Company and its counsel regarding any business, legal or other matters (including but not limited to litigation, arbitration, investigations or governmental proceedings) in which Executive&#8217;s participation and&#47;or involvement is necessary or desirable, all in a timely fashion and at such times as may be mutually agreeable to the parties concerned.  Such assistance shall include appearing from time to time at the office of the Company or its counsel for conferences and interviews and, in general, providing the Company and its counsel with the full benefit of Executive&#8217;s knowledge, in a complete, candid, and truthful manner, with respect to any matter involving or arising out of his employment with the Company, and shall include the obligation to testify truthfully in connection with any such matter.  </font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Executive&#8217;s Covenant of Non-Disparagement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Subject to the provisions of Section 9, including the provisions of Section 9(c) which allow full cooperation with any government investigation, Executive agrees that he will not make any disparaging statements to current, former or known-to-be-prospective Company customers, contractors, vendors, stockholders, board members or executive officers, or to any media representatives or any other person about the Company, its affiliates or subsidiaries, or the Company&#8217;s or their employees, officers or directors. As used in this Agreement, &#8220;disparaging statement&#8221; means any communication, statement, dissemination of information, or other representation, oral, written or otherwise, directly or indirectly, which would cause or tend to cause the recipient of the communication to question the business condition, integrity, competence, fairness or good character of the person or entity to whom the communication relates or has as its subject. Notwithstanding the foregoing, this covenant of nondisparagement shall not preclude Executive from making truthful statements that are, as a matter of law, required to be made in a public judicial setting by applicable law, regulation or process. Executive&#8217;s covenant of nondisparagement shall remain in full force and effect for a period of three (3) years after the Effective Date. </font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Right to Review and Revoke</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">. Executive acknowledges and agrees that, in addition to his previous familiarity with this Agreement&#8217;s template as an exhibit to the Severance Plan, he has a period of twenty-one (21) days beginning on the day when he received the original form of the Company&#8217;s proposal of this Agreement to consider, execute, and deliver this Agreement to the Company. Executive further acknowledges, understands and agrees that for a period of seven (7) days following the execution of this Agreement, he may revoke this Agreement in writing and that such revocation must be timely received by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">&#91;Name&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">&#91;Title&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">, Amedisys, Inc., 49 Music Square West, Suite 410, Nashville, Tennessee 37203.  The twenty-eight (28) day period described in this Section 12 that includes the maximum consideration and revocation period shall be referred to as the &#8220;Release Execution Period&#8221; for purposes of this Agreement.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;13.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Equitable and Legal Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">General Company Rights and Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event of Executive&#8217;s breach or violation of, or Executive&#8217;s failure to completely and timely perform Sections 8, 9, 10 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#123;06726100.1&#125;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or 11 of this Agreement in any respect, (i) the Company&#8217;s obligation to perform any of its remaining obligations hereunder (except as provided below), including the obligation to provide any further compensation under any provision of Section 3 (a) and&#47;or (b) above, shall immediately terminate and (ii) Executive shall be required to repay to the Company, as Liquidated Damages, all prior Severance Payments paid by the Company to Executive, as of the date of the breach, pursuant to Section 3 (a) and&#47;or (b) of this Agreement (Executive&#8217;s repayment obligation is referred to and regarded as &#8220;Liquidated Damages&#8221;), which repayment shall be made by Executive within thirty (30) calendar days after the date of the Company&#8217;s written notice to Executive notifying Executive of such breach.   To the extent that Executive does not make a required repayment to the Company pursuant to this Section 13 within thirty (30) calendar days following demand by the Company, the Company shall have the right to reduce, cancel or withhold against any outstanding equity-based compensation, or require a substitute form of repayment, in each case to the maximum extent permitted under applicable law. For the avoidance of doubt, Executive&#8217;s releases set forth above in Section 7 and all of Executive&#8217;s other restrictive covenants and obligations stated or incorporated herein by reference shall remain in full force and effect following any such breach by Executive. The Company shall be entitled under the Agreement to stop making any further payments or awards that have been made prior to the Company&#8217;s actual discovery of Executive&#8217;s breach when and if the Company proves the Executive&#8217;s breach of any of Sections 8, 9, 10 or 11 of this Agreement. Executive agrees that the Company shall not have any requirement of any kind to allege or prove in court or arbitration that any damages were actually inflicted upon or suffered by the Company as a result of the Executive&#8217;s breach in order to be entitled to recover Liquidated Damages under Section 13(a). Damage to the Company being caused by any such breach shall be presumed as a matter of law with regard to Liquidated Damages.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Parties&#8217; Equitable Relief</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each of the Parties shall have the right to enforce its rights, if any, to equitable relief hereunder through any one or more of the following mechanisms, which may be pursued by a Party at any time and at such Party&#8217;s sole discretion&#58; judicial action before any court of competent jurisdiction in Davidson County Tennessee to obtain equitable remedies and&#47;or judicial action before any court of competent jurisdiction in Davidson County Tennessee to obtain temporary and&#47;or permanent injunctive relief. In the event a Party breaches, or threatens to breach, any of the provisions of this Agreement, the other Party shall have the right to have the provisions of this Agreement specifically enforced by any court having equity jurisdiction, it being acknowledged and agreed that any such breach or threatened breach may possibly cause irreparable injury to the other Party and that money damages may not provide the other Party with an adequate remedy.  Such equitable rights and remedies shall be in addition to, and not in lieu of, any other legal rights&#47;remedies available to a Party under law in arbitration as provided herein below. The Parties recognize and agree that a Party&#8217;s remedy at law for breach of this Agreement might be inadequate, and further agrees that, for breach of such provisions, a Party may be entitled to equitable remedies.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Parties&#8217; Legal Relief</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except for the specific equitable remedies provided above, any dispute, controversy, or claim arising out of or related to this Agreement or any breach or termination of this Agreement, including but not limited to the covenants Executive provides to the Company, the consideration the Company provides to Executive, and any alleged violation of any federal, state, or local statute, regulation, common law, or public policy, whether sounding in contract, tort, or statute, shall be submitted by either or both Parties to and decided solely by binding private confidential arbitration. Arbitration shall be administered by a single neutral arbitrator mutually agreeable to Executive and the Company or, if the Parties are not able to reach mutual agreement in the selection of the arbitrator, with the American Arbitration Association using the Employment Arbitration Rules and Mediation Procedures and held in Davidson County Tennessee. Any arbitral award determination shall be final and binding upon the Parties and to the maximum extent legally permissible, private and confidential. Judgment on the arbitrator's award may be entered in any court of competent jurisdiction. Arbitration shall </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#123;06726100.1&#125;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">proceed only on an individual basis. The Parties waive all rights to have their legal disputes (without limiting the equitable remedies provided above) heard or decided by a jury or in a court trial and the right to pursue any class or collective claims against each other in court, arbitration, or any other proceeding. Each party shall only submit their own individual claims against the other and will not seek to represent the interests of any other person. The arbitrator shall have no jurisdiction or authority to compel any class or collective claim, or to consolidate different arbitration proceedings with or join any other party to an arbitration between the Parties. The arbitrator, not any court, shall have exclusive authority to resolve any dispute, except those involving the equitable remedies provided above, relating to the enforceability or formation of this Agreement and the arbitrability of any legal damages dispute between the Parties, except for any dispute relating to the enforceability or scope of the class and collective action waiver, which shall be determined by a court of competent jurisdiction. Further, in the event of any litigation for equitable relief in court and&#47;or litigation for legal remedies in arbitration arising out of or in connection with a breach of this Agreement by either Party, the prevailing Party shall be entitled to recover from the non-prevailing party, the prevailing Party&#8217;s reasonable attorneys' fees and expenses. </font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Construction and Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> This Agreement is not and cannot be construed as an admission by the Company or Executive that either has acted wrongfully with respect to the other or that either of them has any claim whatsoever against the other.  This Agreement is governed by and is to be construed in accordance with the law of the State of Tennessee.  The provisions of this Agreement are severable and, if any part of it is found to be unenforceable, the other Sections and&#47;or provisions shall remain fully valid and enforceable.  No provision of this Agreement may be modified, amended or revoked, except in a writing signed by Executive and an authorized officer of the Company.  This Agreement, except as specifically provided hereinabove, supersedes, terminates and replaces any and all previous or contemporaneous written or oral communications or agreements relating to Executive&#8217;s employment and the period thereof, and the parties, except as specifically provided hereinabove, hereby acknowledge that no other contracts, arrangements or understandings exist that pertain to any of the subjects, matters or issues addressed by this Agreement.    </font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">No Reliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Each Party represents, acknowledges and agrees that, in executing this Agreement, such Party does not rely and has not relied upon any promise, representation or statement not expressly set forth herein made by the other Party or, in the case of the Company,  its executive officers, board of directors or agents with regard to the subject matter, basis or effect of this Agreement or otherwise, and each Party further represents, acknowledges and agrees that there have been no such representations, promises, or statements made by the other Party, except as specifically set forth in this Agreement.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Code Section&#160;409A Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The compensation and benefits payable pursuant this Agreement are intended to be exempt from, or comply with, as applicable, the requirements of Internal Revenue Code Section&#160;409A and Department of Treasury regulations and other interpretative guidance issued thereunder, including without limitation any such regulations or other such guidance that may be issued after the Effective Date (collectively, &#8220;Section 409A&#8221;).  To the extent applicable, this Agreement shall be interpreted in accordance with Section 409A.  Notwithstanding any other provision of this Agreement to the contrary, if Executive is a &#8220;specified employee&#8221; within the meaning of Section&#160;409A, and a payment or benefit provided for in this Agreement would be subject to additional tax under Section&#160;409A if such payment or benefit is paid within six (6) months after Executive&#8217;s &#8220;separation from service&#8221; (within the meaning of Section&#160;409A), then such payment or benefit required under this Agreement shall not be paid (or commence) during the six-month period immediately following Executive&#8217;s separation from service.  If the payment of any such amount is delayed in accordance with the previous sentence, then any payments or benefits that would otherwise have been made or provided during such six-month period and which would have incurred such additional tax under Section&#160;409A shall instead be paid to Executive in a lump-sum cash </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#123;06726100.1&#125;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">payment in the seventh month following Executive&#8217;s separation from service (or such earlier date upon which such amount can be paid under Section 409A without resulting in a prohibited distribution, including as a result of Executive&#8217;s death).  If Executive&#8217;s termination of employment hereunder does not constitute a &#8220;separation from service&#8221; within the meaning of Section&#160;409A, then any amounts payable hereunder on account of a termination of Executive&#8217;s employment and which are subject to Section&#160;409A (or any exemption therefrom that requires the occurrence of a &#8220;separation from service&#8221; as a condition to payment) shall not be paid until Executive has experienced a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;separation from service&#8221; within the meaning of Section&#160;409A.  In addition, no reimbursement or in-kind benefit shall be subject to liquidation or exchange for another benefit and the amount available for reimbursement, or in-kind benefits provided, during any calendar year shall not affect the amount available for reimbursement, or in-kind benefits to be provided, in a subsequent calendar year.  Any reimbursement to which Executive is entitled hereunder shall be made no later than the last day of the calendar year following the calendar year in which such expenses were incurred.  Notwithstanding any provision of this Agreement to the contrary, in the event that following the Effective Date, the Company or the Executive reasonably determines that any compensation or benefits payable under this Agreement may be subject to Section 409A, the Company and Executive shall cooperate in good faith to adopt such amendments to this Agreement or adopt other policies or procedures (including amendments, policies and procedures with retroactive effect), or take any other actions that the Parties determine are reasonably necessary or appropriate to preserve the intended tax treatment of the compensation and benefits payable hereunder, including without limitation actions intended to (i) exempt the compensation and benefits payable under this Agreement from Section 409A, and&#47;or (ii) comply with the requirements of Section 409A, provided, that this Section 16 does not, and shall not be construed so as to, create any obligation on the part of the Company or any affiliate or Executive to adopt any such amendments, policies or procedures or to take any other such actions.  Notwithstanding anything herein to the contrary, neither the Company nor any of its affiliates shall have any liability to Executive or to any other person if the payments and benefits provided in this Agreement that are intended to be exempt from, or compliant with, Section&#160;409A are not so exempt or compliant or for any taxes, interest or penalties imposed under Section 409A or any corresponding provision of state or local law.  Each payment payable hereunder in series of installments, including without limitation any payment of the Severance Payment or other benefits, shall be treated as a separate payment in a series of payments within the meaning of, and for purposes of, Section&#160;409A.  </font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Non-Interference</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything in this Agreement to the contrary, nothing in this Agreement prohibits the Executive from confidentially or otherwise communicating or filing a charge or complaint with a governmental or regulatory entity, participating in a governmental or regulatory entity investigation, or giving truthful testimony or statements to a governmental or regulatory entity, or from responding if properly subpoenaed or otherwise required to do so under applicable law.  &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Consultation with Attorney</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Executive is advised in writing by the Company to consult with an attorney prior to executing the Agreement. Executive, who is represented in the review of this Agreement by legal counsel of his own choosing represents and agrees he has carefully read and fully understands all the provisions of this Agreement and that he is voluntarily entering into this Agreement. Executive further acknowledges and agrees (i) the Company&#8217;s position is that the compensation and benefits he will receive hereunder exceed what he may otherwise be entitled to receive, and (ii) that the above Section 7 of this Agreement includes a release and waiver of any and all claims of age discrimination Executive may have under the Age Discrimination in Employment Act (ADEA) and the Older Worker Benefits Protection Act (&#8220;OWBPA&#8221;).  Executive understands that Executive does not waive rights or claims under the ADEA that may arise after the date this Agreement is Effective.</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(signature page follows)</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#123;06726100.1&#125;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.06pt;padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">PLEASE READ CAREFULLY.  THIS IS A RELEASE OF ALL CLAIMS, KNOWN OR UNKNOWN.</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executed this ____ day of ___________, 20__.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXECUTIVE</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">__________________________________________</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Type Executive&#8217;s Name&#93;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br>Executed this ____ day of ___________, 20__.</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMEDISYS, INC. (&#8220;COMPANY&#8221;)</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;_______________________________________</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date proposed Agreement delivered to Executive&#58; ___________ __, ____.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21-day period to consider this Agreement ends&#58; _________ __, ____.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#123;06726100.1&#125;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>a202210-kexhibit211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i7af01d4287ba439690f519cfbf5de7e8_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIST OF SUBSIDIARIES</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CORPORATIONS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE GROUP, INC., a Florida corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF CENTRAL FLORIDA, INC., a Florida corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF LAKE AND SUMTER, INC., a Florida corporation </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF MIAMI DADE AND THE FLORIDA KEYS, INC., a Florida corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">GUARDIAN HEALTH CARE, INC., a Texas corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">GUARDIAN HEALTH CARE GROUP, INC., a Delaware corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">GUARDIAN HEALTH CARE HOLDINGS, INC., a Delaware corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HEALTH PRIORITY HOME CARE, INC., a Texas corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HI-TECH CARE, INC., a Florida Corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HOMECARE PREFERRED CHOICE, INC., a Delaware corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HOSPICE OF EASTERN CAROLINA, INC., a North Carolina corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HOSPICE PREFERRED CHOICE, INC., a Delaware corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">INFINITY HOME CARE ACQUISITION CORP., a Florida corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">JLM HEALTHCARE, INC., a Texas corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">OHERBST, INC., a Texas corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">S. FISHER &#38; S. THOMAS, INC., a Texas corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TKG, INC., an Oklahoma corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">VELITA SMITH HOME HEALTHCARE, Inc., a Texas corporation</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">LIMITED LIABILITY COMPANIES</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ACCUMED HEALTH SERVICES, L.L.C., a Texas limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ACCUMED HOME HEALTH OF GEORGIA, L.L.C.., a Georgia limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ADVENTA HOSPICE, L.L.C., a Florida limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AGAPE HEALTH CARE AGENCY, LLC, an Ohio limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ALBERT GALLATIN HOME CARE AND HOSPICE SERVICES, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS ALABAMA, L.L.C., an Alabama limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS ARIZONA, L.L.C., an Arizona limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS ARKANSAS, LLC, an Arkansas limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS BA, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS DELAWARE, L.L.C., a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS FLORIDA, L.L.C., a Florida limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS GEORGIA, L.L.C., a Georgia limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS HEALTH CARE WEST, L.L.C., a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS HOLDING, L.L.C., a Louisiana limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS HOME HEALTH OF ALABAMA, L.L.C. an Alabama limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS HOME HEALTH OF NEBRASKA, L.L.C., a Nebraska limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS HOME HEALTH OF SOUTH CAROLINA, L.L.C. a South Carolina limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS HOME HEALTH OF VIRGINIA, L.L.C. a Virginia limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS HOSPICE, L.L.C., a Louisiana limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS IDAHO, L.L.C., an Idaho limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS ILLINOIS, L.L.C., an Illinois limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS INDIANA, L.L.C., an Indiana limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS KANSAS, L.L.C., a Kansas limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS LA ACQUISITIONS, L.L.C., a Louisiana limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS LOUISIANA, L.L.C., a Louisiana limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS MAINE, P.L.L.C., a Maine professional limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS MARYLAND, L.L.C., a Maryland limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS MISSISSIPPI, L.L.C., a Mississippi limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS MISSOURI, L.L.C., a Missouri limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS NEBRASKA, L.L.C., a Nebraska limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS NEW HAMPSHIRE, L.L.C., a New Hampshire limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS NEW JERSEY, L.L.C., a New Jersey limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS NORTH CAROLINA, L.L.C., a North Carolina limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS NORTHWEST, L.L.C., a Georgia limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS OHIO, L.L.C., an Ohio limited liability company</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS OKLAHOMA, L.L.C., an Oklahoma limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS OREGON, L.L.C., an Oregon limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS PENNSYLVANIA, L.L.C., a Pennsylvania limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS PERSONAL CARE, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS RHODE ISLAND, L.L.C., a Rhode Island limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS SC, L.L.C., a South Carolina limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS SP-IN, L.L.C., an Indiana limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS SP-KY, L.L.C., a Kentucky limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS SP-OH, L.L.C., an Ohio limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS SP-TN, L.L.C., a Tennessee limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS TENNESSEE, L.L.C., a Tennessee limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS TEXAS, L.L.C., a Texas limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS TLC ACQUISITION, L.L.C., a Louisiana limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS WASHINGTON, L.L.C., a Washington limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS WEST VIRGINIA, L.L.C., a West Virginia limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS WISCONSIN, L.L.C., a Wisconsin limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ANGEL WATCH HOME CARE, L.L.C., a Florida limited liability company  </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASANA HOSPICE CLEVELAND, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASANA PALLIATIVE CLEVELAND, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASERACARE HOSPICE &#8211; DEMOPOLIS, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASERACARE HOSPICE &#8211; HAMILTON, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASERACARE HOSPICE &#8211; JACKSON, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASERACARE HOSPICE &#8211; MONROEVILLE, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASERACARE HOSPICE &#8211; NEW HORIZONS, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASERACARE HOSPICE &#8211; RUSSELLVILLE, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASERACARE HOSPICE &#8211; SENTOBIA, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASERACARE HOSPICE &#8211; TENNESSEE, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ASSOCIATED HOME CARE, L.L.C., a Massachusetts limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AVENIR VENTURES, L.L.C., a Louisiana limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">BEACON HOSPICE, L.L.C., a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">BEAUFORT HOME HEALTH PARTNERS, L.L.C., a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CARE CONNECTION OF CINCINNATI, LLC, an Ohio limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE, L.L.C., a Pennsylvania limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF BRYAN TEXAS, LLC, a Texas limited liability company </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF CENTRAL GEORGIA, LLC, a Georgia limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF CENTRAL LOUISIANA, LLC, a Louisiana limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF CENTRAL TEXAS, LLC, a Texas limited liability company </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF CLIFTON, LLC, a New Jersey limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF DELAWARE, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF GWYNEDD, L.L.C., a Pennsylvania limited liability company </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF HOUSTON, LLC, a Texas limited liability company </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF ILLINOIS, LLC, an Illinois limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF KANSAS CITY, LLC, a Kansas limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF MARLTON, LLC, a New Jersey limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF MASSACHUSETTS, LLC, a Massachusetts limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF MICHIGAN, LLC, a Michigan limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF MINNESOTA, LLC, a Minnesota limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF NEW HAMPSHIRE, LLC, a New Hampshire limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF NORTH TEXAS, LLC, a Texas limited liability company </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF NORTHERN GEORGIA, LLC, a Georgia limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF NORTHERN NEW JERSEY, LLC, a New Jersey limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF NORTHWESTERN PENNSYLVANIA, LLC, a Pennsylvania limited liability company </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF OHIO, LLC, an Ohio limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF PITTSBURG, LLC, a Pennsylvania limited liability company </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF SAVANNAH, LLC, a Georgia limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF SOUTH CAROLINA, LLC, a South Carolina limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF SOUTHEASTERN MASSACHUSETTS, LLC, a Massachusetts limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF SOUTHEASTERN TEXAS, LLC, a Texas limited liability company </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF SOUTHERN MISSISSIPPI, LLC, a Mississippi limited liability company COMPASSIONATE CARE HOSPICE OF THE CHESAPEAKE BAY, LLC, a Virginia limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF THE DELMAR PENINSULA, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF THE MIDWEST, LLC, a South Dakota limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPASSIONATE CARE HOSPICE OF WISCONSIN, LLC, a Wisconsin limited liability company </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">COMPREHENSIVE HOME HEALTHCARE SERVICES, L.L.C., a Tennessee limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EMERALD CARE, L.L.C., a North Carolina limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EVOLUTION HEALTH, L.L.C.,  a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">FAMILY HOME HEALTH CARE, L.L.C., a Kentucky limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">GEM CITY HOME CARE, LLC, an Ohio limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">GUARDIAN OHIO NEWCO, LLC, an Ohio limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HHC, L.L.C., a Tennessee limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HOME HEALTH OF ALEXANDRIA, L.L.C., a Louisiana limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HOME HEALTH PARTNERSHIP OPERATING COMPANY, L.L.C., a Texas limited liability company (100% owned by UMC Home Health and Hospice, an Amedisys Partner, L.L.C. JV)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HORIZONS HOSPICE CARE, L.L.C., an Alabama limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HOSPICE HOLDINGS DFW, LLC, a Texas limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HOSPICE HOLDINGS HARRISBURG, LLC, a Pennsylvania Limited Liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HOSPICE PARTNERSHIP OPERATING COMPANY, L.L.C., a Texas limited liability company (100% owned by UMC Home Health and Hospice, an Amedisys Partner, L.L.C. JV)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HOUSECALL HOME HEALTH, L.L.C., a Tennessee limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">INFINITY HOME CARE, L.L.C., a Florida limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">INFINITY HOME CARE OF JACKSONVILLE, LLC, a Florida limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">INFINITY HOME CARE OF LAKELAND, LLC, a Florida limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">INFINITY HOME CARE OF OCALA, LLC, a Florida limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">INFINITY HOME CARE OF PORT CHARLOTTE, LLC, a Florida limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">INFINITY HOMECARE OF DISTRICT 9, LLC, a Florida limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">MISSOURI HOSPICE HOLDINGS, LLC, a Missouri limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">NINE PALMS 1, L.L.C., a Virginia limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">NINE PALMS 2, LLC, a Mississippi limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">OHIO HOSPICE HOLDINGS, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PATHWAYS TO COMPASSION, LLC, a Nebraska limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PATHWAYS TO COMPASSION, LLC, a New Jersey limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PENNSYLVANIA HOSPICE HOLDINGS, LLC, a Pennsylvania limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TAYLOR HOSPICE HOLDINGS, LLC, a Pennsylvania limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TENDER LOVING CARE HEALTH CARE SERVICES INTERNATIONAL, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TENDER LOVING CARE HEALTH CARE SERVICES OF ERIE NIAGARA, LLC, a New York limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TENDER LOVING CARE HEALTH CARE SERVICES OF GEORGIA, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TENDER LOVING CARE HEALTH CARE SERVICES OF NASSAU SUFFOLK, LLC, a New York limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TENDER LOVING CARE HEALTH CARE SERVICES OF NEW ENGLAND, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TENDER LOVING CARE HEALTH CARE SERVICES OF WEST VIRGINIA, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TENDER LOVING CARE HEALTH CARE SERVICES SOUTHEAST, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TENDER LOVING CARE HEALTH CARE SERVICES WESTERN, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TEXAS HOSPICE HOLDINGS, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TLC HOLDINGS I, L.L.C., a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TLC HEALTH CARE SERVICES, L.L.C., a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TUCSON HOME HEALTH, LLC, a Delaware limited liability company </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">UAMS HEALTH COMPREHENSIVE CARE AT HOME, L.L.C., an Arkansas limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">WT HOSPICE HOLDINGS, LLC, a Pennsylvania limited liability company</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">JOINT VENTURES</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">AMEDISYS HOME HEALTH, A LAWRENCE MEDICAL CENTER PARTNER, L.L.C, a Delaware limited liability company </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(66.67% ownership)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">GEORGETOWN HOSPITAL HOME HEALTH, LLC, a Delaware limited liability company </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(70% ownership)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">MARIETTA HOME HEALTH AND HOSPICE, L.L.C., an Ohio limited liability company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> (50% ownership)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">MORGANTOWN HOSPICE, LLC, a Delaware limited liability company </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(80% ownership)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TRI-CITIES HOME HEALTH, LLC, a Delaware limited liability company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> (50% ownership)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">WENTWORTH HOME CARE AND HOSPICE, LLC, a New Hampshire limited liability company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> (50% ownership)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">UMC HOME HEALH AND HOSPICE, AN AMEDISYS PARTNER, L.L.C., a Texas limited liability company </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(50% ownership)</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">CONTESSA COMPANIES</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">BSW HOME  RECOVERY CARE, LLC, a Texas limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CONTESSA HEALTH, INC., a Delaware corporation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CONTESSA HEALTH HOLDING COMPANY, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CONTESSA HEALTH MANAGEMENT COMPANY, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CONTESSA HEALTH OF FLORIDA, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CONTESSA HEALTH OF TENNESSEE, LLC, a Tennessee limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CONTRADO CLAIM, LLC, a Delaware limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">DIGNITY HOME RECOVERY CARE, LLC, a Delaware limited liability company </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(49.9% ownership)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">GUNDERSON HOSPITAL AT HOME, LLC, a Delaware limited liability company </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(51% ownership)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HENRY FORD HOME RECOVERY CARE, LLC, a Delaware limited liability company </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(51% ownership)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">HOME RECOVERY CARE, LLC, a Delaware limited liability company </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(51% ownership)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">MEMORIAL HERMAN HOME-BASED SERVICES, L.L.C., a Delaware corporation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(51.1% ownership)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">OGL HOLDINGS, LLC, a New York limited liability company</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ONE GUSTAVE L. LEVY PLACE, LLC, a Delaware limited liability company </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(51% ownership)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ONE GUSTAVE L. LEVY PLACE INDEPENDENT PRACTICE ASSOCIATION, LLC, a New York limited liability company </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PENN STATE HEALTH HOME RECOVERY CARE, LLC, a Delaware limited liability company </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(51% ownership)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PERSONALIZED RECOVERY CARE, LLC, a Delaware limited liability company </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(51% ownership)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PRISMA HEALTH HOME RECOVERY, LLC, a Delaware limited liability company </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(51% ownership)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">SAINT THOMAS HOME RECOVERY CARE, LLC, a Tennessee limited liability company </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(49% ownership)</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>a202210-kexhibit231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i33a38a7edc304e2f8a677449466be194_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the registration statements (No. 333-138255) on Form&#160;S&#8209;3 and (Nos.&#160;333&#8209;60525, 333&#8209;51704, 333&#8209;53786, 333&#8209;143967, 333&#8209;152359, 333&#8209;182347, 222&#8209;205267, and 333-225461) on Form&#160;S&#8209;8 of our reports dated February 16, 2023, with respect to the consolidated financial statements of Amedisys, Inc. and the effectiveness of internal control over financial reporting. </font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; KPMG LLP</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Baton Rouge, Louisiana</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 16, 2023</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>a202210-kexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i40368010427541778d3a318d48dd9f25_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Paul B. Kusserow, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Annual Report on Form 10-K for the year ended December&#160;31, 2022, of Amedisys, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c. Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d. Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;16, 2023 </font></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:34.064%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;S&#47;&#160;Paul B. Kusserow</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Paul B. Kusserow</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer and Chairman of the Board</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>a202210-kexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i17b7b7d282d6435aaf147b6d07b65cd1_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Scott G. Ginn, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Annual Report on Form 10-K for the year ended December&#160;31, 2022, of Amedisys, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c. Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d. Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;16, 2023 </font></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:34.064%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;S&#47;&#160;Scott G. Ginn</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Scott G. Ginn</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Acting Chief Operating Officer, Executive Vice President and Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>a202210-kexhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ica70d79695d245988c85cc6708c2c9a8_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Amedisys, Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December&#160;31, 2022 (the &#8220;Report&#8221;), I, Paul B. Kusserow, Chief Executive Officer of the Company, hereby certify to my knowledge, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:6pt;padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods presented in the Report.</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;16, 2023 </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:34.064%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;S&#47;&#160;Paul B. Kusserow</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Paul B. Kusserow</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer and Chairman of the Board</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>a202210-kexhibit322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i919dfa6dfc0f48c88779944bcf102460_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Amedisys, Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December&#160;31, 2022 (the &#8220;Report&#8221;), I, Scott G. Ginn, Executive Vice President and Chief Financial Officer of the Company, hereby certify to my knowledge, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:6pt;padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods presented in the Report.</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;16, 2023 </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:34.064%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;S&#47;&#160;Scott G. Ginn</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Scott G. Ginn</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Acting Chief Operating Officer, Executive Vice President and Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>amed-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:c9bac751-1ef0-45f1-8208-1bc5d72ec892,g:1d8a20b2-a85c-4def-9d57-f7b6e7a974de-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:amed="http://www.amedisys.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.amedisys.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amed-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amed-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amed-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amed-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.amedisys.com/role/DocumentandEntityInformation">
        <link:definition>0000001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.amedisys.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS" roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS">
        <link:definition>0000009 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>0000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NOVELCORONAVIRUSPANDEMICCOVID19" roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19">
        <link:definition>0000011 - Disclosure - NOVEL CORONAVIRUS PANDEMIC ("COVID-19")</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONS" roleURI="http://www.amedisys.com/role/ACQUISITIONS">
        <link:definition>0000012 - Disclosure - ACQUISITIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDOTHERINTANGIBLEASSETSNET" roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET">
        <link:definition>0000013 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ASSETSHELDFORSALE" roleURI="http://www.amedisys.com/role/ASSETSHELDFORSALE">
        <link:definition>0000014 - Disclosure - ASSETS HELD FOR SALE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DETAILSOFCERTAINBALANCESHEETACCOUNTS" roleURI="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTS">
        <link:definition>0000015 - Disclosure - DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://www.amedisys.com/role/LEASES">
        <link:definition>0000016 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONS" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONS">
        <link:definition>0000017 - Disclosure - LONG-TERM OBLIGATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.amedisys.com/role/INCOMETAXES">
        <link:definition>0000018 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CAPITALSTOCKANDSHAREBASEDCOMPENSATION" roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATION">
        <link:definition>0000019 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>0000020 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANS" roleURI="http://www.amedisys.com/role/EMPLOYEEBENEFITPLANS">
        <link:definition>0000021 - Disclosure - EMPLOYEE BENEFIT PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREREPURCHASE" roleURI="http://www.amedisys.com/role/SHAREREPURCHASE">
        <link:definition>0000022 - Disclosure - SHARE REPURCHASE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATION" roleURI="http://www.amedisys.com/role/SEGMENTINFORMATION">
        <link:definition>0000023 - Disclosure - SEGMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONS" roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONS">
        <link:definition>0000024 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENTS">
        <link:definition>0000025 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationConsolidationandPresentationofFinancialStatementsPolicies" roleURI="http://www.amedisys.com/role/OrganizationConsolidationandPresentationofFinancialStatementsPolicies">
        <link:definition>0000026 - Disclosure - Organization, Consolidation and Presentation of Financial Statements (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>0000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesCodificationTopic842Policies" roleURI="http://www.amedisys.com/role/LeasesCodificationTopic842Policies">
        <link:definition>0000028 - Disclosure - Leases, Codification Topic 842 (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSTables" roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSTables">
        <link:definition>0000029 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>0000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NOVELCORONAVIRUSPANDEMICCOVID19Tables" roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables">
        <link:definition>0000031 - Disclosure - NOVEL CORONAVIRUS PANDEMIC ("COVID-19") (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSTables" roleURI="http://www.amedisys.com/role/ACQUISITIONSTables">
        <link:definition>0000032 - Disclosure - ACQUISITIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDOTHERINTANGIBLEASSETSNETTables" roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETTables">
        <link:definition>0000033 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ASSETSHELDFORSALETables" roleURI="http://www.amedisys.com/role/ASSETSHELDFORSALETables">
        <link:definition>0000034 - Disclosure - ASSETS HELD FOR SALE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DETAILSOFCERTAINBALANCESHEETACCOUNTSTables" roleURI="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSTables">
        <link:definition>0000035 - Disclosure - DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTables" roleURI="http://www.amedisys.com/role/LEASESTables">
        <link:definition>0000036 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSTables" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSTables">
        <link:definition>0000037 - Disclosure - LONG-TERM OBLIGATIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESTables" roleURI="http://www.amedisys.com/role/INCOMETAXESTables">
        <link:definition>0000038 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables" roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables">
        <link:definition>0000039 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESTables" roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESTables">
        <link:definition>0000040 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONTables" roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONTables">
        <link:definition>0000041 - Disclosure - SEGMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails">
        <link:definition>0000042 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails" roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails">
        <link:definition>0000043 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Recently Issued Accounting Pronouncements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails">
        <link:definition>0000044 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails">
        <link:definition>0000045 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition by Payor Class (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>0000046 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails">
        <link:definition>0000047 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails">
        <link:definition>0000048 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails">
        <link:definition>0000049 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails">
        <link:definition>0000050 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Balances Related to Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails">
        <link:definition>0000051 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Financial Instruments Where Carrying Value and Fair Value Differ (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails">
        <link:definition>0000052 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted Average Shares Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NOVELCORONAVIRUSPANDEMICCOVID19Details" roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details">
        <link:definition>0000053 - Disclosure - NOVEL CORONAVIRUS PANDEMIC ("COVID-19") (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSNarrativeDetails" roleURI="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails">
        <link:definition>0000054 - Disclosure - ACQUISITIONS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails" roleURI="http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails">
        <link:definition>0000055 - Disclosure - ACQUISITIONS - Pro Forma Condensed Consolidated Statement of Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails" roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails">
        <link:definition>0000056 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Activity Related to Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails" roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails">
        <link:definition>0000057 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Goodwill and Intangibles (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails" roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails">
        <link:definition>0000058 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Activity Related to Other Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails" roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails">
        <link:definition>0000059 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Estimated Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsandAssetsHeldForSaleAdditionalInformationDetail" roleURI="http://www.amedisys.com/role/DiscontinuedOperationsandAssetsHeldForSaleAdditionalInformationDetail">
        <link:definition>0000060 - Disclosure - Discontinued Operations and Assets Held For Sale - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsHeldForSaleAssetsandLiabilitiesDetail" roleURI="http://www.amedisys.com/role/AssetsHeldForSaleAssetsandLiabilitiesDetail">
        <link:definition>0000061 - Disclosure - Assets Held For Sale - Assets and Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails" roleURI="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails">
        <link:definition>0000062 - Disclosure - DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS - Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESDetails" roleURI="http://www.amedisys.com/role/LEASESDetails">
        <link:definition>0000063 - Disclosure - LEASES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESLeaseCostDetails" roleURI="http://www.amedisys.com/role/LEASESLeaseCostDetails">
        <link:definition>0000064 - Disclosure - LEASES - Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESOperatingLeaseDetails" roleURI="http://www.amedisys.com/role/LEASESOperatingLeaseDetails">
        <link:definition>0000065 - Disclosure - LEASES - Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESFinanceLeasesDetails" roleURI="http://www.amedisys.com/role/LEASESFinanceLeasesDetails">
        <link:definition>0000066 - Disclosure - LEASES - Finance Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESSupplementalCashflowInformationDetails" roleURI="http://www.amedisys.com/role/LEASESSupplementalCashflowInformationDetails">
        <link:definition>0000067 - Disclosure - LEASES - Supplemental Cashflow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESWeightedAverageRemainingTermandDiscountRateDetails" roleURI="http://www.amedisys.com/role/LEASESWeightedAverageRemainingTermandDiscountRateDetails">
        <link:definition>0000068 - Disclosure - LEASES- Weighted Average Remaining Term and Discount Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESMaturitiesDetails" roleURI="http://www.amedisys.com/role/LEASESMaturitiesDetails">
        <link:definition>0000069 - Disclosure - LEASES - Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails">
        <link:definition>0000070 - Disclosure - LONG-TERM OBLIGATIONS - Summary of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails_1" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails_1">
        <link:definition>0000070 - Disclosure - LONG-TERM OBLIGATIONS - Summary of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails">
        <link:definition>0000071 - Disclosure - LONG-TERM OBLIGATIONS - Summary of Long-Term Debt Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSMaturitiesofDebtDetails" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails">
        <link:definition>0000072 - Disclosure - LONG-TERM OBLIGATIONS - Maturities of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails">
        <link:definition>0000073 - Disclosure - LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSNarrativeDetails" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails">
        <link:definition>0000074 - Disclosure - LONG-TERM OBLIGATIONS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESNarrativeDetails" roleURI="http://www.amedisys.com/role/INCOMETAXESNarrativeDetails">
        <link:definition>0000075 - Disclosure - INCOME TAXES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails" roleURI="http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails">
        <link:definition>0000076 - Disclosure - INCOME TAXES - Components of Tax Provision by Jurisdiction (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESIncomeTaxExpenseAllocationDetails" roleURI="http://www.amedisys.com/role/INCOMETAXESIncomeTaxExpenseAllocationDetails">
        <link:definition>0000077 - Disclosure - INCOME TAXES - Income Tax Expense Allocation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESReconciliationofEffectiveTaxRateDetails" roleURI="http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails">
        <link:definition>0000078 - Disclosure - INCOME TAXES - Reconciliation of Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails" roleURI="http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails">
        <link:definition>0000079 - Disclosure - INCOME TAXES - Components of Deferred Tax Assets (Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails" roleURI="http://www.amedisys.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails">
        <link:definition>0000080 - Disclosure - INCOME TAXES - Reconciliation of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>0000081 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CAPITALSTOCKANDSHAREBASEDCOMPENSATIONEmployeeStockPurchasePlanPurchasesDetails" roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONEmployeeStockPurchasePlanPurchasesDetails">
        <link:definition>0000082 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Employee Stock Purchase Plan Purchases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails" roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails">
        <link:definition>0000083 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Stock Option Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails" roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails">
        <link:definition>0000084 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails" roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails">
        <link:definition>0000085 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Non-Vested Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails" roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails">
        <link:definition>0000086 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Non-Vested Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails" roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails">
        <link:definition>0000087 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Non-Vested Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESNarrativeDetails" roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails">
        <link:definition>0000088 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails" roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails">
        <link:definition>0000089 - Disclosure - COMMITMENTS AND CONTINGENCIES - Insurance Programs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANSNarrativeDetails" roleURI="http://www.amedisys.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails">
        <link:definition>0000090 - Disclosure - EMPLOYEE BENEFIT PLANS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREREPURCHASENarrativeDetails" roleURI="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails">
        <link:definition>0000091 - Disclosure - SHARE REPURCHASE - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONNarrativeDetails" roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails">
        <link:definition>0000092 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails">
        <link:definition>0000093 - Disclosure - SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSNarrativeDetails" roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails">
        <link:definition>0000094 - Disclosure - RELATED PARTY TRANSACTIONS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSNarrativeDetails" roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENTSNarrativeDetails">
        <link:definition>0000095 - Disclosure - SUBSEQUENT EVENTS Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSDetails" roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENTSDetails">
        <link:definition>0000096 - Disclosure - SUBSEQUENT EVENTS - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets" abstract="false" name="DeferredTaxLiabilitiesAmortizationOfIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale" abstract="false" name="IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_OperatingLeaseTermYears" abstract="false" name="OperatingLeaseTermYears" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan" abstract="false" name="CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amed_CertificateOfNeedMember" abstract="true" name="CertificateOfNeedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_SharedBasedPaymentArrangementNonVestedOptionActivityTableTextBlock" abstract="false" name="SharedBasedPaymentArrangementNonVestedOptionActivityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amed_BusinessAcquisitionProFormaInformationAseraCareTableTextBlock" abstract="false" name="BusinessAcquisitionProFormaInformationAseraCareTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amed_AlternativeMinimumTaxCreditMember" abstract="true" name="AlternativeMinimumTaxCreditMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_DetailsOfCertainBalanceSheetAccountsAbstract" abstract="true" name="DetailsOfCertainBalanceSheetAccountsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amed_A2023ShareRepurchaseProgramMember" abstract="true" name="A2023ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_IncreaseDecreaseInAssetsAcquired" abstract="false" name="IncreaseDecreaseInAssetsAcquired" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_LeaseTypeDomain" abstract="true" name="LeaseTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_NetServiceRevenueEpisodePaymentRateDuration" abstract="false" name="NetServiceRevenueEpisodePaymentRateDuration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_ConnectRNMember" abstract="true" name="ConnectRNMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_LegalAndOtherSettlements" abstract="false" name="LegalAndOtherSettlements" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_PersonalCareMember" abstract="true" name="PersonalCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember" abstract="true" name="CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_ReductionToNetServiceRevenue" abstract="false" name="ReductionToNetServiceRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_LetterOfCreditFee" abstract="false" name="LetterOfCreditFee" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale" abstract="false" name="IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_FinancialInstrumentDetailsTableTextBlock" abstract="false" name="FinancialInstrumentDetailsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amed_LowUtilizationPaymentAdjustmentNumberOfVisits" abstract="false" name="LowUtilizationPaymentAdjustmentNumberOfVisits" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_Percentageofownershipinsubsidiaries" abstract="false" name="Percentageofownershipinsubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_FourHundredFiftyMillionTermLoanFacilityMember" abstract="true" name="FourHundredFiftyMillionTermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DebtIssuanceCostsPolicyPolicyTextBlock" abstract="false" name="DebtIssuanceCostsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amed_COVID19DeferralOfSocialSecurityTaxesMember" abstract="true" name="COVID19DeferralOfSocialSecurityTaxesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_ClearwaterFloridaMember" abstract="true" name="ClearwaterFloridaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_NoncontrollingInterestRepurchased" abstract="false" name="NoncontrollingInterestRepurchased" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_BuildingAndLeaseholdImprovementsMember" abstract="true" name="BuildingAndLeaseholdImprovementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_NumberOfCareCentersExited" abstract="false" name="NumberOfCareCentersExited" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_AmortizableAcquiredNamesMember" abstract="true" name="AmortizableAcquiredNamesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_SurrenderedSharesInShares" abstract="false" name="SurrenderedSharesInShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amed_MedalogixMember" abstract="true" name="MedalogixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_DebtInstrumentByLeverageRatioTrancheThreeMember" abstract="true" name="DebtInstrumentByLeverageRatioTrancheThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_OrganizationAndNatureOfOperationsTable" abstract="true" name="OrganizationAndNatureOfOperationsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_CashBalanceAssociatedWithProviderReliefFund" abstract="false" name="CashBalanceAssociatedWithProviderReliefFund" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ExecutiveStockOptionExerciseMember" abstract="true" name="ExecutiveStockOptionExerciseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_ContributionsAttributableToNoncontrollingInterest" abstract="false" name="ContributionsAttributableToNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" abstract="false" name="StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_FloridaZpicRevenueReduction" abstract="false" name="FloridaZpicRevenueReduction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CashDistributionToNoncontrollingInterest" abstract="false" name="CashDistributionToNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" abstract="false" name="EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" abstract="false" name="RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_LegalSettlementPaymentLessInterest" abstract="false" name="LegalSettlementPaymentLessInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_NumberOfCareCentersSold" abstract="false" name="NumberOfCareCentersSold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_DeferredTaxLiabilitiesRightOfUseAssets" abstract="false" name="DeferredTaxLiabilitiesRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ConsolidatedLeverageRatio" abstract="false" name="ConsolidatedLeverageRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="amed_LettersofCreditmaximumcommitment" abstract="false" name="LettersofCreditmaximumcommitment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DepreciationAndAmortizationForContinuingOperations" abstract="false" name="DepreciationAndAmortizationForContinuingOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation" abstract="false" name="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_OrganizationAndNatureOfOperationsLineItems" abstract="true" name="OrganizationAndNatureOfOperationsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amed_EstimatedMedicareCapLiability" abstract="false" name="EstimatedMedicareCapLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_A2037ExpirationMember" abstract="true" name="A2037ExpirationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" abstract="false" name="DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_FundingForHealthcareProvidersIncludingHospitals" abstract="false" name="FundingForHealthcareProvidersIncludingHospitals" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DeferredCompensationPlanLiability" abstract="false" name="DeferredCompensationPlanLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" abstract="false" name="DebtInstrumentCarryingAmountExcludingFinanceLeases" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CertificatesOfNeedMember" abstract="true" name="CertificatesOfNeedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_DeferredTaxAssetsLegalAndComplianceMatters" abstract="false" name="DeferredTaxAssetsLegalAndComplianceMatters" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_SocialSecurityTaxMember" abstract="true" name="SocialSecurityTaxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_CARESActProviderReliefFundsRepaidByUnconsolidatedJointVentures" abstract="false" name="CARESActProviderReliefFundsRepaidByUnconsolidatedJointVentures" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_FinanceLeasesTableTextBlock" abstract="false" name="FinanceLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amed_IncreaseDecreaseInLiabilitiesAssumed" abstract="false" name="IncreaseDecreaseInLiabilitiesAssumed" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_AmendedCreditAgreementMember" abstract="true" name="AmendedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_UnfavorableMember" abstract="true" name="UnfavorableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct" abstract="false" name="PaymentOfDeferredSocialSecurityTaxUnderCARESAct" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_RecognizedTaxBenefitThatImpactsEffectiveTaxRate" abstract="false" name="RecognizedTaxBenefitThatImpactsEffectiveTaxRate" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" abstract="false" name="GoodwillDeductibleForIncomeTaxPurposesPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_UnrecognizedTaxBenefitsDomain" abstract="true" name="UnrecognizedTaxBenefitsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_SafeguardZoneProgramIntegrityContractorMember" abstract="true" name="SafeguardZoneProgramIntegrityContractorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_LesseeLeasesTextBlock" abstract="false" name="LesseeLeasesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" abstract="false" name="WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amed_InternallyDevelopedComputerSoftware" abstract="false" name="InternallyDevelopedComputerSoftware" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock" abstract="false" name="ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amed_RandolphCountyNorthCarolinaMember" abstract="true" name="RandolphCountyNorthCarolinaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_NumberOfCareCentersIncludedInDiscontinuedOperations" abstract="false" name="NumberOfCareCentersIncludedInDiscontinuedOperations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_BusinessAcquisitionWorkingCapitalAdjustment" abstract="false" name="BusinessAcquisitionWorkingCapitalAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate" abstract="false" name="UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_LineOfCreditFacilityAdditionalBorrowingCapacity" abstract="false" name="LineOfCreditFacilityAdditionalBorrowingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" abstract="true" name="OneHundredSeventyFiveMillionTermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_NonVestedStockUnitsMember" abstract="true" name="NonVestedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_FundingReceivedFromCARESAct" abstract="false" name="FundingReceivedFromCARESAct" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_NumberOfCareCentersConsolidated" abstract="false" name="NumberOfCareCentersConsolidated" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_EstimatedInsuranceExcludingLongTermPortion" abstract="false" name="EstimatedInsuranceExcludingLongTermPortion" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_FundsReceivedFromProviderReliefFundAdvance" abstract="false" name="FundsReceivedFromProviderReliefFundAdvance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" abstract="false" name="NetServiceRevenuePeriodOfCarePaymentRateDuration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_HomeHealthBenefitManagerMember" abstract="true" name="HomeHealthBenefitManagerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock" abstract="false" name="ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amed_CreditAgreementMember" abstract="true" name="CreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_PayrollTaxEscrow" abstract="false" name="PayrollTaxEscrow" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1" abstract="false" name="DeferredTaxAssetsGoodwillAndIntangibleAssets1" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_InfinityHomeCareMember" abstract="true" name="InfinityHomeCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_OperatingCareCenters" abstract="false" name="OperatingCareCenters" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_FinanceLeaseCost" abstract="false" name="FinanceLeaseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CurrentPortionOfLongTermObligationsMember" abstract="true" name="CurrentPortionOfLongTermObligationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_TypeOfEquityMethodInvestmentAxis" abstract="true" name="TypeOfEquityMethodInvestmentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_NumberOfCareCentersIncludedInDivestiturePlan" abstract="false" name="NumberOfCareCentersIncludedInDivestiturePlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_IncomeTaxEffectsAllocatedToGoodwill" abstract="false" name="IncomeTaxEffectsAllocatedToGoodwill" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_OtherMiscellaneousDeposits" abstract="false" name="OtherMiscellaneousDeposits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations" abstract="false" name="LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember" abstract="true" name="ShareBasedAwardsToMoreThanTenPercentOwnerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_EstimatedInsuranceTotal" abstract="false" name="EstimatedInsuranceTotal" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_Fairvalueofshareofcommonstockpercentage" abstract="false" name="Fairvalueofshareofcommonstockpercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_CARESActDeferralOfEmployerShareSocialSecurityTax" abstract="false" name="CARESActDeferralOfEmployerShareSocialSecurityTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BusinessAcquisitionClosingPaymentAdjustment" abstract="false" name="BusinessAcquisitionClosingPaymentAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_UnamortizedDebtIssuanceCostAmortizationPeriod" abstract="false" name="UnamortizedDebtIssuanceCostAmortizationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_HealthInsuranceRetentionLimit" abstract="false" name="HealthInsuranceRetentionLimit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_AseraCareHospiceMember" abstract="true" name="AseraCareHospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock" abstract="false" name="ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" abstract="false" name="FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_IndemnificationAmount" abstract="false" name="IndemnificationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DebtInstrumentByLeverageRatioTrancheTwoMember" abstract="true" name="DebtInstrumentByLeverageRatioTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued" abstract="false" name="NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_AmortizableAcquiredNameAndNoncompeteAgreementsMember" abstract="true" name="AmortizableAcquiredNameAndNoncompeteAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_TaxExpenseRecordedToAdditionalPaidInCapital" abstract="false" name="TaxExpenseRecordedToAdditionalPaidInCapital" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_OtherLongTermObligationsMember" abstract="true" name="OtherLongTermObligationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ProfessionalLiabilityInsuranceRetentionLimit" abstract="false" name="ProfessionalLiabilityInsuranceRetentionLimit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DebtInstrumentInterestRateatPeriodEnd" abstract="false" name="DebtInstrumentInterestRateatPeriodEnd" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_ExtrapolatedMember" abstract="true" name="ExtrapolatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_Creditfacilitymaximumallowableconsolidatedleverageratio" abstract="false" name="Creditfacilitymaximumallowableconsolidatedleverageratio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="amed_TypeOfIncomeTaxDeferralDomain" abstract="true" name="TypeOfIncomeTaxDeferralDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_NumberOfBeneficiaries" abstract="false" name="NumberOfBeneficiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" abstract="false" name="CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="amed_UnrecognizedTaxBenefitsAxis" abstract="true" name="UnrecognizedTaxBenefitsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_ScheduleOfBusinessAcquisitionsContessaHealthTableTextBlock" abstract="false" name="ScheduleOfBusinessAcquisitionsContessaHealthTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amed_UsDepartmentOfJusticeMember" abstract="true" name="UsDepartmentOfJusticeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_LakelandFloridaMember" abstract="true" name="LakelandFloridaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" abstract="false" name="PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock" abstract="false" name="EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amed_NumberOfCareCentersRemovedFromAvailableForSale" abstract="false" name="NumberOfCareCentersRemovedFromAvailableForSale" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_TaxCreditCarryforwardMember" abstract="true" name="TaxCreditCarryforwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="amed_DebtInstrumentByLeverageRatioTrancheFourMember" abstract="true" name="DebtInstrumentByLeverageRatioTrancheFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" abstract="false" name="StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amed_PercentageofSharesOutstanding" abstract="false" name="PercentageofSharesOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_HealthInsuranceDeposits" abstract="false" name="HealthInsuranceDeposits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CompassionateCareHospiceCIAMember" abstract="true" name="CompassionateCareHospiceCIAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_DefinedContributionPlanEmployerMatchingContribution" abstract="false" name="DefinedContributionPlanEmployerMatchingContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock" abstract="false" name="DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amed_HighAcuityCareMember" abstract="true" name="HighAcuityCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_Performancebasedawardtargetshareamount" abstract="false" name="Performancebasedawardtargetshareamount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_MaximumPercentOwnershipForEquityMethodPercent" abstract="false" name="MaximumPercentOwnershipForEquityMethodPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" abstract="false" name="ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amed_ReclassToAmortizableIntangible" abstract="false" name="ReclassToAmortizableIntangible" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" abstract="false" name="RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CashContributionToNoncontrollingInterest" abstract="false" name="CashContributionToNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_PotentialClosingPaymentAdjustmentMember" abstract="true" name="PotentialClosingPaymentAdjustmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" abstract="false" name="DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_SwingLineFacility" abstract="false" name="SwingLineFacility" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CARESActProviderReliefFundsRepaidToTheGovernment" abstract="false" name="CARESActProviderReliefFundsRepaidToTheGovernment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_LongTermObligationsLessCurrentPortionMember" abstract="true" name="LongTermObligationsLessCurrentPortionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_MaximumPercentOwnershipForCostMethodPercent" abstract="false" name="MaximumPercentOwnershipForCostMethodPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_DeferredTaxAssetDeferredSocialSecurityTaxes" abstract="false" name="DeferredTaxAssetDeferredSocialSecurityTaxes" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DeferredTaxAssetsProviderReliefFundAdvance" abstract="false" name="DeferredTaxAssetsProviderReliefFundAdvance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ImpactOfChangeInMedicareCollectionRate" abstract="false" name="ImpactOfChangeInMedicareCollectionRate" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_WorkersCompensationInsuranceRetentionLimit" abstract="false" name="WorkersCompensationInsuranceRetentionLimit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ProceedsReceivedFromLoanPartyOfSubsidiary" abstract="false" name="ProceedsReceivedFromLoanPartyOfSubsidiary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CertificatesOfNeedAndLicensesMember" abstract="true" name="CertificatesOfNeedAndLicensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_DebtInstrumentPeriodicPaymentPercentage" abstract="false" name="DebtInstrumentPeriodicPaymentPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_HomeHealthNonMedicareNonEpisodicBasedMember" abstract="true" name="HomeHealthNonMedicareNonEpisodicBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" abstract="false" name="MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_SwingLineLoanMember" abstract="true" name="SwingLineLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_MinimumPercentOwnershipForControllingInterestPercent" abstract="false" name="MinimumPercentOwnershipForControllingInterestPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_UncertainTaxBenefitsInLongTermObligations" abstract="false" name="UncertainTaxBenefitsInLongTermObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_OtherIntangibleAssetsAdditions" abstract="false" name="OtherIntangibleAssetsAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_OperatingLeasesTableTextBlock" abstract="false" name="OperatingLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" abstract="false" name="RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_DeferredOperatingIncomeCARESAct" abstract="false" name="DeferredOperatingIncomeCARESAct" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_COVID19TextBlock" abstract="false" name="COVID19TextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage" abstract="false" name="DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_PaymentsRelatedToTaxAsset" abstract="false" name="PaymentsRelatedToTaxAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_RevolvingCreditFacilityTotal" abstract="false" name="RevolvingCreditFacilityTotal" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_AmedisysCIAMember" abstract="true" name="AmedisysCIAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_NetOperatingLossMember" abstract="true" name="NetOperatingLossMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_PortionOfPatientAccountsReceivableDerivedFromMedicare" abstract="false" name="PortionOfPatientAccountsReceivableDerivedFromMedicare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" abstract="true" name="NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_HomeHealthMedicareMember" abstract="true" name="HomeHealthMedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ShareBasedAwardsMember" abstract="true" name="ShareBasedAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_TypeOfEquityMethodInvestmentDomain" abstract="true" name="TypeOfEquityMethodInvestmentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_NumberOfCareCentersAvailableForSale" abstract="false" name="NumberOfCareCentersAvailableForSale" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_ReversalOfLossContingencyAccrual" abstract="false" name="ReversalOfLossContingencyAccrual" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_LeaseLiabilityMaturityTableTextBlock" abstract="false" name="LeaseLiabilityMaturityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_SecondAmendedCreditAgreementMember" abstract="true" name="SecondAmendedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_NumberOfCareCentersClosed" abstract="false" name="NumberOfCareCentersClosed" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_AdditionalPerformanceBasedAwardTargetShareAmount" abstract="false" name="AdditionalPerformanceBasedAwardTargetShareAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" abstract="false" name="EpisodeOfCareAsEpisodicBasedRevenueDuration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments" abstract="false" name="PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_AmountReleasedFromEscrow" abstract="false" name="AmountReleasedFromEscrow" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_AccruedInterest" abstract="false" name="AccruedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_WorkersCompensationDeposits" abstract="false" name="WorkersCompensationDeposits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_EvolutionHealthMember" abstract="true" name="EvolutionHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_ProceedsFromBorrowingsUnderTermLoan" abstract="false" name="ProceedsFromBorrowingsUnderTermLoan" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock" abstract="false" name="ScheduleOfCaresActProviderReliefFundsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amed_CharityCare" abstract="false" name="CharityCare" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BusinessCombinationAdjustmentsDomain" abstract="true" name="BusinessCombinationAdjustmentsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_A2021ShareRepurchaseProgramMember" abstract="true" name="A2021ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_SurrenderedShares" abstract="false" name="SurrenderedShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_A2019StockRepurchaseProgramMember" abstract="true" name="A2019StockRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_A2022NewJointVentureMember" abstract="true" name="A2022NewJointVentureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_BusinessCombinationAdjustmentsAxis" abstract="true" name="BusinessCombinationAdjustmentsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_ProvisionforIncomeTaxesTableTextBlock" abstract="false" name="ProvisionforIncomeTaxesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amed_ProfessionalLiability" abstract="false" name="ProfessionalLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_TotalLeverageRatio" abstract="false" name="TotalLeverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome" abstract="false" name="EquityImpactOfWriteOffOfOtherComprehensiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_IncomeTaxEffectsAllocatedToInterestExpense" abstract="false" name="IncomeTaxEffectsAllocatedToInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ErrorRatePercentage" abstract="false" name="ErrorRatePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_HeritageHealthcareInnovationFundLPMember" abstract="true" name="HeritageHealthcareInnovationFundLPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock" abstract="false" name="SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amed_A30InterestSoldInTwoCareCentersMember" abstract="true" name="A30InterestSoldInTwoCareCentersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_HomeHealthMember" abstract="true" name="HomeHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_A49InterestSoldInTwoCareCentersMember" abstract="true" name="A49InterestSoldInTwoCareCentersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_PatientLiability" abstract="false" name="PatientLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_HospiceMedicareRevenueRateAccountedForRoutineCare" abstract="false" name="HospiceMedicareRevenueRateAccountedForRoutineCare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_CARESActInterestRepaidToGovernment" abstract="false" name="CARESActInterestRepaidToGovernment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CARESActProviderReliefFundUtilizedByUnconsolidatedJointVentures" abstract="false" name="CARESActProviderReliefFundUtilizedByUnconsolidatedJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_MorgantownWestVirginiaMember" abstract="true" name="MorgantownWestVirginiaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_ParkersburgWestVirginiaMember" abstract="true" name="ParkersburgWestVirginiaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" abstract="false" name="FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CashPaidForInfinityZPICInterest" abstract="false" name="CashPaidForInfinityZPICInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_GovernmentGrantsPolicyTextBlock" abstract="false" name="GovernmentGrantsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amed_NonMedicareRevenueTermRates" abstract="false" name="NonMedicareRevenueTermRates" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_BenefitAsComponentOfInterestExpense" abstract="false" name="BenefitAsComponentOfInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_WokersCompensation" abstract="false" name="WokersCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_VariousAcquisitionsMember" abstract="true" name="VariousAcquisitionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_HospiceMember" abstract="true" name="HospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations" abstract="false" name="LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_PromissoryNotesMember" abstract="true" name="PromissoryNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_ActualClaimsPayment" abstract="false" name="ActualClaimsPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_PayorClassDomain" abstract="true" name="PayorClassDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset" abstract="false" name="AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_TelehealthKitsMember" abstract="true" name="TelehealthKitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_DeferredTaxAssetsLeaseLiability" abstract="false" name="DeferredTaxAssetsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_NewShareRepurchaseProgramMember" abstract="true" name="NewShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_ProvisionForLiabilityOnRegulatoryAudit" abstract="false" name="ProvisionForLiabilityOnRegulatoryAudit" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CurrentAndLongTermObligationsMember" abstract="true" name="CurrentAndLongTermObligationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_EquipmentAndFurnitureMember" abstract="true" name="EquipmentAndFurnitureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_Numberofpatients" abstract="false" name="Numberofpatients" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_NumberOfAdmittingJointVentures" abstract="false" name="NumberOfAdmittingJointVentures" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" abstract="false" name="PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_AssistedCareHomeHealthMember" abstract="true" name="AssistedCareHomeHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_StateTaxCreditMember" abstract="true" name="StateTaxCreditMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_NonCashAccruedContingentConsideration" abstract="false" name="NonCashAccruedContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DebtInstrumentByLeverageRatioTrancheOneMember" abstract="true" name="DebtInstrumentByLeverageRatioTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" abstract="false" name="RecoveryAmountOfOverpaymentMadeToSubsidiary" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_PeriodOfCareAsEpisodicBasedRevenueDuration" abstract="false" name="PeriodOfCareAsEpisodicBasedRevenueDuration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries" abstract="false" name="Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_TotalCARESActProviderReliefFundsReceived" abstract="false" name="TotalCARESActProviderReliefFundsReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_HospiceMedicareMember" abstract="true" name="HospiceMedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_FleetLeaseMember" abstract="true" name="FleetLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_ContessaHealthMember" abstract="true" name="ContessaHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_NumberOfClaimsSubmittedBySubsidiary" abstract="false" name="NumberOfClaimsSubmittedBySubsidiary" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_LeaseTypeAxis" abstract="true" name="LeaseTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_HospiceNonMedicareMember" abstract="true" name="HospiceNonMedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_ShareRepurchaseLineItems" abstract="true" name="ShareRepurchaseLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amed_PercentageOfTotalReimbursementOfOutlierPayment" abstract="false" name="PercentageOfTotalReimbursementOfOutlierPayment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_UnamortizableAcquiredNamesMember" abstract="true" name="UnamortizableAcquiredNamesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_EstimatedInsuranceLongTermPortion" abstract="false" name="EstimatedInsuranceLongTermPortion" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_InsuranceProgramsTableTableTextBlock" abstract="false" name="InsuranceProgramsTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" abstract="false" name="ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CapYearAxis" abstract="true" name="CapYearAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_PayorClassAxis" abstract="true" name="PayorClassAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_ShareRepurchaseTable" abstract="true" name="ShareRepurchaseTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_CommonStockSharesAvailableForIssuanceToEmployeeStockPurchasePlan" abstract="false" name="CommonStockSharesAvailableForIssuanceToEmployeeStockPurchasePlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" abstract="false" name="MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_ConsolidatedInterestCoverageRatio" abstract="false" name="ConsolidatedInterestCoverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" abstract="false" name="Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_NonVestedStockAndStockUnits" abstract="false" name="NonVestedStockAndStockUnits" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amed_BusinessAcquisitionProFormaOperatingIncomeLoss" abstract="false" name="BusinessAcquisitionProFormaOperatingIncomeLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_LicensesMember" abstract="true" name="LicensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_CARESActProviderReliefFundsUtilized" abstract="false" name="CARESActProviderReliefFundsUtilized" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BusinessCombinationAcquiredNoncontrollingInterest" abstract="false" name="BusinessCombinationAcquiredNoncontrollingInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_HospiceAccruals" abstract="false" name="HospiceAccruals" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CorporateIntegrityAgreementTerm" abstract="false" name="CorporateIntegrityAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_NonVestedStockUnitsServiceMember" abstract="true" name="NonVestedStockUnitsServiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_AcquiredNamesMember" abstract="true" name="AcquiredNamesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_ProviderReliefFundAdvance" abstract="false" name="ProviderReliefFundAdvance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_MedicareRevenueMember" abstract="true" name="MedicareRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember" abstract="true" name="CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_NonCashNoncontrollingInterestContribution" abstract="false" name="NonCashNoncontrollingInterestContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CapYearDomain" abstract="true" name="CapYearDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_DocumentAndEntityInformationAbstract" abstract="true" name="DocumentAndEntityInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" abstract="true" name="FiveHundredFiftyMillionRevolvingCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_TotalLegalSettlementPayment" abstract="false" name="TotalLegalSettlementPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_TypeOfIncomeTaxDeferralAxis" abstract="true" name="TypeOfIncomeTaxDeferralAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_HomeHealthNonMedicareEpisodicBasedMember" abstract="true" name="HomeHealthNonMedicareEpisodicBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_HealthInsurance" abstract="false" name="HealthInsurance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_GainRelatedToSaleOfNoncontrollingInterestNetOfTax" abstract="false" name="GainRelatedToSaleOfNoncontrollingInterestNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram" abstract="false" name="DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_WriteOffOfOtherComprehensiveIncome" abstract="false" name="WriteOffOfOtherComprehensiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_VisitingNurseAssociationMember" abstract="true" name="VisitingNurseAssociationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_PercentageOfPatientReceivablesOutstanding" abstract="false" name="PercentageOfPatientReceivablesOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities" abstract="false" name="NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_HistoricalCollectionRateFromMedicare" abstract="false" name="HistoricalCollectionRateFromMedicare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" abstract="false" name="Revenuebypayorclassasapercentageoftotalnetservicerevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="amed_HomeHealthAndHospiceMember" abstract="true" name="HomeHealthAndHospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale" abstract="false" name="IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>amed-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:c9bac751-1ef0-45f1-8208-1bc5d72ec892,g:1d8a20b2-a85c-4def-9d57-f7b6e7a974de-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="amed-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dbf6ef35-3e27-4c27-b815-17066159e953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_3d1f09d1-2bcb-4091-aaee-14e2f925585a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dbf6ef35-3e27-4c27-b815-17066159e953" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_3d1f09d1-2bcb-4091-aaee-14e2f925585a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_c522fb84-464d-43dd-b8c1-ca4b2c6ce448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dbf6ef35-3e27-4c27-b815-17066159e953" xlink:to="loc_us-gaap_CommonStockValueOutstanding_c522fb84-464d-43dd-b8c1-ca4b2c6ce448" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_379d181e-a754-4c21-a61f-566e672aa898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dbf6ef35-3e27-4c27-b815-17066159e953" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_379d181e-a754-4c21-a61f-566e672aa898" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_3fec9bf4-69b1-4340-9edd-bfd14d79862b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dbf6ef35-3e27-4c27-b815-17066159e953" xlink:to="loc_us-gaap_TreasuryStockValue_3fec9bf4-69b1-4340-9edd-bfd14d79862b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5ea7bede-b8a1-478c-97ca-b20aff28ea08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dbf6ef35-3e27-4c27-b815-17066159e953" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5ea7bede-b8a1-478c-97ca-b20aff28ea08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a6933cb7-9153-488f-afdd-216e87142d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3dab058c-7d98-4925-aca2-3230d8412f03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a6933cb7-9153-488f-afdd-216e87142d25" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3dab058c-7d98-4925-aca2-3230d8412f03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_f359d8dd-31ce-41c2-ae17-387e699ee552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a6933cb7-9153-488f-afdd-216e87142d25" xlink:to="loc_us-gaap_RestrictedCash_f359d8dd-31ce-41c2-ae17-387e699ee552" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8ce24a28-f003-4c7a-9f73-f11947e664a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a6933cb7-9153-488f-afdd-216e87142d25" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8ce24a28-f003-4c7a-9f73-f11947e664a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_008caa93-c277-403b-9e52-38b1f0b7f26b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a6933cb7-9153-488f-afdd-216e87142d25" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_008caa93-c277-403b-9e52-38b1f0b7f26b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_c82d95dd-89ab-4451-b17a-c0414bc33ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a6933cb7-9153-488f-afdd-216e87142d25" xlink:to="loc_us-gaap_OtherAssetsCurrent_c82d95dd-89ab-4451-b17a-c0414bc33ddc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_516ec9be-3283-45a1-9db1-3fde98ad419b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_9aa82be2-0f2d-4230-a4b9-e95b426f9a55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_516ec9be-3283-45a1-9db1-3fde98ad419b" xlink:to="loc_us-gaap_AccountsPayableCurrent_9aa82be2-0f2d-4230-a4b9-e95b426f9a55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_337e5d99-b77f-4083-9a1e-aea0affb7aca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_516ec9be-3283-45a1-9db1-3fde98ad419b" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_337e5d99-b77f-4083-9a1e-aea0affb7aca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_bff99197-3f8c-46f7-8ae9-68ec9519d168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_516ec9be-3283-45a1-9db1-3fde98ad419b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_bff99197-3f8c-46f7-8ae9-68ec9519d168" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProviderReliefFundAdvance_b6e0f043-45b2-44e9-9213-1aa114cb1b7d" xlink:href="amed-20221231.xsd#amed_ProviderReliefFundAdvance"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_516ec9be-3283-45a1-9db1-3fde98ad419b" xlink:to="loc_amed_ProviderReliefFundAdvance_b6e0f043-45b2-44e9-9213-1aa114cb1b7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_691f1fff-ba52-4bbb-a475-db035ffaa010" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_516ec9be-3283-45a1-9db1-3fde98ad419b" xlink:to="loc_us-gaap_DebtCurrent_691f1fff-ba52-4bbb-a475-db035ffaa010" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_333dbf19-2e14-4f3e-8827-9c4e72308dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_516ec9be-3283-45a1-9db1-3fde98ad419b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_333dbf19-2e14-4f3e-8827-9c4e72308dd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1e30e05e-7244-4823-bf09-6bbd9c515d59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0d19a882-b31e-488b-a842-9c7f0369f9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1e30e05e-7244-4823-bf09-6bbd9c515d59" xlink:to="loc_us-gaap_LiabilitiesCurrent_0d19a882-b31e-488b-a842-9c7f0369f9e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_eb993979-6641-402f-a672-f669324438ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1e30e05e-7244-4823-bf09-6bbd9c515d59" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_eb993979-6641-402f-a672-f669324438ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_40f160b3-db7f-4ea7-af16-c392db58b07c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1e30e05e-7244-4823-bf09-6bbd9c515d59" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_40f160b3-db7f-4ea7-af16-c392db58b07c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e17e9bad-d5c5-4507-ae0d-4e82b745903f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1e30e05e-7244-4823-bf09-6bbd9c515d59" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e17e9bad-d5c5-4507-ae0d-4e82b745903f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_adeeeb86-a98d-415f-bf76-72b435a8ee48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1e30e05e-7244-4823-bf09-6bbd9c515d59" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_adeeeb86-a98d-415f-bf76-72b435a8ee48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5003a26c-faa5-4254-854f-739502d2e5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_37c8a068-57ff-43cf-a981-221205b971fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5003a26c-faa5-4254-854f-739502d2e5ea" xlink:to="loc_us-gaap_AssetsCurrent_37c8a068-57ff-43cf-a981-221205b971fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e3673009-8a3d-4312-b167-12dee4ffde89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5003a26c-faa5-4254-854f-739502d2e5ea" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e3673009-8a3d-4312-b167-12dee4ffde89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1890e230-d12a-4639-af03-c58cef67a567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5003a26c-faa5-4254-854f-739502d2e5ea" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1890e230-d12a-4639-af03-c58cef67a567" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a7946af0-84cb-4364-b065-422cf9102383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5003a26c-faa5-4254-854f-739502d2e5ea" xlink:to="loc_us-gaap_Goodwill_a7946af0-84cb-4364-b065-422cf9102383" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3af3b42a-0ee8-4aab-a59f-092159c4ddf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5003a26c-faa5-4254-854f-739502d2e5ea" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3af3b42a-0ee8-4aab-a59f-092159c4ddf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_53e8751e-40c3-4f95-aab1-68255e3942b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5003a26c-faa5-4254-854f-739502d2e5ea" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_53e8751e-40c3-4f95-aab1-68255e3942b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ea020c56-04ac-40fe-875e-90b45a9d63f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5003a26c-faa5-4254-854f-739502d2e5ea" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ea020c56-04ac-40fe-875e-90b45a9d63f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dc1bf19e-1a56-4aa6-90a5-15733876e944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_94765ac3-45dc-4979-b6bd-8004c8bd7a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dc1bf19e-1a56-4aa6-90a5-15733876e944" xlink:to="loc_us-gaap_StockholdersEquity_94765ac3-45dc-4979-b6bd-8004c8bd7a7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_3602d343-d505-4798-a9e8-53ca21085227" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dc1bf19e-1a56-4aa6-90a5-15733876e944" xlink:to="loc_us-gaap_MinorityInterest_3602d343-d505-4798-a9e8-53ca21085227" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7ec4eaa1-c739-412e-93ee-38e1c88c5dde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_cc8c618e-e6ce-436c-b30c-dd8e209cffc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7ec4eaa1-c739-412e-93ee-38e1c88c5dde" xlink:to="loc_us-gaap_Liabilities_cc8c618e-e6ce-436c-b30c-dd8e209cffc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_500050ac-53a3-4653-9af6-0e78a3d66073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7ec4eaa1-c739-412e-93ee-38e1c88c5dde" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_500050ac-53a3-4653-9af6-0e78a3d66073" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="amed-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_4e29115a-5dee-4bb4-a24e-1d43e0d445c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_f85047d6-e97d-4fdf-98b1-8f5ecc58619d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4e29115a-5dee-4bb4-a24e-1d43e0d445c2" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_f85047d6-e97d-4fdf-98b1-8f5ecc58619d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_ede3548e-a3e4-4c43-a68a-4943f9953e87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4e29115a-5dee-4bb4-a24e-1d43e0d445c2" xlink:to="loc_us-gaap_LaborAndRelatedExpense_ede3548e-a3e4-4c43-a68a-4943f9953e87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_8e945d0c-121d-4a57-8565-0cef4bf58368" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4e29115a-5dee-4bb4-a24e-1d43e0d445c2" xlink:to="loc_us-gaap_ShareBasedCompensation_8e945d0c-121d-4a57-8565-0cef4bf58368" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_823734bc-c826-47e2-a6cf-a8564d23a548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4e29115a-5dee-4bb4-a24e-1d43e0d445c2" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_823734bc-c826-47e2-a6cf-a8564d23a548" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DepreciationAndAmortizationForContinuingOperations_cc771354-3677-4b6f-b04f-89db07b9def1" xlink:href="amed-20221231.xsd#amed_DepreciationAndAmortizationForContinuingOperations"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4e29115a-5dee-4bb4-a24e-1d43e0d445c2" xlink:to="loc_amed_DepreciationAndAmortizationForContinuingOperations_cc771354-3677-4b6f-b04f-89db07b9def1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_c0432322-6efd-4213-9745-7cd202be9013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_4e29115a-5dee-4bb4-a24e-1d43e0d445c2" xlink:to="loc_us-gaap_AssetImpairmentCharges_c0432322-6efd-4213-9745-7cd202be9013" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_afefee16-312f-42f8-aa04-1599c21a0f01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_31416f9e-fe06-4b56-8e3e-a1f26fb82455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_afefee16-312f-42f8-aa04-1599c21a0f01" xlink:to="loc_us-gaap_OperatingIncomeLoss_31416f9e-fe06-4b56-8e3e-a1f26fb82455" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6b4dae70-42fd-4269-861a-987de227c4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_afefee16-312f-42f8-aa04-1599c21a0f01" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_6b4dae70-42fd-4269-861a-987de227c4e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5638e288-80e1-4526-b7f9-4b33a9afb092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_27f2f9ea-cc18-4cf2-b781-6a9b49efaca4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5638e288-80e1-4526-b7f9-4b33a9afb092" xlink:to="loc_us-gaap_ProfitLoss_27f2f9ea-cc18-4cf2-b781-6a9b49efaca4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ee249680-a0c6-4fe5-bfdc-fcee7aa4d9be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5638e288-80e1-4526-b7f9-4b33a9afb092" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ee249680-a0c6-4fe5-bfdc-fcee7aa4d9be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2120cb9d-4545-4f43-b09c-29598d903929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_c8d96d40-1131-48de-8b63-ac141ed3df40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2120cb9d-4545-4f43-b09c-29598d903929" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_c8d96d40-1131-48de-8b63-ac141ed3df40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_6e3fb3b9-b9f1-4a55-93c8-12167c872802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2120cb9d-4545-4f43-b09c-29598d903929" xlink:to="loc_us-gaap_OtherOperatingIncome_6e3fb3b9-b9f1-4a55-93c8-12167c872802" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_67329ea3-9873-4879-bf9b-b74780507246" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2120cb9d-4545-4f43-b09c-29598d903929" xlink:to="loc_us-gaap_CostsAndExpenses_67329ea3-9873-4879-bf9b-b74780507246" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_b3ac6afe-82bc-4670-8883-53ebf3616cae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_eb629dcc-9ca8-4cc2-b9b4-2a002d703d18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b3ac6afe-82bc-4670-8883-53ebf3616cae" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_eb629dcc-9ca8-4cc2-b9b4-2a002d703d18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_88c7295d-ad70-4408-9da4-363c94ff3395" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b3ac6afe-82bc-4670-8883-53ebf3616cae" xlink:to="loc_us-gaap_InterestExpense_88c7295d-ad70-4408-9da4-363c94ff3395" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_f2f0cdc5-cd3f-438d-969f-ca198e80eb72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b3ac6afe-82bc-4670-8883-53ebf3616cae" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_f2f0cdc5-cd3f-438d-969f-ca198e80eb72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_188d368f-490d-4830-9899-7bc3ba3a98b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b3ac6afe-82bc-4670-8883-53ebf3616cae" xlink:to="loc_us-gaap_GainLossOnInvestments_188d368f-490d-4830-9899-7bc3ba3a98b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0d038cf1-99d2-4ade-a373-f5bba0ab0e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b3ac6afe-82bc-4670-8883-53ebf3616cae" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0d038cf1-99d2-4ade-a373-f5bba0ab0e7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1f7cdde4-3b6c-44c4-a7e9-69130f67bcef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a62b736c-9ebe-4457-9a55-a4a5370f70fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_1f7cdde4-3b6c-44c4-a7e9-69130f67bcef" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a62b736c-9ebe-4457-9a55-a4a5370f70fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_01a5ee97-3cd7-422a-bcdd-7b3721ce7de9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_1f7cdde4-3b6c-44c4-a7e9-69130f67bcef" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_01a5ee97-3cd7-422a-bcdd-7b3721ce7de9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="amed-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_23327c70-098e-4583-8aff-b459396f7306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7f39ae32-7aba-4392-a12a-4ab24710bb4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_23327c70-098e-4583-8aff-b459396f7306" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7f39ae32-7aba-4392-a12a-4ab24710bb4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1101f1a8-cdb2-4b49-819d-142ac88ae994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_23327c70-098e-4583-8aff-b459396f7306" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1101f1a8-cdb2-4b49-819d-142ac88ae994" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_dcf22405-bf18-4e78-a61f-aa2318b0d160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e0e447d8-702b-4a3d-9bb0-8fc0ff6d0f97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_dcf22405-bf18-4e78-a61f-aa2318b0d160" xlink:to="loc_us-gaap_ProfitLoss_e0e447d8-702b-4a3d-9bb0-8fc0ff6d0f97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8e9a8de1-c70d-46de-b466-f59cde432f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_dcf22405-bf18-4e78-a61f-aa2318b0d160" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8e9a8de1-c70d-46de-b466-f59cde432f2f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="amed-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_8ad674e2-eac6-4a7a-9e7a-1747d36b4629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01dc70ec-5a44-4b2b-aac8-fdc63d54647b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_8ad674e2-eac6-4a7a-9e7a-1747d36b4629" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01dc70ec-5a44-4b2b-aac8-fdc63d54647b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_10accb12-1498-45c3-bf93-a65371510925" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_8ad674e2-eac6-4a7a-9e7a-1747d36b4629" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_10accb12-1498-45c3-bf93-a65371510925" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1eb3a1a5-0beb-4f29-8b4c-67c09bfaef2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_8ad674e2-eac6-4a7a-9e7a-1747d36b4629" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1eb3a1a5-0beb-4f29-8b4c-67c09bfaef2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eab3e652-11d6-48ec-bbb8-3fa16e45687b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_7b302082-7900-4472-a8fc-ab25f0773038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eab3e652-11d6-48ec-bbb8-3fa16e45687b" xlink:to="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_7b302082-7900-4472-a8fc-ab25f0773038" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1cfab6ad-66d5-480b-8198-e9cfd4bc1d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eab3e652-11d6-48ec-bbb8-3fa16e45687b" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1cfab6ad-66d5-480b-8198-e9cfd4bc1d2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_aa49d341-7012-4a1c-948d-0ad07f706f24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eab3e652-11d6-48ec-bbb8-3fa16e45687b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_aa49d341-7012-4a1c-948d-0ad07f706f24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToDevelopSoftware_36e69745-3a38-4188-8627-d865ed479fef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToDevelopSoftware"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eab3e652-11d6-48ec-bbb8-3fa16e45687b" xlink:to="loc_us-gaap_PaymentsToDevelopSoftware_36e69745-3a38-4188-8627-d865ed479fef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_a3ef5638-a54f-47bf-aacb-d3ba7c95ee00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eab3e652-11d6-48ec-bbb8-3fa16e45687b" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_a3ef5638-a54f-47bf-aacb-d3ba7c95ee00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_14b20839-8f9f-44a6-a2ad-20f5f721a09b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eab3e652-11d6-48ec-bbb8-3fa16e45687b" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_14b20839-8f9f-44a6-a2ad-20f5f721a09b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_f456b870-9880-43fe-a528-fefaed064b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eab3e652-11d6-48ec-bbb8-3fa16e45687b" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_f456b870-9880-43fe-a528-fefaed064b4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_9764892c-18b6-4621-9535-2c072b525c51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eab3e652-11d6-48ec-bbb8-3fa16e45687b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_9764892c-18b6-4621-9535-2c072b525c51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ad325c5a-97b1-454b-960c-d1577642edd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_6bce3a2f-c164-43d8-927a-cdf983fe5cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ad325c5a-97b1-454b-960c-d1577642edd3" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_6bce3a2f-c164-43d8-927a-cdf983fe5cbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_c8e08b65-89a1-46d4-b27c-33696748d165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ad325c5a-97b1-454b-960c-d1577642edd3" xlink:to="loc_us-gaap_ProceedsFromStockPlans_c8e08b65-89a1-46d4-b27c-33696748d165" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_aba2b9e4-3793-4963-af80-187870b65bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ad325c5a-97b1-454b-960c-d1577642edd3" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_aba2b9e4-3793-4963-af80-187870b65bbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashContributionToNoncontrollingInterest_458d461a-6d99-43d8-b766-ad79fc9fa9cd" xlink:href="amed-20221231.xsd#amed_CashContributionToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ad325c5a-97b1-454b-960c-d1577642edd3" xlink:to="loc_amed_CashContributionToNoncontrollingInterest_458d461a-6d99-43d8-b766-ad79fc9fa9cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashDistributionToNoncontrollingInterest_6450407d-4bb8-4cc4-8d84-2caa648e9833" xlink:href="amed-20221231.xsd#amed_CashDistributionToNoncontrollingInterest"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ad325c5a-97b1-454b-960c-d1577642edd3" xlink:to="loc_amed_CashDistributionToNoncontrollingInterest_6450407d-4bb8-4cc4-8d84-2caa648e9833" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_17cf935d-4305-46e3-a789-a09c14fbfe95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ad325c5a-97b1-454b-960c-d1577642edd3" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_17cf935d-4305-46e3-a789-a09c14fbfe95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProceedsFromBorrowingsUnderTermLoan_8ae5ea4d-7a67-4a59-b6e1-84c1393abfde" xlink:href="amed-20221231.xsd#amed_ProceedsFromBorrowingsUnderTermLoan"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ad325c5a-97b1-454b-960c-d1577642edd3" xlink:to="loc_amed_ProceedsFromBorrowingsUnderTermLoan_8ae5ea4d-7a67-4a59-b6e1-84c1393abfde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_c89d56b7-cd3b-4147-ba8a-cb690734330a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ad325c5a-97b1-454b-960c-d1577642edd3" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_c89d56b7-cd3b-4147-ba8a-cb690734330a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_4de827d5-ccf9-4f90-902b-10c9dc790de0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ad325c5a-97b1-454b-960c-d1577642edd3" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_4de827d5-ccf9-4f90-902b-10c9dc790de0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_fc7adc76-0023-4631-b2ab-d884b61adbc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ad325c5a-97b1-454b-960c-d1577642edd3" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_fc7adc76-0023-4631-b2ab-d884b61adbc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_0d6cc166-7145-46d6-9f80-374c44132cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ad325c5a-97b1-454b-960c-d1577642edd3" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_0d6cc166-7145-46d6-9f80-374c44132cf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundsReceivedFromProviderReliefFundAdvance_d32c85db-36cf-4c6e-aad1-425306b13681" xlink:href="amed-20221231.xsd#amed_FundsReceivedFromProviderReliefFundAdvance"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ad325c5a-97b1-454b-960c-d1577642edd3" xlink:to="loc_amed_FundsReceivedFromProviderReliefFundAdvance_d32c85db-36cf-4c6e-aad1-425306b13681" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_a1eab4de-56c6-445c-a19b-7da604e79eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ad325c5a-97b1-454b-960c-d1577642edd3" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_a1eab4de-56c6-445c-a19b-7da604e79eb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_f66bfe7e-f5ce-4175-b6f1-dcf954415571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ad325c5a-97b1-454b-960c-d1577642edd3" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_f66bfe7e-f5ce-4175-b6f1-dcf954415571" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8859a6-f287-4acb-bf29-884c04da9575" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_41635ca7-9ad9-4836-9c17-fe89c29447ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8859a6-f287-4acb-bf29-884c04da9575" xlink:to="loc_us-gaap_ProfitLoss_41635ca7-9ad9-4836-9c17-fe89c29447ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8a882577-22cd-4e7a-ae3a-8038afedb610" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8859a6-f287-4acb-bf29-884c04da9575" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_8a882577-22cd-4e7a-ae3a-8038afedb610" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_6f5880a2-42a2-4702-bbd9-100ec4787f02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8859a6-f287-4acb-bf29-884c04da9575" xlink:to="loc_us-gaap_ShareBasedCompensation_6f5880a2-42a2-4702-bbd9-100ec4787f02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset_70216278-938e-47f7-adca-19a14a2b5259" xlink:href="amed-20221231.xsd#amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8859a6-f287-4acb-bf29-884c04da9575" xlink:to="loc_amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset_70216278-938e-47f7-adca-19a14a2b5259" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_c2b21400-6478-4605-9c72-2bc7112f0ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8859a6-f287-4acb-bf29-884c04da9575" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_c2b21400-6478-4605-9c72-2bc7112f0ef9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_5dc96b92-bdc8-45f2-bf1a-e2d86fb92499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8859a6-f287-4acb-bf29-884c04da9575" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_5dc96b92-bdc8-45f2-bf1a-e2d86fb92499" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WriteOffOfOtherComprehensiveIncome_cd59d71b-2068-4ebf-b56e-f72abe5c0f0d" xlink:href="amed-20221231.xsd#amed_WriteOffOfOtherComprehensiveIncome"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8859a6-f287-4acb-bf29-884c04da9575" xlink:to="loc_amed_WriteOffOfOtherComprehensiveIncome_cd59d71b-2068-4ebf-b56e-f72abe5c0f0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_898adb5f-0932-40ca-88e3-9ba286378e02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8859a6-f287-4acb-bf29-884c04da9575" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_898adb5f-0932-40ca-88e3-9ba286378e02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_75844c48-138f-4b84-b55b-b628fa21f0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8859a6-f287-4acb-bf29-884c04da9575" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_75844c48-138f-4b84-b55b-b628fa21f0b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_e6cc181f-4507-481f-9ced-a25c96970912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8859a6-f287-4acb-bf29-884c04da9575" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_e6cc181f-4507-481f-9ced-a25c96970912" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_6eaa133b-dd13-4656-b569-f002a9daf95a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8859a6-f287-4acb-bf29-884c04da9575" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_6eaa133b-dd13-4656-b569-f002a9daf95a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_f4187c57-5bd2-4f30-92ce-ec003c1fc093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8859a6-f287-4acb-bf29-884c04da9575" xlink:to="loc_us-gaap_AssetImpairmentCharges_f4187c57-5bd2-4f30-92ce-ec003c1fc093" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b3346b5e-3b91-49c8-b0ca-6eb3e108695a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8859a6-f287-4acb-bf29-884c04da9575" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b3346b5e-3b91-49c8-b0ca-6eb3e108695a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b57fbdaa-0f16-4a9f-9b79-570f794f310d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8859a6-f287-4acb-bf29-884c04da9575" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b57fbdaa-0f16-4a9f-9b79-570f794f310d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c5c809c7-a10e-48c3-b861-ab000acfe2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8859a6-f287-4acb-bf29-884c04da9575" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c5c809c7-a10e-48c3-b861-ab000acfe2f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_692a0cd2-63a2-4919-8455-b573fd4a8cab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8859a6-f287-4acb-bf29-884c04da9575" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_692a0cd2-63a2-4919-8455-b573fd4a8cab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_43bb1069-2eae-4c79-ad0d-73e7fc482a91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8859a6-f287-4acb-bf29-884c04da9575" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_43bb1069-2eae-4c79-ad0d-73e7fc482a91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_0dfab140-1cf4-4255-b16e-72f42fdcc743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8859a6-f287-4acb-bf29-884c04da9575" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_0dfab140-1cf4-4255-b16e-72f42fdcc743" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_580ef554-9c21-4f83-a124-ee7870300827" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8859a6-f287-4acb-bf29-884c04da9575" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_580ef554-9c21-4f83-a124-ee7870300827" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_690c6130-3133-4c68-8e15-5e6a6fc34afd" xlink:href="amed-20221231.xsd#amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8859a6-f287-4acb-bf29-884c04da9575" xlink:to="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_690c6130-3133-4c68-8e15-5e6a6fc34afd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_609c8f2f-9cfa-4e77-a47f-40b9fe9f877c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_7451ca36-fb07-4c0c-b5de-09d8efb18e22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_609c8f2f-9cfa-4e77-a47f-40b9fe9f877c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_7451ca36-fb07-4c0c-b5de-09d8efb18e22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_66278a83-be1b-4272-9bd2-c05390907ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_609c8f2f-9cfa-4e77-a47f-40b9fe9f877c" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_66278a83-be1b-4272-9bd2-c05390907ec1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fbb6dff4-d641-4cbe-b773-649966695755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_21f12395-743e-4a71-b13f-86dae4702b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fbb6dff4-d641-4cbe-b773-649966695755" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_21f12395-743e-4a71-b13f-86dae4702b7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_a415a3e5-ec50-425e-8ce6-ede14fb99a44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fbb6dff4-d641-4cbe-b773-649966695755" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_a415a3e5-ec50-425e-8ce6-ede14fb99a44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockAndStockUnits_e145a868-092d-465b-bc7c-7495c47fae79" xlink:href="amed-20221231.xsd#amed_NonVestedStockAndStockUnits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fbb6dff4-d641-4cbe-b773-649966695755" xlink:to="loc_amed_NonVestedStockAndStockUnits_e145a868-092d-465b-bc7c-7495c47fae79" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_959f93f8-0458-4d20-84c1-36c79c7263f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_d4815d59-bb21-496f-ab56-3b1fbc9060d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_959f93f8-0458-4d20-84c1-36c79c7263f8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_d4815d59-bb21-496f-ab56-3b1fbc9060d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3aa14cea-54bd-4fa3-8343-8da3aee70f49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_959f93f8-0458-4d20-84c1-36c79c7263f8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3aa14cea-54bd-4fa3-8343-8da3aee70f49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6af933c8-2362-4b29-b6f3-1fb7a46758cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_959f93f8-0458-4d20-84c1-36c79c7263f8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6af933c8-2362-4b29-b6f3-1fb7a46758cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ecd2981c-03a9-4f73-8fe1-846675ccd68f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_959f93f8-0458-4d20-84c1-36c79c7263f8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ecd2981c-03a9-4f73-8fe1-846675ccd68f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_dac7bf50-3d5a-427c-8413-a3e5d07d8fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_959f93f8-0458-4d20-84c1-36c79c7263f8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_dac7bf50-3d5a-427c-8413-a3e5d07d8fdf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/AssetsHeldForSaleAssetsandLiabilitiesDetail" xlink:type="simple" xlink:href="amed-20221231.xsd#AssetsHeldForSaleAssetsandLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/AssetsHeldForSaleAssetsandLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_8c0655c3-6e94-4ee0-ac90-eba74a6ca2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_8b7351b5-2a26-4fc2-bb78-2a7f3786e510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_8c0655c3-6e94-4ee0-ac90-eba74a6ca2b9" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_8b7351b5-2a26-4fc2-bb78-2a7f3786e510" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_f2910558-bc21-451a-ab5b-8b35a069f88b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_8c0655c3-6e94-4ee0-ac90-eba74a6ca2b9" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_f2910558-bc21-451a-ab5b-8b35a069f88b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale_52f792ee-ff98-410c-9664-43987809eb2a" xlink:href="amed-20221231.xsd#amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale_9d12e13d-a873-42bf-9699-35fb91d96ede" xlink:href="amed-20221231.xsd#amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale_52f792ee-ff98-410c-9664-43987809eb2a" xlink:to="loc_amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale_9d12e13d-a873-42bf-9699-35fb91d96ede" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale_47d83ddb-79b7-4ed2-973a-0f1f8ebac304" xlink:href="amed-20221231.xsd#amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale_52f792ee-ff98-410c-9664-43987809eb2a" xlink:to="loc_amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale_47d83ddb-79b7-4ed2-973a-0f1f8ebac304" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_8a63e38a-4f31-4a99-92dc-bdb1b7abcbd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayrollTaxEscrow_b16d5b40-2fa9-4d3f-9251-edc363597e1a" xlink:href="amed-20221231.xsd#amed_PayrollTaxEscrow"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_8a63e38a-4f31-4a99-92dc-bdb1b7abcbd4" xlink:to="loc_amed_PayrollTaxEscrow_b16d5b40-2fa9-4d3f-9251-edc363597e1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_dcf1cad3-e526-4cbe-9fd6-694b9ec12531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_8a63e38a-4f31-4a99-92dc-bdb1b7abcbd4" xlink:to="loc_us-gaap_IncomeTaxesReceivable_dcf1cad3-e526-4cbe-9fd6-694b9ec12531" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromJointVenturesCurrent_f8f3d9b8-bad7-4b58-8d79-13f2ee863670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromJointVenturesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_8a63e38a-4f31-4a99-92dc-bdb1b7abcbd4" xlink:to="loc_us-gaap_DueFromJointVenturesCurrent_f8f3d9b8-bad7-4b58-8d79-13f2ee863670" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousCurrent_dc00dc11-2a4e-4a56-bb21-c5996e4f5fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMiscellaneousCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent_8a63e38a-4f31-4a99-92dc-bdb1b7abcbd4" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousCurrent_dc00dc11-2a4e-4a56-bb21-c5996e4f5fe3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_60756abc-9e35-4984-b77b-699f356f761e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent_e4844428-e674-4bb8-aba7-b3c8f3505baa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_60756abc-9e35-4984-b77b-699f356f761e" xlink:to="loc_us-gaap_AccruedInsuranceCurrent_e4844428-e674-4bb8-aba7-b3c8f3505baa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WorkersCompensationLiabilityCurrent_a48b86c5-7a1d-4dcf-9065-f86698e738b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WorkersCompensationLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_60756abc-9e35-4984-b77b-699f356f761e" xlink:to="loc_us-gaap_WorkersCompensationLiabilityCurrent_a48b86c5-7a1d-4dcf-9065-f86698e738b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProvisionForLiabilityOnRegulatoryAudit_f482fbfb-632a-4b8d-ad96-2a45e7bdbe99" xlink:href="amed-20221231.xsd#amed_ProvisionForLiabilityOnRegulatoryAudit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_60756abc-9e35-4984-b77b-699f356f761e" xlink:to="loc_amed_ProvisionForLiabilityOnRegulatoryAudit_f482fbfb-632a-4b8d-ad96-2a45e7bdbe99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LegalAndOtherSettlements_0bfc2ed3-70a4-4a32-8eb0-894c2c0b01cc" xlink:href="amed-20221231.xsd#amed_LegalAndOtherSettlements"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_60756abc-9e35-4984-b77b-699f356f761e" xlink:to="loc_amed_LegalAndOtherSettlements_0bfc2ed3-70a4-4a32-8eb0-894c2c0b01cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CharityCare_9a1d1225-78a5-4217-a8b3-53bf59488aad" xlink:href="amed-20221231.xsd#amed_CharityCare"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_60756abc-9e35-4984-b77b-699f356f761e" xlink:to="loc_amed_CharityCare_9a1d1225-78a5-4217-a8b3-53bf59488aad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedMedicareCapLiability_d97085e6-98e6-41a6-b552-f04cdf3e1dda" xlink:href="amed-20221231.xsd#amed_EstimatedMedicareCapLiability"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_60756abc-9e35-4984-b77b-699f356f761e" xlink:to="loc_amed_EstimatedMedicareCapLiability_d97085e6-98e6-41a6-b552-f04cdf3e1dda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceAccruals_d2672122-bc50-42e4-88d6-372687287f69" xlink:href="amed-20221231.xsd#amed_HospiceAccruals"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_60756abc-9e35-4984-b77b-699f356f761e" xlink:to="loc_amed_HospiceAccruals_d2672122-bc50-42e4-88d6-372687287f69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PatientLiability_3c30820f-4482-424d-9dbc-566b750ce2e2" xlink:href="amed-20221231.xsd#amed_PatientLiability"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_60756abc-9e35-4984-b77b-699f356f761e" xlink:to="loc_amed_PatientLiability_3c30820f-4482-424d-9dbc-566b750ce2e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_6cb7bd93-0374-4472-8f6f-a949b58d8e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_60756abc-9e35-4984-b77b-699f356f761e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_6cb7bd93-0374-4472-8f6f-a949b58d8e34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AccruedInterest_99a14bd7-846b-42b7-b7e4-21ffd1fbb59c" xlink:href="amed-20221231.xsd#amed_AccruedInterest"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_60756abc-9e35-4984-b77b-699f356f761e" xlink:to="loc_amed_AccruedInterest_99a14bd7-846b-42b7-b7e4-21ffd1fbb59c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b51d8551-8148-43b4-825c-b8ed24dfa6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_60756abc-9e35-4984-b77b-699f356f761e" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b51d8551-8148-43b4-825c-b8ed24dfa6cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_dbcd5359-d566-443d-b780-455db58d7ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UncertainTaxBenefitsInLongTermObligations_320cc14e-5699-4c67-b45a-78f83a9001cd" xlink:href="amed-20221231.xsd#amed_UncertainTaxBenefitsInLongTermObligations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_dbcd5359-d566-443d-b780-455db58d7ee0" xlink:to="loc_amed_UncertainTaxBenefitsInLongTermObligations_320cc14e-5699-4c67-b45a-78f83a9001cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredCompensationPlanLiability_26812439-888c-4495-ac34-5f1599577c48" xlink:href="amed-20221231.xsd#amed_DeferredCompensationPlanLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_dbcd5359-d566-443d-b780-455db58d7ee0" xlink:to="loc_amed_DeferredCompensationPlanLiability_26812439-888c-4495-ac34-5f1599577c48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_85ed57c2-7460-44ed-bea9-cc8162998e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_dbcd5359-d566-443d-b780-455db58d7ee0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_85ed57c2-7460-44ed-bea9-cc8162998e45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_e9d79ed1-052e-4102-bcfb-3af5aee73a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_dbcd5359-d566-443d-b780-455db58d7ee0" xlink:to="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_e9d79ed1-052e-4102-bcfb-3af5aee73a7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f996019a-6846-4e02-ad04-d9b1ed938471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WorkersCompensationDeposits_98cfcaf9-10d7-487a-ad66-bf3664bd36d2" xlink:href="amed-20221231.xsd#amed_WorkersCompensationDeposits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_f996019a-6846-4e02-ad04-d9b1ed938471" xlink:to="loc_amed_WorkersCompensationDeposits_98cfcaf9-10d7-487a-ad66-bf3664bd36d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthInsuranceDeposits_5f0ea716-9d6a-42f6-86be-9e396d5205ce" xlink:href="amed-20221231.xsd#amed_HealthInsuranceDeposits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_f996019a-6846-4e02-ad04-d9b1ed938471" xlink:to="loc_amed_HealthInsuranceDeposits_5f0ea716-9d6a-42f6-86be-9e396d5205ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OtherMiscellaneousDeposits_3ebc6b4d-f13a-4d5c-af4f-4b43304d4205" xlink:href="amed-20221231.xsd#amed_OtherMiscellaneousDeposits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_f996019a-6846-4e02-ad04-d9b1ed938471" xlink:to="loc_amed_OtherMiscellaneousDeposits_3ebc6b4d-f13a-4d5c-af4f-4b43304d4205" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableNoncurrent_f6e7c333-d8ae-4a03-889c-164656af610f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyReceivableNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_f996019a-6846-4e02-ad04-d9b1ed938471" xlink:to="loc_us-gaap_LossContingencyReceivableNoncurrent_f6e7c333-d8ae-4a03-889c-164656af610f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_73b73c94-de15-498f-96f5-e34de0108d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_f996019a-6846-4e02-ad04-d9b1ed938471" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_73b73c94-de15-498f-96f5-e34de0108d2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtCost_b88935c7-3a18-4621-a41a-888b04c6b50a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_f996019a-6846-4e02-ad04-d9b1ed938471" xlink:to="loc_us-gaap_InvestmentOwnedAtCost_b88935c7-3a18-4621-a41a-888b04c6b50a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_b832af9c-6dc6-42de-afe3-b021b05535c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_f996019a-6846-4e02-ad04-d9b1ed938471" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_b832af9c-6dc6-42de-afe3-b021b05535c0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_bc6eefca-21c5-40d7-acaf-ccdcd1276cde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_5ad91262-435e-438e-aa5d-81d737e28321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_bc6eefca-21c5-40d7-acaf-ccdcd1276cde" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_5ad91262-435e-438e-aa5d-81d737e28321" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_1454398e-1318-4263-826c-c224de8026af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_bc6eefca-21c5-40d7-acaf-ccdcd1276cde" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_1454398e-1318-4263-826c-c224de8026af" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails_1" xlink:type="simple" xlink:href="amed-20221231.xsd#LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails_1"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_b84bba19-2907-4df0-987f-56140da1699f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_86b6beb8-9ab8-477e-870d-d7317b7df3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_b84bba19-2907-4df0-987f-56140da1699f" xlink:to="loc_us-gaap_LongTermDebtCurrent_86b6beb8-9ab8-477e-870d-d7317b7df3c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_0544023d-0bbe-4937-bfdc-b7c66d62d87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_b84bba19-2907-4df0-987f-56140da1699f" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_0544023d-0bbe-4937-bfdc-b7c66d62d87d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#LONGTERMOBLIGATIONSMaturitiesofDebtDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0d5ea4ec-db74-4597-9658-12722fad83b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_27686a46-fa60-4cb5-bf46-7a6582d965f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_0d5ea4ec-db74-4597-9658-12722fad83b4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_27686a46-fa60-4cb5-bf46-7a6582d965f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_64895031-5083-4aa8-98b3-729a9053d2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_0d5ea4ec-db74-4597-9658-12722fad83b4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_64895031-5083-4aa8-98b3-729a9053d2a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7156bdf0-023c-41e6-8953-8538de65404a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_0d5ea4ec-db74-4597-9658-12722fad83b4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7156bdf0-023c-41e6-8953-8538de65404a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_0748aef5-14cd-468c-bc3f-0adc1f223a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_0d5ea4ec-db74-4597-9658-12722fad83b4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_0748aef5-14cd-468c-bc3f-0adc1f223a5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_44b0ab21-5d80-4d21-be9a-bfdf45b8a72c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_0d5ea4ec-db74-4597-9658-12722fad83b4" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_44b0ab21-5d80-4d21-be9a-bfdf45b8a72c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ff088182-2efc-4b5d-8ab0-fdca08ffca93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_5f1c0f4a-1d56-4998-9619-2afccf01f8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ff088182-2efc-4b5d-8ab0-fdca08ffca93" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_5f1c0f4a-1d56-4998-9619-2afccf01f8ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_573dc35e-b786-4d5a-8b3a-652ecbbbdd93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ff088182-2efc-4b5d-8ab0-fdca08ffca93" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_573dc35e-b786-4d5a-8b3a-652ecbbbdd93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_69ef803b-ee46-4b6f-861e-132f0c25f4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_297a9084-81b8-402e-bb3b-fc5c7be471da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_69ef803b-ee46-4b6f-861e-132f0c25f4a2" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_297a9084-81b8-402e-bb3b-fc5c7be471da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_0ef2802a-9cb4-493e-a67c-d5ec37f57e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_69ef803b-ee46-4b6f-861e-132f0c25f4a2" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_0ef2802a-9cb4-493e-a67c-d5ec37f57e3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_76969778-400c-4a32-95ee-2a98d7d1948d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_dba6fcc8-04e7-4fb9-9159-0c4e808e4034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_76969778-400c-4a32-95ee-2a98d7d1948d" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_dba6fcc8-04e7-4fb9-9159-0c4e808e4034" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2bddf7a1-4f41-49cf-851d-10ee9537e1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_76969778-400c-4a32-95ee-2a98d7d1948d" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2bddf7a1-4f41-49cf-851d-10ee9537e1c9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESIncomeTaxExpenseAllocationDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#INCOMETAXESIncomeTaxExpenseAllocationDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/INCOMETAXESIncomeTaxExpenseAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_fa34c1d2-fb09-4108-b3db-931d4d8c8158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1b668c77-b73a-4a24-bc3a-b2b4f8d9b31f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_fa34c1d2-fb09-4108-b3db-931d4d8c8158" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1b668c77-b73a-4a24-bc3a-b2b4f8d9b31f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncomeTaxEffectsAllocatedToInterestExpense_ca660460-52d1-4891-a9b4-10339f27e6e5" xlink:href="amed-20221231.xsd#amed_IncomeTaxEffectsAllocatedToInterestExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_fa34c1d2-fb09-4108-b3db-931d4d8c8158" xlink:to="loc_amed_IncomeTaxEffectsAllocatedToInterestExpense_ca660460-52d1-4891-a9b4-10339f27e6e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncomeTaxEffectsAllocatedToGoodwill_510cbbc7-31da-49e5-a924-f1503ea58e5f" xlink:href="amed-20221231.xsd#amed_IncomeTaxEffectsAllocatedToGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_fa34c1d2-fb09-4108-b3db-931d4d8c8158" xlink:to="loc_amed_IncomeTaxEffectsAllocatedToGoodwill_510cbbc7-31da-49e5-a924-f1503ea58e5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TaxExpenseRecordedToAdditionalPaidInCapital_0c0802a5-646e-407c-8465-2682947c2dec" xlink:href="amed-20221231.xsd#amed_TaxExpenseRecordedToAdditionalPaidInCapital"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_fa34c1d2-fb09-4108-b3db-931d4d8c8158" xlink:to="loc_amed_TaxExpenseRecordedToAdditionalPaidInCapital_0c0802a5-646e-407c-8465-2682947c2dec" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#INCOMETAXESReconciliationofEffectiveTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_41a5eff1-d2f7-438d-a3cb-17a36b27098f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_163b120d-a8a3-4272-9c91-5ddd39c74c09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_41a5eff1-d2f7-438d-a3cb-17a36b27098f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_163b120d-a8a3-4272-9c91-5ddd39c74c09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2ab345c9-25f9-4381-bbb1-5b2afb08087f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_41a5eff1-d2f7-438d-a3cb-17a36b27098f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2ab345c9-25f9-4381-bbb1-5b2afb08087f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent_477e7b06-c32f-495b-b307-7ca496214740" xlink:href="amed-20221231.xsd#amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_41a5eff1-d2f7-438d-a3cb-17a36b27098f" xlink:to="loc_amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent_477e7b06-c32f-495b-b307-7ca496214740" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent_100422a0-c183-4fb5-81f1-fdc48bfd748b" xlink:href="amed-20221231.xsd#amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_41a5eff1-d2f7-438d-a3cb-17a36b27098f" xlink:to="loc_amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent_100422a0-c183-4fb5-81f1-fdc48bfd748b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_77dc4c05-fc35-418b-b3e3-6e246f31728b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_41a5eff1-d2f7-438d-a3cb-17a36b27098f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_77dc4c05-fc35-418b-b3e3-6e246f31728b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent_eed238fa-d895-4185-a872-729654173246" xlink:href="amed-20221231.xsd#amed_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_41a5eff1-d2f7-438d-a3cb-17a36b27098f" xlink:to="loc_amed_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent_eed238fa-d895-4185-a872-729654173246" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_f45145af-9eb1-46d5-b9ea-6a134d03278d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_81f417f9-9a5e-4d0d-bb8c-ac256f9ae15e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_f45145af-9eb1-46d5-b9ea-6a134d03278d" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_81f417f9-9a5e-4d0d-bb8c-ac256f9ae15e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_eda604f0-f777-464e-ae69-741e47fee5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_f45145af-9eb1-46d5-b9ea-6a134d03278d" xlink:to="loc_us-gaap_DeferredTaxLiabilities_eda604f0-f777-464e-ae69-741e47fee5ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_c38ecce8-ea6e-4319-8d09-bb4bd778e055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_46697358-f640-4f43-9330-4cf96e52acc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_c38ecce8-ea6e-4319-8d09-bb4bd778e055" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_46697358-f640-4f43-9330-4cf96e52acc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets_48ea5b84-c3a1-477a-8b6c-f7f36b4e4b2f" xlink:href="amed-20221231.xsd#amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_c38ecce8-ea6e-4319-8d09-bb4bd778e055" xlink:to="loc_amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets_48ea5b84-c3a1-477a-8b6c-f7f36b4e4b2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_4426f545-3036-4a38-98f9-3b599f5bf0af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_c38ecce8-ea6e-4319-8d09-bb4bd778e055" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_4426f545-3036-4a38-98f9-3b599f5bf0af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_f051d64a-46a4-4c2e-9762-f1d1b643b6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_c38ecce8-ea6e-4319-8d09-bb4bd778e055" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_f051d64a-46a4-4c2e-9762-f1d1b643b6fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxLiabilitiesRightOfUseAssets_3d806cf1-6680-4546-9767-653f1cb02821" xlink:href="amed-20221231.xsd#amed_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_c38ecce8-ea6e-4319-8d09-bb4bd778e055" xlink:to="loc_amed_DeferredTaxLiabilitiesRightOfUseAssets_3d806cf1-6680-4546-9767-653f1cb02821" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_ecff49da-6e06-4898-95e7-5aa366158f38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_c38ecce8-ea6e-4319-8d09-bb4bd778e055" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_ecff49da-6e06-4898-95e7-5aa366158f38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1bab3508-128e-42f4-8652-259700a47ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_5dc00f7e-f806-4056-b9ed-18cb903c26d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1bab3508-128e-42f4-8652-259700a47ef1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_5dc00f7e-f806-4056-b9ed-18cb903c26d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation_11047549-bce7-4d79-9d99-a4e09aff86c5" xlink:href="amed-20221231.xsd#amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1bab3508-128e-42f4-8652-259700a47ef1" xlink:to="loc_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation_11047549-bce7-4d79-9d99-a4e09aff86c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_3b0d417e-975a-494e-a682-fc03afc5fb18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1bab3508-128e-42f4-8652-259700a47ef1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_3b0d417e-975a-494e-a682-fc03afc5fb18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxAssetsLegalAndComplianceMatters_c5215c4e-af99-4960-a3c7-7e6e3ff22fe9" xlink:href="amed-20221231.xsd#amed_DeferredTaxAssetsLegalAndComplianceMatters"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1bab3508-128e-42f4-8652-259700a47ef1" xlink:to="loc_amed_DeferredTaxAssetsLegalAndComplianceMatters_c5215c4e-af99-4960-a3c7-7e6e3ff22fe9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxAssetsLeaseLiability_4b6d3aca-e236-4c73-8d71-6079aa0bbd45" xlink:href="amed-20221231.xsd#amed_DeferredTaxAssetsLeaseLiability"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1bab3508-128e-42f4-8652-259700a47ef1" xlink:to="loc_amed_DeferredTaxAssetsLeaseLiability_4b6d3aca-e236-4c73-8d71-6079aa0bbd45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxAssetDeferredSocialSecurityTaxes_e7423b48-2cb1-49d0-a32d-8507a8d768bc" xlink:href="amed-20221231.xsd#amed_DeferredTaxAssetDeferredSocialSecurityTaxes"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1bab3508-128e-42f4-8652-259700a47ef1" xlink:to="loc_amed_DeferredTaxAssetDeferredSocialSecurityTaxes_e7423b48-2cb1-49d0-a32d-8507a8d768bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherLossCarryforwards_8dbec314-d494-4430-a25b-1d4e6ab1ec28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1bab3508-128e-42f4-8652-259700a47ef1" xlink:to="loc_us-gaap_DeferredTaxAssetsOtherLossCarryforwards_8dbec314-d494-4430-a25b-1d4e6ab1ec28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_c0251b73-2920-440b-9502-1442cd53584f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1bab3508-128e-42f4-8652-259700a47ef1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_c0251b73-2920-440b-9502-1442cd53584f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_93d6c4be-3841-4b68-98dd-70dacd151346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1bab3508-128e-42f4-8652-259700a47ef1" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_93d6c4be-3841-4b68-98dd-70dacd151346" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_69d3c178-4372-44c7-82b8-0a49dab91528" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_b9732b35-b7b0-4d21-88f9-4020cca9004a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet_69d3c178-4372-44c7-82b8-0a49dab91528" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_b9732b35-b7b0-4d21-88f9-4020cca9004a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_175023f6-d21d-48f2-849f-459eaa19e44c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet_69d3c178-4372-44c7-82b8-0a49dab91528" xlink:to="loc_us-gaap_DeferredTaxLiabilities_175023f6-d21d-48f2-849f-459eaa19e44c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_b0560570-3dee-4093-89ba-e14ce7b9a563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_3c4a7550-da09-4c1b-a145-f35eefa6f0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_b0560570-3dee-4093-89ba-e14ce7b9a563" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_3c4a7550-da09-4c1b-a145-f35eefa6f0cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1ef74780-929c-494e-95b6-072a038cde5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_b0560570-3dee-4093-89ba-e14ce7b9a563" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1ef74780-929c-494e-95b6-072a038cde5d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedInsuranceTotal_826681b6-3b0f-4496-b7d3-8ff0d690c680" xlink:href="amed-20221231.xsd#amed_EstimatedInsuranceTotal"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthInsurance_37665be7-5399-4e05-be1d-92eea014c73c" xlink:href="amed-20221231.xsd#amed_HealthInsurance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amed_EstimatedInsuranceTotal_826681b6-3b0f-4496-b7d3-8ff0d690c680" xlink:to="loc_amed_HealthInsurance_37665be7-5399-4e05-be1d-92eea014c73c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WokersCompensation_eec56b3f-602a-4cbf-a8d2-3d100c63a652" xlink:href="amed-20221231.xsd#amed_WokersCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amed_EstimatedInsuranceTotal_826681b6-3b0f-4496-b7d3-8ff0d690c680" xlink:to="loc_amed_WokersCompensation_eec56b3f-602a-4cbf-a8d2-3d100c63a652" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProfessionalLiability_16b8055e-fda8-4f5e-9508-4dcb645c707b" xlink:href="amed-20221231.xsd#amed_ProfessionalLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amed_EstimatedInsuranceTotal_826681b6-3b0f-4496-b7d3-8ff0d690c680" xlink:to="loc_amed_ProfessionalLiability_16b8055e-fda8-4f5e-9508-4dcb645c707b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedInsuranceExcludingLongTermPortion_5c814316-7871-40f6-ab1c-694f9c24f9e6" xlink:href="amed-20221231.xsd#amed_EstimatedInsuranceExcludingLongTermPortion"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedInsuranceTotal_377b4603-5972-451c-b245-a6d538e87d1a" xlink:href="amed-20221231.xsd#amed_EstimatedInsuranceTotal"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amed_EstimatedInsuranceExcludingLongTermPortion_5c814316-7871-40f6-ab1c-694f9c24f9e6" xlink:to="loc_amed_EstimatedInsuranceTotal_377b4603-5972-451c-b245-a6d538e87d1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedInsuranceLongTermPortion_2701bea6-fd8e-4af2-8548-4cda232bc8f4" xlink:href="amed-20221231.xsd#amed_EstimatedInsuranceLongTermPortion"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_amed_EstimatedInsuranceExcludingLongTermPortion_5c814316-7871-40f6-ab1c-694f9c24f9e6" xlink:to="loc_amed_EstimatedInsuranceLongTermPortion_2701bea6-fd8e-4af2-8548-4cda232bc8f4" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>amed-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:c9bac751-1ef0-45f1-8208-1bc5d72ec892,g:1d8a20b2-a85c-4def-9d57-f7b6e7a974de-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="amed-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i26dad0c0ad8e435a915e6c5f2b565134_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3e9bb752-66ff-4d1e-aa84-75738745cf4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3e9bb752-66ff-4d1e-aa84-75738745cf4a" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_35fe633e-9f2d-4a86-ae27-fdf6500fa079" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_35fe633e-9f2d-4a86-ae27-fdf6500fa079" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_8e16caa3-7bc5-4790-a21d-1d5c8c084b21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_us-gaap_SharesOutstanding_8e16caa3-7bc5-4790-a21d-1d5c8c084b21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_e7d91f5a-771a-4e72-8628-d6830d391fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_e7d91f5a-771a-4e72-8628-d6830d391fdd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e13106a3-6a36-42e1-b1ce-88a097ca8362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e13106a3-6a36-42e1-b1ce-88a097ca8362" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_870589b8-9f30-468b-ab9f-1681b71ae57e" xlink:href="amed-20221231.xsd#amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_870589b8-9f30-468b-ab9f-1681b71ae57e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_a2d16f35-09b5-401c-979a-f28010f3e35e" xlink:href="amed-20221231.xsd#amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_a2d16f35-09b5-401c-979a-f28010f3e35e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_b0d03062-3ac0-4a2a-9ca1-d44c826c764b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_b0d03062-3ac0-4a2a-9ca1-d44c826c764b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_38364dd0-5ae1-409b-b833-c579f35b42ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_38364dd0-5ae1-409b-b833-c579f35b42ce" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_26d93df6-a3d4-4330-9a00-61905c4189b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_26d93df6-a3d4-4330-9a00-61905c4189b2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c802017c-21a0-4737-9c8e-36752d621dea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c802017c-21a0-4737-9c8e-36752d621dea" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f467614b-90db-491f-b8a9-8a7cab4e9825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f467614b-90db-491f-b8a9-8a7cab4e9825" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SurrenderedShares_55fac99e-397f-484a-b9e0-a05d1fb3716f" xlink:href="amed-20221231.xsd#amed_SurrenderedShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_amed_SurrenderedShares_55fac99e-397f-484a-b9e0-a05d1fb3716f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_6c10458f-e65e-4695-a3fe-7d0a78777a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_6c10458f-e65e-4695-a3fe-7d0a78777a7d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ContributionsAttributableToNoncontrollingInterest_96706a6d-3d34-41f2-9b1f-532791f0bb76" xlink:href="amed-20221231.xsd#amed_ContributionsAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_amed_ContributionsAttributableToNoncontrollingInterest_96706a6d-3d34-41f2-9b1f-532791f0bb76" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_0e3e9da6-5039-4949-a185-d155e58984b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_0e3e9da6-5039-4949-a185-d155e58984b1" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_0bbebe9a-2dfa-4e8c-ac49-a5310ea04695" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_0bbebe9a-2dfa-4e8c-ac49-a5310ea04695" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_a66ee0ec-75a1-4a46-92d0-20df06bd16d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_a66ee0ec-75a1-4a46-92d0-20df06bd16d9" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome_c9e7ccc3-acbe-4ce7-afec-2ada73ff8234" xlink:href="amed-20221231.xsd#amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome_c9e7ccc3-acbe-4ce7-afec-2ada73ff8234" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4087b066-8879-412e-9447-ba32f2c1758c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_us-gaap_ProfitLoss_4087b066-8879-412e-9447-ba32f2c1758c" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cdd1f8e4-0ad7-439a-a4ca-c2d96c161487" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_6233c9f6-6bfd-4558-bb36-2b6e609a382a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ae82aeea-f84b-4d43-abaa-dfd563735a06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3e9bb752-66ff-4d1e-aa84-75738745cf4a" xlink:to="loc_us-gaap_StatementTable_ae82aeea-f84b-4d43-abaa-dfd563735a06" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c64e028e-ca64-42bb-a57c-7cb872b83146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ae82aeea-f84b-4d43-abaa-dfd563735a06" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c64e028e-ca64-42bb-a57c-7cb872b83146" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c64e028e-ca64-42bb-a57c-7cb872b83146_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c64e028e-ca64-42bb-a57c-7cb872b83146" xlink:to="loc_us-gaap_EquityComponentDomain_c64e028e-ca64-42bb-a57c-7cb872b83146_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6fabf9dd-e85f-4493-84ae-5628dce713bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c64e028e-ca64-42bb-a57c-7cb872b83146" xlink:to="loc_us-gaap_EquityComponentDomain_6fabf9dd-e85f-4493-84ae-5628dce713bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c309d383-4e3e-4c93-9bce-05f5c449191d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6fabf9dd-e85f-4493-84ae-5628dce713bf" xlink:to="loc_us-gaap_CommonStockMember_c309d383-4e3e-4c93-9bce-05f5c449191d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_23be0558-24c9-4698-8ce8-39554866ec75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6fabf9dd-e85f-4493-84ae-5628dce713bf" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_23be0558-24c9-4698-8ce8-39554866ec75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_f3f207bc-03d6-454e-815a-7f9af835dd48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6fabf9dd-e85f-4493-84ae-5628dce713bf" xlink:to="loc_us-gaap_TreasuryStockMember_f3f207bc-03d6-454e-815a-7f9af835dd48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_67f500c4-cd77-41f7-9935-816658fd1e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6fabf9dd-e85f-4493-84ae-5628dce713bf" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_67f500c4-cd77-41f7-9935-816658fd1e0d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_b355760c-691a-48b4-9c38-1deca8c00d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6fabf9dd-e85f-4493-84ae-5628dce713bf" xlink:to="loc_us-gaap_RetainedEarningsMember_b355760c-691a-48b4-9c38-1deca8c00d8e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_4059e11f-bb52-428c-be6e-a880c74861c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6fabf9dd-e85f-4493-84ae-5628dce713bf" xlink:to="loc_us-gaap_NoncontrollingInterestMember_4059e11f-bb52-428c-be6e-a880c74861c0" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" xlink:type="extended" id="i69780554955a4927bc929b90e7827712_NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:href="amed-20221231.xsd#amed_OrganizationAndNatureOfOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_b79357fa-6148-478f-995b-26ceb66c1976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_b79357fa-6148-478f-995b-26ceb66c1976" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OperatingCareCenters_e1aba56e-f7f0-4c49-89f7-6422324909a0" xlink:href="amed-20221231.xsd#amed_OperatingCareCenters"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_amed_OperatingCareCenters_e1aba56e-f7f0-4c49-89f7-6422324909a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_a6559c0a-68fd-4da1-90f3-247c2890154e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_a6559c0a-68fd-4da1-90f3-247c2890154e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MinimumPercentOwnershipForControllingInterestPercent_739e15dc-2cba-445f-9891-804242263882" xlink:href="amed-20221231.xsd#amed_MinimumPercentOwnershipForControllingInterestPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_amed_MinimumPercentOwnershipForControllingInterestPercent_739e15dc-2cba-445f-9891-804242263882" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_0743fbc0-10bb-476b-9e44-6631c2384973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_0743fbc0-10bb-476b-9e44-6631c2384973" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NoncontrollingInterestRepurchased_1d72a8a3-04ef-401f-b17c-4c81e93b5e0c" xlink:href="amed-20221231.xsd#amed_NoncontrollingInterestRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_amed_NoncontrollingInterestRepurchased_1d72a8a3-04ef-401f-b17c-4c81e93b5e0c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForEquityMethodPercent_3712f89d-7cec-4dc9-8fe6-12a96420e7a0" xlink:href="amed-20221231.xsd#amed_MaximumPercentOwnershipForEquityMethodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_amed_MaximumPercentOwnershipForEquityMethodPercent_3712f89d-7cec-4dc9-8fe6-12a96420e7a0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_fee736fa-167b-41d8-95e4-eeb5ed3214ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_fee736fa-167b-41d8-95e4-eeb5ed3214ca" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_9b9b960d-2708-425c-b074-dea09b321d39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_9b9b960d-2708-425c-b074-dea09b321d39" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForCostMethodPercent_ab53eae8-54cc-47d6-a98d-d5a19ebf1a1d" xlink:href="amed-20221231.xsd#amed_MaximumPercentOwnershipForCostMethodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_amed_MaximumPercentOwnershipForCostMethodPercent_ab53eae8-54cc-47d6-a98d-d5a19ebf1a1d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtCost_39ee145d-4e5e-43d2-808a-64d162deeb80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_InvestmentOwnedAtCost_39ee145d-4e5e-43d2-808a-64d162deeb80" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_2509f851-236e-423c-8b09-778ae4a6791d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_2509f851-236e-423c-8b09-778ae4a6791d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities_107195a6-3eca-4342-bb27-a7bc63a7eda3" xlink:href="amed-20221231.xsd#amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities_107195a6-3eca-4342-bb27-a7bc63a7eda3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfAdmittingJointVentures_a6dda4ad-7deb-49bd-a850-9fbda7433510" xlink:href="amed-20221231.xsd#amed_NumberOfAdmittingJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_amed_NumberOfAdmittingJointVentures_a6dda4ad-7deb-49bd-a850-9fbda7433510" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6e244f69-eb5b-423c-b2bf-ffbe32e578e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6e244f69-eb5b-423c-b2bf-ffbe32e578e2" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_67cd1e57-10d3-4443-9d5e-8b108bb30189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_67cd1e57-10d3-4443-9d5e-8b108bb30189" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_b9b7666a-e544-4fca-9db9-ba56eee89870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_OtherAssetsCurrent_b9b7666a-e544-4fca-9db9-ba56eee89870" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_447f1086-74cd-41d9-8c4f-575a8bd4a7fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_AssetsCurrent_447f1086-74cd-41d9-8c4f-575a8bd4a7fb" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f79a5ec8-a2d2-40fe-ade3-6b8ffabfb919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f79a5ec8-a2d2-40fe-ade3-6b8ffabfb919" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ba0d0139-3282-41b5-b341-9f9c4cc78961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ba0d0139-3282-41b5-b341-9f9c4cc78961" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_85dd0c9a-ff81-461c-9694-9159c60d7c74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_Goodwill_85dd0c9a-ff81-461c-9694-9159c60d7c74" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a6cc0aac-8791-4223-b8f0-58254d827dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a6cc0aac-8791-4223-b8f0-58254d827dac" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_fae7197a-5f34-4b4b-9473-41ccf6aebf72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_fae7197a-5f34-4b4b-9473-41ccf6aebf72" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_04492700-282e-4e50-896a-1d1ce57d946c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_Assets_04492700-282e-4e50-896a-1d1ce57d946c" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_fa09964e-a27f-4cf4-a7f8-290bc9c5af1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_AccountsPayableCurrent_fa09964e-a27f-4cf4-a7f8-290bc9c5af1e" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4aaa2f94-9ebf-4669-9b46-41525e53ac54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4aaa2f94-9ebf-4669-9b46-41525e53ac54" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_39f8a5a1-5858-42db-9022-676d8bdc187f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_39f8a5a1-5858-42db-9022-676d8bdc187f" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_4968eeea-5b19-46e8-953e-c9827216ce61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_DebtCurrent_4968eeea-5b19-46e8-953e-c9827216ce61" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a51967cd-3bdd-4589-9876-3142cb6c7b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_LiabilitiesCurrent_a51967cd-3bdd-4589-9876-3142cb6c7b6a" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f7328ac2-48c2-47cc-b9fb-f93b95a29acf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f7328ac2-48c2-47cc-b9fb-f93b95a29acf" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b6d47b20-74b5-4a3a-aafb-125b6ec16f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b6d47b20-74b5-4a3a-aafb-125b6ec16f9a" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ea88097e-1c2e-4aaf-8d5a-4fc29f764f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_Liabilities_ea88097e-1c2e-4aaf-8d5a-4fc29f764f6f" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_b133aa67-810e-40cb-80f3-1c6d2d6c7aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_b133aa67-810e-40cb-80f3-1c6d2d6c7aaa" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_GainRelatedToSaleOfNoncontrollingInterestNetOfTax_0c59bbfd-ea24-4457-b91e-5241088b55c4" xlink:href="amed-20221231.xsd#amed_GainRelatedToSaleOfNoncontrollingInterestNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_amed_GainRelatedToSaleOfNoncontrollingInterestNetOfTax_0c59bbfd-ea24-4457-b91e-5241088b55c4" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_80d6a47a-5391-4c5f-92c6-1823365a9fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_80d6a47a-5391-4c5f-92c6-1823365a9fa5" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_51c27b7d-79f2-4d8f-8efc-593fe1c86131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_AssetImpairmentCharges_51c27b7d-79f2-4d8f-8efc-593fe1c86131" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OrganizationAndNatureOfOperationsTable_70977094-39e5-4c18-a119-c5ec1f7f551b" xlink:href="amed-20221231.xsd#amed_OrganizationAndNatureOfOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_amed_OrganizationAndNatureOfOperationsTable_70977094-39e5-4c18-a119-c5ec1f7f551b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_d0be1aa3-e814-47c0-917a-dc0dc9597ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_amed_OrganizationAndNatureOfOperationsTable_70977094-39e5-4c18-a119-c5ec1f7f551b" xlink:to="loc_us-gaap_InvestmentTypeAxis_d0be1aa3-e814-47c0-917a-dc0dc9597ed0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_d0be1aa3-e814-47c0-917a-dc0dc9597ed0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_d0be1aa3-e814-47c0-917a-dc0dc9597ed0" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_d0be1aa3-e814-47c0-917a-dc0dc9597ed0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_24a68301-3342-44a2-ba99-05c2ee175f24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_d0be1aa3-e814-47c0-917a-dc0dc9597ed0" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_24a68301-3342-44a2-ba99-05c2ee175f24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HeritageHealthcareInnovationFundLPMember_d8580f58-45a2-4114-9d2b-5152cef95619" xlink:href="amed-20221231.xsd#amed_HeritageHealthcareInnovationFundLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_24a68301-3342-44a2-ba99-05c2ee175f24" xlink:to="loc_amed_HeritageHealthcareInnovationFundLPMember_d8580f58-45a2-4114-9d2b-5152cef95619" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedalogixMember_6eb32fe8-20ef-4d28-a203-3a2049f3c847" xlink:href="amed-20221231.xsd#amed_MedalogixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_24a68301-3342-44a2-ba99-05c2ee175f24" xlink:to="loc_amed_MedalogixMember_6eb32fe8-20ef-4d28-a203-3a2049f3c847" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConnectRNMember_ee9bd3ee-7093-4dce-9f91-0dba946f81e6" xlink:href="amed-20221231.xsd#amed_ConnectRNMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_24a68301-3342-44a2-ba99-05c2ee175f24" xlink:to="loc_amed_ConnectRNMember_ee9bd3ee-7093-4dce-9f91-0dba946f81e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthBenefitManagerMember_f23aedc5-6357-4c7f-b0cd-c15163cc8756" xlink:href="amed-20221231.xsd#amed_HomeHealthBenefitManagerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_24a68301-3342-44a2-ba99-05c2ee175f24" xlink:to="loc_amed_HomeHealthBenefitManagerMember_f23aedc5-6357-4c7f-b0cd-c15163cc8756" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d3c5827f-a82b-486c-b584-15eeda654671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_amed_OrganizationAndNatureOfOperationsTable_70977094-39e5-4c18-a119-c5ec1f7f551b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d3c5827f-a82b-486c-b584-15eeda654671" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d3c5827f-a82b-486c-b584-15eeda654671_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d3c5827f-a82b-486c-b584-15eeda654671" xlink:to="loc_us-gaap_SegmentDomain_d3c5827f-a82b-486c-b584-15eeda654671_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f41611f3-d27c-4a3c-ba6f-292d891448e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d3c5827f-a82b-486c-b584-15eeda654671" xlink:to="loc_us-gaap_SegmentDomain_f41611f3-d27c-4a3c-ba6f-292d891448e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_e7aa03e6-269a-492e-b2bd-0f1ecdf226d1" xlink:href="amed-20221231.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f41611f3-d27c-4a3c-ba6f-292d891448e2" xlink:to="loc_amed_HomeHealthMember_e7aa03e6-269a-492e-b2bd-0f1ecdf226d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_f0c434ac-f020-4c04-9583-93cc4ed03258" xlink:href="amed-20221231.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f41611f3-d27c-4a3c-ba6f-292d891448e2" xlink:to="loc_amed_HospiceMember_f0c434ac-f020-4c04-9583-93cc4ed03258" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_2392ca54-967f-4002-9378-89e38fb5edbc" xlink:href="amed-20221231.xsd#amed_PersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f41611f3-d27c-4a3c-ba6f-292d891448e2" xlink:to="loc_amed_PersonalCareMember_2392ca54-967f-4002-9378-89e38fb5edbc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_f33764ec-bea6-41dd-806d-ca09544007bd" xlink:href="amed-20221231.xsd#amed_HighAcuityCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f41611f3-d27c-4a3c-ba6f-292d891448e2" xlink:to="loc_amed_HighAcuityCareMember_f33764ec-bea6-41dd-806d-ca09544007bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_669d3018-d48e-4617-ac9c-da5961261eea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_amed_OrganizationAndNatureOfOperationsTable_70977094-39e5-4c18-a119-c5ec1f7f551b" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_669d3018-d48e-4617-ac9c-da5961261eea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_669d3018-d48e-4617-ac9c-da5961261eea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_669d3018-d48e-4617-ac9c-da5961261eea" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_669d3018-d48e-4617-ac9c-da5961261eea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1cc2448c-59b5-49e0-9d33-9559f022aaf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_669d3018-d48e-4617-ac9c-da5961261eea" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1cc2448c-59b5-49e0-9d33-9559f022aaf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_63a0d1c3-7a2e-4249-b0fd-32f019870f95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1cc2448c-59b5-49e0-9d33-9559f022aaf8" xlink:to="loc_us-gaap_SalesRevenueNetMember_63a0d1c3-7a2e-4249-b0fd-32f019870f95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_31d4c0c0-c3d1-49f8-a0a7-a0eb2dcc5860" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_amed_OrganizationAndNatureOfOperationsTable_70977094-39e5-4c18-a119-c5ec1f7f551b" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_31d4c0c0-c3d1-49f8-a0a7-a0eb2dcc5860" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_31d4c0c0-c3d1-49f8-a0a7-a0eb2dcc5860_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_31d4c0c0-c3d1-49f8-a0a7-a0eb2dcc5860" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_31d4c0c0-c3d1-49f8-a0a7-a0eb2dcc5860_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_8efee37e-a777-4873-9a21-51d14d3fb8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_31d4c0c0-c3d1-49f8-a0a7-a0eb2dcc5860" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_8efee37e-a777-4873-9a21-51d14d3fb8f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_4d1e10a2-fae1-434c-a332-7ab7a3448969" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_8efee37e-a777-4873-9a21-51d14d3fb8f4" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_4d1e10a2-fae1-434c-a332-7ab7a3448969" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_791fe8c4-23b3-400a-b1f7-811bbde30465" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_amed_OrganizationAndNatureOfOperationsTable_70977094-39e5-4c18-a119-c5ec1f7f551b" xlink:to="loc_srt_ConsolidatedEntitiesAxis_791fe8c4-23b3-400a-b1f7-811bbde30465" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_791fe8c4-23b3-400a-b1f7-811bbde30465_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_791fe8c4-23b3-400a-b1f7-811bbde30465" xlink:to="loc_srt_ConsolidatedEntitiesDomain_791fe8c4-23b3-400a-b1f7-811bbde30465_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_9d0adbc5-3f12-4e1e-a7e0-932ee99d4fd2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_791fe8c4-23b3-400a-b1f7-811bbde30465" xlink:to="loc_srt_ConsolidatedEntitiesDomain_9d0adbc5-3f12-4e1e-a7e0-932ee99d4fd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_704e7977-d1ba-488b-bee6-a4eba907b34c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_9d0adbc5-3f12-4e1e-a7e0-932ee99d4fd2" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_704e7977-d1ba-488b-bee6-a4eba907b34c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_74031307-5da1-48fe-bde5-ce67aa410555" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_amed_OrganizationAndNatureOfOperationsTable_70977094-39e5-4c18-a119-c5ec1f7f551b" xlink:to="loc_srt_ProductOrServiceAxis_74031307-5da1-48fe-bde5-ce67aa410555" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_74031307-5da1-48fe-bde5-ce67aa410555_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_74031307-5da1-48fe-bde5-ce67aa410555" xlink:to="loc_srt_ProductsAndServicesDomain_74031307-5da1-48fe-bde5-ce67aa410555_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f23d09cb-a549-45a8-aab8-a6bc44dc7c56" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_74031307-5da1-48fe-bde5-ce67aa410555" xlink:to="loc_srt_ProductsAndServicesDomain_f23d09cb-a549-45a8-aab8-a6bc44dc7c56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_965023ce-787f-47b8-acb4-efc8091314b1" xlink:href="amed-20221231.xsd#amed_MedicareRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f23d09cb-a549-45a8-aab8-a6bc44dc7c56" xlink:to="loc_amed_MedicareRevenueMember_965023ce-787f-47b8-acb4-efc8091314b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeOfEquityMethodInvestmentAxis_8c29759e-eb06-48b6-a1bc-c6917012cf6b" xlink:href="amed-20221231.xsd#amed_TypeOfEquityMethodInvestmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_amed_OrganizationAndNatureOfOperationsTable_70977094-39e5-4c18-a119-c5ec1f7f551b" xlink:to="loc_amed_TypeOfEquityMethodInvestmentAxis_8c29759e-eb06-48b6-a1bc-c6917012cf6b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeOfEquityMethodInvestmentDomain_8c29759e-eb06-48b6-a1bc-c6917012cf6b_default" xlink:href="amed-20221231.xsd#amed_TypeOfEquityMethodInvestmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_TypeOfEquityMethodInvestmentAxis_8c29759e-eb06-48b6-a1bc-c6917012cf6b" xlink:to="loc_amed_TypeOfEquityMethodInvestmentDomain_8c29759e-eb06-48b6-a1bc-c6917012cf6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeOfEquityMethodInvestmentDomain_9ffe3e0e-b762-43c8-ab61-644fb3315c3b" xlink:href="amed-20221231.xsd#amed_TypeOfEquityMethodInvestmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_TypeOfEquityMethodInvestmentAxis_8c29759e-eb06-48b6-a1bc-c6917012cf6b" xlink:to="loc_amed_TypeOfEquityMethodInvestmentDomain_9ffe3e0e-b762-43c8-ab61-644fb3315c3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A30InterestSoldInTwoCareCentersMember_aedfd1cf-31cf-4605-a71a-23c4be516b30" xlink:href="amed-20221231.xsd#amed_A30InterestSoldInTwoCareCentersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_TypeOfEquityMethodInvestmentDomain_9ffe3e0e-b762-43c8-ab61-644fb3315c3b" xlink:to="loc_amed_A30InterestSoldInTwoCareCentersMember_aedfd1cf-31cf-4605-a71a-23c4be516b30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A49InterestSoldInTwoCareCentersMember_0a614685-7e61-410a-9338-5f40f828cb08" xlink:href="amed-20221231.xsd#amed_A49InterestSoldInTwoCareCentersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_TypeOfEquityMethodInvestmentDomain_9ffe3e0e-b762-43c8-ab61-644fb3315c3b" xlink:to="loc_amed_A49InterestSoldInTwoCareCentersMember_0a614685-7e61-410a-9338-5f40f828cb08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedalogixMember_c1448a04-b5e9-4a0e-9933-a9cd55a67ba3" xlink:href="amed-20221231.xsd#amed_MedalogixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_TypeOfEquityMethodInvestmentDomain_9ffe3e0e-b762-43c8-ab61-644fb3315c3b" xlink:to="loc_amed_MedalogixMember_c1448a04-b5e9-4a0e-9933-a9cd55a67ba3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_860b762a-e858-4449-9335-4582129a81ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_amed_OrganizationAndNatureOfOperationsTable_70977094-39e5-4c18-a119-c5ec1f7f551b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_860b762a-e858-4449-9335-4582129a81ab" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_860b762a-e858-4449-9335-4582129a81ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_860b762a-e858-4449-9335-4582129a81ab" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_860b762a-e858-4449-9335-4582129a81ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5deda8b8-f0e1-428f-a20b-c495cd0b1c46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_860b762a-e858-4449-9335-4582129a81ab" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5deda8b8-f0e1-428f-a20b-c495cd0b1c46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ContessaHealthMember_6da0fec1-7d6f-49de-b6ca-324f7e140353" xlink:href="amed-20221231.xsd#amed_ContessaHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5deda8b8-f0e1-428f-a20b-c495cd0b1c46" xlink:to="loc_amed_ContessaHealthMember_6da0fec1-7d6f-49de-b6ca-324f7e140353" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails" xlink:type="extended" id="icf4c3cb2dce24840ae191517e25a37ea_NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_9a98b68a-a30d-4bbe-bc03-564ddf47e38c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9e2f1a86-fdfd-4a54-a159-5c1a75d0e633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_9a98b68a-a30d-4bbe-bc03-564ddf47e38c" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9e2f1a86-fdfd-4a54-a159-5c1a75d0e633" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_55c70ddf-f6fb-4518-afc6-1ce856028acd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9e2f1a86-fdfd-4a54-a159-5c1a75d0e633" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_55c70ddf-f6fb-4518-afc6-1ce856028acd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_55c70ddf-f6fb-4518-afc6-1ce856028acd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_55c70ddf-f6fb-4518-afc6-1ce856028acd" xlink:to="loc_us-gaap_TypeOfAdoptionMember_55c70ddf-f6fb-4518-afc6-1ce856028acd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_1e835691-6cd6-4f68-9681-cd52f6d40cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_55c70ddf-f6fb-4518-afc6-1ce856028acd" xlink:to="loc_us-gaap_TypeOfAdoptionMember_1e835691-6cd6-4f68-9681-cd52f6d40cb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_153e9c54-4070-48cb-9a0a-ddbfd5fc4b88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_1e835691-6cd6-4f68-9681-cd52f6d40cb7" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_153e9c54-4070-48cb-9a0a-ddbfd5fc4b88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6b0a349f-8e26-4866-a248-e41e1bd14d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9e2f1a86-fdfd-4a54-a159-5c1a75d0e633" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6b0a349f-8e26-4866-a248-e41e1bd14d6c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6b0a349f-8e26-4866-a248-e41e1bd14d6c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6b0a349f-8e26-4866-a248-e41e1bd14d6c" xlink:to="loc_us-gaap_EquityComponentDomain_6b0a349f-8e26-4866-a248-e41e1bd14d6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2da3dda4-d142-4fbb-a7b5-889fbce4664a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6b0a349f-8e26-4866-a248-e41e1bd14d6c" xlink:to="loc_us-gaap_EquityComponentDomain_2da3dda4-d142-4fbb-a7b5-889fbce4664a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_75fa7fa8-e800-40f5-8cdf-6cd33f014366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2da3dda4-d142-4fbb-a7b5-889fbce4664a" xlink:to="loc_us-gaap_RetainedEarningsMember_75fa7fa8-e800-40f5-8cdf-6cd33f014366" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="extended" id="i4cb11ce7998040ff85703fa32c1d42ac_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7a008296-8b5a-4c1f-ad81-a4c834f002ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_8cb9ab3e-92d4-40f5-96fe-ae0d049d0c54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7a008296-8b5a-4c1f-ad81-a4c834f002ec" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_8cb9ab3e-92d4-40f5-96fe-ae0d049d0c54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_a375fb6e-9fc0-4e66-9269-2699ce4398a8" xlink:href="amed-20221231.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenueDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7a008296-8b5a-4c1f-ad81-a4c834f002ec" xlink:to="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_a375fb6e-9fc0-4e66-9269-2699ce4398a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenueEpisodePaymentRateDuration_bf5fa286-18cd-4631-bb0b-c6c981b226de" xlink:href="amed-20221231.xsd#amed_NetServiceRevenueEpisodePaymentRateDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7a008296-8b5a-4c1f-ad81-a4c834f002ec" xlink:to="loc_amed_NetServiceRevenueEpisodePaymentRateDuration_bf5fa286-18cd-4631-bb0b-c6c981b226de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment_a418e252-a5af-467f-8f0e-dcb2915dcfb6" xlink:href="amed-20221231.xsd#amed_PercentageOfTotalReimbursementOfOutlierPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7a008296-8b5a-4c1f-ad81-a4c834f002ec" xlink:to="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment_a418e252-a5af-467f-8f0e-dcb2915dcfb6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_e5ebd131-0cf0-41b4-94a3-9c7e61102589" xlink:href="amed-20221231.xsd#amed_LowUtilizationPaymentAdjustmentNumberOfVisits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7a008296-8b5a-4c1f-ad81-a4c834f002ec" xlink:to="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_e5ebd131-0cf0-41b4-94a3-9c7e61102589" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HistoricalCollectionRateFromMedicare_d5986175-d875-4998-83e8-721d5668888d" xlink:href="amed-20221231.xsd#amed_HistoricalCollectionRateFromMedicare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7a008296-8b5a-4c1f-ad81-a4c834f002ec" xlink:to="loc_amed_HistoricalCollectionRateFromMedicare_d5986175-d875-4998-83e8-721d5668888d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonMedicareRevenueTermRates_9bd8a28d-8bd4-49ff-8ff9-8a78e9b6c24c" xlink:href="amed-20221231.xsd#amed_NonMedicareRevenueTermRates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7a008296-8b5a-4c1f-ad81-a4c834f002ec" xlink:to="loc_amed_NonMedicareRevenueTermRates_9bd8a28d-8bd4-49ff-8ff9-8a78e9b6c24c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_809b634f-1cbe-4578-a973-86d871fc0e57" xlink:href="amed-20221231.xsd#amed_HospiceMedicareRevenueRateAccountedForRoutineCare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7a008296-8b5a-4c1f-ad81-a4c834f002ec" xlink:to="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_809b634f-1cbe-4578-a973-86d871fc0e57" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_2cf1de7a-1bed-46ac-b1cf-805380770ca6" xlink:href="amed-20221231.xsd#amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7a008296-8b5a-4c1f-ad81-a4c834f002ec" xlink:to="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_2cf1de7a-1bed-46ac-b1cf-805380770ca6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_03ca4765-a499-4d9c-bbdd-546ab35f0e9b" xlink:href="amed-20221231.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7a008296-8b5a-4c1f-ad81-a4c834f002ec" xlink:to="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_03ca4765-a499-4d9c-bbdd-546ab35f0e9b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_0b83fb1b-5ba9-482c-b520-744cdc0b9344" xlink:href="amed-20221231.xsd#amed_PeriodOfCareAsEpisodicBasedRevenueDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7a008296-8b5a-4c1f-ad81-a4c834f002ec" xlink:to="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_0b83fb1b-5ba9-482c-b520-744cdc0b9344" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_2e69beab-68de-40d5-b249-0205e0ae0f42" xlink:href="amed-20221231.xsd#amed_NetServiceRevenuePeriodOfCarePaymentRateDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7a008296-8b5a-4c1f-ad81-a4c834f002ec" xlink:to="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_2e69beab-68de-40d5-b249-0205e0ae0f42" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ImpactOfChangeInMedicareCollectionRate_74e23ae9-ba96-47ab-a483-9d890d52e93d" xlink:href="amed-20221231.xsd#amed_ImpactOfChangeInMedicareCollectionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7a008296-8b5a-4c1f-ad81-a4c834f002ec" xlink:to="loc_amed_ImpactOfChangeInMedicareCollectionRate_74e23ae9-ba96-47ab-a483-9d890d52e93d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments_4a60d050-a146-4352-b9cc-1a46996fc581" xlink:href="amed-20221231.xsd#amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7a008296-8b5a-4c1f-ad81-a4c834f002ec" xlink:to="loc_amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments_4a60d050-a146-4352-b9cc-1a46996fc581" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_21cf6987-5a74-4d3b-9bde-d6d59748491d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7a008296-8b5a-4c1f-ad81-a4c834f002ec" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_21cf6987-5a74-4d3b-9bde-d6d59748491d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearAxis_a1d2910b-0f66-4ac2-ac70-7635bae2cc50" xlink:href="amed-20221231.xsd#amed_CapYearAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_21cf6987-5a74-4d3b-9bde-d6d59748491d" xlink:to="loc_amed_CapYearAxis_a1d2910b-0f66-4ac2-ac70-7635bae2cc50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearDomain_a1d2910b-0f66-4ac2-ac70-7635bae2cc50_default" xlink:href="amed-20221231.xsd#amed_CapYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_CapYearAxis_a1d2910b-0f66-4ac2-ac70-7635bae2cc50" xlink:to="loc_amed_CapYearDomain_a1d2910b-0f66-4ac2-ac70-7635bae2cc50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearDomain_b01ff157-7e5b-4800-8590-8c2df208d6ca" xlink:href="amed-20221231.xsd#amed_CapYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_CapYearAxis_a1d2910b-0f66-4ac2-ac70-7635bae2cc50" xlink:to="loc_amed_CapYearDomain_b01ff157-7e5b-4800-8590-8c2df208d6ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember_2d3d7fe9-64ea-455f-b6a7-0eecdee8580c" xlink:href="amed-20221231.xsd#amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_CapYearDomain_b01ff157-7e5b-4800-8590-8c2df208d6ca" xlink:to="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember_2d3d7fe9-64ea-455f-b6a7-0eecdee8580c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember_b6530c4e-0935-46ef-9faf-868106a28680" xlink:href="amed-20221231.xsd#amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_CapYearDomain_b01ff157-7e5b-4800-8590-8c2df208d6ca" xlink:to="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember_b6530c4e-0935-46ef-9faf-868106a28680" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f25b0708-4cc0-45c4-acf4-1939bdc10472" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_21cf6987-5a74-4d3b-9bde-d6d59748491d" xlink:to="loc_srt_RangeAxis_f25b0708-4cc0-45c4-acf4-1939bdc10472" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f25b0708-4cc0-45c4-acf4-1939bdc10472_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f25b0708-4cc0-45c4-acf4-1939bdc10472" xlink:to="loc_srt_RangeMember_f25b0708-4cc0-45c4-acf4-1939bdc10472_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_23bedd5d-020f-4e9e-ae56-eaf684f9a660" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f25b0708-4cc0-45c4-acf4-1939bdc10472" xlink:to="loc_srt_RangeMember_23bedd5d-020f-4e9e-ae56-eaf684f9a660" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2c4cf8c4-eb16-4f1d-914d-ec458d53f81c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_23bedd5d-020f-4e9e-ae56-eaf684f9a660" xlink:to="loc_srt_MinimumMember_2c4cf8c4-eb16-4f1d-914d-ec458d53f81c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_20e43976-c589-4a5c-9c27-6921b156c6ee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_23bedd5d-020f-4e9e-ae56-eaf684f9a660" xlink:to="loc_srt_MaximumMember_20e43976-c589-4a5c-9c27-6921b156c6ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f5bf3c90-b45b-48dc-8da0-2b45e6af05aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_21cf6987-5a74-4d3b-9bde-d6d59748491d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f5bf3c90-b45b-48dc-8da0-2b45e6af05aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f5bf3c90-b45b-48dc-8da0-2b45e6af05aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f5bf3c90-b45b-48dc-8da0-2b45e6af05aa" xlink:to="loc_us-gaap_SegmentDomain_f5bf3c90-b45b-48dc-8da0-2b45e6af05aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2ef7ff41-b967-4553-af2e-0c3d340c417f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f5bf3c90-b45b-48dc-8da0-2b45e6af05aa" xlink:to="loc_us-gaap_SegmentDomain_2ef7ff41-b967-4553-af2e-0c3d340c417f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_a8225b36-0ca9-4427-8e81-3023aabd0286" xlink:href="amed-20221231.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2ef7ff41-b967-4553-af2e-0c3d340c417f" xlink:to="loc_amed_HomeHealthMember_a8225b36-0ca9-4427-8e81-3023aabd0286" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_82fa4cd1-93e9-4403-a081-01d6577cd273" xlink:href="amed-20221231.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2ef7ff41-b967-4553-af2e-0c3d340c417f" xlink:to="loc_amed_HospiceMember_82fa4cd1-93e9-4403-a081-01d6577cd273" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_5231335a-2ebd-47c1-823d-f460230bae95" xlink:href="amed-20221231.xsd#amed_HighAcuityCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2ef7ff41-b967-4553-af2e-0c3d340c417f" xlink:to="loc_amed_HighAcuityCareMember_5231335a-2ebd-47c1-823d-f460230bae95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_33044601-7499-4857-9a4e-bb206c1dba68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_21cf6987-5a74-4d3b-9bde-d6d59748491d" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_33044601-7499-4857-9a4e-bb206c1dba68" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_33044601-7499-4857-9a4e-bb206c1dba68_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_33044601-7499-4857-9a4e-bb206c1dba68" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_33044601-7499-4857-9a4e-bb206c1dba68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_08e8b536-ad75-45cc-99da-0ed07633f8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_33044601-7499-4857-9a4e-bb206c1dba68" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_08e8b536-ad75-45cc-99da-0ed07633f8ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_6adbc48e-715c-40b7-893e-11b335394f07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_08e8b536-ad75-45cc-99da-0ed07633f8ba" xlink:to="loc_us-gaap_SalesRevenueNetMember_6adbc48e-715c-40b7-893e-11b335394f07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_b37327c2-276c-4cb1-82bf-fba6bef34439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_21cf6987-5a74-4d3b-9bde-d6d59748491d" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_b37327c2-276c-4cb1-82bf-fba6bef34439" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b37327c2-276c-4cb1-82bf-fba6bef34439_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b37327c2-276c-4cb1-82bf-fba6bef34439" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b37327c2-276c-4cb1-82bf-fba6bef34439_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_dac5e838-69dd-46a0-af26-3f24d014a270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b37327c2-276c-4cb1-82bf-fba6bef34439" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_dac5e838-69dd-46a0-af26-3f24d014a270" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_b6adfb2d-1b6c-4c52-b24a-2a1112505980" xlink:href="amed-20221231.xsd#amed_MedicareRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_dac5e838-69dd-46a0-af26-3f24d014a270" xlink:to="loc_amed_MedicareRevenueMember_b6adfb2d-1b6c-4c52-b24a-2a1112505980" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_71d29870-8d30-4e14-8fb2-2bf81c374314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_dac5e838-69dd-46a0-af26-3f24d014a270" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_71d29870-8d30-4e14-8fb2-2bf81c374314" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8581b174-f3e2-416a-bb63-8315ff2d1cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_21cf6987-5a74-4d3b-9bde-d6d59748491d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8581b174-f3e2-416a-bb63-8315ff2d1cc0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8581b174-f3e2-416a-bb63-8315ff2d1cc0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8581b174-f3e2-416a-bb63-8315ff2d1cc0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8581b174-f3e2-416a-bb63-8315ff2d1cc0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_77cb1417-30f3-4b5f-b9b5-82f778636ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8581b174-f3e2-416a-bb63-8315ff2d1cc0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_77cb1417-30f3-4b5f-b9b5-82f778636ebd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_5f2f7705-fd6f-4538-9cbb-2fb6976957c6" xlink:href="amed-20221231.xsd#amed_AseraCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_77cb1417-30f3-4b5f-b9b5-82f778636ebd" xlink:to="loc_amed_AseraCareHospiceMember_5f2f7705-fd6f-4538-9cbb-2fb6976957c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a4ed61cf-b472-417c-a472-9a7b3fb849e1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_21cf6987-5a74-4d3b-9bde-d6d59748491d" xlink:to="loc_srt_ProductOrServiceAxis_a4ed61cf-b472-417c-a472-9a7b3fb849e1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a4ed61cf-b472-417c-a472-9a7b3fb849e1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a4ed61cf-b472-417c-a472-9a7b3fb849e1" xlink:to="loc_srt_ProductsAndServicesDomain_a4ed61cf-b472-417c-a472-9a7b3fb849e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_75bd1c66-7665-4f4e-a89b-67b0fbd11eab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a4ed61cf-b472-417c-a472-9a7b3fb849e1" xlink:to="loc_srt_ProductsAndServicesDomain_75bd1c66-7665-4f4e-a89b-67b0fbd11eab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_dbf620f2-6aab-4200-9468-f62af17bd9e0" xlink:href="amed-20221231.xsd#amed_MedicareRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_75bd1c66-7665-4f4e-a89b-67b0fbd11eab" xlink:to="loc_amed_MedicareRevenueMember_dbf620f2-6aab-4200-9468-f62af17bd9e0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails" xlink:type="extended" id="i00940408c70744bc9f21b620c903b6a2_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_6cbec178-a968-4b31-b6a7-b91a6f1e12cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_93d48002-c1d6-4fc9-984a-8e5041a48c82" xlink:href="amed-20221231.xsd#amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_6cbec178-a968-4b31-b6a7-b91a6f1e12cc" xlink:to="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_93d48002-c1d6-4fc9-984a-8e5041a48c82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_949cff44-be2a-46bf-aebe-dddb8de0d256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_6cbec178-a968-4b31-b6a7-b91a6f1e12cc" xlink:to="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_949cff44-be2a-46bf-aebe-dddb8de0d256" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassAxis_445a8da9-d6ac-42ad-a6a2-3a50fce01291" xlink:href="amed-20221231.xsd#amed_PayorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_949cff44-be2a-46bf-aebe-dddb8de0d256" xlink:to="loc_amed_PayorClassAxis_445a8da9-d6ac-42ad-a6a2-3a50fce01291" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassDomain_445a8da9-d6ac-42ad-a6a2-3a50fce01291_default" xlink:href="amed-20221231.xsd#amed_PayorClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_PayorClassAxis_445a8da9-d6ac-42ad-a6a2-3a50fce01291" xlink:to="loc_amed_PayorClassDomain_445a8da9-d6ac-42ad-a6a2-3a50fce01291_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassDomain_60cf1553-cdb3-43cf-8a5a-a8943855ae57" xlink:href="amed-20221231.xsd#amed_PayorClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_PayorClassAxis_445a8da9-d6ac-42ad-a6a2-3a50fce01291" xlink:to="loc_amed_PayorClassDomain_60cf1553-cdb3-43cf-8a5a-a8943855ae57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMedicareMember_d362c55f-3b34-49e4-bc6f-b755d9293ee9" xlink:href="amed-20221231.xsd#amed_HomeHealthMedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_60cf1553-cdb3-43cf-8a5a-a8943855ae57" xlink:to="loc_amed_HomeHealthMedicareMember_d362c55f-3b34-49e4-bc6f-b755d9293ee9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareEpisodicBasedMember_25732579-392d-4ceb-a7af-d1489e850227" xlink:href="amed-20221231.xsd#amed_HomeHealthNonMedicareEpisodicBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_60cf1553-cdb3-43cf-8a5a-a8943855ae57" xlink:to="loc_amed_HomeHealthNonMedicareEpisodicBasedMember_25732579-392d-4ceb-a7af-d1489e850227" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember_37b1a8d0-cf1f-4f0b-b910-16f5ba1d9e39" xlink:href="amed-20221231.xsd#amed_HomeHealthNonMedicareNonEpisodicBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_60cf1553-cdb3-43cf-8a5a-a8943855ae57" xlink:to="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember_37b1a8d0-cf1f-4f0b-b910-16f5ba1d9e39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareMember_debd002a-e5e1-4e52-b705-24611ddaf7b8" xlink:href="amed-20221231.xsd#amed_HospiceMedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_60cf1553-cdb3-43cf-8a5a-a8943855ae57" xlink:to="loc_amed_HospiceMedicareMember_debd002a-e5e1-4e52-b705-24611ddaf7b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceNonMedicareMember_89eaa18b-6fdc-43ec-907e-350df944a8e5" xlink:href="amed-20221231.xsd#amed_HospiceNonMedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_60cf1553-cdb3-43cf-8a5a-a8943855ae57" xlink:to="loc_amed_HospiceNonMedicareMember_89eaa18b-6fdc-43ec-907e-350df944a8e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_6a9e7c19-4a56-4db1-8161-2eda7eb85df6" xlink:href="amed-20221231.xsd#amed_PersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_60cf1553-cdb3-43cf-8a5a-a8943855ae57" xlink:to="loc_amed_PersonalCareMember_6a9e7c19-4a56-4db1-8161-2eda7eb85df6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_83bc4b13-5ab7-4668-8bc7-6b7c429874cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_949cff44-be2a-46bf-aebe-dddb8de0d256" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_83bc4b13-5ab7-4668-8bc7-6b7c429874cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_83bc4b13-5ab7-4668-8bc7-6b7c429874cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_83bc4b13-5ab7-4668-8bc7-6b7c429874cc" xlink:to="loc_us-gaap_SegmentDomain_83bc4b13-5ab7-4668-8bc7-6b7c429874cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a0fb3f35-c570-4150-82bc-d81b60dfaa61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_83bc4b13-5ab7-4668-8bc7-6b7c429874cc" xlink:to="loc_us-gaap_SegmentDomain_a0fb3f35-c570-4150-82bc-d81b60dfaa61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_910acb7e-d5ec-43ab-b364-bca512ef094b" xlink:href="amed-20221231.xsd#amed_HighAcuityCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_a0fb3f35-c570-4150-82bc-d81b60dfaa61" xlink:to="loc_amed_HighAcuityCareMember_910acb7e-d5ec-43ab-b364-bca512ef094b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended" id="i550c98df8bb940f59f6e1840c23e2ebe_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_9da41391-ba31-4e4e-bd73-0c30f3e08c00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_086b2470-ecee-4ba8-80cb-bb5d42cc3ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_9da41391-ba31-4e4e-bd73-0c30f3e08c00" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_086b2470-ecee-4ba8-80cb-bb5d42cc3ebf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_c1ca2d42-efde-48eb-bd21-e56248544557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_9da41391-ba31-4e4e-bd73-0c30f3e08c00" xlink:to="loc_us-gaap_RestrictedCash_c1ca2d42-efde-48eb-bd21-e56248544557" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9bd8066f-3b8e-43a8-b4d2-380bb91ba44c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_9da41391-ba31-4e4e-bd73-0c30f3e08c00" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9bd8066f-3b8e-43a8-b4d2-380bb91ba44c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashBalanceAssociatedWithProviderReliefFund_bdc1994d-6703-4f03-9a6b-d4c91fdb2ad0" xlink:href="amed-20221231.xsd#amed_CashBalanceAssociatedWithProviderReliefFund"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_9da41391-ba31-4e4e-bd73-0c30f3e08c00" xlink:to="loc_amed_CashBalanceAssociatedWithProviderReliefFund_bdc1994d-6703-4f03-9a6b-d4c91fdb2ad0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashBalanceAssociatedWithProviderReliefFund_03714da0-bb78-4677-a2fb-25e6ef487a53" xlink:href="amed-20221231.xsd#amed_CashBalanceAssociatedWithProviderReliefFund"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_1b3bfdf5-2f72-4c84-9fbc-bc979a568304" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_9da41391-ba31-4e4e-bd73-0c30f3e08c00" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_1b3bfdf5-2f72-4c84-9fbc-bc979a568304" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_eee2bb28-d605-4006-a603-428342e4f0c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_1b3bfdf5-2f72-4c84-9fbc-bc979a568304" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_eee2bb28-d605-4006-a603-428342e4f0c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eee2bb28-d605-4006-a603-428342e4f0c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_eee2bb28-d605-4006-a603-428342e4f0c6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eee2bb28-d605-4006-a603-428342e4f0c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_116a26b9-a3d2-4f3a-9c69-6874f6964505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_eee2bb28-d605-4006-a603-428342e4f0c6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_116a26b9-a3d2-4f3a-9c69-6874f6964505" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_VariousAcquisitionsMember_87d50160-6fd5-4e86-bd2d-4a94f4d40e9f" xlink:href="amed-20221231.xsd#amed_VariousAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_116a26b9-a3d2-4f3a-9c69-6874f6964505" xlink:to="loc_amed_VariousAcquisitionsMember_87d50160-6fd5-4e86-bd2d-4a94f4d40e9f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails" xlink:type="extended" id="iea52735198ca404fa3a132cef22fc23b_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bb9235c2-7f28-4c43-a02d-923a9395ed76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_880ed8c1-9139-442f-b380-551d4030baa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bb9235c2-7f28-4c43-a02d-923a9395ed76" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_880ed8c1-9139-442f-b380-551d4030baa8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_df4184c1-27e6-4afb-afa7-61d74b2bb281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bb9235c2-7f28-4c43-a02d-923a9395ed76" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_df4184c1-27e6-4afb-afa7-61d74b2bb281" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_30fb1bb8-bdaf-4129-8ff0-b33cae3c0f45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bb9235c2-7f28-4c43-a02d-923a9395ed76" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_30fb1bb8-bdaf-4129-8ff0-b33cae3c0f45" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d4a77311-1af9-4270-a819-57719ed857bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_30fb1bb8-bdaf-4129-8ff0-b33cae3c0f45" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d4a77311-1af9-4270-a819-57719ed857bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d4a77311-1af9-4270-a819-57719ed857bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d4a77311-1af9-4270-a819-57719ed857bd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d4a77311-1af9-4270-a819-57719ed857bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6e181ed4-1707-475a-9c0b-f33e8fb9e300" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d4a77311-1af9-4270-a819-57719ed857bd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6e181ed4-1707-475a-9c0b-f33e8fb9e300" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_d7ce9777-ddef-4d81-9977-072979e0b59c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6e181ed4-1707-475a-9c0b-f33e8fb9e300" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_d7ce9777-ddef-4d81-9977-072979e0b59c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNamesMember_22321059-f848-47e4-a737-65ccc55850e5" xlink:href="amed-20221231.xsd#amed_AcquiredNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6e181ed4-1707-475a-9c0b-f33e8fb9e300" xlink:to="loc_amed_AcquiredNamesMember_22321059-f848-47e4-a737-65ccc55850e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_eb97db18-72a0-4ad0-b9fb-47ae8843405b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6e181ed4-1707-475a-9c0b-f33e8fb9e300" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_eb97db18-72a0-4ad0-b9fb-47ae8843405b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7235d976-3d19-482f-b696-bd7e7e8ccecb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_30fb1bb8-bdaf-4129-8ff0-b33cae3c0f45" xlink:to="loc_srt_RangeAxis_7235d976-3d19-482f-b696-bd7e7e8ccecb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7235d976-3d19-482f-b696-bd7e7e8ccecb_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7235d976-3d19-482f-b696-bd7e7e8ccecb" xlink:to="loc_srt_RangeMember_7235d976-3d19-482f-b696-bd7e7e8ccecb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d18b0d39-bcd4-4cf2-b8b5-0028f3a49648" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7235d976-3d19-482f-b696-bd7e7e8ccecb" xlink:to="loc_srt_RangeMember_d18b0d39-bcd4-4cf2-b8b5-0028f3a49648" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d3a63d89-e398-4f7f-b89d-3acf2adfc385" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d18b0d39-bcd4-4cf2-b8b5-0028f3a49648" xlink:to="loc_srt_MinimumMember_d3a63d89-e398-4f7f-b89d-3acf2adfc385" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_587fb0c0-c479-40b2-a758-ed7d85638e4d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d18b0d39-bcd4-4cf2-b8b5-0028f3a49648" xlink:to="loc_srt_MaximumMember_587fb0c0-c479-40b2-a758-ed7d85638e4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0dbbd10b-8a97-4f5f-a65c-273c3dc838f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_30fb1bb8-bdaf-4129-8ff0-b33cae3c0f45" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0dbbd10b-8a97-4f5f-a65c-273c3dc838f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0dbbd10b-8a97-4f5f-a65c-273c3dc838f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0dbbd10b-8a97-4f5f-a65c-273c3dc838f8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0dbbd10b-8a97-4f5f-a65c-273c3dc838f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_774977ea-32b6-4a8a-90bf-68a2e2c36bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0dbbd10b-8a97-4f5f-a65c-273c3dc838f8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_774977ea-32b6-4a8a-90bf-68a2e2c36bdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNamesMember_237761aa-ca17-4563-9f66-38cfdf4d17cf" xlink:href="amed-20221231.xsd#amed_AcquiredNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_774977ea-32b6-4a8a-90bf-68a2e2c36bdc" xlink:to="loc_amed_AcquiredNamesMember_237761aa-ca17-4563-9f66-38cfdf4d17cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1bd7e257-ee7b-43d1-a3f5-ae4f86832eac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_30fb1bb8-bdaf-4129-8ff0-b33cae3c0f45" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1bd7e257-ee7b-43d1-a3f5-ae4f86832eac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1bd7e257-ee7b-43d1-a3f5-ae4f86832eac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1bd7e257-ee7b-43d1-a3f5-ae4f86832eac" xlink:to="loc_us-gaap_SegmentDomain_1bd7e257-ee7b-43d1-a3f5-ae4f86832eac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_60293145-a842-4b01-865a-b03668b7c743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1bd7e257-ee7b-43d1-a3f5-ae4f86832eac" xlink:to="loc_us-gaap_SegmentDomain_60293145-a842-4b01-865a-b03668b7c743" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_75cbe8b6-ba59-4a08-b056-a73eab8ab880" xlink:href="amed-20221231.xsd#amed_PersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_60293145-a842-4b01-865a-b03668b7c743" xlink:to="loc_amed_PersonalCareMember_75cbe8b6-ba59-4a08-b056-a73eab8ab880" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails" xlink:type="extended" id="i8e83409b6b1d49c7be8b6f3a88bc0ed7_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5c121a83-b293-4322-b27d-90a8245b5630" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_e4fb1a91-311f-4cb2-a6b3-a6c562f88f01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5c121a83-b293-4322-b27d-90a8245b5630" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_e4fb1a91-311f-4cb2-a6b3-a6c562f88f01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_16a19e91-289a-4c25-85c5-8c2818bddf15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5c121a83-b293-4322-b27d-90a8245b5630" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_16a19e91-289a-4c25-85c5-8c2818bddf15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a7b48111-2a96-4bcc-b1f9-b1aaa6b4f947" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5c121a83-b293-4322-b27d-90a8245b5630" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a7b48111-2a96-4bcc-b1f9-b1aaa6b4f947" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9781dd85-815d-4430-8440-fc9e4b79505a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a7b48111-2a96-4bcc-b1f9-b1aaa6b4f947" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9781dd85-815d-4430-8440-fc9e4b79505a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9781dd85-815d-4430-8440-fc9e4b79505a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9781dd85-815d-4430-8440-fc9e4b79505a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9781dd85-815d-4430-8440-fc9e4b79505a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1228cead-92d5-435e-90f0-6c0e395a1ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9781dd85-815d-4430-8440-fc9e4b79505a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1228cead-92d5-435e-90f0-6c0e395a1ff8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_d39bd697-39a4-4424-b1f0-5cba2911e36f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1228cead-92d5-435e-90f0-6c0e395a1ff8" xlink:to="loc_us-gaap_BuildingMember_d39bd697-39a4-4424-b1f0-5cba2911e36f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_a5e783ab-c509-42cd-91c9-9c3a853b931d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1228cead-92d5-435e-90f0-6c0e395a1ff8" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_a5e783ab-c509-42cd-91c9-9c3a853b931d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquipmentAndFurnitureMember_ea9c9c55-83cc-494c-bac3-3ebd94260790" xlink:href="amed-20221231.xsd#amed_EquipmentAndFurnitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1228cead-92d5-435e-90f0-6c0e395a1ff8" xlink:to="loc_amed_EquipmentAndFurnitureMember_ea9c9c55-83cc-494c-bac3-3ebd94260790" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_a5d80320-fe81-4d1f-8550-2ff8fac1cb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1228cead-92d5-435e-90f0-6c0e395a1ff8" xlink:to="loc_us-gaap_VehiclesMember_a5d80320-fe81-4d1f-8550-2ff8fac1cb9c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_1b76f457-47c1-4f44-aaa0-001c34de3dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1228cead-92d5-435e-90f0-6c0e395a1ff8" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_1b76f457-47c1-4f44-aaa0-001c34de3dcc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember_41aac2ac-cfed-496d-8c9b-abe5ddc49e98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLeaseObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1228cead-92d5-435e-90f0-6c0e395a1ff8" xlink:to="loc_us-gaap_CapitalLeaseObligationsMember_41aac2ac-cfed-496d-8c9b-abe5ddc49e98" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f1bbddd6-0f8e-4474-82a9-01dd93339b01" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a7b48111-2a96-4bcc-b1f9-b1aaa6b4f947" xlink:to="loc_srt_RangeAxis_f1bbddd6-0f8e-4474-82a9-01dd93339b01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f1bbddd6-0f8e-4474-82a9-01dd93339b01_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f1bbddd6-0f8e-4474-82a9-01dd93339b01" xlink:to="loc_srt_RangeMember_f1bbddd6-0f8e-4474-82a9-01dd93339b01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3b89b91b-12d2-42a3-a7f4-dc7e561f9396" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f1bbddd6-0f8e-4474-82a9-01dd93339b01" xlink:to="loc_srt_RangeMember_3b89b91b-12d2-42a3-a7f4-dc7e561f9396" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fa6aa454-803d-4ab1-b3e3-9f0cbf992af0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3b89b91b-12d2-42a3-a7f4-dc7e561f9396" xlink:to="loc_srt_MinimumMember_fa6aa454-803d-4ab1-b3e3-9f0cbf992af0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_43b19b28-ad79-4ddc-b44b-08e23e2d4d5f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3b89b91b-12d2-42a3-a7f4-dc7e561f9396" xlink:to="loc_srt_MaximumMember_43b19b28-ad79-4ddc-b44b-08e23e2d4d5f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails" xlink:type="extended" id="i2dd02f8725b4464d877287d5e98be001_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3241d2be-51bf-41a5-94ff-519f31649f95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_176c6bfa-6b01-4407-ad71-6f175717c575" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3241d2be-51bf-41a5-94ff-519f31649f95" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_176c6bfa-6b01-4407-ad71-6f175717c575" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b5260663-8a1e-474a-bae9-02026569a865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3241d2be-51bf-41a5-94ff-519f31649f95" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b5260663-8a1e-474a-bae9-02026569a865" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3a553157-1487-4743-933d-7f163eb85276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3241d2be-51bf-41a5-94ff-519f31649f95" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3a553157-1487-4743-933d-7f163eb85276" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_44f0d57a-0ee7-45dc-999d-1c9745319906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3241d2be-51bf-41a5-94ff-519f31649f95" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_44f0d57a-0ee7-45dc-999d-1c9745319906" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ef157339-d5aa-438a-b1a8-4c47aa9d8a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_44f0d57a-0ee7-45dc-999d-1c9745319906" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ef157339-d5aa-438a-b1a8-4c47aa9d8a0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ef157339-d5aa-438a-b1a8-4c47aa9d8a0a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ef157339-d5aa-438a-b1a8-4c47aa9d8a0a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ef157339-d5aa-438a-b1a8-4c47aa9d8a0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7bbaa90d-dd87-4d4f-bace-b3179a93517c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ef157339-d5aa-438a-b1a8-4c47aa9d8a0a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7bbaa90d-dd87-4d4f-bace-b3179a93517c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BuildingAndLeaseholdImprovementsMember_b6f919ec-60aa-402f-a4ff-25adf3147d9a" xlink:href="amed-20221231.xsd#amed_BuildingAndLeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7bbaa90d-dd87-4d4f-bace-b3179a93517c" xlink:to="loc_amed_BuildingAndLeaseholdImprovementsMember_b6f919ec-60aa-402f-a4ff-25adf3147d9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquipmentAndFurnitureMember_b0eb13fd-7a55-4d4a-ab7a-5333408f7f9c" xlink:href="amed-20221231.xsd#amed_EquipmentAndFurnitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7bbaa90d-dd87-4d4f-bace-b3179a93517c" xlink:to="loc_amed_EquipmentAndFurnitureMember_b0eb13fd-7a55-4d4a-ab7a-5333408f7f9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldUnderCapitalLeasesMember_49fe237f-7eb5-4b87-aa6b-41a875fcf16f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldUnderCapitalLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7bbaa90d-dd87-4d4f-bace-b3179a93517c" xlink:to="loc_us-gaap_AssetsHeldUnderCapitalLeasesMember_49fe237f-7eb5-4b87-aa6b-41a875fcf16f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_ca2c3cbf-18b9-4126-bf8f-bbd1e99971bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7bbaa90d-dd87-4d4f-bace-b3179a93517c" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_ca2c3cbf-18b9-4126-bf8f-bbd1e99971bc" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails" xlink:type="extended" id="i97b7235f055e4235af396b81c0a97d7e_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_224b741d-3646-4928-8f90-53654a1b0d42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_96d0e21b-ec2c-4d0b-b965-0fc8e8182da0" xlink:href="amed-20221231.xsd#amed_DebtInstrumentCarryingAmountExcludingFinanceLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_224b741d-3646-4928-8f90-53654a1b0d42" xlink:to="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_96d0e21b-ec2c-4d0b-b965-0fc8e8182da0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_d14f4c02-215a-425a-a9e9-0decfbb9b342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_224b741d-3646-4928-8f90-53654a1b0d42" xlink:to="loc_us-gaap_LongTermDebtFairValue_d14f4c02-215a-425a-a9e9-0decfbb9b342" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca69b4b9-f415-4fa5-b031-07b10145884d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_224b741d-3646-4928-8f90-53654a1b0d42" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca69b4b9-f415-4fa5-b031-07b10145884d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6c324bb0-a457-4f3a-8722-e44d1ac12420" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca69b4b9-f415-4fa5-b031-07b10145884d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6c324bb0-a457-4f3a-8722-e44d1ac12420" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6c324bb0-a457-4f3a-8722-e44d1ac12420_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6c324bb0-a457-4f3a-8722-e44d1ac12420" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6c324bb0-a457-4f3a-8722-e44d1ac12420_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_620968be-9fec-47c9-89ea-ec6e83374c79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6c324bb0-a457-4f3a-8722-e44d1ac12420" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_620968be-9fec-47c9-89ea-ec6e83374c79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_83a91842-45ba-419e-8cea-88f60b9a67a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_620968be-9fec-47c9-89ea-ec6e83374c79" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_83a91842-45ba-419e-8cea-88f60b9a67a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ec327723-96f6-49d1-a3e1-a48e3d9f880e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_620968be-9fec-47c9-89ea-ec6e83374c79" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ec327723-96f6-49d1-a3e1-a48e3d9f880e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_84b2bd41-118a-44a0-ab5c-db8d2374b1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_620968be-9fec-47c9-89ea-ec6e83374c79" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_84b2bd41-118a-44a0-ab5c-db8d2374b1f2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details" xlink:type="simple" xlink:href="amed-20221231.xsd#NOVELCORONAVIRUSPANDEMICCOVID19Details"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details" xlink:type="extended" id="i8f19bc93496d478b8d74a9802c44b810_NOVELCORONAVIRUSPANDEMICCOVID19Details">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemLineItems_e297a038-1f5c-4aae-8545-b5eb73904627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingForHealthcareProvidersIncludingHospitals_6b76cac6-5217-4c0b-a469-ec7375044aa0" xlink:href="amed-20221231.xsd#amed_FundingForHealthcareProvidersIncludingHospitals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_e297a038-1f5c-4aae-8545-b5eb73904627" xlink:to="loc_amed_FundingForHealthcareProvidersIncludingHospitals_6b76cac6-5217-4c0b-a469-ec7375044aa0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_e901ea20-7c49-48e0-a08c-62259b5dd4a2" xlink:href="amed-20221231.xsd#amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_e297a038-1f5c-4aae-8545-b5eb73904627" xlink:to="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_e901ea20-7c49-48e0-a08c-62259b5dd4a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingReceivedFromCARESAct_11926208-7f02-4f0c-89ac-9267abf09580" xlink:href="amed-20221231.xsd#amed_FundingReceivedFromCARESAct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_e297a038-1f5c-4aae-8545-b5eb73904627" xlink:to="loc_amed_FundingReceivedFromCARESAct_11926208-7f02-4f0c-89ac-9267abf09580" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundsUtilized_e7e5a2ad-277c-4d6b-883a-f2ab2655a3f1" xlink:href="amed-20221231.xsd#amed_CARESActProviderReliefFundsUtilized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_e297a038-1f5c-4aae-8545-b5eb73904627" xlink:to="loc_amed_CARESActProviderReliefFundsUtilized_e7e5a2ad-277c-4d6b-883a-f2ab2655a3f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActInterestRepaidToGovernment_53e6fe3e-5e26-4115-9b37-04283d763f05" xlink:href="amed-20221231.xsd#amed_CARESActInterestRepaidToGovernment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_e297a038-1f5c-4aae-8545-b5eb73904627" xlink:to="loc_amed_CARESActInterestRepaidToGovernment_53e6fe3e-5e26-4115-9b37-04283d763f05" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundsRepaidToTheGovernment_b43c4143-ec93-4a8a-a3a3-18c810ff10dc" xlink:href="amed-20221231.xsd#amed_CARESActProviderReliefFundsRepaidToTheGovernment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_e297a038-1f5c-4aae-8545-b5eb73904627" xlink:to="loc_amed_CARESActProviderReliefFundsRepaidToTheGovernment_b43c4143-ec93-4a8a-a3a3-18c810ff10dc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundUtilizedByUnconsolidatedJointVentures_61119757-b539-452d-9278-0b7ba7c7ad7b" xlink:href="amed-20221231.xsd#amed_CARESActProviderReliefFundUtilizedByUnconsolidatedJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_e297a038-1f5c-4aae-8545-b5eb73904627" xlink:to="loc_amed_CARESActProviderReliefFundUtilizedByUnconsolidatedJointVentures_61119757-b539-452d-9278-0b7ba7c7ad7b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundsRepaidByUnconsolidatedJointVentures_d3d6af68-d6de-4ea0-ac8f-cfd0d3b0da2f" xlink:href="amed-20221231.xsd#amed_CARESActProviderReliefFundsRepaidByUnconsolidatedJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_e297a038-1f5c-4aae-8545-b5eb73904627" xlink:to="loc_amed_CARESActProviderReliefFundsRepaidByUnconsolidatedJointVentures_d3d6af68-d6de-4ea0-ac8f-cfd0d3b0da2f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalCARESActProviderReliefFundsReceived_5c14726d-a45b-4210-8dc8-282065f7acd6" xlink:href="amed-20221231.xsd#amed_TotalCARESActProviderReliefFundsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_e297a038-1f5c-4aae-8545-b5eb73904627" xlink:to="loc_amed_TotalCARESActProviderReliefFundsReceived_5c14726d-a45b-4210-8dc8-282065f7acd6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact_6e2ad796-3a06-4cb4-aa0f-66e587c8aca3" xlink:href="amed-20221231.xsd#amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_e297a038-1f5c-4aae-8545-b5eb73904627" xlink:to="loc_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact_6e2ad796-3a06-4cb4-aa0f-66e587c8aca3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_fb10a9c9-7f82-4f4b-99ee-7a3ca88386e3" xlink:href="amed-20221231.xsd#amed_CARESActDeferralOfEmployerShareSocialSecurityTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_e297a038-1f5c-4aae-8545-b5eb73904627" xlink:to="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_fb10a9c9-7f82-4f4b-99ee-7a3ca88386e3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct_689978e2-e2c8-4073-8b7f-9b8d222a7c27" xlink:href="amed-20221231.xsd#amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_e297a038-1f5c-4aae-8545-b5eb73904627" xlink:to="loc_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct_689978e2-e2c8-4073-8b7f-9b8d222a7c27" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_5270d6eb-51bd-4d53-83b8-5f29a4f3cbf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_e297a038-1f5c-4aae-8545-b5eb73904627" xlink:to="loc_us-gaap_OtherOperatingIncome_5270d6eb-51bd-4d53-83b8-5f29a4f3cbf9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram_41714a62-0daf-4856-8250-d78ff56b9f9f" xlink:href="amed-20221231.xsd#amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_e297a038-1f5c-4aae-8545-b5eb73904627" xlink:to="loc_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram_41714a62-0daf-4856-8250-d78ff56b9f9f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemTable_0b1abe50-e23b-46f9-9969-42cad973f3c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_e297a038-1f5c-4aae-8545-b5eb73904627" xlink:to="loc_us-gaap_UnusualOrInfrequentItemTable_0b1abe50-e23b-46f9-9969-42cad973f3c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_3f882e7e-e63b-48cd-8c35-47071c636ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_0b1abe50-e23b-46f9-9969-42cad973f3c2" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_3f882e7e-e63b-48cd-8c35-47071c636ce6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3f882e7e-e63b-48cd-8c35-47071c636ce6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_3f882e7e-e63b-48cd-8c35-47071c636ce6" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3f882e7e-e63b-48cd-8c35-47071c636ce6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_33b6d372-4755-451c-87b6-d0446496a763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_3f882e7e-e63b-48cd-8c35-47071c636ce6" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_33b6d372-4755-451c-87b6-d0446496a763" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsMember_497b30ec-954a-439e-8fa0-2f3523a31081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_33b6d372-4755-451c-87b6-d0446496a763" xlink:to="loc_us-gaap_EquityMethodInvestmentsMember_497b30ec-954a-439e-8fa0-2f3523a31081" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8380bee0-d32b-44ed-a92d-060da8c85b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_0b1abe50-e23b-46f9-9969-42cad973f3c2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8380bee0-d32b-44ed-a92d-060da8c85b8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8380bee0-d32b-44ed-a92d-060da8c85b8d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8380bee0-d32b-44ed-a92d-060da8c85b8d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8380bee0-d32b-44ed-a92d-060da8c85b8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e5c112b-1968-43ed-940f-67e447a97055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8380bee0-d32b-44ed-a92d-060da8c85b8d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e5c112b-1968-43ed-940f-67e447a97055" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_db35755c-1a51-4f27-8ab9-64ccb5f4a0c8" xlink:href="amed-20221231.xsd#amed_AseraCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e5c112b-1968-43ed-940f-67e447a97055" xlink:to="loc_amed_AseraCareHospiceMember_db35755c-1a51-4f27-8ab9-64ccb5f4a0c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_19fc418b-c802-4087-a9c2-11d582423191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_0b1abe50-e23b-46f9-9969-42cad973f3c2" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_19fc418b-c802-4087-a9c2-11d582423191" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_19fc418b-c802-4087-a9c2-11d582423191_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_19fc418b-c802-4087-a9c2-11d582423191" xlink:to="loc_us-gaap_SegmentDomain_19fc418b-c802-4087-a9c2-11d582423191_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_cdcd3bfd-fe04-42bb-976b-3ffc1a43f27a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_19fc418b-c802-4087-a9c2-11d582423191" xlink:to="loc_us-gaap_SegmentDomain_cdcd3bfd-fe04-42bb-976b-3ffc1a43f27a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthAndHospiceMember_5b673ab0-a76f-495e-b43f-5a5715705b2a" xlink:href="amed-20221231.xsd#amed_HomeHealthAndHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_cdcd3bfd-fe04-42bb-976b-3ffc1a43f27a" xlink:to="loc_amed_HomeHealthAndHospiceMember_5b673ab0-a76f-495e-b43f-5a5715705b2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_3072d006-3915-4944-80d6-59dd740a6880" xlink:href="amed-20221231.xsd#amed_PersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_cdcd3bfd-fe04-42bb-976b-3ffc1a43f27a" xlink:to="loc_amed_PersonalCareMember_3072d006-3915-4944-80d6-59dd740a6880" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis_885e0c9d-558c-44d3-818e-d40ffed4da69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_0b1abe50-e23b-46f9-9969-42cad973f3c2" xlink:to="loc_us-gaap_UnusualOrInfrequentItemAxis_885e0c9d-558c-44d3-818e-d40ffed4da69" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_885e0c9d-558c-44d3-818e-d40ffed4da69_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_885e0c9d-558c-44d3-818e-d40ffed4da69" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_885e0c9d-558c-44d3-818e-d40ffed4da69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_c5d67b74-d4ec-46c0-ad47-f1e9b83d7fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_885e0c9d-558c-44d3-818e-d40ffed4da69" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_c5d67b74-d4ec-46c0-ad47-f1e9b83d7fa4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19DeferralOfSocialSecurityTaxesMember_b8ba82ac-5e44-4791-b8ea-7d228dc28f9f" xlink:href="amed-20221231.xsd#amed_COVID19DeferralOfSocialSecurityTaxesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain_c5d67b74-d4ec-46c0-ad47-f1e9b83d7fa4" xlink:to="loc_amed_COVID19DeferralOfSocialSecurityTaxesMember_b8ba82ac-5e44-4791-b8ea-7d228dc28f9f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#ACQUISITIONSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails" xlink:type="extended" id="i4b8534687e584c71ac542099e2964dff_ACQUISITIONSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_11137ee4-8f4f-4891-8a19-c64cc538b17f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_11137ee4-8f4f-4891-8a19-c64cc538b17f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_44acaf52-d648-409a-853d-0759a2ce0147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_44acaf52-d648-409a-853d-0759a2ce0147" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_a640374b-f150-42ab-9026-e86ea1feb0df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_NotesPayable_a640374b-f150-42ab-9026-e86ea1feb0df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_aaa4c1a6-38e7-4bbe-8d6e-75a646a6e2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_aaa4c1a6-38e7-4bbe-8d6e-75a646a6e2fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_297c7b24-64c0-4b09-90c7-c33bf6600a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_297c7b24-64c0-4b09-90c7-c33bf6600a4b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment_e4328c7a-7a63-431d-b4e1-35420903639f" xlink:href="amed-20221231.xsd#amed_BusinessAcquisitionWorkingCapitalAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment_e4328c7a-7a63-431d-b4e1-35420903639f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_58f5dae6-e312-4be1-96d7-91a7da5fb2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_58f5dae6-e312-4be1-96d7-91a7da5fb2a7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense_b19fa72f-8a6a-4172-8f62-d6e9e4c6cd85" xlink:href="amed-20221231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense_b19fa72f-8a6a-4172-8f62-d6e9e4c6cd85" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_27c7e7b1-768b-41bb-8795-0e33c813f7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_27c7e7b1-768b-41bb-8795-0e33c813f7ea" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_540b7cc1-d0cc-4556-adae-003d5371ac29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_540b7cc1-d0cc-4556-adae-003d5371ac29" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_44dfc4ab-c514-45ce-b259-6d5e7784d5a9" xlink:href="amed-20221231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_44dfc4ab-c514-45ce-b259-6d5e7784d5a9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_a432b60c-4bf0-49b2-93b9-07525435564b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_a432b60c-4bf0-49b2-93b9-07525435564b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_b2e085ba-7520-4542-b736-1ea0e10b9d49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_b2e085ba-7520-4542-b736-1ea0e10b9d49" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_a1a7e6cc-d228-4496-902d-4d9ae998ebd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_a1a7e6cc-d228-4496-902d-4d9ae998ebd1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_c7e7dabb-71dc-4aa1-a934-2768d77e2de3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_c7e7dabb-71dc-4aa1-a934-2768d77e2de3" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits_f968f009-0982-4b68-8d40-f274d268012d" xlink:href="amed-20221231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits_f968f009-0982-4b68-8d40-f274d268012d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_127669a4-f81a-4069-86fc-b0f54a2a8b64" xlink:href="amed-20221231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_127669a4-f81a-4069-86fc-b0f54a2a8b64" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities_cf22bb10-40d9-40d9-8944-880c3fd123e5" xlink:href="amed-20221231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities_cf22bb10-40d9-40d9-8944-880c3fd123e5" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_e66686fc-c9b2-4f31-ae94-9932a4d1f5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_e66686fc-c9b2-4f31-ae94-9932a4d1f5bf" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_2c2bf9b2-78af-4fa1-90dd-cc005adbbf87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_2c2bf9b2-78af-4fa1-90dd-cc005adbbf87" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_7001b502-bcc3-4f31-99fb-4618e6fdc9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_7001b502-bcc3-4f31-99fb-4618e6fdc9e3" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_ee889061-3b5f-45d2-a9ad-7bed9b16c49a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_ee889061-3b5f-45d2-a9ad-7bed9b16c49a" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_3628d0a7-9290-4aec-96c5-0ce785a3b85e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_3628d0a7-9290-4aec-96c5-0ce785a3b85e" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity_17f28061-9a55-4a97-9ba3-349d8da85831" xlink:href="amed-20221231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity_17f28061-9a55-4a97-9ba3-349d8da85831" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity_13256b01-5d12-488d-b023-c94817f738c6" xlink:href="amed-20221231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity_13256b01-5d12-488d-b023-c94817f738c6" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_34946312-7eee-49f9-92fd-eba077cded75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_34946312-7eee-49f9-92fd-eba077cded75" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_44aab3e2-fe78-45b9-a7fc-4b2ddea16228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_44aab3e2-fe78-45b9-a7fc-4b2ddea16228" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_3e1674c7-6207-43ec-afed-ad4fe109d48c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_3e1674c7-6207-43ec-afed-ad4fe109d48c" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_a30c9b19-b29f-43db-b380-7e60b91db5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_a30c9b19-b29f-43db-b380-7e60b91db5d2" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit_fb412677-a3f3-4783-a52b-08d24a173112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EscrowDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_EscrowDeposit_fb412677-a3f3-4783-a52b-08d24a173112" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_6b169bac-b62c-487b-8214-bc79c29eefe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_6b169bac-b62c-487b-8214-bc79c29eefe8" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_980cd43e-c13e-4bf1-a2f3-4ab51491b63e" xlink:href="amed-20221231.xsd#amed_GoodwillDeductibleForIncomeTaxPurposesPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_980cd43e-c13e-4bf1-a2f3-4ab51491b63e" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PaymentsRelatedToTaxAsset_c48ba830-6caf-472a-8a2d-6a49437a05bf" xlink:href="amed-20221231.xsd#amed_PaymentsRelatedToTaxAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_amed_PaymentsRelatedToTaxAsset_c48ba830-6caf-472a-8a2d-6a49437a05bf" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionClosingPaymentAdjustment_99e0dd02-7359-4552-b8ee-52cc143bdfb8" xlink:href="amed-20221231.xsd#amed_BusinessAcquisitionClosingPaymentAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_amed_BusinessAcquisitionClosingPaymentAdjustment_99e0dd02-7359-4552-b8ee-52cc143bdfb8" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_4f022087-4e50-4dad-929f-d57d9628583b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_4f022087-4e50-4dad-929f-d57d9628583b" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_1b5704cf-4732-4a1b-bd8f-094798158762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_1b5704cf-4732-4a1b-bd8f-094798158762" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_da0a1f3d-ba94-4292-bfd7-0714ea431d26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_OperatingIncomeLoss_da0a1f3d-ba94-4292-bfd7-0714ea431d26" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInAssetsAcquired_940f2d4e-e44a-4092-92c4-8d3c9704036e" xlink:href="amed-20221231.xsd#amed_IncreaseDecreaseInAssetsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_amed_IncreaseDecreaseInAssetsAcquired_940f2d4e-e44a-4092-92c4-8d3c9704036e" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInLiabilitiesAssumed_2dfed4fe-7f10-4e50-91a3-3edfbeb71f27" xlink:href="amed-20221231.xsd#amed_IncreaseDecreaseInLiabilitiesAssumed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_amed_IncreaseDecreaseInLiabilitiesAssumed_2dfed4fe-7f10-4e50-91a3-3edfbeb71f27" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_2778113f-d160-4aee-b612-c17c2b96d572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_2778113f-d160-4aee-b612-c17c2b96d572" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_2df3e8be-b048-44ec-9edd-d1bdeb2d30db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_2df3e8be-b048-44ec-9edd-d1bdeb2d30db" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DepreciationAndAmortizationForContinuingOperations_db48fb8b-f83d-4c11-8bba-2ed49ccdae77" xlink:href="amed-20221231.xsd#amed_DepreciationAndAmortizationForContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_amed_DepreciationAndAmortizationForContinuingOperations_db48fb8b-f83d-4c11-8bba-2ed49ccdae77" xlink:type="arc" order="41"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationAcquiredNoncontrollingInterest_11d44850-d577-428a-901e-53c3c5d1c3b2" xlink:href="amed-20221231.xsd#amed_BusinessCombinationAcquiredNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_amed_BusinessCombinationAcquiredNoncontrollingInterest_11d44850-d577-428a-901e-53c3c5d1c3b2" xlink:type="arc" order="42"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_5ea569a9-cde3-4f85-b71c-dc45ab1141d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_RestrictedCash_5ea569a9-cde3-4f85-b71c-dc45ab1141d7" xlink:type="arc" order="43"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonCashAccruedContingentConsideration_93eb3525-2dea-437c-ae3c-0f74e823ba22" xlink:href="amed-20221231.xsd#amed_NonCashAccruedContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_amed_NonCashAccruedContingentConsideration_93eb3525-2dea-437c-ae3c-0f74e823ba22" xlink:type="arc" order="44"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmountReleasedFromEscrow_5cd5ef5b-3ca4-4e39-8fd3-96bf197f2813" xlink:href="amed-20221231.xsd#amed_AmountReleasedFromEscrow"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_amed_AmountReleasedFromEscrow_5cd5ef5b-3ca4-4e39-8fd3-96bf197f2813" xlink:type="arc" order="45"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d7c8f5e-2f0e-4cde-aaab-a463075b33a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d7c8f5e-2f0e-4cde-aaab-a463075b33a9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5a37eb01-354f-464a-abc0-e35798607bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d7c8f5e-2f0e-4cde-aaab-a463075b33a9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5a37eb01-354f-464a-abc0-e35798607bbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a37eb01-354f-464a-abc0-e35798607bbc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5a37eb01-354f-464a-abc0-e35798607bbc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5a37eb01-354f-464a-abc0-e35798607bbc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8936fec-2bba-4bc0-bda2-08eb497826f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5a37eb01-354f-464a-abc0-e35798607bbc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8936fec-2bba-4bc0-bda2-08eb497826f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2022NewJointVentureMember_4df61190-1e9c-41f5-aa6b-f9ca564d7db0" xlink:href="amed-20221231.xsd#amed_A2022NewJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8936fec-2bba-4bc0-bda2-08eb497826f5" xlink:to="loc_amed_A2022NewJointVentureMember_4df61190-1e9c-41f5-aa6b-f9ca564d7db0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EvolutionHealthMember_bf828f84-50ad-4233-9d1b-556e47bf5b07" xlink:href="amed-20221231.xsd#amed_EvolutionHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8936fec-2bba-4bc0-bda2-08eb497826f5" xlink:to="loc_amed_EvolutionHealthMember_bf828f84-50ad-4233-9d1b-556e47bf5b07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AssistedCareHomeHealthMember_9ff40d57-ae0b-4154-8b6c-a892b8d18339" xlink:href="amed-20221231.xsd#amed_AssistedCareHomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8936fec-2bba-4bc0-bda2-08eb497826f5" xlink:to="loc_amed_AssistedCareHomeHealthMember_9ff40d57-ae0b-4154-8b6c-a892b8d18339" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_VisitingNurseAssociationMember_cc402fa6-1495-4c23-8cac-57beb0cc06f8" xlink:href="amed-20221231.xsd#amed_VisitingNurseAssociationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8936fec-2bba-4bc0-bda2-08eb497826f5" xlink:to="loc_amed_VisitingNurseAssociationMember_cc402fa6-1495-4c23-8cac-57beb0cc06f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ContessaHealthMember_03c055fb-d0eb-4306-ba00-b32675363661" xlink:href="amed-20221231.xsd#amed_ContessaHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8936fec-2bba-4bc0-bda2-08eb497826f5" xlink:to="loc_amed_ContessaHealthMember_03c055fb-d0eb-4306-ba00-b32675363661" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a5cd7280-20ca-40d6-9169-4318ef2cef37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d7c8f5e-2f0e-4cde-aaab-a463075b33a9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a5cd7280-20ca-40d6-9169-4318ef2cef37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a5cd7280-20ca-40d6-9169-4318ef2cef37_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a5cd7280-20ca-40d6-9169-4318ef2cef37" xlink:to="loc_us-gaap_SegmentDomain_a5cd7280-20ca-40d6-9169-4318ef2cef37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_864aac71-dc20-4968-9959-c12d37fa5355" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a5cd7280-20ca-40d6-9169-4318ef2cef37" xlink:to="loc_us-gaap_SegmentDomain_864aac71-dc20-4968-9959-c12d37fa5355" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_7cabeb39-4f60-43d9-a15c-53fafd84c1e2" xlink:href="amed-20221231.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_864aac71-dc20-4968-9959-c12d37fa5355" xlink:to="loc_amed_HomeHealthMember_7cabeb39-4f60-43d9-a15c-53fafd84c1e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthAndHospiceMember_2e54c647-aa65-415d-8736-e0d6a1bfbff7" xlink:href="amed-20221231.xsd#amed_HomeHealthAndHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_864aac71-dc20-4968-9959-c12d37fa5355" xlink:to="loc_amed_HomeHealthAndHospiceMember_2e54c647-aa65-415d-8736-e0d6a1bfbff7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_e48b018b-76b7-4b9c-a44f-98367e7550b6" xlink:href="amed-20221231.xsd#amed_PersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_864aac71-dc20-4968-9959-c12d37fa5355" xlink:to="loc_amed_PersonalCareMember_e48b018b-76b7-4b9c-a44f-98367e7550b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_bb56e4d2-d8f9-438f-9cdc-0a8f5925cc36" xlink:href="amed-20221231.xsd#amed_HighAcuityCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_864aac71-dc20-4968-9959-c12d37fa5355" xlink:to="loc_amed_HighAcuityCareMember_bb56e4d2-d8f9-438f-9cdc-0a8f5925cc36" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c71819c6-7d17-4c6e-b204-1221e07186c8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d7c8f5e-2f0e-4cde-aaab-a463075b33a9" xlink:to="loc_srt_StatementGeographicalAxis_c71819c6-7d17-4c6e-b204-1221e07186c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c71819c6-7d17-4c6e-b204-1221e07186c8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_c71819c6-7d17-4c6e-b204-1221e07186c8" xlink:to="loc_srt_SegmentGeographicalDomain_c71819c6-7d17-4c6e-b204-1221e07186c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_439cab5a-099a-4b4d-81d6-88a5c3d25e63" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_c71819c6-7d17-4c6e-b204-1221e07186c8" xlink:to="loc_srt_SegmentGeographicalDomain_439cab5a-099a-4b4d-81d6-88a5c3d25e63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_883037cc-911d-4e92-bef1-f4495653353c" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_439cab5a-099a-4b4d-81d6-88a5c3d25e63" xlink:to="loc_stpr_MA_883037cc-911d-4e92-bef1-f4495653353c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL_0349a967-2c7e-439d-bb28-013de18f5c8f" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_IL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_439cab5a-099a-4b4d-81d6-88a5c3d25e63" xlink:to="loc_stpr_IL_0349a967-2c7e-439d-bb28-013de18f5c8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_AZ_42ec9922-1b69-40e9-aa6e-96b876ca7fc6" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_AZ"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_439cab5a-099a-4b4d-81d6-88a5c3d25e63" xlink:to="loc_stpr_AZ_42ec9922-1b69-40e9-aa6e-96b876ca7fc6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TN_9311e853-f9ba-47ae-85e9-9656c4a4f338" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_TN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_439cab5a-099a-4b4d-81d6-88a5c3d25e63" xlink:to="loc_stpr_TN_9311e853-f9ba-47ae-85e9-9656c4a4f338" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL_8e177a86-0ee4-482c-ae86-52213833d678" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_FL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_439cab5a-099a-4b4d-81d6-88a5c3d25e63" xlink:to="loc_stpr_FL_8e177a86-0ee4-482c-ae86-52213833d678" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA_03aed8b0-7d76-48fa-97d5-892dd0c550fd" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_439cab5a-099a-4b4d-81d6-88a5c3d25e63" xlink:to="loc_stpr_WA_03aed8b0-7d76-48fa-97d5-892dd0c550fd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_KY_e66ebc2d-4ba6-4a88-a2f7-2e4f0d16f883" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_KY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_439cab5a-099a-4b4d-81d6-88a5c3d25e63" xlink:to="loc_stpr_KY_e66ebc2d-4ba6-4a88-a2f7-2e4f0d16f883" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NC_82faf634-fe01-40b4-9c34-a82f0613b4df" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_439cab5a-099a-4b4d-81d6-88a5c3d25e63" xlink:to="loc_stpr_NC_82faf634-fe01-40b4-9c34-a82f0613b4df" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY_1a2929ae-47b2-4c72-938b-04e3ecc3b384" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_439cab5a-099a-4b4d-81d6-88a5c3d25e63" xlink:to="loc_stpr_NY_1a2929ae-47b2-4c72-938b-04e3ecc3b384" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RandolphCountyNorthCarolinaMember_787231b1-1166-48ac-8003-4a05f4527a7c" xlink:href="amed-20221231.xsd#amed_RandolphCountyNorthCarolinaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_439cab5a-099a-4b4d-81d6-88a5c3d25e63" xlink:to="loc_amed_RandolphCountyNorthCarolinaMember_787231b1-1166-48ac-8003-4a05f4527a7c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4bc42cbe-c693-432f-86a9-5f6d4fad3040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d7c8f5e-2f0e-4cde-aaab-a463075b33a9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4bc42cbe-c693-432f-86a9-5f6d4fad3040" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4bc42cbe-c693-432f-86a9-5f6d4fad3040_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4bc42cbe-c693-432f-86a9-5f6d4fad3040" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4bc42cbe-c693-432f-86a9-5f6d4fad3040_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0e14b46-53e8-4b31-bb13-b9939783b16e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4bc42cbe-c693-432f-86a9-5f6d4fad3040" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0e14b46-53e8-4b31-bb13-b9939783b16e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificatesOfNeedMember_052397a5-b5a5-4139-8372-64ecf78b00af" xlink:href="amed-20221231.xsd#amed_CertificatesOfNeedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0e14b46-53e8-4b31-bb13-b9939783b16e" xlink:to="loc_amed_CertificatesOfNeedMember_052397a5-b5a5-4139-8372-64ecf78b00af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_e4a86ba6-9dc3-4d3e-ab11-183fb0a39b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0e14b46-53e8-4b31-bb13-b9939783b16e" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_e4a86ba6-9dc3-4d3e-ab11-183fb0a39b4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LicensesMember_cf63b4fb-3ff8-4c33-a02b-90e68666c9fd" xlink:href="amed-20221231.xsd#amed_LicensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0e14b46-53e8-4b31-bb13-b9939783b16e" xlink:to="loc_amed_LicensesMember_cf63b4fb-3ff8-4c33-a02b-90e68666c9fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificatesOfNeedAndLicensesMember_97db1c20-09c5-4e1b-ad13-bf940ad45d7d" xlink:href="amed-20221231.xsd#amed_CertificatesOfNeedAndLicensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0e14b46-53e8-4b31-bb13-b9939783b16e" xlink:to="loc_amed_CertificatesOfNeedAndLicensesMember_97db1c20-09c5-4e1b-ad13-bf940ad45d7d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificateOfNeedMember_37c53c2e-8777-4c11-b42c-d2f0214270d4" xlink:href="amed-20221231.xsd#amed_CertificateOfNeedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0e14b46-53e8-4b31-bb13-b9939783b16e" xlink:to="loc_amed_CertificateOfNeedMember_37c53c2e-8777-4c11-b42c-d2f0214270d4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNamesMember_da048025-d7a9-49fd-a82b-9a1781247124" xlink:href="amed-20221231.xsd#amed_AcquiredNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0e14b46-53e8-4b31-bb13-b9939783b16e" xlink:to="loc_amed_AcquiredNamesMember_da048025-d7a9-49fd-a82b-9a1781247124" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_b3883925-06e4-4ca5-82e3-9172935f34ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0e14b46-53e8-4b31-bb13-b9939783b16e" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_b3883925-06e4-4ca5-82e3-9172935f34ac" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnamortizableAcquiredNamesMember_0bfc73b7-37f8-41eb-b75c-a53a9f38f7ae" xlink:href="amed-20221231.xsd#amed_UnamortizableAcquiredNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0e14b46-53e8-4b31-bb13-b9939783b16e" xlink:to="loc_amed_UnamortizableAcquiredNamesMember_0bfc73b7-37f8-41eb-b75c-a53a9f38f7ae" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmortizableAcquiredNamesMember_3c3d7d45-193c-449e-9f21-c9110863b8c2" xlink:href="amed-20221231.xsd#amed_AmortizableAcquiredNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0e14b46-53e8-4b31-bb13-b9939783b16e" xlink:to="loc_amed_AmortizableAcquiredNamesMember_3c3d7d45-193c-449e-9f21-c9110863b8c2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmortizableAcquiredNameAndNoncompeteAgreementsMember_97a57946-bca4-4a5b-bc7c-84c99d6975e6" xlink:href="amed-20221231.xsd#amed_AmortizableAcquiredNameAndNoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0e14b46-53e8-4b31-bb13-b9939783b16e" xlink:to="loc_amed_AmortizableAcquiredNameAndNoncompeteAgreementsMember_97a57946-bca4-4a5b-bc7c-84c99d6975e6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7bba2540-4549-4b08-a4e8-6ac232ff1993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d7c8f5e-2f0e-4cde-aaab-a463075b33a9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7bba2540-4549-4b08-a4e8-6ac232ff1993" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7bba2540-4549-4b08-a4e8-6ac232ff1993_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7bba2540-4549-4b08-a4e8-6ac232ff1993" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7bba2540-4549-4b08-a4e8-6ac232ff1993_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e63a1972-056f-40e9-b412-4f17b5da18c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7bba2540-4549-4b08-a4e8-6ac232ff1993" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e63a1972-056f-40e9-b412-4f17b5da18c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PromissoryNotesMember_5e464730-c201-4265-93e3-81d3b0809b76" xlink:href="amed-20221231.xsd#amed_PromissoryNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e63a1972-056f-40e9-b412-4f17b5da18c4" xlink:to="loc_amed_PromissoryNotesMember_5e464730-c201-4265-93e3-81d3b0809b76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3df06b80-10ef-4432-9426-1eacd9319c42" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d7c8f5e-2f0e-4cde-aaab-a463075b33a9" xlink:to="loc_srt_RangeAxis_3df06b80-10ef-4432-9426-1eacd9319c42" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3df06b80-10ef-4432-9426-1eacd9319c42_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3df06b80-10ef-4432-9426-1eacd9319c42" xlink:to="loc_srt_RangeMember_3df06b80-10ef-4432-9426-1eacd9319c42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3bba4aa7-c619-4472-a9ff-a8d4ec479fc9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3df06b80-10ef-4432-9426-1eacd9319c42" xlink:to="loc_srt_RangeMember_3bba4aa7-c619-4472-a9ff-a8d4ec479fc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_001184f1-44aa-41ca-b84f-f4dc2ad106d5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3bba4aa7-c619-4472-a9ff-a8d4ec479fc9" xlink:to="loc_srt_MaximumMember_001184f1-44aa-41ca-b84f-f4dc2ad106d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_42808cf2-c313-4cbd-9913-7fbe17de85be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d7c8f5e-2f0e-4cde-aaab-a463075b33a9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_42808cf2-c313-4cbd-9913-7fbe17de85be" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_42808cf2-c313-4cbd-9913-7fbe17de85be_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_42808cf2-c313-4cbd-9913-7fbe17de85be" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_42808cf2-c313-4cbd-9913-7fbe17de85be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_fead0ea7-c816-4788-9df1-7993060940d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_42808cf2-c313-4cbd-9913-7fbe17de85be" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_fead0ea7-c816-4788-9df1-7993060940d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnamortizableAcquiredNamesMember_a8520ac4-fcaf-433d-a58b-bec6d75944cf" xlink:href="amed-20221231.xsd#amed_UnamortizableAcquiredNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_fead0ea7-c816-4788-9df1-7993060940d5" xlink:to="loc_amed_UnamortizableAcquiredNamesMember_a8520ac4-fcaf-433d-a58b-bec6d75944cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificatesOfNeedAndLicensesMember_99422c67-23ba-405d-8bb4-4d087932b8a5" xlink:href="amed-20221231.xsd#amed_CertificatesOfNeedAndLicensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_fead0ea7-c816-4788-9df1-7993060940d5" xlink:to="loc_amed_CertificatesOfNeedAndLicensesMember_99422c67-23ba-405d-8bb4-4d087932b8a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationAdjustmentsAxis_55d730c2-8357-4dd0-a7dd-82cd7dcbd818" xlink:href="amed-20221231.xsd#amed_BusinessCombinationAdjustmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d7c8f5e-2f0e-4cde-aaab-a463075b33a9" xlink:to="loc_amed_BusinessCombinationAdjustmentsAxis_55d730c2-8357-4dd0-a7dd-82cd7dcbd818" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationAdjustmentsDomain_55d730c2-8357-4dd0-a7dd-82cd7dcbd818_default" xlink:href="amed-20221231.xsd#amed_BusinessCombinationAdjustmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_BusinessCombinationAdjustmentsAxis_55d730c2-8357-4dd0-a7dd-82cd7dcbd818" xlink:to="loc_amed_BusinessCombinationAdjustmentsDomain_55d730c2-8357-4dd0-a7dd-82cd7dcbd818_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationAdjustmentsDomain_15226a7f-5f18-4017-a8bb-c01bcd8146ad" xlink:href="amed-20221231.xsd#amed_BusinessCombinationAdjustmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_BusinessCombinationAdjustmentsAxis_55d730c2-8357-4dd0-a7dd-82cd7dcbd818" xlink:to="loc_amed_BusinessCombinationAdjustmentsDomain_15226a7f-5f18-4017-a8bb-c01bcd8146ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PotentialClosingPaymentAdjustmentMember_be31aeee-12d9-4850-986f-fb5803875052" xlink:href="amed-20221231.xsd#amed_PotentialClosingPaymentAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_BusinessCombinationAdjustmentsDomain_15226a7f-5f18-4017-a8bb-c01bcd8146ad" xlink:to="loc_amed_PotentialClosingPaymentAdjustmentMember_be31aeee-12d9-4850-986f-fb5803875052" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails" xlink:type="extended" id="i1528d8f10e0148ee85d6b9672b489a81_ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_682b99e7-20f9-4791-9d15-1b1d8bcd49ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_5bc47d2a-4528-4b62-a6a5-02c813f2f235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682b99e7-20f9-4791-9d15-1b1d8bcd49ef" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_5bc47d2a-4528-4b62-a6a5-02c813f2f235" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionProFormaOperatingIncomeLoss_c86a84d8-9e96-4532-8dfe-f26270c4a514" xlink:href="amed-20221231.xsd#amed_BusinessAcquisitionProFormaOperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682b99e7-20f9-4791-9d15-1b1d8bcd49ef" xlink:to="loc_amed_BusinessAcquisitionProFormaOperatingIncomeLoss_c86a84d8-9e96-4532-8dfe-f26270c4a514" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_308acf11-948f-44c6-847b-d3ecc32f2cec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682b99e7-20f9-4791-9d15-1b1d8bcd49ef" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_308acf11-948f-44c6-847b-d3ecc32f2cec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_b6483b8f-a2f0-4d4b-81aa-602fcdd46167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682b99e7-20f9-4791-9d15-1b1d8bcd49ef" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_b6483b8f-a2f0-4d4b-81aa-602fcdd46167" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_213d3d28-ee23-4dd1-b4a9-00c7f9f83919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682b99e7-20f9-4791-9d15-1b1d8bcd49ef" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_213d3d28-ee23-4dd1-b4a9-00c7f9f83919" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5abf2f55-45e7-46b0-aa30-883cbcd88b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682b99e7-20f9-4791-9d15-1b1d8bcd49ef" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5abf2f55-45e7-46b0-aa30-883cbcd88b5b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a1b86744-37e9-4a33-9ab5-5b719fb4af40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5abf2f55-45e7-46b0-aa30-883cbcd88b5b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a1b86744-37e9-4a33-9ab5-5b719fb4af40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a1b86744-37e9-4a33-9ab5-5b719fb4af40_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a1b86744-37e9-4a33-9ab5-5b719fb4af40" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a1b86744-37e9-4a33-9ab5-5b719fb4af40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06357d0a-e697-4438-9e1d-9461ab007260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a1b86744-37e9-4a33-9ab5-5b719fb4af40" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06357d0a-e697-4438-9e1d-9461ab007260" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_c4a8c236-e1df-47d7-a608-abb3e4aca7bf" xlink:href="amed-20221231.xsd#amed_AseraCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06357d0a-e697-4438-9e1d-9461ab007260" xlink:to="loc_amed_AseraCareHospiceMember_c4a8c236-e1df-47d7-a608-abb3e4aca7bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_83713860-0483-4cbb-a881-b185a3aabd50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5abf2f55-45e7-46b0-aa30-883cbcd88b5b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_83713860-0483-4cbb-a881-b185a3aabd50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_83713860-0483-4cbb-a881-b185a3aabd50_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_83713860-0483-4cbb-a881-b185a3aabd50" xlink:to="loc_us-gaap_SegmentDomain_83713860-0483-4cbb-a881-b185a3aabd50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_22f6f306-b053-443f-9363-92b5cb7c7f99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_83713860-0483-4cbb-a881-b185a3aabd50" xlink:to="loc_us-gaap_SegmentDomain_22f6f306-b053-443f-9363-92b5cb7c7f99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_98a77afd-8643-435f-bff1-91473f09eb90" xlink:href="amed-20221231.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_22f6f306-b053-443f-9363-92b5cb7c7f99" xlink:to="loc_amed_HospiceMember_98a77afd-8643-435f-bff1-91473f09eb90" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails" xlink:type="extended" id="id0e06b3649af4d5d80f652840925dd49_GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_4f244af6-2ee0-4074-9f6b-0d264f7a14e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_fdfe6a1e-d469-4ff8-b617-05ec494d5160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_4f244af6-2ee0-4074-9f6b-0d264f7a14e6" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_fdfe6a1e-d469-4ff8-b617-05ec494d5160" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_a19b612c-47e9-4355-8f23-6a000ba7c473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_4f244af6-2ee0-4074-9f6b-0d264f7a14e6" xlink:to="loc_us-gaap_GoodwillRollForward_a19b612c-47e9-4355-8f23-6a000ba7c473" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_55d4dc56-c001-421e-b8a9-138cc269904f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_a19b612c-47e9-4355-8f23-6a000ba7c473" xlink:to="loc_us-gaap_Goodwill_55d4dc56-c001-421e-b8a9-138cc269904f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_aae87feb-132d-4880-949e-12c0a2cb5ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_a19b612c-47e9-4355-8f23-6a000ba7c473" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_aae87feb-132d-4880-949e-12c0a2cb5ecc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_be2cccc3-00f5-416b-9697-3b711ddf1469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_a19b612c-47e9-4355-8f23-6a000ba7c473" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_be2cccc3-00f5-416b-9697-3b711ddf1469" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e5dc895f-f46b-4aa9-8e3f-19334a4e9fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_b730b9c3-342a-423f-91e7-8490f49ed678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_4f244af6-2ee0-4074-9f6b-0d264f7a14e6" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_b730b9c3-342a-423f-91e7-8490f49ed678" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_843e7bb7-670c-4aa8-95f7-acbdafe73721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_b730b9c3-342a-423f-91e7-8490f49ed678" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_843e7bb7-670c-4aa8-95f7-acbdafe73721" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_843e7bb7-670c-4aa8-95f7-acbdafe73721_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_843e7bb7-670c-4aa8-95f7-acbdafe73721" xlink:to="loc_us-gaap_SegmentDomain_843e7bb7-670c-4aa8-95f7-acbdafe73721_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9e8275cc-b3cf-4583-b7f1-051165c9dbe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_843e7bb7-670c-4aa8-95f7-acbdafe73721" xlink:to="loc_us-gaap_SegmentDomain_9e8275cc-b3cf-4583-b7f1-051165c9dbe1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_1860f866-9b07-4636-85ad-30730326e257" xlink:href="amed-20221231.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9e8275cc-b3cf-4583-b7f1-051165c9dbe1" xlink:to="loc_amed_HomeHealthMember_1860f866-9b07-4636-85ad-30730326e257" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_bdf8c23a-d5d5-4c4f-b5aa-b0e0976a4892" xlink:href="amed-20221231.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9e8275cc-b3cf-4583-b7f1-051165c9dbe1" xlink:to="loc_amed_HospiceMember_bdf8c23a-d5d5-4c4f-b5aa-b0e0976a4892" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_f2d0d1c1-7c06-4922-9dad-d7eeb5337eaf" xlink:href="amed-20221231.xsd#amed_PersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9e8275cc-b3cf-4583-b7f1-051165c9dbe1" xlink:to="loc_amed_PersonalCareMember_f2d0d1c1-7c06-4922-9dad-d7eeb5337eaf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_9f9a5722-a35f-45f1-b133-e81a88375547" xlink:href="amed-20221231.xsd#amed_HighAcuityCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9e8275cc-b3cf-4583-b7f1-051165c9dbe1" xlink:to="loc_amed_HighAcuityCareMember_9f9a5722-a35f-45f1-b133-e81a88375547" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails" xlink:type="extended" id="ia969ade66b8a4afca1fa7f2c01712e1a_GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_1323e231-1110-4532-9fdd-b4c721c83412" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_18db9f17-2ae7-4835-918e-df97d72627fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_1323e231-1110-4532-9fdd-b4c721c83412" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_18db9f17-2ae7-4835-918e-df97d72627fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_ca539ac0-e78b-4bbe-90d4-a37cdee81c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_1323e231-1110-4532-9fdd-b4c721c83412" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_ca539ac0-e78b-4bbe-90d4-a37cdee81c6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b9ef7206-6591-4c95-977c-50b4a79a7b44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_1323e231-1110-4532-9fdd-b4c721c83412" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b9ef7206-6591-4c95-977c-50b4a79a7b44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_74fbecb8-5ba9-49b4-8efd-e25c93b67da9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_1323e231-1110-4532-9fdd-b4c721c83412" xlink:to="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_74fbecb8-5ba9-49b4-8efd-e25c93b67da9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3ee85435-3229-49a4-ae4c-237febf36438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_74fbecb8-5ba9-49b4-8efd-e25c93b67da9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3ee85435-3229-49a4-ae4c-237febf36438" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3ee85435-3229-49a4-ae4c-237febf36438_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3ee85435-3229-49a4-ae4c-237febf36438" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3ee85435-3229-49a4-ae4c-237febf36438_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_20bf3d92-16a5-4c13-8ec4-7c1f340bbb63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3ee85435-3229-49a4-ae4c-237febf36438" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_20bf3d92-16a5-4c13-8ec4-7c1f340bbb63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificatesOfNeedAndLicensesMember_17692c22-dbf7-4a7a-bc3f-7ce8056baf5f" xlink:href="amed-20221231.xsd#amed_CertificatesOfNeedAndLicensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_20bf3d92-16a5-4c13-8ec4-7c1f340bbb63" xlink:to="loc_amed_CertificatesOfNeedAndLicensesMember_17692c22-dbf7-4a7a-bc3f-7ce8056baf5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNamesMember_79dcbfcd-f94e-4bb5-b70a-80013c3057b7" xlink:href="amed-20221231.xsd#amed_AcquiredNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_20bf3d92-16a5-4c13-8ec4-7c1f340bbb63" xlink:to="loc_amed_AcquiredNamesMember_79dcbfcd-f94e-4bb5-b70a-80013c3057b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_da1a06c0-c4a9-4c78-b4f9-416344b198e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_74fbecb8-5ba9-49b4-8efd-e25c93b67da9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_da1a06c0-c4a9-4c78-b4f9-416344b198e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_da1a06c0-c4a9-4c78-b4f9-416344b198e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_da1a06c0-c4a9-4c78-b4f9-416344b198e7" xlink:to="loc_us-gaap_SegmentDomain_da1a06c0-c4a9-4c78-b4f9-416344b198e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c7b4f3a6-eb8a-4307-8798-3f42b1dd805a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_da1a06c0-c4a9-4c78-b4f9-416344b198e7" xlink:to="loc_us-gaap_SegmentDomain_c7b4f3a6-eb8a-4307-8798-3f42b1dd805a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_747853da-637b-453a-93e0-206a34bc4d20" xlink:href="amed-20221231.xsd#amed_PersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c7b4f3a6-eb8a-4307-8798-3f42b1dd805a" xlink:to="loc_amed_PersonalCareMember_747853da-637b-453a-93e0-206a34bc4d20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0d35cf37-657d-4c79-a797-c0532bdd5ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_74fbecb8-5ba9-49b4-8efd-e25c93b67da9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0d35cf37-657d-4c79-a797-c0532bdd5ef0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0d35cf37-657d-4c79-a797-c0532bdd5ef0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0d35cf37-657d-4c79-a797-c0532bdd5ef0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0d35cf37-657d-4c79-a797-c0532bdd5ef0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58ab67d3-83d4-437a-bfad-0383b6a7d1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0d35cf37-657d-4c79-a797-c0532bdd5ef0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58ab67d3-83d4-437a-bfad-0383b6a7d1a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_72376f4b-6f97-41e8-aa74-f0c26776abb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58ab67d3-83d4-437a-bfad-0383b6a7d1a6" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_72376f4b-6f97-41e8-aa74-f0c26776abb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_0c61e7e8-2157-4133-92d5-158b9bb20f72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58ab67d3-83d4-437a-bfad-0383b6a7d1a6" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_0c61e7e8-2157-4133-92d5-158b9bb20f72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNamesMember_ff3dc035-e3ac-4af7-ada1-e2cf37ed1c82" xlink:href="amed-20221231.xsd#amed_AcquiredNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58ab67d3-83d4-437a-bfad-0383b6a7d1a6" xlink:to="loc_amed_AcquiredNamesMember_ff3dc035-e3ac-4af7-ada1-e2cf37ed1c82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmortizableAcquiredNamesMember_73d68caf-ae61-419c-9d15-9f54501e0541" xlink:href="amed-20221231.xsd#amed_AmortizableAcquiredNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58ab67d3-83d4-437a-bfad-0383b6a7d1a6" xlink:to="loc_amed_AmortizableAcquiredNamesMember_73d68caf-ae61-419c-9d15-9f54501e0541" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails" xlink:type="extended" id="id80f37d392474abd8817d243bf43ddc0_GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_4d25115b-fcf3-460d-aa5a-ae3215dcb633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_0c76b343-682f-441b-bdcd-7befb6ded54e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_4d25115b-fcf3-460d-aa5a-ae3215dcb633" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_0c76b343-682f-441b-bdcd-7befb6ded54e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_13290ffd-5f77-44fe-9601-25163907cedf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_0c76b343-682f-441b-bdcd-7befb6ded54e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_13290ffd-5f77-44fe-9601-25163907cedf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OtherIntangibleAssetsAdditions_f485230e-b86d-4cf9-811e-968179eeac32" xlink:href="amed-20221231.xsd#amed_OtherIntangibleAssetsAdditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_0c76b343-682f-441b-bdcd-7befb6ded54e" xlink:to="loc_amed_OtherIntangibleAssetsAdditions_f485230e-b86d-4cf9-811e-968179eeac32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ReclassToAmortizableIntangible_989e23b3-d471-4dd7-815a-9e5b3ddc3ce3" xlink:href="amed-20221231.xsd#amed_ReclassToAmortizableIntangible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_0c76b343-682f-441b-bdcd-7befb6ded54e" xlink:to="loc_amed_ReclassToAmortizableIntangible_989e23b3-d471-4dd7-815a-9e5b3ddc3ce3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_655ab10e-d145-424d-8aff-dcc9e6e72501" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_0c76b343-682f-441b-bdcd-7befb6ded54e" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_655ab10e-d145-424d-8aff-dcc9e6e72501" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_f7fe3e8e-19f4-41e4-9799-733ef19e47e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_0c76b343-682f-441b-bdcd-7befb6ded54e" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_f7fe3e8e-19f4-41e4-9799-733ef19e47e1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0813d0e2-132e-446c-b70e-2cedf6873874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_ad4ab4dd-3922-4109-9450-69621bea4bda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_4d25115b-fcf3-460d-aa5a-ae3215dcb633" xlink:to="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_ad4ab4dd-3922-4109-9450-69621bea4bda" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1e80bb53-4c60-40b7-b30e-28a00cb0c44a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_ad4ab4dd-3922-4109-9450-69621bea4bda" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1e80bb53-4c60-40b7-b30e-28a00cb0c44a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1e80bb53-4c60-40b7-b30e-28a00cb0c44a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1e80bb53-4c60-40b7-b30e-28a00cb0c44a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1e80bb53-4c60-40b7-b30e-28a00cb0c44a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_09f7acfd-02ef-462b-8f3f-bca63e045ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1e80bb53-4c60-40b7-b30e-28a00cb0c44a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_09f7acfd-02ef-462b-8f3f-bca63e045ff8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificatesOfNeedAndLicensesMember_333c6343-b0ae-4521-a6c6-36524f025ac7" xlink:href="amed-20221231.xsd#amed_CertificatesOfNeedAndLicensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_09f7acfd-02ef-462b-8f3f-bca63e045ff8" xlink:to="loc_amed_CertificatesOfNeedAndLicensesMember_333c6343-b0ae-4521-a6c6-36524f025ac7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnamortizableAcquiredNamesMember_c8db2c63-9562-4683-a4cb-769b8fab93e2" xlink:href="amed-20221231.xsd#amed_UnamortizableAcquiredNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_09f7acfd-02ef-462b-8f3f-bca63e045ff8" xlink:to="loc_amed_UnamortizableAcquiredNamesMember_c8db2c63-9562-4683-a4cb-769b8fab93e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a8fb067d-8a33-49ff-9e91-c457f4cdc6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_ad4ab4dd-3922-4109-9450-69621bea4bda" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a8fb067d-8a33-49ff-9e91-c457f4cdc6e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a8fb067d-8a33-49ff-9e91-c457f4cdc6e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a8fb067d-8a33-49ff-9e91-c457f4cdc6e8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a8fb067d-8a33-49ff-9e91-c457f4cdc6e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_39e7d4a0-d7c8-4837-b78b-b3d89996694f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a8fb067d-8a33-49ff-9e91-c457f4cdc6e8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_39e7d4a0-d7c8-4837-b78b-b3d89996694f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmortizableAcquiredNamesMember_d7bd4b9a-bd62-4b83-be63-a14eaecfa811" xlink:href="amed-20221231.xsd#amed_AmortizableAcquiredNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_39e7d4a0-d7c8-4837-b78b-b3d89996694f" xlink:to="loc_amed_AmortizableAcquiredNamesMember_d7bd4b9a-bd62-4b83-be63-a14eaecfa811" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_04695078-5370-483e-a6d8-da06be0646ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_39e7d4a0-d7c8-4837-b78b-b3d89996694f" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_04695078-5370-483e-a6d8-da06be0646ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_22d05c85-62f7-45b2-9d5e-24d5ab556632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_39e7d4a0-d7c8-4837-b78b-b3d89996694f" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_22d05c85-62f7-45b2-9d5e-24d5ab556632" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/DiscontinuedOperationsandAssetsHeldForSaleAdditionalInformationDetail" xlink:type="simple" xlink:href="amed-20221231.xsd#DiscontinuedOperationsandAssetsHeldForSaleAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/DiscontinuedOperationsandAssetsHeldForSaleAdditionalInformationDetail" xlink:type="extended" id="ifcca100664344f32abe8af21bea45962_DiscontinuedOperationsandAssetsHeldForSaleAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d8b14102-ff85-4cb2-b70c-5abd87ee0baa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfCareCentersConsolidated_c6aa7e32-2d3c-4fe4-befb-aa769de5b141" xlink:href="amed-20221231.xsd#amed_NumberOfCareCentersConsolidated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d8b14102-ff85-4cb2-b70c-5abd87ee0baa" xlink:to="loc_amed_NumberOfCareCentersConsolidated_c6aa7e32-2d3c-4fe4-befb-aa769de5b141" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfCareCentersClosed_b17eeb67-9d10-4f6e-b795-2885a139f5e1" xlink:href="amed-20221231.xsd#amed_NumberOfCareCentersClosed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d8b14102-ff85-4cb2-b70c-5abd87ee0baa" xlink:to="loc_amed_NumberOfCareCentersClosed_b17eeb67-9d10-4f6e-b795-2885a139f5e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued_8e4882c5-8279-433d-8824-0ce51e2094ec" xlink:href="amed-20221231.xsd#amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d8b14102-ff85-4cb2-b70c-5abd87ee0baa" xlink:to="loc_amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued_8e4882c5-8279-433d-8824-0ce51e2094ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfCareCentersExited_da4f41f9-4ad3-4f25-82fd-aae99c386cd9" xlink:href="amed-20221231.xsd#amed_NumberOfCareCentersExited"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d8b14102-ff85-4cb2-b70c-5abd87ee0baa" xlink:to="loc_amed_NumberOfCareCentersExited_da4f41f9-4ad3-4f25-82fd-aae99c386cd9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfCareCentersAvailableForSale_a535b79e-012b-4418-b1f3-0bb2dfe5d382" xlink:href="amed-20221231.xsd#amed_NumberOfCareCentersAvailableForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d8b14102-ff85-4cb2-b70c-5abd87ee0baa" xlink:to="loc_amed_NumberOfCareCentersAvailableForSale_a535b79e-012b-4418-b1f3-0bb2dfe5d382" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfCareCentersSold_7f394eed-ad2c-49da-8d78-20623d2ce30d" xlink:href="amed-20221231.xsd#amed_NumberOfCareCentersSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d8b14102-ff85-4cb2-b70c-5abd87ee0baa" xlink:to="loc_amed_NumberOfCareCentersSold_7f394eed-ad2c-49da-8d78-20623d2ce30d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfCareCentersIncludedInDivestiturePlan_865886a5-71e7-444f-a9c9-0396d53e2304" xlink:href="amed-20221231.xsd#amed_NumberOfCareCentersIncludedInDivestiturePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d8b14102-ff85-4cb2-b70c-5abd87ee0baa" xlink:to="loc_amed_NumberOfCareCentersIncludedInDivestiturePlan_865886a5-71e7-444f-a9c9-0396d53e2304" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfCareCentersIncludedInDiscontinuedOperations_515f93a6-b543-45bd-a1c4-7a0918f0287c" xlink:href="amed-20221231.xsd#amed_NumberOfCareCentersIncludedInDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d8b14102-ff85-4cb2-b70c-5abd87ee0baa" xlink:to="loc_amed_NumberOfCareCentersIncludedInDiscontinuedOperations_515f93a6-b543-45bd-a1c4-7a0918f0287c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfCareCentersRemovedFromAvailableForSale_19bd04e1-b010-49b0-ba32-3bb4bbb636fc" xlink:href="amed-20221231.xsd#amed_NumberOfCareCentersRemovedFromAvailableForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d8b14102-ff85-4cb2-b70c-5abd87ee0baa" xlink:to="loc_amed_NumberOfCareCentersRemovedFromAvailableForSale_19bd04e1-b010-49b0-ba32-3bb4bbb636fc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_783dfa4e-b81a-45bd-8ed3-b951f1854cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d8b14102-ff85-4cb2-b70c-5abd87ee0baa" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_783dfa4e-b81a-45bd-8ed3-b951f1854cc7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_891ebe4f-6ee3-49ca-b46d-ef629e326c87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d8b14102-ff85-4cb2-b70c-5abd87ee0baa" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_891ebe4f-6ee3-49ca-b46d-ef629e326c87" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_b9568940-964e-47ed-81cd-3210be31fbb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d8b14102-ff85-4cb2-b70c-5abd87ee0baa" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_b9568940-964e-47ed-81cd-3210be31fbb1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2f213f74-ca23-4764-9470-edacd83b244b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d8b14102-ff85-4cb2-b70c-5abd87ee0baa" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2f213f74-ca23-4764-9470-edacd83b244b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_793f9a2e-4a61-4055-b80b-524a21b20ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2f213f74-ca23-4764-9470-edacd83b244b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_793f9a2e-4a61-4055-b80b-524a21b20ea6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_793f9a2e-4a61-4055-b80b-524a21b20ea6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_793f9a2e-4a61-4055-b80b-524a21b20ea6" xlink:to="loc_us-gaap_SegmentDomain_793f9a2e-4a61-4055-b80b-524a21b20ea6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_dfcf2839-c43a-4a15-ade8-1ac29dd9efef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_793f9a2e-4a61-4055-b80b-524a21b20ea6" xlink:to="loc_us-gaap_SegmentDomain_dfcf2839-c43a-4a15-ade8-1ac29dd9efef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_c7490af4-f494-457f-a12f-f01e89477c74" xlink:href="amed-20221231.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_dfcf2839-c43a-4a15-ade8-1ac29dd9efef" xlink:to="loc_amed_HomeHealthMember_c7490af4-f494-457f-a12f-f01e89477c74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_4ae14f94-0100-4e4a-86d8-a2e25d6def41" xlink:href="amed-20221231.xsd#amed_PersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_dfcf2839-c43a-4a15-ade8-1ac29dd9efef" xlink:to="loc_amed_PersonalCareMember_4ae14f94-0100-4e4a-86d8-a2e25d6def41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_1d04d407-88f8-4f4b-a3e7-8c4f4498b3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2f213f74-ca23-4764-9470-edacd83b244b" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_1d04d407-88f8-4f4b-a3e7-8c4f4498b3c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_1d04d407-88f8-4f4b-a3e7-8c4f4498b3c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_1d04d407-88f8-4f4b-a3e7-8c4f4498b3c5" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_1d04d407-88f8-4f4b-a3e7-8c4f4498b3c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_1604096f-a77e-4e0f-873a-50fcdf36c97f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_1d04d407-88f8-4f4b-a3e7-8c4f4498b3c5" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_1604096f-a77e-4e0f-873a-50fcdf36c97f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_c428f598-ed5d-401e-8f0f-17d84fa132d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_1604096f-a77e-4e0f-873a-50fcdf36c97f" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_c428f598-ed5d-401e-8f0f-17d84fa132d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5f3937d4-5a18-46ca-a44f-402834da8bac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2f213f74-ca23-4764-9470-edacd83b244b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5f3937d4-5a18-46ca-a44f-402834da8bac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_5f3937d4-5a18-46ca-a44f-402834da8bac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5f3937d4-5a18-46ca-a44f-402834da8bac" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_5f3937d4-5a18-46ca-a44f-402834da8bac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6bfa208d-8cb6-45de-818c-d2395c96ac6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5f3937d4-5a18-46ca-a44f-402834da8bac" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6bfa208d-8cb6-45de-818c-d2395c96ac6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_0ed25bad-01c2-452e-b0c5-9c06e5c9404c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6bfa208d-8cb6-45de-818c-d2395c96ac6a" xlink:to="loc_us-gaap_SubsequentEventMember_0ed25bad-01c2-452e-b0c5-9c06e5c9404c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/AssetsHeldForSaleAssetsandLiabilitiesDetail" xlink:type="simple" xlink:href="amed-20221231.xsd#AssetsHeldForSaleAssetsandLiabilitiesDetail"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/AssetsHeldForSaleAssetsandLiabilitiesDetail" xlink:type="extended" id="i16b0856bdff2454890217a4298839182_AssetsHeldForSaleAssetsandLiabilitiesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_77cc7602-01bd-456e-a1a8-4940ee44f6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_ab5d8b91-84e1-4968-be0c-e60e0fa7dbc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_77cc7602-01bd-456e-a1a8-4940ee44f6f7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_ab5d8b91-84e1-4968-be0c-e60e0fa7dbc5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_5f914b68-6874-4b2d-bd01-e1383b9c13bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_77cc7602-01bd-456e-a1a8-4940ee44f6f7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_5f914b68-6874-4b2d-bd01-e1383b9c13bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_5d57bb36-c268-4efc-ad68-5a3dd875cd5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_77cc7602-01bd-456e-a1a8-4940ee44f6f7" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_5d57bb36-c268-4efc-ad68-5a3dd875cd5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_3337dbc3-315b-4083-adc7-54521b677d48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_77cc7602-01bd-456e-a1a8-4940ee44f6f7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_3337dbc3-315b-4083-adc7-54521b677d48" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent_ac03b5e9-ff6c-4e94-9ebf-5adec575fb74" xlink:href="amed-20221231.xsd#amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_77cc7602-01bd-456e-a1a8-4940ee44f6f7" xlink:to="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent_ac03b5e9-ff6c-4e94-9ebf-5adec575fb74" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_ea3fb82e-9971-4a89-9425-cdf21fade928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_77cc7602-01bd-456e-a1a8-4940ee44f6f7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_ea3fb82e-9971-4a89-9425-cdf21fade928" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_78099880-18f9-48de-a21b-f89107cf1f74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_77cc7602-01bd-456e-a1a8-4940ee44f6f7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_78099880-18f9-48de-a21b-f89107cf1f74" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_29409f52-ae35-4269-bf71-b47ec7a40f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_77cc7602-01bd-456e-a1a8-4940ee44f6f7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_29409f52-ae35-4269-bf71-b47ec7a40f0e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_a5b72f10-5f59-4cc7-85eb-47e50d5f9371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_77cc7602-01bd-456e-a1a8-4940ee44f6f7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_a5b72f10-5f59-4cc7-85eb-47e50d5f9371" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent_a20f439d-02f8-4427-9d1b-001b09097d11" xlink:href="amed-20221231.xsd#amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_77cc7602-01bd-456e-a1a8-4940ee44f6f7" xlink:to="loc_amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent_a20f439d-02f8-4427-9d1b-001b09097d11" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent_a5e1b9ec-fb4e-4e3f-a93f-cf2e62b68d8c" xlink:href="amed-20221231.xsd#amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_77cc7602-01bd-456e-a1a8-4940ee44f6f7" xlink:to="loc_amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent_a5e1b9ec-fb4e-4e3f-a93f-cf2e62b68d8c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent_08190859-431f-4c1b-ad3f-3258a05c52eb" xlink:href="amed-20221231.xsd#amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_77cc7602-01bd-456e-a1a8-4940ee44f6f7" xlink:to="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent_08190859-431f-4c1b-ad3f-3258a05c52eb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_412c7a77-2e5e-4a44-84d0-dc3ee386e443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_77cc7602-01bd-456e-a1a8-4940ee44f6f7" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_412c7a77-2e5e-4a44-84d0-dc3ee386e443" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent_d5bded43-d3e0-490a-9667-fd93600654e5" xlink:href="amed-20221231.xsd#amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_77cc7602-01bd-456e-a1a8-4940ee44f6f7" xlink:to="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent_d5bded43-d3e0-490a-9667-fd93600654e5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_2dcbab11-75be-4f50-934d-b3ab1a20529f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_77cc7602-01bd-456e-a1a8-4940ee44f6f7" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_2dcbab11-75be-4f50-934d-b3ab1a20529f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_add5a077-3acb-4e85-bc77-ad9ff5eb0206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_77cc7602-01bd-456e-a1a8-4940ee44f6f7" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_add5a077-3acb-4e85-bc77-ad9ff5eb0206" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_dd436934-0acb-4d9e-8938-eec8b3fa1d32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_add5a077-3acb-4e85-bc77-ad9ff5eb0206" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_dd436934-0acb-4d9e-8938-eec8b3fa1d32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_dd436934-0acb-4d9e-8938-eec8b3fa1d32_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_dd436934-0acb-4d9e-8938-eec8b3fa1d32" xlink:to="loc_us-gaap_SegmentDomain_dd436934-0acb-4d9e-8938-eec8b3fa1d32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_eb9ef0ab-c25b-4e2c-9483-a10c2d5f5885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_dd436934-0acb-4d9e-8938-eec8b3fa1d32" xlink:to="loc_us-gaap_SegmentDomain_eb9ef0ab-c25b-4e2c-9483-a10c2d5f5885" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_b3b8f841-1231-4fd8-993e-788cadabb624" xlink:href="amed-20221231.xsd#amed_PersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_eb9ef0ab-c25b-4e2c-9483-a10c2d5f5885" xlink:to="loc_amed_PersonalCareMember_b3b8f841-1231-4fd8-993e-788cadabb624" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASESDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#LEASESDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LEASESDetails" xlink:type="extended" id="i68eb2b08586e420db930b9eec0c82579_LEASESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_55f77d77-26b3-4e9f-8235-b2d9bacc96f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ec459c74-8870-46a4-b154-b274bc45b3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_55f77d77-26b3-4e9f-8235-b2d9bacc96f5" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ec459c74-8870-46a4-b154-b274bc45b3c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_ad5ef4a0-f835-4298-b83b-98a3509d2769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_55f77d77-26b3-4e9f-8235-b2d9bacc96f5" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_ad5ef4a0-f835-4298-b83b-98a3509d2769" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate_9f223b4d-be26-4ebb-9344-328908bff095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_55f77d77-26b3-4e9f-8235-b2d9bacc96f5" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate_9f223b4d-be26-4ebb-9344-328908bff095" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8584e7c0-4a01-4756-bf09-ad843a1d5af9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_55f77d77-26b3-4e9f-8235-b2d9bacc96f5" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8584e7c0-4a01-4756-bf09-ad843a1d5af9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_de518dbc-a961-4039-9213-6a45bc79fe2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_55f77d77-26b3-4e9f-8235-b2d9bacc96f5" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_de518dbc-a961-4039-9213-6a45bc79fe2f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_360d38ae-7b8e-4dd8-b16a-71adbde3c060" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_de518dbc-a961-4039-9213-6a45bc79fe2f" xlink:to="loc_srt_RangeAxis_360d38ae-7b8e-4dd8-b16a-71adbde3c060" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_360d38ae-7b8e-4dd8-b16a-71adbde3c060_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_360d38ae-7b8e-4dd8-b16a-71adbde3c060" xlink:to="loc_srt_RangeMember_360d38ae-7b8e-4dd8-b16a-71adbde3c060_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7c4abea0-915f-4232-ac82-8fd165bed1a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_360d38ae-7b8e-4dd8-b16a-71adbde3c060" xlink:to="loc_srt_RangeMember_7c4abea0-915f-4232-ac82-8fd165bed1a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_39d049de-1f0b-4164-ace6-545470555361" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7c4abea0-915f-4232-ac82-8fd165bed1a4" xlink:to="loc_srt_MinimumMember_39d049de-1f0b-4164-ace6-545470555361" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f4ba61c1-3fc6-4bff-9f0f-996d090febe3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7c4abea0-915f-4232-ac82-8fd165bed1a4" xlink:to="loc_srt_MaximumMember_f4ba61c1-3fc6-4bff-9f0f-996d090febe3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LeaseTypeAxis_266d4527-4d94-4544-ac6f-e2eee93991da" xlink:href="amed-20221231.xsd#amed_LeaseTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_de518dbc-a961-4039-9213-6a45bc79fe2f" xlink:to="loc_amed_LeaseTypeAxis_266d4527-4d94-4544-ac6f-e2eee93991da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LeaseTypeDomain_266d4527-4d94-4544-ac6f-e2eee93991da_default" xlink:href="amed-20221231.xsd#amed_LeaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_LeaseTypeAxis_266d4527-4d94-4544-ac6f-e2eee93991da" xlink:to="loc_amed_LeaseTypeDomain_266d4527-4d94-4544-ac6f-e2eee93991da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LeaseTypeDomain_eb5fdfac-3468-4850-befb-68afcd6ebbca" xlink:href="amed-20221231.xsd#amed_LeaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_LeaseTypeAxis_266d4527-4d94-4544-ac6f-e2eee93991da" xlink:to="loc_amed_LeaseTypeDomain_eb5fdfac-3468-4850-befb-68afcd6ebbca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FleetLeaseMember_e0daf1ba-c867-4967-bc4c-f5ee6d144ead" xlink:href="amed-20221231.xsd#amed_FleetLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_LeaseTypeDomain_eb5fdfac-3468-4850-befb-68afcd6ebbca" xlink:to="loc_amed_FleetLeaseMember_e0daf1ba-c867-4967-bc4c-f5ee6d144ead" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ed7344cb-82e6-4bdd-a9b7-f7aea8ae748d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_de518dbc-a961-4039-9213-6a45bc79fe2f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ed7344cb-82e6-4bdd-a9b7-f7aea8ae748d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ed7344cb-82e6-4bdd-a9b7-f7aea8ae748d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ed7344cb-82e6-4bdd-a9b7-f7aea8ae748d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ed7344cb-82e6-4bdd-a9b7-f7aea8ae748d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3d6e820c-d237-4122-8006-00b4e82c54ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ed7344cb-82e6-4bdd-a9b7-f7aea8ae748d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3d6e820c-d237-4122-8006-00b4e82c54ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TelehealthKitsMember_6571f804-09da-4b5d-aa9a-40e7a60c41bb" xlink:href="amed-20221231.xsd#amed_TelehealthKitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3d6e820c-d237-4122-8006-00b4e82c54ea" xlink:to="loc_amed_TelehealthKitsMember_6571f804-09da-4b5d-aa9a-40e7a60c41bb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASESFinanceLeasesDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#LEASESFinanceLeasesDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LEASESFinanceLeasesDetails" xlink:type="extended" id="i812cd22141424f038f95b618800f9b10_LEASESFinanceLeasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_00152a9c-844d-485d-a54a-6b8b01f259b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_d57483c9-5d63-40a6-8e91-31a4c560c8de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00152a9c-844d-485d-a54a-6b8b01f259b8" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_d57483c9-5d63-40a6-8e91-31a4c560c8de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_533adf0c-ab7d-47ea-870b-7584b68901d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00152a9c-844d-485d-a54a-6b8b01f259b8" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_533adf0c-ab7d-47ea-870b-7584b68901d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_72aea46f-86d6-46e0-97ee-5f25285addda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00152a9c-844d-485d-a54a-6b8b01f259b8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_72aea46f-86d6-46e0-97ee-5f25285addda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_567fd6b7-7b15-4bee-876f-a9a221df78c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00152a9c-844d-485d-a54a-6b8b01f259b8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_567fd6b7-7b15-4bee-876f-a9a221df78c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_f83ad2ae-c895-4b38-8071-e6d465a38794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00152a9c-844d-485d-a54a-6b8b01f259b8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_f83ad2ae-c895-4b38-8071-e6d465a38794" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_0ff58a73-61a4-44b4-92b8-38d6946a17e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00152a9c-844d-485d-a54a-6b8b01f259b8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_0ff58a73-61a4-44b4-92b8-38d6946a17e2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_5ccff8aa-656c-4ef0-a50e-87bfdbbe1fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00152a9c-844d-485d-a54a-6b8b01f259b8" xlink:to="loc_us-gaap_FinanceLeaseLiability_5ccff8aa-656c-4ef0-a50e-87bfdbbe1fe8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_68fddeae-0168-4f85-a53d-ce271a619fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00152a9c-844d-485d-a54a-6b8b01f259b8" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_68fddeae-0168-4f85-a53d-ce271a619fc9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_afa693d7-0216-4086-a8f5-e0fb14705ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_68fddeae-0168-4f85-a53d-ce271a619fc9" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_afa693d7-0216-4086-a8f5-e0fb14705ed3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_afa693d7-0216-4086-a8f5-e0fb14705ed3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_afa693d7-0216-4086-a8f5-e0fb14705ed3" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_afa693d7-0216-4086-a8f5-e0fb14705ed3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3da100f3-2914-484a-81fc-f11548269fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_afa693d7-0216-4086-a8f5-e0fb14705ed3" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3da100f3-2914-484a-81fc-f11548269fc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember_4eb3c58c-093d-4a0e-a0bf-89e969409b80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3da100f3-2914-484a-81fc-f11548269fc1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentMember_4eb3c58c-093d-4a0e-a0bf-89e969409b80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CurrentPortionOfLongTermObligationsMember_a3bdf5d9-b3ed-47cf-be3b-f8e375e628f8" xlink:href="amed-20221231.xsd#amed_CurrentPortionOfLongTermObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3da100f3-2914-484a-81fc-f11548269fc1" xlink:to="loc_amed_CurrentPortionOfLongTermObligationsMember_a3bdf5d9-b3ed-47cf-be3b-f8e375e628f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LongTermObligationsLessCurrentPortionMember_3a33ffc2-bd6a-44a1-a579-c49204bc1dfb" xlink:href="amed-20221231.xsd#amed_LongTermObligationsLessCurrentPortionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3da100f3-2914-484a-81fc-f11548269fc1" xlink:to="loc_amed_LongTermObligationsLessCurrentPortionMember_3a33ffc2-bd6a-44a1-a579-c49204bc1dfb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CurrentAndLongTermObligationsMember_ef528d93-5974-42d2-a8ac-6d0b2e6172c6" xlink:href="amed-20221231.xsd#amed_CurrentAndLongTermObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3da100f3-2914-484a-81fc-f11548269fc1" xlink:to="loc_amed_CurrentAndLongTermObligationsMember_ef528d93-5974-42d2-a8ac-6d0b2e6172c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_94ea1a22-877a-44f8-a471-ebd159210f94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_68fddeae-0168-4f85-a53d-ce271a619fc9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_94ea1a22-877a-44f8-a471-ebd159210f94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_94ea1a22-877a-44f8-a471-ebd159210f94_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_94ea1a22-877a-44f8-a471-ebd159210f94" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_94ea1a22-877a-44f8-a471-ebd159210f94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3eabe267-3631-44d3-b10e-a4613359b0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_94ea1a22-877a-44f8-a471-ebd159210f94" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3eabe267-3631-44d3-b10e-a4613359b0ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldUnderCapitalLeasesMember_5c2e82ee-47a3-4d08-9475-e27ff0421f64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldUnderCapitalLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3eabe267-3631-44d3-b10e-a4613359b0ae" xlink:to="loc_us-gaap_AssetsHeldUnderCapitalLeasesMember_5c2e82ee-47a3-4d08-9475-e27ff0421f64" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASESMaturitiesDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#LEASESMaturitiesDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LEASESMaturitiesDetails" xlink:type="extended" id="i2684a91403e443bbaddf5fbe0bd646eb_LEASESMaturitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_63b363ae-dc3c-45c3-a65e-b9e48f2ef0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_63b363ae-dc3c-45c3-a65e-b9e48f2ef0ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5fd7b9ea-cd46-4aa9-886b-e80c0404dffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5fd7b9ea-cd46-4aa9-886b-e80c0404dffe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f5992f5d-373b-475d-9c68-d597bb274fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f5992f5d-373b-475d-9c68-d597bb274fba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e1e883cd-113f-42cc-9a2b-2e9de24b70b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e1e883cd-113f-42cc-9a2b-2e9de24b70b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_25131f43-fa09-4dda-ba49-4a8aee46cbae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_25131f43-fa09-4dda-ba49-4a8aee46cbae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_66c8c939-c310-42dc-8b77-d5c89d83b9ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_66c8c939-c310-42dc-8b77-d5c89d83b9ae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cc2e8560-16a5-43b5-9565-3c65e28a8429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cc2e8560-16a5-43b5-9565-3c65e28a8429" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_29ecbf22-5778-4ef3-a1da-a6ae9c774244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_29ecbf22-5778-4ef3-a1da-a6ae9c774244" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c46688d9-3937-49b0-b9a6-55fa4d0df4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_OperatingLeaseLiability_c46688d9-3937-49b0-b9a6-55fa4d0df4ac" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_7aca2219-23a1-4886-ab68-4848e304362b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_7aca2219-23a1-4886-ab68-4848e304362b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_da16a445-85bf-4795-8012-cd7d3f37f50a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_da16a445-85bf-4795-8012-cd7d3f37f50a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_d2e6c734-bf38-47a0-b107-dd64a51bb60f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_d2e6c734-bf38-47a0-b107-dd64a51bb60f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_c7b4ed3c-bb48-49e4-8095-0d8854253dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_c7b4ed3c-bb48-49e4-8095-0d8854253dc8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_0d6c536c-4669-4d28-9899-3f105ceee314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_0d6c536c-4669-4d28-9899-3f105ceee314" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_c4579ed5-d581-4734-84fe-3e228df0f21a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_c4579ed5-d581-4734-84fe-3e228df0f21a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_9dfb2a2d-42f3-4536-9cc6-2688d7d75a02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_9dfb2a2d-42f3-4536-9cc6-2688d7d75a02" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_0721a426-5242-41b7-838e-cb2200f8bbeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_0721a426-5242-41b7-838e-cb2200f8bbeb" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_b7413681-7d34-4a80-9d54-460d1fa5b6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_b7413681-7d34-4a80-9d54-460d1fa5b6aa" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_dc7bb483-b4bc-4cff-a298-571fd7ceac12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_dc7bb483-b4bc-4cff-a298-571fd7ceac12" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1379465e-2fda-4504-9900-e31f71289ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_dc7bb483-b4bc-4cff-a298-571fd7ceac12" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1379465e-2fda-4504-9900-e31f71289ec6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1379465e-2fda-4504-9900-e31f71289ec6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1379465e-2fda-4504-9900-e31f71289ec6" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1379465e-2fda-4504-9900-e31f71289ec6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_65a647b0-bf79-4db8-a3f4-fae53aea3800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1379465e-2fda-4504-9900-e31f71289ec6" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_65a647b0-bf79-4db8-a3f4-fae53aea3800" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CurrentAndLongTermObligationsMember_9e6a84c0-3488-4e3d-bfea-c22469f30919" xlink:href="amed-20221231.xsd#amed_CurrentAndLongTermObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_65a647b0-bf79-4db8-a3f4-fae53aea3800" xlink:to="loc_amed_CurrentAndLongTermObligationsMember_9e6a84c0-3488-4e3d-bfea-c22469f30919" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails" xlink:type="extended" id="i82f45217fd354d2fa50a17d03600941a_LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9313d631-7060-4f00-9117-9896f16f974e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_6a221ea8-3474-4d5b-9539-d69c1de140d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9313d631-7060-4f00-9117-9896f16f974e" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_6a221ea8-3474-4d5b-9539-d69c1de140d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_59dc40e1-3f53-45aa-a501-7dfbd408bf00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9313d631-7060-4f00-9117-9896f16f974e" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_59dc40e1-3f53-45aa-a501-7dfbd408bf00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_de3d04cd-09a9-4304-8fbc-ccdc31f941cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9313d631-7060-4f00-9117-9896f16f974e" xlink:to="loc_us-gaap_LongTermDebt_de3d04cd-09a9-4304-8fbc-ccdc31f941cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_b4ffa5d9-ec0c-4375-8f85-36b9309209e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9313d631-7060-4f00-9117-9896f16f974e" xlink:to="loc_us-gaap_LongTermDebtCurrent_b4ffa5d9-ec0c-4375-8f85-36b9309209e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_a75b61d0-2c42-4628-ab52-da3bebc8aae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9313d631-7060-4f00-9117-9896f16f974e" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_a75b61d0-2c42-4628-ab52-da3bebc8aae2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6758d166-a199-4bac-9d26-4d61f64e1bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9313d631-7060-4f00-9117-9896f16f974e" xlink:to="loc_us-gaap_DebtInstrumentTable_6758d166-a199-4bac-9d26-4d61f64e1bd7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_00ce0f30-76fe-4af2-99d1-3dd76c1c137a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6758d166-a199-4bac-9d26-4d61f64e1bd7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_00ce0f30-76fe-4af2-99d1-3dd76c1c137a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_00ce0f30-76fe-4af2-99d1-3dd76c1c137a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_00ce0f30-76fe-4af2-99d1-3dd76c1c137a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_00ce0f30-76fe-4af2-99d1-3dd76c1c137a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_23b0c5ce-8672-471e-bb4f-4739c1322a85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_00ce0f30-76fe-4af2-99d1-3dd76c1c137a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_23b0c5ce-8672-471e-bb4f-4739c1322a85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_1edb054b-27e0-430d-bf28-d75cce97ded2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_23b0c5ce-8672-471e-bb4f-4739c1322a85" xlink:to="loc_us-gaap_LoansPayableMember_1edb054b-27e0-430d-bf28-d75cce97ded2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_cc508230-992d-4091-8924-61f626dc4b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_23b0c5ce-8672-471e-bb4f-4739c1322a85" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_cc508230-992d-4091-8924-61f626dc4b1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PromissoryNotesMember_c6c3e81d-ce0f-47f0-8696-cf7ab3f881ed" xlink:href="amed-20221231.xsd#amed_PromissoryNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_23b0c5ce-8672-471e-bb4f-4739c1322a85" xlink:to="loc_amed_PromissoryNotesMember_c6c3e81d-ce0f-47f0-8696-cf7ab3f881ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember_60012caa-c452-4df2-9e68-785a9bacf30c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLeaseObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_23b0c5ce-8672-471e-bb4f-4739c1322a85" xlink:to="loc_us-gaap_CapitalLeaseObligationsMember_60012caa-c452-4df2-9e68-785a9bacf30c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f55f6bb6-affd-4f86-9afd-64bd866428a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6758d166-a199-4bac-9d26-4d61f64e1bd7" xlink:to="loc_us-gaap_DebtInstrumentAxis_f55f6bb6-affd-4f86-9afd-64bd866428a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f55f6bb6-affd-4f86-9afd-64bd866428a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f55f6bb6-affd-4f86-9afd-64bd866428a2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f55f6bb6-affd-4f86-9afd-64bd866428a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e30a9da3-9bbb-4b41-95f4-985330ef3ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f55f6bb6-affd-4f86-9afd-64bd866428a2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e30a9da3-9bbb-4b41-95f4-985330ef3ad8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_8140fe81-8f83-44d7-b75a-55bff96a0d8c" xlink:href="amed-20221231.xsd#amed_FourHundredFiftyMillionTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e30a9da3-9bbb-4b41-95f4-985330ef3ad8" xlink:to="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_8140fe81-8f83-44d7-b75a-55bff96a0d8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_11d0305f-5f2b-4ab2-b839-508d277d9e27" xlink:href="amed-20221231.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e30a9da3-9bbb-4b41-95f4-985330ef3ad8" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_11d0305f-5f2b-4ab2-b839-508d277d9e27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_8878d85e-646f-4b91-bec4-0d7ba0886792" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6758d166-a199-4bac-9d26-4d61f64e1bd7" xlink:to="loc_us-gaap_VariableRateAxis_8878d85e-646f-4b91-bec4-0d7ba0886792" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_8878d85e-646f-4b91-bec4-0d7ba0886792_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_8878d85e-646f-4b91-bec4-0d7ba0886792" xlink:to="loc_us-gaap_VariableRateDomain_8878d85e-646f-4b91-bec4-0d7ba0886792_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_4979406e-2538-4b17-b955-bdc2faaaf43d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_8878d85e-646f-4b91-bec4-0d7ba0886792" xlink:to="loc_us-gaap_VariableRateDomain_4979406e-2538-4b17-b955-bdc2faaaf43d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_d03ece2f-9141-479e-a440-d3e953949590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_4979406e-2538-4b17-b955-bdc2faaaf43d" xlink:to="loc_us-gaap_EurodollarMember_d03ece2f-9141-479e-a440-d3e953949590" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_9cea1043-c759-43d6-a5a7-0e6a5efcd8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_4979406e-2538-4b17-b955-bdc2faaaf43d" xlink:to="loc_us-gaap_BaseRateMember_9cea1043-c759-43d6-a5a7-0e6a5efcd8b0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails" xlink:type="extended" id="i71396591438f49e68dfb83d677053896_LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ed4814ed-e663-4b06-983c-f8cf261f462c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_60c0142e-0ff5-4e23-944c-88eb064e168e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ed4814ed-e663-4b06-983c-f8cf261f462c" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_60c0142e-0ff5-4e23-944c-88eb064e168e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd_4d3644f1-b2d2-4752-8592-e5ac88f80598" xlink:href="amed-20221231.xsd#amed_DebtInstrumentInterestRateatPeriodEnd"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ed4814ed-e663-4b06-983c-f8cf261f462c" xlink:to="loc_amed_DebtInstrumentInterestRateatPeriodEnd_4d3644f1-b2d2-4752-8592-e5ac88f80598" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_71aec0f5-25fa-4b33-ad66-df8bf4dc80cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ed4814ed-e663-4b06-983c-f8cf261f462c" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_71aec0f5-25fa-4b33-ad66-df8bf4dc80cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_3ae89904-bcbc-4e01-a0f8-cad9099b839d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ed4814ed-e663-4b06-983c-f8cf261f462c" xlink:to="loc_us-gaap_DebtInstrumentTable_3ae89904-bcbc-4e01-a0f8-cad9099b839d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ec427fd4-614b-4b3d-8503-57c81022d652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3ae89904-bcbc-4e01-a0f8-cad9099b839d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ec427fd4-614b-4b3d-8503-57c81022d652" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ec427fd4-614b-4b3d-8503-57c81022d652_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ec427fd4-614b-4b3d-8503-57c81022d652" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ec427fd4-614b-4b3d-8503-57c81022d652_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9306b426-99b5-49fd-b5c6-a02717218249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ec427fd4-614b-4b3d-8503-57c81022d652" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9306b426-99b5-49fd-b5c6-a02717218249" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_e125298f-2c1f-48d6-9a07-1dd39d950745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9306b426-99b5-49fd-b5c6-a02717218249" xlink:to="loc_us-gaap_LoansPayableMember_e125298f-2c1f-48d6-9a07-1dd39d950745" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_eeabdbe8-65d0-45cb-a304-d65f4b6f6a17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9306b426-99b5-49fd-b5c6-a02717218249" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_eeabdbe8-65d0-45cb-a304-d65f4b6f6a17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a860b7a6-8110-4680-94b8-64ae51f03062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3ae89904-bcbc-4e01-a0f8-cad9099b839d" xlink:to="loc_us-gaap_DebtInstrumentAxis_a860b7a6-8110-4680-94b8-64ae51f03062" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a860b7a6-8110-4680-94b8-64ae51f03062_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a860b7a6-8110-4680-94b8-64ae51f03062" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a860b7a6-8110-4680-94b8-64ae51f03062_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_47727090-a978-4d87-bdda-ea04431f9531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a860b7a6-8110-4680-94b8-64ae51f03062" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_47727090-a978-4d87-bdda-ea04431f9531" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_c4b0e8e6-fc9d-4d91-921e-8259127df09b" xlink:href="amed-20221231.xsd#amed_FourHundredFiftyMillionTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_47727090-a978-4d87-bdda-ea04431f9531" xlink:to="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_c4b0e8e6-fc9d-4d91-921e-8259127df09b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_c8c6aafc-39db-4371-9569-96a403646fad" xlink:href="amed-20221231.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_47727090-a978-4d87-bdda-ea04431f9531" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_c8c6aafc-39db-4371-9569-96a403646fad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_91ab946d-e56b-47b4-9fe8-b903438ae94c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3ae89904-bcbc-4e01-a0f8-cad9099b839d" xlink:to="loc_us-gaap_VariableRateAxis_91ab946d-e56b-47b4-9fe8-b903438ae94c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_91ab946d-e56b-47b4-9fe8-b903438ae94c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_91ab946d-e56b-47b4-9fe8-b903438ae94c" xlink:to="loc_us-gaap_VariableRateDomain_91ab946d-e56b-47b4-9fe8-b903438ae94c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_8fbf676d-dced-4b66-8d55-98394b2add2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_91ab946d-e56b-47b4-9fe8-b903438ae94c" xlink:to="loc_us-gaap_VariableRateDomain_8fbf676d-dced-4b66-8d55-98394b2add2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_d3c8d588-ff36-46cf-a95e-b8fc7b29a6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_8fbf676d-dced-4b66-8d55-98394b2add2e" xlink:to="loc_us-gaap_EurodollarMember_d3c8d588-ff36-46cf-a95e-b8fc7b29a6ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_1af371b2-b2a1-4c81-a8f3-d11e12df888a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_8fbf676d-dced-4b66-8d55-98394b2add2e" xlink:to="loc_us-gaap_BaseRateMember_1af371b2-b2a1-4c81-a8f3-d11e12df888a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" xlink:type="extended" id="i548fe3c9a57e4aef8ba4194c0f3a99c8_LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_a45a3cf1-8147-489d-9e66-8eac37716439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedLeverageRatio_493c7dfb-5e77-4540-a2ff-ca18cc2388cb" xlink:href="amed-20221231.xsd#amed_ConsolidatedLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_a45a3cf1-8147-489d-9e66-8eac37716439" xlink:to="loc_amed_ConsolidatedLeverageRatio_493c7dfb-5e77-4540-a2ff-ca18cc2388cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_06412e0b-cfa0-4105-b1f7-d20b6f3f51ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_a45a3cf1-8147-489d-9e66-8eac37716439" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_06412e0b-cfa0-4105-b1f7-d20b6f3f51ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_7aa0ee13-3d48-45a5-8e5e-3a9e7e87c2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_a45a3cf1-8147-489d-9e66-8eac37716439" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_7aa0ee13-3d48-45a5-8e5e-3a9e7e87c2f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LetterOfCreditFee_ed2c4c0d-26f2-48df-8286-5f88064f3cc2" xlink:href="amed-20221231.xsd#amed_LetterOfCreditFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_a45a3cf1-8147-489d-9e66-8eac37716439" xlink:to="loc_amed_LetterOfCreditFee_ed2c4c0d-26f2-48df-8286-5f88064f3cc2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_ad0b1873-36f6-45c1-bb0e-adec052b127c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_a45a3cf1-8147-489d-9e66-8eac37716439" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_ad0b1873-36f6-45c1-bb0e-adec052b127c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7671a4d5-415e-49c4-8d9a-9bb8c9ece78b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_ad0b1873-36f6-45c1-bb0e-adec052b127c" xlink:to="loc_us-gaap_DebtInstrumentAxis_7671a4d5-415e-49c4-8d9a-9bb8c9ece78b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7671a4d5-415e-49c4-8d9a-9bb8c9ece78b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7671a4d5-415e-49c4-8d9a-9bb8c9ece78b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7671a4d5-415e-49c4-8d9a-9bb8c9ece78b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_65297769-35f9-4294-a4dc-0283c456e4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7671a4d5-415e-49c4-8d9a-9bb8c9ece78b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_65297769-35f9-4294-a4dc-0283c456e4c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheOneMember_ddb76f77-b455-4483-a042-8a60fc6354ff" xlink:href="amed-20221231.xsd#amed_DebtInstrumentByLeverageRatioTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_65297769-35f9-4294-a4dc-0283c456e4c3" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheOneMember_ddb76f77-b455-4483-a042-8a60fc6354ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_cf1ada97-df3b-4bf2-b0d8-1c1cb027f1eb" xlink:href="amed-20221231.xsd#amed_DebtInstrumentByLeverageRatioTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_65297769-35f9-4294-a4dc-0283c456e4c3" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_cf1ada97-df3b-4bf2-b0d8-1c1cb027f1eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_03d59de4-efef-442a-81a8-9cc7d6a5e18a" xlink:href="amed-20221231.xsd#amed_DebtInstrumentByLeverageRatioTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_65297769-35f9-4294-a4dc-0283c456e4c3" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_03d59de4-efef-442a-81a8-9cc7d6a5e18a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheFourMember_20b9bc75-88b3-4ed3-b081-865f1d9257b3" xlink:href="amed-20221231.xsd#amed_DebtInstrumentByLeverageRatioTrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_65297769-35f9-4294-a4dc-0283c456e4c3" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheFourMember_20b9bc75-88b3-4ed3-b081-865f1d9257b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_ffde19ec-2715-4553-be66-5c79ae7895c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_ad0b1873-36f6-45c1-bb0e-adec052b127c" xlink:to="loc_us-gaap_VariableRateAxis_ffde19ec-2715-4553-be66-5c79ae7895c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_ffde19ec-2715-4553-be66-5c79ae7895c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_ffde19ec-2715-4553-be66-5c79ae7895c3" xlink:to="loc_us-gaap_VariableRateDomain_ffde19ec-2715-4553-be66-5c79ae7895c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_cc04c579-a46e-4049-9bd8-73ef6dc7d1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_ffde19ec-2715-4553-be66-5c79ae7895c3" xlink:to="loc_us-gaap_VariableRateDomain_cc04c579-a46e-4049-9bd8-73ef6dc7d1ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_9cfbff96-a836-40d7-8116-30a584b233b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_cc04c579-a46e-4049-9bd8-73ef6dc7d1ea" xlink:to="loc_us-gaap_BaseRateMember_9cfbff96-a836-40d7-8116-30a584b233b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_65616662-cdb5-481d-9d5d-66b0b3457e56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_cc04c579-a46e-4049-9bd8-73ef6dc7d1ea" xlink:to="loc_us-gaap_EurodollarMember_65616662-cdb5-481d-9d5d-66b0b3457e56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d3c2b4f0-643e-489e-b80a-6156beb5a915" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_ad0b1873-36f6-45c1-bb0e-adec052b127c" xlink:to="loc_srt_RangeAxis_d3c2b4f0-643e-489e-b80a-6156beb5a915" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d3c2b4f0-643e-489e-b80a-6156beb5a915_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d3c2b4f0-643e-489e-b80a-6156beb5a915" xlink:to="loc_srt_RangeMember_d3c2b4f0-643e-489e-b80a-6156beb5a915_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9bb88709-b257-464d-a791-d4815ac2598f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d3c2b4f0-643e-489e-b80a-6156beb5a915" xlink:to="loc_srt_RangeMember_9bb88709-b257-464d-a791-d4815ac2598f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3d1b7cc3-7171-4a67-b849-97889a162da0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9bb88709-b257-464d-a791-d4815ac2598f" xlink:to="loc_srt_MaximumMember_3d1b7cc3-7171-4a67-b849-97889a162da0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9c1e394b-ffd8-49e7-8d12-e7170c810af1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9bb88709-b257-464d-a791-d4815ac2598f" xlink:to="loc_srt_MinimumMember_9c1e394b-ffd8-49e7-8d12-e7170c810af1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#LONGTERMOBLIGATIONSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails" xlink:type="extended" id="i0eba4c4dd48e4a71a7ec9a6ba4a05adf_LONGTERMOBLIGATIONSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4bb99e03-c5c0-4dde-b40c-13d3d9c3abad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4bb99e03-c5c0-4dde-b40c-13d3d9c3abad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1fa8134e-502e-410b-bf6e-6b25f0033cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1fa8134e-502e-410b-bf6e-6b25f0033cbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_3c4650be-4085-4602-ab4b-7acbb4196649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_3c4650be-4085-4602-ab4b-7acbb4196649" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RevolvingCreditFacilityTotal_82732302-6408-4ce0-b654-0b4147a0ac60" xlink:href="amed-20221231.xsd#amed_RevolvingCreditFacilityTotal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_amed_RevolvingCreditFacilityTotal_82732302-6408-4ce0-b654-0b4147a0ac60" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_b291d561-a02b-41d1-ad4a-2de43d961525" xlink:href="amed-20221231.xsd#amed_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_b291d561-a02b-41d1-ad4a-2de43d961525" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_3cff3c92-b2f1-4626-b0c8-9c52383f704b" xlink:href="amed-20221231.xsd#amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_3cff3c92-b2f1-4626-b0c8-9c52383f704b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_ff085890-dabc-45c2-9b48-6d7fb3a1b12a" xlink:href="amed-20221231.xsd#amed_Creditfacilitymaximumallowableconsolidatedleverageratio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_ff085890-dabc-45c2-9b48-6d7fb3a1b12a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_12febea9-5902-4a56-8fca-28b06de19b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_12febea9-5902-4a56-8fca-28b06de19b9b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_2fd41fde-d016-43ae-af7e-c2c625709416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_2fd41fde-d016-43ae-af7e-c2c625709416" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_00769d6c-b535-4cf3-93b1-b80e53364be8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_00769d6c-b535-4cf3-93b1-b80e53364be8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_47b9d6bd-9bae-475c-8734-be368d1af450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_47b9d6bd-9bae-475c-8734-be368d1af450" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_9edcdad5-4e3d-4dba-9de6-8f06d2e62fed" xlink:href="amed-20221231.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_9edcdad5-4e3d-4dba-9de6-8f06d2e62fed" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_5bddae56-787b-4e48-86f1-689301973318" xlink:href="amed-20221231.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_5bddae56-787b-4e48-86f1-689301973318" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_76ae7102-a636-49cf-bcd6-9545ab78e554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_76ae7102-a636-49cf-bcd6-9545ab78e554" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_c1c122d9-475a-4015-a838-e9dc4f860bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_c1c122d9-475a-4015-a838-e9dc4f860bd8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_4ba4c9df-7d90-43ac-90e8-4826676dbf82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_4ba4c9df-7d90-43ac-90e8-4826676dbf82" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalLeverageRatio_0decd79c-b4d4-467d-bfff-d5d581cd427c" xlink:href="amed-20221231.xsd#amed_TotalLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_amed_TotalLeverageRatio_0decd79c-b4d4-467d-bfff-d5d581cd427c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedInterestCoverageRatio_29ae100e-88cd-4666-8bde-86114836d034" xlink:href="amed-20221231.xsd#amed_ConsolidatedInterestCoverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_amed_ConsolidatedInterestCoverageRatio_29ae100e-88cd-4666-8bde-86114836d034" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_2806e7a1-8da5-40a4-98ca-69be45263772" xlink:href="amed-20221231.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_2806e7a1-8da5-40a4-98ca-69be45263772" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_b20f3a8d-b6db-45b9-97bc-53ceb399d875" xlink:href="amed-20221231.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_b20f3a8d-b6db-45b9-97bc-53ceb399d875" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_70268c3b-3e6a-44ad-9478-2649c6351e09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_70268c3b-3e6a-44ad-9478-2649c6351e09" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c2bc8044-1d24-4614-85fe-33de93c9ad09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_c2bc8044-1d24-4614-85fe-33de93c9ad09" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a3dfe25e-66d1-485d-ab20-ae06bfff1299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a3dfe25e-66d1-485d-ab20-ae06bfff1299" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_fa3c171b-92e0-40b3-b1c7-4d20c1cba823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_fa3c171b-92e0-40b3-b1c7-4d20c1cba823" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_18c99947-4a65-4485-900a-2fb301be20c1" xlink:href="amed-20221231.xsd#amed_ProceedsReceivedFromLoanPartyOfSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_18c99947-4a65-4485-900a-2fb301be20c1" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentPeriodicPaymentPercentage_101ad125-60a6-480f-a644-3c23a9924d29" xlink:href="amed-20221231.xsd#amed_DebtInstrumentPeriodicPaymentPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_amed_DebtInstrumentPeriodicPaymentPercentage_101ad125-60a6-480f-a644-3c23a9924d29" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SwingLineFacility_b7580854-089b-42d5-aa02-73cf8912a617" xlink:href="amed-20221231.xsd#amed_SwingLineFacility"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_amed_SwingLineFacility_b7580854-089b-42d5-aa02-73cf8912a617" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LettersofCreditmaximumcommitment_68c53e0a-f809-40a9-bf44-5ee701bac34b" xlink:href="amed-20221231.xsd#amed_LettersofCreditmaximumcommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_amed_LettersofCreditmaximumcommitment_68c53e0a-f809-40a9-bf44-5ee701bac34b" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e3762134-bc23-42a7-a3ad-0228efc353fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_us-gaap_DebtInstrumentTable_e3762134-bc23-42a7-a3ad-0228efc353fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2c3b946d-08e4-41cf-9ac1-054ae3105f94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e3762134-bc23-42a7-a3ad-0228efc353fd" xlink:to="loc_us-gaap_DebtInstrumentAxis_2c3b946d-08e4-41cf-9ac1-054ae3105f94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2c3b946d-08e4-41cf-9ac1-054ae3105f94_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2c3b946d-08e4-41cf-9ac1-054ae3105f94" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2c3b946d-08e4-41cf-9ac1-054ae3105f94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3ef480f8-704e-4e61-bb0d-4d49bc81f513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2c3b946d-08e4-41cf-9ac1-054ae3105f94" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3ef480f8-704e-4e61-bb0d-4d49bc81f513" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_47ebf7c7-e563-465f-b9b3-74a91edc0690" xlink:href="amed-20221231.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3ef480f8-704e-4e61-bb0d-4d49bc81f513" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_47ebf7c7-e563-465f-b9b3-74a91edc0690" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_83c8a36f-9d70-45d6-acb2-a1e0d89f5863" xlink:href="amed-20221231.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3ef480f8-704e-4e61-bb0d-4d49bc81f513" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_83c8a36f-9d70-45d6-acb2-a1e0d89f5863" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_91bea098-0b58-4139-b4d7-34925e2c963d" xlink:href="amed-20221231.xsd#amed_FourHundredFiftyMillionTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3ef480f8-704e-4e61-bb0d-4d49bc81f513" xlink:to="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_91bea098-0b58-4139-b4d7-34925e2c963d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_02943cbb-5e63-4fcc-adbf-a5ba881328fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e3762134-bc23-42a7-a3ad-0228efc353fd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_02943cbb-5e63-4fcc-adbf-a5ba881328fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_02943cbb-5e63-4fcc-adbf-a5ba881328fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_02943cbb-5e63-4fcc-adbf-a5ba881328fc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_02943cbb-5e63-4fcc-adbf-a5ba881328fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f1bf0d6b-6686-4390-bdfb-c38b65817a99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_02943cbb-5e63-4fcc-adbf-a5ba881328fc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f1bf0d6b-6686-4390-bdfb-c38b65817a99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_8d02ed5a-36a0-4c7d-8a26-a655dd60c69e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f1bf0d6b-6686-4390-bdfb-c38b65817a99" xlink:to="loc_us-gaap_LoansPayableMember_8d02ed5a-36a0-4c7d-8a26-a655dd60c69e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_a6313cc2-0ff9-44f0-bc8b-fde1b7a7626c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f1bf0d6b-6686-4390-bdfb-c38b65817a99" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_a6313cc2-0ff9-44f0-bc8b-fde1b7a7626c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_488d394e-9d73-4082-96fa-ea521eead8d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f1bf0d6b-6686-4390-bdfb-c38b65817a99" xlink:to="loc_us-gaap_LineOfCreditMember_488d394e-9d73-4082-96fa-ea521eead8d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SwingLineLoanMember_5bd21dd4-224e-4a2f-9de2-1118b016d3c2" xlink:href="amed-20221231.xsd#amed_SwingLineLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f1bf0d6b-6686-4390-bdfb-c38b65817a99" xlink:to="loc_amed_SwingLineLoanMember_5bd21dd4-224e-4a2f-9de2-1118b016d3c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_4d260e7e-8f87-4d6b-86f7-3171703b71f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f1bf0d6b-6686-4390-bdfb-c38b65817a99" xlink:to="loc_us-gaap_LetterOfCreditMember_4d260e7e-8f87-4d6b-86f7-3171703b71f9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CreditAgreementMember_b55099c8-b3e5-4c34-b724-5381d7c84ab4" xlink:href="amed-20221231.xsd#amed_CreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f1bf0d6b-6686-4390-bdfb-c38b65817a99" xlink:to="loc_amed_CreditAgreementMember_b55099c8-b3e5-4c34-b724-5381d7c84ab4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember_e269aa11-7a68-4715-8bb0-116a071c8e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLeaseObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f1bf0d6b-6686-4390-bdfb-c38b65817a99" xlink:to="loc_us-gaap_CapitalLeaseObligationsMember_e269aa11-7a68-4715-8bb0-116a071c8e5e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedCreditAgreementMember_fe9497dc-838f-4f85-b312-b4fe1527e897" xlink:href="amed-20221231.xsd#amed_AmendedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f1bf0d6b-6686-4390-bdfb-c38b65817a99" xlink:to="loc_amed_AmendedCreditAgreementMember_fe9497dc-838f-4f85-b312-b4fe1527e897" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondAmendedCreditAgreementMember_1b5a3d40-d8a2-4ade-b93c-904cbe05f1de" xlink:href="amed-20221231.xsd#amed_SecondAmendedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f1bf0d6b-6686-4390-bdfb-c38b65817a99" xlink:to="loc_amed_SecondAmendedCreditAgreementMember_1b5a3d40-d8a2-4ade-b93c-904cbe05f1de" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PromissoryNotesMember_b7e4da6a-b5f8-4a7d-8b92-1916cacc1bfd" xlink:href="amed-20221231.xsd#amed_PromissoryNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f1bf0d6b-6686-4390-bdfb-c38b65817a99" xlink:to="loc_amed_PromissoryNotesMember_b7e4da6a-b5f8-4a7d-8b92-1916cacc1bfd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_64a23ea1-2a15-4d3e-adec-0e169bb560f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e3762134-bc23-42a7-a3ad-0228efc353fd" xlink:to="loc_us-gaap_VariableRateAxis_64a23ea1-2a15-4d3e-adec-0e169bb560f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_64a23ea1-2a15-4d3e-adec-0e169bb560f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_64a23ea1-2a15-4d3e-adec-0e169bb560f6" xlink:to="loc_us-gaap_VariableRateDomain_64a23ea1-2a15-4d3e-adec-0e169bb560f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_e7bad463-81de-433a-a84e-c94e82f462d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_64a23ea1-2a15-4d3e-adec-0e169bb560f6" xlink:to="loc_us-gaap_VariableRateDomain_e7bad463-81de-433a-a84e-c94e82f462d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_780478a1-7313-460d-95bf-0d8765cbf740" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_e7bad463-81de-433a-a84e-c94e82f462d8" xlink:to="loc_us-gaap_BaseRateMember_780478a1-7313-460d-95bf-0d8765cbf740" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_321bb5af-b11d-45da-8e81-98853f18b7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_e7bad463-81de-433a-a84e-c94e82f462d8" xlink:to="loc_us-gaap_EurodollarMember_321bb5af-b11d-45da-8e81-98853f18b7e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2f378a43-c5ac-4faa-afea-2ff176b0295d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e3762134-bc23-42a7-a3ad-0228efc353fd" xlink:to="loc_srt_RangeAxis_2f378a43-c5ac-4faa-afea-2ff176b0295d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2f378a43-c5ac-4faa-afea-2ff176b0295d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2f378a43-c5ac-4faa-afea-2ff176b0295d" xlink:to="loc_srt_RangeMember_2f378a43-c5ac-4faa-afea-2ff176b0295d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8886c6b8-6721-4dc0-b842-d471a8c5de45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2f378a43-c5ac-4faa-afea-2ff176b0295d" xlink:to="loc_srt_RangeMember_8886c6b8-6721-4dc0-b842-d471a8c5de45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7b61d258-738d-45b3-b505-8381f3041886" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8886c6b8-6721-4dc0-b842-d471a8c5de45" xlink:to="loc_srt_MinimumMember_7b61d258-738d-45b3-b505-8381f3041886" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_32ef8fb5-a5f3-45c7-b787-719fc39db30f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8886c6b8-6721-4dc0-b842-d471a8c5de45" xlink:to="loc_srt_MaximumMember_32ef8fb5-a5f3-45c7-b787-719fc39db30f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_652dcbc8-719b-484d-9e4f-0eba74f2a9e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e3762134-bc23-42a7-a3ad-0228efc353fd" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_652dcbc8-719b-484d-9e4f-0eba74f2a9e0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_652dcbc8-719b-484d-9e4f-0eba74f2a9e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_652dcbc8-719b-484d-9e4f-0eba74f2a9e0" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_652dcbc8-719b-484d-9e4f-0eba74f2a9e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9fddb8ea-32e9-4366-9be5-d68ee9446905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_652dcbc8-719b-484d-9e4f-0eba74f2a9e0" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9fddb8ea-32e9-4366-9be5-d68ee9446905" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_199f549c-3d45-4128-bbfc-cc2e3e83931a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_9fddb8ea-32e9-4366-9be5-d68ee9446905" xlink:to="loc_us-gaap_SubsequentEventMember_199f549c-3d45-4128-bbfc-cc2e3e83931a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended" id="i8a94289f72e94094b8149ce666a0e01f_INCOMETAXESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_bc44a2c4-9f73-49ee-8ac0-76fe9e8493a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_bc44a2c4-9f73-49ee-8ac0-76fe9e8493a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_1af3ee61-411e-4a3a-848c-72af4169a347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_1af3ee61-411e-4a3a-848c-72af4169a347" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_a9b5c712-73dd-4652-9539-59969f17e7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_us-gaap_IncomeTaxesReceivable_a9b5c712-73dd-4652-9539-59969f17e7b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxCreditsAndAdjustments_d0aa8781-3c1c-436d-9815-2997e12a03d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxCreditsAndAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_us-gaap_IncomeTaxCreditsAndAdjustments_d0aa8781-3c1c-436d-9815-2997e12a03d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecognizedTaxBenefitThatImpactsEffectiveTaxRate_1603d489-9f64-4d0a-a073-852896a17f98" xlink:href="amed-20221231.xsd#amed_RecognizedTaxBenefitThatImpactsEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_amed_RecognizedTaxBenefitThatImpactsEffectiveTaxRate_1603d489-9f64-4d0a-a073-852896a17f98" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_8ce09c4e-854d-4393-9716-d7f9452dad93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_8ce09c4e-854d-4393-9716-d7f9452dad93" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate_da46e427-b843-4b42-b2cf-0884ee5a9a06" xlink:href="amed-20221231.xsd#amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate_da46e427-b843-4b42-b2cf-0884ee5a9a06" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_c56d0784-62f6-49d1-a8bd-dc5d6a37117d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BenefitAsComponentOfInterestExpense_254553aa-c888-420f-aa01-6edde1ef757d" xlink:href="amed-20221231.xsd#amed_BenefitAsComponentOfInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_amed_BenefitAsComponentOfInterestExpense_254553aa-c888-420f-aa01-6edde1ef757d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_9df3732b-c6ed-4236-9e91-93d84fcfb7da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_us-gaap_OperatingLossCarryforwards_9df3732b-c6ed-4236-9e91-93d84fcfb7da" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_83eb62b0-8d93-4466-992b-1ce0f97fa4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_83eb62b0-8d93-4466-992b-1ce0f97fa4b5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_c6539bb8-c1f3-476d-a03e-cbf11cf01245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_c6539bb8-c1f3-476d-a03e-cbf11cf01245" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_1c9fe050-389a-4c33-bd6f-3b1366754baf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_1c9fe050-389a-4c33-bd6f-3b1366754baf" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_28110976-305d-460e-8855-8bc9ad4cfb94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_28110976-305d-460e-8855-8bc9ad4cfb94" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenTaxYear_cf1bd5ce-ae91-4c7c-b109-846cc910be50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenTaxYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_us-gaap_OpenTaxYear_cf1bd5ce-ae91-4c7c-b109-846cc910be50" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_cc8f91d1-ff79-4434-922c-eeb54b495d39" xlink:href="amed-20221231.xsd#amed_CARESActDeferralOfEmployerShareSocialSecurityTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_cc8f91d1-ff79-4434-922c-eeb54b495d39" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct_3943837a-b19f-4594-80e6-75b822f8c9fb" xlink:href="amed-20221231.xsd#amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct_3943837a-b19f-4594-80e6-75b822f8c9fb" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProviderReliefFundAdvance_dc38adcd-b39a-4212-87d2-4ef668466787" xlink:href="amed-20221231.xsd#amed_ProviderReliefFundAdvance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_amed_ProviderReliefFundAdvance_dc38adcd-b39a-4212-87d2-4ef668466787" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c2b446b5-8116-461f-a56d-2045684dd1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c2b446b5-8116-461f-a56d-2045684dd1a2" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_77ca82a2-e676-4a90-91ee-ffd582e26e62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_77ca82a2-e676-4a90-91ee-ffd582e26e62" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_1ab7d868-e9fa-49ca-bc3d-76c40b102a40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_1ab7d868-e9fa-49ca-bc3d-76c40b102a40" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_50b9b6d6-2a30-480c-9663-92b79a7a9f52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_1ab7d868-e9fa-49ca-bc3d-76c40b102a40" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_50b9b6d6-2a30-480c-9663-92b79a7a9f52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_50b9b6d6-2a30-480c-9663-92b79a7a9f52_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_50b9b6d6-2a30-480c-9663-92b79a7a9f52" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_50b9b6d6-2a30-480c-9663-92b79a7a9f52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_55a02d1e-76a9-4287-9e8c-50a585580cde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_50b9b6d6-2a30-480c-9663-92b79a7a9f52" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_55a02d1e-76a9-4287-9e8c-50a585580cde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_62940a2f-feb3-4208-8474-ac65fe252d58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_55a02d1e-76a9-4287-9e8c-50a585580cde" xlink:to="loc_us-gaap_DomesticCountryMember_62940a2f-feb3-4208-8474-ac65fe252d58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_37d6f4ed-14b5-4223-8cb3-dbc84b688892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_55a02d1e-76a9-4287-9e8c-50a585580cde" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_37d6f4ed-14b5-4223-8cb3-dbc84b688892" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_86b659f4-ebc9-4b1f-9002-61d9c72515a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_1ab7d868-e9fa-49ca-bc3d-76c40b102a40" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_86b659f4-ebc9-4b1f-9002-61d9c72515a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_86b659f4-ebc9-4b1f-9002-61d9c72515a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_86b659f4-ebc9-4b1f-9002-61d9c72515a6" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_86b659f4-ebc9-4b1f-9002-61d9c72515a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_bf6cbe80-4837-4aaa-9f04-7b45c4463e20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_86b659f4-ebc9-4b1f-9002-61d9c72515a6" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_bf6cbe80-4837-4aaa-9f04-7b45c4463e20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AlternativeMinimumTaxCreditMember_e98f4ce0-96bc-461b-801d-9e182b26ada8" xlink:href="amed-20221231.xsd#amed_AlternativeMinimumTaxCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_bf6cbe80-4837-4aaa-9f04-7b45c4463e20" xlink:to="loc_amed_AlternativeMinimumTaxCreditMember_e98f4ce0-96bc-461b-801d-9e182b26ada8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StateTaxCreditMember_a5b80592-39b9-49f1-97d9-168717fa115b" xlink:href="amed-20221231.xsd#amed_StateTaxCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_bf6cbe80-4837-4aaa-9f04-7b45c4463e20" xlink:to="loc_amed_StateTaxCreditMember_a5b80592-39b9-49f1-97d9-168717fa115b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnrecognizedTaxBenefitsAxis_b1e17b83-ff23-4226-85e7-a38e48c67716" xlink:href="amed-20221231.xsd#amed_UnrecognizedTaxBenefitsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_1ab7d868-e9fa-49ca-bc3d-76c40b102a40" xlink:to="loc_amed_UnrecognizedTaxBenefitsAxis_b1e17b83-ff23-4226-85e7-a38e48c67716" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnrecognizedTaxBenefitsDomain_b1e17b83-ff23-4226-85e7-a38e48c67716_default" xlink:href="amed-20221231.xsd#amed_UnrecognizedTaxBenefitsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_UnrecognizedTaxBenefitsAxis_b1e17b83-ff23-4226-85e7-a38e48c67716" xlink:to="loc_amed_UnrecognizedTaxBenefitsDomain_b1e17b83-ff23-4226-85e7-a38e48c67716_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnrecognizedTaxBenefitsDomain_ae267ae4-4e5e-4b07-9d8d-8bfe1ed7f3e4" xlink:href="amed-20221231.xsd#amed_UnrecognizedTaxBenefitsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_UnrecognizedTaxBenefitsAxis_b1e17b83-ff23-4226-85e7-a38e48c67716" xlink:to="loc_amed_UnrecognizedTaxBenefitsDomain_ae267ae4-4e5e-4b07-9d8d-8bfe1ed7f3e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetOperatingLossMember_d4acbc0f-b184-40a5-942d-c46e01a42f8a" xlink:href="amed-20221231.xsd#amed_NetOperatingLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_UnrecognizedTaxBenefitsDomain_ae267ae4-4e5e-4b07-9d8d-8bfe1ed7f3e4" xlink:to="loc_amed_NetOperatingLossMember_d4acbc0f-b184-40a5-942d-c46e01a42f8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TaxCreditCarryforwardMember_c4b710be-bc63-4003-a14e-2bad61af75e2" xlink:href="amed-20221231.xsd#amed_TaxCreditCarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_UnrecognizedTaxBenefitsDomain_ae267ae4-4e5e-4b07-9d8d-8bfe1ed7f3e4" xlink:to="loc_amed_TaxCreditCarryforwardMember_c4b710be-bc63-4003-a14e-2bad61af75e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a0d9b3b0-02c9-4515-ac5a-c702b50a385f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_1ab7d868-e9fa-49ca-bc3d-76c40b102a40" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a0d9b3b0-02c9-4515-ac5a-c702b50a385f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a0d9b3b0-02c9-4515-ac5a-c702b50a385f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a0d9b3b0-02c9-4515-ac5a-c702b50a385f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a0d9b3b0-02c9-4515-ac5a-c702b50a385f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2341c1a9-5098-45e4-9248-ad39b097f7ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a0d9b3b0-02c9-4515-ac5a-c702b50a385f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2341c1a9-5098-45e4-9248-ad39b097f7ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OtherLongTermObligationsMember_3d91ac90-15db-46bc-9e85-c86544e587ac" xlink:href="amed-20221231.xsd#amed_OtherLongTermObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2341c1a9-5098-45e4-9248-ad39b097f7ac" xlink:to="loc_amed_OtherLongTermObligationsMember_3d91ac90-15db-46bc-9e85-c86544e587ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_afa53b96-d3c8-496c-a8b9-d62a90d2f3fb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_1ab7d868-e9fa-49ca-bc3d-76c40b102a40" xlink:to="loc_srt_RangeAxis_afa53b96-d3c8-496c-a8b9-d62a90d2f3fb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_afa53b96-d3c8-496c-a8b9-d62a90d2f3fb_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_afa53b96-d3c8-496c-a8b9-d62a90d2f3fb" xlink:to="loc_srt_RangeMember_afa53b96-d3c8-496c-a8b9-d62a90d2f3fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_01a9372e-2eb3-45de-9426-08a2dc7b4e57" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_afa53b96-d3c8-496c-a8b9-d62a90d2f3fb" xlink:to="loc_srt_RangeMember_01a9372e-2eb3-45de-9426-08a2dc7b4e57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8fbbfb23-9bb9-445b-b124-c49478df62e7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_01a9372e-2eb3-45de-9426-08a2dc7b4e57" xlink:to="loc_srt_MinimumMember_8fbbfb23-9bb9-445b-b124-c49478df62e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9f2d277e-1506-4395-ab20-01ac3b131243" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_01a9372e-2eb3-45de-9426-08a2dc7b4e57" xlink:to="loc_srt_MaximumMember_9f2d277e-1506-4395-ab20-01ac3b131243" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d1ad3c66-baf6-423b-99ce-e7cee95adc62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_1ab7d868-e9fa-49ca-bc3d-76c40b102a40" xlink:to="loc_us-gaap_AwardTypeAxis_d1ad3c66-baf6-423b-99ce-e7cee95adc62" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d1ad3c66-baf6-423b-99ce-e7cee95adc62_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d1ad3c66-baf6-423b-99ce-e7cee95adc62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d1ad3c66-baf6-423b-99ce-e7cee95adc62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21f6f70f-3f8f-407b-92f1-d3c67f7067aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d1ad3c66-baf6-423b-99ce-e7cee95adc62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21f6f70f-3f8f-407b-92f1-d3c67f7067aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExecutiveStockOptionExerciseMember_746812f3-ae3f-4f56-ab91-b127ed3f2f9e" xlink:href="amed-20221231.xsd#amed_ExecutiveStockOptionExerciseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21f6f70f-3f8f-407b-92f1-d3c67f7067aa" xlink:to="loc_amed_ExecutiveStockOptionExerciseMember_746812f3-ae3f-4f56-ab91-b127ed3f2f9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeOfIncomeTaxDeferralAxis_52ad63da-68cf-4a18-bb84-a353b32fae1a" xlink:href="amed-20221231.xsd#amed_TypeOfIncomeTaxDeferralAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_1ab7d868-e9fa-49ca-bc3d-76c40b102a40" xlink:to="loc_amed_TypeOfIncomeTaxDeferralAxis_52ad63da-68cf-4a18-bb84-a353b32fae1a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeOfIncomeTaxDeferralDomain_52ad63da-68cf-4a18-bb84-a353b32fae1a_default" xlink:href="amed-20221231.xsd#amed_TypeOfIncomeTaxDeferralDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_TypeOfIncomeTaxDeferralAxis_52ad63da-68cf-4a18-bb84-a353b32fae1a" xlink:to="loc_amed_TypeOfIncomeTaxDeferralDomain_52ad63da-68cf-4a18-bb84-a353b32fae1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeOfIncomeTaxDeferralDomain_9fa9a8b5-c1a4-46b7-9093-c56fc349d30f" xlink:href="amed-20221231.xsd#amed_TypeOfIncomeTaxDeferralDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_TypeOfIncomeTaxDeferralAxis_52ad63da-68cf-4a18-bb84-a353b32fae1a" xlink:to="loc_amed_TypeOfIncomeTaxDeferralDomain_9fa9a8b5-c1a4-46b7-9093-c56fc349d30f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SocialSecurityTaxMember_ef89abfa-11d1-4d24-8565-7788181e1c68" xlink:href="amed-20221231.xsd#amed_SocialSecurityTaxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_TypeOfIncomeTaxDeferralDomain_9fa9a8b5-c1a4-46b7-9093-c56fc349d30f" xlink:to="loc_amed_SocialSecurityTaxMember_ef89abfa-11d1-4d24-8565-7788181e1c68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_26ef8de1-b7d8-4131-b3b5-68f19e3956f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_1ab7d868-e9fa-49ca-bc3d-76c40b102a40" xlink:to="loc_us-gaap_TaxPeriodAxis_26ef8de1-b7d8-4131-b3b5-68f19e3956f7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_26ef8de1-b7d8-4131-b3b5-68f19e3956f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_26ef8de1-b7d8-4131-b3b5-68f19e3956f7" xlink:to="loc_us-gaap_TaxPeriodDomain_26ef8de1-b7d8-4131-b3b5-68f19e3956f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_5a27dcdb-0fbc-45e6-851c-a5f971971e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_26ef8de1-b7d8-4131-b3b5-68f19e3956f7" xlink:to="loc_us-gaap_TaxPeriodDomain_5a27dcdb-0fbc-45e6-851c-a5f971971e45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2037ExpirationMember_bec128ba-1bda-4ba3-afc8-bd1ffb245978" xlink:href="amed-20221231.xsd#amed_A2037ExpirationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_5a27dcdb-0fbc-45e6-851c-a5f971971e45" xlink:to="loc_amed_A2037ExpirationMember_bec128ba-1bda-4ba3-afc8-bd1ffb245978" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis_5e30f6f1-c7be-4ad2-b834-f1fa27e86ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_1ab7d868-e9fa-49ca-bc3d-76c40b102a40" xlink:to="loc_us-gaap_UnusualOrInfrequentItemAxis_5e30f6f1-c7be-4ad2-b834-f1fa27e86ad6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_5e30f6f1-c7be-4ad2-b834-f1fa27e86ad6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_5e30f6f1-c7be-4ad2-b834-f1fa27e86ad6" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_5e30f6f1-c7be-4ad2-b834-f1fa27e86ad6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_51083f8e-d8ed-474b-97ef-a3d58a6bf8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_5e30f6f1-c7be-4ad2-b834-f1fa27e86ad6" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_51083f8e-d8ed-474b-97ef-a3d58a6bf8d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19DeferralOfSocialSecurityTaxesMember_8777f3a0-3af9-4c00-844f-bc213b50b738" xlink:href="amed-20221231.xsd#amed_COVID19DeferralOfSocialSecurityTaxesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain_51083f8e-d8ed-474b-97ef-a3d58a6bf8d6" xlink:to="loc_amed_COVID19DeferralOfSocialSecurityTaxesMember_8777f3a0-3af9-4c00-844f-bc213b50b738" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="extended" id="i5e6b2289ec6d49a494345057f8abd4a4_INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_73b8045e-f11c-42e4-93e0-ba1007854fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_1c6c2fc3-f273-4394-a8d8-8eebf336c0f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_73b8045e-f11c-42e4-93e0-ba1007854fba" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_1c6c2fc3-f273-4394-a8d8-8eebf336c0f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended" id="i7365d91f23aa4cb5bd83ef3bfa5aaf68_CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e689648e-65e5-441d-a814-df169fce3d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e689648e-65e5-441d-a814-df169fce3d7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_4fae7b9a-5d9e-41ca-901b-04a5196aa75e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_4fae7b9a-5d9e-41ca-901b-04a5196aa75e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_f1684184-9bf8-44a7-b14e-ee9e4804a898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_f1684184-9bf8-44a7-b14e-ee9e4804a898" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a08e4b36-18c9-4461-94cb-77ddba014f33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a08e4b36-18c9-4461-94cb-77ddba014f33" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_cc4ca1c6-4c47-4773-9ef1-d7efd18c1bca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_CommonStockSharesIssued_cc4ca1c6-4c47-4773-9ef1-d7efd18c1bca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9bd505ce-2888-46ad-8ca8-b42589c175df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9bd505ce-2888-46ad-8ca8-b42589c175df" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_d83bbe87-c2fd-4a93-a2ff-154d46846a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_PreferredStockSharesIssued_d83bbe87-c2fd-4a93-a2ff-154d46846a9d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Percentageofownershipinsubsidiaries_81069455-bad4-4eb3-a8f5-2771085eace4" xlink:href="amed-20221231.xsd#amed_Percentageofownershipinsubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_amed_Percentageofownershipinsubsidiaries_81069455-bad4-4eb3-a8f5-2771085eace4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_fa80e1d1-9c4e-46c4-8d1b-0b4a56b8bde7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_fa80e1d1-9c4e-46c4-8d1b-0b4a56b8bde7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5f3d9569-bff4-44ff-880a-4b88e884682c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5f3d9569-bff4-44ff-880a-4b88e884682c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Fairvalueofshareofcommonstockpercentage_dbedf5d5-717f-4817-9e53-b06918e34391" xlink:href="amed-20221231.xsd#amed_Fairvalueofshareofcommonstockpercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_amed_Fairvalueofshareofcommonstockpercentage_dbedf5d5-717f-4817-9e53-b06918e34391" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries_5ccc2d55-0cf9-415e-a952-fa525543004e" xlink:href="amed-20221231.xsd#amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries_5ccc2d55-0cf9-415e-a952-fa525543004e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_d31c552e-45c0-4221-9fac-7e087424bfee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_d31c552e-45c0-4221-9fac-7e087424bfee" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_48d4a6e6-a6c3-4253-9916-731b7f921181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_48d4a6e6-a6c3-4253-9916-731b7f921181" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CommonStockSharesAvailableForIssuanceToEmployeeStockPurchasePlan_a0540bcc-fbaf-47f1-a58f-cc61062e77d5" xlink:href="amed-20221231.xsd#amed_CommonStockSharesAvailableForIssuanceToEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_amed_CommonStockSharesAvailableForIssuanceToEmployeeStockPurchasePlan_a0540bcc-fbaf-47f1-a58f-cc61062e77d5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_c9aa2d7e-848f-4539-a946-77cf40eb94e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_c9aa2d7e-848f-4539-a946-77cf40eb94e3" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_fa144c68-aa49-4135-9f1f-0e453c4b86e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_fa144c68-aa49-4135-9f1f-0e453c4b86e1" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4b135fb4-00a5-42bb-b304-43737fd8101e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4b135fb4-00a5-42bb-b304-43737fd8101e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_9ffc5f22-2f18-4859-9283-eb65c8d450d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_9ffc5f22-2f18-4859-9283-eb65c8d450d5" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_de0bb397-81f9-4bbb-b048-2cb1b7bc2c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_de0bb397-81f9-4bbb-b048-2cb1b7bc2c3c" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f268f278-3bfb-4b60-a488-d4cdf4fae3df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f268f278-3bfb-4b60-a488-d4cdf4fae3df" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ea3f5038-8a29-415e-9e27-4e863c592835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ea3f5038-8a29-415e-9e27-4e863c592835" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_502444df-740a-40ec-921f-68a679489c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_502444df-740a-40ec-921f-68a679489c9c" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_722ae895-5f5e-4196-8102-7f9acc7797f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_722ae895-5f5e-4196-8102-7f9acc7797f0" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7091a529-67b3-4785-971d-935f3a37f5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7091a529-67b3-4785-971d-935f3a37f5b1" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f7cc88d2-c655-4ed0-84b0-66003c4bdd08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f7cc88d2-c655-4ed0-84b0-66003c4bdd08" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Performancebasedawardtargetshareamount_93fdb2a4-02e5-4d3f-8373-d95938d25c40" xlink:href="amed-20221231.xsd#amed_Performancebasedawardtargetshareamount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_amed_Performancebasedawardtargetshareamount_93fdb2a4-02e5-4d3f-8373-d95938d25c40" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan_a636c513-28f4-4b41-96c4-44aea22894eb" xlink:href="amed-20221231.xsd#amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan_a636c513-28f4-4b41-96c4-44aea22894eb" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7b25635b-0b89-427c-a619-d691ba6440fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7b25635b-0b89-427c-a619-d691ba6440fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8a2c3755-5580-42fa-8118-04ccfe155ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7b25635b-0b89-427c-a619-d691ba6440fc" xlink:to="loc_us-gaap_AwardTypeAxis_8a2c3755-5580-42fa-8118-04ccfe155ccd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a2c3755-5580-42fa-8118-04ccfe155ccd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8a2c3755-5580-42fa-8118-04ccfe155ccd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a2c3755-5580-42fa-8118-04ccfe155ccd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a76c229-4727-4fb1-963b-6fc1b5bbf44f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8a2c3755-5580-42fa-8118-04ccfe155ccd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a76c229-4727-4fb1-963b-6fc1b5bbf44f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareBasedAwardsMember_5ced76b1-bed8-4bfc-9ed0-826aa26221c7" xlink:href="amed-20221231.xsd#amed_ShareBasedAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a76c229-4727-4fb1-963b-6fc1b5bbf44f" xlink:to="loc_amed_ShareBasedAwardsMember_5ced76b1-bed8-4bfc-9ed0-826aa26221c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember_6fa27546-f4da-46b3-95fd-3b5db0439a40" xlink:href="amed-20221231.xsd#amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a76c229-4727-4fb1-963b-6fc1b5bbf44f" xlink:to="loc_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember_6fa27546-f4da-46b3-95fd-3b5db0439a40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9e06ea51-4dc4-452c-982f-b962a6b086fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a76c229-4727-4fb1-963b-6fc1b5bbf44f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9e06ea51-4dc4-452c-982f-b962a6b086fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockUnitsMember_936ab452-4477-4b7c-b967-3f7107687565" xlink:href="amed-20221231.xsd#amed_NonVestedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a76c229-4727-4fb1-963b-6fc1b5bbf44f" xlink:to="loc_amed_NonVestedStockUnitsMember_936ab452-4477-4b7c-b967-3f7107687565" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockUnitsServiceMember_efa2cab9-c9ea-4d16-82a0-eae651ddcf00" xlink:href="amed-20221231.xsd#amed_NonVestedStockUnitsServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_NonVestedStockUnitsMember_936ab452-4477-4b7c-b967-3f7107687565" xlink:to="loc_amed_NonVestedStockUnitsServiceMember_efa2cab9-c9ea-4d16-82a0-eae651ddcf00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember_49f74a59-4d15-4f85-a8cb-4e6a4c311030" xlink:href="amed-20221231.xsd#amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_NonVestedStockUnitsMember_936ab452-4477-4b7c-b967-3f7107687565" xlink:to="loc_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember_49f74a59-4d15-4f85-a8cb-4e6a4c311030" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fa77b6ca-e04c-4c32-8e80-aa8cf5616220" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7b25635b-0b89-427c-a619-d691ba6440fc" xlink:to="loc_srt_RangeAxis_fa77b6ca-e04c-4c32-8e80-aa8cf5616220" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fa77b6ca-e04c-4c32-8e80-aa8cf5616220_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fa77b6ca-e04c-4c32-8e80-aa8cf5616220" xlink:to="loc_srt_RangeMember_fa77b6ca-e04c-4c32-8e80-aa8cf5616220_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9d5c70c0-c92e-4687-a32e-2af384302697" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fa77b6ca-e04c-4c32-8e80-aa8cf5616220" xlink:to="loc_srt_RangeMember_9d5c70c0-c92e-4687-a32e-2af384302697" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b7bb8e4b-8f32-433a-a412-4b81c20dd851" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9d5c70c0-c92e-4687-a32e-2af384302697" xlink:to="loc_srt_MaximumMember_b7bb8e4b-8f32-433a-a412-4b81c20dd851" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0355f0a9-b30f-4053-ab14-bfac02c2ddbe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9d5c70c0-c92e-4687-a32e-2af384302697" xlink:to="loc_srt_MinimumMember_0355f0a9-b30f-4053-ab14-bfac02c2ddbe" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails" xlink:type="extended" id="id0c23fa662134cce9b41e54901139de6_CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8146ab39-f55c-438d-bff1-661442f6b085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_a89b334a-895d-496a-9bf9-c8f365a3fc3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8146ab39-f55c-438d-bff1-661442f6b085" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_a89b334a-895d-496a-9bf9-c8f365a3fc3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_1ee85fff-2b1e-4e8c-ae70-acf83761df1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8146ab39-f55c-438d-bff1-661442f6b085" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_1ee85fff-2b1e-4e8c-ae70-acf83761df1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d5eb839d-0289-46ee-9d22-f62221e66f37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8146ab39-f55c-438d-bff1-661442f6b085" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d5eb839d-0289-46ee-9d22-f62221e66f37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_3557bf35-7802-45d9-a063-7e16e01d0f08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8146ab39-f55c-438d-bff1-661442f6b085" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_3557bf35-7802-45d9-a063-7e16e01d0f08" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_d1c0ad8b-1a9b-437c-9f7d-b826a2bef43e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8146ab39-f55c-438d-bff1-661442f6b085" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_d1c0ad8b-1a9b-437c-9f7d-b826a2bef43e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_48418ffb-941f-4a23-9171-1b6af6dd86e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8146ab39-f55c-438d-bff1-661442f6b085" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_48418ffb-941f-4a23-9171-1b6af6dd86e1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ab2afc31-2408-4658-a15a-44b619fda4b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8146ab39-f55c-438d-bff1-661442f6b085" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ab2afc31-2408-4658-a15a-44b619fda4b6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue_fa4d46df-4eae-4aaf-bf03-57ad78adc107" xlink:href="amed-20221231.xsd#amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8146ab39-f55c-438d-bff1-661442f6b085" xlink:to="loc_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue_fa4d46df-4eae-4aaf-bf03-57ad78adc107" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_63bad52e-96b5-4018-93c6-ef8e0ec1d491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8146ab39-f55c-438d-bff1-661442f6b085" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_63bad52e-96b5-4018-93c6-ef8e0ec1d491" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e1197293-e28c-4986-b026-835bc39f5ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8146ab39-f55c-438d-bff1-661442f6b085" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e1197293-e28c-4986-b026-835bc39f5ea4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_59e8e318-e9f1-4494-a23a-60b32edf87c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e1197293-e28c-4986-b026-835bc39f5ea4" xlink:to="loc_us-gaap_AwardTypeAxis_59e8e318-e9f1-4494-a23a-60b32edf87c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59e8e318-e9f1-4494-a23a-60b32edf87c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_59e8e318-e9f1-4494-a23a-60b32edf87c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_59e8e318-e9f1-4494-a23a-60b32edf87c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e8a0ab12-63d8-4e9a-8539-9dc126c0c0ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_59e8e318-e9f1-4494-a23a-60b32edf87c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e8a0ab12-63d8-4e9a-8539-9dc126c0c0ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_cb4bfa03-6b0c-46df-a151-4c02911f78d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e8a0ab12-63d8-4e9a-8539-9dc126c0c0ea" xlink:to="loc_us-gaap_EmployeeStockOptionMember_cb4bfa03-6b0c-46df-a151-4c02911f78d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9d1ff1b3-c127-4e81-9596-5ffd0437ecca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e1197293-e28c-4986-b026-835bc39f5ea4" xlink:to="loc_srt_RangeAxis_9d1ff1b3-c127-4e81-9596-5ffd0437ecca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9d1ff1b3-c127-4e81-9596-5ffd0437ecca_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9d1ff1b3-c127-4e81-9596-5ffd0437ecca" xlink:to="loc_srt_RangeMember_9d1ff1b3-c127-4e81-9596-5ffd0437ecca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_04baa939-476f-4414-91d4-d3f276391e27" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9d1ff1b3-c127-4e81-9596-5ffd0437ecca" xlink:to="loc_srt_RangeMember_04baa939-476f-4414-91d4-d3f276391e27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_88756eff-8883-44dd-9a63-cf5c82482b90" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_04baa939-476f-4414-91d4-d3f276391e27" xlink:to="loc_srt_MinimumMember_88756eff-8883-44dd-9a63-cf5c82482b90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7ea397c1-bab1-450f-bbb5-1d1995eb7c03" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_04baa939-476f-4414-91d4-d3f276391e27" xlink:to="loc_srt_MaximumMember_7ea397c1-bab1-450f-bbb5-1d1995eb7c03" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails" xlink:type="extended" id="i6510429e9bbd4e0bb4c5c13a1bb1a5e7_CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_395f0b2d-14c1-4294-898d-daf0a1bc59fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_55c5c548-1cda-404a-8359-b23405fcf1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_395f0b2d-14c1-4294-898d-daf0a1bc59fe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_55c5c548-1cda-404a-8359-b23405fcf1e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SurrenderedSharesInShares_693b64b5-6bf7-4782-bf0c-aec50634062b" xlink:href="amed-20221231.xsd#amed_SurrenderedSharesInShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_395f0b2d-14c1-4294-898d-daf0a1bc59fe" xlink:to="loc_amed_SurrenderedSharesInShares_693b64b5-6bf7-4782-bf0c-aec50634062b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e31eb234-f03a-4350-9b5b-4c0381d7253e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_395f0b2d-14c1-4294-898d-daf0a1bc59fe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e31eb234-f03a-4350-9b5b-4c0381d7253e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_f5f00415-ef0f-42d6-9753-fc84c1d8f28d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_395f0b2d-14c1-4294-898d-daf0a1bc59fe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_f5f00415-ef0f-42d6-9753-fc84c1d8f28d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1daae67f-1ee6-4430-b54e-4c5cefa40cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_395f0b2d-14c1-4294-898d-daf0a1bc59fe" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1daae67f-1ee6-4430-b54e-4c5cefa40cb2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c6501271-d6c5-489d-86ac-4399cd51df2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_395f0b2d-14c1-4294-898d-daf0a1bc59fe" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c6501271-d6c5-489d-86ac-4399cd51df2f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b51970f9-c829-4133-a485-2eff60af6664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c6501271-d6c5-489d-86ac-4399cd51df2f" xlink:to="loc_us-gaap_AwardTypeAxis_b51970f9-c829-4133-a485-2eff60af6664" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b51970f9-c829-4133-a485-2eff60af6664_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b51970f9-c829-4133-a485-2eff60af6664" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b51970f9-c829-4133-a485-2eff60af6664_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03ad957d-eb2b-41b3-839f-e6fa95896d44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b51970f9-c829-4133-a485-2eff60af6664" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03ad957d-eb2b-41b3-839f-e6fa95896d44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExecutiveStockOptionExerciseMember_89abab85-2718-401d-85cf-c2633a4ebdf4" xlink:href="amed-20221231.xsd#amed_ExecutiveStockOptionExerciseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03ad957d-eb2b-41b3-839f-e6fa95896d44" xlink:to="loc_amed_ExecutiveStockOptionExerciseMember_89abab85-2718-401d-85cf-c2633a4ebdf4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails" xlink:type="extended" id="ic42c575837c4465984be4b74461b6531_CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5f9f78e-2675-482c-8f76-e82a712a9e52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0fd3be4-9404-4329-9156-5ee9e310543b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5f9f78e-2675-482c-8f76-e82a712a9e52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0fd3be4-9404-4329-9156-5ee9e310543b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a24210d7-2f2c-4019-b8b2-2fb4cf540699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0fd3be4-9404-4329-9156-5ee9e310543b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a24210d7-2f2c-4019-b8b2-2fb4cf540699" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_64a4ee52-badb-4572-8981-8fa3948c7048" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0fd3be4-9404-4329-9156-5ee9e310543b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_64a4ee52-badb-4572-8981-8fa3948c7048" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_dc57d5eb-aaef-4282-a1d5-d0f4bd6cc9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0fd3be4-9404-4329-9156-5ee9e310543b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_dc57d5eb-aaef-4282-a1d5-d0f4bd6cc9c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6fbbb719-a47e-4dd3-8a01-a0664cd1e60f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0fd3be4-9404-4329-9156-5ee9e310543b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6fbbb719-a47e-4dd3-8a01-a0664cd1e60f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0ec39b73-10e7-4b7c-8cab-f225ff0c231e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d506dc55-6fe1-4a7d-9eab-b8cc9e9234dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5f9f78e-2675-482c-8f76-e82a712a9e52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d506dc55-6fe1-4a7d-9eab-b8cc9e9234dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7c4ae4ae-6c23-433d-b8d9-32314784a217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d506dc55-6fe1-4a7d-9eab-b8cc9e9234dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7c4ae4ae-6c23-433d-b8d9-32314784a217" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e770641b-44ee-4e53-b993-39b36f6e72fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d506dc55-6fe1-4a7d-9eab-b8cc9e9234dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e770641b-44ee-4e53-b993-39b36f6e72fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f1527b70-21e7-40e6-90c1-1141e028d993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d506dc55-6fe1-4a7d-9eab-b8cc9e9234dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f1527b70-21e7-40e6-90c1-1141e028d993" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5e40519e-3ce0-498b-ad1f-6f9438f9a393" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d506dc55-6fe1-4a7d-9eab-b8cc9e9234dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5e40519e-3ce0-498b-ad1f-6f9438f9a393" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bd06d434-f93c-4331-92dd-f27678fc8c42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0bf1d6ac-94c1-4029-9ec3-92b0f9b835c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5f9f78e-2675-482c-8f76-e82a712a9e52" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0bf1d6ac-94c1-4029-9ec3-92b0f9b835c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6a0ff42d-ab7d-4179-b9b2-b94bace23025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0bf1d6ac-94c1-4029-9ec3-92b0f9b835c3" xlink:to="loc_us-gaap_AwardTypeAxis_6a0ff42d-ab7d-4179-b9b2-b94bace23025" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a0ff42d-ab7d-4179-b9b2-b94bace23025_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6a0ff42d-ab7d-4179-b9b2-b94bace23025" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a0ff42d-ab7d-4179-b9b2-b94bace23025_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c9aea28-61d7-4b3d-af33-f8596ba92cad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6a0ff42d-ab7d-4179-b9b2-b94bace23025" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c9aea28-61d7-4b3d-af33-f8596ba92cad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockUnitsMember_d512ff0c-f6a1-452e-a3e5-064b62eb0aed" xlink:href="amed-20221231.xsd#amed_NonVestedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c9aea28-61d7-4b3d-af33-f8596ba92cad" xlink:to="loc_amed_NonVestedStockUnitsMember_d512ff0c-f6a1-452e-a3e5-064b62eb0aed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_af11a312-5b95-4a3b-954c-85ed60ea3099" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0bf1d6ac-94c1-4029-9ec3-92b0f9b835c3" xlink:to="loc_srt_RangeAxis_af11a312-5b95-4a3b-954c-85ed60ea3099" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_af11a312-5b95-4a3b-954c-85ed60ea3099_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_af11a312-5b95-4a3b-954c-85ed60ea3099" xlink:to="loc_srt_RangeMember_af11a312-5b95-4a3b-954c-85ed60ea3099_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9939232f-c82b-4b06-8978-d1fdd010f755" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_af11a312-5b95-4a3b-954c-85ed60ea3099" xlink:to="loc_srt_RangeMember_9939232f-c82b-4b06-8978-d1fdd010f755" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_80250be7-2d3e-467d-8724-994ee39ae829" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9939232f-c82b-4b06-8978-d1fdd010f755" xlink:to="loc_srt_MinimumMember_80250be7-2d3e-467d-8724-994ee39ae829" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails" xlink:type="extended" id="i164806b3301443a3bde17abe1c3ef8f6_CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad9c26db-9e0b-480e-b706-2977ef404104" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_81197340-fd2d-4402-a106-278c64ef9e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad9c26db-9e0b-480e-b706-2977ef404104" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_81197340-fd2d-4402-a106-278c64ef9e6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9e3f089b-c308-4378-9904-33d9ac5aec50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_81197340-fd2d-4402-a106-278c64ef9e6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9e3f089b-c308-4378-9904-33d9ac5aec50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_bbdb4d49-47af-479e-af23-b68d11b6c709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_81197340-fd2d-4402-a106-278c64ef9e6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_bbdb4d49-47af-479e-af23-b68d11b6c709" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d451ac36-8171-4628-a8ad-4d91b0103eef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_81197340-fd2d-4402-a106-278c64ef9e6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d451ac36-8171-4628-a8ad-4d91b0103eef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_725a1feb-85d8-4322-b405-0975e23c3d34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_81197340-fd2d-4402-a106-278c64ef9e6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_725a1feb-85d8-4322-b405-0975e23c3d34" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6414e479-e5da-4380-b1b0-c678d3988ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_bd6bc0d8-0b0d-4e9c-87e5-066d6ec4ffae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad9c26db-9e0b-480e-b706-2977ef404104" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_bd6bc0d8-0b0d-4e9c-87e5-066d6ec4ffae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_456c87a6-8560-4940-b855-ed23a204c0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_bd6bc0d8-0b0d-4e9c-87e5-066d6ec4ffae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_456c87a6-8560-4940-b855-ed23a204c0bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_58aa29e1-4a67-4613-a106-97191a7ef22f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_bd6bc0d8-0b0d-4e9c-87e5-066d6ec4ffae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_58aa29e1-4a67-4613-a106-97191a7ef22f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a6305ae3-e528-483c-8f11-b52b0cce800d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_bd6bc0d8-0b0d-4e9c-87e5-066d6ec4ffae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a6305ae3-e528-483c-8f11-b52b0cce800d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_bac65403-e90b-43de-9aad-594c5f8e8b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_bd6bc0d8-0b0d-4e9c-87e5-066d6ec4ffae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_bac65403-e90b-43de-9aad-594c5f8e8b2e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1f3e165a-25d2-432d-96f3-37c19d47311b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AdditionalPerformanceBasedAwardTargetShareAmount_8b5bb698-3822-42c4-921e-b01cb596e97a" xlink:href="amed-20221231.xsd#amed_AdditionalPerformanceBasedAwardTargetShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad9c26db-9e0b-480e-b706-2977ef404104" xlink:to="loc_amed_AdditionalPerformanceBasedAwardTargetShareAmount_8b5bb698-3822-42c4-921e-b01cb596e97a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8288c076-1301-49e6-bdcc-1152c89ecce9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad9c26db-9e0b-480e-b706-2977ef404104" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8288c076-1301-49e6-bdcc-1152c89ecce9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bade8913-f44d-4a69-81d7-35626df2a88f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8288c076-1301-49e6-bdcc-1152c89ecce9" xlink:to="loc_us-gaap_AwardTypeAxis_bade8913-f44d-4a69-81d7-35626df2a88f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bade8913-f44d-4a69-81d7-35626df2a88f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_bade8913-f44d-4a69-81d7-35626df2a88f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bade8913-f44d-4a69-81d7-35626df2a88f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15e780f8-ac9d-4ddf-9da3-110e7d8c4cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_bade8913-f44d-4a69-81d7-35626df2a88f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15e780f8-ac9d-4ddf-9da3-110e7d8c4cb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockUnitsServiceMember_0ce3794d-ae60-46b0-8acf-878245a90d34" xlink:href="amed-20221231.xsd#amed_NonVestedStockUnitsServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15e780f8-ac9d-4ddf-9da3-110e7d8c4cb7" xlink:to="loc_amed_NonVestedStockUnitsServiceMember_0ce3794d-ae60-46b0-8acf-878245a90d34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember_0bd162d9-2fb4-4e90-88bc-9efd6bc63770" xlink:href="amed-20221231.xsd#amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15e780f8-ac9d-4ddf-9da3-110e7d8c4cb7" xlink:to="loc_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember_0bd162d9-2fb4-4e90-88bc-9efd6bc63770" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended" id="i6069dbe0f86a4fc2ae3cb0fd9b426d62_COMMITMENTSANDCONTINGENCIESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Numberofpatients_7bf82a38-d8aa-4a91-904c-e1c3937777d4" xlink:href="amed-20221231.xsd#amed_Numberofpatients"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_Numberofpatients_7bf82a38-d8aa-4a91-904c-e1c3937777d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_8d2dec3f-9809-418f-9a3e-d0478a5325f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_8d2dec3f-9809-418f-9a3e-d0478a5325f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_3a047c57-d631-4381-9359-b0b35d48f779" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_3a047c57-d631-4381-9359-b0b35d48f779" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_55eb63ac-8bfe-4a57-b58f-6b84cd03d0a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_55eb63ac-8bfe-4a57-b58f-6b84cd03d0a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_b5b010c2-f197-4f4c-ab1a-605eea4eccad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_b5b010c2-f197-4f4c-ab1a-605eea4eccad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfCareCentersSold_8d80a05a-196a-4641-9041-45e148da60eb" xlink:href="amed-20221231.xsd#amed_NumberOfCareCentersSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_NumberOfCareCentersSold_8d80a05a-196a-4641-9041-45e148da60eb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableCurrent_1bf60a58-eb67-4ad3-8b5a-aa989fa0b940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_us-gaap_LossContingencyReceivableCurrent_1bf60a58-eb67-4ad3-8b5a-aa989fa0b940" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CorporateIntegrityAgreementTerm_ab1e6c15-fba4-4b35-a548-4aac56b21044" xlink:href="amed-20221231.xsd#amed_CorporateIntegrityAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_CorporateIntegrityAgreementTerm_ab1e6c15-fba4-4b35-a548-4aac56b21044" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfBeneficiaries_c37d9ab3-f601-47d8-819e-e889876c0c7a" xlink:href="amed-20221231.xsd#amed_NumberOfBeneficiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_NumberOfBeneficiaries_c37d9ab3-f601-47d8-819e-e889876c0c7a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_e6d08860-73c8-453d-80a8-02ec9d11837e" xlink:href="amed-20221231.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_e6d08860-73c8-453d-80a8-02ec9d11837e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_0620bfa5-fed5-447a-80ee-fcf933ef356a" xlink:href="amed-20221231.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_0620bfa5-fed5-447a-80ee-fcf933ef356a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfClaimsSubmittedBySubsidiary_fdab569e-6f73-48c0-b599-6e8867cfc1d2" xlink:href="amed-20221231.xsd#amed_NumberOfClaimsSubmittedBySubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_NumberOfClaimsSubmittedBySubsidiary_fdab569e-6f73-48c0-b599-6e8867cfc1d2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_0a209fcf-9d78-45db-b244-62b3bb4fa073" xlink:href="amed-20221231.xsd#amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_0a209fcf-9d78-45db-b244-62b3bb4fa073" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableNoncurrent_f591c407-c153-4335-ba2e-0af703cca87b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyReceivableNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_us-gaap_LossContingencyReceivableNoncurrent_f591c407-c153-4335-ba2e-0af703cca87b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ActualClaimsPayment_286e7afd-ee77-47ba-88f7-7aa904f64f51" xlink:href="amed-20221231.xsd#amed_ActualClaimsPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_ActualClaimsPayment_286e7afd-ee77-47ba-88f7-7aa904f64f51" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ErrorRatePercentage_9560c9e2-22f7-48a2-9363-6b19f925b96d" xlink:href="amed-20221231.xsd#amed_ErrorRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_ErrorRatePercentage_9560c9e2-22f7-48a2-9363-6b19f925b96d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IndemnificationAmount_2ab24bff-8871-4f9c-84f0-56ef615dfeae" xlink:href="amed-20221231.xsd#amed_IndemnificationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_IndemnificationAmount_2ab24bff-8871-4f9c-84f0-56ef615dfeae" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FloridaZpicRevenueReduction_7fe23147-0b02-40d5-8b6d-5f2e1c66e41b" xlink:href="amed-20221231.xsd#amed_FloridaZpicRevenueReduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_FloridaZpicRevenueReduction_7fe23147-0b02-40d5-8b6d-5f2e1c66e41b" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_10d4696b-93e6-455c-a543-a8073de77a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_10d4696b-93e6-455c-a543-a8073de77a5f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OperatingLeaseTermYears_0213391c-6720-480b-8438-49cbcb1ea0ff" xlink:href="amed-20221231.xsd#amed_OperatingLeaseTermYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_OperatingLeaseTermYears_0213391c-6720-480b-8438-49cbcb1ea0ff" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_376c6055-b540-49a8-823b-6c3f520be95b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_us-gaap_LeaseAndRentalExpense_376c6055-b540-49a8-823b-6c3f520be95b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthInsuranceRetentionLimit_62cf9c9d-4593-4389-b048-f2aeb9d5605f" xlink:href="amed-20221231.xsd#amed_HealthInsuranceRetentionLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_HealthInsuranceRetentionLimit_62cf9c9d-4593-4389-b048-f2aeb9d5605f" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WorkersCompensationInsuranceRetentionLimit_cb208866-6777-4e1d-828d-c807df52be4d" xlink:href="amed-20221231.xsd#amed_WorkersCompensationInsuranceRetentionLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_WorkersCompensationInsuranceRetentionLimit_cb208866-6777-4e1d-828d-c807df52be4d" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit_f816feae-48c5-4768-a097-6bb5cd052926" xlink:href="amed-20221231.xsd#amed_ProfessionalLiabilityInsuranceRetentionLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit_f816feae-48c5-4768-a097-6bb5cd052926" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ReversalOfLossContingencyAccrual_ed4474f4-4af7-409b-9f1e-f8fa3622d0bf" xlink:href="amed-20221231.xsd#amed_ReversalOfLossContingencyAccrual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_ReversalOfLossContingencyAccrual_ed4474f4-4af7-409b-9f1e-f8fa3622d0bf" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementInterest_36680b7e-3999-49fe-b521-f1df045f37a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_us-gaap_LitigationSettlementInterest_36680b7e-3999-49fe-b521-f1df045f37a3" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalLegalSettlementPayment_de5a4d68-758e-48d3-9ff7-43c012ed50d8" xlink:href="amed-20221231.xsd#amed_TotalLegalSettlementPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_TotalLegalSettlementPayment_de5a4d68-758e-48d3-9ff7-43c012ed50d8" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LegalSettlementPaymentLessInterest_bb2759d0-9677-419c-885f-e3852a8fe919" xlink:href="amed-20221231.xsd#amed_LegalSettlementPaymentLessInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_LegalSettlementPaymentLessInterest_bb2759d0-9677-419c-885f-e3852a8fe919" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_c6a0e184-f271-4786-a31f-5d399497add6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_c6a0e184-f271-4786-a31f-5d399497add6" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ReductionToNetServiceRevenue_3188a685-71d1-4940-abf8-e47c1f4f3fc8" xlink:href="amed-20221231.xsd#amed_ReductionToNetServiceRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_ReductionToNetServiceRevenue_3188a685-71d1-4940-abf8-e47c1f4f3fc8" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_c83fca81-31c8-4e20-b986-e89023e0485b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_us-gaap_LossContingenciesTable_c83fca81-31c8-4e20-b986-e89023e0485b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_992b05fe-a604-4042-afc4-0a97784826d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c83fca81-31c8-4e20-b986-e89023e0485b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_992b05fe-a604-4042-afc4-0a97784826d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_992b05fe-a604-4042-afc4-0a97784826d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_992b05fe-a604-4042-afc4-0a97784826d5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_992b05fe-a604-4042-afc4-0a97784826d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_02655973-d2e5-466e-adbc-8856add58d65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_992b05fe-a604-4042-afc4-0a97784826d5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_02655973-d2e5-466e-adbc-8856add58d65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_0fd889d4-38db-44b2-a321-86883e3d3259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_02655973-d2e5-466e-adbc-8856add58d65" xlink:to="loc_us-gaap_SubsequentEventMember_0fd889d4-38db-44b2-a321-86883e3d3259" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_aa361f14-13e0-4f5e-a8e0-d8fbd4c9c9bd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c83fca81-31c8-4e20-b986-e89023e0485b" xlink:to="loc_srt_LitigationCaseAxis_aa361f14-13e0-4f5e-a8e0-d8fbd4c9c9bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_aa361f14-13e0-4f5e-a8e0-d8fbd4c9c9bd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_aa361f14-13e0-4f5e-a8e0-d8fbd4c9c9bd" xlink:to="loc_srt_LitigationCaseTypeDomain_aa361f14-13e0-4f5e-a8e0-d8fbd4c9c9bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_b981ba2f-482f-422b-94bc-d7f0efa5537f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_aa361f14-13e0-4f5e-a8e0-d8fbd4c9c9bd" xlink:to="loc_srt_LitigationCaseTypeDomain_b981ba2f-482f-422b-94bc-d7f0efa5537f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UsDepartmentOfJusticeMember_87794fc0-e059-4be1-8fff-da9fe890afec" xlink:href="amed-20221231.xsd#amed_UsDepartmentOfJusticeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_b981ba2f-482f-422b-94bc-d7f0efa5537f" xlink:to="loc_amed_UsDepartmentOfJusticeMember_87794fc0-e059-4be1-8fff-da9fe890afec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SafeguardZoneProgramIntegrityContractorMember_3e5c99dd-9358-49a7-b8a9-786483592fa2" xlink:href="amed-20221231.xsd#amed_SafeguardZoneProgramIntegrityContractorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_b981ba2f-482f-422b-94bc-d7f0efa5537f" xlink:to="loc_amed_SafeguardZoneProgramIntegrityContractorMember_3e5c99dd-9358-49a7-b8a9-786483592fa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmedisysCIAMember_bac27c6e-8f91-4be1-b55a-cbe71b07d2d3" xlink:href="amed-20221231.xsd#amed_AmedisysCIAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_b981ba2f-482f-422b-94bc-d7f0efa5537f" xlink:to="loc_amed_AmedisysCIAMember_bac27c6e-8f91-4be1-b55a-cbe71b07d2d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceCIAMember_5ba21142-af30-45b9-ba1a-5325b1e5d174" xlink:href="amed-20221231.xsd#amed_CompassionateCareHospiceCIAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_b981ba2f-482f-422b-94bc-d7f0efa5537f" xlink:to="loc_amed_CompassionateCareHospiceCIAMember_5ba21142-af30-45b9-ba1a-5325b1e5d174" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_bd696b10-de8b-44e4-97c0-f89e13046ef2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c83fca81-31c8-4e20-b986-e89023e0485b" xlink:to="loc_srt_StatementGeographicalAxis_bd696b10-de8b-44e4-97c0-f89e13046ef2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_bd696b10-de8b-44e4-97c0-f89e13046ef2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_bd696b10-de8b-44e4-97c0-f89e13046ef2" xlink:to="loc_srt_SegmentGeographicalDomain_bd696b10-de8b-44e4-97c0-f89e13046ef2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_80c95b8d-bf5f-42cd-8d29-0f42c29820e8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_bd696b10-de8b-44e4-97c0-f89e13046ef2" xlink:to="loc_srt_SegmentGeographicalDomain_80c95b8d-bf5f-42cd-8d29-0f42c29820e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_58249567-dfe1-4209-b395-b64d32dcc642" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_80c95b8d-bf5f-42cd-8d29-0f42c29820e8" xlink:to="loc_stpr_MA_58249567-dfe1-4209-b395-b64d32dcc642" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MorgantownWestVirginiaMember_807e978b-5d0a-4411-ba5b-7a206bd7c03a" xlink:href="amed-20221231.xsd#amed_MorgantownWestVirginiaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_80c95b8d-bf5f-42cd-8d29-0f42c29820e8" xlink:to="loc_amed_MorgantownWestVirginiaMember_807e978b-5d0a-4411-ba5b-7a206bd7c03a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ParkersburgWestVirginiaMember_56d8ca30-175c-480b-9eb3-0aa493b0eb6e" xlink:href="amed-20221231.xsd#amed_ParkersburgWestVirginiaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_80c95b8d-bf5f-42cd-8d29-0f42c29820e8" xlink:to="loc_amed_ParkersburgWestVirginiaMember_56d8ca30-175c-480b-9eb3-0aa493b0eb6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CT_3091d01b-98dc-4dc8-b31b-944c8a3145d5" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CT"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_80c95b8d-bf5f-42cd-8d29-0f42c29820e8" xlink:to="loc_stpr_CT_3091d01b-98dc-4dc8-b31b-944c8a3145d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL_7eab7c72-cd67-4c6c-aad2-97751832a12f" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_IL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_80c95b8d-bf5f-42cd-8d29-0f42c29820e8" xlink:to="loc_stpr_IL_7eab7c72-cd67-4c6c-aad2-97751832a12f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_SC_64c04685-cbe7-4cd6-94a2-a3465e2f59b0" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_SC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_80c95b8d-bf5f-42cd-8d29-0f42c29820e8" xlink:to="loc_stpr_SC_64c04685-cbe7-4cd6-94a2-a3465e2f59b0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL_54f72521-9f34-4458-b481-55728fb100c5" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_FL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_80c95b8d-bf5f-42cd-8d29-0f42c29820e8" xlink:to="loc_stpr_FL_54f72521-9f34-4458-b481-55728fb100c5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LakelandFloridaMember_d4281867-fca8-4030-ba4c-314e4e309b6f" xlink:href="amed-20221231.xsd#amed_LakelandFloridaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_stpr_FL_54f72521-9f34-4458-b481-55728fb100c5" xlink:to="loc_amed_LakelandFloridaMember_d4281867-fca8-4030-ba4c-314e4e309b6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ClearwaterFloridaMember_750a26c9-e1d0-4cc3-aef7-9a336980ce78" xlink:href="amed-20221231.xsd#amed_ClearwaterFloridaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_stpr_FL_54f72521-9f34-4458-b481-55728fb100c5" xlink:to="loc_amed_ClearwaterFloridaMember_750a26c9-e1d0-4cc3-aef7-9a336980ce78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c9e19c68-25e8-49b8-bd04-0f0c0ec109ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c83fca81-31c8-4e20-b986-e89023e0485b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c9e19c68-25e8-49b8-bd04-0f0c0ec109ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c9e19c68-25e8-49b8-bd04-0f0c0ec109ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c9e19c68-25e8-49b8-bd04-0f0c0ec109ca" xlink:to="loc_us-gaap_SegmentDomain_c9e19c68-25e8-49b8-bd04-0f0c0ec109ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b7013f9a-b372-4666-aa99-6671109a1291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c9e19c68-25e8-49b8-bd04-0f0c0ec109ca" xlink:to="loc_us-gaap_SegmentDomain_b7013f9a-b372-4666-aa99-6671109a1291" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_6e2dbca6-0e6c-497a-a748-a1079513df64" xlink:href="amed-20221231.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b7013f9a-b372-4666-aa99-6671109a1291" xlink:to="loc_amed_HospiceMember_6e2dbca6-0e6c-497a-a748-a1079513df64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_be8469c5-85a7-428c-a295-6499b87d9046" xlink:href="amed-20221231.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b7013f9a-b372-4666-aa99-6671109a1291" xlink:to="loc_amed_HomeHealthMember_be8469c5-85a7-428c-a295-6499b87d9046" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a8fe4766-9ee5-4177-8688-88e9bdda602a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c83fca81-31c8-4e20-b986-e89023e0485b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a8fe4766-9ee5-4177-8688-88e9bdda602a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a8fe4766-9ee5-4177-8688-88e9bdda602a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a8fe4766-9ee5-4177-8688-88e9bdda602a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a8fe4766-9ee5-4177-8688-88e9bdda602a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d5bab84a-8b8c-4ede-bf3a-36f2eec83665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a8fe4766-9ee5-4177-8688-88e9bdda602a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d5bab84a-8b8c-4ede-bf3a-36f2eec83665" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InfinityHomeCareMember_71683bcb-daf7-49af-be00-6a4c01ba81cf" xlink:href="amed-20221231.xsd#amed_InfinityHomeCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d5bab84a-8b8c-4ede-bf3a-36f2eec83665" xlink:to="loc_amed_InfinityHomeCareMember_71683bcb-daf7-49af-be00-6a4c01ba81cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_d72026df-56b8-4a7d-a9be-162e55cf7da3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c83fca81-31c8-4e20-b986-e89023e0485b" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_d72026df-56b8-4a7d-a9be-162e55cf7da3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_d72026df-56b8-4a7d-a9be-162e55cf7da3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_d72026df-56b8-4a7d-a9be-162e55cf7da3" xlink:to="loc_us-gaap_LossContingencyNatureDomain_d72026df-56b8-4a7d-a9be-162e55cf7da3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_56fd3294-4c7b-440e-b3b1-710d501756d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_d72026df-56b8-4a7d-a9be-162e55cf7da3" xlink:to="loc_us-gaap_LossContingencyNatureDomain_56fd3294-4c7b-440e-b3b1-710d501756d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExtrapolatedMember_a59c4d38-7cab-467e-9f61-5414362a7a27" xlink:href="amed-20221231.xsd#amed_ExtrapolatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_56fd3294-4c7b-440e-b3b1-710d501756d1" xlink:to="loc_amed_ExtrapolatedMember_a59c4d38-7cab-467e-9f61-5414362a7a27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnfavorableMember_24e27d05-dc07-43ee-ac31-96bb092966ee" xlink:href="amed-20221231.xsd#amed_UnfavorableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_56fd3294-4c7b-440e-b3b1-710d501756d1" xlink:to="loc_amed_UnfavorableMember_24e27d05-dc07-43ee-ac31-96bb092966ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5c558c6b-ce3e-4cba-b7bd-e2576ffb2c6f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_c83fca81-31c8-4e20-b986-e89023e0485b" xlink:to="loc_srt_RangeAxis_5c558c6b-ce3e-4cba-b7bd-e2576ffb2c6f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5c558c6b-ce3e-4cba-b7bd-e2576ffb2c6f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5c558c6b-ce3e-4cba-b7bd-e2576ffb2c6f" xlink:to="loc_srt_RangeMember_5c558c6b-ce3e-4cba-b7bd-e2576ffb2c6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_99a3c3f9-f035-49a2-8a50-0189edf948c6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5c558c6b-ce3e-4cba-b7bd-e2576ffb2c6f" xlink:to="loc_srt_RangeMember_99a3c3f9-f035-49a2-8a50-0189edf948c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_70d426db-e147-498d-94c2-1bdadd295047" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_99a3c3f9-f035-49a2-8a50-0189edf948c6" xlink:to="loc_srt_MinimumMember_70d426db-e147-498d-94c2-1bdadd295047" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b2d47dc9-adf9-4305-acf4-276c15625201" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_99a3c3f9-f035-49a2-8a50-0189edf948c6" xlink:to="loc_srt_MaximumMember_b2d47dc9-adf9-4305-acf4-276c15625201" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#SHAREREPURCHASENarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails" xlink:type="extended" id="i15deed4249754cb3ad622ea85c151917_SHAREREPURCHASENarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseLineItems_0beb3219-6f54-46df-89ff-31dc35543069" xlink:href="amed-20221231.xsd#amed_ShareRepurchaseLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofSharesOutstanding_e90af3c0-f339-4c24-a98e-6c3365c01e70" xlink:href="amed-20221231.xsd#amed_PercentageofSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_0beb3219-6f54-46df-89ff-31dc35543069" xlink:to="loc_amed_PercentageofSharesOutstanding_e90af3c0-f339-4c24-a98e-6c3365c01e70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b8fed3a3-a3f0-41a7-bf30-7c93a1c10067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_0beb3219-6f54-46df-89ff-31dc35543069" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b8fed3a3-a3f0-41a7-bf30-7c93a1c10067" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_eabdfdbf-ea3f-4b08-92b1-13d45ed47b16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_0beb3219-6f54-46df-89ff-31dc35543069" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_eabdfdbf-ea3f-4b08-92b1-13d45ed47b16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramExpirationDate_34a116db-a218-49c7-b61e-680959923def" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramExpirationDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_0beb3219-6f54-46df-89ff-31dc35543069" xlink:to="loc_us-gaap_StockRepurchaseProgramExpirationDate_34a116db-a218-49c7-b61e-680959923def" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_049a180a-14fa-4de2-94c9-a09da562430c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_0beb3219-6f54-46df-89ff-31dc35543069" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_049a180a-14fa-4de2-94c9-a09da562430c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_b595f4f3-930c-422c-ae5e-2db92889fb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_0beb3219-6f54-46df-89ff-31dc35543069" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_b595f4f3-930c-422c-ae5e-2db92889fb3d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseTable_fc808542-58e0-44d8-8a89-f19e0f3c5f27" xlink:href="amed-20221231.xsd#amed_ShareRepurchaseTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_amed_ShareRepurchaseLineItems_0beb3219-6f54-46df-89ff-31dc35543069" xlink:to="loc_amed_ShareRepurchaseTable_fc808542-58e0-44d8-8a89-f19e0f3c5f27" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_aaeeed58-846e-4961-96f8-56a6de273b08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_amed_ShareRepurchaseTable_fc808542-58e0-44d8-8a89-f19e0f3c5f27" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_aaeeed58-846e-4961-96f8-56a6de273b08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_aaeeed58-846e-4961-96f8-56a6de273b08_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_aaeeed58-846e-4961-96f8-56a6de273b08" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_aaeeed58-846e-4961-96f8-56a6de273b08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_32d89908-b219-4d16-a444-a664a8d41bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_aaeeed58-846e-4961-96f8-56a6de273b08" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_32d89908-b219-4d16-a444-a664a8d41bb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_3afdaccf-6744-40d6-a752-1d9345808232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_32d89908-b219-4d16-a444-a664a8d41bb1" xlink:to="loc_us-gaap_SubsequentEventMember_3afdaccf-6744-40d6-a752-1d9345808232" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_4b8d88d5-5d59-45a0-b40d-c5f89b332e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_amed_ShareRepurchaseTable_fc808542-58e0-44d8-8a89-f19e0f3c5f27" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_4b8d88d5-5d59-45a0-b40d-c5f89b332e6c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_4b8d88d5-5d59-45a0-b40d-c5f89b332e6c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_4b8d88d5-5d59-45a0-b40d-c5f89b332e6c" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_4b8d88d5-5d59-45a0-b40d-c5f89b332e6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_5d34c09f-5cfb-417f-8c5d-74f930de430b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_4b8d88d5-5d59-45a0-b40d-c5f89b332e6c" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_5d34c09f-5cfb-417f-8c5d-74f930de430b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2021ShareRepurchaseProgramMember_b07b4651-ab50-48f0-9ace-476c6639f7da" xlink:href="amed-20221231.xsd#amed_A2021ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_5d34c09f-5cfb-417f-8c5d-74f930de430b" xlink:to="loc_amed_A2021ShareRepurchaseProgramMember_b07b4651-ab50-48f0-9ace-476c6639f7da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NewShareRepurchaseProgramMember_acf72101-3215-485d-91c9-c4553c0a0794" xlink:href="amed-20221231.xsd#amed_NewShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_5d34c09f-5cfb-417f-8c5d-74f930de430b" xlink:to="loc_amed_NewShareRepurchaseProgramMember_acf72101-3215-485d-91c9-c4553c0a0794" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2019StockRepurchaseProgramMember_74429cf9-b8cd-4413-90b6-7170df844eeb" xlink:href="amed-20221231.xsd#amed_A2019StockRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_5d34c09f-5cfb-417f-8c5d-74f930de430b" xlink:to="loc_amed_A2019StockRepurchaseProgramMember_74429cf9-b8cd-4413-90b6-7170df844eeb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2023ShareRepurchaseProgramMember_1c36f8b8-3b56-4b46-85a5-5f6700c8944a" xlink:href="amed-20221231.xsd#amed_A2023ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_5d34c09f-5cfb-417f-8c5d-74f930de430b" xlink:to="loc_amed_A2023ShareRepurchaseProgramMember_1c36f8b8-3b56-4b46-85a5-5f6700c8944a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" xlink:type="extended" id="i4c91f21c68654d7fad010ec7ea663755_SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_ccc14d39-9a9f-430a-8882-3896dd1174a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_a6692abf-f9b2-4111-983d-0effb1bce5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ccc14d39-9a9f-430a-8882-3896dd1174a7" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_a6692abf-f9b2-4111-983d-0effb1bce5a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_af4d4fed-05b5-40d9-885e-269ce8ddce0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ccc14d39-9a9f-430a-8882-3896dd1174a7" xlink:to="loc_us-gaap_OtherOperatingIncome_af4d4fed-05b5-40d9-885e-269ce8ddce0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_690624b1-114e-4391-b87c-55109637f8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ccc14d39-9a9f-430a-8882-3896dd1174a7" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_690624b1-114e-4391-b87c-55109637f8e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_e0dfa03f-5aa1-4c8d-9c5b-ae5ea99b67f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ccc14d39-9a9f-430a-8882-3896dd1174a7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_e0dfa03f-5aa1-4c8d-9c5b-ae5ea99b67f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DepreciationAndAmortizationForContinuingOperations_771ba385-be91-4640-adb7-bdfefafe5941" xlink:href="amed-20221231.xsd#amed_DepreciationAndAmortizationForContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ccc14d39-9a9f-430a-8882-3896dd1174a7" xlink:to="loc_amed_DepreciationAndAmortizationForContinuingOperations_771ba385-be91-4640-adb7-bdfefafe5941" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_beae0ebe-b7ba-4d47-85a6-ef11aa727a57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ccc14d39-9a9f-430a-8882-3896dd1174a7" xlink:to="loc_us-gaap_AssetImpairmentCharges_beae0ebe-b7ba-4d47-85a6-ef11aa727a57" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_a3698e1b-535e-43fc-9722-6d25d4b1443a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ccc14d39-9a9f-430a-8882-3896dd1174a7" xlink:to="loc_us-gaap_CostsAndExpenses_a3698e1b-535e-43fc-9722-6d25d4b1443a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_40c67597-2927-4435-8261-6f159477af17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ccc14d39-9a9f-430a-8882-3896dd1174a7" xlink:to="loc_us-gaap_OperatingIncomeLoss_40c67597-2927-4435-8261-6f159477af17" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_050b62c0-b444-414b-b352-3c8d34a48d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ccc14d39-9a9f-430a-8882-3896dd1174a7" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_050b62c0-b444-414b-b352-3c8d34a48d25" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_68871170-c694-4627-863b-c249ce97c32e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_050b62c0-b444-414b-b352-3c8d34a48d25" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_68871170-c694-4627-863b-c249ce97c32e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_68871170-c694-4627-863b-c249ce97c32e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_68871170-c694-4627-863b-c249ce97c32e" xlink:to="loc_us-gaap_SegmentDomain_68871170-c694-4627-863b-c249ce97c32e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8bdb23b8-e145-4fe4-846e-509981795d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_68871170-c694-4627-863b-c249ce97c32e" xlink:to="loc_us-gaap_SegmentDomain_8bdb23b8-e145-4fe4-846e-509981795d0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_a69d798e-3794-4e33-9323-d41b85ce2527" xlink:href="amed-20221231.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8bdb23b8-e145-4fe4-846e-509981795d0d" xlink:to="loc_amed_HomeHealthMember_a69d798e-3794-4e33-9323-d41b85ce2527" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_7c6574ab-2dbe-46ef-9c29-2941ca088253" xlink:href="amed-20221231.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8bdb23b8-e145-4fe4-846e-509981795d0d" xlink:to="loc_amed_HospiceMember_7c6574ab-2dbe-46ef-9c29-2941ca088253" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_e220661a-ac2c-4ccb-a24f-f4a14fcb8dec" xlink:href="amed-20221231.xsd#amed_PersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8bdb23b8-e145-4fe4-846e-509981795d0d" xlink:to="loc_amed_PersonalCareMember_e220661a-ac2c-4ccb-a24f-f4a14fcb8dec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_ec09012c-4e64-45fb-81f5-5c07d390f208" xlink:href="amed-20221231.xsd#amed_HighAcuityCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8bdb23b8-e145-4fe4-846e-509981795d0d" xlink:to="loc_amed_HighAcuityCareMember_ec09012c-4e64-45fb-81f5-5c07d390f208" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateMember_cd0659ad-18fe-45da-abc9-bb8c3197a7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8bdb23b8-e145-4fe4-846e-509981795d0d" xlink:to="loc_us-gaap_CorporateMember_cd0659ad-18fe-45da-abc9-bb8c3197a7ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_b77363a6-2044-429e-9ac0-ffbfe5c05ecb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_050b62c0-b444-414b-b352-3c8d34a48d25" xlink:to="loc_srt_ConsolidationItemsAxis_b77363a6-2044-429e-9ac0-ffbfe5c05ecb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_b77363a6-2044-429e-9ac0-ffbfe5c05ecb_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_b77363a6-2044-429e-9ac0-ffbfe5c05ecb" xlink:to="loc_srt_ConsolidationItemsDomain_b77363a6-2044-429e-9ac0-ffbfe5c05ecb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_1ca43fac-c552-476e-832a-accd596a1db3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_b77363a6-2044-429e-9ac0-ffbfe5c05ecb" xlink:to="loc_srt_ConsolidationItemsDomain_1ca43fac-c552-476e-832a-accd596a1db3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_5ebeaac7-9426-469c-8a53-11f21c4457f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_1ca43fac-c552-476e-832a-accd596a1db3" xlink:to="loc_us-gaap_OperatingSegmentsMember_5ebeaac7-9426-469c-8a53-11f21c4457f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_784e8e23-d3f6-4a1a-ab5a-f4e7cafd306b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_1ca43fac-c552-476e-832a-accd596a1db3" xlink:to="loc_us-gaap_CorporateNonSegmentMember_784e8e23-d3f6-4a1a-ab5a-f4e7cafd306b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#RELATEDPARTYTRANSACTIONSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="extended" id="ica743cb5c04542ecb162f32c89146ab6_RELATEDPARTYTRANSACTIONSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_2e937f96-48d5-4cf8-be7b-600c76349fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_f85323f4-2e2a-45c4-9e00-23d05ff6bcf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2e937f96-48d5-4cf8-be7b-600c76349fa4" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_f85323f4-2e2a-45c4-9e00-23d05ff6bcf6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_000bc1e6-2ff0-483b-8301-5be05d37c23e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2e937f96-48d5-4cf8-be7b-600c76349fa4" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_000bc1e6-2ff0-483b-8301-5be05d37c23e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_5a2292fa-72fe-4bbe-a764-3bde841073ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_000bc1e6-2ff0-483b-8301-5be05d37c23e" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_5a2292fa-72fe-4bbe-a764-3bde841073ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_5a2292fa-72fe-4bbe-a764-3bde841073ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_5a2292fa-72fe-4bbe-a764-3bde841073ec" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_5a2292fa-72fe-4bbe-a764-3bde841073ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_65e088e1-15d1-4ce2-9436-a9cba54b23fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_5a2292fa-72fe-4bbe-a764-3bde841073ec" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_65e088e1-15d1-4ce2-9436-a9cba54b23fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedalogixMember_817a4845-bb63-417f-b485-0fa800a2736a" xlink:href="amed-20221231.xsd#amed_MedalogixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_65e088e1-15d1-4ce2-9436-a9cba54b23fe" xlink:to="loc_amed_MedalogixMember_817a4845-bb63-417f-b485-0fa800a2736a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENTSNarrativeDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#SUBSEQUENTEVENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUBSEQUENTEVENTSNarrativeDetails" xlink:type="extended" id="ifdb1d44d39f9425bbf96e68d0d7b38ca_SUBSEQUENTEVENTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_dcaefe08-0fa6-45b9-bf13-bcae79bbb93d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_36b3b10e-a36c-41c1-9f92-272030fc43e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_dcaefe08-0fa6-45b9-bf13-bcae79bbb93d" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_36b3b10e-a36c-41c1-9f92-272030fc43e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramExpirationDate_c5cbd6f5-cba3-4cb6-a253-54495e7e13c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramExpirationDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_dcaefe08-0fa6-45b9-bf13-bcae79bbb93d" xlink:to="loc_us-gaap_StockRepurchaseProgramExpirationDate_c5cbd6f5-cba3-4cb6-a253-54495e7e13c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_b290114e-6351-4839-8fae-09ddba5098c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_dcaefe08-0fa6-45b9-bf13-bcae79bbb93d" xlink:to="loc_us-gaap_SubsequentEventTable_b290114e-6351-4839-8fae-09ddba5098c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d86ae93f-e555-4a2f-a556-0f0ec6ed85d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_b290114e-6351-4839-8fae-09ddba5098c2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d86ae93f-e555-4a2f-a556-0f0ec6ed85d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d86ae93f-e555-4a2f-a556-0f0ec6ed85d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d86ae93f-e555-4a2f-a556-0f0ec6ed85d5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d86ae93f-e555-4a2f-a556-0f0ec6ed85d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e1078399-1759-468a-b08c-55ab7a25e964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d86ae93f-e555-4a2f-a556-0f0ec6ed85d5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e1078399-1759-468a-b08c-55ab7a25e964" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c4de2b82-5aaf-4c3a-b513-53e8398af410" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e1078399-1759-468a-b08c-55ab7a25e964" xlink:to="loc_us-gaap_SubsequentEventMember_c4de2b82-5aaf-4c3a-b513-53e8398af410" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_cb72bdb5-3db9-41be-9765-0106e22d9aba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_b290114e-6351-4839-8fae-09ddba5098c2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_cb72bdb5-3db9-41be-9765-0106e22d9aba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cb72bdb5-3db9-41be-9765-0106e22d9aba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_cb72bdb5-3db9-41be-9765-0106e22d9aba" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cb72bdb5-3db9-41be-9765-0106e22d9aba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_df694c7b-9174-4bcd-b907-121b866b7b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_cb72bdb5-3db9-41be-9765-0106e22d9aba" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_df694c7b-9174-4bcd-b907-121b866b7b8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EvolutionHealthMember_c6ee19a3-e1fb-4951-83c2-9e94b4acec3a" xlink:href="amed-20221231.xsd#amed_EvolutionHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_df694c7b-9174-4bcd-b907-121b866b7b8e" xlink:to="loc_amed_EvolutionHealthMember_c6ee19a3-e1fb-4951-83c2-9e94b4acec3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AssistedCareHomeHealthMember_8e826a89-ee23-4fa7-9ae1-3013ea23ceaf" xlink:href="amed-20221231.xsd#amed_AssistedCareHomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_df694c7b-9174-4bcd-b907-121b866b7b8e" xlink:to="loc_amed_AssistedCareHomeHealthMember_8e826a89-ee23-4fa7-9ae1-3013ea23ceaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_9997287c-fded-411e-8aa3-45bdea679a11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_b290114e-6351-4839-8fae-09ddba5098c2" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_9997287c-fded-411e-8aa3-45bdea679a11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_9997287c-fded-411e-8aa3-45bdea679a11_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_9997287c-fded-411e-8aa3-45bdea679a11" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_9997287c-fded-411e-8aa3-45bdea679a11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_4366f034-057e-4403-a55b-1b53ed16d8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_9997287c-fded-411e-8aa3-45bdea679a11" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_4366f034-057e-4403-a55b-1b53ed16d8e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2023ShareRepurchaseProgramMember_e6d7b7eb-3161-44be-8a03-9e3dd51daec6" xlink:href="amed-20221231.xsd#amed_A2023ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_4366f034-057e-4403-a55b-1b53ed16d8e4" xlink:to="loc_amed_A2023ShareRepurchaseProgramMember_e6d7b7eb-3161-44be-8a03-9e3dd51daec6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended" id="i1a3edb87057a42b986eb494c962d980f_SUBSEQUENTEVENTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_8040adae-cf9e-427d-9e87-a84d3085eabc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_290906e9-c8a3-4b19-a838-00c2c6e10ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_8040adae-cf9e-427d-9e87-a84d3085eabc" xlink:to="loc_us-gaap_SubsequentEventTable_290906e9-c8a3-4b19-a838-00c2c6e10ef2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7c7c0690-5c4a-4dbb-8b01-df85e2e05cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_290906e9-c8a3-4b19-a838-00c2c6e10ef2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7c7c0690-5c4a-4dbb-8b01-df85e2e05cff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7c7c0690-5c4a-4dbb-8b01-df85e2e05cff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7c7c0690-5c4a-4dbb-8b01-df85e2e05cff" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7c7c0690-5c4a-4dbb-8b01-df85e2e05cff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_940bb2fe-457b-419e-ab38-df57e92afddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7c7c0690-5c4a-4dbb-8b01-df85e2e05cff" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_940bb2fe-457b-419e-ab38-df57e92afddd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_157bca8e-3e82-47bf-8c80-17791e080825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_940bb2fe-457b-419e-ab38-df57e92afddd" xlink:to="loc_us-gaap_SubsequentEventMember_157bca8e-3e82-47bf-8c80-17791e080825" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>amed-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:c9bac751-1ef0-45f1-8208-1bc5d72ec892,g:1d8a20b2-a85c-4def-9d57-f7b6e7a974de-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_6e3f11e2-2b29-4247-a124-4a5ba7993892_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Payor Class</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Sources, Health Care Organization [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_c3e8a473-09e2-4b45-b038-824c715aa9cf_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_5ac23068-41ef-4761-a8fe-fd9f523259a7_terseLabel_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Operating Lease Right Of Use Asset</link:label>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of increase (decrease) In Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:href="amed-20221231.xsd#amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_VisitingNurseAssociationMember_c73bf2db-2393-4660-8a04-adf95ccf8c94_terseLabel_en-US" xlink:label="lab_amed_VisitingNurseAssociationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Visiting Nurse Association</link:label>
    <link:label id="lab_amed_VisitingNurseAssociationMember_label_en-US" xlink:label="lab_amed_VisitingNurseAssociationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Visiting Nurse Association [Member]</link:label>
    <link:label id="lab_amed_VisitingNurseAssociationMember_documentation_en-US" xlink:label="lab_amed_VisitingNurseAssociationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Visiting Nurse Association</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_VisitingNurseAssociationMember" xlink:href="amed-20221231.xsd#amed_VisitingNurseAssociationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_VisitingNurseAssociationMember" xlink:to="lab_amed_VisitingNurseAssociationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_c750de84-9d00-4c2b-bb76-c5e5f309c392_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_897ae346-f1a6-4b9b-9e31-ca6d2a67aace_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term obligations</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_0c63a601-08fc-45f4-a32d-7eed1f9ccb67_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_d486ab79-859c-46df-ab44-383b97199b43_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_6b9a0c6a-6bf3-4fb0-920c-00ac65a1b264_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_0b76d31c-856a-485e-b64c-3a75733a0b8f_negatedTerseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Current Liabilities Accrued Expenses</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:href="amed-20221231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_a19eac0b-3c13-4a9b-9689-02ef42fcba8b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax expense/(benefit):</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_2af7bb86-be59-47c3-ae7b-7bf9952a6b2e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NumberOfCareCentersExited_72e06e85-5830-41aa-912a-cbe518416cae_terseLabel_en-US" xlink:label="lab_amed_NumberOfCareCentersExited" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of care centers exited</link:label>
    <link:label id="lab_amed_NumberOfCareCentersExited_label_en-US" xlink:label="lab_amed_NumberOfCareCentersExited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Care Centers Exited</link:label>
    <link:label id="lab_amed_NumberOfCareCentersExited_documentation_en-US" xlink:label="lab_amed_NumberOfCareCentersExited" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Care Centers that were exited during the period though closure, consolidation or discontinued start-up process.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfCareCentersExited" xlink:href="amed-20221231.xsd#amed_NumberOfCareCentersExited"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NumberOfCareCentersExited" xlink:to="lab_amed_NumberOfCareCentersExited" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_55419e40-ccc2-4ed4-bb53-898c37bbef3d_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on equity method investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_540504c9-7576-40d6-add9-ece961f83e55_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MorgantownWestVirginiaMember_76b9895b-b560-4766-a4d3-8db20181fd69_terseLabel_en-US" xlink:label="lab_amed_MorgantownWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Morgantown, West Virginia [Member]</link:label>
    <link:label id="lab_amed_MorgantownWestVirginiaMember_label_en-US" xlink:label="lab_amed_MorgantownWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Morgantown, West Virginia [Member]</link:label>
    <link:label id="lab_amed_MorgantownWestVirginiaMember_documentation_en-US" xlink:label="lab_amed_MorgantownWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Morgantown, West Virginia [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MorgantownWestVirginiaMember" xlink:href="amed-20221231.xsd#amed_MorgantownWestVirginiaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MorgantownWestVirginiaMember" xlink:to="lab_amed_MorgantownWestVirginiaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_19885afb-a110-4175-997b-529af5831a80_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_ca67c234-67b6-438b-9c2a-8c37b232e65f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_fd7e5cfc-bae9-417c-a115-251efa26dc6a_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets:</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_8bb6ba03-6bc2-4a53-9406-aa5e7850556d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EstimatedInsuranceExcludingLongTermPortion_032c4ec0-b289-4aa9-a500-ceed9880744d_totalLabel_en-US" xlink:label="lab_amed_EstimatedInsuranceExcludingLongTermPortion" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Insurance Excluding Long Term Portion</link:label>
    <link:label id="lab_amed_EstimatedInsuranceExcludingLongTermPortion_label_en-US" xlink:label="lab_amed_EstimatedInsuranceExcludingLongTermPortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Insurance Excluding Long Term Portion</link:label>
    <link:label id="lab_amed_EstimatedInsuranceExcludingLongTermPortion_documentation_en-US" xlink:label="lab_amed_EstimatedInsuranceExcludingLongTermPortion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated insurance liability, excluding long-term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedInsuranceExcludingLongTermPortion" xlink:href="amed-20221231.xsd#amed_EstimatedInsuranceExcludingLongTermPortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EstimatedInsuranceExcludingLongTermPortion" xlink:to="lab_amed_EstimatedInsuranceExcludingLongTermPortion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_624c44a1-0db1-4ad7-81c3-f9eb7fe60ca9_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of former employees who filled a putative collective and class action complaint</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ConsolidatedLeverageRatio_fd7c2c6d-b354-439d-b544-fa26022fe751_terseLabel_en-US" xlink:label="lab_amed_ConsolidatedLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio</link:label>
    <link:label id="lab_amed_ConsolidatedLeverageRatio_label_en-US" xlink:label="lab_amed_ConsolidatedLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio</link:label>
    <link:label id="lab_amed_ConsolidatedLeverageRatio_documentation_en-US" xlink:label="lab_amed_ConsolidatedLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedLeverageRatio" xlink:href="amed-20221231.xsd#amed_ConsolidatedLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ConsolidatedLeverageRatio" xlink:to="lab_amed_ConsolidatedLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock_6fa4ae4e-0b90-4f02-b013-ed533d500330_terseLabel_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, Evolution Health</link:label>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock_label_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, Evolution Health [Table Text Block]</link:label>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock_documentation_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, Evolution Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock" xlink:href="amed-20221231.xsd#amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock" xlink:to="lab_amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_735c68fc-2ef9-44fc-8728-0a4ebfac25a9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Margin on Loans</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_62de0a19-ca64-4614-9d03-c9daa3768cf0_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_ca37f00f-4722-404b-a004-bf769cd977c0_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease - 2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_561b560e-b80a-47e2-a0ca-030f9f1151b7_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2deb844e-1346-432f-8c2b-9509bc0f36a9_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_99b7843a-d284-4a2e-bbbe-116c9a012d51_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_02b890bc-04f0-4ab4-b3ea-23021b33142f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance/(cancellation) of non-vested stock (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_631c6c40-433c-4658-b815-cbb62f8c3d30_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d711686f-2461-4414-acf8-64791c5023d3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NumberOfCareCentersConsolidated_e875645f-e244-4d85-8da0-0df1f85edebb_terseLabel_en-US" xlink:label="lab_amed_NumberOfCareCentersConsolidated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of care centers consolidated</link:label>
    <link:label id="lab_amed_NumberOfCareCentersConsolidated_label_en-US" xlink:label="lab_amed_NumberOfCareCentersConsolidated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Care Centers Consolidated</link:label>
    <link:label id="lab_amed_NumberOfCareCentersConsolidated_documentation_en-US" xlink:label="lab_amed_NumberOfCareCentersConsolidated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating care centers that were consolidated with care centers servicing the same market during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfCareCentersConsolidated" xlink:href="amed-20221231.xsd#amed_NumberOfCareCentersConsolidated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NumberOfCareCentersConsolidated" xlink:to="lab_amed_NumberOfCareCentersConsolidated" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_InternallyDevelopedComputerSoftware_c595b838-4a00-410b-80f4-0a9acc378ed6_terseLabel_en-US" xlink:label="lab_amed_InternallyDevelopedComputerSoftware" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internally developed computer software</link:label>
    <link:label id="lab_amed_InternallyDevelopedComputerSoftware_label_en-US" xlink:label="lab_amed_InternallyDevelopedComputerSoftware" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internally Developed Computer Software</link:label>
    <link:label id="lab_amed_InternallyDevelopedComputerSoftware_documentation_en-US" xlink:label="lab_amed_InternallyDevelopedComputerSoftware" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internally developed AMS3 computer software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InternallyDevelopedComputerSoftware" xlink:href="amed-20221231.xsd#amed_InternallyDevelopedComputerSoftware"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_InternallyDevelopedComputerSoftware" xlink:to="lab_amed_InternallyDevelopedComputerSoftware" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_b238f227-a229-4ba1-a4f6-01eee6c630b9_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmortizableAcquiredNamesMember_df5e850f-e837-4eca-a800-ef5d4dce2e6d_terseLabel_en-US" xlink:label="lab_amed_AmortizableAcquiredNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortizable acquired names [Member]</link:label>
    <link:label id="lab_amed_AmortizableAcquiredNamesMember_label_en-US" xlink:label="lab_amed_AmortizableAcquiredNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortizable acquired names [Member]</link:label>
    <link:label id="lab_amed_AmortizableAcquiredNamesMember_documentation_en-US" xlink:label="lab_amed_AmortizableAcquiredNamesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortizable acquired names</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmortizableAcquiredNamesMember" xlink:href="amed-20221231.xsd#amed_AmortizableAcquiredNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmortizableAcquiredNamesMember" xlink:to="lab_amed_AmortizableAcquiredNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageOfPatientReceivablesOutstanding_d1a9ff27-c609-4e57-a65c-6a4ba7bd2225_terseLabel_en-US" xlink:label="lab_amed_PercentageOfPatientReceivablesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of patient receivables outstanding</link:label>
    <link:label id="lab_amed_PercentageOfPatientReceivablesOutstanding_label_en-US" xlink:label="lab_amed_PercentageOfPatientReceivablesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Patient Receivables Outstanding</link:label>
    <link:label id="lab_amed_PercentageOfPatientReceivablesOutstanding_documentation_en-US" xlink:label="lab_amed_PercentageOfPatientReceivablesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of patient receivables outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfPatientReceivablesOutstanding" xlink:href="amed-20221231.xsd#amed_PercentageOfPatientReceivablesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageOfPatientReceivablesOutstanding" xlink:to="lab_amed_PercentageOfPatientReceivablesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_986702df-7a55-4447-8dce-2b3e37f29e70_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Percentageofownershipinsubsidiaries_682674ae-0da8-469c-a504-6e9c1ed454a5_terseLabel_en-US" xlink:label="lab_amed_Percentageofownershipinsubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of ownership in subsidiaries</link:label>
    <link:label id="lab_amed_Percentageofownershipinsubsidiaries_label_en-US" xlink:label="lab_amed_Percentageofownershipinsubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentageofownershipinsubsidiaries</link:label>
    <link:label id="lab_amed_Percentageofownershipinsubsidiaries_documentation_en-US" xlink:label="lab_amed_Percentageofownershipinsubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of ownership in subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Percentageofownershipinsubsidiaries" xlink:href="amed-20221231.xsd#amed_Percentageofownershipinsubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Percentageofownershipinsubsidiaries" xlink:to="lab_amed_Percentageofownershipinsubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent_91f99ced-a435-4bfc-888b-91ef0eab7f81_terseLabel_en-US" xlink:label="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, less current portion</link:label>
    <link:label id="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent_label_en-US" xlink:label="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Including Discontinued Operation Operating Lease Liabilities Noncurrent</link:label>
    <link:label id="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent_documentation_en-US" xlink:label="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount classified as operating lease liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent" xlink:href="amed-20221231.xsd#amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent" xlink:to="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_bfcb1140-dfea-4532-886a-5eb641448eac_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Business Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_0e2754de-3e7c-40a7-8099-8a2d70256682_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease - 2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_f5a65bcc-3037-44dd-8146-b25ce628d4e5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HistoricalCollectionRateFromMedicare_1e2097aa-cba6-437a-b44a-f0d9bc02ce0a_terseLabel_en-US" xlink:label="lab_amed_HistoricalCollectionRateFromMedicare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Historical collection rate from Medicare</link:label>
    <link:label id="lab_amed_HistoricalCollectionRateFromMedicare_label_en-US" xlink:label="lab_amed_HistoricalCollectionRateFromMedicare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Historical Collection Rate From Medicare</link:label>
    <link:label id="lab_amed_HistoricalCollectionRateFromMedicare_documentation_en-US" xlink:label="lab_amed_HistoricalCollectionRateFromMedicare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Historical collection rate from Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HistoricalCollectionRateFromMedicare" xlink:href="amed-20221231.xsd#amed_HistoricalCollectionRateFromMedicare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HistoricalCollectionRateFromMedicare" xlink:to="lab_amed_HistoricalCollectionRateFromMedicare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d70c15eb-8232-4406-9dc8-0bc4cf537e71_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_e0358634-855e-463b-a1ba-2a094c18a1ed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_ea89d607-d6bd-4811-ace2-ef650dfed780_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Basic</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CashDistributionToNoncontrollingInterest_2d4d6a98-3561-4935-ad4e-839f78449832_negatedLabel_en-US" xlink:label="lab_amed_CashDistributionToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest distributions</link:label>
    <link:label id="lab_amed_CashDistributionToNoncontrollingInterest_label_en-US" xlink:label="lab_amed_CashDistributionToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Distribution To Noncontrolling Interest</link:label>
    <link:label id="lab_amed_CashDistributionToNoncontrollingInterest_documentation_en-US" xlink:label="lab_amed_CashDistributionToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of dividends or other distributions to noncontrolling interest holders.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashDistributionToNoncontrollingInterest" xlink:href="amed-20221231.xsd#amed_CashDistributionToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CashDistributionToNoncontrollingInterest" xlink:to="lab_amed_CashDistributionToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_f4cfb62a-cd67-4935-8c25-49b0b610062d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease - Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_597417a1-3c3a-475e-a8bc-69715f255331_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of states with facilities</link:label>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of States in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_84d7299c-a574-4abd-9429-9b55cdb159c2_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_20649ab4-fc0b-4a4b-a878-7a6a8f458ee8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LongTermObligationsLessCurrentPortionMember_44eba94a-0edf-4dd7-a17b-f0d3ec5697b6_terseLabel_en-US" xlink:label="lab_amed_LongTermObligationsLessCurrentPortionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term obligations, less current portion</link:label>
    <link:label id="lab_amed_LongTermObligationsLessCurrentPortionMember_label_en-US" xlink:label="lab_amed_LongTermObligationsLessCurrentPortionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term obligations, less current portion [Member]</link:label>
    <link:label id="lab_amed_LongTermObligationsLessCurrentPortionMember_documentation_en-US" xlink:label="lab_amed_LongTermObligationsLessCurrentPortionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term obligations, less current portion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LongTermObligationsLessCurrentPortionMember" xlink:href="amed-20221231.xsd#amed_LongTermObligationsLessCurrentPortionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LongTermObligationsLessCurrentPortionMember" xlink:to="lab_amed_LongTermObligationsLessCurrentPortionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_88a0f5b4-993e-4823-95fe-383cfb97c9f9_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions for tax positions related to current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_f7932b57-9a74-4138-8204-191165ed8d81_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Amortization of ROU assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_76f4ae8e-b9c1-4db9-a96f-c4abd6e14d59_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_d29618ed-5738-4eb4-9ca2-a0857622b511_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_4d87940b-99af-4588-b7fa-5f0fb38e7547_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_538ec120-14f0-4112-b364-8d0fae704da3_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_3de56f6d-c634-4d71-bd16-2c7236f99920_terseLabel_en-US" xlink:label="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Medicare revenue rate accounted for routine care</link:label>
    <link:label id="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_label_en-US" xlink:label="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Medicare Revenue Rate Accounted For Routine Care</link:label>
    <link:label id="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_documentation_en-US" xlink:label="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage of the entity's Hospice net Medicare service revenue that is derived from routine care.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:href="amed-20221231.xsd#amed_HospiceMedicareRevenueRateAccountedForRoutineCare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:to="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_478f01ed-ff75-4991-8a89-64022e21b07b_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosures of Cash Flow Information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_7554bf11-5629-42d8-bb92-0e4550f64df8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of variable rate basis</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Description of Variable Rate Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_StateTaxCreditMember_c2c4f29f-abbe-4b0b-8277-3f262775e240_terseLabel_en-US" xlink:label="lab_amed_StateTaxCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State Tax Credit [Member]</link:label>
    <link:label id="lab_amed_StateTaxCreditMember_label_en-US" xlink:label="lab_amed_StateTaxCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State Tax Credit [Member]</link:label>
    <link:label id="lab_amed_StateTaxCreditMember_documentation_en-US" xlink:label="lab_amed_StateTaxCreditMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State Tax Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StateTaxCreditMember" xlink:href="amed-20221231.xsd#amed_StateTaxCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_StateTaxCreditMember" xlink:to="lab_amed_StateTaxCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_5b3eb527-d894-4869-b030-31884cea7d77_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value, 60,000,000 shares authorized; 37,891,186 and 37,674,868 shares issued; and 32,518,278 and 32,509,969 shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_4b120dce-a859-4234-92c5-1f0aead04af3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeHealthMember_ffc34ea2-f8a9-4770-8fbf-bfec38ee645d_terseLabel_en-US" xlink:label="lab_amed_HomeHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health [Member]</link:label>
    <link:label id="lab_amed_HomeHealthMember_label_en-US" xlink:label="lab_amed_HomeHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health [Member]</link:label>
    <link:label id="lab_amed_HomeHealthMember_documentation_en-US" xlink:label="lab_amed_HomeHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember" xlink:href="amed-20221231.xsd#amed_HomeHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthMember" xlink:to="lab_amed_HomeHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_38ef9839-55a3-43d4-913c-557154aa3892_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Sale of Parent Equity Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1f2b6320-71d1-434f-ad56-886111eade1b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, weighted average contractual life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_750a4782-cb5f-49b1-87ca-b406fb2ce6a6_terseLabel_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of request for anticipated payment submitted for subsequent episodes of care</link:label>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_label_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate Of Request For Anticipated Payment Submitted For Subsequent Episodes Of Care</link:label>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_documentation_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage of estimated payment that is requested at the start of care for any subsequent episodes of care.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:href="amed-20221231.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:to="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_b0119dea-d01b-4839-948c-6ac39e6ef493_terseLabel_en-US" xlink:label="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Low utilization payment adjustment, maximum number of visits</link:label>
    <link:label id="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_label_en-US" xlink:label="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Low Utilization Payment Adjustment Number Of Visits</link:label>
    <link:label id="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_documentation_en-US" xlink:label="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the visit threshold for a low utilization payment adjustment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:href="amed-20221231.xsd#amed_LowUtilizationPaymentAdjustmentNumberOfVisits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:to="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_7ddf4df3-ebd1-4a82-b89f-4c6651ac149f_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_af0a106a-cc7c-4896-88a3-b081ba1efd7e_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Lived Assets Held-for-sale by Asset Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets Held-for-sale by Asset Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:to="lab_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_e253add5-2e11-4628-a594-839a73083abb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_4c805c2d-c007-4a30-afa5-fad198df2030_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent_6467749b-983d-4602-9bb7-f8630e1936db_terseLabel_en-US" xlink:label="lab_amed_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits (2)</link:label>
    <link:label id="lab_amed_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent_label_en-US" xlink:label="lab_amed_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Unrecognized Tax Benefits, Percent</link:label>
    <link:label id="lab_amed_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent_documentation_en-US" xlink:label="lab_amed_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Unrecognized Tax Benefits, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent" xlink:href="amed-20221231.xsd#amed_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent" xlink:to="lab_amed_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_GovernmentGrantsPolicyTextBlock_788bc14b-917b-44a4-a0b9-46200f22a6de_terseLabel_en-US" xlink:label="lab_amed_GovernmentGrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Grants</link:label>
    <link:label id="lab_amed_GovernmentGrantsPolicyTextBlock_label_en-US" xlink:label="lab_amed_GovernmentGrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Grants [Policy Text Block]</link:label>
    <link:label id="lab_amed_GovernmentGrantsPolicyTextBlock_documentation_en-US" xlink:label="lab_amed_GovernmentGrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting policy disclosure text block for government grants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_GovernmentGrantsPolicyTextBlock" xlink:href="amed-20221231.xsd#amed_GovernmentGrantsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_GovernmentGrantsPolicyTextBlock" xlink:to="lab_amed_GovernmentGrantsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_e1b89f14-bba3-4674-860a-47d8f6eaa126_negatedLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_5a1290d1-5cf7-4cb4-a882-7d03bb90e1d4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_06798766-011c-48e7-870b-ba168b58209c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_15c432be-2db4-4284-a390-12ef2dc549cd_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term obligations, less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_e6a5bb23-734b-4fb9-97cb-ce91888dd192_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition and Deferred Revenue [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition and Deferred Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_bd4cf35e-e72b-4c7d-853e-29b7528c9e44_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_7458899a-4aef-47fe-903d-38428320f3cf_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_19ea7f29-dd4c-44e0-a168-dc1afce35809_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b89a1ef0-f420-4455-a5d4-0032bbf4693e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_efb5de0c-c48b-49c4-85c9-f4d202c60988_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments related to acquisitions</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:to="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3ebe302c-218e-4d76-810d-4a7cd024d0ef_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram_8f13f881-3f74-4f40-8147-161a21b39fdb_terseLabel_en-US" xlink:label="lab_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Received From Mass HomeCare ASAP COVID19 Provider Sustainability Program</link:label>
    <link:label id="lab_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram_label_en-US" xlink:label="lab_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Received From Mass HomeCare ASAP COVID19 Provider Sustainability Program</link:label>
    <link:label id="lab_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram_documentation_en-US" xlink:label="lab_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Received From Mass Home Care ASAP COVID-19 Provider Sustainability Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" xlink:href="amed-20221231.xsd#amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" xlink:to="lab_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_cb0d988f-4242-41b5-abcd-15e635dd96a7_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ed140083-652c-4988-ae68-dd9c2eeb4e26_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_3753cb88-386f-44f9-b0cc-824ff1622559_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_62a2f6fb-a83a-40e4-b727-39645f87e81b_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current income tax expense/(benefit):</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_138cba55-c800-4819-9863-ed75084c1210_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Numberofpatients_51d6590f-8e21-4dcd-aebd-53adeb704208_terseLabel_en-US" xlink:label="lab_amed_Numberofpatients" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients</link:label>
    <link:label id="lab_amed_Numberofpatients_label_en-US" xlink:label="lab_amed_Numberofpatients" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients</link:label>
    <link:label id="lab_amed_Numberofpatients_documentation_en-US" xlink:label="lab_amed_Numberofpatients" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Numberofpatients" xlink:href="amed-20221231.xsd#amed_Numberofpatients"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Numberofpatients" xlink:to="lab_amed_Numberofpatients" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fbd88170-1244-43f2-a616-1a0f04ddbb3e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average&#160;Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeHealthAndHospiceMember_2f6239cb-5ab4-4121-82fc-c48c2235461a_terseLabel_en-US" xlink:label="lab_amed_HomeHealthAndHospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health And Hospice [Member]</link:label>
    <link:label id="lab_amed_HomeHealthAndHospiceMember_label_en-US" xlink:label="lab_amed_HomeHealthAndHospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health And Hospice [Member]</link:label>
    <link:label id="lab_amed_HomeHealthAndHospiceMember_documentation_en-US" xlink:label="lab_amed_HomeHealthAndHospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health And Hospice [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthAndHospiceMember" xlink:href="amed-20221231.xsd#amed_HomeHealthAndHospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthAndHospiceMember" xlink:to="lab_amed_HomeHealthAndHospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits_3cb8610f-5a5d-447f-b338-16b5f70d0367_negatedTerseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Current Liabilities Payroll and Employee Benefits</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits" xlink:href="amed-20221231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_40036f55-4f15-467e-92e2-593d57bface9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful Life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_293cf0f4-43d6-45c1-b563-8c62db5e322a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled, forfeited or expired (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c6907b72-e8c6-48de-8028-65e2ef739bac_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9935c9b4-866b-4cea-8bf8-fb5aee6f4a41_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested, beginning balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b35d716c-c006-4008-bbc4-b984dc6ceff3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested, ending balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_30099ef3-a067-437b-af2a-40cf8a09ed53_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in partnerships</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Investment in Noncontrolled Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_ede8e84e-8c49-4e12-b91b-240975bd0b66_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_c92b4c85-9847-4cc6-a701-4f97520855b6_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EstimatedInsuranceTotal_d22dbb95-d9af-4623-8c7d-ef6af71bdc27_totalLabel_en-US" xlink:label="lab_amed_EstimatedInsuranceTotal" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Insurance Total</link:label>
    <link:label id="lab_amed_EstimatedInsuranceTotal_label_en-US" xlink:label="lab_amed_EstimatedInsuranceTotal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Insurance Total</link:label>
    <link:label id="lab_amed_EstimatedInsuranceTotal_documentation_en-US" xlink:label="lab_amed_EstimatedInsuranceTotal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated insurance, total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedInsuranceTotal" xlink:href="amed-20221231.xsd#amed_EstimatedInsuranceTotal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EstimatedInsuranceTotal" xlink:to="lab_amed_EstimatedInsuranceTotal" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NumberOfAdmittingJointVentures_23673419-7d18-479b-b320-8205f6412fba_terseLabel_en-US" xlink:label="lab_amed_NumberOfAdmittingJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Admitting Joint Ventures</link:label>
    <link:label id="lab_amed_NumberOfAdmittingJointVentures_label_en-US" xlink:label="lab_amed_NumberOfAdmittingJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Admitting Joint Ventures</link:label>
    <link:label id="lab_amed_NumberOfAdmittingJointVentures_documentation_en-US" xlink:label="lab_amed_NumberOfAdmittingJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Admitting Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfAdmittingJointVentures" xlink:href="amed-20221231.xsd#amed_NumberOfAdmittingJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NumberOfAdmittingJointVentures" xlink:to="lab_amed_NumberOfAdmittingJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MedicareRevenueMember_2e9caa3a-a648-4061-b4c1-7a700574b063_terseLabel_en-US" xlink:label="lab_amed_MedicareRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Revenue [Member]</link:label>
    <link:label id="lab_amed_MedicareRevenueMember_label_en-US" xlink:label="lab_amed_MedicareRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Revenue [Member]</link:label>
    <link:label id="lab_amed_MedicareRevenueMember_documentation_en-US" xlink:label="lab_amed_MedicareRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember" xlink:href="amed-20221231.xsd#amed_MedicareRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MedicareRevenueMember" xlink:to="lab_amed_MedicareRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_5316fcc5-d70e-4cb3-8014-64414d62aa40_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationTable" xlink:to="lab_us-gaap_IncomeTaxExaminationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense_a79573c6-ff8e-4a75-b82b-5e638c44a965_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Current Assets Prepaid Expense</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Current Assets Prepaid Expense</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:href="amed-20221231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e946b09c-04a4-42a9-9365-fdf39ed0500b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_c8ad5f01-4ece-4e00-9f79-93885d1f756b_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_c62bc5f5-d111-47c6-91fa-e6a21f68f2ff_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_fbf0cf18-4cc7-4166-bd64-cbf5ca1d66d1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent_b7f154cc-a2bf-4c04-9ba6-16e2ae4536b3_terseLabel_en-US" xlink:label="lab_amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent_label_en-US" xlink:label="lab_amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Including Discontinued Operation Accrued Expenses Current</link:label>
    <link:label id="lab_amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent_documentation_en-US" xlink:label="lab_amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount classified as accrued expenses attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent" xlink:href="amed-20221231.xsd#amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent" xlink:to="lab_amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_155c1b0e-d68e-4f4c-aba2-287d6e1c84bc_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_8636729a-5c84-4555-a42e-0e10fcc5b765_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Diluted</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock_2030f9f6-346d-4207-a7cb-b86951c4066a_terseLabel_en-US" xlink:label="lab_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Cares Act Provider Relief Funds</link:label>
    <link:label id="lab_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock_label_en-US" xlink:label="lab_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Cares Act Provider Relief Funds [Table Text Block]</link:label>
    <link:label id="lab_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock_documentation_en-US" xlink:label="lab_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cares Act Provider Relief Funds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock" xlink:href="amed-20221231.xsd#amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock" xlink:to="lab_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LeaseTypeAxis_9743cb3f-1320-4d6c-83e0-db8d8476a7b5_terseLabel_en-US" xlink:label="lab_amed_LeaseTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease type [Axis]</link:label>
    <link:label id="lab_amed_LeaseTypeAxis_label_en-US" xlink:label="lab_amed_LeaseTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease type [Axis]</link:label>
    <link:label id="lab_amed_LeaseTypeAxis_documentation_en-US" xlink:label="lab_amed_LeaseTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LeaseTypeAxis" xlink:href="amed-20221231.xsd#amed_LeaseTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LeaseTypeAxis" xlink:to="lab_amed_LeaseTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_e87c1852-a0bf-42a7-b8ea-45352fa7f181_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_77dcd890-ff2e-4c59-834c-9a97da163984_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_3287edd8-a293-4ec8-83c7-ee4aacbc6db7_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term obligations</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_968cf329-46a7-40d4-85e8-441db20999c6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmountReleasedFromEscrow_06d73594-f4b1-4605-a2a9-7bcd6f170543_terseLabel_en-US" xlink:label="lab_amed_AmountReleasedFromEscrow" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Released From Escrow</link:label>
    <link:label id="lab_amed_AmountReleasedFromEscrow_label_en-US" xlink:label="lab_amed_AmountReleasedFromEscrow" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Released From Escrow</link:label>
    <link:label id="lab_amed_AmountReleasedFromEscrow_documentation_en-US" xlink:label="lab_amed_AmountReleasedFromEscrow" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Released From Escrow</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmountReleasedFromEscrow" xlink:href="amed-20221231.xsd#amed_AmountReleasedFromEscrow"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmountReleasedFromEscrow" xlink:to="lab_amed_AmountReleasedFromEscrow" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_9b8def4c-c654-4698-9aa9-16f65f22874b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SwingLineFacility_7aee2f35-023f-434c-af5a-43a8e91f1d95_terseLabel_en-US" xlink:label="lab_amed_SwingLineFacility" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swing Line Facility</link:label>
    <link:label id="lab_amed_SwingLineFacility_label_en-US" xlink:label="lab_amed_SwingLineFacility" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swing Line Facility</link:label>
    <link:label id="lab_amed_SwingLineFacility_documentation_en-US" xlink:label="lab_amed_SwingLineFacility" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swing Line Facility included within Revolving Credit Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SwingLineFacility" xlink:href="amed-20221231.xsd#amed_SwingLineFacility"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SwingLineFacility" xlink:to="lab_amed_SwingLineFacility" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_A49InterestSoldInTwoCareCentersMember_c80a7416-0839-4011-b000-6eed7f7617e1_terseLabel_en-US" xlink:label="lab_amed_A49InterestSoldInTwoCareCentersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">49% Interest Sold in Two Care Centers</link:label>
    <link:label id="lab_amed_A49InterestSoldInTwoCareCentersMember_label_en-US" xlink:label="lab_amed_A49InterestSoldInTwoCareCentersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">49% Interest Sold in Two Care Centers [Member]</link:label>
    <link:label id="lab_amed_A49InterestSoldInTwoCareCentersMember_documentation_en-US" xlink:label="lab_amed_A49InterestSoldInTwoCareCentersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">49% Interest Sold in Two Care Centers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A49InterestSoldInTwoCareCentersMember" xlink:href="amed-20221231.xsd#amed_A49InterestSoldInTwoCareCentersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_A49InterestSoldInTwoCareCentersMember" xlink:to="lab_amed_A49InterestSoldInTwoCareCentersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_edf94352-b203-4016-8958-6185ff016374_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_1c008058-7a6d-4729-9222-92edf26a37f2_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheOneMember_4a0cdc81-627d-416a-8114-5953dd0f67a8_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio: Greater Than 3.00 to 1.0</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheOneMember_label_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche One [Member]</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheOneMember_documentation_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheOneMember" xlink:href="amed-20221231.xsd#amed_DebtInstrumentByLeverageRatioTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentByLeverageRatioTrancheOneMember" xlink:to="lab_amed_DebtInstrumentByLeverageRatioTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_AZ_904d80ea-e719-4e46-b2a7-fdd39bea6868_terseLabel_en-US" xlink:label="lab_stpr_AZ" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arizona [Member]</link:label>
    <link:label id="lab_stpr_AZ_label_en-US" xlink:label="lab_stpr_AZ" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ARIZONA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_AZ" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_AZ"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_AZ" xlink:to="lab_stpr_AZ" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmendedCreditAgreementMember_bb812273-2398-4423-a499-f8938c27e08c_terseLabel_en-US" xlink:label="lab_amed_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_AmendedCreditAgreementMember_label_en-US" xlink:label="lab_amed_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_AmendedCreditAgreementMember_documentation_en-US" xlink:label="lab_amed_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedCreditAgreementMember" xlink:href="amed-20221231.xsd#amed_AmendedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmendedCreditAgreementMember" xlink:to="lab_amed_AmendedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_50860f3a-8870-4c3d-8ea1-46118540c12a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ReversalOfLossContingencyAccrual_f122be49-c658-4a81-ac1e-0c122fc71cbb_terseLabel_en-US" xlink:label="lab_amed_ReversalOfLossContingencyAccrual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal of Loss Contingency Accrual</link:label>
    <link:label id="lab_amed_ReversalOfLossContingencyAccrual_label_en-US" xlink:label="lab_amed_ReversalOfLossContingencyAccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal of Loss Contingency Accrual</link:label>
    <link:label id="lab_amed_ReversalOfLossContingencyAccrual_documentation_en-US" xlink:label="lab_amed_ReversalOfLossContingencyAccrual" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal of Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ReversalOfLossContingencyAccrual" xlink:href="amed-20221231.xsd#amed_ReversalOfLossContingencyAccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ReversalOfLossContingencyAccrual" xlink:to="lab_amed_ReversalOfLossContingencyAccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DeferredOperatingIncomeCARESAct_9cb5b04e-e0d1-4037-891e-f1cdc0ae0a56_terseLabel_en-US" xlink:label="lab_amed_DeferredOperatingIncomeCARESAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred operating income (CARES Act)</link:label>
    <link:label id="lab_amed_DeferredOperatingIncomeCARESAct_label_en-US" xlink:label="lab_amed_DeferredOperatingIncomeCARESAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Operating Income (CARES Act)</link:label>
    <link:label id="lab_amed_DeferredOperatingIncomeCARESAct_documentation_en-US" xlink:label="lab_amed_DeferredOperatingIncomeCARESAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred operating income as a result of the CARES Act in relation to the Novel Coronavirus Pandemic ("COVID-19")</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredOperatingIncomeCARESAct" xlink:href="amed-20221231.xsd#amed_DeferredOperatingIncomeCARESAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DeferredOperatingIncomeCARESAct" xlink:to="lab_amed_DeferredOperatingIncomeCARESAct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c19c44d5-4fe3-41ef-baaf-9f7e20dd7bb9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_fd11ee9f-3eab-41d4-9365-ff4facc50ad8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DefinedContributionPlanEmployerMatchingContribution_bb8d43d2-7e3b-42f3-bb28-44c7e8bc2fef_terseLabel_en-US" xlink:label="lab_amed_DefinedContributionPlanEmployerMatchingContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer match amount</link:label>
    <link:label id="lab_amed_DefinedContributionPlanEmployerMatchingContribution_label_en-US" xlink:label="lab_amed_DefinedContributionPlanEmployerMatchingContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Employer Matching Contribution</link:label>
    <link:label id="lab_amed_DefinedContributionPlanEmployerMatchingContribution_documentation_en-US" xlink:label="lab_amed_DefinedContributionPlanEmployerMatchingContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan employer matching contribution.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DefinedContributionPlanEmployerMatchingContribution" xlink:href="amed-20221231.xsd#amed_DefinedContributionPlanEmployerMatchingContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DefinedContributionPlanEmployerMatchingContribution" xlink:to="lab_amed_DefinedContributionPlanEmployerMatchingContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_976c5ba4-1ac8-4e56-83df-9ac42fec4365_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense weighted-average period for recognitions (years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_791d74d9-32d3-42c2-967c-cede0adc1bb9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, weighted average contractual life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_d42355fa-f646-49d0-8e80-b9e0c7f1894b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_5e76e660-ee1b-40e2-b003-1192577fd7ce_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of cost method investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_c3f41864-141a-4d76-bebc-3ae897b66bb1_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NewShareRepurchaseProgramMember_395446b8-c330-43f7-8c6a-25f64a628927_terseLabel_en-US" xlink:label="lab_amed_NewShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Share Repurchase Program [Member]</link:label>
    <link:label id="lab_amed_NewShareRepurchaseProgramMember_label_en-US" xlink:label="lab_amed_NewShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Share Repurchase Program [Member]</link:label>
    <link:label id="lab_amed_NewShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_amed_NewShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NewShareRepurchaseProgramMember" xlink:href="amed-20221231.xsd#amed_NewShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NewShareRepurchaseProgramMember" xlink:to="lab_amed_NewShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_fb2d9d80-5750-447c-b501-fd038213bbc7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per Employee Stock Purchase Plan share issued (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Per Share Weighted Average Price of Shares Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_2c07536e-168b-4210-bb12-08f5a1a09da7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6af8679b-115b-4c33-9c50-65c75cbacb02_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_8977179f-b76e-428b-9b6f-e86bb114dc65_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMPLOYEE BENEFIT PLANS</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FinancialInstrumentDetailsTableTextBlock_efbd5856-2a3d-420e-b8a7-a6909755643e_terseLabel_en-US" xlink:label="lab_amed_FinancialInstrumentDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Financial Instruments</link:label>
    <link:label id="lab_amed_FinancialInstrumentDetailsTableTextBlock_label_en-US" xlink:label="lab_amed_FinancialInstrumentDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument Details [Table Text Block]</link:label>
    <link:label id="lab_amed_FinancialInstrumentDetailsTableTextBlock_documentation_en-US" xlink:label="lab_amed_FinancialInstrumentDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument Details, table</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FinancialInstrumentDetailsTableTextBlock" xlink:href="amed-20221231.xsd#amed_FinancialInstrumentDetailsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FinancialInstrumentDetailsTableTextBlock" xlink:to="lab_amed_FinancialInstrumentDetailsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bdb63534-4c47-4407-ab7d-bd52caaae992_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ee2f4bc3-44d4-4dc4-b973-017f157a1ab1_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Stockholders Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d55e79df-1a74-436e-b1f8-17dd2845f8a3_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Stockholders Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_7d59a3af-796b-48f2-acb1-4cdd702576d0_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9e5f0f9b-96fe-4bde-9c8c-23c0acf8f746_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockTextBlock_2ad4c9c0-9dde-410d-806b-232ec64207b6_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHARE REPURCHASE</link:label>
    <link:label id="lab_us-gaap_TreasuryStockTextBlock_label_en-US" xlink:label="lab_us-gaap_TreasuryStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockTextBlock" xlink:to="lab_us-gaap_TreasuryStockTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TotalCARESActProviderReliefFundsReceived_d94ccaf3-2a59-4c0b-92ec-0307fdf51d5a_terseLabel_en-US" xlink:label="lab_amed_TotalCARESActProviderReliefFundsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total CARES Act Provider Relief Funds Received</link:label>
    <link:label id="lab_amed_TotalCARESActProviderReliefFundsReceived_label_en-US" xlink:label="lab_amed_TotalCARESActProviderReliefFundsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total CARES Act Provider Relief Funds Received</link:label>
    <link:label id="lab_amed_TotalCARESActProviderReliefFundsReceived_documentation_en-US" xlink:label="lab_amed_TotalCARESActProviderReliefFundsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total CARES Act Provider Relief Funds Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalCARESActProviderReliefFundsReceived" xlink:href="amed-20221231.xsd#amed_TotalCARESActProviderReliefFundsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TotalCARESActProviderReliefFundsReceived" xlink:to="lab_amed_TotalCARESActProviderReliefFundsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_5fd1cca7-8b60-44aa-bdf6-3c540fe374d0_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_03e44f16-866a-48c6-8549-ac82425de0f8_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_7fb12b9b-b1df-4f65-b7b7-9de86a176263_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_ba36d3f4-1da8-49be-931b-1eee168d8190_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition, other intangibles recorded</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_65be81c0-56a5-449f-bc10-3f41709d6836_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:to="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ffa6d9d6-1307-4e92-90f6-1bc1f3197ccc_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_37db4c8e-6006-41c4-a6d7-3707f2f2e772_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_1c075dce-852d-4d37-b30b-ab8addaf6295_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_c387a5e7-9412-4b9e-a197-c4793c31ea5d_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased, weighted average price per share (usd per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NumberOfClaimsSubmittedBySubsidiary_d4a71013-6d20-44ef-879e-14dd88e059c2_terseLabel_en-US" xlink:label="lab_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims submitted by subsidiary</link:label>
    <link:label id="lab_amed_NumberOfClaimsSubmittedBySubsidiary_label_en-US" xlink:label="lab_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Claims Submitted By Subsidiary</link:label>
    <link:label id="lab_amed_NumberOfClaimsSubmittedBySubsidiary_documentation_en-US" xlink:label="lab_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims submitted by subsidiary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:href="amed-20221231.xsd#amed_NumberOfClaimsSubmittedBySubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:to="lab_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_fdf227d7-a98e-4eb4-b598-b05b54dd0e6c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_3e37d96e-06f6-4399-8b8f-2a08cdb641c6_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_GainRelatedToSaleOfNoncontrollingInterestNetOfTax_70c49ded-5573-4337-9e53-6a6a12a181dd_terseLabel_en-US" xlink:label="lab_amed_GainRelatedToSaleOfNoncontrollingInterestNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Related To Sale Of Noncontrolling Interest Net Of Tax</link:label>
    <link:label id="lab_amed_GainRelatedToSaleOfNoncontrollingInterestNetOfTax_label_en-US" xlink:label="lab_amed_GainRelatedToSaleOfNoncontrollingInterestNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Related To Sale Of Noncontrolling Interest Net Of Tax</link:label>
    <link:label id="lab_amed_GainRelatedToSaleOfNoncontrollingInterestNetOfTax_documentation_en-US" xlink:label="lab_amed_GainRelatedToSaleOfNoncontrollingInterestNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Related To Sale Of Noncontrolling Interest Net Of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_GainRelatedToSaleOfNoncontrollingInterestNetOfTax" xlink:href="amed-20221231.xsd#amed_GainRelatedToSaleOfNoncontrollingInterestNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_GainRelatedToSaleOfNoncontrollingInterestNetOfTax" xlink:to="lab_amed_GainRelatedToSaleOfNoncontrollingInterestNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ddb580e0-6cca-464f-9c62-74b64692ba82_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss (income) attributable to non-controlling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b2b1b33f-bbd9-4bb4-9352-baaea3360dea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3695f16d-3986-428c-bd56-b1048eb666e1_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_74445c64-9b93-4f14-a391-437d123b7c09_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Commitment Fee Under Credit Facilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Line of Credit Facilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_b35d1d9e-f390-4828-a683-fcca605a03ce_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AssistedCareHomeHealthMember_6c459421-aba4-46dc-8cc3-25afcb4414af_terseLabel_en-US" xlink:label="lab_amed_AssistedCareHomeHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AssistedCare Home Health</link:label>
    <link:label id="lab_amed_AssistedCareHomeHealthMember_label_en-US" xlink:label="lab_amed_AssistedCareHomeHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AssistedCare Home Health [Member]</link:label>
    <link:label id="lab_amed_AssistedCareHomeHealthMember_documentation_en-US" xlink:label="lab_amed_AssistedCareHomeHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AssistedCare Home Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AssistedCareHomeHealthMember" xlink:href="amed-20221231.xsd#amed_AssistedCareHomeHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AssistedCareHomeHealthMember" xlink:to="lab_amed_AssistedCareHomeHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_666d5079-4e17-49d3-a95e-aeb1b90b1ef0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_ee85a5f7-9b59-4b9a-8cb2-341bca70e76f_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_4f41203a-6f17-4051-b807-23fbd21800d3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACQUISITIONS</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_c3a90fd7-4763-4841-98fd-55190d482deb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_b79a9418-8924-432b-8fd8-0c6c6ab6c652_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_82a0afb7-d066-46ec-97df-8b92afff9852_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of net services revenue provided by Medicare</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_e5d2a5e5-8657-4414-ae14-cb7afa2b1e91_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_07ab9799-0215-4b37-8665-c96cd23b6bf4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_0b955a50-5b71-4928-81c9-58674ac973f4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NonVestedStockUnitsMember_50364b1e-322d-4906-b3d4-88b84eabd255_terseLabel_en-US" xlink:label="lab_amed_NonVestedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Vested Stock Units [Member]</link:label>
    <link:label id="lab_amed_NonVestedStockUnitsMember_label_en-US" xlink:label="lab_amed_NonVestedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Vested Stock Units [Member]</link:label>
    <link:label id="lab_amed_NonVestedStockUnitsMember_documentation_en-US" xlink:label="lab_amed_NonVestedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Vested Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockUnitsMember" xlink:href="amed-20221231.xsd#amed_NonVestedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NonVestedStockUnitsMember" xlink:to="lab_amed_NonVestedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CARESActProviderReliefFundUtilizedByUnconsolidatedJointVentures_f02c786c-7d48-4956-bb7b-aa5920967916_terseLabel_en-US" xlink:label="lab_amed_CARESActProviderReliefFundUtilizedByUnconsolidatedJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Funds Utilized By Unconsolidated Joint Ventures</link:label>
    <link:label id="lab_amed_CARESActProviderReliefFundUtilizedByUnconsolidatedJointVentures_label_en-US" xlink:label="lab_amed_CARESActProviderReliefFundUtilizedByUnconsolidatedJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Fund Utilized By Unconsolidated Joint Ventures</link:label>
    <link:label id="lab_amed_CARESActProviderReliefFundUtilizedByUnconsolidatedJointVentures_documentation_en-US" xlink:label="lab_amed_CARESActProviderReliefFundUtilizedByUnconsolidatedJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Fund Utilized By Unconsolidated Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundUtilizedByUnconsolidatedJointVentures" xlink:href="amed-20221231.xsd#amed_CARESActProviderReliefFundUtilizedByUnconsolidatedJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CARESActProviderReliefFundUtilizedByUnconsolidatedJointVentures" xlink:to="lab_amed_CARESActProviderReliefFundUtilizedByUnconsolidatedJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmortizableAcquiredNameAndNoncompeteAgreementsMember_ab5f42a9-e2e4-4103-a7aa-a10d955539f8_terseLabel_en-US" xlink:label="lab_amed_AmortizableAcquiredNameAndNoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortizable acquired name and noncompete agreements</link:label>
    <link:label id="lab_amed_AmortizableAcquiredNameAndNoncompeteAgreementsMember_label_en-US" xlink:label="lab_amed_AmortizableAcquiredNameAndNoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortizable acquired name and noncompete agreements [Member]</link:label>
    <link:label id="lab_amed_AmortizableAcquiredNameAndNoncompeteAgreementsMember_documentation_en-US" xlink:label="lab_amed_AmortizableAcquiredNameAndNoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortizable acquired name and noncompete agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmortizableAcquiredNameAndNoncompeteAgreementsMember" xlink:href="amed-20221231.xsd#amed_AmortizableAcquiredNameAndNoncompeteAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmortizableAcquiredNameAndNoncompeteAgreementsMember" xlink:to="lab_amed_AmortizableAcquiredNameAndNoncompeteAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_523e3a42-4f36-4d7e-b217-c49a554a7c4e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_470c492b-9212-4f78-9c3c-d579b881b44d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValueOutstanding" xlink:to="lab_us-gaap_PreferredStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NumberOfCareCentersClosed_495d535b-a7d2-40c7-9f25-f1b75b2747ea_terseLabel_en-US" xlink:label="lab_amed_NumberOfCareCentersClosed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of care centers closed</link:label>
    <link:label id="lab_amed_NumberOfCareCentersClosed_label_en-US" xlink:label="lab_amed_NumberOfCareCentersClosed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Care Centers Closed</link:label>
    <link:label id="lab_amed_NumberOfCareCentersClosed_documentation_en-US" xlink:label="lab_amed_NumberOfCareCentersClosed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating care centers that were closed during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfCareCentersClosed" xlink:href="amed-20221231.xsd#amed_NumberOfCareCentersClosed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NumberOfCareCentersClosed" xlink:to="lab_amed_NumberOfCareCentersClosed" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NonCashNoncontrollingInterestContribution_e25686de-5893-49e5-adf7-d55c98cdd4bb_terseLabel_en-US" xlink:label="lab_amed_NonCashNoncontrollingInterestContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest contribution</link:label>
    <link:label id="lab_amed_NonCashNoncontrollingInterestContribution_label_en-US" xlink:label="lab_amed_NonCashNoncontrollingInterestContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Noncontrolling Interest Contribution</link:label>
    <link:label id="lab_amed_NonCashNoncontrollingInterestContribution_documentation_en-US" xlink:label="lab_amed_NonCashNoncontrollingInterestContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Noncontrolling Interest Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonCashNoncontrollingInterestContribution" xlink:href="amed-20221231.xsd#amed_NonCashNoncontrollingInterestContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NonCashNoncontrollingInterestContribution" xlink:to="lab_amed_NonCashNoncontrollingInterestContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_1afcb8ca-5264-4004-87e8-d2ea7646c54e_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Amedisys, Inc. common stockholders (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HospiceMedicareMember_51d1d0ce-4e91-4311-8659-2bc49bd7711d_terseLabel_en-US" xlink:label="lab_amed_HospiceMedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Medicare [Member]</link:label>
    <link:label id="lab_amed_HospiceMedicareMember_label_en-US" xlink:label="lab_amed_HospiceMedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Medicare [Member]</link:label>
    <link:label id="lab_amed_HospiceMedicareMember_documentation_en-US" xlink:label="lab_amed_HospiceMedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Medicare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareMember" xlink:href="amed-20221231.xsd#amed_HospiceMedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HospiceMedicareMember" xlink:to="lab_amed_HospiceMedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment_a960aeb7-6de1-459b-b82e-63113c08c08c_terseLabel_en-US" xlink:label="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Working Capital Adjustment</link:label>
    <link:label id="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment_label_en-US" xlink:label="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Working Capital Adjustment</link:label>
    <link:label id="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment_documentation_en-US" xlink:label="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Working Capital Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:href="amed-20221231.xsd#amed_BusinessAcquisitionWorkingCapitalAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:to="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NonVestedStockAndStockUnits_6a68d2de-d349-4a6c-9b40-087c20f700bd_terseLabel_en-US" xlink:label="lab_amed_NonVestedStockAndStockUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested stock and stock units</link:label>
    <link:label id="lab_amed_NonVestedStockAndStockUnits_label_en-US" xlink:label="lab_amed_NonVestedStockAndStockUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Vested Stock And Stock Units</link:label>
    <link:label id="lab_amed_NonVestedStockAndStockUnits_documentation_en-US" xlink:label="lab_amed_NonVestedStockAndStockUnits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non vested stock and stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockAndStockUnits" xlink:href="amed-20221231.xsd#amed_NonVestedStockAndStockUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NonVestedStockAndStockUnits" xlink:to="lab_amed_NonVestedStockAndStockUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_a325f880-8278-4581-b54c-9a683ee0cd97_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_8c07592e-52af-481a-a42f-1e7ebdc33e2b_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Segment [Member]</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_IncomeTaxEffectsAllocatedToGoodwill_d72476e1-ba35-4574-b7a9-5fc0b9c2b4fb_terseLabel_en-US" xlink:label="lab_amed_IncomeTaxEffectsAllocatedToGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_amed_IncomeTaxEffectsAllocatedToGoodwill_label_en-US" xlink:label="lab_amed_IncomeTaxEffectsAllocatedToGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Effects Allocated To Goodwill</link:label>
    <link:label id="lab_amed_IncomeTaxEffectsAllocatedToGoodwill_documentation_en-US" xlink:label="lab_amed_IncomeTaxEffectsAllocatedToGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Effects Allocated To Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncomeTaxEffectsAllocatedToGoodwill" xlink:href="amed-20221231.xsd#amed_IncomeTaxEffectsAllocatedToGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_IncomeTaxEffectsAllocatedToGoodwill" xlink:to="lab_amed_IncomeTaxEffectsAllocatedToGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_9b9fd502-3f28-475d-807f-4536bbc90f9b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageofSharesOutstanding_dc2f364a-aa8f-4582-8946-37689f73b08b_terseLabel_en-US" xlink:label="lab_amed_PercentageofSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Shares Outstanding</link:label>
    <link:label id="lab_amed_PercentageofSharesOutstanding_label_en-US" xlink:label="lab_amed_PercentageofSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Shares Outstanding</link:label>
    <link:label id="lab_amed_PercentageofSharesOutstanding_documentation_en-US" xlink:label="lab_amed_PercentageofSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofSharesOutstanding" xlink:href="amed-20221231.xsd#amed_PercentageofSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageofSharesOutstanding" xlink:to="lab_amed_PercentageofSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_055224b7-8aa3-4357-a8af-e514828c4344_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_cee4852b-d653-4849-9c0b-de1630797d42_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ProvisionForLiabilityOnRegulatoryAudit_313cf82a-35f3-4628-98f4-f981f24db6c1_terseLabel_en-US" xlink:label="lab_amed_ProvisionForLiabilityOnRegulatoryAudit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida ZPIC audit, gross liability</link:label>
    <link:label id="lab_amed_ProvisionForLiabilityOnRegulatoryAudit_label_en-US" xlink:label="lab_amed_ProvisionForLiabilityOnRegulatoryAudit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Liability On Regulatory Audit</link:label>
    <link:label id="lab_amed_ProvisionForLiabilityOnRegulatoryAudit_documentation_en-US" xlink:label="lab_amed_ProvisionForLiabilityOnRegulatoryAudit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Liability On Regulatory Audit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProvisionForLiabilityOnRegulatoryAudit" xlink:href="amed-20221231.xsd#amed_ProvisionForLiabilityOnRegulatoryAudit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ProvisionForLiabilityOnRegulatoryAudit" xlink:to="lab_amed_ProvisionForLiabilityOnRegulatoryAudit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_9182b6e2-5c21-463d-9237-39585c48f712_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e5d9a6bd-047b-498c-a603-a8e31035f298_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9a2729c3-a72d-40c2-89b1-6bc5abb85717_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of impact of acquisitions:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_adc19795-7839-4863-9f79-e216126d4ddf_terseLabel_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of request for anticipated payment submitted for the initial period of care</link:label>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_label_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate Of Request For Anticipated Payment Submitted For Initial Period Of Care</link:label>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_documentation_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage of estimated payment that is requested at the start of care for an initial period of care.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:href="amed-20221231.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:to="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_2bc5a963-4dd2-42b3-9e06-06274b3c842f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease - 2027</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_9cd0254c-0bfe-4759-b952-601af51e610c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1042b49f-0ffc-4712-b6e3-14f268be1193_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FundingReceivedFromCARESAct_f5586e04-8520-40bb-a5e7-19b5948b0122_terseLabel_en-US" xlink:label="lab_amed_FundingReceivedFromCARESAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Received From CARES Act</link:label>
    <link:label id="lab_amed_FundingReceivedFromCARESAct_label_en-US" xlink:label="lab_amed_FundingReceivedFromCARESAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Received From CARES Act</link:label>
    <link:label id="lab_amed_FundingReceivedFromCARESAct_documentation_en-US" xlink:label="lab_amed_FundingReceivedFromCARESAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding received by the Company from the Coronavirus Aid Relief and Economic Security (CARES) Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingReceivedFromCARESAct" xlink:href="amed-20221231.xsd#amed_FundingReceivedFromCARESAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FundingReceivedFromCARESAct" xlink:to="lab_amed_FundingReceivedFromCARESAct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_b35ad293-89f1-4c7e-8956-1b75cbaed5aa_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of company stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_6e6079a2-a2ba-4b64-962a-23fbe359435d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of company stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TypeOfIncomeTaxDeferralAxis_e77f19d0-80e4-4443-8f4a-413565f00801_terseLabel_en-US" xlink:label="lab_amed_TypeOfIncomeTaxDeferralAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Income Tax Deferral [Axis]</link:label>
    <link:label id="lab_amed_TypeOfIncomeTaxDeferralAxis_label_en-US" xlink:label="lab_amed_TypeOfIncomeTaxDeferralAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Income Tax Deferral [Axis]</link:label>
    <link:label id="lab_amed_TypeOfIncomeTaxDeferralAxis_documentation_en-US" xlink:label="lab_amed_TypeOfIncomeTaxDeferralAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Income Tax Deferral</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeOfIncomeTaxDeferralAxis" xlink:href="amed-20221231.xsd#amed_TypeOfIncomeTaxDeferralAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TypeOfIncomeTaxDeferralAxis" xlink:to="lab_amed_TypeOfIncomeTaxDeferralAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_4cf11782-da1a-4be1-997b-28063107df5b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_c6360d5d-18b5-4443-a2c3-e1efbd9b8f73_terseLabel_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of overpayment made to subsidiary including interest</link:label>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_label_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery Amount of Overpayment Made To Subsidiary Including Interest</link:label>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_documentation_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of overpayment made to subsidiary including interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:href="amed-20221231.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:to="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_60b8d295-042a-4b27-95d1-653ea193d53f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_5cac3024-9a01-434e-8f82-f9111d2de9bf_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_FL_6fa1a113-153a-499c-aebb-6aef6d827bd9_terseLabel_en-US" xlink:label="lab_stpr_FL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida [Member]</link:label>
    <link:label id="lab_stpr_FL_label_en-US" xlink:label="lab_stpr_FL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLORIDA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_FL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_FL" xlink:to="lab_stpr_FL" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_f0dc4b07-5d78-480f-937a-45447f0a2464_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_cabf4bf0-ecba-4d5a-b263-be424a1eac08_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent_7ed88474-10c8-4daf-b5ae-ef88abd2fa2b_terseLabel_en-US" xlink:label="lab_amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll and employee benefits</link:label>
    <link:label id="lab_amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Including Discontinued Operation Payroll and Employee Benefits Current</link:label>
    <link:label id="lab_amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent_documentation_en-US" xlink:label="lab_amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount classified as payroll and employee benefits payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent" xlink:href="amed-20221231.xsd#amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent" xlink:to="lab_amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_IncreaseDecreaseInAssetsAcquired_3e0b931b-ad56-4698-b897-a4282d1aada9_terseLabel_en-US" xlink:label="lab_amed_IncreaseDecreaseInAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Assets Acquired</link:label>
    <link:label id="lab_amed_IncreaseDecreaseInAssetsAcquired_label_en-US" xlink:label="lab_amed_IncreaseDecreaseInAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Assets Acquired</link:label>
    <link:label id="lab_amed_IncreaseDecreaseInAssetsAcquired_documentation_en-US" xlink:label="lab_amed_IncreaseDecreaseInAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInAssetsAcquired" xlink:href="amed-20221231.xsd#amed_IncreaseDecreaseInAssetsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_IncreaseDecreaseInAssetsAcquired" xlink:to="lab_amed_IncreaseDecreaseInAssetsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HighAcuityCareMember_43c995ce-d8e1-4e0c-96f5-bc53be7f4566_terseLabel_en-US" xlink:label="lab_amed_HighAcuityCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">High Acuity Care [Member]</link:label>
    <link:label id="lab_amed_HighAcuityCareMember_label_en-US" xlink:label="lab_amed_HighAcuityCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">High Acuity Care [Member]</link:label>
    <link:label id="lab_amed_HighAcuityCareMember_documentation_en-US" xlink:label="lab_amed_HighAcuityCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">High Acuity Care</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember" xlink:href="amed-20221231.xsd#amed_HighAcuityCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HighAcuityCareMember" xlink:to="lab_amed_HighAcuityCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyReceivableCurrent_4536cba1-0c6e-464f-8b06-61b5052c39d4_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement amount to be paid by Company's insurance carriers</link:label>
    <link:label id="lab_us-gaap_LossContingencyReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_LossContingencyReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyReceivableCurrent" xlink:to="lab_us-gaap_LossContingencyReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_767bd982-5827-4145-b68c-b5f0ad7e67af_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_OtherIntangibleAssetsAdditions_31e597af-13dd-4d6f-951d-b7048411bfb6_terseLabel_en-US" xlink:label="lab_amed_OtherIntangibleAssetsAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_amed_OtherIntangibleAssetsAdditions_label_en-US" xlink:label="lab_amed_OtherIntangibleAssetsAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets Additions</link:label>
    <link:label id="lab_amed_OtherIntangibleAssetsAdditions_documentation_en-US" xlink:label="lab_amed_OtherIntangibleAssetsAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to Other Intangible Assets that occurred during the period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OtherIntangibleAssetsAdditions" xlink:href="amed-20221231.xsd#amed_OtherIntangibleAssetsAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OtherIntangibleAssetsAdditions" xlink:to="lab_amed_OtherIntangibleAssetsAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_OperatingLeaseTermYears_38a2468b-2016-4ba2-8f0c-e1460060c409_terseLabel_en-US" xlink:label="lab_amed_OperatingLeaseTermYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease term (years)</link:label>
    <link:label id="lab_amed_OperatingLeaseTermYears_label_en-US" xlink:label="lab_amed_OperatingLeaseTermYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Term Years</link:label>
    <link:label id="lab_amed_OperatingLeaseTermYears_documentation_en-US" xlink:label="lab_amed_OperatingLeaseTermYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease term, years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OperatingLeaseTermYears" xlink:href="amed-20221231.xsd#amed_OperatingLeaseTermYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OperatingLeaseTermYears" xlink:to="lab_amed_OperatingLeaseTermYears" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued_9522853c-da88-4d19-9af9-155e3e5898f8_terseLabel_en-US" xlink:label="lab_amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of care centers start-up process discontinued</link:label>
    <link:label id="lab_amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued_label_en-US" xlink:label="lab_amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Prospective Unopened Care Centers Start Up Process Discontinued</link:label>
    <link:label id="lab_amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued_documentation_en-US" xlink:label="lab_amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of prospective unopened care centers for which the start-up process was discontinued during the period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued" xlink:href="amed-20221231.xsd#amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued" xlink:to="lab_amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f506dd13-0879-4635-9fd5-8e4746b78453_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_COVID19DeferralOfSocialSecurityTaxesMember_2b93879f-4bb4-477f-a515-800f66bc3f7a_terseLabel_en-US" xlink:label="lab_amed_COVID19DeferralOfSocialSecurityTaxesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Deferral of Social Security Taxes [Member]</link:label>
    <link:label id="lab_amed_COVID19DeferralOfSocialSecurityTaxesMember_label_en-US" xlink:label="lab_amed_COVID19DeferralOfSocialSecurityTaxesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Deferral of Social Security Taxes [Member]</link:label>
    <link:label id="lab_amed_COVID19DeferralOfSocialSecurityTaxesMember_documentation_en-US" xlink:label="lab_amed_COVID19DeferralOfSocialSecurityTaxesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Deferral of Social Security Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19DeferralOfSocialSecurityTaxesMember" xlink:href="amed-20221231.xsd#amed_COVID19DeferralOfSocialSecurityTaxesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_COVID19DeferralOfSocialSecurityTaxesMember" xlink:to="lab_amed_COVID19DeferralOfSocialSecurityTaxesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_fb7daf06-6988-44ba-9932-ccd156caf23d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ShareBasedAwardsMember_90f3bd4c-2b9b-4417-a7a8-e826b19b96c9_terseLabel_en-US" xlink:label="lab_amed_ShareBasedAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Awards [Member]</link:label>
    <link:label id="lab_amed_ShareBasedAwardsMember_label_en-US" xlink:label="lab_amed_ShareBasedAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Awards [Member]</link:label>
    <link:label id="lab_amed_ShareBasedAwardsMember_documentation_en-US" xlink:label="lab_amed_ShareBasedAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareBasedAwardsMember" xlink:href="amed-20221231.xsd#amed_ShareBasedAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ShareBasedAwardsMember" xlink:to="lab_amed_ShareBasedAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_ae89e323-2f36-4440-88bc-955cb8e10cc1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_ce26a739-7125-4bf2-ab4f-9cbce0870432_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_A2037ExpirationMember_a9e0dfea-e0f1-4e7b-abe2-9f47aa829f22_terseLabel_en-US" xlink:label="lab_amed_A2037ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2037 Expiration</link:label>
    <link:label id="lab_amed_A2037ExpirationMember_label_en-US" xlink:label="lab_amed_A2037ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2037 Expiration [Member]</link:label>
    <link:label id="lab_amed_A2037ExpirationMember_documentation_en-US" xlink:label="lab_amed_A2037ExpirationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2037 Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2037ExpirationMember" xlink:href="amed-20221231.xsd#amed_A2037ExpirationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_A2037ExpirationMember" xlink:to="lab_amed_A2037ExpirationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CT_017f412a-bc22-4a32-bca5-0026d77b87d9_terseLabel_en-US" xlink:label="lab_stpr_CT" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Connecticut [Member]</link:label>
    <link:label id="lab_stpr_CT_label_en-US" xlink:label="lab_stpr_CT" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONNECTICUT</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CT" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CT"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CT" xlink:to="lab_stpr_CT" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HospiceAccruals_a540ee1f-e412-40ca-93b3-3f4cd7437457_terseLabel_en-US" xlink:label="lab_amed_HospiceAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice accruals (room and board, general in-patient and other)</link:label>
    <link:label id="lab_amed_HospiceAccruals_label_en-US" xlink:label="lab_amed_HospiceAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice accruals</link:label>
    <link:label id="lab_amed_HospiceAccruals_documentation_en-US" xlink:label="lab_amed_HospiceAccruals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of accrued expenses related to Hospice room and board, general in-patient and other expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceAccruals" xlink:href="amed-20221231.xsd#amed_HospiceAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HospiceAccruals" xlink:to="lab_amed_HospiceAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_a5a65b1f-4442-4c4d-abfa-930607326e15_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b7501814-b3bc-4ac7-8821-785cc08a572b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_ab116a8b-e902-4c76-a28e-e892837b5c2a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing cash flow from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_85788ba3-17eb-4976-8325-72f4ef7d3bcf_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AcquiredNamesMember_8428e899-92e6-4b72-89ab-126847538692_terseLabel_en-US" xlink:label="lab_amed_AcquiredNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Names [Member]</link:label>
    <link:label id="lab_amed_AcquiredNamesMember_1d71c555-8c97-4aaf-b49b-0b75c174dcb0_verboseLabel_en-US" xlink:label="lab_amed_AcquiredNamesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Names [Member]</link:label>
    <link:label id="lab_amed_AcquiredNamesMember_label_en-US" xlink:label="lab_amed_AcquiredNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Names [Member]</link:label>
    <link:label id="lab_amed_AcquiredNamesMember_documentation_en-US" xlink:label="lab_amed_AcquiredNamesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNamesMember" xlink:href="amed-20221231.xsd#amed_AcquiredNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AcquiredNamesMember" xlink:to="lab_amed_AcquiredNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_15d26ffe-62a9-48c3-90d5-08fbbc8f9bc5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock_c8020944-6a52-42d9-8afc-ddb3557ef59e_terseLabel_en-US" xlink:label="lab_amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Remaining Lease Term and Discount Rate</link:label>
    <link:label id="lab_amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock_label_en-US" xlink:label="lab_amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term and discount rate [Table Text Block]</link:label>
    <link:label id="lab_amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock_documentation_en-US" xlink:label="lab_amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term and discount rate Table Text Block</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:href="amed-20221231.xsd#amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:to="lab_amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_7231d979-0b67-4883-a901-37a3afe30db9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_82152fbb-b02e-4e0d-8f37-0853d32c6d1f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_9c4e7de4-a341-43bb-9f4b-f9821bfa7200_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_9a8468c2-82d2-47e5-b1a4-276cd719b3d9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromJointVenturesCurrent_5777eeec-ef1c-4280-92c9-a6d681234708_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromJointVenturesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from joint ventures</link:label>
    <link:label id="lab_us-gaap_DueFromJointVenturesCurrent_label_en-US" xlink:label="lab_us-gaap_DueFromJointVenturesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Joint Ventures, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromJointVenturesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromJointVenturesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromJointVenturesCurrent" xlink:to="lab_us-gaap_DueFromJointVenturesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_ecdccc8a-5c67-4a6f-8e9d-57a5e3c4b10e_terseLabel_en-US" xlink:label="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds Received From Loan Party Of Subsidiary</link:label>
    <link:label id="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_label_en-US" xlink:label="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds Received From Loan Party Of Subsidiary</link:label>
    <link:label id="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_documentation_en-US" xlink:label="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds Received From Loan Party Of Subsidiary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:href="amed-20221231.xsd#amed_ProceedsReceivedFromLoanPartyOfSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:to="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_cf49aad3-f6b5-41cc-b98d-e925213b6ec0_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DocumentAndEntityInformationAbstract_d6eaf54b-9b47-42cd-820b-264c1be9a5c1_terseLabel_en-US" xlink:label="lab_amed_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_amed_DocumentAndEntityInformationAbstract_label_en-US" xlink:label="lab_amed_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_amed_DocumentAndEntityInformationAbstract_documentation_en-US" xlink:label="lab_amed_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DocumentAndEntityInformationAbstract" xlink:href="amed-20221231.xsd#amed_DocumentAndEntityInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DocumentAndEntityInformationAbstract" xlink:to="lab_amed_DocumentAndEntityInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesNoncurrent_c758dfea-87b1-4072-ba76-2f0992185e70_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sundry Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_82e63d1d-734a-4c7a-abfe-92e390fbbe07_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d36026e0-e697-4434-8d5b-881b1dcc79a4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NonMedicareRevenueTermRates_21f81c2c-4bd3-48d8-bccd-a5f2b855cdd7_terseLabel_en-US" xlink:label="lab_amed_NonMedicareRevenueTermRates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-medicare revenue term rates</link:label>
    <link:label id="lab_amed_NonMedicareRevenueTermRates_label_en-US" xlink:label="lab_amed_NonMedicareRevenueTermRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Medicare Revenue Term Rates</link:label>
    <link:label id="lab_amed_NonMedicareRevenueTermRates_documentation_en-US" xlink:label="lab_amed_NonMedicareRevenueTermRates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Medicare Revenue Term Rates as a percentage of Medicare Term Rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonMedicareRevenueTermRates" xlink:href="amed-20221231.xsd#amed_NonMedicareRevenueTermRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NonMedicareRevenueTermRates" xlink:to="lab_amed_NonMedicareRevenueTermRates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_842b32cc-61e3-4192-8ef9-8f31f369619c_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_b09a5968-61b5-48c0-9778-49758693118a_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_84e05b14-f20b-405f-ace4-ac2697f78bf6_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_OrganizationAndNatureOfOperationsTable_cae4bc22-62ff-495b-8acc-8c22fb731f61_terseLabel_en-US" xlink:label="lab_amed_OrganizationAndNatureOfOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Nature Of Operations [Table]</link:label>
    <link:label id="lab_amed_OrganizationAndNatureOfOperationsTable_label_en-US" xlink:label="lab_amed_OrganizationAndNatureOfOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Nature Of Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OrganizationAndNatureOfOperationsTable" xlink:href="amed-20221231.xsd#amed_OrganizationAndNatureOfOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OrganizationAndNatureOfOperationsTable" xlink:to="lab_amed_OrganizationAndNatureOfOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_41925ca0-99fe-4d6e-aa94-6c2bdbff83e8_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock at cost (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_298a8305-112a-44d3-b880-a0ddc13eb642_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayable_82df2317-6c31-4abe-a267-abd6f60d8a27_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable issued in acquisition</link:label>
    <link:label id="lab_us-gaap_NotesPayable_label_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_420dc84a-580f-4523-b221-df9dabd53a41_terseLabel_en-US" xlink:label="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility maximum allowable consolidated leverage ratio</link:label>
    <link:label id="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_label_en-US" xlink:label="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility maximum allowable consolidated leverage ratio</link:label>
    <link:label id="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_documentation_en-US" xlink:label="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility maximum allowable consolidated leverage ratio as defined in the Company's Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:href="amed-20221231.xsd#amed_Creditfacilitymaximumallowableconsolidatedleverageratio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:to="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_efd7dafa-a22e-48b3-ab04-7c8fac51391e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ea25a134-95ca-4799-8acb-a84898fa37aa_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_bd9ec47c-633a-4272-bfb0-e8df697d86c7_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_3e0f45a0-daab-4b6c-a416-4515ef0e9aa2_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_6afe1aef-db02-4026-a870-d3c73b7bfffd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_65071c47-62ba-4739-9105-5e5026c8485f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_927c3444-738e-4123-8d57-19829e794d25_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_26db5226-f7b7-4d70-9b7a-9a3f49a57b86_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_7ee13905-5a80-416e-9b0d-2dff3a3a4b5a_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HealthInsuranceRetentionLimit_7ad04244-d6c1-4824-b930-420054e31dad_terseLabel_en-US" xlink:label="lab_amed_HealthInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health insurance retention limit</link:label>
    <link:label id="lab_amed_HealthInsuranceRetentionLimit_label_en-US" xlink:label="lab_amed_HealthInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Insurance Retention Limit</link:label>
    <link:label id="lab_amed_HealthInsuranceRetentionLimit_documentation_en-US" xlink:label="lab_amed_HealthInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential amount of future payments the entity could be required to make related to a specific Health Insurance Claim.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthInsuranceRetentionLimit" xlink:href="amed-20221231.xsd#amed_HealthInsuranceRetentionLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HealthInsuranceRetentionLimit" xlink:to="lab_amed_HealthInsuranceRetentionLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_c6c6b5f6-1cd7-4fb1-ab51-236b51f9e0c5_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_3a0d84f7-b7de-461d-bb41-3e1b03c1b35f_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of service, excluding depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit_8e594cf8-1c6a-48ca-a15f-268dbcda6dea_terseLabel_en-US" xlink:label="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional liability insurance retention limit</link:label>
    <link:label id="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit_label_en-US" xlink:label="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Liability Insurance Retention Limit</link:label>
    <link:label id="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit_documentation_en-US" xlink:label="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential amount of future payments the entity could be required to make related to a specific Professional Liability Claim.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:href="amed-20221231.xsd#amed_ProfessionalLiabilityInsuranceRetentionLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:to="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e9bd7d8e-7c0f-47d1-b2f1-76622d9de68d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_04a4f0fe-daa1-4de5-a10c-7cdc3731cde2_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_IL_9497cb59-cd29-4a80-925b-b6b89a77cb7b_terseLabel_en-US" xlink:label="lab_stpr_IL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Illinois [Member]</link:label>
    <link:label id="lab_stpr_IL_label_en-US" xlink:label="lab_stpr_IL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ILLINOIS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_IL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_IL" xlink:to="lab_stpr_IL" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_d5b1705f-400f-4c6b-9933-d1c6973fac16_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember_4bbf7105-7e39-4c00-bf7b-b596f9d6dfbf_terseLabel_en-US" xlink:label="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year 2016 Through 2023 [Member]</link:label>
    <link:label id="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember_label_en-US" xlink:label="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year Two Thousand Sixteen Through Two Thousand Twenty Three [Member]</link:label>
    <link:label id="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember_documentation_en-US" xlink:label="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year Two Thousand Sixteen Through Two Thousand Twenty Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember" xlink:href="amed-20221231.xsd#amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember" xlink:to="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsContessaHealthTableTextBlock_24e3fa0a-351a-4463-81f8-96ea1e42308c_terseLabel_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsContessaHealthTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, Contessa Health</link:label>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsContessaHealthTableTextBlock_label_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsContessaHealthTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, Contessa Health [Table Text Block]</link:label>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsContessaHealthTableTextBlock_documentation_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsContessaHealthTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, Contessa Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfBusinessAcquisitionsContessaHealthTableTextBlock" xlink:href="amed-20221231.xsd#amed_ScheduleOfBusinessAcquisitionsContessaHealthTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ScheduleOfBusinessAcquisitionsContessaHealthTableTextBlock" xlink:to="lab_amed_ScheduleOfBusinessAcquisitionsContessaHealthTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_f74e8eaf-f71b-4210-95d6-9caafb2d172f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EvolutionHealthMember_5aa028ea-370c-4073-a33c-a28aa5bcab0b_terseLabel_en-US" xlink:label="lab_amed_EvolutionHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolution Health</link:label>
    <link:label id="lab_amed_EvolutionHealthMember_label_en-US" xlink:label="lab_amed_EvolutionHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolution Health [Member]</link:label>
    <link:label id="lab_amed_EvolutionHealthMember_documentation_en-US" xlink:label="lab_amed_EvolutionHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolution Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EvolutionHealthMember" xlink:href="amed-20221231.xsd#amed_EvolutionHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EvolutionHealthMember" xlink:to="lab_amed_EvolutionHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxCreditsAndAdjustments_1ca2dc27-5af1-4d7a-a011-11f4b176edaa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxCreditsAndAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxCreditsAndAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxCreditsAndAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Credits and Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxCreditsAndAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxCreditsAndAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxCreditsAndAdjustments" xlink:to="lab_us-gaap_IncomeTaxCreditsAndAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_d11eea40-b710-4123-86db-7c5fa669db7e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_3501c896-2026-48b8-9d74-f5f9399ae36a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Integration Related Costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Integration Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TaxExpenseRecordedToAdditionalPaidInCapital_e713b90a-3cd7-4e05-991a-78ff73697fd1_terseLabel_en-US" xlink:label="lab_amed_TaxExpenseRecordedToAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax expense recorded to additional paid-in-capital</link:label>
    <link:label id="lab_amed_TaxExpenseRecordedToAdditionalPaidInCapital_label_en-US" xlink:label="lab_amed_TaxExpenseRecordedToAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Expense Recorded to Additional Paid-in-Capital</link:label>
    <link:label id="lab_amed_TaxExpenseRecordedToAdditionalPaidInCapital_documentation_en-US" xlink:label="lab_amed_TaxExpenseRecordedToAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Expense Recorded to Additional Paid-in-Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TaxExpenseRecordedToAdditionalPaidInCapital" xlink:href="amed-20221231.xsd#amed_TaxExpenseRecordedToAdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TaxExpenseRecordedToAdditionalPaidInCapital" xlink:to="lab_amed_TaxExpenseRecordedToAdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember_ebf9c753-9564-4474-99a5-7670c572914f_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held-for-sale [Member]</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Held-for-sale [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:to="lab_us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_1624f363-9405-4c1d-8dd4-f9b47c496f90_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional interest rate above Federal Fund rate (percent)</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_label_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Additional Interest Above Federal Fund Rate</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_documentation_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Additional Interest Above Federal Fund Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:href="amed-20221231.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:to="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CARESActProviderReliefFundsRepaidToTheGovernment_72798703-c352-4908-af39-6607931df7b0_terseLabel_en-US" xlink:label="lab_amed_CARESActProviderReliefFundsRepaidToTheGovernment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Funds Repaid</link:label>
    <link:label id="lab_amed_CARESActProviderReliefFundsRepaidToTheGovernment_label_en-US" xlink:label="lab_amed_CARESActProviderReliefFundsRepaidToTheGovernment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Funds repaid to the government</link:label>
    <link:label id="lab_amed_CARESActProviderReliefFundsRepaidToTheGovernment_documentation_en-US" xlink:label="lab_amed_CARESActProviderReliefFundsRepaidToTheGovernment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Funds repaid to the government by consolidated entities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundsRepaidToTheGovernment" xlink:href="amed-20221231.xsd#amed_CARESActProviderReliefFundsRepaidToTheGovernment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CARESActProviderReliefFundsRepaidToTheGovernment" xlink:to="lab_amed_CARESActProviderReliefFundsRepaidToTheGovernment" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PayorClassAxis_3a704987-9faa-46ff-988c-f74a34e3c4fc_terseLabel_en-US" xlink:label="lab_amed_PayorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Class [Axis]</link:label>
    <link:label id="lab_amed_PayorClassAxis_label_en-US" xlink:label="lab_amed_PayorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Class [Axis]</link:label>
    <link:label id="lab_amed_PayorClassAxis_documentation_en-US" xlink:label="lab_amed_PayorClassAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassAxis" xlink:href="amed-20221231.xsd#amed_PayorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PayorClassAxis" xlink:to="lab_amed_PayorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock_5632752a-51ae-48e3-961c-dd21ee63ff41_terseLabel_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Business Acquisitions, Asana Hospice</link:label>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock_label_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Business Acquisitions Asana Hospice [Table Text Block]</link:label>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock_documentation_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the Asana business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock" xlink:href="amed-20221231.xsd#amed_ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock" xlink:to="lab_amed_ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_37b66ff7-59ae-4c11-82b2-0173d46f7e33_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ab0e13a3-9e0c-4146-8d1f-f0ecc585bb5b_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_90a09e2e-7929-4322-9dca-3dbe0d2f5fc2_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_defc9375-b1c5-4355-9421-b93bf88c7143_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_b89e9b91-baf4-4bdb-ae31-fbf4531408ce_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment_17350d20-ff8e-4a98-bc74-ceb68946355d_terseLabel_en-US" xlink:label="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of total reimbursement of outlier payment</link:label>
    <link:label id="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment_label_en-US" xlink:label="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Total Reimbursement Of Outlier Payment</link:label>
    <link:label id="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment_documentation_en-US" xlink:label="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage at which total reimbursement is capped if cost of care is unusually costly.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:href="amed-20221231.xsd#amed_PercentageOfTotalReimbursementOfOutlierPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:to="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_e61c0153-2f86-467b-9d27-4b565e0ae07c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASU 2016-02 [Member]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_cee460dd-29a3-496d-a836-bfac1d2ba103_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan_4fa47c7d-32ba-439d-b9ef-59b816bca43a_terseLabel_en-US" xlink:label="lab_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Shares Authorized For Issuance To Employee Stock Purchase Plan</link:label>
    <link:label id="lab_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Shares Authorized For Issuance To Employee Stock Purchase Plan</link:label>
    <link:label id="lab_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan_documentation_en-US" xlink:label="lab_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized for issuance to the Company's employee stock purchase plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan" xlink:href="amed-20221231.xsd#amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan" xlink:to="lab_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_732ffa06-84d0-43cd-a615-08bd5be4a4f2_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ddc1b9d0-2793-4738-9a8d-32645f8efb6d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life of intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_5a879a95-bb57-43af-97a7-9475a0d37d8a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DeferredTaxAssetsLegalAndComplianceMatters_a56c41ad-85ac-4cca-95e8-5ecd86efe4ef_terseLabel_en-US" xlink:label="lab_amed_DeferredTaxAssetsLegalAndComplianceMatters" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal &amp; compliance matters</link:label>
    <link:label id="lab_amed_DeferredTaxAssetsLegalAndComplianceMatters_label_en-US" xlink:label="lab_amed_DeferredTaxAssetsLegalAndComplianceMatters" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Legal and Compliance Matters</link:label>
    <link:label id="lab_amed_DeferredTaxAssetsLegalAndComplianceMatters_documentation_en-US" xlink:label="lab_amed_DeferredTaxAssetsLegalAndComplianceMatters" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from legal and compliance matters.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxAssetsLegalAndComplianceMatters" xlink:href="amed-20221231.xsd#amed_DeferredTaxAssetsLegalAndComplianceMatters"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DeferredTaxAssetsLegalAndComplianceMatters" xlink:to="lab_amed_DeferredTaxAssetsLegalAndComplianceMatters" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_0e88d338-84df-48c1-9801-8a4a7f620772_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Investment [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cb0ac831-6e74-437f-bcd0-f48ff61744d6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_eb1af56e-2675-4cc0-bca4-2344010c83a5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill recorded during period</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_3afdcd62-ab25-4742-8770-76abaaca1302_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_80d774a1-2e03-47f9-9fab-533d11bc2d18_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_b42a0626-9111-4e11-8041-79c17207009d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ErrorRatePercentage_71719675-5b3c-4bb5-af97-55fde49fb5c7_terseLabel_en-US" xlink:label="lab_amed_ErrorRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error rate (percent)</link:label>
    <link:label id="lab_amed_ErrorRatePercentage_label_en-US" xlink:label="lab_amed_ErrorRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Rate Percentage</link:label>
    <link:label id="lab_amed_ErrorRatePercentage_documentation_en-US" xlink:label="lab_amed_ErrorRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Rate Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ErrorRatePercentage" xlink:href="amed-20221231.xsd#amed_ErrorRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ErrorRatePercentage" xlink:to="lab_amed_ErrorRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_12a39e60-21d9-437c-b157-1a37b5680743_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0fa7ecef-4c92-4b61-97ac-eadc343ab1ec_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_c9296300-fe68-41ee-9b6a-3cd9b3284820_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_1164aba3-7183-4a89-b44d-e552709d5404_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_ef3c0ed5-5998-483d-9ce5-4684e83e98a6_totalLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5da8ec8a-5b33-4462-a123-cd0d0a48013e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average&#160;Contractual Life&#160;(Years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d5bff401-e477-466b-ad6c-cbf8034a2bfe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_46df7ba6-d6d9-4d19-ab13-9e6fa1be45f6_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TypeOfEquityMethodInvestmentAxis_a4c77105-fb3e-4597-9d13-b805c50b60a6_terseLabel_en-US" xlink:label="lab_amed_TypeOfEquityMethodInvestmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Equity Method Investment [Axis]</link:label>
    <link:label id="lab_amed_TypeOfEquityMethodInvestmentAxis_label_en-US" xlink:label="lab_amed_TypeOfEquityMethodInvestmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Equity Method Investment [Axis]</link:label>
    <link:label id="lab_amed_TypeOfEquityMethodInvestmentAxis_documentation_en-US" xlink:label="lab_amed_TypeOfEquityMethodInvestmentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Equity Method Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeOfEquityMethodInvestmentAxis" xlink:href="amed-20221231.xsd#amed_TypeOfEquityMethodInvestmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TypeOfEquityMethodInvestmentAxis" xlink:to="lab_amed_TypeOfEquityMethodInvestmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_396758e1-7b3d-4028-a75d-30c608edbf4d_terseLabel_en-US" xlink:label="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of over payment made to subsidiary including interest withheld</link:label>
    <link:label id="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_label_en-US" xlink:label="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery Amount Of Over Payment Made To Subsidiary Including Interest Withheld</link:label>
    <link:label id="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_documentation_en-US" xlink:label="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of over payment made to subsidiary including interest withheld</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:href="amed-20221231.xsd#amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:to="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_1cc57aee-0abe-4e54-9f2c-43ef4cf86710_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NC_edc56c7b-4e23-41b0-8d62-5ccffdf79a23_terseLabel_en-US" xlink:label="lab_stpr_NC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NORTH CAROLINA</link:label>
    <link:label id="lab_stpr_NC_label_en-US" xlink:label="lab_stpr_NC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NORTH CAROLINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NC" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NC" xlink:to="lab_stpr_NC" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock_4837cb72-2b41-4f0c-a440-d8f3b66b2376_terseLabel_en-US" xlink:label="lab_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Useful Lives of Property and Equipment</link:label>
    <link:label id="lab_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock_label_en-US" xlink:label="lab_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Lives Of Property And Equipment [Text Block]</link:label>
    <link:label id="lab_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock_documentation_en-US" xlink:label="lab_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">stimated Useful Lives Of Property And Equipment, table</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock" xlink:href="amed-20221231.xsd#amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock" xlink:to="lab_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FourHundredFiftyMillionTermLoanFacilityMember_952e0e12-9097-44b0-94c4-8523d2f993b1_terseLabel_en-US" xlink:label="lab_amed_FourHundredFiftyMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Hundred Fifty Million Term Loan Facility [Member]</link:label>
    <link:label id="lab_amed_FourHundredFiftyMillionTermLoanFacilityMember_label_en-US" xlink:label="lab_amed_FourHundredFiftyMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Hundred Fifty Million Term Loan Facility [Member]</link:label>
    <link:label id="lab_amed_FourHundredFiftyMillionTermLoanFacilityMember_documentation_en-US" xlink:label="lab_amed_FourHundredFiftyMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Hundred Fifty Million Term Loan Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember" xlink:href="amed-20221231.xsd#amed_FourHundredFiftyMillionTermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember" xlink:to="lab_amed_FourHundredFiftyMillionTermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_91f21a48-0a24-48cc-bfbb-79721fc8f8e7_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_8b8fde39-483a-4f7f-8ca2-0795cf622e70_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flow from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_e7495fc9-3a3a-4f6d-b295-ef56d977e51d_terseLabel_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries and benefits</link:label>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_label_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Labor and Related Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LaborAndRelatedExpense" xlink:to="lab_us-gaap_LaborAndRelatedExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_25089dd3-afc6-4246-92e9-1df280194e7b_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments of long-term obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_d5d485ba-c1b8-4fe2-b102-236520ad63b5_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments of long-term obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_14003a40-0f9e-426e-965a-555847272902_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_d7e1c854-f9c2-4c7d-b472-d2d6276d309a_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock at cost, 5,372,908 and 5,164,899 shares of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_196e3cda-f15d-4f74-877b-eb7a102c6cb7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Volatility Rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_11573796-10b4-4d35-a250-8c1dc3442738_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock_63121b89-ecda-4c22-b5ae-8d3b6d28a314_terseLabel_en-US" xlink:label="lab_amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS</link:label>
    <link:label id="lab_amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock_label_en-US" xlink:label="lab_amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Details of Certain Balance Sheet Accounts Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock" xlink:href="amed-20221231.xsd#amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock" xlink:to="lab_amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OpenTaxYear_f6de14c8-b92a-4a47-b274-30434ce1f3a6_terseLabel_en-US" xlink:label="lab_us-gaap_OpenTaxYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax years open to examination</link:label>
    <link:label id="lab_us-gaap_OpenTaxYear_label_en-US" xlink:label="lab_us-gaap_OpenTaxYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Tax Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenTaxYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenTaxYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OpenTaxYear" xlink:to="lab_us-gaap_OpenTaxYear" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CashBalanceAssociatedWithProviderReliefFund_9b3d7009-1f0e-4d2d-b021-baf8e8192ac1_terseLabel_en-US" xlink:label="lab_amed_CashBalanceAssociatedWithProviderReliefFund" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Balance Associated With Provider Relief Fund</link:label>
    <link:label id="lab_amed_CashBalanceAssociatedWithProviderReliefFund_label_en-US" xlink:label="lab_amed_CashBalanceAssociatedWithProviderReliefFund" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Balance Associated With Provider Relief Fund</link:label>
    <link:label id="lab_amed_CashBalanceAssociatedWithProviderReliefFund_documentation_en-US" xlink:label="lab_amed_CashBalanceAssociatedWithProviderReliefFund" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Balance Associated with the CARES Act Provider Relief Fund</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashBalanceAssociatedWithProviderReliefFund" xlink:href="amed-20221231.xsd#amed_CashBalanceAssociatedWithProviderReliefFund"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CashBalanceAssociatedWithProviderReliefFund" xlink:to="lab_amed_CashBalanceAssociatedWithProviderReliefFund" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_ec8ed776-6232-4df1-bd62-5d35eaa2ab3a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_64cb3f83-c963-4066-8a1a-6a11a6c6d678_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_22c4f345-6153-4208-92da-01223a242e37_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_2cdce95d-f453-45c5-ade3-3209c284acf2_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PayrollTaxEscrow_0b747564-6f2a-4357-986d-0bfea3920a6a_terseLabel_en-US" xlink:label="lab_amed_PayrollTaxEscrow" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll tax escrow</link:label>
    <link:label id="lab_amed_PayrollTaxEscrow_label_en-US" xlink:label="lab_amed_PayrollTaxEscrow" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll tax escrow</link:label>
    <link:label id="lab_amed_PayrollTaxEscrow_documentation_en-US" xlink:label="lab_amed_PayrollTaxEscrow" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll tax escrow</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayrollTaxEscrow" xlink:href="amed-20221231.xsd#amed_PayrollTaxEscrow"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PayrollTaxEscrow" xlink:to="lab_amed_PayrollTaxEscrow" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_COVID19TextBlock_8431564a-8ed1-42bb-9356-fcbcf89b679a_terseLabel_en-US" xlink:label="lab_amed_COVID19TextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOVEL CORONAVIRUS PANDEMIC ("COVID-19")</link:label>
    <link:label id="lab_amed_COVID19TextBlock_label_en-US" xlink:label="lab_amed_COVID19TextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID19 [Text Block]</link:label>
    <link:label id="lab_amed_COVID19TextBlock_documentation_en-US" xlink:label="lab_amed_COVID19TextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure for Novel Coronavirus Pandemic "COVID-19"</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19TextBlock" xlink:href="amed-20221231.xsd#amed_COVID19TextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_COVID19TextBlock" xlink:to="lab_amed_COVID19TextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BenefitAsComponentOfInterestExpense_f5fc5abf-0b63-41b0-aab6-02ae7a8498be_terseLabel_en-US" xlink:label="lab_amed_BenefitAsComponentOfInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit as Component of Interest Expense</link:label>
    <link:label id="lab_amed_BenefitAsComponentOfInterestExpense_label_en-US" xlink:label="lab_amed_BenefitAsComponentOfInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit as Component of Interest Expense</link:label>
    <link:label id="lab_amed_BenefitAsComponentOfInterestExpense_documentation_en-US" xlink:label="lab_amed_BenefitAsComponentOfInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit as Component of Interest Expense, resulting from the lapse of statute of limitations regarding uncertain tax positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BenefitAsComponentOfInterestExpense" xlink:href="amed-20221231.xsd#amed_BenefitAsComponentOfInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BenefitAsComponentOfInterestExpense" xlink:to="lab_amed_BenefitAsComponentOfInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NY_0769fe3d-8b3b-40ba-88e4-0896663c6e09_terseLabel_en-US" xlink:label="lab_stpr_NY" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW YORK</link:label>
    <link:label id="lab_stpr_NY_label_en-US" xlink:label="lab_stpr_NY" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW YORK</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NY"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NY" xlink:to="lab_stpr_NY" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6d3a6f6d-82c3-4b8c-9a6e-eecb249ae5f7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_acd6de87-8de9-41f3-97c6-e5018c3bb601_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_8a420287-49c4-4c89-aabc-0dcb529164a1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted&#160;Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_b27aa35e-50c7-4c09-9214-221bf92d357d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_4256501b-c605-4e17-a845-71fab148bba4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_ae7553f8-ff7a-4ded-86fc-65f330d23b7d_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net service revenue</link:label>
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_label_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Revenue Net of Patient Service Revenue Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:to="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TotalLeverageRatio_ea75d27d-8f4e-421b-951a-274d1d9bf06d_terseLabel_en-US" xlink:label="lab_amed_TotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated leverage ratio</link:label>
    <link:label id="lab_amed_TotalLeverageRatio_label_en-US" xlink:label="lab_amed_TotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Leverage Ratio</link:label>
    <link:label id="lab_amed_TotalLeverageRatio_documentation_en-US" xlink:label="lab_amed_TotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ratio of debt to earnings before interest, taxes, depreciation and amortization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalLeverageRatio" xlink:href="amed-20221231.xsd#amed_TotalLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TotalLeverageRatio" xlink:to="lab_amed_TotalLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_f33a6508-0233-4b46-b822-c2a3f26886bb_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemDomain_bfd18f15-168d-4e7f-8b65-7441449fa774_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Domain]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemDomain_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain" xlink:to="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WorkersCompensationLiabilityCurrent_df741852-361c-4609-9be7-64d479e1d269_terseLabel_en-US" xlink:label="lab_us-gaap_WorkersCompensationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers&#8217; compensation</link:label>
    <link:label id="lab_us-gaap_WorkersCompensationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_WorkersCompensationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers' Compensation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WorkersCompensationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WorkersCompensationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WorkersCompensationLiabilityCurrent" xlink:to="lab_us-gaap_WorkersCompensationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage_aa29d058-8700-4e18-8cd3-cd9e7a3bfaf3_terseLabel_en-US" xlink:label="lab_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of employee salary eligible for employer match (percent)</link:label>
    <link:label id="lab_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage_label_en-US" xlink:label="lab_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defind Contribution Plan Maximum Annual Match Per Employee Salary Percentage</link:label>
    <link:label id="lab_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage_documentation_en-US" xlink:label="lab_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Percentage of Employee Salary Eligible for Employer Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage" xlink:href="amed-20221231.xsd#amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage" xlink:to="lab_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_KY_37985091-0f08-47a9-b8e0-03dc993919bc_terseLabel_en-US" xlink:label="lab_stpr_KY" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KENTUCKY</link:label>
    <link:label id="lab_stpr_KY_label_en-US" xlink:label="lab_stpr_KY" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KENTUCKY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_KY" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_KY"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_KY" xlink:to="lab_stpr_KY" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract_label_en-US" xlink:label="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Items, or Both [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtraordinaryAndUnusualItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:to="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_edff25d4-de21-40a3-819c-f8f596c5224a_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_69be441e-d6b9-40b4-b9f0-45e91dd6d92b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, tax benefit recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CashPaidForInfinityZPICInterest_b5202304-1752-4a10-9496-bcfbe04ecb68_terseLabel_en-US" xlink:label="lab_amed_CashPaidForInfinityZPICInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid For Infinity ZPIC Interest</link:label>
    <link:label id="lab_amed_CashPaidForInfinityZPICInterest_label_en-US" xlink:label="lab_amed_CashPaidForInfinityZPICInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid For Infinity ZPIC Interest</link:label>
    <link:label id="lab_amed_CashPaidForInfinityZPICInterest_documentation_en-US" xlink:label="lab_amed_CashPaidForInfinityZPICInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid For Infinity ZPIC Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashPaidForInfinityZPICInterest" xlink:href="amed-20221231.xsd#amed_CashPaidForInfinityZPICInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CashPaidForInfinityZPICInterest" xlink:to="lab_amed_CashPaidForInfinityZPICInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_3550b1ec-8e3e-4d7e-8f72-b5c8b5ffb066_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_a157e694-2480-48b6-8a96-249f5742bbf3_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_06ff5616-cf31-441f-b361-5411e94d139a_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmedisysCIAMember_981540a6-cd1c-4e97-945e-a915436cfc50_terseLabel_en-US" xlink:label="lab_amed_AmedisysCIAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amedisys CIA [Member]</link:label>
    <link:label id="lab_amed_AmedisysCIAMember_label_en-US" xlink:label="lab_amed_AmedisysCIAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amedisys CIA [Member]</link:label>
    <link:label id="lab_amed_AmedisysCIAMember_documentation_en-US" xlink:label="lab_amed_AmedisysCIAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amedisys CIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmedisysCIAMember" xlink:href="amed-20221231.xsd#amed_AmedisysCIAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmedisysCIAMember" xlink:to="lab_amed_AmedisysCIAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_0fec2d1c-fd29-4f25-ba7d-9172eadf2bb2_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest, ownership percentage by noncontrolling owners (percent)</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_3018554f-f3d9-44a3-9a32-f346ac690e45_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Uncertain Tax Positions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_UncertainTaxBenefitsInLongTermObligations_34963450-24e5-4ca0-96e4-ad5565153ce5_terseLabel_en-US" xlink:label="lab_amed_UncertainTaxBenefitsInLongTermObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for uncertain tax positions</link:label>
    <link:label id="lab_amed_UncertainTaxBenefitsInLongTermObligations_label_en-US" xlink:label="lab_amed_UncertainTaxBenefitsInLongTermObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain Tax Benefits In Long Term Obligations</link:label>
    <link:label id="lab_amed_UncertainTaxBenefitsInLongTermObligations_documentation_en-US" xlink:label="lab_amed_UncertainTaxBenefitsInLongTermObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain Tax Benefits In Long Term Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UncertainTaxBenefitsInLongTermObligations" xlink:href="amed-20221231.xsd#amed_UncertainTaxBenefitsInLongTermObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_UncertainTaxBenefitsInLongTermObligations" xlink:to="lab_amed_UncertainTaxBenefitsInLongTermObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_c57aa68d-0d73-4431-a4a3-90af44b0fefd_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of Shares</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentPeriodicPaymentPercentage_d8e42f50-47cb-456f-ae2a-3bef2d51d44e_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Periodic Payment Percentage</link:label>
    <link:label id="lab_amed_DebtInstrumentPeriodicPaymentPercentage_label_en-US" xlink:label="lab_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Periodic Payment Percentage</link:label>
    <link:label id="lab_amed_DebtInstrumentPeriodicPaymentPercentage_documentation_en-US" xlink:label="lab_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of the Term Loan that is required as periodic payments including both interest and principal payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:href="amed-20221231.xsd#amed_DebtInstrumentPeriodicPaymentPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:to="lab_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_4a38ff71-1028-4da7-be62-f2ddefa5e222_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_A30InterestSoldInTwoCareCentersMember_6c525209-103a-496b-a90a-c0ce97d7be1e_terseLabel_en-US" xlink:label="lab_amed_A30InterestSoldInTwoCareCentersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">30% Interest Sold in Two Care Centers</link:label>
    <link:label id="lab_amed_A30InterestSoldInTwoCareCentersMember_label_en-US" xlink:label="lab_amed_A30InterestSoldInTwoCareCentersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">30% Interest Sold in Two Care Centers [Member]</link:label>
    <link:label id="lab_amed_A30InterestSoldInTwoCareCentersMember_documentation_en-US" xlink:label="lab_amed_A30InterestSoldInTwoCareCentersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">30% Interest Sold in Two Care Centers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A30InterestSoldInTwoCareCentersMember" xlink:href="amed-20221231.xsd#amed_A30InterestSoldInTwoCareCentersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_A30InterestSoldInTwoCareCentersMember" xlink:to="lab_amed_A30InterestSoldInTwoCareCentersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_WriteOffOfOtherComprehensiveIncome_c8a9aa59-4bc9-4586-81ec-75f2b8af780d_negatedTerseLabel_en-US" xlink:label="lab_amed_WriteOffOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-off of other comprehensive income</link:label>
    <link:label id="lab_amed_WriteOffOfOtherComprehensiveIncome_label_en-US" xlink:label="lab_amed_WriteOffOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write Off Of Other Comprehensive Income</link:label>
    <link:label id="lab_amed_WriteOffOfOtherComprehensiveIncome_documentation_en-US" xlink:label="lab_amed_WriteOffOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write Off Of Other Comprehensive Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WriteOffOfOtherComprehensiveIncome" xlink:href="amed-20221231.xsd#amed_WriteOffOfOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_WriteOffOfOtherComprehensiveIncome" xlink:to="lab_amed_WriteOffOfOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MA_f8b65a7c-662c-477c-ad2a-aeed7d871391_terseLabel_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Massachusetts [Member]</link:label>
    <link:label id="lab_stpr_MA_label_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MASSACHUSETTS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MA" xlink:to="lab_stpr_MA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_90217b66-1dff-4789-a940-7765a893f194_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEGMENT INFORMATION</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_54a23872-7ddb-44e0-bf4d-624596a92fad_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_dea8739f-d8ad-4b55-aafa-dde4b882822d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Goodwill and Other Intangible Assets Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_1b4db644-6ddc-46de-8c99-22b49bf6dce8_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized share-based compensation tax benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_48ba7a82-8ee1-405d-8964-38d3c42fda3f_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_da1d9c98-c63a-42c5-98ea-785f56d7d1eb_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ad921aeb-7bf4-4166-9542-d17dfb511d4d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_a6fdce9b-4f2c-421e-b779-c7ba791d8938_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement awarded to other party</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_f57ef7fd-0222-4a0e-813f-9eaccb7a48a2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled, forfeited or expired (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseOptionToTerminate_7ac04ddc-84a1-4053-912e-487a55a99e4d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option to Terminate</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseOptionToTerminate_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option to Terminate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:to="lab_us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TypeOfIncomeTaxDeferralDomain_66d59b90-0e4c-4f50-8028-ebf95c517114_terseLabel_en-US" xlink:label="lab_amed_TypeOfIncomeTaxDeferralDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Income Tax Deferral [Domain]</link:label>
    <link:label id="lab_amed_TypeOfIncomeTaxDeferralDomain_label_en-US" xlink:label="lab_amed_TypeOfIncomeTaxDeferralDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Income Tax Deferral [Domain]</link:label>
    <link:label id="lab_amed_TypeOfIncomeTaxDeferralDomain_documentation_en-US" xlink:label="lab_amed_TypeOfIncomeTaxDeferralDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Income Tax Deferral</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeOfIncomeTaxDeferralDomain" xlink:href="amed-20221231.xsd#amed_TypeOfIncomeTaxDeferralDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TypeOfIncomeTaxDeferralDomain" xlink:to="lab_amed_TypeOfIncomeTaxDeferralDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ConnectRNMember_2264f9c6-8b2c-4337-8430-b0e0b7b6335f_terseLabel_en-US" xlink:label="lab_amed_ConnectRNMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ConnectRN [Member]</link:label>
    <link:label id="lab_amed_ConnectRNMember_label_en-US" xlink:label="lab_amed_ConnectRNMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ConnectRN [Member]</link:label>
    <link:label id="lab_amed_ConnectRNMember_documentation_en-US" xlink:label="lab_amed_ConnectRNMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ConnectRN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConnectRNMember" xlink:href="amed-20221231.xsd#amed_ConnectRNMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ConnectRNMember" xlink:to="lab_amed_ConnectRNMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_292dd4d5-bef7-4498-8a74-50f65b899f73_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_6b25b0f7-0118-47ac-9606-3d4139668593_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_29016885-a786-4b74-8ee8-997c1026480e_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition, number of care centers acquired</link:label>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_label_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Businesses Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfBusinessesAcquired" xlink:to="lab_us-gaap_NumberOfBusinessesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyReceivableNoncurrent_909fd7ff-b32b-4a36-abfb-74f7168ea8bd_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyReceivableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnity receivable</link:label>
    <link:label id="lab_us-gaap_LossContingencyReceivableNoncurrent_label_en-US" xlink:label="lab_us-gaap_LossContingencyReceivableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Receivable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyReceivableNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyReceivableNoncurrent" xlink:to="lab_us-gaap_LossContingencyReceivableNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0de0ee31-3bd9-437d-a12f-a1fbf798faea_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_76fafaa6-3246-4270-9b3d-24b1f8c7fcf6_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares outstanding &#8211; basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_f5194a97-7b0f-49e4-b2fb-08b65143ccea_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d7403f9d-7c32-40a0-89ad-111d97e864f5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_ed3df9c5-3d1a-4d24-a5d4-734f64464bf3_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_89246010-b491-48f3-a796-ac53790a4f5d_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember_895a48fe-7e5b-424b-b412-79690f5aa798_terseLabel_en-US" xlink:label="lab_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Vested Stock Units - Service-Based and Performance-Based [Member]</link:label>
    <link:label id="lab_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember_label_en-US" xlink:label="lab_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Vested Stock Units - Service-Based and Performance-Based [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" xlink:href="amed-20221231.xsd#amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" xlink:to="lab_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_3f5f9168-1b7b-4b3a-8f4b-2f065f15857d_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses:</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FleetLeaseMember_03e83a95-e1cf-4d50-ae65-6a5f6671c9a5_terseLabel_en-US" xlink:label="lab_amed_FleetLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fleet Lease [Member]</link:label>
    <link:label id="lab_amed_FleetLeaseMember_label_en-US" xlink:label="lab_amed_FleetLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fleet Lease [Member]</link:label>
    <link:label id="lab_amed_FleetLeaseMember_documentation_en-US" xlink:label="lab_amed_FleetLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fleet Lease Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FleetLeaseMember" xlink:href="amed-20221231.xsd#amed_FleetLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FleetLeaseMember" xlink:to="lab_amed_FleetLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_f28f4595-4867-4160-84bd-c8987f210cc9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_SC_4127483e-71e7-416f-9c5c-239f0f20fc06_terseLabel_en-US" xlink:label="lab_stpr_SC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">South Carolina [Member]</link:label>
    <link:label id="lab_stpr_SC_label_en-US" xlink:label="lab_stpr_SC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOUTH CAROLINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_SC" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_SC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_SC" xlink:to="lab_stpr_SC" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_e48b144e-3cb8-4e2e-ab03-dccf5ff10c9f_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_UsDepartmentOfJusticeMember_7115c074-15c5-4159-9dd8-edb6a209a47b_terseLabel_en-US" xlink:label="lab_amed_UsDepartmentOfJusticeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Department of Justice [Member]</link:label>
    <link:label id="lab_amed_UsDepartmentOfJusticeMember_label_en-US" xlink:label="lab_amed_UsDepartmentOfJusticeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Department of Justice [Member]</link:label>
    <link:label id="lab_amed_UsDepartmentOfJusticeMember_documentation_en-US" xlink:label="lab_amed_UsDepartmentOfJusticeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Department of Justice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UsDepartmentOfJusticeMember" xlink:href="amed-20221231.xsd#amed_UsDepartmentOfJusticeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_UsDepartmentOfJusticeMember" xlink:to="lab_amed_UsDepartmentOfJusticeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_321d6559-d865-4f58-8068-432b3c05247e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term obligations</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ShareRepurchaseTable_b1358faf-7fa3-4f12-a25f-ed6eb2218c8f_terseLabel_en-US" xlink:label="lab_amed_ShareRepurchaseTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Table]</link:label>
    <link:label id="lab_amed_ShareRepurchaseTable_label_en-US" xlink:label="lab_amed_ShareRepurchaseTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Table]</link:label>
    <link:label id="lab_amed_ShareRepurchaseTable_documentation_en-US" xlink:label="lab_amed_ShareRepurchaseTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseTable" xlink:href="amed-20221231.xsd#amed_ShareRepurchaseTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ShareRepurchaseTable" xlink:to="lab_amed_ShareRepurchaseTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_fc43cbe2-ef96-441c-8b2f-684aea74dec2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_e81e2804-9678-4ce3-9f1a-70a3d23dbeed_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_37865372-3cd9-421b-8e1c-0a99327d89e7_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CAPITAL SOCK AND SHARE-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_33099cc5-395a-492d-a24f-248d72931835_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ConsolidatedInterestCoverageRatio_0ca47866-5614-4a3a-b7f8-4f5e8e697185_terseLabel_en-US" xlink:label="lab_amed_ConsolidatedInterestCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated interest coverage ratio</link:label>
    <link:label id="lab_amed_ConsolidatedInterestCoverageRatio_label_en-US" xlink:label="lab_amed_ConsolidatedInterestCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Interest Coverage Ratio</link:label>
    <link:label id="lab_amed_ConsolidatedInterestCoverageRatio_documentation_en-US" xlink:label="lab_amed_ConsolidatedInterestCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ratio of adjusted earnings before interest, taxes, depreciation and amortization to cash interest charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedInterestCoverageRatio" xlink:href="amed-20221231.xsd#amed_ConsolidatedInterestCoverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ConsolidatedInterestCoverageRatio" xlink:to="lab_amed_ConsolidatedInterestCoverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FloridaZpicRevenueReduction_923b14f8-6226-49e5-bc04-a22acb3990b2_terseLabel_en-US" xlink:label="lab_amed_FloridaZpicRevenueReduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida Zpic revenue reduction</link:label>
    <link:label id="lab_amed_FloridaZpicRevenueReduction_label_en-US" xlink:label="lab_amed_FloridaZpicRevenueReduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida Zpic Revenue Reduction</link:label>
    <link:label id="lab_amed_FloridaZpicRevenueReduction_documentation_en-US" xlink:label="lab_amed_FloridaZpicRevenueReduction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in revenue as a result of the Florida ZPIC audit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FloridaZpicRevenueReduction" xlink:href="amed-20221231.xsd#amed_FloridaZpicRevenueReduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FloridaZpicRevenueReduction" xlink:to="lab_amed_FloridaZpicRevenueReduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_6117ab6e-e4e6-4a89-bd8e-8378eebf8524_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_UnrecognizedTaxBenefitsAxis_5d5c1b6b-efd3-45ff-b88d-f1ef5c2b443a_terseLabel_en-US" xlink:label="lab_amed_UnrecognizedTaxBenefitsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits [Axis]</link:label>
    <link:label id="lab_amed_UnrecognizedTaxBenefitsAxis_label_en-US" xlink:label="lab_amed_UnrecognizedTaxBenefitsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits [Axis]</link:label>
    <link:label id="lab_amed_UnrecognizedTaxBenefitsAxis_documentation_en-US" xlink:label="lab_amed_UnrecognizedTaxBenefitsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnrecognizedTaxBenefitsAxis" xlink:href="amed-20221231.xsd#amed_UnrecognizedTaxBenefitsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_UnrecognizedTaxBenefitsAxis" xlink:to="lab_amed_UnrecognizedTaxBenefitsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_d8e81e8f-4b55-45c1-90cd-e7cde586ec3a_terseLabel_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock - 401 (k) plan (shares)</link:label>
    <link:label id="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_label_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Four Zero One K Employer Match</link:label>
    <link:label id="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_documentation_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued during the period to employees as employer's matching contribution to the company's 401(K) plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:href="amed-20221231.xsd#amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:to="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_OperatingCareCenters_ce82112c-719a-4f54-b593-c29c3b0f6161_terseLabel_en-US" xlink:label="lab_amed_OperatingCareCenters" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of owned and operated care centers</link:label>
    <link:label id="lab_amed_OperatingCareCenters_label_en-US" xlink:label="lab_amed_OperatingCareCenters" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Care Centers</link:label>
    <link:label id="lab_amed_OperatingCareCenters_documentation_en-US" xlink:label="lab_amed_OperatingCareCenters" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of care centers owned by the entity as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OperatingCareCenters" xlink:href="amed-20221231.xsd#amed_OperatingCareCenters"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OperatingCareCenters" xlink:to="lab_amed_OperatingCareCenters" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_b9600d3d-056f-4fed-9cdc-a4538d0f4804_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EurodollarMember_34766a56-2091-4ba3-b719-db88e7dc76dd_terseLabel_en-US" xlink:label="lab_us-gaap_EurodollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurodollar [Member]</link:label>
    <link:label id="lab_us-gaap_EurodollarMember_label_en-US" xlink:label="lab_us-gaap_EurodollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurodollar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EurodollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EurodollarMember" xlink:to="lab_us-gaap_EurodollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_ee678fbd-723a-4e2b-98eb-adbd3af0ff76_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram_7ddc2787-c33d-4c19-a202-33577e7f181a_terseLabel_en-US" xlink:label="lab_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee contribution amount</link:label>
    <link:label id="lab_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram_label_en-US" xlink:label="lab_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Employee Contribution For Employee Matching Program</link:label>
    <link:label id="lab_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram_documentation_en-US" xlink:label="lab_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Employee Contribution For Employer Matching Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram" xlink:href="amed-20221231.xsd#amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram" xlink:to="lab_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8960dadd-1d80-446f-8967-d6d4252f1624_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_166f5787-4e93-432a-9fb5-2a74eab16e68_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4d23be2f-560a-4da0-8055-de6b4ea33e8e_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f032d13b-38b0-481f-a6ca-8ff8791b7c85_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of businesses, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_7e383457-19e4-4361-a9d3-c04c6060433c_terseLabel_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of the overpayment made to the subsidiary</link:label>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_label_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery Amount Of Overpayment Made To Subsidiary</link:label>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_documentation_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of the overpayment made to the subsidiary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:href="amed-20221231.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:to="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_39aa3078-9562-4ff9-91ea-b386ccaf6e45_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill deductible for income tax purposes</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_19ebbb74-22cf-47e1-a49b-424ca195286e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_WorkersCompensationDeposits_c63e5be1-87a2-4884-a2be-c033b1e9487b_terseLabel_en-US" xlink:label="lab_amed_WorkersCompensationDeposits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers&#8217; compensation deposits</link:label>
    <link:label id="lab_amed_WorkersCompensationDeposits_label_en-US" xlink:label="lab_amed_WorkersCompensationDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers Compensation Deposits</link:label>
    <link:label id="lab_amed_WorkersCompensationDeposits_documentation_en-US" xlink:label="lab_amed_WorkersCompensationDeposits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers Compensation Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WorkersCompensationDeposits" xlink:href="amed-20221231.xsd#amed_WorkersCompensationDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_WorkersCompensationDeposits" xlink:to="lab_amed_WorkersCompensationDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SurrenderedShares_8fb56479-2fa4-4ed1-a1b7-b16e8ab12787_terseLabel_en-US" xlink:label="lab_amed_SurrenderedShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surrendered shares</link:label>
    <link:label id="lab_amed_SurrenderedShares_label_en-US" xlink:label="lab_amed_SurrenderedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surrendered Shares</link:label>
    <link:label id="lab_amed_SurrenderedShares_documentation_en-US" xlink:label="lab_amed_SurrenderedShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock surrendered by certain employees to satisfy obligations in connection with the vesting of stock. Shares held in Treasury Stock at cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SurrenderedShares" xlink:href="amed-20221231.xsd#amed_SurrenderedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SurrenderedShares" xlink:to="lab_amed_SurrenderedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_d1fbd926-ce4d-4956-8065-0f669cc3842e_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_a020bc20-b287-4463-bb72-ffe56adb508d_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EstimatedInsuranceLongTermPortion_b5e66b92-aeed-4b49-9d71-b40d27332739_negatedTerseLabel_en-US" xlink:label="lab_amed_EstimatedInsuranceLongTermPortion" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Insurance Long Term Portion</link:label>
    <link:label id="lab_amed_EstimatedInsuranceLongTermPortion_label_en-US" xlink:label="lab_amed_EstimatedInsuranceLongTermPortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Insurance Long Term Portion</link:label>
    <link:label id="lab_amed_EstimatedInsuranceLongTermPortion_documentation_en-US" xlink:label="lab_amed_EstimatedInsuranceLongTermPortion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term portion of estimated insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedInsuranceLongTermPortion" xlink:href="amed-20221231.xsd#amed_EstimatedInsuranceLongTermPortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EstimatedInsuranceLongTermPortion" xlink:to="lab_amed_EstimatedInsuranceLongTermPortion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_951a711e-44f6-491e-918a-1d538d2139b1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_158b8183-65cb-47ba-b19e-997cb1e1fa10_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_c7dd5f42-1128-4f3d-a7a0-4bee5187d6e4_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net of accumulated amortization of $14,604 and $19,900</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_714a8838-07e6-45f6-8eee-f10b5ec0e4bc_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_fd2938e6-50a9-4344-a6c0-de3150ab4b78_periodStartLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_76b676e5-26ef-4826-ab23-61f40fe8b13a_periodEndLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_89378ad2-1fcd-48bd-903d-336f5b545328_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (gain) on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c916beee-13f0-4e80-aebf-b8322addb2e3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NumberOfBeneficiaries_02de6628-4c11-4e91-82c4-b511ae59cfaf_terseLabel_en-US" xlink:label="lab_amed_NumberOfBeneficiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of beneficiaries</link:label>
    <link:label id="lab_amed_NumberOfBeneficiaries_label_en-US" xlink:label="lab_amed_NumberOfBeneficiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of beneficiaries</link:label>
    <link:label id="lab_amed_NumberOfBeneficiaries_documentation_en-US" xlink:label="lab_amed_NumberOfBeneficiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of beneficiaries who received services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfBeneficiaries" xlink:href="amed-20221231.xsd#amed_NumberOfBeneficiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NumberOfBeneficiaries" xlink:to="lab_amed_NumberOfBeneficiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_50168610-1b5c-46f0-9b81-b23fa20c8a7d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_5f7e5ba6-b9a0-44b4-a47e-830be981eb1e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_900a9228-0630-43f2-bd73-ef9c57d93393_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_039a2952-9cce-400c-9df3-120bf4657b9a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Free Rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DeferredTaxLiabilitiesRightOfUseAssets_436e37f0-3c24-4ce7-9768-1840d69a29ff_negatedTerseLabel_en-US" xlink:label="lab_amed_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset</link:label>
    <link:label id="lab_amed_DeferredTaxLiabilitiesRightOfUseAssets_label_en-US" xlink:label="lab_amed_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Right of Use Assets</link:label>
    <link:label id="lab_amed_DeferredTaxLiabilitiesRightOfUseAssets_documentation_en-US" xlink:label="lab_amed_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from right-of-use assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxLiabilitiesRightOfUseAssets" xlink:href="amed-20221231.xsd#amed_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="lab_amed_DeferredTaxLiabilitiesRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_e5c5b38e-d735-4c65-864e-95bdc6a4bc21_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease ROU assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, before Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_546af3d8-b7e4-4b83-a779-3bb3ef789719_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS HELD FOR SALE</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CompassionateCareHospiceCIAMember_a86179df-1150-4286-9945-77fd8fdd4cbd_terseLabel_en-US" xlink:label="lab_amed_CompassionateCareHospiceCIAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice CIA [Member]</link:label>
    <link:label id="lab_amed_CompassionateCareHospiceCIAMember_label_en-US" xlink:label="lab_amed_CompassionateCareHospiceCIAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice CIA [Member]</link:label>
    <link:label id="lab_amed_CompassionateCareHospiceCIAMember_documentation_en-US" xlink:label="lab_amed_CompassionateCareHospiceCIAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice CIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceCIAMember" xlink:href="amed-20221231.xsd#amed_CompassionateCareHospiceCIAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CompassionateCareHospiceCIAMember" xlink:to="lab_amed_CompassionateCareHospiceCIAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_A2023ShareRepurchaseProgramMember_4db1f1d0-3fbb-4053-b9ae-4b60a34b1e79_terseLabel_en-US" xlink:label="lab_amed_A2023ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Share Repurchase Program</link:label>
    <link:label id="lab_amed_A2023ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_amed_A2023ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_amed_A2023ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_amed_A2023ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2023ShareRepurchaseProgramMember" xlink:href="amed-20221231.xsd#amed_A2023ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_A2023ShareRepurchaseProgramMember" xlink:to="lab_amed_A2023ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_f9c0dc14-0ac3-4f64-aa8e-77d96021d57d_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_4ef26df0-45ef-42f7-b28c-db6b7ec5b0b8_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Free Rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_ad33d97c-69b1-44f7-9cfd-854969a2adae_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient accounts receivable</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_a6d6c08e-833a-4949-9cc8-399e287c720c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CorporateIntegrityAgreementTerm_d72f5932-6427-4654-8545-f45728d11e76_terseLabel_en-US" xlink:label="lab_amed_CorporateIntegrityAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate integrity agreement term (years)</link:label>
    <link:label id="lab_amed_CorporateIntegrityAgreementTerm_label_en-US" xlink:label="lab_amed_CorporateIntegrityAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Integrity Agreement Term</link:label>
    <link:label id="lab_amed_CorporateIntegrityAgreementTerm_documentation_en-US" xlink:label="lab_amed_CorporateIntegrityAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Integrity Agreement Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CorporateIntegrityAgreementTerm" xlink:href="amed-20221231.xsd#amed_CorporateIntegrityAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CorporateIntegrityAgreementTerm" xlink:to="lab_amed_CorporateIntegrityAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrentAbstract_aa08a0dd-3ce3-48b7-b490-af2f0213ed05_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets:</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrentAbstract" xlink:to="lab_us-gaap_OtherAssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_f3801548-08ba-4b96-bd3d-2d3b4dbd3520_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in total valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_58e3068c-b92f-4a70-b939-84ebc9e9d8bc_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_5bb08d89-468b-4d93-9419-8e23102a0930_terseLabel_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock - 401 (k) plan</link:label>
    <link:label id="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_label_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Four Zero One K Employer Match</link:label>
    <link:label id="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_documentation_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of stock issued during the period to employees as employer's matching contribution to the company's 401(K) plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:href="amed-20221231.xsd#amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:to="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SocialSecurityTaxMember_ebdeffee-f3cb-4177-9652-ad5aef1975f5_terseLabel_en-US" xlink:label="lab_amed_SocialSecurityTaxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Social Security Tax [Member]</link:label>
    <link:label id="lab_amed_SocialSecurityTaxMember_label_en-US" xlink:label="lab_amed_SocialSecurityTaxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Social Security Tax [Member]</link:label>
    <link:label id="lab_amed_SocialSecurityTaxMember_documentation_en-US" xlink:label="lab_amed_SocialSecurityTaxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Social Security Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SocialSecurityTaxMember" xlink:href="amed-20221231.xsd#amed_SocialSecurityTaxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SocialSecurityTaxMember" xlink:to="lab_amed_SocialSecurityTaxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_25ea718f-bb16-40ec-bc33-65c5d10b5e0e_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining availability under the revolving credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CreditAgreementMember_64d44e82-f946-4cab-9134-31aac29096e8_terseLabel_en-US" xlink:label="lab_amed_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_CreditAgreementMember_label_en-US" xlink:label="lab_amed_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_CreditAgreementMember_documentation_en-US" xlink:label="lab_amed_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CreditAgreementMember" xlink:href="amed-20221231.xsd#amed_CreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CreditAgreementMember" xlink:to="lab_amed_CreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_180aa1a1-8c2a-426b-9c57-171d005e36a1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term obligations, less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_7cc9b798-4296-40e5-8f0e-bdab5cfa8534_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transaction, amount of transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CertificatesOfNeedMember_06eea2ff-67b2-4c8a-b20d-5e0ea0401e34_terseLabel_en-US" xlink:label="lab_amed_CertificatesOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates Of Need [Member]</link:label>
    <link:label id="lab_amed_CertificatesOfNeedMember_label_en-US" xlink:label="lab_amed_CertificatesOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates Of Need [Member]</link:label>
    <link:label id="lab_amed_CertificatesOfNeedMember_documentation_en-US" xlink:label="lab_amed_CertificatesOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates Of Need [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificatesOfNeedMember" xlink:href="amed-20221231.xsd#amed_CertificatesOfNeedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CertificatesOfNeedMember" xlink:to="lab_amed_CertificatesOfNeedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_1b107acf-003d-4c87-904f-7b4399563e6d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_eed85a0c-e0e4-45ff-a5e4-49fb77bad7b4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ac6b7878-3318-4934-86c8-f482dedcc175_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_8ad361c7-fa08-473f-9bea-dcb61b1a19ad_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_906ae307-e18c-4c3d-b412-14ba7fcf930a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based awards, number of shares authorized (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_44ffb9f8-6786-42da-afca-af14db7f116b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of market value for purchases under Employee Stock Purchase Program (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_19868ca2-46a8-4834-90b0-5a7110af96ad_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Non-Vested Stock Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Share Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_WA_1e558578-f0b3-468f-91ec-ccd9812b5529_terseLabel_en-US" xlink:label="lab_stpr_WA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WASHINGTON</link:label>
    <link:label id="lab_stpr_WA_label_en-US" xlink:label="lab_stpr_WA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WASHINGTON</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_WA" xlink:to="lab_stpr_WA" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_5f354326-2393-4761-b84b-22b2e18c07cc_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LeaseTypeDomain_0e7c1df0-95a9-4930-ba29-e5ea7a98c013_terseLabel_en-US" xlink:label="lab_amed_LeaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Type [Domain]</link:label>
    <link:label id="lab_amed_LeaseTypeDomain_label_en-US" xlink:label="lab_amed_LeaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Type [Domain]</link:label>
    <link:label id="lab_amed_LeaseTypeDomain_documentation_en-US" xlink:label="lab_amed_LeaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LeaseTypeDomain" xlink:href="amed-20221231.xsd#amed_LeaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LeaseTypeDomain" xlink:to="lab_amed_LeaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock_71cec265-3037-43e8-89c9-0472a225982a_terseLabel_en-US" xlink:label="lab_amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Supplemental CashFlow Information and NonCash Activity for Leases</link:label>
    <link:label id="lab_amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock_label_en-US" xlink:label="lab_amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental CashFlow Information and NonCash Activity for Leases [Table Text Block]</link:label>
    <link:label id="lab_amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock_documentation_en-US" xlink:label="lab_amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental CashFlow Information and NonCash Activity for Leases Table Text Block</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock" xlink:href="amed-20221231.xsd#amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock" xlink:to="lab_amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_f2b54479-86f6-4010-ab90-9955f4cd0ac3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Sources of Tax Effects</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AlternativeMinimumTaxCreditMember_19905cd6-94d1-4ca1-b7b6-f1cbe15faa98_terseLabel_en-US" xlink:label="lab_amed_AlternativeMinimumTaxCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Minimum Tax Credit [Member]</link:label>
    <link:label id="lab_amed_AlternativeMinimumTaxCreditMember_label_en-US" xlink:label="lab_amed_AlternativeMinimumTaxCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Minimum Tax Credit [Member]</link:label>
    <link:label id="lab_amed_AlternativeMinimumTaxCreditMember_documentation_en-US" xlink:label="lab_amed_AlternativeMinimumTaxCreditMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternative Minimum Tax Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AlternativeMinimumTaxCreditMember" xlink:href="amed-20221231.xsd#amed_AlternativeMinimumTaxCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AlternativeMinimumTaxCreditMember" xlink:to="lab_amed_AlternativeMinimumTaxCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedAtCost_19d971f9-a282-44b3-84e5-c14a7b267bf1_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedAtCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost method investments</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedAtCost_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedAtCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, at Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedAtCost" xlink:to="lab_us-gaap_InvestmentOwnedAtCost" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_TN_09aa6a3d-5d78-439f-bffc-fdcef8690976_terseLabel_en-US" xlink:label="lab_stpr_TN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tennessee [Member]</link:label>
    <link:label id="lab_stpr_TN_label_en-US" xlink:label="lab_stpr_TN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TENNESSEE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TN" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_TN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_TN" xlink:to="lab_stpr_TN" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct_f9a5d6f9-3c8d-491a-8e7e-78e4fbd451f7_terseLabel_en-US" xlink:label="lab_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Deferred Social Security Tax Under CARES Act</link:label>
    <link:label id="lab_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct_label_en-US" xlink:label="lab_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Deferred Social Security Tax Under CARES Act</link:label>
    <link:label id="lab_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct_documentation_en-US" xlink:label="lab_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Deferred Social Security Tax Under CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct" xlink:href="amed-20221231.xsd#amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct" xlink:to="lab_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_38aa9a4f-6da7-4bf6-a189-104e3d88ba45_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_8fe9a8ca-783c-4655-aa1d-6720f3e14d91_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5bac187b-b82e-4767-b5b0-07397111c0b9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a99d89e8-0a61-4915-8392-6eac52eb1133_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_78bd67bb-d317-4b34-bf62-137c21a29e0d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition, total purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset_279c1770-89ea-4092-bbf2-6ed6b868a3e9_terseLabel_en-US" xlink:label="lab_amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and impairment of operating lease right of use assets</link:label>
    <link:label id="lab_amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Impairment of Operating Lease Right Of Use Asset</link:label>
    <link:label id="lab_amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Impairment of Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset" xlink:href="amed-20221231.xsd#amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset" xlink:to="lab_amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_897569e7-e7be-4cc0-ade0-a3aac72fd61c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_17eeb2a8-5996-4337-9fcc-2b7830503cbe_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_ec842f96-d7ba-4873-aea0-0e73f2b574c0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_a6027ac2-008a-4154-84d2-32ae50ce831d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_dbc1fc9e-5857-40c0-b934-492a7ba5de06_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeHealthBenefitManagerMember_3dd51f63-1c38-4a5b-b04a-bc0ccf325b48_terseLabel_en-US" xlink:label="lab_amed_HomeHealthBenefitManagerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home health benefit manager</link:label>
    <link:label id="lab_amed_HomeHealthBenefitManagerMember_label_en-US" xlink:label="lab_amed_HomeHealthBenefitManagerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home health benefit manager [Member]</link:label>
    <link:label id="lab_amed_HomeHealthBenefitManagerMember_documentation_en-US" xlink:label="lab_amed_HomeHealthBenefitManagerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home health benefit manager</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthBenefitManagerMember" xlink:href="amed-20221231.xsd#amed_HomeHealthBenefitManagerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthBenefitManagerMember" xlink:to="lab_amed_HomeHealthBenefitManagerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_602d68e0-935e-46e9-a192-d53968aa7f73_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of borrowings under revolving line of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_8cac0436-e57a-4af4-9ce5-18373f93852f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CARESActProviderReliefFundsUtilized_260f5542-ca6d-4817-be1a-307b31b6ad8d_terseLabel_en-US" xlink:label="lab_amed_CARESActProviderReliefFundsUtilized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Funds Utilized</link:label>
    <link:label id="lab_amed_CARESActProviderReliefFundsUtilized_label_en-US" xlink:label="lab_amed_CARESActProviderReliefFundsUtilized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Funds Utilized</link:label>
    <link:label id="lab_amed_CARESActProviderReliefFundsUtilized_documentation_en-US" xlink:label="lab_amed_CARESActProviderReliefFundsUtilized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Funds Utilized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundsUtilized" xlink:href="amed-20221231.xsd#amed_CARESActProviderReliefFundsUtilized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CARESActProviderReliefFundsUtilized" xlink:to="lab_amed_CARESActProviderReliefFundsUtilized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_2eea405b-a942-482c-ba38-e79b6b347fc5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in equity method investee</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact_bf7a623e-e399-44da-80bb-f00f330f4feb_terseLabel_en-US" xlink:label="lab_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extension Of Temporary Suspension Of Sequestration Revenue Impact</link:label>
    <link:label id="lab_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact_label_en-US" xlink:label="lab_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extension Of Temporary Suspension Of Sequestration Revenue Impact</link:label>
    <link:label id="lab_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact_documentation_en-US" xlink:label="lab_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The impact on revenue due to the extension of the temporary suspension of sequestration as a result of the novel coronavirus pandemic ("COVID-19").</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" xlink:href="amed-20221231.xsd#amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" xlink:to="lab_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ff551824-0bdc-44a5-ba03-5e3ff19d403e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_488eb8c2-2c17-4abe-a6b6-8dc9f5b14993_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_2057d14c-89d4-4e58-bd15-14c52215ed39_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term obligations</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_638f77bc-bee7-4a7f-b295-fbfa3edd78a5_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term obligations</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_d927b4b9-af7f-4b1f-b604-9163e75ce1f2_terseLabel_en-US" xlink:label="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility, maximum allowable consolidated leverage ratio multiple</link:label>
    <link:label id="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_label_en-US" xlink:label="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Maximum Allowable Consolidated Leverage Ratio Multiple</link:label>
    <link:label id="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_documentation_en-US" xlink:label="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Maximum Allowable Consolidated Leverage Ratio Multiple</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:href="amed-20221231.xsd#amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:to="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_19b1f75f-0e6a-43d6-882b-46c23014bf0c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in (loss) earnings from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_6428275f-c11e-4e41-a74f-320b19191ed5_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in loss (earnings) from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ec534533-ec62-4c83-917b-0ec545051a71_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EscrowDeposit_a5eaca9c-b1cd-44f9-a602-884da28339fb_terseLabel_en-US" xlink:label="lab_us-gaap_EscrowDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrow deposit for indemnification purposes and working capital price adjustments</link:label>
    <link:label id="lab_us-gaap_EscrowDeposit_label_en-US" xlink:label="lab_us-gaap_EscrowDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrow Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EscrowDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EscrowDeposit" xlink:to="lab_us-gaap_EscrowDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0ba2a145-a82e-4f30-bfcf-e5ff550cdc6e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_ec5e220b-b360-4a81-b04c-a9ca166be731_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease - Thereafter</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e14848b8-d371-4979-9d65-11d88d6744fa_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_1ed67363-bec4-45d5-8693-c5acec8c11c3_terseLabel_en-US" xlink:label="lab_amed_CARESActDeferralOfEmployerShareSocialSecurityTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Deferral Of Employer Share Social Security Tax</link:label>
    <link:label id="lab_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_label_en-US" xlink:label="lab_amed_CARESActDeferralOfEmployerShareSocialSecurityTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Deferral Of Employer Share Social Security Tax</link:label>
    <link:label id="lab_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_documentation_en-US" xlink:label="lab_amed_CARESActDeferralOfEmployerShareSocialSecurityTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The deferral of the employer's share social security tax provided by the CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax" xlink:href="amed-20221231.xsd#amed_CARESActDeferralOfEmployerShareSocialSecurityTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax" xlink:to="lab_amed_CARESActDeferralOfEmployerShareSocialSecurityTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_69d679a8-0c09-4d57-96c4-4d7638e50d42_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other items, net (3)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_030e94a8-b1a6-42bb-9e47-174c1625e52c_terseLabel_en-US" xlink:label="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Service Revenue Period Of Care Payment Rate Duration</link:label>
    <link:label id="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_label_en-US" xlink:label="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Service Revenue Period Of Care Payment Rate Duration</link:label>
    <link:label id="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_documentation_en-US" xlink:label="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:href="amed-20221231.xsd#amed_NetServiceRevenuePeriodOfCarePaymentRateDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:to="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ClearwaterFloridaMember_f5a524d5-4fea-46af-b19e-5334acdd090d_terseLabel_en-US" xlink:label="lab_amed_ClearwaterFloridaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clearwater, Florida [Member]</link:label>
    <link:label id="lab_amed_ClearwaterFloridaMember_label_en-US" xlink:label="lab_amed_ClearwaterFloridaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clearwater, Florida [Member]</link:label>
    <link:label id="lab_amed_ClearwaterFloridaMember_documentation_en-US" xlink:label="lab_amed_ClearwaterFloridaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clearwater, Florida [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ClearwaterFloridaMember" xlink:href="amed-20221231.xsd#amed_ClearwaterFloridaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ClearwaterFloridaMember" xlink:to="lab_amed_ClearwaterFloridaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries_838e0c43-e457-4d21-9d19-f48958ff2f18_terseLabel_en-US" xlink:label="lab_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of total combined voting power of the Company and subsidiaries</link:label>
    <link:label id="lab_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries_label_en-US" xlink:label="lab_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries</link:label>
    <link:label id="lab_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries_documentation_en-US" xlink:label="lab_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of total combined voting power of the Company and our subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries" xlink:href="amed-20221231.xsd#amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries" xlink:to="lab_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e1cd3208-9988-463c-8838-3c50309a29d6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9fb24101-3964-428c-8b0f-4816914cc3d4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease - Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_ac672a50-00e9-4768-9353-b1ee944b4a2c_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_69de8c88-7138-4d24-bed7-9e1498cb546b_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_09dc070d-ac08-411e-89c9-bd5691772cc8_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_2979128c-4235-43b1-96fe-8a415b534a08_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent_2b833f6a-5a7a-40f9-a647-8e2ca08ba2d9_terseLabel_en-US" xlink:label="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent_label_en-US" xlink:label="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Including Discontinued Operation Operating Lease Liabilities Current</link:label>
    <link:label id="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent_documentation_en-US" xlink:label="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount classified as operating lease liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent" xlink:href="amed-20221231.xsd#amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent" xlink:to="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_dd8a4d50-d09e-435c-a312-a7fd112668cd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_f2458399-0a02-42e4-b564-a1171396d079_terseLabel_en-US" xlink:label="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Of Care As Episodic Based Revenue Duration</link:label>
    <link:label id="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_label_en-US" xlink:label="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Of Care As Episodic Based Revenue Duration</link:label>
    <link:label id="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_documentation_en-US" xlink:label="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days in a home health period of care using PDGM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:href="amed-20221231.xsd#amed_PeriodOfCareAsEpisodicBasedRevenueDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:to="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations_17df7cf2-75c4-461c-a00f-9d6f7a2332ba_terseLabel_en-US" xlink:label="lab_amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating lease Reductions to ROU assets resulting from reductions to lease obligations</link:label>
    <link:label id="lab_amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations_label_en-US" xlink:label="lab_amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating lease Reductions to ROU assets resulting from reductions to lease obligations</link:label>
    <link:label id="lab_amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations_documentation_en-US" xlink:label="lab_amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations" xlink:href="amed-20221231.xsd#amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations" xlink:to="lab_amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a378e6d9-97f7-422b-b13c-3abb002702f1_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_f6dad893-3c34-4519-9dd3-b77c6ee26bb0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnTerminationOfLease_eabff91d-4006-4f23-912c-40be5ced55df_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnTerminationOfLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Loss on Termination</link:label>
    <link:label id="lab_us-gaap_GainLossOnTerminationOfLease_label_en-US" xlink:label="lab_us-gaap_GainLossOnTerminationOfLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Termination of Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnTerminationOfLease" xlink:to="lab_us-gaap_GainLossOnTerminationOfLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_f3b46e04-1b36-4f17-9414-a2e1f04ad461_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongLivedAssetsHeldForSaleNameDomain_b305c532-e679-4b4e-9836-545e66d23737_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Lived Assets Held-for-sale, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsHeldForSaleNameDomain_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets Held-for-sale, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:to="lab_us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5b879451-ad0a-41f8-b0a8-384ffd9659fd_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_5b3688af-596e-4d89-ad79-38d149480058_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_67025515-d218-406b-bab8-da69e9a74e1b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_951913a6-8d6d-4e62-b0ae-01637a224397_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Software [Member]</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_0f2211b0-3f82-46a4-8c32-fb8aa8d5a2df_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Interest Rate</link:label>
    <link:label id="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_label_en-US" xlink:label="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Weighted Average Interest Rate, over Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:to="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_4d0cb021-a489-4985-9376-2755bd9a167a_terseLabel_en-US" xlink:label="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Immediately Distributed To Healthcare Providers Based On Their 2019 Medicare Fee For Service Reimbursements</link:label>
    <link:label id="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_label_en-US" xlink:label="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Immediately Distributed To Healthcare Providers Based On Their 2019 Medicare Fee For Service Reimbursements</link:label>
    <link:label id="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_documentation_en-US" xlink:label="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding immediately distributed to healthcare providers based on their 2019 Medicare Fee-For-Service reimbursements provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:href="amed-20221231.xsd#amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:to="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1_69f03b88-4a3d-486f-89dd-98f31dd5cf56_terseLabel_en-US" xlink:label="lab_amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Goodwill And Intangible Assets</link:label>
    <link:label id="lab_amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1_label_en-US" xlink:label="lab_amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Goodwill And Intangible Assets</link:label>
    <link:label id="lab_amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1_documentation_en-US" xlink:label="lab_amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cumulative amount of the estimated future tax effects attributable to the difference between the tax basis of intangible assets and the basis of intangible assets computed in accordance with generally accepted accounting principles. The difference in basis, whether due to amortization or other reasons, will increase future taxable income when such difference reverses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1" xlink:href="amed-20221231.xsd#amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1" xlink:to="lab_amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_bbc4704d-ae91-402a-90e6-d7495cc3530c_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b5001858-12a5-4948-ae74-f735a2056ea6_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CARESActProviderReliefFundsRepaidByUnconsolidatedJointVentures_db6cac56-57c7-411b-aabc-e694a9d94402_terseLabel_en-US" xlink:label="lab_amed_CARESActProviderReliefFundsRepaidByUnconsolidatedJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Funds Repaid By Unconsolidated Joint Ventures</link:label>
    <link:label id="lab_amed_CARESActProviderReliefFundsRepaidByUnconsolidatedJointVentures_label_en-US" xlink:label="lab_amed_CARESActProviderReliefFundsRepaidByUnconsolidatedJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Funds Repaid By Unconsolidated Joint Ventures</link:label>
    <link:label id="lab_amed_CARESActProviderReliefFundsRepaidByUnconsolidatedJointVentures_documentation_en-US" xlink:label="lab_amed_CARESActProviderReliefFundsRepaidByUnconsolidatedJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Funds Repaid By Unconsolidated Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundsRepaidByUnconsolidatedJointVentures" xlink:href="amed-20221231.xsd#amed_CARESActProviderReliefFundsRepaidByUnconsolidatedJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CARESActProviderReliefFundsRepaidByUnconsolidatedJointVentures" xlink:to="lab_amed_CARESActProviderReliefFundsRepaidByUnconsolidatedJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MinimumPercentOwnershipForControllingInterestPercent_33ac6ed5-0696-41c1-afd8-aea768184c4f_terseLabel_en-US" xlink:label="lab_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum percent ownership for controlling interest (percent)</link:label>
    <link:label id="lab_amed_MinimumPercentOwnershipForControllingInterestPercent_label_en-US" xlink:label="lab_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Percent Ownership For Controlling Interest Percent</link:label>
    <link:label id="lab_amed_MinimumPercentOwnershipForControllingInterestPercent_documentation_en-US" xlink:label="lab_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage ownership required in order for a variable interest entity (VIE) to be consolidated in the entity's financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:href="amed-20221231.xsd#amed_MinimumPercentOwnershipForControllingInterestPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:to="lab_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8682c44a-6466-43a1-90e4-257c15c13045_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_448e1721-a20c-4391-ba4e-b9a210e594e6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_OtherLongTermObligationsMember_0ef979bc-3bba-4324-a18b-6a8ff1548c75_terseLabel_en-US" xlink:label="lab_amed_OtherLongTermObligationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Obligations [Member]</link:label>
    <link:label id="lab_amed_OtherLongTermObligationsMember_label_en-US" xlink:label="lab_amed_OtherLongTermObligationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Obligations [Member]</link:label>
    <link:label id="lab_amed_OtherLongTermObligationsMember_documentation_en-US" xlink:label="lab_amed_OtherLongTermObligationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OtherLongTermObligationsMember" xlink:href="amed-20221231.xsd#amed_OtherLongTermObligationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OtherLongTermObligationsMember" xlink:to="lab_amed_OtherLongTermObligationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NumberOfCareCentersSold_9351bf8e-e28f-45cd-bdc3-4362d6450197_terseLabel_en-US" xlink:label="lab_amed_NumberOfCareCentersSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of care centers sold</link:label>
    <link:label id="lab_amed_NumberOfCareCentersSold_label_en-US" xlink:label="lab_amed_NumberOfCareCentersSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Care Centers Sold</link:label>
    <link:label id="lab_amed_NumberOfCareCentersSold_documentation_en-US" xlink:label="lab_amed_NumberOfCareCentersSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of care centers sold during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfCareCentersSold" xlink:href="amed-20221231.xsd#amed_NumberOfCareCentersSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NumberOfCareCentersSold" xlink:to="lab_amed_NumberOfCareCentersSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_d79269b1-3916-48ee-bfcf-d0c53b7d6764_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal [Member]</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_b30e1a7f-ef05-4020-9015-0b847673805a_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_a2f38d9b-7025-4cf7-8340-be5bf99e7b86_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Amedisys, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_e5633917-fbc1-4e04-b699-7de77b1b40c1_terseLabel_en-US" xlink:label="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Episode of care as episodic-based revenue, days</link:label>
    <link:label id="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_label_en-US" xlink:label="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Episode Of Care As Episodic Based Revenue Duration</link:label>
    <link:label id="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_documentation_en-US" xlink:label="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days in a home health episode of care.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:href="amed-20221231.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenueDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:to="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_51633592-cc40-41e9-bafe-9b41c6afedf5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DetailsOfCertainBalanceSheetAccountsAbstract_8c253f94-1f33-4914-a74c-cbba0d626764_terseLabel_en-US" xlink:label="lab_amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Details Of Certain Balance Sheet Accounts [Abstract]</link:label>
    <link:label id="lab_amed_DetailsOfCertainBalanceSheetAccountsAbstract_label_en-US" xlink:label="lab_amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Details Of Certain Balance Sheet Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:href="amed-20221231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:to="lab_amed_DetailsOfCertainBalanceSheetAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_846de40c-ee35-4a82-ad45-4c385900205d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_3740e157-e17f-4032-a606-fa031fba4297_terseLabel_en-US" xlink:label="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_label_en-US" xlink:label="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Cash Equivalents and Restricted Cash [Table Text Block]</link:label>
    <link:label id="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_documentation_en-US" xlink:label="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Cash Equivalents and Restricted Cash Table Text Block</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:href="amed-20221231.xsd#amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:to="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_a26579b5-3282-4d4d-8a89-1f012beb57bb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll&#160;&amp; employee benefits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_c32aae71-b4ec-4453-ab32-aba26ba11bc8_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember_a6a9f66e-4ecc-48aa-b09e-7441a453919b_terseLabel_en-US" xlink:label="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Non-Episodic Based [Member]</link:label>
    <link:label id="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember_label_en-US" xlink:label="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Non-Episodic Based [Member]</link:label>
    <link:label id="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember_documentation_en-US" xlink:label="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Non-Episodic Based [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:href="amed-20221231.xsd#amed_HomeHealthNonMedicareNonEpisodicBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:to="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CapYearDomain_53b4e93b-af9d-4b5c-8753-23fc05a9bb15_terseLabel_en-US" xlink:label="lab_amed_CapYearDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Domain]</link:label>
    <link:label id="lab_amed_CapYearDomain_label_en-US" xlink:label="lab_amed_CapYearDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Domain]</link:label>
    <link:label id="lab_amed_CapYearDomain_documentation_en-US" xlink:label="lab_amed_CapYearDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearDomain" xlink:href="amed-20221231.xsd#amed_CapYearDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CapYearDomain" xlink:to="lab_amed_CapYearDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterestAndDividend_52a23167-7594-47e3-af0e-c2b6eb7728df_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterestAndDividend_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest and Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsMember_35257786-ea98-4b9c-83d2-eb0711c20ece_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Leases [Member]</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsMember_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Lease Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLeaseObligationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsMember" xlink:to="lab_us-gaap_CapitalLeaseObligationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_d5d4a599-4595-4071-a0fa-11c55a215dfb_terseLabel_en-US" xlink:label="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Hundred Fifty Million Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_label_en-US" xlink:label="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Hundred Fifty Million Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_documentation_en-US" xlink:label="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Hundred Fifty Million Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:href="amed-20221231.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:to="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ProviderReliefFundAdvance_11bf5262-037e-4bdb-b67c-80c238f56ac7_terseLabel_en-US" xlink:label="lab_amed_ProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider Relief Fund Advance</link:label>
    <link:label id="lab_amed_ProviderReliefFundAdvance_label_en-US" xlink:label="lab_amed_ProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider Relief Fund Advance</link:label>
    <link:label id="lab_amed_ProviderReliefFundAdvance_documentation_en-US" xlink:label="lab_amed_ProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payable related to funds received from the government related to COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProviderReliefFundAdvance" xlink:href="amed-20221231.xsd#amed_ProviderReliefFundAdvance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ProviderReliefFundAdvance" xlink:to="lab_amed_ProviderReliefFundAdvance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_e91d18c5-fd63-4beb-91e4-fc71ee80d981_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_ae87e732-6c13-4e5d-b700-7dbce8e0ec74_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_012671a5-60e6-4043-ac3d-c4ce349210fd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_45fd1132-b2d2-4d6c-91ac-37760d71f82f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted-Average Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DeferredTaxAssetDeferredSocialSecurityTaxes_22bce81b-0df0-45b5-ab97-2b1b3448b04a_terseLabel_en-US" xlink:label="lab_amed_DeferredTaxAssetDeferredSocialSecurityTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred social security taxes (1)</link:label>
    <link:label id="lab_amed_DeferredTaxAssetDeferredSocialSecurityTaxes_label_en-US" xlink:label="lab_amed_DeferredTaxAssetDeferredSocialSecurityTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Deferred Social Security Taxes</link:label>
    <link:label id="lab_amed_DeferredTaxAssetDeferredSocialSecurityTaxes_documentation_en-US" xlink:label="lab_amed_DeferredTaxAssetDeferredSocialSecurityTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred social security taxes which are the result of the novel coronavirus pandemic ("COVID-19").</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxAssetDeferredSocialSecurityTaxes" xlink:href="amed-20221231.xsd#amed_DeferredTaxAssetDeferredSocialSecurityTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DeferredTaxAssetDeferredSocialSecurityTaxes" xlink:to="lab_amed_DeferredTaxAssetDeferredSocialSecurityTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ContributionsAttributableToNoncontrollingInterest_b3e16375-2204-4765-bbd2-f0b9a6db1563_terseLabel_en-US" xlink:label="lab_amed_ContributionsAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest contributions</link:label>
    <link:label id="lab_amed_ContributionsAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_amed_ContributionsAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions attributable to noncontrolling interest</link:label>
    <link:label id="lab_amed_ContributionsAttributableToNoncontrollingInterest_documentation_en-US" xlink:label="lab_amed_ContributionsAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of increase in noncontrolling interest related to capital contributions received from noncontrolling interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ContributionsAttributableToNoncontrollingInterest" xlink:href="amed-20221231.xsd#amed_ContributionsAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ContributionsAttributableToNoncontrollingInterest" xlink:to="lab_amed_ContributionsAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_2c882270-5904-4a65-9717-b78d18c9190d_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_f17254ef-aaa3-43cc-9473-a220920c1b64_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentMember_b92d6eb6-9783-487c-adb0-ea864cfb8ea7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentMember" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_cc235e95-5291-40e3-8cff-c10f52ebe3c5_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Fairvalueofshareofcommonstockpercentage_b42951a6-4a6a-4f5e-adcb-3622c58a1c1d_terseLabel_en-US" xlink:label="lab_amed_Fairvalueofshareofcommonstockpercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of share of common stock (percent)</link:label>
    <link:label id="lab_amed_Fairvalueofshareofcommonstockpercentage_label_en-US" xlink:label="lab_amed_Fairvalueofshareofcommonstockpercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fairvalueofshareofcommonstockpercentage</link:label>
    <link:label id="lab_amed_Fairvalueofshareofcommonstockpercentage_documentation_en-US" xlink:label="lab_amed_Fairvalueofshareofcommonstockpercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of a share of common stock, percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Fairvalueofshareofcommonstockpercentage" xlink:href="amed-20221231.xsd#amed_Fairvalueofshareofcommonstockpercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Fairvalueofshareofcommonstockpercentage" xlink:to="lab_amed_Fairvalueofshareofcommonstockpercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_InfinityHomeCareMember_8d83f431-b034-4f5f-afbe-d6d18a916808_terseLabel_en-US" xlink:label="lab_amed_InfinityHomeCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infinity HomeCare [Member]</link:label>
    <link:label id="lab_amed_InfinityHomeCareMember_label_en-US" xlink:label="lab_amed_InfinityHomeCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infinity HomeCare [Member]</link:label>
    <link:label id="lab_amed_InfinityHomeCareMember_documentation_en-US" xlink:label="lab_amed_InfinityHomeCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infinity HomeCare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InfinityHomeCareMember" xlink:href="amed-20221231.xsd#amed_InfinityHomeCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_InfinityHomeCareMember" xlink:to="lab_amed_InfinityHomeCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_495c59d3-6c8b-4ca3-8169-076c41510e0e_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_167462b5-8591-4b90-9477-8f2d5d804f2f_terseLabel_en-US" xlink:label="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Hundred Seventy Five Million Term Loan Facility [Member]</link:label>
    <link:label id="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_label_en-US" xlink:label="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Hundred Seventy Five Million Term Loan Facility [Member]</link:label>
    <link:label id="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_documentation_en-US" xlink:label="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Hundred Seventy Five Million Term Loan Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:href="amed-20221231.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:to="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_95b11236-0205-4d8f-ad23-cd3449b529f4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LettersofCreditmaximumcommitment_0defa785-1757-42e0-a862-cd82007d3545_terseLabel_en-US" xlink:label="lab_amed_LettersofCreditmaximumcommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit, maximum commitment</link:label>
    <link:label id="lab_amed_LettersofCreditmaximumcommitment_label_en-US" xlink:label="lab_amed_LettersofCreditmaximumcommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LettersofCreditmaximumcommitment</link:label>
    <link:label id="lab_amed_LettersofCreditmaximumcommitment_documentation_en-US" xlink:label="lab_amed_LettersofCreditmaximumcommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit, maximum commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LettersofCreditmaximumcommitment" xlink:href="amed-20221231.xsd#amed_LettersofCreditmaximumcommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LettersofCreditmaximumcommitment" xlink:to="lab_amed_LettersofCreditmaximumcommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_2702ee7d-88c3-46a3-9e28-a481b0ed98f3_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ProceedsFromBorrowingsUnderTermLoan_06febc13-e234-4d19-94e6-e77f51af94d9_terseLabel_en-US" xlink:label="lab_amed_ProceedsFromBorrowingsUnderTermLoan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowings under term loan</link:label>
    <link:label id="lab_amed_ProceedsFromBorrowingsUnderTermLoan_label_en-US" xlink:label="lab_amed_ProceedsFromBorrowingsUnderTermLoan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Borrowings Under Term Loan</link:label>
    <link:label id="lab_amed_ProceedsFromBorrowingsUnderTermLoan_documentation_en-US" xlink:label="lab_amed_ProceedsFromBorrowingsUnderTermLoan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash inflow from borrowings under the term loan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProceedsFromBorrowingsUnderTermLoan" xlink:href="amed-20221231.xsd#amed_ProceedsFromBorrowingsUnderTermLoan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ProceedsFromBorrowingsUnderTermLoan" xlink:to="lab_amed_ProceedsFromBorrowingsUnderTermLoan" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheFourMember_482546de-1e68-4868-bb8e-c3d1e12e0672_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio: Less Than Equal To 0.75 to 1.0</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheFourMember_label_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche Four [Member]</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheFourMember_documentation_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheFourMember" xlink:href="amed-20221231.xsd#amed_DebtInstrumentByLeverageRatioTrancheFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentByLeverageRatioTrancheFourMember" xlink:to="lab_amed_DebtInstrumentByLeverageRatioTrancheFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_16aa8d1b-e2a2-4965-bd2d-7574871a978b_terseLabel_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology-Based Intangible Assets</link:label>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_2dc69f0a-4cd0-4cec-95d5-3fc06a249acf_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_1a90df11-1bab-426b-a654-9a0789bf3ea4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, issued (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2af6a3f5-5cd0-43d3-997a-2040ccb86d88_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_72ad8031-d989-4dd4-a868-cbec855a137e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_7776051d-4b11-46cc-b03a-30fc7256f00e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments_d540ed9d-f154-44ea-ac0f-e94392a0a969_terseLabel_en-US" xlink:label="lab_amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Managed Care Contract Volume Able To Receive Additional Payments</link:label>
    <link:label id="lab_amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments_label_en-US" xlink:label="lab_amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Managed Care Contract Volume Able To Receive Additional Payments</link:label>
    <link:label id="lab_amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments_documentation_en-US" xlink:label="lab_amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of managed care contract volume given opportunity to receive additional payments if certain metrics are met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments" xlink:href="amed-20221231.xsd#amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments" xlink:to="lab_amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_2daf8c93-16f7-415f-a5dd-cf869b31637a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_bc6417be-2bcd-43e3-b982-a6483f0477df_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LONG-TERM OBLIGATIONS</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_VariousAcquisitionsMember_c02b0288-b7c1-4cbf-b505-83be1f7fc033_terseLabel_en-US" xlink:label="lab_amed_VariousAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Various Acquisitions [Member]</link:label>
    <link:label id="lab_amed_VariousAcquisitionsMember_label_en-US" xlink:label="lab_amed_VariousAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Various Acquisitions [Member]</link:label>
    <link:label id="lab_amed_VariousAcquisitionsMember_documentation_en-US" xlink:label="lab_amed_VariousAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Various Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_VariousAcquisitionsMember" xlink:href="amed-20221231.xsd#amed_VariousAcquisitionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_VariousAcquisitionsMember" xlink:to="lab_amed_VariousAcquisitionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NonVestedStockUnitsServiceMember_50b3b8e0-7cef-4a9c-a6e3-16186a0c028a_terseLabel_en-US" xlink:label="lab_amed_NonVestedStockUnitsServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Vested Stock Units - Service-Based [Member]</link:label>
    <link:label id="lab_amed_NonVestedStockUnitsServiceMember_label_en-US" xlink:label="lab_amed_NonVestedStockUnitsServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Vested Stock Units Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockUnitsServiceMember" xlink:href="amed-20221231.xsd#amed_NonVestedStockUnitsServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NonVestedStockUnitsServiceMember" xlink:to="lab_amed_NonVestedStockUnitsServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_4935dcb6-6311-459c-83be-e4cf138d249b_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_0ceabc53-0d6c-4df0-80c1-1dec02aa0d6c_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_e6868e0a-9524-4514-b4f9-f2abd6188bd3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_4093aa0b-2fc9-4f7e-b720-b5bbbef61d86_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions for tax positions related to prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NoncontrollingInterestRepurchased_437b31f0-a84c-48d5-9aa7-24abc193e06f_terseLabel_en-US" xlink:label="lab_amed_NoncontrollingInterestRepurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest Repurchased</link:label>
    <link:label id="lab_amed_NoncontrollingInterestRepurchased_label_en-US" xlink:label="lab_amed_NoncontrollingInterestRepurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest Repurchased</link:label>
    <link:label id="lab_amed_NoncontrollingInterestRepurchased_documentation_en-US" xlink:label="lab_amed_NoncontrollingInterestRepurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest Repurchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NoncontrollingInterestRepurchased" xlink:href="amed-20221231.xsd#amed_NoncontrollingInterestRepurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NoncontrollingInterestRepurchased" xlink:to="lab_amed_NoncontrollingInterestRepurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9b401359-f93f-4405-9950-bb88e312e719_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease - 2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_5c1e4df0-8c05-44a6-89e3-7dbf1a8980c8_terseLabel_en-US" xlink:label="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility, maximum additional borrowing capacity</link:label>
    <link:label id="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_label_en-US" xlink:label="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility Additional Borrowing Capacity</link:label>
    <link:label id="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_documentation_en-US" xlink:label="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility Additional Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:href="amed-20221231.xsd#amed_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:to="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_6c150a5f-c3a8-4bf4-a9c0-0759138dd191_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_IncreaseDecreaseInLiabilitiesAssumed_1856cfeb-9a87-4952-a2c9-e7c8fa544511_terseLabel_en-US" xlink:label="lab_amed_IncreaseDecreaseInLiabilitiesAssumed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Liabilities Assumed</link:label>
    <link:label id="lab_amed_IncreaseDecreaseInLiabilitiesAssumed_label_en-US" xlink:label="lab_amed_IncreaseDecreaseInLiabilitiesAssumed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Liabilities Assumed</link:label>
    <link:label id="lab_amed_IncreaseDecreaseInLiabilitiesAssumed_documentation_en-US" xlink:label="lab_amed_IncreaseDecreaseInLiabilitiesAssumed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInLiabilitiesAssumed" xlink:href="amed-20221231.xsd#amed_IncreaseDecreaseInLiabilitiesAssumed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_IncreaseDecreaseInLiabilitiesAssumed" xlink:to="lab_amed_IncreaseDecreaseInLiabilitiesAssumed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_baa6a363-123c-4cae-9fd9-1112cadfbc60_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VehiclesMember_37309114-c0c4-4988-a222-d46065bf6abe_terseLabel_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vehicles [Member]</link:label>
    <link:label id="lab_us-gaap_VehiclesMember_label_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vehicles [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VehiclesMember" xlink:to="lab_us-gaap_VehiclesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_2db944d1-ca79-4141-9aa6-34d67070eea6_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_b81bc0ba-c7cb-47c5-9dfb-615774f7c783_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_a54c9718-84fe-4408-8616-f659eb40167a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_1e1a497e-06ba-4297-b1d4-a1cea9a6d93f_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TotalLegalSettlementPayment_d4d343bc-ceb8-4608-a94a-6392de4bb697_terseLabel_en-US" xlink:label="lab_amed_TotalLegalSettlementPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Legal Settlement Payment</link:label>
    <link:label id="lab_amed_TotalLegalSettlementPayment_label_en-US" xlink:label="lab_amed_TotalLegalSettlementPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Legal Settlement Payment</link:label>
    <link:label id="lab_amed_TotalLegalSettlementPayment_documentation_en-US" xlink:label="lab_amed_TotalLegalSettlementPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Legal Settlement Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalLegalSettlementPayment" xlink:href="amed-20221231.xsd#amed_TotalLegalSettlementPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TotalLegalSettlementPayment" xlink:to="lab_amed_TotalLegalSettlementPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_489d92a7-53fc-42a3-aaca-054f81e325fb_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CommonStockSharesAvailableForIssuanceToEmployeeStockPurchasePlan_3d1797bb-a2f7-4e43-bbe9-dbda634c7668_terseLabel_en-US" xlink:label="lab_amed_CommonStockSharesAvailableForIssuanceToEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock available for issuance under Employee Stock Purchase Plan (shares)</link:label>
    <link:label id="lab_amed_CommonStockSharesAvailableForIssuanceToEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_amed_CommonStockSharesAvailableForIssuanceToEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Shares Available For Issuance To Employee Stock Purchase Plan</link:label>
    <link:label id="lab_amed_CommonStockSharesAvailableForIssuanceToEmployeeStockPurchasePlan_documentation_en-US" xlink:label="lab_amed_CommonStockSharesAvailableForIssuanceToEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for issuance to the Company's employee stock purchase plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CommonStockSharesAvailableForIssuanceToEmployeeStockPurchasePlan" xlink:href="amed-20221231.xsd#amed_CommonStockSharesAvailableForIssuanceToEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CommonStockSharesAvailableForIssuanceToEmployeeStockPurchasePlan" xlink:to="lab_amed_CommonStockSharesAvailableForIssuanceToEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_1599e0cb-de6f-4894-ae25-615541f117fc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on equity method investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_156af46e-a3e4-4e86-8c39-7ffc08dae6a0_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on equity method investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PatientLiability_907ca67f-2053-4a2f-ab1d-2343c89ee4b8_terseLabel_en-US" xlink:label="lab_amed_PatientLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient and payor liabilities</link:label>
    <link:label id="lab_amed_PatientLiability_label_en-US" xlink:label="lab_amed_PatientLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Liability</link:label>
    <link:label id="lab_amed_PatientLiability_documentation_en-US" xlink:label="lab_amed_PatientLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of accrued expenses related to Patient liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PatientLiability" xlink:href="amed-20221231.xsd#amed_PatientLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PatientLiability" xlink:to="lab_amed_PatientLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemAxis_e81ff476-87fb-4cd3-8023-2e2ece3c2645_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Axis]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemAxis_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis" xlink:to="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_299364b3-720b-4c6a-a8ce-461af2ba83e1_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_b094cd53-2a7f-4fa4-8d24-6e73f7887a37_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_9b64d1f6-2fdf-4459-aa98-1996dff68779_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_label_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche Three [Member]</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_documentation_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheThreeMember" xlink:href="amed-20221231.xsd#amed_DebtInstrumentByLeverageRatioTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentByLeverageRatioTrancheThreeMember" xlink:to="lab_amed_DebtInstrumentByLeverageRatioTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLineItems_label_en-US" xlink:label="lab_dei_AuditorLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLineItems" xlink:to="lab_dei_AuditorLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_UnamortizableAcquiredNamesMember_0fedf8d5-1b9d-46a5-b82b-d1b970e8a479_terseLabel_en-US" xlink:label="lab_amed_UnamortizableAcquiredNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortizable acquired names [Member]</link:label>
    <link:label id="lab_amed_UnamortizableAcquiredNamesMember_label_en-US" xlink:label="lab_amed_UnamortizableAcquiredNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortizable acquired names [Member]</link:label>
    <link:label id="lab_amed_UnamortizableAcquiredNamesMember_documentation_en-US" xlink:label="lab_amed_UnamortizableAcquiredNamesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortizable acquired names</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnamortizableAcquiredNamesMember" xlink:href="amed-20221231.xsd#amed_UnamortizableAcquiredNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_UnamortizableAcquiredNamesMember" xlink:to="lab_amed_UnamortizableAcquiredNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_OrganizationAndNatureOfOperationsLineItems_273f9f3d-1bbe-43ff-b6a5-9ece7b143096_terseLabel_en-US" xlink:label="lab_amed_OrganizationAndNatureOfOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Nature Of Operations [Line Items]</link:label>
    <link:label id="lab_amed_OrganizationAndNatureOfOperationsLineItems_label_en-US" xlink:label="lab_amed_OrganizationAndNatureOfOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Nature Of Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OrganizationAndNatureOfOperationsLineItems" xlink:href="amed-20221231.xsd#amed_OrganizationAndNatureOfOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems" xlink:to="lab_amed_OrganizationAndNatureOfOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ce647168-a775-4426-8c6f-f6c2dc8befdf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_38710490-8e39-4dd4-bec1-9cf2d02fbf02_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease - 2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentInterestRateatPeriodEnd_0b51edd1-542a-4724-9f37-29e0eb766840_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Rate at Period End</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestRateatPeriodEnd_label_en-US" xlink:label="lab_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Rate at Period End</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestRateatPeriodEnd_documentation_en-US" xlink:label="lab_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Rate at Period End</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:href="amed-20221231.xsd#amed_DebtInstrumentInterestRateatPeriodEnd"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:to="lab_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_101f5751-4231-4fa8-8c43-55488db707a2_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term obligations, fair value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare_0822301a-b1e6-47af-bfa3-a6af555fe9eb_terseLabel_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum days to submit final bill from the start of period of care</link:label>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare_label_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Days To Submit Final Bill From Start Of Period of Care</link:label>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare_documentation_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days from the start of the period of care in which the final bill must be submitted to Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:href="amed-20221231.xsd#amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:to="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ImpactOfChangeInMedicareCollectionRate_27315ed4-274f-4035-9efc-0a36294d63a9_terseLabel_en-US" xlink:label="lab_amed_ImpactOfChangeInMedicareCollectionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of Change in Medicare Collection Rate</link:label>
    <link:label id="lab_amed_ImpactOfChangeInMedicareCollectionRate_label_en-US" xlink:label="lab_amed_ImpactOfChangeInMedicareCollectionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of Change in Medicare Collection Rate</link:label>
    <link:label id="lab_amed_ImpactOfChangeInMedicareCollectionRate_documentation_en-US" xlink:label="lab_amed_ImpactOfChangeInMedicareCollectionRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact on Medicare Revenue due to a 0.1% change in our Medicare Collection Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ImpactOfChangeInMedicareCollectionRate" xlink:href="amed-20221231.xsd#amed_ImpactOfChangeInMedicareCollectionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ImpactOfChangeInMedicareCollectionRate" xlink:to="lab_amed_ImpactOfChangeInMedicareCollectionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d20377ce-94ec-4708-b876-6561e3bbc996_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_d05a7a38-c8de-4e93-8865-f4f57f318228_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll and employee benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_UnamortizedDebtIssuanceCostAmortizationPeriod_08440181-c4a9-46ab-9c5e-cc80bd7522fd_terseLabel_en-US" xlink:label="lab_amed_UnamortizedDebtIssuanceCostAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance costs, weighted average amortization period, years</link:label>
    <link:label id="lab_amed_UnamortizedDebtIssuanceCostAmortizationPeriod_label_en-US" xlink:label="lab_amed_UnamortizedDebtIssuanceCostAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Debt Issuance Cost Amortization Period</link:label>
    <link:label id="lab_amed_UnamortizedDebtIssuanceCostAmortizationPeriod_documentation_en-US" xlink:label="lab_amed_UnamortizedDebtIssuanceCostAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected amortization period of debt issuance cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnamortizedDebtIssuanceCostAmortizationPeriod" xlink:href="amed-20221231.xsd#amed_UnamortizedDebtIssuanceCostAmortizationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_UnamortizedDebtIssuanceCostAmortizationPeriod" xlink:to="lab_amed_UnamortizedDebtIssuanceCostAmortizationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_53ad963b-b2b9-43c7-8d87-b1a7b90a7d8f_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_525db4b4-483b-403d-9e76-c7b5414eec8f_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EstimatedMedicareCapLiability_34cfe484-3da8-4aed-a0c3-5a0f23a936f5_terseLabel_en-US" xlink:label="lab_amed_EstimatedMedicareCapLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Medicare cap liability</link:label>
    <link:label id="lab_amed_EstimatedMedicareCapLiability_label_en-US" xlink:label="lab_amed_EstimatedMedicareCapLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Medicare Cap Liability</link:label>
    <link:label id="lab_amed_EstimatedMedicareCapLiability_documentation_en-US" xlink:label="lab_amed_EstimatedMedicareCapLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of accrued expenses related to the estimated Medicare CAP liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedMedicareCapLiability" xlink:href="amed-20221231.xsd#amed_EstimatedMedicareCapLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EstimatedMedicareCapLiability" xlink:to="lab_amed_EstimatedMedicareCapLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_4d5ab1dd-79b9-4456-9b97-58fe14e6cb53_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_bcda508c-7945-4321-b058-f8dda979fe7b_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred debt issuance costs/debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_b0582cfd-598a-44ea-84db-9537d185cdb9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_54acd84d-9a6e-42c0-bbdb-7d5765c89314_terseLabel_en-US" xlink:label="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of time goodwill is expected to be deductible for income tax purposes</link:label>
    <link:label id="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_label_en-US" xlink:label="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Deductible For Income Tax Purposes, Period</link:label>
    <link:label id="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_documentation_en-US" xlink:label="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Deductible For Income Tax Purposes, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:href="amed-20221231.xsd#amed_GoodwillDeductibleForIncomeTaxPurposesPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:to="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome_6cc0e313-877a-41dd-9553-fd601d6399d0_negatedTerseLabel_en-US" xlink:label="lab_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-off of other comprehensive income</link:label>
    <link:label id="lab_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome_label_en-US" xlink:label="lab_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Impact Of Write Off Of Other Comprehensive Income</link:label>
    <link:label id="lab_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome_documentation_en-US" xlink:label="lab_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Impact Of Write Off Of Other Comprehensive Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome" xlink:href="amed-20221231.xsd#amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome" xlink:to="lab_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RandolphCountyNorthCarolinaMember_83cd619d-4ef2-4a7f-8025-25b305a53208_terseLabel_en-US" xlink:label="lab_amed_RandolphCountyNorthCarolinaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Randolph County, North Carolina</link:label>
    <link:label id="lab_amed_RandolphCountyNorthCarolinaMember_label_en-US" xlink:label="lab_amed_RandolphCountyNorthCarolinaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Randolph County, North Carolina [Member]</link:label>
    <link:label id="lab_amed_RandolphCountyNorthCarolinaMember_documentation_en-US" xlink:label="lab_amed_RandolphCountyNorthCarolinaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Randolph County, North Carolina</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RandolphCountyNorthCarolinaMember" xlink:href="amed-20221231.xsd#amed_RandolphCountyNorthCarolinaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RandolphCountyNorthCarolinaMember" xlink:to="lab_amed_RandolphCountyNorthCarolinaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_72a2afb1-1d1b-441d-adb7-0404b4b2c9cf_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6f9cfa4a-c003-48e3-b1ed-1516027312f1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock_ff9906b3-8fad-4800-8088-19327b986da0_terseLabel_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Business Acquisitions, AseraCare Hospice</link:label>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock_label_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Business Acquisitions AseraCare Hospice [Table Text Block]</link:label>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock_documentation_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of AseraCare business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock" xlink:href="amed-20221231.xsd#amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock" xlink:to="lab_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_7dbfb851-f0da-4284-aba3-24534440195f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of stock to employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_c9401c57-64aa-4df3-8241-082d5e12db9a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_d416d68c-47ac-4e3d-8fd3-9443263e28b7_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Other Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity_93dd95ef-86c2-46e0-aad4-cce7a332623b_negatedTerseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities And Equity</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities And Equity</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity assumed at the acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity" xlink:href="amed-20221231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FinanceLeasesTableTextBlock_aacba071-25db-494e-8558-6392ebe288f6_terseLabel_en-US" xlink:label="lab_amed_FinanceLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finance Leases</link:label>
    <link:label id="lab_amed_FinanceLeasesTableTextBlock_label_en-US" xlink:label="lab_amed_FinanceLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases [Table Text Block]</link:label>
    <link:label id="lab_amed_FinanceLeasesTableTextBlock_documentation_en-US" xlink:label="lab_amed_FinanceLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases Table Text Block</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FinanceLeasesTableTextBlock" xlink:href="amed-20221231.xsd#amed_FinanceLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FinanceLeasesTableTextBlock" xlink:to="lab_amed_FinanceLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_5ff9716b-8b2e-4da4-84de-bc5105240ced_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio: Less Than Equal To 3.00 to 1.0 but Greater Than 2.00 to 1.0</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_label_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche Two [Member]</link:label>
    <link:label id="lab_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_documentation_en-US" xlink:label="lab_amed_DebtInstrumentByLeverageRatioTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, By Leverage Ratio, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheTwoMember" xlink:href="amed-20221231.xsd#amed_DebtInstrumentByLeverageRatioTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentByLeverageRatioTrancheTwoMember" xlink:to="lab_amed_DebtInstrumentByLeverageRatioTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramExpirationDate_f4b783b5-7509-4047-be63-94d869ed182b_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, expiration date</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramExpirationDate_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramExpirationDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramExpirationDate" xlink:to="lab_us-gaap_StockRepurchaseProgramExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_919a7fec-d10f-43d3-9e05-dc166f3eed22_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RevolvingCreditFacilityTotal_bd4e05e5-c6fb-47c9-9f1c-6beb34b3acc7_terseLabel_en-US" xlink:label="lab_amed_RevolvingCreditFacilityTotal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of revolving credit facility</link:label>
    <link:label id="lab_amed_RevolvingCreditFacilityTotal_label_en-US" xlink:label="lab_amed_RevolvingCreditFacilityTotal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RevolvingCreditFacilityTotal" xlink:href="amed-20221231.xsd#amed_RevolvingCreditFacilityTotal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RevolvingCreditFacilityTotal" xlink:to="lab_amed_RevolvingCreditFacilityTotal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_071eb667-21b8-40a3-aaee-1b8016e3bcaa_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance/(cancellation) of non-vested stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RecognizedTaxBenefitThatImpactsEffectiveTaxRate_97c6e10e-cfea-45b2-86a6-9022f566568b_terseLabel_en-US" xlink:label="lab_amed_RecognizedTaxBenefitThatImpactsEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized Tax Benefit that Impacts Effective Tax Rate</link:label>
    <link:label id="lab_amed_RecognizedTaxBenefitThatImpactsEffectiveTaxRate_label_en-US" xlink:label="lab_amed_RecognizedTaxBenefitThatImpactsEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized Tax Benefit that Impacts Effective Tax Rate</link:label>
    <link:label id="lab_amed_RecognizedTaxBenefitThatImpactsEffectiveTaxRate_documentation_en-US" xlink:label="lab_amed_RecognizedTaxBenefitThatImpactsEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized Tax Benefit that Impacts Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecognizedTaxBenefitThatImpactsEffectiveTaxRate" xlink:href="amed-20221231.xsd#amed_RecognizedTaxBenefitThatImpactsEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RecognizedTaxBenefitThatImpactsEffectiveTaxRate" xlink:to="lab_amed_RecognizedTaxBenefitThatImpactsEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CertificateOfNeedMember_f18132f8-3da7-4241-8c8f-4503074b7f90_terseLabel_en-US" xlink:label="lab_amed_CertificateOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of Need [Member]</link:label>
    <link:label id="lab_amed_CertificateOfNeedMember_label_en-US" xlink:label="lab_amed_CertificateOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of Need [Member]</link:label>
    <link:label id="lab_amed_CertificateOfNeedMember_documentation_en-US" xlink:label="lab_amed_CertificateOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of Need</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificateOfNeedMember" xlink:href="amed-20221231.xsd#amed_CertificateOfNeedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CertificateOfNeedMember" xlink:to="lab_amed_CertificateOfNeedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CARESActInterestRepaidToGovernment_395b04c2-1caa-4743-afb3-93c8e622f244_terseLabel_en-US" xlink:label="lab_amed_CARESActInterestRepaidToGovernment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Interest Repaid to Government</link:label>
    <link:label id="lab_amed_CARESActInterestRepaidToGovernment_label_en-US" xlink:label="lab_amed_CARESActInterestRepaidToGovernment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Interest Repaid to Government</link:label>
    <link:label id="lab_amed_CARESActInterestRepaidToGovernment_documentation_en-US" xlink:label="lab_amed_CARESActInterestRepaidToGovernment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Interest Repaid to Government</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActInterestRepaidToGovernment" xlink:href="amed-20221231.xsd#amed_CARESActInterestRepaidToGovernment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CARESActInterestRepaidToGovernment" xlink:to="lab_amed_CARESActInterestRepaidToGovernment" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MedalogixMember_1defabd3-a2e9-4d3e-895d-02ba30110812_terseLabel_en-US" xlink:label="lab_amed_MedalogixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medalogix [Member]</link:label>
    <link:label id="lab_amed_MedalogixMember_label_en-US" xlink:label="lab_amed_MedalogixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medalogix [Member]</link:label>
    <link:label id="lab_amed_MedalogixMember_documentation_en-US" xlink:label="lab_amed_MedalogixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medalogix</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedalogixMember" xlink:href="amed-20221231.xsd#amed_MedalogixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MedalogixMember" xlink:to="lab_amed_MedalogixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_0b0e7349-de33-443e-af07-2ba5efa4ba38_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_fe3c4694-c1e9-4280-91a8-d5730eb21c5b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DeferredTaxAssetsLeaseLiability_85808652-cfb6-428b-9b0f-fd69eb213031_terseLabel_en-US" xlink:label="lab_amed_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_amed_DeferredTaxAssetsLeaseLiability_label_en-US" xlink:label="lab_amed_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:label id="lab_amed_DeferredTaxAssetsLeaseLiability_documentation_en-US" xlink:label="lab_amed_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxAssetsLeaseLiability" xlink:href="amed-20221231.xsd#amed_DeferredTaxAssetsLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DeferredTaxAssetsLeaseLiability" xlink:to="lab_amed_DeferredTaxAssetsLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember_aef74193-cb5f-44a6-8672-2250aae277b4_terseLabel_en-US" xlink:label="lab_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Awards to More Than Ten Percent Owner [Member]</link:label>
    <link:label id="lab_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember_label_en-US" xlink:label="lab_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Awards To More Than Ten Percent Owner [Member]</link:label>
    <link:label id="lab_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember_documentation_en-US" xlink:label="lab_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based awards to any owner of 10% or more of our total combined voting power of us and our subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember" xlink:href="amed-20221231.xsd#amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember" xlink:to="lab_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_17290244-9b15-478b-a334-5a326c8eed99_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_421237cb-3f72-423c-a62f-95673facfb7d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_414d945c-2006-4d29-8036-a5150557342f_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_0004468e-d4be-4660-b041-049d3bd5e077_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_0286a538-0875-4140-8a2c-76d66bc13c78_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HealthInsurance_757df582-ed25-4e47-9601-00f074bc78c7_terseLabel_en-US" xlink:label="lab_amed_HealthInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health insurance</link:label>
    <link:label id="lab_amed_HealthInsurance_label_en-US" xlink:label="lab_amed_HealthInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Insurance</link:label>
    <link:label id="lab_amed_HealthInsurance_documentation_en-US" xlink:label="lab_amed_HealthInsurance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health insurance, estimated liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthInsurance" xlink:href="amed-20221231.xsd#amed_HealthInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HealthInsurance" xlink:to="lab_amed_HealthInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LegalAndOtherSettlements_4872069d-b47a-47c2-9ce1-d61e682457ad_terseLabel_en-US" xlink:label="lab_amed_LegalAndOtherSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal settlements and other audits</link:label>
    <link:label id="lab_amed_LegalAndOtherSettlements_label_en-US" xlink:label="lab_amed_LegalAndOtherSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal And Other Settlements</link:label>
    <link:label id="lab_amed_LegalAndOtherSettlements_documentation_en-US" xlink:label="lab_amed_LegalAndOtherSettlements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of accrued expenses related to legal and other settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LegalAndOtherSettlements" xlink:href="amed-20221231.xsd#amed_LegalAndOtherSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LegalAndOtherSettlements" xlink:to="lab_amed_LegalAndOtherSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CertificatesOfNeedAndLicensesMember_ceaf37e5-0b3c-4b3d-8073-958338e0f46f_terseLabel_en-US" xlink:label="lab_amed_CertificatesOfNeedAndLicensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Need and Licenses [Member]</link:label>
    <link:label id="lab_amed_CertificatesOfNeedAndLicensesMember_label_en-US" xlink:label="lab_amed_CertificatesOfNeedAndLicensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates Of Need And Licenses [Member]</link:label>
    <link:label id="lab_amed_CertificatesOfNeedAndLicensesMember_documentation_en-US" xlink:label="lab_amed_CertificatesOfNeedAndLicensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates Of Need And Licenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificatesOfNeedAndLicensesMember" xlink:href="amed-20221231.xsd#amed_CertificatesOfNeedAndLicensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CertificatesOfNeedAndLicensesMember" xlink:to="lab_amed_CertificatesOfNeedAndLicensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_85f1ace5-ee6a-46c4-96c8-af4632174c78_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions for tax positions related to prior year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LakelandFloridaMember_96e07cd6-d349-4f40-9eec-ff613cb19101_terseLabel_en-US" xlink:label="lab_amed_LakelandFloridaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lakeland, Florida [Member]</link:label>
    <link:label id="lab_amed_LakelandFloridaMember_label_en-US" xlink:label="lab_amed_LakelandFloridaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lakeland, Florida [Member]</link:label>
    <link:label id="lab_amed_LakelandFloridaMember_documentation_en-US" xlink:label="lab_amed_LakelandFloridaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lakeland, Florida [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LakelandFloridaMember" xlink:href="amed-20221231.xsd#amed_LakelandFloridaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LakelandFloridaMember" xlink:to="lab_amed_LakelandFloridaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncome_b53f2fe1-ae95-4e73-a0ac-c988fe0e9ce6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating income</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncome_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncome" xlink:to="lab_us-gaap_OtherOperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_3818d13e-a750-484f-8729-28d57def401c_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax expense allocation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Intraperiod Tax Allocation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedInsuranceCurrent_460047a7-bea0-4017-8c3d-02a7edef0b8e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedInsuranceCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health insurance</link:label>
    <link:label id="lab_us-gaap_AccruedInsuranceCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedInsuranceCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Insurance, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedInsuranceCurrent" xlink:to="lab_us-gaap_AccruedInsuranceCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_abeba3b5-e4e7-45ed-83c4-3d56b3559c40_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_A2022NewJointVentureMember_26d77805-a215-4f77-8a55-ebbe814444c3_terseLabel_en-US" xlink:label="lab_amed_A2022NewJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 New Joint Venture</link:label>
    <link:label id="lab_amed_A2022NewJointVentureMember_label_en-US" xlink:label="lab_amed_A2022NewJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 New Joint Venture [Member]</link:label>
    <link:label id="lab_amed_A2022NewJointVentureMember_documentation_en-US" xlink:label="lab_amed_A2022NewJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 New Joint Venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2022NewJointVentureMember" xlink:href="amed-20221231.xsd#amed_A2022NewJointVentureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_A2022NewJointVentureMember" xlink:to="lab_amed_A2022NewJointVentureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e20c7fa3-bee5-4705-9300-02e4ab483530_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_13d1b50b-6dff-41dd-8756-048fc52b7307_negatedLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_fc8ccd4c-5506-4076-9f5e-d0e1c4c24869_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TypeOfEquityMethodInvestmentDomain_f75401de-7054-4d9a-b806-8d6b053d8974_terseLabel_en-US" xlink:label="lab_amed_TypeOfEquityMethodInvestmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Equity Method Investment [Domain]</link:label>
    <link:label id="lab_amed_TypeOfEquityMethodInvestmentDomain_label_en-US" xlink:label="lab_amed_TypeOfEquityMethodInvestmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Equity Method Investment [Domain]</link:label>
    <link:label id="lab_amed_TypeOfEquityMethodInvestmentDomain_documentation_en-US" xlink:label="lab_amed_TypeOfEquityMethodInvestmentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Equity Method Investment [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeOfEquityMethodInvestmentDomain" xlink:href="amed-20221231.xsd#amed_TypeOfEquityMethodInvestmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TypeOfEquityMethodInvestmentDomain" xlink:to="lab_amed_TypeOfEquityMethodInvestmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_95ebacf0-27dd-4b9d-8b00-5e002db03cf3_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7210eda3-3540-45d6-bc87-f1f806a5d09b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease - 2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SurrenderedSharesInShares_fb3e106e-b8b8-41e7-b6ae-33729ff6a1bb_terseLabel_en-US" xlink:label="lab_amed_SurrenderedSharesInShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surrendered Shares In Shares</link:label>
    <link:label id="lab_amed_SurrenderedSharesInShares_label_en-US" xlink:label="lab_amed_SurrenderedSharesInShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surrendered Shares In Shares</link:label>
    <link:label id="lab_amed_SurrenderedSharesInShares_documentation_en-US" xlink:label="lab_amed_SurrenderedSharesInShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surrendered Shares In Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SurrenderedSharesInShares" xlink:href="amed-20221231.xsd#amed_SurrenderedSharesInShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SurrenderedSharesInShares" xlink:to="lab_amed_SurrenderedSharesInShares" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TaxCreditCarryforwardMember_d1bd0dd6-288d-4745-a5c4-665ba06852d8_terseLabel_en-US" xlink:label="lab_amed_TaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Member]</link:label>
    <link:label id="lab_amed_TaxCreditCarryforwardMember_label_en-US" xlink:label="lab_amed_TaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Member]</link:label>
    <link:label id="lab_amed_TaxCreditCarryforwardMember_documentation_en-US" xlink:label="lab_amed_TaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TaxCreditCarryforwardMember" xlink:href="amed-20221231.xsd#amed_TaxCreditCarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TaxCreditCarryforwardMember" xlink:to="lab_amed_TaxCreditCarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_170d383b-5e92-467a-8b55-425b50d4ad5a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CurrentPortionOfLongTermObligationsMember_42fea6a1-9dc3-4e2b-af21-a8b94b91763c_terseLabel_en-US" xlink:label="lab_amed_CurrentPortionOfLongTermObligationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term obligations</link:label>
    <link:label id="lab_amed_CurrentPortionOfLongTermObligationsMember_label_en-US" xlink:label="lab_amed_CurrentPortionOfLongTermObligationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term obligations [Member]</link:label>
    <link:label id="lab_amed_CurrentPortionOfLongTermObligationsMember_documentation_en-US" xlink:label="lab_amed_CurrentPortionOfLongTermObligationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CurrentPortionOfLongTermObligationsMember" xlink:href="amed-20221231.xsd#amed_CurrentPortionOfLongTermObligationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CurrentPortionOfLongTermObligationsMember" xlink:to="lab_amed_CurrentPortionOfLongTermObligationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_2b8f69a5-7cc1-46f6-ad8c-bc0f2d8c6fb1_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_8eceafcd-abea-4401-a94b-3bed1f6026d5_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Amedisys, Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_5fe4acd0-836b-4933-b35d-53a0fc753eb6_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_12e8b05e-b915-4475-b617-ab830426b2e6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled, forfeited or expired (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ProfessionalLiability_987618c4-a07c-4985-8767-11a0410098b3_terseLabel_en-US" xlink:label="lab_amed_ProfessionalLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional liability</link:label>
    <link:label id="lab_amed_ProfessionalLiability_label_en-US" xlink:label="lab_amed_ProfessionalLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Liability</link:label>
    <link:label id="lab_amed_ProfessionalLiability_documentation_en-US" xlink:label="lab_amed_ProfessionalLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional liability insurance, estimated liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProfessionalLiability" xlink:href="amed-20221231.xsd#amed_ProfessionalLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ProfessionalLiability" xlink:to="lab_amed_ProfessionalLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_83492d72-e2bc-4270-82de-28b82d31f076_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_350abf19-ca90-40db-9a6d-1467dcb7a1f5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_5fb57bd5-41d7-4542-b2a0-19a4d97d2013_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_86b17f12-2112-426e-9a4d-692525241ce7_terseLabel_en-US" xlink:label="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated amounts due back to Medicare</link:label>
    <link:label id="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_label_en-US" xlink:label="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Amount Due Back To Medicare In Other Accrued Liabilities</link:label>
    <link:label id="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_documentation_en-US" xlink:label="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of obligations due Medicare upon demand due to overages for the inpatient cap and/or overall payment cap.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:href="amed-20221231.xsd#amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:to="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1daece96-06ca-4fbc-812a-d928e713f749_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PersonalCareMember_103eb6f3-9ddb-4c7f-bf49-228a283b3a01_terseLabel_en-US" xlink:label="lab_amed_PersonalCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personal Care [Member]</link:label>
    <link:label id="lab_amed_PersonalCareMember_label_en-US" xlink:label="lab_amed_PersonalCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personal Care [Member]</link:label>
    <link:label id="lab_amed_PersonalCareMember_documentation_en-US" xlink:label="lab_amed_PersonalCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personal Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember" xlink:href="amed-20221231.xsd#amed_PersonalCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PersonalCareMember" xlink:to="lab_amed_PersonalCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_71f26aa6-a399-4d31-8cc6-1b70a8780d26_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent_23525d10-ac20-4447-9148-72b59fc02b8e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Miscellaneous, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:to="lab_us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NonCashAccruedContingentConsideration_39f1b19e-08de-4d3f-8065-5f0f7ad45f8d_terseLabel_en-US" xlink:label="lab_amed_NonCashAccruedContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued contingent consideration</link:label>
    <link:label id="lab_amed_NonCashAccruedContingentConsideration_label_en-US" xlink:label="lab_amed_NonCashAccruedContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Accrued Contingent Consideration</link:label>
    <link:label id="lab_amed_NonCashAccruedContingentConsideration_documentation_en-US" xlink:label="lab_amed_NonCashAccruedContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Accrued Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonCashAccruedContingentConsideration" xlink:href="amed-20221231.xsd#amed_NonCashAccruedContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NonCashAccruedContingentConsideration" xlink:to="lab_amed_NonCashAccruedContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_0079aefc-9b3b-4f5b-8a18-8c724061cf87_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_0966fa9f-e3d5-49c1-a782-7fc451f49a36_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_8698acdc-640e-4d6c-aca2-0e1800b119d1_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NumberOfCareCentersIncludedInDiscontinuedOperations_97d094f5-548b-4634-8ac6-5db93bd35570_terseLabel_en-US" xlink:label="lab_amed_NumberOfCareCentersIncludedInDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of care centers included in discontinued operations</link:label>
    <link:label id="lab_amed_NumberOfCareCentersIncludedInDiscontinuedOperations_label_en-US" xlink:label="lab_amed_NumberOfCareCentersIncludedInDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Care Centers Included In Discontinued Operations</link:label>
    <link:label id="lab_amed_NumberOfCareCentersIncludedInDiscontinuedOperations_documentation_en-US" xlink:label="lab_amed_NumberOfCareCentersIncludedInDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of care centers included in discontinued operations during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfCareCentersIncludedInDiscontinuedOperations" xlink:href="amed-20221231.xsd#amed_NumberOfCareCentersIncludedInDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NumberOfCareCentersIncludedInDiscontinuedOperations" xlink:to="lab_amed_NumberOfCareCentersIncludedInDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_75e147bf-4ae4-4477-bad7-61de4222e350_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ParkersburgWestVirginiaMember_4d5edd3c-48b7-4bc2-882f-76ecd7a37af0_terseLabel_en-US" xlink:label="lab_amed_ParkersburgWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parkersburg, West Virginia [Member]</link:label>
    <link:label id="lab_amed_ParkersburgWestVirginiaMember_label_en-US" xlink:label="lab_amed_ParkersburgWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parkersburg, West Virginia [Member]</link:label>
    <link:label id="lab_amed_ParkersburgWestVirginiaMember_documentation_en-US" xlink:label="lab_amed_ParkersburgWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parkersburg, West Virginia [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ParkersburgWestVirginiaMember" xlink:href="amed-20221231.xsd#amed_ParkersburgWestVirginiaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ParkersburgWestVirginiaMember" xlink:to="lab_amed_ParkersburgWestVirginiaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_26bd11de-8423-44aa-a75f-01310c64c124_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_076f0ad5-47ce-4c19-aa55-968ed3241924_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable business segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_57e19cde-dc9c-4492-98e2-b883191b43dd_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f808e58a-d63a-4639-8ec3-a17a406ca71a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-based awards, shares available for grant (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_37a43011-4e3a-46c6-84ac-6646c1ab729f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Non-Vested Stock Unit Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_d2882f1d-820b-49b1-a585-1ff2293854fe_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_55e81b4d-b3b9-49c2-8910-e7ef41d2513b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_6474b26c-deda-42e0-9d18-8da40e07e2a9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Amount of Assets and Liabilities for Disposal Group</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3e9ed5eb-cf3a-42e2-a1bb-27d020d71096_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_16ec6640-eb60-4015-94d4-4aa556822c00_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Non-Vested Performance-based Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Performance-Based Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_21c2287d-ba1d-4de0-9c37-61329cc2196b_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_a66f1b2c-2534-417b-9e88-ea671b4a50cc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, less current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PayorClassDomain_1f11db8d-81f3-4ca1-99ed-109e5bc2c17a_terseLabel_en-US" xlink:label="lab_amed_PayorClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Class [Domain]</link:label>
    <link:label id="lab_amed_PayorClassDomain_label_en-US" xlink:label="lab_amed_PayorClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Class [Domain]</link:label>
    <link:label id="lab_amed_PayorClassDomain_documentation_en-US" xlink:label="lab_amed_PayorClassDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Payor Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassDomain" xlink:href="amed-20221231.xsd#amed_PayorClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PayorClassDomain" xlink:to="lab_amed_PayorClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_6c31ef02-fa5a-4e1b-b927-4d82fe161ddc_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">401(k) expense recognized</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_1d5a77d2-f179-4eda-ae44-24ac4f8c2731_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_2f72ca2a-d461-44d7-b272-21b0cf629b5e_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_f9fe4744-d2fe-43e1-ab74-f6b0fd0e252b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of accrued contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_a65a5299-cf10-4c8b-90fc-e79a7d78ebbd_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_713c60f6-a182-4082-b50a-64ebc8d166fa_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_22bae57e-263c-4dae-ad6c-b7f187bc5c9c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_e5476392-0677-4850-8a8f-569b38e6aed4_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LeaseLiabilityMaturityTableTextBlock_1a05af4a-0d37-44bf-9690-9a1b41d6adf2_terseLabel_en-US" xlink:label="lab_amed_LeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Liability Maturity</link:label>
    <link:label id="lab_amed_LeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_amed_LeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Liability Maturity [Table Text Block]</link:label>
    <link:label id="lab_amed_LeaseLiabilityMaturityTableTextBlock_documentation_en-US" xlink:label="lab_amed_LeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Liability Maturity Table Text Block</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LeaseLiabilityMaturityTableTextBlock" xlink:href="amed-20221231.xsd#amed_LeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LeaseLiabilityMaturityTableTextBlock" xlink:to="lab_amed_LeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_97e7dda3-f84d-4e9a-9f9d-2ce4ad0a97c7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_3132586b-fa21-4137-843a-664c314a6664_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:to="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_bd685b57-aa0f-4361-bcc3-a6ef442c6487_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SharedBasedPaymentArrangementNonVestedOptionActivityTableTextBlock_dcdd51de-7eac-49ba-ac78-0eeb5e0b4c1f_terseLabel_en-US" xlink:label="lab_amed_SharedBasedPaymentArrangementNonVestedOptionActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shared-based Payment Arrangement, Non-vested Option, Activity</link:label>
    <link:label id="lab_amed_SharedBasedPaymentArrangementNonVestedOptionActivityTableTextBlock_label_en-US" xlink:label="lab_amed_SharedBasedPaymentArrangementNonVestedOptionActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shared-based Payment Arrangement, Non-vested Option, Activity [Table Text Block]</link:label>
    <link:label id="lab_amed_SharedBasedPaymentArrangementNonVestedOptionActivityTableTextBlock_documentation_en-US" xlink:label="lab_amed_SharedBasedPaymentArrangementNonVestedOptionActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure for non-vested stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, vestings, forfeitures, and weighted-average grant date fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SharedBasedPaymentArrangementNonVestedOptionActivityTableTextBlock" xlink:href="amed-20221231.xsd#amed_SharedBasedPaymentArrangementNonVestedOptionActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SharedBasedPaymentArrangementNonVestedOptionActivityTableTextBlock" xlink:to="lab_amed_SharedBasedPaymentArrangementNonVestedOptionActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HospiceMember_48468cf0-7450-4082-b248-ca6748f5185d_terseLabel_en-US" xlink:label="lab_amed_HospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice [Member]</link:label>
    <link:label id="lab_amed_HospiceMember_label_en-US" xlink:label="lab_amed_HospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice [Member]</link:label>
    <link:label id="lab_amed_HospiceMember_documentation_en-US" xlink:label="lab_amed_HospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember" xlink:href="amed-20221231.xsd#amed_HospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HospiceMember" xlink:to="lab_amed_HospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HealthInsuranceDeposits_0e6d41d0-7ce7-4328-8ecf-64541473adb6_terseLabel_en-US" xlink:label="lab_amed_HealthInsuranceDeposits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health insurance deposits</link:label>
    <link:label id="lab_amed_HealthInsuranceDeposits_label_en-US" xlink:label="lab_amed_HealthInsuranceDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Insurance Deposits</link:label>
    <link:label id="lab_amed_HealthInsuranceDeposits_documentation_en-US" xlink:label="lab_amed_HealthInsuranceDeposits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Insurance Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthInsuranceDeposits" xlink:href="amed-20221231.xsd#amed_HealthInsuranceDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HealthInsuranceDeposits" xlink:to="lab_amed_HealthInsuranceDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_3305d839-4ce3-4a41-b359-9c847bd2daba_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessAcquisitionProFormaInformationAseraCareTableTextBlock_8732b0d8-5163-431e-8fc8-0eaf1c2c397f_terseLabel_en-US" xlink:label="lab_amed_BusinessAcquisitionProFormaInformationAseraCareTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Pro Forma Financial Information, AseraCare</link:label>
    <link:label id="lab_amed_BusinessAcquisitionProFormaInformationAseraCareTableTextBlock_label_en-US" xlink:label="lab_amed_BusinessAcquisitionProFormaInformationAseraCareTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information, AseraCare [Table Text Block]</link:label>
    <link:label id="lab_amed_BusinessAcquisitionProFormaInformationAseraCareTableTextBlock_documentation_en-US" xlink:label="lab_amed_BusinessAcquisitionProFormaInformationAseraCareTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of pro forma results of operations for a the AseraCare acquisition .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionProFormaInformationAseraCareTableTextBlock" xlink:href="amed-20221231.xsd#amed_BusinessAcquisitionProFormaInformationAseraCareTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessAcquisitionProFormaInformationAseraCareTableTextBlock" xlink:to="lab_amed_BusinessAcquisitionProFormaInformationAseraCareTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_41035700-b6ea-4d12-8671-1e353ac28b7c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_83416f53-eaa0-4720-8bae-bb4b52689b9e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested, beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4080871f-7445-439f-8d5f-7a0b23fd27e3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested, ending balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_825d4a41-e34d-483b-a75e-6b30c12402a6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Frequency of periodic payment</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Frequency of Periodic Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:to="lab_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_cec2d2ff-0560-4a96-ac39-98bd48cad8aa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual term of share-based award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_37ccffa1-fc05-4e2a-b35e-6e7d2423d90e_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_1488ec8d-52f1-4906-9487-b7e62b270c28_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets_5764f411-b4d8-4d0d-b16f-44a73990eebc_negatedTerseLabel_en-US" xlink:label="lab_amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Amortization of Intangible Assets</link:label>
    <link:label id="lab_amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets_documentation_en-US" xlink:label="lab_amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from amortization of intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets" xlink:href="amed-20221231.xsd#amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets" xlink:to="lab_amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_d5561a03-71f1-4d90-923d-371da7d707f1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_7e6de3bc-f118-4456-a566-d7eb0f4c15d2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_24489490-f2f3-460f-aabc-c88992544a48_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease ROU assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ReclassToAmortizableIntangible_8f97d8fd-58cb-49eb-8509-6589432fcfff_terseLabel_en-US" xlink:label="lab_amed_ReclassToAmortizableIntangible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclass to amortizable intangible</link:label>
    <link:label id="lab_amed_ReclassToAmortizableIntangible_label_en-US" xlink:label="lab_amed_ReclassToAmortizableIntangible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclass to amortizable intangible</link:label>
    <link:label id="lab_amed_ReclassToAmortizableIntangible_documentation_en-US" xlink:label="lab_amed_ReclassToAmortizableIntangible" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from unamortizable intangible asset to amortizable intangible asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ReclassToAmortizableIntangible" xlink:href="amed-20221231.xsd#amed_ReclassToAmortizableIntangible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ReclassToAmortizableIntangible" xlink:to="lab_amed_ReclassToAmortizableIntangible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_414a14e5-a019-42e6-8cf6-9c6badbddee1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ContessaHealthMember_3666ada7-5671-4c3e-88ff-7bc4e012387a_terseLabel_en-US" xlink:label="lab_amed_ContessaHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contessa Health</link:label>
    <link:label id="lab_amed_ContessaHealthMember_label_en-US" xlink:label="lab_amed_ContessaHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contessa Health [Member]</link:label>
    <link:label id="lab_amed_ContessaHealthMember_documentation_en-US" xlink:label="lab_amed_ContessaHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contessa Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ContessaHealthMember" xlink:href="amed-20221231.xsd#amed_ContessaHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ContessaHealthMember" xlink:to="lab_amed_ContessaHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_38d67193-eb3c-4716-96e7-558d693a8bdc_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ActualClaimsPayment_1b7012c6-4e04-426d-a091-8d890b9feb91_terseLabel_en-US" xlink:label="lab_amed_ActualClaimsPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual claims payment</link:label>
    <link:label id="lab_amed_ActualClaimsPayment_label_en-US" xlink:label="lab_amed_ActualClaimsPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual Claims Payment</link:label>
    <link:label id="lab_amed_ActualClaimsPayment_documentation_en-US" xlink:label="lab_amed_ActualClaimsPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual Claims Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ActualClaimsPayment" xlink:href="amed-20221231.xsd#amed_ActualClaimsPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ActualClaimsPayment" xlink:to="lab_amed_ActualClaimsPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_f20e232e-bb6a-44d4-a845-5cb49c9a3036_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_ff7ac5b9-d8c1-457f-954c-afdbe4db817b_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_71b10844-26fb-47d4-9292-eae227a0794d_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_63ef910d-9884-45b5-a613-6046a71063bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_03a29d39-b883-40d3-b986-52ab843ee8a4_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_d5550019-5279-45d7-ac65-571ce3387bbb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_84e6af6c-85c2-4f11-b185-6dda90ba59b6_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_0123b36f-cc7d-4aee-a9aa-f5f9d73e7aba_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_84323594-29e3-4e73-9bd5-af224e7af9e5_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_95bd3330-f862-46c3-863d-ac6b6f8bebc6_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent_2dc3785b-9095-4139-8420-dd6e4de1217f_terseLabel_en-US" xlink:label="lab_amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible executive compensation</link:label>
    <link:label id="lab_amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent_label_en-US" xlink:label="lab_amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Non-deductible Executive Compensation, Percent</link:label>
    <link:label id="lab_amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent_documentation_en-US" xlink:label="lab_amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Non-deductible Executive Compensation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent" xlink:href="amed-20221231.xsd#amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent" xlink:to="lab_amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_bd548938-378d-43a8-8038-b4bd8920a777_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember_ee84a4d0-8f23-4484-b325-07bbcaa91b0c_terseLabel_en-US" xlink:label="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year 2016 Through 2022 [Member]</link:label>
    <link:label id="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember_label_en-US" xlink:label="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year Two Thousand Sixteen Through Two Thousand Twenty Two [Member]</link:label>
    <link:label id="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember_documentation_en-US" xlink:label="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year Two Thousand Sixteen Through Two Thousand Twenty Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember" xlink:href="amed-20221231.xsd#amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember" xlink:to="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3780bd2a-d5cd-4f27-9bf4-3fd42d64afe6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_13520f56-40a8-4169-ad6d-1901751909fa_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GOODWILL AND OTHER INTANGIBLE ASSETS, NET</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_0d51a384-881d-4fcf-912f-b28896687672_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Line of Credit Arrangements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:to="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PromissoryNotesMember_71056e1d-7dc3-4562-9c53-6f3bf487257b_terseLabel_en-US" xlink:label="lab_amed_PromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory Notes [Member]</link:label>
    <link:label id="lab_amed_PromissoryNotesMember_label_en-US" xlink:label="lab_amed_PromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory Notes [Member]</link:label>
    <link:label id="lab_amed_PromissoryNotesMember_documentation_en-US" xlink:label="lab_amed_PromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PromissoryNotesMember" xlink:href="amed-20221231.xsd#amed_PromissoryNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PromissoryNotesMember" xlink:to="lab_amed_PromissoryNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_be1a9505-4510-4ea5-86ad-1397d9ca6622_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NetOperatingLossMember_48fa1e80-af3d-4895-bd3b-7ef39c626287_terseLabel_en-US" xlink:label="lab_amed_NetOperatingLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss [Member]</link:label>
    <link:label id="lab_amed_NetOperatingLossMember_label_en-US" xlink:label="lab_amed_NetOperatingLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss [Member]</link:label>
    <link:label id="lab_amed_NetOperatingLossMember_documentation_en-US" xlink:label="lab_amed_NetOperatingLossMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetOperatingLossMember" xlink:href="amed-20221231.xsd#amed_NetOperatingLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NetOperatingLossMember" xlink:to="lab_amed_NetOperatingLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_1d998ebe-d9e5-4f49-b10a-c959fd44f83b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_14ec0d3b-2538-4c81-b103-200514256a40_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease - 2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_b528a962-b380-461d-8d43-0bddb3ce8d99_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowings under revolving line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_276e3f81-9ef7-4466-8718-f2ea8ff90e24_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a826be79-2598-4610-9d6e-faf56bc0a859_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_e812e71a-7e22-4ba4-adf8-73420eadf399_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_b9595df7-3b9a-4822-87cd-a5c23eb90cbb_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_a8977f03-f1bd-4e91-af4d-53a77785f027_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_0e819852-3f44-4676-aa98-25d3f719c589_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_96c89a26-b4a9-422b-a6e0-93c90192cd9b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised during the period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_8fe68c8b-74ea-4284-9b94-e87bac8ffe8c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of equity method investment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6555d6cb-b649-4f4a-8842-b50f5cd2fbf1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_88d4d6de-b24f-49b4-b6f4-763dac795a2c_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares outstanding &#8211; diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_58ef2fef-aa54-4be4-b69d-f21c59d8074c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_3dc9c783-e51e-4ff7-95b1-0d2524fb6fe5_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DepreciationAndAmortizationForContinuingOperations_e50ea5aa-d1d3-487f-ae1f-7a26181eebe6_terseLabel_en-US" xlink:label="lab_amed_DepreciationAndAmortizationForContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_amed_DepreciationAndAmortizationForContinuingOperations_label_en-US" xlink:label="lab_amed_DepreciationAndAmortizationForContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation And Amortization For Continuing Operations</link:label>
    <link:label id="lab_amed_DepreciationAndAmortizationForContinuingOperations_documentation_en-US" xlink:label="lab_amed_DepreciationAndAmortizationForContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation And Amortization For Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DepreciationAndAmortizationForContinuingOperations" xlink:href="amed-20221231.xsd#amed_DepreciationAndAmortizationForContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DepreciationAndAmortizationForContinuingOperations" xlink:to="lab_amed_DepreciationAndAmortizationForContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_844ea23e-55ee-4f3b-9576-5b9888d5e8a6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_2c465737-f280-4436-ae6b-db69a3f27074_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ExtrapolatedMember_5f1e962c-1062-4f6c-aa82-a6921b14d0ec_terseLabel_en-US" xlink:label="lab_amed_ExtrapolatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extrapolated [Member]</link:label>
    <link:label id="lab_amed_ExtrapolatedMember_label_en-US" xlink:label="lab_amed_ExtrapolatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extrapolated [Member]</link:label>
    <link:label id="lab_amed_ExtrapolatedMember_documentation_en-US" xlink:label="lab_amed_ExtrapolatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extrapolated [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExtrapolatedMember" xlink:href="amed-20221231.xsd#amed_ExtrapolatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ExtrapolatedMember" xlink:to="lab_amed_ExtrapolatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherGeneralAndAdministrativeExpense_b8b13262-2e13-44b0-8b22-c4b05a47fbbd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_IndemnificationAmount_0334e276-e90b-490d-91c5-0eb020d730c9_terseLabel_en-US" xlink:label="lab_amed_IndemnificationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification amount</link:label>
    <link:label id="lab_amed_IndemnificationAmount_label_en-US" xlink:label="lab_amed_IndemnificationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Amount</link:label>
    <link:label id="lab_amed_IndemnificationAmount_documentation_en-US" xlink:label="lab_amed_IndemnificationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount to be reimbursed if and when certain assumed liabilities are paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IndemnificationAmount" xlink:href="amed-20221231.xsd#amed_IndemnificationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_IndemnificationAmount" xlink:to="lab_amed_IndemnificationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeHealthMedicareMember_0a39594c-c1fa-4c08-af7c-9b750c345b02_terseLabel_en-US" xlink:label="lab_amed_HomeHealthMedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Medicare [Member]</link:label>
    <link:label id="lab_amed_HomeHealthMedicareMember_label_en-US" xlink:label="lab_amed_HomeHealthMedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Medicare [Member]</link:label>
    <link:label id="lab_amed_HomeHealthMedicareMember_documentation_en-US" xlink:label="lab_amed_HomeHealthMedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Medicare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMedicareMember" xlink:href="amed-20221231.xsd#amed_HomeHealthMedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthMedicareMember" xlink:to="lab_amed_HomeHealthMedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtIssuanceCostsPolicyPolicyTextBlock_7a6aa049-6927-44c9-a66a-d0d040984d42_terseLabel_en-US" xlink:label="lab_amed_DebtIssuanceCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs</link:label>
    <link:label id="lab_amed_DebtIssuanceCostsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_amed_DebtIssuanceCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs Policy [Policy Text Block]</link:label>
    <link:label id="lab_amed_DebtIssuanceCostsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_amed_DebtIssuanceCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting policy for debt issuance costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtIssuanceCostsPolicyPolicyTextBlock" xlink:href="amed-20221231.xsd#amed_DebtIssuanceCostsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtIssuanceCostsPolicyPolicyTextBlock" xlink:to="lab_amed_DebtIssuanceCostsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_673bf1ed-d736-48f8-aee0-1f59bab14b98_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DeferredTaxAssetsProviderReliefFundAdvance_7c83d1f1-5418-4105-84b8-e364fc74f9e1_terseLabel_en-US" xlink:label="lab_amed_DeferredTaxAssetsProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Provider Relief Fund Advance</link:label>
    <link:label id="lab_amed_DeferredTaxAssetsProviderReliefFundAdvance_label_en-US" xlink:label="lab_amed_DeferredTaxAssetsProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Provider Relief Fund Advance</link:label>
    <link:label id="lab_amed_DeferredTaxAssetsProviderReliefFundAdvance_documentation_en-US" xlink:label="lab_amed_DeferredTaxAssetsProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the Provider Relief Fund Advance set up as a result of the novel coronavirus pandemic ("COVID-19").</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxAssetsProviderReliefFundAdvance" xlink:href="amed-20221231.xsd#amed_DeferredTaxAssetsProviderReliefFundAdvance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DeferredTaxAssetsProviderReliefFundAdvance" xlink:to="lab_amed_DeferredTaxAssetsProviderReliefFundAdvance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_9dcce117-8a42-4ca5-95eb-033ecac5cf2a_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_3824e8ba-b45e-4834-9a14-ece78f58da6d_verboseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementInterest_815bf022-7063-4b46-bdc6-c5625a75484c_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement Interest</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementInterest_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementInterest" xlink:to="lab_us-gaap_LitigationSettlementInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SecondAmendedCreditAgreementMember_b52c4a72-b5a8-4a25-9d51-37a2e0435d3a_terseLabel_en-US" xlink:label="lab_amed_SecondAmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amended Credit Agreement</link:label>
    <link:label id="lab_amed_SecondAmendedCreditAgreementMember_label_en-US" xlink:label="lab_amed_SecondAmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amended Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_SecondAmendedCreditAgreementMember_documentation_en-US" xlink:label="lab_amed_SecondAmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amended Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondAmendedCreditAgreementMember" xlink:href="amed-20221231.xsd#amed_SecondAmendedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SecondAmendedCreditAgreementMember" xlink:to="lab_amed_SecondAmendedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CurrentAndLongTermObligationsMember_b12e6fc9-cee0-4715-be3c-979e2a1b231a_terseLabel_en-US" xlink:label="lab_amed_CurrentAndLongTermObligationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current and Long-Term obligations</link:label>
    <link:label id="lab_amed_CurrentAndLongTermObligationsMember_label_en-US" xlink:label="lab_amed_CurrentAndLongTermObligationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current and Long-Term obligations [Member]</link:label>
    <link:label id="lab_amed_CurrentAndLongTermObligationsMember_documentation_en-US" xlink:label="lab_amed_CurrentAndLongTermObligationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current and Long-Term obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CurrentAndLongTermObligationsMember" xlink:href="amed-20221231.xsd#amed_CurrentAndLongTermObligationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CurrentAndLongTermObligationsMember" xlink:to="lab_amed_CurrentAndLongTermObligationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AdditionalPerformanceBasedAwardTargetShareAmount_b77d4388-5559-40a6-ad3f-ee9b8ef8d43a_terseLabel_en-US" xlink:label="lab_amed_AdditionalPerformanceBasedAwardTargetShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Performance Based Award Target share Max Amount</link:label>
    <link:label id="lab_amed_AdditionalPerformanceBasedAwardTargetShareAmount_label_en-US" xlink:label="lab_amed_AdditionalPerformanceBasedAwardTargetShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Performance Based Award Target share Amount</link:label>
    <link:label id="lab_amed_AdditionalPerformanceBasedAwardTargetShareAmount_documentation_en-US" xlink:label="lab_amed_AdditionalPerformanceBasedAwardTargetShareAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional stock units authorized for achievement of targeted performance if target objective is surpassed to the point of achieving the projected maximum payout</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AdditionalPerformanceBasedAwardTargetShareAmount" xlink:href="amed-20221231.xsd#amed_AdditionalPerformanceBasedAwardTargetShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AdditionalPerformanceBasedAwardTargetShareAmount" xlink:to="lab_amed_AdditionalPerformanceBasedAwardTargetShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue_ddab268c-2e1a-4c8f-b77e-73b3c1d7fd82_terseLabel_en-US" xlink:label="lab_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Fair Value</link:label>
    <link:label id="lab_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue_label_en-US" xlink:label="lab_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value</link:label>
    <link:label id="lab_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue_documentation_en-US" xlink:label="lab_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The calculated fair value of a stock-based compensation award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue" xlink:href="amed-20221231.xsd#amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue" xlink:to="lab_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2a7a88df-3302-4e4c-9b01-54ccea147b8d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested stock granted, weighted average grant date fair value (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d8fbb7eb-29db-4736-b74b-1d4144efcb9c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_12c834ef-c549-49fd-a6f1-4eb34c2c21ba_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reportable Business Segments [Member]</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MaximumPercentOwnershipForEquityMethodPercent_de09e9bf-99f2-414b-bfdc-b3aaae1a20ab_terseLabel_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum ownership percentage for equity method investment (percent)</link:label>
    <link:label id="lab_amed_MaximumPercentOwnershipForEquityMethodPercent_label_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Percent Ownership For Equity Method Percent</link:label>
    <link:label id="lab_amed_MaximumPercentOwnershipForEquityMethodPercent_documentation_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage ownership required in order for an investment to be treated under the equity method of accounting in the entity's financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:href="amed-20221231.xsd#amed_MaximumPercentOwnershipForEquityMethodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:to="lab_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_203e78e1-afbc-4b6c-a509-cbe0e6b2c7ea_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exerciseable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_d755247f-dcac-4cd2-b748-a75899ca49f8_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_9b9d4294-ff3f-451a-a48a-f375f58575a3_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemTable_7983cc70-b7dc-410e-aea6-4a49ca1fa27b_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Table]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemTable_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable" xlink:to="lab_us-gaap_UnusualOrInfrequentItemTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HospiceNonMedicareMember_e16d14e0-9160-4d17-a334-51416f01f56b_terseLabel_en-US" xlink:label="lab_amed_HospiceNonMedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Non-Medicare [Member]</link:label>
    <link:label id="lab_amed_HospiceNonMedicareMember_label_en-US" xlink:label="lab_amed_HospiceNonMedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Non-Medicare [Member]</link:label>
    <link:label id="lab_amed_HospiceNonMedicareMember_documentation_en-US" xlink:label="lab_amed_HospiceNonMedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Non-Medicare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceNonMedicareMember" xlink:href="amed-20221231.xsd#amed_HospiceNonMedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HospiceNonMedicareMember" xlink:to="lab_amed_HospiceNonMedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_3612f673-7f5f-4e8a-805a-3299fe73f009_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_bb0349d1-a6d1-4131-ace1-87550862792f_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_45fcaeba-1a5f-421f-a7d3-1e4bd354a8e8_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss (income) attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f07c4385-4f5c-4b23-8fc5-45290c6cf04c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_54e88b14-2ed9-46e6-977e-99f45c9c93c5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationAdjustmentsAxis_bf7afa99-0b66-45e4-98a3-c7e4bd17e057_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationAdjustmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Adjustments [Axis]</link:label>
    <link:label id="lab_amed_BusinessCombinationAdjustmentsAxis_label_en-US" xlink:label="lab_amed_BusinessCombinationAdjustmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Adjustments [Axis]</link:label>
    <link:label id="lab_amed_BusinessCombinationAdjustmentsAxis_documentation_en-US" xlink:label="lab_amed_BusinessCombinationAdjustmentsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationAdjustmentsAxis" xlink:href="amed-20221231.xsd#amed_BusinessCombinationAdjustmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationAdjustmentsAxis" xlink:to="lab_amed_BusinessCombinationAdjustmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments_57feee1d-010b-4734-8035-1a61821a25a5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of deferred compensation plan assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Restricted Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_dd18ce0b-9bbf-4099-a699-21c46f3177e4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_3e11405b-7077-4778-a81f-009c08e19cfb_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessAcquisitionClosingPaymentAdjustment_7ca7b891-32f9-4fc1-a5e7-769005e9d2f0_terseLabel_en-US" xlink:label="lab_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Closing Payment Adjustment</link:label>
    <link:label id="lab_amed_BusinessAcquisitionClosingPaymentAdjustment_label_en-US" xlink:label="lab_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Closing Payment Adjustment</link:label>
    <link:label id="lab_amed_BusinessAcquisitionClosingPaymentAdjustment_documentation_en-US" xlink:label="lab_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Closing Payment Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:href="amed-20221231.xsd#amed_BusinessAcquisitionClosingPaymentAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:to="lab_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PotentialClosingPaymentAdjustmentMember_dde796ed-8fab-4d02-84a0-f8fd2e38a620_terseLabel_en-US" xlink:label="lab_amed_PotentialClosingPaymentAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Closing Payment Adjustment</link:label>
    <link:label id="lab_amed_PotentialClosingPaymentAdjustmentMember_label_en-US" xlink:label="lab_amed_PotentialClosingPaymentAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Closing Payment Adjustment [Member]</link:label>
    <link:label id="lab_amed_PotentialClosingPaymentAdjustmentMember_documentation_en-US" xlink:label="lab_amed_PotentialClosingPaymentAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Closing Payment Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PotentialClosingPaymentAdjustmentMember" xlink:href="amed-20221231.xsd#amed_PotentialClosingPaymentAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PotentialClosingPaymentAdjustmentMember" xlink:to="lab_amed_PotentialClosingPaymentAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_57d4a5b8-2a32-487b-b50e-89414b777b28_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FundingForHealthcareProvidersIncludingHospitals_7653aafa-c2ee-4950-9677-bf44920c195e_terseLabel_en-US" xlink:label="lab_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding For Healthcare Providers Including Hospitals</link:label>
    <link:label id="lab_amed_FundingForHealthcareProvidersIncludingHospitals_label_en-US" xlink:label="lab_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding For Healthcare Providers Including Hospitals</link:label>
    <link:label id="lab_amed_FundingForHealthcareProvidersIncludingHospitals_documentation_en-US" xlink:label="lab_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding for healthcare providers, including hospitals provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:href="amed-20221231.xsd#amed_FundingForHealthcareProvidersIncludingHospitals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:to="lab_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_d48627ad-b5a7-44c9-b212-6ccfe2fcf7e3_terseLabel_en-US" xlink:label="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of consolidated revenue and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</link:label>
    <link:label id="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_label_en-US" xlink:label="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Revenue And Of Earnings Before Interest Taxes Depreciation And Amortization From Wholly Owned Subsidiaries</link:label>
    <link:label id="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_documentation_en-US" xlink:label="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of consolidated net revenues and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:href="amed-20221231.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:to="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_5902571b-5a4f-4426-a64f-340bb5da1de3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_405d1e46-b301-4bfa-b61e-4501522ad0c0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TelehealthKitsMember_2a2f6a43-8550-4831-b4a6-b097a19c2414_terseLabel_en-US" xlink:label="lab_amed_TelehealthKitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Telehealth Kits</link:label>
    <link:label id="lab_amed_TelehealthKitsMember_label_en-US" xlink:label="lab_amed_TelehealthKitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Telehealth Kits [Member]</link:label>
    <link:label id="lab_amed_TelehealthKitsMember_documentation_en-US" xlink:label="lab_amed_TelehealthKitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Telehealth Kits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TelehealthKitsMember" xlink:href="amed-20221231.xsd#amed_TelehealthKitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TelehealthKitsMember" xlink:to="lab_amed_TelehealthKitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_26e186c0-0d9b-4ed9-94be-c7e0740ef71c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock - employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_a5955e5d-8172-426c-ab4e-592d14ab005a_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to Amedisys, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_fe401b2f-27e9-48e3-833d-474f4c25673a_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ReductionToNetServiceRevenue_285607cd-06f8-4b90-b2a9-1cdb1dd2311e_terseLabel_en-US" xlink:label="lab_amed_ReductionToNetServiceRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction To Net Service Revenue</link:label>
    <link:label id="lab_amed_ReductionToNetServiceRevenue_label_en-US" xlink:label="lab_amed_ReductionToNetServiceRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction To Net Service Revenue</link:label>
    <link:label id="lab_amed_ReductionToNetServiceRevenue_documentation_en-US" xlink:label="lab_amed_ReductionToNetServiceRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction To Net Service Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ReductionToNetServiceRevenue" xlink:href="amed-20221231.xsd#amed_ReductionToNetServiceRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ReductionToNetServiceRevenue" xlink:to="lab_amed_ReductionToNetServiceRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_OtherMiscellaneousDeposits_8910e222-1e80-40f7-93dd-2207f4ad29aa_terseLabel_en-US" xlink:label="lab_amed_OtherMiscellaneousDeposits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other miscellaneous deposits</link:label>
    <link:label id="lab_amed_OtherMiscellaneousDeposits_label_en-US" xlink:label="lab_amed_OtherMiscellaneousDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Miscellaneous Deposits</link:label>
    <link:label id="lab_amed_OtherMiscellaneousDeposits_documentation_en-US" xlink:label="lab_amed_OtherMiscellaneousDeposits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Miscellaneous Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OtherMiscellaneousDeposits" xlink:href="amed-20221231.xsd#amed_OtherMiscellaneousDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OtherMiscellaneousDeposits" xlink:to="lab_amed_OtherMiscellaneousDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_53a96039-f0e4-4233-8f5e-fa8323989888_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Income of Reportable Segments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_ee3d4015-a1f2-47e2-811f-286a08806e0c_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_79deb48e-dbca-416e-9491-c17a4406e116_terseLabel_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum days to submit final bill from the date the request for anticipated payment was paid</link:label>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_label_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Days To Submit Final Bill From Date Request For Anticipated Payment Was Paid</link:label>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_documentation_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:href="amed-20221231.xsd#amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:to="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NetServiceRevenueEpisodePaymentRateDuration_49291149-0cae-4ef9-9a2e-5eff97850bbc_terseLabel_en-US" xlink:label="lab_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net service revenue episode payment rate</link:label>
    <link:label id="lab_amed_NetServiceRevenueEpisodePaymentRateDuration_label_en-US" xlink:label="lab_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Service Revenue, Episode Payment Rate Duration</link:label>
    <link:label id="lab_amed_NetServiceRevenueEpisodePaymentRateDuration_documentation_en-US" xlink:label="lab_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:href="amed-20221231.xsd#amed_NetServiceRevenueEpisodePaymentRateDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:to="lab_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_ac1ca880-e82a-442b-a944-d8f791132e1d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Obligations, Fiscal Year Maturity</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_6a3a4691-663f-4929-a365-9a4b6d3b7b08_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease - 2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EquipmentAndFurnitureMember_3badb1bb-b713-4fc4-bf2e-0a83b4fd81b8_terseLabel_en-US" xlink:label="lab_amed_EquipmentAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment and Furniture [Member]</link:label>
    <link:label id="lab_amed_EquipmentAndFurnitureMember_label_en-US" xlink:label="lab_amed_EquipmentAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment And Furniture [Member]</link:label>
    <link:label id="lab_amed_EquipmentAndFurnitureMember_documentation_en-US" xlink:label="lab_amed_EquipmentAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment And Furniture [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquipmentAndFurnitureMember" xlink:href="amed-20221231.xsd#amed_EquipmentAndFurnitureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EquipmentAndFurnitureMember" xlink:to="lab_amed_EquipmentAndFurnitureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities_b0484f6c-cfe7-4903-93df-62891a86d78c_negatedTerseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Operating Lease Liabilities</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" xlink:href="amed-20221231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_7ef01f34-87b2-46f8-98c5-1784ea017cc9_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_3af779b3-11a7-4085-807b-4b84ee2144d9_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense at U.S. federal statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_85a01ca5-3de3-423c-96e7-aa2c366263fb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of operating lease ROU assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_1112ae4e-b6d9-429d-a540-41bc6130555e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_940c0216-f7f8-4968-8116-b1e89fe1a1a4_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock - employee stock purchase plan (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2912f7bf-4a24-4465-b9d5-9c72d75a8073_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan shares issued (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AccruedInterest_cdaf6eab-fad6-44d7-90af-4b62df005656_terseLabel_en-US" xlink:label="lab_amed_AccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Interest</link:label>
    <link:label id="lab_amed_AccruedInterest_label_en-US" xlink:label="lab_amed_AccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Interest</link:label>
    <link:label id="lab_amed_AccruedInterest_documentation_en-US" xlink:label="lab_amed_AccruedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AccruedInterest" xlink:href="amed-20221231.xsd#amed_AccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AccruedInterest" xlink:to="lab_amed_AccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3414bec8-54fa-4a40-a9f9-fc5b50bfd1fb_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_72bb3aca-3546-4373-90c5-e91b4377cba0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CashContributionToNoncontrollingInterest_2470b0dd-5e58-4794-b1b8-c60a03b2cf7d_terseLabel_en-US" xlink:label="lab_amed_CashContributionToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest contributions</link:label>
    <link:label id="lab_amed_CashContributionToNoncontrollingInterest_label_en-US" xlink:label="lab_amed_CashContributionToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Contribution To Noncontrolling Interest</link:label>
    <link:label id="lab_amed_CashContributionToNoncontrollingInterest_documentation_en-US" xlink:label="lab_amed_CashContributionToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Contribution To Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashContributionToNoncontrollingInterest" xlink:href="amed-20221231.xsd#amed_CashContributionToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CashContributionToNoncontrollingInterest" xlink:to="lab_amed_CashContributionToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_cd5309c0-ec24-40cc-b9c8-0d88b949e2b0_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local income taxes, net of federal income tax benefit (1)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_8e0e77c7-04c7-46ff-986d-aad878a07c83_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease - 2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_bb11e9ba-6097-43c9-ae21-552e4e3b5af2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation of $101,364 and $96,937</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_4ffd068b-ae7a-4463-a558-385b6103e40c_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_01f5ce93-b4a4-4a29-96f0-527ca271a785_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SafeguardZoneProgramIntegrityContractorMember_8b02896d-f451-4e76-ae22-b3400e247df4_terseLabel_en-US" xlink:label="lab_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Safeguard Zone Program Integrity Contractor [Member]</link:label>
    <link:label id="lab_amed_SafeguardZoneProgramIntegrityContractorMember_label_en-US" xlink:label="lab_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Safeguard Zone Program Integrity Contractor [Member]</link:label>
    <link:label id="lab_amed_SafeguardZoneProgramIntegrityContractorMember_documentation_en-US" xlink:label="lab_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Safeguard Zone Program Integrity Contractor [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:href="amed-20221231.xsd#amed_SafeguardZoneProgramIntegrityContractorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:to="lab_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsHeldUnderCapitalLeasesMember_f4943f18-e6f9-4871-a6db-d665c437226b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsHeldUnderCapitalLeasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Leases [Member]</link:label>
    <link:label id="lab_us-gaap_AssetsHeldUnderCapitalLeasesMember_label_en-US" xlink:label="lab_us-gaap_AssetsHeldUnderCapitalLeasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held under Capital Leases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldUnderCapitalLeasesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldUnderCapitalLeasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldUnderCapitalLeasesMember" xlink:to="lab_us-gaap_AssetsHeldUnderCapitalLeasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock_cc645aed-51b5-4989-97df-bb5e401cdd96_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Long-Term Obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Assets and Other Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Performancebasedawardtargetshareamount_c5f93c03-2e4a-45ae-9138-c0799c654ba1_terseLabel_en-US" xlink:label="lab_amed_Performancebasedawardtargetshareamount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based award, target number of units to be received (shares)</link:label>
    <link:label id="lab_amed_Performancebasedawardtargetshareamount_label_en-US" xlink:label="lab_amed_Performancebasedawardtargetshareamount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Award Target Share Amount</link:label>
    <link:label id="lab_amed_Performancebasedawardtargetshareamount_documentation_en-US" xlink:label="lab_amed_Performancebasedawardtargetshareamount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock units authorized for achievement of targeted performance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Performancebasedawardtargetshareamount" xlink:href="amed-20221231.xsd#amed_Performancebasedawardtargetshareamount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Performancebasedawardtargetshareamount" xlink:to="lab_amed_Performancebasedawardtargetshareamount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_53db43e3-a5c6-4ceb-a10d-b561eeab936f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Aggregate Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_A2019StockRepurchaseProgramMember_e5b7ce4f-77db-460b-b8b8-131ad72d15e5_terseLabel_en-US" xlink:label="lab_amed_A2019StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Stock Repurchase Program [Member]</link:label>
    <link:label id="lab_amed_A2019StockRepurchaseProgramMember_label_en-US" xlink:label="lab_amed_A2019StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Stock Repurchase Program [Member]</link:label>
    <link:label id="lab_amed_A2019StockRepurchaseProgramMember_documentation_en-US" xlink:label="lab_amed_A2019StockRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Stock Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2019StockRepurchaseProgramMember" xlink:href="amed-20221231.xsd#amed_A2019StockRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_A2019StockRepurchaseProgramMember" xlink:to="lab_amed_A2019StockRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_OperatingLeasesTableTextBlock_6bc7ed60-d875-4ef6-a2ff-e0e89b763fb4_terseLabel_en-US" xlink:label="lab_amed_OperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leases</link:label>
    <link:label id="lab_amed_OperatingLeasesTableTextBlock_label_en-US" xlink:label="lab_amed_OperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases [Table Text Block]</link:label>
    <link:label id="lab_amed_OperatingLeasesTableTextBlock_documentation_en-US" xlink:label="lab_amed_OperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases Table Text Block</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OperatingLeasesTableTextBlock" xlink:href="amed-20221231.xsd#amed_OperatingLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OperatingLeasesTableTextBlock" xlink:to="lab_amed_OperatingLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_be3b0337-28f8-4c95-bc83-89809ca5b778_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c2829e62-eb52-4903-a0ca-289014a3ca91_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled, forfeited or expired (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_c2416bc4-232c-499b-9845-5e7cff3d7724_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term obligations, including current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_2fc85313-ba42-46a3-8af2-758d8966c4ae_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Miscellaneous, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_fca34373-e6b6-47c5-84d8-f31c82f4d741_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_fbcb7839-f7ab-4548-bb88-4d7ff918f1bd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_32f91639-d749-4065-ac36-7a6a933ad10e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_UnrecognizedTaxBenefitsDomain_c854a0f8-3ca2-461b-948c-2f7b6c8b16e7_terseLabel_en-US" xlink:label="lab_amed_UnrecognizedTaxBenefitsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits [Domain]</link:label>
    <link:label id="lab_amed_UnrecognizedTaxBenefitsDomain_label_en-US" xlink:label="lab_amed_UnrecognizedTaxBenefitsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits [Domain]</link:label>
    <link:label id="lab_amed_UnrecognizedTaxBenefitsDomain_documentation_en-US" xlink:label="lab_amed_UnrecognizedTaxBenefitsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnrecognizedTaxBenefitsDomain" xlink:href="amed-20221231.xsd#amed_UnrecognizedTaxBenefitsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_UnrecognizedTaxBenefitsDomain" xlink:to="lab_amed_UnrecognizedTaxBenefitsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOtherLossCarryforwards_c13e1680-4050-4fec-a3f1-9d95f82a1b5a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOtherLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_8e12be5f-e07d-4d51-94e3-0d3018d9acb8_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_7de9efba-09c9-4755-8bc2-9004a4daa988_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases rent expense</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense" xlink:to="lab_us-gaap_LeaseAndRentalExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_08dac26f-5191-4dc4-97c7-19c4b68d0b75_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_8b6e7722-ff6c-442d-aa9b-6e404b4cf970_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_b17d6698-8f52-4c92-8246-b8c09b673863_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maturity Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_977fc2c2-be18-4639-ba6d-1c0587aa3bdb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes, net of refunds received</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_d8177ca7-ea26-4d43-bf2a-2a69fb298f82_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_IncomeTaxEffectsAllocatedToInterestExpense_35cd8593-1ff1-4c0d-93e8-8f676a2ee95a_terseLabel_en-US" xlink:label="lab_amed_IncomeTaxEffectsAllocatedToInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_amed_IncomeTaxEffectsAllocatedToInterestExpense_label_en-US" xlink:label="lab_amed_IncomeTaxEffectsAllocatedToInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Effects Allocated to Interest Expense</link:label>
    <link:label id="lab_amed_IncomeTaxEffectsAllocatedToInterestExpense_documentation_en-US" xlink:label="lab_amed_IncomeTaxEffectsAllocatedToInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The tax effect of items occuring during the period that have been charged or credited directly to interest expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncomeTaxEffectsAllocatedToInterestExpense" xlink:href="amed-20221231.xsd#amed_IncomeTaxEffectsAllocatedToInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_IncomeTaxEffectsAllocatedToInterestExpense" xlink:to="lab_amed_IncomeTaxEffectsAllocatedToInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_ee1c4774-8fec-44f7-8960-424b20a1518a_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_4e14a7a6-3be1-4458-aa11-cd54e324cf28_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_5a2cde98-82f3-4285-b6d5-6cca8fc93334_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_a0f9d3dc-505c-4604-8fb8-fb8499cea5a3_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LegalSettlementPaymentLessInterest_bb629e22-ed3d-4fe0-bb17-5cfa7caf30ef_terseLabel_en-US" xlink:label="lab_amed_LegalSettlementPaymentLessInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Settlement Payment Less Interest</link:label>
    <link:label id="lab_amed_LegalSettlementPaymentLessInterest_label_en-US" xlink:label="lab_amed_LegalSettlementPaymentLessInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Settlement Payment Less Interest</link:label>
    <link:label id="lab_amed_LegalSettlementPaymentLessInterest_documentation_en-US" xlink:label="lab_amed_LegalSettlementPaymentLessInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Settlement Payment Less Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LegalSettlementPaymentLessInterest" xlink:href="amed-20221231.xsd#amed_LegalSettlementPaymentLessInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LegalSettlementPaymentLessInterest" xlink:to="lab_amed_LegalSettlementPaymentLessInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_fa123ec6-c72c-40ec-bde8-9a0e9e043f87_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest distributions</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_00816e2b-3e59-45ef-ac39-9f8c7837694d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SwingLineLoanMember_d88088d1-ea8c-4400-ba1e-e844fbc13bcd_terseLabel_en-US" xlink:label="lab_amed_SwingLineLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swing Line Loan [Member]</link:label>
    <link:label id="lab_amed_SwingLineLoanMember_label_en-US" xlink:label="lab_amed_SwingLineLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swing Line Loan [Member]</link:label>
    <link:label id="lab_amed_SwingLineLoanMember_documentation_en-US" xlink:label="lab_amed_SwingLineLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swing Line Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SwingLineLoanMember" xlink:href="amed-20221231.xsd#amed_SwingLineLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SwingLineLoanMember" xlink:to="lab_amed_SwingLineLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LicensesMember_cf41d072-89e2-4df3-9c63-c32e238a19ef_terseLabel_en-US" xlink:label="lab_amed_LicensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licenses [Member]</link:label>
    <link:label id="lab_amed_LicensesMember_label_en-US" xlink:label="lab_amed_LicensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licenses [Member]</link:label>
    <link:label id="lab_amed_LicensesMember_documentation_en-US" xlink:label="lab_amed_LicensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LicensesMember" xlink:href="amed-20221231.xsd#amed_LicensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LicensesMember" xlink:to="lab_amed_LicensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_c57c3b78-05dc-4e5e-aa61-41597d7c4ec7_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f1b899fa-d180-4be2-ab79-68d86a27ffe4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_a8e38c0d-1b3c-436d-bc84-79bd52b866d0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit from stock option exercise</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Exercise of Option, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_38c7875a-8a63-4cfc-9eec-adaf3642a6fb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities_f6a82c42-5ff1-44a1-a998-d7bef0e1d94e_terseLabel_en-US" xlink:label="lab_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Consolidated Entities Classified As Variable Interest Entities</link:label>
    <link:label id="lab_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities_label_en-US" xlink:label="lab_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Consolidated Entities Classified As Variable Interest Entities</link:label>
    <link:label id="lab_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities_documentation_en-US" xlink:label="lab_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of consolidated entities classified as variable interest entities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities" xlink:href="amed-20221231.xsd#amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities" xlink:to="lab_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7ad6bd82-7d00-4c92-ac72-ec4e6efe780b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_dcbd4e45-491f-4490-9ce1-125c6efc9e2c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent_cd3f54a8-1879-4e3e-b481-650ca47319fd_terseLabel_en-US" xlink:label="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Including Discontinued Operation Operating Lease Right Of Use Assets Noncurrent</link:label>
    <link:label id="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent_label_en-US" xlink:label="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Including Discontinued Operation Operating Lease Right Of Use Assets Noncurrent</link:label>
    <link:label id="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent_documentation_en-US" xlink:label="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount classified as operating lease right of use asset attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent" xlink:href="amed-20221231.xsd#amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent" xlink:to="lab_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_1bed63e3-71d3-446c-8a93-d5dc53ef48db_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate_a67c14a8-5b73-4ff5-9eb7-5de30cd97093_terseLabel_en-US" xlink:label="lab_amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in uncertain tax positions from change in enacted tax rate</link:label>
    <link:label id="lab_amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate_label_en-US" xlink:label="lab_amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits Decreases Resulting From Change In Statutory Tax Rate</link:label>
    <link:label id="lab_amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate_documentation_en-US" xlink:label="lab_amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits Decreases Resulting From Change In Statutory Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate" xlink:href="amed-20221231.xsd#amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate" xlink:to="lab_amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_0b87f363-9b1b-4a54-92e8-eb8908ccebd8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, ROU Asset, Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationAdjustmentsDomain_31778e4d-0a7d-41f4-b354-ec1e7d296f59_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationAdjustmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Adjustments [Domain]</link:label>
    <link:label id="lab_amed_BusinessCombinationAdjustmentsDomain_label_en-US" xlink:label="lab_amed_BusinessCombinationAdjustmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Adjustments [Domain]</link:label>
    <link:label id="lab_amed_BusinessCombinationAdjustmentsDomain_documentation_en-US" xlink:label="lab_amed_BusinessCombinationAdjustmentsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Adjustments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationAdjustmentsDomain" xlink:href="amed-20221231.xsd#amed_BusinessCombinationAdjustmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationAdjustmentsDomain" xlink:to="lab_amed_BusinessCombinationAdjustmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_f4e0d645-347f-4197-9959-4ea9e793d4e3_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return on equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:to="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_A2021ShareRepurchaseProgramMember_e6b7a07a-8d74-43d8-bd56-bd2fab6a1786_terseLabel_en-US" xlink:label="lab_amed_A2021ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_amed_A2021ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_amed_A2021ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_amed_A2021ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_amed_A2021ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2021ShareRepurchaseProgramMember" xlink:href="amed-20221231.xsd#amed_A2021ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_A2021ShareRepurchaseProgramMember" xlink:to="lab_amed_A2021ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_f649a552-cefe-49de-b615-2db569e406e5_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_429c89e4-0a9e-42d0-b318-267b88e05405_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_35ee5e5e-8a19-49b3-b4db-1e62b8eafff9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_ce2c2ccd-0957-48cb-a249-e21fdcabe564_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ProvisionforIncomeTaxesTableTextBlock_a8daae0a-ec12-4c05-98a1-e1e37e31321f_terseLabel_en-US" xlink:label="lab_amed_ProvisionforIncomeTaxesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income Tax Provision</link:label>
    <link:label id="lab_amed_ProvisionforIncomeTaxesTableTextBlock_label_en-US" xlink:label="lab_amed_ProvisionforIncomeTaxesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for Income Taxes [Table Text Block]</link:label>
    <link:label id="lab_amed_ProvisionforIncomeTaxesTableTextBlock_documentation_en-US" xlink:label="lab_amed_ProvisionforIncomeTaxesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for Income Taxes Table</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProvisionforIncomeTaxesTableTextBlock" xlink:href="amed-20221231.xsd#amed_ProvisionforIncomeTaxesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ProvisionforIncomeTaxesTableTextBlock" xlink:to="lab_amed_ProvisionforIncomeTaxesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_a22c67b3-91a0-4a04-8f00-7feed171ede8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ef931912-e826-4aab-a916-37fd2ad7f9cf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_d634a485-e131-4471-a055-10b4f22dfad2_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease - Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0f439f13-8742-4c87-a06d-52ce13b21abd_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BuildingAndLeaseholdImprovementsMember_97f2c992-eaf4-413c-92cb-5fa1f6a03162_terseLabel_en-US" xlink:label="lab_amed_BuildingAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Leasehold Improvements [Member]</link:label>
    <link:label id="lab_amed_BuildingAndLeaseholdImprovementsMember_label_en-US" xlink:label="lab_amed_BuildingAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building And Leasehold Improvements [Member]</link:label>
    <link:label id="lab_amed_BuildingAndLeaseholdImprovementsMember_documentation_en-US" xlink:label="lab_amed_BuildingAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building And Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BuildingAndLeaseholdImprovementsMember" xlink:href="amed-20221231.xsd#amed_BuildingAndLeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BuildingAndLeaseholdImprovementsMember" xlink:to="lab_amed_BuildingAndLeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_3459ef0c-ad6a-45fc-8e5f-95d79494b4b4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Term of Contract</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:to="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemLineItems_01917a26-1a94-4b6b-aeab-a05a05a5202a_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOVEL CORONAVIRUS PANDEMIC ("COVID-19") [Line Items]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemLineItems_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems" xlink:to="lab_us-gaap_UnusualOrInfrequentItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NumberOfCareCentersAvailableForSale_3d727fc0-3f7c-4a2c-a88d-55a0655075a3_terseLabel_en-US" xlink:label="lab_amed_NumberOfCareCentersAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of care centers available for sale</link:label>
    <link:label id="lab_amed_NumberOfCareCentersAvailableForSale_label_en-US" xlink:label="lab_amed_NumberOfCareCentersAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Care Centers Available For Sale</link:label>
    <link:label id="lab_amed_NumberOfCareCentersAvailableForSale_documentation_en-US" xlink:label="lab_amed_NumberOfCareCentersAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of care centers that were classified as available for sale during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfCareCentersAvailableForSale" xlink:href="amed-20221231.xsd#amed_NumberOfCareCentersAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NumberOfCareCentersAvailableForSale" xlink:to="lab_amed_NumberOfCareCentersAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_67ab9ce5-650b-4ff3-9233-2e9005d86fcf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_3cbc9f7b-3466-49a1-9fc7-619d3b001320_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Stock Purchase Plan Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_39350b66-5136-404e-99ab-e4f16e52e9ca_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Carrying Amount Excluding Finance Leases</link:label>
    <link:label id="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_label_en-US" xlink:label="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Carrying Amount Excluding Finance Leases</link:label>
    <link:label id="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_documentation_en-US" xlink:label="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Carrying Amount Excluding Finance Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:href="amed-20221231.xsd#amed_DebtInstrumentCarryingAmountExcludingFinanceLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:to="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c8046717-7666-440b-a53b-3dce2ce3778c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_e8d0878d-bc42-4e20-97d8-2e59801bcf4d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_6bf38085-8295-42f6-83e0-82571030da7f_terseLabel_en-US" xlink:label="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of adjusted EBITDA that guarantor subsidiaries represent</link:label>
    <link:label id="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_label_en-US" xlink:label="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Earnings Before Interest Taxes Depreciation And Amortization From Subsidiaries</link:label>
    <link:label id="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_documentation_en-US" xlink:label="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of adjusted EBITDA that guarantor subsidiaries represent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:href="amed-20221231.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:to="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_9adda4c6-d30f-41a7-9fbe-c8aca35da827_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_a8d8a62c-7cc5-4a99-bc62-5a9eeb0b507a_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e93cbb28-08aa-49d3-9288-cddfcf9bea42_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_309e7f1f-acbc-4c25-95c5-d22ce97de051_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HeritageHealthcareInnovationFundLPMember_14c06c14-4046-43bb-ae28-95cc8867a022_terseLabel_en-US" xlink:label="lab_amed_HeritageHealthcareInnovationFundLPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heritage Healthcare Innovation Fund LP [Member]</link:label>
    <link:label id="lab_amed_HeritageHealthcareInnovationFundLPMember_label_en-US" xlink:label="lab_amed_HeritageHealthcareInnovationFundLPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heritage Healthcare Innovation Fund LP [Member]</link:label>
    <link:label id="lab_amed_HeritageHealthcareInnovationFundLPMember_documentation_en-US" xlink:label="lab_amed_HeritageHealthcareInnovationFundLPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heritage Healthcare Innovation Fund LP Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HeritageHealthcareInnovationFundLPMember" xlink:href="amed-20221231.xsd#amed_HeritageHealthcareInnovationFundLPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HeritageHealthcareInnovationFundLPMember" xlink:to="lab_amed_HeritageHealthcareInnovationFundLPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_871b1125-99d6-4ed4-a9fe-a232bf375abc_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ExecutiveStockOptionExerciseMember_31b38cd7-e4d8-47a2-9516-340e09b55ee6_terseLabel_en-US" xlink:label="lab_amed_ExecutiveStockOptionExerciseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Stock Option Exercise [Member]</link:label>
    <link:label id="lab_amed_ExecutiveStockOptionExerciseMember_label_en-US" xlink:label="lab_amed_ExecutiveStockOptionExerciseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Stock Option Exercise [Member]</link:label>
    <link:label id="lab_amed_ExecutiveStockOptionExerciseMember_documentation_en-US" xlink:label="lab_amed_ExecutiveStockOptionExerciseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Stock Option Exercise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExecutiveStockOptionExerciseMember" xlink:href="amed-20221231.xsd#amed_ExecutiveStockOptionExerciseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ExecutiveStockOptionExerciseMember" xlink:to="lab_amed_ExecutiveStockOptionExerciseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_0e4ffac1-0278-4be8-a4c9-853fbd5f46b2_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_79770e21-9669-4aac-8231-9b7e231e8bf2_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_UnfavorableMember_68b7a7df-759f-4654-9985-36c07c4fc6b6_terseLabel_en-US" xlink:label="lab_amed_UnfavorableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable [Member]</link:label>
    <link:label id="lab_amed_UnfavorableMember_label_en-US" xlink:label="lab_amed_UnfavorableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnfavorableMember" xlink:href="amed-20221231.xsd#amed_UnfavorableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_UnfavorableMember" xlink:to="lab_amed_UnfavorableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b3742767-c68b-4ead-8a2b-d5e280cbd738_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e839d0f2-5f97-42e8-a520-f42dc0e6a4a0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_WokersCompensation_7bd0c49c-cb25-4e0e-a109-ff85808b1909_terseLabel_en-US" xlink:label="lab_amed_WokersCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers&#8217; compensation</link:label>
    <link:label id="lab_amed_WokersCompensation_label_en-US" xlink:label="lab_amed_WokersCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wokers Compensation</link:label>
    <link:label id="lab_amed_WokersCompensation_documentation_en-US" xlink:label="lab_amed_WokersCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers' Compensation insurance, estimated liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WokersCompensation" xlink:href="amed-20221231.xsd#amed_WokersCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_WokersCompensation" xlink:to="lab_amed_WokersCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_760c4e8b-78f9-4132-b4c6-a9ff46ebfad5_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average amortization period</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_ef3f8a28-cfc4-42e2-8d8f-a52da0987cc7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_baf92604-95fd-4889-b047-b0caad14d8cf_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding letters of credit</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_4b5958f6-7d54-4d3a-9a4f-6c3610674a53_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NumberOfCareCentersRemovedFromAvailableForSale_9c402e43-b52f-4685-b54f-22ca464aff27_terseLabel_en-US" xlink:label="lab_amed_NumberOfCareCentersRemovedFromAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of care centers removed from available for sale</link:label>
    <link:label id="lab_amed_NumberOfCareCentersRemovedFromAvailableForSale_label_en-US" xlink:label="lab_amed_NumberOfCareCentersRemovedFromAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Care Centers Removed From Available For Sale</link:label>
    <link:label id="lab_amed_NumberOfCareCentersRemovedFromAvailableForSale_documentation_en-US" xlink:label="lab_amed_NumberOfCareCentersRemovedFromAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of care centers that were removed from available for sale classification during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfCareCentersRemovedFromAvailableForSale" xlink:href="amed-20221231.xsd#amed_NumberOfCareCentersRemovedFromAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NumberOfCareCentersRemovedFromAvailableForSale" xlink:to="lab_amed_NumberOfCareCentersRemovedFromAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CapYearAxis_b34e21fa-01e7-4738-afae-25e6af281bf0_terseLabel_en-US" xlink:label="lab_amed_CapYearAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Axis]</link:label>
    <link:label id="lab_amed_CapYearAxis_label_en-US" xlink:label="lab_amed_CapYearAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Axis]</link:label>
    <link:label id="lab_amed_CapYearAxis_documentation_en-US" xlink:label="lab_amed_CapYearAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearAxis" xlink:href="amed-20221231.xsd#amed_CapYearAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CapYearAxis" xlink:to="lab_amed_CapYearAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_ddbdde6a-f072-4d7e-a5e0-44eaf0b052b0_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DeferredCompensationPlanLiability_0232960d-e83b-4e52-b2d1-9bc4b41e9f18_terseLabel_en-US" xlink:label="lab_amed_DeferredCompensationPlanLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation plan liability</link:label>
    <link:label id="lab_amed_DeferredCompensationPlanLiability_label_en-US" xlink:label="lab_amed_DeferredCompensationPlanLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Plan Liability</link:label>
    <link:label id="lab_amed_DeferredCompensationPlanLiability_documentation_en-US" xlink:label="lab_amed_DeferredCompensationPlanLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Plan Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredCompensationPlanLiability" xlink:href="amed-20221231.xsd#amed_DeferredCompensationPlanLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DeferredCompensationPlanLiability" xlink:to="lab_amed_DeferredCompensationPlanLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e2366bb2-f82d-43e6-a7cf-92617cef2952_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_44806cf7-826a-4056-8178-14549caeba48_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_463c25bc-5027-4742-acc1-def40268449b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_label_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeHealthNonMedicareEpisodicBasedMember_dea5a60a-ca55-45e4-9362-39250714ac7c_terseLabel_en-US" xlink:label="lab_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Episodic Based [Member]</link:label>
    <link:label id="lab_amed_HomeHealthNonMedicareEpisodicBasedMember_label_en-US" xlink:label="lab_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Episodic Based [Member]</link:label>
    <link:label id="lab_amed_HomeHealthNonMedicareEpisodicBasedMember_documentation_en-US" xlink:label="lab_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Episodic Based [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:href="amed-20221231.xsd#amed_HomeHealthNonMedicareEpisodicBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:to="lab_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_cf5ed3d4-edef-4299-a723-6a505e663af3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_c875eb17-fe1a-49a6-b34f-b6c32a76103b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AseraCareHospiceMember_a4715b2e-2266-400f-922b-1e1cf7013712_terseLabel_en-US" xlink:label="lab_amed_AseraCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AseraCare Hospice [Member]</link:label>
    <link:label id="lab_amed_AseraCareHospiceMember_label_en-US" xlink:label="lab_amed_AseraCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AseraCare Hospice [Member]</link:label>
    <link:label id="lab_amed_AseraCareHospiceMember_documentation_en-US" xlink:label="lab_amed_AseraCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AseraCare Hospice Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember" xlink:href="amed-20221231.xsd#amed_AseraCareHospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AseraCareHospiceMember" xlink:to="lab_amed_AseraCareHospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_3337119a-f5d6-42f4-b681-f610d2ae79e6_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested stock options beginning balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_ececaaa4-ee3e-4bf9-acea-fd57c6987709_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested stock options ending balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateMember_43cd3be6-cf9c-4abe-8302-4ff4a279c60f_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:label id="lab_us-gaap_CorporateMember_label_en-US" xlink:label="lab_us-gaap_CorporateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateMember" xlink:to="lab_us-gaap_CorporateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_4d82f1e7-f165-4356-9c0d-166f61faaa86_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_92502463-83c5-4b56-bbf9-9232e9f273dc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Free Interest Rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_61b73af0-57c3-4cef-afeb-e268cb3e68be_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares withheld to pay taxes on non-cash compensation</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_9e586d89-f29c-473d-8547-89d8616b9e8d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Related to Tax Withholding for Share-based Compensation</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_e4b48213-5bb5-433a-a911-a6a355f0e9e6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ShareRepurchaseLineItems_9f453282-dde1-43b8-a9fb-ba1b694758ee_terseLabel_en-US" xlink:label="lab_amed_ShareRepurchaseLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Line Items]</link:label>
    <link:label id="lab_amed_ShareRepurchaseLineItems_label_en-US" xlink:label="lab_amed_ShareRepurchaseLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Line Items]</link:label>
    <link:label id="lab_amed_ShareRepurchaseLineItems_documentation_en-US" xlink:label="lab_amed_ShareRepurchaseLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Share Repurchase [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseLineItems" xlink:href="amed-20221231.xsd#amed_ShareRepurchaseLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ShareRepurchaseLineItems" xlink:to="lab_amed_ShareRepurchaseLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract_5651e522-1f1e-4f50-9435-b4d53d99867a_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses:</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_InsuranceProgramsTableTableTextBlock_abbc6d61-d9b5-4597-85f2-5e736b45b971_terseLabel_en-US" xlink:label="lab_amed_InsuranceProgramsTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Insurance Programs</link:label>
    <link:label id="lab_amed_InsuranceProgramsTableTableTextBlock_label_en-US" xlink:label="lab_amed_InsuranceProgramsTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Programs Table [Table Text Block]</link:label>
    <link:label id="lab_amed_InsuranceProgramsTableTableTextBlock_documentation_en-US" xlink:label="lab_amed_InsuranceProgramsTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Programs Details, Table</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InsuranceProgramsTableTableTextBlock" xlink:href="amed-20221231.xsd#amed_InsuranceProgramsTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_InsuranceProgramsTableTableTextBlock" xlink:to="lab_amed_InsuranceProgramsTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_97164ca5-cf43-4b99-a356-b860b45a9445_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_f4338e04-3515-4719-ba20-594064979a91_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LetterOfCreditFee_66df475d-fa4c-48bb-8982-aea4552f3696_terseLabel_en-US" xlink:label="lab_amed_LetterOfCreditFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit Fee</link:label>
    <link:label id="lab_amed_LetterOfCreditFee_label_en-US" xlink:label="lab_amed_LetterOfCreditFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter Of Credit Fee</link:label>
    <link:label id="lab_amed_LetterOfCreditFee_documentation_en-US" xlink:label="lab_amed_LetterOfCreditFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The fee, expressed as a percentage of the letters of credit, for the letters of credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LetterOfCreditFee" xlink:href="amed-20221231.xsd#amed_LetterOfCreditFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LetterOfCreditFee" xlink:to="lab_amed_LetterOfCreditFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_5947f2af-a5e0-408a-a500-f3fc5b97bc90_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_232d4017-5f7d-48c0-af7d-22613d9ca6ff_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsMember_63ff6284-1099-4db6-a647-003b9975e64a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Member]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsMember" xlink:to="lab_us-gaap_EquityMethodInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_411697b8-2109-4c3c-a949-01a5834617ec_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_52fbf18c-8eba-47a9-b8b0-f7fbd75d4d13_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan expense</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_2b528c00-8f9b-403e-83ab-a959d716d802_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and penalties accrued related to uncertain income tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_18c0a7d2-afbe-4189-a995-c94f6a650956_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease - Less: Imputed Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_10b404c7-e7f2-48eb-8b91-2ee3ec8cf6f9_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Amedisys, Inc. common stockholders (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_8e23dbdf-38fc-4bba-adb4-f451533b8242_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b0350379-ce48-47f4-80fc-6507fd152d85_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period of equity-based awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock_14b4b596-2f1f-4c3f-988a-35dfcd08a4dc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_8686d171-1d8b-4d95-8d52-30a711ecc5b2_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c17e02c9-13ce-442b-9562-bc6095c85899_negatedLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_0926b3b7-89b2-4cef-8c54-bfc3447a9972_terseLabel_en-US" xlink:label="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue by payor class as a percentage of total net service revenue</link:label>
    <link:label id="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_label_en-US" xlink:label="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue by payor class as a percentage of total net service revenue</link:label>
    <link:label id="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_documentation_en-US" xlink:label="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue by payor class as a percentage of total net service revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:href="amed-20221231.xsd#amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:to="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ea73ba9a-7964-430f-a404-ecbeace7fadd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease - 2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_9dd5ff73-8fa5-43a2-8985-66c79f5e4d9f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_bd593c2d-c2fb-4392-a8de-40fb6b88fa83_totalLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_eda2c283-1241-4a34-b6a0-372b3e4a9ff8_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_797230fa-b09f-4747-bf88-bc2b9038bfcc_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain tax benefits accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_64bcbb05-430b-4fe9-a6d9-223e18350dc8_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain tax benefits, beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_6e5cb519-a4a9-466e-ba6e-8d6e0f03dcc8_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain tax benefits, ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_4b5da638-58b4-45c5-a2b0-c782e0d9f830_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right of Use Assets</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Operating lease right of use assets</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:href="amed-20221231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_292623b1-8537-46bd-a7f4-5706be88ecaf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToDevelopSoftware_1fb755a2-360b-4ae8-bdd5-7a5ad52c2034_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToDevelopSoftware" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in technology assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToDevelopSoftware_label_en-US" xlink:label="lab_us-gaap_PaymentsToDevelopSoftware" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Develop Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToDevelopSoftware" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToDevelopSoftware"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToDevelopSoftware" xlink:to="lab_us-gaap_PaymentsToDevelopSoftware" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract_1f6dba06-2474-435f-8e13-e2426e867f24_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term obligations:</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_9d820ef1-771c-4dac-8e8b-918acd94f9a2_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment Fee</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PaymentsRelatedToTaxAsset_e3cc7bf0-6a43-46b8-8cf6-f24f37833761_terseLabel_en-US" xlink:label="lab_amed_PaymentsRelatedToTaxAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to tax asset</link:label>
    <link:label id="lab_amed_PaymentsRelatedToTaxAsset_label_en-US" xlink:label="lab_amed_PaymentsRelatedToTaxAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to tax asset</link:label>
    <link:label id="lab_amed_PaymentsRelatedToTaxAsset_documentation_en-US" xlink:label="lab_amed_PaymentsRelatedToTaxAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to tax asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PaymentsRelatedToTaxAsset" xlink:href="amed-20221231.xsd#amed_PaymentsRelatedToTaxAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PaymentsRelatedToTaxAsset" xlink:to="lab_amed_PaymentsRelatedToTaxAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation_5840e5ca-8cbe-4f06-afcd-c568fef289b2_terseLabel_en-US" xlink:label="lab_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers&#8217; compensation</link:label>
    <link:label id="lab_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation_label_en-US" xlink:label="lab_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Workers Compensation</link:label>
    <link:label id="lab_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation_documentation_en-US" xlink:label="lab_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets tax deferred expense compensation and benefits workers compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation" xlink:href="amed-20221231.xsd#amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation" xlink:to="lab_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_8f75d58c-3b90-4f30-8276-0f1b8f104216_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_1e81aa30-16e3-4963-b8fe-b35d758c02e7_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_475b55c9-32e3-4069-b862-59b567b47a5d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Sources, Health Care Organization [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Sources, Health Care Organization [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:to="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_af1b0472-059b-4664-9eef-bcabdfce326f_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional interest rate above Eurodollar Rate (percent)</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_label_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Additional Interest Above Eurodollar Rate</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_documentation_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Additional Interest Above Eurodollar Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:href="amed-20221231.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:to="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_126c10c7-6cb3-49ca-ae7c-c61761ab69fc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_80674c53-f8fa-406e-95d9-da185382367a_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_d0d8e0fb-a738-4263-bd49-829e2215b752_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_a1028ca6-72f3-430f-aa77-8d69c057d714_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (usd per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MaximumPercentOwnershipForCostMethodPercent_f6f5ce88-b2a9-4969-a3e2-d684b02e3f05_terseLabel_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum ownership percentage for cost method investment (percent)</link:label>
    <link:label id="lab_amed_MaximumPercentOwnershipForCostMethodPercent_label_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Percent Ownership For Cost Method Percent</link:label>
    <link:label id="lab_amed_MaximumPercentOwnershipForCostMethodPercent_documentation_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage ownership required in order for an investment to be treated under the cost method of accounting in the entity's financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:href="amed-20221231.xsd#amed_MaximumPercentOwnershipForCostMethodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:to="lab_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9d93674c-18f7-4f13-8052-66892eb8d04e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_8fdd02b6-a4f7-4e57-9a81-d5e07b8fea2d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_430da0f6-505e-45ce-846d-3116f6c69bd1_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_1f87f500-25a4-43f5-a024-f884f4ae48ca_terseLabel_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_label_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_2059b1dd-752e-40ab-b63e-37fd03674d2a_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_3840bc6a-4d12-42c4-bed6-c70cad1a8c6e_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_7ae2e64c-c014-46d5-9aee-0998404bb23b_terseLabel_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_label_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncompeteAgreementsMember" xlink:to="lab_us-gaap_NoncompeteAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FinanceLeaseCost_99e18725-0f02-4789-8376-f6b50176d162_terseLabel_en-US" xlink:label="lab_amed_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease Cost</link:label>
    <link:label id="lab_amed_FinanceLeaseCost_label_en-US" xlink:label="lab_amed_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease Cost</link:label>
    <link:label id="lab_amed_FinanceLeaseCost_documentation_en-US" xlink:label="lab_amed_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total amount of finance lease cost including amortization of ROU asset and interest expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FinanceLeaseCost" xlink:href="amed-20221231.xsd#amed_FinanceLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FinanceLeaseCost" xlink:to="lab_amed_FinanceLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_32c34f71-9814-46d6-87b1-6506d2b96e71_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Indefinite-lived Intangible Assets by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Indefinite-Lived Intangible Assets by Major Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:to="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousCurrent_f63a3604-1e73-44d2-9869-3876c912eccd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMiscellaneousCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Miscellaneous, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMiscellaneousCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:to="lab_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity_038c9db7-3fc8-406a-a6a7-dadd40a88780_negatedTerseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Equity</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Equity</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of equity assumed at the acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity" xlink:href="amed-20221231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_66327331-c088-4c97-8bf4-94d51df43664_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Tax Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations_e5c14219-ec32-4218-8ebd-e60150abb9b0_terseLabel_en-US" xlink:label="lab_amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Finance lease Reduction to ROU assets resulting from reductions to lease obligations</link:label>
    <link:label id="lab_amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations_label_en-US" xlink:label="lab_amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Finance lease Reduction to ROU assets resulting from reductions to lease obligations</link:label>
    <link:label id="lab_amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations_documentation_en-US" xlink:label="lab_amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance lease, Reduction to ROU assets resulting from reductions to lease obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations" xlink:href="amed-20221231.xsd#amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations" xlink:to="lab_amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_WorkersCompensationInsuranceRetentionLimit_17042fab-c28c-44b1-85a5-56c3a40bb8f8_terseLabel_en-US" xlink:label="lab_amed_WorkersCompensationInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers' compensation insurance retention limit</link:label>
    <link:label id="lab_amed_WorkersCompensationInsuranceRetentionLimit_label_en-US" xlink:label="lab_amed_WorkersCompensationInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers Compensation Insurance Retention Limit</link:label>
    <link:label id="lab_amed_WorkersCompensationInsuranceRetentionLimit_documentation_en-US" xlink:label="lab_amed_WorkersCompensationInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential amount of future payments the entity could be required to make related to a specific Workers' Compensation Insurance Claim.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WorkersCompensationInsuranceRetentionLimit" xlink:href="amed-20221231.xsd#amed_WorkersCompensationInsuranceRetentionLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_WorkersCompensationInsuranceRetentionLimit" xlink:to="lab_amed_WorkersCompensationInsuranceRetentionLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NumberOfCareCentersIncludedInDivestiturePlan_86b4e14f-96af-4295-956e-a69a2d169959_terseLabel_en-US" xlink:label="lab_amed_NumberOfCareCentersIncludedInDivestiturePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of care centers included in divestiture plan</link:label>
    <link:label id="lab_amed_NumberOfCareCentersIncludedInDivestiturePlan_label_en-US" xlink:label="lab_amed_NumberOfCareCentersIncludedInDivestiturePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Care Centers Included in Divestiture Plan</link:label>
    <link:label id="lab_amed_NumberOfCareCentersIncludedInDivestiturePlan_documentation_en-US" xlink:label="lab_amed_NumberOfCareCentersIncludedInDivestiturePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of care centers that were included in the divestiture plan during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfCareCentersIncludedInDivestiturePlan" xlink:href="amed-20221231.xsd#amed_NumberOfCareCentersIncludedInDivestiturePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NumberOfCareCentersIncludedInDivestiturePlan" xlink:to="lab_amed_NumberOfCareCentersIncludedInDivestiturePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_6bf38c2b-f5c9-4513-9d14-9f9c74edcdc0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5d9c6110-bbf2-4931-ad92-833659bd7010_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_0aca1785-6176-41ba-91e8-b9aec267c1fd_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_8c0d2401-11c0-4054-b288-ed6ddb7a46cb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_4a0c85ea-39d1-4ee2-81e3-cd6bf124c252_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessAcquisitionProFormaOperatingIncomeLoss_9fdef880-d801-4c81-a7ba-3b767fc2e635_terseLabel_en-US" xlink:label="lab_amed_BusinessAcquisitionProFormaOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition pro forma operating income loss</link:label>
    <link:label id="lab_amed_BusinessAcquisitionProFormaOperatingIncomeLoss_label_en-US" xlink:label="lab_amed_BusinessAcquisitionProFormaOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition pro forma operating income loss</link:label>
    <link:label id="lab_amed_BusinessAcquisitionProFormaOperatingIncomeLoss_documentation_en-US" xlink:label="lab_amed_BusinessAcquisitionProFormaOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The pro forma operating income (loss) for the period as if the business combination or combinations had been completed at the beginning of a period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionProFormaOperatingIncomeLoss" xlink:href="amed-20221231.xsd#amed_BusinessAcquisitionProFormaOperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessAcquisitionProFormaOperatingIncomeLoss" xlink:to="lab_amed_BusinessAcquisitionProFormaOperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent_af8d7849-514e-4791-adc0-7233a71074c2_negatedTerseLabel_en-US" xlink:label="lab_amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess tax benefits from share-based compensation (1)</link:label>
    <link:label id="lab_amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent_label_en-US" xlink:label="lab_amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Excess Tax Benefit, Share-based Compensation, Percent</link:label>
    <link:label id="lab_amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent_documentation_en-US" xlink:label="lab_amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Excess Tax Benefit, Share-based Compensation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent" xlink:href="amed-20221231.xsd#amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent" xlink:to="lab_amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_3792fa14-f872-446c-b301-20f258c544a3_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_a6d3de9f-879c-4287-b751-b9efca104ad5_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses, excluding depreciation and amortization and impairment charge</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CharityCare_27fd57df-b416-48ea-81ef-76169fc800f1_terseLabel_en-US" xlink:label="lab_amed_CharityCare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charity care</link:label>
    <link:label id="lab_amed_CharityCare_label_en-US" xlink:label="lab_amed_CharityCare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charity Care</link:label>
    <link:label id="lab_amed_CharityCare_documentation_en-US" xlink:label="lab_amed_CharityCare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of accrued expenses related to charity care</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CharityCare" xlink:href="amed-20221231.xsd#amed_CharityCare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CharityCare" xlink:to="lab_amed_CharityCare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_8746273d-dfb9-4e9f-a0a2-f0d902e67cc8_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash impairment charge for write-off of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1121f6c1-a390-4134-bbbb-2b01d33c1f81_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-off</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_3d7a1b7b-2379-4a29-9435-7dbcc4005ab8_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_59274d4e-3beb-4bd4-9f12-22ddd35c49d5_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0479b048-b0f3-4437-9548-24af31c0bfec_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested stock options beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_50b1bf23-666a-4323-9a58-59438cd81866_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested stock options ending balance (shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_7bd30723-fdbc-4a9d-8763-dd3fd35a746c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FundsReceivedFromProviderReliefFundAdvance_c626171c-fd40-41e0-a10d-ec85425bbae0_terseLabel_en-US" xlink:label="lab_amed_FundsReceivedFromProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider relief fund advance</link:label>
    <link:label id="lab_amed_FundsReceivedFromProviderReliefFundAdvance_label_en-US" xlink:label="lab_amed_FundsReceivedFromProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funds Received From Provider Relief Fund Advance</link:label>
    <link:label id="lab_amed_FundsReceivedFromProviderReliefFundAdvance_documentation_en-US" xlink:label="lab_amed_FundsReceivedFromProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash inflow from funds received by the government related to the Novel Coronavirus Pandemic "COVID-19"</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundsReceivedFromProviderReliefFundAdvance" xlink:href="amed-20221231.xsd#amed_FundsReceivedFromProviderReliefFundAdvance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FundsReceivedFromProviderReliefFundAdvance" xlink:to="lab_amed_FundsReceivedFromProviderReliefFundAdvance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_98edf872-366f-45fb-abff-cff2247d72c2_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_49a2b417-9027-4273-8d1c-1f1f0e4b39d0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare_3fb4156f-3d54-4132-b0b8-e0a209dbd640_terseLabel_en-US" xlink:label="lab_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion of accounts receivable derived from Medicare</link:label>
    <link:label id="lab_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare_label_en-US" xlink:label="lab_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion Of Patient Accounts Receivable Derived From Medicare</link:label>
    <link:label id="lab_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare_documentation_en-US" xlink:label="lab_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage of the entity's net patient accounts receivable that is derived from Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare" xlink:href="amed-20221231.xsd#amed_PortionOfPatientAccountsReceivableDerivedFromMedicare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare" xlink:to="lab_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_a4f41e01-5bca-484a-9392-ff313858fcdd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease - Less: Imputed Interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_3ff3232f-aa4b-44a8-b546-cef1c1fc31b0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment charge</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LesseeLeasesTextBlock_b3375103-d90d-4201-a468-f36a4a1ed5f9_terseLabel_en-US" xlink:label="lab_amed_LesseeLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_amed_LesseeLeasesTextBlock_label_en-US" xlink:label="lab_amed_LesseeLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Text Block]</link:label>
    <link:label id="lab_amed_LesseeLeasesTextBlock_documentation_en-US" xlink:label="lab_amed_LesseeLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure for operating and finance leases of lessee. Includes, but is not limited to, description of operating and finance lease and maturity analysis of operating and finance lease liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LesseeLeasesTextBlock" xlink:href="amed-20221231.xsd#amed_LesseeLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LesseeLeasesTextBlock" xlink:to="lab_amed_LesseeLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_68604744-d7cf-4d38-af04-d8b1f2c1d407_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (usd per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_37319611-b198-4ad5-8920-1b8e162f8616_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Aggregate Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationAcquiredNoncontrollingInterest_5794b026-5e3d-4d70-97db-0a91a8dddb12_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationAcquiredNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Acquired Noncontrolling Interest</link:label>
    <link:label id="lab_amed_BusinessCombinationAcquiredNoncontrollingInterest_label_en-US" xlink:label="lab_amed_BusinessCombinationAcquiredNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Acquired Noncontrolling Interest</link:label>
    <link:label id="lab_amed_BusinessCombinationAcquiredNoncontrollingInterest_documentation_en-US" xlink:label="lab_amed_BusinessCombinationAcquiredNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents the amount of noncontrolling interest acquired at the acquisition date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationAcquiredNoncontrollingInterest" xlink:href="amed-20221231.xsd#amed_BusinessCombinationAcquiredNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationAcquiredNoncontrollingInterest" xlink:to="lab_amed_BusinessCombinationAcquiredNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilities_label_en-US" xlink:label="lab_us-gaap_OtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilities" xlink:to="lab_us-gaap_OtherLiabilities" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>amed-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:c9bac751-1ef0-45f1-8208-1bc5d72ec892,g:1d8a20b2-a85c-4def-9d57-f7b6e7a974de-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amedisys.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="amed-20221231.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_amed_DocumentAndEntityInformationAbstract_c3705f35-773a-4ec4-8c12-59cac0a3253c" xlink:href="amed-20221231.xsd#amed_DocumentAndEntityInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_94412d60-f942-4b18-937e-4f91f2213082" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_c3705f35-773a-4ec4-8c12-59cac0a3253c" xlink:to="loc_dei_DocumentType_94412d60-f942-4b18-937e-4f91f2213082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_a7f1f6f2-6ced-4d58-8cf9-ee346a68df2a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_c3705f35-773a-4ec4-8c12-59cac0a3253c" xlink:to="loc_dei_DocumentAnnualReport_a7f1f6f2-6ced-4d58-8cf9-ee346a68df2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4e60002c-bbff-4cdc-aa3e-02b66534b860" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_c3705f35-773a-4ec4-8c12-59cac0a3253c" xlink:to="loc_dei_DocumentPeriodEndDate_4e60002c-bbff-4cdc-aa3e-02b66534b860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_dcfaa11b-edda-4a92-b4c4-461c96665fe9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_c3705f35-773a-4ec4-8c12-59cac0a3253c" xlink:to="loc_dei_DocumentTransitionReport_dcfaa11b-edda-4a92-b4c4-461c96665fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_264373bc-81a9-4068-b9b2-846ab9fc8142" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_c3705f35-773a-4ec4-8c12-59cac0a3253c" xlink:to="loc_dei_EntityFileNumber_264373bc-81a9-4068-b9b2-846ab9fc8142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9fc5ca85-7262-40bc-be57-8c66eb436161" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_c3705f35-773a-4ec4-8c12-59cac0a3253c" xlink:to="loc_dei_EntityRegistrantName_9fc5ca85-7262-40bc-be57-8c66eb436161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f9359886-b9ac-434a-9c6a-b3a14302260d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_c3705f35-773a-4ec4-8c12-59cac0a3253c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f9359886-b9ac-434a-9c6a-b3a14302260d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d389eb2a-e25b-4f1d-bf1e-6ec8dce5c284" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_c3705f35-773a-4ec4-8c12-59cac0a3253c" xlink:to="loc_dei_EntityTaxIdentificationNumber_d389eb2a-e25b-4f1d-bf1e-6ec8dce5c284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_97de15ae-cc79-45a1-8529-7dbaa36dfd99" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_c3705f35-773a-4ec4-8c12-59cac0a3253c" xlink:to="loc_dei_EntityAddressAddressLine1_97de15ae-cc79-45a1-8529-7dbaa36dfd99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_ba237397-6e88-447b-ac08-f6d376029014" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_c3705f35-773a-4ec4-8c12-59cac0a3253c" xlink:to="loc_dei_EntityAddressCityOrTown_ba237397-6e88-447b-ac08-f6d376029014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_5eab6dbd-05cb-4c00-a3be-8aaaaeb7af0f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_c3705f35-773a-4ec4-8c12-59cac0a3253c" xlink:to="loc_dei_EntityAddressStateOrProvince_5eab6dbd-05cb-4c00-a3be-8aaaaeb7af0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_cffeac16-d3b1-4273-ba6a-50e451e3be6f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_c3705f35-773a-4ec4-8c12-59cac0a3253c" xlink:to="loc_dei_EntityAddressPostalZipCode_cffeac16-d3b1-4273-ba6a-50e451e3be6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_74f5eba8-6505-4694-9032-e6aef20ccb54" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_c3705f35-773a-4ec4-8c12-59cac0a3253c" xlink:to="loc_dei_CityAreaCode_74f5eba8-6505-4694-9032-e6aef20ccb54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_498e3496-b31c-4fbc-ad56-159071095bb5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_c3705f35-773a-4ec4-8c12-59cac0a3253c" xlink:to="loc_dei_LocalPhoneNumber_498e3496-b31c-4fbc-ad56-159071095bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_2a1d3b0a-c290-445a-b347-ed2deb227afc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_c3705f35-773a-4ec4-8c12-59cac0a3253c" xlink:to="loc_dei_Security12bTitle_2a1d3b0a-c290-445a-b347-ed2deb227afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c141b34b-be65-40ec-b00a-23c400cbc65f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_c3705f35-773a-4ec4-8c12-59cac0a3253c" xlink:to="loc_dei_SecurityExchangeName_c141b34b-be65-40ec-b00a-23c400cbc65f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_23bbb07c-0959-40ba-adaa-3b5a18a74334" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_c3705f35-773a-4ec4-8c12-59cac0a3253c" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_23bbb07c-0959-40ba-adaa-3b5a18a74334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_53e62321-bd5f-420d-906c-0ae4154da78c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_c3705f35-773a-4ec4-8c12-59cac0a3253c" xlink:to="loc_dei_EntityVoluntaryFilers_53e62321-bd5f-420d-906c-0ae4154da78c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_0d0a9657-787a-42f7-a8da-beb8c8466687" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_c3705f35-773a-4ec4-8c12-59cac0a3253c" xlink:to="loc_dei_EntityCurrentReportingStatus_0d0a9657-787a-42f7-a8da-beb8c8466687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_89c1ec8f-3151-4b2a-9e91-6834c3a4207b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_c3705f35-773a-4ec4-8c12-59cac0a3253c" xlink:to="loc_dei_EntityInteractiveDataCurrent_89c1ec8f-3151-4b2a-9e91-6834c3a4207b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_235574c4-15c3-4119-a9d5-7693eff13fe6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_c3705f35-773a-4ec4-8c12-59cac0a3253c" xlink:to="loc_dei_EntityFilerCategory_235574c4-15c3-4119-a9d5-7693eff13fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_803cfc9a-4fc0-4502-b8ee-3efb5417c920" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_c3705f35-773a-4ec4-8c12-59cac0a3253c" xlink:to="loc_dei_EntitySmallBusiness_803cfc9a-4fc0-4502-b8ee-3efb5417c920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c3ac2d11-3c7a-4040-a564-1275998151fa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_c3705f35-773a-4ec4-8c12-59cac0a3253c" xlink:to="loc_dei_EntityEmergingGrowthCompany_c3ac2d11-3c7a-4040-a564-1275998151fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_5b8e6871-f240-41c0-b167-9aa5f9d4bda0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_c3705f35-773a-4ec4-8c12-59cac0a3253c" xlink:to="loc_dei_IcfrAuditorAttestationFlag_5b8e6871-f240-41c0-b167-9aa5f9d4bda0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_17ecbbbe-2c77-4d62-bc43-e768613cb85b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_c3705f35-773a-4ec4-8c12-59cac0a3253c" xlink:to="loc_dei_EntityShellCompany_17ecbbbe-2c77-4d62-bc43-e768613cb85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_eb2ed875-9af6-4c7d-9a62-93669f6d4ea7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_c3705f35-773a-4ec4-8c12-59cac0a3253c" xlink:to="loc_dei_EntityPublicFloat_eb2ed875-9af6-4c7d-9a62-93669f6d4ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_110da8b5-241c-47d3-b372-1d7f04105d79" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_c3705f35-773a-4ec4-8c12-59cac0a3253c" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_110da8b5-241c-47d3-b372-1d7f04105d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_db3a0182-140f-42e6-a7c7-cd4eb6da2972" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_c3705f35-773a-4ec4-8c12-59cac0a3253c" xlink:to="loc_dei_AmendmentFlag_db3a0182-140f-42e6-a7c7-cd4eb6da2972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_c261f485-8578-422d-b365-c90e109bc568" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_c3705f35-773a-4ec4-8c12-59cac0a3253c" xlink:to="loc_dei_DocumentFiscalYearFocus_c261f485-8578-422d-b365-c90e109bc568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_4092794f-14af-4cc6-b194-8c7f5af3c899" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_c3705f35-773a-4ec4-8c12-59cac0a3253c" xlink:to="loc_dei_DocumentFiscalPeriodFocus_4092794f-14af-4cc6-b194-8c7f5af3c899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_1fe30980-2c3e-44fa-a141-0bf8eb3b052c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_c3705f35-773a-4ec4-8c12-59cac0a3253c" xlink:to="loc_dei_TradingSymbol_1fe30980-2c3e-44fa-a141-0bf8eb3b052c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f7659c2b-4cf5-4390-9393-9b254c680715" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_c3705f35-773a-4ec4-8c12-59cac0a3253c" xlink:to="loc_dei_EntityCentralIndexKey_f7659c2b-4cf5-4390-9393-9b254c680715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_c2d6cb00-e96b-421b-b040-109f704f0919" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DocumentAndEntityInformationAbstract_c3705f35-773a-4ec4-8c12-59cac0a3253c" xlink:to="loc_dei_CurrentFiscalYearEndDate_c2d6cb00-e96b-421b-b040-109f704f0919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/AuditInformation" xlink:type="simple" xlink:href="amed-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLineItems_c42b0487-2d62-46e2-9284-876ef0ca6d02" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_8d27436f-4ddf-4230-ac39-506f75821b3b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AuditorLineItems_c42b0487-2d62-46e2-9284-876ef0ca6d02" xlink:to="loc_dei_AuditorName_8d27436f-4ddf-4230-ac39-506f75821b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_6ffabb4c-63a3-401c-85d3-cbd4635c0625" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AuditorLineItems_c42b0487-2d62-46e2-9284-876ef0ca6d02" xlink:to="loc_dei_AuditorLocation_6ffabb4c-63a3-401c-85d3-cbd4635c0625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_35a5a12c-8467-42c4-9a2a-9000b65942d7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AuditorLineItems_c42b0487-2d62-46e2-9284-876ef0ca6d02" xlink:to="loc_dei_AuditorFirmId_35a5a12c-8467-42c4-9a2a-9000b65942d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="amed-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_fcfecf52-1eaf-4a69-8ac9-d72d2b67b98f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_c262478f-e302-4a48-ab5a-63c2a9a596b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fcfecf52-1eaf-4a69-8ac9-d72d2b67b98f" xlink:to="loc_us-gaap_AssetsAbstract_c262478f-e302-4a48-ab5a-63c2a9a596b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_87dca6c2-dfbc-4783-88e2-a802090f3675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c262478f-e302-4a48-ab5a-63c2a9a596b2" xlink:to="loc_us-gaap_AssetsCurrentAbstract_87dca6c2-dfbc-4783-88e2-a802090f3675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_61af1ab3-d49d-4a45-9dbb-2189d971a147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_87dca6c2-dfbc-4783-88e2-a802090f3675" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_61af1ab3-d49d-4a45-9dbb-2189d971a147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_74d28529-e89b-4db0-8c51-2d7a985b846e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_87dca6c2-dfbc-4783-88e2-a802090f3675" xlink:to="loc_us-gaap_RestrictedCash_74d28529-e89b-4db0-8c51-2d7a985b846e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_98489e05-ea25-4bea-bb3b-0a2ae0ea65bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_87dca6c2-dfbc-4783-88e2-a802090f3675" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_98489e05-ea25-4bea-bb3b-0a2ae0ea65bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_1601c138-09a4-4e3a-ae80-3edb50a2668f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_87dca6c2-dfbc-4783-88e2-a802090f3675" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_1601c138-09a4-4e3a-ae80-3edb50a2668f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_f552f3fa-5c1c-4451-afb8-a7c744856886" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_87dca6c2-dfbc-4783-88e2-a802090f3675" xlink:to="loc_us-gaap_OtherAssetsCurrent_f552f3fa-5c1c-4451-afb8-a7c744856886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_788c67a2-924d-4e1e-9e49-62561985ba93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_87dca6c2-dfbc-4783-88e2-a802090f3675" xlink:to="loc_us-gaap_AssetsCurrent_788c67a2-924d-4e1e-9e49-62561985ba93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c06dfad6-d91c-42f4-b1f2-53e8cc718d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c262478f-e302-4a48-ab5a-63c2a9a596b2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c06dfad6-d91c-42f4-b1f2-53e8cc718d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d2634318-4b4b-44cc-9423-d44f55ef508e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c262478f-e302-4a48-ab5a-63c2a9a596b2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d2634318-4b4b-44cc-9423-d44f55ef508e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0e89daf2-8e4f-4ca1-9352-3c5db63b6a16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c262478f-e302-4a48-ab5a-63c2a9a596b2" xlink:to="loc_us-gaap_Goodwill_0e89daf2-8e4f-4ca1-9352-3c5db63b6a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_aa3cb3cb-9b4e-4537-8569-d7cbfe2ac05b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c262478f-e302-4a48-ab5a-63c2a9a596b2" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_aa3cb3cb-9b4e-4537-8569-d7cbfe2ac05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_8880c578-7f9c-434a-8298-7a85d36e2896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c262478f-e302-4a48-ab5a-63c2a9a596b2" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_8880c578-7f9c-434a-8298-7a85d36e2896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_03e9e4e1-6648-4349-9798-10a260aca3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c262478f-e302-4a48-ab5a-63c2a9a596b2" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_03e9e4e1-6648-4349-9798-10a260aca3cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0761c845-8046-41a8-93b1-19882ec7c278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c262478f-e302-4a48-ab5a-63c2a9a596b2" xlink:to="loc_us-gaap_Assets_0761c845-8046-41a8-93b1-19882ec7c278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8382ba27-b30a-4a6d-ae4c-3e3ee5696e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fcfecf52-1eaf-4a69-8ac9-d72d2b67b98f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8382ba27-b30a-4a6d-ae4c-3e3ee5696e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_f29e5c08-69db-46be-b74a-9ec0e7cee630" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8382ba27-b30a-4a6d-ae4c-3e3ee5696e70" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_f29e5c08-69db-46be-b74a-9ec0e7cee630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_adb3cedd-fe60-4967-b57c-2f2b22534722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f29e5c08-69db-46be-b74a-9ec0e7cee630" xlink:to="loc_us-gaap_AccountsPayableCurrent_adb3cedd-fe60-4967-b57c-2f2b22534722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_63649dca-9603-432a-a83a-cdbd8e0828b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f29e5c08-69db-46be-b74a-9ec0e7cee630" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_63649dca-9603-432a-a83a-cdbd8e0828b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e815baaa-14f9-4ed2-af2b-ce434d6e780f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f29e5c08-69db-46be-b74a-9ec0e7cee630" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_e815baaa-14f9-4ed2-af2b-ce434d6e780f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProviderReliefFundAdvance_93d64c95-f4ba-4e52-a65d-720dab437927" xlink:href="amed-20221231.xsd#amed_ProviderReliefFundAdvance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f29e5c08-69db-46be-b74a-9ec0e7cee630" xlink:to="loc_amed_ProviderReliefFundAdvance_93d64c95-f4ba-4e52-a65d-720dab437927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_918bb23c-eb9e-4c87-bcf4-4775501f9d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f29e5c08-69db-46be-b74a-9ec0e7cee630" xlink:to="loc_us-gaap_DebtCurrent_918bb23c-eb9e-4c87-bcf4-4775501f9d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5b14cd36-a5ad-4c08-8d5d-f6c95a01ef07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f29e5c08-69db-46be-b74a-9ec0e7cee630" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5b14cd36-a5ad-4c08-8d5d-f6c95a01ef07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3aea0143-290c-45fc-9b4a-143631d8a8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f29e5c08-69db-46be-b74a-9ec0e7cee630" xlink:to="loc_us-gaap_LiabilitiesCurrent_3aea0143-290c-45fc-9b4a-143631d8a8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_93283af7-ca40-4114-b77b-3dfcb35a8f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8382ba27-b30a-4a6d-ae4c-3e3ee5696e70" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_93283af7-ca40-4114-b77b-3dfcb35a8f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_74554a1a-1542-4bff-b3bf-bdde7dc66d82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8382ba27-b30a-4a6d-ae4c-3e3ee5696e70" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_74554a1a-1542-4bff-b3bf-bdde7dc66d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_395da66c-291f-458a-aceb-9a0b55a254fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8382ba27-b30a-4a6d-ae4c-3e3ee5696e70" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_395da66c-291f-458a-aceb-9a0b55a254fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_1d4a9db3-9236-402a-92cc-553a322e46f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8382ba27-b30a-4a6d-ae4c-3e3ee5696e70" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_1d4a9db3-9236-402a-92cc-553a322e46f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ca7168c0-253e-458d-a448-bf2b83e0f52b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8382ba27-b30a-4a6d-ae4c-3e3ee5696e70" xlink:to="loc_us-gaap_Liabilities_ca7168c0-253e-458d-a448-bf2b83e0f52b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_6afb4562-cb6c-47a2-b761-7cd46067ecbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8382ba27-b30a-4a6d-ae4c-3e3ee5696e70" xlink:to="loc_us-gaap_CommitmentsAndContingencies_6afb4562-cb6c-47a2-b761-7cd46067ecbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_98b09cc7-12cf-46b2-9569-b52075324077" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8382ba27-b30a-4a6d-ae4c-3e3ee5696e70" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_98b09cc7-12cf-46b2-9569-b52075324077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_5973a3e5-93f8-4636-b727-3962fd9d4257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_98b09cc7-12cf-46b2-9569-b52075324077" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_5973a3e5-93f8-4636-b727-3962fd9d4257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_ed5ca64b-94a0-4b19-bd9f-25e7e228c4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_98b09cc7-12cf-46b2-9569-b52075324077" xlink:to="loc_us-gaap_CommonStockValueOutstanding_ed5ca64b-94a0-4b19-bd9f-25e7e228c4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_dcacea81-e66f-474a-9b38-f80de3e2f910" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_98b09cc7-12cf-46b2-9569-b52075324077" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_dcacea81-e66f-474a-9b38-f80de3e2f910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_1a7548d0-4020-492c-a32e-6c0c405cadfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_98b09cc7-12cf-46b2-9569-b52075324077" xlink:to="loc_us-gaap_TreasuryStockValue_1a7548d0-4020-492c-a32e-6c0c405cadfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b02ea8aa-1547-443b-94dc-1ad24d62eda3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_98b09cc7-12cf-46b2-9569-b52075324077" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b02ea8aa-1547-443b-94dc-1ad24d62eda3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_96bf58b7-6997-4494-8998-2049b8690268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_98b09cc7-12cf-46b2-9569-b52075324077" xlink:to="loc_us-gaap_StockholdersEquity_96bf58b7-6997-4494-8998-2049b8690268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_97fbeb3a-24f9-44a6-b39f-58dfc368ac85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_98b09cc7-12cf-46b2-9569-b52075324077" xlink:to="loc_us-gaap_MinorityInterest_97fbeb3a-24f9-44a6-b39f-58dfc368ac85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b408e47e-c41a-4662-8ae6-bc158ae6ed8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_98b09cc7-12cf-46b2-9569-b52075324077" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b408e47e-c41a-4662-8ae6-bc158ae6ed8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9bbacc55-16c5-4ea1-8e32-104e9d27d7be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8382ba27-b30a-4a6d-ae4c-3e3ee5696e70" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_9bbacc55-16c5-4ea1-8e32-104e9d27d7be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="amed-20221231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_5b222778-a776-4323-8d3a-5edf90c36860" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c5c2df62-6af7-4cf0-bf11-4f78c797175c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5b222778-a776-4323-8d3a-5edf90c36860" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c5c2df62-6af7-4cf0-bf11-4f78c797175c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_edde03fa-1e13-4716-8c20-63d0c078b113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5b222778-a776-4323-8d3a-5edf90c36860" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_edde03fa-1e13-4716-8c20-63d0c078b113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2bddb06b-7fd5-4179-b3be-e77957dc2f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5b222778-a776-4323-8d3a-5edf90c36860" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2bddb06b-7fd5-4179-b3be-e77957dc2f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_e14986dd-f337-4a14-afc8-892910966f22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5b222778-a776-4323-8d3a-5edf90c36860" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_e14986dd-f337-4a14-afc8-892910966f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_8f0567cf-9fdd-46d4-959c-8e7faa5e927f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5b222778-a776-4323-8d3a-5edf90c36860" xlink:to="loc_us-gaap_PreferredStockSharesIssued_8f0567cf-9fdd-46d4-959c-8e7faa5e927f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_54899d7e-05b8-4954-932d-9873c593c7aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5b222778-a776-4323-8d3a-5edf90c36860" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_54899d7e-05b8-4954-932d-9873c593c7aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_abcaeabb-8cc7-49d2-9327-3cc2bdcbb2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5b222778-a776-4323-8d3a-5edf90c36860" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_abcaeabb-8cc7-49d2-9327-3cc2bdcbb2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_f21bcc18-de8e-4181-98cc-ed1deecb8f40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5b222778-a776-4323-8d3a-5edf90c36860" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_f21bcc18-de8e-4181-98cc-ed1deecb8f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_0c93477c-140e-43d6-a35b-c01238021c64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5b222778-a776-4323-8d3a-5edf90c36860" xlink:to="loc_us-gaap_CommonStockSharesIssued_0c93477c-140e-43d6-a35b-c01238021c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_edbcdc18-6135-49f3-9cbe-d883c759eeaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5b222778-a776-4323-8d3a-5edf90c36860" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_edbcdc18-6135-49f3-9cbe-d883c759eeaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_2ce41db1-d2dd-4605-8714-7e4c7a53ecb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5b222778-a776-4323-8d3a-5edf90c36860" xlink:to="loc_us-gaap_TreasuryStockShares_2ce41db1-d2dd-4605-8714-7e4c7a53ecb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="amed-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_9811455b-c0f4-4dd6-b3a3-757ac7f9e232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_7cc8fc08-4c25-4d06-a161-e1a7fcfe1fda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9811455b-c0f4-4dd6-b3a3-757ac7f9e232" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_7cc8fc08-4c25-4d06-a161-e1a7fcfe1fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_f2c42b34-c4b6-4d90-b377-bd6b0686a708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9811455b-c0f4-4dd6-b3a3-757ac7f9e232" xlink:to="loc_us-gaap_OtherOperatingIncome_f2c42b34-c4b6-4d90-b377-bd6b0686a708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_8553ab6e-dd4b-4cf3-aaef-56bfe08f66b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9811455b-c0f4-4dd6-b3a3-757ac7f9e232" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_8553ab6e-dd4b-4cf3-aaef-56bfe08f66b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0569f4aa-522b-461d-b785-33eff5110f37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9811455b-c0f4-4dd6-b3a3-757ac7f9e232" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0569f4aa-522b-461d-b785-33eff5110f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_74355a6e-2e67-4b89-a7b1-6c722872d1b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0569f4aa-522b-461d-b785-33eff5110f37" xlink:to="loc_us-gaap_LaborAndRelatedExpense_74355a6e-2e67-4b89-a7b1-6c722872d1b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4dba7306-86cb-4f62-95ab-b5c6eab2366d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0569f4aa-522b-461d-b785-33eff5110f37" xlink:to="loc_us-gaap_ShareBasedCompensation_4dba7306-86cb-4f62-95ab-b5c6eab2366d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_bde269af-39a4-4c30-a71f-ea87bcbfcb55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_0569f4aa-522b-461d-b785-33eff5110f37" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_bde269af-39a4-4c30-a71f-ea87bcbfcb55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DepreciationAndAmortizationForContinuingOperations_6b9ed4f2-f6a4-4b05-94c4-ca33aaa1b05d" xlink:href="amed-20221231.xsd#amed_DepreciationAndAmortizationForContinuingOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9811455b-c0f4-4dd6-b3a3-757ac7f9e232" xlink:to="loc_amed_DepreciationAndAmortizationForContinuingOperations_6b9ed4f2-f6a4-4b05-94c4-ca33aaa1b05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_9ce3d038-9477-460a-8135-cfd0edffda18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9811455b-c0f4-4dd6-b3a3-757ac7f9e232" xlink:to="loc_us-gaap_AssetImpairmentCharges_9ce3d038-9477-460a-8135-cfd0edffda18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_68b546e1-1c23-4be8-a5e8-26b6bfd835ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9811455b-c0f4-4dd6-b3a3-757ac7f9e232" xlink:to="loc_us-gaap_CostsAndExpenses_68b546e1-1c23-4be8-a5e8-26b6bfd835ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2bf5b5a0-7d80-4d15-ab0a-db4abb838d09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9811455b-c0f4-4dd6-b3a3-757ac7f9e232" xlink:to="loc_us-gaap_OperatingIncomeLoss_2bf5b5a0-7d80-4d15-ab0a-db4abb838d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_88c9622a-5f73-4547-87d4-7d7350c25059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9811455b-c0f4-4dd6-b3a3-757ac7f9e232" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_88c9622a-5f73-4547-87d4-7d7350c25059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_841b19e6-7745-4163-8fcc-25a3bf06c586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_88c9622a-5f73-4547-87d4-7d7350c25059" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_841b19e6-7745-4163-8fcc-25a3bf06c586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_77bb406f-844e-4614-80f1-675d6cdc5558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_88c9622a-5f73-4547-87d4-7d7350c25059" xlink:to="loc_us-gaap_InterestExpense_77bb406f-844e-4614-80f1-675d6cdc5558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_858a09f4-75c3-41a9-bde2-a10be9d15920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_88c9622a-5f73-4547-87d4-7d7350c25059" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_858a09f4-75c3-41a9-bde2-a10be9d15920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_205222e7-ea7d-4715-94a6-e2c44cf6a3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_88c9622a-5f73-4547-87d4-7d7350c25059" xlink:to="loc_us-gaap_GainLossOnInvestments_205222e7-ea7d-4715-94a6-e2c44cf6a3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_87480013-7815-48fc-b0b0-df3241139221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_88c9622a-5f73-4547-87d4-7d7350c25059" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_87480013-7815-48fc-b0b0-df3241139221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_ea9a4608-0a8e-48b4-9d15-a2a5089811a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_88c9622a-5f73-4547-87d4-7d7350c25059" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_ea9a4608-0a8e-48b4-9d15-a2a5089811a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f8e7b20c-76b6-49f8-bcda-a93a3fbc538f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9811455b-c0f4-4dd6-b3a3-757ac7f9e232" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f8e7b20c-76b6-49f8-bcda-a93a3fbc538f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c62f2b5d-710e-484a-adc4-073b2ed5b599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9811455b-c0f4-4dd6-b3a3-757ac7f9e232" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c62f2b5d-710e-484a-adc4-073b2ed5b599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_195215c7-1569-41eb-b641-59e617c09ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9811455b-c0f4-4dd6-b3a3-757ac7f9e232" xlink:to="loc_us-gaap_ProfitLoss_195215c7-1569-41eb-b641-59e617c09ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_463a152c-220c-4215-9bf9-e23f925b74d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9811455b-c0f4-4dd6-b3a3-757ac7f9e232" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_463a152c-220c-4215-9bf9-e23f925b74d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5935279b-daf8-469f-a8ad-83ce1e0bf6af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9811455b-c0f4-4dd6-b3a3-757ac7f9e232" xlink:to="loc_us-gaap_NetIncomeLoss_5935279b-daf8-469f-a8ad-83ce1e0bf6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_fd288fac-49ff-4022-a605-2eb2320a3088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9811455b-c0f4-4dd6-b3a3-757ac7f9e232" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_fd288fac-49ff-4022-a605-2eb2320a3088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ba416e2a-b001-4dbf-a642-406dc62eee67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_fd288fac-49ff-4022-a605-2eb2320a3088" xlink:to="loc_us-gaap_EarningsPerShareBasic_ba416e2a-b001-4dbf-a642-406dc62eee67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_09bcc29f-fceb-46ed-85c4-77c6b5b34914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_fd288fac-49ff-4022-a605-2eb2320a3088" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_09bcc29f-fceb-46ed-85c4-77c6b5b34914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_ec6f32d9-db27-4958-93aa-ceb6401b550a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9811455b-c0f4-4dd6-b3a3-757ac7f9e232" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_ec6f32d9-db27-4958-93aa-ceb6401b550a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_63ae5265-dbdf-451a-9a62-df52096befdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_ec6f32d9-db27-4958-93aa-ceb6401b550a" xlink:to="loc_us-gaap_EarningsPerShareDiluted_63ae5265-dbdf-451a-9a62-df52096befdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a3dbf96d-1b32-4d5b-8e20-b728d70554ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_ec6f32d9-db27-4958-93aa-ceb6401b550a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a3dbf96d-1b32-4d5b-8e20-b728d70554ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="amed-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cdd11bbc-ccc4-4569-a4e3-e41d579deef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7bc64f7a-03ae-4e9c-8353-173a888af113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cdd11bbc-ccc4-4569-a4e3-e41d579deef0" xlink:to="loc_us-gaap_ProfitLoss_7bc64f7a-03ae-4e9c-8353-173a888af113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e15a86fc-3fc2-4610-9165-fe6a0f70fd2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cdd11bbc-ccc4-4569-a4e3-e41d579deef0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e15a86fc-3fc2-4610-9165-fe6a0f70fd2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_f73cee16-4117-4076-95f6-2676c9233f33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cdd11bbc-ccc4-4569-a4e3-e41d579deef0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_f73cee16-4117-4076-95f6-2676c9233f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_240243e5-ab09-4ba6-ba00-0402e807e5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cdd11bbc-ccc4-4569-a4e3-e41d579deef0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_240243e5-ab09-4ba6-ba00-0402e807e5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_4dd3ae85-b48e-4a34-bd6b-e49e2d0ff22f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cdd11bbc-ccc4-4569-a4e3-e41d579deef0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_4dd3ae85-b48e-4a34-bd6b-e49e2d0ff22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="amed-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_57448993-dd3c-4f47-a46b-941d677e3f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ae82aeea-f84b-4d43-abaa-dfd563735a06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_57448993-dd3c-4f47-a46b-941d677e3f9b" xlink:to="loc_us-gaap_StatementTable_ae82aeea-f84b-4d43-abaa-dfd563735a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c64e028e-ca64-42bb-a57c-7cb872b83146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ae82aeea-f84b-4d43-abaa-dfd563735a06" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c64e028e-ca64-42bb-a57c-7cb872b83146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6fabf9dd-e85f-4493-84ae-5628dce713bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c64e028e-ca64-42bb-a57c-7cb872b83146" xlink:to="loc_us-gaap_EquityComponentDomain_6fabf9dd-e85f-4493-84ae-5628dce713bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c309d383-4e3e-4c93-9bce-05f5c449191d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6fabf9dd-e85f-4493-84ae-5628dce713bf" xlink:to="loc_us-gaap_CommonStockMember_c309d383-4e3e-4c93-9bce-05f5c449191d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_23be0558-24c9-4698-8ce8-39554866ec75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6fabf9dd-e85f-4493-84ae-5628dce713bf" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_23be0558-24c9-4698-8ce8-39554866ec75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_f3f207bc-03d6-454e-815a-7f9af835dd48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6fabf9dd-e85f-4493-84ae-5628dce713bf" xlink:to="loc_us-gaap_TreasuryStockMember_f3f207bc-03d6-454e-815a-7f9af835dd48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_67f500c4-cd77-41f7-9935-816658fd1e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6fabf9dd-e85f-4493-84ae-5628dce713bf" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_67f500c4-cd77-41f7-9935-816658fd1e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_b355760c-691a-48b4-9c38-1deca8c00d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6fabf9dd-e85f-4493-84ae-5628dce713bf" xlink:to="loc_us-gaap_RetainedEarningsMember_b355760c-691a-48b4-9c38-1deca8c00d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_4059e11f-bb52-428c-be6e-a880c74861c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6fabf9dd-e85f-4493-84ae-5628dce713bf" xlink:to="loc_us-gaap_NoncontrollingInterestMember_4059e11f-bb52-428c-be6e-a880c74861c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3e9bb752-66ff-4d1e-aa84-75738745cf4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ae82aeea-f84b-4d43-abaa-dfd563735a06" xlink:to="loc_us-gaap_StatementLineItems_3e9bb752-66ff-4d1e-aa84-75738745cf4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3e9bb752-66ff-4d1e-aa84-75738745cf4a" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_35fe633e-9f2d-4a86-ae27-fdf6500fa079" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_35fe633e-9f2d-4a86-ae27-fdf6500fa079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_8e16caa3-7bc5-4790-a21d-1d5c8c084b21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_us-gaap_SharesOutstanding_8e16caa3-7bc5-4790-a21d-1d5c8c084b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_e7d91f5a-771a-4e72-8628-d6830d391fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_e7d91f5a-771a-4e72-8628-d6830d391fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e13106a3-6a36-42e1-b1ce-88a097ca8362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e13106a3-6a36-42e1-b1ce-88a097ca8362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_870589b8-9f30-468b-ab9f-1681b71ae57e" xlink:href="amed-20221231.xsd#amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_870589b8-9f30-468b-ab9f-1681b71ae57e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_a2d16f35-09b5-401c-979a-f28010f3e35e" xlink:href="amed-20221231.xsd#amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_a2d16f35-09b5-401c-979a-f28010f3e35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_b0d03062-3ac0-4a2a-9ca1-d44c826c764b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_b0d03062-3ac0-4a2a-9ca1-d44c826c764b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_38364dd0-5ae1-409b-b833-c579f35b42ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_38364dd0-5ae1-409b-b833-c579f35b42ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_26d93df6-a3d4-4330-9a00-61905c4189b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_26d93df6-a3d4-4330-9a00-61905c4189b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c802017c-21a0-4737-9c8e-36752d621dea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c802017c-21a0-4737-9c8e-36752d621dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f467614b-90db-491f-b8a9-8a7cab4e9825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f467614b-90db-491f-b8a9-8a7cab4e9825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SurrenderedShares_55fac99e-397f-484a-b9e0-a05d1fb3716f" xlink:href="amed-20221231.xsd#amed_SurrenderedShares"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_amed_SurrenderedShares_55fac99e-397f-484a-b9e0-a05d1fb3716f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_6c10458f-e65e-4695-a3fe-7d0a78777a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_6c10458f-e65e-4695-a3fe-7d0a78777a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ContributionsAttributableToNoncontrollingInterest_96706a6d-3d34-41f2-9b1f-532791f0bb76" xlink:href="amed-20221231.xsd#amed_ContributionsAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_amed_ContributionsAttributableToNoncontrollingInterest_96706a6d-3d34-41f2-9b1f-532791f0bb76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_0e3e9da6-5039-4949-a185-d155e58984b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_0e3e9da6-5039-4949-a185-d155e58984b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_0bbebe9a-2dfa-4e8c-ac49-a5310ea04695" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_0bbebe9a-2dfa-4e8c-ac49-a5310ea04695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_a66ee0ec-75a1-4a46-92d0-20df06bd16d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_a66ee0ec-75a1-4a46-92d0-20df06bd16d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome_c9e7ccc3-acbe-4ce7-afec-2ada73ff8234" xlink:href="amed-20221231.xsd#amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome_c9e7ccc3-acbe-4ce7-afec-2ada73ff8234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4087b066-8879-412e-9447-ba32f2c1758c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_us-gaap_ProfitLoss_4087b066-8879-412e-9447-ba32f2c1758c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cdd1f8e4-0ad7-439a-a4ca-c2d96c161487" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cdd1f8e4-0ad7-439a-a4ca-c2d96c161487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_6233c9f6-6bfd-4558-bb36-2b6e609a382a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3c9eaaa6-8a64-4b3b-bc01-fd07bed46f7f" xlink:to="loc_us-gaap_SharesOutstanding_6233c9f6-6bfd-4558-bb36-2b6e609a382a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="amed-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_78c206a0-8948-47c2-99be-70b11addc80d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_41d8d61c-0fb4-4547-b583-a9bad2bad922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_78c206a0-8948-47c2-99be-70b11addc80d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_41d8d61c-0fb4-4547-b583-a9bad2bad922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_62b089ce-85b5-499b-a1ab-2f15338918e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_41d8d61c-0fb4-4547-b583-a9bad2bad922" xlink:to="loc_us-gaap_ProfitLoss_62b089ce-85b5-499b-a1ab-2f15338918e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c704bbb3-8269-4909-806a-a52d08287ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_41d8d61c-0fb4-4547-b583-a9bad2bad922" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c704bbb3-8269-4909-806a-a52d08287ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ab18da91-37e0-438a-80c2-4353f6c7786c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c704bbb3-8269-4909-806a-a52d08287ddb" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ab18da91-37e0-438a-80c2-4353f6c7786c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7926855e-ac13-4e8d-9a61-9f2fc27404af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c704bbb3-8269-4909-806a-a52d08287ddb" xlink:to="loc_us-gaap_ShareBasedCompensation_7926855e-ac13-4e8d-9a61-9f2fc27404af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset_5ab7c3c7-c2c3-4cd6-8538-ae70e245aa3b" xlink:href="amed-20221231.xsd#amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c704bbb3-8269-4909-806a-a52d08287ddb" xlink:to="loc_amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset_5ab7c3c7-c2c3-4cd6-8538-ae70e245aa3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1b39b9e5-543e-40f7-befb-3e44e27b3c28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c704bbb3-8269-4909-806a-a52d08287ddb" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1b39b9e5-543e-40f7-befb-3e44e27b3c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_d3a051c6-5182-4a5f-a7db-055a22cf9d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c704bbb3-8269-4909-806a-a52d08287ddb" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_d3a051c6-5182-4a5f-a7db-055a22cf9d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WriteOffOfOtherComprehensiveIncome_9d8eb692-6e3a-4d92-8fa8-ecad597ba7ec" xlink:href="amed-20221231.xsd#amed_WriteOffOfOtherComprehensiveIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c704bbb3-8269-4909-806a-a52d08287ddb" xlink:to="loc_amed_WriteOffOfOtherComprehensiveIncome_9d8eb692-6e3a-4d92-8fa8-ecad597ba7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_473c51e1-3dc0-4bb8-a1a2-e7dd1a84e636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c704bbb3-8269-4909-806a-a52d08287ddb" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_473c51e1-3dc0-4bb8-a1a2-e7dd1a84e636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fdb0b31a-4866-44d5-9a67-ff47e04be0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c704bbb3-8269-4909-806a-a52d08287ddb" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fdb0b31a-4866-44d5-9a67-ff47e04be0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_14968aa0-414d-4ae6-914b-09a3911dd50f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c704bbb3-8269-4909-806a-a52d08287ddb" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_14968aa0-414d-4ae6-914b-09a3911dd50f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_4acd067e-5c4b-4c3b-861b-f5bc9da31503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c704bbb3-8269-4909-806a-a52d08287ddb" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_4acd067e-5c4b-4c3b-861b-f5bc9da31503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_e437df4d-3626-4714-b3f5-c51d485d7181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c704bbb3-8269-4909-806a-a52d08287ddb" xlink:to="loc_us-gaap_AssetImpairmentCharges_e437df4d-3626-4714-b3f5-c51d485d7181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ba8a549f-8ef4-4832-8e38-0fa800b5ec4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c704bbb3-8269-4909-806a-a52d08287ddb" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ba8a549f-8ef4-4832-8e38-0fa800b5ec4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_98aa0866-a029-47f9-a5d3-1f34f3ab5f96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ba8a549f-8ef4-4832-8e38-0fa800b5ec4d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_98aa0866-a029-47f9-a5d3-1f34f3ab5f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d52d5cf7-fa90-4de0-9967-7db3fbbf1d67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ba8a549f-8ef4-4832-8e38-0fa800b5ec4d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d52d5cf7-fa90-4de0-9967-7db3fbbf1d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a98de8a1-0f40-44bc-8801-aa67895b19f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ba8a549f-8ef4-4832-8e38-0fa800b5ec4d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a98de8a1-0f40-44bc-8801-aa67895b19f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_3d4d475e-4d9f-461f-922c-74d7653fcd52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ba8a549f-8ef4-4832-8e38-0fa800b5ec4d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_3d4d475e-4d9f-461f-922c-74d7653fcd52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_5f8094fc-4e8a-46eb-b599-5a1665354847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ba8a549f-8ef4-4832-8e38-0fa800b5ec4d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_5f8094fc-4e8a-46eb-b599-5a1665354847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_67a762ea-f274-47b9-bcff-a5859132ff3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ba8a549f-8ef4-4832-8e38-0fa800b5ec4d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_67a762ea-f274-47b9-bcff-a5859132ff3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_b4a5ea6f-bfe4-489a-8042-7599f33964e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ba8a549f-8ef4-4832-8e38-0fa800b5ec4d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_b4a5ea6f-bfe4-489a-8042-7599f33964e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_7a3a3d76-28d4-4c80-ae74-93449b0fc2a7" xlink:href="amed-20221231.xsd#amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ba8a549f-8ef4-4832-8e38-0fa800b5ec4d" xlink:to="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_7a3a3d76-28d4-4c80-ae74-93449b0fc2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa092abc-70aa-4330-a71d-e8601254455e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_41d8d61c-0fb4-4547-b583-a9bad2bad922" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa092abc-70aa-4330-a71d-e8601254455e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_756d41b8-f5e0-4310-8aaf-5503d4757bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_78c206a0-8948-47c2-99be-70b11addc80d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_756d41b8-f5e0-4310-8aaf-5503d4757bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_adf1c10f-76c7-4570-ab2b-67fa0097d6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_756d41b8-f5e0-4310-8aaf-5503d4757bc4" xlink:to="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_adf1c10f-76c7-4570-ab2b-67fa0097d6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2ed9c3d8-73ec-4dfe-a10c-b9b693859654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_756d41b8-f5e0-4310-8aaf-5503d4757bc4" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2ed9c3d8-73ec-4dfe-a10c-b9b693859654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ae18f4e8-542b-4cf9-9e4b-f82637d6c903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_756d41b8-f5e0-4310-8aaf-5503d4757bc4" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ae18f4e8-542b-4cf9-9e4b-f82637d6c903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToDevelopSoftware_8bdfba7f-40a3-487d-a061-8762a6f20990" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToDevelopSoftware"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_756d41b8-f5e0-4310-8aaf-5503d4757bc4" xlink:to="loc_us-gaap_PaymentsToDevelopSoftware_8bdfba7f-40a3-487d-a061-8762a6f20990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_04d25afa-a155-45f0-99ef-ce84a67d0f42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_756d41b8-f5e0-4310-8aaf-5503d4757bc4" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_04d25afa-a155-45f0-99ef-ce84a67d0f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_2c4b1fa9-7ef0-470b-b7aa-55d78ebb0479" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_756d41b8-f5e0-4310-8aaf-5503d4757bc4" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_2c4b1fa9-7ef0-470b-b7aa-55d78ebb0479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_52492a31-b446-442a-b93d-c025c34a0ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_756d41b8-f5e0-4310-8aaf-5503d4757bc4" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_52492a31-b446-442a-b93d-c025c34a0ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0f640568-39ff-45ae-80ad-1166b18a7b02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_756d41b8-f5e0-4310-8aaf-5503d4757bc4" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0f640568-39ff-45ae-80ad-1166b18a7b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6cdd2928-7f40-43f1-a24d-6dd2b33bde3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_756d41b8-f5e0-4310-8aaf-5503d4757bc4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6cdd2928-7f40-43f1-a24d-6dd2b33bde3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bedf7001-94da-4e00-99cc-840c1b97a3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_78c206a0-8948-47c2-99be-70b11addc80d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bedf7001-94da-4e00-99cc-840c1b97a3d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_26539d7f-cd37-4c90-b4d8-7c0b9a0987fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bedf7001-94da-4e00-99cc-840c1b97a3d6" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_26539d7f-cd37-4c90-b4d8-7c0b9a0987fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_e48121cf-8312-4dcd-af0c-09b953ec598c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bedf7001-94da-4e00-99cc-840c1b97a3d6" xlink:to="loc_us-gaap_ProceedsFromStockPlans_e48121cf-8312-4dcd-af0c-09b953ec598c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4bda27f2-1e3e-48f0-9c52-4a1bc3592f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bedf7001-94da-4e00-99cc-840c1b97a3d6" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4bda27f2-1e3e-48f0-9c52-4a1bc3592f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashContributionToNoncontrollingInterest_2c6b6a2f-050a-48a9-804a-e5e11bd00811" xlink:href="amed-20221231.xsd#amed_CashContributionToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bedf7001-94da-4e00-99cc-840c1b97a3d6" xlink:to="loc_amed_CashContributionToNoncontrollingInterest_2c6b6a2f-050a-48a9-804a-e5e11bd00811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashDistributionToNoncontrollingInterest_795c07ce-b6ec-491a-8351-d7a0ddd09b82" xlink:href="amed-20221231.xsd#amed_CashDistributionToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bedf7001-94da-4e00-99cc-840c1b97a3d6" xlink:to="loc_amed_CashDistributionToNoncontrollingInterest_795c07ce-b6ec-491a-8351-d7a0ddd09b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_335549b8-0e53-4f22-a5b1-5e31ff1f7d16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bedf7001-94da-4e00-99cc-840c1b97a3d6" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_335549b8-0e53-4f22-a5b1-5e31ff1f7d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProceedsFromBorrowingsUnderTermLoan_eb693ddb-17fb-49d7-84f6-285e35fd151c" xlink:href="amed-20221231.xsd#amed_ProceedsFromBorrowingsUnderTermLoan"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bedf7001-94da-4e00-99cc-840c1b97a3d6" xlink:to="loc_amed_ProceedsFromBorrowingsUnderTermLoan_eb693ddb-17fb-49d7-84f6-285e35fd151c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_edb3c614-57f3-4f1a-86ab-ee150e57ce04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bedf7001-94da-4e00-99cc-840c1b97a3d6" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_edb3c614-57f3-4f1a-86ab-ee150e57ce04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_b6814afe-741a-4ee2-bf08-4833f61f083c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bedf7001-94da-4e00-99cc-840c1b97a3d6" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_b6814afe-741a-4ee2-bf08-4833f61f083c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_12c3e46a-7e56-4d56-81ca-3b895562bbb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bedf7001-94da-4e00-99cc-840c1b97a3d6" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_12c3e46a-7e56-4d56-81ca-3b895562bbb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_4a5bf237-e5dc-4666-a0e0-70d605ec5bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bedf7001-94da-4e00-99cc-840c1b97a3d6" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_4a5bf237-e5dc-4666-a0e0-70d605ec5bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundsReceivedFromProviderReliefFundAdvance_5ce5ac04-6d37-4729-a038-582eb7ccbb3c" xlink:href="amed-20221231.xsd#amed_FundsReceivedFromProviderReliefFundAdvance"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bedf7001-94da-4e00-99cc-840c1b97a3d6" xlink:to="loc_amed_FundsReceivedFromProviderReliefFundAdvance_5ce5ac04-6d37-4729-a038-582eb7ccbb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3de68464-922d-4d7a-b626-9410ba8fdd2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bedf7001-94da-4e00-99cc-840c1b97a3d6" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3de68464-922d-4d7a-b626-9410ba8fdd2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_e1c51812-525c-4f10-ae08-b18436d7fa5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bedf7001-94da-4e00-99cc-840c1b97a3d6" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_e1c51812-525c-4f10-ae08-b18436d7fa5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0244bb91-bf61-4987-8191-0e642eedb3c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bedf7001-94da-4e00-99cc-840c1b97a3d6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0244bb91-bf61-4987-8191-0e642eedb3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_13d3701a-d24e-4776-a19a-b71cb510b8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_78c206a0-8948-47c2-99be-70b11addc80d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_13d3701a-d24e-4776-a19a-b71cb510b8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_baa4259f-2700-4b6a-9f24-3ace0366e693" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_78c206a0-8948-47c2-99be-70b11addc80d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_baa4259f-2700-4b6a-9f24-3ace0366e693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f08dd8a8-9867-4943-858c-e1f0b49e84c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_78c206a0-8948-47c2-99be-70b11addc80d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f08dd8a8-9867-4943-858c-e1f0b49e84c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_6e7fbcf8-ae6e-4531-b709-a93178365f00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_78c206a0-8948-47c2-99be-70b11addc80d" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_6e7fbcf8-ae6e-4531-b709-a93178365f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_d604fce5-ad6d-4ce8-a414-f75003623b92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6e7fbcf8-ae6e-4531-b709-a93178365f00" xlink:to="loc_us-gaap_InterestPaidNet_d604fce5-ad6d-4ce8-a414-f75003623b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashPaidForInfinityZPICInterest_45b88fb2-0ed3-4543-8297-4cf1106d434e" xlink:href="amed-20221231.xsd#amed_CashPaidForInfinityZPICInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6e7fbcf8-ae6e-4531-b709-a93178365f00" xlink:to="loc_amed_CashPaidForInfinityZPICInterest_45b88fb2-0ed3-4543-8297-4cf1106d434e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_b3990b48-f4f9-4203-80dc-b84649dc6e66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6e7fbcf8-ae6e-4531-b709-a93178365f00" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_b3990b48-f4f9-4203-80dc-b84649dc6e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonCashAccruedContingentConsideration_8ef02584-c4b1-42d8-aae5-fca69475c51e" xlink:href="amed-20221231.xsd#amed_NonCashAccruedContingentConsideration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6e7fbcf8-ae6e-4531-b709-a93178365f00" xlink:to="loc_amed_NonCashAccruedContingentConsideration_8ef02584-c4b1-42d8-aae5-fca69475c51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonCashNoncontrollingInterestContribution_a8d2d194-551e-478e-b806-05860f0fbef8" xlink:href="amed-20221231.xsd#amed_NonCashNoncontrollingInterestContribution"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6e7fbcf8-ae6e-4531-b709-a93178365f00" xlink:to="loc_amed_NonCashNoncontrollingInterestContribution_a8d2d194-551e-478e-b806-05860f0fbef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS" xlink:type="simple" xlink:href="amed-20221231.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_55f3f0cd-dfd7-4a0c-8b99-5a39dcb510bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_08efbefe-0b12-47a8-a2da-30e3c2a2a2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_55f3f0cd-dfd7-4a0c-8b99-5a39dcb510bd" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_08efbefe-0b12-47a8-a2da-30e3c2a2a2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="amed-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5c2401fd-fd5a-427e-b7c2-0da745607658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4db8e5dc-7fbe-4623-9124-2b8df803e1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5c2401fd-fd5a-427e-b7c2-0da745607658" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4db8e5dc-7fbe-4623-9124-2b8df803e1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19" xlink:type="simple" xlink:href="amed-20221231.xsd#NOVELCORONAVIRUSPANDEMICCOVID19"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_6db44b32-01ee-4c71-afce-4daadba5c873" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtraordinaryAndUnusualItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19TextBlock_5f9413b0-4614-448a-890a-d64a66cc26ce" xlink:href="amed-20221231.xsd#amed_COVID19TextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_6db44b32-01ee-4c71-afce-4daadba5c873" xlink:to="loc_amed_COVID19TextBlock_5f9413b0-4614-448a-890a-d64a66cc26ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONS" xlink:type="simple" xlink:href="amed-20221231.xsd#ACQUISITIONS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_9bbad54d-a40c-4db9-b614-9ed1ba8a956b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_f2da215e-834f-48d7-be6f-8d9abdd92252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_9bbad54d-a40c-4db9-b614-9ed1ba8a956b" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_f2da215e-834f-48d7-be6f-8d9abdd92252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET" xlink:type="simple" xlink:href="amed-20221231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSNET"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_64c22a3a-bde6-4f4d-be8a-4e43bf4465f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_e3b38a4e-b2d9-4b35-99a6-4999d9ae6d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_64c22a3a-bde6-4f4d-be8a-4e43bf4465f9" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_e3b38a4e-b2d9-4b35-99a6-4999d9ae6d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ASSETSHELDFORSALE" xlink:type="simple" xlink:href="amed-20221231.xsd#ASSETSHELDFORSALE"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ASSETSHELDFORSALE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_a12878d6-5636-4580-8abf-dd5cae70c827" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_94779467-48db-47df-a503-c8c139613d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_a12878d6-5636-4580-8abf-dd5cae70c827" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_94779467-48db-47df-a503-c8c139613d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTS" xlink:type="simple" xlink:href="amed-20221231.xsd#DETAILSOFCERTAINBALANCESHEETACCOUNTS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_amed_DetailsOfCertainBalanceSheetAccountsAbstract_da29d450-997f-4f7e-8987-30960a1a5841" xlink:href="amed-20221231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock_41df5074-e297-4b22-80e4-56b08a1ead61" xlink:href="amed-20221231.xsd#amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DetailsOfCertainBalanceSheetAccountsAbstract_da29d450-997f-4f7e-8987-30960a1a5841" xlink:to="loc_amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock_41df5074-e297-4b22-80e4-56b08a1ead61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASES" xlink:type="simple" xlink:href="amed-20221231.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9cecc0a5-389b-4961-bad2-227df7ae8202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LesseeLeasesTextBlock_6b354e2c-f9c8-4741-be6f-6fd73cf402b5" xlink:href="amed-20221231.xsd#amed_LesseeLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9cecc0a5-389b-4961-bad2-227df7ae8202" xlink:to="loc_amed_LesseeLeasesTextBlock_6b354e2c-f9c8-4741-be6f-6fd73cf402b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONS" xlink:type="simple" xlink:href="amed-20221231.xsd#LONGTERMOBLIGATIONS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_83e7e767-0c27-4af7-a75f-cb6091148fee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_20ffab01-0da6-4670-8441-367621acd55e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_83e7e767-0c27-4af7-a75f-cb6091148fee" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_20ffab01-0da6-4670-8441-367621acd55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXES" xlink:type="simple" xlink:href="amed-20221231.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bb27e2d7-dd35-49ae-b2f1-6cf0b97b2326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_e4d6250d-8113-4826-b5c8-6120f3cb0f31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bb27e2d7-dd35-49ae-b2f1-6cf0b97b2326" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_e4d6250d-8113-4826-b5c8-6120f3cb0f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATION" xlink:type="simple" xlink:href="amed-20221231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_417a9937-7272-4acd-8804-a9b0285a64a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5500a52e-5fb5-4180-af9b-3d5cb1df056b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_417a9937-7272-4acd-8804-a9b0285a64a5" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5500a52e-5fb5-4180-af9b-3d5cb1df056b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="amed-20221231.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f217c150-0b2c-4879-9729-42128e45a336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d776c60b-eadc-4e39-8693-bce22f790846" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f217c150-0b2c-4879-9729-42128e45a336" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d776c60b-eadc-4e39-8693-bce22f790846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/EMPLOYEEBENEFITPLANS" xlink:type="simple" xlink:href="amed-20221231.xsd#EMPLOYEEBENEFITPLANS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/EMPLOYEEBENEFITPLANS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4bac2a63-febc-4a75-9781-7ef059f9f80b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_0636272c-b09e-44c3-a8c4-980593209e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4bac2a63-febc-4a75-9781-7ef059f9f80b" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_0636272c-b09e-44c3-a8c4-980593209e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SHAREREPURCHASE" xlink:type="simple" xlink:href="amed-20221231.xsd#SHAREREPURCHASE"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SHAREREPURCHASE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_50ffffe0-5769-48ab-ba4b-f6fbb5bb9fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockTextBlock_8b6ccc8e-ada8-4fc8-a1ec-5f6e719b4671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_50ffffe0-5769-48ab-ba4b-f6fbb5bb9fa3" xlink:to="loc_us-gaap_TreasuryStockTextBlock_8b6ccc8e-ada8-4fc8-a1ec-5f6e719b4671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATION" xlink:type="simple" xlink:href="amed-20221231.xsd#SEGMENTINFORMATION"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_d180587d-ec71-4a62-b95b-e5cd2615e6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_040d6d04-6196-47e6-b9d0-fb5c39b2a3a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d180587d-ec71-4a62-b95b-e5cd2615e6cc" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_040d6d04-6196-47e6-b9d0-fb5c39b2a3a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="amed-20221231.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_c3eee71c-8b38-4109-9893-bd17751a060e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_8154829d-fb9c-4a77-91cc-9e62dbed1b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_c3eee71c-8b38-4109-9893-bd17751a060e" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_8154829d-fb9c-4a77-91cc-9e62dbed1b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="amed-20221231.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_4f4f5480-8a98-4978-9a36-6ece458cd839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_410d75e0-07f5-4d17-9f4b-04542e9235a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_4f4f5480-8a98-4978-9a36-6ece458cd839" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_410d75e0-07f5-4d17-9f4b-04542e9235a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/OrganizationConsolidationandPresentationofFinancialStatementsPolicies" xlink:type="simple" xlink:href="amed-20221231.xsd#OrganizationConsolidationandPresentationofFinancialStatementsPolicies"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/OrganizationConsolidationandPresentationofFinancialStatementsPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f34f00f0-9ea0-4803-93fa-59b1f4547f24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="amed-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8f687527-cd70-4777-8ee0-42859b8125eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b7f5995e-aa7c-4ed6-b0ca-24e0ae4f6556" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f687527-cd70-4777-8ee0-42859b8125eb" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b7f5995e-aa7c-4ed6-b0ca-24e0ae4f6556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_160e7cf5-e9b5-4109-993e-604455e8dfa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f687527-cd70-4777-8ee0-42859b8125eb" xlink:to="loc_us-gaap_UseOfEstimates_160e7cf5-e9b5-4109-993e-604455e8dfa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_68e4b7a1-422d-4804-ad60-3197551750bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f687527-cd70-4777-8ee0-42859b8125eb" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_68e4b7a1-422d-4804-ad60-3197551750bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_fd18ed9d-7963-47db-ba4e-4cabce27befc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f687527-cd70-4777-8ee0-42859b8125eb" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_fd18ed9d-7963-47db-ba4e-4cabce27befc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_c5ca0fc1-b250-4172-83e0-c9edce6f2541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f687527-cd70-4777-8ee0-42859b8125eb" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_c5ca0fc1-b250-4172-83e0-c9edce6f2541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_GovernmentGrantsPolicyTextBlock_237a3faa-68d4-4671-832c-6646ed88f6a3" xlink:href="amed-20221231.xsd#amed_GovernmentGrantsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f687527-cd70-4777-8ee0-42859b8125eb" xlink:to="loc_amed_GovernmentGrantsPolicyTextBlock_237a3faa-68d4-4671-832c-6646ed88f6a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_807a9a93-b155-4dc8-8579-b039116f7c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f687527-cd70-4777-8ee0-42859b8125eb" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_807a9a93-b155-4dc8-8579-b039116f7c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_75c7588c-b4e9-4e94-9208-cc3c03e886ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f687527-cd70-4777-8ee0-42859b8125eb" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_75c7588c-b4e9-4e94-9208-cc3c03e886ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_5fd56dbc-f862-4bc4-8979-f6f9a8761ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f687527-cd70-4777-8ee0-42859b8125eb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_5fd56dbc-f862-4bc4-8979-f6f9a8761ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_06ed01ca-fea6-4f8e-b774-f9b58bb95e86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f687527-cd70-4777-8ee0-42859b8125eb" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_06ed01ca-fea6-4f8e-b774-f9b58bb95e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_6813013d-6b30-413f-87fc-ce2a67690dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f687527-cd70-4777-8ee0-42859b8125eb" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_6813013d-6b30-413f-87fc-ce2a67690dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtIssuanceCostsPolicyPolicyTextBlock_a86b4c68-f7fb-4033-8cf0-341fd2e81dab" xlink:href="amed-20221231.xsd#amed_DebtIssuanceCostsPolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f687527-cd70-4777-8ee0-42859b8125eb" xlink:to="loc_amed_DebtIssuanceCostsPolicyPolicyTextBlock_a86b4c68-f7fb-4033-8cf0-341fd2e81dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_2da6a693-c335-4e52-898a-9feda36a4961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f687527-cd70-4777-8ee0-42859b8125eb" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_2da6a693-c335-4e52-898a-9feda36a4961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_0ae2b6f2-7488-4f74-b0b9-48d756aa9bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f687527-cd70-4777-8ee0-42859b8125eb" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_0ae2b6f2-7488-4f74-b0b9-48d756aa9bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_eab6c8cc-009e-43d5-90bd-11a547b66fae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f687527-cd70-4777-8ee0-42859b8125eb" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_eab6c8cc-009e-43d5-90bd-11a547b66fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_1ba42eb6-36ee-4209-9b8f-0879e2c65c40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f687527-cd70-4777-8ee0-42859b8125eb" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_1ba42eb6-36ee-4209-9b8f-0879e2c65c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_2e3669c0-dcdb-4f97-be47-e0bcb122ff4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8f687527-cd70-4777-8ee0-42859b8125eb" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_2e3669c0-dcdb-4f97-be47-e0bcb122ff4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LeasesCodificationTopic842Policies" xlink:type="simple" xlink:href="amed-20221231.xsd#LeasesCodificationTopic842Policies"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LeasesCodificationTopic842Policies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_19fddaec-9b3f-4d25-9ab2-2e9a207aa3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSTables" xlink:type="simple" xlink:href="amed-20221231.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4905492f-21b3-4e1c-81b6-3979d697e8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_973a2e4c-b09f-4347-9a19-1765385120ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4905492f-21b3-4e1c-81b6-3979d697e8e7" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_973a2e4c-b09f-4347-9a19-1765385120ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="amed-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6a8b0d07-f6dc-4f85-97ae-b5fb124cc01d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_338a843d-0af6-4cc8-ab81-3d13bccc2574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a8b0d07-f6dc-4f85-97ae-b5fb124cc01d" xlink:to="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_338a843d-0af6-4cc8-ab81-3d13bccc2574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_fc473efe-bfb9-46a9-9b91-3f6175c159f0" xlink:href="amed-20221231.xsd#amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a8b0d07-f6dc-4f85-97ae-b5fb124cc01d" xlink:to="loc_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_fc473efe-bfb9-46a9-9b91-3f6175c159f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock_297abaf5-ae95-4e79-b1c3-0aad70867bf0" xlink:href="amed-20221231.xsd#amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a8b0d07-f6dc-4f85-97ae-b5fb124cc01d" xlink:to="loc_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock_297abaf5-ae95-4e79-b1c3-0aad70867bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_847a4954-1a11-48dc-b0f9-f748a6af5597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a8b0d07-f6dc-4f85-97ae-b5fb124cc01d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_847a4954-1a11-48dc-b0f9-f748a6af5597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FinancialInstrumentDetailsTableTextBlock_1414e9d8-e9b4-4b60-b3c9-f356e6efb793" xlink:href="amed-20221231.xsd#amed_FinancialInstrumentDetailsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a8b0d07-f6dc-4f85-97ae-b5fb124cc01d" xlink:to="loc_amed_FinancialInstrumentDetailsTableTextBlock_1414e9d8-e9b4-4b60-b3c9-f356e6efb793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_126a3963-343e-4416-a546-b41ed60c0b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a8b0d07-f6dc-4f85-97ae-b5fb124cc01d" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_126a3963-343e-4416-a546-b41ed60c0b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables" xlink:type="simple" xlink:href="amed-20221231.xsd#NOVELCORONAVIRUSPANDEMICCOVID19Tables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_380f0897-630a-41ea-8930-c4feecba7126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtraordinaryAndUnusualItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock_65d148d2-6275-4950-be7e-64a67eea5020" xlink:href="amed-20221231.xsd#amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_380f0897-630a-41ea-8930-c4feecba7126" xlink:to="loc_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock_65d148d2-6275-4950-be7e-64a67eea5020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSTables" xlink:type="simple" xlink:href="amed-20221231.xsd#ACQUISITIONSTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_249a016f-12a1-4b20-8ee5-c7fe36b1d9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfBusinessAcquisitionsContessaHealthTableTextBlock_37218bd2-8a58-4517-90ac-9a6b4ebd93fe" xlink:href="amed-20221231.xsd#amed_ScheduleOfBusinessAcquisitionsContessaHealthTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_249a016f-12a1-4b20-8ee5-c7fe36b1d9c0" xlink:to="loc_amed_ScheduleOfBusinessAcquisitionsContessaHealthTableTextBlock_37218bd2-8a58-4517-90ac-9a6b4ebd93fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock_3a5e7eba-5a96-4f27-9562-1e890c48eedb" xlink:href="amed-20221231.xsd#amed_ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_249a016f-12a1-4b20-8ee5-c7fe36b1d9c0" xlink:to="loc_amed_ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock_3a5e7eba-5a96-4f27-9562-1e890c48eedb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock_a49ee405-d3d3-4e73-badd-63fe68305877" xlink:href="amed-20221231.xsd#amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_249a016f-12a1-4b20-8ee5-c7fe36b1d9c0" xlink:to="loc_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock_a49ee405-d3d3-4e73-badd-63fe68305877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionProFormaInformationAseraCareTableTextBlock_c04aff8f-a3e1-4822-a868-b525e13b6051" xlink:href="amed-20221231.xsd#amed_BusinessAcquisitionProFormaInformationAseraCareTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_249a016f-12a1-4b20-8ee5-c7fe36b1d9c0" xlink:to="loc_amed_BusinessAcquisitionProFormaInformationAseraCareTableTextBlock_c04aff8f-a3e1-4822-a868-b525e13b6051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock_5aa859d4-850c-4ea2-81b7-837ef0f9e0de" xlink:href="amed-20221231.xsd#amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_249a016f-12a1-4b20-8ee5-c7fe36b1d9c0" xlink:to="loc_amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock_5aa859d4-850c-4ea2-81b7-837ef0f9e0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETTables" xlink:type="simple" xlink:href="amed-20221231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSNETTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1e7770ea-ec27-4f67-b1ee-a444f2b9a50d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_938f0a82-ce7c-4d37-8bdc-ecdb8a4defaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1e7770ea-ec27-4f67-b1ee-a444f2b9a50d" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_938f0a82-ce7c-4d37-8bdc-ecdb8a4defaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_94dff3b3-42a5-4e9a-bdb1-8baaab94480c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1e7770ea-ec27-4f67-b1ee-a444f2b9a50d" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_94dff3b3-42a5-4e9a-bdb1-8baaab94480c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ASSETSHELDFORSALETables" xlink:type="simple" xlink:href="amed-20221231.xsd#ASSETSHELDFORSALETables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ASSETSHELDFORSALETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_099e4657-c7ad-4384-88c7-55d0548007c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_c2e1efcb-1e59-47ea-bc66-e195edfa787e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_099e4657-c7ad-4384-88c7-55d0548007c7" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_c2e1efcb-1e59-47ea-bc66-e195edfa787e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSTables" xlink:type="simple" xlink:href="amed-20221231.xsd#DETAILSOFCERTAINBALANCESHEETACCOUNTSTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_amed_DetailsOfCertainBalanceSheetAccountsAbstract_e4e8bbca-ba4f-4377-9f5c-6041224abe2c" xlink:href="amed-20221231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_fbdd3aa1-041e-4683-9233-6abe80eca55c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DetailsOfCertainBalanceSheetAccountsAbstract_e4e8bbca-ba4f-4377-9f5c-6041224abe2c" xlink:to="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_fbdd3aa1-041e-4683-9233-6abe80eca55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_4713bcbe-d28a-4d6b-9e09-43c37f9245d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DetailsOfCertainBalanceSheetAccountsAbstract_e4e8bbca-ba4f-4377-9f5c-6041224abe2c" xlink:to="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_4713bcbe-d28a-4d6b-9e09-43c37f9245d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_612a9987-99a8-4e13-b1a8-e673dc11d86d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DetailsOfCertainBalanceSheetAccountsAbstract_e4e8bbca-ba4f-4377-9f5c-6041224abe2c" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_612a9987-99a8-4e13-b1a8-e673dc11d86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock_48641a18-e116-4355-897f-7323e82bdc4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DetailsOfCertainBalanceSheetAccountsAbstract_e4e8bbca-ba4f-4377-9f5c-6041224abe2c" xlink:to="loc_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock_48641a18-e116-4355-897f-7323e82bdc4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASESTables" xlink:type="simple" xlink:href="amed-20221231.xsd#LEASESTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LEASESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_24b23149-d3d2-4144-b273-ca9228009ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_ac219ffd-1579-44c8-af82-b30a92569f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_24b23149-d3d2-4144-b273-ca9228009ed6" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_ac219ffd-1579-44c8-af82-b30a92569f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OperatingLeasesTableTextBlock_a6f1eff1-5600-4d0b-b9fb-14d7ade26a58" xlink:href="amed-20221231.xsd#amed_OperatingLeasesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_24b23149-d3d2-4144-b273-ca9228009ed6" xlink:to="loc_amed_OperatingLeasesTableTextBlock_a6f1eff1-5600-4d0b-b9fb-14d7ade26a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FinanceLeasesTableTextBlock_06fa0d51-0bbf-42fd-bb46-714bccda88a9" xlink:href="amed-20221231.xsd#amed_FinanceLeasesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_24b23149-d3d2-4144-b273-ca9228009ed6" xlink:to="loc_amed_FinanceLeasesTableTextBlock_06fa0d51-0bbf-42fd-bb46-714bccda88a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock_09087c33-6838-4206-b594-1c110d121b02" xlink:href="amed-20221231.xsd#amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_24b23149-d3d2-4144-b273-ca9228009ed6" xlink:to="loc_amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock_09087c33-6838-4206-b594-1c110d121b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock_7c0c0da2-bd47-4920-983a-7d38cfce1310" xlink:href="amed-20221231.xsd#amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_24b23149-d3d2-4144-b273-ca9228009ed6" xlink:to="loc_amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock_7c0c0da2-bd47-4920-983a-7d38cfce1310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LeaseLiabilityMaturityTableTextBlock_30481399-c941-4437-8787-eb97db0b4f21" xlink:href="amed-20221231.xsd#amed_LeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_24b23149-d3d2-4144-b273-ca9228009ed6" xlink:to="loc_amed_LeaseLiabilityMaturityTableTextBlock_30481399-c941-4437-8787-eb97db0b4f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSTables" xlink:type="simple" xlink:href="amed-20221231.xsd#LONGTERMOBLIGATIONSTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7da38d79-396d-4190-815b-b1eaa1786a67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_ac391857-f8b6-4ca3-a449-04561f39f272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7da38d79-396d-4190-815b-b1eaa1786a67" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_ac391857-f8b6-4ca3-a449-04561f39f272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_e3a4edab-ae3c-4608-95f1-5118ef6a93a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7da38d79-396d-4190-815b-b1eaa1786a67" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_e3a4edab-ae3c-4608-95f1-5118ef6a93a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_33bb6eed-23a6-4ae9-9022-c21ca8584f44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7da38d79-396d-4190-815b-b1eaa1786a67" xlink:to="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_33bb6eed-23a6-4ae9-9022-c21ca8584f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="amed-20221231.xsd#INCOMETAXESTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/INCOMETAXESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_01bd4ecb-7dee-43c2-8396-d1e1287d802d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProvisionforIncomeTaxesTableTextBlock_d129dc6d-9a3a-42be-a903-169435bafa02" xlink:href="amed-20221231.xsd#amed_ProvisionforIncomeTaxesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_01bd4ecb-7dee-43c2-8396-d1e1287d802d" xlink:to="loc_amed_ProvisionforIncomeTaxesTableTextBlock_d129dc6d-9a3a-42be-a903-169435bafa02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2079722b-29d9-482d-b46f-a14512853699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_01bd4ecb-7dee-43c2-8396-d1e1287d802d" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2079722b-29d9-482d-b46f-a14512853699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_26ad451a-451d-4ba6-b3ce-78887ab2eeba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_01bd4ecb-7dee-43c2-8396-d1e1287d802d" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_26ad451a-451d-4ba6-b3ce-78887ab2eeba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_39672edd-1c1e-4b05-b8fc-af100a2d9dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_01bd4ecb-7dee-43c2-8396-d1e1287d802d" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_39672edd-1c1e-4b05-b8fc-af100a2d9dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="amed-20221231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2658ab9e-c46d-4219-a329-c5112fef078e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_bc6aef79-abca-4f2b-a8ad-86234e2d6b54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2658ab9e-c46d-4219-a329-c5112fef078e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_bc6aef79-abca-4f2b-a8ad-86234e2d6b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ebfc4b93-a757-467d-8a87-f3222cf78d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2658ab9e-c46d-4219-a329-c5112fef078e" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ebfc4b93-a757-467d-8a87-f3222cf78d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3274d011-0bb0-4dd5-bee2-0cee1b67f1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2658ab9e-c46d-4219-a329-c5112fef078e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3274d011-0bb0-4dd5-bee2-0cee1b67f1a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SharedBasedPaymentArrangementNonVestedOptionActivityTableTextBlock_fef1162a-dba1-42b6-90bf-0eab89143bef" xlink:href="amed-20221231.xsd#amed_SharedBasedPaymentArrangementNonVestedOptionActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2658ab9e-c46d-4219-a329-c5112fef078e" xlink:to="loc_amed_SharedBasedPaymentArrangementNonVestedOptionActivityTableTextBlock_fef1162a-dba1-42b6-90bf-0eab89143bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_56f70797-1311-48d0-b88a-0a4c1cb50b70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2658ab9e-c46d-4219-a329-c5112fef078e" xlink:to="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_56f70797-1311-48d0-b88a-0a4c1cb50b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_9ab9c91b-198a-429f-9c90-53dde6f33dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2658ab9e-c46d-4219-a329-c5112fef078e" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_9ab9c91b-198a-429f-9c90-53dde6f33dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_d64d127c-76fd-4b16-b1d2-e0424f6350b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2658ab9e-c46d-4219-a329-c5112fef078e" xlink:to="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_d64d127c-76fd-4b16-b1d2-e0424f6350b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="simple" xlink:href="amed-20221231.xsd#COMMITMENTSANDCONTINGENCIESTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b63b4d99-81b1-425c-995c-8e0d662f54c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InsuranceProgramsTableTableTextBlock_9a43da03-72b3-4ced-9cc9-dd4f1a7d3407" xlink:href="amed-20221231.xsd#amed_InsuranceProgramsTableTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b63b4d99-81b1-425c-995c-8e0d662f54c2" xlink:to="loc_amed_InsuranceProgramsTableTableTextBlock_9a43da03-72b3-4ced-9cc9-dd4f1a7d3407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="amed-20221231.xsd#SEGMENTINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4a91db27-b384-43db-8a44-35600eaf8d03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_58d8831c-65d2-4978-9253-95e08daad77b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4a91db27-b384-43db-8a44-35600eaf8d03" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_58d8831c-65d2-4978-9253-95e08daad77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_20569662-4412-4664-ae6f-3b893e11c56c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OrganizationAndNatureOfOperationsTable_70977094-39e5-4c18-a119-c5ec1f7f551b" xlink:href="amed-20221231.xsd#amed_OrganizationAndNatureOfOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_20569662-4412-4664-ae6f-3b893e11c56c" xlink:to="loc_amed_OrganizationAndNatureOfOperationsTable_70977094-39e5-4c18-a119-c5ec1f7f551b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_d0be1aa3-e814-47c0-917a-dc0dc9597ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsTable_70977094-39e5-4c18-a119-c5ec1f7f551b" xlink:to="loc_us-gaap_InvestmentTypeAxis_d0be1aa3-e814-47c0-917a-dc0dc9597ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_24a68301-3342-44a2-ba99-05c2ee175f24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_d0be1aa3-e814-47c0-917a-dc0dc9597ed0" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_24a68301-3342-44a2-ba99-05c2ee175f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HeritageHealthcareInnovationFundLPMember_d8580f58-45a2-4114-9d2b-5152cef95619" xlink:href="amed-20221231.xsd#amed_HeritageHealthcareInnovationFundLPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_24a68301-3342-44a2-ba99-05c2ee175f24" xlink:to="loc_amed_HeritageHealthcareInnovationFundLPMember_d8580f58-45a2-4114-9d2b-5152cef95619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedalogixMember_6eb32fe8-20ef-4d28-a203-3a2049f3c847" xlink:href="amed-20221231.xsd#amed_MedalogixMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_24a68301-3342-44a2-ba99-05c2ee175f24" xlink:to="loc_amed_MedalogixMember_6eb32fe8-20ef-4d28-a203-3a2049f3c847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConnectRNMember_ee9bd3ee-7093-4dce-9f91-0dba946f81e6" xlink:href="amed-20221231.xsd#amed_ConnectRNMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_24a68301-3342-44a2-ba99-05c2ee175f24" xlink:to="loc_amed_ConnectRNMember_ee9bd3ee-7093-4dce-9f91-0dba946f81e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthBenefitManagerMember_f23aedc5-6357-4c7f-b0cd-c15163cc8756" xlink:href="amed-20221231.xsd#amed_HomeHealthBenefitManagerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_24a68301-3342-44a2-ba99-05c2ee175f24" xlink:to="loc_amed_HomeHealthBenefitManagerMember_f23aedc5-6357-4c7f-b0cd-c15163cc8756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d3c5827f-a82b-486c-b584-15eeda654671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsTable_70977094-39e5-4c18-a119-c5ec1f7f551b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d3c5827f-a82b-486c-b584-15eeda654671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f41611f3-d27c-4a3c-ba6f-292d891448e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d3c5827f-a82b-486c-b584-15eeda654671" xlink:to="loc_us-gaap_SegmentDomain_f41611f3-d27c-4a3c-ba6f-292d891448e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_e7aa03e6-269a-492e-b2bd-0f1ecdf226d1" xlink:href="amed-20221231.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f41611f3-d27c-4a3c-ba6f-292d891448e2" xlink:to="loc_amed_HomeHealthMember_e7aa03e6-269a-492e-b2bd-0f1ecdf226d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_f0c434ac-f020-4c04-9583-93cc4ed03258" xlink:href="amed-20221231.xsd#amed_HospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f41611f3-d27c-4a3c-ba6f-292d891448e2" xlink:to="loc_amed_HospiceMember_f0c434ac-f020-4c04-9583-93cc4ed03258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_2392ca54-967f-4002-9378-89e38fb5edbc" xlink:href="amed-20221231.xsd#amed_PersonalCareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f41611f3-d27c-4a3c-ba6f-292d891448e2" xlink:to="loc_amed_PersonalCareMember_2392ca54-967f-4002-9378-89e38fb5edbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_f33764ec-bea6-41dd-806d-ca09544007bd" xlink:href="amed-20221231.xsd#amed_HighAcuityCareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f41611f3-d27c-4a3c-ba6f-292d891448e2" xlink:to="loc_amed_HighAcuityCareMember_f33764ec-bea6-41dd-806d-ca09544007bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_669d3018-d48e-4617-ac9c-da5961261eea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsTable_70977094-39e5-4c18-a119-c5ec1f7f551b" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_669d3018-d48e-4617-ac9c-da5961261eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1cc2448c-59b5-49e0-9d33-9559f022aaf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_669d3018-d48e-4617-ac9c-da5961261eea" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1cc2448c-59b5-49e0-9d33-9559f022aaf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_63a0d1c3-7a2e-4249-b0fd-32f019870f95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1cc2448c-59b5-49e0-9d33-9559f022aaf8" xlink:to="loc_us-gaap_SalesRevenueNetMember_63a0d1c3-7a2e-4249-b0fd-32f019870f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_31d4c0c0-c3d1-49f8-a0a7-a0eb2dcc5860" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsTable_70977094-39e5-4c18-a119-c5ec1f7f551b" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_31d4c0c0-c3d1-49f8-a0a7-a0eb2dcc5860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_8efee37e-a777-4873-9a21-51d14d3fb8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_31d4c0c0-c3d1-49f8-a0a7-a0eb2dcc5860" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_8efee37e-a777-4873-9a21-51d14d3fb8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_4d1e10a2-fae1-434c-a332-7ab7a3448969" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_8efee37e-a777-4873-9a21-51d14d3fb8f4" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_4d1e10a2-fae1-434c-a332-7ab7a3448969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_791fe8c4-23b3-400a-b1f7-811bbde30465" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsTable_70977094-39e5-4c18-a119-c5ec1f7f551b" xlink:to="loc_srt_ConsolidatedEntitiesAxis_791fe8c4-23b3-400a-b1f7-811bbde30465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_9d0adbc5-3f12-4e1e-a7e0-932ee99d4fd2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_791fe8c4-23b3-400a-b1f7-811bbde30465" xlink:to="loc_srt_ConsolidatedEntitiesDomain_9d0adbc5-3f12-4e1e-a7e0-932ee99d4fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_704e7977-d1ba-488b-bee6-a4eba907b34c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_9d0adbc5-3f12-4e1e-a7e0-932ee99d4fd2" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_704e7977-d1ba-488b-bee6-a4eba907b34c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_74031307-5da1-48fe-bde5-ce67aa410555" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsTable_70977094-39e5-4c18-a119-c5ec1f7f551b" xlink:to="loc_srt_ProductOrServiceAxis_74031307-5da1-48fe-bde5-ce67aa410555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f23d09cb-a549-45a8-aab8-a6bc44dc7c56" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_74031307-5da1-48fe-bde5-ce67aa410555" xlink:to="loc_srt_ProductsAndServicesDomain_f23d09cb-a549-45a8-aab8-a6bc44dc7c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_965023ce-787f-47b8-acb4-efc8091314b1" xlink:href="amed-20221231.xsd#amed_MedicareRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f23d09cb-a549-45a8-aab8-a6bc44dc7c56" xlink:to="loc_amed_MedicareRevenueMember_965023ce-787f-47b8-acb4-efc8091314b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeOfEquityMethodInvestmentAxis_8c29759e-eb06-48b6-a1bc-c6917012cf6b" xlink:href="amed-20221231.xsd#amed_TypeOfEquityMethodInvestmentAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsTable_70977094-39e5-4c18-a119-c5ec1f7f551b" xlink:to="loc_amed_TypeOfEquityMethodInvestmentAxis_8c29759e-eb06-48b6-a1bc-c6917012cf6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeOfEquityMethodInvestmentDomain_9ffe3e0e-b762-43c8-ab61-644fb3315c3b" xlink:href="amed-20221231.xsd#amed_TypeOfEquityMethodInvestmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_TypeOfEquityMethodInvestmentAxis_8c29759e-eb06-48b6-a1bc-c6917012cf6b" xlink:to="loc_amed_TypeOfEquityMethodInvestmentDomain_9ffe3e0e-b762-43c8-ab61-644fb3315c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A30InterestSoldInTwoCareCentersMember_aedfd1cf-31cf-4605-a71a-23c4be516b30" xlink:href="amed-20221231.xsd#amed_A30InterestSoldInTwoCareCentersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_TypeOfEquityMethodInvestmentDomain_9ffe3e0e-b762-43c8-ab61-644fb3315c3b" xlink:to="loc_amed_A30InterestSoldInTwoCareCentersMember_aedfd1cf-31cf-4605-a71a-23c4be516b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A49InterestSoldInTwoCareCentersMember_0a614685-7e61-410a-9338-5f40f828cb08" xlink:href="amed-20221231.xsd#amed_A49InterestSoldInTwoCareCentersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_TypeOfEquityMethodInvestmentDomain_9ffe3e0e-b762-43c8-ab61-644fb3315c3b" xlink:to="loc_amed_A49InterestSoldInTwoCareCentersMember_0a614685-7e61-410a-9338-5f40f828cb08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedalogixMember_c1448a04-b5e9-4a0e-9933-a9cd55a67ba3" xlink:href="amed-20221231.xsd#amed_MedalogixMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_TypeOfEquityMethodInvestmentDomain_9ffe3e0e-b762-43c8-ab61-644fb3315c3b" xlink:to="loc_amed_MedalogixMember_c1448a04-b5e9-4a0e-9933-a9cd55a67ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_860b762a-e858-4449-9335-4582129a81ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsTable_70977094-39e5-4c18-a119-c5ec1f7f551b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_860b762a-e858-4449-9335-4582129a81ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5deda8b8-f0e1-428f-a20b-c495cd0b1c46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_860b762a-e858-4449-9335-4582129a81ab" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5deda8b8-f0e1-428f-a20b-c495cd0b1c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ContessaHealthMember_6da0fec1-7d6f-49de-b6ca-324f7e140353" xlink:href="amed-20221231.xsd#amed_ContessaHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5deda8b8-f0e1-428f-a20b-c495cd0b1c46" xlink:to="loc_amed_ContessaHealthMember_6da0fec1-7d6f-49de-b6ca-324f7e140353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:href="amed-20221231.xsd#amed_OrganizationAndNatureOfOperationsLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsTable_70977094-39e5-4c18-a119-c5ec1f7f551b" xlink:to="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_b79357fa-6148-478f-995b-26ceb66c1976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_b79357fa-6148-478f-995b-26ceb66c1976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OperatingCareCenters_e1aba56e-f7f0-4c49-89f7-6422324909a0" xlink:href="amed-20221231.xsd#amed_OperatingCareCenters"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_amed_OperatingCareCenters_e1aba56e-f7f0-4c49-89f7-6422324909a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_a6559c0a-68fd-4da1-90f3-247c2890154e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_a6559c0a-68fd-4da1-90f3-247c2890154e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MinimumPercentOwnershipForControllingInterestPercent_739e15dc-2cba-445f-9891-804242263882" xlink:href="amed-20221231.xsd#amed_MinimumPercentOwnershipForControllingInterestPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_amed_MinimumPercentOwnershipForControllingInterestPercent_739e15dc-2cba-445f-9891-804242263882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_0743fbc0-10bb-476b-9e44-6631c2384973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_0743fbc0-10bb-476b-9e44-6631c2384973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NoncontrollingInterestRepurchased_1d72a8a3-04ef-401f-b17c-4c81e93b5e0c" xlink:href="amed-20221231.xsd#amed_NoncontrollingInterestRepurchased"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_amed_NoncontrollingInterestRepurchased_1d72a8a3-04ef-401f-b17c-4c81e93b5e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForEquityMethodPercent_3712f89d-7cec-4dc9-8fe6-12a96420e7a0" xlink:href="amed-20221231.xsd#amed_MaximumPercentOwnershipForEquityMethodPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_amed_MaximumPercentOwnershipForEquityMethodPercent_3712f89d-7cec-4dc9-8fe6-12a96420e7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_fee736fa-167b-41d8-95e4-eeb5ed3214ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_fee736fa-167b-41d8-95e4-eeb5ed3214ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_9b9b960d-2708-425c-b074-dea09b321d39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_9b9b960d-2708-425c-b074-dea09b321d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForCostMethodPercent_ab53eae8-54cc-47d6-a98d-d5a19ebf1a1d" xlink:href="amed-20221231.xsd#amed_MaximumPercentOwnershipForCostMethodPercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_amed_MaximumPercentOwnershipForCostMethodPercent_ab53eae8-54cc-47d6-a98d-d5a19ebf1a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtCost_39ee145d-4e5e-43d2-808a-64d162deeb80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_InvestmentOwnedAtCost_39ee145d-4e5e-43d2-808a-64d162deeb80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_2509f851-236e-423c-8b09-778ae4a6791d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_2509f851-236e-423c-8b09-778ae4a6791d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities_107195a6-3eca-4342-bb27-a7bc63a7eda3" xlink:href="amed-20221231.xsd#amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities_107195a6-3eca-4342-bb27-a7bc63a7eda3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfAdmittingJointVentures_a6dda4ad-7deb-49bd-a850-9fbda7433510" xlink:href="amed-20221231.xsd#amed_NumberOfAdmittingJointVentures"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_amed_NumberOfAdmittingJointVentures_a6dda4ad-7deb-49bd-a850-9fbda7433510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6e244f69-eb5b-423c-b2bf-ffbe32e578e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6e244f69-eb5b-423c-b2bf-ffbe32e578e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_67cd1e57-10d3-4443-9d5e-8b108bb30189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_67cd1e57-10d3-4443-9d5e-8b108bb30189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_b9b7666a-e544-4fca-9db9-ba56eee89870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_OtherAssetsCurrent_b9b7666a-e544-4fca-9db9-ba56eee89870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_447f1086-74cd-41d9-8c4f-575a8bd4a7fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_AssetsCurrent_447f1086-74cd-41d9-8c4f-575a8bd4a7fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f79a5ec8-a2d2-40fe-ade3-6b8ffabfb919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f79a5ec8-a2d2-40fe-ade3-6b8ffabfb919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ba0d0139-3282-41b5-b341-9f9c4cc78961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ba0d0139-3282-41b5-b341-9f9c4cc78961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_85dd0c9a-ff81-461c-9694-9159c60d7c74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_Goodwill_85dd0c9a-ff81-461c-9694-9159c60d7c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a6cc0aac-8791-4223-b8f0-58254d827dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a6cc0aac-8791-4223-b8f0-58254d827dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_fae7197a-5f34-4b4b-9473-41ccf6aebf72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_fae7197a-5f34-4b4b-9473-41ccf6aebf72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_04492700-282e-4e50-896a-1d1ce57d946c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_Assets_04492700-282e-4e50-896a-1d1ce57d946c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_fa09964e-a27f-4cf4-a7f8-290bc9c5af1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_AccountsPayableCurrent_fa09964e-a27f-4cf4-a7f8-290bc9c5af1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4aaa2f94-9ebf-4669-9b46-41525e53ac54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4aaa2f94-9ebf-4669-9b46-41525e53ac54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_39f8a5a1-5858-42db-9022-676d8bdc187f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_39f8a5a1-5858-42db-9022-676d8bdc187f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_4968eeea-5b19-46e8-953e-c9827216ce61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_DebtCurrent_4968eeea-5b19-46e8-953e-c9827216ce61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a51967cd-3bdd-4589-9876-3142cb6c7b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_LiabilitiesCurrent_a51967cd-3bdd-4589-9876-3142cb6c7b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f7328ac2-48c2-47cc-b9fb-f93b95a29acf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f7328ac2-48c2-47cc-b9fb-f93b95a29acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b6d47b20-74b5-4a3a-aafb-125b6ec16f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b6d47b20-74b5-4a3a-aafb-125b6ec16f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ea88097e-1c2e-4aaf-8d5a-4fc29f764f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_Liabilities_ea88097e-1c2e-4aaf-8d5a-4fc29f764f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_b133aa67-810e-40cb-80f3-1c6d2d6c7aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_b133aa67-810e-40cb-80f3-1c6d2d6c7aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_GainRelatedToSaleOfNoncontrollingInterestNetOfTax_0c59bbfd-ea24-4457-b91e-5241088b55c4" xlink:href="amed-20221231.xsd#amed_GainRelatedToSaleOfNoncontrollingInterestNetOfTax"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_amed_GainRelatedToSaleOfNoncontrollingInterestNetOfTax_0c59bbfd-ea24-4457-b91e-5241088b55c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_80d6a47a-5391-4c5f-92c6-1823365a9fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_80d6a47a-5391-4c5f-92c6-1823365a9fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_51c27b7d-79f2-4d8f-8efc-593fe1c86131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_OrganizationAndNatureOfOperationsLineItems_8d11791d-1c44-4d32-a37d-c13d0cce3261" xlink:to="loc_us-gaap_AssetImpairmentCharges_51c27b7d-79f2-4d8f-8efc-593fe1c86131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_56eb676d-5c53-44fd-87bb-d6323cc966b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9e2f1a86-fdfd-4a54-a159-5c1a75d0e633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_56eb676d-5c53-44fd-87bb-d6323cc966b5" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9e2f1a86-fdfd-4a54-a159-5c1a75d0e633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_55c70ddf-f6fb-4518-afc6-1ce856028acd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9e2f1a86-fdfd-4a54-a159-5c1a75d0e633" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_55c70ddf-f6fb-4518-afc6-1ce856028acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_1e835691-6cd6-4f68-9681-cd52f6d40cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_55c70ddf-f6fb-4518-afc6-1ce856028acd" xlink:to="loc_us-gaap_TypeOfAdoptionMember_1e835691-6cd6-4f68-9681-cd52f6d40cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_153e9c54-4070-48cb-9a0a-ddbfd5fc4b88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_1e835691-6cd6-4f68-9681-cd52f6d40cb7" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_153e9c54-4070-48cb-9a0a-ddbfd5fc4b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6b0a349f-8e26-4866-a248-e41e1bd14d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9e2f1a86-fdfd-4a54-a159-5c1a75d0e633" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6b0a349f-8e26-4866-a248-e41e1bd14d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2da3dda4-d142-4fbb-a7b5-889fbce4664a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6b0a349f-8e26-4866-a248-e41e1bd14d6c" xlink:to="loc_us-gaap_EquityComponentDomain_2da3dda4-d142-4fbb-a7b5-889fbce4664a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_75fa7fa8-e800-40f5-8cdf-6cd33f014366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2da3dda4-d142-4fbb-a7b5-889fbce4664a" xlink:to="loc_us-gaap_RetainedEarningsMember_75fa7fa8-e800-40f5-8cdf-6cd33f014366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_9a98b68a-a30d-4bbe-bc03-564ddf47e38c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9e2f1a86-fdfd-4a54-a159-5c1a75d0e633" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_9a98b68a-a30d-4bbe-bc03-564ddf47e38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7243861e-5073-41a7-aaf7-8a02f40afc87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_21cf6987-5a74-4d3b-9bde-d6d59748491d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7243861e-5073-41a7-aaf7-8a02f40afc87" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_21cf6987-5a74-4d3b-9bde-d6d59748491d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearAxis_a1d2910b-0f66-4ac2-ac70-7635bae2cc50" xlink:href="amed-20221231.xsd#amed_CapYearAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_21cf6987-5a74-4d3b-9bde-d6d59748491d" xlink:to="loc_amed_CapYearAxis_a1d2910b-0f66-4ac2-ac70-7635bae2cc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearDomain_b01ff157-7e5b-4800-8590-8c2df208d6ca" xlink:href="amed-20221231.xsd#amed_CapYearDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_CapYearAxis_a1d2910b-0f66-4ac2-ac70-7635bae2cc50" xlink:to="loc_amed_CapYearDomain_b01ff157-7e5b-4800-8590-8c2df208d6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember_2d3d7fe9-64ea-455f-b6a7-0eecdee8580c" xlink:href="amed-20221231.xsd#amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_CapYearDomain_b01ff157-7e5b-4800-8590-8c2df208d6ca" xlink:to="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember_2d3d7fe9-64ea-455f-b6a7-0eecdee8580c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember_b6530c4e-0935-46ef-9faf-868106a28680" xlink:href="amed-20221231.xsd#amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_CapYearDomain_b01ff157-7e5b-4800-8590-8c2df208d6ca" xlink:to="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember_b6530c4e-0935-46ef-9faf-868106a28680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f25b0708-4cc0-45c4-acf4-1939bdc10472" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_21cf6987-5a74-4d3b-9bde-d6d59748491d" xlink:to="loc_srt_RangeAxis_f25b0708-4cc0-45c4-acf4-1939bdc10472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_23bedd5d-020f-4e9e-ae56-eaf684f9a660" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f25b0708-4cc0-45c4-acf4-1939bdc10472" xlink:to="loc_srt_RangeMember_23bedd5d-020f-4e9e-ae56-eaf684f9a660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2c4cf8c4-eb16-4f1d-914d-ec458d53f81c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_23bedd5d-020f-4e9e-ae56-eaf684f9a660" xlink:to="loc_srt_MinimumMember_2c4cf8c4-eb16-4f1d-914d-ec458d53f81c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_20e43976-c589-4a5c-9c27-6921b156c6ee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_23bedd5d-020f-4e9e-ae56-eaf684f9a660" xlink:to="loc_srt_MaximumMember_20e43976-c589-4a5c-9c27-6921b156c6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f5bf3c90-b45b-48dc-8da0-2b45e6af05aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_21cf6987-5a74-4d3b-9bde-d6d59748491d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f5bf3c90-b45b-48dc-8da0-2b45e6af05aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2ef7ff41-b967-4553-af2e-0c3d340c417f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f5bf3c90-b45b-48dc-8da0-2b45e6af05aa" xlink:to="loc_us-gaap_SegmentDomain_2ef7ff41-b967-4553-af2e-0c3d340c417f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_a8225b36-0ca9-4427-8e81-3023aabd0286" xlink:href="amed-20221231.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2ef7ff41-b967-4553-af2e-0c3d340c417f" xlink:to="loc_amed_HomeHealthMember_a8225b36-0ca9-4427-8e81-3023aabd0286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_82fa4cd1-93e9-4403-a081-01d6577cd273" xlink:href="amed-20221231.xsd#amed_HospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2ef7ff41-b967-4553-af2e-0c3d340c417f" xlink:to="loc_amed_HospiceMember_82fa4cd1-93e9-4403-a081-01d6577cd273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_5231335a-2ebd-47c1-823d-f460230bae95" xlink:href="amed-20221231.xsd#amed_HighAcuityCareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2ef7ff41-b967-4553-af2e-0c3d340c417f" xlink:to="loc_amed_HighAcuityCareMember_5231335a-2ebd-47c1-823d-f460230bae95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_33044601-7499-4857-9a4e-bb206c1dba68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_21cf6987-5a74-4d3b-9bde-d6d59748491d" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_33044601-7499-4857-9a4e-bb206c1dba68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_08e8b536-ad75-45cc-99da-0ed07633f8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_33044601-7499-4857-9a4e-bb206c1dba68" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_08e8b536-ad75-45cc-99da-0ed07633f8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_6adbc48e-715c-40b7-893e-11b335394f07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_08e8b536-ad75-45cc-99da-0ed07633f8ba" xlink:to="loc_us-gaap_SalesRevenueNetMember_6adbc48e-715c-40b7-893e-11b335394f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_b37327c2-276c-4cb1-82bf-fba6bef34439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_21cf6987-5a74-4d3b-9bde-d6d59748491d" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_b37327c2-276c-4cb1-82bf-fba6bef34439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_dac5e838-69dd-46a0-af26-3f24d014a270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b37327c2-276c-4cb1-82bf-fba6bef34439" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_dac5e838-69dd-46a0-af26-3f24d014a270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_b6adfb2d-1b6c-4c52-b24a-2a1112505980" xlink:href="amed-20221231.xsd#amed_MedicareRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_dac5e838-69dd-46a0-af26-3f24d014a270" xlink:to="loc_amed_MedicareRevenueMember_b6adfb2d-1b6c-4c52-b24a-2a1112505980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_71d29870-8d30-4e14-8fb2-2bf81c374314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_dac5e838-69dd-46a0-af26-3f24d014a270" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_71d29870-8d30-4e14-8fb2-2bf81c374314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8581b174-f3e2-416a-bb63-8315ff2d1cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_21cf6987-5a74-4d3b-9bde-d6d59748491d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8581b174-f3e2-416a-bb63-8315ff2d1cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_77cb1417-30f3-4b5f-b9b5-82f778636ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8581b174-f3e2-416a-bb63-8315ff2d1cc0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_77cb1417-30f3-4b5f-b9b5-82f778636ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_5f2f7705-fd6f-4538-9cbb-2fb6976957c6" xlink:href="amed-20221231.xsd#amed_AseraCareHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_77cb1417-30f3-4b5f-b9b5-82f778636ebd" xlink:to="loc_amed_AseraCareHospiceMember_5f2f7705-fd6f-4538-9cbb-2fb6976957c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a4ed61cf-b472-417c-a472-9a7b3fb849e1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_21cf6987-5a74-4d3b-9bde-d6d59748491d" xlink:to="loc_srt_ProductOrServiceAxis_a4ed61cf-b472-417c-a472-9a7b3fb849e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_75bd1c66-7665-4f4e-a89b-67b0fbd11eab" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a4ed61cf-b472-417c-a472-9a7b3fb849e1" xlink:to="loc_srt_ProductsAndServicesDomain_75bd1c66-7665-4f4e-a89b-67b0fbd11eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_dbf620f2-6aab-4200-9468-f62af17bd9e0" xlink:href="amed-20221231.xsd#amed_MedicareRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_75bd1c66-7665-4f4e-a89b-67b0fbd11eab" xlink:to="loc_amed_MedicareRevenueMember_dbf620f2-6aab-4200-9468-f62af17bd9e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7a008296-8b5a-4c1f-ad81-a4c834f002ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_21cf6987-5a74-4d3b-9bde-d6d59748491d" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7a008296-8b5a-4c1f-ad81-a4c834f002ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_8cb9ab3e-92d4-40f5-96fe-ae0d049d0c54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7a008296-8b5a-4c1f-ad81-a4c834f002ec" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_8cb9ab3e-92d4-40f5-96fe-ae0d049d0c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_a375fb6e-9fc0-4e66-9269-2699ce4398a8" xlink:href="amed-20221231.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenueDuration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7a008296-8b5a-4c1f-ad81-a4c834f002ec" xlink:to="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_a375fb6e-9fc0-4e66-9269-2699ce4398a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenueEpisodePaymentRateDuration_bf5fa286-18cd-4631-bb0b-c6c981b226de" xlink:href="amed-20221231.xsd#amed_NetServiceRevenueEpisodePaymentRateDuration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7a008296-8b5a-4c1f-ad81-a4c834f002ec" xlink:to="loc_amed_NetServiceRevenueEpisodePaymentRateDuration_bf5fa286-18cd-4631-bb0b-c6c981b226de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment_a418e252-a5af-467f-8f0e-dcb2915dcfb6" xlink:href="amed-20221231.xsd#amed_PercentageOfTotalReimbursementOfOutlierPayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7a008296-8b5a-4c1f-ad81-a4c834f002ec" xlink:to="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment_a418e252-a5af-467f-8f0e-dcb2915dcfb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_e5ebd131-0cf0-41b4-94a3-9c7e61102589" xlink:href="amed-20221231.xsd#amed_LowUtilizationPaymentAdjustmentNumberOfVisits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7a008296-8b5a-4c1f-ad81-a4c834f002ec" xlink:to="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_e5ebd131-0cf0-41b4-94a3-9c7e61102589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HistoricalCollectionRateFromMedicare_d5986175-d875-4998-83e8-721d5668888d" xlink:href="amed-20221231.xsd#amed_HistoricalCollectionRateFromMedicare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7a008296-8b5a-4c1f-ad81-a4c834f002ec" xlink:to="loc_amed_HistoricalCollectionRateFromMedicare_d5986175-d875-4998-83e8-721d5668888d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonMedicareRevenueTermRates_9bd8a28d-8bd4-49ff-8ff9-8a78e9b6c24c" xlink:href="amed-20221231.xsd#amed_NonMedicareRevenueTermRates"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7a008296-8b5a-4c1f-ad81-a4c834f002ec" xlink:to="loc_amed_NonMedicareRevenueTermRates_9bd8a28d-8bd4-49ff-8ff9-8a78e9b6c24c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_809b634f-1cbe-4578-a973-86d871fc0e57" xlink:href="amed-20221231.xsd#amed_HospiceMedicareRevenueRateAccountedForRoutineCare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7a008296-8b5a-4c1f-ad81-a4c834f002ec" xlink:to="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_809b634f-1cbe-4578-a973-86d871fc0e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_2cf1de7a-1bed-46ac-b1cf-805380770ca6" xlink:href="amed-20221231.xsd#amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7a008296-8b5a-4c1f-ad81-a4c834f002ec" xlink:to="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_2cf1de7a-1bed-46ac-b1cf-805380770ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_03ca4765-a499-4d9c-bbdd-546ab35f0e9b" xlink:href="amed-20221231.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7a008296-8b5a-4c1f-ad81-a4c834f002ec" xlink:to="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_03ca4765-a499-4d9c-bbdd-546ab35f0e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_0b83fb1b-5ba9-482c-b520-744cdc0b9344" xlink:href="amed-20221231.xsd#amed_PeriodOfCareAsEpisodicBasedRevenueDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7a008296-8b5a-4c1f-ad81-a4c834f002ec" xlink:to="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_0b83fb1b-5ba9-482c-b520-744cdc0b9344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_2e69beab-68de-40d5-b249-0205e0ae0f42" xlink:href="amed-20221231.xsd#amed_NetServiceRevenuePeriodOfCarePaymentRateDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7a008296-8b5a-4c1f-ad81-a4c834f002ec" xlink:to="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_2e69beab-68de-40d5-b249-0205e0ae0f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ImpactOfChangeInMedicareCollectionRate_74e23ae9-ba96-47ab-a483-9d890d52e93d" xlink:href="amed-20221231.xsd#amed_ImpactOfChangeInMedicareCollectionRate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7a008296-8b5a-4c1f-ad81-a4c834f002ec" xlink:to="loc_amed_ImpactOfChangeInMedicareCollectionRate_74e23ae9-ba96-47ab-a483-9d890d52e93d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments_4a60d050-a146-4352-b9cc-1a46996fc581" xlink:href="amed-20221231.xsd#amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_7a008296-8b5a-4c1f-ad81-a4c834f002ec" xlink:to="loc_amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments_4a60d050-a146-4352-b9cc-1a46996fc581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_fe6bd904-b7ef-4134-8603-ac0d43452177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_949cff44-be2a-46bf-aebe-dddb8de0d256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_fe6bd904-b7ef-4134-8603-ac0d43452177" xlink:to="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_949cff44-be2a-46bf-aebe-dddb8de0d256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassAxis_445a8da9-d6ac-42ad-a6a2-3a50fce01291" xlink:href="amed-20221231.xsd#amed_PayorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_949cff44-be2a-46bf-aebe-dddb8de0d256" xlink:to="loc_amed_PayorClassAxis_445a8da9-d6ac-42ad-a6a2-3a50fce01291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassDomain_60cf1553-cdb3-43cf-8a5a-a8943855ae57" xlink:href="amed-20221231.xsd#amed_PayorClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassAxis_445a8da9-d6ac-42ad-a6a2-3a50fce01291" xlink:to="loc_amed_PayorClassDomain_60cf1553-cdb3-43cf-8a5a-a8943855ae57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMedicareMember_d362c55f-3b34-49e4-bc6f-b755d9293ee9" xlink:href="amed-20221231.xsd#amed_HomeHealthMedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_60cf1553-cdb3-43cf-8a5a-a8943855ae57" xlink:to="loc_amed_HomeHealthMedicareMember_d362c55f-3b34-49e4-bc6f-b755d9293ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareEpisodicBasedMember_25732579-392d-4ceb-a7af-d1489e850227" xlink:href="amed-20221231.xsd#amed_HomeHealthNonMedicareEpisodicBasedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_60cf1553-cdb3-43cf-8a5a-a8943855ae57" xlink:to="loc_amed_HomeHealthNonMedicareEpisodicBasedMember_25732579-392d-4ceb-a7af-d1489e850227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember_37b1a8d0-cf1f-4f0b-b910-16f5ba1d9e39" xlink:href="amed-20221231.xsd#amed_HomeHealthNonMedicareNonEpisodicBasedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_60cf1553-cdb3-43cf-8a5a-a8943855ae57" xlink:to="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember_37b1a8d0-cf1f-4f0b-b910-16f5ba1d9e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareMember_debd002a-e5e1-4e52-b705-24611ddaf7b8" xlink:href="amed-20221231.xsd#amed_HospiceMedicareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_60cf1553-cdb3-43cf-8a5a-a8943855ae57" xlink:to="loc_amed_HospiceMedicareMember_debd002a-e5e1-4e52-b705-24611ddaf7b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceNonMedicareMember_89eaa18b-6fdc-43ec-907e-350df944a8e5" xlink:href="amed-20221231.xsd#amed_HospiceNonMedicareMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_60cf1553-cdb3-43cf-8a5a-a8943855ae57" xlink:to="loc_amed_HospiceNonMedicareMember_89eaa18b-6fdc-43ec-907e-350df944a8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_6a9e7c19-4a56-4db1-8161-2eda7eb85df6" xlink:href="amed-20221231.xsd#amed_PersonalCareMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_60cf1553-cdb3-43cf-8a5a-a8943855ae57" xlink:to="loc_amed_PersonalCareMember_6a9e7c19-4a56-4db1-8161-2eda7eb85df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_83bc4b13-5ab7-4668-8bc7-6b7c429874cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_949cff44-be2a-46bf-aebe-dddb8de0d256" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_83bc4b13-5ab7-4668-8bc7-6b7c429874cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a0fb3f35-c570-4150-82bc-d81b60dfaa61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_83bc4b13-5ab7-4668-8bc7-6b7c429874cc" xlink:to="loc_us-gaap_SegmentDomain_a0fb3f35-c570-4150-82bc-d81b60dfaa61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_910acb7e-d5ec-43ab-b364-bca512ef094b" xlink:href="amed-20221231.xsd#amed_HighAcuityCareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_a0fb3f35-c570-4150-82bc-d81b60dfaa61" xlink:to="loc_amed_HighAcuityCareMember_910acb7e-d5ec-43ab-b364-bca512ef094b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_6cbec178-a968-4b31-b6a7-b91a6f1e12cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_949cff44-be2a-46bf-aebe-dddb8de0d256" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_6cbec178-a968-4b31-b6a7-b91a6f1e12cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_93d48002-c1d6-4fc9-984a-8e5041a48c82" xlink:href="amed-20221231.xsd#amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_6cbec178-a968-4b31-b6a7-b91a6f1e12cc" xlink:to="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_93d48002-c1d6-4fc9-984a-8e5041a48c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bf099f3d-3a61-4a2c-bcb1-e2671732ee0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_1b3bfdf5-2f72-4c84-9fbc-bc979a568304" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bf099f3d-3a61-4a2c-bcb1-e2671732ee0b" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_1b3bfdf5-2f72-4c84-9fbc-bc979a568304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_eee2bb28-d605-4006-a603-428342e4f0c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_1b3bfdf5-2f72-4c84-9fbc-bc979a568304" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_eee2bb28-d605-4006-a603-428342e4f0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_116a26b9-a3d2-4f3a-9c69-6874f6964505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_eee2bb28-d605-4006-a603-428342e4f0c6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_116a26b9-a3d2-4f3a-9c69-6874f6964505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_VariousAcquisitionsMember_87d50160-6fd5-4e86-bd2d-4a94f4d40e9f" xlink:href="amed-20221231.xsd#amed_VariousAcquisitionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_116a26b9-a3d2-4f3a-9c69-6874f6964505" xlink:to="loc_amed_VariousAcquisitionsMember_87d50160-6fd5-4e86-bd2d-4a94f4d40e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_9da41391-ba31-4e4e-bd73-0c30f3e08c00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_1b3bfdf5-2f72-4c84-9fbc-bc979a568304" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_9da41391-ba31-4e4e-bd73-0c30f3e08c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_086b2470-ecee-4ba8-80cb-bb5d42cc3ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_9da41391-ba31-4e4e-bd73-0c30f3e08c00" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_086b2470-ecee-4ba8-80cb-bb5d42cc3ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_c1ca2d42-efde-48eb-bd21-e56248544557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_9da41391-ba31-4e4e-bd73-0c30f3e08c00" xlink:to="loc_us-gaap_RestrictedCash_c1ca2d42-efde-48eb-bd21-e56248544557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9bd8066f-3b8e-43a8-b4d2-380bb91ba44c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_9da41391-ba31-4e4e-bd73-0c30f3e08c00" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9bd8066f-3b8e-43a8-b4d2-380bb91ba44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashBalanceAssociatedWithProviderReliefFund_bdc1994d-6703-4f03-9a6b-d4c91fdb2ad0" xlink:href="amed-20221231.xsd#amed_CashBalanceAssociatedWithProviderReliefFund"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_9da41391-ba31-4e4e-bd73-0c30f3e08c00" xlink:to="loc_amed_CashBalanceAssociatedWithProviderReliefFund_bdc1994d-6703-4f03-9a6b-d4c91fdb2ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashBalanceAssociatedWithProviderReliefFund_03714da0-bb78-4677-a2fb-25e6ef487a53" xlink:href="amed-20221231.xsd#amed_CashBalanceAssociatedWithProviderReliefFund"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_54fb08d6-6d6c-486a-9d9c-cd5effd1e248" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfPatientReceivablesOutstanding_998d8afa-b1aa-4009-996a-24504966af69" xlink:href="amed-20221231.xsd#amed_PercentageOfPatientReceivablesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54fb08d6-6d6c-486a-9d9c-cd5effd1e248" xlink:to="loc_amed_PercentageOfPatientReceivablesOutstanding_998d8afa-b1aa-4009-996a-24504966af69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HistoricalCollectionRateFromMedicare_f5f9df20-9d40-4cd5-9140-b9e2641c21cd" xlink:href="amed-20221231.xsd#amed_HistoricalCollectionRateFromMedicare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54fb08d6-6d6c-486a-9d9c-cd5effd1e248" xlink:to="loc_amed_HistoricalCollectionRateFromMedicare_f5f9df20-9d40-4cd5-9140-b9e2641c21cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare_6cd8567b-ac00-49cf-b379-461032bb84f7" xlink:href="amed-20221231.xsd#amed_PortionOfPatientAccountsReceivableDerivedFromMedicare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54fb08d6-6d6c-486a-9d9c-cd5effd1e248" xlink:to="loc_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare_6cd8567b-ac00-49cf-b379-461032bb84f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_47e2d8d4-2e0f-4ba3-9c17-0724eb0d6943" xlink:href="amed-20221231.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54fb08d6-6d6c-486a-9d9c-cd5effd1e248" xlink:to="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_47e2d8d4-2e0f-4ba3-9c17-0724eb0d6943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare_6a2ae360-a9be-4d15-8038-6d8951cd59b5" xlink:href="amed-20221231.xsd#amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54fb08d6-6d6c-486a-9d9c-cd5effd1e248" xlink:to="loc_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare_6a2ae360-a9be-4d15-8038-6d8951cd59b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_48ebaf40-6823-43da-8cfa-ab15c13d3a0c" xlink:href="amed-20221231.xsd#amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54fb08d6-6d6c-486a-9d9c-cd5effd1e248" xlink:to="loc_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_48ebaf40-6823-43da-8cfa-ab15c13d3a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_d5c9a51b-3ba4-409f-bed2-fb3888feb5ef" xlink:href="amed-20221231.xsd#amed_NetServiceRevenuePeriodOfCarePaymentRateDuration"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54fb08d6-6d6c-486a-9d9c-cd5effd1e248" xlink:to="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_d5c9a51b-3ba4-409f-bed2-fb3888feb5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_30a2927f-b556-44ff-a4d5-0e06e220a512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_395034be-ed05-44c4-8dc9-0ab6a4582959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30a2927f-b556-44ff-a4d5-0e06e220a512" xlink:to="loc_us-gaap_Goodwill_395034be-ed05-44c4-8dc9-0ab6a4582959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0ae062f3-b362-422f-b62b-f1af50066e47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30a2927f-b556-44ff-a4d5-0e06e220a512" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0ae062f3-b362-422f-b62b-f1af50066e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_fb473a9b-93d4-4210-bb2a-2783c61e7eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30a2927f-b556-44ff-a4d5-0e06e220a512" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_fb473a9b-93d4-4210-bb2a-2783c61e7eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_0feb3737-a361-4c73-8d2b-c62173253a66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30a2927f-b556-44ff-a4d5-0e06e220a512" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_0feb3737-a361-4c73-8d2b-c62173253a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InternallyDevelopedComputerSoftware_ad563548-4efd-4bcc-ac36-05120d571f9f" xlink:href="amed-20221231.xsd#amed_InternallyDevelopedComputerSoftware"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30a2927f-b556-44ff-a4d5-0e06e220a512" xlink:to="loc_amed_InternallyDevelopedComputerSoftware_ad563548-4efd-4bcc-ac36-05120d571f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_479f6b73-a1cc-4f84-857b-f68971ea50c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30a2927f-b556-44ff-a4d5-0e06e220a512" xlink:to="loc_us-gaap_Depreciation_479f6b73-a1cc-4f84-857b-f68971ea50c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_f58ef149-c7cd-4fbe-8708-a01439cdc1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30a2927f-b556-44ff-a4d5-0e06e220a512" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_f58ef149-c7cd-4fbe-8708-a01439cdc1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_04c23908-b482-4618-a214-dbdf157da3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30a2927f-b556-44ff-a4d5-0e06e220a512" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_04c23908-b482-4618-a214-dbdf157da3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnamortizedDebtIssuanceCostAmortizationPeriod_ec38b843-0f61-4a24-8e1b-785fcde60de9" xlink:href="amed-20221231.xsd#amed_UnamortizedDebtIssuanceCostAmortizationPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30a2927f-b556-44ff-a4d5-0e06e220a512" xlink:to="loc_amed_UnamortizedDebtIssuanceCostAmortizationPeriod_ec38b843-0f61-4a24-8e1b-785fcde60de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_b0a003e5-999f-49a5-8251-bc4ee790c370" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30a2927f-b556-44ff-a4d5-0e06e220a512" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_b0a003e5-999f-49a5-8251-bc4ee790c370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_35e8aea1-f691-4087-a5cd-2a9a72e68bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30a2927f-b556-44ff-a4d5-0e06e220a512" xlink:to="loc_us-gaap_ShareBasedCompensation_35e8aea1-f691-4087-a5cd-2a9a72e68bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_32be6e66-1427-4bf9-a51e-616d4cc95c72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30a2927f-b556-44ff-a4d5-0e06e220a512" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_32be6e66-1427-4bf9-a51e-616d4cc95c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_ae51f2ab-2603-4a87-82a1-0933ad813f15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30a2927f-b556-44ff-a4d5-0e06e220a512" xlink:to="loc_us-gaap_AdvertisingExpense_ae51f2ab-2603-4a87-82a1-0933ad813f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_84c73e96-be34-4729-9fed-d3790c0fb7f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30a2927f-b556-44ff-a4d5-0e06e220a512" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_84c73e96-be34-4729-9fed-d3790c0fb7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecognizedTaxBenefitThatImpactsEffectiveTaxRate_a9bcd7b1-e085-4cb4-bbb6-ccf083a05e35" xlink:href="amed-20221231.xsd#amed_RecognizedTaxBenefitThatImpactsEffectiveTaxRate"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30a2927f-b556-44ff-a4d5-0e06e220a512" xlink:to="loc_amed_RecognizedTaxBenefitThatImpactsEffectiveTaxRate_a9bcd7b1-e085-4cb4-bbb6-ccf083a05e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_30fb1bb8-bdaf-4129-8ff0-b33cae3c0f45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30a2927f-b556-44ff-a4d5-0e06e220a512" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_30fb1bb8-bdaf-4129-8ff0-b33cae3c0f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d4a77311-1af9-4270-a819-57719ed857bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_30fb1bb8-bdaf-4129-8ff0-b33cae3c0f45" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d4a77311-1af9-4270-a819-57719ed857bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6e181ed4-1707-475a-9c0b-f33e8fb9e300" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d4a77311-1af9-4270-a819-57719ed857bd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6e181ed4-1707-475a-9c0b-f33e8fb9e300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_d7ce9777-ddef-4d81-9977-072979e0b59c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6e181ed4-1707-475a-9c0b-f33e8fb9e300" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_d7ce9777-ddef-4d81-9977-072979e0b59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNamesMember_22321059-f848-47e4-a737-65ccc55850e5" xlink:href="amed-20221231.xsd#amed_AcquiredNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6e181ed4-1707-475a-9c0b-f33e8fb9e300" xlink:to="loc_amed_AcquiredNamesMember_22321059-f848-47e4-a737-65ccc55850e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_eb97db18-72a0-4ad0-b9fb-47ae8843405b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6e181ed4-1707-475a-9c0b-f33e8fb9e300" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_eb97db18-72a0-4ad0-b9fb-47ae8843405b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7235d976-3d19-482f-b696-bd7e7e8ccecb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_30fb1bb8-bdaf-4129-8ff0-b33cae3c0f45" xlink:to="loc_srt_RangeAxis_7235d976-3d19-482f-b696-bd7e7e8ccecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d18b0d39-bcd4-4cf2-b8b5-0028f3a49648" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7235d976-3d19-482f-b696-bd7e7e8ccecb" xlink:to="loc_srt_RangeMember_d18b0d39-bcd4-4cf2-b8b5-0028f3a49648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d3a63d89-e398-4f7f-b89d-3acf2adfc385" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d18b0d39-bcd4-4cf2-b8b5-0028f3a49648" xlink:to="loc_srt_MinimumMember_d3a63d89-e398-4f7f-b89d-3acf2adfc385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_587fb0c0-c479-40b2-a758-ed7d85638e4d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d18b0d39-bcd4-4cf2-b8b5-0028f3a49648" xlink:to="loc_srt_MaximumMember_587fb0c0-c479-40b2-a758-ed7d85638e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0dbbd10b-8a97-4f5f-a65c-273c3dc838f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_30fb1bb8-bdaf-4129-8ff0-b33cae3c0f45" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0dbbd10b-8a97-4f5f-a65c-273c3dc838f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_774977ea-32b6-4a8a-90bf-68a2e2c36bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0dbbd10b-8a97-4f5f-a65c-273c3dc838f8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_774977ea-32b6-4a8a-90bf-68a2e2c36bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNamesMember_237761aa-ca17-4563-9f66-38cfdf4d17cf" xlink:href="amed-20221231.xsd#amed_AcquiredNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_774977ea-32b6-4a8a-90bf-68a2e2c36bdc" xlink:to="loc_amed_AcquiredNamesMember_237761aa-ca17-4563-9f66-38cfdf4d17cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1bd7e257-ee7b-43d1-a3f5-ae4f86832eac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_30fb1bb8-bdaf-4129-8ff0-b33cae3c0f45" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1bd7e257-ee7b-43d1-a3f5-ae4f86832eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_60293145-a842-4b01-865a-b03668b7c743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1bd7e257-ee7b-43d1-a3f5-ae4f86832eac" xlink:to="loc_us-gaap_SegmentDomain_60293145-a842-4b01-865a-b03668b7c743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_75cbe8b6-ba59-4a08-b056-a73eab8ab880" xlink:href="amed-20221231.xsd#amed_PersonalCareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_60293145-a842-4b01-865a-b03668b7c743" xlink:to="loc_amed_PersonalCareMember_75cbe8b6-ba59-4a08-b056-a73eab8ab880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bb9235c2-7f28-4c43-a02d-923a9395ed76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_30fb1bb8-bdaf-4129-8ff0-b33cae3c0f45" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bb9235c2-7f28-4c43-a02d-923a9395ed76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_880ed8c1-9139-442f-b380-551d4030baa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bb9235c2-7f28-4c43-a02d-923a9395ed76" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_880ed8c1-9139-442f-b380-551d4030baa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_df4184c1-27e6-4afb-afa7-61d74b2bb281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_bb9235c2-7f28-4c43-a02d-923a9395ed76" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_df4184c1-27e6-4afb-afa7-61d74b2bb281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_74ef50f1-4430-4562-9ea1-03c78fb4fe9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a7b48111-2a96-4bcc-b1f9-b1aaa6b4f947" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_74ef50f1-4430-4562-9ea1-03c78fb4fe9d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a7b48111-2a96-4bcc-b1f9-b1aaa6b4f947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9781dd85-815d-4430-8440-fc9e4b79505a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a7b48111-2a96-4bcc-b1f9-b1aaa6b4f947" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9781dd85-815d-4430-8440-fc9e4b79505a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1228cead-92d5-435e-90f0-6c0e395a1ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9781dd85-815d-4430-8440-fc9e4b79505a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1228cead-92d5-435e-90f0-6c0e395a1ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_d39bd697-39a4-4424-b1f0-5cba2911e36f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1228cead-92d5-435e-90f0-6c0e395a1ff8" xlink:to="loc_us-gaap_BuildingMember_d39bd697-39a4-4424-b1f0-5cba2911e36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_a5e783ab-c509-42cd-91c9-9c3a853b931d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1228cead-92d5-435e-90f0-6c0e395a1ff8" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_a5e783ab-c509-42cd-91c9-9c3a853b931d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquipmentAndFurnitureMember_ea9c9c55-83cc-494c-bac3-3ebd94260790" xlink:href="amed-20221231.xsd#amed_EquipmentAndFurnitureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1228cead-92d5-435e-90f0-6c0e395a1ff8" xlink:to="loc_amed_EquipmentAndFurnitureMember_ea9c9c55-83cc-494c-bac3-3ebd94260790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_a5d80320-fe81-4d1f-8550-2ff8fac1cb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1228cead-92d5-435e-90f0-6c0e395a1ff8" xlink:to="loc_us-gaap_VehiclesMember_a5d80320-fe81-4d1f-8550-2ff8fac1cb9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_1b76f457-47c1-4f44-aaa0-001c34de3dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1228cead-92d5-435e-90f0-6c0e395a1ff8" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_1b76f457-47c1-4f44-aaa0-001c34de3dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember_41aac2ac-cfed-496d-8c9b-abe5ddc49e98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLeaseObligationsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1228cead-92d5-435e-90f0-6c0e395a1ff8" xlink:to="loc_us-gaap_CapitalLeaseObligationsMember_41aac2ac-cfed-496d-8c9b-abe5ddc49e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f1bbddd6-0f8e-4474-82a9-01dd93339b01" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a7b48111-2a96-4bcc-b1f9-b1aaa6b4f947" xlink:to="loc_srt_RangeAxis_f1bbddd6-0f8e-4474-82a9-01dd93339b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3b89b91b-12d2-42a3-a7f4-dc7e561f9396" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f1bbddd6-0f8e-4474-82a9-01dd93339b01" xlink:to="loc_srt_RangeMember_3b89b91b-12d2-42a3-a7f4-dc7e561f9396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fa6aa454-803d-4ab1-b3e3-9f0cbf992af0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3b89b91b-12d2-42a3-a7f4-dc7e561f9396" xlink:to="loc_srt_MinimumMember_fa6aa454-803d-4ab1-b3e3-9f0cbf992af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_43b19b28-ad79-4ddc-b44b-08e23e2d4d5f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3b89b91b-12d2-42a3-a7f4-dc7e561f9396" xlink:to="loc_srt_MaximumMember_43b19b28-ad79-4ddc-b44b-08e23e2d4d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5c121a83-b293-4322-b27d-90a8245b5630" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a7b48111-2a96-4bcc-b1f9-b1aaa6b4f947" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5c121a83-b293-4322-b27d-90a8245b5630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_e4fb1a91-311f-4cb2-a6b3-a6c562f88f01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5c121a83-b293-4322-b27d-90a8245b5630" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_e4fb1a91-311f-4cb2-a6b3-a6c562f88f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_16a19e91-289a-4c25-85c5-8c2818bddf15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5c121a83-b293-4322-b27d-90a8245b5630" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_16a19e91-289a-4c25-85c5-8c2818bddf15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_54e5f261-3953-4d55-b7d9-a37cdeaa2346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_44f0d57a-0ee7-45dc-999d-1c9745319906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54e5f261-3953-4d55-b7d9-a37cdeaa2346" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_44f0d57a-0ee7-45dc-999d-1c9745319906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ef157339-d5aa-438a-b1a8-4c47aa9d8a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_44f0d57a-0ee7-45dc-999d-1c9745319906" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ef157339-d5aa-438a-b1a8-4c47aa9d8a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7bbaa90d-dd87-4d4f-bace-b3179a93517c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ef157339-d5aa-438a-b1a8-4c47aa9d8a0a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7bbaa90d-dd87-4d4f-bace-b3179a93517c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BuildingAndLeaseholdImprovementsMember_b6f919ec-60aa-402f-a4ff-25adf3147d9a" xlink:href="amed-20221231.xsd#amed_BuildingAndLeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7bbaa90d-dd87-4d4f-bace-b3179a93517c" xlink:to="loc_amed_BuildingAndLeaseholdImprovementsMember_b6f919ec-60aa-402f-a4ff-25adf3147d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquipmentAndFurnitureMember_b0eb13fd-7a55-4d4a-ab7a-5333408f7f9c" xlink:href="amed-20221231.xsd#amed_EquipmentAndFurnitureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7bbaa90d-dd87-4d4f-bace-b3179a93517c" xlink:to="loc_amed_EquipmentAndFurnitureMember_b0eb13fd-7a55-4d4a-ab7a-5333408f7f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldUnderCapitalLeasesMember_49fe237f-7eb5-4b87-aa6b-41a875fcf16f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldUnderCapitalLeasesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7bbaa90d-dd87-4d4f-bace-b3179a93517c" xlink:to="loc_us-gaap_AssetsHeldUnderCapitalLeasesMember_49fe237f-7eb5-4b87-aa6b-41a875fcf16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_ca2c3cbf-18b9-4126-bf8f-bbd1e99971bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7bbaa90d-dd87-4d4f-bace-b3179a93517c" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_ca2c3cbf-18b9-4126-bf8f-bbd1e99971bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3241d2be-51bf-41a5-94ff-519f31649f95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_44f0d57a-0ee7-45dc-999d-1c9745319906" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3241d2be-51bf-41a5-94ff-519f31649f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_176c6bfa-6b01-4407-ad71-6f175717c575" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3241d2be-51bf-41a5-94ff-519f31649f95" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_176c6bfa-6b01-4407-ad71-6f175717c575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b5260663-8a1e-474a-bae9-02026569a865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3241d2be-51bf-41a5-94ff-519f31649f95" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b5260663-8a1e-474a-bae9-02026569a865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3a553157-1487-4743-933d-7f163eb85276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3241d2be-51bf-41a5-94ff-519f31649f95" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3a553157-1487-4743-933d-7f163eb85276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9fb91735-70e5-4710-8086-fe4aa1f3afa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca69b4b9-f415-4fa5-b031-07b10145884d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9fb91735-70e5-4710-8086-fe4aa1f3afa0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca69b4b9-f415-4fa5-b031-07b10145884d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6c324bb0-a457-4f3a-8722-e44d1ac12420" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca69b4b9-f415-4fa5-b031-07b10145884d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6c324bb0-a457-4f3a-8722-e44d1ac12420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_620968be-9fec-47c9-89ea-ec6e83374c79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6c324bb0-a457-4f3a-8722-e44d1ac12420" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_620968be-9fec-47c9-89ea-ec6e83374c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_83a91842-45ba-419e-8cea-88f60b9a67a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_620968be-9fec-47c9-89ea-ec6e83374c79" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_83a91842-45ba-419e-8cea-88f60b9a67a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ec327723-96f6-49d1-a3e1-a48e3d9f880e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_620968be-9fec-47c9-89ea-ec6e83374c79" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ec327723-96f6-49d1-a3e1-a48e3d9f880e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_84b2bd41-118a-44a0-ab5c-db8d2374b1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_620968be-9fec-47c9-89ea-ec6e83374c79" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_84b2bd41-118a-44a0-ab5c-db8d2374b1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_224b741d-3646-4928-8f90-53654a1b0d42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ca69b4b9-f415-4fa5-b031-07b10145884d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_224b741d-3646-4928-8f90-53654a1b0d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_96d0e21b-ec2c-4d0b-b965-0fc8e8182da0" xlink:href="amed-20221231.xsd#amed_DebtInstrumentCarryingAmountExcludingFinanceLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_224b741d-3646-4928-8f90-53654a1b0d42" xlink:to="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_96d0e21b-ec2c-4d0b-b965-0fc8e8182da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_d14f4c02-215a-425a-a9e9-0decfbb9b342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_224b741d-3646-4928-8f90-53654a1b0d42" xlink:to="loc_us-gaap_LongTermDebtFairValue_d14f4c02-215a-425a-a9e9-0decfbb9b342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e539dda9-614d-4454-b8cc-ec8ce0b1c796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_094c6840-ad0b-47c1-93ac-6da310816148" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e539dda9-614d-4454-b8cc-ec8ce0b1c796" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_094c6840-ad0b-47c1-93ac-6da310816148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_5795aa48-3183-4111-ba67-200fad7e0fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e539dda9-614d-4454-b8cc-ec8ce0b1c796" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_5795aa48-3183-4111-ba67-200fad7e0fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_b5e2877a-910c-4120-8a4c-c2629a0c16e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_5795aa48-3183-4111-ba67-200fad7e0fc4" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_b5e2877a-910c-4120-8a4c-c2629a0c16e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockAndStockUnits_7fdbb60b-85a1-42e6-9a3f-5f0513d5f576" xlink:href="amed-20221231.xsd#amed_NonVestedStockAndStockUnits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_5795aa48-3183-4111-ba67-200fad7e0fc4" xlink:to="loc_amed_NonVestedStockAndStockUnits_7fdbb60b-85a1-42e6-9a3f-5f0513d5f576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_61004f28-435d-42e9-8757-95dae3ff7bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e539dda9-614d-4454-b8cc-ec8ce0b1c796" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_61004f28-435d-42e9-8757-95dae3ff7bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_37918766-91bf-4953-b263-9199f1001f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e539dda9-614d-4454-b8cc-ec8ce0b1c796" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_37918766-91bf-4953-b263-9199f1001f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details" xlink:type="simple" xlink:href="amed-20221231.xsd#NOVELCORONAVIRUSPANDEMICCOVID19Details"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_383c1013-73b0-444e-94b5-7fb64df67e37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtraordinaryAndUnusualItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemTable_0b1abe50-e23b-46f9-9969-42cad973f3c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_383c1013-73b0-444e-94b5-7fb64df67e37" xlink:to="loc_us-gaap_UnusualOrInfrequentItemTable_0b1abe50-e23b-46f9-9969-42cad973f3c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_3f882e7e-e63b-48cd-8c35-47071c636ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_0b1abe50-e23b-46f9-9969-42cad973f3c2" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_3f882e7e-e63b-48cd-8c35-47071c636ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_33b6d372-4755-451c-87b6-d0446496a763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_3f882e7e-e63b-48cd-8c35-47071c636ce6" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_33b6d372-4755-451c-87b6-d0446496a763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsMember_497b30ec-954a-439e-8fa0-2f3523a31081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_33b6d372-4755-451c-87b6-d0446496a763" xlink:to="loc_us-gaap_EquityMethodInvestmentsMember_497b30ec-954a-439e-8fa0-2f3523a31081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8380bee0-d32b-44ed-a92d-060da8c85b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_0b1abe50-e23b-46f9-9969-42cad973f3c2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8380bee0-d32b-44ed-a92d-060da8c85b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e5c112b-1968-43ed-940f-67e447a97055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8380bee0-d32b-44ed-a92d-060da8c85b8d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e5c112b-1968-43ed-940f-67e447a97055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_db35755c-1a51-4f27-8ab9-64ccb5f4a0c8" xlink:href="amed-20221231.xsd#amed_AseraCareHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e5c112b-1968-43ed-940f-67e447a97055" xlink:to="loc_amed_AseraCareHospiceMember_db35755c-1a51-4f27-8ab9-64ccb5f4a0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_19fc418b-c802-4087-a9c2-11d582423191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_0b1abe50-e23b-46f9-9969-42cad973f3c2" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_19fc418b-c802-4087-a9c2-11d582423191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_cdcd3bfd-fe04-42bb-976b-3ffc1a43f27a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_19fc418b-c802-4087-a9c2-11d582423191" xlink:to="loc_us-gaap_SegmentDomain_cdcd3bfd-fe04-42bb-976b-3ffc1a43f27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthAndHospiceMember_5b673ab0-a76f-495e-b43f-5a5715705b2a" xlink:href="amed-20221231.xsd#amed_HomeHealthAndHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_cdcd3bfd-fe04-42bb-976b-3ffc1a43f27a" xlink:to="loc_amed_HomeHealthAndHospiceMember_5b673ab0-a76f-495e-b43f-5a5715705b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_3072d006-3915-4944-80d6-59dd740a6880" xlink:href="amed-20221231.xsd#amed_PersonalCareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_cdcd3bfd-fe04-42bb-976b-3ffc1a43f27a" xlink:to="loc_amed_PersonalCareMember_3072d006-3915-4944-80d6-59dd740a6880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis_885e0c9d-558c-44d3-818e-d40ffed4da69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_0b1abe50-e23b-46f9-9969-42cad973f3c2" xlink:to="loc_us-gaap_UnusualOrInfrequentItemAxis_885e0c9d-558c-44d3-818e-d40ffed4da69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_c5d67b74-d4ec-46c0-ad47-f1e9b83d7fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_885e0c9d-558c-44d3-818e-d40ffed4da69" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_c5d67b74-d4ec-46c0-ad47-f1e9b83d7fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19DeferralOfSocialSecurityTaxesMember_b8ba82ac-5e44-4791-b8ea-7d228dc28f9f" xlink:href="amed-20221231.xsd#amed_COVID19DeferralOfSocialSecurityTaxesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain_c5d67b74-d4ec-46c0-ad47-f1e9b83d7fa4" xlink:to="loc_amed_COVID19DeferralOfSocialSecurityTaxesMember_b8ba82ac-5e44-4791-b8ea-7d228dc28f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemLineItems_e297a038-1f5c-4aae-8545-b5eb73904627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_0b1abe50-e23b-46f9-9969-42cad973f3c2" xlink:to="loc_us-gaap_UnusualOrInfrequentItemLineItems_e297a038-1f5c-4aae-8545-b5eb73904627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingForHealthcareProvidersIncludingHospitals_6b76cac6-5217-4c0b-a469-ec7375044aa0" xlink:href="amed-20221231.xsd#amed_FundingForHealthcareProvidersIncludingHospitals"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_e297a038-1f5c-4aae-8545-b5eb73904627" xlink:to="loc_amed_FundingForHealthcareProvidersIncludingHospitals_6b76cac6-5217-4c0b-a469-ec7375044aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_e901ea20-7c49-48e0-a08c-62259b5dd4a2" xlink:href="amed-20221231.xsd#amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_e297a038-1f5c-4aae-8545-b5eb73904627" xlink:to="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_e901ea20-7c49-48e0-a08c-62259b5dd4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingReceivedFromCARESAct_11926208-7f02-4f0c-89ac-9267abf09580" xlink:href="amed-20221231.xsd#amed_FundingReceivedFromCARESAct"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_e297a038-1f5c-4aae-8545-b5eb73904627" xlink:to="loc_amed_FundingReceivedFromCARESAct_11926208-7f02-4f0c-89ac-9267abf09580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundsUtilized_e7e5a2ad-277c-4d6b-883a-f2ab2655a3f1" xlink:href="amed-20221231.xsd#amed_CARESActProviderReliefFundsUtilized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_e297a038-1f5c-4aae-8545-b5eb73904627" xlink:to="loc_amed_CARESActProviderReliefFundsUtilized_e7e5a2ad-277c-4d6b-883a-f2ab2655a3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActInterestRepaidToGovernment_53e6fe3e-5e26-4115-9b37-04283d763f05" xlink:href="amed-20221231.xsd#amed_CARESActInterestRepaidToGovernment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_e297a038-1f5c-4aae-8545-b5eb73904627" xlink:to="loc_amed_CARESActInterestRepaidToGovernment_53e6fe3e-5e26-4115-9b37-04283d763f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundsRepaidToTheGovernment_b43c4143-ec93-4a8a-a3a3-18c810ff10dc" xlink:href="amed-20221231.xsd#amed_CARESActProviderReliefFundsRepaidToTheGovernment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_e297a038-1f5c-4aae-8545-b5eb73904627" xlink:to="loc_amed_CARESActProviderReliefFundsRepaidToTheGovernment_b43c4143-ec93-4a8a-a3a3-18c810ff10dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundUtilizedByUnconsolidatedJointVentures_61119757-b539-452d-9278-0b7ba7c7ad7b" xlink:href="amed-20221231.xsd#amed_CARESActProviderReliefFundUtilizedByUnconsolidatedJointVentures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_e297a038-1f5c-4aae-8545-b5eb73904627" xlink:to="loc_amed_CARESActProviderReliefFundUtilizedByUnconsolidatedJointVentures_61119757-b539-452d-9278-0b7ba7c7ad7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundsRepaidByUnconsolidatedJointVentures_d3d6af68-d6de-4ea0-ac8f-cfd0d3b0da2f" xlink:href="amed-20221231.xsd#amed_CARESActProviderReliefFundsRepaidByUnconsolidatedJointVentures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_e297a038-1f5c-4aae-8545-b5eb73904627" xlink:to="loc_amed_CARESActProviderReliefFundsRepaidByUnconsolidatedJointVentures_d3d6af68-d6de-4ea0-ac8f-cfd0d3b0da2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalCARESActProviderReliefFundsReceived_5c14726d-a45b-4210-8dc8-282065f7acd6" xlink:href="amed-20221231.xsd#amed_TotalCARESActProviderReliefFundsReceived"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_e297a038-1f5c-4aae-8545-b5eb73904627" xlink:to="loc_amed_TotalCARESActProviderReliefFundsReceived_5c14726d-a45b-4210-8dc8-282065f7acd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact_6e2ad796-3a06-4cb4-aa0f-66e587c8aca3" xlink:href="amed-20221231.xsd#amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_e297a038-1f5c-4aae-8545-b5eb73904627" xlink:to="loc_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact_6e2ad796-3a06-4cb4-aa0f-66e587c8aca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_fb10a9c9-7f82-4f4b-99ee-7a3ca88386e3" xlink:href="amed-20221231.xsd#amed_CARESActDeferralOfEmployerShareSocialSecurityTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_e297a038-1f5c-4aae-8545-b5eb73904627" xlink:to="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_fb10a9c9-7f82-4f4b-99ee-7a3ca88386e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct_689978e2-e2c8-4073-8b7f-9b8d222a7c27" xlink:href="amed-20221231.xsd#amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_e297a038-1f5c-4aae-8545-b5eb73904627" xlink:to="loc_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct_689978e2-e2c8-4073-8b7f-9b8d222a7c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_5270d6eb-51bd-4d53-83b8-5f29a4f3cbf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncome"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_e297a038-1f5c-4aae-8545-b5eb73904627" xlink:to="loc_us-gaap_OtherOperatingIncome_5270d6eb-51bd-4d53-83b8-5f29a4f3cbf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram_41714a62-0daf-4856-8250-d78ff56b9f9f" xlink:href="amed-20221231.xsd#amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_e297a038-1f5c-4aae-8545-b5eb73904627" xlink:to="loc_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram_41714a62-0daf-4856-8250-d78ff56b9f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#ACQUISITIONSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_202f50dc-868b-4815-b556-995921982f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d7c8f5e-2f0e-4cde-aaab-a463075b33a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_202f50dc-868b-4815-b556-995921982f4a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d7c8f5e-2f0e-4cde-aaab-a463075b33a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5a37eb01-354f-464a-abc0-e35798607bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d7c8f5e-2f0e-4cde-aaab-a463075b33a9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5a37eb01-354f-464a-abc0-e35798607bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8936fec-2bba-4bc0-bda2-08eb497826f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5a37eb01-354f-464a-abc0-e35798607bbc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8936fec-2bba-4bc0-bda2-08eb497826f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2022NewJointVentureMember_4df61190-1e9c-41f5-aa6b-f9ca564d7db0" xlink:href="amed-20221231.xsd#amed_A2022NewJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8936fec-2bba-4bc0-bda2-08eb497826f5" xlink:to="loc_amed_A2022NewJointVentureMember_4df61190-1e9c-41f5-aa6b-f9ca564d7db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EvolutionHealthMember_bf828f84-50ad-4233-9d1b-556e47bf5b07" xlink:href="amed-20221231.xsd#amed_EvolutionHealthMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8936fec-2bba-4bc0-bda2-08eb497826f5" xlink:to="loc_amed_EvolutionHealthMember_bf828f84-50ad-4233-9d1b-556e47bf5b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AssistedCareHomeHealthMember_9ff40d57-ae0b-4154-8b6c-a892b8d18339" xlink:href="amed-20221231.xsd#amed_AssistedCareHomeHealthMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8936fec-2bba-4bc0-bda2-08eb497826f5" xlink:to="loc_amed_AssistedCareHomeHealthMember_9ff40d57-ae0b-4154-8b6c-a892b8d18339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_VisitingNurseAssociationMember_cc402fa6-1495-4c23-8cac-57beb0cc06f8" xlink:href="amed-20221231.xsd#amed_VisitingNurseAssociationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8936fec-2bba-4bc0-bda2-08eb497826f5" xlink:to="loc_amed_VisitingNurseAssociationMember_cc402fa6-1495-4c23-8cac-57beb0cc06f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ContessaHealthMember_03c055fb-d0eb-4306-ba00-b32675363661" xlink:href="amed-20221231.xsd#amed_ContessaHealthMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8936fec-2bba-4bc0-bda2-08eb497826f5" xlink:to="loc_amed_ContessaHealthMember_03c055fb-d0eb-4306-ba00-b32675363661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a5cd7280-20ca-40d6-9169-4318ef2cef37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d7c8f5e-2f0e-4cde-aaab-a463075b33a9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a5cd7280-20ca-40d6-9169-4318ef2cef37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_864aac71-dc20-4968-9959-c12d37fa5355" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a5cd7280-20ca-40d6-9169-4318ef2cef37" xlink:to="loc_us-gaap_SegmentDomain_864aac71-dc20-4968-9959-c12d37fa5355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_7cabeb39-4f60-43d9-a15c-53fafd84c1e2" xlink:href="amed-20221231.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_864aac71-dc20-4968-9959-c12d37fa5355" xlink:to="loc_amed_HomeHealthMember_7cabeb39-4f60-43d9-a15c-53fafd84c1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthAndHospiceMember_2e54c647-aa65-415d-8736-e0d6a1bfbff7" xlink:href="amed-20221231.xsd#amed_HomeHealthAndHospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_864aac71-dc20-4968-9959-c12d37fa5355" xlink:to="loc_amed_HomeHealthAndHospiceMember_2e54c647-aa65-415d-8736-e0d6a1bfbff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_e48b018b-76b7-4b9c-a44f-98367e7550b6" xlink:href="amed-20221231.xsd#amed_PersonalCareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_864aac71-dc20-4968-9959-c12d37fa5355" xlink:to="loc_amed_PersonalCareMember_e48b018b-76b7-4b9c-a44f-98367e7550b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_bb56e4d2-d8f9-438f-9cdc-0a8f5925cc36" xlink:href="amed-20221231.xsd#amed_HighAcuityCareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_864aac71-dc20-4968-9959-c12d37fa5355" xlink:to="loc_amed_HighAcuityCareMember_bb56e4d2-d8f9-438f-9cdc-0a8f5925cc36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c71819c6-7d17-4c6e-b204-1221e07186c8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d7c8f5e-2f0e-4cde-aaab-a463075b33a9" xlink:to="loc_srt_StatementGeographicalAxis_c71819c6-7d17-4c6e-b204-1221e07186c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_439cab5a-099a-4b4d-81d6-88a5c3d25e63" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_c71819c6-7d17-4c6e-b204-1221e07186c8" xlink:to="loc_srt_SegmentGeographicalDomain_439cab5a-099a-4b4d-81d6-88a5c3d25e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_883037cc-911d-4e92-bef1-f4495653353c" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_439cab5a-099a-4b4d-81d6-88a5c3d25e63" xlink:to="loc_stpr_MA_883037cc-911d-4e92-bef1-f4495653353c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL_0349a967-2c7e-439d-bb28-013de18f5c8f" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_IL"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_439cab5a-099a-4b4d-81d6-88a5c3d25e63" xlink:to="loc_stpr_IL_0349a967-2c7e-439d-bb28-013de18f5c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_AZ_42ec9922-1b69-40e9-aa6e-96b876ca7fc6" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_AZ"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_439cab5a-099a-4b4d-81d6-88a5c3d25e63" xlink:to="loc_stpr_AZ_42ec9922-1b69-40e9-aa6e-96b876ca7fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TN_9311e853-f9ba-47ae-85e9-9656c4a4f338" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_TN"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_439cab5a-099a-4b4d-81d6-88a5c3d25e63" xlink:to="loc_stpr_TN_9311e853-f9ba-47ae-85e9-9656c4a4f338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL_8e177a86-0ee4-482c-ae86-52213833d678" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_FL"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_439cab5a-099a-4b4d-81d6-88a5c3d25e63" xlink:to="loc_stpr_FL_8e177a86-0ee4-482c-ae86-52213833d678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA_03aed8b0-7d76-48fa-97d5-892dd0c550fd" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WA"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_439cab5a-099a-4b4d-81d6-88a5c3d25e63" xlink:to="loc_stpr_WA_03aed8b0-7d76-48fa-97d5-892dd0c550fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_KY_e66ebc2d-4ba6-4a88-a2f7-2e4f0d16f883" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_KY"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_439cab5a-099a-4b4d-81d6-88a5c3d25e63" xlink:to="loc_stpr_KY_e66ebc2d-4ba6-4a88-a2f7-2e4f0d16f883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NC_82faf634-fe01-40b4-9c34-a82f0613b4df" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NC"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_439cab5a-099a-4b4d-81d6-88a5c3d25e63" xlink:to="loc_stpr_NC_82faf634-fe01-40b4-9c34-a82f0613b4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY_1a2929ae-47b2-4c72-938b-04e3ecc3b384" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NY"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_439cab5a-099a-4b4d-81d6-88a5c3d25e63" xlink:to="loc_stpr_NY_1a2929ae-47b2-4c72-938b-04e3ecc3b384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RandolphCountyNorthCarolinaMember_787231b1-1166-48ac-8003-4a05f4527a7c" xlink:href="amed-20221231.xsd#amed_RandolphCountyNorthCarolinaMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_439cab5a-099a-4b4d-81d6-88a5c3d25e63" xlink:to="loc_amed_RandolphCountyNorthCarolinaMember_787231b1-1166-48ac-8003-4a05f4527a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4bc42cbe-c693-432f-86a9-5f6d4fad3040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d7c8f5e-2f0e-4cde-aaab-a463075b33a9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4bc42cbe-c693-432f-86a9-5f6d4fad3040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0e14b46-53e8-4b31-bb13-b9939783b16e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4bc42cbe-c693-432f-86a9-5f6d4fad3040" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0e14b46-53e8-4b31-bb13-b9939783b16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificatesOfNeedMember_052397a5-b5a5-4139-8372-64ecf78b00af" xlink:href="amed-20221231.xsd#amed_CertificatesOfNeedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0e14b46-53e8-4b31-bb13-b9939783b16e" xlink:to="loc_amed_CertificatesOfNeedMember_052397a5-b5a5-4139-8372-64ecf78b00af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_e4a86ba6-9dc3-4d3e-ab11-183fb0a39b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0e14b46-53e8-4b31-bb13-b9939783b16e" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_e4a86ba6-9dc3-4d3e-ab11-183fb0a39b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LicensesMember_cf63b4fb-3ff8-4c33-a02b-90e68666c9fd" xlink:href="amed-20221231.xsd#amed_LicensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0e14b46-53e8-4b31-bb13-b9939783b16e" xlink:to="loc_amed_LicensesMember_cf63b4fb-3ff8-4c33-a02b-90e68666c9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificatesOfNeedAndLicensesMember_97db1c20-09c5-4e1b-ad13-bf940ad45d7d" xlink:href="amed-20221231.xsd#amed_CertificatesOfNeedAndLicensesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0e14b46-53e8-4b31-bb13-b9939783b16e" xlink:to="loc_amed_CertificatesOfNeedAndLicensesMember_97db1c20-09c5-4e1b-ad13-bf940ad45d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificateOfNeedMember_37c53c2e-8777-4c11-b42c-d2f0214270d4" xlink:href="amed-20221231.xsd#amed_CertificateOfNeedMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0e14b46-53e8-4b31-bb13-b9939783b16e" xlink:to="loc_amed_CertificateOfNeedMember_37c53c2e-8777-4c11-b42c-d2f0214270d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNamesMember_da048025-d7a9-49fd-a82b-9a1781247124" xlink:href="amed-20221231.xsd#amed_AcquiredNamesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0e14b46-53e8-4b31-bb13-b9939783b16e" xlink:to="loc_amed_AcquiredNamesMember_da048025-d7a9-49fd-a82b-9a1781247124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_b3883925-06e4-4ca5-82e3-9172935f34ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0e14b46-53e8-4b31-bb13-b9939783b16e" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_b3883925-06e4-4ca5-82e3-9172935f34ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnamortizableAcquiredNamesMember_0bfc73b7-37f8-41eb-b75c-a53a9f38f7ae" xlink:href="amed-20221231.xsd#amed_UnamortizableAcquiredNamesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0e14b46-53e8-4b31-bb13-b9939783b16e" xlink:to="loc_amed_UnamortizableAcquiredNamesMember_0bfc73b7-37f8-41eb-b75c-a53a9f38f7ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmortizableAcquiredNamesMember_3c3d7d45-193c-449e-9f21-c9110863b8c2" xlink:href="amed-20221231.xsd#amed_AmortizableAcquiredNamesMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0e14b46-53e8-4b31-bb13-b9939783b16e" xlink:to="loc_amed_AmortizableAcquiredNamesMember_3c3d7d45-193c-449e-9f21-c9110863b8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmortizableAcquiredNameAndNoncompeteAgreementsMember_97a57946-bca4-4a5b-bc7c-84c99d6975e6" xlink:href="amed-20221231.xsd#amed_AmortizableAcquiredNameAndNoncompeteAgreementsMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b0e14b46-53e8-4b31-bb13-b9939783b16e" xlink:to="loc_amed_AmortizableAcquiredNameAndNoncompeteAgreementsMember_97a57946-bca4-4a5b-bc7c-84c99d6975e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7bba2540-4549-4b08-a4e8-6ac232ff1993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d7c8f5e-2f0e-4cde-aaab-a463075b33a9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7bba2540-4549-4b08-a4e8-6ac232ff1993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e63a1972-056f-40e9-b412-4f17b5da18c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7bba2540-4549-4b08-a4e8-6ac232ff1993" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e63a1972-056f-40e9-b412-4f17b5da18c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PromissoryNotesMember_5e464730-c201-4265-93e3-81d3b0809b76" xlink:href="amed-20221231.xsd#amed_PromissoryNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e63a1972-056f-40e9-b412-4f17b5da18c4" xlink:to="loc_amed_PromissoryNotesMember_5e464730-c201-4265-93e3-81d3b0809b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3df06b80-10ef-4432-9426-1eacd9319c42" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d7c8f5e-2f0e-4cde-aaab-a463075b33a9" xlink:to="loc_srt_RangeAxis_3df06b80-10ef-4432-9426-1eacd9319c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3bba4aa7-c619-4472-a9ff-a8d4ec479fc9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3df06b80-10ef-4432-9426-1eacd9319c42" xlink:to="loc_srt_RangeMember_3bba4aa7-c619-4472-a9ff-a8d4ec479fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_001184f1-44aa-41ca-b84f-f4dc2ad106d5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3bba4aa7-c619-4472-a9ff-a8d4ec479fc9" xlink:to="loc_srt_MaximumMember_001184f1-44aa-41ca-b84f-f4dc2ad106d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_42808cf2-c313-4cbd-9913-7fbe17de85be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d7c8f5e-2f0e-4cde-aaab-a463075b33a9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_42808cf2-c313-4cbd-9913-7fbe17de85be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_fead0ea7-c816-4788-9df1-7993060940d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_42808cf2-c313-4cbd-9913-7fbe17de85be" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_fead0ea7-c816-4788-9df1-7993060940d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnamortizableAcquiredNamesMember_a8520ac4-fcaf-433d-a58b-bec6d75944cf" xlink:href="amed-20221231.xsd#amed_UnamortizableAcquiredNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_fead0ea7-c816-4788-9df1-7993060940d5" xlink:to="loc_amed_UnamortizableAcquiredNamesMember_a8520ac4-fcaf-433d-a58b-bec6d75944cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificatesOfNeedAndLicensesMember_99422c67-23ba-405d-8bb4-4d087932b8a5" xlink:href="amed-20221231.xsd#amed_CertificatesOfNeedAndLicensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_fead0ea7-c816-4788-9df1-7993060940d5" xlink:to="loc_amed_CertificatesOfNeedAndLicensesMember_99422c67-23ba-405d-8bb4-4d087932b8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationAdjustmentsAxis_55d730c2-8357-4dd0-a7dd-82cd7dcbd818" xlink:href="amed-20221231.xsd#amed_BusinessCombinationAdjustmentsAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d7c8f5e-2f0e-4cde-aaab-a463075b33a9" xlink:to="loc_amed_BusinessCombinationAdjustmentsAxis_55d730c2-8357-4dd0-a7dd-82cd7dcbd818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationAdjustmentsDomain_15226a7f-5f18-4017-a8bb-c01bcd8146ad" xlink:href="amed-20221231.xsd#amed_BusinessCombinationAdjustmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_BusinessCombinationAdjustmentsAxis_55d730c2-8357-4dd0-a7dd-82cd7dcbd818" xlink:to="loc_amed_BusinessCombinationAdjustmentsDomain_15226a7f-5f18-4017-a8bb-c01bcd8146ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PotentialClosingPaymentAdjustmentMember_be31aeee-12d9-4850-986f-fb5803875052" xlink:href="amed-20221231.xsd#amed_PotentialClosingPaymentAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_BusinessCombinationAdjustmentsDomain_15226a7f-5f18-4017-a8bb-c01bcd8146ad" xlink:to="loc_amed_PotentialClosingPaymentAdjustmentMember_be31aeee-12d9-4850-986f-fb5803875052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d7c8f5e-2f0e-4cde-aaab-a463075b33a9" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_11137ee4-8f4f-4891-8a19-c64cc538b17f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_11137ee4-8f4f-4891-8a19-c64cc538b17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_44acaf52-d648-409a-853d-0759a2ce0147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_44acaf52-d648-409a-853d-0759a2ce0147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_a640374b-f150-42ab-9026-e86ea1feb0df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_NotesPayable_a640374b-f150-42ab-9026-e86ea1feb0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_aaa4c1a6-38e7-4bbe-8d6e-75a646a6e2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_aaa4c1a6-38e7-4bbe-8d6e-75a646a6e2fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_297c7b24-64c0-4b09-90c7-c33bf6600a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_297c7b24-64c0-4b09-90c7-c33bf6600a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment_e4328c7a-7a63-431d-b4e1-35420903639f" xlink:href="amed-20221231.xsd#amed_BusinessAcquisitionWorkingCapitalAdjustment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment_e4328c7a-7a63-431d-b4e1-35420903639f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_58f5dae6-e312-4be1-96d7-91a7da5fb2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_58f5dae6-e312-4be1-96d7-91a7da5fb2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense_b19fa72f-8a6a-4172-8f62-d6e9e4c6cd85" xlink:href="amed-20221231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense_b19fa72f-8a6a-4172-8f62-d6e9e4c6cd85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_27c7e7b1-768b-41bb-8795-0e33c813f7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_27c7e7b1-768b-41bb-8795-0e33c813f7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_540b7cc1-d0cc-4556-adae-003d5371ac29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_540b7cc1-d0cc-4556-adae-003d5371ac29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_44dfc4ab-c514-45ce-b259-6d5e7784d5a9" xlink:href="amed-20221231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_44dfc4ab-c514-45ce-b259-6d5e7784d5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_a432b60c-4bf0-49b2-93b9-07525435564b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_a432b60c-4bf0-49b2-93b9-07525435564b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_b2e085ba-7520-4542-b736-1ea0e10b9d49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_b2e085ba-7520-4542-b736-1ea0e10b9d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_a1a7e6cc-d228-4496-902d-4d9ae998ebd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_a1a7e6cc-d228-4496-902d-4d9ae998ebd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_c7e7dabb-71dc-4aa1-a934-2768d77e2de3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_c7e7dabb-71dc-4aa1-a934-2768d77e2de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits_f968f009-0982-4b68-8d40-f274d268012d" xlink:href="amed-20221231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits_f968f009-0982-4b68-8d40-f274d268012d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_127669a4-f81a-4069-86fc-b0f54a2a8b64" xlink:href="amed-20221231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_127669a4-f81a-4069-86fc-b0f54a2a8b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities_cf22bb10-40d9-40d9-8944-880c3fd123e5" xlink:href="amed-20221231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities_cf22bb10-40d9-40d9-8944-880c3fd123e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_e66686fc-c9b2-4f31-ae94-9932a4d1f5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_e66686fc-c9b2-4f31-ae94-9932a4d1f5bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_2c2bf9b2-78af-4fa1-90dd-cc005adbbf87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_2c2bf9b2-78af-4fa1-90dd-cc005adbbf87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_7001b502-bcc3-4f31-99fb-4618e6fdc9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_7001b502-bcc3-4f31-99fb-4618e6fdc9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_ee889061-3b5f-45d2-a9ad-7bed9b16c49a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_ee889061-3b5f-45d2-a9ad-7bed9b16c49a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_3628d0a7-9290-4aec-96c5-0ce785a3b85e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_3628d0a7-9290-4aec-96c5-0ce785a3b85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity_17f28061-9a55-4a97-9ba3-349d8da85831" xlink:href="amed-20221231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity_17f28061-9a55-4a97-9ba3-349d8da85831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity_13256b01-5d12-488d-b023-c94817f738c6" xlink:href="amed-20221231.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity_13256b01-5d12-488d-b023-c94817f738c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_34946312-7eee-49f9-92fd-eba077cded75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_34946312-7eee-49f9-92fd-eba077cded75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_44aab3e2-fe78-45b9-a7fc-4b2ddea16228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_44aab3e2-fe78-45b9-a7fc-4b2ddea16228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_3e1674c7-6207-43ec-afed-ad4fe109d48c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_3e1674c7-6207-43ec-afed-ad4fe109d48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_a30c9b19-b29f-43db-b380-7e60b91db5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_a30c9b19-b29f-43db-b380-7e60b91db5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit_fb412677-a3f3-4783-a52b-08d24a173112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EscrowDeposit"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_EscrowDeposit_fb412677-a3f3-4783-a52b-08d24a173112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_6b169bac-b62c-487b-8214-bc79c29eefe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_6b169bac-b62c-487b-8214-bc79c29eefe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_980cd43e-c13e-4bf1-a2f3-4ab51491b63e" xlink:href="amed-20221231.xsd#amed_GoodwillDeductibleForIncomeTaxPurposesPeriod"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_980cd43e-c13e-4bf1-a2f3-4ab51491b63e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PaymentsRelatedToTaxAsset_c48ba830-6caf-472a-8a2d-6a49437a05bf" xlink:href="amed-20221231.xsd#amed_PaymentsRelatedToTaxAsset"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_amed_PaymentsRelatedToTaxAsset_c48ba830-6caf-472a-8a2d-6a49437a05bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionClosingPaymentAdjustment_99e0dd02-7359-4552-b8ee-52cc143bdfb8" xlink:href="amed-20221231.xsd#amed_BusinessAcquisitionClosingPaymentAdjustment"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_amed_BusinessAcquisitionClosingPaymentAdjustment_99e0dd02-7359-4552-b8ee-52cc143bdfb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_4f022087-4e50-4dad-929f-d57d9628583b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_4f022087-4e50-4dad-929f-d57d9628583b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_1b5704cf-4732-4a1b-bd8f-094798158762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_1b5704cf-4732-4a1b-bd8f-094798158762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_da0a1f3d-ba94-4292-bfd7-0714ea431d26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_OperatingIncomeLoss_da0a1f3d-ba94-4292-bfd7-0714ea431d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInAssetsAcquired_940f2d4e-e44a-4092-92c4-8d3c9704036e" xlink:href="amed-20221231.xsd#amed_IncreaseDecreaseInAssetsAcquired"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_amed_IncreaseDecreaseInAssetsAcquired_940f2d4e-e44a-4092-92c4-8d3c9704036e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInLiabilitiesAssumed_2dfed4fe-7f10-4e50-91a3-3edfbeb71f27" xlink:href="amed-20221231.xsd#amed_IncreaseDecreaseInLiabilitiesAssumed"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_amed_IncreaseDecreaseInLiabilitiesAssumed_2dfed4fe-7f10-4e50-91a3-3edfbeb71f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_2778113f-d160-4aee-b612-c17c2b96d572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_2778113f-d160-4aee-b612-c17c2b96d572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_2df3e8be-b048-44ec-9edd-d1bdeb2d30db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_2df3e8be-b048-44ec-9edd-d1bdeb2d30db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DepreciationAndAmortizationForContinuingOperations_db48fb8b-f83d-4c11-8bba-2ed49ccdae77" xlink:href="amed-20221231.xsd#amed_DepreciationAndAmortizationForContinuingOperations"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_amed_DepreciationAndAmortizationForContinuingOperations_db48fb8b-f83d-4c11-8bba-2ed49ccdae77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationAcquiredNoncontrollingInterest_11d44850-d577-428a-901e-53c3c5d1c3b2" xlink:href="amed-20221231.xsd#amed_BusinessCombinationAcquiredNoncontrollingInterest"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_amed_BusinessCombinationAcquiredNoncontrollingInterest_11d44850-d577-428a-901e-53c3c5d1c3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_5ea569a9-cde3-4f85-b71c-dc45ab1141d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="44" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_us-gaap_RestrictedCash_5ea569a9-cde3-4f85-b71c-dc45ab1141d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonCashAccruedContingentConsideration_93eb3525-2dea-437c-ae3c-0f74e823ba22" xlink:href="amed-20221231.xsd#amed_NonCashAccruedContingentConsideration"/>
    <link:presentationArc order="45" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_amed_NonCashAccruedContingentConsideration_93eb3525-2dea-437c-ae3c-0f74e823ba22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmountReleasedFromEscrow_5cd5ef5b-3ca4-4e39-8fd3-96bf197f2813" xlink:href="amed-20221231.xsd#amed_AmountReleasedFromEscrow"/>
    <link:presentationArc order="46" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f9661870-d22f-45c1-a7db-0954292bd69f" xlink:to="loc_amed_AmountReleasedFromEscrow_5cd5ef5b-3ca4-4e39-8fd3-96bf197f2813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_b9375ec6-d12b-4bc2-aac9-d53bf3b69a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5abf2f55-45e7-46b0-aa30-883cbcd88b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_b9375ec6-d12b-4bc2-aac9-d53bf3b69a8f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5abf2f55-45e7-46b0-aa30-883cbcd88b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a1b86744-37e9-4a33-9ab5-5b719fb4af40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5abf2f55-45e7-46b0-aa30-883cbcd88b5b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a1b86744-37e9-4a33-9ab5-5b719fb4af40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06357d0a-e697-4438-9e1d-9461ab007260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a1b86744-37e9-4a33-9ab5-5b719fb4af40" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06357d0a-e697-4438-9e1d-9461ab007260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_c4a8c236-e1df-47d7-a608-abb3e4aca7bf" xlink:href="amed-20221231.xsd#amed_AseraCareHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06357d0a-e697-4438-9e1d-9461ab007260" xlink:to="loc_amed_AseraCareHospiceMember_c4a8c236-e1df-47d7-a608-abb3e4aca7bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_83713860-0483-4cbb-a881-b185a3aabd50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5abf2f55-45e7-46b0-aa30-883cbcd88b5b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_83713860-0483-4cbb-a881-b185a3aabd50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_22f6f306-b053-443f-9363-92b5cb7c7f99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_83713860-0483-4cbb-a881-b185a3aabd50" xlink:to="loc_us-gaap_SegmentDomain_22f6f306-b053-443f-9363-92b5cb7c7f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_98a77afd-8643-435f-bff1-91473f09eb90" xlink:href="amed-20221231.xsd#amed_HospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_22f6f306-b053-443f-9363-92b5cb7c7f99" xlink:to="loc_amed_HospiceMember_98a77afd-8643-435f-bff1-91473f09eb90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_682b99e7-20f9-4791-9d15-1b1d8bcd49ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5abf2f55-45e7-46b0-aa30-883cbcd88b5b" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_682b99e7-20f9-4791-9d15-1b1d8bcd49ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_5bc47d2a-4528-4b62-a6a5-02c813f2f235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682b99e7-20f9-4791-9d15-1b1d8bcd49ef" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_5bc47d2a-4528-4b62-a6a5-02c813f2f235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionProFormaOperatingIncomeLoss_c86a84d8-9e96-4532-8dfe-f26270c4a514" xlink:href="amed-20221231.xsd#amed_BusinessAcquisitionProFormaOperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682b99e7-20f9-4791-9d15-1b1d8bcd49ef" xlink:to="loc_amed_BusinessAcquisitionProFormaOperatingIncomeLoss_c86a84d8-9e96-4532-8dfe-f26270c4a514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_308acf11-948f-44c6-847b-d3ecc32f2cec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682b99e7-20f9-4791-9d15-1b1d8bcd49ef" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_308acf11-948f-44c6-847b-d3ecc32f2cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_b6483b8f-a2f0-4d4b-81aa-602fcdd46167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682b99e7-20f9-4791-9d15-1b1d8bcd49ef" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_b6483b8f-a2f0-4d4b-81aa-602fcdd46167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_213d3d28-ee23-4dd1-b4a9-00c7f9f83919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682b99e7-20f9-4791-9d15-1b1d8bcd49ef" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_213d3d28-ee23-4dd1-b4a9-00c7f9f83919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_69a787e7-9bdf-4bbe-9f78-1a4104b113ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_b730b9c3-342a-423f-91e7-8490f49ed678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_69a787e7-9bdf-4bbe-9f78-1a4104b113ca" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_b730b9c3-342a-423f-91e7-8490f49ed678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_843e7bb7-670c-4aa8-95f7-acbdafe73721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_b730b9c3-342a-423f-91e7-8490f49ed678" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_843e7bb7-670c-4aa8-95f7-acbdafe73721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9e8275cc-b3cf-4583-b7f1-051165c9dbe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_843e7bb7-670c-4aa8-95f7-acbdafe73721" xlink:to="loc_us-gaap_SegmentDomain_9e8275cc-b3cf-4583-b7f1-051165c9dbe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_1860f866-9b07-4636-85ad-30730326e257" xlink:href="amed-20221231.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9e8275cc-b3cf-4583-b7f1-051165c9dbe1" xlink:to="loc_amed_HomeHealthMember_1860f866-9b07-4636-85ad-30730326e257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_bdf8c23a-d5d5-4c4f-b5aa-b0e0976a4892" xlink:href="amed-20221231.xsd#amed_HospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9e8275cc-b3cf-4583-b7f1-051165c9dbe1" xlink:to="loc_amed_HospiceMember_bdf8c23a-d5d5-4c4f-b5aa-b0e0976a4892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_f2d0d1c1-7c06-4922-9dad-d7eeb5337eaf" xlink:href="amed-20221231.xsd#amed_PersonalCareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9e8275cc-b3cf-4583-b7f1-051165c9dbe1" xlink:to="loc_amed_PersonalCareMember_f2d0d1c1-7c06-4922-9dad-d7eeb5337eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_9f9a5722-a35f-45f1-b133-e81a88375547" xlink:href="amed-20221231.xsd#amed_HighAcuityCareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9e8275cc-b3cf-4583-b7f1-051165c9dbe1" xlink:to="loc_amed_HighAcuityCareMember_9f9a5722-a35f-45f1-b133-e81a88375547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_4f244af6-2ee0-4074-9f6b-0d264f7a14e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_b730b9c3-342a-423f-91e7-8490f49ed678" xlink:to="loc_us-gaap_GoodwillLineItems_4f244af6-2ee0-4074-9f6b-0d264f7a14e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_fdfe6a1e-d469-4ff8-b617-05ec494d5160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_4f244af6-2ee0-4074-9f6b-0d264f7a14e6" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_fdfe6a1e-d469-4ff8-b617-05ec494d5160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_a19b612c-47e9-4355-8f23-6a000ba7c473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_4f244af6-2ee0-4074-9f6b-0d264f7a14e6" xlink:to="loc_us-gaap_GoodwillRollForward_a19b612c-47e9-4355-8f23-6a000ba7c473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_55d4dc56-c001-421e-b8a9-138cc269904f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_a19b612c-47e9-4355-8f23-6a000ba7c473" xlink:to="loc_us-gaap_Goodwill_55d4dc56-c001-421e-b8a9-138cc269904f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_aae87feb-132d-4880-949e-12c0a2cb5ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_a19b612c-47e9-4355-8f23-6a000ba7c473" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_aae87feb-132d-4880-949e-12c0a2cb5ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_be2cccc3-00f5-416b-9697-3b711ddf1469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_a19b612c-47e9-4355-8f23-6a000ba7c473" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_be2cccc3-00f5-416b-9697-3b711ddf1469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e5dc895f-f46b-4aa9-8e3f-19334a4e9fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_a19b612c-47e9-4355-8f23-6a000ba7c473" xlink:to="loc_us-gaap_Goodwill_e5dc895f-f46b-4aa9-8e3f-19334a4e9fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c74a1c74-b1dc-4a06-a653-bfbc465e4407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_74fbecb8-5ba9-49b4-8efd-e25c93b67da9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c74a1c74-b1dc-4a06-a653-bfbc465e4407" xlink:to="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_74fbecb8-5ba9-49b4-8efd-e25c93b67da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3ee85435-3229-49a4-ae4c-237febf36438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_74fbecb8-5ba9-49b4-8efd-e25c93b67da9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3ee85435-3229-49a4-ae4c-237febf36438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_20bf3d92-16a5-4c13-8ec4-7c1f340bbb63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3ee85435-3229-49a4-ae4c-237febf36438" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_20bf3d92-16a5-4c13-8ec4-7c1f340bbb63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificatesOfNeedAndLicensesMember_17692c22-dbf7-4a7a-bc3f-7ce8056baf5f" xlink:href="amed-20221231.xsd#amed_CertificatesOfNeedAndLicensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_20bf3d92-16a5-4c13-8ec4-7c1f340bbb63" xlink:to="loc_amed_CertificatesOfNeedAndLicensesMember_17692c22-dbf7-4a7a-bc3f-7ce8056baf5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNamesMember_79dcbfcd-f94e-4bb5-b70a-80013c3057b7" xlink:href="amed-20221231.xsd#amed_AcquiredNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_20bf3d92-16a5-4c13-8ec4-7c1f340bbb63" xlink:to="loc_amed_AcquiredNamesMember_79dcbfcd-f94e-4bb5-b70a-80013c3057b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_da1a06c0-c4a9-4c78-b4f9-416344b198e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_74fbecb8-5ba9-49b4-8efd-e25c93b67da9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_da1a06c0-c4a9-4c78-b4f9-416344b198e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c7b4f3a6-eb8a-4307-8798-3f42b1dd805a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_da1a06c0-c4a9-4c78-b4f9-416344b198e7" xlink:to="loc_us-gaap_SegmentDomain_c7b4f3a6-eb8a-4307-8798-3f42b1dd805a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_747853da-637b-453a-93e0-206a34bc4d20" xlink:href="amed-20221231.xsd#amed_PersonalCareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c7b4f3a6-eb8a-4307-8798-3f42b1dd805a" xlink:to="loc_amed_PersonalCareMember_747853da-637b-453a-93e0-206a34bc4d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0d35cf37-657d-4c79-a797-c0532bdd5ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_74fbecb8-5ba9-49b4-8efd-e25c93b67da9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0d35cf37-657d-4c79-a797-c0532bdd5ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58ab67d3-83d4-437a-bfad-0383b6a7d1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0d35cf37-657d-4c79-a797-c0532bdd5ef0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58ab67d3-83d4-437a-bfad-0383b6a7d1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_72376f4b-6f97-41e8-aa74-f0c26776abb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58ab67d3-83d4-437a-bfad-0383b6a7d1a6" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_72376f4b-6f97-41e8-aa74-f0c26776abb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_0c61e7e8-2157-4133-92d5-158b9bb20f72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58ab67d3-83d4-437a-bfad-0383b6a7d1a6" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_0c61e7e8-2157-4133-92d5-158b9bb20f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNamesMember_ff3dc035-e3ac-4af7-ada1-e2cf37ed1c82" xlink:href="amed-20221231.xsd#amed_AcquiredNamesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58ab67d3-83d4-437a-bfad-0383b6a7d1a6" xlink:to="loc_amed_AcquiredNamesMember_ff3dc035-e3ac-4af7-ada1-e2cf37ed1c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmortizableAcquiredNamesMember_73d68caf-ae61-419c-9d15-9f54501e0541" xlink:href="amed-20221231.xsd#amed_AmortizableAcquiredNamesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58ab67d3-83d4-437a-bfad-0383b6a7d1a6" xlink:to="loc_amed_AmortizableAcquiredNamesMember_73d68caf-ae61-419c-9d15-9f54501e0541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_1323e231-1110-4532-9fdd-b4c721c83412" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_74fbecb8-5ba9-49b4-8efd-e25c93b67da9" xlink:to="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_1323e231-1110-4532-9fdd-b4c721c83412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_18db9f17-2ae7-4835-918e-df97d72627fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_1323e231-1110-4532-9fdd-b4c721c83412" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_18db9f17-2ae7-4835-918e-df97d72627fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_ca539ac0-e78b-4bbe-90d4-a37cdee81c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_1323e231-1110-4532-9fdd-b4c721c83412" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_ca539ac0-e78b-4bbe-90d4-a37cdee81c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b9ef7206-6591-4c95-977c-50b4a79a7b44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_1323e231-1110-4532-9fdd-b4c721c83412" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b9ef7206-6591-4c95-977c-50b4a79a7b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a5fa0396-bfd6-49e6-9ef9-978019de60a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_ad4ab4dd-3922-4109-9450-69621bea4bda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a5fa0396-bfd6-49e6-9ef9-978019de60a2" xlink:to="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_ad4ab4dd-3922-4109-9450-69621bea4bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1e80bb53-4c60-40b7-b30e-28a00cb0c44a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_ad4ab4dd-3922-4109-9450-69621bea4bda" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1e80bb53-4c60-40b7-b30e-28a00cb0c44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_09f7acfd-02ef-462b-8f3f-bca63e045ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1e80bb53-4c60-40b7-b30e-28a00cb0c44a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_09f7acfd-02ef-462b-8f3f-bca63e045ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificatesOfNeedAndLicensesMember_333c6343-b0ae-4521-a6c6-36524f025ac7" xlink:href="amed-20221231.xsd#amed_CertificatesOfNeedAndLicensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_09f7acfd-02ef-462b-8f3f-bca63e045ff8" xlink:to="loc_amed_CertificatesOfNeedAndLicensesMember_333c6343-b0ae-4521-a6c6-36524f025ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnamortizableAcquiredNamesMember_c8db2c63-9562-4683-a4cb-769b8fab93e2" xlink:href="amed-20221231.xsd#amed_UnamortizableAcquiredNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_09f7acfd-02ef-462b-8f3f-bca63e045ff8" xlink:to="loc_amed_UnamortizableAcquiredNamesMember_c8db2c63-9562-4683-a4cb-769b8fab93e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a8fb067d-8a33-49ff-9e91-c457f4cdc6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_ad4ab4dd-3922-4109-9450-69621bea4bda" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a8fb067d-8a33-49ff-9e91-c457f4cdc6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_39e7d4a0-d7c8-4837-b78b-b3d89996694f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a8fb067d-8a33-49ff-9e91-c457f4cdc6e8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_39e7d4a0-d7c8-4837-b78b-b3d89996694f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmortizableAcquiredNamesMember_d7bd4b9a-bd62-4b83-be63-a14eaecfa811" xlink:href="amed-20221231.xsd#amed_AmortizableAcquiredNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_39e7d4a0-d7c8-4837-b78b-b3d89996694f" xlink:to="loc_amed_AmortizableAcquiredNamesMember_d7bd4b9a-bd62-4b83-be63-a14eaecfa811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_04695078-5370-483e-a6d8-da06be0646ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_39e7d4a0-d7c8-4837-b78b-b3d89996694f" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_04695078-5370-483e-a6d8-da06be0646ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_22d05c85-62f7-45b2-9d5e-24d5ab556632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_39e7d4a0-d7c8-4837-b78b-b3d89996694f" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_22d05c85-62f7-45b2-9d5e-24d5ab556632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_4d25115b-fcf3-460d-aa5a-ae3215dcb633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_ad4ab4dd-3922-4109-9450-69621bea4bda" xlink:to="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_4d25115b-fcf3-460d-aa5a-ae3215dcb633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_0c76b343-682f-441b-bdcd-7befb6ded54e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_4d25115b-fcf3-460d-aa5a-ae3215dcb633" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_0c76b343-682f-441b-bdcd-7befb6ded54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_13290ffd-5f77-44fe-9601-25163907cedf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_0c76b343-682f-441b-bdcd-7befb6ded54e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_13290ffd-5f77-44fe-9601-25163907cedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OtherIntangibleAssetsAdditions_f485230e-b86d-4cf9-811e-968179eeac32" xlink:href="amed-20221231.xsd#amed_OtherIntangibleAssetsAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_0c76b343-682f-441b-bdcd-7befb6ded54e" xlink:to="loc_amed_OtherIntangibleAssetsAdditions_f485230e-b86d-4cf9-811e-968179eeac32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ReclassToAmortizableIntangible_989e23b3-d471-4dd7-815a-9e5b3ddc3ce3" xlink:href="amed-20221231.xsd#amed_ReclassToAmortizableIntangible"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_0c76b343-682f-441b-bdcd-7befb6ded54e" xlink:to="loc_amed_ReclassToAmortizableIntangible_989e23b3-d471-4dd7-815a-9e5b3ddc3ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_655ab10e-d145-424d-8aff-dcc9e6e72501" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_0c76b343-682f-441b-bdcd-7befb6ded54e" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_655ab10e-d145-424d-8aff-dcc9e6e72501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_f7fe3e8e-19f4-41e4-9799-733ef19e47e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_0c76b343-682f-441b-bdcd-7befb6ded54e" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_f7fe3e8e-19f4-41e4-9799-733ef19e47e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0813d0e2-132e-446c-b70e-2cedf6873874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_0c76b343-682f-441b-bdcd-7befb6ded54e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0813d0e2-132e-446c-b70e-2cedf6873874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8d189b46-6ab2-4abd-b465-046087b04305" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_6cfa0116-3792-4690-9148-49596f3905b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8d189b46-6ab2-4abd-b465-046087b04305" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_6cfa0116-3792-4690-9148-49596f3905b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_84df0c1f-e1d0-48e5-875a-1b050cad5ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_6cfa0116-3792-4690-9148-49596f3905b2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_84df0c1f-e1d0-48e5-875a-1b050cad5ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_211ff01c-13ed-4e4b-9392-468f5c02b88e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_6cfa0116-3792-4690-9148-49596f3905b2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_211ff01c-13ed-4e4b-9392-468f5c02b88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b60cdcb8-c5b2-4eb4-a7bc-48c855e9d264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_6cfa0116-3792-4690-9148-49596f3905b2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b60cdcb8-c5b2-4eb4-a7bc-48c855e9d264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ab4d40e9-94cd-426a-9360-04f97604564c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_6cfa0116-3792-4690-9148-49596f3905b2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ab4d40e9-94cd-426a-9360-04f97604564c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1de52057-b475-4cee-ae4c-aa022214005e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_6cfa0116-3792-4690-9148-49596f3905b2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_1de52057-b475-4cee-ae4c-aa022214005e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d06d0bb5-6a0f-4c26-bd54-2e0e76f524bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_6cfa0116-3792-4690-9148-49596f3905b2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d06d0bb5-6a0f-4c26-bd54-2e0e76f524bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/DiscontinuedOperationsandAssetsHeldForSaleAdditionalInformationDetail" xlink:type="simple" xlink:href="amed-20221231.xsd#DiscontinuedOperationsandAssetsHeldForSaleAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/DiscontinuedOperationsandAssetsHeldForSaleAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_a77bf28e-0784-4f8a-8869-f29d14c4bd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2f213f74-ca23-4764-9470-edacd83b244b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_a77bf28e-0784-4f8a-8869-f29d14c4bd4e" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2f213f74-ca23-4764-9470-edacd83b244b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_793f9a2e-4a61-4055-b80b-524a21b20ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2f213f74-ca23-4764-9470-edacd83b244b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_793f9a2e-4a61-4055-b80b-524a21b20ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_dfcf2839-c43a-4a15-ade8-1ac29dd9efef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_793f9a2e-4a61-4055-b80b-524a21b20ea6" xlink:to="loc_us-gaap_SegmentDomain_dfcf2839-c43a-4a15-ade8-1ac29dd9efef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_c7490af4-f494-457f-a12f-f01e89477c74" xlink:href="amed-20221231.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_dfcf2839-c43a-4a15-ade8-1ac29dd9efef" xlink:to="loc_amed_HomeHealthMember_c7490af4-f494-457f-a12f-f01e89477c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_4ae14f94-0100-4e4a-86d8-a2e25d6def41" xlink:href="amed-20221231.xsd#amed_PersonalCareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_dfcf2839-c43a-4a15-ade8-1ac29dd9efef" xlink:to="loc_amed_PersonalCareMember_4ae14f94-0100-4e4a-86d8-a2e25d6def41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_1d04d407-88f8-4f4b-a3e7-8c4f4498b3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2f213f74-ca23-4764-9470-edacd83b244b" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_1d04d407-88f8-4f4b-a3e7-8c4f4498b3c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_1604096f-a77e-4e0f-873a-50fcdf36c97f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis_1d04d407-88f8-4f4b-a3e7-8c4f4498b3c5" xlink:to="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_1604096f-a77e-4e0f-873a-50fcdf36c97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_c428f598-ed5d-401e-8f0f-17d84fa132d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongLivedAssetsHeldForSaleNameDomain_1604096f-a77e-4e0f-873a-50fcdf36c97f" xlink:to="loc_us-gaap_DiscontinuedOperationsHeldforsaleMember_c428f598-ed5d-401e-8f0f-17d84fa132d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5f3937d4-5a18-46ca-a44f-402834da8bac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2f213f74-ca23-4764-9470-edacd83b244b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5f3937d4-5a18-46ca-a44f-402834da8bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6bfa208d-8cb6-45de-818c-d2395c96ac6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5f3937d4-5a18-46ca-a44f-402834da8bac" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6bfa208d-8cb6-45de-818c-d2395c96ac6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_0ed25bad-01c2-452e-b0c5-9c06e5c9404c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6bfa208d-8cb6-45de-818c-d2395c96ac6a" xlink:to="loc_us-gaap_SubsequentEventMember_0ed25bad-01c2-452e-b0c5-9c06e5c9404c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d8b14102-ff85-4cb2-b70c-5abd87ee0baa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2f213f74-ca23-4764-9470-edacd83b244b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d8b14102-ff85-4cb2-b70c-5abd87ee0baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfCareCentersConsolidated_c6aa7e32-2d3c-4fe4-befb-aa769de5b141" xlink:href="amed-20221231.xsd#amed_NumberOfCareCentersConsolidated"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d8b14102-ff85-4cb2-b70c-5abd87ee0baa" xlink:to="loc_amed_NumberOfCareCentersConsolidated_c6aa7e32-2d3c-4fe4-befb-aa769de5b141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfCareCentersClosed_b17eeb67-9d10-4f6e-b795-2885a139f5e1" xlink:href="amed-20221231.xsd#amed_NumberOfCareCentersClosed"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d8b14102-ff85-4cb2-b70c-5abd87ee0baa" xlink:to="loc_amed_NumberOfCareCentersClosed_b17eeb67-9d10-4f6e-b795-2885a139f5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued_8e4882c5-8279-433d-8824-0ce51e2094ec" xlink:href="amed-20221231.xsd#amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d8b14102-ff85-4cb2-b70c-5abd87ee0baa" xlink:to="loc_amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued_8e4882c5-8279-433d-8824-0ce51e2094ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfCareCentersExited_da4f41f9-4ad3-4f25-82fd-aae99c386cd9" xlink:href="amed-20221231.xsd#amed_NumberOfCareCentersExited"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d8b14102-ff85-4cb2-b70c-5abd87ee0baa" xlink:to="loc_amed_NumberOfCareCentersExited_da4f41f9-4ad3-4f25-82fd-aae99c386cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfCareCentersAvailableForSale_a535b79e-012b-4418-b1f3-0bb2dfe5d382" xlink:href="amed-20221231.xsd#amed_NumberOfCareCentersAvailableForSale"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d8b14102-ff85-4cb2-b70c-5abd87ee0baa" xlink:to="loc_amed_NumberOfCareCentersAvailableForSale_a535b79e-012b-4418-b1f3-0bb2dfe5d382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfCareCentersSold_7f394eed-ad2c-49da-8d78-20623d2ce30d" xlink:href="amed-20221231.xsd#amed_NumberOfCareCentersSold"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d8b14102-ff85-4cb2-b70c-5abd87ee0baa" xlink:to="loc_amed_NumberOfCareCentersSold_7f394eed-ad2c-49da-8d78-20623d2ce30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfCareCentersIncludedInDivestiturePlan_865886a5-71e7-444f-a9c9-0396d53e2304" xlink:href="amed-20221231.xsd#amed_NumberOfCareCentersIncludedInDivestiturePlan"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d8b14102-ff85-4cb2-b70c-5abd87ee0baa" xlink:to="loc_amed_NumberOfCareCentersIncludedInDivestiturePlan_865886a5-71e7-444f-a9c9-0396d53e2304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfCareCentersIncludedInDiscontinuedOperations_515f93a6-b543-45bd-a1c4-7a0918f0287c" xlink:href="amed-20221231.xsd#amed_NumberOfCareCentersIncludedInDiscontinuedOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d8b14102-ff85-4cb2-b70c-5abd87ee0baa" xlink:to="loc_amed_NumberOfCareCentersIncludedInDiscontinuedOperations_515f93a6-b543-45bd-a1c4-7a0918f0287c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfCareCentersRemovedFromAvailableForSale_19bd04e1-b010-49b0-ba32-3bb4bbb636fc" xlink:href="amed-20221231.xsd#amed_NumberOfCareCentersRemovedFromAvailableForSale"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d8b14102-ff85-4cb2-b70c-5abd87ee0baa" xlink:to="loc_amed_NumberOfCareCentersRemovedFromAvailableForSale_19bd04e1-b010-49b0-ba32-3bb4bbb636fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_783dfa4e-b81a-45bd-8ed3-b951f1854cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d8b14102-ff85-4cb2-b70c-5abd87ee0baa" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_783dfa4e-b81a-45bd-8ed3-b951f1854cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_891ebe4f-6ee3-49ca-b46d-ef629e326c87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d8b14102-ff85-4cb2-b70c-5abd87ee0baa" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_891ebe4f-6ee3-49ca-b46d-ef629e326c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_b9568940-964e-47ed-81cd-3210be31fbb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d8b14102-ff85-4cb2-b70c-5abd87ee0baa" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_b9568940-964e-47ed-81cd-3210be31fbb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/AssetsHeldForSaleAssetsandLiabilitiesDetail" xlink:type="simple" xlink:href="amed-20221231.xsd#AssetsHeldForSaleAssetsandLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/AssetsHeldForSaleAssetsandLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_207c4f37-e08c-43f2-ace6-b05d3317fbcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_add5a077-3acb-4e85-bc77-ad9ff5eb0206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract_207c4f37-e08c-43f2-ace6-b05d3317fbcc" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_add5a077-3acb-4e85-bc77-ad9ff5eb0206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_dd436934-0acb-4d9e-8938-eec8b3fa1d32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_add5a077-3acb-4e85-bc77-ad9ff5eb0206" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_dd436934-0acb-4d9e-8938-eec8b3fa1d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_eb9ef0ab-c25b-4e2c-9483-a10c2d5f5885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_dd436934-0acb-4d9e-8938-eec8b3fa1d32" xlink:to="loc_us-gaap_SegmentDomain_eb9ef0ab-c25b-4e2c-9483-a10c2d5f5885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_b3b8f841-1231-4fd8-993e-788cadabb624" xlink:href="amed-20221231.xsd#amed_PersonalCareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_eb9ef0ab-c25b-4e2c-9483-a10c2d5f5885" xlink:to="loc_amed_PersonalCareMember_b3b8f841-1231-4fd8-993e-788cadabb624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_77cc7602-01bd-456e-a1a8-4940ee44f6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_add5a077-3acb-4e85-bc77-ad9ff5eb0206" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_77cc7602-01bd-456e-a1a8-4940ee44f6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_ab5d8b91-84e1-4968-be0c-e60e0fa7dbc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_77cc7602-01bd-456e-a1a8-4940ee44f6f7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_ab5d8b91-84e1-4968-be0c-e60e0fa7dbc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_5f914b68-6874-4b2d-bd01-e1383b9c13bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_77cc7602-01bd-456e-a1a8-4940ee44f6f7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_5f914b68-6874-4b2d-bd01-e1383b9c13bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_5d57bb36-c268-4efc-ad68-5a3dd875cd5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_77cc7602-01bd-456e-a1a8-4940ee44f6f7" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_5d57bb36-c268-4efc-ad68-5a3dd875cd5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_3337dbc3-315b-4083-adc7-54521b677d48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_77cc7602-01bd-456e-a1a8-4940ee44f6f7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_3337dbc3-315b-4083-adc7-54521b677d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent_ac03b5e9-ff6c-4e94-9ebf-5adec575fb74" xlink:href="amed-20221231.xsd#amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_77cc7602-01bd-456e-a1a8-4940ee44f6f7" xlink:to="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent_ac03b5e9-ff6c-4e94-9ebf-5adec575fb74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_ea3fb82e-9971-4a89-9425-cdf21fade928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_77cc7602-01bd-456e-a1a8-4940ee44f6f7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_ea3fb82e-9971-4a89-9425-cdf21fade928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_78099880-18f9-48de-a21b-f89107cf1f74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_77cc7602-01bd-456e-a1a8-4940ee44f6f7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_78099880-18f9-48de-a21b-f89107cf1f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_29409f52-ae35-4269-bf71-b47ec7a40f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_77cc7602-01bd-456e-a1a8-4940ee44f6f7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_29409f52-ae35-4269-bf71-b47ec7a40f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_a5b72f10-5f59-4cc7-85eb-47e50d5f9371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_77cc7602-01bd-456e-a1a8-4940ee44f6f7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_a5b72f10-5f59-4cc7-85eb-47e50d5f9371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent_a20f439d-02f8-4427-9d1b-001b09097d11" xlink:href="amed-20221231.xsd#amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_77cc7602-01bd-456e-a1a8-4940ee44f6f7" xlink:to="loc_amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent_a20f439d-02f8-4427-9d1b-001b09097d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent_a5e1b9ec-fb4e-4e3f-a93f-cf2e62b68d8c" xlink:href="amed-20221231.xsd#amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_77cc7602-01bd-456e-a1a8-4940ee44f6f7" xlink:to="loc_amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent_a5e1b9ec-fb4e-4e3f-a93f-cf2e62b68d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent_08190859-431f-4c1b-ad3f-3258a05c52eb" xlink:href="amed-20221231.xsd#amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_77cc7602-01bd-456e-a1a8-4940ee44f6f7" xlink:to="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent_08190859-431f-4c1b-ad3f-3258a05c52eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_412c7a77-2e5e-4a44-84d0-dc3ee386e443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_77cc7602-01bd-456e-a1a8-4940ee44f6f7" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_412c7a77-2e5e-4a44-84d0-dc3ee386e443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent_d5bded43-d3e0-490a-9667-fd93600654e5" xlink:href="amed-20221231.xsd#amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_77cc7602-01bd-456e-a1a8-4940ee44f6f7" xlink:to="loc_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent_d5bded43-d3e0-490a-9667-fd93600654e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_2dcbab11-75be-4f50-934d-b3ab1a20529f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_77cc7602-01bd-456e-a1a8-4940ee44f6f7" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_2dcbab11-75be-4f50-934d-b3ab1a20529f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_amed_DetailsOfCertainBalanceSheetAccountsAbstract_04a4e38a-3bed-41ba-acdd-166d6739d51b" xlink:href="amed-20221231.xsd#amed_DetailsOfCertainBalanceSheetAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_b7fd89c8-0226-4337-9f4d-ed76366e7c31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DetailsOfCertainBalanceSheetAccountsAbstract_04a4e38a-3bed-41ba-acdd-166d6739d51b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_b7fd89c8-0226-4337-9f4d-ed76366e7c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayrollTaxEscrow_b8c70ec4-4f25-4cd2-8307-d08471bfeca6" xlink:href="amed-20221231.xsd#amed_PayrollTaxEscrow"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_b7fd89c8-0226-4337-9f4d-ed76366e7c31" xlink:to="loc_amed_PayrollTaxEscrow_b8c70ec4-4f25-4cd2-8307-d08471bfeca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_d874464f-d885-43c9-9601-6e8dd2b09161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_b7fd89c8-0226-4337-9f4d-ed76366e7c31" xlink:to="loc_us-gaap_IncomeTaxesReceivable_d874464f-d885-43c9-9601-6e8dd2b09161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromJointVenturesCurrent_af2d93b2-1704-406b-aaf8-e61b929c9b50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromJointVenturesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_b7fd89c8-0226-4337-9f4d-ed76366e7c31" xlink:to="loc_us-gaap_DueFromJointVenturesCurrent_af2d93b2-1704-406b-aaf8-e61b929c9b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousCurrent_05b3e701-5fa8-46ea-b519-499b42248ace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMiscellaneousCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_b7fd89c8-0226-4337-9f4d-ed76366e7c31" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousCurrent_05b3e701-5fa8-46ea-b519-499b42248ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_a8f30679-e177-4de3-a812-0852cd3208c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_b7fd89c8-0226-4337-9f4d-ed76366e7c31" xlink:to="loc_us-gaap_OtherAssetsCurrent_a8f30679-e177-4de3-a812-0852cd3208c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrentAbstract_08744e54-41da-482e-8dba-8ddbee2c9722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DetailsOfCertainBalanceSheetAccountsAbstract_04a4e38a-3bed-41ba-acdd-166d6739d51b" xlink:to="loc_us-gaap_OtherAssetsNoncurrentAbstract_08744e54-41da-482e-8dba-8ddbee2c9722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WorkersCompensationDeposits_1ecfc341-24d4-482a-a00d-0b9a46ac1384" xlink:href="amed-20221231.xsd#amed_WorkersCompensationDeposits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsNoncurrentAbstract_08744e54-41da-482e-8dba-8ddbee2c9722" xlink:to="loc_amed_WorkersCompensationDeposits_1ecfc341-24d4-482a-a00d-0b9a46ac1384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthInsuranceDeposits_5ee823c6-50f6-4bd5-9b4d-1a57bc2768d6" xlink:href="amed-20221231.xsd#amed_HealthInsuranceDeposits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsNoncurrentAbstract_08744e54-41da-482e-8dba-8ddbee2c9722" xlink:to="loc_amed_HealthInsuranceDeposits_5ee823c6-50f6-4bd5-9b4d-1a57bc2768d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OtherMiscellaneousDeposits_8ff8c421-487d-43b6-be53-f3c68afdfeac" xlink:href="amed-20221231.xsd#amed_OtherMiscellaneousDeposits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsNoncurrentAbstract_08744e54-41da-482e-8dba-8ddbee2c9722" xlink:to="loc_amed_OtherMiscellaneousDeposits_8ff8c421-487d-43b6-be53-f3c68afdfeac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableNoncurrent_8371c71a-7f80-420c-bcae-ea3fa093d328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyReceivableNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsNoncurrentAbstract_08744e54-41da-482e-8dba-8ddbee2c9722" xlink:to="loc_us-gaap_LossContingencyReceivableNoncurrent_8371c71a-7f80-420c-bcae-ea3fa093d328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_fdf9c5d3-d6be-448c-a0f2-39e06ef1fb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsNoncurrentAbstract_08744e54-41da-482e-8dba-8ddbee2c9722" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_fdf9c5d3-d6be-448c-a0f2-39e06ef1fb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtCost_de2ca50e-e302-427a-837f-e4f927d75192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsNoncurrentAbstract_08744e54-41da-482e-8dba-8ddbee2c9722" xlink:to="loc_us-gaap_InvestmentOwnedAtCost_de2ca50e-e302-427a-837f-e4f927d75192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_20417326-55a5-449b-81b7-1d30a57edf35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsNoncurrentAbstract_08744e54-41da-482e-8dba-8ddbee2c9722" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousNoncurrent_20417326-55a5-449b-81b7-1d30a57edf35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f367c940-20dc-4f9a-8cbb-ff2c8d804939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsNoncurrentAbstract_08744e54-41da-482e-8dba-8ddbee2c9722" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f367c940-20dc-4f9a-8cbb-ff2c8d804939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_092ad49d-6ac5-4219-b57f-a3caac69d0e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DetailsOfCertainBalanceSheetAccountsAbstract_04a4e38a-3bed-41ba-acdd-166d6739d51b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_092ad49d-6ac5-4219-b57f-a3caac69d0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent_f65f3042-b5ba-48df-826d-9e66ea222676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_092ad49d-6ac5-4219-b57f-a3caac69d0e5" xlink:to="loc_us-gaap_AccruedInsuranceCurrent_f65f3042-b5ba-48df-826d-9e66ea222676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WorkersCompensationLiabilityCurrent_1ac9d446-9d97-44dc-93ef-e67aa9562dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WorkersCompensationLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_092ad49d-6ac5-4219-b57f-a3caac69d0e5" xlink:to="loc_us-gaap_WorkersCompensationLiabilityCurrent_1ac9d446-9d97-44dc-93ef-e67aa9562dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProvisionForLiabilityOnRegulatoryAudit_1905ba76-e531-45bc-af2d-04828e0d35bf" xlink:href="amed-20221231.xsd#amed_ProvisionForLiabilityOnRegulatoryAudit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_092ad49d-6ac5-4219-b57f-a3caac69d0e5" xlink:to="loc_amed_ProvisionForLiabilityOnRegulatoryAudit_1905ba76-e531-45bc-af2d-04828e0d35bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LegalAndOtherSettlements_1382493b-9078-43eb-b10d-aa204b54276a" xlink:href="amed-20221231.xsd#amed_LegalAndOtherSettlements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_092ad49d-6ac5-4219-b57f-a3caac69d0e5" xlink:to="loc_amed_LegalAndOtherSettlements_1382493b-9078-43eb-b10d-aa204b54276a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_270884ec-10cd-4747-b668-be428fb0db4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_092ad49d-6ac5-4219-b57f-a3caac69d0e5" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_270884ec-10cd-4747-b668-be428fb0db4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CharityCare_4a543d8c-193b-4461-8160-064d057485bb" xlink:href="amed-20221231.xsd#amed_CharityCare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_092ad49d-6ac5-4219-b57f-a3caac69d0e5" xlink:to="loc_amed_CharityCare_4a543d8c-193b-4461-8160-064d057485bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedMedicareCapLiability_f0e181ce-3d0b-414e-a489-6197b28e5040" xlink:href="amed-20221231.xsd#amed_EstimatedMedicareCapLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_092ad49d-6ac5-4219-b57f-a3caac69d0e5" xlink:to="loc_amed_EstimatedMedicareCapLiability_f0e181ce-3d0b-414e-a489-6197b28e5040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceAccruals_e1a51d31-0e12-4e7c-a454-fbf5903e623c" xlink:href="amed-20221231.xsd#amed_HospiceAccruals"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_092ad49d-6ac5-4219-b57f-a3caac69d0e5" xlink:to="loc_amed_HospiceAccruals_e1a51d31-0e12-4e7c-a454-fbf5903e623c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PatientLiability_bec4f58e-4580-4e85-8f5e-6da4dd50081d" xlink:href="amed-20221231.xsd#amed_PatientLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_092ad49d-6ac5-4219-b57f-a3caac69d0e5" xlink:to="loc_amed_PatientLiability_bec4f58e-4580-4e85-8f5e-6da4dd50081d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredOperatingIncomeCARESAct_a73d7d23-f0a0-42ab-9a52-e4b5a506376c" xlink:href="amed-20221231.xsd#amed_DeferredOperatingIncomeCARESAct"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_092ad49d-6ac5-4219-b57f-a3caac69d0e5" xlink:to="loc_amed_DeferredOperatingIncomeCARESAct_a73d7d23-f0a0-42ab-9a52-e4b5a506376c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_878d2faa-fc44-4764-ae5f-0fdf90c1f287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_092ad49d-6ac5-4219-b57f-a3caac69d0e5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_878d2faa-fc44-4764-ae5f-0fdf90c1f287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AccruedInterest_4913ed7f-9976-4a2e-8474-70194ae8940a" xlink:href="amed-20221231.xsd#amed_AccruedInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_092ad49d-6ac5-4219-b57f-a3caac69d0e5" xlink:to="loc_amed_AccruedInterest_4913ed7f-9976-4a2e-8474-70194ae8940a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7147a30e-6e46-4d06-a79b-0a07c81f6bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_092ad49d-6ac5-4219-b57f-a3caac69d0e5" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7147a30e-6e46-4d06-a79b-0a07c81f6bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f83a37a8-286d-44b9-a9ad-e5d998e80aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_092ad49d-6ac5-4219-b57f-a3caac69d0e5" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_f83a37a8-286d-44b9-a9ad-e5d998e80aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_430722d6-188e-4aca-bcba-0f5b07e02e60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_DetailsOfCertainBalanceSheetAccountsAbstract_04a4e38a-3bed-41ba-acdd-166d6739d51b" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_430722d6-188e-4aca-bcba-0f5b07e02e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UncertainTaxBenefitsInLongTermObligations_52b83ade-ea22-44f6-baea-7f9f5c0bff14" xlink:href="amed-20221231.xsd#amed_UncertainTaxBenefitsInLongTermObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_430722d6-188e-4aca-bcba-0f5b07e02e60" xlink:to="loc_amed_UncertainTaxBenefitsInLongTermObligations_52b83ade-ea22-44f6-baea-7f9f5c0bff14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredCompensationPlanLiability_f45bae27-7233-4395-89aa-28a30cf187b5" xlink:href="amed-20221231.xsd#amed_DeferredCompensationPlanLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_430722d6-188e-4aca-bcba-0f5b07e02e60" xlink:to="loc_amed_DeferredCompensationPlanLiability_f45bae27-7233-4395-89aa-28a30cf187b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_31495640-eaf9-475b-999e-c20fcf2525a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_430722d6-188e-4aca-bcba-0f5b07e02e60" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_31495640-eaf9-475b-999e-c20fcf2525a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_c5465352-ea49-43ce-8698-e73dccd7eee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_430722d6-188e-4aca-bcba-0f5b07e02e60" xlink:to="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_c5465352-ea49-43ce-8698-e73dccd7eee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3458e234-a04c-4b0a-9b8d-03b5d201edbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_430722d6-188e-4aca-bcba-0f5b07e02e60" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3458e234-a04c-4b0a-9b8d-03b5d201edbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASESDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#LEASESDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LEASESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b2810e42-6e62-4400-bda0-6537bd78ce05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_de518dbc-a961-4039-9213-6a45bc79fe2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b2810e42-6e62-4400-bda0-6537bd78ce05" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_de518dbc-a961-4039-9213-6a45bc79fe2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_360d38ae-7b8e-4dd8-b16a-71adbde3c060" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_de518dbc-a961-4039-9213-6a45bc79fe2f" xlink:to="loc_srt_RangeAxis_360d38ae-7b8e-4dd8-b16a-71adbde3c060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7c4abea0-915f-4232-ac82-8fd165bed1a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_360d38ae-7b8e-4dd8-b16a-71adbde3c060" xlink:to="loc_srt_RangeMember_7c4abea0-915f-4232-ac82-8fd165bed1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_39d049de-1f0b-4164-ace6-545470555361" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7c4abea0-915f-4232-ac82-8fd165bed1a4" xlink:to="loc_srt_MinimumMember_39d049de-1f0b-4164-ace6-545470555361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f4ba61c1-3fc6-4bff-9f0f-996d090febe3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7c4abea0-915f-4232-ac82-8fd165bed1a4" xlink:to="loc_srt_MaximumMember_f4ba61c1-3fc6-4bff-9f0f-996d090febe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LeaseTypeAxis_266d4527-4d94-4544-ac6f-e2eee93991da" xlink:href="amed-20221231.xsd#amed_LeaseTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_de518dbc-a961-4039-9213-6a45bc79fe2f" xlink:to="loc_amed_LeaseTypeAxis_266d4527-4d94-4544-ac6f-e2eee93991da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LeaseTypeDomain_eb5fdfac-3468-4850-befb-68afcd6ebbca" xlink:href="amed-20221231.xsd#amed_LeaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_LeaseTypeAxis_266d4527-4d94-4544-ac6f-e2eee93991da" xlink:to="loc_amed_LeaseTypeDomain_eb5fdfac-3468-4850-befb-68afcd6ebbca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FleetLeaseMember_e0daf1ba-c867-4967-bc4c-f5ee6d144ead" xlink:href="amed-20221231.xsd#amed_FleetLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_LeaseTypeDomain_eb5fdfac-3468-4850-befb-68afcd6ebbca" xlink:to="loc_amed_FleetLeaseMember_e0daf1ba-c867-4967-bc4c-f5ee6d144ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ed7344cb-82e6-4bdd-a9b7-f7aea8ae748d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_de518dbc-a961-4039-9213-6a45bc79fe2f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ed7344cb-82e6-4bdd-a9b7-f7aea8ae748d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3d6e820c-d237-4122-8006-00b4e82c54ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ed7344cb-82e6-4bdd-a9b7-f7aea8ae748d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3d6e820c-d237-4122-8006-00b4e82c54ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TelehealthKitsMember_6571f804-09da-4b5d-aa9a-40e7a60c41bb" xlink:href="amed-20221231.xsd#amed_TelehealthKitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3d6e820c-d237-4122-8006-00b4e82c54ea" xlink:to="loc_amed_TelehealthKitsMember_6571f804-09da-4b5d-aa9a-40e7a60c41bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_55f77d77-26b3-4e9f-8235-b2d9bacc96f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_de518dbc-a961-4039-9213-6a45bc79fe2f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_55f77d77-26b3-4e9f-8235-b2d9bacc96f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ec459c74-8870-46a4-b154-b274bc45b3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_55f77d77-26b3-4e9f-8235-b2d9bacc96f5" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ec459c74-8870-46a4-b154-b274bc45b3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_ad5ef4a0-f835-4298-b83b-98a3509d2769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_55f77d77-26b3-4e9f-8235-b2d9bacc96f5" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_ad5ef4a0-f835-4298-b83b-98a3509d2769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate_9f223b4d-be26-4ebb-9344-328908bff095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_55f77d77-26b3-4e9f-8235-b2d9bacc96f5" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToTerminate_9f223b4d-be26-4ebb-9344-328908bff095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8584e7c0-4a01-4756-bf09-ad843a1d5af9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_55f77d77-26b3-4e9f-8235-b2d9bacc96f5" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8584e7c0-4a01-4756-bf09-ad843a1d5af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASESLeaseCostDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#LEASESLeaseCostDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LEASESLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2fc9c29e-5e5f-4e1a-9c1d-7d3127d91fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_827b279e-98f9-4e8f-8489-61312837a047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2fc9c29e-5e5f-4e1a-9c1d-7d3127d91fd8" xlink:to="loc_us-gaap_OperatingLeaseExpense_827b279e-98f9-4e8f-8489-61312837a047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_99971756-4deb-4e36-ab54-c880313efe39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2fc9c29e-5e5f-4e1a-9c1d-7d3127d91fd8" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_99971756-4deb-4e36-ab54-c880313efe39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_66c83b80-69c9-4998-8c60-8b73386b136f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2fc9c29e-5e5f-4e1a-9c1d-7d3127d91fd8" xlink:to="loc_us-gaap_OperatingLeaseCost_66c83b80-69c9-4998-8c60-8b73386b136f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease_bc70372e-c873-4229-b651-2b2ca8a6c79a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2fc9c29e-5e5f-4e1a-9c1d-7d3127d91fd8" xlink:to="loc_us-gaap_GainLossOnTerminationOfLease_bc70372e-c873-4229-b651-2b2ca8a6c79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_2dc6284e-a770-4cd6-8a7c-6b161afc8e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2fc9c29e-5e5f-4e1a-9c1d-7d3127d91fd8" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_2dc6284e-a770-4cd6-8a7c-6b161afc8e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_a03ca518-2020-401a-a2db-42bc62a5d87c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2fc9c29e-5e5f-4e1a-9c1d-7d3127d91fd8" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_a03ca518-2020-401a-a2db-42bc62a5d87c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FinanceLeaseCost_1c4c9704-2a40-4897-804b-db36f154614f" xlink:href="amed-20221231.xsd#amed_FinanceLeaseCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2fc9c29e-5e5f-4e1a-9c1d-7d3127d91fd8" xlink:to="loc_amed_FinanceLeaseCost_1c4c9704-2a40-4897-804b-db36f154614f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_0be5ba0f-5b06-4bed-93ce-3adbc92cd49d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2fc9c29e-5e5f-4e1a-9c1d-7d3127d91fd8" xlink:to="loc_us-gaap_VariableLeaseCost_0be5ba0f-5b06-4bed-93ce-3adbc92cd49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_a63f51f6-ae81-4c6d-917c-ca5944f987b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2fc9c29e-5e5f-4e1a-9c1d-7d3127d91fd8" xlink:to="loc_us-gaap_ShortTermLeaseCost_a63f51f6-ae81-4c6d-917c-ca5944f987b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_17953f44-c32c-46bf-bf43-1e9391992350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2fc9c29e-5e5f-4e1a-9c1d-7d3127d91fd8" xlink:to="loc_us-gaap_LeaseCost_17953f44-c32c-46bf-bf43-1e9391992350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASESOperatingLeaseDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#LEASESOperatingLeaseDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LEASESOperatingLeaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4cb0495d-c5e9-47c2-bc09-8fe238ce05d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1de7b3d9-1c7e-422c-8fc3-1750a1392dff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4cb0495d-c5e9-47c2-bc09-8fe238ce05d7" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1de7b3d9-1c7e-422c-8fc3-1750a1392dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6cb66b1a-2c6b-4345-b8bf-750fa9aff56e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4cb0495d-c5e9-47c2-bc09-8fe238ce05d7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6cb66b1a-2c6b-4345-b8bf-750fa9aff56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a8c0d16f-8ffe-4ad9-9d0b-bec5dfed0055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4cb0495d-c5e9-47c2-bc09-8fe238ce05d7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a8c0d16f-8ffe-4ad9-9d0b-bec5dfed0055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b0be6cc3-3f6b-4937-8480-258119a88b11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4cb0495d-c5e9-47c2-bc09-8fe238ce05d7" xlink:to="loc_us-gaap_OperatingLeaseLiability_b0be6cc3-3f6b-4937-8480-258119a88b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASESFinanceLeasesDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#LEASESFinanceLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LEASESFinanceLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_19df053c-c1f7-42df-9da4-9d9c02650a68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_68fddeae-0168-4f85-a53d-ce271a619fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_19df053c-c1f7-42df-9da4-9d9c02650a68" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_68fddeae-0168-4f85-a53d-ce271a619fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_afa693d7-0216-4086-a8f5-e0fb14705ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_68fddeae-0168-4f85-a53d-ce271a619fc9" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_afa693d7-0216-4086-a8f5-e0fb14705ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3da100f3-2914-484a-81fc-f11548269fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_afa693d7-0216-4086-a8f5-e0fb14705ed3" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3da100f3-2914-484a-81fc-f11548269fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember_4eb3c58c-093d-4a0e-a0bf-89e969409b80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3da100f3-2914-484a-81fc-f11548269fc1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentMember_4eb3c58c-093d-4a0e-a0bf-89e969409b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CurrentPortionOfLongTermObligationsMember_a3bdf5d9-b3ed-47cf-be3b-f8e375e628f8" xlink:href="amed-20221231.xsd#amed_CurrentPortionOfLongTermObligationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3da100f3-2914-484a-81fc-f11548269fc1" xlink:to="loc_amed_CurrentPortionOfLongTermObligationsMember_a3bdf5d9-b3ed-47cf-be3b-f8e375e628f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LongTermObligationsLessCurrentPortionMember_3a33ffc2-bd6a-44a1-a579-c49204bc1dfb" xlink:href="amed-20221231.xsd#amed_LongTermObligationsLessCurrentPortionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3da100f3-2914-484a-81fc-f11548269fc1" xlink:to="loc_amed_LongTermObligationsLessCurrentPortionMember_3a33ffc2-bd6a-44a1-a579-c49204bc1dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CurrentAndLongTermObligationsMember_ef528d93-5974-42d2-a8ac-6d0b2e6172c6" xlink:href="amed-20221231.xsd#amed_CurrentAndLongTermObligationsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3da100f3-2914-484a-81fc-f11548269fc1" xlink:to="loc_amed_CurrentAndLongTermObligationsMember_ef528d93-5974-42d2-a8ac-6d0b2e6172c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_94ea1a22-877a-44f8-a471-ebd159210f94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_68fddeae-0168-4f85-a53d-ce271a619fc9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_94ea1a22-877a-44f8-a471-ebd159210f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3eabe267-3631-44d3-b10e-a4613359b0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_94ea1a22-877a-44f8-a471-ebd159210f94" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3eabe267-3631-44d3-b10e-a4613359b0ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldUnderCapitalLeasesMember_5c2e82ee-47a3-4d08-9475-e27ff0421f64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldUnderCapitalLeasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3eabe267-3631-44d3-b10e-a4613359b0ae" xlink:to="loc_us-gaap_AssetsHeldUnderCapitalLeasesMember_5c2e82ee-47a3-4d08-9475-e27ff0421f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_00152a9c-844d-485d-a54a-6b8b01f259b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_68fddeae-0168-4f85-a53d-ce271a619fc9" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_00152a9c-844d-485d-a54a-6b8b01f259b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_d57483c9-5d63-40a6-8e91-31a4c560c8de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00152a9c-844d-485d-a54a-6b8b01f259b8" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_d57483c9-5d63-40a6-8e91-31a4c560c8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_533adf0c-ab7d-47ea-870b-7584b68901d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00152a9c-844d-485d-a54a-6b8b01f259b8" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_533adf0c-ab7d-47ea-870b-7584b68901d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_72aea46f-86d6-46e0-97ee-5f25285addda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00152a9c-844d-485d-a54a-6b8b01f259b8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_72aea46f-86d6-46e0-97ee-5f25285addda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_567fd6b7-7b15-4bee-876f-a9a221df78c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00152a9c-844d-485d-a54a-6b8b01f259b8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_567fd6b7-7b15-4bee-876f-a9a221df78c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_f83ad2ae-c895-4b38-8071-e6d465a38794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00152a9c-844d-485d-a54a-6b8b01f259b8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_f83ad2ae-c895-4b38-8071-e6d465a38794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_0ff58a73-61a4-44b4-92b8-38d6946a17e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00152a9c-844d-485d-a54a-6b8b01f259b8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_0ff58a73-61a4-44b4-92b8-38d6946a17e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_5ccff8aa-656c-4ef0-a50e-87bfdbbe1fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_00152a9c-844d-485d-a54a-6b8b01f259b8" xlink:to="loc_us-gaap_FinanceLeaseLiability_5ccff8aa-656c-4ef0-a50e-87bfdbbe1fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASESSupplementalCashflowInformationDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#LEASESSupplementalCashflowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LEASESSupplementalCashflowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_fb940317-3edf-48bc-8026-6ac195108af4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_e0ac12e9-3b89-4d96-a92d-54ae3db7535f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fb940317-3edf-48bc-8026-6ac195108af4" xlink:to="loc_us-gaap_OperatingLeasePayments_e0ac12e9-3b89-4d96-a92d-54ae3db7535f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_5b982c9d-f394-45ab-82fc-bde4021516df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fb940317-3edf-48bc-8026-6ac195108af4" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_5b982c9d-f394-45ab-82fc-bde4021516df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5ea39a02-05ed-475f-a7c5-2869a5d2e95a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fb940317-3edf-48bc-8026-6ac195108af4" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5ea39a02-05ed-475f-a7c5-2869a5d2e95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_b7147caf-3730-4e65-98c1-6b375a3a5de0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fb940317-3edf-48bc-8026-6ac195108af4" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_b7147caf-3730-4e65-98c1-6b375a3a5de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations_da6ff7d8-93ae-474a-be86-73c4ad7a293b" xlink:href="amed-20221231.xsd#amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fb940317-3edf-48bc-8026-6ac195108af4" xlink:to="loc_amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations_da6ff7d8-93ae-474a-be86-73c4ad7a293b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations_2344adb8-5d5a-4ab3-b6ea-bf03e2acccc3" xlink:href="amed-20221231.xsd#amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fb940317-3edf-48bc-8026-6ac195108af4" xlink:to="loc_amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations_2344adb8-5d5a-4ab3-b6ea-bf03e2acccc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASESWeightedAverageRemainingTermandDiscountRateDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#LEASESWeightedAverageRemainingTermandDiscountRateDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LEASESWeightedAverageRemainingTermandDiscountRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5636e428-3475-44f6-a9df-8103c7d037f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ffa173a7-2198-4f52-8ba2-b4d7a094f72b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5636e428-3475-44f6-a9df-8103c7d037f3" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ffa173a7-2198-4f52-8ba2-b4d7a094f72b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_394df906-9909-4765-8113-9205e222e4f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5636e428-3475-44f6-a9df-8103c7d037f3" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_394df906-9909-4765-8113-9205e222e4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_fa6c42af-c20a-4e51-847a-5ef42890bd48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5636e428-3475-44f6-a9df-8103c7d037f3" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_fa6c42af-c20a-4e51-847a-5ef42890bd48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_2e00b044-b339-47f8-b206-9b5b6045e5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5636e428-3475-44f6-a9df-8103c7d037f3" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_2e00b044-b339-47f8-b206-9b5b6045e5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LEASESMaturitiesDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#LEASESMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LEASESMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6f0880ea-c9c5-4bd4-ba4c-e0c2f34162f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_dc7bb483-b4bc-4cff-a298-571fd7ceac12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6f0880ea-c9c5-4bd4-ba4c-e0c2f34162f4" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_dc7bb483-b4bc-4cff-a298-571fd7ceac12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1379465e-2fda-4504-9900-e31f71289ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_dc7bb483-b4bc-4cff-a298-571fd7ceac12" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1379465e-2fda-4504-9900-e31f71289ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_65a647b0-bf79-4db8-a3f4-fae53aea3800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1379465e-2fda-4504-9900-e31f71289ec6" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_65a647b0-bf79-4db8-a3f4-fae53aea3800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CurrentAndLongTermObligationsMember_9e6a84c0-3488-4e3d-bfea-c22469f30919" xlink:href="amed-20221231.xsd#amed_CurrentAndLongTermObligationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_65a647b0-bf79-4db8-a3f4-fae53aea3800" xlink:to="loc_amed_CurrentAndLongTermObligationsMember_9e6a84c0-3488-4e3d-bfea-c22469f30919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_dc7bb483-b4bc-4cff-a298-571fd7ceac12" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_63b363ae-dc3c-45c3-a65e-b9e48f2ef0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_63b363ae-dc3c-45c3-a65e-b9e48f2ef0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5fd7b9ea-cd46-4aa9-886b-e80c0404dffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5fd7b9ea-cd46-4aa9-886b-e80c0404dffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f5992f5d-373b-475d-9c68-d597bb274fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f5992f5d-373b-475d-9c68-d597bb274fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e1e883cd-113f-42cc-9a2b-2e9de24b70b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e1e883cd-113f-42cc-9a2b-2e9de24b70b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_25131f43-fa09-4dda-ba49-4a8aee46cbae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_25131f43-fa09-4dda-ba49-4a8aee46cbae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_66c8c939-c310-42dc-8b77-d5c89d83b9ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_66c8c939-c310-42dc-8b77-d5c89d83b9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cc2e8560-16a5-43b5-9565-3c65e28a8429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cc2e8560-16a5-43b5-9565-3c65e28a8429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_29ecbf22-5778-4ef3-a1da-a6ae9c774244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_29ecbf22-5778-4ef3-a1da-a6ae9c774244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c46688d9-3937-49b0-b9a6-55fa4d0df4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_OperatingLeaseLiability_c46688d9-3937-49b0-b9a6-55fa4d0df4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_7aca2219-23a1-4886-ab68-4848e304362b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_7aca2219-23a1-4886-ab68-4848e304362b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_da16a445-85bf-4795-8012-cd7d3f37f50a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_da16a445-85bf-4795-8012-cd7d3f37f50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_d2e6c734-bf38-47a0-b107-dd64a51bb60f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_d2e6c734-bf38-47a0-b107-dd64a51bb60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_c7b4ed3c-bb48-49e4-8095-0d8854253dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_c7b4ed3c-bb48-49e4-8095-0d8854253dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_0d6c536c-4669-4d28-9899-3f105ceee314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_0d6c536c-4669-4d28-9899-3f105ceee314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_c4579ed5-d581-4734-84fe-3e228df0f21a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_c4579ed5-d581-4734-84fe-3e228df0f21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_9dfb2a2d-42f3-4536-9cc6-2688d7d75a02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_9dfb2a2d-42f3-4536-9cc6-2688d7d75a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_0721a426-5242-41b7-838e-cb2200f8bbeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_0721a426-5242-41b7-838e-cb2200f8bbeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_b7413681-7d34-4a80-9d54-460d1fa5b6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_327fc6f6-6c39-4e50-9f98-3bf1e38511d2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList_b7413681-7d34-4a80-9d54-460d1fa5b6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c31a3192-27a7-49d2-9bd0-4269f8af7848" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6758d166-a199-4bac-9d26-4d61f64e1bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c31a3192-27a7-49d2-9bd0-4269f8af7848" xlink:to="loc_us-gaap_DebtInstrumentTable_6758d166-a199-4bac-9d26-4d61f64e1bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_00ce0f30-76fe-4af2-99d1-3dd76c1c137a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6758d166-a199-4bac-9d26-4d61f64e1bd7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_00ce0f30-76fe-4af2-99d1-3dd76c1c137a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_23b0c5ce-8672-471e-bb4f-4739c1322a85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_00ce0f30-76fe-4af2-99d1-3dd76c1c137a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_23b0c5ce-8672-471e-bb4f-4739c1322a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_1edb054b-27e0-430d-bf28-d75cce97ded2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_23b0c5ce-8672-471e-bb4f-4739c1322a85" xlink:to="loc_us-gaap_LoansPayableMember_1edb054b-27e0-430d-bf28-d75cce97ded2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_cc508230-992d-4091-8924-61f626dc4b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_23b0c5ce-8672-471e-bb4f-4739c1322a85" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_cc508230-992d-4091-8924-61f626dc4b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PromissoryNotesMember_c6c3e81d-ce0f-47f0-8696-cf7ab3f881ed" xlink:href="amed-20221231.xsd#amed_PromissoryNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_23b0c5ce-8672-471e-bb4f-4739c1322a85" xlink:to="loc_amed_PromissoryNotesMember_c6c3e81d-ce0f-47f0-8696-cf7ab3f881ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember_60012caa-c452-4df2-9e68-785a9bacf30c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLeaseObligationsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_23b0c5ce-8672-471e-bb4f-4739c1322a85" xlink:to="loc_us-gaap_CapitalLeaseObligationsMember_60012caa-c452-4df2-9e68-785a9bacf30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f55f6bb6-affd-4f86-9afd-64bd866428a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6758d166-a199-4bac-9d26-4d61f64e1bd7" xlink:to="loc_us-gaap_DebtInstrumentAxis_f55f6bb6-affd-4f86-9afd-64bd866428a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e30a9da3-9bbb-4b41-95f4-985330ef3ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f55f6bb6-affd-4f86-9afd-64bd866428a2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e30a9da3-9bbb-4b41-95f4-985330ef3ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_8140fe81-8f83-44d7-b75a-55bff96a0d8c" xlink:href="amed-20221231.xsd#amed_FourHundredFiftyMillionTermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e30a9da3-9bbb-4b41-95f4-985330ef3ad8" xlink:to="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_8140fe81-8f83-44d7-b75a-55bff96a0d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_11d0305f-5f2b-4ab2-b839-508d277d9e27" xlink:href="amed-20221231.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e30a9da3-9bbb-4b41-95f4-985330ef3ad8" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_11d0305f-5f2b-4ab2-b839-508d277d9e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_8878d85e-646f-4b91-bec4-0d7ba0886792" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6758d166-a199-4bac-9d26-4d61f64e1bd7" xlink:to="loc_us-gaap_VariableRateAxis_8878d85e-646f-4b91-bec4-0d7ba0886792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_4979406e-2538-4b17-b955-bdc2faaaf43d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_8878d85e-646f-4b91-bec4-0d7ba0886792" xlink:to="loc_us-gaap_VariableRateDomain_4979406e-2538-4b17-b955-bdc2faaaf43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_d03ece2f-9141-479e-a440-d3e953949590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_4979406e-2538-4b17-b955-bdc2faaaf43d" xlink:to="loc_us-gaap_EurodollarMember_d03ece2f-9141-479e-a440-d3e953949590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_9cea1043-c759-43d6-a5a7-0e6a5efcd8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_4979406e-2538-4b17-b955-bdc2faaaf43d" xlink:to="loc_us-gaap_BaseRateMember_9cea1043-c759-43d6-a5a7-0e6a5efcd8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9313d631-7060-4f00-9117-9896f16f974e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6758d166-a199-4bac-9d26-4d61f64e1bd7" xlink:to="loc_us-gaap_DebtInstrumentLineItems_9313d631-7060-4f00-9117-9896f16f974e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_6a221ea8-3474-4d5b-9539-d69c1de140d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9313d631-7060-4f00-9117-9896f16f974e" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_6a221ea8-3474-4d5b-9539-d69c1de140d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_59dc40e1-3f53-45aa-a501-7dfbd408bf00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9313d631-7060-4f00-9117-9896f16f974e" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_59dc40e1-3f53-45aa-a501-7dfbd408bf00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_de3d04cd-09a9-4304-8fbc-ccdc31f941cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9313d631-7060-4f00-9117-9896f16f974e" xlink:to="loc_us-gaap_LongTermDebt_de3d04cd-09a9-4304-8fbc-ccdc31f941cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_b4ffa5d9-ec0c-4375-8f85-36b9309209e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9313d631-7060-4f00-9117-9896f16f974e" xlink:to="loc_us-gaap_LongTermDebtCurrent_b4ffa5d9-ec0c-4375-8f85-36b9309209e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_a75b61d0-2c42-4628-ab52-da3bebc8aae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9313d631-7060-4f00-9117-9896f16f974e" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_a75b61d0-2c42-4628-ab52-da3bebc8aae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails_1" xlink:type="simple" xlink:href="amed-20221231.xsd#LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails_1"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_40b88e71-5d17-4524-a894-0240b429a80e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_3ae89904-bcbc-4e01-a0f8-cad9099b839d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_40b88e71-5d17-4524-a894-0240b429a80e" xlink:to="loc_us-gaap_DebtInstrumentTable_3ae89904-bcbc-4e01-a0f8-cad9099b839d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ec427fd4-614b-4b3d-8503-57c81022d652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3ae89904-bcbc-4e01-a0f8-cad9099b839d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ec427fd4-614b-4b3d-8503-57c81022d652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9306b426-99b5-49fd-b5c6-a02717218249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ec427fd4-614b-4b3d-8503-57c81022d652" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9306b426-99b5-49fd-b5c6-a02717218249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_e125298f-2c1f-48d6-9a07-1dd39d950745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9306b426-99b5-49fd-b5c6-a02717218249" xlink:to="loc_us-gaap_LoansPayableMember_e125298f-2c1f-48d6-9a07-1dd39d950745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_eeabdbe8-65d0-45cb-a304-d65f4b6f6a17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9306b426-99b5-49fd-b5c6-a02717218249" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_eeabdbe8-65d0-45cb-a304-d65f4b6f6a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a860b7a6-8110-4680-94b8-64ae51f03062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3ae89904-bcbc-4e01-a0f8-cad9099b839d" xlink:to="loc_us-gaap_DebtInstrumentAxis_a860b7a6-8110-4680-94b8-64ae51f03062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_47727090-a978-4d87-bdda-ea04431f9531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a860b7a6-8110-4680-94b8-64ae51f03062" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_47727090-a978-4d87-bdda-ea04431f9531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_c4b0e8e6-fc9d-4d91-921e-8259127df09b" xlink:href="amed-20221231.xsd#amed_FourHundredFiftyMillionTermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_47727090-a978-4d87-bdda-ea04431f9531" xlink:to="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_c4b0e8e6-fc9d-4d91-921e-8259127df09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_c8c6aafc-39db-4371-9569-96a403646fad" xlink:href="amed-20221231.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_47727090-a978-4d87-bdda-ea04431f9531" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_c8c6aafc-39db-4371-9569-96a403646fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_91ab946d-e56b-47b4-9fe8-b903438ae94c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3ae89904-bcbc-4e01-a0f8-cad9099b839d" xlink:to="loc_us-gaap_VariableRateAxis_91ab946d-e56b-47b4-9fe8-b903438ae94c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_8fbf676d-dced-4b66-8d55-98394b2add2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_91ab946d-e56b-47b4-9fe8-b903438ae94c" xlink:to="loc_us-gaap_VariableRateDomain_8fbf676d-dced-4b66-8d55-98394b2add2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_d3c8d588-ff36-46cf-a95e-b8fc7b29a6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_8fbf676d-dced-4b66-8d55-98394b2add2e" xlink:to="loc_us-gaap_EurodollarMember_d3c8d588-ff36-46cf-a95e-b8fc7b29a6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_1af371b2-b2a1-4c81-a8f3-d11e12df888a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_8fbf676d-dced-4b66-8d55-98394b2add2e" xlink:to="loc_us-gaap_BaseRateMember_1af371b2-b2a1-4c81-a8f3-d11e12df888a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ed4814ed-e663-4b06-983c-f8cf261f462c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3ae89904-bcbc-4e01-a0f8-cad9099b839d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_ed4814ed-e663-4b06-983c-f8cf261f462c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_60c0142e-0ff5-4e23-944c-88eb064e168e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ed4814ed-e663-4b06-983c-f8cf261f462c" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_60c0142e-0ff5-4e23-944c-88eb064e168e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd_4d3644f1-b2d2-4752-8592-e5ac88f80598" xlink:href="amed-20221231.xsd#amed_DebtInstrumentInterestRateatPeriodEnd"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ed4814ed-e663-4b06-983c-f8cf261f462c" xlink:to="loc_amed_DebtInstrumentInterestRateatPeriodEnd_4d3644f1-b2d2-4752-8592-e5ac88f80598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_71aec0f5-25fa-4b33-ad66-df8bf4dc80cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ed4814ed-e663-4b06-983c-f8cf261f462c" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_71aec0f5-25fa-4b33-ad66-df8bf4dc80cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#LONGTERMOBLIGATIONSMaturitiesofDebtDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b34aec56-3aa3-4b9b-b76f-72f73e1c711a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_d97e5215-9934-4384-ba11-7d622704e080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b34aec56-3aa3-4b9b-b76f-72f73e1c711a" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_d97e5215-9934-4384-ba11-7d622704e080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_14f82211-a5a3-47f3-9c42-5aca0ddde3d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_d97e5215-9934-4384-ba11-7d622704e080" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_14f82211-a5a3-47f3-9c42-5aca0ddde3d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2b6c2e83-f2de-45c9-afea-712cf62e31e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_d97e5215-9934-4384-ba11-7d622704e080" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2b6c2e83-f2de-45c9-afea-712cf62e31e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_b2e35b7d-9a3e-435c-ba4e-b3c006c66769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_d97e5215-9934-4384-ba11-7d622704e080" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_b2e35b7d-9a3e-435c-ba4e-b3c006c66769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_05dbcbae-e0de-456e-9f0f-f6fbc19d9110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_d97e5215-9934-4384-ba11-7d622704e080" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_05dbcbae-e0de-456e-9f0f-f6fbc19d9110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_7d56b188-43b0-477f-8e9c-13f18758e8f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_d97e5215-9934-4384-ba11-7d622704e080" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_7d56b188-43b0-477f-8e9c-13f18758e8f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_1ddd0b97-872d-4762-9b69-590e0efdc18e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_d97e5215-9934-4384-ba11-7d622704e080" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_1ddd0b97-872d-4762-9b69-590e0efdc18e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a673a20d-4120-4d92-bd2d-c7c90f240680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_ad0b1873-36f6-45c1-bb0e-adec052b127c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a673a20d-4120-4d92-bd2d-c7c90f240680" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_ad0b1873-36f6-45c1-bb0e-adec052b127c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7671a4d5-415e-49c4-8d9a-9bb8c9ece78b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_ad0b1873-36f6-45c1-bb0e-adec052b127c" xlink:to="loc_us-gaap_DebtInstrumentAxis_7671a4d5-415e-49c4-8d9a-9bb8c9ece78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_65297769-35f9-4294-a4dc-0283c456e4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7671a4d5-415e-49c4-8d9a-9bb8c9ece78b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_65297769-35f9-4294-a4dc-0283c456e4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheOneMember_ddb76f77-b455-4483-a042-8a60fc6354ff" xlink:href="amed-20221231.xsd#amed_DebtInstrumentByLeverageRatioTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_65297769-35f9-4294-a4dc-0283c456e4c3" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheOneMember_ddb76f77-b455-4483-a042-8a60fc6354ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_cf1ada97-df3b-4bf2-b0d8-1c1cb027f1eb" xlink:href="amed-20221231.xsd#amed_DebtInstrumentByLeverageRatioTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_65297769-35f9-4294-a4dc-0283c456e4c3" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheTwoMember_cf1ada97-df3b-4bf2-b0d8-1c1cb027f1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_03d59de4-efef-442a-81a8-9cc7d6a5e18a" xlink:href="amed-20221231.xsd#amed_DebtInstrumentByLeverageRatioTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_65297769-35f9-4294-a4dc-0283c456e4c3" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheThreeMember_03d59de4-efef-442a-81a8-9cc7d6a5e18a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentByLeverageRatioTrancheFourMember_20b9bc75-88b3-4ed3-b081-865f1d9257b3" xlink:href="amed-20221231.xsd#amed_DebtInstrumentByLeverageRatioTrancheFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_65297769-35f9-4294-a4dc-0283c456e4c3" xlink:to="loc_amed_DebtInstrumentByLeverageRatioTrancheFourMember_20b9bc75-88b3-4ed3-b081-865f1d9257b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_ffde19ec-2715-4553-be66-5c79ae7895c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_ad0b1873-36f6-45c1-bb0e-adec052b127c" xlink:to="loc_us-gaap_VariableRateAxis_ffde19ec-2715-4553-be66-5c79ae7895c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_cc04c579-a46e-4049-9bd8-73ef6dc7d1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_ffde19ec-2715-4553-be66-5c79ae7895c3" xlink:to="loc_us-gaap_VariableRateDomain_cc04c579-a46e-4049-9bd8-73ef6dc7d1ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_9cfbff96-a836-40d7-8116-30a584b233b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_cc04c579-a46e-4049-9bd8-73ef6dc7d1ea" xlink:to="loc_us-gaap_BaseRateMember_9cfbff96-a836-40d7-8116-30a584b233b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_65616662-cdb5-481d-9d5d-66b0b3457e56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_cc04c579-a46e-4049-9bd8-73ef6dc7d1ea" xlink:to="loc_us-gaap_EurodollarMember_65616662-cdb5-481d-9d5d-66b0b3457e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d3c2b4f0-643e-489e-b80a-6156beb5a915" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_ad0b1873-36f6-45c1-bb0e-adec052b127c" xlink:to="loc_srt_RangeAxis_d3c2b4f0-643e-489e-b80a-6156beb5a915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9bb88709-b257-464d-a791-d4815ac2598f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d3c2b4f0-643e-489e-b80a-6156beb5a915" xlink:to="loc_srt_RangeMember_9bb88709-b257-464d-a791-d4815ac2598f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3d1b7cc3-7171-4a67-b849-97889a162da0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9bb88709-b257-464d-a791-d4815ac2598f" xlink:to="loc_srt_MaximumMember_3d1b7cc3-7171-4a67-b849-97889a162da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9c1e394b-ffd8-49e7-8d12-e7170c810af1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9bb88709-b257-464d-a791-d4815ac2598f" xlink:to="loc_srt_MinimumMember_9c1e394b-ffd8-49e7-8d12-e7170c810af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_a45a3cf1-8147-489d-9e66-8eac37716439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_ad0b1873-36f6-45c1-bb0e-adec052b127c" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_a45a3cf1-8147-489d-9e66-8eac37716439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedLeverageRatio_493c7dfb-5e77-4540-a2ff-ca18cc2388cb" xlink:href="amed-20221231.xsd#amed_ConsolidatedLeverageRatio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_a45a3cf1-8147-489d-9e66-8eac37716439" xlink:to="loc_amed_ConsolidatedLeverageRatio_493c7dfb-5e77-4540-a2ff-ca18cc2388cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_06412e0b-cfa0-4105-b1f7-d20b6f3f51ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_a45a3cf1-8147-489d-9e66-8eac37716439" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_06412e0b-cfa0-4105-b1f7-d20b6f3f51ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_7aa0ee13-3d48-45a5-8e5e-3a9e7e87c2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_a45a3cf1-8147-489d-9e66-8eac37716439" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_7aa0ee13-3d48-45a5-8e5e-3a9e7e87c2f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LetterOfCreditFee_ed2c4c0d-26f2-48df-8286-5f88064f3cc2" xlink:href="amed-20221231.xsd#amed_LetterOfCreditFee"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_a45a3cf1-8147-489d-9e66-8eac37716439" xlink:to="loc_amed_LetterOfCreditFee_ed2c4c0d-26f2-48df-8286-5f88064f3cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#LONGTERMOBLIGATIONSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8245789b-9c09-48a0-98ab-8f1258b2c381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e3762134-bc23-42a7-a3ad-0228efc353fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8245789b-9c09-48a0-98ab-8f1258b2c381" xlink:to="loc_us-gaap_DebtInstrumentTable_e3762134-bc23-42a7-a3ad-0228efc353fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2c3b946d-08e4-41cf-9ac1-054ae3105f94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e3762134-bc23-42a7-a3ad-0228efc353fd" xlink:to="loc_us-gaap_DebtInstrumentAxis_2c3b946d-08e4-41cf-9ac1-054ae3105f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3ef480f8-704e-4e61-bb0d-4d49bc81f513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2c3b946d-08e4-41cf-9ac1-054ae3105f94" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3ef480f8-704e-4e61-bb0d-4d49bc81f513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_47ebf7c7-e563-465f-b9b3-74a91edc0690" xlink:href="amed-20221231.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3ef480f8-704e-4e61-bb0d-4d49bc81f513" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_47ebf7c7-e563-465f-b9b3-74a91edc0690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_83c8a36f-9d70-45d6-acb2-a1e0d89f5863" xlink:href="amed-20221231.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3ef480f8-704e-4e61-bb0d-4d49bc81f513" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_83c8a36f-9d70-45d6-acb2-a1e0d89f5863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_91bea098-0b58-4139-b4d7-34925e2c963d" xlink:href="amed-20221231.xsd#amed_FourHundredFiftyMillionTermLoanFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3ef480f8-704e-4e61-bb0d-4d49bc81f513" xlink:to="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_91bea098-0b58-4139-b4d7-34925e2c963d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_02943cbb-5e63-4fcc-adbf-a5ba881328fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e3762134-bc23-42a7-a3ad-0228efc353fd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_02943cbb-5e63-4fcc-adbf-a5ba881328fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f1bf0d6b-6686-4390-bdfb-c38b65817a99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_02943cbb-5e63-4fcc-adbf-a5ba881328fc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f1bf0d6b-6686-4390-bdfb-c38b65817a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_8d02ed5a-36a0-4c7d-8a26-a655dd60c69e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f1bf0d6b-6686-4390-bdfb-c38b65817a99" xlink:to="loc_us-gaap_LoansPayableMember_8d02ed5a-36a0-4c7d-8a26-a655dd60c69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_a6313cc2-0ff9-44f0-bc8b-fde1b7a7626c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f1bf0d6b-6686-4390-bdfb-c38b65817a99" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_a6313cc2-0ff9-44f0-bc8b-fde1b7a7626c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_488d394e-9d73-4082-96fa-ea521eead8d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f1bf0d6b-6686-4390-bdfb-c38b65817a99" xlink:to="loc_us-gaap_LineOfCreditMember_488d394e-9d73-4082-96fa-ea521eead8d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SwingLineLoanMember_5bd21dd4-224e-4a2f-9de2-1118b016d3c2" xlink:href="amed-20221231.xsd#amed_SwingLineLoanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f1bf0d6b-6686-4390-bdfb-c38b65817a99" xlink:to="loc_amed_SwingLineLoanMember_5bd21dd4-224e-4a2f-9de2-1118b016d3c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_4d260e7e-8f87-4d6b-86f7-3171703b71f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f1bf0d6b-6686-4390-bdfb-c38b65817a99" xlink:to="loc_us-gaap_LetterOfCreditMember_4d260e7e-8f87-4d6b-86f7-3171703b71f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CreditAgreementMember_b55099c8-b3e5-4c34-b724-5381d7c84ab4" xlink:href="amed-20221231.xsd#amed_CreditAgreementMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f1bf0d6b-6686-4390-bdfb-c38b65817a99" xlink:to="loc_amed_CreditAgreementMember_b55099c8-b3e5-4c34-b724-5381d7c84ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember_e269aa11-7a68-4715-8bb0-116a071c8e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalLeaseObligationsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f1bf0d6b-6686-4390-bdfb-c38b65817a99" xlink:to="loc_us-gaap_CapitalLeaseObligationsMember_e269aa11-7a68-4715-8bb0-116a071c8e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedCreditAgreementMember_fe9497dc-838f-4f85-b312-b4fe1527e897" xlink:href="amed-20221231.xsd#amed_AmendedCreditAgreementMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f1bf0d6b-6686-4390-bdfb-c38b65817a99" xlink:to="loc_amed_AmendedCreditAgreementMember_fe9497dc-838f-4f85-b312-b4fe1527e897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondAmendedCreditAgreementMember_1b5a3d40-d8a2-4ade-b93c-904cbe05f1de" xlink:href="amed-20221231.xsd#amed_SecondAmendedCreditAgreementMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f1bf0d6b-6686-4390-bdfb-c38b65817a99" xlink:to="loc_amed_SecondAmendedCreditAgreementMember_1b5a3d40-d8a2-4ade-b93c-904cbe05f1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PromissoryNotesMember_b7e4da6a-b5f8-4a7d-8b92-1916cacc1bfd" xlink:href="amed-20221231.xsd#amed_PromissoryNotesMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f1bf0d6b-6686-4390-bdfb-c38b65817a99" xlink:to="loc_amed_PromissoryNotesMember_b7e4da6a-b5f8-4a7d-8b92-1916cacc1bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_64a23ea1-2a15-4d3e-adec-0e169bb560f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e3762134-bc23-42a7-a3ad-0228efc353fd" xlink:to="loc_us-gaap_VariableRateAxis_64a23ea1-2a15-4d3e-adec-0e169bb560f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_e7bad463-81de-433a-a84e-c94e82f462d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_64a23ea1-2a15-4d3e-adec-0e169bb560f6" xlink:to="loc_us-gaap_VariableRateDomain_e7bad463-81de-433a-a84e-c94e82f462d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_780478a1-7313-460d-95bf-0d8765cbf740" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_e7bad463-81de-433a-a84e-c94e82f462d8" xlink:to="loc_us-gaap_BaseRateMember_780478a1-7313-460d-95bf-0d8765cbf740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_321bb5af-b11d-45da-8e81-98853f18b7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_e7bad463-81de-433a-a84e-c94e82f462d8" xlink:to="loc_us-gaap_EurodollarMember_321bb5af-b11d-45da-8e81-98853f18b7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2f378a43-c5ac-4faa-afea-2ff176b0295d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e3762134-bc23-42a7-a3ad-0228efc353fd" xlink:to="loc_srt_RangeAxis_2f378a43-c5ac-4faa-afea-2ff176b0295d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8886c6b8-6721-4dc0-b842-d471a8c5de45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2f378a43-c5ac-4faa-afea-2ff176b0295d" xlink:to="loc_srt_RangeMember_8886c6b8-6721-4dc0-b842-d471a8c5de45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7b61d258-738d-45b3-b505-8381f3041886" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8886c6b8-6721-4dc0-b842-d471a8c5de45" xlink:to="loc_srt_MinimumMember_7b61d258-738d-45b3-b505-8381f3041886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_32ef8fb5-a5f3-45c7-b787-719fc39db30f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8886c6b8-6721-4dc0-b842-d471a8c5de45" xlink:to="loc_srt_MaximumMember_32ef8fb5-a5f3-45c7-b787-719fc39db30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_652dcbc8-719b-484d-9e4f-0eba74f2a9e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e3762134-bc23-42a7-a3ad-0228efc353fd" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_652dcbc8-719b-484d-9e4f-0eba74f2a9e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9fddb8ea-32e9-4366-9be5-d68ee9446905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_652dcbc8-719b-484d-9e4f-0eba74f2a9e0" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9fddb8ea-32e9-4366-9be5-d68ee9446905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_199f549c-3d45-4128-bbfc-cc2e3e83931a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_9fddb8ea-32e9-4366-9be5-d68ee9446905" xlink:to="loc_us-gaap_SubsequentEventMember_199f549c-3d45-4128-bbfc-cc2e3e83931a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e3762134-bc23-42a7-a3ad-0228efc353fd" xlink:to="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4bb99e03-c5c0-4dde-b40c-13d3d9c3abad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_4bb99e03-c5c0-4dde-b40c-13d3d9c3abad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1fa8134e-502e-410b-bf6e-6b25f0033cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1fa8134e-502e-410b-bf6e-6b25f0033cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_3c4650be-4085-4602-ab4b-7acbb4196649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_3c4650be-4085-4602-ab4b-7acbb4196649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RevolvingCreditFacilityTotal_82732302-6408-4ce0-b654-0b4147a0ac60" xlink:href="amed-20221231.xsd#amed_RevolvingCreditFacilityTotal"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_amed_RevolvingCreditFacilityTotal_82732302-6408-4ce0-b654-0b4147a0ac60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_b291d561-a02b-41d1-ad4a-2de43d961525" xlink:href="amed-20221231.xsd#amed_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_b291d561-a02b-41d1-ad4a-2de43d961525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_3cff3c92-b2f1-4626-b0c8-9c52383f704b" xlink:href="amed-20221231.xsd#amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_3cff3c92-b2f1-4626-b0c8-9c52383f704b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_ff085890-dabc-45c2-9b48-6d7fb3a1b12a" xlink:href="amed-20221231.xsd#amed_Creditfacilitymaximumallowableconsolidatedleverageratio"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_ff085890-dabc-45c2-9b48-6d7fb3a1b12a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_12febea9-5902-4a56-8fca-28b06de19b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_12febea9-5902-4a56-8fca-28b06de19b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_2fd41fde-d016-43ae-af7e-c2c625709416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_2fd41fde-d016-43ae-af7e-c2c625709416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_00769d6c-b535-4cf3-93b1-b80e53364be8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_00769d6c-b535-4cf3-93b1-b80e53364be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_47b9d6bd-9bae-475c-8734-be368d1af450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_47b9d6bd-9bae-475c-8734-be368d1af450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_9edcdad5-4e3d-4dba-9de6-8f06d2e62fed" xlink:href="amed-20221231.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_9edcdad5-4e3d-4dba-9de6-8f06d2e62fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_5bddae56-787b-4e48-86f1-689301973318" xlink:href="amed-20221231.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_5bddae56-787b-4e48-86f1-689301973318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_76ae7102-a636-49cf-bcd6-9545ab78e554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_76ae7102-a636-49cf-bcd6-9545ab78e554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_c1c122d9-475a-4015-a838-e9dc4f860bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_c1c122d9-475a-4015-a838-e9dc4f860bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_4ba4c9df-7d90-43ac-90e8-4826676dbf82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_4ba4c9df-7d90-43ac-90e8-4826676dbf82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalLeverageRatio_0decd79c-b4d4-467d-bfff-d5d581cd427c" xlink:href="amed-20221231.xsd#amed_TotalLeverageRatio"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_amed_TotalLeverageRatio_0decd79c-b4d4-467d-bfff-d5d581cd427c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedInterestCoverageRatio_29ae100e-88cd-4666-8bde-86114836d034" xlink:href="amed-20221231.xsd#amed_ConsolidatedInterestCoverageRatio"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_amed_ConsolidatedInterestCoverageRatio_29ae100e-88cd-4666-8bde-86114836d034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_2806e7a1-8da5-40a4-98ca-69be45263772" xlink:href="amed-20221231.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_2806e7a1-8da5-40a4-98ca-69be45263772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_b20f3a8d-b6db-45b9-97bc-53ceb399d875" xlink:href="amed-20221231.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_b20f3a8d-b6db-45b9-97bc-53ceb399d875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_70268c3b-3e6a-44ad-9478-2649c6351e09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_70268c3b-3e6a-44ad-9478-2649c6351e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c2bc8044-1d24-4614-85fe-33de93c9ad09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_c2bc8044-1d24-4614-85fe-33de93c9ad09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a3dfe25e-66d1-485d-ab20-ae06bfff1299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a3dfe25e-66d1-485d-ab20-ae06bfff1299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_fa3c171b-92e0-40b3-b1c7-4d20c1cba823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_fa3c171b-92e0-40b3-b1c7-4d20c1cba823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_18c99947-4a65-4485-900a-2fb301be20c1" xlink:href="amed-20221231.xsd#amed_ProceedsReceivedFromLoanPartyOfSubsidiary"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_18c99947-4a65-4485-900a-2fb301be20c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentPeriodicPaymentPercentage_101ad125-60a6-480f-a644-3c23a9924d29" xlink:href="amed-20221231.xsd#amed_DebtInstrumentPeriodicPaymentPercentage"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_amed_DebtInstrumentPeriodicPaymentPercentage_101ad125-60a6-480f-a644-3c23a9924d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SwingLineFacility_b7580854-089b-42d5-aa02-73cf8912a617" xlink:href="amed-20221231.xsd#amed_SwingLineFacility"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_amed_SwingLineFacility_b7580854-089b-42d5-aa02-73cf8912a617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LettersofCreditmaximumcommitment_68c53e0a-f809-40a9-bf44-5ee701bac34b" xlink:href="amed-20221231.xsd#amed_LettersofCreditmaximumcommitment"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_925f840b-95c4-4a22-930b-2b07110e4119" xlink:to="loc_amed_LettersofCreditmaximumcommitment_68c53e0a-f809-40a9-bf44-5ee701bac34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_376ea6e8-b4da-4f9d-a64d-43d53223e939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_1ab7d868-e9fa-49ca-bc3d-76c40b102a40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_376ea6e8-b4da-4f9d-a64d-43d53223e939" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_1ab7d868-e9fa-49ca-bc3d-76c40b102a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_50b9b6d6-2a30-480c-9663-92b79a7a9f52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_1ab7d868-e9fa-49ca-bc3d-76c40b102a40" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_50b9b6d6-2a30-480c-9663-92b79a7a9f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_55a02d1e-76a9-4287-9e8c-50a585580cde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_50b9b6d6-2a30-480c-9663-92b79a7a9f52" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_55a02d1e-76a9-4287-9e8c-50a585580cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_62940a2f-feb3-4208-8474-ac65fe252d58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_55a02d1e-76a9-4287-9e8c-50a585580cde" xlink:to="loc_us-gaap_DomesticCountryMember_62940a2f-feb3-4208-8474-ac65fe252d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_37d6f4ed-14b5-4223-8cb3-dbc84b688892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_55a02d1e-76a9-4287-9e8c-50a585580cde" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_37d6f4ed-14b5-4223-8cb3-dbc84b688892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_86b659f4-ebc9-4b1f-9002-61d9c72515a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_1ab7d868-e9fa-49ca-bc3d-76c40b102a40" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_86b659f4-ebc9-4b1f-9002-61d9c72515a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_bf6cbe80-4837-4aaa-9f04-7b45c4463e20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_86b659f4-ebc9-4b1f-9002-61d9c72515a6" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_bf6cbe80-4837-4aaa-9f04-7b45c4463e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AlternativeMinimumTaxCreditMember_e98f4ce0-96bc-461b-801d-9e182b26ada8" xlink:href="amed-20221231.xsd#amed_AlternativeMinimumTaxCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_bf6cbe80-4837-4aaa-9f04-7b45c4463e20" xlink:to="loc_amed_AlternativeMinimumTaxCreditMember_e98f4ce0-96bc-461b-801d-9e182b26ada8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StateTaxCreditMember_a5b80592-39b9-49f1-97d9-168717fa115b" xlink:href="amed-20221231.xsd#amed_StateTaxCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_bf6cbe80-4837-4aaa-9f04-7b45c4463e20" xlink:to="loc_amed_StateTaxCreditMember_a5b80592-39b9-49f1-97d9-168717fa115b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnrecognizedTaxBenefitsAxis_b1e17b83-ff23-4226-85e7-a38e48c67716" xlink:href="amed-20221231.xsd#amed_UnrecognizedTaxBenefitsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_1ab7d868-e9fa-49ca-bc3d-76c40b102a40" xlink:to="loc_amed_UnrecognizedTaxBenefitsAxis_b1e17b83-ff23-4226-85e7-a38e48c67716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnrecognizedTaxBenefitsDomain_ae267ae4-4e5e-4b07-9d8d-8bfe1ed7f3e4" xlink:href="amed-20221231.xsd#amed_UnrecognizedTaxBenefitsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_UnrecognizedTaxBenefitsAxis_b1e17b83-ff23-4226-85e7-a38e48c67716" xlink:to="loc_amed_UnrecognizedTaxBenefitsDomain_ae267ae4-4e5e-4b07-9d8d-8bfe1ed7f3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetOperatingLossMember_d4acbc0f-b184-40a5-942d-c46e01a42f8a" xlink:href="amed-20221231.xsd#amed_NetOperatingLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_UnrecognizedTaxBenefitsDomain_ae267ae4-4e5e-4b07-9d8d-8bfe1ed7f3e4" xlink:to="loc_amed_NetOperatingLossMember_d4acbc0f-b184-40a5-942d-c46e01a42f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TaxCreditCarryforwardMember_c4b710be-bc63-4003-a14e-2bad61af75e2" xlink:href="amed-20221231.xsd#amed_TaxCreditCarryforwardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_UnrecognizedTaxBenefitsDomain_ae267ae4-4e5e-4b07-9d8d-8bfe1ed7f3e4" xlink:to="loc_amed_TaxCreditCarryforwardMember_c4b710be-bc63-4003-a14e-2bad61af75e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a0d9b3b0-02c9-4515-ac5a-c702b50a385f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_1ab7d868-e9fa-49ca-bc3d-76c40b102a40" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a0d9b3b0-02c9-4515-ac5a-c702b50a385f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2341c1a9-5098-45e4-9248-ad39b097f7ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a0d9b3b0-02c9-4515-ac5a-c702b50a385f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2341c1a9-5098-45e4-9248-ad39b097f7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OtherLongTermObligationsMember_3d91ac90-15db-46bc-9e85-c86544e587ac" xlink:href="amed-20221231.xsd#amed_OtherLongTermObligationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2341c1a9-5098-45e4-9248-ad39b097f7ac" xlink:to="loc_amed_OtherLongTermObligationsMember_3d91ac90-15db-46bc-9e85-c86544e587ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_afa53b96-d3c8-496c-a8b9-d62a90d2f3fb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_1ab7d868-e9fa-49ca-bc3d-76c40b102a40" xlink:to="loc_srt_RangeAxis_afa53b96-d3c8-496c-a8b9-d62a90d2f3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_01a9372e-2eb3-45de-9426-08a2dc7b4e57" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_afa53b96-d3c8-496c-a8b9-d62a90d2f3fb" xlink:to="loc_srt_RangeMember_01a9372e-2eb3-45de-9426-08a2dc7b4e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8fbbfb23-9bb9-445b-b124-c49478df62e7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_01a9372e-2eb3-45de-9426-08a2dc7b4e57" xlink:to="loc_srt_MinimumMember_8fbbfb23-9bb9-445b-b124-c49478df62e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9f2d277e-1506-4395-ab20-01ac3b131243" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_01a9372e-2eb3-45de-9426-08a2dc7b4e57" xlink:to="loc_srt_MaximumMember_9f2d277e-1506-4395-ab20-01ac3b131243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d1ad3c66-baf6-423b-99ce-e7cee95adc62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_1ab7d868-e9fa-49ca-bc3d-76c40b102a40" xlink:to="loc_us-gaap_AwardTypeAxis_d1ad3c66-baf6-423b-99ce-e7cee95adc62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21f6f70f-3f8f-407b-92f1-d3c67f7067aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d1ad3c66-baf6-423b-99ce-e7cee95adc62" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21f6f70f-3f8f-407b-92f1-d3c67f7067aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExecutiveStockOptionExerciseMember_746812f3-ae3f-4f56-ab91-b127ed3f2f9e" xlink:href="amed-20221231.xsd#amed_ExecutiveStockOptionExerciseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21f6f70f-3f8f-407b-92f1-d3c67f7067aa" xlink:to="loc_amed_ExecutiveStockOptionExerciseMember_746812f3-ae3f-4f56-ab91-b127ed3f2f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeOfIncomeTaxDeferralAxis_52ad63da-68cf-4a18-bb84-a353b32fae1a" xlink:href="amed-20221231.xsd#amed_TypeOfIncomeTaxDeferralAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_1ab7d868-e9fa-49ca-bc3d-76c40b102a40" xlink:to="loc_amed_TypeOfIncomeTaxDeferralAxis_52ad63da-68cf-4a18-bb84-a353b32fae1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeOfIncomeTaxDeferralDomain_9fa9a8b5-c1a4-46b7-9093-c56fc349d30f" xlink:href="amed-20221231.xsd#amed_TypeOfIncomeTaxDeferralDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_TypeOfIncomeTaxDeferralAxis_52ad63da-68cf-4a18-bb84-a353b32fae1a" xlink:to="loc_amed_TypeOfIncomeTaxDeferralDomain_9fa9a8b5-c1a4-46b7-9093-c56fc349d30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SocialSecurityTaxMember_ef89abfa-11d1-4d24-8565-7788181e1c68" xlink:href="amed-20221231.xsd#amed_SocialSecurityTaxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_TypeOfIncomeTaxDeferralDomain_9fa9a8b5-c1a4-46b7-9093-c56fc349d30f" xlink:to="loc_amed_SocialSecurityTaxMember_ef89abfa-11d1-4d24-8565-7788181e1c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_26ef8de1-b7d8-4131-b3b5-68f19e3956f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_1ab7d868-e9fa-49ca-bc3d-76c40b102a40" xlink:to="loc_us-gaap_TaxPeriodAxis_26ef8de1-b7d8-4131-b3b5-68f19e3956f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_5a27dcdb-0fbc-45e6-851c-a5f971971e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_26ef8de1-b7d8-4131-b3b5-68f19e3956f7" xlink:to="loc_us-gaap_TaxPeriodDomain_5a27dcdb-0fbc-45e6-851c-a5f971971e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2037ExpirationMember_bec128ba-1bda-4ba3-afc8-bd1ffb245978" xlink:href="amed-20221231.xsd#amed_A2037ExpirationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_5a27dcdb-0fbc-45e6-851c-a5f971971e45" xlink:to="loc_amed_A2037ExpirationMember_bec128ba-1bda-4ba3-afc8-bd1ffb245978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis_5e30f6f1-c7be-4ad2-b834-f1fa27e86ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_1ab7d868-e9fa-49ca-bc3d-76c40b102a40" xlink:to="loc_us-gaap_UnusualOrInfrequentItemAxis_5e30f6f1-c7be-4ad2-b834-f1fa27e86ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_51083f8e-d8ed-474b-97ef-a3d58a6bf8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_5e30f6f1-c7be-4ad2-b834-f1fa27e86ad6" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_51083f8e-d8ed-474b-97ef-a3d58a6bf8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19DeferralOfSocialSecurityTaxesMember_8777f3a0-3af9-4c00-844f-bc213b50b738" xlink:href="amed-20221231.xsd#amed_COVID19DeferralOfSocialSecurityTaxesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain_51083f8e-d8ed-474b-97ef-a3d58a6bf8d6" xlink:to="loc_amed_COVID19DeferralOfSocialSecurityTaxesMember_8777f3a0-3af9-4c00-844f-bc213b50b738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_1ab7d868-e9fa-49ca-bc3d-76c40b102a40" xlink:to="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_bc44a2c4-9f73-49ee-8ac0-76fe9e8493a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_bc44a2c4-9f73-49ee-8ac0-76fe9e8493a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_1af3ee61-411e-4a3a-848c-72af4169a347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_1af3ee61-411e-4a3a-848c-72af4169a347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_a9b5c712-73dd-4652-9539-59969f17e7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_us-gaap_IncomeTaxesReceivable_a9b5c712-73dd-4652-9539-59969f17e7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxCreditsAndAdjustments_d0aa8781-3c1c-436d-9815-2997e12a03d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxCreditsAndAdjustments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_us-gaap_IncomeTaxCreditsAndAdjustments_d0aa8781-3c1c-436d-9815-2997e12a03d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecognizedTaxBenefitThatImpactsEffectiveTaxRate_1603d489-9f64-4d0a-a073-852896a17f98" xlink:href="amed-20221231.xsd#amed_RecognizedTaxBenefitThatImpactsEffectiveTaxRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_amed_RecognizedTaxBenefitThatImpactsEffectiveTaxRate_1603d489-9f64-4d0a-a073-852896a17f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_8ce09c4e-854d-4393-9716-d7f9452dad93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_8ce09c4e-854d-4393-9716-d7f9452dad93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate_da46e427-b843-4b42-b2cf-0884ee5a9a06" xlink:href="amed-20221231.xsd#amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate_da46e427-b843-4b42-b2cf-0884ee5a9a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_c56d0784-62f6-49d1-a8bd-dc5d6a37117d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BenefitAsComponentOfInterestExpense_254553aa-c888-420f-aa01-6edde1ef757d" xlink:href="amed-20221231.xsd#amed_BenefitAsComponentOfInterestExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_amed_BenefitAsComponentOfInterestExpense_254553aa-c888-420f-aa01-6edde1ef757d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_9df3732b-c6ed-4236-9e91-93d84fcfb7da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_us-gaap_OperatingLossCarryforwards_9df3732b-c6ed-4236-9e91-93d84fcfb7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_83eb62b0-8d93-4466-992b-1ce0f97fa4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_83eb62b0-8d93-4466-992b-1ce0f97fa4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_c6539bb8-c1f3-476d-a03e-cbf11cf01245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_c6539bb8-c1f3-476d-a03e-cbf11cf01245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_1c9fe050-389a-4c33-bd6f-3b1366754baf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_1c9fe050-389a-4c33-bd6f-3b1366754baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_28110976-305d-460e-8855-8bc9ad4cfb94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_28110976-305d-460e-8855-8bc9ad4cfb94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenTaxYear_cf1bd5ce-ae91-4c7c-b109-846cc910be50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenTaxYear"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_us-gaap_OpenTaxYear_cf1bd5ce-ae91-4c7c-b109-846cc910be50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_cc8f91d1-ff79-4434-922c-eeb54b495d39" xlink:href="amed-20221231.xsd#amed_CARESActDeferralOfEmployerShareSocialSecurityTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_cc8f91d1-ff79-4434-922c-eeb54b495d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct_3943837a-b19f-4594-80e6-75b822f8c9fb" xlink:href="amed-20221231.xsd#amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct_3943837a-b19f-4594-80e6-75b822f8c9fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProviderReliefFundAdvance_dc38adcd-b39a-4212-87d2-4ef668466787" xlink:href="amed-20221231.xsd#amed_ProviderReliefFundAdvance"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_amed_ProviderReliefFundAdvance_dc38adcd-b39a-4212-87d2-4ef668466787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c2b446b5-8116-461f-a56d-2045684dd1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c2b446b5-8116-461f-a56d-2045684dd1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_77ca82a2-e676-4a90-91ee-ffd582e26e62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_ce3420d1-c5be-4ab6-a9a6-ce2f7f379508" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_77ca82a2-e676-4a90-91ee-ffd582e26e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_45f74ec6-200d-4a22-95a7-b86847db0862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_fbf465ab-2f0e-43f0-8b26-d1837eced53e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_45f74ec6-200d-4a22-95a7-b86847db0862" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_fbf465ab-2f0e-43f0-8b26-d1837eced53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_f1c717d3-7104-4d2d-9d86-d416fc2c1417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_fbf465ab-2f0e-43f0-8b26-d1837eced53e" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_f1c717d3-7104-4d2d-9d86-d416fc2c1417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_f7435e6f-757a-40b3-adb5-63bae6705122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_fbf465ab-2f0e-43f0-8b26-d1837eced53e" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_f7435e6f-757a-40b3-adb5-63bae6705122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_57444dd6-b0f5-4a64-af6f-39c39e37a8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_fbf465ab-2f0e-43f0-8b26-d1837eced53e" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_57444dd6-b0f5-4a64-af6f-39c39e37a8ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3629464e-7fea-48ae-9ae9-8ac90eabb26f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_45f74ec6-200d-4a22-95a7-b86847db0862" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3629464e-7fea-48ae-9ae9-8ac90eabb26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_12c541eb-b190-4925-9236-8539196b3944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3629464e-7fea-48ae-9ae9-8ac90eabb26f" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_12c541eb-b190-4925-9236-8539196b3944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_c8cd066b-1e16-43b2-8ce2-b603ec79e9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3629464e-7fea-48ae-9ae9-8ac90eabb26f" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_c8cd066b-1e16-43b2-8ce2-b603ec79e9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6e001e6d-4f14-4096-a8a0-d272c2258f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3629464e-7fea-48ae-9ae9-8ac90eabb26f" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6e001e6d-4f14-4096-a8a0-d272c2258f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5bc16279-177c-4552-9704-409127a70a86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_45f74ec6-200d-4a22-95a7-b86847db0862" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5bc16279-177c-4552-9704-409127a70a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESIncomeTaxExpenseAllocationDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#INCOMETAXESIncomeTaxExpenseAllocationDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/INCOMETAXESIncomeTaxExpenseAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f0d891e7-9b3a-497f-907d-52b4993e9d13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_783ae9f1-6514-4ba2-ae3a-61ca80578d47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f0d891e7-9b3a-497f-907d-52b4993e9d13" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_783ae9f1-6514-4ba2-ae3a-61ca80578d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncomeTaxEffectsAllocatedToInterestExpense_71ad677d-d791-4f1c-9271-ea259db6b092" xlink:href="amed-20221231.xsd#amed_IncomeTaxEffectsAllocatedToInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f0d891e7-9b3a-497f-907d-52b4993e9d13" xlink:to="loc_amed_IncomeTaxEffectsAllocatedToInterestExpense_71ad677d-d791-4f1c-9271-ea259db6b092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncomeTaxEffectsAllocatedToGoodwill_29e217dd-7768-4a61-aac9-b83df1cd83e8" xlink:href="amed-20221231.xsd#amed_IncomeTaxEffectsAllocatedToGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f0d891e7-9b3a-497f-907d-52b4993e9d13" xlink:to="loc_amed_IncomeTaxEffectsAllocatedToGoodwill_29e217dd-7768-4a61-aac9-b83df1cd83e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TaxExpenseRecordedToAdditionalPaidInCapital_1feb8795-2c28-49b7-9d9b-c6ef26eeb5e9" xlink:href="amed-20221231.xsd#amed_TaxExpenseRecordedToAdditionalPaidInCapital"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f0d891e7-9b3a-497f-907d-52b4993e9d13" xlink:to="loc_amed_TaxExpenseRecordedToAdditionalPaidInCapital_1feb8795-2c28-49b7-9d9b-c6ef26eeb5e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_cea914e0-a37c-4b24-9e93-54cc410beeea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f0d891e7-9b3a-497f-907d-52b4993e9d13" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_cea914e0-a37c-4b24-9e93-54cc410beeea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#INCOMETAXESReconciliationofEffectiveTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_fbca0262-f0d2-4706-9cfe-f308778e5d45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_e6ded786-b35e-4282-9cdb-8ac715a5cbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fbca0262-f0d2-4706-9cfe-f308778e5d45" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_e6ded786-b35e-4282-9cdb-8ac715a5cbf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8be5ef32-3317-4508-a1d2-54bf52eb1a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fbca0262-f0d2-4706-9cfe-f308778e5d45" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8be5ef32-3317-4508-a1d2-54bf52eb1a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent_43cbba1c-51c1-4777-a84d-5703e6ceadb0" xlink:href="amed-20221231.xsd#amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fbca0262-f0d2-4706-9cfe-f308778e5d45" xlink:to="loc_amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent_43cbba1c-51c1-4777-a84d-5703e6ceadb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent_5c137288-9519-40f1-82ff-664857886c53" xlink:href="amed-20221231.xsd#amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fbca0262-f0d2-4706-9cfe-f308778e5d45" xlink:to="loc_amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent_5c137288-9519-40f1-82ff-664857886c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent_9bdba722-7834-4d47-a324-3b420ba51818" xlink:href="amed-20221231.xsd#amed_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fbca0262-f0d2-4706-9cfe-f308778e5d45" xlink:to="loc_amed_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent_9bdba722-7834-4d47-a324-3b420ba51818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_7b3c0309-718b-4c57-948d-d48e2fb8ce55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fbca0262-f0d2-4706-9cfe-f308778e5d45" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_7b3c0309-718b-4c57-948d-d48e2fb8ce55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa6709d1-ca9b-4ce7-a1b9-0028c91b97cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fbca0262-f0d2-4706-9cfe-f308778e5d45" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa6709d1-ca9b-4ce7-a1b9-0028c91b97cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0da562d8-c0a5-42a6-9483-72f60c5b9279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_0b9c96d0-5de8-453f-ba0b-f15c96d70183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0da562d8-c0a5-42a6-9483-72f60c5b9279" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_0b9c96d0-5de8-453f-ba0b-f15c96d70183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_1e699e6a-62af-43cd-860d-d5ada5c252af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_0b9c96d0-5de8-453f-ba0b-f15c96d70183" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_1e699e6a-62af-43cd-860d-d5ada5c252af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_4bde88c6-0a1a-4486-9f74-7a7986782376" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_0b9c96d0-5de8-453f-ba0b-f15c96d70183" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_4bde88c6-0a1a-4486-9f74-7a7986782376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation_5d7a1140-383e-40e4-94ab-7e2cf5d800e2" xlink:href="amed-20221231.xsd#amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_0b9c96d0-5de8-453f-ba0b-f15c96d70183" xlink:to="loc_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation_5d7a1140-383e-40e4-94ab-7e2cf5d800e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1_e2f7bb31-b463-4507-a223-1cfb5d726c13" xlink:href="amed-20221231.xsd#amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_0b9c96d0-5de8-453f-ba0b-f15c96d70183" xlink:to="loc_amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1_e2f7bb31-b463-4507-a223-1cfb5d726c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9eaa1927-3826-4202-b1a1-f21ba5b6d31d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_0b9c96d0-5de8-453f-ba0b-f15c96d70183" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9eaa1927-3826-4202-b1a1-f21ba5b6d31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxAssetsLegalAndComplianceMatters_70b2dada-29f8-4fff-93f8-41ad30025327" xlink:href="amed-20221231.xsd#amed_DeferredTaxAssetsLegalAndComplianceMatters"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_0b9c96d0-5de8-453f-ba0b-f15c96d70183" xlink:to="loc_amed_DeferredTaxAssetsLegalAndComplianceMatters_70b2dada-29f8-4fff-93f8-41ad30025327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxAssetsLeaseLiability_d2343463-d84a-464f-9ca0-34c9196248e4" xlink:href="amed-20221231.xsd#amed_DeferredTaxAssetsLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_0b9c96d0-5de8-453f-ba0b-f15c96d70183" xlink:to="loc_amed_DeferredTaxAssetsLeaseLiability_d2343463-d84a-464f-9ca0-34c9196248e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxAssetsProviderReliefFundAdvance_52de96a1-38c3-4c22-b5ae-93e76d665c1a" xlink:href="amed-20221231.xsd#amed_DeferredTaxAssetsProviderReliefFundAdvance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_0b9c96d0-5de8-453f-ba0b-f15c96d70183" xlink:to="loc_amed_DeferredTaxAssetsProviderReliefFundAdvance_52de96a1-38c3-4c22-b5ae-93e76d665c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxAssetDeferredSocialSecurityTaxes_e427b023-2116-4500-ba31-460d0539c6a0" xlink:href="amed-20221231.xsd#amed_DeferredTaxAssetDeferredSocialSecurityTaxes"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_0b9c96d0-5de8-453f-ba0b-f15c96d70183" xlink:to="loc_amed_DeferredTaxAssetDeferredSocialSecurityTaxes_e427b023-2116-4500-ba31-460d0539c6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherLossCarryforwards_ff1d730c-f586-4147-b14e-bdfa099b3e44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_0b9c96d0-5de8-453f-ba0b-f15c96d70183" xlink:to="loc_us-gaap_DeferredTaxAssetsOtherLossCarryforwards_ff1d730c-f586-4147-b14e-bdfa099b3e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_66b60739-ad3f-48ec-982f-392c39af9989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_0b9c96d0-5de8-453f-ba0b-f15c96d70183" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_66b60739-ad3f-48ec-982f-392c39af9989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_3fa75968-3cc8-48d9-9f6b-6864f4daca70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_0b9c96d0-5de8-453f-ba0b-f15c96d70183" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_3fa75968-3cc8-48d9-9f6b-6864f4daca70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_fea1159c-ff67-4ec7-9aaa-d4956d5c4d94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_0b9c96d0-5de8-453f-ba0b-f15c96d70183" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_fea1159c-ff67-4ec7-9aaa-d4956d5c4d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_16e23459-495f-43b9-862e-dc833718d800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_0b9c96d0-5de8-453f-ba0b-f15c96d70183" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_16e23459-495f-43b9-862e-dc833718d800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_2f79127d-1509-4627-9bad-2be1ab45b1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_0b9c96d0-5de8-453f-ba0b-f15c96d70183" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_2f79127d-1509-4627-9bad-2be1ab45b1b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_147f7686-a7ae-453f-8284-9c4cd49f1e97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0da562d8-c0a5-42a6-9483-72f60c5b9279" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_147f7686-a7ae-453f-8284-9c4cd49f1e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_7224a57f-3684-48db-a268-04bf0ae5ae29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_147f7686-a7ae-453f-8284-9c4cd49f1e97" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_7224a57f-3684-48db-a268-04bf0ae5ae29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets_b8214a1c-17e3-4fb2-b155-845bca0956e1" xlink:href="amed-20221231.xsd#amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_147f7686-a7ae-453f-8284-9c4cd49f1e97" xlink:to="loc_amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets_b8214a1c-17e3-4fb2-b155-845bca0956e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_f1891944-8ea0-42de-8c22-aa4aec1d51a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_147f7686-a7ae-453f-8284-9c4cd49f1e97" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_f1891944-8ea0-42de-8c22-aa4aec1d51a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_103bdf98-8c88-4a0b-a548-86943989cff2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_147f7686-a7ae-453f-8284-9c4cd49f1e97" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_103bdf98-8c88-4a0b-a548-86943989cff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DeferredTaxLiabilitiesRightOfUseAssets_c79c5386-733d-4fd1-b21d-1791d7b2635f" xlink:href="amed-20221231.xsd#amed_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_147f7686-a7ae-453f-8284-9c4cd49f1e97" xlink:to="loc_amed_DeferredTaxLiabilitiesRightOfUseAssets_c79c5386-733d-4fd1-b21d-1791d7b2635f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_8bcf2b10-b6a7-43a4-893e-0c9dd2c4d95e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_147f7686-a7ae-453f-8284-9c4cd49f1e97" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_8bcf2b10-b6a7-43a4-893e-0c9dd2c4d95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_dff32ac3-88aa-4a95-815a-780b9d1c99db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_147f7686-a7ae-453f-8284-9c4cd49f1e97" xlink:to="loc_us-gaap_DeferredTaxLiabilities_dff32ac3-88aa-4a95-815a-780b9d1c99db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_79b53d1f-673e-4c35-80e6-3a227c4f678b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0da562d8-c0a5-42a6-9483-72f60c5b9279" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_79b53d1f-673e-4c35-80e6-3a227c4f678b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_33b70a12-8366-468e-8b75-99610770f009" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0da562d8-c0a5-42a6-9483-72f60c5b9279" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_33b70a12-8366-468e-8b75-99610770f009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f520984b-e4c3-4272-9355-4ecd12d05a58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_61d99e1d-e926-4491-8d10-6faea1699d04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f520984b-e4c3-4272-9355-4ecd12d05a58" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_61d99e1d-e926-4491-8d10-6faea1699d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1f5706f4-7ef0-4d09-8c86-096ac7e89c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_61d99e1d-e926-4491-8d10-6faea1699d04" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1f5706f4-7ef0-4d09-8c86-096ac7e89c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_90431d45-6e4a-4d26-9ec4-310c16dd234d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_61d99e1d-e926-4491-8d10-6faea1699d04" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_90431d45-6e4a-4d26-9ec4-310c16dd234d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_4ef1d870-8291-4274-83c5-8793a9f1690e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_61d99e1d-e926-4491-8d10-6faea1699d04" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_4ef1d870-8291-4274-83c5-8793a9f1690e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_0aa39599-7425-4142-a8fd-90471840b572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_61d99e1d-e926-4491-8d10-6faea1699d04" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_0aa39599-7425-4142-a8fd-90471840b572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_caf203e8-41a1-45b7-95f7-cb87f250f802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_61d99e1d-e926-4491-8d10-6faea1699d04" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_caf203e8-41a1-45b7-95f7-cb87f250f802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_1844bd18-b9d1-4277-bda7-87736d92da04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_61d99e1d-e926-4491-8d10-6faea1699d04" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_1844bd18-b9d1-4277-bda7-87736d92da04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_af4e6870-57e2-4b24-9d45-7c73a6b74cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_61d99e1d-e926-4491-8d10-6faea1699d04" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_af4e6870-57e2-4b24-9d45-7c73a6b74cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_1c6c2fc3-f273-4394-a8d8-8eebf336c0f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f520984b-e4c3-4272-9355-4ecd12d05a58" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_1c6c2fc3-f273-4394-a8d8-8eebf336c0f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_73b8045e-f11c-42e4-93e0-ba1007854fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_1c6c2fc3-f273-4394-a8d8-8eebf336c0f1" xlink:to="loc_us-gaap_IncomeTaxExaminationLineItems_73b8045e-f11c-42e4-93e0-ba1007854fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7d43c3d6-30ad-4341-974f-03269ffe7202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7b25635b-0b89-427c-a619-d691ba6440fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7d43c3d6-30ad-4341-974f-03269ffe7202" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7b25635b-0b89-427c-a619-d691ba6440fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8a2c3755-5580-42fa-8118-04ccfe155ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7b25635b-0b89-427c-a619-d691ba6440fc" xlink:to="loc_us-gaap_AwardTypeAxis_8a2c3755-5580-42fa-8118-04ccfe155ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a76c229-4727-4fb1-963b-6fc1b5bbf44f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8a2c3755-5580-42fa-8118-04ccfe155ccd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a76c229-4727-4fb1-963b-6fc1b5bbf44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareBasedAwardsMember_5ced76b1-bed8-4bfc-9ed0-826aa26221c7" xlink:href="amed-20221231.xsd#amed_ShareBasedAwardsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a76c229-4727-4fb1-963b-6fc1b5bbf44f" xlink:to="loc_amed_ShareBasedAwardsMember_5ced76b1-bed8-4bfc-9ed0-826aa26221c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember_6fa27546-f4da-46b3-95fd-3b5db0439a40" xlink:href="amed-20221231.xsd#amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a76c229-4727-4fb1-963b-6fc1b5bbf44f" xlink:to="loc_amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember_6fa27546-f4da-46b3-95fd-3b5db0439a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9e06ea51-4dc4-452c-982f-b962a6b086fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a76c229-4727-4fb1-963b-6fc1b5bbf44f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9e06ea51-4dc4-452c-982f-b962a6b086fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockUnitsMember_936ab452-4477-4b7c-b967-3f7107687565" xlink:href="amed-20221231.xsd#amed_NonVestedStockUnitsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a76c229-4727-4fb1-963b-6fc1b5bbf44f" xlink:to="loc_amed_NonVestedStockUnitsMember_936ab452-4477-4b7c-b967-3f7107687565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockUnitsServiceMember_efa2cab9-c9ea-4d16-82a0-eae651ddcf00" xlink:href="amed-20221231.xsd#amed_NonVestedStockUnitsServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_NonVestedStockUnitsMember_936ab452-4477-4b7c-b967-3f7107687565" xlink:to="loc_amed_NonVestedStockUnitsServiceMember_efa2cab9-c9ea-4d16-82a0-eae651ddcf00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember_49f74a59-4d15-4f85-a8cb-4e6a4c311030" xlink:href="amed-20221231.xsd#amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_NonVestedStockUnitsMember_936ab452-4477-4b7c-b967-3f7107687565" xlink:to="loc_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember_49f74a59-4d15-4f85-a8cb-4e6a4c311030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fa77b6ca-e04c-4c32-8e80-aa8cf5616220" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7b25635b-0b89-427c-a619-d691ba6440fc" xlink:to="loc_srt_RangeAxis_fa77b6ca-e04c-4c32-8e80-aa8cf5616220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9d5c70c0-c92e-4687-a32e-2af384302697" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fa77b6ca-e04c-4c32-8e80-aa8cf5616220" xlink:to="loc_srt_RangeMember_9d5c70c0-c92e-4687-a32e-2af384302697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b7bb8e4b-8f32-433a-a412-4b81c20dd851" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9d5c70c0-c92e-4687-a32e-2af384302697" xlink:to="loc_srt_MaximumMember_b7bb8e4b-8f32-433a-a412-4b81c20dd851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0355f0a9-b30f-4053-ab14-bfac02c2ddbe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9d5c70c0-c92e-4687-a32e-2af384302697" xlink:to="loc_srt_MinimumMember_0355f0a9-b30f-4053-ab14-bfac02c2ddbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7b25635b-0b89-427c-a619-d691ba6440fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e689648e-65e5-441d-a814-df169fce3d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e689648e-65e5-441d-a814-df169fce3d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_4fae7b9a-5d9e-41ca-901b-04a5196aa75e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_4fae7b9a-5d9e-41ca-901b-04a5196aa75e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_f1684184-9bf8-44a7-b14e-ee9e4804a898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_f1684184-9bf8-44a7-b14e-ee9e4804a898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a08e4b36-18c9-4461-94cb-77ddba014f33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a08e4b36-18c9-4461-94cb-77ddba014f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_cc4ca1c6-4c47-4773-9ef1-d7efd18c1bca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_CommonStockSharesIssued_cc4ca1c6-4c47-4773-9ef1-d7efd18c1bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9bd505ce-2888-46ad-8ca8-b42589c175df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9bd505ce-2888-46ad-8ca8-b42589c175df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_d83bbe87-c2fd-4a93-a2ff-154d46846a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_PreferredStockSharesIssued_d83bbe87-c2fd-4a93-a2ff-154d46846a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Percentageofownershipinsubsidiaries_81069455-bad4-4eb3-a8f5-2771085eace4" xlink:href="amed-20221231.xsd#amed_Percentageofownershipinsubsidiaries"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_amed_Percentageofownershipinsubsidiaries_81069455-bad4-4eb3-a8f5-2771085eace4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_fa80e1d1-9c4e-46c4-8d1b-0b4a56b8bde7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_fa80e1d1-9c4e-46c4-8d1b-0b4a56b8bde7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5f3d9569-bff4-44ff-880a-4b88e884682c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5f3d9569-bff4-44ff-880a-4b88e884682c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Fairvalueofshareofcommonstockpercentage_dbedf5d5-717f-4817-9e53-b06918e34391" xlink:href="amed-20221231.xsd#amed_Fairvalueofshareofcommonstockpercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_amed_Fairvalueofshareofcommonstockpercentage_dbedf5d5-717f-4817-9e53-b06918e34391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries_5ccc2d55-0cf9-415e-a952-fa525543004e" xlink:href="amed-20221231.xsd#amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries_5ccc2d55-0cf9-415e-a952-fa525543004e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_d31c552e-45c0-4221-9fac-7e087424bfee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_d31c552e-45c0-4221-9fac-7e087424bfee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_48d4a6e6-a6c3-4253-9916-731b7f921181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_48d4a6e6-a6c3-4253-9916-731b7f921181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CommonStockSharesAvailableForIssuanceToEmployeeStockPurchasePlan_a0540bcc-fbaf-47f1-a58f-cc61062e77d5" xlink:href="amed-20221231.xsd#amed_CommonStockSharesAvailableForIssuanceToEmployeeStockPurchasePlan"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_amed_CommonStockSharesAvailableForIssuanceToEmployeeStockPurchasePlan_a0540bcc-fbaf-47f1-a58f-cc61062e77d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_c9aa2d7e-848f-4539-a946-77cf40eb94e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_c9aa2d7e-848f-4539-a946-77cf40eb94e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_fa144c68-aa49-4135-9f1f-0e453c4b86e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_fa144c68-aa49-4135-9f1f-0e453c4b86e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4b135fb4-00a5-42bb-b304-43737fd8101e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4b135fb4-00a5-42bb-b304-43737fd8101e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_9ffc5f22-2f18-4859-9283-eb65c8d450d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_9ffc5f22-2f18-4859-9283-eb65c8d450d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_de0bb397-81f9-4bbb-b048-2cb1b7bc2c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_de0bb397-81f9-4bbb-b048-2cb1b7bc2c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f268f278-3bfb-4b60-a488-d4cdf4fae3df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f268f278-3bfb-4b60-a488-d4cdf4fae3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ea3f5038-8a29-415e-9e27-4e863c592835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ea3f5038-8a29-415e-9e27-4e863c592835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_502444df-740a-40ec-921f-68a679489c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_502444df-740a-40ec-921f-68a679489c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_722ae895-5f5e-4196-8102-7f9acc7797f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_722ae895-5f5e-4196-8102-7f9acc7797f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7091a529-67b3-4785-971d-935f3a37f5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7091a529-67b3-4785-971d-935f3a37f5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f7cc88d2-c655-4ed0-84b0-66003c4bdd08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f7cc88d2-c655-4ed0-84b0-66003c4bdd08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Performancebasedawardtargetshareamount_93fdb2a4-02e5-4d3f-8373-d95938d25c40" xlink:href="amed-20221231.xsd#amed_Performancebasedawardtargetshareamount"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_amed_Performancebasedawardtargetshareamount_93fdb2a4-02e5-4d3f-8373-d95938d25c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan_a636c513-28f4-4b41-96c4-44aea22894eb" xlink:href="amed-20221231.xsd#amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b142a289-faa8-4ec2-8eb5-eb9e941cdc87" xlink:to="loc_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan_a636c513-28f4-4b41-96c4-44aea22894eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONEmployeeStockPurchasePlanPurchasesDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONEmployeeStockPurchasePlanPurchasesDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONEmployeeStockPurchasePlanPurchasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fc68924c-d2ce-423a-a846-bbd5a5d1ef24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1af1ac46-2847-459e-a7f8-12bda0129f33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fc68924c-d2ce-423a-a846-bbd5a5d1ef24" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1af1ac46-2847-459e-a7f8-12bda0129f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_70009b9e-1030-44e4-8dd3-27bb130eb4cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fc68924c-d2ce-423a-a846-bbd5a5d1ef24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_70009b9e-1030-44e4-8dd3-27bb130eb4cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1f39995c-d6f5-44fd-b0c0-826e12b213fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e1197293-e28c-4986-b026-835bc39f5ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1f39995c-d6f5-44fd-b0c0-826e12b213fd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e1197293-e28c-4986-b026-835bc39f5ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_59e8e318-e9f1-4494-a23a-60b32edf87c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e1197293-e28c-4986-b026-835bc39f5ea4" xlink:to="loc_us-gaap_AwardTypeAxis_59e8e318-e9f1-4494-a23a-60b32edf87c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e8a0ab12-63d8-4e9a-8539-9dc126c0c0ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_59e8e318-e9f1-4494-a23a-60b32edf87c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e8a0ab12-63d8-4e9a-8539-9dc126c0c0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_cb4bfa03-6b0c-46df-a151-4c02911f78d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e8a0ab12-63d8-4e9a-8539-9dc126c0c0ea" xlink:to="loc_us-gaap_EmployeeStockOptionMember_cb4bfa03-6b0c-46df-a151-4c02911f78d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9d1ff1b3-c127-4e81-9596-5ffd0437ecca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e1197293-e28c-4986-b026-835bc39f5ea4" xlink:to="loc_srt_RangeAxis_9d1ff1b3-c127-4e81-9596-5ffd0437ecca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_04baa939-476f-4414-91d4-d3f276391e27" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9d1ff1b3-c127-4e81-9596-5ffd0437ecca" xlink:to="loc_srt_RangeMember_04baa939-476f-4414-91d4-d3f276391e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_88756eff-8883-44dd-9a63-cf5c82482b90" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_04baa939-476f-4414-91d4-d3f276391e27" xlink:to="loc_srt_MinimumMember_88756eff-8883-44dd-9a63-cf5c82482b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7ea397c1-bab1-450f-bbb5-1d1995eb7c03" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_04baa939-476f-4414-91d4-d3f276391e27" xlink:to="loc_srt_MaximumMember_7ea397c1-bab1-450f-bbb5-1d1995eb7c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8146ab39-f55c-438d-bff1-661442f6b085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e1197293-e28c-4986-b026-835bc39f5ea4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8146ab39-f55c-438d-bff1-661442f6b085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_a89b334a-895d-496a-9bf9-c8f365a3fc3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8146ab39-f55c-438d-bff1-661442f6b085" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_a89b334a-895d-496a-9bf9-c8f365a3fc3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_1ee85fff-2b1e-4e8c-ae70-acf83761df1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8146ab39-f55c-438d-bff1-661442f6b085" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_1ee85fff-2b1e-4e8c-ae70-acf83761df1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d5eb839d-0289-46ee-9d22-f62221e66f37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8146ab39-f55c-438d-bff1-661442f6b085" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d5eb839d-0289-46ee-9d22-f62221e66f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_3557bf35-7802-45d9-a063-7e16e01d0f08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8146ab39-f55c-438d-bff1-661442f6b085" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_3557bf35-7802-45d9-a063-7e16e01d0f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_d1c0ad8b-1a9b-437c-9f7d-b826a2bef43e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8146ab39-f55c-438d-bff1-661442f6b085" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_d1c0ad8b-1a9b-437c-9f7d-b826a2bef43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_48418ffb-941f-4a23-9171-1b6af6dd86e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8146ab39-f55c-438d-bff1-661442f6b085" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_48418ffb-941f-4a23-9171-1b6af6dd86e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ab2afc31-2408-4658-a15a-44b619fda4b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8146ab39-f55c-438d-bff1-661442f6b085" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ab2afc31-2408-4658-a15a-44b619fda4b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue_fa4d46df-4eae-4aaf-bf03-57ad78adc107" xlink:href="amed-20221231.xsd#amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8146ab39-f55c-438d-bff1-661442f6b085" xlink:to="loc_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue_fa4d46df-4eae-4aaf-bf03-57ad78adc107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_63bad52e-96b5-4018-93c6-ef8e0ec1d491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8146ab39-f55c-438d-bff1-661442f6b085" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_63bad52e-96b5-4018-93c6-ef8e0ec1d491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd80020a-1b71-4477-a463-2e59647aa660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3718e648-2902-422e-afa1-e2b7c2786e21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd80020a-1b71-4477-a463-2e59647aa660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3718e648-2902-422e-afa1-e2b7c2786e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8c8bdd9c-ec8f-4b1d-acbe-777ede4cb722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3718e648-2902-422e-afa1-e2b7c2786e21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8c8bdd9c-ec8f-4b1d-acbe-777ede4cb722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_caccbc32-2f35-403d-8dc8-cec83afbe2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3718e648-2902-422e-afa1-e2b7c2786e21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_caccbc32-2f35-403d-8dc8-cec83afbe2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1f3dcde4-3ece-4f11-b34b-d224892e757d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3718e648-2902-422e-afa1-e2b7c2786e21" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1f3dcde4-3ece-4f11-b34b-d224892e757d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_6253c488-8528-44c8-acb7-cc4d261817f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3718e648-2902-422e-afa1-e2b7c2786e21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_6253c488-8528-44c8-acb7-cc4d261817f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3d315367-d33f-4c05-b7c3-690250befcdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3718e648-2902-422e-afa1-e2b7c2786e21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3d315367-d33f-4c05-b7c3-690250befcdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e1a5c593-f4c0-48aa-b601-2a53ab7286a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3718e648-2902-422e-afa1-e2b7c2786e21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e1a5c593-f4c0-48aa-b601-2a53ab7286a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d21840c0-bb54-4b07-9c47-3cd297d92f14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd80020a-1b71-4477-a463-2e59647aa660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d21840c0-bb54-4b07-9c47-3cd297d92f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e2133787-e99e-4a27-9cbb-2b0c64615542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d21840c0-bb54-4b07-9c47-3cd297d92f14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e2133787-e99e-4a27-9cbb-2b0c64615542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1250f3b5-d1a9-43a6-9647-6023d86052fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d21840c0-bb54-4b07-9c47-3cd297d92f14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1250f3b5-d1a9-43a6-9647-6023d86052fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b9f6bb55-7e19-48b3-8472-a44c70067df4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d21840c0-bb54-4b07-9c47-3cd297d92f14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b9f6bb55-7e19-48b3-8472-a44c70067df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_405039e9-0e01-47ed-990a-7d3f7a832313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d21840c0-bb54-4b07-9c47-3cd297d92f14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_405039e9-0e01-47ed-990a-7d3f7a832313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4e1e4c6f-8f06-4c07-951b-78795fb765d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d21840c0-bb54-4b07-9c47-3cd297d92f14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4e1e4c6f-8f06-4c07-951b-78795fb765d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c2dbdd3d-de12-4f6f-a77c-c6a15b75626b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d21840c0-bb54-4b07-9c47-3cd297d92f14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c2dbdd3d-de12-4f6f-a77c-c6a15b75626b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_940a9de8-c3e3-4b6d-b661-3be638f27e02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd80020a-1b71-4477-a463-2e59647aa660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_940a9de8-c3e3-4b6d-b661-3be638f27e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_89167260-0051-4eb6-9fab-9b7e353793c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_940a9de8-c3e3-4b6d-b661-3be638f27e02" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_89167260-0051-4eb6-9fab-9b7e353793c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_db54c9a0-c61c-4a3a-99ad-f1ea5864ab58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_940a9de8-c3e3-4b6d-b661-3be638f27e02" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_db54c9a0-c61c-4a3a-99ad-f1ea5864ab58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c6501271-d6c5-489d-86ac-4399cd51df2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd80020a-1b71-4477-a463-2e59647aa660" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c6501271-d6c5-489d-86ac-4399cd51df2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b51970f9-c829-4133-a485-2eff60af6664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c6501271-d6c5-489d-86ac-4399cd51df2f" xlink:to="loc_us-gaap_AwardTypeAxis_b51970f9-c829-4133-a485-2eff60af6664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03ad957d-eb2b-41b3-839f-e6fa95896d44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b51970f9-c829-4133-a485-2eff60af6664" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03ad957d-eb2b-41b3-839f-e6fa95896d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExecutiveStockOptionExerciseMember_89abab85-2718-401d-85cf-c2633a4ebdf4" xlink:href="amed-20221231.xsd#amed_ExecutiveStockOptionExerciseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03ad957d-eb2b-41b3-839f-e6fa95896d44" xlink:to="loc_amed_ExecutiveStockOptionExerciseMember_89abab85-2718-401d-85cf-c2633a4ebdf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_395f0b2d-14c1-4294-898d-daf0a1bc59fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c6501271-d6c5-489d-86ac-4399cd51df2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_395f0b2d-14c1-4294-898d-daf0a1bc59fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_55c5c548-1cda-404a-8359-b23405fcf1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_395f0b2d-14c1-4294-898d-daf0a1bc59fe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_55c5c548-1cda-404a-8359-b23405fcf1e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SurrenderedSharesInShares_693b64b5-6bf7-4782-bf0c-aec50634062b" xlink:href="amed-20221231.xsd#amed_SurrenderedSharesInShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_395f0b2d-14c1-4294-898d-daf0a1bc59fe" xlink:to="loc_amed_SurrenderedSharesInShares_693b64b5-6bf7-4782-bf0c-aec50634062b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e31eb234-f03a-4350-9b5b-4c0381d7253e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_395f0b2d-14c1-4294-898d-daf0a1bc59fe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e31eb234-f03a-4350-9b5b-4c0381d7253e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_f5f00415-ef0f-42d6-9753-fc84c1d8f28d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_395f0b2d-14c1-4294-898d-daf0a1bc59fe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_f5f00415-ef0f-42d6-9753-fc84c1d8f28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1daae67f-1ee6-4430-b54e-4c5cefa40cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_395f0b2d-14c1-4294-898d-daf0a1bc59fe" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1daae67f-1ee6-4430-b54e-4c5cefa40cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_059c866f-f90b-42cb-81c1-7c2c29a92d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_f0216fed-ddcc-4f23-84fc-6381cdef8854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_059c866f-f90b-42cb-81c1-7c2c29a92d5c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_f0216fed-ddcc-4f23-84fc-6381cdef8854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_92504151-72fa-452a-bc8f-3123498397bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_f0216fed-ddcc-4f23-84fc-6381cdef8854" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_92504151-72fa-452a-bc8f-3123498397bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e62849d3-a33e-4012-8bc6-bebd7d387928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_f0216fed-ddcc-4f23-84fc-6381cdef8854" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e62849d3-a33e-4012-8bc6-bebd7d387928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_740aba4a-f7ab-46da-8e6b-a38d5239ed0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_f0216fed-ddcc-4f23-84fc-6381cdef8854" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_740aba4a-f7ab-46da-8e6b-a38d5239ed0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_d201d608-3843-4747-a8b8-770c8b654065" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_f0216fed-ddcc-4f23-84fc-6381cdef8854" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_d201d608-3843-4747-a8b8-770c8b654065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_17855320-89f9-4bf1-a8f6-03bddcd9fc76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_f0216fed-ddcc-4f23-84fc-6381cdef8854" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_17855320-89f9-4bf1-a8f6-03bddcd9fc76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_00593103-db3e-4014-a637-42afb3e920d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_059c866f-f90b-42cb-81c1-7c2c29a92d5c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_00593103-db3e-4014-a637-42afb3e920d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_fd416eb2-23d6-4ef0-a4d5-09deecb6ee46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_00593103-db3e-4014-a637-42afb3e920d5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_fd416eb2-23d6-4ef0-a4d5-09deecb6ee46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4896f792-7561-4688-945a-8ee49d4eb06c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_00593103-db3e-4014-a637-42afb3e920d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4896f792-7561-4688-945a-8ee49d4eb06c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_84bb6e7b-3c94-45d7-b067-2a516fcb1f18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_00593103-db3e-4014-a637-42afb3e920d5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_84bb6e7b-3c94-45d7-b067-2a516fcb1f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_8c2f96fe-89ad-4425-b5f0-287dc4b57ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_00593103-db3e-4014-a637-42afb3e920d5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_8c2f96fe-89ad-4425-b5f0-287dc4b57ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_f913a5ee-a9b0-41f2-9562-d4b25af541b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_00593103-db3e-4014-a637-42afb3e920d5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_f913a5ee-a9b0-41f2-9562-d4b25af541b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e1ad350a-dfaa-414e-92f7-0cbe547cc29e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0bf1d6ac-94c1-4029-9ec3-92b0f9b835c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e1ad350a-dfaa-414e-92f7-0cbe547cc29e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0bf1d6ac-94c1-4029-9ec3-92b0f9b835c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6a0ff42d-ab7d-4179-b9b2-b94bace23025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0bf1d6ac-94c1-4029-9ec3-92b0f9b835c3" xlink:to="loc_us-gaap_AwardTypeAxis_6a0ff42d-ab7d-4179-b9b2-b94bace23025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c9aea28-61d7-4b3d-af33-f8596ba92cad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6a0ff42d-ab7d-4179-b9b2-b94bace23025" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c9aea28-61d7-4b3d-af33-f8596ba92cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockUnitsMember_d512ff0c-f6a1-452e-a3e5-064b62eb0aed" xlink:href="amed-20221231.xsd#amed_NonVestedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c9aea28-61d7-4b3d-af33-f8596ba92cad" xlink:to="loc_amed_NonVestedStockUnitsMember_d512ff0c-f6a1-452e-a3e5-064b62eb0aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_af11a312-5b95-4a3b-954c-85ed60ea3099" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0bf1d6ac-94c1-4029-9ec3-92b0f9b835c3" xlink:to="loc_srt_RangeAxis_af11a312-5b95-4a3b-954c-85ed60ea3099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9939232f-c82b-4b06-8978-d1fdd010f755" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_af11a312-5b95-4a3b-954c-85ed60ea3099" xlink:to="loc_srt_RangeMember_9939232f-c82b-4b06-8978-d1fdd010f755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_80250be7-2d3e-467d-8724-994ee39ae829" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9939232f-c82b-4b06-8978-d1fdd010f755" xlink:to="loc_srt_MinimumMember_80250be7-2d3e-467d-8724-994ee39ae829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5f9f78e-2675-482c-8f76-e82a712a9e52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0bf1d6ac-94c1-4029-9ec3-92b0f9b835c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5f9f78e-2675-482c-8f76-e82a712a9e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0fd3be4-9404-4329-9156-5ee9e310543b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5f9f78e-2675-482c-8f76-e82a712a9e52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0fd3be4-9404-4329-9156-5ee9e310543b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a24210d7-2f2c-4019-b8b2-2fb4cf540699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0fd3be4-9404-4329-9156-5ee9e310543b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a24210d7-2f2c-4019-b8b2-2fb4cf540699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_64a4ee52-badb-4572-8981-8fa3948c7048" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0fd3be4-9404-4329-9156-5ee9e310543b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_64a4ee52-badb-4572-8981-8fa3948c7048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_dc57d5eb-aaef-4282-a1d5-d0f4bd6cc9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0fd3be4-9404-4329-9156-5ee9e310543b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_dc57d5eb-aaef-4282-a1d5-d0f4bd6cc9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6fbbb719-a47e-4dd3-8a01-a0664cd1e60f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0fd3be4-9404-4329-9156-5ee9e310543b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6fbbb719-a47e-4dd3-8a01-a0664cd1e60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0ec39b73-10e7-4b7c-8cab-f225ff0c231e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d0fd3be4-9404-4329-9156-5ee9e310543b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0ec39b73-10e7-4b7c-8cab-f225ff0c231e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d506dc55-6fe1-4a7d-9eab-b8cc9e9234dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c5f9f78e-2675-482c-8f76-e82a712a9e52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d506dc55-6fe1-4a7d-9eab-b8cc9e9234dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7c4ae4ae-6c23-433d-b8d9-32314784a217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d506dc55-6fe1-4a7d-9eab-b8cc9e9234dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7c4ae4ae-6c23-433d-b8d9-32314784a217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e770641b-44ee-4e53-b993-39b36f6e72fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d506dc55-6fe1-4a7d-9eab-b8cc9e9234dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e770641b-44ee-4e53-b993-39b36f6e72fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f1527b70-21e7-40e6-90c1-1141e028d993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d506dc55-6fe1-4a7d-9eab-b8cc9e9234dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f1527b70-21e7-40e6-90c1-1141e028d993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5e40519e-3ce0-498b-ad1f-6f9438f9a393" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d506dc55-6fe1-4a7d-9eab-b8cc9e9234dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5e40519e-3ce0-498b-ad1f-6f9438f9a393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bd06d434-f93c-4331-92dd-f27678fc8c42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d506dc55-6fe1-4a7d-9eab-b8cc9e9234dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bd06d434-f93c-4331-92dd-f27678fc8c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ccd13413-7a1c-4aba-bb3b-ca6930227efa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8288c076-1301-49e6-bdcc-1152c89ecce9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ccd13413-7a1c-4aba-bb3b-ca6930227efa" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8288c076-1301-49e6-bdcc-1152c89ecce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bade8913-f44d-4a69-81d7-35626df2a88f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8288c076-1301-49e6-bdcc-1152c89ecce9" xlink:to="loc_us-gaap_AwardTypeAxis_bade8913-f44d-4a69-81d7-35626df2a88f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15e780f8-ac9d-4ddf-9da3-110e7d8c4cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_bade8913-f44d-4a69-81d7-35626df2a88f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15e780f8-ac9d-4ddf-9da3-110e7d8c4cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockUnitsServiceMember_0ce3794d-ae60-46b0-8acf-878245a90d34" xlink:href="amed-20221231.xsd#amed_NonVestedStockUnitsServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15e780f8-ac9d-4ddf-9da3-110e7d8c4cb7" xlink:to="loc_amed_NonVestedStockUnitsServiceMember_0ce3794d-ae60-46b0-8acf-878245a90d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember_0bd162d9-2fb4-4e90-88bc-9efd6bc63770" xlink:href="amed-20221231.xsd#amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15e780f8-ac9d-4ddf-9da3-110e7d8c4cb7" xlink:to="loc_amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember_0bd162d9-2fb4-4e90-88bc-9efd6bc63770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad9c26db-9e0b-480e-b706-2977ef404104" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8288c076-1301-49e6-bdcc-1152c89ecce9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad9c26db-9e0b-480e-b706-2977ef404104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_81197340-fd2d-4402-a106-278c64ef9e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad9c26db-9e0b-480e-b706-2977ef404104" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_81197340-fd2d-4402-a106-278c64ef9e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9e3f089b-c308-4378-9904-33d9ac5aec50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_81197340-fd2d-4402-a106-278c64ef9e6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9e3f089b-c308-4378-9904-33d9ac5aec50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_bbdb4d49-47af-479e-af23-b68d11b6c709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_81197340-fd2d-4402-a106-278c64ef9e6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_bbdb4d49-47af-479e-af23-b68d11b6c709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d451ac36-8171-4628-a8ad-4d91b0103eef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_81197340-fd2d-4402-a106-278c64ef9e6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d451ac36-8171-4628-a8ad-4d91b0103eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_725a1feb-85d8-4322-b405-0975e23c3d34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_81197340-fd2d-4402-a106-278c64ef9e6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_725a1feb-85d8-4322-b405-0975e23c3d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6414e479-e5da-4380-b1b0-c678d3988ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_81197340-fd2d-4402-a106-278c64ef9e6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6414e479-e5da-4380-b1b0-c678d3988ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_bd6bc0d8-0b0d-4e9c-87e5-066d6ec4ffae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad9c26db-9e0b-480e-b706-2977ef404104" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_bd6bc0d8-0b0d-4e9c-87e5-066d6ec4ffae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_456c87a6-8560-4940-b855-ed23a204c0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_bd6bc0d8-0b0d-4e9c-87e5-066d6ec4ffae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_456c87a6-8560-4940-b855-ed23a204c0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_58aa29e1-4a67-4613-a106-97191a7ef22f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_bd6bc0d8-0b0d-4e9c-87e5-066d6ec4ffae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_58aa29e1-4a67-4613-a106-97191a7ef22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a6305ae3-e528-483c-8f11-b52b0cce800d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_bd6bc0d8-0b0d-4e9c-87e5-066d6ec4ffae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a6305ae3-e528-483c-8f11-b52b0cce800d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_bac65403-e90b-43de-9aad-594c5f8e8b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_bd6bc0d8-0b0d-4e9c-87e5-066d6ec4ffae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_bac65403-e90b-43de-9aad-594c5f8e8b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1f3e165a-25d2-432d-96f3-37c19d47311b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_bd6bc0d8-0b0d-4e9c-87e5-066d6ec4ffae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1f3e165a-25d2-432d-96f3-37c19d47311b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AdditionalPerformanceBasedAwardTargetShareAmount_8b5bb698-3822-42c4-921e-b01cb596e97a" xlink:href="amed-20221231.xsd#amed_AdditionalPerformanceBasedAwardTargetShareAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad9c26db-9e0b-480e-b706-2977ef404104" xlink:to="loc_amed_AdditionalPerformanceBasedAwardTargetShareAmount_8b5bb698-3822-42c4-921e-b01cb596e97a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_56e5be01-735c-4829-bd0b-2fb85fea5750" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_c83fca81-31c8-4e20-b986-e89023e0485b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_56e5be01-735c-4829-bd0b-2fb85fea5750" xlink:to="loc_us-gaap_LossContingenciesTable_c83fca81-31c8-4e20-b986-e89023e0485b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_992b05fe-a604-4042-afc4-0a97784826d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c83fca81-31c8-4e20-b986-e89023e0485b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_992b05fe-a604-4042-afc4-0a97784826d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_02655973-d2e5-466e-adbc-8856add58d65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_992b05fe-a604-4042-afc4-0a97784826d5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_02655973-d2e5-466e-adbc-8856add58d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_0fd889d4-38db-44b2-a321-86883e3d3259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_02655973-d2e5-466e-adbc-8856add58d65" xlink:to="loc_us-gaap_SubsequentEventMember_0fd889d4-38db-44b2-a321-86883e3d3259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_aa361f14-13e0-4f5e-a8e0-d8fbd4c9c9bd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c83fca81-31c8-4e20-b986-e89023e0485b" xlink:to="loc_srt_LitigationCaseAxis_aa361f14-13e0-4f5e-a8e0-d8fbd4c9c9bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_b981ba2f-482f-422b-94bc-d7f0efa5537f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_aa361f14-13e0-4f5e-a8e0-d8fbd4c9c9bd" xlink:to="loc_srt_LitigationCaseTypeDomain_b981ba2f-482f-422b-94bc-d7f0efa5537f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UsDepartmentOfJusticeMember_87794fc0-e059-4be1-8fff-da9fe890afec" xlink:href="amed-20221231.xsd#amed_UsDepartmentOfJusticeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_b981ba2f-482f-422b-94bc-d7f0efa5537f" xlink:to="loc_amed_UsDepartmentOfJusticeMember_87794fc0-e059-4be1-8fff-da9fe890afec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SafeguardZoneProgramIntegrityContractorMember_3e5c99dd-9358-49a7-b8a9-786483592fa2" xlink:href="amed-20221231.xsd#amed_SafeguardZoneProgramIntegrityContractorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_b981ba2f-482f-422b-94bc-d7f0efa5537f" xlink:to="loc_amed_SafeguardZoneProgramIntegrityContractorMember_3e5c99dd-9358-49a7-b8a9-786483592fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmedisysCIAMember_bac27c6e-8f91-4be1-b55a-cbe71b07d2d3" xlink:href="amed-20221231.xsd#amed_AmedisysCIAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_b981ba2f-482f-422b-94bc-d7f0efa5537f" xlink:to="loc_amed_AmedisysCIAMember_bac27c6e-8f91-4be1-b55a-cbe71b07d2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceCIAMember_5ba21142-af30-45b9-ba1a-5325b1e5d174" xlink:href="amed-20221231.xsd#amed_CompassionateCareHospiceCIAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_b981ba2f-482f-422b-94bc-d7f0efa5537f" xlink:to="loc_amed_CompassionateCareHospiceCIAMember_5ba21142-af30-45b9-ba1a-5325b1e5d174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_bd696b10-de8b-44e4-97c0-f89e13046ef2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c83fca81-31c8-4e20-b986-e89023e0485b" xlink:to="loc_srt_StatementGeographicalAxis_bd696b10-de8b-44e4-97c0-f89e13046ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_80c95b8d-bf5f-42cd-8d29-0f42c29820e8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_bd696b10-de8b-44e4-97c0-f89e13046ef2" xlink:to="loc_srt_SegmentGeographicalDomain_80c95b8d-bf5f-42cd-8d29-0f42c29820e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_58249567-dfe1-4209-b395-b64d32dcc642" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_80c95b8d-bf5f-42cd-8d29-0f42c29820e8" xlink:to="loc_stpr_MA_58249567-dfe1-4209-b395-b64d32dcc642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MorgantownWestVirginiaMember_807e978b-5d0a-4411-ba5b-7a206bd7c03a" xlink:href="amed-20221231.xsd#amed_MorgantownWestVirginiaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_80c95b8d-bf5f-42cd-8d29-0f42c29820e8" xlink:to="loc_amed_MorgantownWestVirginiaMember_807e978b-5d0a-4411-ba5b-7a206bd7c03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ParkersburgWestVirginiaMember_56d8ca30-175c-480b-9eb3-0aa493b0eb6e" xlink:href="amed-20221231.xsd#amed_ParkersburgWestVirginiaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_80c95b8d-bf5f-42cd-8d29-0f42c29820e8" xlink:to="loc_amed_ParkersburgWestVirginiaMember_56d8ca30-175c-480b-9eb3-0aa493b0eb6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CT_3091d01b-98dc-4dc8-b31b-944c8a3145d5" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CT"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_80c95b8d-bf5f-42cd-8d29-0f42c29820e8" xlink:to="loc_stpr_CT_3091d01b-98dc-4dc8-b31b-944c8a3145d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL_7eab7c72-cd67-4c6c-aad2-97751832a12f" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_IL"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_80c95b8d-bf5f-42cd-8d29-0f42c29820e8" xlink:to="loc_stpr_IL_7eab7c72-cd67-4c6c-aad2-97751832a12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_SC_64c04685-cbe7-4cd6-94a2-a3465e2f59b0" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_SC"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_80c95b8d-bf5f-42cd-8d29-0f42c29820e8" xlink:to="loc_stpr_SC_64c04685-cbe7-4cd6-94a2-a3465e2f59b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL_54f72521-9f34-4458-b481-55728fb100c5" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_FL"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_80c95b8d-bf5f-42cd-8d29-0f42c29820e8" xlink:to="loc_stpr_FL_54f72521-9f34-4458-b481-55728fb100c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LakelandFloridaMember_d4281867-fca8-4030-ba4c-314e4e309b6f" xlink:href="amed-20221231.xsd#amed_LakelandFloridaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_stpr_FL_54f72521-9f34-4458-b481-55728fb100c5" xlink:to="loc_amed_LakelandFloridaMember_d4281867-fca8-4030-ba4c-314e4e309b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ClearwaterFloridaMember_750a26c9-e1d0-4cc3-aef7-9a336980ce78" xlink:href="amed-20221231.xsd#amed_ClearwaterFloridaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_stpr_FL_54f72521-9f34-4458-b481-55728fb100c5" xlink:to="loc_amed_ClearwaterFloridaMember_750a26c9-e1d0-4cc3-aef7-9a336980ce78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c9e19c68-25e8-49b8-bd04-0f0c0ec109ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c83fca81-31c8-4e20-b986-e89023e0485b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c9e19c68-25e8-49b8-bd04-0f0c0ec109ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b7013f9a-b372-4666-aa99-6671109a1291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c9e19c68-25e8-49b8-bd04-0f0c0ec109ca" xlink:to="loc_us-gaap_SegmentDomain_b7013f9a-b372-4666-aa99-6671109a1291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_6e2dbca6-0e6c-497a-a748-a1079513df64" xlink:href="amed-20221231.xsd#amed_HospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b7013f9a-b372-4666-aa99-6671109a1291" xlink:to="loc_amed_HospiceMember_6e2dbca6-0e6c-497a-a748-a1079513df64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_be8469c5-85a7-428c-a295-6499b87d9046" xlink:href="amed-20221231.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b7013f9a-b372-4666-aa99-6671109a1291" xlink:to="loc_amed_HomeHealthMember_be8469c5-85a7-428c-a295-6499b87d9046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a8fe4766-9ee5-4177-8688-88e9bdda602a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c83fca81-31c8-4e20-b986-e89023e0485b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a8fe4766-9ee5-4177-8688-88e9bdda602a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d5bab84a-8b8c-4ede-bf3a-36f2eec83665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a8fe4766-9ee5-4177-8688-88e9bdda602a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d5bab84a-8b8c-4ede-bf3a-36f2eec83665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InfinityHomeCareMember_71683bcb-daf7-49af-be00-6a4c01ba81cf" xlink:href="amed-20221231.xsd#amed_InfinityHomeCareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d5bab84a-8b8c-4ede-bf3a-36f2eec83665" xlink:to="loc_amed_InfinityHomeCareMember_71683bcb-daf7-49af-be00-6a4c01ba81cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_d72026df-56b8-4a7d-a9be-162e55cf7da3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c83fca81-31c8-4e20-b986-e89023e0485b" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_d72026df-56b8-4a7d-a9be-162e55cf7da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_56fd3294-4c7b-440e-b3b1-710d501756d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_d72026df-56b8-4a7d-a9be-162e55cf7da3" xlink:to="loc_us-gaap_LossContingencyNatureDomain_56fd3294-4c7b-440e-b3b1-710d501756d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExtrapolatedMember_a59c4d38-7cab-467e-9f61-5414362a7a27" xlink:href="amed-20221231.xsd#amed_ExtrapolatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_56fd3294-4c7b-440e-b3b1-710d501756d1" xlink:to="loc_amed_ExtrapolatedMember_a59c4d38-7cab-467e-9f61-5414362a7a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnfavorableMember_24e27d05-dc07-43ee-ac31-96bb092966ee" xlink:href="amed-20221231.xsd#amed_UnfavorableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_56fd3294-4c7b-440e-b3b1-710d501756d1" xlink:to="loc_amed_UnfavorableMember_24e27d05-dc07-43ee-ac31-96bb092966ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5c558c6b-ce3e-4cba-b7bd-e2576ffb2c6f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c83fca81-31c8-4e20-b986-e89023e0485b" xlink:to="loc_srt_RangeAxis_5c558c6b-ce3e-4cba-b7bd-e2576ffb2c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_99a3c3f9-f035-49a2-8a50-0189edf948c6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5c558c6b-ce3e-4cba-b7bd-e2576ffb2c6f" xlink:to="loc_srt_RangeMember_99a3c3f9-f035-49a2-8a50-0189edf948c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_70d426db-e147-498d-94c2-1bdadd295047" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_99a3c3f9-f035-49a2-8a50-0189edf948c6" xlink:to="loc_srt_MinimumMember_70d426db-e147-498d-94c2-1bdadd295047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b2d47dc9-adf9-4305-acf4-276c15625201" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_99a3c3f9-f035-49a2-8a50-0189edf948c6" xlink:to="loc_srt_MaximumMember_b2d47dc9-adf9-4305-acf4-276c15625201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_c83fca81-31c8-4e20-b986-e89023e0485b" xlink:to="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Numberofpatients_7bf82a38-d8aa-4a91-904c-e1c3937777d4" xlink:href="amed-20221231.xsd#amed_Numberofpatients"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_Numberofpatients_7bf82a38-d8aa-4a91-904c-e1c3937777d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_8d2dec3f-9809-418f-9a3e-d0478a5325f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_8d2dec3f-9809-418f-9a3e-d0478a5325f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_3a047c57-d631-4381-9359-b0b35d48f779" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_3a047c57-d631-4381-9359-b0b35d48f779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_55eb63ac-8bfe-4a57-b58f-6b84cd03d0a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_55eb63ac-8bfe-4a57-b58f-6b84cd03d0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_b5b010c2-f197-4f4c-ab1a-605eea4eccad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_b5b010c2-f197-4f4c-ab1a-605eea4eccad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfCareCentersSold_8d80a05a-196a-4641-9041-45e148da60eb" xlink:href="amed-20221231.xsd#amed_NumberOfCareCentersSold"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_NumberOfCareCentersSold_8d80a05a-196a-4641-9041-45e148da60eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableCurrent_1bf60a58-eb67-4ad3-8b5a-aa989fa0b940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyReceivableCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_us-gaap_LossContingencyReceivableCurrent_1bf60a58-eb67-4ad3-8b5a-aa989fa0b940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CorporateIntegrityAgreementTerm_ab1e6c15-fba4-4b35-a548-4aac56b21044" xlink:href="amed-20221231.xsd#amed_CorporateIntegrityAgreementTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_CorporateIntegrityAgreementTerm_ab1e6c15-fba4-4b35-a548-4aac56b21044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfBeneficiaries_c37d9ab3-f601-47d8-819e-e889876c0c7a" xlink:href="amed-20221231.xsd#amed_NumberOfBeneficiaries"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_NumberOfBeneficiaries_c37d9ab3-f601-47d8-819e-e889876c0c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_e6d08860-73c8-453d-80a8-02ec9d11837e" xlink:href="amed-20221231.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiary"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_e6d08860-73c8-453d-80a8-02ec9d11837e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_0620bfa5-fed5-447a-80ee-fcf933ef356a" xlink:href="amed-20221231.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_0620bfa5-fed5-447a-80ee-fcf933ef356a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfClaimsSubmittedBySubsidiary_fdab569e-6f73-48c0-b599-6e8867cfc1d2" xlink:href="amed-20221231.xsd#amed_NumberOfClaimsSubmittedBySubsidiary"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_NumberOfClaimsSubmittedBySubsidiary_fdab569e-6f73-48c0-b599-6e8867cfc1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_0a209fcf-9d78-45db-b244-62b3bb4fa073" xlink:href="amed-20221231.xsd#amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_0a209fcf-9d78-45db-b244-62b3bb4fa073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableNoncurrent_f591c407-c153-4335-ba2e-0af703cca87b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyReceivableNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_us-gaap_LossContingencyReceivableNoncurrent_f591c407-c153-4335-ba2e-0af703cca87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ActualClaimsPayment_286e7afd-ee77-47ba-88f7-7aa904f64f51" xlink:href="amed-20221231.xsd#amed_ActualClaimsPayment"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_ActualClaimsPayment_286e7afd-ee77-47ba-88f7-7aa904f64f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ErrorRatePercentage_9560c9e2-22f7-48a2-9363-6b19f925b96d" xlink:href="amed-20221231.xsd#amed_ErrorRatePercentage"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_ErrorRatePercentage_9560c9e2-22f7-48a2-9363-6b19f925b96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IndemnificationAmount_2ab24bff-8871-4f9c-84f0-56ef615dfeae" xlink:href="amed-20221231.xsd#amed_IndemnificationAmount"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_IndemnificationAmount_2ab24bff-8871-4f9c-84f0-56ef615dfeae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FloridaZpicRevenueReduction_7fe23147-0b02-40d5-8b6d-5f2e1c66e41b" xlink:href="amed-20221231.xsd#amed_FloridaZpicRevenueReduction"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_FloridaZpicRevenueReduction_7fe23147-0b02-40d5-8b6d-5f2e1c66e41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_10d4696b-93e6-455c-a543-a8073de77a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_10d4696b-93e6-455c-a543-a8073de77a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OperatingLeaseTermYears_0213391c-6720-480b-8438-49cbcb1ea0ff" xlink:href="amed-20221231.xsd#amed_OperatingLeaseTermYears"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_OperatingLeaseTermYears_0213391c-6720-480b-8438-49cbcb1ea0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_376c6055-b540-49a8-823b-6c3f520be95b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_us-gaap_LeaseAndRentalExpense_376c6055-b540-49a8-823b-6c3f520be95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthInsuranceRetentionLimit_62cf9c9d-4593-4389-b048-f2aeb9d5605f" xlink:href="amed-20221231.xsd#amed_HealthInsuranceRetentionLimit"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_HealthInsuranceRetentionLimit_62cf9c9d-4593-4389-b048-f2aeb9d5605f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WorkersCompensationInsuranceRetentionLimit_cb208866-6777-4e1d-828d-c807df52be4d" xlink:href="amed-20221231.xsd#amed_WorkersCompensationInsuranceRetentionLimit"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_WorkersCompensationInsuranceRetentionLimit_cb208866-6777-4e1d-828d-c807df52be4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit_f816feae-48c5-4768-a097-6bb5cd052926" xlink:href="amed-20221231.xsd#amed_ProfessionalLiabilityInsuranceRetentionLimit"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit_f816feae-48c5-4768-a097-6bb5cd052926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ReversalOfLossContingencyAccrual_ed4474f4-4af7-409b-9f1e-f8fa3622d0bf" xlink:href="amed-20221231.xsd#amed_ReversalOfLossContingencyAccrual"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_ReversalOfLossContingencyAccrual_ed4474f4-4af7-409b-9f1e-f8fa3622d0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementInterest_36680b7e-3999-49fe-b521-f1df045f37a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementInterest"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_us-gaap_LitigationSettlementInterest_36680b7e-3999-49fe-b521-f1df045f37a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalLegalSettlementPayment_de5a4d68-758e-48d3-9ff7-43c012ed50d8" xlink:href="amed-20221231.xsd#amed_TotalLegalSettlementPayment"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_TotalLegalSettlementPayment_de5a4d68-758e-48d3-9ff7-43c012ed50d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LegalSettlementPaymentLessInterest_bb2759d0-9677-419c-885f-e3852a8fe919" xlink:href="amed-20221231.xsd#amed_LegalSettlementPaymentLessInterest"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_LegalSettlementPaymentLessInterest_bb2759d0-9677-419c-885f-e3852a8fe919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_c6a0e184-f271-4786-a31f-5d399497add6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_c6a0e184-f271-4786-a31f-5d399497add6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ReductionToNetServiceRevenue_3188a685-71d1-4940-abf8-e47c1f4f3fc8" xlink:href="amed-20221231.xsd#amed_ReductionToNetServiceRevenue"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_2ac30206-e195-4863-ac67-5fedb833cc46" xlink:to="loc_amed_ReductionToNetServiceRevenue_3188a685-71d1-4940-abf8-e47c1f4f3fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4da97eb3-2359-4810-bdca-a06ad2dda0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthInsurance_5fe1eaa2-df4d-4e77-812c-013d009f52df" xlink:href="amed-20221231.xsd#amed_HealthInsurance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4da97eb3-2359-4810-bdca-a06ad2dda0fe" xlink:to="loc_amed_HealthInsurance_5fe1eaa2-df4d-4e77-812c-013d009f52df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WokersCompensation_53970681-bb6a-45f7-993d-c71aad2778ec" xlink:href="amed-20221231.xsd#amed_WokersCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4da97eb3-2359-4810-bdca-a06ad2dda0fe" xlink:to="loc_amed_WokersCompensation_53970681-bb6a-45f7-993d-c71aad2778ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProfessionalLiability_1b76b3ff-707f-45f2-9288-2143991a213f" xlink:href="amed-20221231.xsd#amed_ProfessionalLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4da97eb3-2359-4810-bdca-a06ad2dda0fe" xlink:to="loc_amed_ProfessionalLiability_1b76b3ff-707f-45f2-9288-2143991a213f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedInsuranceTotal_041ec13a-3295-4ab2-800d-50fda7b0310f" xlink:href="amed-20221231.xsd#amed_EstimatedInsuranceTotal"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4da97eb3-2359-4810-bdca-a06ad2dda0fe" xlink:to="loc_amed_EstimatedInsuranceTotal_041ec13a-3295-4ab2-800d-50fda7b0310f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedInsuranceLongTermPortion_dfbce7c8-6b68-4089-954b-ef022c82fbf9" xlink:href="amed-20221231.xsd#amed_EstimatedInsuranceLongTermPortion"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4da97eb3-2359-4810-bdca-a06ad2dda0fe" xlink:to="loc_amed_EstimatedInsuranceLongTermPortion_dfbce7c8-6b68-4089-954b-ef022c82fbf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedInsuranceExcludingLongTermPortion_020b3d6f-3f9d-410d-a8a4-87f3d330fd57" xlink:href="amed-20221231.xsd#amed_EstimatedInsuranceExcludingLongTermPortion"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4da97eb3-2359-4810-bdca-a06ad2dda0fe" xlink:to="loc_amed_EstimatedInsuranceExcludingLongTermPortion_020b3d6f-3f9d-410d-a8a4-87f3d330fd57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#EMPLOYEEBENEFITPLANSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ab3ddd5e-7c1b-480e-9f6b-329440a0cde6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DefinedContributionPlanEmployerMatchingContribution_53bc9665-5b0c-41a9-a520-fa773ac970f4" xlink:href="amed-20221231.xsd#amed_DefinedContributionPlanEmployerMatchingContribution"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ab3ddd5e-7c1b-480e-9f6b-329440a0cde6" xlink:to="loc_amed_DefinedContributionPlanEmployerMatchingContribution_53bc9665-5b0c-41a9-a520-fa773ac970f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram_f7ca3358-6b29-44c5-840e-063ba7f6e9cb" xlink:href="amed-20221231.xsd#amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ab3ddd5e-7c1b-480e-9f6b-329440a0cde6" xlink:to="loc_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram_f7ca3358-6b29-44c5-840e-063ba7f6e9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage_87304c06-a11e-4e99-bc80-ebde6afbeee7" xlink:href="amed-20221231.xsd#amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ab3ddd5e-7c1b-480e-9f6b-329440a0cde6" xlink:to="loc_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage_87304c06-a11e-4e99-bc80-ebde6afbeee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_bdcc222d-5221-4f9f-94ba-b7b9939be91d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ab3ddd5e-7c1b-480e-9f6b-329440a0cde6" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_bdcc222d-5221-4f9f-94ba-b7b9939be91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#SHAREREPURCHASENarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_bf65833a-82a7-4f37-b79a-b54be234f4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseTable_fc808542-58e0-44d8-8a89-f19e0f3c5f27" xlink:href="amed-20221231.xsd#amed_ShareRepurchaseTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bf65833a-82a7-4f37-b79a-b54be234f4ee" xlink:to="loc_amed_ShareRepurchaseTable_fc808542-58e0-44d8-8a89-f19e0f3c5f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_aaeeed58-846e-4961-96f8-56a6de273b08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseTable_fc808542-58e0-44d8-8a89-f19e0f3c5f27" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_aaeeed58-846e-4961-96f8-56a6de273b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_32d89908-b219-4d16-a444-a664a8d41bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_aaeeed58-846e-4961-96f8-56a6de273b08" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_32d89908-b219-4d16-a444-a664a8d41bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_3afdaccf-6744-40d6-a752-1d9345808232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_32d89908-b219-4d16-a444-a664a8d41bb1" xlink:to="loc_us-gaap_SubsequentEventMember_3afdaccf-6744-40d6-a752-1d9345808232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_4b8d88d5-5d59-45a0-b40d-c5f89b332e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseTable_fc808542-58e0-44d8-8a89-f19e0f3c5f27" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_4b8d88d5-5d59-45a0-b40d-c5f89b332e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_5d34c09f-5cfb-417f-8c5d-74f930de430b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_4b8d88d5-5d59-45a0-b40d-c5f89b332e6c" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_5d34c09f-5cfb-417f-8c5d-74f930de430b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2021ShareRepurchaseProgramMember_b07b4651-ab50-48f0-9ace-476c6639f7da" xlink:href="amed-20221231.xsd#amed_A2021ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_5d34c09f-5cfb-417f-8c5d-74f930de430b" xlink:to="loc_amed_A2021ShareRepurchaseProgramMember_b07b4651-ab50-48f0-9ace-476c6639f7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NewShareRepurchaseProgramMember_acf72101-3215-485d-91c9-c4553c0a0794" xlink:href="amed-20221231.xsd#amed_NewShareRepurchaseProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_5d34c09f-5cfb-417f-8c5d-74f930de430b" xlink:to="loc_amed_NewShareRepurchaseProgramMember_acf72101-3215-485d-91c9-c4553c0a0794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2019StockRepurchaseProgramMember_74429cf9-b8cd-4413-90b6-7170df844eeb" xlink:href="amed-20221231.xsd#amed_A2019StockRepurchaseProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_5d34c09f-5cfb-417f-8c5d-74f930de430b" xlink:to="loc_amed_A2019StockRepurchaseProgramMember_74429cf9-b8cd-4413-90b6-7170df844eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2023ShareRepurchaseProgramMember_1c36f8b8-3b56-4b46-85a5-5f6700c8944a" xlink:href="amed-20221231.xsd#amed_A2023ShareRepurchaseProgramMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_5d34c09f-5cfb-417f-8c5d-74f930de430b" xlink:to="loc_amed_A2023ShareRepurchaseProgramMember_1c36f8b8-3b56-4b46-85a5-5f6700c8944a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseLineItems_0beb3219-6f54-46df-89ff-31dc35543069" xlink:href="amed-20221231.xsd#amed_ShareRepurchaseLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseTable_fc808542-58e0-44d8-8a89-f19e0f3c5f27" xlink:to="loc_amed_ShareRepurchaseLineItems_0beb3219-6f54-46df-89ff-31dc35543069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofSharesOutstanding_e90af3c0-f339-4c24-a98e-6c3365c01e70" xlink:href="amed-20221231.xsd#amed_PercentageofSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_0beb3219-6f54-46df-89ff-31dc35543069" xlink:to="loc_amed_PercentageofSharesOutstanding_e90af3c0-f339-4c24-a98e-6c3365c01e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b8fed3a3-a3f0-41a7-bf30-7c93a1c10067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_0beb3219-6f54-46df-89ff-31dc35543069" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b8fed3a3-a3f0-41a7-bf30-7c93a1c10067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_eabdfdbf-ea3f-4b08-92b1-13d45ed47b16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_0beb3219-6f54-46df-89ff-31dc35543069" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_eabdfdbf-ea3f-4b08-92b1-13d45ed47b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramExpirationDate_34a116db-a218-49c7-b61e-680959923def" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramExpirationDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_0beb3219-6f54-46df-89ff-31dc35543069" xlink:to="loc_us-gaap_StockRepurchaseProgramExpirationDate_34a116db-a218-49c7-b61e-680959923def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_049a180a-14fa-4de2-94c9-a09da562430c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_0beb3219-6f54-46df-89ff-31dc35543069" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_049a180a-14fa-4de2-94c9-a09da562430c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_b595f4f3-930c-422c-ae5e-2db92889fb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_0beb3219-6f54-46df-89ff-31dc35543069" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_b595f4f3-930c-422c-ae5e-2db92889fb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#SEGMENTINFORMATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c3d52d2f-db09-4b25-a7ca-48615c5d034c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_5d6de341-315f-4c0b-a2f6-f215aac50465" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c3d52d2f-db09-4b25-a7ca-48615c5d034c" xlink:to="loc_us-gaap_NumberOfReportableSegments_5d6de341-315f-4c0b-a2f6-f215aac50465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_70c2b4ac-1149-4ad1-83ab-25aa98664830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_050b62c0-b444-414b-b352-3c8d34a48d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_70c2b4ac-1149-4ad1-83ab-25aa98664830" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_050b62c0-b444-414b-b352-3c8d34a48d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_68871170-c694-4627-863b-c249ce97c32e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_050b62c0-b444-414b-b352-3c8d34a48d25" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_68871170-c694-4627-863b-c249ce97c32e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8bdb23b8-e145-4fe4-846e-509981795d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_68871170-c694-4627-863b-c249ce97c32e" xlink:to="loc_us-gaap_SegmentDomain_8bdb23b8-e145-4fe4-846e-509981795d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_a69d798e-3794-4e33-9323-d41b85ce2527" xlink:href="amed-20221231.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8bdb23b8-e145-4fe4-846e-509981795d0d" xlink:to="loc_amed_HomeHealthMember_a69d798e-3794-4e33-9323-d41b85ce2527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_7c6574ab-2dbe-46ef-9c29-2941ca088253" xlink:href="amed-20221231.xsd#amed_HospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8bdb23b8-e145-4fe4-846e-509981795d0d" xlink:to="loc_amed_HospiceMember_7c6574ab-2dbe-46ef-9c29-2941ca088253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_e220661a-ac2c-4ccb-a24f-f4a14fcb8dec" xlink:href="amed-20221231.xsd#amed_PersonalCareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8bdb23b8-e145-4fe4-846e-509981795d0d" xlink:to="loc_amed_PersonalCareMember_e220661a-ac2c-4ccb-a24f-f4a14fcb8dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_ec09012c-4e64-45fb-81f5-5c07d390f208" xlink:href="amed-20221231.xsd#amed_HighAcuityCareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8bdb23b8-e145-4fe4-846e-509981795d0d" xlink:to="loc_amed_HighAcuityCareMember_ec09012c-4e64-45fb-81f5-5c07d390f208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateMember_cd0659ad-18fe-45da-abc9-bb8c3197a7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8bdb23b8-e145-4fe4-846e-509981795d0d" xlink:to="loc_us-gaap_CorporateMember_cd0659ad-18fe-45da-abc9-bb8c3197a7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_b77363a6-2044-429e-9ac0-ffbfe5c05ecb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_050b62c0-b444-414b-b352-3c8d34a48d25" xlink:to="loc_srt_ConsolidationItemsAxis_b77363a6-2044-429e-9ac0-ffbfe5c05ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_1ca43fac-c552-476e-832a-accd596a1db3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_b77363a6-2044-429e-9ac0-ffbfe5c05ecb" xlink:to="loc_srt_ConsolidationItemsDomain_1ca43fac-c552-476e-832a-accd596a1db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_5ebeaac7-9426-469c-8a53-11f21c4457f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_1ca43fac-c552-476e-832a-accd596a1db3" xlink:to="loc_us-gaap_OperatingSegmentsMember_5ebeaac7-9426-469c-8a53-11f21c4457f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_784e8e23-d3f6-4a1a-ab5a-f4e7cafd306b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_1ca43fac-c552-476e-832a-accd596a1db3" xlink:to="loc_us-gaap_CorporateNonSegmentMember_784e8e23-d3f6-4a1a-ab5a-f4e7cafd306b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_ccc14d39-9a9f-430a-8882-3896dd1174a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_050b62c0-b444-414b-b352-3c8d34a48d25" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_ccc14d39-9a9f-430a-8882-3896dd1174a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_a6692abf-f9b2-4111-983d-0effb1bce5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ccc14d39-9a9f-430a-8882-3896dd1174a7" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_a6692abf-f9b2-4111-983d-0effb1bce5a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_af4d4fed-05b5-40d9-885e-269ce8ddce0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ccc14d39-9a9f-430a-8882-3896dd1174a7" xlink:to="loc_us-gaap_OtherOperatingIncome_af4d4fed-05b5-40d9-885e-269ce8ddce0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_690624b1-114e-4391-b87c-55109637f8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ccc14d39-9a9f-430a-8882-3896dd1174a7" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_690624b1-114e-4391-b87c-55109637f8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_e0dfa03f-5aa1-4c8d-9c5b-ae5ea99b67f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ccc14d39-9a9f-430a-8882-3896dd1174a7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_e0dfa03f-5aa1-4c8d-9c5b-ae5ea99b67f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DepreciationAndAmortizationForContinuingOperations_771ba385-be91-4640-adb7-bdfefafe5941" xlink:href="amed-20221231.xsd#amed_DepreciationAndAmortizationForContinuingOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ccc14d39-9a9f-430a-8882-3896dd1174a7" xlink:to="loc_amed_DepreciationAndAmortizationForContinuingOperations_771ba385-be91-4640-adb7-bdfefafe5941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_beae0ebe-b7ba-4d47-85a6-ef11aa727a57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ccc14d39-9a9f-430a-8882-3896dd1174a7" xlink:to="loc_us-gaap_AssetImpairmentCharges_beae0ebe-b7ba-4d47-85a6-ef11aa727a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_a3698e1b-535e-43fc-9722-6d25d4b1443a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ccc14d39-9a9f-430a-8882-3896dd1174a7" xlink:to="loc_us-gaap_CostsAndExpenses_a3698e1b-535e-43fc-9722-6d25d4b1443a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_40c67597-2927-4435-8261-6f159477af17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ccc14d39-9a9f-430a-8882-3896dd1174a7" xlink:to="loc_us-gaap_OperatingIncomeLoss_40c67597-2927-4435-8261-6f159477af17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#RELATEDPARTYTRANSACTIONSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0fcdf58b-c254-44e2-8d93-ce5d7169b1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_000bc1e6-2ff0-483b-8301-5be05d37c23e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0fcdf58b-c254-44e2-8d93-ce5d7169b1ed" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_000bc1e6-2ff0-483b-8301-5be05d37c23e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_5a2292fa-72fe-4bbe-a764-3bde841073ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_000bc1e6-2ff0-483b-8301-5be05d37c23e" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_5a2292fa-72fe-4bbe-a764-3bde841073ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_65e088e1-15d1-4ce2-9436-a9cba54b23fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_5a2292fa-72fe-4bbe-a764-3bde841073ec" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_65e088e1-15d1-4ce2-9436-a9cba54b23fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedalogixMember_817a4845-bb63-417f-b485-0fa800a2736a" xlink:href="amed-20221231.xsd#amed_MedalogixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_65e088e1-15d1-4ce2-9436-a9cba54b23fe" xlink:to="loc_amed_MedalogixMember_817a4845-bb63-417f-b485-0fa800a2736a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_2e937f96-48d5-4cf8-be7b-600c76349fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_000bc1e6-2ff0-483b-8301-5be05d37c23e" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_2e937f96-48d5-4cf8-be7b-600c76349fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_f85323f4-2e2a-45c4-9e00-23d05ff6bcf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2e937f96-48d5-4cf8-be7b-600c76349fa4" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_f85323f4-2e2a-45c4-9e00-23d05ff6bcf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENTSNarrativeDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#SUBSEQUENTEVENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUBSEQUENTEVENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_61c7c3b3-c663-477f-b47c-59329c8eaba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_b290114e-6351-4839-8fae-09ddba5098c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_61c7c3b3-c663-477f-b47c-59329c8eaba4" xlink:to="loc_us-gaap_SubsequentEventTable_b290114e-6351-4839-8fae-09ddba5098c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d86ae93f-e555-4a2f-a556-0f0ec6ed85d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_b290114e-6351-4839-8fae-09ddba5098c2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d86ae93f-e555-4a2f-a556-0f0ec6ed85d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e1078399-1759-468a-b08c-55ab7a25e964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d86ae93f-e555-4a2f-a556-0f0ec6ed85d5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e1078399-1759-468a-b08c-55ab7a25e964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c4de2b82-5aaf-4c3a-b513-53e8398af410" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e1078399-1759-468a-b08c-55ab7a25e964" xlink:to="loc_us-gaap_SubsequentEventMember_c4de2b82-5aaf-4c3a-b513-53e8398af410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_cb72bdb5-3db9-41be-9765-0106e22d9aba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_b290114e-6351-4839-8fae-09ddba5098c2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_cb72bdb5-3db9-41be-9765-0106e22d9aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_df694c7b-9174-4bcd-b907-121b866b7b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_cb72bdb5-3db9-41be-9765-0106e22d9aba" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_df694c7b-9174-4bcd-b907-121b866b7b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EvolutionHealthMember_c6ee19a3-e1fb-4951-83c2-9e94b4acec3a" xlink:href="amed-20221231.xsd#amed_EvolutionHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_df694c7b-9174-4bcd-b907-121b866b7b8e" xlink:to="loc_amed_EvolutionHealthMember_c6ee19a3-e1fb-4951-83c2-9e94b4acec3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AssistedCareHomeHealthMember_8e826a89-ee23-4fa7-9ae1-3013ea23ceaf" xlink:href="amed-20221231.xsd#amed_AssistedCareHomeHealthMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_df694c7b-9174-4bcd-b907-121b866b7b8e" xlink:to="loc_amed_AssistedCareHomeHealthMember_8e826a89-ee23-4fa7-9ae1-3013ea23ceaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_9997287c-fded-411e-8aa3-45bdea679a11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_b290114e-6351-4839-8fae-09ddba5098c2" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_9997287c-fded-411e-8aa3-45bdea679a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_4366f034-057e-4403-a55b-1b53ed16d8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_9997287c-fded-411e-8aa3-45bdea679a11" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_4366f034-057e-4403-a55b-1b53ed16d8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2023ShareRepurchaseProgramMember_e6d7b7eb-3161-44be-8a03-9e3dd51daec6" xlink:href="amed-20221231.xsd#amed_A2023ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_4366f034-057e-4403-a55b-1b53ed16d8e4" xlink:to="loc_amed_A2023ShareRepurchaseProgramMember_e6d7b7eb-3161-44be-8a03-9e3dd51daec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_dcaefe08-0fa6-45b9-bf13-bcae79bbb93d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_b290114e-6351-4839-8fae-09ddba5098c2" xlink:to="loc_us-gaap_SubsequentEventLineItems_dcaefe08-0fa6-45b9-bf13-bcae79bbb93d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_36b3b10e-a36c-41c1-9f92-272030fc43e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_dcaefe08-0fa6-45b9-bf13-bcae79bbb93d" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_36b3b10e-a36c-41c1-9f92-272030fc43e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramExpirationDate_c5cbd6f5-cba3-4cb6-a253-54495e7e13c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramExpirationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_dcaefe08-0fa6-45b9-bf13-bcae79bbb93d" xlink:to="loc_us-gaap_StockRepurchaseProgramExpirationDate_c5cbd6f5-cba3-4cb6-a253-54495e7e13c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="amed-20221231.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_146dd793-2245-4f7b-9eb9-5512c22ca80f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_290906e9-c8a3-4b19-a838-00c2c6e10ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_146dd793-2245-4f7b-9eb9-5512c22ca80f" xlink:to="loc_us-gaap_SubsequentEventTable_290906e9-c8a3-4b19-a838-00c2c6e10ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7c7c0690-5c4a-4dbb-8b01-df85e2e05cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_290906e9-c8a3-4b19-a838-00c2c6e10ef2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7c7c0690-5c4a-4dbb-8b01-df85e2e05cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_940bb2fe-457b-419e-ab38-df57e92afddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7c7c0690-5c4a-4dbb-8b01-df85e2e05cff" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_940bb2fe-457b-419e-ab38-df57e92afddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_157bca8e-3e82-47bf-8c80-17791e080825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_940bb2fe-457b-419e-ab38-df57e92afddd" xlink:to="loc_us-gaap_SubsequentEventMember_157bca8e-3e82-47bf-8c80-17791e080825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_8040adae-cf9e-427d-9e87-a84d3085eabc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_290906e9-c8a3-4b19-a838-00c2c6e10ef2" xlink:to="loc_us-gaap_SubsequentEventLineItems_8040adae-cf9e-427d-9e87-a84d3085eabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>amed-20221231_g1.jpg
<TEXT>
begin 644 amed-20221231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !> )4# 2(  A$! Q$!_\0
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M^YF#Q=5Q=2-K))V]5??_ (!TV@?M6>!O$OB>+2;75V\^Y?RK>:6UECM[ELX
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M:RHTY-2DE=!1116IH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
..4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>amed-20221231_g2.jpg
<TEXT>
begin 644 amed-20221231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UA8WD@1V]O
M9')U;0    60 P "    %   $*:0!  "    %   $+J2D0 "     S T  "2
MD@ "     S T  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M_)Q7PW_ZXZE_Z3F@#U&BODOX;>)9/A[#XCU*28I;ZOI=Y-;9. ;R"8HBC\)
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M/ACX\\-:79Z7I?Q1\K3K,!8[?_A'H#A<Y(W,Y/<\YKK?'O@W_A-]'LK'[?\
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M-O)R<\UZ!10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8R54 ]4HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %9WB'_D6=4_Z\Y?_ $ UHUG>(?\
MD6=4_P"O.7_T T :-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %4=9UFRT'2Y+_49"D2$*JJI9
MY')PJ(HY9B> !R31K.LV6@Z5+J&IS>5!%@<*69V)PJ*HY9B2 %'))Q6)HND7
MVK:I'XC\4P^5<H#_ &?II8,M@A&-S8X:9AU;HH.U>Y8 DT72+W4-23Q#XFC"
M7@!%E8;@R:>AZ\]&E8?>;M]U>,ENEHHH **** "BBB@ HHHH *QO$7A_^V8H
M;BRN/L.K69+V5ZJY,;'JK#^*-L89>X]" 1LT4 8?AOQ$=86>SU"W^P:S8D+>
MV1;.TGI(A_BC;!*M]0<$$#<K$\0>'VU-X-0TR9;/6;('[+=$94@_>BD ^]&V
M!D=N",$"IM!UQ-9MY4FA:SU"U81WEDYRT#XXY_B4CE6'!'OD  U:*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&L[Q#_R+.J?]><O_ * : -&BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MEV2 EVW;U;=N.1TP^7X2:$]G' EWJ,6Z&6"]D22/=J$<LHED67*$?,^3E A
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MV;@ /F)&3V'AC1I]"T/['>7<=Y</=7-U+-%"849IIWF(5"S$ &3 RQZ5KT4
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M#_R+.J?]><O_ * :T:SO$/\ R+.J?]><O_H!H T:*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BD)"J2Q  &23VKG)O&VGRS/;>'X+C7[E3M9=.4-$C>C
MS$B-?<;MW7@T =)6;J_B'2=!1#JU_#;-*<11$YDE/HB#+.?90365_9WBC6N=
M6U.+1+5O^772OWDQ'HT[C _X @(YPU:6D>&=(T-WETZR5;B08ENI6,L\O^_*
MY+M^)H S?[9\1ZSE=!T8:9 >E]K(()]UMU.\_1VC/M2IX)M;V19O%%Y<Z_*#
MD1W9"VRGV@7"'V+!F]ZZ:B@!L<:11K'$BHB@!548 'H!3J** "BBB@ HHHH
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MM=)8W]IJ=C%>Z=<Q75K,NZ.:%PRN/4$4 3T444 %%%% !1110 4444 %%%%
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M@^D"_*P_ZZ;S[UT<,,5M"D-O&D42#"(BA54>@ Z4^B@ HHHH **** "BBB@
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M:WJ2.*TQK=A_:TFF22M%=QQ>:4EB9 4P"2KD;6QGG:3COTK0!R,B@#GM.\5
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MW?1A[IQZI#T3ZR9/^Q5_2?"NFZ3=&]Q+?:DPVOJ%Z_FSL/0-T0?[*!5]JV:
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MBL 0& 8$9P2,^YJCI_@KPMI%_'>Z5X:T>QNXL^7<6UA%'(F00<,J@C()'T-
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M2^^UW$;+VVK)<,0P]22/I72SV6IW.J3//_9<MFD9^R"2V9I8Y"!RS%L8SGH
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M3C382MGI+7OF'S4-W*L>SL5;RR<^Q&/>K#2:U_:5RJVM@;(1$V\AN7\QI,#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "L[Q#_R+.J?]><O_ * :T:SO$/\ R+.J?]><O_H!H T:*** "BBB@ HH
MHH **** "BBB@ J.YMH+RUEM;R&.>WF0QRQ2H&212,%6!X((."#4E% '-_\
M"N?!'_0F^'__  5P?_$UTE%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ6JS^1:0XWOM+')(50%4$L22   220!0!'_:=W_T!+__ +[@_P#CM']IW?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%9&J^);'1KI;>\@U21V0.#9Z3=728R1R\4
M;*#QT)ST..10!KT5S?\ PGFD?\^?B#_PG-0_^,5PE[\3]?'AW6=:LYXXTLGO
MC!:S>$-28%8))%0/<"144D(-Q(&PD@@;2* /7Z*YO_A/-(_Y\_$'_A.:A_\
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MKW3>40K2 J0& 49.Y@!FO2["Z^W:;;7?E^7Y\2R[-ZOMW '&Y25/7J"0>QH
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M2Z$I@_>^]P:[+QEXCUC0?!UK-'!:6VL7]Y;V";7:XAMWFD";\E4+@ D\A<G
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7 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675801760176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 10, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-24260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AMEDISYS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">11-3131700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3854 American Way, Suite A,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Baton Rouge,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">LA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">70816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">292-2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,550,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMED<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000896262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Document And Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675801634048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLineItems', window );"><strong>Auditor [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Baton Rouge, Louisiana<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675804413296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 40,540<span></span>
</td>
<td class="nump">$ 42,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">13,593<span></span>
</td>
<td class="nump">3,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Patient accounts receivable</a></td>
<td class="nump">296,785<span></span>
</td>
<td class="nump">274,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">11,628<span></span>
</td>
<td class="nump">10,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">26,415<span></span>
</td>
<td class="nump">25,598<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">388,961<span></span>
</td>
<td class="nump">356,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation of $101,364 and $96,937</a></td>
<td class="nump">16,026<span></span>
</td>
<td class="nump">18,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">102,856<span></span>
</td>
<td class="nump">101,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,287,399<span></span>
</td>
<td class="nump">1,196,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net of accumulated amortization of $14,604 and $19,900</a></td>
<td class="nump">101,167<span></span>
</td>
<td class="nump">111,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income tax assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">79,836<span></span>
</td>
<td class="nump">73,023<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,976,245<span></span>
</td>
<td class="nump">1,856,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">43,735<span></span>
</td>
<td class="nump">38,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee benefits</a></td>
<td class="nump">125,387<span></span>
</td>
<td class="nump">141,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">137,390<span></span>
</td>
<td class="nump">150,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current portion of long-term obligations</a></td>
<td class="nump">15,496<span></span>
</td>
<td class="nump">12,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">33,521<span></span>
</td>
<td class="nump">31,233<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">355,529<span></span>
</td>
<td class="nump">374,282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term obligations, less current portion</a></td>
<td class="nump">419,420<span></span>
</td>
<td class="nump">432,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="nump">69,504<span></span>
</td>
<td class="nump">69,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax liabilities</a></td>
<td class="nump">20,411<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term obligations</a></td>
<td class="nump">4,808<span></span>
</td>
<td class="nump">4,979<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">869,672<span></span>
</td>
<td class="nump">880,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.001 par value, 60,000,000 shares authorized; 37,891,186 and 37,674,868 shares issued; and 32,518,278 and 32,509,969 shares outstanding</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">755,063<span></span>
</td>
<td class="nump">728,118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock at cost, 5,372,908 and 5,164,899 shares of common stock</a></td>
<td class="num">(461,200)<span></span>
</td>
<td class="num">(435,868)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">757,672<span></span>
</td>
<td class="nump">639,063<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Amedisys, Inc. stockholders&#8217; equity</a></td>
<td class="nump">1,051,573<span></span>
</td>
<td class="nump">931,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">55,000<span></span>
</td>
<td class="nump">44,972<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">1,106,573<span></span>
</td>
<td class="nump">976,323<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 1,976,245<span></span>
</td>
<td class="nump">$ 1,856,968<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675801636816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property and equipment, accumulated depreciation</a></td>
<td class="nump">$ 101,364<span></span>
</td>
<td class="nump">$ 96,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="nump">$ 14,604<span></span>
</td>
<td class="nump">$ 19,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (shares)</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (shares)</a></td>
<td class="nump">37,891,186<span></span>
</td>
<td class="nump">37,674,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (shares)</a></td>
<td class="nump">32,518,278<span></span>
</td>
<td class="nump">32,509,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock at cost (shares)</a></td>
<td class="nump">5,372,908<span></span>
</td>
<td class="nump">5,164,899<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675805896544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">$ 2,223,199<span></span>
</td>
<td class="nump">$ 2,214,112<span></span>
</td>
<td class="nump">$ 2,071,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,300<span></span>
</td>
<td class="nump">34,372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">1,260,425<span></span>
</td>
<td class="nump">1,233,356<span></span>
</td>
<td class="nump">1,185,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and benefits</a></td>
<td class="nump">508,791<span></span>
</td>
<td class="nump">474,718<span></span>
</td>
<td class="nump">449,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash compensation</a></td>
<td class="nump">16,560<span></span>
</td>
<td class="nump">23,809<span></span>
</td>
<td class="nump">26,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other</a></td>
<td class="nump">228,707<span></span>
</td>
<td class="nump">212,713<span></span>
</td>
<td class="nump">192,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DepreciationAndAmortizationForContinuingOperations', window );">Depreciation and amortization</a></td>
<td class="nump">24,935<span></span>
</td>
<td class="nump">30,901<span></span>
</td>
<td class="nump">28,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charge</a></td>
<td class="nump">3,009<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,152<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">2,042,427<span></span>
</td>
<td class="nump">1,975,497<span></span>
</td>
<td class="nump">1,886,623<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">180,772<span></span>
</td>
<td class="nump">251,915<span></span>
</td>
<td class="nump">219,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Interest income</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(22,228)<span></span>
</td>
<td class="num">(9,525)<span></span>
</td>
<td class="num">(11,038)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in (loss) earnings from equity method investments</a></td>
<td class="num">(45)<span></span>
</td>
<td class="nump">4,949<span></span>
</td>
<td class="nump">3,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain (loss) on equity method investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,098<span></span>
</td>
<td class="num">(2,980)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Miscellaneous, net</a></td>
<td class="nump">1,567<span></span>
</td>
<td class="nump">1,745<span></span>
</td>
<td class="nump">1,311<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="num">(20,528)<span></span>
</td>
<td class="nump">28,316<span></span>
</td>
<td class="num">(8,449)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">160,244<span></span>
</td>
<td class="nump">280,231<span></span>
</td>
<td class="nump">210,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(42,545)<span></span>
</td>
<td class="num">(70,065)<span></span>
</td>
<td class="num">(25,635)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">117,699<span></span>
</td>
<td class="nump">210,166<span></span>
</td>
<td class="nump">185,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss (income) attributable to noncontrolling interests</a></td>
<td class="nump">910<span></span>
</td>
<td class="num">(1,094)<span></span>
</td>
<td class="num">(1,576)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Amedisys, Inc.</a></td>
<td class="nump">$ 118,609<span></span>
</td>
<td class="nump">$ 209,072<span></span>
</td>
<td class="nump">$ 183,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic earnings per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income attributable to Amedisys, Inc. common stockholders (usd per share)</a></td>
<td class="nump">$ 3.65<span></span>
</td>
<td class="nump">$ 6.41<span></span>
</td>
<td class="nump">$ 5.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding (shares)</a></td>
<td class="nump">32,517<span></span>
</td>
<td class="nump">32,642<span></span>
</td>
<td class="nump">32,559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted earnings per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income attributable to Amedisys, Inc. common stockholders (usd per share)</a></td>
<td class="nump">$ 3.63<span></span>
</td>
<td class="nump">$ 6.34<span></span>
</td>
<td class="nump">$ 5.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding (shares)</a></td>
<td class="nump">32,653<span></span>
</td>
<td class="nump">32,972<span></span>
</td>
<td class="nump">33,268<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DepreciationAndAmortizationForContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation And Amortization For Continuing Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DepreciationAndAmortizationForContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of patient service revenue recognized, net of contractual allowances and discounts, less the provision for bad debts related to patient service revenue plus all other revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675804353056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 117,699<span></span>
</td>
<td class="nump">$ 210,166<span></span>
</td>
<td class="nump">$ 185,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">117,699<span></span>
</td>
<td class="nump">210,166<span></span>
</td>
<td class="nump">185,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss (income) attributable to non-controlling interests</a></td>
<td class="nump">910<span></span>
</td>
<td class="num">(1,094)<span></span>
</td>
<td class="num">(1,576)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Amedisys, Inc.</a></td>
<td class="nump">$ 118,609<span></span>
</td>
<td class="nump">$ 209,072<span></span>
</td>
<td class="nump">$ 183,608<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675798305872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Noncontrolling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Dec. 31, 2019</a></td>
<td class="nump">$ 641,513<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 645,256<span></span>
</td>
<td class="num">$ (251,241)<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 246,383<span></span>
</td>
<td class="nump">$ 1,063<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,638,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock - employee stock purchase plan</a></td>
<td class="nump">3,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock - employee stock purchase plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch', window );">Issuance of stock - 401 (k) plan</a></td>
<td class="nump">3,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch', window );">Issuance of stock - 401 (k) plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">6,325<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">6,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">622,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Non-cash compensation</a></td>
<td class="nump">26,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_SurrenderedShares', window );">Surrendered shares</a></td>
<td class="num">(54,493)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,358<span></span>
</td>
<td class="num">(67,851)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distributions</a></td>
<td class="num">(1,122)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,122)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome', window );">Write-off of other comprehensive income</a></td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">185,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,608<span></span>
</td>
<td class="nump">1,576<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Dec. 31, 2020</a></td>
<td class="nump">810,741<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">698,287<span></span>
</td>
<td class="num">(319,092)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">429,991<span></span>
</td>
<td class="nump">1,517<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,470,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock - employee stock purchase plan</a></td>
<td class="nump">3,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock - employee stock purchase plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">2,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Non-cash compensation</a></td>
<td class="nump">23,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_SurrenderedShares', window );">Surrendered shares</a></td>
<td class="num">(16,898)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,898)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Shares repurchased</a></td>
<td class="num">(99,878)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(99,878)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ContributionsAttributableToNoncontrollingInterest', window );">Noncontrolling interest contributions</a></td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distributions</a></td>
<td class="num">(1,747)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,747)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination', window );">Acquired noncontrolling interest</a></td>
<td class="nump">43,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">210,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,072<span></span>
</td>
<td class="nump">1,094<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Dec. 31, 2021</a></td>
<td class="nump">976,323<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">728,118<span></span>
</td>
<td class="num">(435,868)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">639,063<span></span>
</td>
<td class="nump">44,972<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,674,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock - employee stock purchase plan</a></td>
<td class="nump">3,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock - employee stock purchase plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 2,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">37,635<span></span>
</td>
<td class="nump">37,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Non-cash compensation</a></td>
<td class="nump">$ 16,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_SurrenderedShares', window );">Surrendered shares</a></td>
<td class="num">(7,981)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,981)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Shares repurchased</a></td>
<td class="num">(17,351)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,351)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ContributionsAttributableToNoncontrollingInterest', window );">Noncontrolling interest contributions</a></td>
<td class="nump">12,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distributions</a></td>
<td class="num">(1,561)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,561)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest', window );">Sale of noncontrolling interest</a></td>
<td class="nump">4,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">117,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,609<span></span>
</td>
<td class="num">(910)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Dec. 31, 2022</a></td>
<td class="nump">$ 1,106,573<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 755,063<span></span>
</td>
<td class="num">$ (461,200)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 757,672<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,891,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ContributionsAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest related to capital contributions received from noncontrolling interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ContributionsAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Impact Of Write Off Of Other Comprehensive Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to employees as employer's matching contribution to the company's 401(K) plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period to employees as employer's matching contribution to the company's 401(K) plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_SurrenderedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares of common stock surrendered by certain employees to satisfy obligations in connection with the vesting of stock. Shares held in Treasury Stock at cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_SurrenderedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569655-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675797147360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 117,699<span></span>
</td>
<td class="nump">$ 210,166<span></span>
</td>
<td class="nump">$ 185,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">24,935<span></span>
</td>
<td class="nump">30,901<span></span>
</td>
<td class="nump">28,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash compensation</a></td>
<td class="nump">16,560<span></span>
</td>
<td class="nump">23,809<span></span>
</td>
<td class="nump">26,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset', window );">Amortization and impairment of operating lease right of use assets</a></td>
<td class="nump">46,029<span></span>
</td>
<td class="nump">40,364<span></span>
</td>
<td class="nump">39,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss (gain) on disposal of property and equipment</a></td>
<td class="nump">519<span></span>
</td>
<td class="num">(124)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(31,098)<span></span>
</td>
<td class="nump">2,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_WriteOffOfOtherComprehensiveIncome', window );">Write-off of other comprehensive income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">23,377<span></span>
</td>
<td class="nump">44,582<span></span>
</td>
<td class="num">(26,560)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in loss (earnings) from equity method investments</a></td>
<td class="nump">45<span></span>
</td>
<td class="num">(4,949)<span></span>
</td>
<td class="num">(3,966)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of deferred debt issuance costs/debt discount</a></td>
<td class="nump">991<span></span>
</td>
<td class="nump">917<span></span>
</td>
<td class="nump">869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Return on equity method investments</a></td>
<td class="nump">5,163<span></span>
</td>
<td class="nump">5,343<span></span>
</td>
<td class="nump">5,444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charge</a></td>
<td class="nump">3,009<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of impact of acquisitions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Patient accounts receivable</a></td>
<td class="num">(14,230)<span></span>
</td>
<td class="num">(18,030)<span></span>
</td>
<td class="nump">2,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Other current assets</a></td>
<td class="num">(3,525)<span></span>
</td>
<td class="num">(12,202)<span></span>
</td>
<td class="num">(7,181)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">438<span></span>
</td>
<td class="num">(1,017)<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">4,894<span></span>
</td>
<td class="num">(4,353)<span></span>
</td>
<td class="nump">1,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(39,382)<span></span>
</td>
<td class="num">(26,915)<span></span>
</td>
<td class="nump">39,839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term obligations</a></td>
<td class="num">(8,822)<span></span>
</td>
<td class="num">(28,796)<span></span>
</td>
<td class="nump">27,717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(41,175)<span></span>
</td>
<td class="num">(36,645)<span></span>
</td>
<td class="num">(34,695)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="num">(3,242)<span></span>
</td>
<td class="num">(3,060)<span></span>
</td>
<td class="num">(3,544)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">133,283<span></span>
</td>
<td class="nump">188,893<span></span>
</td>
<td class="nump">288,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments', window );">Proceeds from the sale of deferred compensation plan assets</a></td>
<td class="nump">252<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the sale of property and equipment</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(6,165)<span></span>
</td>
<td class="num">(6,302)<span></span>
</td>
<td class="num">(5,332)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToDevelopSoftware', window );">Investments in technology assets</a></td>
<td class="num">(1,050)<span></span>
</td>
<td class="num">(419)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Investment in equity method investee</a></td>
<td class="num">(637)<span></span>
</td>
<td class="num">(200)<span></span>
</td>
<td class="num">(875)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Purchase of cost method investment</a></td>
<td class="num">(15,000)<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions of businesses, net of cash acquired</a></td>
<td class="num">(71,952)<span></span>
</td>
<td class="num">(269,965)<span></span>
</td>
<td class="num">(298,958)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(94,486)<span></span>
</td>
<td class="num">(281,607)<span></span>
</td>
<td class="num">(287,108)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of stock upon exercise of stock options</a></td>
<td class="nump">2,304<span></span>
</td>
<td class="nump">2,054<span></span>
</td>
<td class="nump">6,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of stock to employee stock purchase plan</a></td>
<td class="nump">3,848<span></span>
</td>
<td class="nump">3,968<span></span>
</td>
<td class="nump">3,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld to pay taxes on non-cash compensation</a></td>
<td class="num">(7,981)<span></span>
</td>
<td class="num">(16,898)<span></span>
</td>
<td class="num">(54,493)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_CashContributionToNoncontrollingInterest', window );">Noncontrolling interest contributions</a></td>
<td class="nump">3,501<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_CashDistributionToNoncontrollingInterest', window );">Noncontrolling interest distributions</a></td>
<td class="num">(1,561)<span></span>
</td>
<td class="num">(1,747)<span></span>
</td>
<td class="num">(1,122)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Proceeds from sale of noncontrolling interest</a></td>
<td class="nump">5,817<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ProceedsFromBorrowingsUnderTermLoan', window );">Proceeds from borrowings under term loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">290,312<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from borrowings under revolving line of credit</a></td>
<td class="nump">534,500<span></span>
</td>
<td class="nump">500,700<span></span>
</td>
<td class="nump">684,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayments of borrowings under revolving line of credit</a></td>
<td class="num">(534,500)<span></span>
</td>
<td class="num">(551,700)<span></span>
</td>
<td class="num">(703,200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payments of long-term obligations</a></td>
<td class="num">(13,296)<span></span>
</td>
<td class="num">(9,143)<span></span>
</td>
<td class="num">(10,249)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,792)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_FundsReceivedFromProviderReliefFundAdvance', window );">Provider relief fund advance</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(60,000)<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of company stock</a></td>
<td class="num">(17,351)<span></span>
</td>
<td class="num">(99,878)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment of accrued contingent consideration</a></td>
<td class="num">(5,714)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(30,433)<span></span>
</td>
<td class="nump">55,126<span></span>
</td>
<td class="num">(14,977)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">8,364<span></span>
</td>
<td class="num">(37,588)<span></span>
</td>
<td class="num">(13,133)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">45,769<span></span>
</td>
<td class="nump">83,357<span></span>
</td>
<td class="nump">96,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">54,133<span></span>
</td>
<td class="nump">45,769<span></span>
</td>
<td class="nump">83,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosures of Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">14,939<span></span>
</td>
<td class="nump">5,291<span></span>
</td>
<td class="nump">6,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_CashPaidForInfinityZPICInterest', window );">Cash Paid For Infinity ZPIC Interest</a></td>
<td class="nump">12,755<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes, net of refunds received</a></td>
<td class="nump">24,013<span></span>
</td>
<td class="nump">34,097<span></span>
</td>
<td class="nump">50,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_NonCashAccruedContingentConsideration', window );">Accrued contingent consideration</a></td>
<td class="nump">19,195<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_NonCashNoncontrollingInterestContribution', window );">Noncontrolling interest contribution</a></td>
<td class="nump">$ 8,900<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Operating Lease Right Of Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CashContributionToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Contribution To Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CashContributionToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CashDistributionToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of dividends or other distributions to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CashDistributionToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CashPaidForInfinityZPICInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Paid For Infinity ZPIC Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CashPaidForInfinityZPICInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FundsReceivedFromProviderReliefFundAdvance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from funds received by the government related to the Novel Coronavirus Pandemic "COVID-19"</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FundsReceivedFromProviderReliefFundAdvance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) In Operating Lease Right Of Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NonCashAccruedContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Accrued Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NonCashAccruedContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NonCashNoncontrollingInterestContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Cash Noncontrolling Interest Contribution</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NonCashNoncontrollingInterestContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProceedsFromBorrowingsUnderTermLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings under the term loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProceedsFromBorrowingsUnderTermLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_WriteOffOfOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write Off Of Other Comprehensive Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_WriteOffOfOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToDevelopSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the development or modification of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToDevelopSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675807498704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</a></td>
<td class="text">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS<div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amedisys, Inc., a Delaware corporation (together with its consolidated subsidiaries, referred to herein as &#8220;Amedisys,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;), is a multi-state provider of home health, hospice, personal care and high acuity care services with approximately 74%, 75% and 75% of our consolidated net service revenue derived from Medicare for 2022, 2021 and 2020, respectively. As of December&#160;31, 2022, we owned and operated 347 Medicare-certified home health care centers, 164 Medicare-certified hospice care centers, 13 personal-care care centers and 8 admitting high acuity care joint ventures in 37 states within the United States and the District of Columbia.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the Company adopted Accounting Standards Update ("ASU") 2020-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which included minor technical corrections and clarifications to improve consistency and clarify the application of various provisions of the codification by amending the codification to include all disclosure guidance in the appropriate disclosure sections and by amending and adding new headings, cross referencing to other guidance and refining or correcting terminology. Our adoption of this standard did not have a material effect on our consolidated financial statements.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the Company adopted ASU 2021-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was intended to increase transparency around financial reporting regarding government assistance by requiring disclosure of information about (1) the types of government assistance received, (2) an entity's accounting for the government assistance received and (3) the effect of the assistance on an entity's financial statements. The ASU was effective for annual periods beginning after December 15, 2021, with early adoption permitted. See Note 3 &#8211; Novel Coronavirus Pandemic ("COVID-19") for the disclosures associated with this standard. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, the Company adopted ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provided guidance for measuring credit losses on financial instruments. Our adoption of this standard did not have a material effect on our consolidated financial statements. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, the Company adopted ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which eliminated certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating taxes during the interim periods and the recognition of deferred tax liabilities for outside basis differences. This guidance also simplified aspects of the accounting for franchise taxes, enacted changes in tax laws or rates and clarified the accounting for transactions that result in a step-up in the tax basis of goodwill. The guidance was effective for interim and annual periods beginning after December 15, 2020, with early adoption permitted. Our adoption of this standard on a prospective basis was not material to the Company&#8217;s consolidated financial statements.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Financial Accounting Standards Board ("FASB") issued ASU 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides optional expedients and exceptions for applying U.S. Generally Accepted Accounting Principles ("U.S. GAAP") to contract modifications and hedging relationships that reference the London Inter-Bank Offered Rate ("LIBOR") or another reference rate expected to be discontinued, subject to meeting certain criteria. In January 2021, the FASB issued ASU 2021-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Scope</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which adds implementation guidance to ASU 2020-04 to clarify certain optional expedients in Topic 848. The guidance in ASU 2020-04 and ASU 2021-01 was effective upon issuance and may generally be applied prospectively through December 31, 2022. In December 2022, the FASB issued ASU 2022-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which deferred the sunset date of Topic 848 from December 31, 2022 to December 31, 2024. These standards did not have an effect on our consolidated financial statements. </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting and reporting policies conform with U.S. GAAP. In preparing the consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements include the accounts of Amedisys, Inc. and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying consolidated financial </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements, and business combinations accounted for as purchases have been included in our consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consolidate investments when the entity is a variable interest entity ("VIE") and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our consolidated financial statements. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold 50% or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary. The book value of investments that we account for under the equity method of accounting totaled $40.5 million and $48.1 million as of December&#160;31, 2022 and 2021, respectively, and is reflected in other assets within our consolidated balance sheets. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for investments in entities in which we have less than 20% ownership interest under the cost method of accounting if we do not have the ability to exercise significant influence over the investee. During 2022, we made a $15.0&#160;million investment in a home health benefit manager, which is accounted for under the cost method. During 2021, we made a $5.0&#160;million investment in ConnectRN, a workforce optimization company, which is accounted for under the cost method. The book value of investments that we account for under the cost method of accounting was $20.0&#160;million and $5.0&#160;million as of December 31, 2022 and 2021, respectively, and is reflected in other assets within our consolidated balance sheets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three-month period ended December 31, 2022, we sold a 49% interest in two of our home health care centers while maintaining a controlling interest in the newly formed joint venture. We are consolidating this joint venture. The total cash consideration received for the 49% noncontrolling interest was $1.9&#160;million. In connection with the transaction, we recorded an after-tax gain of $1.4&#160;million; this gain was recorded to additional paid-in capital within our consolidated balance sheet. During the three-month period ended September 30, 2022, we sold a 30% interest in two of our home health care centers while maintaining a controlling interest in the newly formed joint venture. We are consolidating this joint venture. The total cash consideration received for the 30% noncontrolling interest was $3.9&#160;million. In connection with the transaction, we recorded an after-tax gain of $2.9&#160;million; this gain was recorded to additional paid-in capital within our consolidated balance sheet.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, a third-party acquired a majority of the issued and outstanding membership interests of one of our equity method investments, Medalogix, for cash, with the remaining membership interests rolling over into a newly formed entity that includes Medalogix as well as another healthcare predictive data and analytics company. We rolled over 100% of our ownership interest in Medalogix to the newly formed entity, and in connection with this transaction, we recognized a $31.1&#160;million gain based on the purchase price of Medalogix, which is reflected in gain on equity method investments within our consolidated statements of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Contessa Health ("Contessa") on August 1, 2021, we obtained interests in several joint ventures with health system partners and a professional corporation that employs clinicians. Each of these entities meets the criteria to be classified as a VIE. As of December 31, 2022, we are consolidating all of our admitting joint ventures with health system partners as well as the professional corporation as we have concluded that we are the primary beneficiary of these VIEs. We have management agreements in place with each of these entities whereby we manage the entities and run the day-to-day operations. As such, we possess the power to direct the activities that most significantly impact the economic performance of the VIEs. The significant activities include, but are not limited to, negotiating provider and payor contracts, establishing patient care policies and protocols, making employment and compensation decisions, developing the operating and capital budgets, performing marketing activities and providing accounting support. We also have the obligation to absorb any expected losses and the right to receive benefits. Additionally, from time to time we may be required to provide joint venture funding. Our high acuity care segment also includes two non-admitting joint ventures with health system partners that are accounted for under the equity method of accounting. Operations of one of these joint ventures have ceased, and we are currently awaiting claims runout to complete financial reconciliations with our health plan partner; we recorded a $3.0&#160;million impairment charge related to our investment in this joint venture during the three-month period ended September 30, 2022.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the agreements with each VIE prohibit us from using the assets of the VIE to satisfy the obligations of other entities. The carrying amount of the VIEs&#8217; assets and liabilities included in our consolidated balance sheets are as follows (amounts in millions):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.669%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Patient accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Payroll and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we sold our investment in the Heritage Healthcare Innovation Fund, LP via a secondary transaction for $17.9&#160;million which resulted in a $3.0&#160;million loss which is reflected in gain (loss) on equity method investments within our consolidated statement of operations for the year ended December 31, 2020. The Company's original investment was made in 2010 and no longer fit within our strategic areas of focus. Proceeds from the sale were used to pay down debt and fund capital needs.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675924395936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for revenue from contracts with customers in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. Our cost of obtaining contracts is not material. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligations relate to contracts with a duration of less than one year; therefore, we have elected to apply the optional exemption provided by ASC 606 and are not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third-party payors and others for services provided. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current industry conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. We assess our ability to collect for the healthcare services provided at the time of patient admission based on our verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represents approximately 74% of our consolidated net service revenue.  </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation based on our historical experience which primarily includes a historical collection rate of over 99% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by payor class as a percentage of total net service revenue is as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:59.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.855%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Home Health:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare - Episodic-based</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare - Non-episodic based</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Hospice:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">High Acuity Care (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Acquired Contessa Health on August 1, 2021.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home Health Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"). PDGM uses 30-day periods of care rather than 60-day episodes of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, we account for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed. Each 60-day episode includes two 30-day payment periods.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net service revenue is recorded based on the established Federal Medicare home health payment rate for a 30-day period of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#8217;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice" practical expedient, and therefore, our revenue recognition is based on the reimbursement we are entitled to for each 30-day period of care. We utilize our historical average length of stay for each 30-day period of care as the measure of progress towards the satisfaction of our performance obligation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables, including, but not limited to (a) an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#8220;LUPA&#8221;) if the number of visits provided was less than the established threshold, which ranges from two to six visits and varies for every case-mix group; (c)&#160;a partial payment if a patient transferred to another provider or from another provider before completing the 30-day period of care; and (d)&#160;the applicable geographic wage index. Payments for routine and non-routine supplies are included in the 30-day payment rate.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered to revenue with a corresponding reduction to patient accounts receivable. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during the novel coronavirus pandemic ("COVID-19"), CMS relaxed the definition of homebound status through the duration of the public health emergency. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their home because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19.  </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, 20% of the reimbursement from each Medicare 30-day payment period was billed near the start of each 30-day period of care, referred to as a request for anticipated payment ("RAP"), and cash was typically received before all services were rendered. Any cash received from Medicare for a RAP for a 30-day period of care that exceeded the associated revenue earned was recorded to accrued expenses within our consolidated balance sheets. CMS fully eliminated all upfront payments associated with RAPs effective January 1, 2021. Effective January 1, 2022, CMS implemented a new one-time Notice of Admission ("NOA") process. The NOA process requires a one-time submission that establishes the home health period of care and covers all contiguous 30-day periods of care until the patient is discharged from Medicare home health services. If the NOA is not submitted timely, a payment reduction will be applied equal to 1/30 of the payment amount for each day from the home health start of care date until the date the NOA is submitted.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments from non-Medicare payors are either a percentage of Medicare rates, per-visit rates or case rates depending upon the terms and conditions established with such payors. Approximately 30% of our managed care contract volume affords us the opportunity to receive additional payments if we achieve certain quality or process metrics as defined in each contract (e.g. star ratings and acute-care hospitalization rates).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Episodic-based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms, the majority of which range from 95% to 100% of Medicare rates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-episodic based Revenue. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our per visit contracts, gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. For our case rate contracts, gross revenue is recorded over our historical average length of stay using the established case rate for each admission. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on our historical experience to reflect the estimated transaction </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our case rate contracts, we may receive reimbursement before all services are rendered. Any cash received that exceeds the associated revenue earned is recorded to deferred revenue in accrued expenses within our consolidated balance sheets.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospice Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Medicare Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for 97% of our total Medicare hospice service revenue for each of 2022, 2021 and 2020, respectively. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#8220;SIA&#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record it during the period services are rendered. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our consolidated balance sheets. Providers are required to self-report and pay their estimated cap liability by February 28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the following year. As of December&#160;31, 2022, we have recorded $4.3 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2023. As of December&#160;31, 2021, we had recorded $4.5 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2022.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Non-Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third-party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on our historical experience to reflect the estimated transaction price.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Personal Care Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Personal Care Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points ("ASAPs"), Senior Care Options ("SCOs"), Program of All-Inclusive Care for the Elderly ("PACE") and the Veterans Administration ("VA"). </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">High Acuity Care Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">High Acuity Care Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues are derived from contracts with (1) health insurance plans for the coordination and provision of home recovery care services to clinically-eligible patients who are enrolled members in those insurance plans, (2) health system partners for the coordination and provision of home recovery care services to clinically-eligible patients who are discharged early from a health system facility to complete their inpatient stay at home and (3) Medicare and other payors for the provision of home health services. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our health insurance plan contracts, we provide home recovery care services, which include hospital-equivalent ("H@H") and skilled nursing facility ("SNF") equivalent services ("SNF@H"), for high acuity care patients on a full risk basis whereby we assume the financial risk for the coordination and payment of all hospital or SNF replacement medical services necessary to treat the medical condition for which the patient was diagnosed in a home-based setting for a 30-day (H@H) or 60-day (SNF@H) episode of care in exchange for a fixed contracted bundled rate. For H@H programs, the fixed rate is based on the assigned diagnosis related group ("DRG") and the 30-day post-discharge related spend. For SNF@H programs, the fixed rate is based on the 60-day post-discharge related spend. Our performance obligation is the coordination and provision of patient care in accordance with physicians&#8217; orders over either a 30-day or 60-day episode of care. The majority of our care coordination services and direct patient care is provided in the first five to seven days of the episode period (the "acute phase"). Monitoring services and follow-up direct patient care, as deemed necessary by the treating physician, are provided throughout the remainder of the episode. Since the majority of our services are provided during the acute phase, we recognize net service revenues over the acute phase based on gross charges for the services provided per the applicable managed care contract rates, reduced by estimates for revenue adjustments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our contracts with health system partners, we provide home recovery care services for high acuity patients on a limited risk basis whereby we assume the risk for certain healthcare services during the remainder of an inpatient acute stay serviced at the patient&#8217;s home in exchange for a contracted per diem rate. The performance obligation is the coordination and provision of required medical services, as determined by the treating physician, for each day the patient receives inpatient-equivalent care at home. As such, revenues are recognized as services are administered and as our performance obligations are satisfied on a per diem basis, reduced by estimates for revenue adjustments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize adjustments to revenue during the period in which changes to estimates of assigned patient diagnoses or episode terminations become known, in accordance with the applicable managed care contracts. For certain health insurance plans, revenue is reduced by amounts owed by enrollees to healthcare providers under deductible, coinsurance or copay provisions of health insurance plan policies, since those amounts are repaid to the health insurance plans by us as part of a retrospective reconciliation process.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, our high acuity care segment entered into a transaction in which one of our health system partners contributed its home health operations to one of our existing high acuity care joint ventures. We recognize Medicare and non-Medicare revenue in a manner that is consistent with our home health segment revenue recognition policy described above.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Grants</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for government grants in accordance with ASU 2021-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance (Topic 832), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by applying the grant model in accordance with International Accounting Standard ("IAS") 20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Government Grants and Disclosure of Government Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and as such, we recognize grant income on a systematic basis in line with the recognition of expenses or the loss of revenues for which the grants are intended to compensate. We recognize grants once both of the following conditions are met: (1) we are able to comply with the relevant conditions of the grant and (2) the grant will be received. See Note 3 &#8211; Novel Coronavirus Pandemic ("COVID-19") for additional information on our accounting for government funds received under the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") and the Mass Home Care ASAP COVID-19 Provider Sustainability Program.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased. Restricted cash includes cash that is not available for ordinary business use. As of December 31, 2022 and 2021, we had $13.6&#160;million and $3.1&#160;million, respectively, classified as restricted cash related to funds placed into escrow accounts in connection with the indemnity, closing payment and other provisions within the purchase agreements of our acquisitions. The increase in restricted cash from December 31, 2021 to December 31, 2022 is related to our acquisitions of Evolution Health, LLC ("Evolution") and Assisted Care Home Health, Inc. and RH Homecare Services, LLC ("Assisted Care") on April 1, 2022. See Note 4 &#8211; Acquisitions for additional information.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patient Accounts Receivable</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. Our non-Medicare third-party payor base is comprised of a diverse group of payors that are geographically dispersed across the country. As of December&#160;31, 2022, there is no single payor, other than Medicare, that accounts for more than 10% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectability risk associated with our Medicare accounts, which represented 67% and 68% of our net patient accounts receivable at December&#160;31, 2022 and 2021, respectively, is limited due to our historical collection rate of over 99% from Medicare and the fact that Medicare is a U.S. government payor. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Home Health</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our home health patients (within both our home health and high acuity care segments), our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare following the end of each 30-day period of care or upon discharge, if earlier, for the services provided to the patient.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Hospice</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Medicare Home Health, Hospice, Personal Care and High Acuity Care</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#8217;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets or life of the lease, if shorter. Additionally, we have internally developed computer software for our own use. Additions and improvements (including interest costs for construction of qualifying long-lived assets) are capitalized. Maintenance and repair expenses are charged to expense as incurred. The cost of property and equipment sold or disposed of and the related accumulated depreciation are eliminated from the property and equipment and related accumulated depreciation accounts, and any gain or loss is credited or charged to other general and administrative expenses.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the impairment of a long-lived asset group whenever events or changes in circumstances indicate that the asset&#8217;s carrying value may not be recoverable. Factors we consider important that could trigger an impairment review include but are not limited to the following:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A significant change in the extent or manner in which the long-lived asset group is being used.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A significant change in the business climate that could affect the value of the long-lived asset group.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A significant change in the market value of the assets included in the asset group.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we determine that the carrying value of long-lived assets may not be recoverable, we compare the carrying value of the asset group to the undiscounted cash flows expected to be generated by the asset group. If the carrying value exceeds the undiscounted cash flows, an impairment charge is indicated. An impairment charge is recognized to the extent that the carrying value of the asset group exceeds its fair value.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally provide for depreciation over the following estimated useful service lives.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.753%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.047%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser&#160;of&#160;lease term&#160;or&#160;expected&#160;useful&#160;life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment and furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 7</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 7</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balances related to our property and equipment for 2022 and 2021 (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment and furniture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for 2022, 2021 and 2020 was $11.5 million, $12.1 million and $12.1 million, respectively.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Acquisitions are accounted for as purchases and are included in our consolidated financial statements from their respective acquisition dates. Assets acquired, liabilities assumed and noncontrolling interests, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets. In determining the fair value of identifiable intangible assets and any noncontrolling interests, we use various valuation techniques including the income approach, the cost approach and the market approach. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, growth rates and discount rates.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Other Intangible Assets</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had a goodwill balance of $1,287.4&#160;million. Goodwill represents the amount of the purchase price in excess of the fair values assigned to the underlying identifiable net assets of acquired businesses. Goodwill is not amortized, but is subject to an annual impairment test. Tests are performed more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount. These events or circumstances include, but are not limited to, a significant adverse change in the business environment, regulatory environment or legal factors, or a substantial decline in the market capitalization of our stock. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of our operating segments described in Note 15 &#8211; Segment Information is considered to represent an individual reporting unit for goodwill impairment testing purposes. We consider each of our home health care centers to constitute an individual business for which discrete financial information is available. However, since these care centers have substantially similar operating and economic characteristics and resource allocations and since significant investment decisions concerning these businesses are centralized and the benefits broadly distributed, we have aggregated these care centers and deemed them to constitute a single reporting unit. We have applied this same aggregation principle to our hospice and personal-care care centers and high acuity care joint ventures and have also deemed each of them to be a single reporting unit.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, we performed a qualitative assessment to determine if it is more likely than not that the fair value of our reporting units are less than their carrying values by evaluating relevant events and circumstances including financial performance, market conditions and share price. Based on this assessment, we concluded that the goodwill associated with our home health, hospice and high acuity care reporting units was not considered at risk of impairment as of October&#160;31, 2022. In addition to the qualitative assessment, we also performed a quantitative analysis for our personal care reporting unit due to the decline in revenues resulting from staffing shortages using an income and market approach. Based on this analysis, we concluded that the goodwill associated with our personal care reporting unit was not considered at risk of impairment as of October 31, 2022. Since the date of our last goodwill impairment analysis, there have been no material developments, events, changes in operating performance or other circumstances that would cause management to believe it is more likely than not that the fair value of any of our reporting units would be less than their carrying amounts.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had an other intangibles assets balance of $101.2&#160;million. Intangible assets consist of certificates of need, licenses, acquired names, non-compete agreements and technology. We amortize non-compete agreements and acquired names that we do not intend to use indefinitely on a straight-line basis over their estimated useful lives, which are generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjg1OTA_1486623a-649a-4c91-b48e-f23d489bb99f">two</span> to three years for non-compete agreements and up to three years for acquired names. We amortize technology over its estimated useful service life, which is generally up to seven years. Our indefinite-lived intangible assets are reviewed for impairment annually or more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the intangible asset below its carrying amount. We performed a qualitative assessment of our indefinite-lived intangible assets during 2022 and determined that there have been no material developments, events, changes in operating performance or other circumstances that would cause management to believe it is more likely than not that the fair value of any of our indefinite-lived intangible assets would be less than their carrying amounts. </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Issuance Costs</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, we recorded $2.8&#160;million in deferred debt issuance costs as a reduction to long-term obligations, less current portion in our consolidated balance sheet in connection with our entry into the Second Amended Credit Agreement (See Note 9 - Long-Term Obligations). As of December&#160;31, 2022 and 2021, we had unamortized debt issuance costs of $3.5 million and $4.5 million, respectively, recorded as a reduction to long-term obligations, less current portion in our accompanying consolidated balance sheets. We amortize deferred debt issuance costs related to our long-term obligations over the term of the obligation through interest expense, unless the debt is extinguished, in which case unamortized balances are immediately expensed. The unamortized debt issuance costs of $3.5 million at December&#160;31, 2022 will be amortized over a weighted-average amortization period of 3.6 years.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</span></div><div style="margin-bottom:9pt;margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"/><td style="width:24.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Financial Instrument</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value as of<br/>December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Items<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1 &#8211; Quoted prices in active markets for identical assets and liabilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2 &#8211; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3 &#8211; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value. </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the asset and liability approach for measuring deferred tax assets and liabilities based on temporary differences existing at each balance sheet date using currently enacted tax rates. Our deferred tax calculation requires us to make certain estimates about future operations. Deferred tax assets are reduced by a valuation allowance when we believe it is more likely than not that some portion or all of the deferred tax assets will not be realized. The effect of a change in tax rate is recognized as income or expense in the period that includes the enactment date. As of December&#160;31, 2022, we had net deferred tax liabilities of $20.4 million. As of December 31, 2021, we had net deferred tax assets of $0.3 million. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management regularly assesses the ability to realize deferred tax assets recorded in the Company&#8217;s entities based upon the weight of available evidence, including such factors as the recent earnings history and expected future taxable income. In the event future taxable income is below management&#8217;s estimates or is generated in tax jurisdictions different than projected, we could be required to increase the valuation allowance for deferred tax assets. This would result in an increase in our effective tax rate.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record all share-based compensation as expense in the financial statements measured at the fair value of the award. We recognize compensation cost on a straight-line basis over the requisite service period for each separately vesting portion of the award. Share-based compensation expense for 2022, 2021 and 2020 was $16.6 million, $23.8 million and $26.7 million, respectively, and the total income tax benefit recognized for these expenses was $4.3 million, $6.0 million and $4.7 million, respectively, prior to the application of the income tax compensation rules under Internal Revenue Code section 162(m) ("162(m)"). As of December 31, 2022, the income tax benefit recognized for the three-year period was reduced by a cumulative $2.7&#160;million, pursuant to 162(m).</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Weighted-Average Shares Outstanding.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares used in our computation of weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:56.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding &#8211; basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,517&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,642&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,559&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested stock and stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding &#8211; diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,653&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,972&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Costs</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense advertising costs as incurred. Advertising expense for 2022, 2021 and 2020 was $7.3 million, $7.4 million and $6.5 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675887412208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOVEL CORONAVIRUS PANDEMIC ("COVID-19")<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtraordinaryAndUnusualItemsAbstract', window );"><strong>Unusual or Infrequent Items, or Both [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_COVID19TextBlock', window );">NOVEL CORONAVIRUS PANDEMIC ("COVID-19")</a></td>
<td class="text">NOVEL CORONAVIRUS PANDEMIC ("COVID-19")<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared COVID-19 a pandemic. As a healthcare at home company, we have been and will continue to be impacted by the effects of COVID-19; however, we remain committed to carrying out our mission of caring for our patients. We will continue to closely monitor the impact of COVID-19 on all aspects of our business, including the impacts to our employees, patients and suppliers; however, at this time, we are unable to estimate the ultimate impact the pandemic will have on our consolidated financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the CARES Act was signed into legislation. The CARES Act provided for $175&#160;billion to healthcare providers, including hospitals on the front lines of the COVID-19 pandemic. Of this total allocated amount, $30&#160;billion was distributed immediately to providers based on their proportionate share of Medicare fee-for-service reimbursements in 2019. Healthcare providers were required to sign an attestation confirming receipt of the Provider Relief Fund ("PRF") funds and agree to the terms and conditions of payment. Our home health and hospice segments received approximately $100&#160;million from the first $30&#160;billion of funds distributed to healthcare providers in April 2020, which is inclusive of $2&#160;million related to our joint venture care centers (equity method investments). We also acquired approximately $6&#160;million of PRF funds in connection with the acquisition of AseraCare Hospice ("AseraCare"). Under the terms and conditions for receipt of the payment, we were allowed to use the funds to cover lost revenues and health care costs related to COVID-19 through June 30, 2021, and we were required to properly and fully document the use of these funds in reports to the U.S. Department of Health and Human Services ("HHS"). All required reporting was completed during the three-month period ended September 30, 2021, and our audit report was submitted to HHS on September 26, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our wholly-owned subsidiaries, we utilized PRF funds to the extent we had qualifying COVID-19 expenses; we did not use PRF funds to cover lost revenues resulting from COVID-19. The grant income associated with the COVID-19 expenses incurred through June 30, 2021 is reflected in other operating income within our consolidated statements of operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not fully utilize the funds received; all unutilized funds were repaid in October 2021. In summary, the total funds that we received from the CARES Act PRF were accounted for as follows (amounts in millions):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"/><td style="width:74.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.186%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds utilized through June 30, 2021 by consolidated entities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds repaid to the government by consolidated entities (excludes $0.2 million of interest repaid)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds utilized through June 30, 2021 by unconsolidated joint ventures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds repaid to the government by unconsolidated joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CARES Act also provided for the temporary suspension of the automatic 2% reduction of Medicare claim reimbursements ("sequestration") for the period May 1, 2020 through December 31, 2020. During 2020 and 2021, Congress passed additional COVID-19 relief legislation which extended the 2% suspension of sequestration through March 31, 2022; sequestration was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reinstated as a 1% reduction to Medicare claim reimbursements effective April 1, 2022 and a 2% reduction to Medicare claim reimbursements effective July 1, 2022. We recognized benefits to net service revenue totalin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g $13&#160;million, $36&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $23&#160;million during 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the CARES Act provided for the deferral of the employer share of social security tax (6.2%), effective for payments due after the enactment date through December 31, 2020. During 2020, we deferred approximately $55&#160;million of social security taxes. Approximately $27&#160;million was paid during December 2021; the remaining balance was paid during December 2022. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our personal care segment did not receive funds under the CARES Act; however, it did receive funds totaling $1&#160;million from the Mass Home Care ASAP COVID-19 Provider Sustainability Program, which were used during 2020 to cover costs related to COVID-19. The grant income associated with the funds received is reflected in other operating income within our consolidated statements of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_COVID19TextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for Novel Coronavirus Pandemic "COVID-19"</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_COVID19TextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtraordinaryAndUnusualItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtraordinaryAndUnusualItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675887427136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ACQUISITIONS</a></td>
<td class="text">ACQUISITIONSWe complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health, hospice, personal care and high acuity care services. The purchase price paid for acquisitions is negotiated through arm&#8217;s length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows. Acquisitions are <div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accounted for as purchases and are included in our consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy. We typically engage outside appraisal firms to assist in the fair value determination of identifiable intangible assets and noncontrolling interests, if any, for significant acquisitions. The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuation and liabilities assumed.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Acquisitions </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2022, we entered into a transaction with one of our high acuity care health system partners in which we contributed cash and our health system partner contributed its home health operations to one of our existing high acuity care joint ventures. As a result of this transaction, we recorded goodwill of $8.5&#160;million, other intangibles of $0.4&#160;million (certificate of need and licenses) and noncontrolling interest of $8.9&#160;million within our consolidated balance sheet. The fair value of noncontrolling interest was determined using an income approach and a market approach.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2022, we acquired 15 home health care centers from Evolution Health, LLC, a division of Envision Healthcare, doing business as Guardian Healthcare, Gem City, and Care Connection of Cincinnati ("Evolution"), for an estimated purchase price of $67.8&#160;million. A portion of the purchase price ($51.1&#160;million) was paid to the seller with cash on hand and proceeds from borrowings under our Revolving Credit Facility. The remainder ($16.7&#160;million) was placed into an escrow account in accordance with the closing payment, indemnity and other provisions within the purchase agreement and recorded as restricted cash within our consolidated balance sheet. Corresponding liabilities were also recorded to accrued expenses and other long-term obligations within our consolidated balance sheet related to these contingent consideration arrangements. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the total $16.7&#160;million placed into escrow, $1.0&#160;million was set aside for the closing payment adjustment. The closing payment calculated on the acquisition date included estimates for cash, working capital and various other items. Under the purchase agreement, the purchase price was subject to an adjustment for any differences between estimated amounts included in the closing payment and actual amounts at close. The closing payment adjustment, which was finalized during the three-month period ended September 30, 2022, decreased the purchase price by $1.3&#160;million from $67.8&#160;million to $66.5&#160;million. The remaining $15.7&#160;million placed into escrow relates to certain outstanding matters existing as of the acquisition date as well as potential losses the Company may incur for which the seller has an obligation to indemnify the Company. This amount will either be paid to third parties as outstanding matters are resolved or to the seller at certain intervals in the future. As of December 31, 2022, $5.7&#160;million of the $16.7&#160;million has been released from escrow.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect $15&#160;million of goodwill recorded for this acquisition to be deductible for income tax purposes over approximately 15 years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolution contributed $29.4&#160;million in net service revenue and an operating loss of $5.3 million during the year ended December 31, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is in the process of reviewing the fair value of the assets acquired and liabilities assumed. During the post-acquisition period ended December 31, 2022, total assets acquired decreased by $2.1&#160;million (primarily patient accounts receivable and property and equipment) and total liabilities assumed (specifically, the deferred income tax liability) decreased by $0.3&#160;million as a result of our review. These adjustments, combined with the closing payment adjustment of $1.3&#160;million described above, resulted in a $0.5&#160;million increase in goodwill. Based on the Company's preliminary valuation, which may be revised as additional information becomes available during the measurement period, the total consideration of $66.5&#160;million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"/><td style="width:74.037%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets (licenses)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities assumed</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net identifiable assets acquired</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2022, we acquired two home health locations from AssistedCare Home Health, Inc. and RH Homecare Services, LLC, doing business as AssistedCare Home Health and AssistedCare of the Carolinas ("AssistedCare"), respectively, for a purchase price of $24.7&#160;million. A portion of the purchase price ($22.2&#160;million) was paid to the seller with cash on hand and proceeds from borrowings under our Revolving Credit Facility. The remainder ($2.5&#160;million) was placed into an escrow account in accordance with the indemnity provisions within the purchase agreement and is reflected in restricted cash within our consolidated balance sheet. A corresponding liability was also recorded to other long-term obligations within our consolidated balance sheet related to this contingent consideration arrangement. The $2.5&#160;million will either be paid to third parties or to the seller at certain intervals in the future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company's preliminary valuation, we recorded goodwill of $24.0&#160;million and other intangibles of $0.7&#160;million in connection with the acquisition. Intangible assets acquired include licenses ($0.5&#160;million), certificates of need ($0.2&#160;million) and acquired names (less than $0.1&#160;million). The acquired names will be amortized over a weighted average period of one year.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the entire amount of goodwill recorded for this acquisition to be deductible for income tax purposes over approximately 15 years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AssistedCare contributed $6.1&#160;million in net service revenue and operating income of $0.8&#160;million during the year ended December 31, 2022.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Acquisitions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 1, 2021, we acquired the regulatory assets of a home health provider in Randolph County, North Carolina for a purchase price of $2.5&#160;million. The purchase price was paid with cash on hand on the date of the transaction. We recorded goodwill of $2.4&#160;million and other intangibles (certificate of need) of $0.1&#160;million in connection with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2021, we acquired Visiting Nurse Association ("VNA"), a home health and hospice provider with locations in Nebraska and Iowa for a purchase price of $20.1&#160;million. The purchase price was paid with cash on hand on the date of the transaction. We recorded goodwill of $19.7&#160;million and other intangibles (licenses) of $0.4&#160;million in connection with the acquisition. We expect the entire amount of goodwill for this acquisition to be deductible for income tax purposes over approximately 15 years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 12, 2021, we acquired the regulatory assets of a home health provider in New York for a purchase price of $1.5&#160;million. The purchase price was paid with cash on hand on the date of the transaction. We recorded goodwill of $1.4&#160;million and other intangibles (certificate of need) of $0.1&#160;million in connection with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2021, we acquired Contessa, a leader in hospital-at-home and skilled nursing facility at-home services for an estimated purchase price of $240.7&#160;million, net of cash acquired. The Contessa purchase price included estimates for cash, working capital and other items. Under the purchase agreement, the purchase price was subject to a closing payment adjustment for any differences between estimated amounts included in the closing payment and actual amounts at close. The closing payment adjustment, which was finalized during the three-month period ended December 31, 2021, increased the purchase price by $0.6&#160;million from $240.7&#160;million to $241.3&#160;million. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has finalized its valuation of the assets acquired, liabilities assumed and noncontrolling interests. During the year ended December 31, 2022, the deferred income tax liability was adjusted downward by $2.8&#160;million resulting in a $2.8&#160;million decrease in goodwill. The total consideration of $241.3&#160;million has been allocated to assets acquired, liabilities assumed and noncontrolling interests as of the acquisition date as follows (amounts in millions):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"/><td style="width:74.037%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities assumed</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and equity assumed</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net identifiable assets acquired</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired include acquired names ($28.3&#160;million), technology ($19.8&#160;million) and non-compete agreements ($6.2&#160;million). The non-compete agreements will be amortized over a weighted-average period of 2.0 years, and the technology will be amortized over a weighted-average period of 7.0 years. The fair value of noncontrolling interest ($43.9&#160;million) was determined using an income approach.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect any of the goodwill recorded for this acquisition to be deductible for income tax purposes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contessa contributed $18.5&#160;million in net service revenue and an operating loss of $39.1&#160;million (inclusive of technology intangibles amortization totaling $3.0&#160;million) during the year ended December 31, 2022 and $3.5&#160;million in net service revenue and an operating loss of $10.3 million (inclusive of technology intangibles amortization totaling $1.2&#160;million) during the year ended December 31, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 18, 2021, we acquired the regulatory assets of a home health provider in North Carolina for a purchase price of $4.5&#160;million. The purchase price was paid with cash on hand on the date of the transaction. We recorded goodwill of $4.3&#160;million and other intangibles (certificate of need) of $0.2&#160;million in connection with the acquisition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675887427136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND OTHER INTANGIBLE ASSETS, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">GOODWILL AND OTHER INTANGIBLE ASSETS, NET</a></td>
<td class="text">GOODWILL AND OTHER INTANGIBLE ASSETS, NET<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, 2021 and 2020, we did not record any goodwill impairment charges as a result of our annual impairment test and none of the goodwill associated with our reporting units was considered impaired as of October 31st of each respective year (the date of our annual goodwill impairment test). Since the date of our last annual goodwill impairment test, there have been no material developments, events, changes in operating performance or other circumstances that would cause management to believe it is more likely than not that the fair value of any of our reporting units would be less than their carrying amounts. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to our goodwill for 2022 and 2021 (amounts in millions):</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Goodwill</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home&#160;Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal&#160;Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High  Acuity Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2020 (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">799.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">932.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">233.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">263.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">800.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">233.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,196.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">800.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,287.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Net of prior years' accumulated impairment losses of $733.7 million, which is inclusive of write-offs related to the sale and closure of care centers.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Company finalized its valuation of the assets acquired, liabilities assumed and noncontrolling interests in connection with the acquisition of Contessa on August 1, 2021. See Note 4 &#8211; Acquisitions for additional information.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Intangible Assets, Net</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022 and 2021, we did not record any impairment charges related to our other intangible assets.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to our other intangible assets, net for 2022 and 2021 (amounts in millions):</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.606%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Intangible Assets, Net</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Certificates of Need and Licenses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired<br/>Names -Unamortizable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired<br/>Names -Amortizable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-Compete<br/>Agreements (3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Technology (3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2020 (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclass to amortizable intangible</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Net of prior years' accumulated amortization of $11.5&#160;million for acquired names and $9.0 million for non-compete agreements. </span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Amortization of certificates of need and licenses is related to care centers that were closed during 2021 and 2022.</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The weighted average remaining amortization period of our amortizable non-compete agreements and technology is 0.6 years and 5.6 years, respectively.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated aggregate amortization expense related to intangible assets for each of the five succeeding years is as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.356%"><tr><td style="width:1.0%"/><td style="width:72.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.255%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intangible Asset Amortization</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 4 &#8211; Acquisitions for further details on additions to goodwill and other intangible assets, net.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675801688528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSETS HELD FOR SALE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract', window );"><strong>Discontinued Operation, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">ASSETS HELD FOR SALE</a></td>
<td class="text">ASSETS HELD FOR SALE<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2023, we signed a definitive agreement to sell our personal care business (excluding the Florida operations) for a purchase price of $50&#160;million. The divestment is expected to close during the second quarter of 2023.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of the assets and liabilities associated with our personal care reporting unit (which approximate fair value) included in our consolidated balance sheets are as follows (amounts in millions):</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.725%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.696%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675804273440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DetailsOfCertainBalanceSheetAccountsAbstract', window );"><strong>Details Of Certain Balance Sheet Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock', window );">DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS</a></td>
<td class="text">DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS<div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information regarding certain balance sheet accounts is presented below (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payroll tax escrow</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due from joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Workers&#8217; compensation deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Health insurance deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other miscellaneous deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indemnity receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Health insurance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Florida ZPIC audit, gross liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Legal settlements and other audits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charity care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated Medicare cap liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hospice accruals (room and board, general in-patient and other)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patient and payor liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term obligations:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reserve for uncertain tax positions</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DetailsOfCertainBalanceSheetAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DetailsOfCertainBalanceSheetAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675798289680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_LesseeLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine whether an arrangement is a lease at inception. We have operating leases, primarily for offices and fleet, that expire at various dates over the next seven years. We have finance leases covering certain office equipment that expire at various dates over the next three years. Our leases do not contain any restrictive covenants.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our office leases generally contain renewal options for periods ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90ZXh0cmVnaW9uOmJiNDEwNTZmMDg4MjQ1MTA5YTBlMWZmY2IxMGRiN2U2XzQyMw_4521311a-fbff-4d4f-a200-9de841dcd915">one</span> to five years. Because we are not reasonably certain to exercise these renewal options, the options are not considered in determining the lease term, and payments associated with the option years are excluded from lease payments. Our office leases also generally include termination options, which allow for early termination of the lease after the first one to three years. Because we are not reasonably certain to exercise these termination options, the options are not considered in determining the lease term; payments for the full lease term are included in lease payments. Our office leases do not contain any material residual value guarantees.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fleet leases include a term of 367 days with monthly renewal options thereafter. Our fleet leases also include terminal rental adjustment clauses (&#8220;TRAC&#8221;), which provide for a final rental payment adjustment at the end of the lease, typically based on </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the amount realized from the sale of the vehicle. The TRAC is structured such that it will almost always result in a significant payment by us to the lessor if the renewal option is not exercised. Based on the significance of the TRAC adjustment at the initial lease expiration, we believe that it is reasonably certain that we will exercise the monthly renewal options; therefore, the renewal options are considered in determining the lease term, and payments associated with the renewal options are included in lease payments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our fleet and office equipment leases, we use the implicit rate in the lease as the discount rate. For our office leases, the implicit rate is typically not available, so we use our incremental borrowing rate as the discount rate. Our lease agreements include both lease and non-lease components. We have elected the practical expedient that allows us to not separate lease and non-lease components for all of our leases.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments due under our operating and finance leases include fixed payments as well as variable payments. For our office leases, variable payments include amounts for our proportionate share of operating expenses, utilities, property taxes, insurance, common area maintenance and other facility-related expenses. For our vehicle and equipment leases, variable payments consist of sales tax. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost for the years ended December 31, 2022 and 2021 are as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:56.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.793%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.794%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of operating lease ROU assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease cost</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on termination</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of ROU assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease cost</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reported in the consolidated balance sheets as of December 31, 2022 and 2021 for our operating leases are as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:56.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.793%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.794%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, less current portion</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reported in the consolidated balance sheets as of December 31, 2022 and 2021 for finance leases are included in the table below. The finance lease ROU assets are recorded within property and equipment, net of accumulated depreciation within our consolidated balance sheets. The finance lease liabilities are recorded within current portion of long-term obligations and long-term obligations, less current portion within our consolidated balance sheets.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:56.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.793%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.794%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease ROU assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease ROU assets, net</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current installments of obligations under finance leases</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzYtMS0xLTEtNTA3MjU_1eca02a9-f1dd-4c12-b3b8-0c54b6fd691a">1.2</span>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzYtMy0xLTEtNTA3MjU_8d1038d1-419b-4128-8314-0aa1a5467841">0.9</span>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of obligations under finance leases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzctMS0xLTEtNTA3MjU_a814e167-8383-4d45-81ca-86cc22f5c011">1.1</span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzctMy0xLTEtNTA3MjU_89a632c7-217b-411e-a52c-c18cee261893">0.7</span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzgtMS0xLTEtNTA3MjU_12d2aa00-0042-4307-aa11-8f39561b8e9d">2.3</span>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzgtMy0xLTEtNTA3MjU_15a6bc06-843b-4c48-b58a-8be83b9c35ba">1.6</span>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information and non-cash activity related to our leases are as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:56.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.793%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.794%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities and ROU assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flow from operating leases</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flow from finance leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions to ROU assets resulting from reductions to lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts disclosed for ROU assets obtained in exchange for lease obligations include amounts added to the carrying amount of ROU assets resulting from lease modifications and reassessments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease terms and discount rates for our leases as of December 31, 2022 and 2021 are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:56.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.793%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.794%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (years):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December 31, 2022 are as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"><tr><td style="width:1.0%"/><td style="width:64.154%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.850%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating <br/>Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance <br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzktMy0xLTEtNTA3MjU_99acfacd-090d-4833-8cd5-0990e12d974a">2.3</span>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LesseeLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating and finance leases of lessee. Includes, but is not limited to, description of operating and finance lease and maturity analysis of operating and finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LesseeLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675798289680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">LONG-TERM OBLIGATIONS</a></td>
<td class="text">LONG-TERM OBLIGATIONS<div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consists of the following for the periods indicated (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$450.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (5.9% at December 31, 2022); due July&#160;30, 2026</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate; due July&#160;30, 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Promissory notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">445.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations, less current portion</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of debt as of December&#160;31, 2022 are as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.783%"><tr><td style="width:1.0%"/><td style="width:72.219%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.581%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term<br/>obligations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Agreement</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 29, 2018, we entered into our Amended and Restated Credit Agreement (the "Credit Agreement") which provided for a senior secured revolving credit facility in an initial aggregate principal amount of up to $550.0 million (the "Revolving Credit Facility"). The Revolving Credit Facility provided for and included within its $550.0 million limit a $25.0 million swingline facility and commitments for up to $60.0 million in letters of credit. Upon lender approval, we could increase the aggregate loan amount under the Revolving Credit Facility by $125.0 million plus an unlimited amount subject to a leverage limit of 0.5x under the maximum allowable consolidated leverage ratio which was 3.0x per the Credit Agreement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final maturity of the Revolving Credit Facility was June 29, 2023, and there was no mandatory amortization on the outstanding principal balances which were payable in full upon maturity. The Revolving Credit Facility was used to provide </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ongoing working capital needs and for general corporate purposes of the Company and our subsidiaries, including permitted acquisitions, as defined in the Credit Agreement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">First Amendment to the Credit Agreement</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 4, 2019, we entered into the First Amendment to the Credit Agreement (as amended by the First Amendment, the &#8220;Amended Credit Agreement&#8221;). The Amended Credit Agreement provided for a senior secured credit facility in an initial aggregate principal amount of up to $725.0 million, which included the $550.0 million Revolving Credit Facility under the Credit Agreement, and a term loan facility with a principal amount of up to $175.0 million (the &#8220;Term Loan Facility&#8221; and collectively with the Revolving Credit Facility, the &#8220;Credit Facility&#8221;), which was added by the First Amendment.  </span></div><div style="margin-top:5pt;padding-right:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We borrowed the entire principal amount of the Term Loan Facility on February&#160;4, 2019 in order to fund a portion of the purchase price of the Compassionate Care Hospice ("CCH") acquisition, with the remainder of the purchase price and associated transactional fees and expenses funded by proceeds from the Revolving Credit Facility. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Second Amendment to the Credit Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 30, 2021, we entered into the Second Amendment to our Credit Agreement (as amended by the Second Amendment, the "Second Amended Credit Agreement"). The Second Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $1.0&#160;billion, which includes the $550.0&#160;million Revolving Credit Facility and a term loan facility with a principal amount of up to $450.0&#160;million (the "Amended Term Loan Facility" and collectively with the Revolving Credit Facility, the "Amended Credit Facility").</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net proceeds from the $450.0&#160;million Amended Term Loan Facility were used to fund the Contessa acquisition. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The loans issued under the Amended Credit Facility bear interest on a per annum basis, at our election, at either: (i) the Base Rate plus the Applicable Rate or (ii) the Eurodollar Rate plus the Applicable Rate. The &#8220;Base Rate&#8221; means a fluctuating rate per annum equal to the highest of (a) the federal funds rate plus 0.50% per annum, (b)&#160;the prime rate of interest established by the Administrative Agent, and (c)&#160;the Eurodollar Rate plus 1% per annum. The &#8220;Eurodollar Rate&#8221; means the quoted rate per annum equal to the London Interbank Offered Rate ("LIBOR") or a comparable successor rate approved by the Administrative Agent for an interest period of one, three or six months (as selected by us). The &#8220;Applicable Rate&#8221; is based on the consolidated leverage ratio and is presented in the table below. As of December&#160;31, 2022, the Applicable Rate is 0.50% per annum for Base Rate Loans and 1.50% per annum for Eurodollar Rate Loans. Our Second Amended Credit Agreement provides for the replacement of LIBOR with the daily or term secured overnight financing rate ("SOFR") whenever LIBOR is discontinued. We are also subject to a commitment fee and letter of credit fee under the terms of the Second Amended Credit Agreement, as presented in the table below.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.578%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pricing Tier</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Leverage Ratio</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Base Rate Loans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eurodollar Rate Loans and Daily Floating LIBOR Rate Loans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commitment<br/>Fee</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Letter&#160;of<br/>Credit&#160;Fee</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">I</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&gt;  3.00 to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">II</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> 3.00 to 1.0 but &gt;&#160;2.00 to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">III</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> 2.00 to 1.0 but &gt;&#160;0.75 to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IV</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  0.75 to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final maturity date of the Amended Credit Facility is July 30, 2026. The Revolving Credit Facility will terminate and be due and payable as of the final maturity date. The Amended Term Loan Facility, however, is subject to quarterly amortization of principal in the amount of (i) 0.625% for the period commencing on July 30, 2021 and ending on September 30, 2023, and (ii) 1.250% for the period commencing on October 1, 2023 and ending on July 30, 2026. The remaining balance of the Amended Term Loan Facility must be paid upon the final maturity date. In addition to the scheduled amortization of the Amended Term Loan Facility, and subject to customary exceptions and reinvestment rights, we are required to prepay the Amended Term Loan Facility first and the Revolving Credit Facility second with 100% of all net cash proceeds received by any loan party or any subsidiary thereof in connection with (a) any asset sale or disposition where such loan party receives net cash proceeds in excess of $5 million or (b) any debt issuance that is not permitted under the Second Amended Credit Agreement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Second Amended Credit Agreement requires maintenance of two financial covenants: (i) a consolidated leverage ratio of funded indebtedness to Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA"), as defined in the Second Amended Credit Agreement, and (ii) a consolidated interest coverage ratio of EBITDA to cash interest charges, as defined in the Second Amended Credit Agreement. Each of these covenants is calculated over rolling four-quarter periods and also is subject to certain exceptions and baskets. The Second Amended Credit Agreement also contains customary covenants, </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including, but not limited to, restrictions on: incurrence of liens, incurrence of additional debt, sales of assets and other fundamental corporate changes, investments and declarations of dividends. These covenants contain customary exclusions and baskets as detailed in the Second Amended Credit Agreement. In connection with our entry into the Second Amended Credit Agreement during the year ended December 31, 2021, we recorded $2.8 million in deferred debt issuance costs as long-term obligations, less current portion within our consolidated balance sheet.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Credit Facility is guaranteed by substantially all of our wholly-owned direct and indirect subsidiaries. The Second Amended Credit Agreement requires at all times that we (i) provide guarantees from wholly-owned subsidiaries that in the aggregate represent not less than 95% of our consolidated net revenues and adjusted EBITDA from all wholly-owned subsidiaries and (ii)&#160;provide guarantees from subsidiaries that in the aggregate represent not less than 70% of consolidated adjusted EBITDA, subject to certain exceptions.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our weighted average interest rate for borrowings under our Amended Term Loan Facility was 3.2% for the year ended December 31, 2022 and 1.6% for the year ended December&#160;31, 2021. Our weighted average interest rate for borrowings under our $550.0 million Revolving Credit Facility was 3.4% for the year ended December 31, 2022 and 1.9% for the year ended December 31, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, our consolidated leverage ratio was 1.7, our consolidated interest coverage ratio was 11.6 and we are in compliance with our covenants under the Second Amended Credit Agreement. In the event we are not in compliance with our debt covenants in the future, we would pursue various alternatives in an attempt to successfully resolve the non-compliance, which might include, among other things, seeking debt covenant waivers or amendments.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, our availability under our $550.0 million Revolving Credit Facility was $520.4 million as we have no outstanding borrowings and $29.6 million outstanding in letters of credit.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Joinder Agreements</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the CCH acquisition, we entered into a Joinder Agreement, dated as of February 4, 2019 (the &#8220;CCH Joinder&#8221;), pursuant to which CCH and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement (now the Second Amended Credit Agreement), the Amended and Restated Security Agreement, dated as of June 29, 2018 (the &#8220;Amended and Restated Security Agreement&#8221;), and the Amended and Restated Pledge Agreement, dated as of June 29, 2018 (the &#8220;Amended and Restated Pledge Agreement&#8221;). In connection with the AseraCare acquisition, we entered into a Joinder Agreement, dated as of June 12, 2020, pursuant to which the AseraCare entities were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement (now the Second Amended Credit Agreement), the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement (the &#8220;AseraCare Joinder"). In connection with the Contessa acquisition and the Second Amendment, we entered into a Joinder Agreement, dated as of September 3, 2021, pursuant to which Contessa and its subsidiaries and Asana, which we acquired on January 1, 2020, and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Second Amended Credit Agreement, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement (the &#8220;Contessa and Asana Joinder,&#8221; and together with the CCH Joinder and the AseraCare Joinder, the &#8220;Joinders&#8221;). </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the Joinders, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement, CCH and its subsidiaries, the AseraCare entities, Contessa and its subsidiaries and Asana and its subsidiaries granted in favor of the Administrative Agent a first lien security interest in substantially all of their personal property assets and pledged to the Administrative Agent each of their respective subsidiaries' issued and outstanding equity interests. CCH and its subsidiaries, the AseraCare entities, Contessa and its subsidiaries and Asana and its subsidiaries also guaranteed our obligations, whether now existing or arising after the respective effective dates of the Joinders, under the Second Amended Credit Agreement pursuant to the terms of the Joinders and the Second Amended Credit Agreement.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Promissory Notes</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our outstanding promissory note totaling $0.2&#160;million, obtained through the acquisition of Contessa on August 1, 2021, bears an interest rate of 6.5%.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finance Leases</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our outstanding finance leases totaling $2.3 million relate to leased equipment and bear interest rates ranging from 2.1% to 5.3%.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675805883520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES<div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes attributable to continuing operations consist of the following (amounts in millions):</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:56.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income tax expense/(benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax expense/(benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total income tax expense for the years ended December&#160;31, 2022, 2021 and 2020 was allocated as follows (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:56.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax expense recorded to additional paid-in-capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of significant differences between the reported amount of income tax expense and the expected amount of income tax expense that would result from applying the U.S. federal statutory income tax rate of 21% to income before income taxes is as follows:</span></div><div style="margin-bottom:6pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:56.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense at U.S. federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local income taxes, net of federal income tax benefit (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess tax benefits from share-based compensation (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible executive compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items, net (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">On August 10, 2020, Paul B. Kusserow, Chief Executive Officer and Chairman of the Board of Amedisys, exercised 500,000 stock options previously awarded to him under our 2008 Omnibus Incentive Compensation Plan. We recognize compensation expense for stock option awards on a straight-line basis over the requisite service period for each separately vesting portion of the award in accordance with ASC 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Compensation: Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">; however, the income tax deduction related to stock options is not recognized until the stock option exercise date. As a result, for awards that are expected to result in a tax deduction, a deferred tax asset is created as the entity recognizes compensation expense for U.S. GAAP purposes. If the tax deduction exceeds the cumulative U.S. GAAP compensation expense for the award, the tax benefit associated with any excess deduction is recognized as an income tax benefit in the statement of operations, resulting in a reduction of the effective tax rate. Mr. Kusserow's stock option exercise produced a $92.1&#160;million tax deduction in excess of U.S. GAAP compensation expense, resulting in a $19.4&#160;million federal income tax benefit and a $4.6&#160;million state and local income tax benefit for the year ended December 31, 2020.</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">For the year ended December 31, 2022, the Company recognized $2.7&#160;million of federal uncertain tax positions due to a lapse of the statute of limitations.</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Includes various items such as non-deductible expenses, non-taxable income, tax credits, valuation allowance, uncertain tax positions and return-to-accrual adjustments.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, the Company had income taxes receivable of $8.8 million and $8.2 million, respectively, included in other current assets within our consolidated balance sheets. </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets (liabilities) consist of the following components (amounts in millions):</span></div><div style="margin-bottom:9pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll&#160;&amp; employee benefits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal &amp; compliance matters</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred social security taxes (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in partnerships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:14pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">The CARES Act provided for the deferral of the employer share of social security tax (6.2%), effective for payments due after the enactment date through December 31, 2020. Fifty percent of the deferred payroll taxes were due on December 31, 2021 with the remaining amounts due on December 31, 2022. As of December 31, 2021, the Company had a remaining balance of deferred social security taxes of $27&#160;million, reflected within our consolidated balance sheets, which was paid in December 2022. For income tax purposes, the deferred social security taxes are deductible when paid, leaving no remaining deferred tax asset as of December 31, 2022. </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we have U.S. net operating loss (&#8220;NOL&#8221;) carryforwards of $20.9&#160;million that are available to reduce future taxable income and may be carried forward indefinitely. While the NOL carryforwards are not subject to expiration, the annual NOL amount that is available to offset future taxable income is subject to limitation. The NOL carryforwards were acquired as part of the stock purchase of Contessa on August 1, 2021. Under Section 382 of the Internal Revenue Code of 1986, as amended ("Section 382"), substantial changes in a Company&#8217;s ownership may limit the amount of NOL carryforwards that can be utilized annually to offset future taxable income. As a result of the ownership change, the Company determined that there is an annual limitation, pursuant to Section 382, on the amount of NOL carryforwards that may be utilized to offset future taxable income. </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we have state NOL carryforwards of $144.7 million that are available to reduce future taxable income and various state tax credits totaling $3.7 million available to reduce future state income taxes. The state NOL and tax credit carryforwards expire at various times.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, the valuation allowance for deferred tax assets, which is related to certain state NOLs, was $5.2 million and $3.3 million, respectively. The net change in the total valuation allowance for the years ended December 31, 2022 and 2021 was an increase of $1.9&#160;million and an increase of $3.2 million, respectively. The $1.9&#160;million increase in the valuation allowance for the year ended December 31, 2022 is due to Contessa's creation of state NOL carryforwards in jurisdictions that require separate company reporting and where the Company does not expect to have sufficient separate company future taxable income available to offset the state NOL carryforwards. </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in those jurisdictions during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities (including the impact of available carryback and carryforward periods), projected future taxable income and tax-planning strategies in making this assessment. In order to fully realize the deferred tax assets, the Company will need to generate future taxable income before the expiration of the carryforwards governed by the tax code. Based on the current level of pre-tax earnings, the Company will generate the minimum amount of future taxable income needed to support the realization of the deferred tax assets. As a result, as of December 31, 2022, management believes that it is more likely than not that we will realize the benefits of these deferred tax assets, net of the existing valuation allowances. The amount of the deferred tax asset considered realizable, however, could be reduced in the near term if estimates of future taxable income during the carryforward period are reduced.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Uncertain Tax Positions</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for uncertain tax positions in accordance with the authoritative guidance for uncertain tax positions. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (amounts in millions):</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:56.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions for tax positions related to current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions for tax positions related to prior year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reductions for tax positions related to prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, there was $2.7 million of unrecognized tax benefits recorded in other long-term obligations within the consolidated balance sheets. During 2022, the statute of limitations lapsed, ultimately removing the uncertainty surrounding the Company's ability to recognize the tax positions, if challenged under audit. As a result, the Company recognized a $2.7&#160;million income tax benefit and corresponding reduction in our effective tax rate for the period ended December 31, 2022.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized $0.1&#160;million and $0.2 million of interest as components of interest expense in connection with our reserve for uncertain tax positions during the years ended December 31, 2021 and 2020, respectively. For the period ended December 31, 2022, the Company recorded a $0.7&#160;million benefit as a component of interest expense, as a result of the lapse of the statute of limitations and corresponding release of the reserve for uncertain tax positions. Accrued interest related to uncertain tax positions included in the consolidated balance sheet at December 31, 2021 was $0.7 million. There was no accrued interest related to uncertain tax positions included in the consolidated balance sheet at December 31, 2022.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income taxes in the U.S. and in many individual states, with significant operations in Louisiana, South Carolina, Alabama, Georgia, Massachusetts and Tennessee. We are open to examination in the U.S. and in various individual states for the tax years ended December&#160;31, 2014 through December&#160;31, 2022. We are also open to examination in various states for the years ended 2007 through 2022 resulting from NOLs generated and available for carryforward from those years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675887643504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK AND SHARE-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">CAPITAL SOCK AND SHARE-BASED COMPENSATION</a></td>
<td class="text">CAPITAL STOCK AND SHARE-BASED COMPENSATION<div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are authorized by our Certificate of Incorporation to issue 60,000,000 shares of common stock, $0.001 par value and 5,000,000 shares of preferred stock, $0.001 par value. As of December&#160;31, 2022, there were 37,891,186 and 32,518,278 shares of common stock issued and outstanding, respectively, and no shares of preferred stock issued or outstanding. Our Board of Directors is authorized to fix the dividend rights and terms, conversion and voting rights, redemption rights and other privileges and restrictions applicable to our preferred stock.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Awards</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 29, 2018, our Board of Directors and the Compensation Committee approved, subject to stockholder approval, the Amedisys, Inc. 2018 Omnibus Incentive Compensation Plan (the &#8220;2018 Plan&#8221;). On June 6, 2018, our stockholders approved the 2018 Plan at the Company's annual meeting of stockholders. The 2018 Plan replaces our 2008 Omnibus Incentive Compensation Plan (the &#8220;2008 Plan&#8221;), which terminated on June 6, 2018 when the stockholders approved the 2018 Plan. The 2018 Plan, as amended to date, authorizes the grant of various types of equity-based awards, such as stock awards, restricted stock units, stock appreciation rights and stock options to eligible participants, which include all of our employees and all employees of our 50% or more owned subsidiaries, our non-employee directors and certain consultants. The vesting terms of the awards may be tied to continued employment (or, for our non-employee directors, continued service on the Board of Directors) and/or achievement of certain pre-determined performance goals. We refer to restricted stock units subject to service-based or a combination of service-based and performance-based vesting conditions as &#8220;non-vested stock units.&#8221; The 2018 Plan is administered by the Compensation Committee of our Board of Directors, which determines, within the provisions of the 2018 Plan, those eligible participants to whom, and the times at which, awards shall be granted. The Compensation Committee, in its discretion, may delegate its authority and duties under the 2018 Plan to specified officers; however, only the Compensation Committee may approve the terms of awards to our executive officers.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity-based awards may be granted for a number of shares not to exceed, in the aggregate, approximately 2.5 million shares of common stock. We had approximately 1.7 million shares available at December&#160;31, 2022. The price per share for stock options shall be no less than the greater of (a) 100% of the fair value of a share of common stock on the date the option is granted or (b)&#160;the aggregate par value of the shares of our common stock on the date the option is granted. If a stock option is granted to any owner of 10% or more of the total combined voting power of us and our subsidiaries, the price is to be at least 110% of the fair value of a share of our common stock on the date the award is granted. Each equity-based award vests ratably over a one year to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzI5NTc_223df790-b680-48db-b730-c00d1beab04b">four</span> year period, with the exception of those issued under contractual arrangements that specify otherwise, and may be exercised during a period as determined by our Compensation Committee or as otherwise approved by our Compensation Committee. The contractual terms of stock options exercised shall not exceed ten years from the date such option is granted. The Company analyzes historical data of forfeited awards to develop an estimated forfeiture rate that is applied to the Company's non-cash compensation expense; however, all non-cash compensation expense is adjusted to reflect actual vestings and forfeitures.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan (&#8220;ESPP&#8221;)                                                                                                                                                                        </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a plan whereby our eligible employees may purchase our common stock at 85% of the market price at the time of purchase. The total number of shares of our common stock authorized for issuance under our ESPP is 4,500,000, and as of December&#160;31, 2022, there were 1,264,302 shares available for future issuance. The following is a detail of the purchases that have been made under the plan:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employee Stock Purchase Plan Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares&#160;Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 and Prior</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,171,373&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January&#160;1, 2021 to March&#160;31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April&#160;1, 2021 to June&#160;30, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July&#160;1, 2021 to September&#160;30, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October&#160;1, 2021 to December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January&#160;1, 2022 to March&#160;31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April&#160;1, 2022 to June&#160;30, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July&#160;1, 2022 to September&#160;30, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October&#160;1, 2022 to December&#160;31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,235,698&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ESPP expense included in general and administrative expense in our accompanying consolidated statements of operations was $0.7 million, $0.7 million and $0.6 million for 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 10, 2020, Paul B. Kusserow, Chief Executive Officer and Chairman of the Board of Amedisys, exercised 500,000 stock options previously awarded to him under the 2008 Plan. In connection with the exercise, Mr. Kusserow surrendered 231,683 shares of common stock to us to satisfy tax withholding and strike price obligations and elected to hold the net 268,317 shares issued to him. The surrendered shares are classified as treasury shares. This transaction resulted in a cash outflow of $40.4&#160;million, reflected within financing activities in our consolidated statement of cash flows, related to the remittance of tax withholding obligations. In addition, Mr. Kusserow's stock option exercise resulted in a $24.0&#160;million income tax benefit that was recorded in our consolidated statement of operations during the year ended December 31, 2020. See Note 10 &#8211; Income Taxes for additional details.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes option pricing model to estimate the fair value of our stock options. There were 33,656, 40,788 and 43,249 options granted during 2022, 2021 and 2020, respectively. Stock option compensation expense included in general and administrative expense in our accompanying consolidated statements of operations was $1.7 million, $3.6 million and $4.3 million for 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the stock option awards were estimated using the following assumptions for 2022, 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk Free Rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.91% </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.80% - 1.35%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.38% - 1.51%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.97% </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.84% - 41.40%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.15% - 42.80%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected Term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.25 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.25 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.25 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Fair Value</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$61.31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$107.45</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$86.72</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend Yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We used the simplified method to estimate the expected term for the stock options granted during 2022, 2021 and 2020 as adequate historical experience is not available to provide a reasonable estimate.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our stock option activity for 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:54.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.297%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average&#160;Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average&#160;Contractual<br/>Life&#160;(Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding options at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">273,973&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.21</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(37,635)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled, forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(51,382)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding options at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218,612&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142.86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.56</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercisable options at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163,286&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.54&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.04</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of our outstanding options and exercisable options at December&#160;31, 2022 was $0.7 million and $0.7 million, respectively. Total intrinsic value of options exercised was $1.5 million, $5.1 million and $121.1 million for 2022, 2021 and 2020, respectively. The tax benefit from stock options exercised during the period amounted to $0.4 million, $1.0 million and $27.9 million for 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our non-vested stock option activity for 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;Average<br/>Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock options at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129,439&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182.45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(64,496)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43,273)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock options at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,326&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.81&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, there was $2.0 million of unrecognized compensation cost related to stock options that we expect to be recognized over a weighted-average period of 1.8 years.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Vested Stock Units</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issue non-vested stock unit awards that are service-based, performance-based or a combination of both with vesting terms ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4Xzc0MzA_f3f1355f-39bb-4d10-ac63-3dcf30959476">one</span> to <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4Xzc0MzY_d0064103-cecb-48d9-8073-473521ccb07a">four</span> years. Based on the terms and conditions of these awards, we determine if the awards should be recorded as either equity or liability instruments. The compensation expense is determined based on the market price of our common stock at the date of grant, applied to the total number of units that are anticipated to vest, unless the award specifies differently. Shares of stock are not issued to the recipient until the stock unit awards have vested and after the pre-determined delivery date has occurred.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Vested Stock Units &#8211; Service-Based ("Service-Based Non-Vested Stock Units")</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service-based non-vested stock unit compensation expense included in general and administrative expenses in our accompanying consolidated statements of operations was $12.1 million, $9.4 million and $7.5 million for 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our service-based non-vested stock units activity for 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of&#160;<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;Average<br/>Grant Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock units at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180,823&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">211,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(59,006)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled, forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(70,025)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock units at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">263,153&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141.62&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value of service-based non-vested stock units granted was $115.07, $234.42 and $206.10 in 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, there was $22.6 million of unrecognized compensation cost related to our service-based non-vested stock units that we expect to be recognized over a weighted average period of 2.2 years.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Vested Stock Units &#8211; Service-Based and Performance-Based Awards ("Performance-Based Non-Vested Stock Units")</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, we awarded performance-based awards to certain employees. The target level established by the award, which is based on the Company&#8217;s 2022 adjusted earnings before interest, taxes, depreciation and amortization (&#8220;Adjusted EBITDA&#8221;), provided for the recipients to receive an aggregate of 71,349 non-vested stock units if the target was achieved. For a select group of employees, if the target objective was surpassed to the point of achieving the projected maximum payout, the recipients would receive an additional aggregate of 32,048 non-vested stock units during 2023. The target number of shares to be potentially awarded was reduced by forfeitures as indicated in the table below. On February 1, 2023, the Compensation Committee determined that the 2022 performance-based objective established by the award was not satisfied, and as a result, the target number of non-vested stock units will be forfeited. Performance-based non-vested stock units compensation expense included in general and administrative expenses in our consolidated statements of operations was $2.2 million, $10.2 million and $13.5 million for 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our performance-based non-vested stock units activity for 2022:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of&#160;<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;Average<br/>Grant Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock units at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186,951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">206.36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(85,767)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156.18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled, forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(104,486)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock units at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,047&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.55&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value of performance-based non-vested stock units granted was $133.70, $262.67 and $201.90 in 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, there was $1.1 million in unrecognized compensation costs related to our performance-based non-vested stock units that we expect to be recognized over a weighted average period of 1.1 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675802978016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings &#8211; Ongoing</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. Based on information available to us as of the date of this filing, we do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal fees related to all legal matters are expensed as incurred.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings - Completed</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subpoena Duces Tecum and Civil Investigative Demands Issued by the U.S. Department of Justice</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 7, 2021, the U.S. Department of Justice notified the Company that they were closing their investigation into the below-referenced Subpoena Duces Tecum ("Subpoena") and civil investigative demands ("CIDs"). At the time, we had $6.5&#160;million recorded to accrued expenses in our consolidated balance sheets related to these matters. We reversed this accrual during the three-month period ended June 30, 2021.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;21, 2015, we received a Subpoena issued by the U.S. Department of Justice. The Subpoena requested the delivery of information regarding 53 identified hospice patients to the United States Attorney&#8217;s Office for the District of Massachusetts. It also requested the delivery of documents relating to our hospice clinical and business operations and related compliance activities. The Subpoena generally covered the period from January&#160;1, 2011 through May 21, 2015. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;3, 2015, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Morgantown, West Virginia area. The CID requested the delivery of information to the United States Attorney&#8217;s Office for the Northern District of West Virginia regarding 66 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Morgantown area. The CID generally covered the period from January&#160;1, 2009 through August&#160;31, 2015.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;27, 2016, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Parkersburg, West Virginia area. The CID requested the delivery of information to the United States Attorney&#8217;s Office for the Southern District of West Virginia regarding 68 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Parkersburg area. The CID generally covered the period from January&#160;1, 2011 through June&#160;20, 2016. </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third Party Audits &#8211; Ongoing</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, in the ordinary course of business, we are subject to audits under various governmental programs in which third party firms engaged by CMS, including Recovery Audit Contractors (&#8220;RACs&#8221;), Zone Program Integrity Contractors (&#8220;ZPICs&#8221;), Uniform Program Integrity Contractors (&#8220;UPICs&#8221;), Program Safeguard Contractors (&#8220;PSCs&#8221;), Medicaid Integrity Contractors (&#8220;MICs&#8221;), Supplemental Medical Review Contractors (&#8220;SMRCs&#8221;) and the Office of the Inspector General ("OIG"), conduct extensive reviews of claims data to identify potential improper payments. We cannot predict the ultimate outcome of any regulatory reviews or other governmental audits and investigations.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a ZPIC a request for records regarding a sample of 30 beneficiaries who received services from the subsidiary during the period of January&#160;1, 2008 through March&#160;31, 2010 (the &#8220;Review Period&#8221;) to determine whether the underlying services met pertinent Medicare payment requirements.&#160;We acquired the hospice operations subject to this review on August&#160;1, 2009; the Review Period covers time periods both before and after our ownership of these hospice operations.&#160;Based on the ZPIC&#8217;s findings for 16 beneficiaries, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June&#160;6, 2011, the Medicare Administrative Contractor ("MAC") for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment. We dispute these findings, and our Florence subsidiary has filed appeals through the Original Medicare Standard Appeals Process, in which we are seeking to have those findings overturned. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An administrative law judge ("ALJ") hearing was held in early January 2015. On January&#160;18, 2016, we received a letter dated January&#160;6, 2016 referencing the ALJ hearing decision for the overpayment issued on June&#160;6, 2011. The decision was partially favorable with a new overpayment amount of $3.7 million with a balance owed of $5.6 million including interest based on 9 disputed claims (originally 16). We filed an appeal to the Medicare Appeals Council on the remaining 9 disputed claims and also argued that the statistical method used to select the sample was not valid.&#160;No assurances can be given as to the timing or outcome of the Medicare Appeals Council decision. As of December 31, 2022, Medicare has withheld payments of $5.7 million (including additional interest) as part of their standard procedures once this level of the appeal process has been reached. In the event we are not able to recoup this alleged overpayment, we are entitled to be indemnified by the prior owners of the hospice operations for amounts relating to the period prior to August&#160;1, 2009. On January 10, 2019, an arbitration panel from the American Health Lawyers Association determined that the prior owners' liability for their indemnification obligation was $2.8 million. This amount is recorded as an indemnity receivable within other assets in our consolidated balance sheets.</span></div><div style="margin-top:5pt;padding-left:2.25pt;padding-right:11.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2016, the Company received a request for medical records from SafeGuard Services, L.L.C (&#8220;SafeGuard&#8221;), a ZPIC, related to services provided by some of the care centers that the Company acquired from Infinity Home Care, L.L.C. The review period covered time periods both before and after our ownership of the care centers, which were acquired on December 31, 2015. In August 2017, the Company received Requests for Repayment from Palmetto GBA, LLC (&#8220;Palmetto&#8221;) regarding Infinity Home Care of Lakeland, LLC, (&#8220;Lakeland Care Centers&#8221;) and Infinity Home Care of Pinellas, LLC, (&#8220;Clearwater Care Center&#8221;). The Palmetto letters were based on a statistical extrapolation performed by SafeGuard which alleged an overpayment of $34.0 million for the Lakeland Care Centers on a universe of 72 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate and an overpayment of $4.8 million for the Clearwater Care Center on a universe of 70 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate. </span></div><div style="margin-top:5pt;padding-left:2.25pt;padding-right:11.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lakeland Request for Repayment covered claims between January 2, 2014 and September 13, 2016. The Clearwater Request for Repayment covered claims between January 2, 2015 and December 9, 2016. As a result of partially successful Level I and Level II Administrative Appeals, the alleged overpayment for the Lakeland Care Centers was reduced to $26.0 million and the alleged overpayment for the Clearwater Care Center was reduced to $3.3 million. The Company filed Level III Administrative Appeals, and the ALJ hearings regarding the Lakeland Request for Repayment and the Clearwater Request for Repayment were held in April 2022.</span></div><div style="margin-top:10pt;padding-left:2.25pt;padding-right:11.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received the results of the ALJ hearings for the Clearwater Care Center and the Lakeland Care Centers on June 23, 2022 and June 30, 2022, respectively. The ALJ decisions for both the Clearwater Care Center and the Lakeland Care Centers were partially favorable for the claims that were reviewed, but the extrapolations were upheld. As a result, we increased our total accrual related to these matters from $17.4&#160;million to $25.8&#160;million during the three-month period ended June 30, 2022. The net of these two amounts, $8.4&#160;million, was recorded as a reduction to net service revenue in our consolidated statement of operations during the three-month period ended June 30, 2022. We received demands for repayment from Palmetto for both the Clearwater Care Center and the Lakeland Care Centers during the three-month period ended September 30, 2022. The demands were slightly less than our estimated accrual of $25.8&#160;million. During the three-month period ended September 30, 2022, we adjusted our accrual to $25.2&#160;million to reflect the final amounts owed, excluding interest. The repayment for the Lakeland Care Centers totaling $34.3&#160;million ($22.8&#160;million extrapolated repayment plus $11.5&#160;million accrued interest) was made during the three-month period ended September 30, 2022. The repayment for the Clearwater Care Center totaling $3.7&#160;million ($2.4&#160;million extrapolated repayment plus $1.2&#160;million accrued interest) was made during the three-month period ended December 31, 2022. Additionally, we wrote off $1.5&#160;million of receivables that were impacted by these matters. We expect to be indemnified by the prior owners, upon exhaustion of the parties' appeal rights, for approximately $10.9&#160;million and have recorded this amount within other assets in our consolidated balance sheets. </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Insurance</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated for certain costs associated with our insurance programs, including employee health, workers&#8217; compensation and professional liability. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs, up to specified deductible limits in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents details of our insurance programs, including amounts recorded, for the periods indicated within accrued expenses in our consolidated balance sheets. The amounts below represent our total estimated liability for individual </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">claims that are less than our noted insurance coverage amounts, which can include outstanding claims and claims incurred but not reported (amounts in millions).</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.035%"><tr><td style="width:1.0%"/><td style="width:67.164%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.196%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.941%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.199%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Type of Insurance</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health insurance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: long-term portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our health insurance has an exposure limit of $1.3 million for any individual covered life. Our workers compensation insurance has a retention limit of $2.0 million per incident, and our professional liability insurance has a retention limit of $0.3 million per incident. </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Severance</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have commitments related to our severance plans applicable to a number of our senior executives and senior management, which generally commit us to pay severance benefits under certain circumstances.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various other types of claims and disputes arising in the ordinary course of our business. While the resolution of such issues is not presently determinable, we believe that the ultimate resolution of such matters will not have a significant effect on our consolidated financial condition, results of operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675887727248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">EMPLOYEE BENEFIT PLANS</a></td>
<td class="text">EMPLOYEE BENEFIT PLANS<div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">401(k) Benefit Plan</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a plan qualified under Section 401(k) of the Internal Revenue Code for all employees who have reached 21 years of age, effective the first month after their hire date. Under the plan, eligible employees may elect to defer a portion of their compensation, subject to Internal Revenue Service limits.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our match of contributions to be made to each eligible employee contribution is $0.44 for every $1.00 contributed up to the first 6% of the employee's salary. The match is discretionary and thus is subject to change at the discretion of management. Our match of contributions is made in the form of cash. We expensed approximately $18.6 million, $17.0 million and $12.9 million related to our 401(k) benefit plan for 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Compensation Plan</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had a Deferred Compensation Plan for additional tax-deferred savings for a select group of management or highly compensated employees. Amounts credited under the Deferred Compensation Plan were funded into a rabbi trust, which is managed by a trustee. The trustee has the discretion to manage the assets of the Deferred Compensation Plan as deemed fit, thus, the assets are not necessarily reflective of the same investment choices that would have been made by the participants.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January&#160;1, 2015, all prospective salary deferrals ceased. Participants are allowed to make transactions with any remaining account balances as they wish per plan guidelines.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675895621248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE REPURCHASE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockTextBlock', window );">SHARE REPURCHASE</a></td>
<td class="text">SHARE REPURCHASES On December 23, 2020, we announced that our Board of Directors authorized a stock repurchase program, under which we could repurchase up to $100&#160;million of our outstanding common stock through December 31, 2021 (the "2021 Share Repurchase Program"). Pursuant to this program, we repurchased 446,832 shares of our common stock at a weighted average price of $223.49 per share and a total cost of approximately $100&#160;million during the year ended December 31, 2021. We did not repurchase any shares pursuant to this stock repurchase program during the year ended December 31, 2020. The repurchased shares were classified as treasury shares. The 2021 Share Repurchase Program expired on December 31, 2021.<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2021, our Board of Directors authorized a share repurchase program, under which we could repurchase up to $100&#160;million of our outstanding common stock through December 31, 2022 to commence upon the completion of the Company's 2021 Share Repurchase Program (the "New Share Repurchase Program"). Pursuant to this program, we repurchased 150,000 shares of our common stock at a weighted average price of $115.64 per share and a total cost of approximately $17&#160;million during the year ended December 31, 2022. The repurchased shares were classified as treasury shares. The New Share Repurchase Program expired on December 31, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2021 Share Repurchase Program and the New Share Repurchase Program, we were allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases were determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2023, our Board of Directors authorized a share repurchase program, under which we may repurchase up to $100&#160;million of our outstanding common stock through December 31, 2023 ("the 2023 Share Repurchase Program"). See Note 17 - Subsequent Events for additional information on the newly authorized share repurchase program.</span></div>Under the terms of the 2023 Share Repurchase Program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2208821<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675887714000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text">SEGMENT INFORMATION<div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations involve servicing patients through our four reportable business segments: home health, hospice, personal care and high acuity care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from an illness, injury or surgery. Our hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. Our personal care segment provides patients with assistance with the essential activities of daily living. Our high acuity care segment, which was established with the acquisition of Contessa on August 1, 2021, delivers the essential elements of inpatient hospital and SNF care to patients in their homes. The &#8220;other&#8221; column in the following tables consists of costs relating to executive management and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management evaluates performance and allocates resources based on the operating income of the reportable segments, which includes an allocation of corporate expenses attributable to the specific segment and includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company&#8217;s chief operating decision maker and therefore are not disclosed below (amounts in millions).</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.554%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home&#160;Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal&#160;Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,355.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">787.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,223.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">769.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,260.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses, excluding depreciation and amortization and impairment charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">348.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">754.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,121.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">632.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,042.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(39.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(175.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.554%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home&#160;Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal&#160;Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,353.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">791.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,214.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">756.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">425.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,233.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses, excluding depreciation and amortization and impairment charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">711.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,089.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,975.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">271.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(185.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">251.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.554%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home&#160;Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal&#160;Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,249.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">750.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,071.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">729.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,185.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses, excluding depreciation and amortization and impairment charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">307.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,044.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">579.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,886.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">225.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(195.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">219.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675802809904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">RELATED PARTY TRANSACTIONSWe have an investment in Medalogix, a healthcare predictive data and analytics company, which is accounted for under the equity method. During the years ended December 31, 2022, 2021 and 2020, we incurred costs of approximately $9.4&#160;million,$5.7&#160;million and $3.9 million, respectively, in connection with our usage of Medalogix's analytics platforms. We believe that the terms of these transactions are consistent with those negotiated at arm&#8217;s length.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675887678416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2023 Share Repurchase Program</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2023, our Board of Directors authorized a share repurchase program, under which we may repurchase up to $100&#160;million of our outstanding common stock through December&#160;31, 2023 (the "2023 Share Repurchase Program"). Under the terms of the 2023 Share Repurchase Program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. Effective January 1, 2023, repurchases are subject to a 1% excise tax under the Inflation Reduction Act.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets Held For Sale</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2023, we signed a definitive agreement to sell our personal care business (excluding the Florida operations). The divestment is expected to close during the second quarter of 2023. See Note 6 - Assets Held For Sale for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675806067136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the Company adopted Accounting Standards Update ("ASU") 2020-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which included minor technical corrections and clarifications to improve consistency and clarify the application of various provisions of the codification by amending the codification to include all disclosure guidance in the appropriate disclosure sections and by amending and adding new headings, cross referencing to other guidance and refining or correcting terminology. Our adoption of this standard did not have a material effect on our consolidated financial statements.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the Company adopted ASU 2021-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was intended to increase transparency around financial reporting regarding government assistance by requiring disclosure of information about (1) the types of government assistance received, (2) an entity's accounting for the government assistance received and (3) the effect of the assistance on an entity's financial statements. The ASU was effective for annual periods beginning after December 15, 2021, with early adoption permitted. See Note 3 &#8211; Novel Coronavirus Pandemic ("COVID-19") for the disclosures associated with this standard. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, the Company adopted ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provided guidance for measuring credit losses on financial instruments. Our adoption of this standard did not have a material effect on our consolidated financial statements. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, the Company adopted ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which eliminated certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating taxes during the interim periods and the recognition of deferred tax liabilities for outside basis differences. This guidance also simplified aspects of the accounting for franchise taxes, enacted changes in tax laws or rates and clarified the accounting for transactions that result in a step-up in the tax basis of goodwill. The guidance was effective for interim and annual periods beginning after December 15, 2020, with early adoption permitted. Our adoption of this standard on a prospective basis was not material to the Company&#8217;s consolidated financial statements.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Financial Accounting Standards Board ("FASB") issued ASU 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides optional expedients and exceptions for applying U.S. Generally Accepted Accounting Principles ("U.S. GAAP") to contract modifications and hedging relationships that reference the London Inter-Bank Offered Rate ("LIBOR") or another reference rate expected to be discontinued, subject to meeting certain criteria. In January 2021, the FASB issued ASU 2021-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Scope</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which adds implementation guidance to ASU 2020-04 to clarify certain optional expedients in Topic 848. The guidance in ASU 2020-04 and ASU 2021-01 was effective upon issuance and may generally be applied prospectively through December 31, 2022. In December 2022, the FASB issued ASU 2022-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848,</span> which deferred the sunset date of Topic 848 from December 31, 2022 to December 31, 2024. These standards did not have an effect on our consolidated financial statements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting and reporting policies conform with U.S. GAAP. In preparing the consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements include the accounts of Amedisys, Inc. and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying consolidated financial </span></div>statements, and business combinations accounted for as purchases have been included in our consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Investments</a></td>
<td class="text"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consolidate investments when the entity is a variable interest entity ("VIE") and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our consolidated financial statements. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold 50% or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary. The book value of investments that we account for under the equity method of accounting totaled $40.5 million and $48.1 million as of December&#160;31, 2022 and 2021, respectively, and is reflected in other assets within our consolidated balance sheets. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for investments in entities in which we have less than 20% ownership interest under the cost method of accounting if we do not have the ability to exercise significant influence over the investee. During 2022, we made a $15.0&#160;million investment in a home health benefit manager, which is accounted for under the cost method. During 2021, we made a $5.0&#160;million investment in ConnectRN, a workforce optimization company, which is accounted for under the cost method. The book value of investments that we account for under the cost method of accounting was $20.0&#160;million and $5.0&#160;million as of December 31, 2022 and 2021, respectively, and is reflected in other assets within our consolidated balance sheets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three-month period ended December 31, 2022, we sold a 49% interest in two of our home health care centers while maintaining a controlling interest in the newly formed joint venture. We are consolidating this joint venture. The total cash consideration received for the 49% noncontrolling interest was $1.9&#160;million. In connection with the transaction, we recorded an after-tax gain of $1.4&#160;million; this gain was recorded to additional paid-in capital within our consolidated balance sheet. During the three-month period ended September 30, 2022, we sold a 30% interest in two of our home health care centers while maintaining a controlling interest in the newly formed joint venture. We are consolidating this joint venture. The total cash consideration received for the 30% noncontrolling interest was $3.9&#160;million. In connection with the transaction, we recorded an after-tax gain of $2.9&#160;million; this gain was recorded to additional paid-in capital within our consolidated balance sheet.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, a third-party acquired a majority of the issued and outstanding membership interests of one of our equity method investments, Medalogix, for cash, with the remaining membership interests rolling over into a newly formed entity that includes Medalogix as well as another healthcare predictive data and analytics company. We rolled over 100% of our ownership interest in Medalogix to the newly formed entity, and in connection with this transaction, we recognized a $31.1&#160;million gain based on the purchase price of Medalogix, which is reflected in gain on equity method investments within our consolidated statements of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Contessa Health ("Contessa") on August 1, 2021, we obtained interests in several joint ventures with health system partners and a professional corporation that employs clinicians. Each of these entities meets the criteria to be classified as a VIE. As of December 31, 2022, we are consolidating all of our admitting joint ventures with health system partners as well as the professional corporation as we have concluded that we are the primary beneficiary of these VIEs. We have management agreements in place with each of these entities whereby we manage the entities and run the day-to-day operations. As such, we possess the power to direct the activities that most significantly impact the economic performance of the VIEs. The significant activities include, but are not limited to, negotiating provider and payor contracts, establishing patient care policies and protocols, making employment and compensation decisions, developing the operating and capital budgets, performing marketing activities and providing accounting support. We also have the obligation to absorb any expected losses and the right to receive benefits. Additionally, from time to time we may be required to provide joint venture funding. Our high acuity care segment also includes two non-admitting joint ventures with health system partners that are accounted for under the equity method of accounting. Operations of one of these joint ventures have ceased, and we are currently awaiting claims runout to complete financial reconciliations with our health plan partner; we recorded a $3.0&#160;million impairment charge related to our investment in this joint venture during the three-month period ended September 30, 2022.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the agreements with each VIE prohibit us from using the assets of the VIE to satisfy the obligations of other entities. The carrying amount of the VIEs&#8217; assets and liabilities included in our consolidated balance sheets are as follows (amounts in millions):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.669%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Patient accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Payroll and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we sold our investment in the Heritage Healthcare Innovation Fund, LP via a secondary transaction for $17.9&#160;million which resulted in a $3.0&#160;million loss which is reflected in gain (loss) on equity method investments within our consolidated statement of operations for the year ended December 31, 2020. The Company's original investment was made in 2010 and no longer fit within our strategic areas of focus. Proceeds from the sale were used to pay down debt and fund capital needs.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for revenue from contracts with customers in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. Our cost of obtaining contracts is not material. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligations relate to contracts with a duration of less than one year; therefore, we have elected to apply the optional exemption provided by ASC 606 and are not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third-party payors and others for services provided. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current industry conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. We assess our ability to collect for the healthcare services provided at the time of patient admission based on our verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represents approximately 74% of our consolidated net service revenue.  </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation based on our historical experience which primarily includes a historical collection rate of over 99% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by payor class as a percentage of total net service revenue is as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:59.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.855%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Home Health:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare - Episodic-based</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare - Non-episodic based</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Hospice:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">High Acuity Care (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Acquired Contessa Health on August 1, 2021.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home Health Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"). PDGM uses 30-day periods of care rather than 60-day episodes of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, we account for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed. Each 60-day episode includes two 30-day payment periods.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net service revenue is recorded based on the established Federal Medicare home health payment rate for a 30-day period of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#8217;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice" practical expedient, and therefore, our revenue recognition is based on the reimbursement we are entitled to for each 30-day period of care. We utilize our historical average length of stay for each 30-day period of care as the measure of progress towards the satisfaction of our performance obligation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables, including, but not limited to (a) an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#8220;LUPA&#8221;) if the number of visits provided was less than the established threshold, which ranges from two to six visits and varies for every case-mix group; (c)&#160;a partial payment if a patient transferred to another provider or from another provider before completing the 30-day period of care; and (d)&#160;the applicable geographic wage index. Payments for routine and non-routine supplies are included in the 30-day payment rate.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered to revenue with a corresponding reduction to patient accounts receivable. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during the novel coronavirus pandemic ("COVID-19"), CMS relaxed the definition of homebound status through the duration of the public health emergency. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their home because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19.  </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, 20% of the reimbursement from each Medicare 30-day payment period was billed near the start of each 30-day period of care, referred to as a request for anticipated payment ("RAP"), and cash was typically received before all services were rendered. Any cash received from Medicare for a RAP for a 30-day period of care that exceeded the associated revenue earned was recorded to accrued expenses within our consolidated balance sheets. CMS fully eliminated all upfront payments associated with RAPs effective January 1, 2021. Effective January 1, 2022, CMS implemented a new one-time Notice of Admission ("NOA") process. The NOA process requires a one-time submission that establishes the home health period of care and covers all contiguous 30-day periods of care until the patient is discharged from Medicare home health services. If the NOA is not submitted timely, a payment reduction will be applied equal to 1/30 of the payment amount for each day from the home health start of care date until the date the NOA is submitted.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments from non-Medicare payors are either a percentage of Medicare rates, per-visit rates or case rates depending upon the terms and conditions established with such payors. Approximately 30% of our managed care contract volume affords us the opportunity to receive additional payments if we achieve certain quality or process metrics as defined in each contract (e.g. star ratings and acute-care hospitalization rates).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Episodic-based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms, the majority of which range from 95% to 100% of Medicare rates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-episodic based Revenue. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our per visit contracts, gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. For our case rate contracts, gross revenue is recorded over our historical average length of stay using the established case rate for each admission. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on our historical experience to reflect the estimated transaction </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our case rate contracts, we may receive reimbursement before all services are rendered. Any cash received that exceeds the associated revenue earned is recorded to deferred revenue in accrued expenses within our consolidated balance sheets.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospice Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Medicare Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for 97% of our total Medicare hospice service revenue for each of 2022, 2021 and 2020, respectively. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#8220;SIA&#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record it during the period services are rendered. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our consolidated balance sheets. Providers are required to self-report and pay their estimated cap liability by February 28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the following year. As of December&#160;31, 2022, we have recorded $4.3 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2023. As of December&#160;31, 2021, we had recorded $4.5 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2022.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Non-Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third-party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on our historical experience to reflect the estimated transaction price.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Personal Care Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Personal Care Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points ("ASAPs"), Senior Care Options ("SCOs"), Program of All-Inclusive Care for the Elderly ("PACE") and the Veterans Administration ("VA"). </span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">High Acuity Care Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">High Acuity Care Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues are derived from contracts with (1) health insurance plans for the coordination and provision of home recovery care services to clinically-eligible patients who are enrolled members in those insurance plans, (2) health system partners for the coordination and provision of home recovery care services to clinically-eligible patients who are discharged early from a health system facility to complete their inpatient stay at home and (3) Medicare and other payors for the provision of home health services. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our health insurance plan contracts, we provide home recovery care services, which include hospital-equivalent ("H@H") and skilled nursing facility ("SNF") equivalent services ("SNF@H"), for high acuity care patients on a full risk basis whereby we assume the financial risk for the coordination and payment of all hospital or SNF replacement medical services necessary to treat the medical condition for which the patient was diagnosed in a home-based setting for a 30-day (H@H) or 60-day (SNF@H) episode of care in exchange for a fixed contracted bundled rate. For H@H programs, the fixed rate is based on the assigned diagnosis related group ("DRG") and the 30-day post-discharge related spend. For SNF@H programs, the fixed rate is based on the 60-day post-discharge related spend. Our performance obligation is the coordination and provision of patient care in accordance with physicians&#8217; orders over either a 30-day or 60-day episode of care. The majority of our care coordination services and direct patient care is provided in the first five to seven days of the episode period (the "acute phase"). Monitoring services and follow-up direct patient care, as deemed necessary by the treating physician, are provided throughout the remainder of the episode. Since the majority of our services are provided during the acute phase, we recognize net service revenues over the acute phase based on gross charges for the services provided per the applicable managed care contract rates, reduced by estimates for revenue adjustments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our contracts with health system partners, we provide home recovery care services for high acuity patients on a limited risk basis whereby we assume the risk for certain healthcare services during the remainder of an inpatient acute stay serviced at the patient&#8217;s home in exchange for a contracted per diem rate. The performance obligation is the coordination and provision of required medical services, as determined by the treating physician, for each day the patient receives inpatient-equivalent care at home. As such, revenues are recognized as services are administered and as our performance obligations are satisfied on a per diem basis, reduced by estimates for revenue adjustments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize adjustments to revenue during the period in which changes to estimates of assigned patient diagnoses or episode terminations become known, in accordance with the applicable managed care contracts. For certain health insurance plans, revenue is reduced by amounts owed by enrollees to healthcare providers under deductible, coinsurance or copay provisions of health insurance plan policies, since those amounts are repaid to the health insurance plans by us as part of a retrospective reconciliation process.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, our high acuity care segment entered into a transaction in which one of our health system partners contributed its home health operations to one of our existing high acuity care joint ventures. We recognize Medicare and non-Medicare revenue in a manner that is consistent with our home health segment revenue recognition policy described above.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_GovernmentGrantsPolicyTextBlock', window );">Government Grants</a></td>
<td class="text"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Grants</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for government grants in accordance with ASU 2021-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance (Topic 832), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by applying the grant model in accordance with International Accounting Standard ("IAS") 20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Government Grants and Disclosure of Government Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and as such, we recognize grant income on a systematic basis in line with the recognition of expenses or the loss of revenues for which the grants are intended to compensate. We recognize grants once both of the following conditions are met: (1) we are able to comply with the relevant conditions of the grant and (2) the grant will be received. See Note 3 &#8211; Novel Coronavirus Pandemic ("COVID-19") for additional information on our accounting for government funds received under the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") and the Mass Home Care ASAP COVID-19 Provider Sustainability Program.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text">Cash, Cash Equivalents and Restricted CashCash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased. Restricted cash includes cash that is not available for ordinary business use.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Patient Accounts Receivable</a></td>
<td class="text"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patient Accounts Receivable</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. Our non-Medicare third-party payor base is comprised of a diverse group of payors that are geographically dispersed across the country. As of December&#160;31, 2022, there is no single payor, other than Medicare, that accounts for more than 10% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectability risk associated with our Medicare accounts, which represented 67% and 68% of our net patient accounts receivable at December&#160;31, 2022 and 2021, respectively, is limited due to our historical collection rate of over 99% from Medicare and the fact that Medicare is a U.S. government payor. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Home Health</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our home health patients (within both our home health and high acuity care segments), our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare following the end of each 30-day period of care or upon discharge, if earlier, for the services provided to the patient.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Hospice</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Medicare Home Health, Hospice, Personal Care and High Acuity Care</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#8217;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets or life of the lease, if shorter. Additionally, we have internally developed computer software for our own use. Additions and improvements (including interest costs for construction of qualifying long-lived assets) are capitalized. Maintenance and repair expenses are charged to expense as incurred. The cost of property and equipment sold or disposed of and the related accumulated depreciation are eliminated from the property and equipment and related accumulated depreciation accounts, and any gain or loss is credited or charged to other general and administrative expenses.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the impairment of a long-lived asset group whenever events or changes in circumstances indicate that the asset&#8217;s carrying value may not be recoverable. Factors we consider important that could trigger an impairment review include but are not limited to the following:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A significant change in the extent or manner in which the long-lived asset group is being used.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A significant change in the business climate that could affect the value of the long-lived asset group.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A significant change in the market value of the assets included in the asset group.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we determine that the carrying value of long-lived assets may not be recoverable, we compare the carrying value of the asset group to the undiscounted cash flows expected to be generated by the asset group. If the carrying value exceeds the undiscounted cash flows, an impairment charge is indicated. An impairment charge is recognized to the extent that the carrying value of the asset group exceeds its fair value.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally provide for depreciation over the following estimated useful service lives.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.753%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.047%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser&#160;of&#160;lease term&#160;or&#160;expected&#160;useful&#160;life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment and furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 7</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 7</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balances related to our property and equipment for 2022 and 2021 (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment and furniture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for 2022, 2021 and 2020 was $11.5 million, $12.1 million and $12.1 million, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Acquisitions are accounted for as purchases and are included in our consolidated financial statements from their respective acquisition dates. Assets acquired, liabilities assumed and noncontrolling interests, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets. In determining the fair value of identifiable intangible assets and any noncontrolling interests, we use various valuation techniques including the income approach, the cost approach and the market approach. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, growth rates and discount rates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill and Other Intangible Assets</a></td>
<td class="text"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Other Intangible Assets</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had a goodwill balance of $1,287.4&#160;million. Goodwill represents the amount of the purchase price in excess of the fair values assigned to the underlying identifiable net assets of acquired businesses. Goodwill is not amortized, but is subject to an annual impairment test. Tests are performed more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount. These events or circumstances include, but are not limited to, a significant adverse change in the business environment, regulatory environment or legal factors, or a substantial decline in the market capitalization of our stock. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of our operating segments described in Note 15 &#8211; Segment Information is considered to represent an individual reporting unit for goodwill impairment testing purposes. We consider each of our home health care centers to constitute an individual business for which discrete financial information is available. However, since these care centers have substantially similar operating and economic characteristics and resource allocations and since significant investment decisions concerning these businesses are centralized and the benefits broadly distributed, we have aggregated these care centers and deemed them to constitute a single reporting unit. We have applied this same aggregation principle to our hospice and personal-care care centers and high acuity care joint ventures and have also deemed each of them to be a single reporting unit.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, we performed a qualitative assessment to determine if it is more likely than not that the fair value of our reporting units are less than their carrying values by evaluating relevant events and circumstances including financial performance, market conditions and share price. Based on this assessment, we concluded that the goodwill associated with our home health, hospice and high acuity care reporting units was not considered at risk of impairment as of October&#160;31, 2022. In addition to the qualitative assessment, we also performed a quantitative analysis for our personal care reporting unit due to the decline in revenues resulting from staffing shortages using an income and market approach. Based on this analysis, we concluded that the goodwill associated with our personal care reporting unit was not considered at risk of impairment as of October 31, 2022. Since the date of our last goodwill impairment analysis, there have been no material developments, events, changes in operating performance or other circumstances that would cause management to believe it is more likely than not that the fair value of any of our reporting units would be less than their carrying amounts.</span></div>As of December 31, 2022, we had an other intangibles assets balance of $101.2&#160;million. Intangible assets consist of certificates of need, licenses, acquired names, non-compete agreements and technology. We amortize non-compete agreements and acquired names that we do not intend to use indefinitely on a straight-line basis over their estimated useful lives, which are generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjg1OTA_1486623a-649a-4c91-b48e-f23d489bb99f">two</span> to three years for non-compete agreements and up to three years for acquired names. We amortize technology over its estimated useful service life, which is generally up to seven years. Our indefinite-lived intangible assets are reviewed for impairment annually or more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the intangible asset below its carrying amount. We performed a qualitative assessment of our indefinite-lived intangible assets during 2022 and determined that there have been no material developments, events, changes in operating performance or other circumstances that would cause management to believe it is more likely than not that the fair value of any of our indefinite-lived intangible assets would be less than their carrying amounts.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DebtIssuanceCostsPolicyPolicyTextBlock', window );">Debt Issuance Costs</a></td>
<td class="text">Debt Issuance CostsDuring 2021, we recorded $2.8&#160;million in deferred debt issuance costs as a reduction to long-term obligations, less current portion in our consolidated balance sheet in connection with our entry into the Second Amended Credit Agreement (See Note 9 - Long-Term Obligations). As of December&#160;31, 2022 and 2021, we had unamortized debt issuance costs of $3.5 million and $4.5 million, respectively, recorded as a reduction to long-term obligations, less current portion in our accompanying consolidated balance sheets. We amortize deferred debt issuance costs related to our long-term obligations over the term of the obligation through interest expense, unless the debt is extinguished, in which case unamortized balances are immediately expensed.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</span></div><div style="margin-bottom:9pt;margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"/><td style="width:24.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Financial Instrument</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value as of<br/>December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Items<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1 &#8211; Quoted prices in active markets for identical assets and liabilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2 &#8211; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3 &#8211; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.</span></div>Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the asset and liability approach for measuring deferred tax assets and liabilities based on temporary differences existing at each balance sheet date using currently enacted tax rates. Our deferred tax calculation requires us to make certain estimates about future operations. Deferred tax assets are reduced by a valuation allowance when we believe it is more likely than not that some portion or all of the deferred tax assets will not be realized. The effect of a change in tax rate is recognized as income or expense in the period that includes the enactment date. As of December&#160;31, 2022, we had net deferred tax liabilities of $20.4 million. As of December 31, 2021, we had net deferred tax assets of $0.3 million. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management regularly assesses the ability to realize deferred tax assets recorded in the Company&#8217;s entities based upon the weight of available evidence, including such factors as the recent earnings history and expected future taxable income. In the event future taxable income is below management&#8217;s estimates or is generated in tax jurisdictions different than projected, we could be required to increase the valuation allowance for deferred tax assets. This would result in an increase in our effective tax rate.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based CompensationWe record all share-based compensation as expense in the financial statements measured at the fair value of the award. We recognize compensation cost on a straight-line basis over the requisite service period for each separately vesting portion of the award.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Weighted-Average Shares Outstanding</a></td>
<td class="text">Weighted-Average Shares Outstanding.Net income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text">Advertising CostsWe expense advertising costs as incurred.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtIssuanceCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtIssuanceCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_GovernmentGrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting policy disclosure text block for government grants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_GovernmentGrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675895621248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock', window );">Schedule of Variable Interest Entities</a></td>
<td class="text">The carrying amount of the VIEs&#8217; assets and liabilities included in our consolidated balance sheets are as follows (amounts in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.669%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Patient accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Payroll and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5747-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6228884-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfVariableInterestEntitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675797122624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock', window );">Schedule of Revenue by Payor Class</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by payor class as a percentage of total net service revenue is as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"><tr><td style="width:1.0%"/><td style="width:59.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.522%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.855%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Home Health:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare - Episodic-based</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare - Non-episodic based</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Hospice:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">High Acuity Care (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Acquired Contessa Health on August 1, 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock', window );">Schedule of Cash Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):</span></div><div style="margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock', window );">Schedule of Estimated Useful Lives of Property and Equipment</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally provide for depreciation over the following estimated useful service lives.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.753%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.047%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser&#160;of&#160;lease term&#160;or&#160;expected&#160;useful&#160;life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment and furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 7</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 7</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balances related to our property and equipment for 2022 and 2021 (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment and furniture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_FinancialInstrumentDetailsTableTextBlock', window );">Schedule of Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</span></div><div style="margin-bottom:9pt;margin-top:14pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"/><td style="width:24.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Financial Instrument</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value as of<br/>December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Items<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of Weighted-Average Shares Outstanding</a></td>
<td class="text">The following table sets forth, for the periods indicated, shares used in our computation of weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:56.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding &#8211; basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,517&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,642&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,559&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested stock and stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding &#8211; diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,653&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,972&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>stimated Useful Lives Of Property And Equipment, table</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FinancialInstrumentDetailsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Instrument Details, table</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FinancialInstrumentDetailsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Cash Cash Equivalents and Restricted Cash Table Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of patient service revenue (net of contractual allowances and discounts), by major payor source of revenue for health care organizations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675887714000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOVEL CORONAVIRUS PANDEMIC ("COVID-19") (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtraordinaryAndUnusualItemsAbstract', window );"><strong>Unusual or Infrequent Items, or Both [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock', window );">Schedule Of Cares Act Provider Relief Funds</a></td>
<td class="text">In summary, the total funds that we received from the CARES Act PRF were accounted for as follows (amounts in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"><tr><td style="width:1.0%"/><td style="width:74.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.186%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds utilized through June 30, 2021 by consolidated entities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds repaid to the government by consolidated entities (excludes $0.2 million of interest repaid)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds utilized through June 30, 2021 by unconsolidated joint ventures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds repaid to the government by unconsolidated joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Cares Act Provider Relief Funds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtraordinaryAndUnusualItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtraordinaryAndUnusualItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675803039600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ScheduleOfBusinessAcquisitionsContessaHealthTableTextBlock', window );">Schedule of Business Acquisitions, Contessa Health</a></td>
<td class="text">The total consideration of $241.3&#160;million has been allocated to assets acquired, liabilities assumed and noncontrolling interests as of the acquisition date as follows (amounts in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"/><td style="width:74.037%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities assumed</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and equity assumed</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net identifiable assets acquired</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock', window );">Schedule of Business Acquisitions, Evolution Health</a></td>
<td class="text">Based on the Company's preliminary valuation, which may be revised as additional information becomes available during the measurement period, the total consideration of $66.5&#160;million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"/><td style="width:74.037%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets (licenses)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities assumed</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net identifiable assets acquired</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ScheduleOfBusinessAcquisitionsContessaHealthTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Business Acquisitions, Contessa Health</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ScheduleOfBusinessAcquisitionsContessaHealthTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Business Acquisitions, Evolution Health</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675802982256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Summary of Activity Related to Goodwill and Other Intangible Assets Net</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to our goodwill for 2022 and 2021 (amounts in millions):</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Goodwill</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home&#160;Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal&#160;Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High  Acuity Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2020 (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">799.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">932.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">233.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">263.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">800.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">233.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,196.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">800.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,287.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Net of prior years' accumulated impairment losses of $733.7 million, which is inclusive of write-offs related to the sale and closure of care centers.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Company finalized its valuation of the assets acquired, liabilities assumed and noncontrolling interests in connection with the acquisition of Contessa on August 1, 2021. See Note 4 &#8211; Acquisitions for additional information.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Intangible Assets, Net</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022 and 2021, we did not record any impairment charges related to our other intangible assets.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to our other intangible assets, net for 2022 and 2021 (amounts in millions):</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.606%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Intangible Assets, Net</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Certificates of Need and Licenses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired<br/>Names -Unamortizable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquired<br/>Names -Amortizable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-Compete<br/>Agreements (3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Technology (3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2020 (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclass to amortizable intangible</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances at December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Net of prior years' accumulated amortization of $11.5&#160;million for acquired names and $9.0 million for non-compete agreements. </span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Amortization of certificates of need and licenses is related to care centers that were closed during 2021 and 2022.</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The weighted average remaining amortization period of our amortizable non-compete agreements and technology is 0.6 years and 5.6 years, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Estimated Aggregate Future Amortization Expense</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated aggregate amortization expense related to intangible assets for each of the five succeeding years is as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.356%"><tr><td style="width:1.0%"/><td style="width:72.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.255%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intangible Asset Amortization</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 4 &#8211; Acquisitions for further details on additions to goodwill and other intangible assets, net.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675887733888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSETS HELD FOR SALE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract', window );"><strong>Discontinued Operation, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of Carrying Amount of Assets and Liabilities for Disposal Group</a></td>
<td class="text">The carrying amount of the assets and liabilities associated with our personal care reporting unit (which approximate fair value) included in our consolidated balance sheets are as follows (amounts in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.725%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.696%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675797082960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DetailsOfCertainBalanceSheetAccountsAbstract', window );"><strong>Details Of Certain Balance Sheet Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Other Current Assets</a></td>
<td class="text"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information regarding certain balance sheet accounts is presented below (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payroll tax escrow</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due from joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Workers&#8217; compensation deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Health insurance deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other miscellaneous deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indemnity receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Health insurance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Florida ZPIC audit, gross liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Legal settlements and other audits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charity care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated Medicare cap liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hospice accruals (room and board, general in-patient and other)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patient and payor liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term obligations:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reserve for uncertain tax positions</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock', window );">Schedule of Other Assets</a></td>
<td class="text"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information regarding certain balance sheet accounts is presented below (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payroll tax escrow</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due from joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Workers&#8217; compensation deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Health insurance deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other miscellaneous deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indemnity receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Health insurance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Florida ZPIC audit, gross liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Legal settlements and other audits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charity care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated Medicare cap liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hospice accruals (room and board, general in-patient and other)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patient and payor liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term obligations:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reserve for uncertain tax positions</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information regarding certain balance sheet accounts is presented below (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payroll tax escrow</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due from joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Workers&#8217; compensation deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Health insurance deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other miscellaneous deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indemnity receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Health insurance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Florida ZPIC audit, gross liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Legal settlements and other audits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charity care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated Medicare cap liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hospice accruals (room and board, general in-patient and other)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patient and payor liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term obligations:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reserve for uncertain tax positions</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock', window );">Schedule of Other Long-Term Obligations</a></td>
<td class="text"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information regarding certain balance sheet accounts is presented below (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payroll tax escrow</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due from joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Workers&#8217; compensation deposits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Health insurance deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other miscellaneous deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indemnity receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Health insurance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Florida ZPIC audit, gross liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Legal settlements and other audits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Charity care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated Medicare cap liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hospice accruals (room and board, general in-patient and other)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patient and payor liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term obligations:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reserve for uncertain tax positions</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DetailsOfCertainBalanceSheetAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DetailsOfCertainBalanceSheetAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675802157312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Cost</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost for the years ended December 31, 2022 and 2021 are as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:56.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.793%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.794%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of operating lease ROU assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease cost</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on termination</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of ROU assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease cost</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_OperatingLeasesTableTextBlock', window );">Schedule of Operating Leases</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reported in the consolidated balance sheets as of December 31, 2022 and 2021 for our operating leases are as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:56.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.793%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.794%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, less current portion</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_FinanceLeasesTableTextBlock', window );">Schedule of Finance Leases</a></td>
<td class="text">Amounts reported in the consolidated balance sheets as of December 31, 2022 and 2021 for finance leases are included in the table below. The finance lease ROU assets are recorded within property and equipment, net of accumulated depreciation within our consolidated balance sheets. The finance lease liabilities are recorded within current portion of long-term obligations and long-term obligations, less current portion within our consolidated balance sheets.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:56.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.793%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.794%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease ROU assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease ROU assets, net</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current installments of obligations under finance leases</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzYtMS0xLTEtNTA3MjU_1eca02a9-f1dd-4c12-b3b8-0c54b6fd691a">1.2</span>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzYtMy0xLTEtNTA3MjU_8d1038d1-419b-4128-8314-0aa1a5467841">0.9</span>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of obligations under finance leases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzctMS0xLTEtNTA3MjU_a814e167-8383-4d45-81ca-86cc22f5c011">1.1</span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzctMy0xLTEtNTA3MjU_89a632c7-217b-411e-a52c-c18cee261893">0.7</span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzgtMS0xLTEtNTA3MjU_12d2aa00-0042-4307-aa11-8f39561b8e9d">2.3</span>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzgtMy0xLTEtNTA3MjU_15a6bc06-843b-4c48-b58a-8be83b9c35ba">1.6</span>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock', window );">Schedule of Supplemental CashFlow Information and NonCash Activity for Leases</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information and non-cash activity related to our leases are as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:56.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.793%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.794%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities and ROU assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flow from operating leases</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flow from finance leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions to ROU assets resulting from reductions to lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock', window );">Schedule of Weighted Average Remaining Lease Term and Discount Rate</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease terms and discount rates for our leases as of December 31, 2022 and 2021 are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:56.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.793%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.794%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (years):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_LeaseLiabilityMaturityTableTextBlock', window );">Schedule of Lease Liability Maturity</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December 31, 2022 are as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"><tr><td style="width:1.0%"/><td style="width:64.154%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.850%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating <br/>Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance <br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzktMy0xLTEtNTA3MjU_99acfacd-090d-4833-8cd5-0990e12d974a">2.3</span>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FinanceLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance leases Table Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FinanceLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Liability Maturity Table Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_OperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating leases Table Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_OperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental CashFlow Information and NonCash Activity for Leases Table Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term and discount rate Table Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675803026704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-Term Debt</a></td>
<td class="text"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consists of the following for the periods indicated (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$450.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (5.9% at December 31, 2022); due July&#160;30, 2026</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate; due July&#160;30, 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Promissory notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">445.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations, less current portion</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-Term Debt</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of debt as of December&#160;31, 2022 are as follows (amounts in millions):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.783%"><tr><td style="width:1.0%"/><td style="width:72.219%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.581%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term<br/>obligations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock', window );">Schedule of Commitment Fee Under Credit Facilities</a></td>
<td class="text">The &#8220;Applicable Rate&#8221; is based on the consolidated leverage ratio and is presented in the table below. As of December&#160;31, 2022, the Applicable Rate is 0.50% per annum for Base Rate Loans and 1.50% per annum for Eurodollar Rate Loans. Our Second Amended Credit Agreement provides for the replacement of LIBOR with the daily or term secured overnight financing rate ("SOFR") whenever LIBOR is discontinued. We are also subject to a commitment fee and letter of credit fee under the terms of the Second Amended Credit Agreement, as presented in the table below.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.578%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pricing Tier</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Leverage Ratio</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Base Rate Loans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eurodollar Rate Loans and Daily Floating LIBOR Rate Loans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commitment<br/>Fee</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Letter&#160;of<br/>Credit&#160;Fee</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">I</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&gt;  3.00 to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">II</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> 3.00 to 1.0 but &gt;&#160;2.00 to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">III</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> 2.00 to 1.0 but &gt;&#160;0.75 to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IV</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  0.75 to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675805995840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ProvisionforIncomeTaxesTableTextBlock', window );">Schedule of Income Tax Provision</a></td>
<td class="text"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes attributable to continuing operations consist of the following (amounts in millions):</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:56.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income tax expense/(benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax expense/(benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total income tax expense for the years ended December&#160;31, 2022, 2021 and 2020 was allocated as follows (amounts in millions):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:56.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax expense recorded to additional paid-in-capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Sources of Tax Effects</a></td>
<td class="text"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of significant differences between the reported amount of income tax expense and the expected amount of income tax expense that would result from applying the U.S. federal statutory income tax rate of 21% to income before income taxes is as follows:</span></div><div style="margin-bottom:6pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:56.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense at U.S. federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local income taxes, net of federal income tax benefit (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess tax benefits from share-based compensation (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible executive compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items, net (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">On August 10, 2020, Paul B. Kusserow, Chief Executive Officer and Chairman of the Board of Amedisys, exercised 500,000 stock options previously awarded to him under our 2008 Omnibus Incentive Compensation Plan. We recognize compensation expense for stock option awards on a straight-line basis over the requisite service period for each separately vesting portion of the award in accordance with ASC 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Compensation: Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">; however, the income tax deduction related to stock options is not recognized until the stock option exercise date. As a result, for awards that are expected to result in a tax deduction, a deferred tax asset is created as the entity recognizes compensation expense for U.S. GAAP purposes. If the tax deduction exceeds the cumulative U.S. GAAP compensation expense for the award, the tax benefit associated with any excess deduction is recognized as an income tax benefit in the statement of operations, resulting in a reduction of the effective tax rate. Mr. Kusserow's stock option exercise produced a $92.1&#160;million tax deduction in excess of U.S. GAAP compensation expense, resulting in a $19.4&#160;million federal income tax benefit and a $4.6&#160;million state and local income tax benefit for the year ended December 31, 2020.</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">For the year ended December 31, 2022, the Company recognized $2.7&#160;million of federal uncertain tax positions due to a lapse of the statute of limitations.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Includes various items such as non-deductible expenses, non-taxable income, tax credits, valuation allowance, uncertain tax positions and return-to-accrual adjustments.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Net Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets (liabilities) consist of the following components (amounts in millions):</span></div><div style="margin-bottom:9pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll&#160;&amp; employee benefits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal &amp; compliance matters</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred social security taxes (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in partnerships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)The CARES Act provided for the deferral of the employer share of social security tax (6.2%), effective for payments due after the enactment date through December 31, 2020. Fifty percent of the deferred payroll taxes were due on December 31, 2021 with the remaining amounts due on December 31, 2022. As of December 31, 2021, the Company had a remaining balance of deferred social security taxes of $27&#160;million, reflected within our consolidated balance sheets, which was paid in December 2022. For income tax purposes, the deferred social security taxes are deductible when paid, leaving no remaining deferred tax asset as of December 31, 2022.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Uncertain Tax Positions</a></td>
<td class="text">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (amounts in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:56.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions for tax positions related to current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions for tax positions related to prior year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reductions for tax positions related to prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProvisionforIncomeTaxesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provision for Income Taxes Table</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProvisionforIncomeTaxesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675797405616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK AND SHARE-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock', window );">Schedule of Employee Stock Purchase Plan Activity</a></td>
<td class="text">The following is a detail of the purchases that have been made under the plan:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employee Stock Purchase Plan Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares&#160;Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 and Prior</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,171,373&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January&#160;1, 2021 to March&#160;31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April&#160;1, 2021 to June&#160;30, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July&#160;1, 2021 to September&#160;30, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October&#160;1, 2021 to December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January&#160;1, 2022 to March&#160;31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April&#160;1, 2022 to June&#160;30, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July&#160;1, 2022 to September&#160;30, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October&#160;1, 2022 to December&#160;31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,235,698&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award Valuation Assumptions</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the stock option awards were estimated using the following assumptions for 2022, 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk Free Rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.91% </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.80% - 1.35%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.38% - 1.51%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected Volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.97% </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.84% - 41.40%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.15% - 42.80%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected Term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.25 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.25 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.25 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Fair Value</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$61.31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$107.45</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$86.72</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend Yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Options Activity</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our stock option activity for 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:54.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.297%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average&#160;Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average&#160;Contractual<br/>Life&#160;(Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding options at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">273,973&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.21</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(37,635)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled, forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(51,382)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding options at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218,612&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142.86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.56</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercisable options at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163,286&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.54&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.04</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_SharedBasedPaymentArrangementNonVestedOptionActivityTableTextBlock', window );">Shared-based Payment Arrangement, Non-vested Option, Activity</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our non-vested stock option activity for 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;Average<br/>Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock options at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129,439&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182.45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(64,496)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43,273)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock options at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,326&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.81&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Non-Vested Stock Unit Activity</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our service-based non-vested stock units activity for 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of&#160;<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;Average<br/>Grant Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock units at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180,823&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">211,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(59,006)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled, forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(70,025)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock units at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">263,153&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141.62&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock', window );">Schedule of Non-Vested Performance-based Units Activity</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our performance-based non-vested stock units activity for 2022:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of&#160;<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;Average<br/>Grant Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock units at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186,951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">206.36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(85,767)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156.18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled, forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(104,486)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-vested stock units at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,047&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.55&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_SharedBasedPaymentArrangementNonVestedOptionActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for non-vested stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, vestings, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_SharedBasedPaymentArrangementNonVestedOptionActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested performance-based units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of employee stock purchase plan activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675803057776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_InsuranceProgramsTableTableTextBlock', window );">Schedule of Insurance Programs</a></td>
<td class="text">The following table presents details of our insurance programs, including amounts recorded, for the periods indicated within accrued expenses in our consolidated balance sheets. The amounts below represent our total estimated liability for individual <div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">claims that are less than our noted insurance coverage amounts, which can include outstanding claims and claims incurred but not reported (amounts in millions).</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.035%"><tr><td style="width:1.0%"/><td style="width:67.164%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.196%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.941%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.199%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Type of Insurance</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health insurance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: long-term portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_InsuranceProgramsTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Insurance Programs Details, Table</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_InsuranceProgramsTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675801487520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Operating Income of Reportable Segments</a></td>
<td class="text"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management evaluates performance and allocates resources based on the operating income of the reportable segments, which includes an allocation of corporate expenses attributable to the specific segment and includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company&#8217;s chief operating decision maker and therefore are not disclosed below (amounts in millions).</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.554%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home&#160;Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal&#160;Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,355.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">787.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,223.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">769.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,260.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses, excluding depreciation and amortization and impairment charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">348.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">754.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,121.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">632.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,042.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(39.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(175.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.554%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home&#160;Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal&#160;Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,353.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">791.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,214.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">756.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">425.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,233.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses, excluding depreciation and amortization and impairment charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">711.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,089.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,975.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">271.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(185.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">251.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.554%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home&#160;Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal&#160;Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,249.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">750.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,071.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">729.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,185.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses, excluding depreciation and amortization and impairment charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">307.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,044.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">579.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,886.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">225.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(195.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">219.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675795264064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>care_center </div>
<div>numberOfJointVentures </div>
<div>state</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>care_center </div>
<div>numberOfJointVentures </div>
<div>state</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of states with facilities | state</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_MinimumPercentOwnershipForControllingInterestPercent', window );">Minimum percent ownership for controlling interest (percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_MaximumPercentOwnershipForEquityMethodPercent', window );">Maximum ownership percentage for equity method investment (percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity method investments</a></td>
<td class="nump">$ 40,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,500<span></span>
</td>
<td class="nump">$ 48,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_MaximumPercentOwnershipForCostMethodPercent', window );">Maximum ownership percentage for cost method investment (percent)</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtCost', window );">Cost method investments</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 17,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">40,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,540<span></span>
</td>
<td class="nump">42,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Patient accounts receivable</a></td>
<td class="nump">296,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">296,785<span></span>
</td>
<td class="nump">274,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">26,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,415<span></span>
</td>
<td class="nump">25,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">388,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">388,961<span></span>
</td>
<td class="nump">356,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment</a></td>
<td class="nump">16,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,026<span></span>
</td>
<td class="nump">18,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">102,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,856<span></span>
</td>
<td class="nump">101,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,287,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,287,399<span></span>
</td>
<td class="nump">1,196,090<span></span>
</td>
<td class="nump">932,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets</a></td>
<td class="nump">101,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,167<span></span>
</td>
<td class="nump">111,190<span></span>
</td>
<td class="nump">74,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">79,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,836<span></span>
</td>
<td class="nump">73,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,976,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,976,245<span></span>
</td>
<td class="nump">1,856,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">43,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,735<span></span>
</td>
<td class="nump">38,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee benefits</a></td>
<td class="nump">125,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,387<span></span>
</td>
<td class="nump">141,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">137,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,390<span></span>
</td>
<td class="nump">150,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current portion of long-term obligations</a></td>
<td class="nump">15,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,496<span></span>
</td>
<td class="nump">12,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">355,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355,529<span></span>
</td>
<td class="nump">374,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term obligations</a></td>
<td class="nump">4,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,808<span></span>
</td>
<td class="nump">4,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">33,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,521<span></span>
</td>
<td class="nump">31,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">869,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">869,672<span></span>
</td>
<td class="nump">880,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Proceeds from sale of noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,817<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain (Loss) on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,098<span></span>
</td>
<td class="num">(2,980)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,009<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 4,152<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_TypeOfEquityMethodInvestmentAxis=amed_A30InterestSoldInTwoCareCentersMember', window );">30% Interest Sold in Two Care Centers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Proceeds from sale of noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_GainRelatedToSaleOfNoncontrollingInterestNetOfTax', window );">Gain Related To Sale Of Noncontrolling Interest Net Of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_TypeOfEquityMethodInvestmentAxis=amed_A49InterestSoldInTwoCareCentersMember', window );">49% Interest Sold in Two Care Centers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Proceeds from sale of noncontrolling interest</a></td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_GainRelatedToSaleOfNoncontrollingInterestNetOfTax', window );">Gain Related To Sale Of Noncontrolling Interest Net Of Tax</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_TypeOfEquityMethodInvestmentAxis=amed_MedalogixMember', window );">Medalogix [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain (Loss) on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">15,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,600<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Patient accounts receivable</a></td>
<td class="nump">6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,100<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">22,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,300<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">31,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,600<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee benefits</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,800<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current portion of long-term obligations</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark [Member] | Product Concentration Risk [Member] | Medicare Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of net services revenue provided by Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_OperatingCareCenters', window );">Number of owned and operated care centers | care_center</a></td>
<td class="nump">347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 203,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 203,800<span></span>
</td>
<td class="nump">$ 118,200<span></span>
</td>
<td class="nump">$ 90,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_OperatingCareCenters', window );">Number of owned and operated care centers | care_center</a></td>
<td class="nump">164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 800,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,900<span></span>
</td>
<td class="nump">800,900<span></span>
</td>
<td class="nump">799,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember', window );">Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_OperatingCareCenters', window );">Number of owned and operated care centers | care_center</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 43,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,100<span></span>
</td>
<td class="nump">43,100<span></span>
</td>
<td class="nump">43,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember', window );">High Acuity Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_NumberOfAdmittingJointVentures', window );">Number Of Admitting Joint Ventures | numberOfJointVentures</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 239,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 239,600<span></span>
</td>
<td class="nump">233,900<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember', window );">High Acuity Care [Member] | Contessa Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=amed_HeritageHealthcareInnovationFundLPMember', window );">Heritage Healthcare Innovation Fund LP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain (Loss) on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=amed_ConnectRNMember', window );">ConnectRN [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchase of investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=amed_HomeHealthBenefitManagerMember', window );">Home health benefit manager</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_OrganizationAndNatureOfOperationsLineItems', window );"><strong>Organization And Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchase of investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_GainRelatedToSaleOfNoncontrollingInterestNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain Related To Sale Of Noncontrolling Interest Net Of Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_GainRelatedToSaleOfNoncontrollingInterestNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MaximumPercentOwnershipForCostMethodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage ownership required in order for an investment to be treated under the cost method of accounting in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MaximumPercentOwnershipForCostMethodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MaximumPercentOwnershipForEquityMethodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage ownership required in order for an investment to be treated under the equity method of accounting in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MaximumPercentOwnershipForEquityMethodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MinimumPercentOwnershipForControllingInterestPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage ownership required in order for a variable interest entity (VIE) to be consolidated in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MinimumPercentOwnershipForControllingInterestPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfAdmittingJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Admitting Joint Ventures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfAdmittingJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_OperatingCareCenters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of care centers owned by the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_OperatingCareCenters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_OrganizationAndNatureOfOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_OrganizationAndNatureOfOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of the investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStatesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of states the entity operates in as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStatesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TypeOfEquityMethodInvestmentAxis=amed_A30InterestSoldInTwoCareCentersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TypeOfEquityMethodInvestmentAxis=amed_A30InterestSoldInTwoCareCentersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TypeOfEquityMethodInvestmentAxis=amed_A49InterestSoldInTwoCareCentersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TypeOfEquityMethodInvestmentAxis=amed_A49InterestSoldInTwoCareCentersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TypeOfEquityMethodInvestmentAxis=amed_MedalogixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TypeOfEquityMethodInvestmentAxis=amed_MedalogixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amed_MedicareRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amed_MedicareRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_ContessaHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_ContessaHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=amed_HeritageHealthcareInnovationFundLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=amed_HeritageHealthcareInnovationFundLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=amed_ConnectRNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=amed_ConnectRNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=amed_HomeHealthBenefitManagerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=amed_HomeHealthBenefitManagerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675806131760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Number_of_Visits</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_NetServiceRevenueEpisodePaymentRateDuration', window );">Net service revenue episode payment rate</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_PercentageOfTotalReimbursementOfOutlierPayment', window );">Percentage of total reimbursement of outlier payment</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_HospiceMedicareRevenueRateAccountedForRoutineCare', window );">Hospice Medicare revenue rate accounted for routine care</a></td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare', window );">Rate of request for anticipated payment submitted for the initial period of care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration', window );">Net Service Revenue Period Of Care Payment Rate Duration</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark [Member] | Product Concentration Risk [Member] | Medicare Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of net services revenue provided by Medicare</a></td>
<td class="nump">74.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments', window );">Percentage Managed Care Contract Volume Able To Receive Additional Payments</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_LowUtilizationPaymentAdjustmentNumberOfVisits', window );">Low utilization payment adjustment, maximum number of visits | Number_of_Visits</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_NonMedicareRevenueTermRates', window );">Non-medicare revenue term rates</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | High Acuity Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_NetServiceRevenueEpisodePaymentRateDuration', window );">Net service revenue episode payment rate</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_LowUtilizationPaymentAdjustmentNumberOfVisits', window );">Low utilization payment adjustment, maximum number of visits | Number_of_Visits</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_NonMedicareRevenueTermRates', window );">Non-medicare revenue term rates</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | High Acuity Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_NetServiceRevenueEpisodePaymentRateDuration', window );">Net service revenue episode payment rate</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_CapYearAxis=amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember', window );">Cap Year 2016 Through 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities', window );">Estimated amounts due back to Medicare | $</a></td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_CapYearAxis=amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember', window );">Cap Year 2016 Through 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities', window );">Estimated amounts due back to Medicare | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimate of obligations due Medicare upon demand due to overages for the inpatient cap and/or overall payment cap.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HistoricalCollectionRateFromMedicare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Historical collection rate from Medicare.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HistoricalCollectionRateFromMedicare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HospiceMedicareRevenueRateAccountedForRoutineCare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage of the entity's Hospice net Medicare service revenue that is derived from routine care.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HospiceMedicareRevenueRateAccountedForRoutineCare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LowUtilizationPaymentAdjustmentNumberOfVisits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description containing the visit threshold for a low utilization payment adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LowUtilizationPaymentAdjustmentNumberOfVisits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NetServiceRevenueEpisodePaymentRateDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NetServiceRevenueEpisodePaymentRateDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NetServiceRevenuePeriodOfCarePaymentRateDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NonMedicareRevenueTermRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Medicare Revenue Term Rates as a percentage of Medicare Term Rates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NonMedicareRevenueTermRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of managed care contract volume given opportunity to receive additional payments if certain metrics are met</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfTotalReimbursementOfOutlierPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage at which total reimbursement is capped if cost of care is unusually costly.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfTotalReimbursementOfOutlierPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage of estimated payment that is requested at the start of care for an initial period of care.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amed_MedicareRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amed_MedicareRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CapYearAxis=amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CapYearAxis=amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CapYearAxis=amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CapYearAxis=amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675806120768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition by Payor Class (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember', window );">High Acuity Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HomeHealthMedicareMember', window );">Home Health Medicare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">41.00%<span></span>
</td>
<td class="nump">41.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HomeHealthNonMedicareEpisodicBasedMember', window );">Home Health Non-Medicare - Episodic Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HomeHealthNonMedicareNonEpisodicBasedMember', window );">Home Health Non-Medicare - Non-Episodic Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HospiceMedicareMember', window );">Hospice Medicare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HospiceNonMedicareMember', window );">Hospice Non-Medicare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_PayorClassAxis=amed_PersonalCareMember', window );">Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue by payor class as a percentage of total net service revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HomeHealthMedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HomeHealthMedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HomeHealthNonMedicareEpisodicBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HomeHealthNonMedicareEpisodicBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HomeHealthNonMedicareNonEpisodicBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HomeHealthNonMedicareNonEpisodicBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HospiceMedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HospiceMedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HospiceNonMedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HospiceNonMedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675797153344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 40,540<span></span>
</td>
<td class="nump">$ 42,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">13,593<span></span>
</td>
<td class="nump">3,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="nump">54,133<span></span>
</td>
<td class="nump">45,769<span></span>
</td>
<td class="nump">$ 83,357<span></span>
</td>
<td class="nump">$ 96,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_VariousAcquisitionsMember', window );">Various Acquisitions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 13,600<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_VariousAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_VariousAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675807526608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_PercentageOfPatientReceivablesOutstanding', window );">Percentage of patient receivables outstanding</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare', window );">Portion of accounts receivable derived from Medicare</a></td>
<td class="nump">67.00%<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration', window );">Net Service Revenue Period Of Care Payment Rate Duration</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HistoricalCollectionRateFromMedicare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Historical collection rate from Medicare.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HistoricalCollectionRateFromMedicare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NetServiceRevenuePeriodOfCarePaymentRateDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfPatientReceivablesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of patient receivables outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfPatientReceivablesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PortionOfPatientAccountsReceivableDerivedFromMedicare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage of the entity's net patient accounts receivable that is derived from Medicare.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PortionOfPatientAccountsReceivableDerivedFromMedicare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675797216656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 1,287,399<span></span>
</td>
<td class="nump">$ 1,196,090<span></span>
</td>
<td class="nump">$ 932,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets</a></td>
<td class="nump">101,167<span></span>
</td>
<td class="nump">111,190<span></span>
</td>
<td class="nump">74,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments of Financing Costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,792<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">11,500<span></span>
</td>
<td class="nump">12,100<span></span>
</td>
<td class="nump">12,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized debt issuance costs</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_UnamortizedDebtIssuanceCostAmortizationPeriod', window );">Unamortized debt issuance costs, weighted average amortization period, years</a></td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash compensation</a></td>
<td class="nump">16,560<span></span>
</td>
<td class="nump">23,809<span></span>
</td>
<td class="nump">26,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Share-based compensation, tax benefit recognized</a></td>
<td class="nump">4,300<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="nump">7,300<span></span>
</td>
<td class="nump">7,400<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax liabilities</a></td>
<td class="nump">20,411<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_RecognizedTaxBenefitThatImpactsEffectiveTaxRate', window );">Recognized Tax Benefit that Impacts Effective Tax Rate</a></td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember', window );">Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">43,100<span></span>
</td>
<td class="nump">43,100<span></span>
</td>
<td class="nump">43,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">6,400<span></span>
</td>
<td class="nump">7,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete Agreements [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete Agreements [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesMember', window );">Acquired Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Technology-Based Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets</a></td>
<td class="nump">$ 17,100<span></span>
</td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life of intangible assets</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RecognizedTaxBenefitThatImpactsEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recognized Tax Benefit that Impacts Effective Tax Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RecognizedTaxBenefitThatImpactsEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_UnamortizedDebtIssuanceCostAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected amortization period of debt issuance cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_UnamortizedDebtIssuanceCostAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675805909056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives of Property and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">39 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated Useful Life</a></td>
<td class="text">Lesser&#160;of&#160;lease term&#160;or&#160;expected&#160;useful&#160;life<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amed_EquipmentAndFurnitureMember', window );">Equipment and Furniture [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amed_EquipmentAndFurnitureMember', window );">Equipment and Furniture [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer Software [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer Software [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_CapitalLeaseObligationsMember', window );">Finance Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905813&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amed_EquipmentAndFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=amed_EquipmentAndFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_CapitalLeaseObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_CapitalLeaseObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675801543984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Balances Related to Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 117,400<span></span>
</td>
<td class="nump">$ 115,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(101,364)<span></span>
</td>
<td class="num">(96,937)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">16,026<span></span>
</td>
<td class="nump">18,435<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amed_BuildingAndLeaseholdImprovementsMember', window );">Building and Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">9,700<span></span>
</td>
<td class="nump">9,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amed_EquipmentAndFurnitureMember', window );">Equipment and Furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">56,900<span></span>
</td>
<td class="nump">54,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetsHeldUnderCapitalLeasesMember', window );">Finance Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">4,100<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 46,700<span></span>
</td>
<td class="nump">$ 47,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amed_BuildingAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=amed_BuildingAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amed_EquipmentAndFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=amed_EquipmentAndFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetsHeldUnderCapitalLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetsHeldUnderCapitalLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675797198272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Financial Instruments Where Carrying Value and Fair Value Differ (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases', window );">Debt Instrument Carrying Amount Excluding Finance Leases</a></td>
<td class="nump">$ 436.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term obligations, fair value</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term obligations, fair value</a></td>
<td class="nump">428.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term obligations, fair value</a></td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Carrying Amount Excluding Finance Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentCarryingAmountExcludingFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675806132320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted Average Shares Outstanding (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding &#8211; basic</a></td>
<td class="nump">32,517<span></span>
</td>
<td class="nump">32,642<span></span>
</td>
<td class="nump">32,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="nump">420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_NonVestedStockAndStockUnits', window );">Non-vested stock and stock units</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding &#8211; diluted</a></td>
<td class="nump">32,653<span></span>
</td>
<td class="nump">32,972<span></span>
</td>
<td class="nump">33,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">303<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NonVestedStockAndStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non vested stock and stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NonVestedStockAndStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675798064592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOVEL CORONAVIRUS PANDEMIC ("COVID-19") (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">15 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Mar. 27, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>NOVEL CORONAVIRUS PANDEMIC ("COVID-19") [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_FundingForHealthcareProvidersIncludingHospitals', window );">Funding For Healthcare Providers Including Hospitals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements', window );">Funding Immediately Distributed To Healthcare Providers Based On Their 2019 Medicare Fee For Service Reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_FundingReceivedFromCARESAct', window );">Funding Received From CARES Act</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_CARESActProviderReliefFundsUtilized', window );">CARES Act Provider Relief Funds Utilized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_CARESActInterestRepaidToGovernment', window );">CARES Act Interest Repaid to Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_CARESActProviderReliefFundsRepaidToTheGovernment', window );">CARES Act Provider Relief Funds Repaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_CARESActProviderReliefFundUtilizedByUnconsolidatedJointVentures', window );">CARES Act Provider Relief Funds Utilized By Unconsolidated Joint Ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_CARESActProviderReliefFundsRepaidByUnconsolidatedJointVentures', window );">CARES Act Provider Relief Funds Repaid By Unconsolidated Joint Ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_TotalCARESActProviderReliefFundsReceived', window );">Total CARES Act Provider Relief Funds Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact', window );">Extension Of Temporary Suspension Of Sequestration Revenue Impact</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_CARESActDeferralOfEmployerShareSocialSecurityTax', window );">CARES Act Deferral Of Employer Share Social Security Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,300<span></span>
</td>
<td class="nump">34,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemAxis=amed_COVID19DeferralOfSocialSecurityTaxesMember', window );">COVID-19 Deferral of Social Security Taxes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>NOVEL CORONAVIRUS PANDEMIC ("COVID-19") [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_CARESActDeferralOfEmployerShareSocialSecurityTax', window );">CARES Act Deferral Of Employer Share Social Security Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct', window );">Payment of Deferred Social Security Tax Under CARES Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember', window );">Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>NOVEL CORONAVIRUS PANDEMIC ("COVID-19") [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram', window );">Funding Received From Mass HomeCare ASAP COVID19 Provider Sustainability Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember', window );">AseraCare Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>NOVEL CORONAVIRUS PANDEMIC ("COVID-19") [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_FundingReceivedFromCARESAct', window );">Funding Received From CARES Act</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquityMethodInvestmentsMember', window );">Equity Method Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>NOVEL CORONAVIRUS PANDEMIC ("COVID-19") [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_FundingReceivedFromCARESAct', window );">Funding Received From CARES Act</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CARESActDeferralOfEmployerShareSocialSecurityTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The deferral of the employer's share social security tax provided by the CARES Act</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CARESActDeferralOfEmployerShareSocialSecurityTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CARESActInterestRepaidToGovernment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>CARES Act Interest Repaid to Government</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CARESActInterestRepaidToGovernment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CARESActProviderReliefFundUtilizedByUnconsolidatedJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>CARES Act Provider Relief Fund Utilized By Unconsolidated Joint Ventures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CARESActProviderReliefFundUtilizedByUnconsolidatedJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CARESActProviderReliefFundsRepaidByUnconsolidatedJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>CARES Act Provider Relief Funds Repaid By Unconsolidated Joint Ventures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CARESActProviderReliefFundsRepaidByUnconsolidatedJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CARESActProviderReliefFundsRepaidToTheGovernment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>CARES Act Provider Relief Funds repaid to the government by consolidated entities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CARESActProviderReliefFundsRepaidToTheGovernment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CARESActProviderReliefFundsUtilized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>CARES Act Provider Relief Funds Utilized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CARESActProviderReliefFundsUtilized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The impact on revenue due to the extension of the temporary suspension of sequestration as a result of the novel coronavirus pandemic ("COVID-19").</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FundingForHealthcareProvidersIncludingHospitals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funding for healthcare providers, including hospitals provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FundingForHealthcareProvidersIncludingHospitals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funding immediately distributed to healthcare providers based on their 2019 Medicare Fee-For-Service reimbursements provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FundingReceivedFromCARESAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funding received by the Company from the Coronavirus Aid Relief and Economic Security (CARES) Act</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FundingReceivedFromCARESAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funding Received From Mass Home Care ASAP COVID-19 Provider Sustainability Program</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of Deferred Social Security Tax Under CARES Act</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TotalCARESActProviderReliefFundsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total CARES Act Provider Relief Funds Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TotalCARESActProviderReliefFundsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemAxis=amed_COVID19DeferralOfSocialSecurityTaxesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemAxis=amed_COVID19DeferralOfSocialSecurityTaxesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquityMethodInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquityMethodInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675788441856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 01, 2022 </div>
<div>USD ($) </div>
<div>care_center</div>
</th>
<th class="th">
<div>Oct. 18, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 12, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 23, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,100<span></span>
</td>
<td class="nump">$ 263,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,223,199<span></span>
</td>
<td class="nump">2,214,112<span></span>
</td>
<td class="nump">$ 2,071,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,772<span></span>
</td>
<td class="nump">251,915<span></span>
</td>
<td class="nump">219,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DepreciationAndAmortizationForContinuingOperations', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,935<span></span>
</td>
<td class="nump">30,901<span></span>
</td>
<td class="nump">28,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,075<span></span>
</td>
<td class="nump">13,593<span></span>
</td>
<td class="nump">3,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_NonCashAccruedContingentConsideration', window );">Accrued contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,195<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Technology-Based Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,600<span></span>
</td>
<td class="nump">27,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member] | NORTH CAROLINA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to Acquire Businesses, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member] | NORTH CAROLINA | Certificate of Need [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member] | NEW YORK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to Acquire Businesses, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member] | NEW YORK | Certificate of Need [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member] | Randolph County, North Carolina</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to Acquire Businesses, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member] | Randolph County, North Carolina | Certificate of Need [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember', window );">Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember', window );">High Acuity Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,500<span></span>
</td>
<td class="nump">233,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_A2022NewJointVentureMember', window );">2022 New Joint Venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_BusinessCombinationAcquiredNoncontrollingInterest', window );">Business Combination Acquired Noncontrolling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_A2022NewJointVentureMember', window );">2022 New Joint Venture | Certificates of Need and Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_EvolutionHealthMember', window );">Evolution Health | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Acquisition, number of care centers acquired | care_center</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Acquisition, total purchase price</a></td>
<td class="nump">$ 67,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to Acquire Businesses, Gross</a></td>
<td class="nump">51,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense', window );">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Current Assets Prepaid Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right of Use Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill deductible for income tax purposes</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod', window );">Period of time goodwill is expected to be deductible for income tax purposes</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_BusinessAcquisitionClosingPaymentAdjustment', window );">Business Acquisition Closing Payment Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_IncreaseDecreaseInAssetsAcquired', window );">Increase Decrease In Assets Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_IncreaseDecreaseInLiabilitiesAssumed', window );">Increase Decrease In Liabilities Assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Reduction in goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 16,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_NonCashAccruedContingentConsideration', window );">Accrued contingent consideration</a></td>
<td class="nump">15,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_AmountReleasedFromEscrow', window );">Amount Released From Escrow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_EvolutionHealthMember', window );">Evolution Health | Home Health [Member] | Potential Closing Payment Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_NonCashAccruedContingentConsideration', window );">Accrued contingent consideration</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_EvolutionHealthMember', window );">Evolution Health | Home Health [Member] | Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_AssistedCareHomeHealthMember', window );">AssistedCare Home Health | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Acquisition, number of care centers acquired | care_center</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Acquisition, total purchase price</a></td>
<td class="nump">$ 24,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to Acquire Businesses, Gross</a></td>
<td class="nump">22,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill deductible for income tax purposes</a></td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod', window );">Period of time goodwill is expected to be deductible for income tax purposes</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_AssistedCareHomeHealthMember', window );">AssistedCare Home Health | Home Health [Member] | Certificates Of Need [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_AssistedCareHomeHealthMember', window );">AssistedCare Home Health | Home Health [Member] | Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_AssistedCareHomeHealthMember', window );">AssistedCare Home Health | Home Health [Member] | Acquired Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_VisitingNurseAssociationMember', window );">Visiting Nurse Association | Home Health And Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to Acquire Businesses, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod', window );">Period of time goodwill is expected to be deductible for income tax purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_VisitingNurseAssociationMember', window );">Visiting Nurse Association | Home Health And Hospice [Member] | Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_ContessaHealthMember', window );">Contessa Health | High Acuity Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Acquisition, total purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense', window );">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Current Assets Prepaid Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right of Use Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue', window );">Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity', window );">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity', window );">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities And Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest', window );">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">231,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_BusinessAcquisitionClosingPaymentAdjustment', window );">Business Acquisition Closing Payment Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,500<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,100)<span></span>
</td>
<td class="num">(10,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_IncreaseDecreaseInLiabilitiesAssumed', window );">Increase Decrease In Liabilities Assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Reduction in goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DepreciationAndAmortizationForContinuingOperations', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_ContessaHealthMember', window );">Contessa Health | High Acuity Care [Member] | Noncompete Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_ContessaHealthMember', window );">Contessa Health | High Acuity Care [Member] | Acquired Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_ContessaHealthMember', window );">Contessa Health | High Acuity Care [Member] | Technology-Based Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_AmountReleasedFromEscrow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount Released From Escrow</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_AmountReleasedFromEscrow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessAcquisitionClosingPaymentAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition Closing Payment Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessAcquisitionClosingPaymentAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationAcquiredNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of noncontrolling interest acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationAcquiredNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity assumed at the acquisition date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total liabilities and equity assumed at the acquisition date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DepreciationAndAmortizationForContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation And Amortization For Continuing Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DepreciationAndAmortizationForContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Deductible For Income Tax Purposes, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_GoodwillDeductibleForIncomeTaxPurposesPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_IncreaseDecreaseInAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease In Assets Acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_IncreaseDecreaseInAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_IncreaseDecreaseInLiabilitiesAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease In Liabilities Assumed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_IncreaseDecreaseInLiabilitiesAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NonCashAccruedContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Accrued Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NonCashAccruedContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the assets, including goodwill, in excess of (less than) the aggregate liabilities assumed, less the noncontrolling interest in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of patient service revenue recognized, net of contractual allowances and discounts, less the provision for bad debts related to patient service revenue plus all other revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfBusinessesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of businesses acquired by the entity during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfBusinessesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificateOfNeedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificateOfNeedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=amed_RandolphCountyNorthCarolinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=amed_RandolphCountyNorthCarolinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_A2022NewJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_A2022NewJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificatesOfNeedAndLicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificatesOfNeedAndLicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_EvolutionHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_EvolutionHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationAdjustmentsAxis=amed_PotentialClosingPaymentAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationAdjustmentsAxis=amed_PotentialClosingPaymentAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_LicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_LicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_AssistedCareHomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_AssistedCareHomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificatesOfNeedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificatesOfNeedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_VisitingNurseAssociationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_VisitingNurseAssociationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthAndHospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthAndHospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_ContessaHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_ContessaHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675797985584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Activity Related to Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Goodwill, Impaired, Accumulated Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 733,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 1,196,090<span></span>
</td>
<td class="nump">$ 932,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="nump">94,100<span></span>
</td>
<td class="nump">263,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Adjustments related to acquisitions</a></td>
<td class="num">(2,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">1,287,399<span></span>
</td>
<td class="nump">1,196,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">118,200<span></span>
</td>
<td class="nump">90,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="nump">85,600<span></span>
</td>
<td class="nump">27,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Adjustments related to acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">203,800<span></span>
</td>
<td class="nump">118,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">800,900<span></span>
</td>
<td class="nump">799,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Adjustments related to acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">800,900<span></span>
</td>
<td class="nump">800,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember', window );">Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">43,100<span></span>
</td>
<td class="nump">43,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Adjustments related to acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">43,100<span></span>
</td>
<td class="nump">43,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember', window );">High Acuity Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">233,900<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="nump">8,500<span></span>
</td>
<td class="nump">233,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Adjustments related to acquisitions</a></td>
<td class="num">(2,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 239,600<span></span>
</td>
<td class="nump">$ 233,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e961-128460<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675806175568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Goodwill and Intangibles (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="nump">$ 14,604<span></span>
</td>
<td class="nump">$ 19,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Technology-Based Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AmortizableAcquiredNamesMember', window );">Amortizable acquired names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AmortizableAcquiredNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AmortizableAcquiredNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675801391696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Activity Related to Other Intangible Assets, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsRollForward', window );"><strong>Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Beginning balance</a></td>
<td class="nump">$ 111,190<span></span>
</td>
<td class="nump">$ 74,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_OtherIntangibleAssetsAdditions', window );">Additions</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">55,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ReclassToAmortizableIntangible', window );">Reclass to amortizable intangible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="num">(13,500)<span></span>
</td>
<td class="num">(18,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Ending balance</a></td>
<td class="nump">101,167<span></span>
</td>
<td class="nump">111,190<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AmortizableAcquiredNamesMember', window );">Amortizable acquired names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsRollForward', window );"><strong>Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Beginning balance</a></td>
<td class="nump">3,100<span></span>
</td>
<td class="nump">5,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_OtherIntangibleAssetsAdditions', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ReclassToAmortizableIntangible', window );">Reclass to amortizable intangible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="num">(3,100)<span></span>
</td>
<td class="num">(9,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsRollForward', window );"><strong>Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Beginning balance</a></td>
<td class="nump">6,400<span></span>
</td>
<td class="nump">7,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_OtherIntangibleAssetsAdditions', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ReclassToAmortizableIntangible', window );">Reclass to amortizable intangible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="num">(4,600)<span></span>
</td>
<td class="num">(7,600)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Ending balance</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">6,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Technology-Based Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsRollForward', window );"><strong>Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Beginning balance</a></td>
<td class="nump">19,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_OtherIntangibleAssetsAdditions', window );">Additions</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">20,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ReclassToAmortizableIntangible', window );">Reclass to amortizable intangible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="num">(3,000)<span></span>
</td>
<td class="num">(1,200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Ending balance</a></td>
<td class="nump">17,100<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificatesOfNeedAndLicensesMember', window );">Certificates of Need and Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsRollForward', window );"><strong>Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Beginning balance</a></td>
<td class="nump">47,100<span></span>
</td>
<td class="nump">47,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_OtherIntangibleAssetsAdditions', window );">Additions</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ReclassToAmortizableIntangible', window );">Reclass to amortizable intangible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="num">(2,800)<span></span>
</td>
<td class="num">(700)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Ending balance</a></td>
<td class="nump">46,700<span></span>
</td>
<td class="nump">47,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=amed_UnamortizableAcquiredNamesMember', window );">Unamortizable acquired names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsRollForward', window );"><strong>Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Beginning balance</a></td>
<td class="nump">35,600<span></span>
</td>
<td class="nump">13,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_OtherIntangibleAssetsAdditions', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">28,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ReclassToAmortizableIntangible', window );">Reclass to amortizable intangible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,600)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Ending balance</a></td>
<td class="nump">$ 35,600<span></span>
</td>
<td class="nump">$ 35,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_OtherIntangibleAssetsAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additions to Other Intangible Assets that occurred during the period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_OtherIntangibleAssetsAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ReclassToAmortizableIntangible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification from unamortizable intangible asset to amortizable intangible asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ReclassToAmortizableIntangible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AmortizableAcquiredNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AmortizableAcquiredNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificatesOfNeedAndLicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificatesOfNeedAndLicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=amed_UnamortizableAcquiredNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=amed_UnamortizableAcquiredNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675807526320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Estimated Future Amortization Expense (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 4.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 16.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675887415312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Discontinued Operations and Assets Held For Sale - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Feb. 10, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember', window );">Personal Care [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Disposal Group, Including Discontinued Operation, Consideration</a></td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675801548512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Assets Held For Sale - Assets and Liabilities (Detail) - Personal Care [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Patient accounts receivable</a></td>
<td class="nump">$ 9.6<span></span>
</td>
<td class="nump">$ 8.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent', window );">Prepaid expenses</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Other current assets</a></td>
<td class="nump">9.7<span></span>
</td>
<td class="nump">8.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent', window );">Property and equipment</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent', window );">Disposal Group Including Discontinued Operation Operating Lease Right Of Use Assets Noncurrent</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent', window );">Goodwill</a></td>
<td class="nump">43.1<span></span>
</td>
<td class="nump">43.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent', window );">Intangible assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Total assets</a></td>
<td class="nump">55.4<span></span>
</td>
<td class="nump">56.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent', window );">Payroll and employee benefits</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current liabilities</a></td>
<td class="nump">3.4<span></span>
</td>
<td class="nump">3.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Total liabilities</a></td>
<td class="nump">$ 5.3<span></span>
</td>
<td class="nump">$ 5.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accrued expenses attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as operating lease liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as operating lease liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as operating lease right of use asset attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as payroll and employee benefits payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2510-110228<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2510-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2510-110228<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2510-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2510-110228<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675797344688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS - Balances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Other current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_PayrollTaxEscrow', window );">Payroll tax escrow</a></td>
<td class="nump">$ 7,600<span></span>
</td>
<td class="nump">$ 7,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income tax receivable</a></td>
<td class="nump">8,800<span></span>
</td>
<td class="nump">8,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromJointVenturesCurrent', window );">Due from joint ventures</a></td>
<td class="nump">3,600<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousCurrent', window );">Other</a></td>
<td class="nump">6,400<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">26,415<span></span>
</td>
<td class="nump">25,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrentAbstract', window );"><strong>Other assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_WorkersCompensationDeposits', window );">Workers&#8217; compensation deposits</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_HealthInsuranceDeposits', window );">Health insurance deposits</a></td>
<td class="nump">900<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_OtherMiscellaneousDeposits', window );">Other miscellaneous deposits</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyReceivableNoncurrent', window );">Indemnity receivable</a></td>
<td class="nump">13,600<span></span>
</td>
<td class="nump">13,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity method investments</a></td>
<td class="nump">40,500<span></span>
</td>
<td class="nump">48,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtCost', window );">Cost method investments</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousNoncurrent', window );">Other</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">79,836<span></span>
</td>
<td class="nump">73,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedInsuranceCurrent', window );">Health insurance</a></td>
<td class="nump">16,200<span></span>
</td>
<td class="nump">16,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WorkersCompensationLiabilityCurrent', window );">Workers&#8217; compensation</a></td>
<td class="nump">40,600<span></span>
</td>
<td class="nump">40,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ProvisionForLiabilityOnRegulatoryAudit', window );">Florida ZPIC audit, gross liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_LegalAndOtherSettlements', window );">Legal settlements and other audits</a></td>
<td class="nump">32,100<span></span>
</td>
<td class="nump">27,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_CharityCare', window );">Charity care</a></td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_EstimatedMedicareCapLiability', window );">Estimated Medicare cap liability</a></td>
<td class="nump">4,300<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_HospiceAccruals', window );">Hospice accruals (room and board, general in-patient and other)</a></td>
<td class="nump">19,100<span></span>
</td>
<td class="nump">23,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_PatientLiability', window );">Patient and payor liabilities</a></td>
<td class="nump">6,700<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Accrued contingent consideration</a></td>
<td class="nump">10,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_AccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">8,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">5,800<span></span>
</td>
<td class="nump">5,800<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">137,390<span></span>
</td>
<td class="nump">150,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrentAbstract', window );"><strong>Other long-term obligations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_UncertainTaxBenefitsInLongTermObligations', window );">Reserve for uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DeferredCompensationPlanLiability', window );">Deferred compensation plan liability</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Accrued contingent consideration</a></td>
<td class="nump">3,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesNoncurrent', window );">Other</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term obligations</a></td>
<td class="nump">$ 4,808<span></span>
</td>
<td class="nump">$ 4,979<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_AccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_AccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CharityCare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued expenses related to charity care</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CharityCare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DeferredCompensationPlanLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Compensation Plan Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DeferredCompensationPlanLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EstimatedMedicareCapLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued expenses related to the estimated Medicare CAP liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EstimatedMedicareCapLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HealthInsuranceDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Health Insurance Deposits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HealthInsuranceDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HospiceAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued expenses related to Hospice room and board, general in-patient and other expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HospiceAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LegalAndOtherSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued expenses related to legal and other settlements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LegalAndOtherSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_OtherMiscellaneousDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Miscellaneous Deposits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_OtherMiscellaneousDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PatientLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued expenses related to Patient liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PatientLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayrollTaxEscrow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payroll tax escrow</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayrollTaxEscrow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProvisionForLiabilityOnRegulatoryAudit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provision For Liability On Regulatory Audit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProvisionForLiabilityOnRegulatoryAudit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_UncertainTaxBenefitsInLongTermObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Uncertain Tax Benefits In Long Term Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_UncertainTaxBenefitsInLongTermObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_WorkersCompensationDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Workers Compensation Deposits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_WorkersCompensationDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedInsuranceCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedInsuranceCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromJointVenturesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts due from an entity in which the reporting entity shares joint control with another party or group, due within 1 year (or 1 business cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39599-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromJointVenturesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of the investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyReceivableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of receivable related to a loss contingency accrual that is expected to be collected after one year or beyond the normal operating cycle, if longer. For example, an insurance recovery receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12053-110248<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyReceivableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsMiscellaneousCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsMiscellaneousNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WorkersCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WorkersCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675797154944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Lessee, Finance Lease, Term of Contract</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amed_TelehealthKitsMember', window );">Telehealth Kits</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Lessee, Finance Lease, Term of Contract</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_LeaseTypeAxis=amed_FleetLeaseMember', window );">Fleet Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">367 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToTerminate', window );">Lessee, Operating Lease, Option to Terminate</a></td>
<td class="text">Option for early termination of lease after one year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, Renewal Term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToTerminate', window );">Lessee, Operating Lease, Option to Terminate</a></td>
<td class="text">Option for early termination of lease after three years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, Renewal Term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=amed_TelehealthKitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=amed_TelehealthKitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LeaseTypeAxis=amed_FleetLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LeaseTypeAxis=amed_FleetLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675807015520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Lease Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease cost</a></td>
<td class="nump">$ 43.9<span></span>
</td>
<td class="nump">$ 40.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment of operating lease ROU assets</a></td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Total operating lease cost</a></td>
<td class="nump">46.0<span></span>
</td>
<td class="nump">40.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Finance Lease, Loss on Termination</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Finance Lease, Amortization of ROU assets</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Finance Lease, Interest Expense</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_FinanceLeaseCost', window );">Finance Lease Cost</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">3.4<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 51.8<span></span>
</td>
<td class="nump">$ 45.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of finance lease cost including amortization of ROU asset and interest expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 40<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123386189&amp;loc=SL77918607-209975<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123399704&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675807534016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Operating Lease (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease ROU assets</a></td>
<td class="nump">$ 102,856<span></span>
</td>
<td class="nump">$ 101,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">33,521<span></span>
</td>
<td class="nump">31,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="nump">69,504<span></span>
</td>
<td class="nump">69,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 103,000<span></span>
</td>
<td class="nump">$ 100,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675801936016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Finance Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization', window );">Finance lease ROU assets</a></td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization', window );">Finance Lease, ROU Asset, Accumulated Amortization</a></td>
<td class="num">(1,800)<span></span>
</td>
<td class="num">(2,800)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment</a></td>
<td class="nump">16,026<span></span>
</td>
<td class="nump">18,435<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetsHeldUnderCapitalLeasesMember', window );">Finance Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=amed_CurrentPortionOfLongTermObligationsMember', window );">Current portion of long-term obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Current portion of long-term obligations<span></span>
</td>
<td class="text">Current portion of long-term obligations<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=amed_LongTermObligationsLessCurrentPortionMember', window );">Long-Term obligations, less current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Long-term obligations, less current portion<span></span>
</td>
<td class="text">Long-term obligations, less current portion<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=amed_CurrentAndLongTermObligationsMember', window );">Current and Long-Term obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other Liabilities<span></span>
</td>
<td class="text">Other Liabilities<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetsHeldUnderCapitalLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetsHeldUnderCapitalLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=amed_CurrentPortionOfLongTermObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=amed_CurrentPortionOfLongTermObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=amed_LongTermObligationsLessCurrentPortionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=amed_LongTermObligationsLessCurrentPortionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=amed_CurrentAndLongTermObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=amed_CurrentAndLongTermObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675801539360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Supplemental Cashflow Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flow from operating leases</a></td>
<td class="num">$ (44.4)<span></span>
</td>
<td class="num">$ (39.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flow from finance leases</a></td>
<td class="num">(1.5)<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</a></td>
<td class="nump">45.1<span></span>
</td>
<td class="nump">46.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</a></td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations', window );">Lessee Operating lease Reductions to ROU assets resulting from reductions to lease obligations</a></td>
<td class="num">(4.2)<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations', window );">Lessee Finance lease Reduction to ROU assets resulting from reductions to lease obligations</a></td>
<td class="num">$ (0.6)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Finance lease, Reduction to ROU assets resulting from reductions to lease obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675895632192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES- Weighted Average Remaining Term and Discount Rate (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating Lease, Weighted Average Discount Rate, Percent</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance Lease, Weighted Average Discount Rate, Percent</a></td>
<td class="nump">5.30%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675798334384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Maturities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Operating Lease - 2023</a></td>
<td class="nump">$ 36.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Operating Lease - 2024</a></td>
<td class="nump">30.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Operating Lease - 2025</a></td>
<td class="nump">20.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">Operating Lease - 2026</a></td>
<td class="nump">12.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">Operating Lease - 2027</a></td>
<td class="nump">6.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Operating Lease - Thereafter</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Operating Lease - Total undiscounted lease payments</a></td>
<td class="nump">109.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Operating Lease - Less: Imputed Interest</a></td>
<td class="num">(6.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">103.0<span></span>
</td>
<td class="nump">$ 100.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Finance Lease - 2023</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">Finance Lease - 2024</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">Finance Lease - 2025</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">Finance Lease - 2026</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">Finance Lease - 2027</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Finance Lease - Thereafter</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Finance Lease - Total undiscounted lease payments</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Finance Lease - Less: Imputed Interest</a></td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=amed_CurrentAndLongTermObligationsMember', window );">Current and Long-Term obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other Liabilities<span></span>
</td>
<td class="text">Other Liabilities<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=amed_CurrentAndLongTermObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=amed_CurrentAndLongTermObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675807184336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS - Summary of Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">$ 438.4<span></span>
</td>
<td class="nump">$ 449.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred debt issuance costs</a></td>
<td class="num">(3.5)<span></span>
</td>
<td class="num">(4.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term obligations, including current portion</a></td>
<td class="nump">434.9<span></span>
</td>
<td class="nump">445.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term obligations</a></td>
<td class="num">(15.5)<span></span>
</td>
<td class="num">(13.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term obligations, less current portion</a></td>
<td class="nump">419.4<span></span>
</td>
<td class="nump">432.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term Loan [Member] | Four Hundred Fifty Million Term Loan Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">435.9<span></span>
</td>
<td class="nump">447.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Five Hundred Fifty Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember', window );">Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember', window );">Finance Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FourHundredFiftyMillionTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FourHundredFiftyMillionTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675797962752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS - Summary of Long-Term Debt Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term Loan [Member] | Four Hundred Fifty Million Term Loan Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, face amount</a></td>
<td class="nump">$ 450,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Jul. 30,  2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term Loan [Member] | Four Hundred Fifty Million Term Loan Facility [Member] | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DebtInstrumentInterestRateatPeriodEnd', window );">Debt Instrument Interest Rate at Period End</a></td>
<td class="nump">5.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Five Hundred Fifty Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, face amount</a></td>
<td class="nump">$ 550,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Jul. 30,  2026<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentInterestRateatPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Interest Rate at Period End</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentInterestRateatPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FourHundredFiftyMillionTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FourHundredFiftyMillionTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675807003440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS - Maturities of Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long-Term Obligations, Fiscal Year Maturity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 15.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">23.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">22.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">376.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2027</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total</a></td>
<td class="nump">$ 438.4<span></span>
</td>
<td class="nump">$ 449.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675796973568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheOneMember', window );">Consolidated Leverage Ratio: Greater Than 3.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment Fee</a></td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter of Credit Fee</a></td>
<td class="nump">1.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheOneMember', window );">Consolidated Leverage Ratio: Greater Than 3.00 to 1.0 | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">3.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheOneMember', window );">Consolidated Leverage Ratio: Greater Than 3.00 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Margin on Loans</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheOneMember', window );">Consolidated Leverage Ratio: Greater Than 3.00 to 1.0 | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Margin on Loans</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheTwoMember', window );">Consolidated Leverage Ratio: Less Than Equal To 3.00 to 1.0 but Greater Than 2.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment Fee</a></td>
<td class="nump">0.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter of Credit Fee</a></td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheTwoMember', window );">Consolidated Leverage Ratio: Less Than Equal To 3.00 to 1.0 but Greater Than 2.00 to 1.0 | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">3.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheTwoMember', window );">Consolidated Leverage Ratio: Less Than Equal To 3.00 to 1.0 but Greater Than 2.00 to 1.0 | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">2.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheTwoMember', window );">Consolidated Leverage Ratio: Less Than Equal To 3.00 to 1.0 but Greater Than 2.00 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Margin on Loans</a></td>
<td class="nump">0.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheTwoMember', window );">Consolidated Leverage Ratio: Less Than Equal To 3.00 to 1.0 but Greater Than 2.00 to 1.0 | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Margin on Loans</a></td>
<td class="nump">1.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheThreeMember', window );">Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment Fee</a></td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter of Credit Fee</a></td>
<td class="nump">1.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheThreeMember', window );">Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0 | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">2.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheThreeMember', window );">Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0 | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">0.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheThreeMember', window );">Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Margin on Loans</a></td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheThreeMember', window );">Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0 | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Margin on Loans</a></td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheFourMember', window );">Consolidated Leverage Ratio: Less Than Equal To 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment Fee</a></td>
<td class="nump">0.15%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter of Credit Fee</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheFourMember', window );">Consolidated Leverage Ratio: Less Than Equal To 0.75 to 1.0 | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">0.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheFourMember', window );">Consolidated Leverage Ratio: Less Than Equal To 0.75 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Margin on Loans</a></td>
<td class="nump">0.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheFourMember', window );">Consolidated Leverage Ratio: Less Than Equal To 0.75 to 1.0 | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Margin on Loans</a></td>
<td class="nump">1.25%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ConsolidatedLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consolidated Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ConsolidatedLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LetterOfCreditFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the letters of credit, for the letters of credit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LetterOfCreditFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_DebtInstrumentByLeverageRatioTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675787985328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">26 Months Ended</th>
<th class="th" colspan="1">34 Months Ended</th>
<th class="th" colspan="1">60 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 29, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jul. 30, 2026</div></th>
<th class="th"><div>Jul. 30, 2026</div></th>
<th class="th">
<div>Feb. 04, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payments of long-term obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,296<span></span>
</td>
<td class="nump">$ 9,143<span></span>
</td>
<td class="nump">$ 10,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_TotalLeverageRatio', window );">Consolidated leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ConsolidatedInterestCoverageRatio', window );">Consolidated interest coverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 438,400<span></span>
</td>
<td class="nump">449,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments of Financing Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,792<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_CreditAgreementMember', window );">Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_SwingLineFacility', window );">Swing Line Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_LettersofCreditmaximumcommitment', window );">Letters of Credit, maximum commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember', window );">Finance Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember', window );">Finance Leases [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember', window );">Finance Leases [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_SecondAmendedCreditAgreementMember', window );">Second Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate', window );">Additional interest rate above Federal Fund rate (percent)</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate', window );">Additional interest rate above Eurodollar Rate (percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries', window );">Percentage of consolidated revenue and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries', window );">Percentage of adjusted EBITDA that guarantor subsidiaries represent</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments of Financing Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_SecondAmendedCreditAgreementMember', window );">Second Amended Credit Agreement | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 30,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_SecondAmendedCreditAgreementMember', window );">Second Amended Credit Agreement | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ProceedsReceivedFromLoanPartyOfSubsidiary', window );">Proceeds Received From Loan Party Of Subsidiary</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_SecondAmendedCreditAgreementMember', window );">Second Amended Credit Agreement | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Description of variable rate basis</a></td>
<td class="text">Fluctuating rate per annum equal to the highest of (a)&#160;the federal funds rate plus 0.50% per annum, (b)&#160;the prime rate of interest established by the Administrative Agent, and (c)&#160;the Eurodollar Rate for an interest period of one month plus 1% per annum.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_SecondAmendedCreditAgreementMember', window );">Second Amended Credit Agreement | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Description of variable rate basis</a></td>
<td class="text">Rate at which Eurodollar deposits in the London interbank market for an interest period of one, two, three or six months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember', window );">Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember', window );">Five Hundred Fifty Million Revolving Credit Facility [Member] | Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime', window );">Weighted Average Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 30,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining availability under the revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 520,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember', window );">Five Hundred Fifty Million Revolving Credit Facility [Member] | Letter of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Outstanding letters of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember', window );">Five Hundred Fifty Million Revolving Credit Facility [Member] | Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_LineOfCreditFacilityAdditionalBorrowingCapacity', window );">Credit facility, maximum additional borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple', window );">Credit facility, maximum allowable consolidated leverage ratio multiple</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_Creditfacilitymaximumallowableconsolidatedleverageratio', window );">Credit facility maximum allowable consolidated leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 29,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember', window );">Five Hundred Fifty Million Revolving Credit Facility [Member] | Amended Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 725,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember', window );">Five Hundred Fifty Million Revolving Credit Facility [Member] | Second Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, maximum borrowing capacity</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, face amount</a></td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_OneHundredSeventyFiveMillionTermLoanFacilityMember', window );">One Hundred Seventy Five Million Term Loan Facility [Member] | Amended Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_FourHundredFiftyMillionTermLoanFacilityMember', window );">Four Hundred Fifty Million Term Loan Facility [Member] | Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime', window );">Weighted Average Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 30,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 435,900<span></span>
</td>
<td class="nump">$ 447,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_FourHundredFiftyMillionTermLoanFacilityMember', window );">Four Hundred Fifty Million Term Loan Facility [Member] | Second Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, face amount</a></td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_FourHundredFiftyMillionTermLoanFacilityMember', window );">Four Hundred Fifty Million Term Loan Facility [Member] | Second Amended Credit Agreement | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DebtInstrumentPeriodicPaymentPercentage', window );">Debt Instrument Periodic Payment Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.625%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ConsolidatedInterestCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio of adjusted earnings before interest, taxes, depreciation and amortization to cash interest charges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ConsolidatedInterestCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Credit Facility, Maximum Allowable Consolidated Leverage Ratio Multiple</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Creditfacilitymaximumallowableconsolidatedleverageratio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Credit facility maximum allowable consolidated leverage ratio as defined in the Company's Credit Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Creditfacilitymaximumallowableconsolidatedleverageratio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Interest Additional Interest Above Eurodollar Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Interest Additional Interest Above Federal Fund Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentPeriodicPaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of the Term Loan that is required as periodic payments including both interest and principal payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentPeriodicPaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LettersofCreditmaximumcommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Letters of Credit, maximum commitment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LettersofCreditmaximumcommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LineOfCreditFacilityAdditionalBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility Additional Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LineOfCreditFacilityAdditionalBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of adjusted EBITDA that guarantor subsidiaries represent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of consolidated net revenues and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProceedsReceivedFromLoanPartyOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds Received From Loan Party Of Subsidiary</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProceedsReceivedFromLoanPartyOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_SwingLineFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Swing Line Facility included within Revolving Credit Facility</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_SwingLineFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TotalLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio of debt to earnings before interest, taxes, depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TotalLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of reference rate used for variable rate of debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of long-term debt outstanding calculated over time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtWeightedAverageInterestRateOverTime</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_SecondAmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_SecondAmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_AmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_AmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_OneHundredSeventyFiveMillionTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_OneHundredSeventyFiveMillionTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FourHundredFiftyMillionTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FourHundredFiftyMillionTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675788096096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 10, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,700)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income tax receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,800<span></span>
</td>
<td class="nump">8,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_RecognizedTaxBenefitThatImpactsEffectiveTaxRate', window );">Recognized Tax Benefit that Impacts Effective Tax Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax benefits accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_BenefitAsComponentOfInterestExpense', window );">Benefit as Component of Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Net change in total valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Interest and penalties accrued related to uncertain income tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_CARESActDeferralOfEmployerShareSocialSecurityTax', window );">CARES Act Deferral Of Employer Share Social Security Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,377<span></span>
</td>
<td class="nump">44,582<span></span>
</td>
<td class="num">(26,560)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemAxis=amed_COVID19DeferralOfSocialSecurityTaxesMember', window );">COVID-19 Deferral of Social Security Taxes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_CARESActDeferralOfEmployerShareSocialSecurityTax', window );">CARES Act Deferral Of Employer Share Social Security Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct', window );">Payment of Deferred Social Security Tax Under CARES Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_ExecutiveStockOptionExerciseMember', window );">Executive Stock Option Exercise [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Recognized share-based compensation tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Tax years open to examination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Tax years open to examination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=amed_StateTaxCreditMember', window );">State Tax Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxCreditsAndAdjustments', window );">Tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Executive Stock Option Exercise [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Recognized share-based compensation tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Net Operating Loss [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member] | Executive Stock Option Exercise [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Recognized share-based compensation tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member] | Net Operating Loss [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BenefitAsComponentOfInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Benefit as Component of Interest Expense, resulting from the lapse of statute of limitations regarding uncertain tax positions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BenefitAsComponentOfInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CARESActDeferralOfEmployerShareSocialSecurityTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The deferral of the employer's share social security tax provided by the CARES Act</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CARESActDeferralOfEmployerShareSocialSecurityTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of Deferred Social Security Tax Under CARES Act</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RecognizedTaxBenefitThatImpactsEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recognized Tax Benefit that Impacts Effective Tax Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RecognizedTaxBenefitThatImpactsEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970579&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxCreditsAndAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxCreditsAndAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemAxis=amed_COVID19DeferralOfSocialSecurityTaxesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemAxis=amed_COVID19DeferralOfSocialSecurityTaxesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amed_ExecutiveStockOptionExerciseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amed_ExecutiveStockOptionExerciseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=amed_StateTaxCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=amed_StateTaxCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_UnrecognizedTaxBenefitsAxis=amed_NetOperatingLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_UnrecognizedTaxBenefitsAxis=amed_NetOperatingLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675797198352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Components of Tax Provision by Jurisdiction (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current income tax expense/(benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 12,200<span></span>
</td>
<td class="nump">$ 20,300<span></span>
</td>
<td class="nump">$ 41,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State and local</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="nump">10,600<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current income tax expense (benefit)</a></td>
<td class="nump">19,200<span></span>
</td>
<td class="nump">25,500<span></span>
</td>
<td class="nump">52,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred income tax expense/(benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">20,400<span></span>
</td>
<td class="nump">35,900<span></span>
</td>
<td class="num">(22,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State and local</a></td>
<td class="nump">2,900<span></span>
</td>
<td class="nump">8,700<span></span>
</td>
<td class="num">(4,100)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax expense (benefit)</a></td>
<td class="nump">23,377<span></span>
</td>
<td class="nump">44,582<span></span>
</td>
<td class="num">(26,560)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 42,545<span></span>
</td>
<td class="nump">$ 70,065<span></span>
</td>
<td class="nump">$ 25,635<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675806071136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Income Tax Expense Allocation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income from continuing operations</a></td>
<td class="nump">$ 42,545<span></span>
</td>
<td class="nump">$ 70,065<span></span>
</td>
<td class="nump">$ 25,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_IncomeTaxEffectsAllocatedToInterestExpense', window );">Interest expense</a></td>
<td class="num">(700)<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_IncomeTaxEffectsAllocatedToGoodwill', window );">Goodwill</a></td>
<td class="num">(2,700)<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_TaxExpenseRecordedToAdditionalPaidInCapital', window );">Tax expense recorded to additional paid-in-capital</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation', window );">Total income tax expense allocation</a></td>
<td class="nump">$ 40,600<span></span>
</td>
<td class="nump">$ 73,300<span></span>
</td>
<td class="nump">$ 25,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_IncomeTaxEffectsAllocatedToGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Effects Allocated To Goodwill</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_IncomeTaxEffectsAllocatedToGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_IncomeTaxEffectsAllocatedToInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax effect of items occuring during the period that have been charged or credited directly to interest expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_IncomeTaxEffectsAllocatedToInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TaxExpenseRecordedToAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Expense Recorded to Additional Paid-in-Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TaxExpenseRecordedToAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) for continuing operations, discontinued operations, other comprehensive income, and items charged (credited) directly to shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675807066784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Reconciliation of Effective Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax expense at U.S. federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and local income taxes, net of federal income tax benefit (1)</a></td>
<td class="nump">5.60%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent', window );">Excess tax benefits from share-based compensation (1)</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="num">(2.10%)<span></span>
</td>
<td class="num">(12.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent', window );">Non-deductible executive compensation</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent', window );">Unrecognized tax benefits (2)</a></td>
<td class="num">(1.70%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other items, net (3)</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax expense</a></td>
<td class="nump">26.50%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">12.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Excess Tax Benefit, Share-based Compensation, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Non-deductible Executive Compensation, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Unrecognized Tax Benefits, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675797458064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Components of Deferred Tax Assets (Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther', window );">Accrued payroll&#160;&amp; employee benefits</a></td>
<td class="nump">$ 14,100<span></span>
</td>
<td class="nump">$ 13,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation', window );">Workers&#8217; compensation</a></td>
<td class="nump">10,600<span></span>
</td>
<td class="nump">10,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">5,700<span></span>
</td>
<td class="nump">6,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DeferredTaxAssetsLegalAndComplianceMatters', window );">Legal &amp; compliance matters</a></td>
<td class="nump">4,700<span></span>
</td>
<td class="nump">6,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">27,800<span></span>
</td>
<td class="nump">27,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DeferredTaxAssetDeferredSocialSecurityTaxes', window );">Deferred social security taxes (1)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOtherLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">11,600<span></span>
</td>
<td class="nump">13,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">2,900<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other assets</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">77,600<span></span>
</td>
<td class="nump">86,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(5,200)<span></span>
</td>
<td class="num">(3,300)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">72,400<span></span>
</td>
<td class="nump">83,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(6,600)<span></span>
</td>
<td class="num">(8,100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="num">(48,500)<span></span>
</td>
<td class="num">(32,300)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates', window );">Investment in partnerships</a></td>
<td class="num">(10,000)<span></span>
</td>
<td class="num">(10,800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DeferredTaxLiabilitiesRightOfUseAssets', window );">Right-of-use asset</a></td>
<td class="num">(27,000)<span></span>
</td>
<td class="num">(26,700)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other liabilities</a></td>
<td class="num">(700)<span></span>
</td>
<td class="num">(900)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="num">(92,800)<span></span>
</td>
<td class="num">(83,300)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred Income Tax Liabilities, Net</a></td>
<td class="num">(20,411)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 289<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DeferredTaxAssetDeferredSocialSecurityTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred social security taxes which are the result of the novel coronavirus pandemic ("COVID-19").</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DeferredTaxAssetDeferredSocialSecurityTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DeferredTaxAssetsLegalAndComplianceMatters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from legal and compliance matters.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DeferredTaxAssetsLegalAndComplianceMatters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax deferred expense compensation and benefits workers compensation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from amortization of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOtherLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible loss carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOtherLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from compensation and benefits, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from investments in unconsolidated subsidiaries and investments in other affiliates which are not controlled nor consolidated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from tax deferred revenue or income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675788410496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax benefits, beginning balance</a></td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions for tax positions related to current year</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions related to prior year</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions related to prior years</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</a></td>
<td class="num">(2.7)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax benefits, ending balance</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675795137296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK AND SHARE-BASED COMPENSATION - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (shares)</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (shares)</a></td>
<td class="nump">37,891,186<span></span>
</td>
<td class="nump">37,674,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (shares)</a></td>
<td class="nump">32,518,278<span></span>
</td>
<td class="nump">32,509,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_Percentageofownershipinsubsidiaries', window );">Percentage of ownership in subsidiaries</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Equity-based awards, number of shares authorized (shares)</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Equity-based awards, shares available for grant (shares)</a></td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries', window );">Percentage of total combined voting power of the Company and subsidiaries</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Percentage of market value for purchases under Employee Stock Purchase Program (percent)</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_CommonStockSharesAvailableForIssuanceToEmployeeStockPurchasePlan', window );">Common stock available for issuance under Employee Stock Purchase Plan (shares)</a></td>
<td class="nump">1,264,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense', window );">Employee Stock Purchase Plan expense</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted (shares)</a></td>
<td class="nump">33,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of equity-based awards</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan', window );">Common Stock Shares Authorized For Issuance To Employee Stock Purchase Plan</a></td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of equity-based awards</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_ShareBasedAwardsMember', window );">Share-Based Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_Fairvalueofshareofcommonstockpercentage', window );">Fair value of share of common stock (percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember', window );">Share Based Awards to More Than Ten Percent Owner [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_Fairvalueofshareofcommonstockpercentage', window );">Fair value of share of common stock (percent)</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted (shares)</a></td>
<td class="nump">33,656<span></span>
</td>
<td class="nump">40,788<span></span>
</td>
<td class="nump">43,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense</a></td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions', window );">Tax benefit from stock option exercise</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">27.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value of options outstanding</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic value of options exerciseable</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised during the period</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="nump">121.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense weighted-average period for recognitions (years)</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Contractual term of share-based award</a></td>
<td class="text">ten years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsMember', window );">Non-Vested Stock Units [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of equity-based awards</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsMember', window );">Non-Vested Stock Units [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of equity-based awards</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceMember', window );">Non-Vested Stock Units - Service-Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense</a></td>
<td class="nump">$ 12.1<span></span>
</td>
<td class="nump">$ 9.4<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 22.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense weighted-average period for recognitions (years)</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Non-vested stock granted, weighted average grant date fair value (usd per share)</a></td>
<td class="nump">$ 115.07<span></span>
</td>
<td class="nump">$ 234.42<span></span>
</td>
<td class="nump">$ 206.10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember', window );">Non-Vested Stock Units - Service-Based and Performance-Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense</a></td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 10.2<span></span>
</td>
<td class="nump">$ 13.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense weighted-average period for recognitions (years)</a></td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Non-vested stock granted, weighted average grant date fair value (usd per share)</a></td>
<td class="nump">$ 133.70<span></span>
</td>
<td class="nump">$ 262.67<span></span>
</td>
<td class="nump">$ 201.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_Performancebasedawardtargetshareamount', window );">Performance-based award, target number of units to be received (shares)</a></td>
<td class="nump">71,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance to the Company's employee stock purchase plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CommonStockSharesAvailableForIssuanceToEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares available for issuance to the Company's employee stock purchase plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CommonStockSharesAvailableForIssuanceToEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Fairvalueofshareofcommonstockpercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of a share of common stock, percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Fairvalueofshareofcommonstockpercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Percentageofownershipinsubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of ownership in subsidiaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Percentageofownershipinsubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of total combined voting power of the Company and our subsidiaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Performancebasedawardtargetshareamount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock units authorized for achievement of targeted performance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Performancebasedawardtargetshareamount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of plan compensation cost recognized during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=109244661&amp;loc=d3e17540-113929<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amed_ShareBasedAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amed_ShareBasedAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675807182112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK AND SHARE-BASED COMPENSATION - Employee Stock Purchase Plan Purchases (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="1">103 Months Ended</th>
<th class="th" colspan="1">127 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee Stock Purchase Plan shares issued (shares)</a></td>
<td class="nump">11,498<span></span>
</td>
<td class="nump">12,047<span></span>
</td>
<td class="nump">10,814<span></span>
</td>
<td class="nump">6,184<span></span>
</td>
<td class="nump">7,161<span></span>
</td>
<td class="nump">7,466<span></span>
</td>
<td class="nump">5,095<span></span>
</td>
<td class="nump">4,060<span></span>
</td>
<td class="nump">3,171,373<span></span>
</td>
<td class="nump">3,235,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased', window );">Price per Employee Stock Purchase Plan share issued (usd per share)</a></td>
<td class="nump">$ 71.01<span></span>
</td>
<td class="nump">$ 82.27<span></span>
</td>
<td class="nump">$ 89.35<span></span>
</td>
<td class="nump">$ 146.45<span></span>
</td>
<td class="nump">$ 137.60<span></span>
</td>
<td class="nump">$ 126.74<span></span>
</td>
<td class="nump">$ 208.19<span></span>
</td>
<td class="nump">$ 225.07<span></span>
</td>
<td class="nump">$ 17.89<span></span>
</td>
<td class="nump">$ 71.01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675804086192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK AND SHARE-BASED COMPENSATION - Stock Option Valuation Assumptions (Details) - Stock Option [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk Free Rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.38%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk Free Rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.35%<span></span>
</td>
<td class="nump">1.51%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free Interest Rate</a></td>
<td class="nump">1.91%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected Volatility, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.84%<span></span>
</td>
<td class="nump">40.15%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected Volatility, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.40%<span></span>
</td>
<td class="nump">42.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility Rate</a></td>
<td class="nump">40.97%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue', window );">Weighted Average Fair Value</a></td>
<td class="nump">$ 61.31<span></span>
</td>
<td class="nump">$ 107.45<span></span>
</td>
<td class="nump">$ 86.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The calculated fair value of a stock-based compensation award</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675807044176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK AND SHARE-BASED COMPENSATION - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 10, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number&#160;of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Canceled, forfeited or expired (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51,382)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218,612<span></span>
</td>
<td class="nump">273,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average&#160;Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 137.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Canceled, forfeited or expired (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142.86<span></span>
</td>
<td class="nump">$ 137.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average&#160;Contractual Life&#160;(Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted average contractual life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 6 months 21 days<span></span>
</td>
<td class="text">7 years 2 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, weighted average contractual life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments Related to Tax Withholding for Share-based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,981<span></span>
</td>
<td class="nump">$ 16,898<span></span>
</td>
<td class="nump">$ 54,493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_ExecutiveStockOptionExerciseMember', window );">Executive Stock Option Exercise [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number&#160;of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock (shares)</a></td>
<td class="nump">268,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_SurrenderedSharesInShares', window );">Surrendered Shares In Shares</a></td>
<td class="nump">231,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions', window );">Tax benefit from stock option exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments Related to Tax Withholding for Share-based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_SurrenderedSharesInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Surrendered Shares In Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_SurrenderedSharesInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amed_ExecutiveStockOptionExerciseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amed_ExecutiveStockOptionExerciseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675807494400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK AND SHARE-BASED COMPENSATION - Non-Vested Stock Option Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Number&#160;of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Non-vested stock options beginning balance (shares) | shares</a></td>
<td class="nump">129,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (shares) | shares</a></td>
<td class="nump">33,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested (shares) | shares</a></td>
<td class="num">(64,496)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Forfeited (shares) | shares</a></td>
<td class="num">(43,273)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Non-vested stock options ending balance (shares) | shares</a></td>
<td class="nump">55,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted&#160;Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested stock options beginning balance (usd per share) | $ / shares</a></td>
<td class="nump">$ 182.45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (usd per share) | $ / shares</a></td>
<td class="nump">143.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Vested (usd per share) | $ / shares</a></td>
<td class="nump">150.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Forfeited (usd per share) | $ / shares</a></td>
<td class="nump">173.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested stock options ending balance (usd per share) | $ / shares</a></td>
<td class="nump">$ 202.81<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675797352560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK AND SHARE-BASED COMPENSATION - Non-Vested Stock Units Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceMember', window );">Non-Vested Stock Units - Service-Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested, beginning balance (shares)</a></td>
<td class="nump">180,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (shares)</a></td>
<td class="nump">211,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (shares)</a></td>
<td class="num">(59,006)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled, forfeited or expired (shares)</a></td>
<td class="num">(70,025)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested, ending balance (shares)</a></td>
<td class="nump">263,153<span></span>
</td>
<td class="nump">180,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested, beginning balance (usd per share)</a></td>
<td class="nump">$ 195.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (usd per share)</a></td>
<td class="nump">115.07<span></span>
</td>
<td class="nump">$ 234.42<span></span>
</td>
<td class="nump">$ 206.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (usd per share)</a></td>
<td class="nump">146.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled, forfeited or expired (usd per share)</a></td>
<td class="nump">194.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested, ending balance (usd per share)</a></td>
<td class="nump">$ 141.62<span></span>
</td>
<td class="nump">$ 195.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember', window );">Non-Vested Stock Units - Service-Based and Performance-Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested, beginning balance (shares)</a></td>
<td class="nump">186,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (shares)</a></td>
<td class="nump">71,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (shares)</a></td>
<td class="num">(85,767)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled, forfeited or expired (shares)</a></td>
<td class="num">(104,486)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested, ending balance (shares)</a></td>
<td class="nump">68,047<span></span>
</td>
<td class="nump">186,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested, beginning balance (usd per share)</a></td>
<td class="nump">$ 206.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (usd per share)</a></td>
<td class="nump">133.70<span></span>
</td>
<td class="nump">$ 262.67<span></span>
</td>
<td class="nump">$ 201.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (usd per share)</a></td>
<td class="nump">156.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled, forfeited or expired (usd per share)</a></td>
<td class="nump">237.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested, ending balance (usd per share)</a></td>
<td class="nump">$ 144.55<span></span>
</td>
<td class="nump">$ 206.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_AdditionalPerformanceBasedAwardTargetShareAmount', window );">Additional Performance Based Award Target share Max Amount</a></td>
<td class="nump">32,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_AdditionalPerformanceBasedAwardTargetShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional stock units authorized for achievement of targeted performance if target objective is surpassed to the point of achieving the projected maximum payout</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_AdditionalPerformanceBasedAwardTargetShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675796503120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">27 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 27, 2016 </div>
<div>patient</div>
</th>
<th class="th">
<div>Jan. 18, 2016 </div>
<div>USD ($) </div>
<div>claim</div>
</th>
<th class="th">
<div>Nov. 03, 2015 </div>
<div>patient</div>
</th>
<th class="th">
<div>May 21, 2015 </div>
<div>patient</div>
</th>
<th class="th">
<div>Jun. 06, 2011 </div>
<div>beneficiary</div>
</th>
<th class="th">
<div>Aug. 31, 2017 </div>
<div>USD ($) </div>
<div>claim</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2010 </div>
<div>beneficiary</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 10, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyReceivableNoncurrent', window );">Indemnity receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Patient accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">296,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">296,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 274,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_HealthInsuranceRetentionLimit', window );">Health insurance retention limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_WorkersCompensationInsuranceRetentionLimit', window );">Workers' compensation insurance retention limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ProfessionalLiabilityInsuranceRetentionLimit', window );">Professional liability insurance retention limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_SC', window );">South Carolina [Member] | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_NumberOfBeneficiaries', window );">Number of beneficiaries | beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyReceivableNoncurrent', window );">Indemnity receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_IndemnificationAmount', window );">Indemnification amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_SC', window );">South Carolina [Member] | Hospice [Member] | Extrapolated [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_NumberOfBeneficiaries', window );">Number of beneficiaries | beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_SC', window );">South Carolina [Member] | Hospice [Member] | Unfavorable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of the overpayment made to the subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest', window );">Recovery amount of overpayment made to subsidiary including interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_NumberOfClaimsSubmittedBySubsidiary', window );">Number of claims submitted by subsidiary | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld', window );">Recovery amount of over payment made to subsidiary including interest withheld</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember', window );">US Department of Justice [Member] | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ReversalOfLossContingencyAccrual', window );">Reversal of Loss Contingency Accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember', window );">US Department of Justice [Member] | Massachusetts [Member] | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_Numberofpatients', window );">Number of patients | patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember', window );">US Department of Justice [Member] | Morgantown, West Virginia [Member] | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_Numberofpatients', window );">Number of patients | patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember', window );">US Department of Justice [Member] | Parkersburg, West Virginia [Member] | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_Numberofpatients', window );">Number of patients | patient</a></td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor [Member] | Florida [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,200<span></span>
</td>
<td class="nump">$ 25,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyReceivableNoncurrent', window );">Indemnity receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Accounts Receivable, Allowance for Credit Loss, Writeoff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ReductionToNetServiceRevenue', window );">Reduction To Net Service Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor [Member] | Lakeland, Florida [Member] | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of the overpayment made to the subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,000<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_NumberOfClaimsSubmittedBySubsidiary', window );">Number of claims submitted by subsidiary | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ActualClaimsPayment', window );">Actual claims payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ErrorRatePercentage', window );">Error rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementInterest', window );">Litigation Settlement Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_TotalLegalSettlementPayment', window );">Total Legal Settlement Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_LegalSettlementPaymentLessInterest', window );">Legal Settlement Payment Less Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor [Member] | Clearwater, Florida [Member] | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of the overpayment made to the subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_NumberOfClaimsSubmittedBySubsidiary', window );">Number of claims submitted by subsidiary | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ActualClaimsPayment', window );">Actual claims payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ErrorRatePercentage', window );">Error rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementInterest', window );">Litigation Settlement Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_TotalLegalSettlementPayment', window );">Total Legal Settlement Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_LegalSettlementPaymentLessInterest', window );">Legal Settlement Payment Less Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ActualClaimsPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Actual Claims Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ActualClaimsPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ErrorRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Error Rate Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ErrorRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HealthInsuranceRetentionLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments the entity could be required to make related to a specific Health Insurance Claim.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HealthInsuranceRetentionLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_IndemnificationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount to be reimbursed if and when certain assumed liabilities are paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_IndemnificationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LegalSettlementPaymentLessInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal Settlement Payment Less Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LegalSettlementPaymentLessInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfBeneficiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of beneficiaries who received services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfBeneficiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfClaimsSubmittedBySubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of claims submitted by subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfClaimsSubmittedBySubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Numberofpatients">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of patients</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Numberofpatients</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProfessionalLiabilityInsuranceRetentionLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments the entity could be required to make related to a specific Professional Liability Claim.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProfessionalLiabilityInsuranceRetentionLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recovery amount of the overpayment made to the subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RecoveryAmountOfOverpaymentMadeToSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recovery amount of overpayment made to subsidiary including interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recovery amount of over payment made to subsidiary including interest withheld</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ReductionToNetServiceRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction To Net Service Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ReductionToNetServiceRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ReversalOfLossContingencyAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reversal of Loss Contingency Accrual</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ReversalOfLossContingencyAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TotalLegalSettlementPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Legal Settlement Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TotalLegalSettlementPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_WorkersCompensationInsuranceRetentionLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments the entity could be required to make related to a specific Workers' Compensation Insurance Claim.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_WorkersCompensationInsuranceRetentionLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest expense (income) directly attributable to an award in settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyReceivableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of receivable related to a loss contingency accrual that is expected to be collected after one year or beyond the normal operating cycle, if longer. For example, an insurance recovery receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12053-110248<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyReceivableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_SC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_SC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_ExtrapolatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_ExtrapolatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_UnfavorableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_UnfavorableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=amed_MorgantownWestVirginiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=amed_MorgantownWestVirginiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=amed_ParkersburgWestVirginiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=amed_ParkersburgWestVirginiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_FL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_FL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=amed_LakelandFloridaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=amed_LakelandFloridaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=amed_ClearwaterFloridaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=amed_ClearwaterFloridaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675801639584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Insurance Programs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_HealthInsurance', window );">Health insurance</a></td>
<td class="nump">$ 16.2<span></span>
</td>
<td class="nump">$ 16.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_WokersCompensation', window );">Workers&#8217; compensation</a></td>
<td class="nump">40.8<span></span>
</td>
<td class="nump">40.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ProfessionalLiability', window );">Professional liability</a></td>
<td class="nump">5.0<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_EstimatedInsuranceTotal', window );">Estimated Insurance Total</a></td>
<td class="nump">62.0<span></span>
</td>
<td class="nump">61.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_EstimatedInsuranceLongTermPortion', window );">Estimated Insurance Long Term Portion</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_EstimatedInsuranceExcludingLongTermPortion', window );">Estimated Insurance Excluding Long Term Portion</a></td>
<td class="nump">$ 61.8<span></span>
</td>
<td class="nump">$ 61.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EstimatedInsuranceExcludingLongTermPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated insurance liability, excluding long-term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EstimatedInsuranceExcludingLongTermPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EstimatedInsuranceLongTermPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term portion of estimated insurance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EstimatedInsuranceLongTermPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EstimatedInsuranceTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated insurance, total</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EstimatedInsuranceTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HealthInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Health insurance, estimated liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HealthInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProfessionalLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Professional liability insurance, estimated liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProfessionalLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_WokersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Workers' Compensation insurance, estimated liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_WokersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675804438016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DefinedContributionPlanEmployerMatchingContribution', window );">Employer match amount</a></td>
<td class="nump">$ 0.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram', window );">Employee contribution amount</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage', window );">Maximum percentage of employee salary eligible for employer match (percent)</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">401(k) expense recognized</a></td>
<td class="nump">$ 18,600,000<span></span>
</td>
<td class="nump">$ 17,000,000<span></span>
</td>
<td class="nump">$ 12,900,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Percentage of Employee Salary Eligible for Employer Match</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan Employee Contribution For Employer Matching Program</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DefinedContributionPlanEmployerMatchingContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan employer matching contribution.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DefinedContributionPlanEmployerMatchingContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675801425968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE REPURCHASE - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1">17 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 02, 2023</div></th>
<th class="th"><div>Aug. 02, 2021</div></th>
<th class="th"><div>Dec. 23, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ShareRepurchaseLineItems', window );"><strong>Share Repurchase [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of company stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,878<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=amed_A2021ShareRepurchaseProgramMember', window );">2021 Share Repurchase Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ShareRepurchaseLineItems', window );"><strong>Share Repurchase [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of company stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramExpirationDate', window );">Stock repurchase program, expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">446,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Shares repurchased, weighted average price per share (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 223.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=amed_NewShareRepurchaseProgramMember', window );">New Share Repurchase Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ShareRepurchaseLineItems', window );"><strong>Share Repurchase [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of company stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramExpirationDate', window );">Stock repurchase program, expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Shares repurchased, weighted average price per share (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | 2023 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_ShareRepurchaseLineItems', window );"><strong>Share Repurchase [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramExpirationDate', window );">Stock repurchase program, expiration date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ShareRepurchaseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Share Repurchase [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ShareRepurchaseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date for the purchase of an entity's own shares under a stock repurchase plan, in the YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=amed_A2021ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=amed_A2021ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=amed_NewShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=amed_NewShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=amed_A2023ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=amed_A2023ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675806889344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable business segments</a></td>
<td class="nump">4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675796863104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Operating Income of Reportable Segments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">$ 2,223,199<span></span>
</td>
<td class="nump">$ 2,214,112<span></span>
</td>
<td class="nump">$ 2,071,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,300<span></span>
</td>
<td class="nump">34,372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">1,260,425<span></span>
</td>
<td class="nump">1,233,356<span></span>
</td>
<td class="nump">1,185,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses, excluding depreciation and amortization and impairment charge</a></td>
<td class="nump">754,100<span></span>
</td>
<td class="nump">711,200<span></span>
</td>
<td class="nump">668,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DepreciationAndAmortizationForContinuingOperations', window );">Depreciation and amortization</a></td>
<td class="nump">24,935<span></span>
</td>
<td class="nump">30,901<span></span>
</td>
<td class="nump">28,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charge</a></td>
<td class="nump">3,009<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,152<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">2,042,427<span></span>
</td>
<td class="nump">1,975,497<span></span>
</td>
<td class="nump">1,886,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">180,772<span></span>
</td>
<td class="nump">251,915<span></span>
</td>
<td class="nump">219,268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member] | Reportable Business Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">1,355,500<span></span>
</td>
<td class="nump">1,353,800<span></span>
</td>
<td class="nump">1,249,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,300<span></span>
</td>
<td class="nump">20,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">769,000<span></span>
</td>
<td class="nump">756,600<span></span>
</td>
<td class="nump">729,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses, excluding depreciation and amortization and impairment charge</a></td>
<td class="nump">348,500<span></span>
</td>
<td class="nump">328,500<span></span>
</td>
<td class="nump">307,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DepreciationAndAmortizationForContinuingOperations', window );">Depreciation and amortization</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charge</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">1,121,500<span></span>
</td>
<td class="nump">1,089,400<span></span>
</td>
<td class="nump">1,044,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">234,000<span></span>
</td>
<td class="nump">271,700<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member] | Reportable Business Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">787,800<span></span>
</td>
<td class="nump">791,800<span></span>
</td>
<td class="nump">750,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">13,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">426,500<span></span>
</td>
<td class="nump">425,200<span></span>
</td>
<td class="nump">400,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses, excluding depreciation and amortization and impairment charge</a></td>
<td class="nump">203,300<span></span>
</td>
<td class="nump">198,400<span></span>
</td>
<td class="nump">175,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DepreciationAndAmortizationForContinuingOperations', window );">Depreciation and amortization</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charge</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">632,100<span></span>
</td>
<td class="nump">626,300<span></span>
</td>
<td class="nump">579,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">155,700<span></span>
</td>
<td class="nump">171,500<span></span>
</td>
<td class="nump">184,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember', window );">Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember', window );">Personal Care [Member] | Reportable Business Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">61,400<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="nump">72,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">46,700<span></span>
</td>
<td class="nump">49,100<span></span>
</td>
<td class="nump">54,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses, excluding depreciation and amortization and impairment charge</a></td>
<td class="nump">9,200<span></span>
</td>
<td class="nump">11,200<span></span>
</td>
<td class="nump">12,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DepreciationAndAmortizationForContinuingOperations', window );">Depreciation and amortization</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charge</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">56,000<span></span>
</td>
<td class="nump">60,500<span></span>
</td>
<td class="nump">67,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">5,400<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="nump">5,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember', window );">High Acuity Care [Member] | Reportable Business Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">18,500<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">18,200<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses, excluding depreciation and amortization and impairment charge</a></td>
<td class="nump">33,100<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DepreciationAndAmortizationForContinuingOperations', window );">Depreciation and amortization</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charge</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">57,600<span></span>
</td>
<td class="nump">13,800<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(39,100)<span></span>
</td>
<td class="num">(10,300)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember', window );">Other [Member] | Other Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses, excluding depreciation and amortization and impairment charge</a></td>
<td class="nump">160,000<span></span>
</td>
<td class="nump">163,100<span></span>
</td>
<td class="nump">173,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_amed_DepreciationAndAmortizationForContinuingOperations', window );">Depreciation and amortization</a></td>
<td class="nump">15,200<span></span>
</td>
<td class="nump">22,400<span></span>
</td>
<td class="nump">22,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charge</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">175,200<span></span>
</td>
<td class="nump">185,500<span></span>
</td>
<td class="nump">195,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">$ (175,200)<span></span>
</td>
<td class="num">$ (185,500)<span></span>
</td>
<td class="num">$ (195,700)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DepreciationAndAmortizationForContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation And Amortization For Continuing Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DepreciationAndAmortizationForContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of patient service revenue recognized, net of contractual allowances and discounts, less the provision for bad debts related to patient service revenue plus all other revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675887493680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=amed_MedalogixMember', window );">Medalogix [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction, amount of transaction</a></td>
<td class="nump">$ 9.4<span></span>
</td>
<td class="nump">$ 5.7<span></span>
</td>
<td class="nump">$ 3.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=amed_MedalogixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=amed_MedalogixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139675806963920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS Narrative (Details) - Subsequent Event [Member] - 2023 Share Repurchase Program - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramExpirationDate', window );">Stock repurchase program, expiration date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date for the purchase of an entity's own shares under a stock repurchase plan, in the YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=amed_A2023ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=amed_A2023ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>amed-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:amed="http://www.amedisys.com/20221231"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="amed-20221231.xsd" xlink:type="simple"/>
    <context id="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i266eb829b984448ebdfabbddfb0be360_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="icd730d7570504ba281605ef8099ea7ec_I20230210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2023-02-10</instant>
        </period>
    </context>
    <context id="ieb5d1b02f637456e95eba5e2817a09ea_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3b13a726ce4740309bdc481148b0ab43_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iab144f7e34ce4a479683c59de399ff42_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4a842a348ea54e2aa7af78df38c5e42a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i812c4f7fd6e8491d8a6c1f0f7f2f0c8a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1184798dbf244669a8ac664a6a3e701e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i94b781b07d4d4409b8dcc3915918b994_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie7347a5a29b245a290ea5780c2f8e972_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i883b9612a1ce4040993b8d0c85aa8244_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idaad48809b5744fabff0426f64590228_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idbbf4b06ee8949419799fc4f109084c8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6914d90131e14c43a26dc97a98c426c8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i76caa3bd393e42e2ba1a0e9df9033378_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7be9b19ba9f7478f8d633e2083f22149_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7f85583bb3f049d3afa37b4d013dcf79_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i42b1e865f1ed4b2e8363dfcc39186a91_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iae6f76a71f3044fc83923db577d2d9bc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id9fa2aa843ed46e5b472b3eebcb45775_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i12929bbf3109412399f3172e7fddd206_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3f961b554cbf4c35b1fa83b2cd487b4e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8a5303400c1a425783f3183ad6fb484d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i95978a83297249e088bf477ac218a6d8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i83305f332a5848699f3e80d713ebcc32_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7a2c2693b2ff45998961c13ebdcfd739_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i95ad470da34d4eb9b8d8e685b7c60a58_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i73ef0a6e63d24e92b674d33b19f2b5ee_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie172076182c0492ea35971de45486231_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3a03e986997443978a0dd90f53d4f1dc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2079949881f8457b9711b22291635c52_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0475ea6bdae24921b04d181f1d8ee6d7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iab17129f66c14badb8c3affdd50289b4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icd498162f85e4b45bc79f00af8af6e6b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7bb8f10d82464615b7fd2f7df5d5bd4e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i18dba7744c814ab9907cd2868da0ddc6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2983eae666eb46e39d6a7d6ffe711703_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i964159f6265c4a9fa26afa837937e2a9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia0d005a9091143199e4be44f3a337678_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8ecdf11c833e48ba8909b67bec1dd8bc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id0db7a80feb5475f810c67719ce36ad3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic7f80dee79fe4ac684481f6cd7fd746b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i83862c03aee5480f950115749f6f0551_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie386fbdef29444a7b1e34af6f9fe68b2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i70cecdb6f3b04a83a501c7724ab21784_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9f3f8f64156c4928a36902ecbfdb0cc5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib60ffa9c6822423ca9d59d283467feaa_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amed:MedicareRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i30a242e707714a1eab7e611922efcc2c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amed:MedicareRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i66aac21e2a3b47cb9f000f260204e4ff_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amed:MedicareRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2f7b8ece18824575809137727a001ab8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4fb0b4ede01d45a8ac9f87b995dfc5bd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i466c99d823de4e3da04d3e6d94ea4feb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibc62063a43fb4e54a4eb1692d07bbee2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idaa8aedfe8c3470cbd124c76fae216cf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">amed:HomeHealthBenefitManagerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i31897eeed2424fdabfb8a7277396df7f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">amed:ConnectRNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i43a583e1be0e4362a0f5b5887d9c279a_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:TypeOfEquityMethodInvestmentAxis">amed:A49InterestSoldInTwoCareCentersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0e9dcae6e6af40a2a3ad82452046bbbb_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:TypeOfEquityMethodInvestmentAxis">amed:A30InterestSoldInTwoCareCentersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id9e57117e59349509aa17240e4b739bb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:TypeOfEquityMethodInvestmentAxis">amed:MedalogixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9dc0472ea16a4281be6243dd9c20268f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7265ebd4cec34caa817f807dc1d6cbc1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0b27a458690140b59e1f60faae27b54c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i18a8ecfea90b46dea16770739b772958_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">amed:HeritageHealthcareInnovationFundLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i332e5cf83f704c55b25091d8aac22686_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icc45e2e2cecf43c7a6bdb033a411f0dc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0ef480ba6e114f2599922f6fecdb6adc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4b7d185a3a5845299460ef91d19e3737_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i20f7b2610db946b6b2c5a7131a2c6402_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i045954bc2da64e639f3d2657db45c8c6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie68834514d89475fa05705e2a104287c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3293bf9528d2455dbef45aa497f1802f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if428e0eafe734ae298c1d7e4fd10018f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i404ba799d43b4f9cbc11bd0f031fa84f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iaf2d05881bc84546bd58a3bfa9971f2a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ife774e47b4e649bbb69a2233094f5f4b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9bb3b80738f34bf39ce177e3aa4c2391_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id3f54ce15271460d90fc908cd65314f0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8da51266d38e4113b6deb81ba671c1f4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i417cb5125535485c9ef0320496af5e26_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9d4251ae99c943f193588862db0c1b69_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i72cdabc594824ec3a9da4123e53b9fbb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia8691440b2404ff496cc413ef83e5825_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic803d3d531314ae89f73add64e4be217_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2045ac339bf340c48bb59e921fe05def_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i89bafb018d3a43eb8a3f1bbb4c93b71b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1a4434e079494d01969542db2a51ebee_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie8d7fbaae8144d01ae5b61ba948ca043_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6d7eeb1ee5ac46b29435cfd337b5b8a7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3d86e0102e724a01b5f8cbf75e5ad801_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id22ec472968f424eaedee0df2c1a6a6c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2c715413d797438591b1cf5dd86e46fa_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifd1a9219629443d5bd28be1543aad1fe_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie980f7f172dd4fc384952e9b8c0724f0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:VariousAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i19a05af82bb1454eb68e81cc291cbc07_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:VariousAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9a008987e83a4ada9f3b12cc812bd0a1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibe86b23f247c43068f7f25f069252db2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic14d437ad5074709988cb2cca394f95f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amed:EquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i000722521f3240b491676997b1fb573f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amed:EquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i21ca39c2911849ffa737ddd3e958f192_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if9c24eced7104a4e97d673f1e2ca0501_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6c4545751ceb443c93f828600b08a087_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4a34fcd3e4ca44f997870b28af217929_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1c1fcea9f947413daad53be6d9712b19_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i289606829e684a02a13b4c2d309ec6a3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amed:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icd970c25fe194ee8bb233e64dbeeb49b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amed:BuildingAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5efc684324124683b1a591012cf24d74_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amed:EquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i75cc8e8f3048499ea5dff437d4511970_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amed:EquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6b2a5e41e9ee4551ba7962246c513287_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetsHeldUnderCapitalLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic9e60ab572054136b724859b7d07a982_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetsHeldUnderCapitalLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i87145fca776747b8862566f844f11da8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i450c80a3586442a8bc78d59bb78f68ce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5ebb0aba87354b6e94fa00495eb40c4c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7ba082d05d43495b95f7c201e8451ff3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iff5859d4cb064056a2a55fa3dc5feb6f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8990c36c1ca24b9b9986a1b57a6b70aa_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i00b2929fc5c94edaa315a2c9b947f6d0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ide5ecdbd8c87484b981d596040ebe425_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0b4aa69adae3479e99bf23edae8da8b3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6711eaed3f0d4ee694ed7955ac3b1e03_I20200327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2020-03-27</instant>
        </period>
    </context>
    <context id="i6d7e910da92c42bc90993e8096f3b599_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i5316c48403b245d7a32babf7c76d35ac_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="idfa6a89efdee40b3b7b70040f4cc830d_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i5b33f1ef384d4000bd6fb60c0d49e71d_D20200401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i144647094c4a4625802e08748d886f42_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="if61757dea5844f219019c3a64a1972b4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">amed:COVID19DeferralOfSocialSecurityTaxesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0530cc1fa306423dba7c186bb6ab97cc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">amed:COVID19DeferralOfSocialSecurityTaxesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i24fd071f2c354373829031fc28f4be1b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">amed:COVID19DeferralOfSocialSecurityTaxesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i06f200e2df374ac19cb47bab63a56b3f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i329d3927fede4bdf9fab592d7ad5bbca_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:A2022NewJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i34442d4c2cdd49e8ad3bacd82824cc9b_I20220323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:A2022NewJointVentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="ib16b4cdc559b48b48aaca7b7709eccf7_I20220323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:A2022NewJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="i3ee24d260ef448cd85330a7919fef9a6_D20220401-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="ib5a9c836f91a48a19480bcf0f161b5ea_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="ie5385a5f630f492ca9a57b76acb56832_D20220401-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="amed:BusinessCombinationAdjustmentsAxis">amed:PotentialClosingPaymentAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i5164993430b74c95b0e12d477628d1e3_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7d98a7f596b54b549b3e1d6ace83797e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i71d46c678b1f4800889099f17f5f7799_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i28853129c6904eb18dd32328ff6639b9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5ce5ed93672d4ebbba91deaaf07e6054_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:EvolutionHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:LicensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9515534e01de4100ba0629e25ec08585_D20220401-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i2021555b705242a99ec6febf31d7a964_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="icb92529d6381424facef8b4b61830b50_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i599a4a53807b476383b1600b004d88dc_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:LicensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i1bf01ffe6b0244e5921dd50351b7b4e7_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i43eafef87dff4c529ba66562fa0cf94e_I20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="i8e2142a5ef784762a3c038048115d45d_D20220401-20220401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AssistedCareHomeHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="i9b54240bf3d2420990c7a9096aefde0b_D20210501-20210501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:RandolphCountyNorthCarolinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-01</endDate>
        </period>
    </context>
    <context id="ie00945c9207e49129104d8327cdab5ac_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:RandolphCountyNorthCarolinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6b9388aa1085440fb4ae49552b5eac30_I20210501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:RandolphCountyNorthCarolinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificateOfNeedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-01</instant>
        </period>
    </context>
    <context id="i3a6a5482d808478ca8d187e7994862e3_D20210701-20210701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:VisitingNurseAssociationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthAndHospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-01</endDate>
        </period>
    </context>
    <context id="iead9a275ae234dd58c7aa7d6084ed1a8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:VisitingNurseAssociationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthAndHospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie4e5e1d9f2c04c828295e9928469b871_I20210701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:VisitingNurseAssociationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:LicensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthAndHospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-01</instant>
        </period>
    </context>
    <context id="id09c2a6d2e8c408fbdffeec1f5145603_D20210712-20210712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-12</startDate>
            <endDate>2021-07-12</endDate>
        </period>
    </context>
    <context id="id4df44aa40d846c888dfefff67b0441e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i52779ae3c4594b42bfa6a1f5c28042c3_I20210712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificateOfNeedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-12</instant>
        </period>
    </context>
    <context id="ia9ad18fcb7674a4ca8ca6600d605a491_D20210801-20210801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-01</endDate>
        </period>
    </context>
    <context id="i63526fb29695460daf7c8961c2d352cc_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2df95a1c5f0f44979741b294afe8e34f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia0cb3457d3634ebab6e8f002cf82c20c_I20210801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-01</instant>
        </period>
    </context>
    <context id="id0b5f88e95e24345a3cc0fc5516016cd_I20210801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-01</instant>
        </period>
    </context>
    <context id="i337a7e831425489abb80a0847c6f2a4b_I20210801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-01</instant>
        </period>
    </context>
    <context id="i3ab1ecd500d7495dae3df1070f41f7cb_D20210801-20210801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-01</endDate>
        </period>
    </context>
    <context id="ib97247344bf049d2bffeb43e431f858c_D20210801-20210801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-01</endDate>
        </period>
    </context>
    <context id="i39143f0cd5e04faf9cb6b93e100ed3a7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i361c6850de2f4f6caca843b2cad888d0_D20211018-20211018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-18</startDate>
            <endDate>2021-10-18</endDate>
        </period>
    </context>
    <context id="i2ed696897d0041f897bb1b2722b9e756_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7063e6037ddf43518429b892fa7cc4a8_I20211018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificateOfNeedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-18</instant>
        </period>
    </context>
    <context id="i51977ad5557047dd858b744031685543_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2b006d894f5b438ca664557b42c11392_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7751bbf329e84761a9116e25c1dcb3c3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i200744aa491542f088ed7c2507164bf0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i17c7b35f5a01427b9c32a21c25a8f6c0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic26ea180cb834e98a9002bae772f59e2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if15a919ad56a4337a9e1425b3d811e04_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i28bb5f40eceb4433925f35b9ac96a7d6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3e7c7cfb405d44b8814669a0483f033c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i279e0b1e700047bf850eaae20ab0fa8f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i53953caaedb34bb19c4ac51bc0d443fd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i306ee8d06e3d4ce9aedc1f8ceaa8c3a6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5f5fa4f13a1b44e0bb2bbf24f19d98ee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i44541ba456f945819b774b06105dc6c8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:UnamortizableAcquiredNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i00a4803566c64d9ab540401d7fabdd92_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AmortizableAcquiredNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6d01709de86048228674a5671c0c2757_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i07c90a9f4c064c94bff73ae8df530042_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib63a631603bd42f9baf706aaa6b526b0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifff3b1dd516d4ca88196cc4ffb04052e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:UnamortizableAcquiredNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie8422ab7dd1f4a4f8d174c43529c7198_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AmortizableAcquiredNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ida06184838c44dd1bcfc0a1cfbb4fa09_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icfe3ab0bd83e411e92a0dd230a06c08b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9523618072184796b42e15f02c400bf6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4ecf9ee75110493892617267abbac656_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:UnamortizableAcquiredNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1b3d453ff35049aca81a81d5e4f888a8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AmortizableAcquiredNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0f475dca4f124f1595292633d4e5f191_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7b493d5524cf479ea3603709ff2740c8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied840af486324d3b938d05e97bc6b784_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5d8cd69d4e1c45f08f19939d27d4ae62_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:UnamortizableAcquiredNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3b384340c0b449dc85760ae9232d9127_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AmortizableAcquiredNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i839a632511504949957616ab961bc135_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i60bbec5fe5254517bcba03cfb32af2a8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie1fdd03a76db4dd099fcd6639124379e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">amed:UnamortizableAcquiredNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i60f209194f5e43898d6ddf2a2eef8d68_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AmortizableAcquiredNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6e005cf326124f079141ed28e6ca38da_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i89dfc092633c4ce0845425c7e17c37c3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i21a308e1f5cd4afdbceafc5966fb3595_I20230210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-10</instant>
        </period>
    </context>
    <context id="i2d9433232b954207a3e4c9d8333d21a2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iabc17e0bc0164f2ab68e1dacdbd3fa3a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i242800e8bae14013ad55b6c47fc0d95c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:LeaseTypeAxis">amed:FleetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5b6ef7c6980a4e1db02f8ba15b55658c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amed:CurrentPortionOfLongTermObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i51a68f127e8d4d428c82dc489e61cc98_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amed:CurrentPortionOfLongTermObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i57ced13309e04a01b09898e7b88dd6f0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amed:LongTermObligationsLessCurrentPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i56be49fb71c4480598cef05e8ba9605a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amed:LongTermObligationsLessCurrentPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iee6010de5eaf4258ad77ac9f7a65376e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amed:CurrentAndLongTermObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i11cb8a9911234299b66dee77ff4909b4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">amed:CurrentAndLongTermObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1fafeebfd1ab4899a21ae02fae464c83_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i03c7e40c5f95416f9b140b596a1f186a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7909f4de3b454ec89111061cf24a2773_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">amed:TelehealthKitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8f4fcaea6b154a0bbd917fba61d92e52_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i916f340079654056b2571fa1ce003955_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3a8567395eba45968f1f59959fef3ffb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic6c3d510a20748ce9ea87e61c6e92cc4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iacc4528c818b4326ae050e255a5a7a3e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idc761fea5e584f6080ec28aa409e26d2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8b6a940fe41e4c4e9bd71fc532b5f27c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2ebd597356dc40a6baa7eabf9da5fb56_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4bb00aa3ab56488ea6e59211d0ec0f49_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id86557107c34492d8c132ad64570a3ed_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icbdaead26d8b4e69b17a84ea4692f399_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i178263b3689c4dbeb4183a1b2a8f06f4_I20180629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-29</instant>
        </period>
    </context>
    <context id="i204f7f8314234638a578a2852af0430f_I20180629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-29</instant>
        </period>
    </context>
    <context id="i76cb131f8a16465eb2fc15903e2b579d_D20180629-20180629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-29</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="ic1af0127cb3643d8b17864fcb195bfd5_I20190204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-04</instant>
        </period>
    </context>
    <context id="i3178979288cb4514826472f72e5bfb60_I20190204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-04</instant>
        </period>
    </context>
    <context id="iba0cc26b6786477a93c245c64b48976e_I20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-30</instant>
        </period>
    </context>
    <context id="i1bb8d308c9224e5b844d2c6db275e492_I20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-30</instant>
        </period>
    </context>
    <context id="ia3eb443904904bc78906ce21c0d215af_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="i07211fe9ad5d4482bd6b137633c2aa1d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ida7bcb808f0e4c318ec059d9ceff470a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iaa67d7d55667443394ca159d57aa511b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ice4835f824f5444f94f1ecd506168658_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie35e7d51c69e442a9aaed895a70d075f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ife65de97c43c4ff38decb113044c4058_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3f84542d7b53490e9e21f12a81a49347_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5ca3fedd3e1b4c93a4622a8fb6dc1a1e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i17742e3ab61d4196b516dfbe59d556fd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib6d924aa96d649d1b106241f0f9d3dc6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibf4da83d5cea4929a377d16e2a794965_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i96a9d31440c94da5a965cfe8fea3f233_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0e09b2632feb4e60a63f4f0811a7e6f8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie6453a68ab024f0481790410c647ca02_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia3fe9ab766bf4b6aac1a8ef448a228af_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0fb8d922ed7840eba4d9f5c8439d8634_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6144bb4d6ba64536b8a021e88b94f277_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia5b4115d16ee4985a95f2ba4f5411a8b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icb4d003ebe754bc288a304ab991ccff7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i346c9bba84d040c583bc1c161bbc63a2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:DebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i492cad6b4f6d4dff915ecfdc41239333_D20210730-20260730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2026-07-30</endDate>
        </period>
    </context>
    <context id="i0b1fdf13b14f42838235e12dc847d78f_D20210730-20230930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="ia4e912d799f345eb811d0a45ef8aad22_D20231001-20260730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2026-07-30</endDate>
        </period>
    </context>
    <context id="i7ac0dcfcf2f843d2ac033b98c430f309_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="ie72df9520c04416783c5c1351b95aa45_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if7b0d6790e424eb28816c7faa3cbcaf5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i31b64bb9856d4b7ab6ed7600628a1276_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib5660c9b896a4ecaa1234048bbedeafa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i41fd72dfb82543b4af87db7a75cd295a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if39b026dc9a34fbe996e7be93272debd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id0706f579da046e79bf159bafde70b5e_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="i4b1209d2737e48bd9bdbd36398d6f1ee_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="if7805668b7a84f7d95cb285d7db5a548_D20200810-20200810">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:ExecutiveStockOptionExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-10</startDate>
            <endDate>2020-08-10</endDate>
        </period>
    </context>
    <context id="i287e698cf9eb4bdfb671be9b8b48fffc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:ExecutiveStockOptionExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibace990f785a497b98867b384cd11b5f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:ExecutiveStockOptionExerciseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i039df82eb47c4820a0f22e9789c65e30_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:ExecutiveStockOptionExerciseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i956eb24e24e0444b86f101edaf26c1b4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="amed:UnrecognizedTaxBenefitsAxis">amed:NetOperatingLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i47060e74f1c24113966bf5b707b10e09_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="amed:UnrecognizedTaxBenefitsAxis">amed:NetOperatingLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3cc7c6096a3746f28dfa0ec43e47b91a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">amed:StateTaxCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9a6f6b5c67ab4519b50f44d3984d3460_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:ShareBasedAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i29922553b57d4a4f913d8dc9ac058907_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:ShareBasedAwardsToMoreThanTenPercentOwnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8f97dee560fa43f381b21ce637429d33_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iaab2533120e743218b94d1ca1acd32ae_D20120607-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2012-06-07</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i88f7ee58380e478992f80d0861c1607f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id59b7e2a3058490b9b7c36016e54fda5_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9ab351315e174023b86cc7cc10277227_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if75caf01fb8b4cf59e6837df49b4e315_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iadba656fc0c44917b7651f7ad78cbd0c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib60868f2b1d84557b45341890a39d860_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic5c669dea2424147a7e748e8a71c927c_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4df39100e7da46d49d9439da9cf924d8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i611f679bc0fc435c9e898dad11348fcf_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5e118c828cfd44b387ff3fef4f4d36ec_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ide0d67cdc1d84448bde7a943cb636abd_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7b2fa1ac38fb4e9f99f2949b063d86c5_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i39be0476e53e4678b7f5eebe2f65b0d1_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7e2596f2753a45a9b4ddde231581db8b_D20120607-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2012-06-07</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i06eb9ed545f04bdcbf647b341b4ab114_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic8002223ee9342dbb6725f50e35539b6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i15f9883719504dad940b79d91d5a68cf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i14c451d987c9475fa3c8992bc94cbf8f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i24418f4a250c4f51b8e485261ec4b457_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4248f5c857bb4a3dbdce56078e7b58f5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icd5a663f1bb844bab57b874fbf18534e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i52a228fca81e41d693cd6d81c49a90c4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i11c1dc78db0e49b68f847e221371a443_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifdd8f4e213094cc396d0fcbfc8c7cc13_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1e87c3e7b1004ea799c3dc520a7f0a4e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i082da853b55e488ab9ef8c389ed4b49f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceBasedAndPerformanceBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia5b0758fc5c841c69f0e3000600e3618_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceBasedAndPerformanceBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iecabe05cd8be4b96a216b1a6513dcb34_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceBasedAndPerformanceBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5aa28b6040cd4209a28424a8ddb8c083_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceBasedAndPerformanceBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2d8e565a484b4115a30a498efd2fead8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:NonVestedStockUnitsServiceBasedAndPerformanceBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i72f8833e23b44a2ea0d2a7d9a3387fad_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic191fcc8192b4608959c14133dc12c5e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ieba00eb7d405413d818c4971105613ee_D20150521-20150521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-05-21</startDate>
            <endDate>2015-05-21</endDate>
        </period>
    </context>
    <context id="i8d55411f20e04d00a2eea8301fc2ae5a_D20151103-20151103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:MorgantownWestVirginiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-11-03</startDate>
            <endDate>2015-11-03</endDate>
        </period>
    </context>
    <context id="i011327a38e254fcaa937ffb2732985d4_D20160627-20160627">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ParkersburgWestVirginiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-27</startDate>
            <endDate>2016-06-27</endDate>
        </period>
    </context>
    <context id="ic16a0c94f3004de7b7a900a946d92672_D20080101-20100331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2008-01-01</startDate>
            <endDate>2010-03-31</endDate>
        </period>
    </context>
    <context id="if1bca261c0b946248dfe5cee858c643d_D20110606-20110606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:ExtrapolatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-06-06</startDate>
            <endDate>2011-06-06</endDate>
        </period>
    </context>
    <context id="i5d52cf787d4f4a21ba644c6537028eca_I20160118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-18</instant>
        </period>
    </context>
    <context id="ibd850077008b489db6c689d6678a854b_D20160118-20160118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-18</startDate>
            <endDate>2016-01-18</endDate>
        </period>
    </context>
    <context id="if8e53a67d325418698e7dff0da8ae0f8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i29b899adcb534d2fb11ae45ba13dffa5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i38abfa2908c74f76a39c59f03f0a1f88_I20190110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-10</instant>
        </period>
    </context>
    <context id="i5ad4b2a4d1904246a60f312fe6e54a55_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="i5d9c1bb997894061aeafb6aabddeffd5_D20170801-20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="id957a4e2cf624f1f8c0755fef660c4fc_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="ica936df2e1054ec1b0ff8eb6510dfbcb_D20170801-20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="i7d88d76487a74a848baa03e874a5eccd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ieaeca3977d8a40ec9994588b4150109b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id2c6967c53284f0ea2b6b8001c55cacd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7c5014c365be4c5d90c38959f215dfb5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ieefca07772a441c18ef7fd78ee354800_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic41315c634e841cc9d84abadce65303b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i868f83b3f18641769d70c97c93d30912_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib79f3470b4c9406fa918cc4fbe458ad1_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie2ead6d6a5b24846a24cab167648cd41_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i23cfc9c5f5334cb98796bce037009c13_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6b610aa7397640f8a2fa1d7a074bd768_I20201223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:A2021ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-23</instant>
        </period>
    </context>
    <context id="if0c9423c441c4978b769e4a86bc9188f_D20201223-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:A2021ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-23</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib4261a3345d54d03886673d73969d061_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:A2021ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia01a4c270b254b66aa3015655785be61_I20210802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:NewShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-02</instant>
        </period>
    </context>
    <context id="ic922798f82384a0cb1c5e20555cd93c6_D20210802-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:NewShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-02</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9fdb42e0a3874ea5a19076aa86bff340_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:NewShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i92bd39f0d2544264b7d724dd1ae6eac3_I20230202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:A2023ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-02</instant>
        </period>
    </context>
    <context id="i4b423f65ef9c451d935438afdcfc2e15_D20230202-20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:A2023ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="icff92844bf7e45cf8941114000e0fa42_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i971b271744ea4a63aca16276f887bcb4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9e623706c1354124a369dc7758938060_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i47b68ba2f13e424bacfacf577053382b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i114e5c43f13843719a8a60aa9fd64db1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifc3b9823141645e68eb892a3c076e69b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6c8bd5c211c94e959f7bcc237d284961_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifc02119e099f490a8a653314b18712d4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i722dd3d3be554fc1bcbc003ddc943c6a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2a8daa3605c04f07bf026bdc825236d7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id362cc93e6cd48da8f96f15cbc8bed2e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6db8f1d2d01b4b87b43031a471f0a747_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iad09634e54b64f4ab4f376450c10a9fe_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if5e19c6308394df88a3ac225cead2412_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i55522935511e4608b35d61ba4b0cb9d2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i65690d26701e4e5ea588f0959375f58b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">amed:MedalogixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idaf95b2f3ae241fa85a7edcd22950e29_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">amed:MedalogixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib9c94f55e0204d55a40837adab0df9ec_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">amed:MedalogixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="care_center">
        <measure>amed:care_center</measure>
    </unit>
    <unit id="numberofjointventures">
        <measure>amed:numberOfJointVentures</measure>
    </unit>
    <unit id="state">
        <measure>amed:state</measure>
    </unit>
    <unit id="number_of_visits">
        <measure>amed:Number_of_Visits</measure>
    </unit>
    <unit id="patient">
        <measure>amed:patient</measure>
    </unit>
    <unit id="beneficiary">
        <measure>amed:beneficiary</measure>
    </unit>
    <unit id="claim">
        <measure>amed:claim</measure>
    </unit>
    <unit id="segment">
        <measure>amed:segment</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV80L2ZyYWc6OTJhYTJmZGU1Yzg1NDgzMWI3NWZlOWNlZjE5ZTQwNjgvdGFibGU6OGY0OTViZDI4NDE0NDViNzgyN2EyYjU3MDIwOTYzZDcvdGFibGVyYW5nZTo4ZjQ5NWJkMjg0MTQ0NWI3ODI3YTJiNTcwMjA5NjNkN180LTEtMS0xLTUwNzI1_21ac5da5-9da0-4696-85f2-4b75924b8945">false</dei:AmendmentFlag>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV80L2ZyYWc6OTJhYTJmZGU1Yzg1NDgzMWI3NWZlOWNlZjE5ZTQwNjgvdGFibGU6OGY0OTViZDI4NDE0NDViNzgyN2EyYjU3MDIwOTYzZDcvdGFibGVyYW5nZTo4ZjQ5NWJkMjg0MTQ0NWI3ODI3YTJiNTcwMjA5NjNkN181LTEtMS0xLTUwNzI1_2a15092f-0699-4600-b4df-7f7e1f1e6206">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV80L2ZyYWc6OTJhYTJmZGU1Yzg1NDgzMWI3NWZlOWNlZjE5ZTQwNjgvdGFibGU6OGY0OTViZDI4NDE0NDViNzgyN2EyYjU3MDIwOTYzZDcvdGFibGVyYW5nZTo4ZjQ5NWJkMjg0MTQ0NWI3ODI3YTJiNTcwMjA5NjNkN183LTEtMS0xLTUwNzI1_91c8946d-b25b-41df-80ec-f48e797a08b6">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV80L2ZyYWc6OTJhYTJmZGU1Yzg1NDgzMWI3NWZlOWNlZjE5ZTQwNjgvdGFibGU6OGY0OTViZDI4NDE0NDViNzgyN2EyYjU3MDIwOTYzZDcvdGFibGVyYW5nZTo4ZjQ5NWJkMjg0MTQ0NWI3ODI3YTJiNTcwMjA5NjNkN184LTEtMS0xLTUwNzI1_fb236a3c-f6cd-4361-958f-b99385c1b2b5">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV80L2ZyYWc6OTJhYTJmZGU1Yzg1NDgzMWI3NWZlOWNlZjE5ZTQwNjgvdGFibGU6OGY0OTViZDI4NDE0NDViNzgyN2EyYjU3MDIwOTYzZDcvdGFibGVyYW5nZTo4ZjQ5NWJkMjg0MTQ0NWI3ODI3YTJiNTcwMjA5NjNkN18xMS0xLTEtMS01MDcyNQ_0e0af890-d6fe-4fe2-9cfc-d07ecd4200e3">0000896262</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV80L2ZyYWc6OTJhYTJmZGU1Yzg1NDgzMWI3NWZlOWNlZjE5ZTQwNjgvdGFibGU6OGY0OTViZDI4NDE0NDViNzgyN2EyYjU3MDIwOTYzZDcvdGFibGVyYW5nZTo4ZjQ5NWJkMjg0MTQ0NWI3ODI3YTJiNTcwMjA5NjNkN18xMi0xLTEtMS01MDcyNQ_77deb875-d8f8-4d7d-b64b-936f2be04ee2">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="i18a8ecfea90b46dea16770739b772958_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83Ni9mcmFnOmE2ZDU3OTMyZTg5YzQ3YjJiZTRjMmNhNzY5NzJiN2JkL3RleHRyZWdpb246YTZkNTc5MzJlODljNDdiMmJlNGMyY2E3Njk3MmI3YmRfNTU_3685d894-7fab-4712-8676-2a5241ef9106"
      unitRef="usd">-3000000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i5ebb0aba87354b6e94fa00495eb40c4c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjg1OTA_1486623a-649a-4c91-b48e-f23d489bb99f">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84Mi9mcmFnOmIxNzE2N2NiZDZkYjQxY2ZiNzQ4NzMzODEzNTQ0ZTBhL3RhYmxlOjZmYWNlZjNjZTBlMTQxYjg5OTI1ZWIyZGFjYTRjODc5L3RhYmxlcmFuZ2U6NmZhY2VmM2NlMGUxNDFiODk5MjVlYjJkYWNhNGM4NzlfNC0xLTEtMS01MDcyNQ_23b89b73-2db2-4a8d-a55f-643213e6b2dd"
      unitRef="usd">115372000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:OperatingIncomeLoss
      contextRef="i28853129c6904eb18dd32328ff6639b9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV85MS9mcmFnOmMxZGY1NjBiOGNiMzQ3MWI4NzEzYTA3OWQ4NGRlNjAyL3RhYmxlOmQ4NTc4Mzg5YzAwOTRkZWVhMThlNWM2MzQxNjJjMmMzL3RhYmxlcmFuZ2U6ZDg1NzgzODljMDA5NGRlZWExOGU1YzYzNDE2MmMyYzNfNS0xLTEtMS01MDcyNQ_98df1124-e97b-480d-aa38-643c379eb40f"
      unitRef="usd">-5300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2df95a1c5f0f44979741b294afe8e34f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV85MS9mcmFnOmMxZGY1NjBiOGNiMzQ3MWI4NzEzYTA3OWQ4NGRlNjAyL3RhYmxlOmQ4NTc4Mzg5YzAwOTRkZWVhMThlNWM2MzQxNjJjMmMzL3RhYmxlcmFuZ2U6ZDg1NzgzODljMDA5NGRlZWExOGU1YzYzNDE2MmMyYzNfNy0xLTEtMS01MDcyNQ_68812500-02b3-46d8-bc2b-da50b449ccc3"
      unitRef="usd">-39100000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i39143f0cd5e04faf9cb6b93e100ed3a7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV85MS9mcmFnOmMxZGY1NjBiOGNiMzQ3MWI4NzEzYTA3OWQ4NGRlNjAyL3RhYmxlOmQ4NTc4Mzg5YzAwOTRkZWVhMThlNWM2MzQxNjJjMmMzL3RhYmxlcmFuZ2U6ZDg1NzgzODljMDA5NGRlZWExOGU1YzYzNDE2MmMyYzNfNy0yLTEtMS02MTU4NQ_170c62db-c59e-4e0f-842c-002f3e79d966"
      unitRef="usd">-10300000</us-gaap:OperatingIncomeLoss>
    <amed:IncreaseDecreaseInAssetsAcquired
      contextRef="i28853129c6904eb18dd32328ff6639b9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV85MS9mcmFnOmMxZGY1NjBiOGNiMzQ3MWI4NzEzYTA3OWQ4NGRlNjAyL3RhYmxlOmQ4NTc4Mzg5YzAwOTRkZWVhMThlNWM2MzQxNjJjMmMzL3RhYmxlcmFuZ2U6ZDg1NzgzODljMDA5NGRlZWExOGU1YzYzNDE2MmMyYzNfMTEtMS0xLTEtNjE0Njk_5927a058-70ec-4679-a54e-720ccd0dbaa4"
      unitRef="usd">-2100000</amed:IncreaseDecreaseInAssetsAcquired>
    <amed:IncreaseDecreaseInLiabilitiesAssumed
      contextRef="i28853129c6904eb18dd32328ff6639b9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV85MS9mcmFnOmMxZGY1NjBiOGNiMzQ3MWI4NzEzYTA3OWQ4NGRlNjAyL3RhYmxlOmQ4NTc4Mzg5YzAwOTRkZWVhMThlNWM2MzQxNjJjMmMzL3RhYmxlcmFuZ2U6ZDg1NzgzODljMDA5NGRlZWExOGU1YzYzNDE2MmMyYzNfMTItMS0xLTEtNjE0NzE_8372a70a-1bdc-44d3-b341-a22e51043417"
      unitRef="usd">-300000</amed:IncreaseDecreaseInLiabilitiesAssumed>
    <amed:IncreaseDecreaseInLiabilitiesAssumed
      contextRef="i2df95a1c5f0f44979741b294afe8e34f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV85MS9mcmFnOmMxZGY1NjBiOGNiMzQ3MWI4NzEzYTA3OWQ4NGRlNjAyL3RhYmxlOmQ4NTc4Mzg5YzAwOTRkZWVhMThlNWM2MzQxNjJjMmMzL3RhYmxlcmFuZ2U6ZDg1NzgzODljMDA5NGRlZWExOGU1YzYzNDE2MmMyYzNfOS0xLTEtMS02MTc5Mg_f491d039-3e3a-4b40-bab0-a54f2f6a2275"
      unitRef="usd">-2800000</amed:IncreaseDecreaseInLiabilitiesAssumed>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i2df95a1c5f0f44979741b294afe8e34f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV85MS9mcmFnOmMxZGY1NjBiOGNiMzQ3MWI4NzEzYTA3OWQ4NGRlNjAyL3RhYmxlOmQ4NTc4Mzg5YzAwOTRkZWVhMThlNWM2MzQxNjJjMmMzL3RhYmxlcmFuZ2U6ZDg1NzgzODljMDA5NGRlZWExOGU1YzYzNDE2MmMyYzNfMTAtMS0xLTEtNjE3OTU_ae8b8cc7-29f8-4a75-b704-f04c3206a804"
      unitRef="usd">-2800000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i2d9433232b954207a3e4c9d8333d21a2_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90ZXh0cmVnaW9uOmJiNDEwNTZmMDg4MjQ1MTA5YTBlMWZmY2IxMGRiN2U2XzQyMw_4521311a-fbff-4d4f-a200-9de841dcd915">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i5b6ef7c6980a4e1db02f8ba15b55658c_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzYtMS0xLTEtNTA3MjU_1eca02a9-f1dd-4c12-b3b8-0c54b6fd691a">http://fasb.org/us-gaap/2022#DebtCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i51a68f127e8d4d428c82dc489e61cc98_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzYtMy0xLTEtNTA3MjU_8d1038d1-419b-4128-8314-0aa1a5467841">http://fasb.org/us-gaap/2022#DebtCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i57ced13309e04a01b09898e7b88dd6f0_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzctMS0xLTEtNTA3MjU_a814e167-8383-4d45-81ca-86cc22f5c011">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i56be49fb71c4480598cef05e8ba9605a_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzctMy0xLTEtNTA3MjU_89a632c7-217b-411e-a52c-c18cee261893">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="iee6010de5eaf4258ad77ac9f7a65376e_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzgtMS0xLTEtNTA3MjU_12d2aa00-0042-4307-aa11-8f39561b8e9d">http://fasb.org/us-gaap/2022#OtherLiabilities</us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="i11cb8a9911234299b66dee77ff4909b4_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzgtMy0xLTEtNTA3MjU_15a6bc06-843b-4c48-b58a-8be83b9c35ba">http://fasb.org/us-gaap/2022#OtherLiabilities</us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="iee6010de5eaf4258ad77ac9f7a65376e_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzktMy0xLTEtNTA3MjU_99acfacd-090d-4833-8cd5-0990e12d974a">http://fasb.org/us-gaap/2022#OtherLiabilities</us-gaap:FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:LesseeOperatingLeaseOptionToTerminate
      contextRef="i1fafeebfd1ab4899a21ae02fae464c83_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDkvZnJhZzplNWVkMTFhOTdlOGI0M2JiOWQ3YWEzNzhiYmE0NDEzZC90ZXh0cmVnaW9uOmU1ZWQxMWE5N2U4YjQzYmI5ZDdhYTM3OGJiYTQ0MTNkXzIwNQ_eb166711-d217-426c-8f01-2c83605f6ecf">Option for early termination of lease after one year</us-gaap:LesseeOperatingLeaseOptionToTerminate>
    <us-gaap:LesseeOperatingLeaseOptionToTerminate
      contextRef="i03c7e40c5f95416f9b140b596a1f186a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDkvZnJhZzplNWVkMTFhOTdlOGI0M2JiOWQ3YWEzNzhiYmE0NDEzZC90ZXh0cmVnaW9uOmU1ZWQxMWE5N2U4YjQzYmI5ZDdhYTM3OGJiYTQ0MTNkXzIwNg_b3d34981-52a2-4207-a6e0-ac9456f7f5f8">Option for early termination of lease after three years</us-gaap:LesseeOperatingLeaseOptionToTerminate>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="i7909f4de3b454ec89111061cf24a2773_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDkvZnJhZzplNWVkMTFhOTdlOGI0M2JiOWQ3YWEzNzhiYmE0NDEzZC90ZXh0cmVnaW9uOmU1ZWQxMWE5N2U4YjQzYmI5ZDdhYTM3OGJiYTQ0MTNkXzU0OTc1NTgxNDEwMA_c5b56727-f558-4a3c-92e9-8654dccd3958">P1Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis
      contextRef="id0706f579da046e79bf159bafde70b5e_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTUvZnJhZzo0YTZiYTFmYzYxYzQ0YjhhYmFmNzE3ODI3ZmJiNGU2YS90ZXh0cmVnaW9uOjRhNmJhMWZjNjFjNDRiOGFiYWY3MTc4MjdmYmI0ZTZhXzQzOQ_c22fed69-f7b6-49ad-bf2a-22c5065ee2bb">Fluctuating rate per annum equal to the highest of (a)&#160;the federal funds rate plus 0.50% per annum, (b)&#160;the prime rate of interest established by the Administrative Agent, and (c)&#160;the Eurodollar Rate for an interest period of one month plus 1% per annum.</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis
      contextRef="i4b1209d2737e48bd9bdbd36398d6f1ee_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTUvZnJhZzo0YTZiYTFmYzYxYzQ0YjhhYmFmNzE3ODI3ZmJiNGU2YS90ZXh0cmVnaW9uOjRhNmJhMWZjNjFjNDRiOGFiYWY3MTc4MjdmYmI0ZTZhXzQ0MA_68ab4404-999e-4074-95fe-e03e89007eb4">Rate at which Eurodollar deposits in the London interbank market for an interest period of one, two, three or six months</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjEvZnJhZzozMzIyYWQ4MTU3OTc0M2QzOWFjMjAwZmVkMTBiZWY0Ny90YWJsZTo3NmFiYWVmN2JmMGE0MzU1OTFiNGIxODgzMmM4OWIyNC90YWJsZXJhbmdlOjc2YWJhZWY3YmYwYTQzNTU5MWI0YjE4ODMyYzg5YjI0XzItMS0xLTEtNjE2MjI_0b17f38b-e7a4-407a-a8e3-ed172a34890c"
      unitRef="usd">23377000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i03c7e40c5f95416f9b140b596a1f186a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzI5NTc_223df790-b680-48db-b730-c00d1beab04b">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i24418f4a250c4f51b8e485261ec4b457_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4Xzc0MzA_f3f1355f-39bb-4d10-ac63-3dcf30959476">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i4248f5c857bb4a3dbdce56078e7b58f5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4Xzc0MzY_d0064103-cecb-48d9-8073-473521ccb07a">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i1fafeebfd1ab4899a21ae02fae464c83_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjcvZnJhZzo4ODIyMDc4YWQxMDY0ZGRhODA5ZGJjYzg4MWI0MmQ5Zi90YWJsZTowNzliNjMzOGMwOTE0NDlhYjU4Y2ZjNzNmM2VkMGUzMi90YWJsZXJhbmdlOjA3OWI2MzM4YzA5MTQ0OWFiNThjZmM3M2YzZWQwZTMyXzItMS0xLTEtNTA3MjU_31f925f4-b205-4406-9c06-3caff312c27f">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8zODM3_f32a86a9-34cb-499c-a4ba-036c145e4dab">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8zODM4_77aff5d6-d1ae-4b5b-9eab-bfc4684a580e">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8yMTk_749aad99-29e1-4351-8fc1-21c12f6723b3">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8zODI3_a0ad69d7-deae-48f8-b86a-aeed4d669344">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8zODM5_74eda771-48bb-4c24-bd36-dcbd5836410d">0-24260</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8zODI5_6e8910a1-75bf-45a9-9ea5-bdd304eac29b">AMEDISYS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGFibGU6YjhiZjc2MGVmMDBmNDBhZWEzYmQ4MDQyMjI4MjMzYzkvdGFibGVyYW5nZTpiOGJmNzYwZWYwMGY0MGFlYTNiZDgwNDIyMjgyMzNjOV8wLTAtMS0xLTUwNzI1_70ea33b3-4f34-469f-9762-7c853ec2387b">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGFibGU6YjhiZjc2MGVmMDBmNDBhZWEzYmQ4MDQyMjI4MjMzYzkvdGFibGVyYW5nZTpiOGJmNzYwZWYwMGY0MGFlYTNiZDgwNDIyMjgyMzNjOV8wLTItMS0xLTUwNzI1_8b0fdd01-f569-46fa-93d3-aeb2de23170a">11-3131700</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8zODQw_33308252-7015-4fc9-9dde-30c66e8082b8">3854 American Way, Suite A,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8zODMz_5a5ab52c-1f5a-4f2b-8c96-918f84a60324">Baton Rouge,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8zODQx_7af42365-6ea5-4ccd-b60a-bc3c598a6e80">LA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8zODI4_942a8c6e-6350-4528-850f-1ef55d3e403f">70816</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8zODQy_8028c5ef-1621-4c81-9e89-76e910def44e">225</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8zODMw_d2ab8b3b-0c7f-4698-8f02-8506f1b3f117">292-2031</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGFibGU6Y2M5OTdhMjNlYmMzNGZlN2ExMDNiMGY0ZjIwZjQxYTIvdGFibGVyYW5nZTpjYzk5N2EyM2ViYzM0ZmU3YTEwM2IwZjRmMjBmNDFhMl8xLTAtMS0xLTUwNzI1_d4747d8f-cadf-442a-91ce-52f8a5fb1844">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGFibGU6Y2M5OTdhMjNlYmMzNGZlN2ExMDNiMGY0ZjIwZjQxYTIvdGFibGVyYW5nZTpjYzk5N2EyM2ViYzM0ZmU3YTEwM2IwZjRmMjBmNDFhMl8xLTItMS0xLTUwNzI1_4adfba1a-d2fa-45b6-b3d5-4f0681800a46">AMED</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGFibGU6Y2M5OTdhMjNlYmMzNGZlN2ExMDNiMGY0ZjIwZjQxYTIvdGFibGVyYW5nZTpjYzk5N2EyM2ViYzM0ZmU3YTEwM2IwZjRmMjBmNDFhMl8xLTQtMS0xLTUwNzI1_3029b9ab-f228-4fce-8b41-792873b6b1f7">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8zODM0_dfc19212-983c-4c7d-99ab-0037b0ac2c99">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8zODMx_708de81f-fd8f-4f5b-8782-8d6b4bfda90e">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8zODM1_644c9052-b87b-47bb-ab60-054752f352da">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8zODMy_36b4da9f-55e3-49e2-95eb-68582249c1ee">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGFibGU6MjczYzRhMmE4NmU1NGMzMzhiZjdlYTk3Y2ZkOGZkMmIvdGFibGVyYW5nZToyNzNjNGEyYTg2ZTU0YzMzOGJmN2VhOTdjZmQ4ZmQyYl8wLTAtMS0xLTUwNzI1_ab496ac6-8b4c-4c18-8af4-283eb2dfe238">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGFibGU6MjczYzRhMmE4NmU1NGMzMzhiZjdlYTk3Y2ZkOGZkMmIvdGFibGVyYW5nZToyNzNjNGEyYTg2ZTU0YzMzOGJmN2VhOTdjZmQ4ZmQyYl8xLTQtMS0xLTUwNzI1_f5579074-985f-4f3c-b5e1-45e4b8d8ece7">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGFibGU6MjczYzRhMmE4NmU1NGMzMzhiZjdlYTk3Y2ZkOGZkMmIvdGFibGVyYW5nZToyNzNjNGEyYTg2ZTU0YzMzOGJmN2VhOTdjZmQ4ZmQyYl8yLTQtMS0xLTUwNzI1_517d2e58-d12f-4fb8-8703-2757397d2727">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF81NDk3NTU4MTg1MDk_cf38efee-e26b-44ed-9f0c-2ad7aaf2ef13">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i266eb829b984448ebdfabbddfb0be360_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8zMTYw_4cf9cc18-b457-41d0-9cc9-7f34f6e934aa"
      unitRef="usd">3000000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="icd730d7570504ba281605ef8099ea7ec_I20230210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xL2ZyYWc6OThjYTM4NzczOGZjNDQ3MmJhYTY0NjM1ZGYxMTQwZjQvdGV4dHJlZ2lvbjo5OGNhMzg3NzM4ZmM0NDcyYmFhNjQ2MzVkZjExNDBmNF8zNDEz_a123f52d-969c-418e-966b-444aa1ecaf39"
      unitRef="shares">32550602</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfNC0xLTEtMS01MDcyNQ_6f8b2a28-6143-476d-81cb-75a622fef5ee"
      unitRef="usd">40540000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfNC0zLTEtMS01MDcyNQ_891ce023-3b48-4297-86bb-209f84968d41"
      unitRef="usd">42694000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfNS0xLTEtMS01MDcyNQ_c840153d-d1b8-44f7-b4e8-be47d9b0c1d6"
      unitRef="usd">13593000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfNS0zLTEtMS01MDcyNQ_6c4113d5-03d4-4ed8-a63a-e734e8fe3b32"
      unitRef="usd">3075000</us-gaap:RestrictedCash>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfNi0xLTEtMS01MDcyNQ_c71c5a72-3675-4b3f-80f9-6e18a2379751"
      unitRef="usd">296785000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfNi0zLTEtMS01MDcyNQ_7a66ed7d-a668-4d78-90f4-168d717424b1"
      unitRef="usd">274961000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfNy0xLTEtMS01MDcyNQ_645c6e15-3044-4624-a7f0-cc5f52bf7d4c"
      unitRef="usd">11628000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfNy0zLTEtMS01MDcyNQ_3c43aaf9-c0ff-4b70-9b80-3818b289610d"
      unitRef="usd">10356000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfOC0xLTEtMS01MDcyNQ_03c1e340-6f28-4b0b-b3f8-4aad82b95efb"
      unitRef="usd">26415000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfOC0zLTEtMS01MDcyNQ_a7237be7-e2e8-4106-a5f0-6579e4582343"
      unitRef="usd">25598000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfOS0xLTEtMS01MDcyNQ_c6a23010-275b-498a-9149-d815b526a0ae"
      unitRef="usd">388961000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfOS0zLTEtMS01MDcyNQ_db2f56bc-8b8b-4ffe-a981-5c9575c87704"
      unitRef="usd">356684000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTAtMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjo2OTg5YzMyY2JmZWQ0ZmQ5YmUwZmM4ZTg1ZGY4MGJlMF82Mw_4e6550d1-4e28-4417-91d4-3be0a5c1d4d1"
      unitRef="usd">101364000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTAtMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjo2OTg5YzMyY2JmZWQ0ZmQ5YmUwZmM4ZTg1ZGY4MGJlMF83MA_292ad74b-57a1-4ae1-846d-0829792ca0e5"
      unitRef="usd">96937000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTAtMS0xLTEtNTA3MjU_131ea69e-2a47-455c-832b-ad68877e3e1e"
      unitRef="usd">16026000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTAtMy0xLTEtNTA3MjU_8cead186-856a-46d3-8a87-5a7e8bd7ee01"
      unitRef="usd">18435000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTEtMS0xLTEtNTA3MjU_998279fe-5330-4bd8-bb85-c0ded6da213a"
      unitRef="usd">102856000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTEtMy0xLTEtNTA3MjU_43487ffb-98c9-4a3d-925f-3ad4fa5d7598"
      unitRef="usd">101257000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTItMS0xLTEtNTA3MjU_c909fdd7-6075-4310-8034-674588aa80b6"
      unitRef="usd">1287399000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTItMy0xLTEtNTA3MjU_fb869bf7-0468-466a-97c6-711bb7927956"
      unitRef="usd">1196090000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTMtMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjpjYWQ0NDYyNGZjYTM0M2YzOGNiYmZlZGIzNGNiZDA1Y181OA_6a04dbe6-02d9-4d74-88b5-7586dcec441c"
      unitRef="usd">14604000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTMtMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjpjYWQ0NDYyNGZjYTM0M2YzOGNiYmZlZGIzNGNiZDA1Y182NQ_b96361e9-b8f0-4ef2-bca0-92b141a47de1"
      unitRef="usd">19900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTMtMS0xLTEtNTA3MjU_22b3900d-0c41-49b5-b5c3-ca84278fc452"
      unitRef="usd">101167000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTMtMy0xLTEtNTA3MjU_34409f6e-a789-447e-9eb1-fa899efcd56a"
      unitRef="usd">111190000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTQtMS0xLTEtNTA3MjU_653345e3-6c4a-4cd9-abab-ecce038639f5"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTQtMy0xLTEtNTA3MjU_b0bad924-63ca-4c6d-bfc0-ef3285ce2b68"
      unitRef="usd">289000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTUtMS0xLTEtNTA3MjU_ec80db31-b01b-4a16-bcc4-40192e2c59a4"
      unitRef="usd">79836000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTUtMy0xLTEtNTA3MjU_bed5561a-2e58-405c-af1c-82f2f1ac9631"
      unitRef="usd">73023000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTYtMS0xLTEtNTA3MjU_9e7aaca5-8188-451d-995f-9a324c5e5535"
      unitRef="usd">1976245000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTYtMy0xLTEtNTA3MjU_0c6c7806-b198-4f52-a475-de95ebb24ff4"
      unitRef="usd">1856968000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTktMS0xLTEtNTA3MjU_970a17c7-efab-4a30-83fb-08429ed00e2d"
      unitRef="usd">43735000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMTktMy0xLTEtNTA3MjU_ade55d32-cd5f-4c88-b209-c4856751d2f0"
      unitRef="usd">38217000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjAtMS0xLTEtNTA3MjU_886578d9-3bb7-4d08-ae8a-069a81258508"
      unitRef="usd">125387000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjAtMy0xLTEtNTA3MjU_3a3bb214-89ec-43eb-b68e-86c9943c90c0"
      unitRef="usd">141001000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjEtMS0xLTEtNTA3MjU_fad362e9-8eae-4bf4-8297-12a6b39b47e8"
      unitRef="usd">137390000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjEtMy0xLTEtNTA3MjU_7cc0a0af-8835-4f14-a77d-cf95a18b7920"
      unitRef="usd">150836000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtCurrent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjMtMS0xLTEtNTA3MjU_a595aca5-6473-4c8a-ac93-e73133832d0e"
      unitRef="usd">15496000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjMtMy0xLTEtNTA3MjU_34454e96-e15a-418a-9cec-a8f1a8101ee8"
      unitRef="usd">12995000</us-gaap:DebtCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjQtMS0xLTEtNTA3MjU_1224af15-10d2-4987-993a-a58c97adcae3"
      unitRef="usd">33521000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjQtMy0xLTEtNTA3MjU_4efa6450-d7fc-4820-8d58-b8432eb7a464"
      unitRef="usd">31233000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjUtMS0xLTEtNTA3MjU_1d3a422f-9f4e-47f1-bbbc-c83aec24e86e"
      unitRef="usd">355529000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjUtMy0xLTEtNTA3MjU_8069e90e-19a7-41ff-9e12-231b215a1089"
      unitRef="usd">374282000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjYtMS0xLTEtNTA3MjU_28b3fcc2-9314-4dae-b39d-b4162fcb6243"
      unitRef="usd">419420000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjYtMy0xLTEtNTA3MjU_bbda2953-2a4e-4499-8866-bfe1918d8618"
      unitRef="usd">432075000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjctMS0xLTEtNTA3MjU_212fe27f-5a7b-495d-a68f-50f237111d5b"
      unitRef="usd">69504000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjctMy0xLTEtNTA3MjU_da38734d-6aba-4753-879c-484a61b89a7e"
      unitRef="usd">69309000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjctMS0xLTEtNTExMjI_9a611df7-5a5a-4365-9ff1-4f976a8da3f3"
      unitRef="usd">20411000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjctMy0xLTEtNTExMjI_86e992f1-0139-4406-b712-00657aea49be"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjgtMS0xLTEtNTA3MjU_8bf8d9ab-047f-41a3-9ed4-163ca6521661"
      unitRef="usd">4808000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjgtMy0xLTEtNTA3MjU_00821ce2-af3d-48c9-9aaf-3ccdac19b58d"
      unitRef="usd">4979000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjktMS0xLTEtNTA3MjU_3b587846-1ae6-4193-aa25-891b42968ce2"
      unitRef="usd">869672000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMjktMy0xLTEtNTA3MjU_9daf0817-3fca-44bc-a816-c03ac82dd840"
      unitRef="usd">880645000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzAtMS0xLTEtNTA3MjU_05885eb5-865c-4335-9034-0cae949b87e2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzAtMy0xLTEtNTA3MjU_f410415d-5669-4383-a3c7-e05b9eb31c19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzItMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjplY2U4MDFjNGI2Yzg0M2NmOTI1MjU0YmNiYzIzZjRhZF8yMQ_0da36e70-6eec-4604-9915-69f595558bae"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzItMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjplY2U4MDFjNGI2Yzg0M2NmOTI1MjU0YmNiYzIzZjRhZF8yMQ_6ef0ea87-680e-4799-8c62-dd614e1efcf5"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzItMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjplY2U4MDFjNGI2Yzg0M2NmOTI1MjU0YmNiYzIzZjRhZF8zNQ_5079b752-0589-4d58-8178-2c2da8650431"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzItMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjplY2U4MDFjNGI2Yzg0M2NmOTI1MjU0YmNiYzIzZjRhZF8zNQ_c5b9ebbd-6547-463b-b680-f15e184428c7"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzItMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjplY2U4MDFjNGI2Yzg0M2NmOTI1MjU0YmNiYzIzZjRhZF81Nw_19f9206f-abbf-4bfe-a37c-5442acf52b27"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzItMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjplY2U4MDFjNGI2Yzg0M2NmOTI1MjU0YmNiYzIzZjRhZF81Nw_353c62cb-52e8-464b-8e0a-cde2d63daa18"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzItMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjplY2U4MDFjNGI2Yzg0M2NmOTI1MjU0YmNiYzIzZjRhZF81Nw_65d78b23-3ae1-4f47-87b2-139ddcb3f1a8"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzItMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjplY2U4MDFjNGI2Yzg0M2NmOTI1MjU0YmNiYzIzZjRhZF81Nw_802ff55d-9717-4a48-b338-7e0e43328366"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzItMS0xLTEtNTA3MjU_28bf9e25-9425-46d8-9b26-e82e23dc9c3c"
      unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzItMy0xLTEtNTA3MjU_d9567e2a-aea7-40d8-8005-38a739cb37a8"
      unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzMtMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjozN2NmM2JhOGY3YzM0ZThjOTNkZmIwNzM1YjdhYjg0NV8xOA_1dc95f66-fc47-4349-82ee-984871a46796"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzMtMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjozN2NmM2JhOGY3YzM0ZThjOTNkZmIwNzM1YjdhYjg0NV8xOA_de9ba54e-599d-4465-92c6-7043baf56329"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzMtMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjozN2NmM2JhOGY3YzM0ZThjOTNkZmIwNzM1YjdhYjg0NV8zMg_67cfa59e-1233-4139-a39a-dafb034ab1dc"
      unitRef="shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzMtMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjozN2NmM2JhOGY3YzM0ZThjOTNkZmIwNzM1YjdhYjg0NV8zMg_91307ad1-b11e-4bce-b71f-a92b5beb517e"
      unitRef="shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzMtMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjozN2NmM2JhOGY3YzM0ZThjOTNkZmIwNzM1YjdhYjg0NV81NA_cb9699bd-06a3-43e0-a2ac-143fa8109c46"
      unitRef="shares">37891186</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzMtMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjozN2NmM2JhOGY3YzM0ZThjOTNkZmIwNzM1YjdhYjg0NV82MQ_f5b352ca-8923-48a5-8d0b-ac7b4dfa030f"
      unitRef="shares">37674868</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzMtMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjozN2NmM2JhOGY3YzM0ZThjOTNkZmIwNzM1YjdhYjg0NV84Mw_eaade403-1975-4e38-861c-875f7f5526a7"
      unitRef="shares">32518278</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzMtMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjozN2NmM2JhOGY3YzM0ZThjOTNkZmIwNzM1YjdhYjg0NV85MA_5653a9f8-98c0-4777-9d9a-3c5b9f5e91de"
      unitRef="shares">32509969</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzMtMS0xLTEtNTA3MjU_6a7c3d33-e6b3-43d0-9e33-21f7c5444a66"
      unitRef="usd">38000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzMtMy0xLTEtNTA3MjU_0eeb59cf-9f90-4f85-8e61-ea65afc273da"
      unitRef="usd">38000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzQtMS0xLTEtNTA3MjU_9d353e0d-55d4-4c46-a60e-e89dbbbdd5bc"
      unitRef="usd">755063000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzQtMy0xLTEtNTA3MjU_f42e7619-b134-4667-9e59-501a403cde63"
      unitRef="usd">728118000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:TreasuryStockShares
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzUtMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjplNmNjOWI3OTQ0ZTI0M2YzODMwOTc1YjI5NGQwNTk1ZV8yOA_c1e8901d-0f27-4cb3-bf8f-95d58d9b6d66"
      unitRef="shares">5372908</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzUtMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjplNmNjOWI3OTQ0ZTI0M2YzODMwOTc1YjI5NGQwNTk1ZV8zNQ_fec8e94d-0228-4bdc-a726-e90bc0fe2e9c"
      unitRef="shares">5164899</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzUtMS0xLTEtNTA3MjU_22a300da-96b4-4557-8563-8e56e645d0be"
      unitRef="usd">461200000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzUtMy0xLTEtNTA3MjU_e05b173a-a4e9-473a-bddd-4b20e109c807"
      unitRef="usd">435868000</us-gaap:TreasuryStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzYtMS0xLTEtNTA3MjU_1fdb871d-9a13-48ff-a94d-c8b606606b47"
      unitRef="usd">757672000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzYtMy0xLTEtNTA3MjU_0d28dfa3-07ef-4d92-b00c-7fc0a35245e6"
      unitRef="usd">639063000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzctMS0xLTEtNTA3MjU_682a11bc-9b99-4143-8d42-51dbf4d31743"
      unitRef="usd">1051573000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzctMy0xLTEtNTA3MjU_0f35b6dd-f3f3-48b1-8785-c67d7d99884b"
      unitRef="usd">931351000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzgtMS0xLTEtNTA3MjU_f123335f-6357-4f70-833e-49e184676039"
      unitRef="usd">55000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzgtMy0xLTEtNTA3MjU_3a8a6ff0-a7e3-445f-b988-e6bc751215ae"
      unitRef="usd">44972000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzktMS0xLTEtNTA3MjU_77646148-adfe-4572-82c6-f394ef6822af"
      unitRef="usd">1106573000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfMzktMy0xLTEtNTA3MjU_c1c3cebb-ba5a-45a4-a38b-4a8de1835f6d"
      unitRef="usd">976323000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfNDAtMS0xLTEtNTA3MjU_8ddcd12c-d6d7-4b4c-a51b-2c9640b6acf5"
      unitRef="usd">1976245000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81Mi9mcmFnOjEwMjBmMTJiYWE4NDQ3N2ZiYmQ4MTBiNDg0MDJmNDM3L3RhYmxlOjQ2MmVjNTU2NDY2OTRmOTFiZTA1M2MwZGY0ZWZkN2VkL3RhYmxlcmFuZ2U6NDYyZWM1NTY0NjY5NGY5MWJlMDUzYzBkZjRlZmQ3ZWRfNDAtMy0xLTEtNTA3MjU_ad9a2267-c71e-4439-aae8-6c4effdb5c89"
      unitRef="usd">1856968000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMi0xLTEtMS01MDcyNQ_8bf5ad3a-1522-44f3-b274-19aa4acb5035"
      unitRef="usd">2223199000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMi0zLTEtMS01MDcyNQ_cfc82291-4e8d-4eb4-976e-e3fcc0b54587"
      unitRef="usd">2214112000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMi01LTEtMS01MDcyNQ_f59a2a88-c0ef-4b12-b659-786847f08c3a"
      unitRef="usd">2071519000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:OtherOperatingIncome
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMy0xLTEtMS01MDcyNQ_ee3574eb-c31d-43d3-8e87-2d0cb46a7ed1"
      unitRef="usd">0</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMy0zLTEtMS01MDcyNQ_5093c418-358c-41cf-96b4-7c2d8a04fe50"
      unitRef="usd">13300000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMy01LTEtMS01MDcyNQ_fa63eade-c98f-42da-9008-722a97834507"
      unitRef="usd">34372000</us-gaap:OtherOperatingIncome>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfNC0xLTEtMS01MDcyNQ_fc49e86f-e678-485f-95fe-019ba0791ba2"
      unitRef="usd">1260425000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfNC0zLTEtMS01MDcyNQ_5f88bf83-dbeb-424d-b548-dd7336ae151d"
      unitRef="usd">1233356000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfNC01LTEtMS01MDcyNQ_d842ec48-dfda-4eb8-84ff-73e902f46b89"
      unitRef="usd">1185369000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfNi0xLTEtMS01MDcyNQ_0c2af7d6-bd3a-49fe-b003-ceadf8b5279a"
      unitRef="usd">508791000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfNi0zLTEtMS01MDcyNQ_38db668c-6b1a-43f4-b4a8-e16fe981ca9b"
      unitRef="usd">474718000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfNi01LTEtMS01MDcyNQ_afdf0e24-698b-41ec-a2be-1a4a3bd21959"
      unitRef="usd">449448000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfNy0xLTEtMS01MDcyNQ_bd3eece0-95c2-4889-a0cf-2f2b4320d625"
      unitRef="usd">16560000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfNy0zLTEtMS01MDcyNQ_3d6a3d57-264c-4b6b-b5a6-918bf81f9d57"
      unitRef="usd">23809000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfNy01LTEtMS01MDcyNQ_12c660fe-3811-46b8-88b2-03c2f582e868"
      unitRef="usd">26730000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfOC0xLTEtMS01MDcyNQ_f5df5eb7-2c95-40b3-b3f7-2996aebdfcce"
      unitRef="usd">228707000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfOC0zLTEtMS01MDcyNQ_1ffdf80b-054f-4dd0-b7a3-e4a634534a3b"
      unitRef="usd">212713000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfOC01LTEtMS01MDcyNQ_3597be2e-7901-45c1-bb8e-908eaa3a2b21"
      unitRef="usd">192122000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfOS0xLTEtMS01MDcyNQ_7fdda89a-2072-4b95-a0b0-cade3ddfe242"
      unitRef="usd">24935000</amed:DepreciationAndAmortizationForContinuingOperations>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfOS0zLTEtMS01MDcyNQ_0fe30948-3140-46dc-a767-3c49d331b93c"
      unitRef="usd">30901000</amed:DepreciationAndAmortizationForContinuingOperations>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfOS01LTEtMS01MDcyNQ_5172eaf9-5b0f-403d-8ae7-e9c9d03dc9ba"
      unitRef="usd">28802000</amed:DepreciationAndAmortizationForContinuingOperations>
    <us-gaap:AssetImpairmentCharges
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTAtMS0xLTEtNTA3MjU_802af9ce-0a16-499a-9fd2-af2e6b2b10c9"
      unitRef="usd">3009000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTAtMy0xLTEtNTA3MjU_d5431d21-9192-4238-a7f0-23fb59da0a98"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTAtNS0xLTEtNTA3MjU_c200f855-d79a-474a-bead-cdc927f8a6c6"
      unitRef="usd">4152000</us-gaap:AssetImpairmentCharges>
    <us-gaap:CostsAndExpenses
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTEtMS0xLTEtNTA3MjU_59198ab9-fbcd-4d74-a292-61dedb62424b"
      unitRef="usd">2042427000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTEtMy0xLTEtNTA3MjU_5510850c-474b-485c-a876-bc9a7a3ba7b4"
      unitRef="usd">1975497000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTEtNS0xLTEtNTA3MjU_76536723-d356-4eb4-b9e4-f6f47d14b672"
      unitRef="usd">1886623000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTItMS0xLTEtNTA3MjU_1b912c8f-7b64-4401-b85e-7c8292596e3b"
      unitRef="usd">180772000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTItMy0xLTEtNTA3MjU_3953b48f-1b37-4a7e-8d33-e61dba4b1232"
      unitRef="usd">251915000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTItNS0xLTEtNTA3MjU_35190b30-c120-490c-ac13-5fb2a98e9d01"
      unitRef="usd">219268000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTQtMS0xLTEtNTA3MjU_dbac5121-6475-41ff-b2e9-1b801d78495b"
      unitRef="usd">178000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTQtMy0xLTEtNTA3MjU_f880c4c9-1099-4eee-ba65-36e335e01c34"
      unitRef="usd">49000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTQtNS0xLTEtNTA3MjU_2ada4277-065c-4ff1-ab10-1392a8f984e2"
      unitRef="usd">292000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InterestExpense
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTUtMS0xLTEtNTA3MjU_3bed6e0a-9327-4bcf-9993-08adbf282b46"
      unitRef="usd">22228000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTUtMy0xLTEtNTA3MjU_c113ced6-b8e9-4275-bf78-0387703b9015"
      unitRef="usd">9525000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTUtNS0xLTEtNTA3MjU_f60e6efe-2eab-4b41-a78f-461edf005890"
      unitRef="usd">11038000</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTYtMS0xLTEtNTA3MjU_9100d8b4-2d12-4819-8bd1-6d50e179530c"
      unitRef="usd">-45000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTYtMy0xLTEtNTA3MjU_96fd99f6-003c-47d2-94ba-b7cbb36a7607"
      unitRef="usd">4949000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTYtNS0xLTEtNTA3MjU_432e75ee-f3cb-4a75-aedc-2cc0f1d6b2b3"
      unitRef="usd">3966000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTctMS0xLTEtNTA3MjU_83805ff3-9181-4c3c-9a5d-02aec335a45e"
      unitRef="usd">0</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTctMy0xLTEtNTA3MjU_9298f8c4-28f9-481c-87f7-800ec4fc70a9"
      unitRef="usd">31098000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTctNS0xLTEtNTA3MjU_ec9ad0c2-7625-49e4-91ce-162fa21adbcf"
      unitRef="usd">-2980000</us-gaap:GainLossOnInvestments>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTgtMS0xLTEtNTA3MjU_bfeaf1b4-127c-4bf3-abdf-09e2bf0580cb"
      unitRef="usd">1567000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTgtMy0xLTEtNTA3MjU_74867bf6-1243-408e-8953-cfb126a533a0"
      unitRef="usd">1745000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTgtNS0xLTEtNTA3MjU_45aebde6-0d7a-42ae-ae85-1f00a394dc6e"
      unitRef="usd">1311000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTktMS0xLTEtNTA3MjU_f9cc5c90-dfff-42ce-89c7-b420a1214b4e"
      unitRef="usd">-20528000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTktMy0xLTEtNTA3MjU_25a29592-6821-40f9-a337-95f529a385bf"
      unitRef="usd">28316000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMTktNS0xLTEtNTA3MjU_2a28008e-7662-4a47-9fbf-f7285701c187"
      unitRef="usd">-8449000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjAtMS0xLTEtNTA3MjU_cc7efc3c-c91b-486b-995c-33bffc7360c3"
      unitRef="usd">160244000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjAtMy0xLTEtNTA3MjU_54f3c0dc-64bb-4b39-87d5-fb889d22796f"
      unitRef="usd">280231000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjAtNS0xLTEtNTA3MjU_b939b3a5-10b8-4503-acc8-8ca0cd65479e"
      unitRef="usd">210819000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjEtMS0xLTEtNTA3MjU_9bdd278e-dadc-4be7-9a26-69e7b2a710c7"
      unitRef="usd">42545000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjEtMy0xLTEtNTA3MjU_3b9ff771-ce42-4b73-a6e3-04b83fa6a849"
      unitRef="usd">70065000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjEtNS0xLTEtNTA3MjU_741f0d51-507b-43fd-a6e7-c91c8417b848"
      unitRef="usd">25635000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjItMS0xLTEtNTA3MjU_0a6c1995-4df1-4ff4-9abf-a507f5920019"
      unitRef="usd">117699000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjItMy0xLTEtNTA3MjU_fa34a7c1-ab53-44e1-ad07-a796093d57a0"
      unitRef="usd">210166000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjItNS0xLTEtNTA3MjU_1e98b1da-59f4-4a6e-b748-c5e189dae34e"
      unitRef="usd">185184000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjMtMS0xLTEtNTA3MjU_a8d495fe-64d2-44a6-bcf7-a193feed41b9"
      unitRef="usd">-910000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjMtMy0xLTEtNTA3MjU_aa92651b-8db5-44a2-894e-51d5a0f5792e"
      unitRef="usd">1094000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjMtNS0xLTEtNTA3MjU_f9a54ea5-4aee-4b2c-9bba-0319ce013072"
      unitRef="usd">1576000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjQtMS0xLTEtNTA3MjU_dca2a6c6-3d54-401a-946a-0cd412e61e14"
      unitRef="usd">118609000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjQtMy0xLTEtNTA3MjU_f42b8cea-f7b2-42a1-b814-3793c4b46b90"
      unitRef="usd">209072000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjQtNS0xLTEtNTA3MjU_67c43d7c-dc62-4f89-adeb-be1201f4c0e2"
      unitRef="usd">183608000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjYtMS0xLTEtNTA3MjU_6aa723cf-fda6-4c11-8559-0e935f9009d8"
      unitRef="usdPerShare">3.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjYtMy0xLTEtNTA3MjU_6334dd9c-c5a9-4cd1-8d6d-4433e355e44a"
      unitRef="usdPerShare">6.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjYtNS0xLTEtNTA3MjU_7d876d0e-a803-4c65-a414-d643cef9508d"
      unitRef="usdPerShare">5.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjctMS0xLTEtNTA3MjU_9a41f619-0df5-48d3-a62d-1603ff021afd"
      unitRef="shares">32517000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjctMy0xLTEtNTA3MjU_0321ec41-3936-4628-a2a4-d5534b673f62"
      unitRef="shares">32642000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjctNS0xLTEtNTA3MjU_0fb87633-aec9-4632-ad0a-3014a98aa05d"
      unitRef="shares">32559000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjktMS0xLTEtNTA3MjU_9a0081af-0624-4f76-9e1b-91b8396ec81f"
      unitRef="usdPerShare">3.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjktMy0xLTEtNTA3MjU_5711ea04-4e7d-4ded-bfce-6846ea737eaa"
      unitRef="usdPerShare">6.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMjktNS0xLTEtNTA3MjU_ac82a575-4342-420a-9998-754b26bf3b50"
      unitRef="usdPerShare">5.52</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMzAtMS0xLTEtNTA3MjU_d08bc5fb-ed43-4e48-a126-03df3455b35c"
      unitRef="shares">32653000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMzAtMy0xLTEtNTA3MjU_54927090-5722-4e2e-850b-bd92016d2763"
      unitRef="shares">32972000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV81OC9mcmFnOjMzNDc3OTgzMDE4OTRiNDk4OTY4Njc5NzUyZmZkMzVlL3RhYmxlOjJjYWVmMTYxYTczODQzOTI4YzA0NWRjNGQwMDBkMGVkL3RhYmxlcmFuZ2U6MmNhZWYxNjFhNzM4NDM5MjhjMDQ1ZGM0ZDAwMGQwZWRfMzAtNS0xLTEtNTA3MjU_0e1a4993-758f-41d0-82cd-15aeaa218065"
      unitRef="shares">33268000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82MS9mcmFnOmZmNmMxY2JlYzg2NjRkNTY4ZjU3ZDM1MWZiYTE3Mjc4L3RhYmxlOjI1NWZiMzZiYTNiMTQ0NjY5MjEzNmExYmU1ZjA3YTI5L3RhYmxlcmFuZ2U6MjU1ZmIzNmJhM2IxNDQ2NjkyMTM2YTFiZTVmMDdhMjlfMi0xLTEtMS01MDcyNQ_1e3a60e5-2a1b-402a-b240-a6addcd06e07"
      unitRef="usd">117699000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82MS9mcmFnOmZmNmMxY2JlYzg2NjRkNTY4ZjU3ZDM1MWZiYTE3Mjc4L3RhYmxlOjI1NWZiMzZiYTNiMTQ0NjY5MjEzNmExYmU1ZjA3YTI5L3RhYmxlcmFuZ2U6MjU1ZmIzNmJhM2IxNDQ2NjkyMTM2YTFiZTVmMDdhMjlfMi0zLTEtMS01MDcyNQ_38eb71d3-a5e4-4ea2-b526-117d34cfa618"
      unitRef="usd">210166000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82MS9mcmFnOmZmNmMxY2JlYzg2NjRkNTY4ZjU3ZDM1MWZiYTE3Mjc4L3RhYmxlOjI1NWZiMzZiYTNiMTQ0NjY5MjEzNmExYmU1ZjA3YTI5L3RhYmxlcmFuZ2U6MjU1ZmIzNmJhM2IxNDQ2NjkyMTM2YTFiZTVmMDdhMjlfMi01LTEtMS01MDcyNQ_63d008bb-1494-4641-8b32-ebb4652dce79"
      unitRef="usd">185184000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82MS9mcmFnOmZmNmMxY2JlYzg2NjRkNTY4ZjU3ZDM1MWZiYTE3Mjc4L3RhYmxlOjI1NWZiMzZiYTNiMTQ0NjY5MjEzNmExYmU1ZjA3YTI5L3RhYmxlcmFuZ2U6MjU1ZmIzNmJhM2IxNDQ2NjkyMTM2YTFiZTVmMDdhMjlfMy0xLTEtMS01MDcyNQ_2ad648f9-7769-48f3-83cc-69918dc7f3f6"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82MS9mcmFnOmZmNmMxY2JlYzg2NjRkNTY4ZjU3ZDM1MWZiYTE3Mjc4L3RhYmxlOjI1NWZiMzZiYTNiMTQ0NjY5MjEzNmExYmU1ZjA3YTI5L3RhYmxlcmFuZ2U6MjU1ZmIzNmJhM2IxNDQ2NjkyMTM2YTFiZTVmMDdhMjlfMy0zLTEtMS01MDcyNQ_6c6498e2-bf07-4117-920c-6a23599ba378"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82MS9mcmFnOmZmNmMxY2JlYzg2NjRkNTY4ZjU3ZDM1MWZiYTE3Mjc4L3RhYmxlOjI1NWZiMzZiYTNiMTQ0NjY5MjEzNmExYmU1ZjA3YTI5L3RhYmxlcmFuZ2U6MjU1ZmIzNmJhM2IxNDQ2NjkyMTM2YTFiZTVmMDdhMjlfMy01LTEtMS01MDcyNQ_61e95ed7-2fb8-4e3c-a01e-f19988fa1f69"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82MS9mcmFnOmZmNmMxY2JlYzg2NjRkNTY4ZjU3ZDM1MWZiYTE3Mjc4L3RhYmxlOjI1NWZiMzZiYTNiMTQ0NjY5MjEzNmExYmU1ZjA3YTI5L3RhYmxlcmFuZ2U6MjU1ZmIzNmJhM2IxNDQ2NjkyMTM2YTFiZTVmMDdhMjlfNC0xLTEtMS01MDcyNQ_97689403-c24b-444f-9d47-58b465a4cbd6"
      unitRef="usd">117699000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82MS9mcmFnOmZmNmMxY2JlYzg2NjRkNTY4ZjU3ZDM1MWZiYTE3Mjc4L3RhYmxlOjI1NWZiMzZiYTNiMTQ0NjY5MjEzNmExYmU1ZjA3YTI5L3RhYmxlcmFuZ2U6MjU1ZmIzNmJhM2IxNDQ2NjkyMTM2YTFiZTVmMDdhMjlfNC0zLTEtMS01MDcyNQ_b0853582-6b63-4dbd-ae1d-33b9dfb9ec2e"
      unitRef="usd">210166000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82MS9mcmFnOmZmNmMxY2JlYzg2NjRkNTY4ZjU3ZDM1MWZiYTE3Mjc4L3RhYmxlOjI1NWZiMzZiYTNiMTQ0NjY5MjEzNmExYmU1ZjA3YTI5L3RhYmxlcmFuZ2U6MjU1ZmIzNmJhM2IxNDQ2NjkyMTM2YTFiZTVmMDdhMjlfNC01LTEtMS01MDcyNQ_54ec4b6e-b875-4858-bb81-47784cfd163e"
      unitRef="usd">185184000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82MS9mcmFnOmZmNmMxY2JlYzg2NjRkNTY4ZjU3ZDM1MWZiYTE3Mjc4L3RhYmxlOjI1NWZiMzZiYTNiMTQ0NjY5MjEzNmExYmU1ZjA3YTI5L3RhYmxlcmFuZ2U6MjU1ZmIzNmJhM2IxNDQ2NjkyMTM2YTFiZTVmMDdhMjlfNS0xLTEtMS01MDcyNQ_b1a553d4-8a4f-49dc-ae16-f9006a26023d"
      unitRef="usd">-910000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82MS9mcmFnOmZmNmMxY2JlYzg2NjRkNTY4ZjU3ZDM1MWZiYTE3Mjc4L3RhYmxlOjI1NWZiMzZiYTNiMTQ0NjY5MjEzNmExYmU1ZjA3YTI5L3RhYmxlcmFuZ2U6MjU1ZmIzNmJhM2IxNDQ2NjkyMTM2YTFiZTVmMDdhMjlfNS0zLTEtMS01MDcyNQ_7d7437bf-7d47-478c-b50a-d7c0fcf39343"
      unitRef="usd">1094000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82MS9mcmFnOmZmNmMxY2JlYzg2NjRkNTY4ZjU3ZDM1MWZiYTE3Mjc4L3RhYmxlOjI1NWZiMzZiYTNiMTQ0NjY5MjEzNmExYmU1ZjA3YTI5L3RhYmxlcmFuZ2U6MjU1ZmIzNmJhM2IxNDQ2NjkyMTM2YTFiZTVmMDdhMjlfNS01LTEtMS01MDcyNQ_929d0838-8bb1-4581-a82b-c9d44dd6417a"
      unitRef="usd">1576000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82MS9mcmFnOmZmNmMxY2JlYzg2NjRkNTY4ZjU3ZDM1MWZiYTE3Mjc4L3RhYmxlOjI1NWZiMzZiYTNiMTQ0NjY5MjEzNmExYmU1ZjA3YTI5L3RhYmxlcmFuZ2U6MjU1ZmIzNmJhM2IxNDQ2NjkyMTM2YTFiZTVmMDdhMjlfNi0xLTEtMS01MDcyNQ_9fcdc65a-097b-4a31-9cb2-6c1828b011af"
      unitRef="usd">118609000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82MS9mcmFnOmZmNmMxY2JlYzg2NjRkNTY4ZjU3ZDM1MWZiYTE3Mjc4L3RhYmxlOjI1NWZiMzZiYTNiMTQ0NjY5MjEzNmExYmU1ZjA3YTI5L3RhYmxlcmFuZ2U6MjU1ZmIzNmJhM2IxNDQ2NjkyMTM2YTFiZTVmMDdhMjlfNi0zLTEtMS01MDcyNQ_50e6af5d-c302-4136-b5ba-65b8d83b033f"
      unitRef="usd">209072000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82MS9mcmFnOmZmNmMxY2JlYzg2NjRkNTY4ZjU3ZDM1MWZiYTE3Mjc4L3RhYmxlOjI1NWZiMzZiYTNiMTQ0NjY5MjEzNmExYmU1ZjA3YTI5L3RhYmxlcmFuZ2U6MjU1ZmIzNmJhM2IxNDQ2NjkyMTM2YTFiZTVmMDdhMjlfNi01LTEtMS01MDcyNQ_c7ed5aed-6bde-4cb0-969a-918a36fb4e97"
      unitRef="usd">183608000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iab144f7e34ce4a479683c59de399ff42_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMi0xLTEtMS01MDcyNQ_752fc10f-d732-4065-ae6c-0318977ae909"
      unitRef="usd">641513000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i4a842a348ea54e2aa7af78df38c5e42a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMi0zLTEtMS01MDcyNQ_2f4570c7-6f39-4d76-952e-8d113890f4da"
      unitRef="shares">36638021</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4a842a348ea54e2aa7af78df38c5e42a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMi01LTEtMS01MDcyNQ_32c486a4-7239-447b-b87d-ded7be7bf1df"
      unitRef="usd">37000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i812c4f7fd6e8491d8a6c1f0f7f2f0c8a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMi03LTEtMS01MDcyNQ_4c26f27a-018c-4803-808e-75bbf2c65a09"
      unitRef="usd">645256000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1184798dbf244669a8ac664a6a3e701e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMi05LTEtMS01MDcyNQ_38635a9a-9189-404c-8925-5928da1ac096"
      unitRef="usd">-251241000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i94b781b07d4d4409b8dcc3915918b994_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMi0xMS0xLTEtNTA3MjU_551a4f65-0f21-4ac4-aaa6-0e586300104e"
      unitRef="usd">15000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie7347a5a29b245a290ea5780c2f8e972_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMi0xMy0xLTEtNTA3MjU_a098ac79-4368-4cf6-ba89-9eacbbaf9cef"
      unitRef="usd">246383000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i883b9612a1ce4040993b8d0c85aa8244_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMi0xNS0xLTEtNTA3MjU_a8f34a6f-1d62-43f0-a013-ab1d6caa59b0"
      unitRef="usd">1063000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMy0xLTEtMS01MDcyNQ_c0a66930-77ed-4e6b-b2f5-5fb4e813deed"
      unitRef="usd">3562000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="idaad48809b5744fabff0426f64590228_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMy0zLTEtMS01MDcyNQ_809c9b59-f1a7-4c5e-8875-743bc9320afe"
      unitRef="shares">21561</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="idbbf4b06ee8949419799fc4f109084c8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMy03LTEtMS01MDcyNQ_58080249-1def-4675-94ab-ac8a6209d72c"
      unitRef="usd">3562000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfNC0xLTEtMS01MDcyNQ_6f9aa1a2-ed54-4e5b-adb5-acb271271fe1"
      unitRef="usd">3057000</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
    <amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch
      contextRef="idaad48809b5744fabff0426f64590228_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfNC0zLTEtMS01MDcyNQ_71656623-1523-42c8-b861-105de191e7d2"
      unitRef="shares">18312</amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch>
    <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch
      contextRef="idbbf4b06ee8949419799fc4f109084c8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfNC03LTEtMS01MDcyNQ_9586d797-8b55-47f1-9f74-54bc155489f5"
      unitRef="usd">3057000</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfNS0xLTEtMS01MDcyNQ_bf7491a2-3878-4e22-9261-f4dc04891aa0"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="idaad48809b5744fabff0426f64590228_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfNS0zLTEtMS01MDcyNQ_ead75d7f-d84f-461c-95bd-ec30c00b4960"
      unitRef="shares">169489</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="idbbf4b06ee8949419799fc4f109084c8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfNS03LTEtMS01MDcyNQ_2b5d7621-e4d8-4fa0-881d-1f81a2cfbd1e"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfNi0xLTEtMS01MDcyNQ_20a5843b-99dd-42fe-ba07-e151c39ccd00"
      unitRef="usd">6325000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="idaad48809b5744fabff0426f64590228_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfNi0zLTEtMS01MDcyNQ_eca0dea0-f972-47d9-bd19-8cf9db3882ea"
      unitRef="shares">622829</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="idaad48809b5744fabff0426f64590228_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfNi01LTEtMS01MDcyNQ_5bc46777-e479-468a-b6ac-896b47129c50"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="idbbf4b06ee8949419799fc4f109084c8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfNi03LTEtMS01MDcyNQ_05ec89fd-b947-42a4-aa8d-ab3b084d8fc8"
      unitRef="usd">6324000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfNy0xLTEtMS01MDcyNQ_5d678602-0494-48b2-913c-1191a52331db"
      unitRef="usd">26730000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idbbf4b06ee8949419799fc4f109084c8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfNy03LTEtMS01MDcyNQ_a46c0102-0e1a-4bdc-a530-0923751e7042"
      unitRef="usd">26730000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <amed:SurrenderedShares
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfOC0xLTEtMS01MDcyNQ_b007ca08-855f-4314-b588-d0c599821958"
      unitRef="usd">-54493000</amed:SurrenderedShares>
    <amed:SurrenderedShares
      contextRef="idbbf4b06ee8949419799fc4f109084c8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfOC03LTEtMS01MDcyNQ_a33ecf4e-d79e-4eb8-9700-0a089ab4963f"
      unitRef="usd">13358000</amed:SurrenderedShares>
    <amed:SurrenderedShares
      contextRef="i6914d90131e14c43a26dc97a98c426c8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfOC05LTEtMS01MDcyNQ_f2b7b2f8-3e3b-42eb-ab31-69b359fbdcd8"
      unitRef="usd">-67851000</amed:SurrenderedShares>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfOS0xLTEtMS01MDcyNQ_da60e754-415a-453e-949f-151824b915a0"
      unitRef="usd">1122000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i76caa3bd393e42e2ba1a0e9df9033378_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfOS0xNS0xLTEtNTA3MjU_c96d9753-873b-4cb0-9555-0131cb11e183"
      unitRef="usd">1122000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <amed:EquityImpactOfWriteOffOfOtherComprehensiveIncome
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTAtMS0xLTEtNTE0MTQ_21f3dbbf-c76b-4259-96eb-52164207b024"
      unitRef="usd">15000</amed:EquityImpactOfWriteOffOfOtherComprehensiveIncome>
    <amed:EquityImpactOfWriteOffOfOtherComprehensiveIncome
      contextRef="i7be9b19ba9f7478f8d633e2083f22149_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTAtMTEtMS0xLTUxNDE0_e7c6bedf-f40e-4484-b11d-dd7549da1b70"
      unitRef="usd">15000</amed:EquityImpactOfWriteOffOfOtherComprehensiveIncome>
    <us-gaap:ProfitLoss
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTAtMS0xLTEtNTA3MjU_ff581590-d3b6-4dd9-b459-a657660cb1ce"
      unitRef="usd">185184000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7f85583bb3f049d3afa37b4d013dcf79_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTAtMTMtMS0xLTUwNzI1_e1e06426-0b44-48be-b28d-ba30cd9d7fec"
      unitRef="usd">183608000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i76caa3bd393e42e2ba1a0e9df9033378_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTAtMTUtMS0xLTUwNzI1_a5242c47-2bb2-48ca-970b-a463d9022751"
      unitRef="usd">1576000</us-gaap:ProfitLoss>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i42b1e865f1ed4b2e8363dfcc39186a91_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTEtMS0xLTEtNTA3MjU_bba6de73-2669-439f-8b12-143f49d0ee08"
      unitRef="usd">810741000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="iae6f76a71f3044fc83923db577d2d9bc_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTEtMy0xLTEtNTA3MjU_5ae4ab2e-e391-4855-bdc3-a7ab8ad48c3f"
      unitRef="shares">37470212</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iae6f76a71f3044fc83923db577d2d9bc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTEtNS0xLTEtNTA3MjU_77f84c59-1e8d-44bd-8be1-67b57e05f7f6"
      unitRef="usd">38000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id9fa2aa843ed46e5b472b3eebcb45775_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTEtNy0xLTEtNTA3MjU_9045baff-168e-42aa-b385-dfa364f6066c"
      unitRef="usd">698287000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i12929bbf3109412399f3172e7fddd206_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTEtOS0xLTEtNTA3MjU_01bdc5bf-c740-4a54-b7f2-6751bf118551"
      unitRef="usd">-319092000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3f961b554cbf4c35b1fa83b2cd487b4e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTEtMTEtMS0xLTUwNzI1_084fe91d-06f7-4942-a6fc-d21cafb20c45"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8a5303400c1a425783f3183ad6fb484d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTEtMTMtMS0xLTUwNzI1_a67e8fde-74e1-45c7-a279-a710fda9ea8d"
      unitRef="usd">429991000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i95978a83297249e088bf477ac218a6d8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTEtMTUtMS0xLTUwNzI1_29614d89-832b-4cb5-b207-e10db88d8889"
      unitRef="usd">1517000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTItMS0xLTEtNTA3MjU_8b469b07-e82c-4cae-8813-df987a66f5dd"
      unitRef="usd">3968000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i83305f332a5848699f3e80d713ebcc32_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTItMy0xLTEtNTA3MjU_35347246-31b6-4544-9e9c-1082ecc455d0"
      unitRef="shares">20823</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i7a2c2693b2ff45998961c13ebdcfd739_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTItNy0xLTEtNTA3MjU_eb6f7825-1a84-4399-946a-720846a1e8ac"
      unitRef="usd">3968000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTQtMS0xLTEtNTA3MjU_aadc2e31-8db2-4925-b9c0-ab9b631993cd"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i83305f332a5848699f3e80d713ebcc32_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTQtMy0xLTEtNTA3MjU_acc0ba2b-4983-4841-8e67-9ccd94c588a4"
      unitRef="shares">151365</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i7a2c2693b2ff45998961c13ebdcfd739_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTQtNy0xLTEtNTA3MjU_30af0a20-3bcd-47fe-9e2a-a12bc6049375"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTUtMS0xLTEtNTA3MjU_02c77b26-633d-4960-ab87-d07e45a3c59f"
      unitRef="usd">2054000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i83305f332a5848699f3e80d713ebcc32_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTUtMy0xLTEtNTA3MjU_ce7c962b-88ad-4d39-8fba-633a7dce3e03"
      unitRef="shares">32468</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7a2c2693b2ff45998961c13ebdcfd739_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTUtNy0xLTEtNTA3MjU_6a88bc2e-7d8b-4eb0-9a24-ea5ac26fdf64"
      unitRef="usd">2054000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTYtMS0xLTEtNTA3MjU_12de6b67-5c18-4146-b00f-e5623bbcee11"
      unitRef="usd">23809000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7a2c2693b2ff45998961c13ebdcfd739_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTYtNy0xLTEtNTA3MjU_5d559494-5fcd-4a7b-9b04-798e367c3711"
      unitRef="usd">23809000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <amed:SurrenderedShares
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTctMS0xLTEtNTA3MjU_dd6dbe50-eb80-4253-948e-461109106408"
      unitRef="usd">-16898000</amed:SurrenderedShares>
    <amed:SurrenderedShares
      contextRef="i95ad470da34d4eb9b8d8e685b7c60a58_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTctOS0xLTEtNTA3MjU_d10fb02d-2374-4e87-b01d-f9ed7e546995"
      unitRef="usd">-16898000</amed:SurrenderedShares>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTgtMS0xLTEtNTE0MjM_60e2331d-4ce1-4b32-bb04-584f41dd9e74"
      unitRef="usd">99878000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i95ad470da34d4eb9b8d8e685b7c60a58_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTgtOS0xLTEtNTE0MjM_72d93f15-fa2d-4102-9e74-d2ed21015e90"
      unitRef="usd">99878000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <amed:ContributionsAttributableToNoncontrollingInterest
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTktMS0xLTEtNTE0MjM_0388bda4-2ca2-470e-acc6-5fd3ae8eabf4"
      unitRef="usd">250000</amed:ContributionsAttributableToNoncontrollingInterest>
    <amed:ContributionsAttributableToNoncontrollingInterest
      contextRef="i73ef0a6e63d24e92b674d33b19f2b5ee_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTktMTUtMS0xLTUxNDIz_a551a580-4206-4651-9d77-fdb23dcd3bcb"
      unitRef="usd">250000</amed:ContributionsAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTgtMS0xLTEtNTA3MjU_6f048e21-04e4-438c-b223-14e54399560c"
      unitRef="usd">1747000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i73ef0a6e63d24e92b674d33b19f2b5ee_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTgtMTUtMS0xLTUwNzI1_4f714211-0190-4080-a2f7-1a594e2f1c40"
      unitRef="usd">1747000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTktMS0xLTEtNTA3MjU_88a767da-58b7-4888-bf61-3cc96df6c589"
      unitRef="usd">43858000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
    <us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination
      contextRef="i73ef0a6e63d24e92b674d33b19f2b5ee_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMTktMTUtMS0xLTUwNzI1_50b41475-6f77-4632-a8aa-183db92080ec"
      unitRef="usd">43858000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
    <us-gaap:ProfitLoss
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjAtMS0xLTEtNTA3MjU_f67611fd-abd9-4e0d-86ef-9cb57ac0d294"
      unitRef="usd">210166000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie172076182c0492ea35971de45486231_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjAtMTMtMS0xLTUwNzI1_300825c7-7ef6-4d2b-bd52-355160e91a27"
      unitRef="usd">209072000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i73ef0a6e63d24e92b674d33b19f2b5ee_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjAtMTUtMS0xLTUwNzI1_0fff34cd-a190-464a-a77f-64057e502d58"
      unitRef="usd">1094000</us-gaap:ProfitLoss>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjEtMS0xLTEtNTA3MjU_662968eb-24ea-450c-a73e-e021bc974f48"
      unitRef="usd">976323000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i3a03e986997443978a0dd90f53d4f1dc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjEtMy0xLTEtNTA3MjU_2d8e1bce-5fb5-42f7-bea7-4ea7cfdebc2a"
      unitRef="shares">37674868</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3a03e986997443978a0dd90f53d4f1dc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjEtNS0xLTEtNTA3MjU_aed87a7c-7ffa-42ea-b357-f2d2ec81c5cc"
      unitRef="usd">38000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2079949881f8457b9711b22291635c52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjEtNy0xLTEtNTA3MjU_b4a61a37-8a9c-43f5-b7ff-54cdf988788c"
      unitRef="usd">728118000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0475ea6bdae24921b04d181f1d8ee6d7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjEtOS0xLTEtNTA3MjU_fd509d9e-32b8-4225-a5cc-1242b95f4314"
      unitRef="usd">-435868000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iab17129f66c14badb8c3affdd50289b4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjEtMTEtMS0xLTUwNzI1_9eb06979-6661-470e-b6ad-5c8f899c2b77"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icd498162f85e4b45bc79f00af8af6e6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjEtMTMtMS0xLTUwNzI1_de551cc6-9fa6-40ff-834c-62fe4460c24f"
      unitRef="usd">639063000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7bb8f10d82464615b7fd2f7df5d5bd4e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjEtMTUtMS0xLTUwNzI1_19a0f02a-ce48-4d9a-8c54-b654b7846243"
      unitRef="usd">44972000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjItMS0xLTEtNTA3MjU_9f29b9f1-888b-40f0-9c48-46eac48dda78"
      unitRef="usd">3848000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i18dba7744c814ab9907cd2868da0ddc6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjItMy0xLTEtNTA3MjU_3fd27364-cc34-468e-a73c-2d79cf40b10d"
      unitRef="shares">36206</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i2983eae666eb46e39d6a7d6ffe711703_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjItNy0xLTEtNTA3MjU_b69b5533-51b0-43c2-a9e3-b0d06e103249"
      unitRef="usd">3848000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjMtMS0xLTEtNTA3MjU_3b0bc60a-93c0-4d12-b410-514c6628970d"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i18dba7744c814ab9907cd2868da0ddc6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjMtMy0xLTEtNTA3MjU_150df73b-86e6-4d37-a053-c2b0745de7de"
      unitRef="shares">142477</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i2983eae666eb46e39d6a7d6ffe711703_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjMtNy0xLTEtNTA3MjU_88bdc8b7-95f6-4dbf-a4cb-9683be0c0688"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjQtMS0xLTEtNTA3MjU_8556fac2-7b3a-489f-905b-02e16447a00c"
      unitRef="usd">2304000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i18dba7744c814ab9907cd2868da0ddc6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjQtMy0xLTEtNTA3MjU_41e22c91-f2ec-4763-953e-ef17274097ab"
      unitRef="shares">37635</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2983eae666eb46e39d6a7d6ffe711703_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjQtNy0xLTEtNTA3MjU_92c100b5-ff8a-4d72-9cf6-1d046e1897ee"
      unitRef="usd">2304000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjUtMS0xLTEtNTA3MjU_dada54b6-ae45-4f5f-b81b-d87c26322b6d"
      unitRef="usd">16560000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2983eae666eb46e39d6a7d6ffe711703_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjUtNy0xLTEtNTA3MjU_783eff72-74dc-4180-a8e3-b6ee4806fa9a"
      unitRef="usd">16560000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <amed:SurrenderedShares
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjYtMS0xLTEtNTA3MjU_5761b0b9-9123-4a38-bbc4-65d90bf6f7b6"
      unitRef="usd">-7981000</amed:SurrenderedShares>
    <amed:SurrenderedShares
      contextRef="i964159f6265c4a9fa26afa837937e2a9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjYtOS0xLTEtNTA3MjU_43d74058-e53d-4025-a2e7-daa65e1caa6e"
      unitRef="usd">-7981000</amed:SurrenderedShares>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjctMS0xLTEtNTA3MjU_d352faeb-512b-4f1b-922b-57619c25eaf0"
      unitRef="usd">17351000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i964159f6265c4a9fa26afa837937e2a9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjctOS0xLTEtNTA3MjU_76391d5f-5f3e-4811-bead-afaeb6e9db99"
      unitRef="usd">17351000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <amed:ContributionsAttributableToNoncontrollingInterest
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjgtMS0xLTEtNTA3MjU_7ab7ef17-d916-495e-8994-7d47bb4aafd9"
      unitRef="usd">12401000</amed:ContributionsAttributableToNoncontrollingInterest>
    <amed:ContributionsAttributableToNoncontrollingInterest
      contextRef="ia0d005a9091143199e4be44f3a337678_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjgtMTUtMS0xLTUwNzI1_8af9cf7e-faf1-46ac-89f1-6d3ab5c63ea7"
      unitRef="usd">12401000</amed:ContributionsAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjktMS0xLTEtNTA3MjU_4ebdc8e0-5b05-4895-a230-b5eec0dd7a00"
      unitRef="usd">1561000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ia0d005a9091143199e4be44f3a337678_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMjktMTUtMS0xLTUwNzI1_30df70f5-1223-4bc2-8f3b-246f93436d94"
      unitRef="usd">1561000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMzAtMS0xLTEtNTA3MjU_29edec74-18d7-4b48-8c98-03857191412b"
      unitRef="usd">4331000</us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="i2983eae666eb46e39d6a7d6ffe711703_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMzAtNy0xLTEtNTA3MjU_8857bd0c-d9a0-4258-bb84-c32e82f4f6ae"
      unitRef="usd">4233000</us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="ia0d005a9091143199e4be44f3a337678_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMzAtMTUtMS0xLTUwNzI1_14ee8248-ed7f-4d55-a01d-eae88b496241"
      unitRef="usd">98000</us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
    <us-gaap:ProfitLoss
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMzEtMS0xLTEtNTA3MjU_7195b38e-6bc0-4f96-b07d-057b49dc2cbc"
      unitRef="usd">117699000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8ecdf11c833e48ba8909b67bec1dd8bc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMzEtMTMtMS0xLTUwNzI1_d2bd1c40-6a49-4760-8763-32deb6d09df4"
      unitRef="usd">118609000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia0d005a9091143199e4be44f3a337678_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMzEtMTUtMS0xLTUwNzI1_28e8ff36-5327-4911-9f67-6a74eecab115"
      unitRef="usd">-910000</us-gaap:ProfitLoss>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMzItMS0xLTEtNTA3MjU_b2a3bbaf-66e7-4c03-a399-8560875585aa"
      unitRef="usd">1106573000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="id0db7a80feb5475f810c67719ce36ad3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMzItMy0xLTEtNTA3MjU_86f9c937-94e5-420d-8da9-e464b94fac8b"
      unitRef="shares">37891186</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id0db7a80feb5475f810c67719ce36ad3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMzItNS0xLTEtNTA3MjU_12817433-e7f8-4047-9822-532228c03035"
      unitRef="usd">38000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic7f80dee79fe4ac684481f6cd7fd746b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMzItNy0xLTEtNTA3MjU_5ed5a8ba-1057-4c6a-9adc-5da507ea4eb4"
      unitRef="usd">755063000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i83862c03aee5480f950115749f6f0551_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMzItOS0xLTEtNTA3MjU_0a11f9c1-2fc8-4a59-a0e2-5813383f6516"
      unitRef="usd">-461200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie386fbdef29444a7b1e34af6f9fe68b2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMzItMTEtMS0xLTUwNzI1_6d8073da-0a5c-4611-b154-46f7b94e0b4c"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i70cecdb6f3b04a83a501c7724ab21784_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMzItMTMtMS0xLTUwNzI1_5c71a25a-a3d7-4b7d-8fee-f0495f6c46b0"
      unitRef="usd">757672000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9f3f8f64156c4928a36902ecbfdb0cc5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82NC9mcmFnOjczN2ZkZWNiN2EwYTRjZDk5N2QyNTg3MWRiNGMwNjBhL3RhYmxlOjNmYTE0OTU4OTU5MzQzZjg5M2NhZTcxNTU5MTcyZmE0L3RhYmxlcmFuZ2U6M2ZhMTQ5NTg5NTkzNDNmODkzY2FlNzE1NTkxNzJmYTRfMzItMTUtMS0xLTUwNzI1_6daae69a-eae2-478b-ab81-ba816f5b1d13"
      unitRef="usd">55000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMy0xLTEtMS01MDcyNQ_b87ea963-adca-4674-81e0-b6fb8f7a4bc8"
      unitRef="usd">117699000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMy0zLTEtMS01MDcyNQ_52e9e4e1-6088-47a8-a3f4-3534de417fa3"
      unitRef="usd">210166000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMy01LTEtMS01MDcyNQ_7aecdc09-d35f-41a6-bdd5-8ecb9be49a48"
      unitRef="usd">185184000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNS0xLTEtMS01MDcyNQ_fe4d1621-390a-438c-80db-b16542f54883"
      unitRef="usd">24935000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNS0zLTEtMS01MDcyNQ_5a906c13-fc10-44e3-af20-923c960329a8"
      unitRef="usd">30901000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNS01LTEtMS01MDcyNQ_ea15f114-553d-4e09-9026-5bbec48cc9e0"
      unitRef="usd">28802000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNi0xLTEtMS01MDcyNQ_954f10ad-ffd8-4f55-8e82-b96bc3a80fce"
      unitRef="usd">16560000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNi0zLTEtMS01MDcyNQ_98682c9c-9261-4f6a-830f-55af728a17f8"
      unitRef="usd">23809000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNi01LTEtMS01MDcyNQ_04e7e61b-942c-469c-b47d-9d85feb38406"
      unitRef="usd">26730000</us-gaap:ShareBasedCompensation>
    <amed:AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfOC0xLTEtMS01MDcyNQ_c811b8eb-f27d-4a64-8576-6023b90608e3"
      unitRef="usd">46029000</amed:AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset>
    <amed:AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfOC0zLTEtMS01MDcyNQ_31dc7990-f0b6-4686-bb2c-5f7726438132"
      unitRef="usd">40364000</amed:AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset>
    <amed:AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfOC01LTEtMS01MDcyNQ_f4bd7bfb-10f5-4ef9-8e18-6ea34f804fb9"
      unitRef="usd">39140000</amed:AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfOS0xLTEtMS01MDcyNQ_a654bdd5-fa57-4919-abff-81f9daa0ecef"
      unitRef="usd">-519000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfOS0zLTEtMS01MDcyNQ_443257e8-2e5d-43d3-b590-e151c98aa6d1"
      unitRef="usd">124000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfOS01LTEtMS01MDcyNQ_cb58a187-b32b-4021-abf4-72604a735eae"
      unitRef="usd">30000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTAtMS0xLTEtNTA3MjU_4d4109f8-f0f8-4b27-bb6f-ef90c139827e"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTAtMy0xLTEtNTA3MjU_29d72665-50da-4090-8dc5-8d6f8111f422"
      unitRef="usd">31098000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTAtNS0xLTEtNTA3MjU_730438c9-4fe5-4473-bb85-835f1863dd8b"
      unitRef="usd">-2980000</us-gaap:GainLossOnSaleOfInvestments>
    <amed:WriteOffOfOtherComprehensiveIncome
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTEtMS0xLTEtNTA3MjU_c06741e9-eead-4b68-b254-35900c84d9d9"
      unitRef="usd">0</amed:WriteOffOfOtherComprehensiveIncome>
    <amed:WriteOffOfOtherComprehensiveIncome
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTEtMy0xLTEtNTA3MjU_c7052eb6-5a51-422d-a28c-bc92e6a74cb0"
      unitRef="usd">0</amed:WriteOffOfOtherComprehensiveIncome>
    <amed:WriteOffOfOtherComprehensiveIncome
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTEtNS0xLTEtNTA3MjU_5e8de6e4-6a86-4e60-8979-6507f810e72a"
      unitRef="usd">15000</amed:WriteOffOfOtherComprehensiveIncome>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTItMS0xLTEtNTA3MjU_04106508-c0ec-4f2f-a8df-1b77d042ba69"
      unitRef="usd">23377000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTItMy0xLTEtNTA3MjU_5d9d21d0-5f14-4add-92a4-62bfc4b97d5e"
      unitRef="usd">44582000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTItNS0xLTEtNTA3MjU_66772a19-e0a7-4e58-aa98-5fbdcf703bb0"
      unitRef="usd">-26560000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTMtMS0xLTEtNTA3MjU_b1ed1acb-b9f3-4d7c-bbe1-fde95c3f3a02"
      unitRef="usd">-45000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTMtMy0xLTEtNTA3MjU_3e20d6a9-716f-4c27-8717-91cf2ee60570"
      unitRef="usd">4949000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTMtNS0xLTEtNTA3MjU_2dcf92f2-9a70-4caf-baef-a3a0047df378"
      unitRef="usd">3966000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTQtMS0xLTEtNTA3MjU_8bed9b13-e364-4c52-863a-405a6719ddc3"
      unitRef="usd">991000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTQtMy0xLTEtNTA3MjU_9f58c7e5-2e6f-4269-9999-a8dc0475e36d"
      unitRef="usd">917000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTQtNS0xLTEtNTA3MjU_504a553d-6b27-4897-8f88-fb32e7ace6c0"
      unitRef="usd">869000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTUtMS0xLTEtNTA3MjU_9a83139a-20ba-4c13-afab-f13e8a966132"
      unitRef="usd">5163000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTUtMy0xLTEtNTA3MjU_e3cecaa0-6a3e-4dd0-b3f2-6be25cdface4"
      unitRef="usd">5343000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTUtNS0xLTEtNTA3MjU_324b7bb7-4027-4667-842c-9a30485ff825"
      unitRef="usd">5444000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:AssetImpairmentCharges
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTYtMS0xLTEtNTA3MjU_bde1d822-acae-4418-9078-27518e848b59"
      unitRef="usd">3009000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTYtMy0xLTEtNTA3MjU_b2e330c5-ced1-461c-b78b-bca97118a4c3"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTYtNS0xLTEtNTA3MjU_f8d00388-ca5a-49b1-aa0b-321b21044483"
      unitRef="usd">4152000</us-gaap:AssetImpairmentCharges>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTgtMS0xLTEtNTA3MjU_a668b41d-7c56-4298-a89c-0e87d160e2ae"
      unitRef="usd">14230000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTgtMy0xLTEtNTA3MjU_a047180a-497c-4c48-a37b-e2c630cf42f3"
      unitRef="usd">18030000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTgtNS0xLTEtNTA3MjU_67250fb5-efa9-4fa3-9203-07b83771f948"
      unitRef="usd">-2114000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTktMS0xLTEtNTA3MjU_e472af02-8e76-4e5b-9419-2be8eda8a72f"
      unitRef="usd">3525000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTktMy0xLTEtNTA3MjU_cde72e20-e4a3-4222-ba76-5d9b060728d0"
      unitRef="usd">12202000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMTktNS0xLTEtNTA3MjU_ca847a5a-9fd4-427a-9c17-b44b9a5a4c6b"
      unitRef="usd">7181000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjAtMS0xLTEtNTA3MjU_de1687d0-eb01-47e7-bbce-c925e347c75c"
      unitRef="usd">-438000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjAtMy0xLTEtNTA3MjU_f35b194e-816d-4ea3-acfa-6b66ffdb7e4b"
      unitRef="usd">1017000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjAtNS0xLTEtNTA3MjU_59d751e6-5348-49c1-bac9-dc0d00de45dc"
      unitRef="usd">-31000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjEtMS0xLTEtNTA3MjU_bb693b5e-67fa-4178-a444-40706fb6a189"
      unitRef="usd">4894000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjEtMy0xLTEtNTA3MjU_6c51db24-e0ee-437b-aeb5-9fed1957f28e"
      unitRef="usd">-4353000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjEtNS0xLTEtNTA3MjU_cee00b30-4cb6-4257-8b5b-11b2f052e7d4"
      unitRef="usd">1941000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjItMS0xLTEtNTA3MjU_9868411f-be56-47b2-b5d6-0e165316fd71"
      unitRef="usd">-39382000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjItMy0xLTEtNTA3MjU_b39a4114-00a8-4aef-95a6-64cb342e35dd"
      unitRef="usd">-26915000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjItNS0xLTEtNTA3MjU_02b05ea5-7db7-4ac1-a35d-e600a39647b7"
      unitRef="usd">39839000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjMtMS0xLTEtNTA3MjU_4d2f7c9c-5d90-43cd-9bca-d1b75bda9723"
      unitRef="usd">-8822000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjMtMy0xLTEtNTA3MjU_af0d56bd-4698-4df8-becb-c89dde78cf41"
      unitRef="usd">-28796000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjMtNS0xLTEtNTA3MjU_dce3c7de-104a-45c5-896b-dd315cf3bc76"
      unitRef="usd">27717000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjQtMS0xLTEtNTA3MjU_aad984f7-a8d9-463e-98ac-ba5dbf852a78"
      unitRef="usd">-41175000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjQtMy0xLTEtNTA3MjU_71213a90-1a74-420b-b6a5-73c908736438"
      unitRef="usd">-36645000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjQtNS0xLTEtNTA3MjU_cbcd1840-d4ff-48c6-b099-6f8b038caea4"
      unitRef="usd">-34695000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjUtMS0xLTEtNTA3MjU_23dbe513-b262-402e-a115-8b2f58e43159"
      unitRef="usd">-3242000</amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjUtMy0xLTEtNTA3MjU_ddbde2b4-0bce-48f6-b2a8-f46013ec43d6"
      unitRef="usd">-3060000</amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjUtNS0xLTEtNTA3MjU_6f3f1c24-336a-4491-bcc7-2f807c1f56b2"
      unitRef="usd">-3544000</amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjYtMS0xLTEtNTA3MjU_ded5d2fb-7adc-4cf6-8fef-b9658ea59300"
      unitRef="usd">133283000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjYtMy0xLTEtNTA3MjU_5dfda47d-d14f-4434-a44b-23707f85157e"
      unitRef="usd">188893000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjYtNS0xLTEtNTA3MjU_bbadf5d5-0d6a-4296-82e6-634457a2333a"
      unitRef="usd">288952000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfRestrictedInvestments
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjgtMS0xLTEtNTA3MjU_311a048c-9c62-41ac-81dd-f88a5e12d58e"
      unitRef="usd">252000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
    <us-gaap:ProceedsFromSaleOfRestrictedInvestments
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjgtMy0xLTEtNTA3MjU_36dde604-9e98-4f94-b565-625c6777d019"
      unitRef="usd">135000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
    <us-gaap:ProceedsFromSaleOfRestrictedInvestments
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjgtNS0xLTEtNTA3MjU_cf046c71-d2fa-4ac5-bbb8-bcfbf82fabbc"
      unitRef="usd">101000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjktMS0xLTEtNTA3MjU_25dbd17f-295e-4da9-8545-b34036dbf494"
      unitRef="usd">66000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjktMy0xLTEtNTA3MjU_5f7a9f44-0c59-42c4-b0ab-7dee863dc888"
      unitRef="usd">144000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMjktNS0xLTEtNTA3MjU_c4ae835e-b693-4e2b-9ddb-2ff7f4176b83"
      unitRef="usd">80000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzAtMS0xLTEtNTA3MjU_0d117e92-4917-4642-b749-1c98adb7375c"
      unitRef="usd">6165000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzAtMy0xLTEtNTA3MjU_59f52e13-7c1b-4b28-b2b5-5a5f24dd0e5b"
      unitRef="usd">6302000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzAtNS0xLTEtNTA3MjU_1eac7c50-f24b-44f6-9dc7-ac12143dc296"
      unitRef="usd">5332000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToDevelopSoftware
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzEtMS0xLTEtNTA3MjU_3a4332cb-0d6c-49ff-ae3d-459138c59ca9"
      unitRef="usd">1050000</us-gaap:PaymentsToDevelopSoftware>
    <us-gaap:PaymentsToDevelopSoftware
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzEtMy0xLTEtNTA3MjU_820520e0-b74e-453e-97ae-e57848fa59f9"
      unitRef="usd">419000</us-gaap:PaymentsToDevelopSoftware>
    <us-gaap:PaymentsToDevelopSoftware
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzEtNS0xLTEtNTA3MjU_ed25c793-0b2a-4ebb-8a4c-78e42c455612"
      unitRef="usd">0</us-gaap:PaymentsToDevelopSoftware>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzItMS0xLTEtNTA3MjU_b1bf03b3-9472-402c-a0e1-064c29e78b13"
      unitRef="usd">637000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzItMy0xLTEtNTA3MjU_df3e9fa2-430f-47db-8194-213349a11d29"
      unitRef="usd">200000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzItNS0xLTEtNTA3MjU_32ad30d3-fbd6-4cd4-885a-173ff1e26523"
      unitRef="usd">875000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzMtMS0xLTEtNTA3MjU_ed23dbe4-38ab-4c13-ae25-974c33ee34ed"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzMtMy0xLTEtNTA3MjU_215d7a5c-b7a3-460e-8ad1-ce7d068dbb8b"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzMtNS0xLTEtNTA3MjU_2189df8b-f97e-4732-84f7-e93922a8b6f5"
      unitRef="usd">17876000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzMtMS0xLTEtNTY5MTI_aa0757c4-1b39-4e8e-9f35-c0d2c5505140"
      unitRef="usd">15000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzMtMy0xLTEtNTY5MTI_cdba32f5-ff05-4dc5-be23-0bf55fadfc4e"
      unitRef="usd">5000000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzMtNS0xLTEtNTY5MTI_9d95dabb-8b19-45bf-aa72-6de47ff1e734"
      unitRef="usd">0</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzQtMS0xLTEtNTA3MjU_9512d324-feab-4e59-b7a9-8e1527e42267"
      unitRef="usd">71952000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzQtMy0xLTEtNTA3MjU_26a36fa6-b05d-432d-8abe-5cd5bc867c62"
      unitRef="usd">269965000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzQtNS0xLTEtNTA3MjU_f829d3fa-de8e-4fba-832e-1cb5816ac76a"
      unitRef="usd">298958000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzUtMS0xLTEtNTA3MjU_0bafed4d-aa53-4f39-bc1e-d5dde3ef162c"
      unitRef="usd">-94486000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzUtMy0xLTEtNTA3MjU_9030369e-a33f-4713-a573-df8eb3f23206"
      unitRef="usd">-281607000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzUtNS0xLTEtNTA3MjU_16f564f3-f21a-450c-a376-2a3a5dcb8705"
      unitRef="usd">-287108000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzctMS0xLTEtNTA3MjU_5d28993d-5132-4405-888f-c23f871cf196"
      unitRef="usd">2304000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzctMy0xLTEtNTA3MjU_981f385f-383a-4763-b858-a36fd1ff9de5"
      unitRef="usd">2054000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzctNS0xLTEtNTA3MjU_cb196d48-f79a-473c-b60c-40b846b25a27"
      unitRef="usd">6325000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzgtMS0xLTEtNTA3MjU_44d2f9bd-dc66-416e-931b-13335e8fddf0"
      unitRef="usd">3848000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzgtMy0xLTEtNTA3MjU_5f834227-9643-4fff-b5a6-619e98b24479"
      unitRef="usd">3968000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzgtNS0xLTEtNTA3MjU_1fbd4d1e-18d5-42d8-922a-26cdc8ae1fe8"
      unitRef="usd">3562000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzktMS0xLTEtNTA3MjU_8543df66-9ed4-4a0f-a6a3-472bcfc54190"
      unitRef="usd">7981000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzktMy0xLTEtNTA3MjU_e13949a2-1282-43e6-9056-c50ec2413135"
      unitRef="usd">16898000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfMzktNS0xLTEtNTA3MjU_c2145af1-10b1-4ea1-867e-3fe8d03e7aec"
      unitRef="usd">54493000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <amed:CashContributionToNoncontrollingInterest
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDAtMS0xLTEtNTA3MjU_cf9d81ea-91aa-4d17-92a0-697a35806732"
      unitRef="usd">3501000</amed:CashContributionToNoncontrollingInterest>
    <amed:CashContributionToNoncontrollingInterest
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDAtMy0xLTEtNTA3MjU_af21a168-64cc-4f1d-9a5f-b25b20a9268b"
      unitRef="usd">250000</amed:CashContributionToNoncontrollingInterest>
    <amed:CashContributionToNoncontrollingInterest
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDAtNS0xLTEtNTA3MjU_d9ed2c1d-6530-405e-a625-542b2a6d45be"
      unitRef="usd">0</amed:CashContributionToNoncontrollingInterest>
    <amed:CashDistributionToNoncontrollingInterest
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDEtMS0xLTEtNTA3MjU_80c7f4c5-b1f3-4ef7-9ff6-605cfad28517"
      unitRef="usd">1561000</amed:CashDistributionToNoncontrollingInterest>
    <amed:CashDistributionToNoncontrollingInterest
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDEtMy0xLTEtNTA3MjU_d2aefcba-50bb-4108-b926-70c151762228"
      unitRef="usd">1747000</amed:CashDistributionToNoncontrollingInterest>
    <amed:CashDistributionToNoncontrollingInterest
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDEtNS0xLTEtNTA3MjU_a08af458-3544-4536-a621-5689be112051"
      unitRef="usd">1122000</amed:CashDistributionToNoncontrollingInterest>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDEtMS0xLTEtNTY4NjU_0e4234fd-f7b9-4333-9939-640e3bad41c0"
      unitRef="usd">5817000</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDEtMy0xLTEtNTY4NjU_9a30a514-0b3e-40ce-82bc-1a16f4ad089c"
      unitRef="usd">0</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDEtNS0xLTEtNTY4NjU_22e90aee-bc04-4c09-8b7a-465a0573c762"
      unitRef="usd">0</us-gaap:ProceedsFromMinorityShareholders>
    <amed:ProceedsFromBorrowingsUnderTermLoan
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDItMS0xLTEtNTA3MjU_e2e45d88-87ed-435a-ab11-d6289347c64c"
      unitRef="usd">0</amed:ProceedsFromBorrowingsUnderTermLoan>
    <amed:ProceedsFromBorrowingsUnderTermLoan
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDItMy0xLTEtNTA3MjU_f45729c2-03f8-4f71-a579-d6874bfe4b3e"
      unitRef="usd">290312000</amed:ProceedsFromBorrowingsUnderTermLoan>
    <amed:ProceedsFromBorrowingsUnderTermLoan
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDItNS0xLTEtNTA3MjU_b5dd1b7e-abd5-42c0-952f-1bc5f7d5215d"
      unitRef="usd">0</amed:ProceedsFromBorrowingsUnderTermLoan>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDMtMS0xLTEtNTA3MjU_bd5c6dff-39ec-43c4-9c16-51b243887118"
      unitRef="usd">534500000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDMtMy0xLTEtNTA3MjU_ad00f0d8-4224-4b7a-8ede-e0261279b5f0"
      unitRef="usd">500700000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDMtNS0xLTEtNTA3MjU_34f21edc-9fde-4fd6-9c89-4f3a9153a799"
      unitRef="usd">684200000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDQtMS0xLTEtNTA3MjU_4997d0cd-bf58-44ef-b9b2-8243e0a110cf"
      unitRef="usd">534500000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDQtMy0xLTEtNTA3MjU_221013c0-c43e-4f5e-ad2f-3b1f97b69dec"
      unitRef="usd">551700000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDQtNS0xLTEtNTA3MjU_4e6b7e87-b5e2-432a-921b-96982bf9f0cb"
      unitRef="usd">703200000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDUtMS0xLTEtNTA3MjU_93380aaf-9188-4a2b-a4a0-d2a1b5208cf4"
      unitRef="usd">13296000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDUtMy0xLTEtNTA3MjU_e2fae318-4947-4d33-a5c4-4e57fa40f113"
      unitRef="usd">9143000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDUtNS0xLTEtNTA3MjU_61c82a25-06ba-4abe-b8cb-19671711c4d8"
      unitRef="usd">10249000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDYtMS0xLTEtNTA3MjU_17325b70-75ca-4950-a068-d0942d86b9c8"
      unitRef="usd">0</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDYtMy0xLTEtNTA3MjU_3a67d3a2-ff6b-4d95-8f8e-1919a299408e"
      unitRef="usd">2792000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDYtNS0xLTEtNTA3MjU_12ae4176-fd8e-4327-b8ad-e31c1c682a73"
      unitRef="usd">0</us-gaap:PaymentsOfFinancingCosts>
    <amed:FundsReceivedFromProviderReliefFundAdvance
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDctMS0xLTEtNTA3MjU_cfc0025c-7214-4ef3-b298-7f9958f576d4"
      unitRef="usd">0</amed:FundsReceivedFromProviderReliefFundAdvance>
    <amed:FundsReceivedFromProviderReliefFundAdvance
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDctMy0xLTEtNTA3MjU_3ae3eaf1-09ab-41f4-ac7a-6f78d68d7fd0"
      unitRef="usd">-60000000</amed:FundsReceivedFromProviderReliefFundAdvance>
    <amed:FundsReceivedFromProviderReliefFundAdvance
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDctNS0xLTEtNTA3MjU_f1f87f55-459c-444a-9f91-98815af23ede"
      unitRef="usd">60000000</amed:FundsReceivedFromProviderReliefFundAdvance>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDgtMS0xLTEtNTA3MjU_cef4f27e-cd43-4fe8-9626-7eca9dd496b0"
      unitRef="usd">17351000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDgtMy0xLTEtNTA3MjU_b9b1092d-df26-4ec6-9077-822c28efe287"
      unitRef="usd">99878000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDgtNS0xLTEtNTA3MjU_7acc0721-009b-4ba6-bed9-92f25f31429e"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDgtMS0xLTEtNTE2NTg_309d9ce5-eac4-4dcd-96dd-f1dad2b39e2d"
      unitRef="usd">5714000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDgtMy0xLTEtNTE2NTg_25f9ebe0-adeb-4394-a5cc-1461aee3cf5b"
      unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDgtNS0xLTEtNTE2NTg_e95bb464-1d03-474e-a35a-8e52570c7cbe"
      unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDktMS0xLTEtNTA3MjU_eecfab13-62a6-49f6-bd6f-52fb22fc93b9"
      unitRef="usd">-30433000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDktMy0xLTEtNTA3MjU_0d18161c-5070-4ad5-b6c4-a7fbfa033244"
      unitRef="usd">55126000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNDktNS0xLTEtNTA3MjU_cca31aa2-0e3e-45b1-8c12-4655d63ca017"
      unitRef="usd">-14977000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTAtMS0xLTEtNTA3MjU_31672a5f-4efb-473a-8a5c-c4c7eca98f30"
      unitRef="usd">8364000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTAtMy0xLTEtNTA3MjU_08c07d42-6e4b-4ff8-bf25-82f81e11c723"
      unitRef="usd">-37588000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTAtNS0xLTEtNTA3MjU_cbe6f7e4-5562-4aae-99ca-bdc5cfc32de2"
      unitRef="usd">-13133000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTEtMS0xLTEtNTA3MjU_19392b76-2928-479e-9518-5a872d155328"
      unitRef="usd">45769000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i42b1e865f1ed4b2e8363dfcc39186a91_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTEtMy0xLTEtNTA3MjU_8c556b6e-bef2-490d-8058-7242fd5b8066"
      unitRef="usd">83357000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iab144f7e34ce4a479683c59de399ff42_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTEtNS0xLTEtNTA3MjU_643c333c-914a-4d88-a7da-258d1947822c"
      unitRef="usd">96490000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTItMS0xLTEtNTA3MjU_b8acc60f-30c9-499d-bb94-af558467ed2b"
      unitRef="usd">54133000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTItMy0xLTEtNTA3MjU_6afb6d52-0d11-4292-84fa-3598e032387f"
      unitRef="usd">45769000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i42b1e865f1ed4b2e8363dfcc39186a91_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTItNS0xLTEtNTA3MjU_fa412156-7c2f-4aa6-887c-410fba926a05"
      unitRef="usd">83357000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTQtMS0xLTEtNTA3MjU_be164efe-1602-4495-b241-595b70f78ceb"
      unitRef="usd">14939000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTQtMy0xLTEtNTA3MjU_7544296c-f580-4e95-b8c8-3abd62a65462"
      unitRef="usd">5291000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTQtNS0xLTEtNTA3MjU_dae34cf8-0953-414a-a5ef-ab6d196946d5"
      unitRef="usd">6207000</us-gaap:InterestPaidNet>
    <amed:CashPaidForInfinityZPICInterest
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTYtMS0xLTEtNTY4NTg_ad81886f-c3a7-40b6-aa9f-a93424ac3516"
      unitRef="usd">12755000</amed:CashPaidForInfinityZPICInterest>
    <amed:CashPaidForInfinityZPICInterest
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTYtMy0xLTEtNTY4NTg_151815be-5ec6-46d3-acaf-cc43cad713cd"
      unitRef="usd">0</amed:CashPaidForInfinityZPICInterest>
    <amed:CashPaidForInfinityZPICInterest
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTYtNS0xLTEtNTY4NTg_e82daa6c-fee8-4fe8-bf9f-c61187e5bfb2"
      unitRef="usd">0</amed:CashPaidForInfinityZPICInterest>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTUtMS0xLTEtNTA3MjU_8c854f5d-22cb-49af-8d9e-91c5a3e0b7a2"
      unitRef="usd">24013000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTUtMy0xLTEtNTA3MjU_98e434a7-8e10-41fd-a7cb-a9ffbca7ae97"
      unitRef="usd">34097000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNTUtNS0xLTEtNTA3MjU_507f04ac-692d-4b8e-a1e1-64dc2aeb4a7b"
      unitRef="usd">50721000</us-gaap:IncomeTaxesPaidNet>
    <amed:NonCashAccruedContingentConsideration
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNjEtMS0xLTEtNTk5MzM_884090b8-450b-4e4d-8430-1bf45f1e0e16"
      unitRef="usd">19195000</amed:NonCashAccruedContingentConsideration>
    <amed:NonCashAccruedContingentConsideration
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNjEtMy0xLTEtNTk5MzM_bf4f1f48-53f9-4750-ac80-76cd72bae963"
      unitRef="usd">0</amed:NonCashAccruedContingentConsideration>
    <amed:NonCashAccruedContingentConsideration
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNjEtNS0xLTEtNjA4MjQ_135a6bae-5b6a-475d-a926-15a7304518d8"
      unitRef="usd">0</amed:NonCashAccruedContingentConsideration>
    <amed:NonCashNoncontrollingInterestContribution
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNjItMS0xLTEtNTk5MzM_7948e71b-606c-4b63-b0a2-0e6c4d1eae24"
      unitRef="usd">8900000</amed:NonCashNoncontrollingInterestContribution>
    <amed:NonCashNoncontrollingInterestContribution
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNjItMy0xLTEtNTk5MzM_6a9d1307-4b8d-4652-9433-252a58743405"
      unitRef="usd">0</amed:NonCashNoncontrollingInterestContribution>
    <amed:NonCashNoncontrollingInterestContribution
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV82Ny9mcmFnOjBkNmRhNjc2MDFkODQzNDViNDdlZjQ4MGZmNmFmYTczL3RhYmxlOmMwNDI2N2ExMjBlNDQ3YjVhMDdkNTViZWQ4ZTllZDI4L3RhYmxlcmFuZ2U6YzA0MjY3YTEyMGU0NDdiNWEwN2Q1NWJlZDhlOWVkMjhfNjItNS0xLTEtNjA4MzA_2ca203e4-3d59-471a-8488-c71281e14de4"
      unitRef="usd">0</amed:NonCashNoncontrollingInterestContribution>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfMTEzNzM_e5cb1ff6-4103-4920-94c4-b9e2d8192e4c">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amedisys, Inc., a Delaware corporation (together with its consolidated subsidiaries, referred to herein as &#x201c;Amedisys,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;), is a multi-state provider of home health, hospice, personal care and high acuity care services with approximately 74%, 75% and 75% of our consolidated net service revenue derived from Medicare for 2022, 2021 and 2020, respectively. As of December&#160;31, 2022, we owned and operated 347 Medicare-certified home health care centers, 164 Medicare-certified hospice care centers, 13 personal-care care centers and 8 admitting high acuity care joint ventures in 37 states within the United States and the District of Columbia.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021, the Company adopted Accounting Standards Update ("ASU") 2020-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Codification Improvements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which included minor technical corrections and clarifications to improve consistency and clarify the application of various provisions of the codification by amending the codification to include all disclosure guidance in the appropriate disclosure sections and by amending and adding new headings, cross referencing to other guidance and refining or correcting terminology. Our adoption of this standard did not have a material effect on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021, the Company adopted ASU 2021-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which was intended to increase transparency around financial reporting regarding government assistance by requiring disclosure of information about (1) the types of government assistance received, (2) an entity's accounting for the government assistance received and (3) the effect of the assistance on an entity's financial statements. The ASU was effective for annual periods beginning after December 15, 2021, with early adoption permitted. See Note 3 &#x2013; Novel Coronavirus Pandemic ("COVID-19") for the disclosures associated with this standard. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, the Company adopted ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses (Topic 326)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provided guidance for measuring credit losses on financial instruments. Our adoption of this standard did not have a material effect on our consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, the Company adopted ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which eliminated certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating taxes during the interim periods and the recognition of deferred tax liabilities for outside basis differences. This guidance also simplified aspects of the accounting for franchise taxes, enacted changes in tax laws or rates and clarified the accounting for transactions that result in a step-up in the tax basis of goodwill. The guidance was effective for interim and annual periods beginning after December 15, 2020, with early adoption permitted. Our adoption of this standard on a prospective basis was not material to the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the Financial Accounting Standards Board ("FASB") issued ASU 2020-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provides optional expedients and exceptions for applying U.S. Generally Accepted Accounting Principles ("U.S. GAAP") to contract modifications and hedging relationships that reference the London Inter-Bank Offered Rate ("LIBOR") or another reference rate expected to be discontinued, subject to meeting certain criteria. In January 2021, the FASB issued ASU 2021-01, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Scope&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which adds implementation guidance to ASU 2020-04 to clarify certain optional expedients in Topic 848. The guidance in ASU 2020-04 and ASU 2021-01 was effective upon issuance and may generally be applied prospectively through December 31, 2022. In December 2022, the FASB issued ASU 2022-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which deferred the sunset date of Topic 848 from December 31, 2022 to December 31, 2024. These standards did not have an effect on our consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our accounting and reporting policies conform with U.S. GAAP. In preparing the consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These consolidated financial statements include the accounts of Amedisys, Inc. and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying consolidated financial &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;statements, and business combinations accounted for as purchases have been included in our consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consolidate investments when the entity is a variable interest entity ("VIE") and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold 50% or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary. The book value of investments that we account for under the equity method of accounting totaled $40.5 million and $48.1 million as of December&#160;31, 2022 and 2021, respectively, and is reflected in other assets within our consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for investments in entities in which we have less than 20% ownership interest under the cost method of accounting if we do not have the ability to exercise significant influence over the investee. During 2022, we made a $15.0&#160;million investment in a home health benefit manager, which is accounted for under the cost method. During 2021, we made a $5.0&#160;million investment in ConnectRN, a workforce optimization company, which is accounted for under the cost method. The book value of investments that we account for under the cost method of accounting was $20.0&#160;million and $5.0&#160;million as of December 31, 2022 and 2021, respectively, and is reflected in other assets within our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three-month period ended December 31, 2022, we sold a 49% interest in two of our home health care centers while maintaining a controlling interest in the newly formed joint venture. We are consolidating this joint venture. The total cash consideration received for the 49% noncontrolling interest was $1.9&#160;million. In connection with the transaction, we recorded an after-tax gain of $1.4&#160;million; this gain was recorded to additional paid-in capital within our consolidated balance sheet. During the three-month period ended September 30, 2022, we sold a 30% interest in two of our home health care centers while maintaining a controlling interest in the newly formed joint venture. We are consolidating this joint venture. The total cash consideration received for the 30% noncontrolling interest was $3.9&#160;million. In connection with the transaction, we recorded an after-tax gain of $2.9&#160;million; this gain was recorded to additional paid-in capital within our consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021, a third-party acquired a majority of the issued and outstanding membership interests of one of our equity method investments, Medalogix, for cash, with the remaining membership interests rolling over into a newly formed entity that includes Medalogix as well as another healthcare predictive data and analytics company. We rolled over 100% of our ownership interest in Medalogix to the newly formed entity, and in connection with this transaction, we recognized a $31.1&#160;million gain based on the purchase price of Medalogix, which is reflected in gain on equity method investments within our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of Contessa Health ("Contessa") on August 1, 2021, we obtained interests in several joint ventures with health system partners and a professional corporation that employs clinicians. Each of these entities meets the criteria to be classified as a VIE. As of December 31, 2022, we are consolidating all of our admitting joint ventures with health system partners as well as the professional corporation as we have concluded that we are the primary beneficiary of these VIEs. We have management agreements in place with each of these entities whereby we manage the entities and run the day-to-day operations. As such, we possess the power to direct the activities that most significantly impact the economic performance of the VIEs. The significant activities include, but are not limited to, negotiating provider and payor contracts, establishing patient care policies and protocols, making employment and compensation decisions, developing the operating and capital budgets, performing marketing activities and providing accounting support. We also have the obligation to absorb any expected losses and the right to receive benefits. Additionally, from time to time we may be required to provide joint venture funding. Our high acuity care segment also includes two non-admitting joint ventures with health system partners that are accounted for under the equity method of accounting. Operations of one of these joint ventures have ceased, and we are currently awaiting claims runout to complete financial reconciliations with our health plan partner; we recorded a $3.0&#160;million impairment charge related to our investment in this joint venture during the three-month period ended September 30, 2022.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms of the agreements with each VIE prohibit us from using the assets of the VIE to satisfy the obligations of other entities. The carrying amount of the VIEs&#x2019; assets and liabilities included in our consolidated balance sheets are as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.669%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, we sold our investment in the Heritage Healthcare Innovation Fund, LP via a secondary transaction for $17.9&#160;million which resulted in a $3.0&#160;million loss which is reflected in gain (loss) on equity method investments within our consolidated statement of operations for the year ended December 31, 2020. The Company's original investment was made in 2010 and no longer fit within our strategic areas of focus. Proceeds from the sale were used to pay down debt and fund capital needs.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib60ffa9c6822423ca9d59d283467feaa_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfMzQy_9ffd9ec7-d761-4a15-8ac3-093e22c35dd7"
      unitRef="number">0.74</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i30a242e707714a1eab7e611922efcc2c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfMzQ2_a1b20370-f314-4392-8d4d-2209b4bcdac5"
      unitRef="number">0.75</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i66aac21e2a3b47cb9f000f260204e4ff_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfMzUz_1fdf8ad8-aa35-4f62-b99d-781b9fd5313c"
      unitRef="number">0.75</us-gaap:ConcentrationRiskPercentage1>
    <amed:OperatingCareCenters
      contextRef="i2f7b8ece18824575809137727a001ab8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfNDU4_9fc8e937-b9c4-4203-90bc-f0c04967f9d6"
      unitRef="care_center">347</amed:OperatingCareCenters>
    <amed:OperatingCareCenters
      contextRef="i4fb0b4ede01d45a8ac9f87b995dfc5bd_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfNTA2_f193d505-f96e-45da-8133-6e5462c28206"
      unitRef="care_center">164</amed:OperatingCareCenters>
    <amed:OperatingCareCenters
      contextRef="i466c99d823de4e3da04d3e6d94ea4feb_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfNTUw_a7bf3541-5fab-47fa-aabb-b4ba8ba406b2"
      unitRef="care_center">13</amed:OperatingCareCenters>
    <amed:NumberOfAdmittingJointVentures
      contextRef="ibc62063a43fb4e54a4eb1692d07bbee2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfNTg0_ec07058f-e8ce-4779-9755-ee6c600ecf16"
      unitRef="numberofjointventures">8</amed:NumberOfAdmittingJointVentures>
    <us-gaap:NumberOfStatesInWhichEntityOperates
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfNjIy_ebb2b6b5-d70f-4556-badd-a5038ce1dce6"
      unitRef="state">37</us-gaap:NumberOfStatesInWhichEntityOperates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfMTEzNTk_85308d9f-0a68-41d2-8847-3c3ceab1da82">&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021, the Company adopted Accounting Standards Update ("ASU") 2020-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Codification Improvements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which included minor technical corrections and clarifications to improve consistency and clarify the application of various provisions of the codification by amending the codification to include all disclosure guidance in the appropriate disclosure sections and by amending and adding new headings, cross referencing to other guidance and refining or correcting terminology. Our adoption of this standard did not have a material effect on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021, the Company adopted ASU 2021-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which was intended to increase transparency around financial reporting regarding government assistance by requiring disclosure of information about (1) the types of government assistance received, (2) an entity's accounting for the government assistance received and (3) the effect of the assistance on an entity's financial statements. The ASU was effective for annual periods beginning after December 15, 2021, with early adoption permitted. See Note 3 &#x2013; Novel Coronavirus Pandemic ("COVID-19") for the disclosures associated with this standard. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, the Company adopted ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses (Topic 326)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provided guidance for measuring credit losses on financial instruments. Our adoption of this standard did not have a material effect on our consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, the Company adopted ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which eliminated certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating taxes during the interim periods and the recognition of deferred tax liabilities for outside basis differences. This guidance also simplified aspects of the accounting for franchise taxes, enacted changes in tax laws or rates and clarified the accounting for transactions that result in a step-up in the tax basis of goodwill. The guidance was effective for interim and annual periods beginning after December 15, 2020, with early adoption permitted. Our adoption of this standard on a prospective basis was not material to the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the Financial Accounting Standards Board ("FASB") issued ASU 2020-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provides optional expedients and exceptions for applying U.S. Generally Accepted Accounting Principles ("U.S. GAAP") to contract modifications and hedging relationships that reference the London Inter-Bank Offered Rate ("LIBOR") or another reference rate expected to be discontinued, subject to meeting certain criteria. In January 2021, the FASB issued ASU 2021-01, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Scope&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which adds implementation guidance to ASU 2020-04 to clarify certain optional expedients in Topic 848. The guidance in ASU 2020-04 and ASU 2021-01 was effective upon issuance and may generally be applied prospectively through December 31, 2022. In December 2022, the FASB issued ASU 2022-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848,&lt;/span&gt; which deferred the sunset date of Topic 848 from December 31, 2022 to December 31, 2024. These standards did not have an effect on our consolidated financial statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfMTEzNzU_b9ae40ac-a91d-437f-a36f-4b9e8ae7f8fc">&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our accounting and reporting policies conform with U.S. GAAP. In preparing the consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfMTEzNjg_d46de7e5-381b-40df-bdf0-f4ee626c0b81">&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These consolidated financial statements include the accounts of Amedisys, Inc. and our wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in our accompanying consolidated financial &lt;/span&gt;&lt;/div&gt;statements, and business combinations accounted for as purchases have been included in our consolidated financial statements from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfMTEzNzI_16d1d022-91e2-4a7b-9a22-b7c90864327b">&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consolidate investments when the entity is a variable interest entity ("VIE") and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold 50% or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary. The book value of investments that we account for under the equity method of accounting totaled $40.5 million and $48.1 million as of December&#160;31, 2022 and 2021, respectively, and is reflected in other assets within our consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for investments in entities in which we have less than 20% ownership interest under the cost method of accounting if we do not have the ability to exercise significant influence over the investee. During 2022, we made a $15.0&#160;million investment in a home health benefit manager, which is accounted for under the cost method. During 2021, we made a $5.0&#160;million investment in ConnectRN, a workforce optimization company, which is accounted for under the cost method. The book value of investments that we account for under the cost method of accounting was $20.0&#160;million and $5.0&#160;million as of December 31, 2022 and 2021, respectively, and is reflected in other assets within our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three-month period ended December 31, 2022, we sold a 49% interest in two of our home health care centers while maintaining a controlling interest in the newly formed joint venture. We are consolidating this joint venture. The total cash consideration received for the 49% noncontrolling interest was $1.9&#160;million. In connection with the transaction, we recorded an after-tax gain of $1.4&#160;million; this gain was recorded to additional paid-in capital within our consolidated balance sheet. During the three-month period ended September 30, 2022, we sold a 30% interest in two of our home health care centers while maintaining a controlling interest in the newly formed joint venture. We are consolidating this joint venture. The total cash consideration received for the 30% noncontrolling interest was $3.9&#160;million. In connection with the transaction, we recorded an after-tax gain of $2.9&#160;million; this gain was recorded to additional paid-in capital within our consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021, a third-party acquired a majority of the issued and outstanding membership interests of one of our equity method investments, Medalogix, for cash, with the remaining membership interests rolling over into a newly formed entity that includes Medalogix as well as another healthcare predictive data and analytics company. We rolled over 100% of our ownership interest in Medalogix to the newly formed entity, and in connection with this transaction, we recognized a $31.1&#160;million gain based on the purchase price of Medalogix, which is reflected in gain on equity method investments within our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of Contessa Health ("Contessa") on August 1, 2021, we obtained interests in several joint ventures with health system partners and a professional corporation that employs clinicians. Each of these entities meets the criteria to be classified as a VIE. As of December 31, 2022, we are consolidating all of our admitting joint ventures with health system partners as well as the professional corporation as we have concluded that we are the primary beneficiary of these VIEs. We have management agreements in place with each of these entities whereby we manage the entities and run the day-to-day operations. As such, we possess the power to direct the activities that most significantly impact the economic performance of the VIEs. The significant activities include, but are not limited to, negotiating provider and payor contracts, establishing patient care policies and protocols, making employment and compensation decisions, developing the operating and capital budgets, performing marketing activities and providing accounting support. We also have the obligation to absorb any expected losses and the right to receive benefits. Additionally, from time to time we may be required to provide joint venture funding. Our high acuity care segment also includes two non-admitting joint ventures with health system partners that are accounted for under the equity method of accounting. Operations of one of these joint ventures have ceased, and we are currently awaiting claims runout to complete financial reconciliations with our health plan partner; we recorded a $3.0&#160;million impairment charge related to our investment in this joint venture during the three-month period ended September 30, 2022.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms of the agreements with each VIE prohibit us from using the assets of the VIE to satisfy the obligations of other entities. The carrying amount of the VIEs&#x2019; assets and liabilities included in our consolidated balance sheets are as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.669%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, we sold our investment in the Heritage Healthcare Innovation Fund, LP via a secondary transaction for $17.9&#160;million which resulted in a $3.0&#160;million loss which is reflected in gain (loss) on equity method investments within our consolidated statement of operations for the year ended December 31, 2020. The Company's original investment was made in 2010 and no longer fit within our strategic areas of focus. Proceeds from the sale were used to pay down debt and fund capital needs.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <amed:MinimumPercentOwnershipForControllingInterestPercent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfNzU2Mg_f65a512a-573a-427e-8957-abc762459bd3"
      unitRef="number">0.50</amed:MinimumPercentOwnershipForControllingInterestPercent>
    <amed:MaximumPercentOwnershipForEquityMethodPercent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfNzg1Mg_f55b2e5d-4ffe-4c8f-8ad8-8c0d91b49769"
      unitRef="number">0.50</amed:MaximumPercentOwnershipForEquityMethodPercent>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfODA0OA_4e7d4cc0-e4e7-4624-8cfb-aa8a754759c2"
      unitRef="usd">40500000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfODA1NQ_d05cb6c3-bb7d-448e-bf1a-34596425284d"
      unitRef="usd">48100000</us-gaap:EquityMethodInvestmentAggregateCost>
    <amed:MaximumPercentOwnershipForCostMethodPercent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfODIyOQ_dd2f0187-0426-4703-ac11-1abf38019454"
      unitRef="number">0.20</amed:MaximumPercentOwnershipForCostMethodPercent>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="idaa8aedfe8c3470cbd124c76fae216cf_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfNTQ5NzU1ODMyMTM1_99fa2d28-5753-4423-ae2d-c51dcbcb5a0f"
      unitRef="usd">15000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i31897eeed2424fdabfb8a7277396df7f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfODM5Mw_399c7bc8-3fd8-4d6a-89ef-f1ebe2f13a70"
      unitRef="usd">5000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfNTQ5NzU1ODMyMTUw_fbe7316e-0bbd-469e-90e1-48dff81edc9c"
      unitRef="usd">20000000</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfNTQ5NzU1ODMyMTY1_195fbc6d-2d3e-4f9f-85d7-87ea4c166fac"
      unitRef="usd">5000000</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="i43a583e1be0e4362a0f5b5887d9c279a_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfNTQ5NzU1ODMyMTc5_f87cd859-d271-4411-bcba-0da06fc4e07f"
      unitRef="usd">1900000</us-gaap:ProceedsFromMinorityShareholders>
    <amed:GainRelatedToSaleOfNoncontrollingInterestNetOfTax
      contextRef="i43a583e1be0e4362a0f5b5887d9c279a_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfNTQ5NzU1ODMyMTkz_98107b0e-27a2-4684-ac91-245b5be6768f"
      unitRef="usd">1400000</amed:GainRelatedToSaleOfNoncontrollingInterestNetOfTax>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="i0e9dcae6e6af40a2a3ad82452046bbbb_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfNTQ5NzU1ODMyMjA3_0f578b9f-b8e7-4c2d-bc70-628a2aa39b20"
      unitRef="usd">3900000</us-gaap:ProceedsFromMinorityShareholders>
    <amed:GainRelatedToSaleOfNoncontrollingInterestNetOfTax
      contextRef="i0e9dcae6e6af40a2a3ad82452046bbbb_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfNTQ5NzU1ODMyMjIx_78fa9b96-4043-4d87-91c8-e83496903cc5"
      unitRef="usd">2900000</amed:GainRelatedToSaleOfNoncontrollingInterestNetOfTax>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="id9e57117e59349509aa17240e4b739bb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfNTQ5NzU1ODMyMjM1_4eed71fe-4802-45e2-9113-26057b6e073b"
      unitRef="usd">31100000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:AssetImpairmentCharges
      contextRef="i9dc0472ea16a4281be6243dd9c20268f_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfNTQ5NzU1ODMyMjUw_6a696926-50ad-472f-b415-95c20aaa9472"
      unitRef="usd">3000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:ScheduleOfVariableInterestEntitiesTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfMTEzNjI_319b53c9-3452-4940-b785-6c717a04b903">The carrying amount of the VIEs&#x2019; assets and liabilities included in our consolidated balance sheets are as follows (amounts in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.669%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfVariableInterestEntitiesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7265ebd4cec34caa817f807dc1d6cbc1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMy0xLTEtMS02MTA5MA_3f051ce5-3b72-4f2d-8213-c062422d916d"
      unitRef="usd">15600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0b27a458690140b59e1f60faae27b54c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMy0xLTEtMS01MDcyNQ_e6c356ca-aa2a-44bd-959c-9119bcca6039"
      unitRef="usd">3100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i7265ebd4cec34caa817f807dc1d6cbc1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfNC0xLTEtMS02MTA5MA_8ec1bb2b-b1a4-4a02-8f49-a077b6c0d580"
      unitRef="usd">6100000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i0b27a458690140b59e1f60faae27b54c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfNC0xLTEtMS01MDcyNQ_07e52500-58c2-4d18-a64a-31b7a6c51b6c"
      unitRef="usd">2400000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i7265ebd4cec34caa817f807dc1d6cbc1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfNS0xLTEtMS02MTA5MA_f2851766-cf7c-4bcd-bba7-20e755e01a35"
      unitRef="usd">600000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i0b27a458690140b59e1f60faae27b54c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfNS0xLTEtMS01MDcyNQ_307f324a-fa50-40e5-8227-46460b8e1682"
      unitRef="usd">100000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i7265ebd4cec34caa817f807dc1d6cbc1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfNi0xLTEtMS02MTA5MA_31d31cdc-e1b9-4695-a4d4-415e830b5394"
      unitRef="usd">22300000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i0b27a458690140b59e1f60faae27b54c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfNi0xLTEtMS01MDcyNQ_19257744-235f-4ec7-bc15-febfb20013b0"
      unitRef="usd">5600000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7265ebd4cec34caa817f807dc1d6cbc1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfNy0xLTEtMS02MTA5MA_9f26a882-5863-41d3-9d5f-b8e8939960e9"
      unitRef="usd">100000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0b27a458690140b59e1f60faae27b54c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfNy0xLTEtMS01MDcyNQ_f46fe9ba-76d5-48a7-a609-076b8a783824"
      unitRef="usd">100000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7265ebd4cec34caa817f807dc1d6cbc1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfOC0xLTEtMS02MTA5Ng_3c664c20-590f-483d-9e8d-5de2a17240bc"
      unitRef="usd">100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i0b27a458690140b59e1f60faae27b54c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfOC0zLTEtMS02MTEwMA_8226f049-5ce4-4f35-ba0b-deb723a13d62"
      unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="i7265ebd4cec34caa817f807dc1d6cbc1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfOS0xLTEtMS02MTA5OA_993afa69-edb4-4d80-8ca3-bab8eb9bc0a1"
      unitRef="usd">8500000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i0b27a458690140b59e1f60faae27b54c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfOS0zLTEtMS02MTEwMA_26d4656b-52f8-4fe0-be4c-938f11650502"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i7265ebd4cec34caa817f807dc1d6cbc1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMTAtMS0xLTEtNjEwOTg_7f4e852b-4174-4e2c-96e4-1200b56999f4"
      unitRef="usd">400000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i0b27a458690140b59e1f60faae27b54c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMTAtMy0xLTEtNjExMDA_110a2b30-6124-497a-952a-cf918e11ac8b"
      unitRef="usd">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7265ebd4cec34caa817f807dc1d6cbc1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMTEtMS0xLTEtNjEwOTg_afe060c8-8530-414b-8f60-047bb7d6fcb5"
      unitRef="usd">200000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0b27a458690140b59e1f60faae27b54c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMTEtMy0xLTEtNjExMDA_c7ceb840-0b7e-48db-8cc6-c1444b0d4b43"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i7265ebd4cec34caa817f807dc1d6cbc1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMTItMS0xLTEtNjEwOTI_6c179717-48ce-41f0-8f83-0fc8e81026eb"
      unitRef="usd">31600000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i0b27a458690140b59e1f60faae27b54c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfOC0xLTEtMS01MDcyNQ_04da706f-8f9d-4ad0-b9b3-36938181fbca"
      unitRef="usd">5700000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i7265ebd4cec34caa817f807dc1d6cbc1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMTUtMS0xLTEtNjExMDI_914cc469-e22f-4868-952a-93d4b602c271"
      unitRef="usd">100000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i0b27a458690140b59e1f60faae27b54c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMTUtMy0xLTEtNjExMDQ_3fe29da7-d6f4-4ad9-b2ed-2ffd30a8b839"
      unitRef="usd">0</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i7265ebd4cec34caa817f807dc1d6cbc1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMTYtMS0xLTEtNjEwOTQ_4e1deab7-4fb7-44b1-bb45-3ef56f9ef6a6"
      unitRef="usd">500000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i0b27a458690140b59e1f60faae27b54c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMTEtMS0xLTEtNTA3MjU_1705f3f1-d225-4f3e-8c1b-d6901078d959"
      unitRef="usd">300000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i7265ebd4cec34caa817f807dc1d6cbc1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMTctMS0xLTEtNjEwOTQ_1273cf9a-9f84-4761-a433-16a990237206"
      unitRef="usd">5800000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i0b27a458690140b59e1f60faae27b54c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMTItMS0xLTEtNTA3MjU_ba98a6d8-51fa-4b73-bdf7-0500444e5449"
      unitRef="usd">3400000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i7265ebd4cec34caa817f807dc1d6cbc1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMTgtMS0xLTEtNjE1NTA_8a5ec1a2-03cb-48fc-abb1-60754870c0eb"
      unitRef="usd">100000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i0b27a458690140b59e1f60faae27b54c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMTgtMy0xLTEtNjE1NTI_fe922089-19a2-49fd-834c-af006c81d017"
      unitRef="usd">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DebtCurrent
      contextRef="i7265ebd4cec34caa817f807dc1d6cbc1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMTgtMS0xLTEtNjEwOTQ_1fadd1fb-fc56-4ed4-b636-8f1192c863a3"
      unitRef="usd">200000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="i0b27a458690140b59e1f60faae27b54c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMTMtMS0xLTEtNTA3MjU_39b5b6be-75c2-45a4-af15-3268735d30c2"
      unitRef="usd">800000</us-gaap:DebtCurrent>
    <us-gaap:Liabilities
      contextRef="i7265ebd4cec34caa817f807dc1d6cbc1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMjEtMS0xLTEtNjEwOTQ_4268ebe3-9161-4abf-8dd0-fbbcd70eb89f"
      unitRef="usd">6700000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i0b27a458690140b59e1f60faae27b54c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RhYmxlOmEyNGU2OTg4YmI4MjQ5ZTlhMTY2YzE2YzY0YmI0MDdhL3RhYmxlcmFuZ2U6YTI0ZTY5ODhiYjgyNDllOWExNjZjMTZjNjRiYjQwN2FfMTYtMS0xLTEtNTA3MjU_ef60b358-09d8-49da-87cb-012b3a39151a"
      unitRef="usd">4500000</us-gaap:Liabilities>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i18a8ecfea90b46dea16770739b772958_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83My9mcmFnOmM0ZjI3NDM1MjFiMzQwYjhiNjU5YmQwNTBiOGQzMDVkL3RleHRyZWdpb246YzRmMjc0MzUyMWIzNDBiOGI2NTliZDA1MGI4ZDMwNWRfMTA5OTg_26c694f7-64b1-4915-b7a4-0013d6b1adeb"
      unitRef="usd">17900000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwMzQ_e9fa762b-0adf-4a46-9432-bdbccda3679a">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for revenue from contracts with customers in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. Our cost of obtaining contracts is not material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our performance obligations relate to contracts with a duration of less than one year; therefore, we have elected to apply the optional exemption provided by ASC 606 and are not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third-party payors and others for services provided. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current industry conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. We assess our ability to collect for the healthcare services provided at the time of patient admission based on our verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represents approximately 74% of our consolidated net service revenue.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation based on our historical experience which primarily includes a historical collection rate of over 99% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by payor class as a percentage of total net service revenue is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Home Health:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-Medicare - Episodic-based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-Medicare - Non-episodic based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Hospice:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Personal Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;High Acuity Care (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Acquired Contessa Health on August 1, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Home Health Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"). PDGM uses 30-day periods of care rather than 60-day episodes of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, we account for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed. Each 60-day episode includes two 30-day payment periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net service revenue is recorded based on the established Federal Medicare home health payment rate for a 30-day period of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#x2019;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice" practical expedient, and therefore, our revenue recognition is based on the reimbursement we are entitled to for each 30-day period of care. We utilize our historical average length of stay for each 30-day period of care as the measure of progress towards the satisfaction of our performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables, including, but not limited to (a) an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#x201c;LUPA&#x201d;) if the number of visits provided was less than the established threshold, which ranges from two to six visits and varies for every case-mix group; (c)&#160;a partial payment if a patient transferred to another provider or from another provider before completing the 30-day period of care; and (d)&#160;the applicable geographic wage index. Payments for routine and non-routine supplies are included in the 30-day payment rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered to revenue with a corresponding reduction to patient accounts receivable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during the novel coronavirus pandemic ("COVID-19"), CMS relaxed the definition of homebound status through the duration of the public health emergency. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their home because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, 20% of the reimbursement from each Medicare 30-day payment period was billed near the start of each 30-day period of care, referred to as a request for anticipated payment ("RAP"), and cash was typically received before all services were rendered. Any cash received from Medicare for a RAP for a 30-day period of care that exceeded the associated revenue earned was recorded to accrued expenses within our consolidated balance sheets. CMS fully eliminated all upfront payments associated with RAPs effective January 1, 2021. Effective January 1, 2022, CMS implemented a new one-time Notice of Admission ("NOA") process. The NOA process requires a one-time submission that establishes the home health period of care and covers all contiguous 30-day periods of care until the patient is discharged from Medicare home health services. If the NOA is not submitted timely, a payment reduction will be applied equal to 1/30 of the payment amount for each day from the home health start of care date until the date the NOA is submitted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Non-Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments from non-Medicare payors are either a percentage of Medicare rates, per-visit rates or case rates depending upon the terms and conditions established with such payors. Approximately 30% of our managed care contract volume affords us the opportunity to receive additional payments if we achieve certain quality or process metrics as defined in each contract (e.g. star ratings and acute-care hospitalization rates).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Episodic-based Revenue.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms, the majority of which range from 95% to 100% of Medicare rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-episodic based Revenue. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our per visit contracts, gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. For our case rate contracts, gross revenue is recorded over our historical average length of stay using the established case rate for each admission. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on our historical experience to reflect the estimated transaction &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our case rate contracts, we may receive reimbursement before all services are rendered. Any cash received that exceeds the associated revenue earned is recorded to deferred revenue in accrued expenses within our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hospice Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Hospice Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for 97% of our total Medicare hospice service revenue for each of 2022, 2021 and 2020, respectively. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#x201c;SIA&#x201d;). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record it during the period services are rendered. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our consolidated balance sheets. Providers are required to self-report and pay their estimated cap liability by February 28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;th&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the following year. As of December&#160;31, 2022, we have recorded $4.3 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2023. As of December&#160;31, 2021, we had recorded $4.5 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Hospice Non-Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third-party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on our historical experience to reflect the estimated transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Personal Care Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Personal Care Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points ("ASAPs"), Senior Care Options ("SCOs"), Program of All-Inclusive Care for the Elderly ("PACE") and the Veterans Administration ("VA"). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;High Acuity Care Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;High Acuity Care Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our revenues are derived from contracts with (1) health insurance plans for the coordination and provision of home recovery care services to clinically-eligible patients who are enrolled members in those insurance plans, (2) health system partners for the coordination and provision of home recovery care services to clinically-eligible patients who are discharged early from a health system facility to complete their inpatient stay at home and (3) Medicare and other payors for the provision of home health services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our health insurance plan contracts, we provide home recovery care services, which include hospital-equivalent ("H@H") and skilled nursing facility ("SNF") equivalent services ("SNF@H"), for high acuity care patients on a full risk basis whereby we assume the financial risk for the coordination and payment of all hospital or SNF replacement medical services necessary to treat the medical condition for which the patient was diagnosed in a home-based setting for a 30-day (H@H) or 60-day (SNF@H) episode of care in exchange for a fixed contracted bundled rate. For H@H programs, the fixed rate is based on the assigned diagnosis related group ("DRG") and the 30-day post-discharge related spend. For SNF@H programs, the fixed rate is based on the 60-day post-discharge related spend. Our performance obligation is the coordination and provision of patient care in accordance with physicians&#x2019; orders over either a 30-day or 60-day episode of care. The majority of our care coordination services and direct patient care is provided in the first five to seven days of the episode period (the "acute phase"). Monitoring services and follow-up direct patient care, as deemed necessary by the treating physician, are provided throughout the remainder of the episode. Since the majority of our services are provided during the acute phase, we recognize net service revenues over the acute phase based on gross charges for the services provided per the applicable managed care contract rates, reduced by estimates for revenue adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our contracts with health system partners, we provide home recovery care services for high acuity patients on a limited risk basis whereby we assume the risk for certain healthcare services during the remainder of an inpatient acute stay serviced at the patient&#x2019;s home in exchange for a contracted per diem rate. The performance obligation is the coordination and provision of required medical services, as determined by the treating physician, for each day the patient receives inpatient-equivalent care at home. As such, revenues are recognized as services are administered and as our performance obligations are satisfied on a per diem basis, reduced by estimates for revenue adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize adjustments to revenue during the period in which changes to estimates of assigned patient diagnoses or episode terminations become known, in accordance with the applicable managed care contracts. For certain health insurance plans, revenue is reduced by amounts owed by enrollees to healthcare providers under deductible, coinsurance or copay provisions of health insurance plan policies, since those amounts are repaid to the health insurance plans by us as part of a retrospective reconciliation process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, our high acuity care segment entered into a transaction in which one of our health system partners contributed its home health operations to one of our existing high acuity care joint ventures. We recognize Medicare and non-Medicare revenue in a manner that is consistent with our home health segment revenue recognition policy described above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Government Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for government grants in accordance with ASU 2021-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Assistance (Topic 832), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;by applying the grant model in accordance with International Accounting Standard ("IAS") 20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Government Grants and Disclosure of Government Assistance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and as such, we recognize grant income on a systematic basis in line with the recognition of expenses or the loss of revenues for which the grants are intended to compensate. We recognize grants once both of the following conditions are met: (1) we are able to comply with the relevant conditions of the grant and (2) the grant will be received. See Note 3 &#x2013; Novel Coronavirus Pandemic ("COVID-19") for additional information on our accounting for government funds received under the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") and the Mass Home Care ASAP COVID-19 Provider Sustainability Program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased. Restricted cash includes cash that is not available for ordinary business use. As of December 31, 2022 and 2021, we had $13.6&#160;million and $3.1&#160;million, respectively, classified as restricted cash related to funds placed into escrow accounts in connection with the indemnity, closing payment and other provisions within the purchase agreements of our acquisitions. The increase in restricted cash from December 31, 2021 to December 31, 2022 is related to our acquisitions of Evolution Health, LLC ("Evolution") and Assisted Care Home Health, Inc. and RH Homecare Services, LLC ("Assisted Care") on April 1, 2022. See Note 4 &#x2013; Acquisitions for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Patient Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. Our non-Medicare third-party payor base is comprised of a diverse group of payors that are geographically dispersed across the country. As of December&#160;31, 2022, there is no single payor, other than Medicare, that accounts for more than 10% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectability risk associated with our Medicare accounts, which represented 67% and 68% of our net patient accounts receivable at December&#160;31, 2022 and 2021, respectively, is limited due to our historical collection rate of over 99% from Medicare and the fact that Medicare is a U.S. government payor. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medicare Home Health&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our home health patients (within both our home health and high acuity care segments), our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare following the end of each 30-day period of care or upon discharge, if earlier, for the services provided to the patient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medicare Hospice&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-Medicare Home Health, Hospice, Personal Care and High Acuity Care&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#x2019;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets or life of the lease, if shorter. Additionally, we have internally developed computer software for our own use. Additions and improvements (including interest costs for construction of qualifying long-lived assets) are capitalized. Maintenance and repair expenses are charged to expense as incurred. The cost of property and equipment sold or disposed of and the related accumulated depreciation are eliminated from the property and equipment and related accumulated depreciation accounts, and any gain or loss is credited or charged to other general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the impairment of a long-lived asset group whenever events or changes in circumstances indicate that the asset&#x2019;s carrying value may not be recoverable. Factors we consider important that could trigger an impairment review include but are not limited to the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A significant change in the extent or manner in which the long-lived asset group is being used.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A significant change in the business climate that could affect the value of the long-lived asset group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A significant change in the market value of the assets included in the asset group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If we determine that the carrying value of long-lived assets may not be recoverable, we compare the carrying value of the asset group to the undiscounted cash flows expected to be generated by the asset group. If the carrying value exceeds the undiscounted cash flows, an impairment charge is indicated. An impairment charge is recognized to the extent that the carrying value of the asset group exceeds its fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generally provide for depreciation over the following estimated useful service lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.753%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser&#160;of&#160;lease term&#160;or&#160;expected&#160;useful&#160;life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 to 7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balances related to our property and equipment for 2022 and 2021 (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense for 2022, 2021 and 2020 was $11.5 million, $12.1 million and $12.1 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Acquisitions are accounted for as purchases and are included in our consolidated financial statements from their respective acquisition dates. Assets acquired, liabilities assumed and noncontrolling interests, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets. In determining the fair value of identifiable intangible assets and any noncontrolling interests, we use various valuation techniques including the income approach, the cost approach and the market approach. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, growth rates and discount rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and Other Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, we had a goodwill balance of $1,287.4&#160;million. Goodwill represents the amount of the purchase price in excess of the fair values assigned to the underlying identifiable net assets of acquired businesses. Goodwill is not amortized, but is subject to an annual impairment test. Tests are performed more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount. These events or circumstances include, but are not limited to, a significant adverse change in the business environment, regulatory environment or legal factors, or a substantial decline in the market capitalization of our stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each of our operating segments described in Note 15 &#x2013; Segment Information is considered to represent an individual reporting unit for goodwill impairment testing purposes. We consider each of our home health care centers to constitute an individual business for which discrete financial information is available. However, since these care centers have substantially similar operating and economic characteristics and resource allocations and since significant investment decisions concerning these businesses are centralized and the benefits broadly distributed, we have aggregated these care centers and deemed them to constitute a single reporting unit. We have applied this same aggregation principle to our hospice and personal-care care centers and high acuity care joint ventures and have also deemed each of them to be a single reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2022, we performed a qualitative assessment to determine if it is more likely than not that the fair value of our reporting units are less than their carrying values by evaluating relevant events and circumstances including financial performance, market conditions and share price. Based on this assessment, we concluded that the goodwill associated with our home health, hospice and high acuity care reporting units was not considered at risk of impairment as of October&#160;31, 2022. In addition to the qualitative assessment, we also performed a quantitative analysis for our personal care reporting unit due to the decline in revenues resulting from staffing shortages using an income and market approach. Based on this analysis, we concluded that the goodwill associated with our personal care reporting unit was not considered at risk of impairment as of October 31, 2022. Since the date of our last goodwill impairment analysis, there have been no material developments, events, changes in operating performance or other circumstances that would cause management to believe it is more likely than not that the fair value of any of our reporting units would be less than their carrying amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, we had an other intangibles assets balance of $101.2&#160;million. Intangible assets consist of certificates of need, licenses, acquired names, non-compete agreements and technology. We amortize non-compete agreements and acquired names that we do not intend to use indefinitely on a straight-line basis over their estimated useful lives, which are generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjg1OTA_1486623a-649a-4c91-b48e-f23d489bb99f"&gt;two&lt;/span&gt; to three years for non-compete agreements and up to three years for acquired names. We amortize technology over its estimated useful service life, which is generally up to seven years. Our indefinite-lived intangible assets are reviewed for impairment annually or more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the intangible asset below its carrying amount. We performed a qualitative assessment of our indefinite-lived intangible assets during 2022 and determined that there have been no material developments, events, changes in operating performance or other circumstances that would cause management to believe it is more likely than not that the fair value of any of our indefinite-lived intangible assets would be less than their carrying amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Issuance Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021, we recorded $2.8&#160;million in deferred debt issuance costs as a reduction to long-term obligations, less current portion in our consolidated balance sheet in connection with our entry into the Second Amended Credit Agreement (See Note 9 - Long-Term Obligations). As of December&#160;31, 2022 and 2021, we had unamortized debt issuance costs of $3.5 million and $4.5 million, respectively, recorded as a reduction to long-term obligations, less current portion in our accompanying consolidated balance sheets. We amortize deferred debt issuance costs related to our long-term obligations over the term of the obligation through interest expense, unless the debt is extinguished, in which case unamortized balances are immediately expensed. The unamortized debt issuance costs of $3.5 million at December&#160;31, 2022 will be amortized over a weighted-average amortization period of 3.6 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Financial Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value as of&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&#160;in&#160;Active&lt;br/&gt;Markets for Identical&lt;br/&gt;Items&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1 &#x2013; Quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2 &#x2013; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3 &#x2013; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the asset and liability approach for measuring deferred tax assets and liabilities based on temporary differences existing at each balance sheet date using currently enacted tax rates. Our deferred tax calculation requires us to make certain estimates about future operations. Deferred tax assets are reduced by a valuation allowance when we believe it is more likely than not that some portion or all of the deferred tax assets will not be realized. The effect of a change in tax rate is recognized as income or expense in the period that includes the enactment date. As of December&#160;31, 2022, we had net deferred tax liabilities of $20.4 million. As of December 31, 2021, we had net deferred tax assets of $0.3 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management regularly assesses the ability to realize deferred tax assets recorded in the Company&#x2019;s entities based upon the weight of available evidence, including such factors as the recent earnings history and expected future taxable income. In the event future taxable income is below management&#x2019;s estimates or is generated in tax jurisdictions different than projected, we could be required to increase the valuation allowance for deferred tax assets. This would result in an increase in our effective tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record all share-based compensation as expense in the financial statements measured at the fair value of the award. We recognize compensation cost on a straight-line basis over the requisite service period for each separately vesting portion of the award. Share-based compensation expense for 2022, 2021 and 2020 was $16.6 million, $23.8 million and $26.7 million, respectively, and the total income tax benefit recognized for these expenses was $4.3 million, $6.0 million and $4.7 million, respectively, prior to the application of the income tax compensation rules under Internal Revenue Code section 162(m) ("162(m)"). As of December 31, 2022, the income tax benefit recognized for the three-year period was reduced by a cumulative $2.7&#160;million, pursuant to 162(m).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Weighted-Average Shares Outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares used in our computation of weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested stock and stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expense advertising costs as incurred. Advertising expense for 2022, 2021 and 2020 was $7.3 million, $7.4 million and $6.5 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwNTA_e3eb1cfe-99d1-4914-9c56-eaa44e39ef41">&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for revenue from contracts with customers in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. Our cost of obtaining contracts is not material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our performance obligations relate to contracts with a duration of less than one year; therefore, we have elected to apply the optional exemption provided by ASC 606 and are not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third-party payors and others for services provided. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current industry conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. We assess our ability to collect for the healthcare services provided at the time of patient admission based on our verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represents approximately 74% of our consolidated net service revenue.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation based on our historical experience which primarily includes a historical collection rate of over 99% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by payor class as a percentage of total net service revenue is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Home Health:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-Medicare - Episodic-based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-Medicare - Non-episodic based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Hospice:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Personal Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;High Acuity Care (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Acquired Contessa Health on August 1, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Home Health Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"). PDGM uses 30-day periods of care rather than 60-day episodes of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, we account for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed. Each 60-day episode includes two 30-day payment periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net service revenue is recorded based on the established Federal Medicare home health payment rate for a 30-day period of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#x2019;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice" practical expedient, and therefore, our revenue recognition is based on the reimbursement we are entitled to for each 30-day period of care. We utilize our historical average length of stay for each 30-day period of care as the measure of progress towards the satisfaction of our performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables, including, but not limited to (a) an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#x201c;LUPA&#x201d;) if the number of visits provided was less than the established threshold, which ranges from two to six visits and varies for every case-mix group; (c)&#160;a partial payment if a patient transferred to another provider or from another provider before completing the 30-day period of care; and (d)&#160;the applicable geographic wage index. Payments for routine and non-routine supplies are included in the 30-day payment rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered to revenue with a corresponding reduction to patient accounts receivable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during the novel coronavirus pandemic ("COVID-19"), CMS relaxed the definition of homebound status through the duration of the public health emergency. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their home because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, 20% of the reimbursement from each Medicare 30-day payment period was billed near the start of each 30-day period of care, referred to as a request for anticipated payment ("RAP"), and cash was typically received before all services were rendered. Any cash received from Medicare for a RAP for a 30-day period of care that exceeded the associated revenue earned was recorded to accrued expenses within our consolidated balance sheets. CMS fully eliminated all upfront payments associated with RAPs effective January 1, 2021. Effective January 1, 2022, CMS implemented a new one-time Notice of Admission ("NOA") process. The NOA process requires a one-time submission that establishes the home health period of care and covers all contiguous 30-day periods of care until the patient is discharged from Medicare home health services. If the NOA is not submitted timely, a payment reduction will be applied equal to 1/30 of the payment amount for each day from the home health start of care date until the date the NOA is submitted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Non-Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments from non-Medicare payors are either a percentage of Medicare rates, per-visit rates or case rates depending upon the terms and conditions established with such payors. Approximately 30% of our managed care contract volume affords us the opportunity to receive additional payments if we achieve certain quality or process metrics as defined in each contract (e.g. star ratings and acute-care hospitalization rates).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Episodic-based Revenue.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms, the majority of which range from 95% to 100% of Medicare rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-episodic based Revenue. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our per visit contracts, gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. For our case rate contracts, gross revenue is recorded over our historical average length of stay using the established case rate for each admission. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on our historical experience to reflect the estimated transaction &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our case rate contracts, we may receive reimbursement before all services are rendered. Any cash received that exceeds the associated revenue earned is recorded to deferred revenue in accrued expenses within our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hospice Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Hospice Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for 97% of our total Medicare hospice service revenue for each of 2022, 2021 and 2020, respectively. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#x201c;SIA&#x201d;). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record it during the period services are rendered. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our consolidated balance sheets. Providers are required to self-report and pay their estimated cap liability by February 28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;th&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the following year. As of December&#160;31, 2022, we have recorded $4.3 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2023. As of December&#160;31, 2021, we had recorded $4.5 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Hospice Non-Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third-party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on our historical experience to reflect the estimated transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Personal Care Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Personal Care Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points ("ASAPs"), Senior Care Options ("SCOs"), Program of All-Inclusive Care for the Elderly ("PACE") and the Veterans Administration ("VA"). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;High Acuity Care Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;High Acuity Care Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our revenues are derived from contracts with (1) health insurance plans for the coordination and provision of home recovery care services to clinically-eligible patients who are enrolled members in those insurance plans, (2) health system partners for the coordination and provision of home recovery care services to clinically-eligible patients who are discharged early from a health system facility to complete their inpatient stay at home and (3) Medicare and other payors for the provision of home health services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our health insurance plan contracts, we provide home recovery care services, which include hospital-equivalent ("H@H") and skilled nursing facility ("SNF") equivalent services ("SNF@H"), for high acuity care patients on a full risk basis whereby we assume the financial risk for the coordination and payment of all hospital or SNF replacement medical services necessary to treat the medical condition for which the patient was diagnosed in a home-based setting for a 30-day (H@H) or 60-day (SNF@H) episode of care in exchange for a fixed contracted bundled rate. For H@H programs, the fixed rate is based on the assigned diagnosis related group ("DRG") and the 30-day post-discharge related spend. For SNF@H programs, the fixed rate is based on the 60-day post-discharge related spend. Our performance obligation is the coordination and provision of patient care in accordance with physicians&#x2019; orders over either a 30-day or 60-day episode of care. The majority of our care coordination services and direct patient care is provided in the first five to seven days of the episode period (the "acute phase"). Monitoring services and follow-up direct patient care, as deemed necessary by the treating physician, are provided throughout the remainder of the episode. Since the majority of our services are provided during the acute phase, we recognize net service revenues over the acute phase based on gross charges for the services provided per the applicable managed care contract rates, reduced by estimates for revenue adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our contracts with health system partners, we provide home recovery care services for high acuity patients on a limited risk basis whereby we assume the risk for certain healthcare services during the remainder of an inpatient acute stay serviced at the patient&#x2019;s home in exchange for a contracted per diem rate. The performance obligation is the coordination and provision of required medical services, as determined by the treating physician, for each day the patient receives inpatient-equivalent care at home. As such, revenues are recognized as services are administered and as our performance obligations are satisfied on a per diem basis, reduced by estimates for revenue adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize adjustments to revenue during the period in which changes to estimates of assigned patient diagnoses or episode terminations become known, in accordance with the applicable managed care contracts. For certain health insurance plans, revenue is reduced by amounts owed by enrollees to healthcare providers under deductible, coinsurance or copay provisions of health insurance plan policies, since those amounts are repaid to the health insurance plans by us as part of a retrospective reconciliation process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, our high acuity care segment entered into a transaction in which one of our health system partners contributed its home health operations to one of our existing high acuity care joint ventures. We recognize Medicare and non-Medicare revenue in a manner that is consistent with our home health segment revenue recognition policy described above.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib60ffa9c6822423ca9d59d283467feaa_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjk5Nw_e712797e-8207-41ad-88e8-ad2bd29e60de"
      unitRef="number">0.74</us-gaap:ConcentrationRiskPercentage1>
    <amed:HistoricalCollectionRateFromMedicare
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzc2OA_b402b9c4-6940-45a5-9f57-995f44df5e60"
      unitRef="number">0.99</amed:HistoricalCollectionRateFromMedicare>
    <us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwMDE_883f993e-dd80-4e7d-afa6-33f37b77fa35">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by payor class as a percentage of total net service revenue is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Home Health:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-Medicare - Episodic-based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-Medicare - Non-episodic based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Hospice:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Personal Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;High Acuity Care (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Acquired Contessa Health on August 1, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i332e5cf83f704c55b25091d8aac22686_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfMy0xLTEtMS01MDcyNQ_5ad47067-b44f-4419-8f66-8dc56e2c2f1d"
      unitRef="number">0.40</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="icc45e2e2cecf43c7a6bdb033a411f0dc_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfMy0zLTEtMS01MDcyNQ_e002a4b5-9382-4a23-8dd8-74fe2877b4f2"
      unitRef="number">0.41</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i0ef480ba6e114f2599922f6fecdb6adc_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfMy01LTEtMS01MDcyNQ_c290bc19-6a0f-49f0-a335-b50fdfde4afa"
      unitRef="number">0.41</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i4b7d185a3a5845299460ef91d19e3737_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfNC0xLTEtMS01MDcyNQ_fd75d430-7f4e-4413-8775-955edc191735"
      unitRef="number">0.08</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i20f7b2610db946b6b2c5a7131a2c6402_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfNC0zLTEtMS01MDcyNQ_6269f89a-a9a7-45a6-bcc2-d19d501a5d35"
      unitRef="number">0.08</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i045954bc2da64e639f3d2657db45c8c6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfNC01LTEtMS01MDcyNQ_c58ffd27-52e3-4c4f-abed-0ad1b9774375"
      unitRef="number">0.07</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="ie68834514d89475fa05705e2a104287c_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfNS0xLTEtMS01MDcyNQ_223d4f9f-6c88-4c8c-aee8-1ba704b87749"
      unitRef="number">0.13</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i3293bf9528d2455dbef45aa497f1802f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfNS0zLTEtMS01MDcyNQ_79888cf2-66f8-43e2-98a3-c03dd2583686"
      unitRef="number">0.12</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="if428e0eafe734ae298c1d7e4fd10018f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfNS01LTEtMS01MDcyNQ_546bd5f7-60a5-413d-af25-2fd4165a62a6"
      unitRef="number">0.13</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i404ba799d43b4f9cbc11bd0f031fa84f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfNy0xLTEtMS01MDcyNQ_823d0ddb-bbaf-489c-850b-fbd66f2973dc"
      unitRef="number">0.33</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="iaf2d05881bc84546bd58a3bfa9971f2a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfNy0zLTEtMS01MDcyNQ_030557f9-2827-41e5-a8a9-afe7d0fd6f8b"
      unitRef="number">0.34</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="ife774e47b4e649bbb69a2233094f5f4b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfNy01LTEtMS01MDcyNQ_c15c61a8-d16c-4930-8ffc-5f71b8ad0c74"
      unitRef="number">0.34</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i9bb3b80738f34bf39ce177e3aa4c2391_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfOC0xLTEtMS01MDcyNQ_56112d79-85bb-48df-a4b7-60a980d1873e"
      unitRef="number">0.02</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="id3f54ce15271460d90fc908cd65314f0_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfOC0zLTEtMS01MDcyNQ_df3647d2-6e71-4c00-adba-bbe72b82fb48"
      unitRef="number">0.02</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i8da51266d38e4113b6deb81ba671c1f4_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfOC01LTEtMS01MDcyNQ_7682715a-cf63-4f05-a453-6e1fe63ed1c8"
      unitRef="number">0.02</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i417cb5125535485c9ef0320496af5e26_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfOS0xLTEtMS01MDcyNQ_6362c605-ae89-42c8-83c0-107851c96aaf"
      unitRef="number">0.03</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i9d4251ae99c943f193588862db0c1b69_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfOS0zLTEtMS01MDcyNQ_5226cf90-d40e-42e7-a9e3-f6ec45f33e94"
      unitRef="number">0.03</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i72cdabc594824ec3a9da4123e53b9fbb_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfOS01LTEtMS01MDcyNQ_51526dd0-116a-425f-bf13-a2a98d335744"
      unitRef="number">0.03</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="ia8691440b2404ff496cc413ef83e5825_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfMTAtMS0xLTEtNTA3MjU_fd81e8d1-5ae6-42db-a96a-abd01f70731b"
      unitRef="number">0.01</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="ic803d3d531314ae89f73add64e4be217_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfMTAtMy0xLTEtNTA3MjU_336748ed-8f86-45bc-811c-2f45fe257be2"
      unitRef="number">0</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i2045ac339bf340c48bb59e921fe05def_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfMTAtNS0xLTEtNTA3MjU_faf3535c-0a4e-4ab2-96bb-b297f11125f1"
      unitRef="number">0</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfMTEtMS0xLTEtNTA3MjU_04d9880d-6631-448c-87bc-c705af7fcae7"
      unitRef="number">1</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfMTEtMy0xLTEtNTA3MjU_05072825-d600-40b8-ac83-251a6256f2ed"
      unitRef="number">1</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmVkNWMzMGIyMmMyNDQ4MjJiMzM3N2U0MDI0ZjYwZjUzL3RhYmxlcmFuZ2U6ZWQ1YzMwYjIyYzI0NDgyMmIzMzc3ZTQwMjRmNjBmNTNfMTEtNS0xLTEtNTA3MjU_ddae85dc-b190-4093-b539-8d897d25adc7"
      unitRef="number">1</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfNDU3MQ_7ec76e96-0e16-472a-a2d5-b10d880ccd02">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <amed:NetServiceRevenueEpisodePaymentRateDuration
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfNDYwNg_fda9264d-9f37-4b33-818f-fd5bdf8247c5">P60D</amed:NetServiceRevenueEpisodePaymentRateDuration>
    <amed:NetServiceRevenueEpisodePaymentRateDuration
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfNTQ4MA_5d789297-fa19-4a2b-b487-906a0c4f87a4">P60D</amed:NetServiceRevenueEpisodePaymentRateDuration>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfNTUwOA_461bf875-8299-41de-83a2-c5a488a93033">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfNTYzNw_0ef2e161-3df6-452b-a262-14dc165f1e03">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfNjE3NQ_62d1cb77-83b8-4b94-a671-e73a6c8ebcee">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfNjQ0NA_65f8868d-af42-48e1-8eb5-4206c1e36ef4">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <amed:PercentageOfTotalReimbursementOfOutlierPayment
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfNjYzOA_4570545f-969e-473a-af47-7264d426c8eb"
      unitRef="number">0.10</amed:PercentageOfTotalReimbursementOfOutlierPayment>
    <amed:LowUtilizationPaymentAdjustmentNumberOfVisits
      contextRef="i89bafb018d3a43eb8a3f1bbb4c93b71b_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfNjgyOA_098d14f8-b79d-4652-befe-e2287e5d9f66"
      unitRef="number_of_visits">2</amed:LowUtilizationPaymentAdjustmentNumberOfVisits>
    <amed:LowUtilizationPaymentAdjustmentNumberOfVisits
      contextRef="i1a4434e079494d01969542db2a51ebee_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfNjgzNA_ee21a25d-1039-44f5-b525-e56c1bd2ed6c"
      unitRef="number_of_visits">6</amed:LowUtilizationPaymentAdjustmentNumberOfVisits>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfNzAwNg_020f53fb-0965-4b94-8481-6705f2d9229d">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <amed:HistoricalCollectionRateFromMedicare
      contextRef="ie8d7fbaae8144d01ae5b61ba948ca043_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfNzQ1OQ_dfd60a43-d8d2-4a3a-9ea0-d8ad6dcde498"
      unitRef="number">0.99</amed:HistoricalCollectionRateFromMedicare>
    <amed:RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfODk3NA_e2e7ce14-680d-4452-a57f-d2ad0b7e62d9"
      unitRef="number">0.20</amed:RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfOTA3Mw_93a176a3-586b-45f1-a08d-0d40d8a34a19">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfOTI2OQ_1413b669-389c-43a2-aa94-dc9d56ade8d8">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <amed:PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments
      contextRef="ie8d7fbaae8144d01ae5b61ba948ca043_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfNTQ5NzU1ODYzMjI3_7762e98b-2e77-4f7a-8a41-45dfdb62a7c3"
      unitRef="number">0.30</amed:PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments>
    <amed:NonMedicareRevenueTermRates
      contextRef="i89bafb018d3a43eb8a3f1bbb4c93b71b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfOTgwOQ_e8900d31-2367-4b24-b240-c7488c499915"
      unitRef="number">0.95</amed:NonMedicareRevenueTermRates>
    <amed:NonMedicareRevenueTermRates
      contextRef="i1a4434e079494d01969542db2a51ebee_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfOTgxNQ_3ed4766e-c000-4cbd-97d9-c60f9ca3b9f9"
      unitRef="number">1</amed:NonMedicareRevenueTermRates>
    <amed:HospiceMedicareRevenueRateAccountedForRoutineCare
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMTA5OTM_2216e347-7cbe-41ac-9e71-e2a12fc01c7d"
      unitRef="number">0.97</amed:HospiceMedicareRevenueRateAccountedForRoutineCare>
    <amed:HospiceMedicareRevenueRateAccountedForRoutineCare
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMTA5OTM_33299017-52e3-443c-a95a-6548becaaa6e"
      unitRef="number">0.97</amed:HospiceMedicareRevenueRateAccountedForRoutineCare>
    <amed:HospiceMedicareRevenueRateAccountedForRoutineCare
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMTA5OTM_c3cdb8b5-62b7-44db-a26f-9358d3f1c541"
      unitRef="number">0.97</amed:HospiceMedicareRevenueRateAccountedForRoutineCare>
    <amed:HistoricalCollectionRateFromMedicare
      contextRef="i6d7eeb1ee5ac46b29435cfd337b5b8a7_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMTE5ODk_abcbd6fe-2521-43eb-b7d8-cd1fd25fbb6b"
      unitRef="number">0.99</amed:HistoricalCollectionRateFromMedicare>
    <amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities
      contextRef="i3d86e0102e724a01b5f8cbf75e5ad801_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMTI4MzY_25cd86bc-1ef2-496d-b6cc-439ca526238b"
      unitRef="usd">4300000</amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities>
    <amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities
      contextRef="id22ec472968f424eaedee0df2c1a6a6c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMTMwMDU_7c253e60-25cd-42a6-bf39-04a6114d92fc"
      unitRef="usd">4500000</amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities>
    <amed:NetServiceRevenueEpisodePaymentRateDuration
      contextRef="i2c715413d797438591b1cf5dd86e46fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMTU0MzA_1d582605-43d5-4e4c-b560-9362d4e238cf">P30D</amed:NetServiceRevenueEpisodePaymentRateDuration>
    <amed:NetServiceRevenueEpisodePaymentRateDuration
      contextRef="ifd1a9219629443d5bd28be1543aad1fe_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMTU0NDA_44bb158e-210e-4091-ac41-fb6e560b032d">P60D</amed:NetServiceRevenueEpisodePaymentRateDuration>
    <amed:NetServiceRevenueEpisodePaymentRateDuration
      contextRef="i2c715413d797438591b1cf5dd86e46fa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMTU2OTc_0f1c7caf-f9f2-4267-9b00-6e834279204b">P30D</amed:NetServiceRevenueEpisodePaymentRateDuration>
    <amed:NetServiceRevenueEpisodePaymentRateDuration
      contextRef="ifd1a9219629443d5bd28be1543aad1fe_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMTU3MDc_47564e4d-b07d-40a5-b177-44e4c1996d82">P60D</amed:NetServiceRevenueEpisodePaymentRateDuration>
    <amed:GovernmentGrantsPolicyTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwMTA_05dc17b0-ba9c-4a20-8bb4-d5f230f0a3b3">&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Government Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for government grants in accordance with ASU 2021-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Assistance (Topic 832), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;by applying the grant model in accordance with International Accounting Standard ("IAS") 20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Government Grants and Disclosure of Government Assistance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and as such, we recognize grant income on a systematic basis in line with the recognition of expenses or the loss of revenues for which the grants are intended to compensate. We recognize grants once both of the following conditions are met: (1) we are able to comply with the relevant conditions of the grant and (2) the grant will be received. See Note 3 &#x2013; Novel Coronavirus Pandemic ("COVID-19") for additional information on our accounting for government funds received under the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") and the Mass Home Care ASAP COVID-19 Provider Sustainability Program.&lt;/span&gt;&lt;/div&gt;</amed:GovernmentGrantsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwMTY_d4a811b7-4c47-4df5-99bf-a5ec2a087068">Cash, Cash Equivalents and Restricted CashCash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased. Restricted cash includes cash that is not available for ordinary business use.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCash
      contextRef="ie980f7f172dd4fc384952e9b8c0724f0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMTg5MDA_22bc7a6b-b957-49cf-bd08-32f42f5e944c"
      unitRef="usd">13600000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="ie980f7f172dd4fc384952e9b8c0724f0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMTg5MDA_7fb034d9-4c3d-43c7-bd16-35ae44efb165"
      unitRef="usd">13600000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i19a05af82bb1454eb68e81cc291cbc07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMTkxMTc_3a6c60cb-1162-482e-b2e1-870a0f0987b7"
      unitRef="usd">3100000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i19a05af82bb1454eb68e81cc291cbc07_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMTkxMTc_bc9ff8a4-5b9e-43a8-afc0-955a437b0c94"
      unitRef="usd">3100000</us-gaap:RestrictedCash>
    <amed:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwMTc_a69314b0-2c13-4331-8057-ed3a79fe03e6">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmNjOWZmZjE2ZjU5ZjQ1MjNhNTFhZWY3NDgzODA4Mjg5L3RhYmxlcmFuZ2U6Y2M5ZmZmMTZmNTlmNDUyM2E1MWFlZjc0ODM4MDgyODlfMi0xLTEtMS01MDcyNQ_f5e075f4-e292-4252-bee9-9b98508cc124"
      unitRef="usd">40500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmNjOWZmZjE2ZjU5ZjQ1MjNhNTFhZWY3NDgzODA4Mjg5L3RhYmxlcmFuZ2U6Y2M5ZmZmMTZmNTlmNDUyM2E1MWFlZjc0ODM4MDgyODlfMi0zLTEtMS01MDcyNQ_d1d45e0e-21b5-490f-960b-3cb79c19c000"
      unitRef="usd">42700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmNjOWZmZjE2ZjU5ZjQ1MjNhNTFhZWY3NDgzODA4Mjg5L3RhYmxlcmFuZ2U6Y2M5ZmZmMTZmNTlmNDUyM2E1MWFlZjc0ODM4MDgyODlfMy0xLTEtMS01MDcyNQ_25d71d73-fad6-4f1e-a87e-618daafff061"
      unitRef="usd">13600000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmNjOWZmZjE2ZjU5ZjQ1MjNhNTFhZWY3NDgzODA4Mjg5L3RhYmxlcmFuZ2U6Y2M5ZmZmMTZmNTlmNDUyM2E1MWFlZjc0ODM4MDgyODlfMy0zLTEtMS01MDcyNQ_ea2f4407-e1dd-4cde-b98b-131dd0479ec3"
      unitRef="usd">3100000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmNjOWZmZjE2ZjU5ZjQ1MjNhNTFhZWY3NDgzODA4Mjg5L3RhYmxlcmFuZ2U6Y2M5ZmZmMTZmNTlmNDUyM2E1MWFlZjc0ODM4MDgyODlfNC0xLTEtMS01MDcyNQ_8d6ee321-a4ca-4e2e-8d70-c57e9702c515"
      unitRef="usd">54100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmNjOWZmZjE2ZjU5ZjQ1MjNhNTFhZWY3NDgzODA4Mjg5L3RhYmxlcmFuZ2U6Y2M5ZmZmMTZmNTlmNDUyM2E1MWFlZjc0ODM4MDgyODlfNC0zLTEtMS02MTEyMA_19b1f978-2bab-4327-97e9-e1614f12e2ba"
      unitRef="usd">45800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwMjY_e68b9e73-dcf2-4aae-a59d-d771f3d079e6">&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Patient Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. Our non-Medicare third-party payor base is comprised of a diverse group of payors that are geographically dispersed across the country. As of December&#160;31, 2022, there is no single payor, other than Medicare, that accounts for more than 10% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectability risk associated with our Medicare accounts, which represented 67% and 68% of our net patient accounts receivable at December&#160;31, 2022 and 2021, respectively, is limited due to our historical collection rate of over 99% from Medicare and the fact that Medicare is a U.S. government payor. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medicare Home Health&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our home health patients (within both our home health and high acuity care segments), our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare following the end of each 30-day period of care or upon discharge, if earlier, for the services provided to the patient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medicare Hospice&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-Medicare Home Health, Hospice, Personal Care and High Acuity Care&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#x2019;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <amed:PercentageOfPatientReceivablesOutstanding
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMTk5OTE_48bd3af0-22a5-4c4f-a28b-b113ddeff0ca"
      unitRef="number">0.10</amed:PercentageOfPatientReceivablesOutstanding>
    <amed:PortionOfPatientAccountsReceivableDerivedFromMedicare
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjA0NDM_4930fd42-4f12-4746-bf80-cd450f7f0301"
      unitRef="number">0.67</amed:PortionOfPatientAccountsReceivableDerivedFromMedicare>
    <amed:PortionOfPatientAccountsReceivableDerivedFromMedicare
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjA0NTA_9a0894a0-6a3e-4922-9c3e-e1df510d7b65"
      unitRef="number">0.68</amed:PortionOfPatientAccountsReceivableDerivedFromMedicare>
    <amed:HistoricalCollectionRateFromMedicare
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjA1Nzk_c0fcdc23-f257-4ab2-9f1e-aee493f1142e"
      unitRef="number">0.99</amed:HistoricalCollectionRateFromMedicare>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfNTQ5NzU1ODYxMjI3_65f8868d-af42-48e1-8eb5-4206c1e36ef4">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwNDY_40efb9d4-cab9-4409-8d0c-6a5429340169">&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets or life of the lease, if shorter. Additionally, we have internally developed computer software for our own use. Additions and improvements (including interest costs for construction of qualifying long-lived assets) are capitalized. Maintenance and repair expenses are charged to expense as incurred. The cost of property and equipment sold or disposed of and the related accumulated depreciation are eliminated from the property and equipment and related accumulated depreciation accounts, and any gain or loss is credited or charged to other general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the impairment of a long-lived asset group whenever events or changes in circumstances indicate that the asset&#x2019;s carrying value may not be recoverable. Factors we consider important that could trigger an impairment review include but are not limited to the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A significant change in the extent or manner in which the long-lived asset group is being used.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A significant change in the business climate that could affect the value of the long-lived asset group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A significant change in the market value of the assets included in the asset group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If we determine that the carrying value of long-lived assets may not be recoverable, we compare the carrying value of the asset group to the undiscounted cash flows expected to be generated by the asset group. If the carrying value exceeds the undiscounted cash flows, an impairment charge is indicated. An impairment charge is recognized to the extent that the carrying value of the asset group exceeds its fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generally provide for depreciation over the following estimated useful service lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.753%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser&#160;of&#160;lease term&#160;or&#160;expected&#160;useful&#160;life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 to 7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balances related to our property and equipment for 2022 and 2021 (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense for 2022, 2021 and 2020 was $11.5 million, $12.1 million and $12.1 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <amed:EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwNjU_34f937e9-669e-4195-a7dd-1267e464906e">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generally provide for depreciation over the following estimated useful service lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.753%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser&#160;of&#160;lease term&#160;or&#160;expected&#160;useful&#160;life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 to 7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i9a008987e83a4ada9f3b12cc812bd0a1_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmQ0YjcwZmYzY2U4NDRmMDFhNTZiYTBkMGVhM2U2OWRmL3RhYmxlcmFuZ2U6ZDRiNzBmZjNjZTg0NGYwMWE1NmJhMGQwZWEzZTY5ZGZfMS0xLTEtMS01MDcyNQ_4c3ecf7c-53e7-45cb-bd0b-d924b9813d56">P39Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="ibe86b23f247c43068f7f25f069252db2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmQ0YjcwZmYzY2U4NDRmMDFhNTZiYTBkMGVhM2U2OWRmL3RhYmxlcmFuZ2U6ZDRiNzBmZjNjZTg0NGYwMWE1NmJhMGQwZWEzZTY5ZGZfMi0xLTEtMS01MDcyNQ_4abdc7f6-5fa2-4b39-b002-d6be444c0def">Lesser&#160;of&#160;lease term&#160;or&#160;expected&#160;useful&#160;life</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ic14d437ad5074709988cb2cca394f95f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmQ0YjcwZmYzY2U4NDRmMDFhNTZiYTBkMGVhM2U2OWRmL3RhYmxlcmFuZ2U6ZDRiNzBmZjNjZTg0NGYwMWE1NmJhMGQwZWEzZTY5ZGZfMy0xLTEtMS01MDcyNS90ZXh0cmVnaW9uOjAwZTM1NWNhOTBhMDQ2OGE5MjNmN2M4ZTU1NzYzYWZkXzQ_2301621f-a392-49a8-adf5-67b7df9306aa">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i000722521f3240b491676997b1fb573f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmQ0YjcwZmYzY2U4NDRmMDFhNTZiYTBkMGVhM2U2OWRmL3RhYmxlcmFuZ2U6ZDRiNzBmZjNjZTg0NGYwMWE1NmJhMGQwZWEzZTY5ZGZfMy0xLTEtMS01MDcyNS90ZXh0cmVnaW9uOjAwZTM1NWNhOTBhMDQ2OGE5MjNmN2M4ZTU1NzYzYWZkXzEw_e5bb2d4a-081a-49b3-9d50-eb9a596dfb25">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i21ca39c2911849ffa737ddd3e958f192_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmQ0YjcwZmYzY2U4NDRmMDFhNTZiYTBkMGVhM2U2OWRmL3RhYmxlcmFuZ2U6ZDRiNzBmZjNjZTg0NGYwMWE1NmJhMGQwZWEzZTY5ZGZfNC0xLTEtMS01MDcyNS90ZXh0cmVnaW9uOjYwNjhhYzBkMGFmYjRjNjlhMjY1MzA1MzExZjFmOTljXzU0OTc1NTgxMzg5Mg_b37c398b-ba25-4fa1-9253-62e8871bdf67">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="if9c24eced7104a4e97d673f1e2ca0501_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmQ0YjcwZmYzY2U4NDRmMDFhNTZiYTBkMGVhM2U2OWRmL3RhYmxlcmFuZ2U6ZDRiNzBmZjNjZTg0NGYwMWE1NmJhMGQwZWEzZTY5ZGZfNC0xLTEtMS01MDcyNS90ZXh0cmVnaW9uOjYwNjhhYzBkMGFmYjRjNjlhMjY1MzA1MzExZjFmOTljXzU0OTc1NTgxMzg5OQ_679659a5-85e1-486f-b0f2-c3cbaf740c32">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i6c4545751ceb443c93f828600b08a087_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmQ0YjcwZmYzY2U4NDRmMDFhNTZiYTBkMGVhM2U2OWRmL3RhYmxlcmFuZ2U6ZDRiNzBmZjNjZTg0NGYwMWE1NmJhMGQwZWEzZTY5ZGZfNS0xLTEtMS01MDcyNS90ZXh0cmVnaW9uOmU0MjlhYTE4MTRiZjRlNDM5Nzg3NjUzYTYyYmVjNGRkXzQ_b2693e20-419c-417e-8934-96d564dbdbc3">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i4a34fcd3e4ca44f997870b28af217929_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmQ0YjcwZmYzY2U4NDRmMDFhNTZiYTBkMGVhM2U2OWRmL3RhYmxlcmFuZ2U6ZDRiNzBmZjNjZTg0NGYwMWE1NmJhMGQwZWEzZTY5ZGZfNS0xLTEtMS01MDcyNS90ZXh0cmVnaW9uOmU0MjlhYTE4MTRiZjRlNDM5Nzg3NjUzYTYyYmVjNGRkXzEw_25bd95d4-f800-46d6-a48b-64a0b4a8d3f8">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i1c1fcea9f947413daad53be6d9712b19_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOmQ0YjcwZmYzY2U4NDRmMDFhNTZiYTBkMGVhM2U2OWRmL3RhYmxlcmFuZ2U6ZDRiNzBmZjNjZTg0NGYwMWE1NmJhMGQwZWEzZTY5ZGZfNi0xLTEtMS01MDcyNQ_aacf1313-e309-42c8-bc02-f8f05e0f299a">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwMjA_1456c619-b639-4acc-ae20-416fe4d1a945">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balances related to our property and equipment for 2022 and 2021 (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i289606829e684a02a13b4c2d309ec6a3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjQ1ODg0N2JjMTdkNDRlOWQ5NTViNGU2ZjBiYjJkZmIwL3RhYmxlcmFuZ2U6NDU4ODQ3YmMxN2Q0NGU5ZDk1NWI0ZTZmMGJiMmRmYjBfMi0xLTEtMS01MDcyNQ_913f62c4-aade-4c5a-9967-04aae86431d5"
      unitRef="usd">9700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icd970c25fe194ee8bb233e64dbeeb49b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjQ1ODg0N2JjMTdkNDRlOWQ5NTViNGU2ZjBiYjJkZmIwL3RhYmxlcmFuZ2U6NDU4ODQ3YmMxN2Q0NGU5ZDk1NWI0ZTZmMGJiMmRmYjBfMi0zLTEtMS01MDcyNQ_3bf8a59b-c3d7-4d75-8ff3-af993e0f2176"
      unitRef="usd">9100000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5efc684324124683b1a591012cf24d74_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjQ1ODg0N2JjMTdkNDRlOWQ5NTViNGU2ZjBiYjJkZmIwL3RhYmxlcmFuZ2U6NDU4ODQ3YmMxN2Q0NGU5ZDk1NWI0ZTZmMGJiMmRmYjBfMy0xLTEtMS01MDcyNQ_1f656a16-4514-4c6a-86f5-f0ab2bd83385"
      unitRef="usd">56900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i75cc8e8f3048499ea5dff437d4511970_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjQ1ODg0N2JjMTdkNDRlOWQ5NTViNGU2ZjBiYjJkZmIwL3RhYmxlcmFuZ2U6NDU4ODQ3YmMxN2Q0NGU5ZDk1NWI0ZTZmMGJiMmRmYjBfMy0zLTEtMS01MDcyNQ_262b8f7b-7dc3-4c69-accf-b2714d395168"
      unitRef="usd">54700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6b2a5e41e9ee4551ba7962246c513287_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjQ1ODg0N2JjMTdkNDRlOWQ5NTViNGU2ZjBiYjJkZmIwL3RhYmxlcmFuZ2U6NDU4ODQ3YmMxN2Q0NGU5ZDk1NWI0ZTZmMGJiMmRmYjBfNC0xLTEtMS01MDcyNQ_b354bd44-870d-4088-9baa-5b0cc9b3c05b"
      unitRef="usd">4100000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic9e60ab572054136b724859b7d07a982_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjQ1ODg0N2JjMTdkNDRlOWQ5NTViNGU2ZjBiYjJkZmIwL3RhYmxlcmFuZ2U6NDU4ODQ3YmMxN2Q0NGU5ZDk1NWI0ZTZmMGJiMmRmYjBfNC0zLTEtMS01MDcyNQ_ac0c96a6-723f-4610-9598-8920f6c8accd"
      unitRef="usd">4500000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i87145fca776747b8862566f844f11da8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjQ1ODg0N2JjMTdkNDRlOWQ5NTViNGU2ZjBiYjJkZmIwL3RhYmxlcmFuZ2U6NDU4ODQ3YmMxN2Q0NGU5ZDk1NWI0ZTZmMGJiMmRmYjBfNS0xLTEtMS01MDcyNQ_e28297ce-32ec-4600-907e-23dfa8090c0a"
      unitRef="usd">46700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i450c80a3586442a8bc78d59bb78f68ce_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjQ1ODg0N2JjMTdkNDRlOWQ5NTViNGU2ZjBiYjJkZmIwL3RhYmxlcmFuZ2U6NDU4ODQ3YmMxN2Q0NGU5ZDk1NWI0ZTZmMGJiMmRmYjBfNS0zLTEtMS01MDcyNQ_bf9369b9-cff4-4d8a-8741-e249b1e84d44"
      unitRef="usd">47000000.0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjQ1ODg0N2JjMTdkNDRlOWQ5NTViNGU2ZjBiYjJkZmIwL3RhYmxlcmFuZ2U6NDU4ODQ3YmMxN2Q0NGU5ZDk1NWI0ZTZmMGJiMmRmYjBfNi0xLTEtMS01MDcyNQ_1a4c6241-b697-4832-a970-95828d2af81a"
      unitRef="usd">117400000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjQ1ODg0N2JjMTdkNDRlOWQ5NTViNGU2ZjBiYjJkZmIwL3RhYmxlcmFuZ2U6NDU4ODQ3YmMxN2Q0NGU5ZDk1NWI0ZTZmMGJiMmRmYjBfNy0xLTEtMS01MDcyNQ_892067a1-1d80-4674-a3ed-e317a7f9f320"
      unitRef="usd">101400000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjQ1ODg0N2JjMTdkNDRlOWQ5NTViNGU2ZjBiYjJkZmIwL3RhYmxlcmFuZ2U6NDU4ODQ3YmMxN2Q0NGU5ZDk1NWI0ZTZmMGJiMmRmYjBfNy0zLTEtMS01MDcyNQ_1c3048bf-5481-4839-9489-b7e78afd0ec1"
      unitRef="usd">96900000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjQ1ODg0N2JjMTdkNDRlOWQ5NTViNGU2ZjBiYjJkZmIwL3RhYmxlcmFuZ2U6NDU4ODQ3YmMxN2Q0NGU5ZDk1NWI0ZTZmMGJiMmRmYjBfOC0xLTEtMS01MDcyNQ_a5d5f6d2-2e77-4aec-bea8-55869aa2a7fc"
      unitRef="usd">16000000.0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjQ1ODg0N2JjMTdkNDRlOWQ5NTViNGU2ZjBiYjJkZmIwL3RhYmxlcmFuZ2U6NDU4ODQ3YmMxN2Q0NGU5ZDk1NWI0ZTZmMGJiMmRmYjBfOC0zLTEtMS01MDcyNQ_ba63daac-ef90-403a-82c9-ddfc43e8a9a7"
      unitRef="usd">18400000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjQ0Mzk_9136898a-293e-4f63-b5b8-18d39fbb3163"
      unitRef="usd">11500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjQ0NDM_487bef3a-39a4-43ea-8260-f50361532278"
      unitRef="usd">12100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjQ0NTA_50916972-9a19-41a8-80e2-8c1c429c8833"
      unitRef="usd">12100000</us-gaap:Depreciation>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwNTk_c61f45d8-ee75-49c8-b3ef-0cc5327814b1">&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Acquisitions are accounted for as purchases and are included in our consolidated financial statements from their respective acquisition dates. Assets acquired, liabilities assumed and noncontrolling interests, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets. In determining the fair value of identifiable intangible assets and any noncontrolling interests, we use various valuation techniques including the income approach, the cost approach and the market approach. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, growth rates and discount rates.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwMDM_5972b940-a5cb-42b7-9782-8dd4256f6022">&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and Other Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, we had a goodwill balance of $1,287.4&#160;million. Goodwill represents the amount of the purchase price in excess of the fair values assigned to the underlying identifiable net assets of acquired businesses. Goodwill is not amortized, but is subject to an annual impairment test. Tests are performed more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount. These events or circumstances include, but are not limited to, a significant adverse change in the business environment, regulatory environment or legal factors, or a substantial decline in the market capitalization of our stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each of our operating segments described in Note 15 &#x2013; Segment Information is considered to represent an individual reporting unit for goodwill impairment testing purposes. We consider each of our home health care centers to constitute an individual business for which discrete financial information is available. However, since these care centers have substantially similar operating and economic characteristics and resource allocations and since significant investment decisions concerning these businesses are centralized and the benefits broadly distributed, we have aggregated these care centers and deemed them to constitute a single reporting unit. We have applied this same aggregation principle to our hospice and personal-care care centers and high acuity care joint ventures and have also deemed each of them to be a single reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2022, we performed a qualitative assessment to determine if it is more likely than not that the fair value of our reporting units are less than their carrying values by evaluating relevant events and circumstances including financial performance, market conditions and share price. Based on this assessment, we concluded that the goodwill associated with our home health, hospice and high acuity care reporting units was not considered at risk of impairment as of October&#160;31, 2022. In addition to the qualitative assessment, we also performed a quantitative analysis for our personal care reporting unit due to the decline in revenues resulting from staffing shortages using an income and market approach. Based on this analysis, we concluded that the goodwill associated with our personal care reporting unit was not considered at risk of impairment as of October 31, 2022. Since the date of our last goodwill impairment analysis, there have been no material developments, events, changes in operating performance or other circumstances that would cause management to believe it is more likely than not that the fair value of any of our reporting units would be less than their carrying amounts.&lt;/span&gt;&lt;/div&gt;As of December 31, 2022, we had an other intangibles assets balance of $101.2&#160;million. Intangible assets consist of certificates of need, licenses, acquired names, non-compete agreements and technology. We amortize non-compete agreements and acquired names that we do not intend to use indefinitely on a straight-line basis over their estimated useful lives, which are generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjg1OTA_1486623a-649a-4c91-b48e-f23d489bb99f"&gt;two&lt;/span&gt; to three years for non-compete agreements and up to three years for acquired names. We amortize technology over its estimated useful service life, which is generally up to seven years. Our indefinite-lived intangible assets are reviewed for impairment annually or more frequently if events occur or circumstances change that would more likely than not reduce the fair value of the intangible asset below its carrying amount. We performed a qualitative assessment of our indefinite-lived intangible assets during 2022 and determined that there have been no material developments, events, changes in operating performance or other circumstances that would cause management to believe it is more likely than not that the fair value of any of our indefinite-lived intangible assets would be less than their carrying amounts.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:Goodwill
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjU1MDI_55755e84-fbbf-4d1e-b484-7ae37a22825f"
      unitRef="usd">1287400000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjgyOTQ_ea380d63-7147-44f3-9a14-5cba456cd60f"
      unitRef="usd">101200000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i7ba082d05d43495b95f7c201e8451ff3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjg1OTY_9febcac8-62bf-4eaf-ba19-3f9d2977cfdc">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="iff5859d4cb064056a2a55fa3dc5feb6f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjg2MzY_0bf38d02-cdcf-4143-87bf-010efa9cf712">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i8990c36c1ca24b9b9986a1b57a6b70aa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjg3NDc_0895515b-cab6-4fd6-9e4e-ebc732b28066">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <amed:DebtIssuanceCostsPolicyPolicyTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwNDE_37b60e16-2e2e-4b87-891d-d576d12109b9">Debt Issuance CostsDuring 2021, we recorded $2.8&#160;million in deferred debt issuance costs as a reduction to long-term obligations, less current portion in our consolidated balance sheet in connection with our entry into the Second Amended Credit Agreement (See Note 9 - Long-Term Obligations). As of December&#160;31, 2022 and 2021, we had unamortized debt issuance costs of $3.5 million and $4.5 million, respectively, recorded as a reduction to long-term obligations, less current portion in our accompanying consolidated balance sheets. We amortize deferred debt issuance costs related to our long-term obligations over the term of the obligation through interest expense, unless the debt is extinguished, in which case unamortized balances are immediately expensed.</amed:DebtIssuanceCostsPolicyPolicyTextBlock>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjk2Mzg_bf601284-a1da-4af5-9ce3-4e67eb22509c"
      unitRef="usd">2800000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjk5Mzc_ec77d7ea-b68e-48a0-94c1-299e18f9bcee"
      unitRef="usd">3500000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMjk5NDQ_61cf16b1-2dbd-4503-a4b3-b3a290063fa0"
      unitRef="usd">4500000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzAzNTE_937b3747-dbe7-4f01-a6c0-5c61a0f39e2f"
      unitRef="usd">3500000</us-gaap:UnamortizedDebtIssuanceExpense>
    <amed:UnamortizedDebtIssuanceCostAmortizationPeriod
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzA0MjU_f0d5b327-82a3-4b8f-89f5-8ffb1093d8a9">P3Y7M6D</amed:UnamortizedDebtIssuanceCostAmortizationPeriod>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwMTM_cb9d0bec-74df-40e9-b18a-826dd0c84e92">&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Financial Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value as of&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&#160;in&#160;Active&lt;br/&gt;Markets for Identical&lt;br/&gt;Items&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1 &#x2013; Quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2 &#x2013; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3 &#x2013; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <amed:FinancialInstrumentDetailsTableTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwNDI_dda42196-dccc-4eb1-af7a-da0ed6dfc815">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Financial Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value as of&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&#160;in&#160;Active&lt;br/&gt;Markets for Identical&lt;br/&gt;Items&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:FinancialInstrumentDetailsTableTextBlock>
    <amed:DebtInstrumentCarryingAmountExcludingFinanceLeases
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjdlNWE2Yjg5ODVlNTRkMjhhZGY1ZWI5MDFhZmNhOGJiL3RhYmxlcmFuZ2U6N2U1YTZiODk4NWU1NGQyOGFkZjVlYjkwMWFmY2E4YmJfMi0xLTEtMS01MDcyNQ_319e78f3-11db-4a55-b802-c2b7bf8bfb79"
      unitRef="usd">436100000</amed:DebtInstrumentCarryingAmountExcludingFinanceLeases>
    <us-gaap:LongTermDebtFairValue
      contextRef="i00b2929fc5c94edaa315a2c9b947f6d0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjdlNWE2Yjg5ODVlNTRkMjhhZGY1ZWI5MDFhZmNhOGJiL3RhYmxlcmFuZ2U6N2U1YTZiODk4NWU1NGQyOGFkZjVlYjkwMWFmY2E4YmJfMi0zLTEtMS01MDcyNQ_552f9919-8040-427b-8e4a-723e646c2c22"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ide5ecdbd8c87484b981d596040ebe425_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjdlNWE2Yjg5ODVlNTRkMjhhZGY1ZWI5MDFhZmNhOGJiL3RhYmxlcmFuZ2U6N2U1YTZiODk4NWU1NGQyOGFkZjVlYjkwMWFmY2E4YmJfMi01LTEtMS01MDcyNQ_cabd6c6b-5ebd-47a8-90a3-bee3bbe57500"
      unitRef="usd">428600000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i0b4aa69adae3479e99bf23edae8da8b3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjdlNWE2Yjg5ODVlNTRkMjhhZGY1ZWI5MDFhZmNhOGJiL3RhYmxlcmFuZ2U6N2U1YTZiODk4NWU1NGQyOGFkZjVlYjkwMWFmY2E4YmJfMi03LTEtMS01MDcyNQ_cf3ec500-25c0-414a-a96a-e6a5e8978c02"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwNDc_ddfdd1a5-139a-4e0a-a46b-86f4fc53b693">&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the asset and liability approach for measuring deferred tax assets and liabilities based on temporary differences existing at each balance sheet date using currently enacted tax rates. Our deferred tax calculation requires us to make certain estimates about future operations. Deferred tax assets are reduced by a valuation allowance when we believe it is more likely than not that some portion or all of the deferred tax assets will not be realized. The effect of a change in tax rate is recognized as income or expense in the period that includes the enactment date. As of December&#160;31, 2022, we had net deferred tax liabilities of $20.4 million. As of December 31, 2021, we had net deferred tax assets of $0.3 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management regularly assesses the ability to realize deferred tax assets recorded in the Company&#x2019;s entities based upon the weight of available evidence, including such factors as the recent earnings history and expected future taxable income. In the event future taxable income is below management&#x2019;s estimates or is generated in tax jurisdictions different than projected, we could be required to increase the valuation allowance for deferred tax assets. This would result in an increase in our effective tax rate.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzIzNjU_a172fe6b-b702-464c-b8ce-cafcb69fa003"
      unitRef="usd">20400000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzIzNzI_db97e10b-64c4-4266-a7e2-44e069d28031"
      unitRef="usd">300000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwMjc_f1e24050-26f2-4454-a0ab-2fd037a54a1f">Share-Based CompensationWe record all share-based compensation as expense in the financial statements measured at the fair value of the award. We recognize compensation cost on a straight-line basis over the requisite service period for each separately vesting portion of the award.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensation
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzMyNDU_18b87dfb-03cd-4643-9b12-ee25ee767a62"
      unitRef="usd">16600000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzMyNDk_96f7fb56-d001-4ca4-a313-31dcdaa983a5"
      unitRef="usd">23800000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzMyNTY_075bc440-db69-4e31-9f44-f66fb9dffaec"
      unitRef="usd">26700000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzMzNDE_a15885c9-2ffe-422b-b89f-9bd951abca6d"
      unitRef="usd">4300000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzMzNDU_be6cc3f7-2621-4b4e-8553-1bd982ae02b7"
      unitRef="usd">6000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzMzNTI_0c2952f1-bbc4-4976-922f-60297760b99a"
      unitRef="usd">4700000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <amed:RecognizedTaxBenefitThatImpactsEffectiveTaxRate
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfNTQ5NzU1ODYxMTk1_b958efd9-c917-4359-83fe-91a9a512ebe5"
      unitRef="usd">2700000</amed:RecognizedTaxBenefitThatImpactsEffectiveTaxRate>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwNDk_b08fe801-7f6c-44cf-a6d7-eb8bab937c9b">Weighted-Average Shares Outstanding.Net income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwNjE_8447d127-5e08-4cdf-92c0-9768d990ec0b">The following table sets forth, for the periods indicated, shares used in our computation of weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested stock and stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjI1MDNhNjY4NzY1NTRiMTNiYWUwZjUwNWZlNzIyYjY0L3RhYmxlcmFuZ2U6MjUwM2E2Njg3NjU1NGIxM2JhZTBmNTA1ZmU3MjJiNjRfMi0xLTEtMS01MDcyNQ_30c215a0-82a9-47c4-ab3d-058d6233f796"
      unitRef="shares">32517000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjI1MDNhNjY4NzY1NTRiMTNiYWUwZjUwNWZlNzIyYjY0L3RhYmxlcmFuZ2U6MjUwM2E2Njg3NjU1NGIxM2JhZTBmNTA1ZmU3MjJiNjRfMi0zLTEtMS01MDcyNQ_95ed5ad8-db7c-4627-97f4-d33232b28eeb"
      unitRef="shares">32642000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjI1MDNhNjY4NzY1NTRiMTNiYWUwZjUwNWZlNzIyYjY0L3RhYmxlcmFuZ2U6MjUwM2E2Njg3NjU1NGIxM2JhZTBmNTA1ZmU3MjJiNjRfMi01LTEtMS01MDcyNQ_65353c4a-51f8-4a61-ab25-2dc18f43375e"
      unitRef="shares">32559000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjI1MDNhNjY4NzY1NTRiMTNiYWUwZjUwNWZlNzIyYjY0L3RhYmxlcmFuZ2U6MjUwM2E2Njg3NjU1NGIxM2JhZTBmNTA1ZmU3MjJiNjRfNC0xLTEtMS01MDcyNQ_f555d96a-ca4f-4008-afac-50c65c7fc4da"
      unitRef="shares">39000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjI1MDNhNjY4NzY1NTRiMTNiYWUwZjUwNWZlNzIyYjY0L3RhYmxlcmFuZ2U6MjUwM2E2Njg3NjU1NGIxM2JhZTBmNTA1ZmU3MjJiNjRfNC0zLTEtMS01MDcyNQ_deaf1f8f-68b6-4b43-8aea-8366cee2dc42"
      unitRef="shares">122000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjI1MDNhNjY4NzY1NTRiMTNiYWUwZjUwNWZlNzIyYjY0L3RhYmxlcmFuZ2U6MjUwM2E2Njg3NjU1NGIxM2JhZTBmNTA1ZmU3MjJiNjRfNC01LTEtMS01MDcyNQ_1dc7f13d-3b8a-40f5-bb23-0a5db1f04d7c"
      unitRef="shares">420000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <amed:NonVestedStockAndStockUnits
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjI1MDNhNjY4NzY1NTRiMTNiYWUwZjUwNWZlNzIyYjY0L3RhYmxlcmFuZ2U6MjUwM2E2Njg3NjU1NGIxM2JhZTBmNTA1ZmU3MjJiNjRfNS0xLTEtMS01MDcyNQ_81a6744f-87bf-473e-94ff-e7c536f5dddd"
      unitRef="shares">97000</amed:NonVestedStockAndStockUnits>
    <amed:NonVestedStockAndStockUnits
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjI1MDNhNjY4NzY1NTRiMTNiYWUwZjUwNWZlNzIyYjY0L3RhYmxlcmFuZ2U6MjUwM2E2Njg3NjU1NGIxM2JhZTBmNTA1ZmU3MjJiNjRfNS0zLTEtMS01MDcyNQ_25c16613-7c99-4329-9240-635e588056aa"
      unitRef="shares">208000</amed:NonVestedStockAndStockUnits>
    <amed:NonVestedStockAndStockUnits
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjI1MDNhNjY4NzY1NTRiMTNiYWUwZjUwNWZlNzIyYjY0L3RhYmxlcmFuZ2U6MjUwM2E2Njg3NjU1NGIxM2JhZTBmNTA1ZmU3MjJiNjRfNS01LTEtMS01MDcyNQ_f9313da4-6729-41be-a1e9-416cfb751181"
      unitRef="shares">289000</amed:NonVestedStockAndStockUnits>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjI1MDNhNjY4NzY1NTRiMTNiYWUwZjUwNWZlNzIyYjY0L3RhYmxlcmFuZ2U6MjUwM2E2Njg3NjU1NGIxM2JhZTBmNTA1ZmU3MjJiNjRfNi0xLTEtMS01MDcyNQ_eb5fbf83-cc7b-43cb-9c2a-1a5e679c843e"
      unitRef="shares">32653000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjI1MDNhNjY4NzY1NTRiMTNiYWUwZjUwNWZlNzIyYjY0L3RhYmxlcmFuZ2U6MjUwM2E2Njg3NjU1NGIxM2JhZTBmNTA1ZmU3MjJiNjRfNi0zLTEtMS01MDcyNQ_4f6aabb1-a72d-4d9c-aece-60854de54c9f"
      unitRef="shares">32972000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjI1MDNhNjY4NzY1NTRiMTNiYWUwZjUwNWZlNzIyYjY0L3RhYmxlcmFuZ2U6MjUwM2E2Njg3NjU1NGIxM2JhZTBmNTA1ZmU3MjJiNjRfNi01LTEtMS01MDcyNQ_6e3fc8cd-9ec8-4da1-8eaf-795f3a16eafd"
      unitRef="shares">33268000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjI1MDNhNjY4NzY1NTRiMTNiYWUwZjUwNWZlNzIyYjY0L3RhYmxlcmFuZ2U6MjUwM2E2Njg3NjU1NGIxM2JhZTBmNTA1ZmU3MjJiNjRfNy0xLTEtMS01MDcyNQ_6a6ab2ca-78d3-4bdc-9554-0d001d4acfef"
      unitRef="shares">303000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjI1MDNhNjY4NzY1NTRiMTNiYWUwZjUwNWZlNzIyYjY0L3RhYmxlcmFuZ2U6MjUwM2E2Njg3NjU1NGIxM2JhZTBmNTA1ZmU3MjJiNjRfNy0zLTEtMS01MDcyNQ_420e45b3-aede-4429-b82b-61f7ac9f3f26"
      unitRef="shares">114000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RhYmxlOjI1MDNhNjY4NzY1NTRiMTNiYWUwZjUwNWZlNzIyYjY0L3RhYmxlcmFuZ2U6MjUwM2E2Njg3NjU1NGIxM2JhZTBmNTA1ZmU3MjJiNjRfNy01LTEtMS01MDcyNQ_9c03c2c3-cf40-4692-9e45-df58a47b7571"
      unitRef="shares">25000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzQwNjI_f34f7b3e-d9d0-4e28-9f4e-ddc124a3f67d">Advertising CostsWe expense advertising costs as incurred.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzM5NzE_3a5e6768-97de-42ec-8404-008501e7b5ee"
      unitRef="usd">7300000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzM5NzU_6af43949-722a-4adc-99a4-f79a6612b9f0"
      unitRef="usd">7400000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV83OS9mcmFnOjkzMjI2MzRlNDAzMDQ3NjM4NjcyZTMxMGNiNWVkZDUxL3RleHRyZWdpb246OTMyMjYzNGU0MDMwNDc2Mzg2NzJlMzEwY2I1ZWRkNTFfMzM5ODI_04d01348-21ba-4056-9ec6-dd1b21e5af3d"
      unitRef="usd">6500000</us-gaap:AdvertisingExpense>
    <amed:COVID19TextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RleHRyZWdpb246Y2E3NmY1NWJjMDUxNDQxNjhiY2I3OGM5MGNkOWJkMDlfNDQxMw_6cc2fe97-e63c-4f05-9c03-0f7668f5bb02">NOVEL CORONAVIRUS PANDEMIC ("COVID-19")&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the World Health Organization declared COVID-19 a pandemic. As a healthcare at home company, we have been and will continue to be impacted by the effects of COVID-19; however, we remain committed to carrying out our mission of caring for our patients. We will continue to closely monitor the impact of COVID-19 on all aspects of our business, including the impacts to our employees, patients and suppliers; however, at this time, we are unable to estimate the ultimate impact the pandemic will have on our consolidated financial condition, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 27, 2020, the CARES Act was signed into legislation. The CARES Act provided for $175&#160;billion to healthcare providers, including hospitals on the front lines of the COVID-19 pandemic. Of this total allocated amount, $30&#160;billion was distributed immediately to providers based on their proportionate share of Medicare fee-for-service reimbursements in 2019. Healthcare providers were required to sign an attestation confirming receipt of the Provider Relief Fund ("PRF") funds and agree to the terms and conditions of payment. Our home health and hospice segments received approximately $100&#160;million from the first $30&#160;billion of funds distributed to healthcare providers in April 2020, which is inclusive of $2&#160;million related to our joint venture care centers (equity method investments). We also acquired approximately $6&#160;million of PRF funds in connection with the acquisition of AseraCare Hospice ("AseraCare"). Under the terms and conditions for receipt of the payment, we were allowed to use the funds to cover lost revenues and health care costs related to COVID-19 through June 30, 2021, and we were required to properly and fully document the use of these funds in reports to the U.S. Department of Health and Human Services ("HHS"). All required reporting was completed during the three-month period ended September 30, 2021, and our audit report was submitted to HHS on September 26, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our wholly-owned subsidiaries, we utilized PRF funds to the extent we had qualifying COVID-19 expenses; we did not use PRF funds to cover lost revenues resulting from COVID-19. The grant income associated with the COVID-19 expenses incurred through June 30, 2021 is reflected in other operating income within our consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We did not fully utilize the funds received; all unutilized funds were repaid in October 2021. In summary, the total funds that we received from the CARES Act PRF were accounted for as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funds utilized through June 30, 2021 by consolidated entities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funds repaid to the government by consolidated entities (excludes $0.2 million of interest repaid)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funds utilized through June 30, 2021 by unconsolidated joint ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funds repaid to the government by unconsolidated joint ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CARES Act also provided for the temporary suspension of the automatic 2% reduction of Medicare claim reimbursements ("sequestration") for the period May 1, 2020 through December 31, 2020. During 2020 and 2021, Congress passed additional COVID-19 relief legislation which extended the 2% suspension of sequestration through March 31, 2022; sequestration was &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reinstated as a 1% reduction to Medicare claim reimbursements effective April 1, 2022 and a 2% reduction to Medicare claim reimbursements effective July 1, 2022. We recognized benefits to net service revenue totalin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;g $13&#160;million, $36&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and $23&#160;million during 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the CARES Act provided for the deferral of the employer share of social security tax (6.2%), effective for payments due after the enactment date through December 31, 2020. During 2020, we deferred approximately $55&#160;million of social security taxes. Approximately $27&#160;million was paid during December 2021; the remaining balance was paid during December 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our personal care segment did not receive funds under the CARES Act; however, it did receive funds totaling $1&#160;million from the Mass Home Care ASAP COVID-19 Provider Sustainability Program, which were used during 2020 to cover costs related to COVID-19. The grant income associated with the funds received is reflected in other operating income within our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</amed:COVID19TextBlock>
    <amed:FundingForHealthcareProvidersIncludingHospitals
      contextRef="i6711eaed3f0d4ee694ed7955ac3b1e03_I20200327"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RleHRyZWdpb246Y2E3NmY1NWJjMDUxNDQxNjhiY2I3OGM5MGNkOWJkMDlfNzMx_8d1366bb-d0dd-43c7-ac2b-f919e30b3156"
      unitRef="usd">175000000000</amed:FundingForHealthcareProvidersIncludingHospitals>
    <amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements
      contextRef="i6711eaed3f0d4ee694ed7955ac3b1e03_I20200327"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RleHRyZWdpb246Y2E3NmY1NWJjMDUxNDQxNjhiY2I3OGM5MGNkOWJkMDlfODU2_3ebe8971-8bf4-482e-95c2-3cd9cc218b11"
      unitRef="usd">30000000000</amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements>
    <amed:FundingReceivedFromCARESAct
      contextRef="i6d7e910da92c42bc90993e8096f3b599_D20200401-20200430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RleHRyZWdpb246Y2E3NmY1NWJjMDUxNDQxNjhiY2I3OGM5MGNkOWJkMDlfMTIxNg_e8a8a8d6-4e83-431f-9aa2-ec734c053fff"
      unitRef="usd">100000000</amed:FundingReceivedFromCARESAct>
    <amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements
      contextRef="i6711eaed3f0d4ee694ed7955ac3b1e03_I20200327"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RleHRyZWdpb246Y2E3NmY1NWJjMDUxNDQxNjhiY2I3OGM5MGNkOWJkMDlfMTIzNA_036d3e3a-8af3-49a0-bcb0-6ff1bc736dbd"
      unitRef="usd">30000000000</amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements>
    <amed:FundingReceivedFromCARESAct
      contextRef="i5316c48403b245d7a32babf7c76d35ac_D20200401-20200430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RleHRyZWdpb246Y2E3NmY1NWJjMDUxNDQxNjhiY2I3OGM5MGNkOWJkMDlfMTMxOQ_f495ffe1-13de-4812-a952-44350ec1c8ad"
      unitRef="usd">2000000</amed:FundingReceivedFromCARESAct>
    <amed:FundingReceivedFromCARESAct
      contextRef="idfa6a89efdee40b3b7b70040f4cc830d_D20200401-20200430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RleHRyZWdpb246Y2E3NmY1NWJjMDUxNDQxNjhiY2I3OGM5MGNkOWJkMDlfMTQyNA_df4c6419-93aa-42c9-91e7-9be147da85cd"
      unitRef="usd">6000000</amed:FundingReceivedFromCARESAct>
    <amed:ScheduleOfCaresActProviderReliefFundsTableTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RleHRyZWdpb246Y2E3NmY1NWJjMDUxNDQxNjhiY2I3OGM5MGNkOWJkMDlfNDQxNA_b8e2520e-ac10-49e8-a2cc-ff89fa82333d">In summary, the total funds that we received from the CARES Act PRF were accounted for as follows (amounts in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.871%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funds utilized through June 30, 2021 by consolidated entities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funds repaid to the government by consolidated entities (excludes $0.2 million of interest repaid)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funds utilized through June 30, 2021 by unconsolidated joint ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funds repaid to the government by unconsolidated joint ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</amed:ScheduleOfCaresActProviderReliefFundsTableTextBlock>
    <amed:CARESActProviderReliefFundsUtilized
      contextRef="i5b33f1ef384d4000bd6fb60c0d49e71d_D20200401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RhYmxlOjM0MGNmYjg1ZDVmMTQzMWZiNTE3M2MzNzcxODBhYzgwL3RhYmxlcmFuZ2U6MzQwY2ZiODVkNWYxNDMxZmI1MTczYzM3NzE4MGFjODBfMS0xLTEtMS01MDcyNQ_a2b41041-573c-484a-a11e-b1565b0392ef"
      unitRef="usd">46600000</amed:CARESActProviderReliefFundsUtilized>
    <amed:CARESActInterestRepaidToGovernment
      contextRef="i144647094c4a4625802e08748d886f42_I20211031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RhYmxlOjM0MGNmYjg1ZDVmMTQzMWZiNTE3M2MzNzcxODBhYzgwL3RhYmxlcmFuZ2U6MzQwY2ZiODVkNWYxNDMxZmI1MTczYzM3NzE4MGFjODBfMi0wLTEtMS01MDcyNS90ZXh0cmVnaW9uOjExYTNjMjY1MTlkZDRiY2ZiMzZiMmEyMGU5NTYwZWI0Xzcw_f543021d-8b65-4897-83f2-d1ed662d7b6d"
      unitRef="usd">200000</amed:CARESActInterestRepaidToGovernment>
    <amed:CARESActProviderReliefFundsRepaidToTheGovernment
      contextRef="i144647094c4a4625802e08748d886f42_I20211031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RhYmxlOjM0MGNmYjg1ZDVmMTQzMWZiNTE3M2MzNzcxODBhYzgwL3RhYmxlcmFuZ2U6MzQwY2ZiODVkNWYxNDMxZmI1MTczYzM3NzE4MGFjODBfMi0xLTEtMS01MDcyNQ_78921f3c-34bd-4523-b810-6e1ce0600c47"
      unitRef="usd">58300000</amed:CARESActProviderReliefFundsRepaidToTheGovernment>
    <amed:CARESActProviderReliefFundUtilizedByUnconsolidatedJointVentures
      contextRef="i5b33f1ef384d4000bd6fb60c0d49e71d_D20200401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RhYmxlOjM0MGNmYjg1ZDVmMTQzMWZiNTE3M2MzNzcxODBhYzgwL3RhYmxlcmFuZ2U6MzQwY2ZiODVkNWYxNDMxZmI1MTczYzM3NzE4MGFjODBfMy0xLTEtMS01MDcyNQ_c017f320-2c04-4425-9d5e-70b0291e2a30"
      unitRef="usd">1300000</amed:CARESActProviderReliefFundUtilizedByUnconsolidatedJointVentures>
    <amed:CARESActProviderReliefFundsRepaidByUnconsolidatedJointVentures
      contextRef="i144647094c4a4625802e08748d886f42_I20211031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RhYmxlOjM0MGNmYjg1ZDVmMTQzMWZiNTE3M2MzNzcxODBhYzgwL3RhYmxlcmFuZ2U6MzQwY2ZiODVkNWYxNDMxZmI1MTczYzM3NzE4MGFjODBfNC0xLTEtMS01MDcyNQ_c9aa5bab-c299-431e-bad7-822506f2b16c"
      unitRef="usd">600000</amed:CARESActProviderReliefFundsRepaidByUnconsolidatedJointVentures>
    <amed:TotalCARESActProviderReliefFundsReceived
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RhYmxlOjM0MGNmYjg1ZDVmMTQzMWZiNTE3M2MzNzcxODBhYzgwL3RhYmxlcmFuZ2U6MzQwY2ZiODVkNWYxNDMxZmI1MTczYzM3NzE4MGFjODBfNS0xLTEtMS01MDcyNQ_58a0e986-8141-4ec2-b9fc-d748d1a81987"
      unitRef="usd">106800000</amed:TotalCARESActProviderReliefFundsReceived>
    <amed:ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RleHRyZWdpb246Y2E3NmY1NWJjMDUxNDQxNjhiY2I3OGM5MGNkOWJkMDlfNTQ5NzU1ODIwOTY3_50e52be8-c4a6-4456-851e-39210828f9ff"
      unitRef="usd">13000000</amed:ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact>
    <amed:ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RleHRyZWdpb246Y2E3NmY1NWJjMDUxNDQxNjhiY2I3OGM5MGNkOWJkMDlfNTQ5NzU1ODIwOTgw_31fd4ba1-e3de-4fb2-a2e1-0cebf08c75d9"
      unitRef="usd">36000000</amed:ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact>
    <amed:ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RleHRyZWdpb246Y2E3NmY1NWJjMDUxNDQxNjhiY2I3OGM5MGNkOWJkMDlfNTQ5NzU1ODIwOTkz_fdcfd07d-8840-44cd-b581-232598717808"
      unitRef="usd">23000000</amed:ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact>
    <amed:CARESActDeferralOfEmployerShareSocialSecurityTax
      contextRef="if61757dea5844f219019c3a64a1972b4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RleHRyZWdpb246Y2E3NmY1NWJjMDUxNDQxNjhiY2I3OGM5MGNkOWJkMDlfMzgxMA_43d20f2c-357e-403a-b2d6-36e3d4d2fdbd"
      unitRef="usd">55000000</amed:CARESActDeferralOfEmployerShareSocialSecurityTax>
    <amed:PaymentOfDeferredSocialSecurityTaxUnderCARESAct
      contextRef="i0530cc1fa306423dba7c186bb6ab97cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RleHRyZWdpb246Y2E3NmY1NWJjMDUxNDQxNjhiY2I3OGM5MGNkOWJkMDlfMzg1Mw_cad47e93-3b80-4114-8ba3-5b026306b2b0"
      unitRef="usd">27000000</amed:PaymentOfDeferredSocialSecurityTaxUnderCARESAct>
    <amed:PaymentOfDeferredSocialSecurityTaxUnderCARESAct
      contextRef="i24fd071f2c354373829031fc28f4be1b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RleHRyZWdpb246Y2E3NmY1NWJjMDUxNDQxNjhiY2I3OGM5MGNkOWJkMDlfMzg1Mw_f9ade2cf-f272-49dd-91c3-fe76ee0f79c5"
      unitRef="usd">27000000</amed:PaymentOfDeferredSocialSecurityTaxUnderCARESAct>
    <us-gaap:OtherOperatingIncome
      contextRef="i06f200e2df374ac19cb47bab63a56b3f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RleHRyZWdpb246Y2E3NmY1NWJjMDUxNDQxNjhiY2I3OGM5MGNkOWJkMDlfNDEzNQ_288c898b-9a0a-4bbd-97c1-610ec14f76da"
      unitRef="usd">1000000</us-gaap:OtherOperatingIncome>
    <amed:FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram
      contextRef="i06f200e2df374ac19cb47bab63a56b3f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84NS9mcmFnOmNhNzZmNTViYzA1MTQ0MTY4YmNiNzhjOTBjZDliZDA5L3RleHRyZWdpb246Y2E3NmY1NWJjMDUxNDQxNjhiY2I3OGM5MGNkOWJkMDlfNDEzNQ_5d79a1bd-b81f-47f1-81c9-566d50db049d"
      unitRef="usd">1000000</amed:FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfOTU5Ng_e90312f4-e505-4f5b-8fae-841fbcfe8355">ACQUISITIONSWe complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health, hospice, personal care and high acuity care services. The purchase price paid for acquisitions is negotiated through arm&#x2019;s length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows. Acquisitions are &lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;accounted for as purchases and are included in our consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy. We typically engage outside appraisal firms to assist in the fair value determination of identifiable intangible assets and noncontrolling interests, if any, for significant acquisitions. The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuation and liabilities assumed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2022 Acquisitions &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 23, 2022, we entered into a transaction with one of our high acuity care health system partners in which we contributed cash and our health system partner contributed its home health operations to one of our existing high acuity care joint ventures. As a result of this transaction, we recorded goodwill of $8.5&#160;million, other intangibles of $0.4&#160;million (certificate of need and licenses) and noncontrolling interest of $8.9&#160;million within our consolidated balance sheet. The fair value of noncontrolling interest was determined using an income approach and a market approach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 1, 2022, we acquired 15 home health care centers from Evolution Health, LLC, a division of Envision Healthcare, doing business as Guardian Healthcare, Gem City, and Care Connection of Cincinnati ("Evolution"), for an estimated purchase price of $67.8&#160;million. A portion of the purchase price ($51.1&#160;million) was paid to the seller with cash on hand and proceeds from borrowings under our Revolving Credit Facility. The remainder ($16.7&#160;million) was placed into an escrow account in accordance with the closing payment, indemnity and other provisions within the purchase agreement and recorded as restricted cash within our consolidated balance sheet. Corresponding liabilities were also recorded to accrued expenses and other long-term obligations within our consolidated balance sheet related to these contingent consideration arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Of the total $16.7&#160;million placed into escrow, $1.0&#160;million was set aside for the closing payment adjustment. The closing payment calculated on the acquisition date included estimates for cash, working capital and various other items. Under the purchase agreement, the purchase price was subject to an adjustment for any differences between estimated amounts included in the closing payment and actual amounts at close. The closing payment adjustment, which was finalized during the three-month period ended September 30, 2022, decreased the purchase price by $1.3&#160;million from $67.8&#160;million to $66.5&#160;million. The remaining $15.7&#160;million placed into escrow relates to certain outstanding matters existing as of the acquisition date as well as potential losses the Company may incur for which the seller has an obligation to indemnify the Company. This amount will either be paid to third parties as outstanding matters are resolved or to the seller at certain intervals in the future. As of December 31, 2022, $5.7&#160;million of the $16.7&#160;million has been released from escrow.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expect $15&#160;million of goodwill recorded for this acquisition to be deductible for income tax purposes over approximately 15 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Evolution contributed $29.4&#160;million in net service revenue and an operating loss of $5.3 million during the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is in the process of reviewing the fair value of the assets acquired and liabilities assumed. During the post-acquisition period ended December 31, 2022, total assets acquired decreased by $2.1&#160;million (primarily patient accounts receivable and property and equipment) and total liabilities assumed (specifically, the deferred income tax liability) decreased by $0.3&#160;million as a result of our review. These adjustments, combined with the closing payment adjustment of $1.3&#160;million described above, resulted in a $0.5&#160;million increase in goodwill. Based on the Company's preliminary valuation, which may be revised as additional information becomes available during the measurement period, the total consideration of $66.5&#160;million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets (licenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 1, 2022, we acquired two home health locations from AssistedCare Home Health, Inc. and RH Homecare Services, LLC, doing business as AssistedCare Home Health and AssistedCare of the Carolinas ("AssistedCare"), respectively, for a purchase price of $24.7&#160;million. A portion of the purchase price ($22.2&#160;million) was paid to the seller with cash on hand and proceeds from borrowings under our Revolving Credit Facility. The remainder ($2.5&#160;million) was placed into an escrow account in accordance with the indemnity provisions within the purchase agreement and is reflected in restricted cash within our consolidated balance sheet. A corresponding liability was also recorded to other long-term obligations within our consolidated balance sheet related to this contingent consideration arrangement. The $2.5&#160;million will either be paid to third parties or to the seller at certain intervals in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the Company's preliminary valuation, we recorded goodwill of $24.0&#160;million and other intangibles of $0.7&#160;million in connection with the acquisition. Intangible assets acquired include licenses ($0.5&#160;million), certificates of need ($0.2&#160;million) and acquired names (less than $0.1&#160;million). The acquired names will be amortized over a weighted average period of one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expect the entire amount of goodwill recorded for this acquisition to be deductible for income tax purposes over approximately 15 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AssistedCare contributed $6.1&#160;million in net service revenue and operating income of $0.8&#160;million during the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2021 Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 1, 2021, we acquired the regulatory assets of a home health provider in Randolph County, North Carolina for a purchase price of $2.5&#160;million. The purchase price was paid with cash on hand on the date of the transaction. We recorded goodwill of $2.4&#160;million and other intangibles (certificate of need) of $0.1&#160;million in connection with the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 1, 2021, we acquired Visiting Nurse Association ("VNA"), a home health and hospice provider with locations in Nebraska and Iowa for a purchase price of $20.1&#160;million. The purchase price was paid with cash on hand on the date of the transaction. We recorded goodwill of $19.7&#160;million and other intangibles (licenses) of $0.4&#160;million in connection with the acquisition. We expect the entire amount of goodwill for this acquisition to be deductible for income tax purposes over approximately 15 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 12, 2021, we acquired the regulatory assets of a home health provider in New York for a purchase price of $1.5&#160;million. The purchase price was paid with cash on hand on the date of the transaction. We recorded goodwill of $1.4&#160;million and other intangibles (certificate of need) of $0.1&#160;million in connection with the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 1, 2021, we acquired Contessa, a leader in hospital-at-home and skilled nursing facility at-home services for an estimated purchase price of $240.7&#160;million, net of cash acquired. The Contessa purchase price included estimates for cash, working capital and other items. Under the purchase agreement, the purchase price was subject to a closing payment adjustment for any differences between estimated amounts included in the closing payment and actual amounts at close. The closing payment adjustment, which was finalized during the three-month period ended December 31, 2021, increased the purchase price by $0.6&#160;million from $240.7&#160;million to $241.3&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has finalized its valuation of the assets acquired, liabilities assumed and noncontrolling interests. During the year ended December 31, 2022, the deferred income tax liability was adjusted downward by $2.8&#160;million resulting in a $2.8&#160;million decrease in goodwill. The total consideration of $241.3&#160;million has been allocated to assets acquired, liabilities assumed and noncontrolling interests as of the acquisition date as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES AND EQUITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total equity assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities and equity assumed&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets acquired include acquired names ($28.3&#160;million), technology ($19.8&#160;million) and non-compete agreements ($6.2&#160;million). The non-compete agreements will be amortized over a weighted-average period of 2.0 years, and the technology will be amortized over a weighted-average period of 7.0 years. The fair value of noncontrolling interest ($43.9&#160;million) was determined using an income approach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not expect any of the goodwill recorded for this acquisition to be deductible for income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contessa contributed $18.5&#160;million in net service revenue and an operating loss of $39.1&#160;million (inclusive of technology intangibles amortization totaling $3.0&#160;million) during the year ended December 31, 2022 and $3.5&#160;million in net service revenue and an operating loss of $10.3 million (inclusive of technology intangibles amortization totaling $1.2&#160;million) during the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 18, 2021, we acquired the regulatory assets of a home health provider in North Carolina for a purchase price of $4.5&#160;million. The purchase price was paid with cash on hand on the date of the transaction. We recorded goodwill of $4.3&#160;million and other intangibles (certificate of need) of $0.2&#160;million in connection with the acquisition.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i329d3927fede4bdf9fab592d7ad5bbca_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMDkz_54335891-1b0a-46f0-ab45-39f6834466fb"
      unitRef="usd">8500000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i34442d4c2cdd49e8ad3bacd82824cc9b_I20220323"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMTA3_8e05b177-702c-46d5-8012-e3492789de33"
      unitRef="usd">400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <amed:BusinessCombinationAcquiredNoncontrollingInterest
      contextRef="ib16b4cdc559b48b48aaca7b7709eccf7_I20220323"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMTIx_04393496-c69b-436b-b450-730c748c169b"
      unitRef="usd">8900000</amed:BusinessCombinationAcquiredNoncontrollingInterest>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="i3ee24d260ef448cd85330a7919fef9a6_D20220401-20220401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMTM1_922300b7-0f58-4b4c-8aad-f06d83ef7494"
      unitRef="care_center">15</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i3ee24d260ef448cd85330a7919fef9a6_D20220401-20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMTM5_711db88a-218f-4ecb-a950-eef986c05793"
      unitRef="usd">67800000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i3ee24d260ef448cd85330a7919fef9a6_D20220401-20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMTU0_f770ff7e-0438-47b4-9ecb-3dfc0f2bf29b"
      unitRef="usd">51100000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:RestrictedCash
      contextRef="ib5a9c836f91a48a19480bcf0f161b5ea_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMTY5_f978f0d3-49f3-41a7-9719-b4333e9906be"
      unitRef="usd">16700000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="ib5a9c836f91a48a19480bcf0f161b5ea_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMTg0_2af2ca20-6fdd-4e67-be73-f35a75cd97f1"
      unitRef="usd">16700000</us-gaap:RestrictedCash>
    <amed:NonCashAccruedContingentConsideration
      contextRef="ie5385a5f630f492ca9a57b76acb56832_D20220401-20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMTk5_b2749947-4b3c-46e2-b6e0-ccdcab6000cd"
      unitRef="usd">1000000</amed:NonCashAccruedContingentConsideration>
    <amed:BusinessAcquisitionClosingPaymentAdjustment
      contextRef="i5164993430b74c95b0e12d477628d1e3_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMjEz_96ad92ae-a25b-487f-810c-b96226290f8b"
      unitRef="usd">1300000</amed:BusinessAcquisitionClosingPaymentAdjustment>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i3ee24d260ef448cd85330a7919fef9a6_D20220401-20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMjI3_fef17a63-e2d5-4b43-9068-3168f4856a72"
      unitRef="usd">67800000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i7d98a7f596b54b549b3e1d6ace83797e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMjQy_30b6003c-c2fb-4c66-969e-c63770f03cd6"
      unitRef="usd">66500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <amed:NonCashAccruedContingentConsideration
      contextRef="i3ee24d260ef448cd85330a7919fef9a6_D20220401-20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMjU3_cbf2557e-3700-49da-84b4-1678d81ca568"
      unitRef="usd">15700000</amed:NonCashAccruedContingentConsideration>
    <amed:AmountReleasedFromEscrow
      contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMjcy_f9adf8f4-5180-43e9-bd62-308e388a8c97"
      unitRef="usd">5700000</amed:AmountReleasedFromEscrow>
    <us-gaap:RestrictedCash
      contextRef="ib5a9c836f91a48a19480bcf0f161b5ea_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMjg2_ee93bf80-301e-40bd-bb88-fd76348aa909"
      unitRef="usd">16700000</us-gaap:RestrictedCash>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="ib5a9c836f91a48a19480bcf0f161b5ea_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMzAx_1738573a-d84d-41fb-8d03-34b11939c7b2"
      unitRef="usd">15000000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <amed:GoodwillDeductibleForIncomeTaxPurposesPeriod
      contextRef="i3ee24d260ef448cd85330a7919fef9a6_D20220401-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMzM0_b3a0aa84-3162-4282-8885-9550d9b137dc">P15Y</amed:GoodwillDeductibleForIncomeTaxPurposesPeriod>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i28853129c6904eb18dd32328ff6639b9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMzE0_c7a189b9-af11-4060-afad-99304038577f"
      unitRef="usd">29400000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <amed:BusinessAcquisitionClosingPaymentAdjustment
      contextRef="i5164993430b74c95b0e12d477628d1e3_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMzc4_3f41f8d1-c1ce-44d7-8cb1-d2665825c7ca"
      unitRef="usd">1300000</amed:BusinessAcquisitionClosingPaymentAdjustment>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i28853129c6904eb18dd32328ff6639b9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwMzky_5740a2b9-4162-4fec-88ed-5223f63b1c9d"
      unitRef="usd">500000</us-gaap:GoodwillOtherIncreaseDecrease>
    <amed:ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwODkw_058d63d3-da01-424c-9c04-5e359e4f05ae">Based on the Company's preliminary valuation, which may be revised as additional information becomes available during the measurement period, the total consideration of $66.5&#160;million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets (licenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</amed:ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNDA2_8d885e29-d48d-475e-a603-8f482bb5dbeb"
      unitRef="usd">66500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfMi0xLTEtMS02MTQ3NA_6395b2e0-eb41-45cd-b472-61f2c7d006e1"
      unitRef="usd">7600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense
      contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfMy0xLTEtMS02MTQ3Nw_b7c67c11-b139-43a0-b1f5-16caa2bb7f9d"
      unitRef="usd">200000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfNC0xLTEtMS02MTQ3Nw_912bc4dd-dc73-457a-a85d-731b2173b891"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfNS0xLTEtMS02MTQ3Nw_52b5eac7-0c39-47f9-827a-27cc242257c5"
      unitRef="usd">1900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets
      contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfNi0xLTEtMS02MTQ3Nw_1450c187-b29f-4924-b712-92eb86e29d6a"
      unitRef="usd">3200000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i5ce5ed93672d4ebbba91deaaf07e6054_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfNy0xLTEtMS02MTQ3Nw_0fad9887-b6ad-4fd9-b73e-43883f6a549f"
      unitRef="usd">1300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfOC0xLTEtMS02MTQ3Nw_bb3a91cd-ea24-4011-93dd-8c9363aff101"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfOS0xLTEtMS02MTQ3Nw_1e8a6336-825d-4317-b672-2494be9fa30b"
      unitRef="usd">14400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfMTEtMS0xLTEtNjE0ODA_c662fe67-7031-42c0-8a29-a0f094af4445"
      unitRef="usd">800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits
      contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfMTItMS0xLTEtNjE0ODA_1d07ade4-def2-4003-88b7-23e7d806b556"
      unitRef="usd">2700000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses
      contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfMTMtMS0xLTEtNjE0ODA_76b5f6ef-3651-4109-a7a6-6688cb949a13"
      unitRef="usd">2400000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities
      contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfMTQtMS0xLTEtNjE0ODA_9f60bf90-8241-48c7-8f07-9a65de1efa4c"
      unitRef="usd">2800000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfMTUtMS0xLTEtNjE0ODA_629fd031-bc73-4436-9cd4-42b4959be393"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt
      contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfMTYtMS0xLTEtNjE0ODA_4f61ddfd-7187-423b-90b0-63bdb5ee5b2f"
      unitRef="usd">600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfMTctMS0xLTEtNjE0ODA_55dcfa80-453c-4171-912c-2123a8dd9efe"
      unitRef="usd">9400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfMTgtMS0xLTEtNjE0ODA_1a5bee49-78a8-465d-93c4-93fef3bbd615"
      unitRef="usd">5000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i28853129c6904eb18dd32328ff6639b9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfMTktMS0xLTEtNjE0ODA_2633a194-2168-42e7-aafb-dbd1714d3187"
      unitRef="usd">61500000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i71d46c678b1f4800889099f17f5f7799_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjYzNTIwNDVmZGU5YzQ4YjA5OTQ5M2YyYTA5MjQ3NWQ0L3RhYmxlcmFuZ2U6NjM1MjA0NWZkZTljNDhiMDk5NDkzZjJhMDkyNDc1ZDRfMjAtMS0xLTEtNjE0ODA_12d6f701-b861-4e9f-8737-b4eb591f4059"
      unitRef="usd">66500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="i9515534e01de4100ba0629e25ec08585_D20220401-20220401"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwODgx_e8ab8682-05dc-40e6-b986-55a9715c2475"
      unitRef="care_center">2</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i9515534e01de4100ba0629e25ec08585_D20220401-20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNDIx_d43e3de4-85ec-492a-b6f1-9c51bba6353d"
      unitRef="usd">24700000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i9515534e01de4100ba0629e25ec08585_D20220401-20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNDM2_707b9635-d0b5-4984-bf51-77e4310d4026"
      unitRef="usd">22200000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:RestrictedCash
      contextRef="i2021555b705242a99ec6febf31d7a964_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNDUx_984e18e4-c3f8-43f4-88c1-92773c10fa2e"
      unitRef="usd">2500000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i2021555b705242a99ec6febf31d7a964_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNDY1_b144d26f-06bb-4af3-9845-5c59c0312b58"
      unitRef="usd">2500000</us-gaap:RestrictedCash>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="i2021555b705242a99ec6febf31d7a964_I20220401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNDc5_4cf55b1e-6e8e-45a1-8417-01463f7628f6"
      unitRef="usd">24000000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="icb92529d6381424facef8b4b61830b50_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNDc5_a27c1098-d33e-4b76-840e-6df6621194f6"
      unitRef="usd">24000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i2021555b705242a99ec6febf31d7a964_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNDk0_f8a95f8f-eaf9-4f58-a21c-b59cd6d9825a"
      unitRef="usd">700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i599a4a53807b476383b1600b004d88dc_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNTA4_a7e79dbe-a589-4d77-aba9-a0566f964cb5"
      unitRef="usd">500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i1bf01ffe6b0244e5921dd50351b7b4e7_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNTIy_70d81a54-1202-4b1d-8576-3418b12eb6c8"
      unitRef="usd">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i43eafef87dff4c529ba66562fa0cf94e_I20220401"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNTM2_c6e6cb0d-369a-446e-846a-9f4dd2acdc00"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i8e2142a5ef784762a3c038048115d45d_D20220401-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNTU0_240ddd94-1c4c-4ca6-9889-b884d91c6557">P1Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <amed:GoodwillDeductibleForIncomeTaxPurposesPeriod
      contextRef="i9515534e01de4100ba0629e25ec08585_D20220401-20220401"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNTc0_ae0105d6-700b-4c42-833b-ed1f4b49f2fc">P15Y</amed:GoodwillDeductibleForIncomeTaxPurposesPeriod>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="icb92529d6381424facef8b4b61830b50_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNTkw_050312da-6ec1-4100-8060-a3f714055482"
      unitRef="usd">6100000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:OperatingIncomeLoss
      contextRef="icb92529d6381424facef8b4b61830b50_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNjA0_9efd71bb-686d-4059-b65e-132a7337a97f"
      unitRef="usd">800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i9b54240bf3d2420990c7a9096aefde0b_D20210501-20210501"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfMTQzNQ_a5c641c9-18ab-47b7-8215-c69ee4bd89a2"
      unitRef="usd">2500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ie00945c9207e49129104d8327cdab5ac_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfMTU4Nw_8a1581cc-a770-41ae-a4e6-cedd8f4c6fdd"
      unitRef="usd">2400000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i6b9388aa1085440fb4ae49552b5eac30_I20210501"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfMTYzNw_8a131438-29dc-4cd5-87c7-201c25783b03"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i3a6a5482d808478ca8d187e7994862e3_D20210701-20210701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfMTgzNg_1b883021-b424-4562-b7be-0c9c392fe3a7"
      unitRef="usd">20100000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="iead9a275ae234dd58c7aa7d6084ed1a8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfMTk4OA_573c7044-e198-4e32-b59d-a5cac47a141b"
      unitRef="usd">19700000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ie4e5e1d9f2c04c828295e9928469b871_I20210701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfMjAyNw_41d1c210-d620-4d31-979e-99cd1bb3a770"
      unitRef="usd">400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <amed:GoodwillDeductibleForIncomeTaxPurposesPeriod
      contextRef="i3a6a5482d808478ca8d187e7994862e3_D20210701-20210701"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfMjE4Nw_06f1c46b-80b3-4bec-8de6-a761b9103bcf">P15Y</amed:GoodwillDeductibleForIncomeTaxPurposesPeriod>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="id09c2a6d2e8c408fbdffeec1f5145603_D20210712-20210712"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfMjMwNQ_6f8ced4d-f024-4aa6-a29a-d1750a9cf62a"
      unitRef="usd">1500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="id4df44aa40d846c888dfefff67b0441e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfMjQ1Nw_099a43b6-9c07-404b-b9f5-aa300c70d062"
      unitRef="usd">1400000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i52779ae3c4594b42bfa6a1f5c28042c3_I20210712"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfMjUwNw_60d8eeef-ee32-4a60-bc56-da8c546cc381"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ia9ad18fcb7674a4ca8ca6600d605a491_D20210801-20210801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNjE4_376eadd3-b5ef-4b4f-a1da-eabbd915e4b6"
      unitRef="usd">240700000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <amed:BusinessAcquisitionClosingPaymentAdjustment
      contextRef="i63526fb29695460daf7c8961c2d352cc_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNjM0_f49a85dc-4ed2-4fa1-a809-88574d6e8cc2"
      unitRef="usd">600000</amed:BusinessAcquisitionClosingPaymentAdjustment>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ia9ad18fcb7674a4ca8ca6600d605a491_D20210801-20210801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNjQ4_359d38af-cd29-4ad6-ab43-9c38a0ebcd18"
      unitRef="usd">240700000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest
      contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNjY0_5b621d20-fb46-4c8a-b035-62f0ce1851a7"
      unitRef="usd">241300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest>
    <amed:ScheduleOfBusinessAcquisitionsContessaHealthTableTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwODg3_f3f8768c-04b5-4824-a1f5-0d15171c0d23">The total consideration of $241.3&#160;million has been allocated to assets acquired, liabilities assumed and noncontrolling interests as of the acquisition date as follows (amounts in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES AND EQUITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total equity assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities and equity assumed&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</amed:ScheduleOfBusinessAcquisitionsContessaHealthTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest
      contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNjgw_25f8a9af-5924-42aa-b5d6-40fe8b91715a"
      unitRef="usd">241300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfMi0xLTEtMS02MTU1OQ_86ddebb4-5ed2-4ab7-88f5-a2921499a8a8"
      unitRef="usd">1500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense
      contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfMy0xLTEtMS02MTU1OQ_28d3c27c-9122-4331-99a3-4e76bdba2cd1"
      unitRef="usd">300000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfNC0xLTEtMS02MTU1OQ_bba6ab11-af17-4b01-adb5-4969c957886c"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfNS0xLTEtMS02MTU1OQ_13eb5555-5fee-49b3-b859-f1d2c326af80"
      unitRef="usd">300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets
      contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfNi0xLTEtMS02MTU1OQ_883b95c9-9ff6-43c2-9aef-605beceefaca"
      unitRef="usd">800000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfNy0xLTEtMS02MTU1OQ_2a27da1b-7ca2-4a98-807d-badfa9210c59"
      unitRef="usd">54300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfOC0xLTEtMS02MTU1OQ_07e72b24-0da2-4435-87a4-3bb44b926802"
      unitRef="usd">3100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfOS0xLTEtMS02MTU1OQ_f623e634-6b4a-45e7-baa7-4414404d2029"
      unitRef="usd">60400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfMTEtMS0xLTEtNjE1NjI_34045cc8-8fa9-48e9-8a9a-666fd0c101d7"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits
      contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfMTItMS0xLTEtNjE1NjI_269c68d3-7c98-4176-9448-e0093330c8f8"
      unitRef="usd">600000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses
      contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfMTMtMS0xLTEtNjE1NjI_1e0db14f-2244-48cb-bb48-84bb5e48d241"
      unitRef="usd">3400000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities
      contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfMTQtMS0xLTEtNjE1NjI_922060e1-1785-4bc6-af10-97fca6e94ca3"
      unitRef="usd">800000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfMTUtMS0xLTEtNjE1NjI_9b97957d-c41c-439d-9d17-0700573ff2dc"
      unitRef="usd">300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt
      contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfMTYtMS0xLTEtNjE1NjI_4cbfb7f7-fea3-48ba-821a-bc33e39a0ca0"
      unitRef="usd">900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
      contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfMTctMS0xLTEtNjE1NzI_2ab4a90a-bc8d-451d-9874-2bbcaa3e582f"
      unitRef="usd">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfMTgtMS0xLTEtNjE1NjQ_f9e82ef9-3f4b-4074-9373-a025958fac2f"
      unitRef="usd">6300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue
      contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfMTktMS0xLTEtNjE1NzQ_37b25562-cb8d-46db-81bd-52329dd06cbc"
      unitRef="usd">43900000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity
      contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfMjAtMS0xLTEtNjE1Nzc_95a5f3de-c6b3-46e6-a656-126500a85503"
      unitRef="usd">43900000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity
      contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfMjEtMS0xLTEtNjE1Nzc_f5f1bd70-46ed-4d42-b91f-14948d9571bd"
      unitRef="usd">50200000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfMjItMS0xLTEtNjE1NjY_7f4c6db1-a42a-4ad1-9804-43bc12583f8e"
      unitRef="usd">10200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i2df95a1c5f0f44979741b294afe8e34f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfMjMtMS0xLTEtNjE1NjY_d6c1f489-cf0f-46ef-87d1-801d4fc72cc3"
      unitRef="usd">231100000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest
      contextRef="i4708a08b473b41e98f9bf1a3d2fdd50c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RhYmxlOjAwZjI5MjZjOTBkNjRmMDNhNGQ0NGNlMzBhMmFmZWFlL3RhYmxlcmFuZ2U6MDBmMjkyNmM5MGQ2NGYwM2E0ZDQ0Y2UzMGEyYWZlYWVfMjQtMS0xLTEtNjE1NjY_b4f03814-a057-4864-b3b1-c6baf5195688"
      unitRef="usd">241300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ia0cb3457d3634ebab6e8f002cf82c20c_I20210801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNzI0_62ea8540-6528-4223-9b94-77b018031cd3"
      unitRef="usd">28300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="id0b5f88e95e24345a3cc0fc5516016cd_I20210801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNzM5_0fffa9e4-4fff-4498-a635-de6ca93c64c2"
      unitRef="usd">19800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i337a7e831425489abb80a0847c6f2a4b_I20210801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNzU0_d336b993-a915-41a5-ba61-6c0cb75eee3f"
      unitRef="usd">6200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i3ab1ecd500d7495dae3df1070f41f7cb_D20210801-20210801"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNzcz_b98768cd-adaa-4791-8660-256404fc394d">P2Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ib97247344bf049d2bffeb43e431f858c_D20210801-20210801"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwNzkx_c1529efc-5ae8-4ef2-b857-d76976de69f1">P7Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i2df95a1c5f0f44979741b294afe8e34f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwODIx_666a50f5-b373-438d-9de5-8ae9c8284984"
      unitRef="usd">18500000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="i2df95a1c5f0f44979741b294afe8e34f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwODM2_f3548a67-a94a-412a-9d09-87447d322da3"
      unitRef="usd">3000000</amed:DepreciationAndAmortizationForContinuingOperations>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i39143f0cd5e04faf9cb6b93e100ed3a7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwODUw_bf059b46-af06-4f16-bec8-f6b36ff6b3ca"
      unitRef="usd">3500000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="i39143f0cd5e04faf9cb6b93e100ed3a7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNTQ5NzU1ODQwODY0_dd209ec2-f888-4d70-9ecc-8f59d07f8923"
      unitRef="usd">1200000</amed:DepreciationAndAmortizationForContinuingOperations>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i361c6850de2f4f6caca843b2cad888d0_D20211018-20211018"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNDc1Mg_8b03bd63-dea5-46a7-9cf8-a685317124de"
      unitRef="usd">4500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i2ed696897d0041f897bb1b2722b9e756_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNDkwNA_1f18ec0e-1713-42a4-bd01-7ac2f0c2c03a"
      unitRef="usd">4300000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i7063e6037ddf43518429b892fa7cc4a8_I20211018"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV84OC9mcmFnOjc0MWU2N2NkYzczZTQ5NTFhY2Q4YmMyYWUwY2ZiYzEzL3RleHRyZWdpb246NzQxZTY3Y2RjNzNlNDk1MWFjZDhiYzJhZTBjZmJjMTNfNDk1NA_157f6cfa-ad66-4c57-ade3-a36f0ace5b9a"
      unitRef="usd">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90ZXh0cmVnaW9uOjdkM2VmNDhlNTQzZjQ4N2NhMWI2MTA1ODI5ZTZmNDY1XzIwNTY_83c0abd1-1cf8-4c95-892a-26fde01a404a">GOODWILL AND OTHER INTANGIBLE ASSETS, NET&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2022, 2021 and 2020, we did not record any goodwill impairment charges as a result of our annual impairment test and none of the goodwill associated with our reporting units was considered impaired as of October 31st of each respective year (the date of our annual goodwill impairment test). Since the date of our last annual goodwill impairment test, there have been no material developments, events, changes in operating performance or other circumstances that would cause management to believe it is more likely than not that the fair value of any of our reporting units would be less than their carrying amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to our goodwill for 2022 and 2021 (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&#160;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&#160;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;High  Acuity Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balances at December 31, 2020 (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;799.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;932.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;233.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;263.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balances at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;800.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;233.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,196.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;85.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustments (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balances at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;203.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;800.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,287.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Net of prior years' accumulated impairment losses of $733.7 million, which is inclusive of write-offs related to the sale and closure of care centers.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The Company finalized its valuation of the assets acquired, liabilities assumed and noncontrolling interests in connection with the acquisition of Contessa on August 1, 2021. See Note 4 &#x2013; Acquisitions for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Intangible Assets, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2022 and 2021, we did not record any impairment charges related to our other intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to our other intangible assets, net for 2022 and 2021 (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Intangible Assets, Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Certificates of Need and Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquired&lt;br/&gt;Names -Unamortizable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquired&lt;br/&gt;Names -Amortizable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-Compete&lt;br/&gt;Agreements (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Technology (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balances at December 31, 2020 (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclass to amortizable intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balances at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balances at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;101.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Net of prior years' accumulated amortization of $11.5&#160;million for acquired names and $9.0 million for non-compete agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Amortization of certificates of need and licenses is related to care centers that were closed during 2021 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The weighted average remaining amortization period of our amortizable non-compete agreements and technology is 0.6 years and 5.6 years, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated aggregate amortization expense related to intangible assets for each of the five succeeding years is as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.356%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.255%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intangible Asset Amortization&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 4 &#x2013; Acquisitions for further details on additions to goodwill and other intangible assets, net.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90ZXh0cmVnaW9uOjdkM2VmNDhlNTQzZjQ4N2NhMWI2MTA1ODI5ZTZmNDY1XzIwNTg_282300b8-f1c6-44fc-a27a-d1a649e7d876">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to our goodwill for 2022 and 2021 (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&#160;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&#160;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;High  Acuity Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balances at December 31, 2020 (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;799.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;932.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;233.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;263.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balances at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;800.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;233.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,196.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;85.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustments (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balances at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;203.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;800.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,287.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Net of prior years' accumulated impairment losses of $733.7 million, which is inclusive of write-offs related to the sale and closure of care centers.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The Company finalized its valuation of the assets acquired, liabilities assumed and noncontrolling interests in connection with the acquisition of Contessa on August 1, 2021. See Note 4 &#x2013; Acquisitions for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Intangible Assets, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2022 and 2021, we did not record any impairment charges related to our other intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to our other intangible assets, net for 2022 and 2021 (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other Intangible Assets, Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Certificates of Need and Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquired&lt;br/&gt;Names -Unamortizable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Acquired&lt;br/&gt;Names -Amortizable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-Compete&lt;br/&gt;Agreements (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Technology (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balances at December 31, 2020 (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclass to amortizable intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balances at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balances at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;101.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Net of prior years' accumulated amortization of $11.5&#160;million for acquired names and $9.0 million for non-compete agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Amortization of certificates of need and licenses is related to care centers that were closed during 2021 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The weighted average remaining amortization period of our amortizable non-compete agreements and technology is 0.6 years and 5.6 years, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:Goodwill
      contextRef="i51977ad5557047dd858b744031685543_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzItMS0xLTEtNTA3MjU_83b7ed52-3fb8-467c-b50c-b24476d9dccd"
      unitRef="usd">90400000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i2b006d894f5b438ca664557b42c11392_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzItMy0xLTEtNTA3MjU_5ffefbbc-9258-48c0-a0ea-3c310af3cbad"
      unitRef="usd">799200000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i7751bbf329e84761a9116e25c1dcb3c3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzItNS0xLTEtNTA3MjU_a5a2ee01-ca2b-4f7a-b369-d27e2a5cf7a5"
      unitRef="usd">43100000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i200744aa491542f088ed7c2507164bf0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzItNy0xLTEtNTA3MjU_514057fe-10a0-4c20-bbd4-5faf9fa7e528"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i42b1e865f1ed4b2e8363dfcc39186a91_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzItOS0xLTEtNTA3MjU_38cb32e0-6f45-49d4-aab2-aed671368e12"
      unitRef="usd">932700000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i17c7b35f5a01427b9c32a21c25a8f6c0_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzMtMS0xLTEtNTA3MjU_9c10e4fa-7968-4aa3-8b2e-1dff13b48500"
      unitRef="usd">27800000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ic26ea180cb834e98a9002bae772f59e2_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzMtMy0xLTEtNTA3MjU_4e7016e9-57a7-4731-abc3-8194382cf746"
      unitRef="usd">1700000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="if15a919ad56a4337a9e1425b3d811e04_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzMtNS0xLTEtNTA3MjU_1d79682c-d552-4624-b51d-7c76a9426187"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ic803d3d531314ae89f73add64e4be217_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzMtNy0xLTEtNTA3MjU_7dee1b50-8385-4523-8e27-96aa9df07d83"
      unitRef="usd">233900000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzMtOS0xLTEtNTA3MjU_03c0d48d-e13e-4d76-bb9b-f955f8576383"
      unitRef="usd">263400000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:Goodwill
      contextRef="i28bb5f40eceb4433925f35b9ac96a7d6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzQtMS0xLTEtNTA3MjU_227b6990-1647-43ea-ba9c-aa10eb6b56b5"
      unitRef="usd">118200000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i3e7c7cfb405d44b8814669a0483f033c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzQtMy0xLTEtNTA3MjU_6a9ed97c-5f08-40e1-8050-1513eed88b42"
      unitRef="usd">800900000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i279e0b1e700047bf850eaae20ab0fa8f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzQtNS0xLTEtNTA3MjU_0d4dd396-6554-44e3-9a82-3543071a1941"
      unitRef="usd">43100000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i53953caaedb34bb19c4ac51bc0d443fd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzQtNy0xLTEtNTA3MjU_a6058967-37ce-46c4-a122-f5b40951ed0e"
      unitRef="usd">233900000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzQtOS0xLTEtNTA3MjU_2dfb87b9-0824-4a2f-a372-1da468a197a5"
      unitRef="usd">1196100000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ie8d7fbaae8144d01ae5b61ba948ca043_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzUtMS0xLTEtNTA3MjU_bc13da6d-b355-4425-b555-fa9e857dde30"
      unitRef="usd">85600000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i6d7eeb1ee5ac46b29435cfd337b5b8a7_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzUtMy0xLTEtNTA3MjU_679258b2-2f48-4f8e-be4e-2ad0cee80e34"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i306ee8d06e3d4ce9aedc1f8ceaa8c3a6_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzUtNS0xLTEtNTA3MjU_afe90ab0-6503-4c8f-9e46-7dc9c18a504f"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ia8691440b2404ff496cc413ef83e5825_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzUtNy0xLTEtNTA3MjU_974befc3-460d-4ed3-9b30-23045a87b653"
      unitRef="usd">8500000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzUtOS0xLTEtNTA3MjU_8b6d0ad7-2e3e-487d-a1c6-792e518d4edc"
      unitRef="usd">94100000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="ie8d7fbaae8144d01ae5b61ba948ca043_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzYtMS0xLTEtNTYxOTY_adf275a1-41f0-4e71-add0-0569d64533e5"
      unitRef="usd">0</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="i6d7eeb1ee5ac46b29435cfd337b5b8a7_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzYtMy0xLTEtNTYxOTY_66c76cde-2912-4d5d-bbc4-58bb3b3e3d3b"
      unitRef="usd">0</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="i306ee8d06e3d4ce9aedc1f8ceaa8c3a6_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzYtNS0xLTEtNTYxOTY_5454f53d-aadd-4a0f-9f14-f5cb104ddf15"
      unitRef="usd">0</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="ia8691440b2404ff496cc413ef83e5825_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzYtNy0xLTEtNTYxOTY_8fb2601b-6606-4fe2-82d7-af72fd6971d9"
      unitRef="usd">-2800000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzYtOS0xLTEtNTYxOTY_c6b5ea76-049f-44a3-a14b-e1d039429255"
      unitRef="usd">-2800000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:Goodwill
      contextRef="i2f7b8ece18824575809137727a001ab8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzYtMS0xLTEtNTA3MjU_aa8940c8-2c7a-4cc4-8d23-e7923eda5797"
      unitRef="usd">203800000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i4fb0b4ede01d45a8ac9f87b995dfc5bd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzYtMy0xLTEtNTA3MjU_71d53045-df42-4844-9e57-b130933cddcd"
      unitRef="usd">800900000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i466c99d823de4e3da04d3e6d94ea4feb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzYtNS0xLTEtNTA3MjU_a993545b-847e-4f6e-abe9-c2c810253edb"
      unitRef="usd">43100000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ibc62063a43fb4e54a4eb1692d07bbee2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzYtNy0xLTEtNTA3MjU_957e331e-f1db-4a1a-a20e-88c71fd1ee84"
      unitRef="usd">239600000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTplOTdmY2UzZTUyNDg0ZWJiYmZmMjI2NzU5NjNmOTJhNi90YWJsZXJhbmdlOmU5N2ZjZTNlNTI0ODRlYmJiZmYyMjY3NTk2M2Y5MmE2XzYtOS0xLTEtNTA3MjU_259676fb-c938-42e4-8d38-6f0bec4a784f"
      unitRef="usd">1287400000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i42b1e865f1ed4b2e8363dfcc39186a91_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90ZXh0cmVnaW9uOjdkM2VmNDhlNTQzZjQ4N2NhMWI2MTA1ODI5ZTZmNDY1XzgzOA_b109c993-79ca-41d9-bc6a-384ef1b9ec8a"
      unitRef="usd">733700000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i5f5fa4f13a1b44e0bb2bbf24f19d98ee_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzItMS0xLTEtNTA3MjU_e6d1a031-0e80-49c4-b883-5f9e73b6d540"
      unitRef="usd">47000000.0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i44541ba456f945819b774b06105dc6c8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzItMy0xLTEtNTA3MjU_c6bec8e2-2652-4ab3-84ee-6deb3c8e82c2"
      unitRef="usd">13900000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i00a4803566c64d9ab540401d7fabdd92_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzItNS0xLTEtNTA3MjU_9c72b3de-b3d8-4601-9c26-83aaa5a1173b"
      unitRef="usd">5500000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i6d01709de86048228674a5671c0c2757_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzItNy0xLTEtNTA3MjU_d10e74c3-86ae-4de4-b9c4-157aaff4f8fa"
      unitRef="usd">7800000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i07c90a9f4c064c94bff73ae8df530042_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzItOS0xLTEtNTA3MjU_06b400db-d0d5-47c3-89f2-c12cd41bf766"
      unitRef="usd">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i42b1e865f1ed4b2e8363dfcc39186a91_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzItMTEtMS0xLTUwNzI1_aacb2ac7-f0c6-4ff6-8f34-db502f259c03"
      unitRef="usd">74200000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <amed:OtherIntangibleAssetsAdditions
      contextRef="ib63a631603bd42f9baf706aaa6b526b0_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzMtMS0xLTEtNTA3MjU_d2a8be55-204c-4be5-865c-222e7dce440a"
      unitRef="usd">800000</amed:OtherIntangibleAssetsAdditions>
    <amed:OtherIntangibleAssetsAdditions
      contextRef="ifff3b1dd516d4ca88196cc4ffb04052e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzMtMy0xLTEtNTA3MjU_d6d8f681-b571-473b-aa5b-3a00934391d2"
      unitRef="usd">28300000</amed:OtherIntangibleAssetsAdditions>
    <amed:OtherIntangibleAssetsAdditions
      contextRef="ie8422ab7dd1f4a4f8d174c43529c7198_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzMtNS0xLTEtNTA3MjU_41ca6b0b-b9c8-47cc-9d18-b31a6417d727"
      unitRef="usd">0</amed:OtherIntangibleAssetsAdditions>
    <amed:OtherIntangibleAssetsAdditions
      contextRef="ida06184838c44dd1bcfc0a1cfbb4fa09_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzMtNy0xLTEtNTA3MjU_157f2b97-1f9a-4ba8-977d-d7d11830d42f"
      unitRef="usd">6200000</amed:OtherIntangibleAssetsAdditions>
    <amed:OtherIntangibleAssetsAdditions
      contextRef="icfe3ab0bd83e411e92a0dd230a06c08b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzMtOS0xLTEtNTA3MjU_19a96725-0dc9-4da4-ba84-e41944ac9a7e"
      unitRef="usd">20200000</amed:OtherIntangibleAssetsAdditions>
    <amed:OtherIntangibleAssetsAdditions
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzMtMTEtMS0xLTUwNzI1_ae84c463-ba2b-43f7-b793-44ab017338f8"
      unitRef="usd">55500000</amed:OtherIntangibleAssetsAdditions>
    <amed:ReclassToAmortizableIntangible
      contextRef="ib63a631603bd42f9baf706aaa6b526b0_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzQtMS0xLTEtNTA3MjU_a659f5c8-25fb-478a-9f73-8717993c7160"
      unitRef="usd">0</amed:ReclassToAmortizableIntangible>
    <amed:ReclassToAmortizableIntangible
      contextRef="ifff3b1dd516d4ca88196cc4ffb04052e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzQtMy0xLTEtNTA3MjU_354aa50b-4456-4723-b611-7660a1dfe361"
      unitRef="usd">-6600000</amed:ReclassToAmortizableIntangible>
    <amed:ReclassToAmortizableIntangible
      contextRef="ie8422ab7dd1f4a4f8d174c43529c7198_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzQtNS0xLTEtNTA3MjU_54568d0e-49bc-4035-9c99-000fb3e93ba8"
      unitRef="usd">6600000</amed:ReclassToAmortizableIntangible>
    <amed:ReclassToAmortizableIntangible
      contextRef="ida06184838c44dd1bcfc0a1cfbb4fa09_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzQtNy0xLTEtNTA3MjU_1058f206-eb3d-4854-9505-db5f4585086a"
      unitRef="usd">0</amed:ReclassToAmortizableIntangible>
    <amed:ReclassToAmortizableIntangible
      contextRef="icfe3ab0bd83e411e92a0dd230a06c08b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzQtOS0xLTEtNTA3MjU_3a4b7d78-7e23-41df-b60f-8e4fc42f9a77"
      unitRef="usd">0</amed:ReclassToAmortizableIntangible>
    <amed:ReclassToAmortizableIntangible
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzQtMTEtMS0xLTUwNzI1_2341d407-fbdd-410c-8312-d17dc8b044c7"
      unitRef="usd">0</amed:ReclassToAmortizableIntangible>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ib63a631603bd42f9baf706aaa6b526b0_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzUtMS0xLTEtNTA3MjU_d3f0c714-0565-41e4-99bb-3ea7b4ed94cc"
      unitRef="usd">700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ifff3b1dd516d4ca88196cc4ffb04052e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzUtMy0xLTEtNTA3MjU_a8b91859-2213-4691-bbb5-b5c7ce91b445"
      unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ie8422ab7dd1f4a4f8d174c43529c7198_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzUtNS0xLTEtNTA3MjU_72ac8c98-557f-4a95-8fe1-b26253f00538"
      unitRef="usd">9000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ida06184838c44dd1bcfc0a1cfbb4fa09_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzUtNy0xLTEtNTA3MjU_81c6f793-5573-4318-a20c-1ddf53476a68"
      unitRef="usd">7600000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="icfe3ab0bd83e411e92a0dd230a06c08b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzUtOS0xLTEtNTA3MjU_456e88b2-43c4-46d1-a41c-40b7c3252b22"
      unitRef="usd">1200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzUtMTEtMS0xLTUwNzI1_18602160-da70-4276-a687-9315a1512625"
      unitRef="usd">18500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i9523618072184796b42e15f02c400bf6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzYtMS0xLTEtNTA3MjU_2470b8db-bef5-4dc8-af32-1cd82bbfa9e2"
      unitRef="usd">47100000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i4ecf9ee75110493892617267abbac656_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzYtMy0xLTEtNTA3MjU_d625904a-94cc-4330-809d-040c29a3fae1"
      unitRef="usd">35600000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i1b3d453ff35049aca81a81d5e4f888a8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzYtNS0xLTEtNTA3MjU_6fcc1ac6-732e-4c4b-b43b-852fcf612ca6"
      unitRef="usd">3100000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i0f475dca4f124f1595292633d4e5f191_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzYtNy0xLTEtNTA3MjU_1a47c1f9-99f8-49fc-92ef-ccc86f3a5263"
      unitRef="usd">6400000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i7b493d5524cf479ea3603709ff2740c8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzYtOS0xLTEtNTA3MjU_4fb4aead-3029-4b1c-89ee-e61fc6f68e62"
      unitRef="usd">19000000.0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzYtMTEtMS0xLTUwNzI1_4f34eed4-4313-4b22-b5ea-e235487d4b02"
      unitRef="usd">111200000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <amed:OtherIntangibleAssetsAdditions
      contextRef="ied840af486324d3b938d05e97bc6b784_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzctMS0xLTEtNTA3MjU_ec7a3211-3fb5-4e36-a437-a8a2d8b4eeac"
      unitRef="usd">2400000</amed:OtherIntangibleAssetsAdditions>
    <amed:OtherIntangibleAssetsAdditions
      contextRef="i5d8cd69d4e1c45f08f19939d27d4ae62_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzctMy0xLTEtNTA3MjU_63b0f7da-5a66-4d19-a2b5-0deba85fc548"
      unitRef="usd">0</amed:OtherIntangibleAssetsAdditions>
    <amed:OtherIntangibleAssetsAdditions
      contextRef="i3b384340c0b449dc85760ae9232d9127_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzctNS0xLTEtNTA3MjU_baba5448-4436-4222-9966-ae2921047f37"
      unitRef="usd">0</amed:OtherIntangibleAssetsAdditions>
    <amed:OtherIntangibleAssetsAdditions
      contextRef="i839a632511504949957616ab961bc135_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzctNy0xLTEtNTA3MjU_2f29d927-33bd-48d1-b59c-f84f7d69dee8"
      unitRef="usd">0</amed:OtherIntangibleAssetsAdditions>
    <amed:OtherIntangibleAssetsAdditions
      contextRef="i8990c36c1ca24b9b9986a1b57a6b70aa_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzctOS0xLTEtNTA3MjU_963160c5-2817-4dbe-8358-cd6b553a3147"
      unitRef="usd">1100000</amed:OtherIntangibleAssetsAdditions>
    <amed:OtherIntangibleAssetsAdditions
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzctMTEtMS0xLTUwNzI1_f8947d7b-ee84-4a33-ad20-9d5183920119"
      unitRef="usd">3500000</amed:OtherIntangibleAssetsAdditions>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ied840af486324d3b938d05e97bc6b784_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzktMS0xLTEtNTA3MjU_4d870798-4700-4e08-88f5-600ba306c514"
      unitRef="usd">2800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i5d8cd69d4e1c45f08f19939d27d4ae62_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzktMy0xLTEtNTA3MjU_2922cd35-9b43-4f74-98c6-b854df8c328f"
      unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i3b384340c0b449dc85760ae9232d9127_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzktNS0xLTEtNTA3MjU_7be99a1e-535c-4995-8f06-fb0c7908cd2a"
      unitRef="usd">3100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i839a632511504949957616ab961bc135_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzktNy0xLTEtNTA3MjU_2d133fe1-264e-4b24-9777-639dd6f7e2ca"
      unitRef="usd">4600000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i8990c36c1ca24b9b9986a1b57a6b70aa_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzktOS0xLTEtNTA3MjU_7295bad3-a026-4797-9610-62e863a42acf"
      unitRef="usd">3000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzktMTEtMS0xLTUwNzI1_860752bd-ba6a-418e-bf9d-10321d4bd9a2"
      unitRef="usd">13500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i60bbec5fe5254517bcba03cfb32af2a8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzEwLTEtMS0xLTUwNzI1_6edac428-f0a8-4971-aa87-40f048dfec2c"
      unitRef="usd">46700000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ie1fdd03a76db4dd099fcd6639124379e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzEwLTMtMS0xLTUwNzI1_d83f846b-43e7-46ed-a07e-f584d95025a3"
      unitRef="usd">35600000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i60f209194f5e43898d6ddf2a2eef8d68_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzEwLTUtMS0xLTUwNzI1_8cde3960-4594-4ef3-b075-40ac50333628"
      unitRef="usd">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i6e005cf326124f079141ed28e6ca38da_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzEwLTctMS0xLTUwNzI1_21f6721c-14ee-4618-9dbb-81cd0fb1f98a"
      unitRef="usd">1800000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i89dfc092633c4ce0845425c7e17c37c3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzEwLTktMS0xLTUwNzI1_b29b2155-d57c-4012-b663-54c21fd6f8bd"
      unitRef="usd">17100000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZTphNWIxM2Q3NjRhMmI0Yzg2OTNmNjBmMDI3ZWYxYmIyNC90YWJsZXJhbmdlOmE1YjEzZDc2NGEyYjRjODY5M2Y2MGYwMjdlZjFiYjI0XzEwLTExLTEtMS01MDcyNQ_ba75553d-237c-4560-a95d-02e171af01ea"
      unitRef="usd">101200000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i00a4803566c64d9ab540401d7fabdd92_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90ZXh0cmVnaW9uOjdkM2VmNDhlNTQzZjQ4N2NhMWI2MTA1ODI5ZTZmNDY1XzEzMzQ_3c0e57c9-45c8-42de-bf21-3d8f2b47ed74"
      unitRef="usd">11500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6d01709de86048228674a5671c0c2757_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90ZXh0cmVnaW9uOjdkM2VmNDhlNTQzZjQ4N2NhMWI2MTA1ODI5ZTZmNDY1XzEzNjA_abdd45ba-54f1-4563-875b-176d5c52edb5"
      unitRef="usd">9000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i839a632511504949957616ab961bc135_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90ZXh0cmVnaW9uOjdkM2VmNDhlNTQzZjQ4N2NhMWI2MTA1ODI5ZTZmNDY1XzE3Njk_1a97e161-dc50-4137-9442-2422e67fdc10">P0Y7M6D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i8990c36c1ca24b9b9986a1b57a6b70aa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90ZXh0cmVnaW9uOjdkM2VmNDhlNTQzZjQ4N2NhMWI2MTA1ODI5ZTZmNDY1XzE3NzY_f978f665-a534-48f8-94ec-756a75e6e8eb">P5Y7M6D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90ZXh0cmVnaW9uOjdkM2VmNDhlNTQzZjQ4N2NhMWI2MTA1ODI5ZTZmNDY1XzIwNjQ_8b306140-d8ea-4172-9986-b2b89606a142">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated aggregate amortization expense related to intangible assets for each of the five succeeding years is as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.356%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.255%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intangible Asset Amortization&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 4 &#x2013; Acquisitions for further details on additions to goodwill and other intangible assets, net.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZToyMjI1NTVjZmUxN2Q0NDhhOTE4NDAxMjJmNWUyZjZjOC90YWJsZXJhbmdlOjIyMjU1NWNmZTE3ZDQ0OGE5MTg0MDEyMmY1ZTJmNmM4XzEtMS0xLTEtNTA3MjU_9b22a163-d789-41b0-b5d0-d9e0928fd91f"
      unitRef="usd">4800000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZToyMjI1NTVjZmUxN2Q0NDhhOTE4NDAxMjJmNWUyZjZjOC90YWJsZXJhbmdlOjIyMjU1NWNmZTE3ZDQ0OGE5MTg0MDEyMmY1ZTJmNmM4XzItMS0xLTEtNTA3MjU_778b5da6-0c3e-4511-9f4f-5686ef0d2458"
      unitRef="usd">3000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZToyMjI1NTVjZmUxN2Q0NDhhOTE4NDAxMjJmNWUyZjZjOC90YWJsZXJhbmdlOjIyMjU1NWNmZTE3ZDQ0OGE5MTg0MDEyMmY1ZTJmNmM4XzMtMS0xLTEtNTA3MjU_bc8ae05c-1636-4496-b30b-77dee72086a4"
      unitRef="usd">3000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZToyMjI1NTVjZmUxN2Q0NDhhOTE4NDAxMjJmNWUyZjZjOC90YWJsZXJhbmdlOjIyMjU1NWNmZTE3ZDQ0OGE5MTg0MDEyMmY1ZTJmNmM4XzQtMS0xLTEtNTA3MjU_ab27d3d5-afd4-404c-9b57-aae362822067"
      unitRef="usd">3000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZToyMjI1NTVjZmUxN2Q0NDhhOTE4NDAxMjJmNWUyZjZjOC90YWJsZXJhbmdlOjIyMjU1NWNmZTE3ZDQ0OGE5MTg0MDEyMmY1ZTJmNmM4XzUtMS0xLTEtNTA3MjU_7f40f172-416d-4ca8-b27b-5ce5c7c767de"
      unitRef="usd">3000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDAvZnJhZzo3ZDNlZjQ4ZTU0M2Y0ODdjYTFiNjEwNTgyOWU2ZjQ2NS90YWJsZToyMjI1NTVjZmUxN2Q0NDhhOTE4NDAxMjJmNWUyZjZjOC90YWJsZXJhbmdlOjIyMjU1NWNmZTE3ZDQ0OGE5MTg0MDEyMmY1ZTJmNmM4XzYtMS0xLTEtNTA3MjU_38adf0b5-ab7c-41d9-b99e-a929d5f88bd8"
      unitRef="usd">16800000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGV4dHJlZ2lvbjozN2MxYzkzNjRkYjU0MmZjYTgzYmMxN2JiODYyOWFhMl81NDk3NTU4MTQ1MTc_97b69e73-b982-4b9f-baf1-fd9778ae4b18">ASSETS HELD FOR SALE&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 10, 2023, we signed a definitive agreement to sell our personal care business (excluding the Florida operations) for a purchase price of $50&#160;million. The divestment is expected to close during the second quarter of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of the assets and liabilities associated with our personal care reporting unit (which approximate fair value) included in our consolidated balance sheets are as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.725%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="i21a308e1f5cd4afdbceafc5966fb3595_I20230210"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGV4dHJlZ2lvbjozN2MxYzkzNjRkYjU0MmZjYTgzYmMxN2JiODYyOWFhMl81NDk3NTU4MTQ1MjA_3a430021-93d0-4964-805c-e9c1563f3f96"
      unitRef="usd">50000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGV4dHJlZ2lvbjozN2MxYzkzNjRkYjU0MmZjYTgzYmMxN2JiODYyOWFhMl81NDk3NTU4MTQ1MTg_01ae8929-d8b6-43ba-a630-5dd69f5126e9">The carrying amount of the assets and liabilities associated with our personal care reporting unit (which approximate fair value) included in our consolidated balance sheets are as follows (amounts in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.725%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
      contextRef="i466c99d823de4e3da04d3e6d94ea4feb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8zLTEtMS0xLTYyMTYx_f0748a3e-6942-4544-a058-368ea9bec7c9"
      unitRef="usd">9600000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
      contextRef="i279e0b1e700047bf850eaae20ab0fa8f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8zLTMtMS0xLTYyMTg4_458b7416-a326-4b32-af73-8c64ae20f664"
      unitRef="usd">8700000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
      contextRef="i466c99d823de4e3da04d3e6d94ea4feb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV80LTEtMS0xLTYyMTY2_309f6b18-7512-439d-a5ab-e1e43fd5dc96"
      unitRef="usd">100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
      contextRef="i279e0b1e700047bf850eaae20ab0fa8f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV80LTMtMS0xLTYyMTg4_9bec1390-492a-4ce3-9996-934fd5c5cc86"
      unitRef="usd">100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i466c99d823de4e3da04d3e6d94ea4feb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV81LTEtMS0xLTYyMTY2_4ed7c14c-da5c-4659-ae46-a3a43fa34968"
      unitRef="usd">9700000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i279e0b1e700047bf850eaae20ab0fa8f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV81LTMtMS0xLTYyMTg4_5fd2fe89-2bf7-48aa-9ad3-7d061fe23043"
      unitRef="usd">8800000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent
      contextRef="i466c99d823de4e3da04d3e6d94ea4feb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV82LTEtMS0xLTYyMTY2_c633498f-ab76-45f2-9944-e00c50f27e08"
      unitRef="usd">100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent
      contextRef="i279e0b1e700047bf850eaae20ab0fa8f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV82LTMtMS0xLTYyMTg4_bf7556ec-1eac-42e6-89f7-30d8af00922f"
      unitRef="usd">200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent>
    <amed:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent
      contextRef="i466c99d823de4e3da04d3e6d94ea4feb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV83LTEtMS0xLTYyMTY2_85fc16b6-31cf-4c61-b501-19002953be18"
      unitRef="usd">2500000</amed:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent>
    <amed:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent
      contextRef="i279e0b1e700047bf850eaae20ab0fa8f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV83LTMtMS0xLTYyMTg4_445717dc-b966-445b-b82a-d03bb647ba05"
      unitRef="usd">2800000</amed:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent
      contextRef="i466c99d823de4e3da04d3e6d94ea4feb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV84LTEtMS0xLTYyMTY2_d3a60b1d-4bb0-4cce-91e0-8164a3b19bcc"
      unitRef="usd">43100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent
      contextRef="i279e0b1e700047bf850eaae20ab0fa8f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV84LTMtMS0xLTYyMTg4_52c909a7-5d42-4b3f-99ea-8a7d7a948726"
      unitRef="usd">43100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent
      contextRef="i466c99d823de4e3da04d3e6d94ea4feb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV85LTEtMS0xLTYyMTY2_c914ad6d-f9de-4a6c-8372-f971c591b43f"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent
      contextRef="i279e0b1e700047bf850eaae20ab0fa8f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV85LTMtMS0xLTYyMTg4_997590ea-cd14-4479-8ca2-8acf346cb38c"
      unitRef="usd">1800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="i466c99d823de4e3da04d3e6d94ea4feb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8xMS0xLTEtMS02MjE2Ng_222434e1-3079-45b9-b8cb-6dfb3c161627"
      unitRef="usd">55400000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="i279e0b1e700047bf850eaae20ab0fa8f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8xMS0zLTEtMS02MjE4OA_05e8e791-5649-4c48-bb8f-2bb1ce08bc11"
      unitRef="usd">56700000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent
      contextRef="i466c99d823de4e3da04d3e6d94ea4feb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8xNC0xLTEtMS02MjE2OA_3938cc52-e84f-425f-9bbf-b776c86bec32"
      unitRef="usd">400000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent
      contextRef="i279e0b1e700047bf850eaae20ab0fa8f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8xNC0zLTEtMS02MjE4OA_4ee2081d-24b0-47d2-954e-8c1fe84163d3"
      unitRef="usd">300000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent>
    <amed:DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent
      contextRef="i466c99d823de4e3da04d3e6d94ea4feb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8xNS0xLTEtMS02MjE2OA_1f96a838-2841-4f0c-bab4-81e52d72f91a"
      unitRef="usd">600000</amed:DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent>
    <amed:DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent
      contextRef="i279e0b1e700047bf850eaae20ab0fa8f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8xNS0zLTEtMS02MjE4OA_a24db23c-7df7-488e-8aa1-e60490ae4535"
      unitRef="usd">2500000</amed:DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent>
    <amed:DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent
      contextRef="i466c99d823de4e3da04d3e6d94ea4feb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8xNi0xLTEtMS02MjE2OA_1b32c71c-8926-4143-93b2-d25f5fafa1a1"
      unitRef="usd">1800000</amed:DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent>
    <amed:DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent
      contextRef="i279e0b1e700047bf850eaae20ab0fa8f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8xNi0zLTEtMS02MjE4OA_71eb62c6-e73e-4165-9f43-e3044c3baab1"
      unitRef="usd">100000</amed:DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent>
    <amed:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent
      contextRef="i466c99d823de4e3da04d3e6d94ea4feb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8xOC0xLTEtMS02MjE2OA_e5035e71-33be-4909-8425-6f194b59faa7"
      unitRef="usd">600000</amed:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent>
    <amed:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent
      contextRef="i279e0b1e700047bf850eaae20ab0fa8f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8xOC0zLTEtMS02MjE4OA_8d026fe2-dd23-4b3d-b802-bf7e60a42d53"
      unitRef="usd">700000</amed:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i466c99d823de4e3da04d3e6d94ea4feb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8xOS0xLTEtMS02MjE2OA_1b3ff10b-a4ae-4ba5-acb7-3684de5b5c76"
      unitRef="usd">3400000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i279e0b1e700047bf850eaae20ab0fa8f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8xOS0zLTEtMS02MjE4OA_b2629056-1408-446b-80cf-33e1fa35d66c"
      unitRef="usd">3600000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <amed:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent
      contextRef="i466c99d823de4e3da04d3e6d94ea4feb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8yMS0xLTEtMS02MjE2OA_010e83b6-7ee4-43bc-ae3e-436a541c37d6"
      unitRef="usd">1900000</amed:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent>
    <amed:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent
      contextRef="i279e0b1e700047bf850eaae20ab0fa8f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8yMS0zLTEtMS02MjE4OA_5d347a27-fc2e-424a-8a16-1e7ef4cc6748"
      unitRef="usd">2200000</amed:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="i466c99d823de4e3da04d3e6d94ea4feb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8yMi0xLTEtMS02MjE2OA_ec4d7f7e-1b9d-4c5f-ab6b-6acd34b3bb87"
      unitRef="usd">5300000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="i279e0b1e700047bf850eaae20ab0fa8f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNzc0L2ZyYWc6MzdjMWM5MzY0ZGI1NDJmY2E4M2JjMTdiYjg2MjlhYTIvdGFibGU6ZTk1NDk0M2NiMWQyNGFhZWE1ZDJhYWFkYzQ2OTQzZmEvdGFibGVyYW5nZTplOTU0OTQzY2IxZDI0YWFlYTVkMmFhYWRjNDY5NDNmYV8yMi0zLTEtMS02MjE4OA_92803c4a-8fb1-4262-941e-b3260a9aedad"
      unitRef="usd">5800000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <amed:DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90ZXh0cmVnaW9uOjMwZjc4NTc2MjZkNTQxYmJhZTg2OTFmMmM0ZWVmNjQ3XzE3NA_78b0ca87-b39b-4548-942b-127f342b5763">DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additional information regarding certain balance sheet accounts is presented below (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As&#160;of&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payroll tax escrow&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due from joint ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Health insurance deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other miscellaneous deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indemnity receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Health insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Florida ZPIC audit, gross liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Legal settlements and other audits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Charity care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated Medicare cap liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Hospice accruals (room and board, general in-patient and other)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Patient and payor liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reserve for uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90ZXh0cmVnaW9uOjMwZjc4NTc2MjZkNTQxYmJhZTg2OTFmMmM0ZWVmNjQ3XzE2MA_decd02bc-5fff-4e10-ab83-5b7d944d930e">&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additional information regarding certain balance sheet accounts is presented below (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As&#160;of&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payroll tax escrow&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due from joint ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Health insurance deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other miscellaneous deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indemnity receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Health insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Florida ZPIC audit, gross liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Legal settlements and other audits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Charity care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated Medicare cap liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Hospice accruals (room and board, general in-patient and other)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Patient and payor liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reserve for uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90ZXh0cmVnaW9uOjMwZjc4NTc2MjZkNTQxYmJhZTg2OTFmMmM0ZWVmNjQ3XzE2Mg_ee6f1818-c60b-4215-8c13-71039cbae4c8">&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additional information regarding certain balance sheet accounts is presented below (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As&#160;of&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payroll tax escrow&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due from joint ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Health insurance deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other miscellaneous deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indemnity receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Health insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Florida ZPIC audit, gross liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Legal settlements and other audits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Charity care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated Medicare cap liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Hospice accruals (room and board, general in-patient and other)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Patient and payor liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reserve for uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90ZXh0cmVnaW9uOjMwZjc4NTc2MjZkNTQxYmJhZTg2OTFmMmM0ZWVmNjQ3XzE2Mw_c373b5be-0ce4-473e-a795-7eca7f67781a">&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additional information regarding certain balance sheet accounts is presented below (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As&#160;of&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payroll tax escrow&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due from joint ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Health insurance deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other miscellaneous deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indemnity receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Health insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Florida ZPIC audit, gross liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Legal settlements and other audits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Charity care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated Medicare cap liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Hospice accruals (room and board, general in-patient and other)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Patient and payor liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reserve for uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:ScheduleOfOtherAssetsTableTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90ZXh0cmVnaW9uOjMwZjc4NTc2MjZkNTQxYmJhZTg2OTFmMmM0ZWVmNjQ3XzE3NQ_f8668efe-eeec-4dfc-94b5-f667858a3cd1">&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additional information regarding certain balance sheet accounts is presented below (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As&#160;of&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payroll tax escrow&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due from joint ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation deposits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Health insurance deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other miscellaneous deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indemnity receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Health insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Florida ZPIC audit, gross liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Legal settlements and other audits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Charity care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated Medicare cap liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Hospice accruals (room and board, general in-patient and other)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Patient and payor liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reserve for uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherAssetsTableTextBlock>
    <amed:PayrollTaxEscrow
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzMtMS0xLTEtNTA3MjU_e2cc6b05-ea06-4b4f-af40-c08085d58cd2"
      unitRef="usd">7600000</amed:PayrollTaxEscrow>
    <amed:PayrollTaxEscrow
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzMtMy0xLTEtNTA3MjU_0520a091-8482-47db-8d16-b63b818b93a8"
      unitRef="usd">7900000</amed:PayrollTaxEscrow>
    <us-gaap:IncomeTaxesReceivable
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzQtMS0xLTEtNTA3MjU_8c7941df-db79-4af2-b12f-7d5bcb27392e"
      unitRef="usd">8800000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzQtMy0xLTEtNTA3MjU_36caa656-e8ae-4cd1-a101-105be273579b"
      unitRef="usd">8200000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:DueFromJointVenturesCurrent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzUtMS0xLTEtNTA3MjU_699f833c-cc3d-405f-9a15-e4baa2db05e3"
      unitRef="usd">3600000</us-gaap:DueFromJointVenturesCurrent>
    <us-gaap:DueFromJointVenturesCurrent
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzUtMy0xLTEtNTA3MjU_d9874756-b221-44b5-b968-0c1e3441db29"
      unitRef="usd">3900000</us-gaap:DueFromJointVenturesCurrent>
    <us-gaap:OtherAssetsMiscellaneousCurrent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzYtMS0xLTEtNTA3MjU_49401d64-49f3-4264-b984-5e5f3353b17a"
      unitRef="usd">6400000</us-gaap:OtherAssetsMiscellaneousCurrent>
    <us-gaap:OtherAssetsMiscellaneousCurrent
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzYtMy0xLTEtNTA3MjU_14decf36-bda9-4214-a3a4-26248ee51afb"
      unitRef="usd">5600000</us-gaap:OtherAssetsMiscellaneousCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzctMS0xLTEtNTA3MjU_e1c2daa0-acb2-4824-8d2f-16873bb1f0e8"
      unitRef="usd">26400000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzctMy0xLTEtNTA3MjU_196edc4e-f8f1-40d6-a55b-b81de44eb20b"
      unitRef="usd">25600000</us-gaap:OtherAssetsCurrent>
    <amed:WorkersCompensationDeposits
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzktMS0xLTEtNTA3MjU_90e1d755-6976-4d0b-8263-a62289182220"
      unitRef="usd">300000</amed:WorkersCompensationDeposits>
    <amed:WorkersCompensationDeposits
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzktMy0xLTEtNTA3MjU_c38d3933-7427-442f-8d38-93b4f67ff96d"
      unitRef="usd">300000</amed:WorkersCompensationDeposits>
    <amed:HealthInsuranceDeposits
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzEwLTEtMS0xLTUwNzI1_8b96ae49-9f2b-440b-8ec3-33154730a819"
      unitRef="usd">900000</amed:HealthInsuranceDeposits>
    <amed:HealthInsuranceDeposits
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzEwLTMtMS0xLTUwNzI1_178385b7-b9f4-44dd-b266-e35e3c02ac98"
      unitRef="usd">900000</amed:HealthInsuranceDeposits>
    <amed:OtherMiscellaneousDeposits
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzExLTEtMS0xLTUwNzI1_179e0877-921b-486c-b180-22ef67bcbd3f"
      unitRef="usd">1000000.0</amed:OtherMiscellaneousDeposits>
    <amed:OtherMiscellaneousDeposits
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzExLTMtMS0xLTUwNzI1_b99ed426-c4e1-4584-8c6f-04e719bd9cb7"
      unitRef="usd">1100000</amed:OtherMiscellaneousDeposits>
    <us-gaap:LossContingencyReceivableNoncurrent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzEyLTEtMS0xLTUwNzI1_2218b6bb-ab4b-4e03-bc0f-568c26ff75a8"
      unitRef="usd">13600000</us-gaap:LossContingencyReceivableNoncurrent>
    <us-gaap:LossContingencyReceivableNoncurrent
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzEyLTMtMS0xLTUwNzI1_242ddc5c-6073-4179-a987-c4982af320de"
      unitRef="usd">13600000</us-gaap:LossContingencyReceivableNoncurrent>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzEzLTEtMS0xLTUwNzI1_ee63ef27-958f-4cc5-9e75-17d63228d1a2"
      unitRef="usd">40500000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzEzLTMtMS0xLTUwNzI1_c434d4bf-487f-43f5-8452-ad078f7305f3"
      unitRef="usd">48100000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzE0LTEtMS0xLTYxNjQ4_edc72b29-bc40-423a-9afa-259ae3d58448"
      unitRef="usd">20000000.0</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzE0LTMtMS0xLTYxNjQ4_0fd9b778-1163-4e0b-bd2a-386c766aaea5"
      unitRef="usd">5000000.0</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzE0LTEtMS0xLTUwNzI1_72927b8d-449b-4fc0-a5a7-261ae1d1d233"
      unitRef="usd">3500000</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzE0LTMtMS0xLTUwNzI1_a2d9dd45-4b5e-4f5d-ad11-6971f74d38ed"
      unitRef="usd">4000000.0</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzE1LTEtMS0xLTUwNzI1_99bac1a2-1594-4ee4-bc83-7f0a61f2db3f"
      unitRef="usd">79800000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzE1LTMtMS0xLTUwNzI1_08aec01f-d969-4147-99b3-48bc0350f929"
      unitRef="usd">73000000.0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AccruedInsuranceCurrent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzE3LTEtMS0xLTUwNzI1_f6552c82-d5b5-4c13-afb5-bf1ca7a66114"
      unitRef="usd">16200000</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:AccruedInsuranceCurrent
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzE3LTMtMS0xLTUwNzI1_43f1b3e4-f586-4817-9f18-ca1b0ac905eb"
      unitRef="usd">16200000</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzE4LTEtMS0xLTUwNzI1_45085d0b-191b-4179-b144-ce138d44e906"
      unitRef="usd">40600000</us-gaap:WorkersCompensationLiabilityCurrent>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzE4LTMtMS0xLTUwNzI1_9e724986-8e21-4c2a-9a9a-c4952eb8fe1b"
      unitRef="usd">40300000</us-gaap:WorkersCompensationLiabilityCurrent>
    <amed:ProvisionForLiabilityOnRegulatoryAudit
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzE5LTEtMS0xLTUwNzI1_b226eaf1-f337-46ef-91c1-49df4624b9d7"
      unitRef="usd">0</amed:ProvisionForLiabilityOnRegulatoryAudit>
    <amed:ProvisionForLiabilityOnRegulatoryAudit
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzE5LTMtMS0xLTUwNzI1_4fda7704-4c20-4b9c-bbdb-08cfa0c715cc"
      unitRef="usd">17400000</amed:ProvisionForLiabilityOnRegulatoryAudit>
    <amed:LegalAndOtherSettlements
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzIwLTEtMS0xLTUwNzI1_f9cc3367-1efb-475c-b743-dc31c3f0da03"
      unitRef="usd">32100000</amed:LegalAndOtherSettlements>
    <amed:LegalAndOtherSettlements
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzIwLTMtMS0xLTUwNzI1_2e1d9a8f-28d8-40be-9100-4624c6f31ece"
      unitRef="usd">27500000</amed:LegalAndOtherSettlements>
    <amed:CharityCare
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzIxLTEtMS0xLTUwNzI1_621d043d-b4b0-45ec-b4bd-4498e89cbd0c"
      unitRef="usd">1900000</amed:CharityCare>
    <amed:CharityCare
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzIxLTMtMS0xLTUwNzI1_ec3c0f84-959a-4fbb-a056-9c41ad61b085"
      unitRef="usd">1400000</amed:CharityCare>
    <amed:EstimatedMedicareCapLiability
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzIyLTEtMS0xLTUwNzI1_d7144eb5-501d-4c2c-a50b-21224367c9b7"
      unitRef="usd">4300000</amed:EstimatedMedicareCapLiability>
    <amed:EstimatedMedicareCapLiability
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzIyLTMtMS0xLTUwNzI1_272e2cb8-97ed-4804-a520-03b31736779a"
      unitRef="usd">4500000</amed:EstimatedMedicareCapLiability>
    <amed:HospiceAccruals
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzIzLTEtMS0xLTUwNzI1_14491b9d-c39e-4064-a495-03321aa6a98a"
      unitRef="usd">19100000</amed:HospiceAccruals>
    <amed:HospiceAccruals
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzIzLTMtMS0xLTUwNzI1_209f754e-7c16-4500-9836-739757a582a6"
      unitRef="usd">23600000</amed:HospiceAccruals>
    <amed:PatientLiability
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzI1LTEtMS0xLTUwNzI1_6f90a3bf-5153-4340-9af1-f3c72f1f5de2"
      unitRef="usd">6700000</amed:PatientLiability>
    <amed:PatientLiability
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzI1LTMtMS0xLTUwNzI1_6dd8b36c-92d6-4aaa-8bbf-00675c3b8465"
      unitRef="usd">6000000.0</amed:PatientLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzI3LTEtMS0xLTYxNjc1_06b3e83b-9da9-44ce-840b-8d1cfd4fcdd6"
      unitRef="usd">10500000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzI3LTMtMS0xLTYxNjc1_554a9407-a2f2-4a63-b742-6d6c002042bc"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <amed:AccruedInterest
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzI4LTEtMS0xLTYxNjc1_69390625-d8f4-4115-b8ba-dee4c332ecd2"
      unitRef="usd">200000</amed:AccruedInterest>
    <amed:AccruedInterest
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzI4LTMtMS0xLTYxNjc1_e465a3b4-4f8c-4f84-87d2-4ad0c5f723f0"
      unitRef="usd">8100000</amed:AccruedInterest>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzI3LTEtMS0xLTUwNzI1_01c986c2-4ebf-43e7-b3ca-442decb831ea"
      unitRef="usd">5800000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzI3LTMtMS0xLTUwNzI1_46f1f2f4-d77c-4f4f-aa2d-337e1da57db4"
      unitRef="usd">5800000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzI4LTEtMS0xLTUwNzI1_6809b42d-d883-453d-95be-94c1192aa889"
      unitRef="usd">137400000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzI4LTMtMS0xLTUwNzI1_2b50eb8d-6da5-44fb-9c85-e116e2b2e528"
      unitRef="usd">150800000</us-gaap:AccruedLiabilitiesCurrent>
    <amed:UncertainTaxBenefitsInLongTermObligations
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzMwLTEtMS0xLTUwNzI1_7164092a-9ab6-47ca-82b1-73b19fc30742"
      unitRef="usd">0</amed:UncertainTaxBenefitsInLongTermObligations>
    <amed:UncertainTaxBenefitsInLongTermObligations
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzMwLTMtMS0xLTUwNzI1_2c31df23-1a5e-45c8-8b25-d0b81f419a0b"
      unitRef="usd">3400000</amed:UncertainTaxBenefitsInLongTermObligations>
    <amed:DeferredCompensationPlanLiability
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzMxLTEtMS0xLTUwNzI1_6f9d3a21-cca0-4797-a56e-db42e410bed9"
      unitRef="usd">600000</amed:DeferredCompensationPlanLiability>
    <amed:DeferredCompensationPlanLiability
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzMxLTMtMS0xLTUwNzI1_27e7468c-eb43-4067-8cb4-63b5ec093bf2"
      unitRef="usd">1000000.0</amed:DeferredCompensationPlanLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzMxLTEtMS0xLTYwMTA5_a2e2ee52-5ae2-4689-bed1-4ccf6a82cb64"
      unitRef="usd">3200000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzMxLTMtMS0xLTYwMTA5_d9e91417-c3f3-4978-98e9-3b1ff4d53054"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:OtherSundryLiabilitiesNoncurrent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzMzLTEtMS0xLTUwNzI1_bcf3c89b-9c65-492d-a278-6159ae913b02"
      unitRef="usd">1000000.0</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherSundryLiabilitiesNoncurrent
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzMzLTMtMS0xLTUwNzI1_c466ab8e-eac2-4a98-9d7b-040f655ea1d9"
      unitRef="usd">600000</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzM0LTEtMS0xLTUwNzI1_a6d4d442-62a9-4da0-883c-47e7dfa1a310"
      unitRef="usd">4800000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDMvZnJhZzozMGY3ODU3NjI2ZDU0MWJiYWU4NjkxZjJjNGVlZjY0Ny90YWJsZTo0NTcxYTIyNjZmMjY0Nzg0YTlmNDc1Y2M4NDY4ZGU3ZS90YWJsZXJhbmdlOjQ1NzFhMjI2NmYyNjQ3ODRhOWY0NzVjYzg0NjhkZTdlXzM0LTMtMS0xLTUwNzI1_23e49173-27ca-4d31-b640-21525f910f84"
      unitRef="usd">5000000.0</us-gaap:OtherLiabilitiesNoncurrent>
    <amed:LesseeLeasesTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90ZXh0cmVnaW9uOmJiNDEwNTZmMDg4MjQ1MTA5YTBlMWZmY2IxMGRiN2U2XzM5Mzg_e8a91122-b0fc-43b7-a4c8-3ebe0a91b65a">LEASES&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine whether an arrangement is a lease at inception. We have operating leases, primarily for offices and fleet, that expire at various dates over the next seven years. We have finance leases covering certain office equipment that expire at various dates over the next three years. Our leases do not contain any restrictive covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our office leases generally contain renewal options for periods ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90ZXh0cmVnaW9uOmJiNDEwNTZmMDg4MjQ1MTA5YTBlMWZmY2IxMGRiN2U2XzQyMw_4521311a-fbff-4d4f-a200-9de841dcd915"&gt;one&lt;/span&gt; to five years. Because we are not reasonably certain to exercise these renewal options, the options are not considered in determining the lease term, and payments associated with the option years are excluded from lease payments. Our office leases also generally include termination options, which allow for early termination of the lease after the first one to three years. Because we are not reasonably certain to exercise these termination options, the options are not considered in determining the lease term; payments for the full lease term are included in lease payments. Our office leases do not contain any material residual value guarantees.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our fleet leases include a term of 367 days with monthly renewal options thereafter. Our fleet leases also include terminal rental adjustment clauses (&#x201c;TRAC&#x201d;), which provide for a final rental payment adjustment at the end of the lease, typically based on &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the amount realized from the sale of the vehicle. The TRAC is structured such that it will almost always result in a significant payment by us to the lessor if the renewal option is not exercised. Based on the significance of the TRAC adjustment at the initial lease expiration, we believe that it is reasonably certain that we will exercise the monthly renewal options; therefore, the renewal options are considered in determining the lease term, and payments associated with the renewal options are included in lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our fleet and office equipment leases, we use the implicit rate in the lease as the discount rate. For our office leases, the implicit rate is typically not available, so we use our incremental borrowing rate as the discount rate. Our lease agreements include both lease and non-lease components. We have elected the practical expedient that allows us to not separate lease and non-lease components for all of our leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments due under our operating and finance leases include fixed payments as well as variable payments. For our office leases, variable payments include amounts for our proportionate share of operating expenses, utilities, property taxes, insurance, common area maintenance and other facility-related expenses. For our vehicle and equipment leases, variable payments consist of sales tax. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease cost for the years ended December 31, 2022 and 2021 are as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of operating lease ROU assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on termination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of ROU assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts reported in the consolidated balance sheets as of December 31, 2022 and 2021 for our operating leases are as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, less current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts reported in the consolidated balance sheets as of December 31, 2022 and 2021 for finance leases are included in the table below. The finance lease ROU assets are recorded within property and equipment, net of accumulated depreciation within our consolidated balance sheets. The finance lease liabilities are recorded within current portion of long-term obligations and long-term obligations, less current portion within our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease ROU assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease ROU assets, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current installments of obligations under finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzYtMS0xLTEtNTA3MjU_1eca02a9-f1dd-4c12-b3b8-0c54b6fd691a"&gt;1.2&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzYtMy0xLTEtNTA3MjU_8d1038d1-419b-4128-8314-0aa1a5467841"&gt;0.9&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion of obligations under finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzctMS0xLTEtNTA3MjU_a814e167-8383-4d45-81ca-86cc22f5c011"&gt;1.1&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzctMy0xLTEtNTA3MjU_89a632c7-217b-411e-a52c-c18cee261893"&gt;0.7&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzgtMS0xLTEtNTA3MjU_12d2aa00-0042-4307-aa11-8f39561b8e9d"&gt;2.3&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzgtMy0xLTEtNTA3MjU_15a6bc06-843b-4c48-b58a-8be83b9c35ba"&gt;1.6&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information and non-cash activity related to our leases are as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities and ROU assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flow from operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flow from finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions to ROU assets resulting from reductions to lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts disclosed for ROU assets obtained in exchange for lease obligations include amounts added to the carrying amount of ROU assets resulting from lease modifications and reassessments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average remaining lease terms and discount rates for our leases as of December 31, 2022 and 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of December 31, 2022 are as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.154%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating &lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance &lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzktMy0xLTEtNTA3MjU_99acfacd-090d-4833-8cd5-0990e12d974a"&gt;2.3&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:LesseeLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90ZXh0cmVnaW9uOmJiNDEwNTZmMDg4MjQ1MTA5YTBlMWZmY2IxMGRiN2U2XzE3OQ_218982f2-799d-42d6-b0e2-521b80b271fe">P7Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90ZXh0cmVnaW9uOmJiNDEwNTZmMDg4MjQ1MTA5YTBlMWZmY2IxMGRiN2U2XzI4OA_e569afb7-baff-4646-bf95-bc2873273209">P3Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="iabc17e0bc0164f2ab68e1dacdbd3fa3a_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90ZXh0cmVnaW9uOmJiNDEwNTZmMDg4MjQ1MTA5YTBlMWZmY2IxMGRiN2U2XzQyOQ_caeaf1b2-d76e-4584-99de-f7c8f76ab3ca">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i242800e8bae14013ad55b6c47fc0d95c_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90ZXh0cmVnaW9uOmJiNDEwNTZmMDg4MjQ1MTA5YTBlMWZmY2IxMGRiN2U2XzExMDY_92709c4b-99dd-481f-b119-67823d5420f4">P367D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90ZXh0cmVnaW9uOmJiNDEwNTZmMDg4MjQ1MTA5YTBlMWZmY2IxMGRiN2U2XzM5NDU_442dd02c-1064-47e3-b733-7e4281de1efc">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease cost for the years ended December 31, 2022 and 2021 are as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment of operating lease ROU assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on termination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of ROU assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzMtMS0xLTEtNTA3MjU_63a66bcc-e595-4e56-bf3c-906adc25b4e4"
      unitRef="usd">43900000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzMtMy0xLTEtNTA3MjU_599ca56a-3bd3-434e-a40f-201105ee3f53"
      unitRef="usd">40300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzQtMS0xLTEtNTA3MjU_6ee6c723-846f-47ce-9ad6-9769f42001c8"
      unitRef="usd">2100000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzQtMy0xLTEtNTA3MjU_43584910-2557-4abf-b709-5093e59d39e2"
      unitRef="usd">100000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseCost
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzUtMS0xLTEtNTA3MjU_ddfde720-eeac-423d-84fe-11d445e7ffd6"
      unitRef="usd">46000000.0</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzUtMy0xLTEtNTA3MjU_cd65656f-962c-4db6-9360-d8ec71f65ae7"
      unitRef="usd">40400000</us-gaap:OperatingLeaseCost>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzgtMS0xLTEtNTU2NTk_cb6a75cd-c348-4b94-ba08-42ff684758e8"
      unitRef="usd">500000</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzgtMy0xLTEtNTU2NTk_05987a37-216d-40a9-8826-eb94c64d1bb8"
      unitRef="usd">0</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzgtMS0xLTEtNTA3MjU_4b2be9db-91c0-4167-a470-11ec11f4ca79"
      unitRef="usd">1800000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzgtMy0xLTEtNTA3MjU_d0495cf5-0cfa-43cb-b6b7-54b33dce3d68"
      unitRef="usd">2000000.0</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzktMS0xLTEtNTA3MjU_12eeea2d-d3b7-48b2-93d8-101bce463611"
      unitRef="usd">100000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzktMy0xLTEtNTA3MjU_369b5849-908a-4200-b43a-be787fb2dea4"
      unitRef="usd">100000</us-gaap:FinanceLeaseInterestExpense>
    <amed:FinanceLeaseCost
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzEwLTEtMS0xLTUwNzI1_d4b35f24-1b20-4e75-9c14-63b733681d13"
      unitRef="usd">2400000</amed:FinanceLeaseCost>
    <amed:FinanceLeaseCost
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzEwLTMtMS0xLTUwNzI1_f6f77c81-c1b3-4a75-bebb-3cb7e396fdd5"
      unitRef="usd">2100000</amed:FinanceLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzEyLTEtMS0xLTUwNzI1_f685e4aa-55f1-4c13-9633-50ed3c553562"
      unitRef="usd">3400000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzEyLTMtMS0xLTUwNzI1_dbbe9b9d-6d20-4662-ae89-4b33a37cbe9a"
      unitRef="usd">3300000</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzEzLTEtMS0xLTUwNzI1_db36f0ea-1712-4e6b-ad5b-6a05140034f5"
      unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzEzLTMtMS0xLTUwNzI1_42cd9adb-1a88-4488-9774-a92857705c3f"
      unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzE0LTEtMS0xLTUwNzI1_72768ca1-9e4e-4af9-80ec-58700c51370a"
      unitRef="usd">51800000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZToyZWY1YWVhMjUyZjQ0ZmZmYjQ2MWQ3NWNhOWUzNDNjZS90YWJsZXJhbmdlOjJlZjVhZWEyNTJmNDRmZmZiNDYxZDc1Y2E5ZTM0M2NlXzE0LTMtMS0xLTUwNzI1_68d38424-68cc-42f2-9b9c-074b13c47825"
      unitRef="usd">45800000</us-gaap:LeaseCost>
    <amed:OperatingLeasesTableTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90ZXh0cmVnaW9uOmJiNDEwNTZmMDg4MjQ1MTA5YTBlMWZmY2IxMGRiN2U2XzM5NDA_9a8a9d1c-324f-4832-ba7e-21daae72e3cb">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts reported in the consolidated balance sheets as of December 31, 2022 and 2021 for our operating leases are as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, less current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:OperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0NTU3NzBiMTQ2OGU0MGVjOGY3NWY1ZDQwYTU4YmVmMC90YWJsZXJhbmdlOjQ1NTc3MGIxNDY4ZTQwZWM4Zjc1ZjVkNDBhNThiZWYwXzItMS0xLTEtNTA3MjU_324d4d05-2cdf-4855-b33d-75e213150c9e"
      unitRef="usd">102900000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0NTU3NzBiMTQ2OGU0MGVjOGY3NWY1ZDQwYTU4YmVmMC90YWJsZXJhbmdlOjQ1NTc3MGIxNDY4ZTQwZWM4Zjc1ZjVkNDBhNThiZWYwXzItMy0xLTEtNTA3MjU_97aec2bb-9214-4515-a1ba-a0951f5fe553"
      unitRef="usd">101300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0NTU3NzBiMTQ2OGU0MGVjOGY3NWY1ZDQwYTU4YmVmMC90YWJsZXJhbmdlOjQ1NTc3MGIxNDY4ZTQwZWM4Zjc1ZjVkNDBhNThiZWYwXzQtMS0xLTEtNTA3MjU_1fb38fe6-19ce-4e82-8fdb-49f3346e3775"
      unitRef="usd">33500000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0NTU3NzBiMTQ2OGU0MGVjOGY3NWY1ZDQwYTU4YmVmMC90YWJsZXJhbmdlOjQ1NTc3MGIxNDY4ZTQwZWM4Zjc1ZjVkNDBhNThiZWYwXzQtMy0xLTEtNTA3MjU_f0076f85-926f-4d05-9365-8b2fe794168c"
      unitRef="usd">31200000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0NTU3NzBiMTQ2OGU0MGVjOGY3NWY1ZDQwYTU4YmVmMC90YWJsZXJhbmdlOjQ1NTc3MGIxNDY4ZTQwZWM4Zjc1ZjVkNDBhNThiZWYwXzUtMS0xLTEtNTA3MjU_49d8625a-75ed-4a8c-9562-7652596a1027"
      unitRef="usd">69500000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0NTU3NzBiMTQ2OGU0MGVjOGY3NWY1ZDQwYTU4YmVmMC90YWJsZXJhbmdlOjQ1NTc3MGIxNDY4ZTQwZWM4Zjc1ZjVkNDBhNThiZWYwXzUtMy0xLTEtNTA3MjU_c22654e8-839e-4dbb-b13c-c449d6e20112"
      unitRef="usd">69300000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0NTU3NzBiMTQ2OGU0MGVjOGY3NWY1ZDQwYTU4YmVmMC90YWJsZXJhbmdlOjQ1NTc3MGIxNDY4ZTQwZWM4Zjc1ZjVkNDBhNThiZWYwXzYtMS0xLTEtNTA3MjU_0414fe15-ac27-4b0f-aa25-8bbc104bc366"
      unitRef="usd">103000000.0</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0NTU3NzBiMTQ2OGU0MGVjOGY3NWY1ZDQwYTU4YmVmMC90YWJsZXJhbmdlOjQ1NTc3MGIxNDY4ZTQwZWM4Zjc1ZjVkNDBhNThiZWYwXzYtMy0xLTEtNTA3MjU_90936908-f73d-4aca-b588-24da3d5033e3"
      unitRef="usd">100500000</us-gaap:OperatingLeaseLiability>
    <amed:FinanceLeasesTableTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90ZXh0cmVnaW9uOmJiNDEwNTZmMDg4MjQ1MTA5YTBlMWZmY2IxMGRiN2U2XzM5MzY_88fac82e-35a8-405e-9735-8ce869ddb361">Amounts reported in the consolidated balance sheets as of December 31, 2022 and 2021 for finance leases are included in the table below. The finance lease ROU assets are recorded within property and equipment, net of accumulated depreciation within our consolidated balance sheets. The finance lease liabilities are recorded within current portion of long-term obligations and long-term obligations, less current portion within our consolidated balance sheets.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease ROU assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease ROU assets, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current installments of obligations under finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzYtMS0xLTEtNTA3MjU_1eca02a9-f1dd-4c12-b3b8-0c54b6fd691a"&gt;1.2&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzYtMy0xLTEtNTA3MjU_8d1038d1-419b-4128-8314-0aa1a5467841"&gt;0.9&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion of obligations under finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzctMS0xLTEtNTA3MjU_a814e167-8383-4d45-81ca-86cc22f5c011"&gt;1.1&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzctMy0xLTEtNTA3MjU_89a632c7-217b-411e-a52c-c18cee261893"&gt;0.7&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzgtMS0xLTEtNTA3MjU_12d2aa00-0042-4307-aa11-8f39561b8e9d"&gt;2.3&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzgtMy0xLTEtNTA3MjU_15a6bc06-843b-4c48-b58a-8be83b9c35ba"&gt;1.6&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</amed:FinanceLeasesTableTextBlock>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzItMS0xLTEtNTA3MjU_b7709235-813a-461b-846e-4887a5040c3f"
      unitRef="usd">4100000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzItMy0xLTEtNTA3MjU_24793e17-a02e-4581-870a-8fa43d205c9f"
      unitRef="usd">4500000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzMtMS0xLTEtNTA3MjU_6f3351e5-08ef-4474-b55c-801ef148ce87"
      unitRef="usd">1800000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzMtMy0xLTEtNTA3MjU_e2bb4c9f-2f0e-49f2-9487-833e1e068ef4"
      unitRef="usd">2800000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6b2a5e41e9ee4551ba7962246c513287_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzQtMS0xLTEtNTA3MjU_e4b2546b-909d-4b24-8ce3-732b41eb7c2d"
      unitRef="usd">2300000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic9e60ab572054136b724859b7d07a982_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo0YjUwZGZlYTQ4ODE0NGMwOTNkOTgzMDAzYzJjMGE4NC90YWJsZXJhbmdlOjRiNTBkZmVhNDg4MTQ0YzA5M2Q5ODMwMDNjMmMwYTg0XzQtMy0xLTEtNTA3MjU_10377fc6-f9ee-4ba8-bc93-fa7e3e0abf7e"
      unitRef="usd">1700000</us-gaap:PropertyPlantAndEquipmentNet>
    <amed:SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90ZXh0cmVnaW9uOmJiNDEwNTZmMDg4MjQ1MTA5YTBlMWZmY2IxMGRiN2U2XzM5Mzk_a01c2d25-7537-4f7f-96db-53966dbb09d4">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information and non-cash activity related to our leases are as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities and ROU assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flow from operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flow from finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions to ROU assets resulting from reductions to lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpkYjM2YjkyOWNmMzc0MWIwYmI4YjIzYmJiMWQ1N2E4OC90YWJsZXJhbmdlOmRiMzZiOTI5Y2YzNzQxYjBiYjhiMjNiYmIxZDU3YTg4XzMtMS0xLTEtNTA3MjU_c047cc3d-2f6c-47bf-8b20-278b2f86e562"
      unitRef="usd">44400000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpkYjM2YjkyOWNmMzc0MWIwYmI4YjIzYmJiMWQ1N2E4OC90YWJsZXJhbmdlOmRiMzZiOTI5Y2YzNzQxYjBiYjhiMjNiYmIxZDU3YTg4XzMtMy0xLTEtNTA3MjU_14173d38-fe00-4695-9753-bb01158a2337"
      unitRef="usd">39700000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpkYjM2YjkyOWNmMzc0MWIwYmI4YjIzYmJiMWQ1N2E4OC90YWJsZXJhbmdlOmRiMzZiOTI5Y2YzNzQxYjBiYjhiMjNiYmIxZDU3YTg4XzQtMS0xLTEtNTA3MjU_65300dc6-5732-4f43-b83a-b6a93938bd16"
      unitRef="usd">1500000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpkYjM2YjkyOWNmMzc0MWIwYmI4YjIzYmJiMWQ1N2E4OC90YWJsZXJhbmdlOmRiMzZiOTI5Y2YzNzQxYjBiYjhiMjNiYmIxZDU3YTg4XzQtMy0xLTEtNTA3MjU_cfc4fe37-4d5c-4830-9e64-cba8fa6b8129"
      unitRef="usd">2000000.0</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpkYjM2YjkyOWNmMzc0MWIwYmI4YjIzYmJiMWQ1N2E4OC90YWJsZXJhbmdlOmRiMzZiOTI5Y2YzNzQxYjBiYjhiMjNiYmIxZDU3YTg4XzctMS0xLTEtNTA3MjU_dcf88387-50c0-4299-8783-f59ada2b4b74"
      unitRef="usd">45100000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpkYjM2YjkyOWNmMzc0MWIwYmI4YjIzYmJiMWQ1N2E4OC90YWJsZXJhbmdlOmRiMzZiOTI5Y2YzNzQxYjBiYjhiMjNiYmIxZDU3YTg4XzctMy0xLTEtNTA3MjU_dca49409-11fa-41f9-a53c-275952f9cc9e"
      unitRef="usd">46100000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpkYjM2YjkyOWNmMzc0MWIwYmI4YjIzYmJiMWQ1N2E4OC90YWJsZXJhbmdlOmRiMzZiOTI5Y2YzNzQxYjBiYjhiMjNiYmIxZDU3YTg4XzgtMS0xLTEtNTA3MjU_1243616d-bc0c-49e0-96c9-bec99c298dcc"
      unitRef="usd">2100000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpkYjM2YjkyOWNmMzc0MWIwYmI4YjIzYmJiMWQ1N2E4OC90YWJsZXJhbmdlOmRiMzZiOTI5Y2YzNzQxYjBiYjhiMjNiYmIxZDU3YTg4XzgtMy0xLTEtNTA3MjU_1fc410c0-1f83-478d-98b6-02e2c86dc9ec"
      unitRef="usd">900000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <amed:LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpkYjM2YjkyOWNmMzc0MWIwYmI4YjIzYmJiMWQ1N2E4OC90YWJsZXJhbmdlOmRiMzZiOTI5Y2YzNzQxYjBiYjhiMjNiYmIxZDU3YTg4XzExLTEtMS0xLTUwNzI1_00305bb1-07c5-4bc3-97e1-35cc18393663"
      unitRef="usd">-4200000</amed:LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations>
    <amed:LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpkYjM2YjkyOWNmMzc0MWIwYmI4YjIzYmJiMWQ1N2E4OC90YWJsZXJhbmdlOmRiMzZiOTI5Y2YzNzQxYjBiYjhiMjNiYmIxZDU3YTg4XzExLTMtMS0xLTUwNzI1_74a185df-e81e-46fa-845e-8f6a2a4eecf2"
      unitRef="usd">-1700000</amed:LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations>
    <amed:LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpkYjM2YjkyOWNmMzc0MWIwYmI4YjIzYmJiMWQ1N2E4OC90YWJsZXJhbmdlOmRiMzZiOTI5Y2YzNzQxYjBiYjhiMjNiYmIxZDU3YTg4XzEyLTEtMS0xLTUwNzI1_ba255dd0-6f4d-497a-95a1-b11da1da58c2"
      unitRef="usd">-600000</amed:LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations>
    <amed:LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpkYjM2YjkyOWNmMzc0MWIwYmI4YjIzYmJiMWQ1N2E4OC90YWJsZXJhbmdlOmRiMzZiOTI5Y2YzNzQxYjBiYjhiMjNiYmIxZDU3YTg4XzEyLTMtMS0xLTUwNzI1_5959351a-a78d-4b1d-9056-5a617d45e55c"
      unitRef="usd">0</amed:LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations>
    <amed:WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90ZXh0cmVnaW9uOmJiNDEwNTZmMDg4MjQ1MTA5YTBlMWZmY2IxMGRiN2U2XzM5NDM_388f9f78-c6db-44a4-9885-b85e391e42ae">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average remaining lease terms and discount rates for our leases as of December 31, 2022 and 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo2NTZkNjk3NGE3ZTg0ZTEzODlmMWEyY2RhMzhmMDc0NS90YWJsZXJhbmdlOjY1NmQ2OTc0YTdlODRlMTM4OWYxYTJjZGEzOGYwNzQ1XzMtMS0xLTEtNTA3MjU_04d172bb-e764-4503-bcce-604eb135ccf1">P3Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo2NTZkNjk3NGE3ZTg0ZTEzODlmMWEyY2RhMzhmMDc0NS90YWJsZXJhbmdlOjY1NmQ2OTc0YTdlODRlMTM4OWYxYTJjZGEzOGYwNzQ1XzMtMy0xLTEtNTA3MjU_b863ef31-a29f-484d-9058-0dc8222e4913">P3Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo2NTZkNjk3NGE3ZTg0ZTEzODlmMWEyY2RhMzhmMDc0NS90YWJsZXJhbmdlOjY1NmQ2OTc0YTdlODRlMTM4OWYxYTJjZGEzOGYwNzQ1XzQtMS0xLTEtNTA3MjU_b101a6ee-3def-41be-9f80-e3b80612a101">P2Y1M6D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo2NTZkNjk3NGE3ZTg0ZTEzODlmMWEyY2RhMzhmMDc0NS90YWJsZXJhbmdlOjY1NmQ2OTc0YTdlODRlMTM4OWYxYTJjZGEzOGYwNzQ1XzQtMy0xLTEtNTA3MjU_a0b6ecd5-f240-4270-ad07-4118571f26c6">P1Y8M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo2NTZkNjk3NGE3ZTg0ZTEzODlmMWEyY2RhMzhmMDc0NS90YWJsZXJhbmdlOjY1NmQ2OTc0YTdlODRlMTM4OWYxYTJjZGEzOGYwNzQ1XzctMS0xLTEtNTA3MjU_218312bd-24ba-4e13-b583-099b20bc06f9"
      unitRef="number">0.034</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo2NTZkNjk3NGE3ZTg0ZTEzODlmMWEyY2RhMzhmMDc0NS90YWJsZXJhbmdlOjY1NmQ2OTc0YTdlODRlMTM4OWYxYTJjZGEzOGYwNzQ1XzctMy0xLTEtNTA3MjU_a287969c-c17b-4081-9ea8-44ea4d85fedd"
      unitRef="number">0.027</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo2NTZkNjk3NGE3ZTg0ZTEzODlmMWEyY2RhMzhmMDc0NS90YWJsZXJhbmdlOjY1NmQ2OTc0YTdlODRlMTM4OWYxYTJjZGEzOGYwNzQ1XzgtMS0xLTEtNTA3MjU_a23da77e-6e4b-47f2-bd66-95b5a73a2cbf"
      unitRef="number">0.053</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTo2NTZkNjk3NGE3ZTg0ZTEzODlmMWEyY2RhMzhmMDc0NS90YWJsZXJhbmdlOjY1NmQ2OTc0YTdlODRlMTM4OWYxYTJjZGEzOGYwNzQ1XzgtMy0xLTEtNTA3MjU_8603ea6c-ff05-4adc-9a03-5436fb82d103"
      unitRef="number">0.052</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <amed:LeaseLiabilityMaturityTableTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90ZXh0cmVnaW9uOmJiNDEwNTZmMDg4MjQ1MTA5YTBlMWZmY2IxMGRiN2U2XzM5Mzc_f9e6a921-f348-4424-a988-f34da96a1466">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of December 31, 2022 are as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.257%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.154%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating &lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance &lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzktMy0xLTEtNTA3MjU_99acfacd-090d-4833-8cd5-0990e12d974a"&gt;2.3&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:LeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzEtMS0xLTEtNTA3MjU_e3364727-cf40-4a77-80f0-86fcf0493822"
      unitRef="usd">36100000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzEtMy0xLTEtNTA3MjU_1ed7f591-d2ee-440d-839d-cb8622bfe34c"
      unitRef="usd">1200000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzItMS0xLTEtNTA3MjU_1e5efa1a-e04c-4f03-ad80-bda4c91ffd48"
      unitRef="usd">30900000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzItMy0xLTEtNTA3MjU_79eb7d2f-0ba1-4d03-b558-6654364d1838"
      unitRef="usd">900000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzMtMS0xLTEtNTA3MjU_158d1774-5577-48dd-92e2-a1ad29933345"
      unitRef="usd">20800000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzMtMy0xLTEtNTA3MjU_59716f1c-10cc-489e-8c51-2d2409d47005"
      unitRef="usd">300000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzQtMS0xLTEtNTA3MjU_d1098cd7-51c9-4e4e-8e0a-d22f3a8c9907"
      unitRef="usd">12700000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzQtMy0xLTEtNTA3MjU_94a759de-d88a-472e-9637-04ffabcbb12f"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzUtMS0xLTEtNTA3MjU_faa260e1-679c-4a49-9749-f0afd9be1bd5"
      unitRef="usd">6700000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzUtMy0xLTEtNTA3MjU_93a20cc4-64a1-47cf-b49e-fdb8ce69b274"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzYtMS0xLTEtNTA3MjU_690d632e-cd83-4e38-98b5-d5ce9cf7df6e"
      unitRef="usd">2400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzYtMy0xLTEtNTA3MjU_7a94734b-c720-4b31-b7e5-7bdde57c24ad"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzctMS0xLTEtNTA3MjU_c03bca8f-a020-43fd-9133-499f391c74a8"
      unitRef="usd">109600000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzctMy0xLTEtNTA3MjU_17cc2cb0-fa1c-413f-8b67-00d09a3de8bf"
      unitRef="usd">2400000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzgtMS0xLTEtNTA3MjU_3cc1daa4-3467-4901-9eb3-d00d188802b6"
      unitRef="usd">6600000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzgtMy0xLTEtNTA3MjU_a1da0392-80ef-4c55-8a3b-fd0e675ba8ee"
      unitRef="usd">100000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMDYvZnJhZzpiYjQxMDU2ZjA4ODI0NTEwOWEwZTFmZmNiMTBkYjdlNi90YWJsZTpiMjY2ZTk5MTFhZGU0ZWYxOGViMTc1YTBmMGNjN2Q0YS90YWJsZXJhbmdlOmIyNjZlOTkxMWFkZTRlZjE4ZWIxNzVhMGYwY2M3ZDRhXzktMS0xLTEtNTA3MjU_4792e780-c5e2-4302-8e3a-8307e1801353"
      unitRef="usd">103000000.0</us-gaap:OperatingLeaseLiability>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzEwMzMw_0b9a52df-87c3-4020-91fb-df6116b093d1">LONG-TERM OBLIGATIONS&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consists of the following for the periods indicated (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As&#160;of&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$450.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (5.9% at December 31, 2022); due July&#160;30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate; due July&#160;30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Promissory notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;445.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term obligations, less current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of debt as of December&#160;31, 2022 are as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Long-term&lt;br/&gt;obligations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 29, 2018, we entered into our Amended and Restated Credit Agreement (the "Credit Agreement") which provided for a senior secured revolving credit facility in an initial aggregate principal amount of up to $550.0 million (the "Revolving Credit Facility"). The Revolving Credit Facility provided for and included within its $550.0 million limit a $25.0 million swingline facility and commitments for up to $60.0 million in letters of credit. Upon lender approval, we could increase the aggregate loan amount under the Revolving Credit Facility by $125.0 million plus an unlimited amount subject to a leverage limit of 0.5x under the maximum allowable consolidated leverage ratio which was 3.0x per the Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The final maturity of the Revolving Credit Facility was June 29, 2023, and there was no mandatory amortization on the outstanding principal balances which were payable in full upon maturity. The Revolving Credit Facility was used to provide &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ongoing working capital needs and for general corporate purposes of the Company and our subsidiaries, including permitted acquisitions, as defined in the Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;First Amendment to the Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 4, 2019, we entered into the First Amendment to the Credit Agreement (as amended by the First Amendment, the &#x201c;Amended Credit Agreement&#x201d;). The Amended Credit Agreement provided for a senior secured credit facility in an initial aggregate principal amount of up to $725.0 million, which included the $550.0 million Revolving Credit Facility under the Credit Agreement, and a term loan facility with a principal amount of up to $175.0 million (the &#x201c;Term Loan Facility&#x201d; and collectively with the Revolving Credit Facility, the &#x201c;Credit Facility&#x201d;), which was added by the First Amendment.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-right:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We borrowed the entire principal amount of the Term Loan Facility on February&#160;4, 2019 in order to fund a portion of the purchase price of the Compassionate Care Hospice ("CCH") acquisition, with the remainder of the purchase price and associated transactional fees and expenses funded by proceeds from the Revolving Credit Facility. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Second Amendment to the Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On July 30, 2021, we entered into the Second Amendment to our Credit Agreement (as amended by the Second Amendment, the "Second Amended Credit Agreement"). The Second Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $1.0&#160;billion, which includes the $550.0&#160;million Revolving Credit Facility and a term loan facility with a principal amount of up to $450.0&#160;million (the "Amended Term Loan Facility" and collectively with the Revolving Credit Facility, the "Amended Credit Facility").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Net proceeds from the $450.0&#160;million Amended Term Loan Facility were used to fund the Contessa acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The loans issued under the Amended Credit Facility bear interest on a per annum basis, at our election, at either: (i) the Base Rate plus the Applicable Rate or (ii) the Eurodollar Rate plus the Applicable Rate. The &#x201c;Base Rate&#x201d; means a fluctuating rate per annum equal to the highest of (a) the federal funds rate plus 0.50% per annum, (b)&#160;the prime rate of interest established by the Administrative Agent, and (c)&#160;the Eurodollar Rate plus 1% per annum. The &#x201c;Eurodollar Rate&#x201d; means the quoted rate per annum equal to the London Interbank Offered Rate ("LIBOR") or a comparable successor rate approved by the Administrative Agent for an interest period of one, three or six months (as selected by us). The &#x201c;Applicable Rate&#x201d; is based on the consolidated leverage ratio and is presented in the table below. As of December&#160;31, 2022, the Applicable Rate is 0.50% per annum for Base Rate Loans and 1.50% per annum for Eurodollar Rate Loans. Our Second Amended Credit Agreement provides for the replacement of LIBOR with the daily or term secured overnight financing rate ("SOFR") whenever LIBOR is discontinued. We are also subject to a commitment fee and letter of credit fee under the terms of the Second Amended Credit Agreement, as presented in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pricing Tier&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Leverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Base Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Eurodollar Rate Loans and Daily Floating LIBOR Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Commitment&lt;br/&gt;Fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Letter&#160;of&lt;br/&gt;Credit&#160;Fee&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&amp;gt;  3.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;II&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&amp;lt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; 3.00 to 1.0 but &amp;gt;&#160;2.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&amp;lt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; 2.00 to 1.0 but &amp;gt;&#160;0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&amp;lt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;  0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The final maturity date of the Amended Credit Facility is July 30, 2026. The Revolving Credit Facility will terminate and be due and payable as of the final maturity date. The Amended Term Loan Facility, however, is subject to quarterly amortization of principal in the amount of (i) 0.625% for the period commencing on July 30, 2021 and ending on September 30, 2023, and (ii) 1.250% for the period commencing on October 1, 2023 and ending on July 30, 2026. The remaining balance of the Amended Term Loan Facility must be paid upon the final maturity date. In addition to the scheduled amortization of the Amended Term Loan Facility, and subject to customary exceptions and reinvestment rights, we are required to prepay the Amended Term Loan Facility first and the Revolving Credit Facility second with 100% of all net cash proceeds received by any loan party or any subsidiary thereof in connection with (a) any asset sale or disposition where such loan party receives net cash proceeds in excess of $5 million or (b) any debt issuance that is not permitted under the Second Amended Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Second Amended Credit Agreement requires maintenance of two financial covenants: (i) a consolidated leverage ratio of funded indebtedness to Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA"), as defined in the Second Amended Credit Agreement, and (ii) a consolidated interest coverage ratio of EBITDA to cash interest charges, as defined in the Second Amended Credit Agreement. Each of these covenants is calculated over rolling four-quarter periods and also is subject to certain exceptions and baskets. The Second Amended Credit Agreement also contains customary covenants, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;including, but not limited to, restrictions on: incurrence of liens, incurrence of additional debt, sales of assets and other fundamental corporate changes, investments and declarations of dividends. These covenants contain customary exclusions and baskets as detailed in the Second Amended Credit Agreement. In connection with our entry into the Second Amended Credit Agreement during the year ended December 31, 2021, we recorded $2.8 million in deferred debt issuance costs as long-term obligations, less current portion within our consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Revolving Credit Facility is guaranteed by substantially all of our wholly-owned direct and indirect subsidiaries. The Second Amended Credit Agreement requires at all times that we (i) provide guarantees from wholly-owned subsidiaries that in the aggregate represent not less than 95% of our consolidated net revenues and adjusted EBITDA from all wholly-owned subsidiaries and (ii)&#160;provide guarantees from subsidiaries that in the aggregate represent not less than 70% of consolidated adjusted EBITDA, subject to certain exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our weighted average interest rate for borrowings under our Amended Term Loan Facility was 3.2% for the year ended December 31, 2022 and 1.6% for the year ended December&#160;31, 2021. Our weighted average interest rate for borrowings under our $550.0 million Revolving Credit Facility was 3.4% for the year ended December 31, 2022 and 1.9% for the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, our consolidated leverage ratio was 1.7, our consolidated interest coverage ratio was 11.6 and we are in compliance with our covenants under the Second Amended Credit Agreement. In the event we are not in compliance with our debt covenants in the future, we would pursue various alternatives in an attempt to successfully resolve the non-compliance, which might include, among other things, seeking debt covenant waivers or amendments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, our availability under our $550.0 million Revolving Credit Facility was $520.4 million as we have no outstanding borrowings and $29.6 million outstanding in letters of credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Joinder Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In connection with the CCH acquisition, we entered into a Joinder Agreement, dated as of February 4, 2019 (the &#x201c;CCH Joinder&#x201d;), pursuant to which CCH and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement (now the Second Amended Credit Agreement), the Amended and Restated Security Agreement, dated as of June 29, 2018 (the &#x201c;Amended and Restated Security Agreement&#x201d;), and the Amended and Restated Pledge Agreement, dated as of June 29, 2018 (the &#x201c;Amended and Restated Pledge Agreement&#x201d;). In connection with the AseraCare acquisition, we entered into a Joinder Agreement, dated as of June 12, 2020, pursuant to which the AseraCare entities were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement (now the Second Amended Credit Agreement), the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement (the &#x201c;AseraCare Joinder"). In connection with the Contessa acquisition and the Second Amendment, we entered into a Joinder Agreement, dated as of September 3, 2021, pursuant to which Contessa and its subsidiaries and Asana, which we acquired on January 1, 2020, and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Second Amended Credit Agreement, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement (the &#x201c;Contessa and Asana Joinder,&#x201d; and together with the CCH Joinder and the AseraCare Joinder, the &#x201c;Joinders&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Pursuant to the Joinders, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement, CCH and its subsidiaries, the AseraCare entities, Contessa and its subsidiaries and Asana and its subsidiaries granted in favor of the Administrative Agent a first lien security interest in substantially all of their personal property assets and pledged to the Administrative Agent each of their respective subsidiaries' issued and outstanding equity interests. CCH and its subsidiaries, the AseraCare entities, Contessa and its subsidiaries and Asana and its subsidiaries also guaranteed our obligations, whether now existing or arising after the respective effective dates of the Joinders, under the Second Amended Credit Agreement pursuant to the terms of the Joinders and the Second Amended Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Promissory Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our outstanding promissory note totaling $0.2&#160;million, obtained through the acquisition of Contessa on August 1, 2021, bears an interest rate of 6.5%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our outstanding finance leases totaling $2.3 million relate to leased equipment and bear interest rates ranging from 2.1% to 5.3%.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzEwMzQ1_7aeb7389-04f8-42bc-85c2-9949a0740ec1">&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consists of the following for the periods indicated (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As&#160;of&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$450.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (5.9% at December 31, 2022); due July&#160;30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate; due July&#160;30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Promissory notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;445.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term obligations, less current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i8f4fcaea6b154a0bbd917fba61d92e52_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzItMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjo5ODc1YWY4ZTM4Njk0M2MxOWNhOTJkMjdkMTQyZjBmMF80_b5aff638-aef7-4735-94f8-59a40c80c53c"
      unitRef="usd">450000000</us-gaap:DebtInstrumentFaceAmount>
    <amed:DebtInstrumentInterestRateatPeriodEnd
      contextRef="i916f340079654056b2571fa1ce003955_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzItMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjo5ODc1YWY4ZTM4Njk0M2MxOWNhOTJkMjdkMTQyZjBmMF8xMDc_30ecc35f-43e6-4d4a-9b11-c618b3711d1d"
      unitRef="number">0.059</amed:DebtInstrumentInterestRateatPeriodEnd>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="i3a8567395eba45968f1f59959fef3ffb_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzItMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjo5ODc1YWY4ZTM4Njk0M2MxOWNhOTJkMjdkMTQyZjBmMF8xMzc_3f6e0cc4-3e3f-469d-b7c1-cc2d19e1cbd7">2026-07-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8f4fcaea6b154a0bbd917fba61d92e52_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzItMS0xLTEtNTA3MjU_85e9978d-1075-4f46-b0a0-446d65811911"
      unitRef="usd">435900000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic6c3d510a20748ce9ea87e61c6e92cc4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzItMy0xLTEtNTA3MjU_75eb04fa-cc09-44a1-a6e9-a9ccff90f763"
      unitRef="usd">447200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iacc4528c818b4326ae050e255a5a7a3e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzMtMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjpjMTMxNzdmODZmOTM0NTZiYjRhMjZmNWEzZjQxZjUzNV80_a7fbab19-8102-4d7d-8251-ac1b7e248d32"
      unitRef="usd">550000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="idc761fea5e584f6080ec28aa409e26d2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzMtMC0xLTEtNTA3MjUvdGV4dHJlZ2lvbjpjMTMxNzdmODZmOTM0NTZiYjRhMjZmNWEzZjQxZjUzNV8xNTE_5cabf2f8-87ab-4bc4-b119-ba4f94d1ac91">2026-07-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iacc4528c818b4326ae050e255a5a7a3e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzMtMS0xLTEtNTA3MjU_634c6356-2fd3-4869-a4d1-47b10a448c22"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8b6a940fe41e4c4e9bd71fc532b5f27c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzMtMy0xLTEtNTA3MjU_1b49b624-ca46-4b88-864e-899c14ac297f"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2ebd597356dc40a6baa7eabf9da5fb56_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzQtMS0xLTEtNTA3MjU_8c949f9e-d34e-467a-bb54-2d93eafa1ae0"
      unitRef="usd">200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4bb00aa3ab56488ea6e59211d0ec0f49_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzQtMy0xLTEtNTA3MjU_e70c2811-d061-43de-9c7b-c10c0c9a4912"
      unitRef="usd">800000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id86557107c34492d8c132ad64570a3ed_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzUtMS0xLTEtNTA3MjU_9ed7270d-f5e0-4346-9cc1-8d3797875d88"
      unitRef="usd">2300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="icbdaead26d8b4e69b17a84ea4692f399_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzUtMy0xLTEtNTA3MjU_4a9cfbbe-07a1-42c0-9c8f-5dd4ec858fb9"
      unitRef="usd">1600000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzYtMS0xLTEtNTA3MjU_569ef6c5-8348-48ca-84ca-08182c519e8e"
      unitRef="usd">438400000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzYtMy0xLTEtNTA3MjU_75ec4add-9657-4e90-964c-7b730ec27e20"
      unitRef="usd">449600000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzctMS0xLTEtNTA3MjU_5795987d-440c-4fc9-8d7a-3f7ffb0bdaf3"
      unitRef="usd">3500000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzctMy0xLTEtNTA3MjU_0a0d5dba-bd3e-4f4b-84c2-eb4358614a2f"
      unitRef="usd">4500000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzgtMS0xLTEtNTA3MjU_02d5ab3a-c804-4c5e-9831-838d13286391"
      unitRef="usd">434900000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzgtMy0xLTEtNTA3MjU_ba297cda-8f51-4506-bc68-0ef22f7b1140"
      unitRef="usd">445100000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzktMS0xLTEtNTA3MjU_428fe96a-4815-4ac6-b964-ae7e8467651a"
      unitRef="usd">15500000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzktMy0xLTEtNTA3MjU_f0e939c9-7ff7-427c-bf71-93580331688d"
      unitRef="usd">13000000.0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzEwLTEtMS0xLTUwNzI1_ac26483c-5ada-4c30-8816-dce191ac1431"
      unitRef="usd">419400000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToxZGQwMzI4Zjg4MmU0NDAzOGVlZGMzMjI4ODMxOWRhMC90YWJsZXJhbmdlOjFkZDAzMjhmODgyZTQ0MDM4ZWVkYzMyMjg4MzE5ZGEwXzEwLTMtMS0xLTUwNzI1_352248d6-e2f3-48b6-a27b-d32ee0f11b27"
      unitRef="usd">432100000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzEwMzI4_a5a42c8b-b8cb-4f24-a16f-e5c0ec9c8703">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of debt as of December&#160;31, 2022 are as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Long-term&lt;br/&gt;obligations&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToyNTI1NWMwZmU2MmI0NTI1OTg3NjBlMGQ0OGZmMjNkMC90YWJsZXJhbmdlOjI1MjU1YzBmZTYyYjQ1MjU5ODc2MGUwZDQ4ZmYyM2QwXzItMS0xLTEtNTA3MjU_07d102e1-4b7b-4c4f-9a98-edb1a59e689e"
      unitRef="usd">15500000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToyNTI1NWMwZmU2MmI0NTI1OTg3NjBlMGQ0OGZmMjNkMC90YWJsZXJhbmdlOjI1MjU1YzBmZTYyYjQ1MjU5ODc2MGUwZDQ4ZmYyM2QwXzMtMS0xLTEtNTA3MjU_761dc80b-9bc2-4175-ad27-2b53e2a3e6e3"
      unitRef="usd">23300000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToyNTI1NWMwZmU2MmI0NTI1OTg3NjBlMGQ0OGZmMjNkMC90YWJsZXJhbmdlOjI1MjU1YzBmZTYyYjQ1MjU5ODc2MGUwZDQ4ZmYyM2QwXzQtMS0xLTEtNTA3MjU_6abab13e-f7ff-4741-8a76-78dbca29d9e9"
      unitRef="usd">22700000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToyNTI1NWMwZmU2MmI0NTI1OTg3NjBlMGQ0OGZmMjNkMC90YWJsZXJhbmdlOjI1MjU1YzBmZTYyYjQ1MjU5ODc2MGUwZDQ4ZmYyM2QwXzUtMS0xLTEtNTA3MjU_f39a4ebd-20df-4f7d-8b6b-deff213c466c"
      unitRef="usd">376900000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToyNTI1NWMwZmU2MmI0NTI1OTg3NjBlMGQ0OGZmMjNkMC90YWJsZXJhbmdlOjI1MjU1YzBmZTYyYjQ1MjU5ODc2MGUwZDQ4ZmYyM2QwXzYtMS0xLTEtNTA3MjU_0edabb4f-b620-4b82-a92f-743cc9367b1f"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZToyNTI1NWMwZmU2MmI0NTI1OTg3NjBlMGQ0OGZmMjNkMC90YWJsZXJhbmdlOjI1MjU1YzBmZTYyYjQ1MjU5ODc2MGUwZDQ4ZmYyM2QwXzctMS0xLTEtNTA3MjU_d1df1a4e-96e2-43c0-8cdb-6131287075fc"
      unitRef="usd">438400000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i178263b3689c4dbeb4183a1b2a8f06f4_I20180629"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzQyMQ_57909d38-6ee1-46ec-b342-951a7852c89f"
      unitRef="usd">550000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i178263b3689c4dbeb4183a1b2a8f06f4_I20180629"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzUyNg_8326705a-6c90-4bae-8dde-e6b68b13a5dc"
      unitRef="usd">550000000</us-gaap:DebtInstrumentFaceAmount>
    <amed:SwingLineFacility
      contextRef="i204f7f8314234638a578a2852af0430f_I20180629"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzUzNw_26b74d87-74cd-4b31-8088-fa2dcb90ce0a"
      unitRef="usd">25000000</amed:SwingLineFacility>
    <amed:LettersofCreditmaximumcommitment
      contextRef="i204f7f8314234638a578a2852af0430f_I20180629"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzU4NQ_1259dd31-0205-42eb-bf09-4ea3a6100a02"
      unitRef="usd">60000000</amed:LettersofCreditmaximumcommitment>
    <amed:LineOfCreditFacilityAdditionalBorrowingCapacity
      contextRef="i178263b3689c4dbeb4183a1b2a8f06f4_I20180629"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzcxNQ_db4bc905-3db1-40dd-9214-9a6e7d422c38"
      unitRef="usd">125000000</amed:LineOfCreditFacilityAdditionalBorrowingCapacity>
    <amed:CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple
      contextRef="i178263b3689c4dbeb4183a1b2a8f06f4_I20180629"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzc3NA_93c39499-2fcc-4869-b1bf-4119612139d2"
      unitRef="number">0.5</amed:CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple>
    <amed:Creditfacilitymaximumallowableconsolidatedleverageratio
      contextRef="i178263b3689c4dbeb4183a1b2a8f06f4_I20180629"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzg0NA_412685a2-98a8-4bf2-a8e1-5a79aa1c14f8"
      unitRef="number">3.0</amed:Creditfacilitymaximumallowableconsolidatedleverageratio>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="i76cb131f8a16465eb2fc15903e2b579d_D20180629-20180629"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzkzMA_3cc4526f-c730-4648-8748-253d9831a0e8">2023-06-29</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ic1af0127cb3643d8b17864fcb195bfd5_I20190204"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzE1OTE_e909783f-6dfb-4ccf-8d13-11e7979fad81"
      unitRef="usd">725000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic1af0127cb3643d8b17864fcb195bfd5_I20190204"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzE2MTQ_e3488dce-ad77-4da3-8d70-931393c5aa10"
      unitRef="usd">550000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3178979288cb4514826472f72e5bfb60_I20190204"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzE3Mjk_68b60548-ca58-40d3-a3eb-6a6bf1f6b938"
      unitRef="usd">175000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="iba0cc26b6786477a93c245c64b48976e_I20210730"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzI1NDA_24ac59bd-c7cc-4d7c-9453-e4ba41ffb73b"
      unitRef="usd">1000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iba0cc26b6786477a93c245c64b48976e_I20210730"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzI1NjM_a9333e02-274b-4fbe-a250-80e17149b262"
      unitRef="usd">550000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i1bb8d308c9224e5b844d2c6db275e492_I20210730"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzI2NTA_2fc31aa8-1c59-459f-a009-0814712e8fd3"
      unitRef="usd">450000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i1bb8d308c9224e5b844d2c6db275e492_I20210730"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzI3OTQ_51b5bbd1-16d2-4252-b486-cdc20c4e76fa"
      unitRef="usd">450000000</us-gaap:DebtInstrumentFaceAmount>
    <amed:DebtInstrumentInterestAdditionalInterestAboveFederalFundRate
      contextRef="ia3eb443904904bc78906ce21c0d215af_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzMxODg_cae4e17f-a083-44dc-8e27-225703f6099a"
      unitRef="number">0.0050</amed:DebtInstrumentInterestAdditionalInterestAboveFederalFundRate>
    <amed:DebtInstrumentInterestAdditionalInterestAboveEurodollarRate
      contextRef="ia3eb443904904bc78906ce21c0d215af_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzMzMDc_9c41b9ae-ea96-4de8-b01f-80fa4337f20a"
      unitRef="number">0.01</amed:DebtInstrumentInterestAdditionalInterestAboveEurodollarRate>
    <us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzEwMzQx_3fef4def-69a3-4975-854b-e13562ab41cc">The &#x201c;Applicable Rate&#x201d; is based on the consolidated leverage ratio and is presented in the table below. As of December&#160;31, 2022, the Applicable Rate is 0.50% per annum for Base Rate Loans and 1.50% per annum for Eurodollar Rate Loans. Our Second Amended Credit Agreement provides for the replacement of LIBOR with the daily or term secured overnight financing rate ("SOFR") whenever LIBOR is discontinued. We are also subject to a commitment fee and letter of credit fee under the terms of the Second Amended Credit Agreement, as presented in the table below.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pricing Tier&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Leverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Base Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Eurodollar Rate Loans and Daily Floating LIBOR Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Commitment&lt;br/&gt;Fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Letter&#160;of&lt;br/&gt;Credit&#160;Fee&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&amp;gt;  3.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;II&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&amp;lt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; 3.00 to 1.0 but &amp;gt;&#160;2.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&amp;lt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; 2.00 to 1.0 but &amp;gt;&#160;0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&amp;lt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;  0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i07211fe9ad5d4482bd6b137633c2aa1d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzM2OTk_e630da29-2351-45c0-b67b-9eb0d7937d4c"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ida7bcb808f0e4c318ec059d9ceff470a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzM3MzY_a979c016-179b-453c-9363-82e357538f73"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <amed:ConsolidatedLeverageRatio
      contextRef="iaa67d7d55667443394ca159d57aa511b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzEtMS0xLTEtNTA3MjUvdGV4dHJlZ2lvbjo1NTlkY2ZjMGM2Njk0NGQzYjQwZDdiOGY5MTU3NzNhOV83_59c520fb-d129-4d3f-a1e2-1d45aaa78eb0"
      unitRef="number">3.00</amed:ConsolidatedLeverageRatio>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ice4835f824f5444f94f1ecd506168658_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzEtMy0xLTEtNTA3MjU_bd39f2af-cb1d-474c-b70a-90beff89fdbf"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ie35e7d51c69e442a9aaed895a70d075f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzEtNS0xLTEtNTA3MjU_68b1d1de-8fff-441a-bb1b-01f327d53c53"
      unitRef="number">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="ife65de97c43c4ff38decb113044c4058_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzEtNy0xLTEtNTA3MjU_3d426991-3762-452e-a277-1cbb0d4b8e7a"
      unitRef="number">0.0030</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="ife65de97c43c4ff38decb113044c4058_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzEtOS0xLTEtNTA3MjU_f4e32285-64ca-4983-bfff-c6a4f26b0958"
      unitRef="number">0.0175</amed:LetterOfCreditFee>
    <amed:ConsolidatedLeverageRatio
      contextRef="i3f84542d7b53490e9e21f12a81a49347_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzItMS0xLTEtNTA3MjUvdGV4dHJlZ2lvbjo3M2ZjOTA0MTE4Mzk0NjllYWVjMTIwYTI2M2Q0MTlkZV82_f5c8a9a9-f3cc-41f7-8c13-acda42f96769"
      unitRef="number">3.00</amed:ConsolidatedLeverageRatio>
    <amed:ConsolidatedLeverageRatio
      contextRef="i5ca3fedd3e1b4c93a4622a8fb6dc1a1e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzItMS0xLTEtNTA3MjUvdGV4dHJlZ2lvbjo3M2ZjOTA0MTE4Mzk0NjllYWVjMTIwYTI2M2Q0MTlkZV8yMg_e7f8ba83-5fe7-4955-aa75-83eb8517d38b"
      unitRef="number">2.00</amed:ConsolidatedLeverageRatio>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i17742e3ab61d4196b516dfbe59d556fd_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzItMy0xLTEtNTA3MjU_5d1810cf-6bbf-46c9-8aed-696928f14d0c"
      unitRef="number">0.0075</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ib6d924aa96d649d1b106241f0f9d3dc6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzItNS0xLTEtNTA3MjU_81661eee-acab-4ef0-a657-19d1c0789763"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="ibf4da83d5cea4929a377d16e2a794965_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzItNy0xLTEtNTA3MjU_996aab97-33c7-4204-8ae2-06740fc720a2"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="ibf4da83d5cea4929a377d16e2a794965_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzItOS0xLTEtNTA3MjU_56485003-e412-42ab-b611-031761023e7b"
      unitRef="number">0.0150</amed:LetterOfCreditFee>
    <amed:ConsolidatedLeverageRatio
      contextRef="i96a9d31440c94da5a965cfe8fea3f233_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzMtMS0xLTEtNTA3MjUvdGV4dHJlZ2lvbjphZDVlMDhmYmQzMzc0ZmI1ODAyNWU2ZGQ4NDhkZWQyMV82_098954f3-c756-4b12-b646-ed0f31b541ba"
      unitRef="number">2.00</amed:ConsolidatedLeverageRatio>
    <amed:ConsolidatedLeverageRatio
      contextRef="i0e09b2632feb4e60a63f4f0811a7e6f8_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzMtMS0xLTEtNTA3MjUvdGV4dHJlZ2lvbjphZDVlMDhmYmQzMzc0ZmI1ODAyNWU2ZGQ4NDhkZWQyMV8yMg_dc954696-f6ed-40cc-ad23-c7f3d2b401d6"
      unitRef="number">0.75</amed:ConsolidatedLeverageRatio>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ie6453a68ab024f0481790410c647ca02_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzMtMy0xLTEtNTA3MjU_003cf89b-81fb-4c35-a8ed-572e4c07b0f0"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia3fe9ab766bf4b6aac1a8ef448a228af_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzMtNS0xLTEtNTA3MjU_c775e579-3aa6-44f4-aed7-dc0719df072d"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i0fb8d922ed7840eba4d9f5c8439d8634_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzMtNy0xLTEtNTA3MjU_64a40c12-b015-4ba8-93a1-910593d47607"
      unitRef="number">0.0020</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="i0fb8d922ed7840eba4d9f5c8439d8634_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzMtOS0xLTEtNTA3MjU_97403a81-b38e-4c7c-813d-2f0b33101875"
      unitRef="number">0.0125</amed:LetterOfCreditFee>
    <amed:ConsolidatedLeverageRatio
      contextRef="i6144bb4d6ba64536b8a021e88b94f277_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzQtMS0xLTEtNTA3MjUvdGV4dHJlZ2lvbjozMTE5ZDI4ZWRjOGQ0ZTViYTg3YmIzZWI3MWU3N2UyZF83_01490d3a-d660-44e5-9dbd-e1c20fc19c1f"
      unitRef="number">0.75</amed:ConsolidatedLeverageRatio>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia5b4115d16ee4985a95f2ba4f5411a8b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzQtMy0xLTEtNTA3MjU_4453e99f-08ed-4fd1-b0cd-160bd8a5aab6"
      unitRef="number">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="icb4d003ebe754bc288a304ab991ccff7_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzQtNS0xLTEtNTA3MjU_a90808f3-9147-4118-94ae-65e40dec1c32"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i346c9bba84d040c583bc1c161bbc63a2_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzQtNy0xLTEtNTA3MjU_c4335a87-adc0-4670-a173-918fc853d87f"
      unitRef="number">0.0015</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="i346c9bba84d040c583bc1c161bbc63a2_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90YWJsZTo5NzEzZGZmYjEwMTM0MWFiYWU4NGEyZDAzMmVhYTI4Zi90YWJsZXJhbmdlOjk3MTNkZmZiMTAxMzQxYWJhZTg0YTJkMDMyZWFhMjhmXzQtOS0xLTEtNTA3MjU_17e892f5-18e4-408b-80ad-52129262e6b2"
      unitRef="number">0.0100</amed:LetterOfCreditFee>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="i492cad6b4f6d4dff915ecfdc41239333_D20210730-20260730"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzM5OTE_f133c67c-241d-420b-b521-8a39cad3231b">2026-07-30</us-gaap:DebtInstrumentMaturityDate>
    <amed:DebtInstrumentPeriodicPaymentPercentage
      contextRef="i0b1fdf13b14f42838235e12dc847d78f_D20210730-20230930"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzQyMDY_ebdc4430-065b-4555-b15f-7662dc77f707"
      unitRef="number">0.00625</amed:DebtInstrumentPeriodicPaymentPercentage>
    <amed:DebtInstrumentPeriodicPaymentPercentage
      contextRef="ia4e912d799f345eb811d0a45ef8aad22_D20231001-20260730"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzQyOTU_c9593dab-de40-425f-92f3-d22fc038a7ad"
      unitRef="number">0.01250</amed:DebtInstrumentPeriodicPaymentPercentage>
    <amed:ProceedsReceivedFromLoanPartyOfSubsidiary
      contextRef="i7ac0dcfcf2f843d2ac033b98c430f309_D20210730-20210730"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzQ5MTY_8760e6a1-cc2c-4cdb-afab-7a1cc65f47ce"
      unitRef="usd">5000000</amed:ProceedsReceivedFromLoanPartyOfSubsidiary>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="ie72df9520c04416783c5c1351b95aa45_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzYwMDU_2f8895e2-bb87-416f-8268-2e9fde4e1c89"
      unitRef="usd">2800000</us-gaap:PaymentsOfFinancingCosts>
    <amed:PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries
      contextRef="ia3eb443904904bc78906ce21c0d215af_D20210730-20210730"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzY0NTE_b72e2c08-e0f2-44a0-8583-230d52388577"
      unitRef="number">0.95</amed:PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries>
    <amed:PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries
      contextRef="ia3eb443904904bc78906ce21c0d215af_D20210730-20210730"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzY2MzQ_27fe7ea3-fe11-4678-b2e7-3275310a58b7"
      unitRef="number">0.70</amed:PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="i3a8567395eba45968f1f59959fef3ffb_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzY3OTU_a8a219fe-bdfa-4409-919f-956d677e37d0"
      unitRef="number">0.032</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="if7b0d6790e424eb28816c7faa3cbcaf5_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzY4Mzk_f5313785-5d94-4525-9f92-7fd21d301e8b"
      unitRef="number">0.016</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iacc4528c818b4326ae050e255a5a7a3e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzY5NDA_a00ebbb7-62c0-403b-8033-59054eacb8a0"
      unitRef="usd">550000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="idc761fea5e584f6080ec28aa409e26d2_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzY5NzM_8d1a3a84-22df-4efe-9477-c34d47a9bf69"
      unitRef="number">0.034</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="i31b64bb9856d4b7ab6ed7600628a1276_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzcwMTc_dbbf6ca9-f5a0-4e05-abd5-561dd11cb71e"
      unitRef="number">0.019</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <amed:TotalLeverageRatio
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzcxMDQ_f97234c6-92fe-4456-a8b3-1ec79ce856ad"
      unitRef="number">1.7</amed:TotalLeverageRatio>
    <amed:ConsolidatedInterestCoverageRatio
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzcxNTM_bffdadfc-cb11-489f-9c03-ef3474ed91ae"
      unitRef="number">11.6</amed:ConsolidatedInterestCoverageRatio>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iacc4528c818b4326ae050e255a5a7a3e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzc1Mzg_2adbcc0a-44d5-4681-8180-e37e7764a852"
      unitRef="usd">550000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="iacc4528c818b4326ae050e255a5a7a3e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzc1NzE_ab99e8e9-1efb-4b11-87ff-b91b73579634"
      unitRef="usd">520400000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="ib5660c9b896a4ecaa1234048bbedeafa_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzc2MTU_247e82bd-7699-489c-9285-71ac74c7d7a9"
      unitRef="usd">29600000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2ebd597356dc40a6baa7eabf9da5fb56_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzEwMDky_4caed8d3-fc12-49a3-966e-ccdc7a765535"
      unitRef="usd">200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2ebd597356dc40a6baa7eabf9da5fb56_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzEwMTk5_8c161f97-8abe-4370-8b93-9085e0a2f35a"
      unitRef="number">0.065</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id86557107c34492d8c132ad64570a3ed_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzEwMjUy_10e36389-eb08-4a79-b57c-f6df36405602"
      unitRef="usd">2300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i41fd72dfb82543b4af87db7a75cd295a_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzEwMzE5_67644588-3fdc-4184-ab4b-04a91d2dfa0c"
      unitRef="number">0.021</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if39b026dc9a34fbe996e7be93272debd_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTIvZnJhZzphNTQzOWRjYzU2YTE0N2ZlYTk1YWY1NGFiYzNlNGJlYy90ZXh0cmVnaW9uOmE1NDM5ZGNjNTZhMTQ3ZmVhOTVhZjU0YWJjM2U0YmVjXzEwMzI1_74292f5a-5f52-4281-a38a-c75fc1413ca3"
      unitRef="number">0.053</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzgyMzA_5cf298cd-3672-4d35-9935-802907962b8b">INCOME TAXES&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes attributable to continuing operations consist of the following (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current income tax expense/(benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax expense/(benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total income tax expense for the years ended December&#160;31, 2022, 2021 and 2020 was allocated as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax expense recorded to additional paid-in-capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of significant differences between the reported amount of income tax expense and the expected amount of income tax expense that would result from applying the U.S. federal statutory income tax rate of 21% to income before income taxes is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense at U.S. federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local income taxes, net of federal income tax benefit (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Excess tax benefits from share-based compensation (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible executive compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other items, net (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt"&gt;On August 10, 2020, Paul B. Kusserow, Chief Executive Officer and Chairman of the Board of Amedisys, exercised 500,000 stock options previously awarded to him under our 2008 Omnibus Incentive Compensation Plan. We recognize compensation expense for stock option awards on a straight-line basis over the requisite service period for each separately vesting portion of the award in accordance with ASC 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Compensation: Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;; however, the income tax deduction related to stock options is not recognized until the stock option exercise date. As a result, for awards that are expected to result in a tax deduction, a deferred tax asset is created as the entity recognizes compensation expense for U.S. GAAP purposes. If the tax deduction exceeds the cumulative U.S. GAAP compensation expense for the award, the tax benefit associated with any excess deduction is recognized as an income tax benefit in the statement of operations, resulting in a reduction of the effective tax rate. Mr. Kusserow's stock option exercise produced a $92.1&#160;million tax deduction in excess of U.S. GAAP compensation expense, resulting in a $19.4&#160;million federal income tax benefit and a $4.6&#160;million state and local income tax benefit for the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt"&gt;For the year ended December 31, 2022, the Company recognized $2.7&#160;million of federal uncertain tax positions due to a lapse of the statute of limitations.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt"&gt;Includes various items such as non-deductible expenses, non-taxable income, tax credits, valuation allowance, uncertain tax positions and return-to-accrual adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022 and 2021, the Company had income taxes receivable of $8.8 million and $8.2 million, respectively, included in other current assets within our consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets (liabilities) consist of the following components (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll&#160;&amp;amp; employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal &amp;amp; compliance matters&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred social security taxes (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt"&gt;The CARES Act provided for the deferral of the employer share of social security tax (6.2%), effective for payments due after the enactment date through December 31, 2020. Fifty percent of the deferred payroll taxes were due on December 31, 2021 with the remaining amounts due on December 31, 2022. As of December 31, 2021, the Company had a remaining balance of deferred social security taxes of $27&#160;million, reflected within our consolidated balance sheets, which was paid in December 2022. For income tax purposes, the deferred social security taxes are deductible when paid, leaving no remaining deferred tax asset as of December 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, we have U.S. net operating loss (&#x201c;NOL&#x201d;) carryforwards of $20.9&#160;million that are available to reduce future taxable income and may be carried forward indefinitely. While the NOL carryforwards are not subject to expiration, the annual NOL amount that is available to offset future taxable income is subject to limitation. The NOL carryforwards were acquired as part of the stock purchase of Contessa on August 1, 2021. Under Section 382 of the Internal Revenue Code of 1986, as amended ("Section 382"), substantial changes in a Company&#x2019;s ownership may limit the amount of NOL carryforwards that can be utilized annually to offset future taxable income. As a result of the ownership change, the Company determined that there is an annual limitation, pursuant to Section 382, on the amount of NOL carryforwards that may be utilized to offset future taxable income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, we have state NOL carryforwards of $144.7 million that are available to reduce future taxable income and various state tax credits totaling $3.7 million available to reduce future state income taxes. The state NOL and tax credit carryforwards expire at various times.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022 and 2021, the valuation allowance for deferred tax assets, which is related to certain state NOLs, was $5.2 million and $3.3 million, respectively. The net change in the total valuation allowance for the years ended December 31, 2022 and 2021 was an increase of $1.9&#160;million and an increase of $3.2 million, respectively. The $1.9&#160;million increase in the valuation allowance for the year ended December 31, 2022 is due to Contessa's creation of state NOL carryforwards in jurisdictions that require separate company reporting and where the Company does not expect to have sufficient separate company future taxable income available to offset the state NOL carryforwards. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in those jurisdictions during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities (including the impact of available carryback and carryforward periods), projected future taxable income and tax-planning strategies in making this assessment. In order to fully realize the deferred tax assets, the Company will need to generate future taxable income before the expiration of the carryforwards governed by the tax code. Based on the current level of pre-tax earnings, the Company will generate the minimum amount of future taxable income needed to support the realization of the deferred tax assets. As a result, as of December 31, 2022, management believes that it is more likely than not that we will realize the benefits of these deferred tax assets, net of the existing valuation allowances. The amount of the deferred tax asset considered realizable, however, could be reduced in the near term if estimates of future taxable income during the carryforward period are reduced.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Uncertain Tax Positions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for uncertain tax positions in accordance with the authoritative guidance for uncertain tax positions. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Additions for tax positions related to current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Additions for tax positions related to prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, there was $2.7 million of unrecognized tax benefits recorded in other long-term obligations within the consolidated balance sheets. During 2022, the statute of limitations lapsed, ultimately removing the uncertainty surrounding the Company's ability to recognize the tax positions, if challenged under audit. As a result, the Company recognized a $2.7&#160;million income tax benefit and corresponding reduction in our effective tax rate for the period ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized $0.1&#160;million and $0.2 million of interest as components of interest expense in connection with our reserve for uncertain tax positions during the years ended December 31, 2021 and 2020, respectively. For the period ended December 31, 2022, the Company recorded a $0.7&#160;million benefit as a component of interest expense, as a result of the lapse of the statute of limitations and corresponding release of the reserve for uncertain tax positions. Accrued interest related to uncertain tax positions included in the consolidated balance sheet at December 31, 2021 was $0.7 million. There was no accrued interest related to uncertain tax positions included in the consolidated balance sheet at December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to income taxes in the U.S. and in many individual states, with significant operations in Louisiana, South Carolina, Alabama, Georgia, Massachusetts and Tennessee. We are open to examination in the U.S. and in various individual states for the tax years ended December&#160;31, 2014 through December&#160;31, 2022. We are also open to examination in various states for the years ended 2007 through 2022 resulting from NOLs generated and available for carryforward from those years.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <amed:ProvisionforIncomeTaxesTableTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzgyNDE_cb37171b-dc73-4fc5-aaf8-1f0b84ef5835">&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes attributable to continuing operations consist of the following (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current income tax expense/(benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax expense/(benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total income tax expense for the years ended December&#160;31, 2022, 2021 and 2020 was allocated as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax expense recorded to additional paid-in-capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:ProvisionforIncomeTaxesTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzMtMS0xLTEtNTA3MjU_3c9bf7da-1b2c-43bf-a397-71fd9b743687"
      unitRef="usd">12200000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzMtMy0xLTEtNTA3MjU_047861e4-918d-47e3-87bf-87095bba23fc"
      unitRef="usd">20300000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzMtNS0xLTEtNTA3MjU_bf828ecd-8d05-431f-b787-169c925199a3"
      unitRef="usd">41600000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzQtMS0xLTEtNTA3MjU_1ee3d975-6a37-499a-8d97-b87961794401"
      unitRef="usd">7000000.0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzQtMy0xLTEtNTA3MjU_c71890f3-aa78-4cf7-b74d-7c0d9d3d6c4f"
      unitRef="usd">5200000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzQtNS0xLTEtNTA3MjU_0433b15a-a284-433f-8730-8ee769a95ced"
      unitRef="usd">10600000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzUtMS0xLTEtNTA3MjU_f1b331a7-a73b-4e2b-aa5a-77594e15d311"
      unitRef="usd">19200000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzUtMy0xLTEtNTA3MjU_0a4d1676-6170-45f1-b9a7-d12ac86a52e2"
      unitRef="usd">25500000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzUtNS0xLTEtNTA3MjU_a618055d-79bc-4ca3-be93-9c8fd54e450b"
      unitRef="usd">52200000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzctMS0xLTEtNTA3MjU_567e5191-96ae-41dc-9b87-53bec15cd305"
      unitRef="usd">20400000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzctMy0xLTEtNTA3MjU_764651a7-4829-46b8-8421-13bf0eb6ce92"
      unitRef="usd">35900000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzctNS0xLTEtNTA3MjU_a855cc3f-54c3-4b49-90f9-1cfe6c4b1248"
      unitRef="usd">-22500000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzgtMS0xLTEtNTA3MjU_366f8d05-934c-4fb8-b3be-f229cde66bad"
      unitRef="usd">2900000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzgtMy0xLTEtNTA3MjU_c0cf6842-16cb-4820-bb5a-53f0d84f6dea"
      unitRef="usd">8700000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzgtNS0xLTEtNTA3MjU_25283f3c-bf2c-4afb-940c-49cebab05976"
      unitRef="usd">-4100000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzktMy0xLTEtNTA3MjU_8abe1d4d-2b16-4806-8b94-b711fab95a57"
      unitRef="usd">44600000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzktNS0xLTEtNTA3MjU_350cdeb5-1be6-4986-af6f-7bc6de7588f4"
      unitRef="usd">-26600000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzEwLTEtMS0xLTUwNzI1_0f76f8f4-0c7b-407c-938d-3b84df643f62"
      unitRef="usd">42500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzEwLTMtMS0xLTUwNzI1_4869e820-2367-4090-bb09-07a4d3450416"
      unitRef="usd">70100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpmYmY2MTExMDQ5NjI0NzM2YTEzMTNkNTljMmU2YWZmNC90YWJsZXJhbmdlOmZiZjYxMTEwNDk2MjQ3MzZhMTMxM2Q1OWMyZTZhZmY0XzEwLTUtMS0xLTUwNzI1_cb21f9c4-ce1c-4126-9bf1-9904d666c04e"
      unitRef="usd">25600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo0NmQyMjg0NzVmZjc0MWQ5OGVhMWQyZmRiZWM4MTY1Yi90YWJsZXJhbmdlOjQ2ZDIyODQ3NWZmNzQxZDk4ZWExZDJmZGJlYzgxNjViXzItMS0xLTEtNTA3MjU_3338b8c1-fa63-45f2-9ca8-47693cea4a53"
      unitRef="usd">42500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo0NmQyMjg0NzVmZjc0MWQ5OGVhMWQyZmRiZWM4MTY1Yi90YWJsZXJhbmdlOjQ2ZDIyODQ3NWZmNzQxZDk4ZWExZDJmZGJlYzgxNjViXzItMy0xLTEtNTA3MjU_fa963ab5-e800-4777-af56-b63f3852ec4d"
      unitRef="usd">70100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo0NmQyMjg0NzVmZjc0MWQ5OGVhMWQyZmRiZWM4MTY1Yi90YWJsZXJhbmdlOjQ2ZDIyODQ3NWZmNzQxZDk4ZWExZDJmZGJlYzgxNjViXzItNS0xLTEtNTA3MjU_92da1f83-4161-4d7a-99de-ddf62b4db7dc"
      unitRef="usd">25600000</us-gaap:IncomeTaxExpenseBenefit>
    <amed:IncomeTaxEffectsAllocatedToInterestExpense
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo0NmQyMjg0NzVmZjc0MWQ5OGVhMWQyZmRiZWM4MTY1Yi90YWJsZXJhbmdlOjQ2ZDIyODQ3NWZmNzQxZDk4ZWExZDJmZGJlYzgxNjViXzMtMS0xLTEtNTA3MjU_e9e58d5b-5648-4791-82cf-8853ecaaabe1"
      unitRef="usd">-700000</amed:IncomeTaxEffectsAllocatedToInterestExpense>
    <amed:IncomeTaxEffectsAllocatedToInterestExpense
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo0NmQyMjg0NzVmZjc0MWQ5OGVhMWQyZmRiZWM4MTY1Yi90YWJsZXJhbmdlOjQ2ZDIyODQ3NWZmNzQxZDk4ZWExZDJmZGJlYzgxNjViXzMtMy0xLTEtNTA3MjU_58d28634-e697-41a7-ab20-a822daffb554"
      unitRef="usd">100000</amed:IncomeTaxEffectsAllocatedToInterestExpense>
    <amed:IncomeTaxEffectsAllocatedToInterestExpense
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo0NmQyMjg0NzVmZjc0MWQ5OGVhMWQyZmRiZWM4MTY1Yi90YWJsZXJhbmdlOjQ2ZDIyODQ3NWZmNzQxZDk4ZWExZDJmZGJlYzgxNjViXzMtNS0xLTEtNTA3MjU_d6a0e4e4-9f5a-48ba-ae42-8f8c93db78fe"
      unitRef="usd">200000</amed:IncomeTaxEffectsAllocatedToInterestExpense>
    <amed:IncomeTaxEffectsAllocatedToGoodwill
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo0NmQyMjg0NzVmZjc0MWQ5OGVhMWQyZmRiZWM4MTY1Yi90YWJsZXJhbmdlOjQ2ZDIyODQ3NWZmNzQxZDk4ZWExZDJmZGJlYzgxNjViXzQtMS0xLTEtNTA3MjU_41d58ed5-80ea-47ea-b0b1-c5320d2ac29a"
      unitRef="usd">-2700000</amed:IncomeTaxEffectsAllocatedToGoodwill>
    <amed:IncomeTaxEffectsAllocatedToGoodwill
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo0NmQyMjg0NzVmZjc0MWQ5OGVhMWQyZmRiZWM4MTY1Yi90YWJsZXJhbmdlOjQ2ZDIyODQ3NWZmNzQxZDk4ZWExZDJmZGJlYzgxNjViXzQtMy0xLTEtNTA3MjU_821ad2bc-764e-4b1c-b7a4-72a73e3ac9ec"
      unitRef="usd">3100000</amed:IncomeTaxEffectsAllocatedToGoodwill>
    <amed:IncomeTaxEffectsAllocatedToGoodwill
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo0NmQyMjg0NzVmZjc0MWQ5OGVhMWQyZmRiZWM4MTY1Yi90YWJsZXJhbmdlOjQ2ZDIyODQ3NWZmNzQxZDk4ZWExZDJmZGJlYzgxNjViXzQtNS0xLTEtNTA3MjU_4ddbafb6-f543-4260-94e0-cb9869199cbe"
      unitRef="usd">0</amed:IncomeTaxEffectsAllocatedToGoodwill>
    <amed:TaxExpenseRecordedToAdditionalPaidInCapital
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo0NmQyMjg0NzVmZjc0MWQ5OGVhMWQyZmRiZWM4MTY1Yi90YWJsZXJhbmdlOjQ2ZDIyODQ3NWZmNzQxZDk4ZWExZDJmZGJlYzgxNjViXzUtMS0xLTEtNTczNTY_dc85fd88-4d9f-468f-a2a7-a58b571c694b"
      unitRef="usd">1500000</amed:TaxExpenseRecordedToAdditionalPaidInCapital>
    <amed:TaxExpenseRecordedToAdditionalPaidInCapital
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo0NmQyMjg0NzVmZjc0MWQ5OGVhMWQyZmRiZWM4MTY1Yi90YWJsZXJhbmdlOjQ2ZDIyODQ3NWZmNzQxZDk4ZWExZDJmZGJlYzgxNjViXzUtMy0xLTEtNTczNTY_b9a4fdac-533b-4f05-ba3e-5c0ad937447b"
      unitRef="usd">0</amed:TaxExpenseRecordedToAdditionalPaidInCapital>
    <amed:TaxExpenseRecordedToAdditionalPaidInCapital
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo0NmQyMjg0NzVmZjc0MWQ5OGVhMWQyZmRiZWM4MTY1Yi90YWJsZXJhbmdlOjQ2ZDIyODQ3NWZmNzQxZDk4ZWExZDJmZGJlYzgxNjViXzUtNS0xLTEtNTczNTY_83518b34-85ba-4576-992b-1a61025776ea"
      unitRef="usd">0</amed:TaxExpenseRecordedToAdditionalPaidInCapital>
    <us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo0NmQyMjg0NzVmZjc0MWQ5OGVhMWQyZmRiZWM4MTY1Yi90YWJsZXJhbmdlOjQ2ZDIyODQ3NWZmNzQxZDk4ZWExZDJmZGJlYzgxNjViXzUtMS0xLTEtNTA3MjU_792dd0e2-8e9a-4981-8005-2fa184707683"
      unitRef="usd">40600000</us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation>
    <us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo0NmQyMjg0NzVmZjc0MWQ5OGVhMWQyZmRiZWM4MTY1Yi90YWJsZXJhbmdlOjQ2ZDIyODQ3NWZmNzQxZDk4ZWExZDJmZGJlYzgxNjViXzUtMy0xLTEtNTA3MjU_8d3e248c-d1e9-4b75-a7e1-5aae759d2378"
      unitRef="usd">73300000</us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation>
    <us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo0NmQyMjg0NzVmZjc0MWQ5OGVhMWQyZmRiZWM4MTY1Yi90YWJsZXJhbmdlOjQ2ZDIyODQ3NWZmNzQxZDk4ZWExZDJmZGJlYzgxNjViXzUtNS0xLTEtNTA3MjU_e74bc42f-545a-4595-9227-2966a16ba958"
      unitRef="usd">25800000</us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzgyMjQ_4db665e2-6b35-4ee7-8183-6274589cb766">&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of significant differences between the reported amount of income tax expense and the expected amount of income tax expense that would result from applying the U.S. federal statutory income tax rate of 21% to income before income taxes is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense at U.S. federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local income taxes, net of federal income tax benefit (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Excess tax benefits from share-based compensation (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible executive compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other items, net (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt"&gt;On August 10, 2020, Paul B. Kusserow, Chief Executive Officer and Chairman of the Board of Amedisys, exercised 500,000 stock options previously awarded to him under our 2008 Omnibus Incentive Compensation Plan. We recognize compensation expense for stock option awards on a straight-line basis over the requisite service period for each separately vesting portion of the award in accordance with ASC 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Compensation: Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;; however, the income tax deduction related to stock options is not recognized until the stock option exercise date. As a result, for awards that are expected to result in a tax deduction, a deferred tax asset is created as the entity recognizes compensation expense for U.S. GAAP purposes. If the tax deduction exceeds the cumulative U.S. GAAP compensation expense for the award, the tax benefit associated with any excess deduction is recognized as an income tax benefit in the statement of operations, resulting in a reduction of the effective tax rate. Mr. Kusserow's stock option exercise produced a $92.1&#160;million tax deduction in excess of U.S. GAAP compensation expense, resulting in a $19.4&#160;million federal income tax benefit and a $4.6&#160;million state and local income tax benefit for the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt"&gt;For the year ended December 31, 2022, the Company recognized $2.7&#160;million of federal uncertain tax positions due to a lapse of the statute of limitations.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt"&gt;Includes various items such as non-deductible expenses, non-taxable income, tax credits, valuation allowance, uncertain tax positions and return-to-accrual adjustments.&lt;/span&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzItMS0xLTEtNTA3MjU_d56eb69a-8990-41e6-aa35-ddef8246ec0b"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzItMy0xLTEtNTA3MjU_f03294d0-348b-4d12-be5d-bdd32165ca91"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzItNS0xLTEtNTA3MjU_638626ad-0d23-4127-8d75-135ebe61392c"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzMtMS0xLTEtNTA3MjU_72a9f8a3-aa3a-4d21-b066-c35f2e624e0b"
      unitRef="number">0.056</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzMtMy0xLTEtNTA3MjU_42625313-e9be-4ac3-842f-658406f4f33e"
      unitRef="number">0.050</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzMtNS0xLTEtNTA3MjU_97a588d5-c1fa-43b1-860d-a89031c1d220"
      unitRef="number">0.024</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <amed:EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzQtMS0xLTEtNTA3MjU_b58b5450-228c-489c-be08-44c78843ccf0"
      unitRef="number">-0.003</amed:EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent>
    <amed:EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzQtMy0xLTEtNTA3MjU_c85e8f77-0467-4f26-8b24-eb3ef2afb859"
      unitRef="number">0.021</amed:EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent>
    <amed:EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzQtNS0xLTEtNTA3MjU_d542ac48-ad5c-4b59-97de-e6cb4958637c"
      unitRef="number">0.127</amed:EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent>
    <amed:EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzUtMS0xLTEtNTA3MjU_fbc275f1-4718-43f4-a9c5-7d11a947df33"
      unitRef="number">0.008</amed:EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent>
    <amed:EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzUtMy0xLTEtNTA3MjU_74acfedf-9d2c-4087-859a-a1a2c6f95600"
      unitRef="number">0.012</amed:EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent>
    <amed:EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzUtNS0xLTEtNTA3MjU_7fbf700b-0de2-486a-a341-9eb37235eb69"
      unitRef="number">0.021</amed:EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent>
    <amed:EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzYtMS0xLTEtNTczODQ_9ce4e54d-7bd1-4523-9494-f90622b03dc9"
      unitRef="number">-0.017</amed:EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent>
    <amed:EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzYtMy0xLTEtNTczODQ_38b776d1-394f-47cd-8b4b-51c9f109ba32"
      unitRef="number">0</amed:EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent>
    <amed:EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzYtNS0xLTEtNTczODQ_5a229fbd-71a4-459a-9d39-a31961faa34a"
      unitRef="number">0</amed:EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzYtMS0xLTEtNTA3MjU_409d7f31-209a-402f-9e62-c91dbcfebd97"
      unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzYtMy0xLTEtNTA3MjU_503eefbf-b610-49f4-812a-47f7b7d900bd"
      unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzYtNS0xLTEtNTA3MjU_f37c988f-ccf0-4fe1-9e50-2cdfeeb3f0b8"
      unitRef="number">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzctMS0xLTEtNTA3MjU_f065029d-571c-44ae-8d1d-34d9a236996f"
      unitRef="number">0.265</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzctMy0xLTEtNTA3MjU_b4609367-06c9-4259-9350-ee76ecb9725a"
      unitRef="number">0.250</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkNmUyYjNiMGI0NGM0YWE5YTNiNmU4ZWI2NDcyMjE5Yi90YWJsZXJhbmdlOmQ2ZTJiM2IwYjQ0YzRhYTlhM2I2ZThlYjY0NzIyMTliXzctNS0xLTEtNTA3MjU_e76fbfc6-428f-4f42-ad22-463e2a886e1c"
      unitRef="number">0.122</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if7805668b7a84f7d95cb285d7db5a548_D20200810-20200810"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzYxNA_9e82c5b9-7774-496a-a5be-1f6dee848490"
      unitRef="shares">500000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="i287e698cf9eb4bdfb671be9b8b48fffc_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzE1NDA_1e744815-c6da-42b3-8e09-5fb1f81d3b02"
      unitRef="usd">92100000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="ibace990f785a497b98867b384cd11b5f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzE2MTc_5642e8d4-4774-44e4-b752-74caf85d818a"
      unitRef="usd">19400000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="i039df82eb47c4820a0f22e9789c65e30_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzE2NTM_2aedc580-50d5-4f4e-8d06-ba44fcf79cee"
      unitRef="usd">4600000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzU0OTc1NTgyNTczNQ_79a212c0-8198-43a8-98e8-02ac3f6aad8e"
      unitRef="usd">2700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxesReceivable
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzE5NTg_8b3ccb13-4682-4a94-93c5-92ceb839fded"
      unitRef="usd">8800000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzE5NjU_359ebf5a-d1cb-46db-9306-b71e9baef8ca"
      unitRef="usd">8200000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzgyMjk_79fe7056-ebdd-4048-9ddc-6ae082c6df4c">&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets (liabilities) consist of the following components (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll&#160;&amp;amp; employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal &amp;amp; compliance matters&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred social security taxes (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)The CARES Act provided for the deferral of the employer share of social security tax (6.2%), effective for payments due after the enactment date through December 31, 2020. Fifty percent of the deferred payroll taxes were due on December 31, 2021 with the remaining amounts due on December 31, 2022. As of December 31, 2021, the Company had a remaining balance of deferred social security taxes of $27&#160;million, reflected within our consolidated balance sheets, which was paid in December 2022. For income tax purposes, the deferred social security taxes are deductible when paid, leaving no remaining deferred tax asset as of December 31, 2022.</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzMtMS0xLTEtNTA3MjU_a1e3afc0-4395-4e00-84ad-b33ca95489c0"
      unitRef="usd">14100000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzMtMy0xLTEtNTA3MjU_e8061607-b6e0-479c-9541-5cb28326ef51"
      unitRef="usd">13200000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther>
    <amed:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzQtMS0xLTEtNTA3MjU_845b3f62-15b3-4af7-badd-79e6df6b67ef"
      unitRef="usd">10600000</amed:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation>
    <amed:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzQtMy0xLTEtNTA3MjU_ace811a6-1dce-4056-b070-0d7d3166aced"
      unitRef="usd">10500000</amed:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzUtMS0xLTEtNTA3MjU_53a57cc9-8ef9-4e28-8f53-ddd3ffcb0f42"
      unitRef="usd">5700000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzUtMy0xLTEtNTA3MjU_1d5bc8e1-4840-4c2c-a433-8b60b395f659"
      unitRef="usd">6200000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <amed:DeferredTaxAssetsLegalAndComplianceMatters
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzYtMS0xLTEtNTA3MjU_e446d865-7ee2-4f3c-953e-d0b61c191632"
      unitRef="usd">4700000</amed:DeferredTaxAssetsLegalAndComplianceMatters>
    <amed:DeferredTaxAssetsLegalAndComplianceMatters
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzYtMy0xLTEtNTA3MjU_bc11d3d3-3b26-4273-8f91-fd02d8bd9057"
      unitRef="usd">6200000</amed:DeferredTaxAssetsLegalAndComplianceMatters>
    <amed:DeferredTaxAssetsLeaseLiability
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzctMS0xLTEtNTA3MjU_1e05f185-6075-488c-9144-8d255a753e1f"
      unitRef="usd">27800000</amed:DeferredTaxAssetsLeaseLiability>
    <amed:DeferredTaxAssetsLeaseLiability
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzctMy0xLTEtNTA3MjU_b5ea4ee4-3b12-413d-9fc8-fb0d7e1bf1cb"
      unitRef="usd">27300000</amed:DeferredTaxAssetsLeaseLiability>
    <amed:DeferredTaxAssetDeferredSocialSecurityTaxes
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzktMS0xLTEtNTA3MjU_772f6682-f71c-482f-a30f-72eabfe1903b"
      unitRef="usd">0</amed:DeferredTaxAssetDeferredSocialSecurityTaxes>
    <amed:DeferredTaxAssetDeferredSocialSecurityTaxes
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzktMy0xLTEtNTA3MjU_cc5e9c11-5f64-42cc-b5c8-de02ee478265"
      unitRef="usd">6900000</amed:DeferredTaxAssetDeferredSocialSecurityTaxes>
    <us-gaap:DeferredTaxAssetsOtherLossCarryforwards
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzEwLTEtMS0xLTUwNzI1_43ec9a18-b04e-4997-a764-baaea10fba97"
      unitRef="usd">11600000</us-gaap:DeferredTaxAssetsOtherLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOtherLossCarryforwards
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzEwLTMtMS0xLTUwNzI1_f454016b-bee9-45a6-baee-de81da40705b"
      unitRef="usd">13600000</us-gaap:DeferredTaxAssetsOtherLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzExLTEtMS0xLTUwNzI1_d1a9093b-9f66-4a69-b289-bad9aa1bc228"
      unitRef="usd">2900000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzExLTMtMS0xLTUwNzI1_5ba16ed9-8581-4df3-a94e-b7935da65b0c"
      unitRef="usd">2500000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzEyLTEtMS0xLTUwNzI1_1f9453f8-1b5e-473e-852c-730d18b92353"
      unitRef="usd">200000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzEyLTMtMS0xLTUwNzI1_a117e200-1203-4866-9dde-c4083251281e"
      unitRef="usd">500000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzEzLTEtMS0xLTUwNzI1_eaaa7b4d-60d6-412e-bbfd-7c48c8a1ed9e"
      unitRef="usd">77600000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzEzLTMtMS0xLTUwNzI1_9fa0022c-e5f8-4c7e-bf2f-ba60427e0cf3"
      unitRef="usd">86900000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzE0LTEtMS0xLTUwNzI1_84d2abbe-750a-470d-b932-6284c3c0637f"
      unitRef="usd">5200000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzE0LTMtMS0xLTUwNzI1_5971f631-74f0-4afd-be8a-26356a024b26"
      unitRef="usd">3300000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzE1LTEtMS0xLTUwNzI1_85ab5afe-9390-4424-9efb-824451a75e1c"
      unitRef="usd">72400000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzE1LTMtMS0xLTUwNzI1_dc500680-0a07-4b7e-8c9d-897b150054a9"
      unitRef="usd">83600000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzE3LTEtMS0xLTUwNzI1_e500becd-bcc6-458a-93ac-ee4655f6e866"
      unitRef="usd">6600000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzE3LTMtMS0xLTUwNzI1_b3df8f63-69a1-4598-b514-7052eff0dd8a"
      unitRef="usd">8100000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <amed:DeferredTaxLiabilitiesAmortizationOfIntangibleAssets
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzE4LTEtMS0xLTUwNzI1_4c8b6650-f3d9-4393-b557-6de3b2a3287c"
      unitRef="usd">48500000</amed:DeferredTaxLiabilitiesAmortizationOfIntangibleAssets>
    <amed:DeferredTaxLiabilitiesAmortizationOfIntangibleAssets
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzE4LTMtMS0xLTUwNzI1_6b24db93-3520-4d66-a462-cce7619d6a43"
      unitRef="usd">32300000</amed:DeferredTaxLiabilitiesAmortizationOfIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzE5LTEtMS0xLTUwNzI1_c9a1674f-bcdf-4c6d-8df2-1892eed0b6fe"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome>
    <us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzE5LTMtMS0xLTUwNzI1_28897efa-4b04-42fa-8eae-1950781d2d30"
      unitRef="usd">4500000</us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome>
    <us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzIwLTEtMS0xLTUwNzI1_06b13f8f-fe17-46e4-aac9-2f5dc89a4350"
      unitRef="usd">10000000.0</us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates>
    <us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzIwLTMtMS0xLTUwNzI1_95bbc7f9-83eb-4c37-aeb1-f499eb2a78c5"
      unitRef="usd">10800000</us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates>
    <amed:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzIxLTEtMS0xLTUwNzI1_103500a7-074e-4f37-a930-a869089171bd"
      unitRef="usd">27000000.0</amed:DeferredTaxLiabilitiesRightOfUseAssets>
    <amed:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzIxLTMtMS0xLTUwNzI1_0c33ab22-7641-4115-b471-aa54627fb4d2"
      unitRef="usd">26700000</amed:DeferredTaxLiabilitiesRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzIyLTEtMS0xLTUwNzI1_353fbf70-1ed5-4b9d-a536-9e2e1d4cd0a0"
      unitRef="usd">700000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzIyLTMtMS0xLTUwNzI1_ef393146-c9d2-4b8a-97af-e8f60ab0d11d"
      unitRef="usd">900000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzIzLTEtMS0xLTUwNzI1_bd197593-a32a-442a-8adc-582bacb87d0d"
      unitRef="usd">92800000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzIzLTMtMS0xLTUwNzI1_3856af32-830a-45ba-839f-8c7d420bbe89"
      unitRef="usd">83300000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzI0LTEtMS0xLTUwNzI1_ec14ab20-f5f3-4391-8f0b-66bf5a6e88d8"
      unitRef="usd">20400000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTo2MWIxM2ZiNmY3NmU0ZmEzYmMyNzY5Yzc2YjAxZjljNC90YWJsZXJhbmdlOjYxYjEzZmI2Zjc2ZTRmYTNiYzI3NjljNzZiMDFmOWM0XzI0LTMtMS0xLTUwNzI1_b5496480-708f-4f75-a51a-4b81a5325324"
      unitRef="usd">300000</us-gaap:DeferredIncomeTaxAssetsNet>
    <amed:PaymentOfDeferredSocialSecurityTaxUnderCARESAct
      contextRef="i0530cc1fa306423dba7c186bb6ab97cc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzMyMDY_361752d2-80dd-4df9-a86c-f0d8a0adb725"
      unitRef="usd">27000000</amed:PaymentOfDeferredSocialSecurityTaxUnderCARESAct>
    <amed:CARESActDeferralOfEmployerShareSocialSecurityTax
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzMyMDY_a271d445-5ac0-4b47-8088-3dfbe72f9fa7"
      unitRef="usd">27000000</amed:CARESActDeferralOfEmployerShareSocialSecurityTax>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i956eb24e24e0444b86f101edaf26c1b4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzM2MDI_2cd8ceb6-d5b6-4d94-befb-674e41ca5a17"
      unitRef="usd">20900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i47060e74f1c24113966bf5b707b10e09_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzQ1MzM_f60c5fb0-ba4a-4bc2-a89a-72e4cbf5c876"
      unitRef="usd">144700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:IncomeTaxCreditsAndAdjustments
      contextRef="i3cc7c6096a3746f28dfa0ec43e47b91a_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzQ1OTE_0f8a49d8-ddef-4689-a1f7-5815bd07c207"
      unitRef="usd">3700000</us-gaap:IncomeTaxCreditsAndAdjustments>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzQ4NjU_a605dfdc-ab14-4850-bc46-6e743fd3669d"
      unitRef="usd">5200000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzQ4NzI_17e42d78-184f-401e-b7e0-6569fa5272ae"
      unitRef="usd">3300000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzUwMDQ_b608e1ff-6e1c-4d26-890a-f1e027a0f097"
      unitRef="usd">1900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzUwMjU_609ee894-3263-4186-bb4b-e67f8da4a172"
      unitRef="usd">3200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzUwNDc_a7bc8912-f386-4d7e-9791-d50d2d3b5b0c"
      unitRef="usd">1900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzgyMjc_560ae8f6-bcce-4203-a426-01b95f1c4e3b">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (amounts in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Additions for tax positions related to current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Additions for tax positions related to prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions related to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzItMS0xLTEtNTA3MjU_dfe9edf9-bceb-4c37-9332-becccc91228a"
      unitRef="usd">2700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i42b1e865f1ed4b2e8363dfcc39186a91_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzItMy0xLTEtNTA3MjU_7d81efe6-6cba-4c58-952f-89c0b9fa552f"
      unitRef="usd">2700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="iab144f7e34ce4a479683c59de399ff42_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzItNS0xLTEtNTA3MjU_abb7fce4-8fed-4eee-8352-096fd7acc676"
      unitRef="usd">2700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzMtMS0xLTEtNTA3MjU_9dabbf5d-7427-4021-ae24-8d917e77cbd2"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzMtMy0xLTEtNTA3MjU_3404922b-fb02-4c37-8a27-3e97d0825153"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzMtNS0xLTEtNTA3MjU_bfcdf2c1-e133-4cdd-bc40-9c80ff435a7a"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzQtMS0xLTEtNTA3MjU_477f61e6-dd65-4b34-841d-b5c19ad432e6"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzQtMy0xLTEtNTA3MjU_ba8ae235-e3c9-4ca7-aedf-6aea1ed76be8"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzQtNS0xLTEtNTA3MjU_95baf012-2743-480e-be99-e305a2839a7a"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzUtMS0xLTEtNTA3MjU_2493b8ad-33e2-47b4-827a-49957b6c473e"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzUtMy0xLTEtNTA3MjU_b6c3b8db-8ea0-40ec-b54f-3197862cad88"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzUtNS0xLTEtNTA3MjU_7d48a60d-8a17-4d88-9bc8-879f527d35d8"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzYtMS0xLTEtNTA3MjU_afa36244-3fd2-4620-9bc9-5b2d2fc97905"
      unitRef="usd">2700000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzYtMy0xLTEtNTA3MjU_d5d154bd-ec94-4667-a2ba-1e384a8b0eb5"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzYtNS0xLTEtNTA3MjU_b5a39cc3-44cc-4567-9473-169446cdb97a"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzctMS0xLTEtNTA3MjU_16146dcf-b323-4aa4-a33b-db66d9e84684"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzctMy0xLTEtNTA3MjU_7cd77c39-e1e0-4c35-ae01-ca606a8ced29"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzctNS0xLTEtNTA3MjU_e445dbdb-125f-4697-990f-97bf2210723a"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzgtMS0xLTEtNTA3MjU_98c5cb9f-519f-40a2-9cf6-bd7f35c054c3"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzgtMy0xLTEtNTA3MjU_6b17dd62-2082-478c-baf6-ec582c1f1d20"
      unitRef="usd">2700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i42b1e865f1ed4b2e8363dfcc39186a91_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90YWJsZTpkZTUzYzA1NWY1YjE0YWRmOTE0NzFlODEyMTliMmVjYi90YWJsZXJhbmdlOmRlNTNjMDU1ZjViMTRhZGY5MTQ3MWU4MTIxOWIyZWNiXzgtNS0xLTEtNTA3MjU_ea84a080-a16c-4ba1-8564-a26ca9829394"
      unitRef="usd">2700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzcwMzk_9da2b196-527b-470d-ba54-b3aeb99deac7"
      unitRef="usd">2700000</us-gaap:UnrecognizedTaxBenefits>
    <amed:RecognizedTaxBenefitThatImpactsEffectiveTaxRate
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzU0OTc1NTgyNTcyMQ_7451dfc3-9bac-4a7b-9e6a-717844368bf4"
      unitRef="usd">2700000</amed:RecognizedTaxBenefitThatImpactsEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzcyNDA_96ca500c-5c38-4d6c-9f84-05c8c31a48b4"
      unitRef="usd">100000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzcyNTE_799078a5-6bf9-4338-99a2-804cebc4866c"
      unitRef="usd">200000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <amed:BenefitAsComponentOfInterestExpense
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzU0OTc1NTgyNTcwNw_5d38c37c-a3d7-4808-b368-f2bd81b34cab"
      unitRef="usd">700000</amed:BenefitAsComponentOfInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzc1NTk_d0a06ff0-ccba-412c-8080-4fb57d2cac99"
      unitRef="usd">700000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:OpenTaxYear
      contextRef="i1fafeebfd1ab4899a21ae02fae464c83_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzgxMzA_caee6b06-d5aa-44b0-a85f-715634aef8ce">2007</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="i03c7e40c5f95416f9b140b596a1f186a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMTgvZnJhZzowYWUwOWI1ZTNmYTk0YjA3ODg2OGUxOGFhYzY5MjM5Yi90ZXh0cmVnaW9uOjBhZTA5YjVlM2ZhOTRiMDc4ODY4ZTE4YWFjNjkyMzliXzgxNDE_1ad1592b-ea7b-4a56-a119-b07806e32f2d">2022</us-gaap:OpenTaxYear>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzEwMTM0_a3c3d42a-ab65-4b9e-8d93-c4c4ced62484">CAPITAL STOCK AND SHARE-BASED COMPENSATION&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are authorized by our Certificate of Incorporation to issue 60,000,000 shares of common stock, $0.001 par value and 5,000,000 shares of preferred stock, $0.001 par value. As of December&#160;31, 2022, there were 37,891,186 and 32,518,278 shares of common stock issued and outstanding, respectively, and no shares of preferred stock issued or outstanding. Our Board of Directors is authorized to fix the dividend rights and terms, conversion and voting rights, redemption rights and other privileges and restrictions applicable to our preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 29, 2018, our Board of Directors and the Compensation Committee approved, subject to stockholder approval, the Amedisys, Inc. 2018 Omnibus Incentive Compensation Plan (the &#x201c;2018 Plan&#x201d;). On June 6, 2018, our stockholders approved the 2018 Plan at the Company's annual meeting of stockholders. The 2018 Plan replaces our 2008 Omnibus Incentive Compensation Plan (the &#x201c;2008 Plan&#x201d;), which terminated on June 6, 2018 when the stockholders approved the 2018 Plan. The 2018 Plan, as amended to date, authorizes the grant of various types of equity-based awards, such as stock awards, restricted stock units, stock appreciation rights and stock options to eligible participants, which include all of our employees and all employees of our 50% or more owned subsidiaries, our non-employee directors and certain consultants. The vesting terms of the awards may be tied to continued employment (or, for our non-employee directors, continued service on the Board of Directors) and/or achievement of certain pre-determined performance goals. We refer to restricted stock units subject to service-based or a combination of service-based and performance-based vesting conditions as &#x201c;non-vested stock units.&#x201d; The 2018 Plan is administered by the Compensation Committee of our Board of Directors, which determines, within the provisions of the 2018 Plan, those eligible participants to whom, and the times at which, awards shall be granted. The Compensation Committee, in its discretion, may delegate its authority and duties under the 2018 Plan to specified officers; however, only the Compensation Committee may approve the terms of awards to our executive officers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity-based awards may be granted for a number of shares not to exceed, in the aggregate, approximately 2.5 million shares of common stock. We had approximately 1.7 million shares available at December&#160;31, 2022. The price per share for stock options shall be no less than the greater of (a) 100% of the fair value of a share of common stock on the date the option is granted or (b)&#160;the aggregate par value of the shares of our common stock on the date the option is granted. If a stock option is granted to any owner of 10% or more of the total combined voting power of us and our subsidiaries, the price is to be at least 110% of the fair value of a share of our common stock on the date the award is granted. Each equity-based award vests ratably over a one year to &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzI5NTc_223df790-b680-48db-b730-c00d1beab04b"&gt;four&lt;/span&gt; year period, with the exception of those issued under contractual arrangements that specify otherwise, and may be exercised during a period as determined by our Compensation Committee or as otherwise approved by our Compensation Committee. The contractual terms of stock options exercised shall not exceed ten years from the date such option is granted. The Company analyzes historical data of forfeited awards to develop an estimated forfeiture rate that is applied to the Company's non-cash compensation expense; however, all non-cash compensation expense is adjusted to reflect actual vestings and forfeitures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;)                                                                                                                                                                        &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a plan whereby our eligible employees may purchase our common stock at 85% of the market price at the time of purchase. The total number of shares of our common stock authorized for issuance under our ESPP is 4,500,000, and as of December&#160;31, 2022, there were 1,264,302 shares available for future issuance. The following is a detail of the purchases that have been made under the plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Employee Stock Purchase Plan Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&#160;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 and Prior&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,171,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January&#160;1, 2021 to March&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April&#160;1, 2021 to June&#160;30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July&#160;1, 2021 to September&#160;30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October&#160;1, 2021 to December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January&#160;1, 2022 to March&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April&#160;1, 2022 to June&#160;30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July&#160;1, 2022 to September&#160;30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October&#160;1, 2022 to December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,235,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ESPP expense included in general and administrative expense in our accompanying consolidated statements of operations was $0.7 million, $0.7 million and $0.6 million for 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 10, 2020, Paul B. Kusserow, Chief Executive Officer and Chairman of the Board of Amedisys, exercised 500,000 stock options previously awarded to him under the 2008 Plan. In connection with the exercise, Mr. Kusserow surrendered 231,683 shares of common stock to us to satisfy tax withholding and strike price obligations and elected to hold the net 268,317 shares issued to him. The surrendered shares are classified as treasury shares. This transaction resulted in a cash outflow of $40.4&#160;million, reflected within financing activities in our consolidated statement of cash flows, related to the remittance of tax withholding obligations. In addition, Mr. Kusserow's stock option exercise resulted in a $24.0&#160;million income tax benefit that was recorded in our consolidated statement of operations during the year ended December 31, 2020. See Note 10 &#x2013; Income Taxes for additional details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the Black-Scholes option pricing model to estimate the fair value of our stock options. There were 33,656, 40,788 and 43,249 options granted during 2022, 2021 and 2020, respectively. Stock option compensation expense included in general and administrative expense in our accompanying consolidated statements of operations was $1.7 million, $3.6 million and $4.3 million for 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of the stock option awards were estimated using the following assumptions for 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk Free Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.91% &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.80% - 1.35%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.38% - 1.51%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.97% &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39.84% - 41.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.15% - 42.80%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted Average Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$61.31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$107.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$86.72&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend Yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We used the simplified method to estimate the expected term for the stock options granted during 2022, 2021 and 2020 as adequate historical experience is not available to provide a reasonable estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our stock option activity for 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&#160;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&#160;Contractual&lt;br/&gt;Life&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding options at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;273,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(37,635)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled, forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(51,382)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding options at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;218,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.56&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercisable options at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;163,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.04&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of our outstanding options and exercisable options at December&#160;31, 2022 was $0.7 million and $0.7 million, respectively. Total intrinsic value of options exercised was $1.5 million, $5.1 million and $121.1 million for 2022, 2021 and 2020, respectively. The tax benefit from stock options exercised during the period amounted to $0.4 million, $1.0 million and $27.9 million for 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our non-vested stock option activity for 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested stock options at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;182.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(64,496)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(43,273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested stock options at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, there was $2.0 million of unrecognized compensation cost related to stock options that we expect to be recognized over a weighted-average period of 1.8 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-Vested Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We issue non-vested stock unit awards that are service-based, performance-based or a combination of both with vesting terms ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4Xzc0MzA_f3f1355f-39bb-4d10-ac63-3dcf30959476"&gt;one&lt;/span&gt; to &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4Xzc0MzY_d0064103-cecb-48d9-8073-473521ccb07a"&gt;four&lt;/span&gt; years. Based on the terms and conditions of these awards, we determine if the awards should be recorded as either equity or liability instruments. The compensation expense is determined based on the market price of our common stock at the date of grant, applied to the total number of units that are anticipated to vest, unless the award specifies differently. Shares of stock are not issued to the recipient until the stock unit awards have vested and after the pre-determined delivery date has occurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-Vested Stock Units &#x2013; Service-Based ("Service-Based Non-Vested Stock Units")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Service-based non-vested stock unit compensation expense included in general and administrative expenses in our accompanying consolidated statements of operations was $12.1 million, $9.4 million and $7.5 million for 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our service-based non-vested stock units activity for 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&#160;&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested stock units at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;211,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;115.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(59,006)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled, forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(70,025)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;194.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested stock units at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;263,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value of service-based non-vested stock units granted was $115.07, $234.42 and $206.10 in 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, there was $22.6 million of unrecognized compensation cost related to our service-based non-vested stock units that we expect to be recognized over a weighted average period of 2.2 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-Vested Stock Units &#x2013; Service-Based and Performance-Based Awards ("Performance-Based Non-Vested Stock Units")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2022, we awarded performance-based awards to certain employees. The target level established by the award, which is based on the Company&#x2019;s 2022 adjusted earnings before interest, taxes, depreciation and amortization (&#x201c;Adjusted EBITDA&#x201d;), provided for the recipients to receive an aggregate of 71,349 non-vested stock units if the target was achieved. For a select group of employees, if the target objective was surpassed to the point of achieving the projected maximum payout, the recipients would receive an additional aggregate of 32,048 non-vested stock units during 2023. The target number of shares to be potentially awarded was reduced by forfeitures as indicated in the table below. On February 1, 2023, the Compensation Committee determined that the 2022 performance-based objective established by the award was not satisfied, and as a result, the target number of non-vested stock units will be forfeited. Performance-based non-vested stock units compensation expense included in general and administrative expenses in our consolidated statements of operations was $2.2 million, $10.2 million and $13.5 million for 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our performance-based non-vested stock units activity for 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&#160;&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested stock units at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;186,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;206.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(85,767)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;156.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled, forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(104,486)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;237.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested stock units at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value of performance-based non-vested stock units granted was $133.70, $262.67 and $201.90 in 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, there was $1.1 million in unrecognized compensation costs related to our performance-based non-vested stock units that we expect to be recognized over a weighted average period of 1.1 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzExNQ_ef85fab0-c051-4221-a92c-da871507f45a"
      unitRef="shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzE0Mg_7f61d458-365c-46b5-9d1b-e0eab095b57c"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzE1OQ_f8650c20-8e3f-4222-a451-c3d83c24abae"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzE4OQ_795e1f16-fd0c-4124-82f8-ffabf6ef4cce"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzIyNA_8f31540c-75ad-4537-8d8d-5c42eeee8531"
      unitRef="shares">37891186</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzIzMQ_3369d22c-0eca-4781-8058-887e70941fd4"
      unitRef="shares">32518278</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzI5OQ_8c438204-5801-43b7-b2b2-fadbaf344b70"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <amed:Percentageofownershipinsubsidiaries
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzEzMDY_3306f861-0c61-413c-9419-5288e6fb06f0"
      unitRef="number">0.50</amed:Percentageofownershipinsubsidiaries>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzIzMzE_0b550b8f-b0e8-4938-ae97-fa7f6845fdcc"
      unitRef="shares">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzIzNzk_299b467d-517d-41d8-939a-d19f7efc3b8f"
      unitRef="shares">1700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <amed:Fairvalueofshareofcommonstockpercentage
      contextRef="i9a6f6b5c67ab4519b50f44d3984d3460_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzI0ODU_ed639610-7d69-43eb-896c-4f4e4c37e4fd"
      unitRef="number">1</amed:Fairvalueofshareofcommonstockpercentage>
    <amed:Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzI3MTI_bb82d683-ae19-4b8f-84a5-f42a470ae63c"
      unitRef="number">0.10</amed:Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries>
    <amed:Fairvalueofshareofcommonstockpercentage
      contextRef="i29922553b57d4a4f913d8dc9ac058907_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzI4MTQ_b7883d35-dde3-440a-b4ea-76adbdf24d3e"
      unitRef="number">1.10</amed:Fairvalueofshareofcommonstockpercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
      contextRef="i8f97dee560fa43f381b21ce637429d33_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzMyNjY_cfe7f456-1df9-4b34-9800-8cb21290372a">ten years</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzM4NTI_707fb8e8-cc52-4f4e-a14c-e7f6b141491d"
      unitRef="number">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <amed:CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan
      contextRef="iabc17e0bc0164f2ab68e1dacdbd3fa3a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzQxMDY_92ed2530-c724-4e06-9972-9d4a658ed879"
      unitRef="shares">4500000</amed:CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan>
    <amed:CommonStockSharesAvailableForIssuanceToEmployeeStockPurchasePlan
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzQxNDI_285079de-8b7e-433e-9985-cec579998610"
      unitRef="shares">1264302</amed:CommonStockSharesAvailableForIssuanceToEmployeeStockPurchasePlan>
    <us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzEwMTM4_5a3813c8-3ca8-4e39-ace9-48382c28d478">The following is a detail of the purchases that have been made under the plan:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Employee Stock Purchase Plan Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&#160;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 and Prior&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,171,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January&#160;1, 2021 to March&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April&#160;1, 2021 to June&#160;30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July&#160;1, 2021 to September&#160;30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October&#160;1, 2021 to December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January&#160;1, 2022 to March&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April&#160;1, 2022 to June&#160;30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July&#160;1, 2022 to September&#160;30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;October&#160;1, 2022 to December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,235,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="iaab2533120e743218b94d1ca1acd32ae_D20120607-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzEtMS0xLTEtNTA3MjU_3c8f5627-e6bb-4d98-9b81-54d4de5bbc8a"
      unitRef="shares">3171373</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="i42b1e865f1ed4b2e8363dfcc39186a91_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzEtMy0xLTEtNTA3MjU_b1042c73-8a1b-4f7a-99a1-38b865b3295d"
      unitRef="usdPerShare">17.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i88f7ee58380e478992f80d0861c1607f_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzItMS0xLTEtNTA3MjU_adf2ca22-4a74-4b8d-a42d-bba2fbb83853"
      unitRef="shares">4060</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="id59b7e2a3058490b9b7c36016e54fda5_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzItMy0xLTEtNTA3MjU_f9b8b617-0453-467c-814b-48b6aca62110"
      unitRef="usdPerShare">225.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i9ab351315e174023b86cc7cc10277227_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzMtMS0xLTEtNTA3MjU_839cd8d6-9217-4854-a53b-d3202b7c79f2"
      unitRef="shares">5095</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="if75caf01fb8b4cf59e6837df49b4e315_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzMtMy0xLTEtNTA3MjU_70686f47-a51c-44fc-aa0a-7a344c99950a"
      unitRef="usdPerShare">208.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="iadba656fc0c44917b7651f7ad78cbd0c_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzQtMS0xLTEtNTA3MjU_00031189-f1cc-4a60-a94a-01cd95e6b807"
      unitRef="shares">7466</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="ib60868f2b1d84557b45341890a39d860_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzQtMy0xLTEtNTA3MjU_be199516-d0a9-45cc-8a57-d8938095ed38"
      unitRef="usdPerShare">126.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ic5c669dea2424147a7e748e8a71c927c_D20211001-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzUtMS0xLTEtNTA3MjU_b28e7fa9-60ed-4095-aa77-2d41a5802c07"
      unitRef="shares">7161</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzUtMy0xLTEtNTA3MjU_0703b281-e6ba-453c-a276-2ebecc8e9e50"
      unitRef="usdPerShare">137.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i4df39100e7da46d49d9439da9cf924d8_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzYtMS0xLTEtNTA3MjU_bf315c17-200e-443b-8171-fdbae778a4ab"
      unitRef="shares">6184</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="i611f679bc0fc435c9e898dad11348fcf_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzYtMy0xLTEtNTA3MjU_161cb5ae-bb7d-4c9b-a899-cd1a3cc5444e"
      unitRef="usdPerShare">146.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i5e118c828cfd44b387ff3fef4f4d36ec_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzctMS0xLTEtNTA3MjU_e3068595-a1fa-43e6-bc2a-03a4d3eb9893"
      unitRef="shares">10814</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="i266eb829b984448ebdfabbddfb0be360_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzctMy0xLTEtNTA3MjU_50a9f05c-ee87-4f2c-8719-894e1cab6ab0"
      unitRef="usdPerShare">89.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ide0d67cdc1d84448bde7a943cb636abd_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzgtMS0xLTEtNTA3MjU_590ef688-5959-4fba-92c6-6707d778eeea"
      unitRef="shares">12047</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="i7b2fa1ac38fb4e9f99f2949b063d86c5_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzgtMy0xLTEtNTA3MjU_6a49f249-30c5-4821-a09e-37cae68c11b9"
      unitRef="usdPerShare">82.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i39be0476e53e4678b7f5eebe2f65b0d1_D20221001-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzktMS0xLTEtNTA3MjU_9b51fdac-0969-4986-abc4-9a6f452c421c"
      unitRef="shares">11498</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzktMy0xLTEtNTA3MjU_a364faf6-5fbe-4157-8ecd-29b6b7c36297"
      unitRef="usdPerShare">71.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i7e2596f2753a45a9b4ddde231581db8b_D20120607-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTpkZTEwNmNjZTFmM2M0MWNhYWJiYjM3NmI3ODQ5Y2ZkMi90YWJsZXJhbmdlOmRlMTA2Y2NlMWYzYzQxY2FhYmJiMzc2Yjc4NDljZmQyXzEwLTEtMS0xLTUwNzI1_fe62a704-3493-41cc-8528-45827d1841d0"
      unitRef="shares">3235698</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzQzODE_1531a7d9-f9ec-4932-bb0f-d313ba64b579"
      unitRef="usd">700000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
    <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzQzODU_d8936329-03a6-4821-91ef-4f817cc07354"
      unitRef="usd">700000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
    <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzQzOTI_df7f6c74-45c3-437f-9d57-074ccf0a5732"
      unitRef="usd">600000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if7805668b7a84f7d95cb285d7db5a548_D20200810-20200810"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzQ1NTM_02728efc-1cf7-4347-8f0d-75191cacb7af"
      unitRef="shares">500000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <amed:SurrenderedSharesInShares
      contextRef="if7805668b7a84f7d95cb285d7db5a548_D20200810-20200810"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzQ2NzU_80fe980b-6a45-4aa2-90ca-74228a0e7182"
      unitRef="shares">231683</amed:SurrenderedSharesInShares>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="if7805668b7a84f7d95cb285d7db5a548_D20200810-20200810"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzQ3OTE_c93a5a74-dca0-4a03-8291-05abddd3852f"
      unitRef="shares">268317</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i287e698cf9eb4bdfb671be9b8b48fffc_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzQ5MjE_3c964460-50f2-427d-9afc-0848470d0b12"
      unitRef="usd">40400000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="i287e698cf9eb4bdfb671be9b8b48fffc_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzUxMzA_6a2f5dcb-8704-40df-bc60-4dcb8b7f7317"
      unitRef="usd">24000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i06eb9ed545f04bdcbf647b341b4ab114_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzYwOTI_3827a44a-f6d7-4d65-b3df-7aca6dbe2212"
      unitRef="shares">33656</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="ic8002223ee9342dbb6725f50e35539b6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzYwOTY_ecc7f639-b972-4497-8145-36ef8048850e"
      unitRef="shares">40788</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i15f9883719504dad940b79d91d5a68cf_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzYxMDM_76027059-03a3-44be-b2bb-fdd5b7e8447e"
      unitRef="shares">43249</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i06eb9ed545f04bdcbf647b341b4ab114_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzYzMDE_0a154a01-3b6e-41ae-853b-7d5aa4f31bcd"
      unitRef="usd">1700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic8002223ee9342dbb6725f50e35539b6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzYzMDU_35feb633-5701-4a38-868a-d324304e2a9d"
      unitRef="usd">3600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i15f9883719504dad940b79d91d5a68cf_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzYzMTI_69c1504b-acca-439f-bcc8-a6c480157890"
      unitRef="usd">4300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzEwMTI0_5fa37eb2-0ce2-499c-bbf5-d241a9fc9fb1">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of the stock option awards were estimated using the following assumptions for 2022, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Risk Free Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.91% &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.80% - 1.35%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.38% - 1.51%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.97% &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39.84% - 41.40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.15% - 42.80%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted Average Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$61.31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$107.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$86.72&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend Yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i06eb9ed545f04bdcbf647b341b4ab114_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzItMS0xLTEtNTA3MjUvdGV4dHJlZ2lvbjpiNGRiODFmOWFhZDc0MWRlYTBjMTM5ODRmYWY5YjE1MF80_6c4605c7-d1c4-4259-b6aa-e512d954ad98"
      unitRef="number">0.0191</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="ic8002223ee9342dbb6725f50e35539b6_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzItMy0xLTEtNTA3MjUvdGV4dHJlZ2lvbjoyNGU2ZjMyNGE0Nzc0ZTM1ODIxN2RlNDM1MDI2MTQ5MV80_d064731b-089d-4589-948d-c1ebbf53f92f"
      unitRef="number">0.0080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="ic8002223ee9342dbb6725f50e35539b6_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzItMy0xLTEtNTA3MjUvdGV4dHJlZ2lvbjoyNGU2ZjMyNGE0Nzc0ZTM1ODIxN2RlNDM1MDI2MTQ5MV85_c75685c6-5e13-49e9-a15e-ea8f2b2b8375"
      unitRef="number">0.0135</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i15f9883719504dad940b79d91d5a68cf_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzItNS0xLTEtNTA3MjUvdGV4dHJlZ2lvbjpmNDY3MDcyMDdlZWQ0YWI0YTc2NDU1ZDZhY2VlMTkyOF80_092f8f71-8f26-4989-92ad-c4e99de8fe7b"
      unitRef="number">0.0038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i15f9883719504dad940b79d91d5a68cf_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzItNS0xLTEtNTA3MjUvdGV4dHJlZ2lvbjpmNDY3MDcyMDdlZWQ0YWI0YTc2NDU1ZDZhY2VlMTkyOF85_160d87bf-8137-4849-a94d-71249d7dcd2f"
      unitRef="number">0.0151</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i06eb9ed545f04bdcbf647b341b4ab114_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzMtMS0xLTEtNTA3MjUvdGV4dHJlZ2lvbjpjM2Y2YjhiOTEwNTM0MzZlYWE0MWJhYzNmOWQ3NzNkMl80_f16044b5-f7b0-4c63-9ded-97c0636d70bb"
      unitRef="number">0.4097</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="ic8002223ee9342dbb6725f50e35539b6_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzMtMy0xLTEtNTA3MjUvdGV4dHJlZ2lvbjpkZjhiMzk0YmFhMjk0MjM1OTBjM2U4OGIxOGZiMTIwOF80_fefae255-7678-4013-9962-db156fc9a9fb"
      unitRef="number">0.3984</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="ic8002223ee9342dbb6725f50e35539b6_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzMtMy0xLTEtNTA3MjUvdGV4dHJlZ2lvbjpkZjhiMzk0YmFhMjk0MjM1OTBjM2U4OGIxOGZiMTIwOF85_c6df0e26-247e-4cb5-9d11-3f56cfdb1272"
      unitRef="number">0.4140</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i15f9883719504dad940b79d91d5a68cf_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzMtNS0xLTEtNTA3MjUvdGV4dHJlZ2lvbjpjNTBiNmI2MWY1OGI0ODY2ODZjMzQ4NTE4MWZiNTI3Yl80_b0447965-1f08-42aa-a00e-92fd40e0e34b"
      unitRef="number">0.4015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i15f9883719504dad940b79d91d5a68cf_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzMtNS0xLTEtNTA3MjUvdGV4dHJlZ2lvbjpjNTBiNmI2MWY1OGI0ODY2ODZjMzQ4NTE4MWZiNTI3Yl85_993d9870-8e61-4969-b647-d90d2e33e3eb"
      unitRef="number">0.4280</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i06eb9ed545f04bdcbf647b341b4ab114_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzQtMS0xLTEtNTA3MjU_c016387d-2d1d-4310-bd68-f4966e333509">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic8002223ee9342dbb6725f50e35539b6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzQtMy0xLTEtNTA3MjUvdGV4dHJlZ2lvbjowOWU3MzAxYWJkZjY0MjkzOTI1NjQ1ODY5ZTZmMzNiZV80_5665c32e-941e-4334-9ad6-577133315625">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i15f9883719504dad940b79d91d5a68cf_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzQtNS0xLTEtNTA3MjUvdGV4dHJlZ2lvbjo3N2E2YzMwMzVmZDQ0MjYxYmY2YWJjNzA2MzExYTUwYV80_31211b7f-52c5-4aad-a7d4-d177d2d08702">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <amed:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue
      contextRef="i06eb9ed545f04bdcbf647b341b4ab114_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzUtMS0xLTEtNTA3MjU_1b6bae82-f430-474c-a7dd-a9b6a1225c94"
      unitRef="usdPerShare">61.31</amed:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue>
    <amed:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue
      contextRef="ic8002223ee9342dbb6725f50e35539b6_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzUtMy0xLTEtNTA3MjU_ba3c22af-8702-4ede-9c7d-1893ec30605e"
      unitRef="usdPerShare">107.45</amed:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue>
    <amed:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue
      contextRef="i15f9883719504dad940b79d91d5a68cf_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzUtNS0xLTEtNTA3MjU_e079b757-8017-4097-8f8a-3b42810f5b03"
      unitRef="usdPerShare">86.72</amed:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i06eb9ed545f04bdcbf647b341b4ab114_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzYtMS0xLTEtNTA3MjU_ae9c62cf-142d-4ce7-a58e-b2dda8036ab9"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ic8002223ee9342dbb6725f50e35539b6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzYtMy0xLTEtNTA3MjU_5e360f60-f298-46f1-8b06-8d2bee67ba13"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i15f9883719504dad940b79d91d5a68cf_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo2Zjk4YWMxZjg2ZTI0ZjEyYmQ1NTc5ODM2OTdmMWNjMC90YWJsZXJhbmdlOjZmOThhYzFmODZlMjRmMTJiZDU1Nzk4MzY5N2YxY2MwXzYtNS0xLTEtNTA3MjU_fe4d98c3-6400-443c-be27-75e613b0b5a7"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzEwMTQz_d5c1d705-1f6c-48d7-85fa-2e177ad64c0c">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our stock option activity for 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&#160;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&#160;Contractual&lt;br/&gt;Life&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding options at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;273,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(37,635)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled, forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(51,382)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding options at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;218,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.56&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercisable options at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;163,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.04&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo1YzcxNGQ1OTcwNTY0ZTk3YTg2OTVhMjMxNTE4YWJlMi90YWJsZXJhbmdlOjVjNzE0ZDU5NzA1NjRlOTdhODY5NWEyMzE1MThhYmUyXzEtMS0xLTEtNTA3MjU_ff1d905e-942b-4e1a-943e-f684afe0a373"
      unitRef="shares">273973</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo1YzcxNGQ1OTcwNTY0ZTk3YTg2OTVhMjMxNTE4YWJlMi90YWJsZXJhbmdlOjVjNzE0ZDU5NzA1NjRlOTdhODY5NWEyMzE1MThhYmUyXzEtMy0xLTEtNTA3MjU_c975ba88-c512-4060-b9bd-bd9f5d1b9061"
      unitRef="usdPerShare">137.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo1YzcxNGQ1OTcwNTY0ZTk3YTg2OTVhMjMxNTE4YWJlMi90YWJsZXJhbmdlOjVjNzE0ZDU5NzA1NjRlOTdhODY5NWEyMzE1MThhYmUyXzEtNS0xLTEtNTA3MjU_2b8955b3-c568-48ab-87d2-a95a10bda660">P7Y2M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo1YzcxNGQ1OTcwNTY0ZTk3YTg2OTVhMjMxNTE4YWJlMi90YWJsZXJhbmdlOjVjNzE0ZDU5NzA1NjRlOTdhODY5NWEyMzE1MThhYmUyXzItMS0xLTEtNTA3MjU_109af690-cba1-4c79-a1cb-d54d0a630b25"
      unitRef="shares">33656</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo1YzcxNGQ1OTcwNTY0ZTk3YTg2OTVhMjMxNTE4YWJlMi90YWJsZXJhbmdlOjVjNzE0ZDU5NzA1NjRlOTdhODY5NWEyMzE1MThhYmUyXzItMy0xLTEtNTA3MjU_3750a641-8a40-45c4-b1aa-db9088a4418c"
      unitRef="usdPerShare">143.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo1YzcxNGQ1OTcwNTY0ZTk3YTg2OTVhMjMxNTE4YWJlMi90YWJsZXJhbmdlOjVjNzE0ZDU5NzA1NjRlOTdhODY5NWEyMzE1MThhYmUyXzMtMS0xLTEtNTA3MjU_00fac2ed-fb6a-4e11-bd82-9a99c305dada"
      unitRef="shares">37635</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo1YzcxNGQ1OTcwNTY0ZTk3YTg2OTVhMjMxNTE4YWJlMi90YWJsZXJhbmdlOjVjNzE0ZDU5NzA1NjRlOTdhODY5NWEyMzE1MThhYmUyXzMtMy0xLTEtNTA3MjU_29d1e22b-6ca3-46ac-8960-f394e958a2e6"
      unitRef="usdPerShare">61.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo1YzcxNGQ1OTcwNTY0ZTk3YTg2OTVhMjMxNTE4YWJlMi90YWJsZXJhbmdlOjVjNzE0ZDU5NzA1NjRlOTdhODY5NWEyMzE1MThhYmUyXzQtMS0xLTEtNTA3MjU_75520116-666c-4010-9e6a-c127db297ec1"
      unitRef="shares">51382</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo1YzcxNGQ1OTcwNTY0ZTk3YTg2OTVhMjMxNTE4YWJlMi90YWJsZXJhbmdlOjVjNzE0ZDU5NzA1NjRlOTdhODY5NWEyMzE1MThhYmUyXzQtMy0xLTEtNTA3MjU_8244fc49-3ec0-481e-bba6-8bb9500913c7"
      unitRef="usdPerShare">174.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo1YzcxNGQ1OTcwNTY0ZTk3YTg2OTVhMjMxNTE4YWJlMi90YWJsZXJhbmdlOjVjNzE0ZDU5NzA1NjRlOTdhODY5NWEyMzE1MThhYmUyXzUtMS0xLTEtNTA3MjU_a89e4a13-1434-46f7-a901-a5bb47b991e9"
      unitRef="shares">218612</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo1YzcxNGQ1OTcwNTY0ZTk3YTg2OTVhMjMxNTE4YWJlMi90YWJsZXJhbmdlOjVjNzE0ZDU5NzA1NjRlOTdhODY5NWEyMzE1MThhYmUyXzUtMy0xLTEtNTA3MjU_d0e7d9d7-19f6-484b-aded-41ffff91fe94"
      unitRef="usdPerShare">142.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo1YzcxNGQ1OTcwNTY0ZTk3YTg2OTVhMjMxNTE4YWJlMi90YWJsZXJhbmdlOjVjNzE0ZDU5NzA1NjRlOTdhODY5NWEyMzE1MThhYmUyXzUtNS0xLTEtNTA3MjU_b2db7a41-af5d-4386-847c-8f0c8850489e">P6Y6M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo1YzcxNGQ1OTcwNTY0ZTk3YTg2OTVhMjMxNTE4YWJlMi90YWJsZXJhbmdlOjVjNzE0ZDU5NzA1NjRlOTdhODY5NWEyMzE1MThhYmUyXzYtMS0xLTEtNTA3MjU_95748358-0963-4e46-b7af-88666970317c"
      unitRef="shares">163286</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo1YzcxNGQ1OTcwNTY0ZTk3YTg2OTVhMjMxNTE4YWJlMi90YWJsZXJhbmdlOjVjNzE0ZDU5NzA1NjRlOTdhODY5NWEyMzE1MThhYmUyXzYtMy0xLTEtNTA3MjU_c2f5893a-52d4-4129-a005-64cce3d12be2"
      unitRef="usdPerShare">122.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo1YzcxNGQ1OTcwNTY0ZTk3YTg2OTVhMjMxNTE4YWJlMi90YWJsZXJhbmdlOjVjNzE0ZDU5NzA1NjRlOTdhODY5NWEyMzE1MThhYmUyXzYtNS0xLTEtNTA3MjU_dfe42436-31d2-4964-a529-4c99c9a76aaa">P6Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i14c451d987c9475fa3c8992bc94cbf8f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzY3OTg_5e15d27c-c0f1-4d45-8a8b-21a2cd0c2ba1"
      unitRef="usd">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i14c451d987c9475fa3c8992bc94cbf8f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzY4MDU_b0822b99-77f1-4981-8a82-3de9cbf7f3e6"
      unitRef="usd">700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i06eb9ed545f04bdcbf647b341b4ab114_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzY4NzA_cb6157bf-74a6-46b4-a8e0-ecfcc469e5d1"
      unitRef="usd">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ic8002223ee9342dbb6725f50e35539b6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzY4NzQ_aa377f4a-4913-4348-a6c2-828cf1efaa13"
      unitRef="usd">5100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i15f9883719504dad940b79d91d5a68cf_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzY4ODE_789a73bd-04b6-4387-a419-2e32d43f3e3a"
      unitRef="usd">121100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="i06eb9ed545f04bdcbf647b341b4ab114_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzY5OTI_d7f242c5-09a1-4304-8cb8-fdb8a460de3c"
      unitRef="usd">400000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="ic8002223ee9342dbb6725f50e35539b6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzY5OTY_646103d9-0066-4fea-a8eb-505527c6c237"
      unitRef="usd">1000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="i15f9883719504dad940b79d91d5a68cf_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzcwMDM_f701659e-0139-4063-97c9-65ea16258457"
      unitRef="usd">27900000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <amed:SharedBasedPaymentArrangementNonVestedOptionActivityTableTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzEwMTQ2_ef5d8f56-1b45-4330-a59d-e5f89b661ff5">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our non-vested stock option activity for 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested stock options at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;182.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(64,496)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(43,273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested stock options at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:SharedBasedPaymentArrangementNonVestedOptionActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTozNWUzZGFhZmEzZWM0NjZlODhmODNlYTBiZjEzMWE1Yi90YWJsZXJhbmdlOjM1ZTNkYWFmYTNlYzQ2NmU4OGY4M2VhMGJmMTMxYTViXzEtMS0xLTEtNTA3MjU_809c547c-0c18-4826-9c08-33ac96d6e2bf"
      unitRef="shares">129439</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i3b13a726ce4740309bdc481148b0ab43_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTozNWUzZGFhZmEzZWM0NjZlODhmODNlYTBiZjEzMWE1Yi90YWJsZXJhbmdlOjM1ZTNkYWFmYTNlYzQ2NmU4OGY4M2VhMGJmMTMxYTViXzEtMy0xLTEtNTA3MjU_82bb4be3-7fe9-4210-bc40-3269e52a52c4"
      unitRef="usdPerShare">182.45</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTozNWUzZGFhZmEzZWM0NjZlODhmODNlYTBiZjEzMWE1Yi90YWJsZXJhbmdlOjM1ZTNkYWFmYTNlYzQ2NmU4OGY4M2VhMGJmMTMxYTViXzItMS0xLTEtNTA3MjU_ddc258fc-613f-4571-8a15-5df44d3c26bd"
      unitRef="shares">33656</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTozNWUzZGFhZmEzZWM0NjZlODhmODNlYTBiZjEzMWE1Yi90YWJsZXJhbmdlOjM1ZTNkYWFmYTNlYzQ2NmU4OGY4M2VhMGJmMTMxYTViXzItMy0xLTEtNTA3MjU_d2486796-f5fa-4925-8c93-938b20e4b8cf"
      unitRef="usdPerShare">143.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTozNWUzZGFhZmEzZWM0NjZlODhmODNlYTBiZjEzMWE1Yi90YWJsZXJhbmdlOjM1ZTNkYWFmYTNlYzQ2NmU4OGY4M2VhMGJmMTMxYTViXzMtMS0xLTEtNTA3MjU_84ef8c43-f6ba-435e-8f89-39160d817f4c"
      unitRef="shares">64496</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTozNWUzZGFhZmEzZWM0NjZlODhmODNlYTBiZjEzMWE1Yi90YWJsZXJhbmdlOjM1ZTNkYWFmYTNlYzQ2NmU4OGY4M2VhMGJmMTMxYTViXzMtMy0xLTEtNTA3MjU_2b3e22d7-b3d0-47bb-93fe-38f94b53463b"
      unitRef="usdPerShare">150.79</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTozNWUzZGFhZmEzZWM0NjZlODhmODNlYTBiZjEzMWE1Yi90YWJsZXJhbmdlOjM1ZTNkYWFmYTNlYzQ2NmU4OGY4M2VhMGJmMTMxYTViXzQtMS0xLTEtNTA3MjU_689ac8cd-9e49-44b5-bb39-83435bf05e5f"
      unitRef="shares">43273</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTozNWUzZGFhZmEzZWM0NjZlODhmODNlYTBiZjEzMWE1Yi90YWJsZXJhbmdlOjM1ZTNkYWFmYTNlYzQ2NmU4OGY4M2VhMGJmMTMxYTViXzQtMy0xLTEtNTA3MjU_dcc58f3d-df2c-4949-95c3-9b48ec98b2f5"
      unitRef="usdPerShare">173.11</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTozNWUzZGFhZmEzZWM0NjZlODhmODNlYTBiZjEzMWE1Yi90YWJsZXJhbmdlOjM1ZTNkYWFmYTNlYzQ2NmU4OGY4M2VhMGJmMTMxYTViXzUtMS0xLTEtNTA3MjU_780a130d-e170-4617-b4ab-09d0300189c3"
      unitRef="shares">55326</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ieb5d1b02f637456e95eba5e2817a09ea_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTozNWUzZGFhZmEzZWM0NjZlODhmODNlYTBiZjEzMWE1Yi90YWJsZXJhbmdlOjM1ZTNkYWFmYTNlYzQ2NmU4OGY4M2VhMGJmMTMxYTViXzUtMy0xLTEtNTA3MjU_f33363f4-4cd4-4729-9cb1-e4b01cd5abd3"
      unitRef="usdPerShare">202.81</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i14c451d987c9475fa3c8992bc94cbf8f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzcxMzI_846f79f1-de55-4c4b-868f-7715e39b7e6e"
      unitRef="usd">2000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i06eb9ed545f04bdcbf647b341b4ab114_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzcyNjA_985b6a63-4836-4dc4-9706-b345c9590167">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icd5a663f1bb844bab57b874fbf18534e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzgxOTI_f5c53bb6-803c-46c2-96f9-e1106395eed5"
      unitRef="usd">12100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i52a228fca81e41d693cd6d81c49a90c4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzgxOTY_064befd9-b396-44ec-bb27-1f7817b5c1ca"
      unitRef="usd">9400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i11c1dc78db0e49b68f847e221371a443_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzgyMDM_5512e455-3444-48b0-8102-8663d16c901f"
      unitRef="usd">7500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzEwMTMz_035dc0c8-1cbb-4c46-87f7-0a9e097d4883">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our service-based non-vested stock units activity for 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&#160;&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested stock units at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;211,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;115.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(59,006)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled, forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(70,025)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;194.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested stock units at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;263,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ifdd8f4e213094cc396d0fcbfc8c7cc13_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo3NDQyODI3YTA0ZDU0MDg1YmFhZmFjMjliODllNjYzZS90YWJsZXJhbmdlOjc0NDI4MjdhMDRkNTQwODViYWFmYWMyOWI4OWU2NjNlXzEtMS0xLTEtNTA3MjU_d66f80cb-efcb-4a0b-8d12-b2276880b3d5"
      unitRef="shares">180823</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ifdd8f4e213094cc396d0fcbfc8c7cc13_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo3NDQyODI3YTA0ZDU0MDg1YmFhZmFjMjliODllNjYzZS90YWJsZXJhbmdlOjc0NDI4MjdhMDRkNTQwODViYWFmYWMyOWI4OWU2NjNlXzEtMy0xLTEtNTA3MjU_df629705-0075-48c0-8266-273802f6a310"
      unitRef="usdPerShare">195.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="icd5a663f1bb844bab57b874fbf18534e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo3NDQyODI3YTA0ZDU0MDg1YmFhZmFjMjliODllNjYzZS90YWJsZXJhbmdlOjc0NDI4MjdhMDRkNTQwODViYWFmYWMyOWI4OWU2NjNlXzItMS0xLTEtNTA3MjU_1441b37c-3fd4-4e90-94aa-2caca853719a"
      unitRef="shares">211361</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="icd5a663f1bb844bab57b874fbf18534e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo3NDQyODI3YTA0ZDU0MDg1YmFhZmFjMjliODllNjYzZS90YWJsZXJhbmdlOjc0NDI4MjdhMDRkNTQwODViYWFmYWMyOWI4OWU2NjNlXzItMy0xLTEtNTA3MjU_74f484cb-ae66-46f1-ac26-14468cb0ccc3"
      unitRef="usdPerShare">115.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="icd5a663f1bb844bab57b874fbf18534e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo3NDQyODI3YTA0ZDU0MDg1YmFhZmFjMjliODllNjYzZS90YWJsZXJhbmdlOjc0NDI4MjdhMDRkNTQwODViYWFmYWMyOWI4OWU2NjNlXzMtMS0xLTEtNTA3MjU_f5733574-b19b-4642-8787-93fb1a2f57dd"
      unitRef="shares">59006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="icd5a663f1bb844bab57b874fbf18534e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo3NDQyODI3YTA0ZDU0MDg1YmFhZmFjMjliODllNjYzZS90YWJsZXJhbmdlOjc0NDI4MjdhMDRkNTQwODViYWFmYWMyOWI4OWU2NjNlXzMtMy0xLTEtNTA3MjU_635479cc-9bc7-49b3-a1dd-fb6f72621ffc"
      unitRef="usdPerShare">146.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="icd5a663f1bb844bab57b874fbf18534e_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo3NDQyODI3YTA0ZDU0MDg1YmFhZmFjMjliODllNjYzZS90YWJsZXJhbmdlOjc0NDI4MjdhMDRkNTQwODViYWFmYWMyOWI4OWU2NjNlXzQtMS0xLTEtNTA3MjU_bd4ce8f6-1f3f-4664-92ea-94ac4d7a614e"
      unitRef="shares">70025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="icd5a663f1bb844bab57b874fbf18534e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo3NDQyODI3YTA0ZDU0MDg1YmFhZmFjMjliODllNjYzZS90YWJsZXJhbmdlOjc0NDI4MjdhMDRkNTQwODViYWFmYWMyOWI4OWU2NjNlXzQtMy0xLTEtNTA3MjU_b3927131-b243-4a7f-be1c-485d4bec7d05"
      unitRef="usdPerShare">194.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i1e87c3e7b1004ea799c3dc520a7f0a4e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo3NDQyODI3YTA0ZDU0MDg1YmFhZmFjMjliODllNjYzZS90YWJsZXJhbmdlOjc0NDI4MjdhMDRkNTQwODViYWFmYWMyOWI4OWU2NjNlXzUtMS0xLTEtNTA3MjU_65949770-9276-46fe-8bc8-771adbdbdf2e"
      unitRef="shares">263153</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i1e87c3e7b1004ea799c3dc520a7f0a4e_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTo3NDQyODI3YTA0ZDU0MDg1YmFhZmFjMjliODllNjYzZS90YWJsZXJhbmdlOjc0NDI4MjdhMDRkNTQwODViYWFmYWMyOWI4OWU2NjNlXzUtMy0xLTEtNTA3MjU_4f54776b-30a3-47b1-a3bf-810879eb398e"
      unitRef="usdPerShare">141.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="icd5a663f1bb844bab57b874fbf18534e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4Xzg0MjM_aab19ca9-b50c-4fcb-97f1-0cb691bc2442"
      unitRef="usdPerShare">115.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i52a228fca81e41d693cd6d81c49a90c4_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4Xzg0Mjc_6d731d12-ebe6-4f87-b177-334f6b21633f"
      unitRef="usdPerShare">234.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i11c1dc78db0e49b68f847e221371a443_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4Xzg0MzQ_55fda94e-a3da-42d0-8832-e2cfe9d494fa"
      unitRef="usdPerShare">206.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i1e87c3e7b1004ea799c3dc520a7f0a4e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4Xzg0ODY_e0a65e52-8f8c-4dce-b63b-5cee7313c8ae"
      unitRef="usd">22600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="icd5a663f1bb844bab57b874fbf18534e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4Xzg2NDE_4df8cbd1-9cb5-413d-8358-920ced97a76f">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <amed:Performancebasedawardtargetshareamount
      contextRef="i082da853b55e488ab9ef8c389ed4b49f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzkwNTk_0c359ec4-d062-4ff6-b30a-f3364ea8ec40"
      unitRef="shares">71349</amed:Performancebasedawardtargetshareamount>
    <amed:AdditionalPerformanceBasedAwardTargetShareAmount
      contextRef="i082da853b55e488ab9ef8c389ed4b49f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzkyOTY_739a2f17-e467-4930-8c6a-16b5f2bdbf98"
      unitRef="shares">32048</amed:AdditionalPerformanceBasedAwardTargetShareAmount>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i082da853b55e488ab9ef8c389ed4b49f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4Xzk2NTM_b6af5307-0e02-4bd0-aaab-8bf22ef82a2c"
      unitRef="usd">2200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia5b0758fc5c841c69f0e3000600e3618_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4Xzk2NTc_c7135539-5a69-4d14-85a4-ac4556196493"
      unitRef="usd">10200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iecabe05cd8be4b96a216b1a6513dcb34_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4Xzk2NjQ_fd37aab0-eced-4213-b670-0416cf21713c"
      unitRef="usd">13500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzEwMTI4_c95a5fbd-4647-417d-ba32-defd02799475">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our performance-based non-vested stock units activity for 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&#160;&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested stock units at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;186,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;206.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(85,767)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;156.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled, forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(104,486)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;237.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-vested stock units at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i5aa28b6040cd4209a28424a8ddb8c083_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTphYmRjZDZkMjliMDk0MTNiYWUxZmQ0YzVlYzNkMmVhYS90YWJsZXJhbmdlOmFiZGNkNmQyOWIwOTQxM2JhZTFmZDRjNWVjM2QyZWFhXzEtMS0xLTEtNTA3MjU_8628ace9-918f-4cba-ab72-cd1cb8917743"
      unitRef="shares">186951</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i5aa28b6040cd4209a28424a8ddb8c083_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTphYmRjZDZkMjliMDk0MTNiYWUxZmQ0YzVlYzNkMmVhYS90YWJsZXJhbmdlOmFiZGNkNmQyOWIwOTQxM2JhZTFmZDRjNWVjM2QyZWFhXzEtMy0xLTEtNTA3MjU_15659e33-e49a-4254-ba3e-fe3abe033661"
      unitRef="usdPerShare">206.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i082da853b55e488ab9ef8c389ed4b49f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTphYmRjZDZkMjliMDk0MTNiYWUxZmQ0YzVlYzNkMmVhYS90YWJsZXJhbmdlOmFiZGNkNmQyOWIwOTQxM2JhZTFmZDRjNWVjM2QyZWFhXzItMS0xLTEtNTA3MjU_28de8a81-488a-417b-bb42-1ae1566bdd6a"
      unitRef="shares">71349</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i082da853b55e488ab9ef8c389ed4b49f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTphYmRjZDZkMjliMDk0MTNiYWUxZmQ0YzVlYzNkMmVhYS90YWJsZXJhbmdlOmFiZGNkNmQyOWIwOTQxM2JhZTFmZDRjNWVjM2QyZWFhXzItMy0xLTEtNTA3MjU_96d22bd5-c103-4a69-9379-1091938a4715"
      unitRef="usdPerShare">133.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i082da853b55e488ab9ef8c389ed4b49f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTphYmRjZDZkMjliMDk0MTNiYWUxZmQ0YzVlYzNkMmVhYS90YWJsZXJhbmdlOmFiZGNkNmQyOWIwOTQxM2JhZTFmZDRjNWVjM2QyZWFhXzMtMS0xLTEtNTA3MjU_41b9770c-cc13-446f-8f99-45e8aa2d9e14"
      unitRef="shares">85767</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i082da853b55e488ab9ef8c389ed4b49f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTphYmRjZDZkMjliMDk0MTNiYWUxZmQ0YzVlYzNkMmVhYS90YWJsZXJhbmdlOmFiZGNkNmQyOWIwOTQxM2JhZTFmZDRjNWVjM2QyZWFhXzMtMy0xLTEtNTA3MjU_96b426e7-df66-47db-b913-cbdb50df71eb"
      unitRef="usdPerShare">156.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i082da853b55e488ab9ef8c389ed4b49f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTphYmRjZDZkMjliMDk0MTNiYWUxZmQ0YzVlYzNkMmVhYS90YWJsZXJhbmdlOmFiZGNkNmQyOWIwOTQxM2JhZTFmZDRjNWVjM2QyZWFhXzQtMS0xLTEtNTA3MjU_e8bf5e0e-3116-41b7-b261-863e7476d675"
      unitRef="shares">104486</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i082da853b55e488ab9ef8c389ed4b49f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTphYmRjZDZkMjliMDk0MTNiYWUxZmQ0YzVlYzNkMmVhYS90YWJsZXJhbmdlOmFiZGNkNmQyOWIwOTQxM2JhZTFmZDRjNWVjM2QyZWFhXzQtMy0xLTEtNTA3MjU_52b15943-c3f1-4a69-85b7-22658e42a790"
      unitRef="usdPerShare">237.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i2d8e565a484b4115a30a498efd2fead8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTphYmRjZDZkMjliMDk0MTNiYWUxZmQ0YzVlYzNkMmVhYS90YWJsZXJhbmdlOmFiZGNkNmQyOWIwOTQxM2JhZTFmZDRjNWVjM2QyZWFhXzUtMS0xLTEtNTA3MjU_317af6e6-b212-4830-8ae8-54039efdf5a8"
      unitRef="shares">68047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i2d8e565a484b4115a30a498efd2fead8_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90YWJsZTphYmRjZDZkMjliMDk0MTNiYWUxZmQ0YzVlYzNkMmVhYS90YWJsZXJhbmdlOmFiZGNkNmQyOWIwOTQxM2JhZTFmZDRjNWVjM2QyZWFhXzUtMy0xLTEtNTA3MjU_0a203911-da95-4e83-8091-581ee75334a0"
      unitRef="usdPerShare">144.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i082da853b55e488ab9ef8c389ed4b49f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4Xzk4OTI_96681dbb-e37a-49ab-b327-bc7a14898cfa"
      unitRef="usdPerShare">133.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia5b0758fc5c841c69f0e3000600e3618_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4Xzk4OTY_4125353f-f0c5-430d-81fc-274fe1f997b6"
      unitRef="usdPerShare">262.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iecabe05cd8be4b96a216b1a6513dcb34_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4Xzk5MDM_bb1d2e6e-197b-4803-9784-204d54a64d44"
      unitRef="usdPerShare">201.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i2d8e565a484b4115a30a498efd2fead8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4Xzk5NTU_eec2f5bd-f84b-42fa-9388-4a4f3ca6cf4c"
      unitRef="usd">1100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i082da853b55e488ab9ef8c389ed4b49f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMjQvZnJhZzpjZTYzYjJjMzIwZDA0OTE2OTY5MWZkMGQ4ZThmZGE0OC90ZXh0cmVnaW9uOmNlNjNiMmMzMjBkMDQ5MTY5NjkxZmQwZDhlOGZkYTQ4XzEwMTE1_1a691d2d-59aa-4a02-84c6-ba02e4f23cc6">P1Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzE0MjQ1_ac8e1eb1-c025-4294-a1e6-546536ee5319">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings &#x2013; Ongoing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. Based on information available to us as of the date of this filing, we do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legal fees related to all legal matters are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings - Completed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Subpoena Duces Tecum and Civil Investigative Demands Issued by the U.S. Department of Justice&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 7, 2021, the U.S. Department of Justice notified the Company that they were closing their investigation into the below-referenced Subpoena Duces Tecum ("Subpoena") and civil investigative demands ("CIDs"). At the time, we had $6.5&#160;million recorded to accrued expenses in our consolidated balance sheets related to these matters. We reversed this accrual during the three-month period ended June 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May&#160;21, 2015, we received a Subpoena issued by the U.S. Department of Justice. The Subpoena requested the delivery of information regarding 53 identified hospice patients to the United States Attorney&#x2019;s Office for the District of Massachusetts. It also requested the delivery of documents relating to our hospice clinical and business operations and related compliance activities. The Subpoena generally covered the period from January&#160;1, 2011 through May 21, 2015. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;3, 2015, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Morgantown, West Virginia area. The CID requested the delivery of information to the United States Attorney&#x2019;s Office for the Northern District of West Virginia regarding 66 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Morgantown area. The CID generally covered the period from January&#160;1, 2009 through August&#160;31, 2015.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June&#160;27, 2016, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Parkersburg, West Virginia area. The CID requested the delivery of information to the United States Attorney&#x2019;s Office for the Southern District of West Virginia regarding 68 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Parkersburg area. The CID generally covered the period from January&#160;1, 2011 through June&#160;20, 2016. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Third Party Audits &#x2013; Ongoing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, in the ordinary course of business, we are subject to audits under various governmental programs in which third party firms engaged by CMS, including Recovery Audit Contractors (&#x201c;RACs&#x201d;), Zone Program Integrity Contractors (&#x201c;ZPICs&#x201d;), Uniform Program Integrity Contractors (&#x201c;UPICs&#x201d;), Program Safeguard Contractors (&#x201c;PSCs&#x201d;), Medicaid Integrity Contractors (&#x201c;MICs&#x201d;), Supplemental Medical Review Contractors (&#x201c;SMRCs&#x201d;) and the Office of the Inspector General ("OIG"), conduct extensive reviews of claims data to identify potential improper payments. We cannot predict the ultimate outcome of any regulatory reviews or other governmental audits and investigations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a ZPIC a request for records regarding a sample of 30 beneficiaries who received services from the subsidiary during the period of January&#160;1, 2008 through March&#160;31, 2010 (the &#x201c;Review Period&#x201d;) to determine whether the underlying services met pertinent Medicare payment requirements.&#160;We acquired the hospice operations subject to this review on August&#160;1, 2009; the Review Period covers time periods both before and after our ownership of these hospice operations.&#160;Based on the ZPIC&#x2019;s findings for 16 beneficiaries, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June&#160;6, 2011, the Medicare Administrative Contractor ("MAC") for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment. We dispute these findings, and our Florence subsidiary has filed appeals through the Original Medicare Standard Appeals Process, in which we are seeking to have those findings overturned. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An administrative law judge ("ALJ") hearing was held in early January 2015. On January&#160;18, 2016, we received a letter dated January&#160;6, 2016 referencing the ALJ hearing decision for the overpayment issued on June&#160;6, 2011. The decision was partially favorable with a new overpayment amount of $3.7 million with a balance owed of $5.6 million including interest based on 9 disputed claims (originally 16). We filed an appeal to the Medicare Appeals Council on the remaining 9 disputed claims and also argued that the statistical method used to select the sample was not valid.&#160;No assurances can be given as to the timing or outcome of the Medicare Appeals Council decision. As of December 31, 2022, Medicare has withheld payments of $5.7 million (including additional interest) as part of their standard procedures once this level of the appeal process has been reached. In the event we are not able to recoup this alleged overpayment, we are entitled to be indemnified by the prior owners of the hospice operations for amounts relating to the period prior to August&#160;1, 2009. On January 10, 2019, an arbitration panel from the American Health Lawyers Association determined that the prior owners' liability for their indemnification obligation was $2.8 million. This amount is recorded as an indemnity receivable within other assets in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:2.25pt;padding-right:11.25pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2016, the Company received a request for medical records from SafeGuard Services, L.L.C (&#x201c;SafeGuard&#x201d;), a ZPIC, related to services provided by some of the care centers that the Company acquired from Infinity Home Care, L.L.C. The review period covered time periods both before and after our ownership of the care centers, which were acquired on December 31, 2015. In August 2017, the Company received Requests for Repayment from Palmetto GBA, LLC (&#x201c;Palmetto&#x201d;) regarding Infinity Home Care of Lakeland, LLC, (&#x201c;Lakeland Care Centers&#x201d;) and Infinity Home Care of Pinellas, LLC, (&#x201c;Clearwater Care Center&#x201d;). The Palmetto letters were based on a statistical extrapolation performed by SafeGuard which alleged an overpayment of $34.0 million for the Lakeland Care Centers on a universe of 72 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate and an overpayment of $4.8 million for the Clearwater Care Center on a universe of 70 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:2.25pt;padding-right:11.25pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Lakeland Request for Repayment covered claims between January 2, 2014 and September 13, 2016. The Clearwater Request for Repayment covered claims between January 2, 2015 and December 9, 2016. As a result of partially successful Level I and Level II Administrative Appeals, the alleged overpayment for the Lakeland Care Centers was reduced to $26.0 million and the alleged overpayment for the Clearwater Care Center was reduced to $3.3 million. The Company filed Level III Administrative Appeals, and the ALJ hearings regarding the Lakeland Request for Repayment and the Clearwater Request for Repayment were held in April 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:2.25pt;padding-right:11.25pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received the results of the ALJ hearings for the Clearwater Care Center and the Lakeland Care Centers on June 23, 2022 and June 30, 2022, respectively. The ALJ decisions for both the Clearwater Care Center and the Lakeland Care Centers were partially favorable for the claims that were reviewed, but the extrapolations were upheld. As a result, we increased our total accrual related to these matters from $17.4&#160;million to $25.8&#160;million during the three-month period ended June 30, 2022. The net of these two amounts, $8.4&#160;million, was recorded as a reduction to net service revenue in our consolidated statement of operations during the three-month period ended June 30, 2022. We received demands for repayment from Palmetto for both the Clearwater Care Center and the Lakeland Care Centers during the three-month period ended September 30, 2022. The demands were slightly less than our estimated accrual of $25.8&#160;million. During the three-month period ended September 30, 2022, we adjusted our accrual to $25.2&#160;million to reflect the final amounts owed, excluding interest. The repayment for the Lakeland Care Centers totaling $34.3&#160;million ($22.8&#160;million extrapolated repayment plus $11.5&#160;million accrued interest) was made during the three-month period ended September 30, 2022. The repayment for the Clearwater Care Center totaling $3.7&#160;million ($2.4&#160;million extrapolated repayment plus $1.2&#160;million accrued interest) was made during the three-month period ended December 31, 2022. Additionally, we wrote off $1.5&#160;million of receivables that were impacted by these matters. We expect to be indemnified by the prior owners, upon exhaustion of the parties' appeal rights, for approximately $10.9&#160;million and have recorded this amount within other assets in our consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Insurance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are obligated for certain costs associated with our insurance programs, including employee health, workers&#x2019; compensation and professional liability. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs, up to specified deductible limits in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents details of our insurance programs, including amounts recorded, for the periods indicated within accrued expenses in our consolidated balance sheets. The amounts below represent our total estimated liability for individual &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;claims that are less than our noted insurance coverage amounts, which can include outstanding claims and claims incurred but not reported (amounts in millions).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.035%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.164%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.196%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.941%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.199%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Type of Insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Health insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our health insurance has an exposure limit of $1.3 million for any individual covered life. Our workers compensation insurance has a retention limit of $2.0 million per incident, and our professional liability insurance has a retention limit of $0.3 million per incident. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Severance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have commitments related to our severance plans applicable to a number of our senior executives and senior management, which generally commit us to pay severance benefits under certain circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to various other types of claims and disputes arising in the ordinary course of our business. While the resolution of such issues is not presently determinable, we believe that the ultimate resolution of such matters will not have a significant effect on our consolidated financial condition, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i72f8833e23b44a2ea0d2a7d9a3387fad_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3Xzg5OA_336ec972-779f-41eb-9790-d737a453aee4"
      unitRef="usd">6500000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <amed:ReversalOfLossContingencyAccrual
      contextRef="ic191fcc8192b4608959c14133dc12c5e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3Xzg5OA_c3a69ad9-c222-4c8a-b4bb-984abb1b7398"
      unitRef="usd">6500000</amed:ReversalOfLossContingencyAccrual>
    <amed:Numberofpatients
      contextRef="ieba00eb7d405413d818c4971105613ee_D20150521-20150521"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzEyMTA_23bc3bc1-99d3-4196-8f1a-c00fb48d5246"
      unitRef="patient">53</amed:Numberofpatients>
    <amed:Numberofpatients
      contextRef="i8d55411f20e04d00a2eea8301fc2ae5a_D20151103-20151103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzE5NTI_b76784e4-6e5c-4068-904a-c05a9441077e"
      unitRef="patient">66</amed:Numberofpatients>
    <amed:Numberofpatients
      contextRef="i011327a38e254fcaa937ffb2732985d4_D20160627-20160627"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzI1ODI_1593d42b-e81d-4353-b3df-c5511a644627"
      unitRef="patient">68</amed:Numberofpatients>
    <amed:NumberOfBeneficiaries
      contextRef="ic16a0c94f3004de7b7a900a946d92672_D20080101-20100331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzY4ODU_89df6d15-523e-4a17-a1ae-ab1ab9e3a4d7"
      unitRef="beneficiary">30</amed:NumberOfBeneficiaries>
    <amed:NumberOfBeneficiaries
      contextRef="if1bca261c0b946248dfe5cee858c643d_D20110606-20110606"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzczMjk_73c541aa-7ac5-4b35-84c7-b99fdd9c3b7a"
      unitRef="beneficiary">16</amed:NumberOfBeneficiaries>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="i5d52cf787d4f4a21ba644c6537028eca_I20160118"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzgxMzI_615d6aab-1681-4ec5-a38b-7d7d8eb3b976"
      unitRef="usd">3700000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest
      contextRef="i5d52cf787d4f4a21ba644c6537028eca_I20160118"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzgxNTg_6316e065-82b3-4548-9dba-ff0dcfb3452f"
      unitRef="usd">5600000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest>
    <amed:NumberOfClaimsSubmittedBySubsidiary
      contextRef="ibd850077008b489db6c689d6678a854b_D20160118-20160118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzgxODk_e59ca91e-056d-453e-a69a-12b13f8826d1"
      unitRef="claim">9</amed:NumberOfClaimsSubmittedBySubsidiary>
    <amed:NumberOfBeneficiaries
      contextRef="if1bca261c0b946248dfe5cee858c643d_D20110606-20110606"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzgyMjA_73c541aa-7ac5-4b35-84c7-b99fdd9c3b7a"
      unitRef="beneficiary">16</amed:NumberOfBeneficiaries>
    <amed:NumberOfClaimsSubmittedBySubsidiary
      contextRef="ibd850077008b489db6c689d6678a854b_D20160118-20160118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzgyOTM_e59ca91e-056d-453e-a69a-12b13f8826d1"
      unitRef="claim">9</amed:NumberOfClaimsSubmittedBySubsidiary>
    <amed:Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld
      contextRef="if8e53a67d325418698e7dff0da8ae0f8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3Xzg1NTM_eda25102-6908-4e98-a63a-6dae0d7cbaba"
      unitRef="usd">5700000</amed:Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld>
    <us-gaap:LossContingencyReceivableNoncurrent
      contextRef="i29b899adcb534d2fb11ae45ba13dffa5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzkwNTg_09ce0ef8-f484-445f-be12-469b7b35de86"
      unitRef="usd">2800000</us-gaap:LossContingencyReceivableNoncurrent>
    <amed:IndemnificationAmount
      contextRef="i38abfa2908c74f76a39c59f03f0a1f88_I20190110"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzkwNTg_6fdb0027-50bf-4210-bf83-f47f2e0c7fac"
      unitRef="usd">2800000</amed:IndemnificationAmount>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="i5ad4b2a4d1904246a60f312fe6e54a55_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3Xzk4OTU_c61da3d7-2e04-45b8-9c41-e48cf48c45f3"
      unitRef="usd">34000000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:NumberOfClaimsSubmittedBySubsidiary
      contextRef="i5d9c1bb997894061aeafb6aabddeffd5_D20170801-20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3Xzk5NDU_36466948-1fdd-4da8-a45a-c70a9901150f"
      unitRef="claim">72</amed:NumberOfClaimsSubmittedBySubsidiary>
    <amed:ActualClaimsPayment
      contextRef="i5ad4b2a4d1904246a60f312fe6e54a55_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3Xzk5NzM_0fa1bc78-5466-4d95-98ec-e4f521badb97"
      unitRef="usd">200000</amed:ActualClaimsPayment>
    <amed:ErrorRatePercentage
      contextRef="i5ad4b2a4d1904246a60f312fe6e54a55_I20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzEwMDEw_7a1203fe-307c-4b17-b7a6-4bff59e8cd5e"
      unitRef="number">1</amed:ErrorRatePercentage>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="id957a4e2cf624f1f8c0755fef660c4fc_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzEwMDQ2_a07aa546-8f98-4924-8efd-6b0e242d865b"
      unitRef="usd">4800000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:NumberOfClaimsSubmittedBySubsidiary
      contextRef="ica936df2e1054ec1b0ff8eb6510dfbcb_D20170801-20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzEwMDk3_a0e3b443-ab27-4eee-8b4a-8c984824ef31"
      unitRef="claim">70</amed:NumberOfClaimsSubmittedBySubsidiary>
    <amed:ActualClaimsPayment
      contextRef="id957a4e2cf624f1f8c0755fef660c4fc_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzEwMTI1_e50612d1-ffd4-407d-82ec-49719281f73e"
      unitRef="usd">200000</amed:ActualClaimsPayment>
    <amed:ErrorRatePercentage
      contextRef="id957a4e2cf624f1f8c0755fef660c4fc_I20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzEwMTYy_61d3129f-bbcd-4fb6-be87-ec6f357dff43"
      unitRef="number">1</amed:ErrorRatePercentage>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="i7d88d76487a74a848baa03e874a5eccd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzEwNTI4_557a48e6-7545-48b8-afbd-61568458375f"
      unitRef="usd">26000000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="ieaeca3977d8a40ec9994588b4150109b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzEwNjEw_2b11bf8d-f387-4bf3-ad27-b6aab49bd56f"
      unitRef="usd">3300000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="id2c6967c53284f0ea2b6b8001c55cacd_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzU0OTc1NTgzODU3Nw_b9853a7d-edd8-4412-9b6e-5677c4bdab3a"
      unitRef="usd">17400000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i7c5014c365be4c5d90c38959f215dfb5_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzU0OTc1NTgzODU5Mg_94531069-6008-4696-8f43-73905bfd9679"
      unitRef="usd">25800000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <amed:ReductionToNetServiceRevenue
      contextRef="ieefca07772a441c18ef7fd78ee354800_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzU0OTc1NTgzODYwNw_e8488a68-1946-4707-83df-968881b215bf"
      unitRef="usd">8400000</amed:ReductionToNetServiceRevenue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i7c5014c365be4c5d90c38959f215dfb5_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzU0OTc1NTgzODYyMQ_f5e94adb-1052-4855-9872-42a03484cd1a"
      unitRef="usd">25800000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="ic41315c634e841cc9d84abadce65303b_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzU0OTc1NTgzODYzNg_9378be21-a6fb-4ba6-a067-74f7f5641652"
      unitRef="usd">25200000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <amed:TotalLegalSettlementPayment
      contextRef="i868f83b3f18641769d70c97c93d30912_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzU0OTc1NTgzODY1MQ_ba8821bd-d4de-4f40-b245-20abb7ae87d2"
      unitRef="usd">34300000</amed:TotalLegalSettlementPayment>
    <amed:LegalSettlementPaymentLessInterest
      contextRef="i868f83b3f18641769d70c97c93d30912_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzU0OTc1NTgzODY2Ng_1efa04cb-50fd-4747-b322-9ef01672a6a8"
      unitRef="usd">22800000</amed:LegalSettlementPaymentLessInterest>
    <us-gaap:LitigationSettlementInterest
      contextRef="i868f83b3f18641769d70c97c93d30912_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzU0OTc1NTgzODY4MQ_af49e68f-36de-4f94-b1d4-4832b54087fe"
      unitRef="usd">11500000</us-gaap:LitigationSettlementInterest>
    <amed:TotalLegalSettlementPayment
      contextRef="ib79f3470b4c9406fa918cc4fbe458ad1_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzU0OTc1NTgzODY5Ng_22661d0b-d757-4a61-ae04-949ee76e8a57"
      unitRef="usd">3700000</amed:TotalLegalSettlementPayment>
    <amed:LegalSettlementPaymentLessInterest
      contextRef="ib79f3470b4c9406fa918cc4fbe458ad1_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzU0OTc1NTgzODcxMA_9873fff9-5348-42a7-a935-c83d799b6eed"
      unitRef="usd">2400000</amed:LegalSettlementPaymentLessInterest>
    <us-gaap:LitigationSettlementInterest
      contextRef="ib79f3470b4c9406fa918cc4fbe458ad1_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzU0OTc1NTgzODcyNA_707ad797-0dbd-412b-a6b3-12530d29d88c"
      unitRef="usd">1200000</us-gaap:LitigationSettlementInterest>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="ie2ead6d6a5b24846a24cab167648cd41_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzU0OTc1NTgzODczOA_53965471-326a-41d3-9e5c-d2baae36d687"
      unitRef="usd">1500000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:LossContingencyReceivableNoncurrent
      contextRef="i23cfc9c5f5334cb98796bce037009c13_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzU0OTc1NTgzODc1Mg_679d615f-8ef0-4162-ae50-9da92f0ee6fb"
      unitRef="usd">10900000</us-gaap:LossContingencyReceivableNoncurrent>
    <amed:InsuranceProgramsTableTableTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzE0MjQw_c46f308e-5e3b-4e29-9404-30dcc1792881">The following table presents details of our insurance programs, including amounts recorded, for the periods indicated within accrued expenses in our consolidated balance sheets. The amounts below represent our total estimated liability for individual &lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;claims that are less than our noted insurance coverage amounts, which can include outstanding claims and claims incurred but not reported (amounts in millions).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:64.035%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.164%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.196%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.941%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.199%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Type of Insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Health insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:InsuranceProgramsTableTableTextBlock>
    <amed:HealthInsurance
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90YWJsZTo0YjIzNzM3ZjY4NmM0YWI1OTYzMzVhMjE5ZDg2MmMyZi90YWJsZXJhbmdlOjRiMjM3MzdmNjg2YzRhYjU5NjMzNWEyMTlkODYyYzJmXzItMS0xLTEtNTA3MjU_3ad6e5c1-e14c-4fc2-8843-cd1e4aa77061"
      unitRef="usd">16200000</amed:HealthInsurance>
    <amed:HealthInsurance
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90YWJsZTo0YjIzNzM3ZjY4NmM0YWI1OTYzMzVhMjE5ZDg2MmMyZi90YWJsZXJhbmdlOjRiMjM3MzdmNjg2YzRhYjU5NjMzNWEyMTlkODYyYzJmXzItMy0xLTEtNTA3MjU_62004978-6120-40f2-883d-0ad8ac7d069d"
      unitRef="usd">16200000</amed:HealthInsurance>
    <amed:WokersCompensation
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90YWJsZTo0YjIzNzM3ZjY4NmM0YWI1OTYzMzVhMjE5ZDg2MmMyZi90YWJsZXJhbmdlOjRiMjM3MzdmNjg2YzRhYjU5NjMzNWEyMTlkODYyYzJmXzMtMS0xLTEtNTA3MjU_eb95ba79-d907-43b7-8a87-c8611a72147f"
      unitRef="usd">40800000</amed:WokersCompensation>
    <amed:WokersCompensation
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90YWJsZTo0YjIzNzM3ZjY4NmM0YWI1OTYzMzVhMjE5ZDg2MmMyZi90YWJsZXJhbmdlOjRiMjM3MzdmNjg2YzRhYjU5NjMzNWEyMTlkODYyYzJmXzMtMy0xLTEtNTA3MjU_831f9801-b5d7-46e9-94cb-e2565cd8979d"
      unitRef="usd">40500000</amed:WokersCompensation>
    <amed:ProfessionalLiability
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90YWJsZTo0YjIzNzM3ZjY4NmM0YWI1OTYzMzVhMjE5ZDg2MmMyZi90YWJsZXJhbmdlOjRiMjM3MzdmNjg2YzRhYjU5NjMzNWEyMTlkODYyYzJmXzQtMS0xLTEtNTA3MjU_2f812967-a579-4ee1-a8c5-5889eb91d14b"
      unitRef="usd">5000000.0</amed:ProfessionalLiability>
    <amed:ProfessionalLiability
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90YWJsZTo0YjIzNzM3ZjY4NmM0YWI1OTYzMzVhMjE5ZDg2MmMyZi90YWJsZXJhbmdlOjRiMjM3MzdmNjg2YzRhYjU5NjMzNWEyMTlkODYyYzJmXzQtMy0xLTEtNTA3MjU_87d89f25-f432-435a-a543-d263100ca75f"
      unitRef="usd">5200000</amed:ProfessionalLiability>
    <amed:EstimatedInsuranceTotal
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90YWJsZTo0YjIzNzM3ZjY4NmM0YWI1OTYzMzVhMjE5ZDg2MmMyZi90YWJsZXJhbmdlOjRiMjM3MzdmNjg2YzRhYjU5NjMzNWEyMTlkODYyYzJmXzUtMS0xLTEtNTA3MjU_dccba1d5-4ad2-4b53-8997-fb801253ac35"
      unitRef="usd">62000000.0</amed:EstimatedInsuranceTotal>
    <amed:EstimatedInsuranceTotal
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90YWJsZTo0YjIzNzM3ZjY4NmM0YWI1OTYzMzVhMjE5ZDg2MmMyZi90YWJsZXJhbmdlOjRiMjM3MzdmNjg2YzRhYjU5NjMzNWEyMTlkODYyYzJmXzUtMy0xLTEtNTA3MjU_1fb5d68a-04e1-40b1-8154-af99968eaf6c"
      unitRef="usd">61900000</amed:EstimatedInsuranceTotal>
    <amed:EstimatedInsuranceLongTermPortion
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90YWJsZTo0YjIzNzM3ZjY4NmM0YWI1OTYzMzVhMjE5ZDg2MmMyZi90YWJsZXJhbmdlOjRiMjM3MzdmNjg2YzRhYjU5NjMzNWEyMTlkODYyYzJmXzYtMS0xLTEtNjI4MzE_338a0f50-80a0-4dd2-a03c-c7e2d320fe5e"
      unitRef="usd">200000</amed:EstimatedInsuranceLongTermPortion>
    <amed:EstimatedInsuranceLongTermPortion
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90YWJsZTo0YjIzNzM3ZjY4NmM0YWI1OTYzMzVhMjE5ZDg2MmMyZi90YWJsZXJhbmdlOjRiMjM3MzdmNjg2YzRhYjU5NjMzNWEyMTlkODYyYzJmXzYtMy0xLTEtNjI4MzE_f4d0f4f5-6baa-43fb-8935-2a52cccc355f"
      unitRef="usd">200000</amed:EstimatedInsuranceLongTermPortion>
    <amed:EstimatedInsuranceExcludingLongTermPortion
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90YWJsZTo0YjIzNzM3ZjY4NmM0YWI1OTYzMzVhMjE5ZDg2MmMyZi90YWJsZXJhbmdlOjRiMjM3MzdmNjg2YzRhYjU5NjMzNWEyMTlkODYyYzJmXzctMS0xLTEtNjI4MzE_1a7bfdf3-ccc8-4d62-9f8c-63ce8d8cee8a"
      unitRef="usd">61800000</amed:EstimatedInsuranceExcludingLongTermPortion>
    <amed:EstimatedInsuranceExcludingLongTermPortion
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90YWJsZTo0YjIzNzM3ZjY4NmM0YWI1OTYzMzVhMjE5ZDg2MmMyZi90YWJsZXJhbmdlOjRiMjM3MzdmNjg2YzRhYjU5NjMzNWEyMTlkODYyYzJmXzctMy0xLTEtNjI4MzE_ac176f1b-7fe0-4671-8ebb-e50681606acb"
      unitRef="usd">61700000</amed:EstimatedInsuranceExcludingLongTermPortion>
    <amed:HealthInsuranceRetentionLimit
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzEzNDgx_bf2b375a-8e96-4456-9637-f4d8eefaf70e"
      unitRef="usd">1300000</amed:HealthInsuranceRetentionLimit>
    <amed:WorkersCompensationInsuranceRetentionLimit
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzEzNTc3_2d94eb5e-b78f-43b3-8df4-93247372fe43"
      unitRef="usd">2000000</amed:WorkersCompensationInsuranceRetentionLimit>
    <amed:ProfessionalLiabilityInsuranceRetentionLimit
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzAvZnJhZzplZmM0ODE4Y2EwNDI0OWZkYjk5MGM0MjIzOTYxMTc1Ny90ZXh0cmVnaW9uOmVmYzQ4MThjYTA0MjQ5ZmRiOTkwYzQyMjM5NjExNzU3XzEzNjU5_a8fe32a9-16f3-4a0c-a74b-2fb48f1677bf"
      unitRef="usd">300000</amed:ProfessionalLiabilityInsuranceRetentionLimit>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzYvZnJhZzo0YmE2YWI5Nzk0OGQ0OGY3YmFhMTE1OWE0MzBhMDhmOS90ZXh0cmVnaW9uOjRiYTZhYjk3OTQ4ZDQ4ZjdiYWExMTU5YTQzMGEwOGY5XzE2NDk_fb267374-cecb-48e1-8c9b-a2a14f8a7f97">EMPLOYEE BENEFIT PLANS&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;401(k) Benefit Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain a plan qualified under Section 401(k) of the Internal Revenue Code for all employees who have reached 21 years of age, effective the first month after their hire date. Under the plan, eligible employees may elect to defer a portion of their compensation, subject to Internal Revenue Service limits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our match of contributions to be made to each eligible employee contribution is $0.44 for every $1.00 contributed up to the first 6% of the employee's salary. The match is discretionary and thus is subject to change at the discretion of management. Our match of contributions is made in the form of cash. We expensed approximately $18.6 million, $17.0 million and $12.9 million related to our 401(k) benefit plan for 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Compensation Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had a Deferred Compensation Plan for additional tax-deferred savings for a select group of management or highly compensated employees. Amounts credited under the Deferred Compensation Plan were funded into a rabbi trust, which is managed by a trustee. The trustee has the discretion to manage the assets of the Deferred Compensation Plan as deemed fit, thus, the assets are not necessarily reflective of the same investment choices that would have been made by the participants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January&#160;1, 2015, all prospective salary deferrals ceased. Participants are allowed to make transactions with any remaining account balances as they wish per plan guidelines.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <amed:DefinedContributionPlanEmployerMatchingContribution
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzYvZnJhZzo0YmE2YWI5Nzk0OGQ0OGY3YmFhMTE1OWE0MzBhMDhmOS90ZXh0cmVnaW9uOjRiYTZhYjk3OTQ4ZDQ4ZjdiYWExMTU5YTQzMGEwOGY5XzQ0Mw_a98cdd23-ea56-4a2a-8df8-20ecbc820c1b"
      unitRef="usd">0.44</amed:DefinedContributionPlanEmployerMatchingContribution>
    <amed:DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzYvZnJhZzo0YmE2YWI5Nzk0OGQ0OGY3YmFhMTE1OWE0MzBhMDhmOS90ZXh0cmVnaW9uOjRiYTZhYjk3OTQ4ZDQ4ZjdiYWExMTU5YTQzMGEwOGY5XzQ1Ng_a43f96a1-263d-4328-bf1a-d72dcada08bb"
      unitRef="usd">1.00</amed:DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram>
    <amed:DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzYvZnJhZzo0YmE2YWI5Nzk0OGQ0OGY3YmFhMTE1OWE0MzBhMDhmOS90ZXh0cmVnaW9uOjRiYTZhYjk3OTQ4ZDQ4ZjdiYWExMTU5YTQzMGEwOGY5XzQ4Nw_c9661498-ac0c-49f5-a167-9e7976173506"
      unitRef="number">0.06</amed:DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzYvZnJhZzo0YmE2YWI5Nzk0OGQ0OGY3YmFhMTE1OWE0MzBhMDhmOS90ZXh0cmVnaW9uOjRiYTZhYjk3OTQ4ZDQ4ZjdiYWExMTU5YTQzMGEwOGY5Xzg3NQ_42e414f3-89f2-4271-803e-474bddc52345"
      unitRef="usd">18600000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzYvZnJhZzo0YmE2YWI5Nzk0OGQ0OGY3YmFhMTE1OWE0MzBhMDhmOS90ZXh0cmVnaW9uOjRiYTZhYjk3OTQ4ZDQ4ZjdiYWExMTU5YTQzMGEwOGY5Xzg3OQ_031adb43-bdfc-4e0d-ad1d-78ca08f091bf"
      unitRef="usd">17000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xMzYvZnJhZzo0YmE2YWI5Nzk0OGQ0OGY3YmFhMTE1OWE0MzBhMDhmOS90ZXh0cmVnaW9uOjRiYTZhYjk3OTQ4ZDQ4ZjdiYWExMTU5YTQzMGEwOGY5Xzg4Ng_45d48851-d36a-44e1-b640-798643a97b49"
      unitRef="usd">12900000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:TreasuryStockTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNDIvZnJhZzozNzJhMTAxNzc4NWE0NWVmYTNmNDk1ZDI1YjQwYjY2My90ZXh0cmVnaW9uOjM3MmExMDE3Nzg1YTQ1ZWZhM2Y0OTVkMjViNDBiNjYzXzI1OTA_b4afff2a-d31d-4e5e-9f7c-40dd1e0a34bb">SHARE REPURCHASES On December 23, 2020, we announced that our Board of Directors authorized a stock repurchase program, under which we could repurchase up to $100&#160;million of our outstanding common stock through December 31, 2021 (the "2021 Share Repurchase Program"). Pursuant to this program, we repurchased 446,832 shares of our common stock at a weighted average price of $223.49 per share and a total cost of approximately $100&#160;million during the year ended December 31, 2021. We did not repurchase any shares pursuant to this stock repurchase program during the year ended December 31, 2020. The repurchased shares were classified as treasury shares. The 2021 Share Repurchase Program expired on December 31, 2021.&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 2, 2021, our Board of Directors authorized a share repurchase program, under which we could repurchase up to $100&#160;million of our outstanding common stock through December 31, 2022 to commence upon the completion of the Company's 2021 Share Repurchase Program (the "New Share Repurchase Program"). Pursuant to this program, we repurchased 150,000 shares of our common stock at a weighted average price of $115.64 per share and a total cost of approximately $17&#160;million during the year ended December 31, 2022. The repurchased shares were classified as treasury shares. The New Share Repurchase Program expired on December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2021 Share Repurchase Program and the New Share Repurchase Program, we were allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases were determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 2, 2023, our Board of Directors authorized a share repurchase program, under which we may repurchase up to $100&#160;million of our outstanding common stock through December 31, 2023 ("the 2023 Share Repurchase Program"). See Note 17 - Subsequent Events for additional information on the newly authorized share repurchase program.&lt;/span&gt;&lt;/div&gt;Under the terms of the 2023 Share Repurchase Program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors.</us-gaap:TreasuryStockTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i6b610aa7397640f8a2fa1d7a074bd768_I20201223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNDIvZnJhZzozNzJhMTAxNzc4NWE0NWVmYTNmNDk1ZDI1YjQwYjY2My90ZXh0cmVnaW9uOjM3MmExMDE3Nzg1YTQ1ZWZhM2Y0OTVkMjViNDBiNjYzXzE5OA_59a9b0e3-32fb-4408-be92-7a680999f9ec"
      unitRef="usd">100000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramExpirationDate
      contextRef="if0c9423c441c4978b769e4a86bc9188f_D20201223-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNDIvZnJhZzozNzJhMTAxNzc4NWE0NWVmYTNmNDk1ZDI1YjQwYjY2My90ZXh0cmVnaW9uOjM3MmExMDE3Nzg1YTQ1ZWZhM2Y0OTVkMjViNDBiNjYzXzI0MQ_80917f09-7429-44d4-ad58-cb948e114c74">2021-12-31</us-gaap:StockRepurchaseProgramExpirationDate>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ib4261a3345d54d03886673d73969d061_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNDIvZnJhZzozNzJhMTAxNzc4NWE0NWVmYTNmNDk1ZDI1YjQwYjY2My90ZXh0cmVnaW9uOjM3MmExMDE3Nzg1YTQ1ZWZhM2Y0OTVkMjViNDBiNjYzXzkxNg_65712b17-b919-4991-ab7c-8a5bcbd34858"
      unitRef="shares">446832</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="ib4261a3345d54d03886673d73969d061_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNDIvZnJhZzozNzJhMTAxNzc4NWE0NWVmYTNmNDk1ZDI1YjQwYjY2My90ZXh0cmVnaW9uOjM3MmExMDE3Nzg1YTQ1ZWZhM2Y0OTVkMjViNDBiNjYzXzk3Nw_d47e30fd-aef6-49f3-bbe9-e7f2afc10086"
      unitRef="usdPerShare">223.49</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ib4261a3345d54d03886673d73969d061_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNDIvZnJhZzozNzJhMTAxNzc4NWE0NWVmYTNmNDk1ZDI1YjQwYjY2My90ZXh0cmVnaW9uOjM3MmExMDE3Nzg1YTQ1ZWZhM2Y0OTVkMjViNDBiNjYzXzEwMjQ_3ff1415c-5023-4c3f-9b04-ee5d7eb7d594"
      unitRef="usd">100000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="ia01a4c270b254b66aa3015655785be61_I20210802"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNDIvZnJhZzozNzJhMTAxNzc4NWE0NWVmYTNmNDk1ZDI1YjQwYjY2My90ZXh0cmVnaW9uOjM3MmExMDE3Nzg1YTQ1ZWZhM2Y0OTVkMjViNDBiNjYzXzEzNjA_fbd21231-48ec-416b-946b-b101c47409f5"
      unitRef="usd">100000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramExpirationDate
      contextRef="ic922798f82384a0cb1c5e20555cd93c6_D20210802-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNDIvZnJhZzozNzJhMTAxNzc4NWE0NWVmYTNmNDk1ZDI1YjQwYjY2My90ZXh0cmVnaW9uOjM3MmExMDE3Nzg1YTQ1ZWZhM2Y0OTVkMjViNDBiNjYzXzE0MDM_7b1fdb24-cc0e-4171-a5a1-514002492165">2022-12-31</us-gaap:StockRepurchaseProgramExpirationDate>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i9fdb42e0a3874ea5a19076aa86bff340_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNDIvZnJhZzozNzJhMTAxNzc4NWE0NWVmYTNmNDk1ZDI1YjQwYjY2My90ZXh0cmVnaW9uOjM3MmExMDE3Nzg1YTQ1ZWZhM2Y0OTVkMjViNDBiNjYzXzU0OTc1NTgxODI4Mw_afd78306-7c54-4128-a36e-0ea28b4fa7b9"
      unitRef="shares">150000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i9fdb42e0a3874ea5a19076aa86bff340_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNDIvZnJhZzozNzJhMTAxNzc4NWE0NWVmYTNmNDk1ZDI1YjQwYjY2My90ZXh0cmVnaW9uOjM3MmExMDE3Nzg1YTQ1ZWZhM2Y0OTVkMjViNDBiNjYzXzU0OTc1NTgxODI5Mg_cb0fb73b-32ab-423e-9dfe-4126ec4af775"
      unitRef="usdPerShare">115.64</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i9fdb42e0a3874ea5a19076aa86bff340_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNDIvZnJhZzozNzJhMTAxNzc4NWE0NWVmYTNmNDk1ZDI1YjQwYjY2My90ZXh0cmVnaW9uOjM3MmExMDE3Nzg1YTQ1ZWZhM2Y0OTVkMjViNDBiNjYzXzU0OTc1NTgxODMwMQ_fafcf368-e75a-40eb-afc8-86d28e7ac53c"
      unitRef="usd">17000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i92bd39f0d2544264b7d724dd1ae6eac3_I20230202"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNDIvZnJhZzozNzJhMTAxNzc4NWE0NWVmYTNmNDk1ZDI1YjQwYjY2My90ZXh0cmVnaW9uOjM3MmExMDE3Nzg1YTQ1ZWZhM2Y0OTVkMjViNDBiNjYzXzU0OTc1NTgxODY2OQ_ddcd0c92-bca9-40db-9ae7-fbb0c6fc8412"
      unitRef="usd">100000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramExpirationDate
      contextRef="i4b423f65ef9c451d935438afdcfc2e15_D20230202-20231231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNDIvZnJhZzozNzJhMTAxNzc4NWE0NWVmYTNmNDk1ZDI1YjQwYjY2My90ZXh0cmVnaW9uOjM3MmExMDE3Nzg1YTQ1ZWZhM2Y0OTVkMjViNDBiNjYzXzU0OTc1NTgxODY4Mw_f6447fc3-3ddf-4d77-ae77-aa64ee3e166e">2023-12-31</us-gaap:StockRepurchaseProgramExpirationDate>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90ZXh0cmVnaW9uOjg3Yjk2YTkwMjNkODRlMjZiNjJkNTBkN2IxYzA4ZjNkXzE1ODQ_ea145558-e1e4-42c7-94f3-fbc0b55a9d73">SEGMENT INFORMATION&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operations involve servicing patients through our four reportable business segments: home health, hospice, personal care and high acuity care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from an illness, injury or surgery. Our hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. Our personal care segment provides patients with assistance with the essential activities of daily living. Our high acuity care segment, which was established with the acquisition of Contessa on August 1, 2021, delivers the essential elements of inpatient hospital and SNF care to patients in their homes. The &#x201c;other&#x201d; column in the following tables consists of costs relating to executive management and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management evaluates performance and allocates resources based on the operating income of the reportable segments, which includes an allocation of corporate expenses attributable to the specific segment and includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company&#x2019;s chief operating decision maker and therefore are not disclosed below (amounts in millions).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&#160;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&#160;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;High Acuity Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,355.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;787.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,223.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;769.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,260.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;General and administrative expenses, excluding depreciation and amortization and impairment charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;348.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;203.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;754.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impairment charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,121.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;632.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,042.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;234.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;155.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(39.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(175.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&#160;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&#160;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;High Acuity Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,353.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;791.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,214.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;756.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;425.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,233.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;General and administrative expenses, excluding depreciation and amortization and impairment charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;328.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;198.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;163.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;711.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,089.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;185.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,975.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;271.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;171.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(185.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;251.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&#160;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&#160;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;High Acuity Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,249.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;750.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,071.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;729.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,185.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;General and administrative expenses, excluding depreciation and amortization and impairment charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;307.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;668.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impairment charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,044.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;579.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,886.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;225.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;184.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(195.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;219.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90ZXh0cmVnaW9uOjg3Yjk2YTkwMjNkODRlMjZiNjJkNTBkN2IxYzA4ZjNkXzgz_d2e7fb2b-fd54-4ec6-b996-ab271f7e03b6"
      unitRef="segment">4</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90ZXh0cmVnaW9uOjg3Yjk2YTkwMjNkODRlMjZiNjJkNTBkN2IxYzA4ZjNkXzE1ODY_376fedda-277d-4166-b114-67a0bd5f10ca">&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management evaluates performance and allocates resources based on the operating income of the reportable segments, which includes an allocation of corporate expenses attributable to the specific segment and includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company&#x2019;s chief operating decision maker and therefore are not disclosed below (amounts in millions).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&#160;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&#160;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;High Acuity Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,355.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;787.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,223.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;769.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,260.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;General and administrative expenses, excluding depreciation and amortization and impairment charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;348.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;203.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;754.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impairment charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,121.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;632.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,042.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;234.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;155.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(39.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(175.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&#160;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&#160;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;High Acuity Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,353.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;791.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,214.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;756.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;425.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,233.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;General and administrative expenses, excluding depreciation and amortization and impairment charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;328.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;198.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;163.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;711.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,089.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;185.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,975.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;271.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;171.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(185.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;251.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&#160;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&#160;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;High Acuity Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,249.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;750.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,071.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;729.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,185.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;General and administrative expenses, excluding depreciation and amortization and impairment charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;307.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;668.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impairment charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,044.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;579.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,886.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;225.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;184.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(195.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;219.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="icff92844bf7e45cf8941114000e0fa42_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzItMS0xLTEtNTA3MjU_98025dbb-a685-4ea2-8993-dcebf855098a"
      unitRef="usd">1355500000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i971b271744ea4a63aca16276f887bcb4_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzItMy0xLTEtNTA3MjU_8a6a173f-a943-4209-b4db-13aa3c8df6c5"
      unitRef="usd">787800000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i9e623706c1354124a369dc7758938060_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzItNS0xLTEtNTA3MjU_96021338-5eeb-43eb-9854-cdb44a6c0eb3"
      unitRef="usd">61400000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i47b68ba2f13e424bacfacf577053382b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzItNy0xLTEtNTA3MjU_9b51fdd4-82e9-4ccd-b2b3-00a63f0fc917"
      unitRef="usd">18500000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i114e5c43f13843719a8a60aa9fd64db1_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzItOS0xLTEtNTA3MjU_2c7aa015-301c-4011-b163-9501ea8459c2"
      unitRef="usd">0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzItMTEtMS0xLTUwNzI1_73135754-663b-4e77-9813-f33a6a310311"
      unitRef="usd">2223200000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="icff92844bf7e45cf8941114000e0fa42_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzQtMS0xLTEtNTA3MjU_be1cbbb1-5b24-4e11-a0ea-76737ce47a24"
      unitRef="usd">769000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i971b271744ea4a63aca16276f887bcb4_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzQtMy0xLTEtNTA3MjU_965847a5-7003-4754-b69f-b33713736ab2"
      unitRef="usd">426500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9e623706c1354124a369dc7758938060_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzQtNS0xLTEtNTA3MjU_50a8c434-6e46-422e-b5c3-a76a9d814af5"
      unitRef="usd">46700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i47b68ba2f13e424bacfacf577053382b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzQtNy0xLTEtNTA3MjU_b295a207-e23d-4a6d-aa62-3e459a94b28b"
      unitRef="usd">18200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i114e5c43f13843719a8a60aa9fd64db1_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzQtOS0xLTEtNTA3MjU_d2ed78a6-dfe1-4dc4-a124-ce102069bb40"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzQtMTEtMS0xLTUwNzI1_83df0b2d-17c4-440b-b52d-0922fde265af"
      unitRef="usd">1260400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="icff92844bf7e45cf8941114000e0fa42_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzUtMS0xLTEtNTA3MjU_ce22a97f-0b52-43a8-8b86-13992e87fee4"
      unitRef="usd">348500000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i971b271744ea4a63aca16276f887bcb4_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzUtMy0xLTEtNTA3MjU_85d1c7d1-4ded-4e81-9881-32f9be4e9c07"
      unitRef="usd">203300000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i9e623706c1354124a369dc7758938060_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzUtNS0xLTEtNTA3MjU_dbbe3ded-cfa1-4f7f-a527-90d22549f2c7"
      unitRef="usd">9200000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i47b68ba2f13e424bacfacf577053382b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzUtNy0xLTEtNTA3MjU_a97702ec-146d-49ff-a467-001a35d06036"
      unitRef="usd">33100000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i114e5c43f13843719a8a60aa9fd64db1_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzUtOS0xLTEtNTA3MjU_0d56f87c-9115-4dd1-bbd9-19e39ba71640"
      unitRef="usd">160000000.0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzUtMTEtMS0xLTUwNzI1_de82981d-4444-49f3-a27c-8d02d4b29570"
      unitRef="usd">754100000</us-gaap:GeneralAndAdministrativeExpense>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="icff92844bf7e45cf8941114000e0fa42_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzYtMS0xLTEtNTA3MjU_8fa9a5fd-0fac-4fad-9d20-80b80b5a192d"
      unitRef="usd">4000000.0</amed:DepreciationAndAmortizationForContinuingOperations>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="i971b271744ea4a63aca16276f887bcb4_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzYtMy0xLTEtNTA3MjU_faee45f7-22f5-4cc1-b503-2f7303b6187a"
      unitRef="usd">2300000</amed:DepreciationAndAmortizationForContinuingOperations>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="i9e623706c1354124a369dc7758938060_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzYtNS0xLTEtNTA3MjU_3f83f096-7ca2-40a8-b0ff-848236d0430d"
      unitRef="usd">100000</amed:DepreciationAndAmortizationForContinuingOperations>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="i47b68ba2f13e424bacfacf577053382b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzYtNy0xLTEtNTA3MjU_1adefd9f-ab9c-42e8-a511-259d86ce2857"
      unitRef="usd">3300000</amed:DepreciationAndAmortizationForContinuingOperations>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="i114e5c43f13843719a8a60aa9fd64db1_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzYtOS0xLTEtNTA3MjU_dc253fd5-ec64-4ad1-bd79-abc4fc293b09"
      unitRef="usd">15200000</amed:DepreciationAndAmortizationForContinuingOperations>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzYtMTEtMS0xLTUwNzI1_b854d0ce-fbb9-4b83-9b1c-2545e75d02fb"
      unitRef="usd">24900000</amed:DepreciationAndAmortizationForContinuingOperations>
    <us-gaap:AssetImpairmentCharges
      contextRef="icff92844bf7e45cf8941114000e0fa42_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzYtMS0xLTEtNTY0Nzk_377d866c-dd85-43ce-9a00-ac7993d16829"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i971b271744ea4a63aca16276f887bcb4_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzYtMy0xLTEtNTY0Nzk_210c4889-c9cf-421d-80b5-e94d8b6afb1b"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i9e623706c1354124a369dc7758938060_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzYtNS0xLTEtNTY0Nzk_7d1b5ddf-1688-4ab7-ab22-c6330048a3d5"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i47b68ba2f13e424bacfacf577053382b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzYtNy0xLTEtNTY0Nzk_6c6d0201-8f12-4d20-a6ec-ae740dcb713c"
      unitRef="usd">3000000.0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i114e5c43f13843719a8a60aa9fd64db1_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzYtOS0xLTEtNTY0Nzk_3e4292b7-a4ef-4b9a-b6bd-5d413a521f7f"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzYtMTEtMS0xLTU2NDc5_83a6c521-2ade-44a1-8a79-edc9d73c4b3b"
      unitRef="usd">3000000.0</us-gaap:AssetImpairmentCharges>
    <us-gaap:CostsAndExpenses
      contextRef="icff92844bf7e45cf8941114000e0fa42_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzctMS0xLTEtNTA3MjU_7d06a697-3b64-48de-91f1-0649c2f4f95c"
      unitRef="usd">1121500000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i971b271744ea4a63aca16276f887bcb4_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzctMy0xLTEtNTA3MjU_e3f20629-2bf0-4700-8b2b-02a0131d5118"
      unitRef="usd">632100000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i9e623706c1354124a369dc7758938060_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzctNS0xLTEtNTA3MjU_15b54cb0-bacf-49e4-b7c4-a7b9e227ba14"
      unitRef="usd">56000000.0</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i47b68ba2f13e424bacfacf577053382b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzctNy0xLTEtNTA3MjU_8b45d9c7-30e6-4674-9582-199030937b07"
      unitRef="usd">57600000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i114e5c43f13843719a8a60aa9fd64db1_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzctOS0xLTEtNTA3MjU_1d00c491-e8a7-43e0-a54b-cf43669e467c"
      unitRef="usd">175200000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzctMTEtMS0xLTUwNzI1_3404920c-b5a3-469c-987c-f9836eb6489c"
      unitRef="usd">2042400000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="icff92844bf7e45cf8941114000e0fa42_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzgtMS0xLTEtNTA3MjU_80f831a5-2645-46cb-96b5-e590f43c46e8"
      unitRef="usd">234000000.0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i971b271744ea4a63aca16276f887bcb4_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzgtMy0xLTEtNTA3MjU_be7008bf-172d-4266-9d19-03b6e16a8087"
      unitRef="usd">155700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9e623706c1354124a369dc7758938060_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzgtNS0xLTEtNTA3MjU_e57f37a5-6ff1-4310-966c-64ef35a61917"
      unitRef="usd">5400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i47b68ba2f13e424bacfacf577053382b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzgtNy0xLTEtNTA3MjU_494a93af-31f8-475d-a0b0-00877815c378"
      unitRef="usd">-39100000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i114e5c43f13843719a8a60aa9fd64db1_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzgtOS0xLTEtNTA3MjU_ecaa5b28-dcd5-45d7-be02-6eb14258e0e2"
      unitRef="usd">-175200000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpjOTI1OTA2YzNkYjA0YmNlOWY4MTk2NmQ1ZmE4NDgxOC90YWJsZXJhbmdlOmM5MjU5MDZjM2RiMDRiY2U5ZjgxOTY2ZDVmYTg0ODE4XzgtMTEtMS0xLTUwNzI1_abc93e10-302e-4a3f-80ab-03d3fd629054"
      unitRef="usd">180800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="ifc3b9823141645e68eb892a3c076e69b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzItMS0xLTEtNTA3MjU_46ad90c5-3e70-46bc-8cd0-8f8b6e994b65"
      unitRef="usd">1353800000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i6c8bd5c211c94e959f7bcc237d284961_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzItMy0xLTEtNTA3MjU_8c20d5fd-aaef-45ea-b1db-5cd10db89376"
      unitRef="usd">791800000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="ifc02119e099f490a8a653314b18712d4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzItNS0xLTEtNTA3MjU_55478176-ca46-43a9-bfc7-aee7a443e042"
      unitRef="usd">65000000.0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i722dd3d3be554fc1bcbc003ddc943c6a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzItNy0xLTEtNTA3MjU_4c5eb07f-4160-4536-af40-a4698b3dea0b"
      unitRef="usd">3500000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i2a8daa3605c04f07bf026bdc825236d7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzItOS0xLTEtNTA3MjU_aef038da-7d85-4787-a6b5-24e5da6c1e7e"
      unitRef="usd">0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzItMTEtMS0xLTUwNzI1_8c2f36ad-5e22-40b1-b4df-ff40d2ccc387"
      unitRef="usd">2214100000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:OtherOperatingIncome
      contextRef="ifc3b9823141645e68eb892a3c076e69b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzMtMS0xLTEtNTA3MjU_00d06b3c-f113-4cc9-bb5a-7de932712880"
      unitRef="usd">7300000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="i6c8bd5c211c94e959f7bcc237d284961_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzMtMy0xLTEtNTA3MjU_15615dd3-7685-4fdb-ba97-b7d10085af95"
      unitRef="usd">6000000.0</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="ifc02119e099f490a8a653314b18712d4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzMtNS0xLTEtNTA3MjU_ffe0c1f0-c5be-4096-8707-b9a85715c016"
      unitRef="usd">0</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="i722dd3d3be554fc1bcbc003ddc943c6a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzMtNy0xLTEtNTA3MjU_2c84430c-9b47-4dfb-a89e-740f07e9c4e9"
      unitRef="usd">0</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="i2a8daa3605c04f07bf026bdc825236d7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzMtOS0xLTEtNTA3MjU_2c3c19d8-328e-4116-8a3c-f326769c06bd"
      unitRef="usd">0</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzMtMTEtMS0xLTUwNzI1_28c2e876-e87f-4ad0-b990-f76a06e898ed"
      unitRef="usd">13300000</us-gaap:OtherOperatingIncome>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ifc3b9823141645e68eb892a3c076e69b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzQtMS0xLTEtNTA3MjU_c5a33982-acf1-4b2c-91dc-0fd5030c31f2"
      unitRef="usd">756600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6c8bd5c211c94e959f7bcc237d284961_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzQtMy0xLTEtNTA3MjU_82f66892-1461-49d8-a727-9bb5f23f9d26"
      unitRef="usd">425200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ifc02119e099f490a8a653314b18712d4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzQtNS0xLTEtNTA3MjU_fb1ea16a-66cd-40ee-a39a-9694d2c321b0"
      unitRef="usd">49100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i722dd3d3be554fc1bcbc003ddc943c6a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzQtNy0xLTEtNTA3MjU_6170fc46-9903-4653-8f22-e7f533f6588b"
      unitRef="usd">2500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i2a8daa3605c04f07bf026bdc825236d7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzQtOS0xLTEtNTA3MjU_fddd1b04-d191-4dc3-bb9e-6a511ff373d3"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzQtMTEtMS0xLTUwNzI1_71cd6a68-8637-4849-82ab-001296e7bf1c"
      unitRef="usd">1233400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ifc3b9823141645e68eb892a3c076e69b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzUtMS0xLTEtNTA3MjU_8a7d363c-b426-4789-b6e9-13edee953960"
      unitRef="usd">328500000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i6c8bd5c211c94e959f7bcc237d284961_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzUtMy0xLTEtNTA3MjU_148eb65b-e24f-4c65-b37e-0102434e45ff"
      unitRef="usd">198400000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ifc02119e099f490a8a653314b18712d4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzUtNS0xLTEtNTA3MjU_540beeb6-2e57-41de-8be6-644fd57c7b33"
      unitRef="usd">11200000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i722dd3d3be554fc1bcbc003ddc943c6a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzUtNy0xLTEtNTA3MjU_9766ec94-d716-425f-aa54-812c62ceddf0"
      unitRef="usd">10000000.0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i2a8daa3605c04f07bf026bdc825236d7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzUtOS0xLTEtNTA3MjU_e467e846-ef81-42cd-a1d3-2be1eba20020"
      unitRef="usd">163100000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzUtMTEtMS0xLTUwNzI1_59927506-4331-4fe2-810f-2d5b5932f1eb"
      unitRef="usd">711200000</us-gaap:GeneralAndAdministrativeExpense>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="ifc3b9823141645e68eb892a3c076e69b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzYtMS0xLTEtNTA3MjU_3b09d31e-e35a-4ebd-97df-2e25057dd7a0"
      unitRef="usd">4300000</amed:DepreciationAndAmortizationForContinuingOperations>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="i6c8bd5c211c94e959f7bcc237d284961_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzYtMy0xLTEtNTA3MjU_af6a1c87-332b-489d-a230-cd3406effa56"
      unitRef="usd">2700000</amed:DepreciationAndAmortizationForContinuingOperations>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="ifc02119e099f490a8a653314b18712d4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzYtNS0xLTEtNTA3MjU_fdc0e99e-36ff-4834-919d-82bd397225f9"
      unitRef="usd">200000</amed:DepreciationAndAmortizationForContinuingOperations>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="i722dd3d3be554fc1bcbc003ddc943c6a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzYtNy0xLTEtNTA3MjU_a0c93d10-efaa-4bbf-9b4a-700e73bb5690"
      unitRef="usd">1300000</amed:DepreciationAndAmortizationForContinuingOperations>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="i2a8daa3605c04f07bf026bdc825236d7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzYtOS0xLTEtNTA3MjU_9e7f39f1-0288-4aa3-91bc-e5273291d6ce"
      unitRef="usd">22400000</amed:DepreciationAndAmortizationForContinuingOperations>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzYtMTEtMS0xLTUwNzI1_4dd07547-70dc-4389-ae11-93721411f769"
      unitRef="usd">30900000</amed:DepreciationAndAmortizationForContinuingOperations>
    <us-gaap:CostsAndExpenses
      contextRef="ifc3b9823141645e68eb892a3c076e69b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzgtMS0xLTEtNTA3MjU_5ef7cf8e-3361-49c2-9722-0f470d3b27d3"
      unitRef="usd">1089400000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i6c8bd5c211c94e959f7bcc237d284961_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzgtMy0xLTEtNTA3MjU_b0764537-ecf7-44c4-8ff6-c759d02e9734"
      unitRef="usd">626300000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ifc02119e099f490a8a653314b18712d4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzgtNS0xLTEtNTA3MjU_618d3e50-dd92-48b2-aa03-fae53f4b4b39"
      unitRef="usd">60500000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i722dd3d3be554fc1bcbc003ddc943c6a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzgtNy0xLTEtNTA3MjU_6746224b-0a46-4e7d-b38a-53a1848685f8"
      unitRef="usd">13800000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i2a8daa3605c04f07bf026bdc825236d7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzgtOS0xLTEtNTA3MjU_919d776c-ce2d-4f18-9737-21eb3dd8cc53"
      unitRef="usd">185500000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzgtMTEtMS0xLTUwNzI1_fa3e2308-4ec2-4e0d-9a83-70b818c18dc4"
      unitRef="usd">1975500000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifc3b9823141645e68eb892a3c076e69b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzktMS0xLTEtNTA3MjU_c5f75d9d-c0fe-4cfe-aef2-69e3fd42b391"
      unitRef="usd">271700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6c8bd5c211c94e959f7bcc237d284961_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzktMy0xLTEtNTA3MjU_bf30f273-4308-4ccc-9cd6-5417588d17a8"
      unitRef="usd">171500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifc02119e099f490a8a653314b18712d4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzktNS0xLTEtNTA3MjU_b62db2e4-c6e4-48dd-ab8d-e8c7e613ffd2"
      unitRef="usd">4500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i722dd3d3be554fc1bcbc003ddc943c6a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzktNy0xLTEtNTA3MjU_faa8abc2-b4d6-42e8-92d6-49bae40035e8"
      unitRef="usd">-10300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2a8daa3605c04f07bf026bdc825236d7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzktOS0xLTEtNTA3MjU_e67646e8-bdf9-4fb5-a632-184c544dfbe5"
      unitRef="usd">-185500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i646a417a08544b8580a68bae1e8abe34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpmZjE5ZjhjYjJhNDk0NDIwYjE5ODA0ZGEyMzI3YzFhZi90YWJsZXJhbmdlOmZmMTlmOGNiMmE0OTQ0MjBiMTk4MDRkYTIzMjdjMWFmXzktMTEtMS0xLTUwNzI1_6dae06b4-9d9e-4998-bdae-038e92418385"
      unitRef="usd">251900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="id362cc93e6cd48da8f96f15cbc8bed2e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzItMS0xLTEtNTA3MjU_edeec692-1355-48fb-b067-29f3e1554dc7"
      unitRef="usd">1249200000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i6db8f1d2d01b4b87b43031a471f0a747_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzItMy0xLTEtNTA3MjU_0d840389-f577-44d4-9394-11c118517e2f"
      unitRef="usd">750100000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="iad09634e54b64f4ab4f376450c10a9fe_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzItNS0xLTEtNTA3MjU_4657c20c-af35-43d2-849a-34821cf7d8fb"
      unitRef="usd">72200000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="if5e19c6308394df88a3ac225cead2412_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzItNy0xLTEtNTA3MjU_4d1e52fd-159a-4fe5-8060-7c865fd45bac"
      unitRef="usd">0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i55522935511e4608b35d61ba4b0cb9d2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzItOS0xLTEtNTA3MjU_06af6548-c20e-4e51-beb4-fcec9ac09435"
      unitRef="usd">0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzItMTEtMS0xLTUwNzI1_9ccc61a6-fa05-4ef8-8247-afb411888ed4"
      unitRef="usd">2071500000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:OtherOperatingIncome
      contextRef="id362cc93e6cd48da8f96f15cbc8bed2e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzMtMS0xLTEtNTMwMTE_43055798-1c53-419a-bf7e-618de9217a3b"
      unitRef="usd">20200000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="i6db8f1d2d01b4b87b43031a471f0a747_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzMtMy0xLTEtNTMwMTE_6c1e0d65-be8b-4e54-abeb-226c92ca2ace"
      unitRef="usd">13100000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="iad09634e54b64f4ab4f376450c10a9fe_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzMtNS0xLTEtNTMwMTE_62384bbe-73db-4db0-86be-45f1d2af145d"
      unitRef="usd">1100000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="if5e19c6308394df88a3ac225cead2412_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzMtNy0xLTEtNTMwMTE_192b7c6a-d2c3-417d-abc5-8032d9505400"
      unitRef="usd">0</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="i55522935511e4608b35d61ba4b0cb9d2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzMtOS0xLTEtNTMwMTE_1eb0914f-f979-46be-bb7c-8cedc5382e80"
      unitRef="usd">0</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzMtMTEtMS0xLTUzMDEx_ad27f933-47ef-45eb-ac11-1101a250a951"
      unitRef="usd">34400000</us-gaap:OtherOperatingIncome>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id362cc93e6cd48da8f96f15cbc8bed2e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzMtMS0xLTEtNTA3MjU_14efe36f-c06a-4ff2-a525-081ac92d7d2b"
      unitRef="usd">729900000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6db8f1d2d01b4b87b43031a471f0a747_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzMtMy0xLTEtNTA3MjU_dc5d5377-8d12-420b-8aec-d9f72fee9689"
      unitRef="usd">400600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iad09634e54b64f4ab4f376450c10a9fe_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzMtNS0xLTEtNTA3MjU_5fede8cc-e22b-4045-ac53-6eaad3f70722"
      unitRef="usd">54900000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if5e19c6308394df88a3ac225cead2412_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzMtNy0xLTEtNTA3MjU_29c8b7fd-93c1-440d-9b12-e057be70a30f"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i55522935511e4608b35d61ba4b0cb9d2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzMtOS0xLTEtNTA3MjU_faa0dfb8-37e9-48e0-80e7-3515cce6cad4"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzMtMTEtMS0xLTUwNzI1_24a77adb-3054-413d-b4fe-7dc9db5ab584"
      unitRef="usd">1185400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id362cc93e6cd48da8f96f15cbc8bed2e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzQtMS0xLTEtNTA3MjU_7b8fe721-00f6-45b6-8133-03387dd6b169"
      unitRef="usd">307200000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i6db8f1d2d01b4b87b43031a471f0a747_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzQtMy0xLTEtNTA3MjU_1f606750-9b60-4cde-a8f9-5e68359faa45"
      unitRef="usd">175400000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="iad09634e54b64f4ab4f376450c10a9fe_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzQtNS0xLTEtNTA3MjU_b0c40367-4c1e-4e55-a6c6-b40ce05b435f"
      unitRef="usd">12400000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="if5e19c6308394df88a3ac225cead2412_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzQtNy0xLTEtNTA3MjU_21ba025d-1b83-493c-8f00-6b464ab269f3"
      unitRef="usd">0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i55522935511e4608b35d61ba4b0cb9d2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzQtOS0xLTEtNTA3MjU_ddf475a2-a7b2-44bd-a00b-361af2edd302"
      unitRef="usd">173200000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzQtMTEtMS0xLTUwNzI1_0f5656be-a3ce-47bf-a5b5-5cc166fac754"
      unitRef="usd">668200000</us-gaap:GeneralAndAdministrativeExpense>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="id362cc93e6cd48da8f96f15cbc8bed2e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzUtMS0xLTEtNTA3MjU_c80f08fd-7550-48b2-a2e8-d163467ccc2d"
      unitRef="usd">3900000</amed:DepreciationAndAmortizationForContinuingOperations>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="i6db8f1d2d01b4b87b43031a471f0a747_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzUtMy0xLTEtNTA3MjU_04ebb8b2-912c-49db-8f2f-230bfae46ea5"
      unitRef="usd">2200000</amed:DepreciationAndAmortizationForContinuingOperations>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="iad09634e54b64f4ab4f376450c10a9fe_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzUtNS0xLTEtNTA3MjU_f323bb55-c1ab-47de-8062-1a545ae6bcc3"
      unitRef="usd">200000</amed:DepreciationAndAmortizationForContinuingOperations>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="if5e19c6308394df88a3ac225cead2412_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzUtNy0xLTEtNTA3MjU_4693b5c5-d125-4bd4-a2a4-6bc3de6a4774"
      unitRef="usd">0</amed:DepreciationAndAmortizationForContinuingOperations>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="i55522935511e4608b35d61ba4b0cb9d2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzUtOS0xLTEtNTA3MjU_b0b97e8d-2db0-45e9-99e2-d21680bca7c5"
      unitRef="usd">22500000</amed:DepreciationAndAmortizationForContinuingOperations>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzUtMTEtMS0xLTUwNzI1_ceea6e92-736f-465b-bc2f-b32ba1b6491f"
      unitRef="usd">28800000</amed:DepreciationAndAmortizationForContinuingOperations>
    <us-gaap:AssetImpairmentCharges
      contextRef="id362cc93e6cd48da8f96f15cbc8bed2e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzYtMS0xLTEtNTA3MjU_3eed6425-ec35-4859-b753-e3e3166d9087"
      unitRef="usd">3400000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i6db8f1d2d01b4b87b43031a471f0a747_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzYtMy0xLTEtNTA3MjU_7ce45c53-2888-402d-bcf5-08babc4985c2"
      unitRef="usd">800000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="iad09634e54b64f4ab4f376450c10a9fe_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzYtNS0xLTEtNTA3MjU_116378d8-e83d-427c-9675-0bfe4d2ae2ac"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="if5e19c6308394df88a3ac225cead2412_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzYtNy0xLTEtNTA3MjU_4ae6fc2c-b32e-4c13-8ce8-5c3e9ce2b9a4"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i55522935511e4608b35d61ba4b0cb9d2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzYtOS0xLTEtNTA3MjU_fdf8de06-66a3-43e5-9a4a-09bafd402fab"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzYtMTEtMS0xLTUwNzI1_f33175d9-105e-4009-8600-f5e2e5e497ba"
      unitRef="usd">4200000</us-gaap:AssetImpairmentCharges>
    <us-gaap:CostsAndExpenses
      contextRef="id362cc93e6cd48da8f96f15cbc8bed2e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzctMS0xLTEtNTA3MjU_c0dd1bd9-54c2-4371-85a8-8ae82e391940"
      unitRef="usd">1044400000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i6db8f1d2d01b4b87b43031a471f0a747_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzctMy0xLTEtNTA3MjU_33ecbbd5-072f-4bd1-bbbc-22ecfe70da32"
      unitRef="usd">579000000.0</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="iad09634e54b64f4ab4f376450c10a9fe_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzctNS0xLTEtNTA3MjU_a132a627-a570-4f2e-8f64-6deb7dd6b3c1"
      unitRef="usd">67500000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="if5e19c6308394df88a3ac225cead2412_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzctNy0xLTEtNTA3MjU_cefec6aa-93d8-4699-a967-dcef877cc4c6"
      unitRef="usd">0</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i55522935511e4608b35d61ba4b0cb9d2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzctOS0xLTEtNTA3MjU_05efa34d-d55a-4a6d-9e28-05c3b6207e5d"
      unitRef="usd">195700000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzctMTEtMS0xLTUwNzI1_aa977a8d-033c-4dc6-bd82-cf02ae161249"
      unitRef="usd">1886600000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="id362cc93e6cd48da8f96f15cbc8bed2e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzgtMS0xLTEtNTA3MjU_47682c55-e89e-4e8a-ba8b-cf1e8f0c4db2"
      unitRef="usd">225000000.0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6db8f1d2d01b4b87b43031a471f0a747_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzgtMy0xLTEtNTA3MjU_d440d613-b7be-438d-b9cf-cfe7f969bef0"
      unitRef="usd">184200000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iad09634e54b64f4ab4f376450c10a9fe_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzgtNS0xLTEtNTA3MjU_8a3af758-7862-4e98-a742-d43f91e37a9b"
      unitRef="usd">5800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if5e19c6308394df88a3ac225cead2412_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzgtNy0xLTEtNTA3MjU_f06873b9-186f-436a-bb2d-c73b67f39892"
      unitRef="usd">0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i55522935511e4608b35d61ba4b0cb9d2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzgtOS0xLTEtNTA3MjU_5baf03e5-6979-4ab4-8902-38526bea33ee"
      unitRef="usd">-195700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6040c9a0afdd44d88bae6545681ae0cb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNTQvZnJhZzo4N2I5NmE5MDIzZDg0ZTI2YjYyZDUwZDdiMWMwOGYzZC90YWJsZTpiNTE1ZjU0ODI4ZWU0MmFkYjU2NWFhYWU2MWZlZTgyNS90YWJsZXJhbmdlOmI1MTVmNTQ4MjhlZTQyYWRiNTY1YWFhZTYxZmVlODI1XzgtMTEtMS0xLTUwNzI1_dee51e80-c325-46c9-b636-cdf5892ada04"
      unitRef="usd">219300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNjMvZnJhZzoyNzYxYjgxNjVhZTY0Mzg0YjRmYzBjOTdhZmY5OTdiMC90ZXh0cmVnaW9uOjI3NjFiODE2NWFlNjQzODRiNGZjMGM5N2FmZjk5N2IwXzQ2MA_fd94ada7-fbd6-4e7f-9459-760b11f8776b">RELATED PARTY TRANSACTIONSWe have an investment in Medalogix, a healthcare predictive data and analytics company, which is accounted for under the equity method. During the years ended December 31, 2022, 2021 and 2020, we incurred costs of approximately $9.4&#160;million,$5.7&#160;million and $3.9 million, respectively, in connection with our usage of Medalogix's analytics platforms. We believe that the terms of these transactions are consistent with those negotiated at arm&#x2019;s length.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="i65690d26701e4e5ea588f0959375f58b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNjMvZnJhZzoyNzYxYjgxNjVhZTY0Mzg0YjRmYzBjOTdhZmY5OTdiMC90ZXh0cmVnaW9uOjI3NjFiODE2NWFlNjQzODRiNGZjMGM5N2FmZjk5N2IwXzI2NA_8fce2aa3-a6c1-4f63-803d-80dcf4cc3d9c"
      unitRef="usd">9400000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="idaf95b2f3ae241fa85a7edcd22950e29_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNjMvZnJhZzoyNzYxYjgxNjVhZTY0Mzg0YjRmYzBjOTdhZmY5OTdiMC90ZXh0cmVnaW9uOjI3NjFiODE2NWFlNjQzODRiNGZjMGM5N2FmZjk5N2IwXzI2Nw_a3dd26f2-4242-483c-99b8-cbaef92240fb"
      unitRef="usd">5700000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="ib9c94f55e0204d55a40837adab0df9ec_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNjMvZnJhZzoyNzYxYjgxNjVhZTY0Mzg0YjRmYzBjOTdhZmY5OTdiMC90ZXh0cmVnaW9uOjI3NjFiODE2NWFlNjQzODRiNGZjMGM5N2FmZjk5N2IwXzI3NA_cb8afad9-801f-48a4-bf1d-3c230300b08d"
      unitRef="usd">3900000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNjkvZnJhZzo4MDhiNzc5Y2Y1OWY0MmY2ODkxYjZmNzM5MDdmZGZiNi90ZXh0cmVnaW9uOjgwOGI3NzljZjU5ZjQyZjY4OTFiNmY3MzkwN2ZkZmI2XzU0OTc1NTgxNjAxMg_eb28e6da-dda8-4c64-b947-7bdb61407045">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2023 Share Repurchase Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 2, 2023, our Board of Directors authorized a share repurchase program, under which we may repurchase up to $100&#160;million of our outstanding common stock through December&#160;31, 2023 (the "2023 Share Repurchase Program"). Under the terms of the 2023 Share Repurchase Program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. Effective January 1, 2023, repurchases are subject to a 1% excise tax under the Inflation Reduction Act.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets Held For Sale&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 10, 2023, we signed a definitive agreement to sell our personal care business (excluding the Florida operations). The divestment is expected to close during the second quarter of 2023. See Note 6 - Assets Held For Sale for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i92bd39f0d2544264b7d724dd1ae6eac3_I20230202"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNjkvZnJhZzo4MDhiNzc5Y2Y1OWY0MmY2ODkxYjZmNzM5MDdmZGZiNi90ZXh0cmVnaW9uOjgwOGI3NzljZjU5ZjQyZjY4OTFiNmY3MzkwN2ZkZmI2XzU0OTc1NTgxNTExMA_ddcd0c92-bca9-40db-9ae7-fbb0c6fc8412"
      unitRef="usd">100000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramExpirationDate
      contextRef="i4b423f65ef9c451d935438afdcfc2e15_D20230202-20231231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8xNjkvZnJhZzo4MDhiNzc5Y2Y1OWY0MmY2ODkxYjZmNzM5MDdmZGZiNi90ZXh0cmVnaW9uOjgwOGI3NzljZjU5ZjQyZjY4OTFiNmY3MzkwN2ZkZmI2XzU0OTc1NTgxNTE1NA_f6447fc3-3ddf-4d77-ae77-aa64ee3e166e">2023-12-31</us-gaap:StockRepurchaseProgramExpirationDate>
    <dei:AuditorName
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8yMDIvZnJhZzpiZTJiNDQ1YjBiZGU0ZmE0OTYyMWM0YmQ3Y2Y1MWQzYi90ZXh0cmVnaW9uOmJlMmI0NDViMGJkZTRmYTQ5NjIxYzRiZDdjZjUxZDNiXzMyOA_5e5a2744-303f-4c02-8d6b-6c799daf2b8e">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8yMDIvZnJhZzpiZTJiNDQ1YjBiZGU0ZmE0OTYyMWM0YmQ3Y2Y1MWQzYi90ZXh0cmVnaW9uOmJlMmI0NDViMGJkZTRmYTQ5NjIxYzRiZDdjZjUxZDNiXzMyOQ_e02937f1-ab9e-43f3-84cf-4e26525f3043">Baton Rouge, Louisiana</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="i3280ba0923f84410aef180ffd57ff732_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTBiNzI0YTY2NzQ5NzliZjNjMzVhMzM5ZjI5Njg1L3NlYzo1YzEwYjcyNGE2Njc0OTc5YmYzYzM1YTMzOWYyOTY4NV8yMDIvZnJhZzpiZTJiNDQ1YjBiZGU0ZmE0OTYyMWM0YmQ3Y2Y1MWQzYi90ZXh0cmVnaW9uOmJlMmI0NDViMGJkZTRmYTQ5NjIxYzRiZDdjZjUxZDNiXzE1Nw_90a60668-65b7-4834-a6f0-afb242aee3c6">185</dei:AuditorFirmId>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>107
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MSWQ?9R5PJF]E#0(]!ZDX-6BJPM>U IJ[)%[Y41!,?4Z9\-+8[6U5&LO&5$S
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MA )[S4'S@9S9'^9Z$*?6FQ?WP8O+T'GP,CMX<VA>V_XAFH>B;D%I+V$D/DW
M1=._">TOM%IW+Q/OE=:JZCZNI(#J-09P?ZF4?KXP[R?W[Z/G_P!02P,$%
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M;"]W;W)K<VAE971S+W-H965T."YX;6RMFVMOVS@6AO\*D1TL6J"NQ9LNW21
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M?X>R_]+*=?=6X9UL6[GJ/BY%IMI="]3?%U*VSU_T#^S>9#W_/U!+ P04
M"  40%!6!7J"9I\1  #1,@  &    'AL+W=O<FMS:&5E=',O<VAE970Y+GAM
M;-U;VW+;2)+]E0J./"-%D!1)29;;MPC:DKNU85L*T>Y^V-B'(E DJPV@T"A
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M[+5G">?"_&]02"SQ2%8XD^2''RZ)#]QUY0,1H4RHQ )!\XL)2?)L*N3\/?_
M.N_:F<<R7O0\C8F.&MNF*&V1?B ]'CKI,0^!/2PB;&F5E8%2U"$]@$EJ:C\
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M:BPNJM+TO<W2A,>\N9C2GQ7GF+<?FW4^1PXL:1PH06=T\'8<F%N*)/!.#JX
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M6RLI:6T+5[<P2-]&,7S?U2"XK V?60_ZO-F!EV$]/7LT.3#Q- [![Y\G1A6
M)C9:=VPBE+%[9YU\,2?;F<'A- DN>WQ$"\KEW/9<9&VJC;HG[J 3-T/@HJ3<
MQIDYS%R+8V3MNG8B#6AW$TV/IG+.G\22%S(N]#R8/\1U<,+4NQZ"=23@ZYR=
M'"^<)604(C.6D]:QA-AKG:WLDD;R5A*1:J3I"MNCC81?A82@>C7^-\83EUR$
M7;(E9.;7N;QG &>['4;GK?3MMIT>/3(ZDZVK DVQ@A,&DD3C!#NC,$42OK/F
MK;WD+%=5Y/8Z6\+M/L9=-R;UA_BTC2\6DHP_T8:> Z M;] C33WFOXO0]O54
MG!1HM>_(;;<.3B!976G["+B=QH_OV7*]\DA4:KW[9!W:4:WL,/8D(-W_U6QR
M_A1"3$5%,%G02=RG2 [0C!3)!33E][_U-53>YL")!][BD# 0!K9^V])QG[/K
M(DS81/ &;X7Z)W@4!NN@N2U$8=7'_7<)H1WM,,A*RCM=@VW.-.CKT'"2"*$R
M-=X1_&$3/K+;U1P,'&8>HBP^&>ZTK#WOI#!KA"O$:[+OM>*^]0N\7)2M$6>[
M"-XM40;NQ,"'8&DX.6"W3[1GO+5DTURR/P<L:%/=%$U=2?_\QJR@T/"&F^"Z
M9/%7A-RE^!T3/NX>]H,GH9"QYQX;S,YQ3<. =-O5V2=M0JZ7M':*:X=7>FS;
M52'1F)S'G3URB=QKK6*Z"NHZXL:%7 MHWPK$5:%Y0::=I BCC9#J#TML,?DP
M1_<-/&!Q#YV[90+HPTBXQ &-O'M!6Y!W9'_P.:@0"K<#OH('PJ#!H1"OTXIX
M@:X: B<[M5&4K;V3$\[![!S>&&_:[_'-%INM71E[D0&AD+M<VU?9N9"'S!N2
M6E&1X2L]-XD>M&2!0UF-U1:M"9@\L="&Z5.F3MMK?T%B.I>4I*V[\Y$;]Q:^
M?&SU-@,FOVZ&>V%3E#$Q^';JMA4=-\]MTXV?3G/3Z.==^J231L>UE2B'84^U
M@?$ J'NJ !/_0@4<]-0E!'UA-NJH'5R";VDI*B%XL8#V8Y.XAX0ZA-;#PZ<D
M#>6-!*,RSKE<L823EO$A(+*]41/MHADX:ES\:6.MW$M8R\94^+'J')%^7+7E
MF"2H/)XXT1/4K8%8UU(%RX=6O_7U /RF&XL&]:VMM>E6ZJ3#6"8T8/Y)1 9[
M^SQ$#ZQ[8#206JDF\V!(>4DD;WR,SWVCPF6D2<WX_LH+-D!. UI JWZ]F0AV
M9S,26LXMR801V&VZ%3,&DM]9/(/7^='>+9<LW!&*31$9$\M7^AO8DVY[QME@
MGQ3"W[5+=Z[F#V^$/U]B3\5S6R:T[!G3+'XEDBWV+76KVKV2UD:CM5&-,,0D
M#"UZ(1Z5WMOW+,9\$Y@NTH-7:M$M]]OT]6]G?%CS!_A?IEO<(00T''!?LPCI
M M)):T5K#;?6@HQL7'*]S[V%>[7G@ 35.</:Q\J( YAQ-'CBS=**Q#]]EU*C
MS18:.BBZ8Z4%WX1?AR1!9+55[WHD'MUE.+6<0*IWL3-]*V6"W S:R)N'[LZ7
M1!558<8D?)FOCWFAK]5K%'9>D4O#B+SD7(57(S-7URS-+LZG3UT$@E^;I+W?
MI#S4CB(9C_T&)QSIE!"7/R4R$1JQ;X-D.I+1[VYN,E98R37W*%:24DR0[#5,
MG#R9;Z0D^E+R67.[(\FQ*Q9\EIPF/P#"GP#A>P_AR6\H,^TKYZV,(@64>A%T
M#.$PSL,PS!,7ND1O#OW#V$3$A811M=/Z[L-]8T)2OG.7!_' 4:!\#%5^$:\H
M.#=E\^TN9Z;A,;RRM+1)&9T= 6 "O^>^(I/@< \<U1#]/M^*0-(&IZVD(ZX.
M[MZ4_!MW;*Q.R;4Q=D/QDE,B"_"JR4]M)U&]0XU)5\J!&DUN]8(4#['Q+U;(
MOG6VSE50?1U';"7Q+&>Q0@<BJ-9F;3,2+O?53TZR2Q.50P'; #K"Q$<G]U]#
M_?W,NGT,9-0@R+SZ+"/V__0U:.=#8]]C/I=PW77@6D@H)+SRPRB-?94\O'C,
M-:OVW7RHAWU*>/57?HI7NBYH3YILO1L<'T89N^^L6%3;_N6#[M7+!T5+?S+Z
MU]2W])=YA=:=OGK)??8O35FV4B[YS='L*+B*KBK?',UGS^?G1P_H27_[JY=;
MHHIW:<.U%:59TJ-GTR>/CN1]3_9+5V\Q)$JPNGK#'\GP)(,%-]#ORYH0J5\P
M 7K^,7BO_C]02P,$%     @ %$!05AE^S%K1"   WQ4  !D   !X;"]W;W)K
M<VAE971S+W-H965T,3$N>&ULM5AM;]LX$OXKA"][2('4L9V7=MLD@)NV2!:7
M)DBV[8?#?:"EL<5;251)*D[VU]\S0TJV\X8N[NY#&TOD#.?EF6>&.EI:]X<O
MB(*ZJ\K:'P^*$)IWN[L^*ZC2?F@;JK$RMZ[2 8]NL>L;1SH7H:K<G8Q&A[N5
M-O7@Y$C>7;F3(]N&TM1TY91OJTJ[^P]4VN7Q8#SH7ER;11'XQ>[)4:,7=$/A
M:W/E\+3;:\E-1;4WME:.YL>#Z?C=AWW>+QN^&5KZM=^*/9E9^P<_G.?'@Q$;
M1"5E@35H_+FE4RI+5@0S?B2=@_Y(%ES_W6G_++[#EYGV=&K+[R8/Q?'@[4#E
M--=M&:[M\HR2/P>L+[.EE__5,N[=Q^:L]<%621@65*:.?_5=BL.:P-O1,P*3
M)# 1N^-!8N5''?3)D;-+Y7@WM/$/<56D89RI.2DWP6'50"Z<?+G\]ND?ZO3R
M^O++]-OY]=<;=37]\O'3Q?FIVAZ<7GX[__AZ_.O@U=%NP&$LLILEQ1^BXLDS
MBL<3=6'K4'CUJ<XIWU2P"RM[4R>=J1\F+VK\2-E0[8UWU&0TF;R@;Z]W?4_T
M[3VC[VO=^E:7RCIU7L\=_6BI#NH\4.5W^.4'&PKUS^G,!P?L_.NI$,0#]I\^
M@.OIG6]T1L<#%(PG=TN#D[__;7PX>O^"^?N]^?LO:?]O,O<_48R@J0OMLH+S
M,=I1H2#UW;HR5V>D2X3NTBUT;?[44GTY9:5VE*M.@=*JT4!&99#5J<=C(6(9
M=BD=5&$K4IFML.E^1RU)%?J6U(P(E5SGJ)*RQ'(=3-V2"A8KRF!S%G#&[%ZL
MH?D<M>^5G?>GOH?>)=V2$Y6.F+;XE,H$%H0>G._N3;U08##\<R@Z+PP$+5CC
M%5"AK#1P#9#Q0_6='AN4E1;D<Z\J6YL ";8H6KAND&)F@J3V36<KJYZU'EGQ
M **IL[+-^=B5 L_Z>1M536GOB;"O,T:BX]NF*0TYO^8O8AH* U%PJGC/@6YK
M/2O%7/)8T('D&%!:?$@&\[LN6]%3R09'!5; :V]+DVL.X=S4NLZ,EF#DAI._
M@T![J(S>->0$$IYK+-.^4'-T!@3QLL?3FYTU3)U.KS_=J"FL6&JOO%G4.,74
M,+FDA?&E*!NJWS>V-L[>FIS-P2%;XS<':@:K.8V06P-:VN<V EU8WYB@2\\.
ML@ESA[PJKA-Q0:SJ\K<"\>4\!=A"EI-J,XF(KFQ;AQVUM3?JK6!7<@-F,;.6
M]YBJHMQ@.P #"WNSI./DR0[C>*&QCCWF[/B"?8!%%Q 6?^9$K^'R:R8;DS'"
M335KG:=*L &P3T;C7X>I1#=# $PXEOC1&A=K@8,-/ $Z ?"(A8RLSHVK.$Z.
M,C)-Z$)RE12I:P+VYNIS"R1N#ZZN/X,LYGB(V-0+1X(XE@GDJOBZ1XN$N-'W
M;#&""GP)%<2DR5;)#YSSM(ANB2&W'.H&WMP)=!'(K?%HA/*-$4<.JYA,XWS8
M2 ;.B^:M9^09G' (IXTS94+HLC! K/$1/M[<2CZV)OVYCDJ=]'&M_-L"NNH6
M9K=0*[HS/+#F;8Y\ &%0*"Q#_!9!%P=?"<, D!933$K/ U</^P-Q/$*>/!)V
MJ^LT BT-(L@Q$"U>PLW[IX"+/F5;SE)HMP?]NP%._UIS7I]-&!?9 S"D! K1
M"*ZX'I8Q#JV/+!--9*JT8"@%O@Q0@]BT%(](.8]1PJI?CV9?@:%PMET4ZK>V
M)K4W$N[ E"!=@AZ#FDN('&+&&^9MB5^YS5JV-G*?I^2$IU44'7'=^0ZW7X<W
M0_61&NTD0RQPM@+H65NA:FYB#2*Q@[.S&P[C%,39FQ(U<ATQ&7"G*XE=RUO7
ML3T\0SU7/$8IV&R "N)A"JH;C"DS!&W37T:8!HF%I#U29CM;M3=8PFRR4C Y
MC /54'U.;6U96 3EM5TRT4+8&S"3,]QD$,\VF-+\B945R%),Z"YP**15Y^H'
M1BLSET[:9XKN<)?PA*Z$3;G)56V#Q'M#UU-HB U$FB_7<:<QTO[":9R+ F2>
MT-[;S A(>K@_,H WMTX \11XN)YQ.>";@_0:A4D0)J76!2/267R >:(',E<F
MQMWH>%+&G=\1>BF<:_70D=E[F0O:N@]X7$YX;K01RRZS8"6-,'O((UFZ7<7>
M&5M1BFRA0QQZ$EGVC+AJFYR'6*U9QDTK-5#-)<[U"RS';B8UD1C'OWJGIO)6
M*-^O(/)T<#&=;40+<0*/("E;:O]P>)B4)!<3MA:,B5I*[5GQ;;KC#LZ*1L/)
M.A\:)E@2/+'25^K@[7#OIXUMZXWS-AC<JW&OZ26+7]8Q@M=;:CPZ'+Y],,<(
MYV\,,Y&$*U0WLHQL^R;=D!/QZA971L M4Y-?8%+>9AW+]T,")G%3/1P-M@>>
M;T!\V6$!;MGIM,0\%_I>Q<O7J(\5KF2)AM(*2#'2EVQC2HKD=&IKM'WOT1<\
M#S0ZC[T#Z.R+T\6Q86VJ2]U5B"67%!%[M>GTAMF]97&2[&Z+[Q_L8EJ$_[44
M:L[XUFJ\'BXD\>5PQ;L%M_LX#:2#XH2S&?J_H.NWMNR"/!&R0+':12WXG%%-
M<Q-;4$U!K48\X<A8ZZC*!>:>O0[]/'6N1@,V;FO2+W:MAD]+<$\9&\G(WD2K
MRGMTKCY?Y?W#L?P1/'.:DW-\LXZ03+<4MYI7A:)+N  6YI$GZ#NU?3B<_/)J
M9RT:K"_-$9C-X**>AS2&4(UKB117'N\L/X-'Z5_1N,<#U,'!.F,\82"!OJ>;
M,I,WO0PC2LH_Q;2WA,/Z7FR.MTU>G.D2=R1Z46@29U\4GY<R$?BDB;?O(8G+
M$\.W_936)V?M_F>BV*9( @UCYO&D?(%:Q42(1B>SX?1F>K6JUG[:OVE11;CT
M89KF2.$]^G'53<;235J_FFLB?W1=_MFI[B<[^V;+_+_U[:<^U^RN?72KR"WD
MTR(/<FB$\?M;_[;_>CF-'^U6V^.G3Y#5 F0$ZIM#=#1\<S!0+GY.C _!-O()
M;V8#V%U^8C9&]'D#UN?6ANZ!#^B_Z9[\!U!+ P04    "  40%!6&'@SYVP.
M   D,0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6S=6VMOVT86_2L#
MK=&5 446)=MQTB2 XZ2-%ZF3QDZ+8K$?1N1(9$-QU.'0BO;7[[EWAB^)4N0V
MVRX6:&.:G+ESG^<^2#];:?,ICY6RXO,BS?+GO=C:Y=.3DSR,U4+F0[U4&9[,
MM%E(BU_-_"1?&B4CWK1(3\:CT?G)0B99[\4SOO?>O'BF"YLFF7IO1%XL%M*L
M7ZI4KY[W@EYYXT,RCRW=.'GQ;"GGZE;9C\OW!K^=5%2B9*&R/-&9,&KVO'<9
M/'UY2NMYP4^)6N6-:T&23+7^1+]<1\][(V)(I2JT1$'BQ[VZ4FE*A,#&;YYF
MKSJ2-C:O2^K?L>R092IS=:73GY/(QL][%ST1J9DL4OM!K]XH+\\9T0MUFO._
M8N763B8]$1:YU0N_&1PLDLS]E)^]'AH;+D8[-HS]AC'S[0YB+E])*U\\,WHE
M#*T&-;I@47DWF$LR,LJM-7B:8)]]<7GUX\?KV^N[ZW<WM\].+"C2_9/0[W[I
M=H]W[ [&X@>=V3@7K[-(16T")V"EXF=<\O-RO)?B*Q4.Q208B/%H/-Y#;U+)
M-V%ZDQWT7A8Y[N2YN-*+:9))<H5<_/-RFEL#C_A7E\R.XFDW18J2I_E2ANIY
M#V&0*W.O>B^^^5MP/OIV#[^G%;^G^ZA_T1Z'[_Y9B5 OEJFR"K[_6Y'DB1-^
M9O1"6$26L-K]3#*A3:0,W5@6)B^4T 4B%RJR:KX6>H8E(6(>NISS(P3P)R &
M*R +E9BNA?J\E%E4+B"])/0 $2-P7Z@LEEE8/EYJQPT='2IC@1YBKO3<R&6<
MA$+268+^$RF0AG8MC;Y/B$<P$VLP'2N9VGB 7_(E3AJ(I3*YSF0J0FSG,V.$
M)&0O$KMV-SU7^5#<Q8I$#6/B;VF(U:5,(@&8:VLKR46FYMHF4$4D;&QT043-
MXIN_78R#Q]_FX#";VUA 65DN&6OR :(8MT)<$L_L=:R*2.""%"#!Z#H'<3T;
M"+G0I!<;DPEB2 L"9#MIY#3=L![K\O,2H 9BH<QC,0.P0J++UBK20!CJ(J-E
M+%1>R>N(T!)8-2T0N.P!X(H8UFD2L:PSA LL!H7F%C> Q+9TGE@E!I"<$QL
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MJ)BSOJ^!6AG0J^0KN^I&YS:28A")E/!&6ZKEH%[HD:*.-EQ1>0\3+N2:#(0
M(Z,Z;380,J8>*&O$)/'FH6>V;E(B8:E.8PL*3N(J81><J@;V)B;BRL,53IWB
M4>H K !@*2S,!F:3:WC=<&I%WLVK@K:@HH-K#N@%K;RW<)4RCYH&\*IK!SX)
M/"4_ABV<+["AG8&XWG8%/!FS2:FJ7"J\<YA *FG8!K),J=J."N1%JJ=IE:\
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M>LW]I [[ZD.+1_01&7__5Z8>(G/>Z T=&.Q8^L6^[]%VWS=&A\S%EOL.@7-
MS>?OH?BXI/B0CSWZ1V3G]B3G@(\_N*:*-,C:LE:ES.&QZBNWJL.Z]&BUHL%%
M:XS_P-=(DR?-%RGL2SE]HD<RU(9HUH+>&.7K1?@LORR=U+..XT/;6N8+._\
M_T'SW<H?X3]HCD .XS_@<O9=:#7=#"Z^5I-P8.-]^A>T"J?--UD/;A7&#VD5
MNKZ./FE\N;Y09L[?Y], $3G.?<1>W:W^!.#2??E>+W=_/_"#-'/ZDC!5,VQ%
M77C6<QFZ_,7J)7\'/]76Z@5?QMR1T (\GVEMRU_H@.H/(U[\!U!+ P04
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MN+/>"Y+IBIU:DR<4\432B$,VFL',"S_?BHX=/@K$O2I3$B_E<NFCV2O<9RF
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MH6$?8%\HH .HA$/($_>!].>2AK%DO>?(](^*R:>//I)SE:, G@@!:F:DFN9
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M]-,/[T:CP>6WA]M[OAU>'I^ 13I>@@'F24,-F24Y7(VF0JY934NC].Q^!8+
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M#TWE\+$GL P.3[J0.?Y"H^0P*Q!>L;/V.%&Q%6"Y$TN>KYT1-3@:B>\8L7-
MA_.<%!-G!3VX3=T:_*4P66?1+-V A!0'T;SQU!+4$7#6XA&]6&\PFN.8UPAB
MG#0)8IE,.1B&7<DK:23^NJ6UR#K@;$N,RHQM&.LB8T8-A1XC:ZVZ#$A8:JW@
MN6ZO A;WXF#2$H21 D2*G 4EW_#D;+'X!Q(@XE^"L1MED&H%;8#O\6A^UU@2
MB46Z*39"DO\SY- &H;,T81>KYAL*P.!'MP@8Q.@=[11,I.MQWIQ+0$^&!3@6
M[\O]9K>,1+81"M%TR*;!),0HO<PUJ.5@C& .TB+X_RD]IN1,&RDH0@/;%JC7
MSKF0&<&4+;DG<@!M%A8V7199!GN#1,GJ8]Y(O!06VH&*@V>"@Y6FL921<@S)
M;>JP>*Y48ED.<JN5RJ'.##HVP"Z.H0)75E7;\87>;&7NG9("']:T:9)* S ;
M!K=G\0!&J6.SQ[\7J4T#/H(U9*CP;W*]'<;YG!IL4@PI#!L0HV\@0=-GM3 %
M4G<Q8W1Z_1"=:.93"1Z".QF0#![=,W7(#PDTH_';$O2Z=/CUY&U C5VC'H&[
M_P#(G38#<AC<JT(F$N2I.44C(+MB^""0@G<?AHV*9<(^O-G#X>1TWH7AH-LJ
M'ZMX"%H-<)AQ$76CLK#,WM!M6:WSKC36L $>,MGM 2/Q=R46VB"%#DK$P]3T
M&X)>/Y2$X*#KN&1?;5C)&B'/*FUD))SW%B9>$U1C)60US8"T5)&2-UQ0OO"3
MMEL:<3BXN/@)NVLC H>UMHRB"IE6[*?/9D7*%J>,M*A,<BNY<(6(2Z4\:J@[
M%..$#\2S5QK\.F9462+IVV^8D?BF@.?)TX*]F6).^B.]CQS!U%-"O3O7>\V@
M^;@GC,ODX)%A9;3;/RW:)XBD16^LV^?%^A^(YUE/6E5JY&$<#/[]6!YT]-Q,
MU7Y5KL<'.[SMYLIOP.7^R:'HXPR^9JUL1I.W/"G)<K6!*350[N!0+!2*J4:)
M1AJEW"S/D>8L)(K?(=5FY+5EIX@?J)0RC3?B,#UB^IWBC9=\6, =IF%X;R77
M,\G+%+"R6J,$WXTB6:589D7L"B0W,)#/$RH1U.\%7"/$XSI=K5G,)2+.,[)4
M"><8I%D;)A,O2/S&+VHZ0W&X\!/@;QOE!X),I3FJ,E!YV74=P6?)!B%#311R
M)P1?M3\=QGNT,&DLVQ*_,[JM!"+W>Z$)&_=I *59 B-?$ML+F?\FKI=+QBS?
M$QA<79Y??P5(,RK$!.:&;6&+&#DA*N90K7/JOE_44'W4*O*=$M*:SA4%#L"(
M%K+IG=CXYACAH.](>MJ%/6JIH.,=I0I2RYW'I,QL]R7E7 ]9P7VIW-6)GV.J
M"^K"CG;U:H:]?IT^\!86O8Z(*PY)6GC2,Z[K!#QZ)*X1<<]"<;^+;C,9^Y<0
M@*U9HU@B4X :#268*<$>=C0Y]6:Y! &6ED%T./AV_?DKU\-(Q#$JT(.\26K!
M&>(-(,,I"#<&,JO;]51=)](6S1KP-6%=$O*+&J:(LRJ[?T1\3M_WV_$+<@>2
MYWL*^A=-K[@JO>(K>T776+U&80$^LA(_ V89;KQ*&F,N:IFO*EDOQ0\K]Y;*
MP#%IAC;'"5V_$)'_-QY-Z=]D=#K'OTN,SSKC%X7S1*+&P[$?'Z:-1Y&_FX^9
M2* 2]5'AF165^;B>!RK^CHE=_LT3:8\/ZT1^U8F_8T%Z2MDD8.6^;2BU[9;=
MHT4E-DYVEI0333+,0G'GCR[+>E76?=N'++7KH8<[[U"LD53#2X;$7<.O@:<&
M2V?=JGK9R$6",]8I">V3X]%)-'_1Z1QSD"@?=KJ35?J<UE?H>/=-;5T I'&S
MYN==E:PQ?H3X=>PT3?=P-NV0[S& S\KI?6@+=.W8D[!L"F#]@IH&:>([!3L-
M<)E3<</)2[E!T:E:4F2^0=-2[OYEO28:5O)G0U33J+L8BN.F*8TQ*LUOL!]Q
MB!H"/LO9.T&8P6:9FK)7H>!'CTF[Y'HL=%[V.*SU6,98/!G#4)!(9M3Q<"*6
M=EWGB :[3AKV5NIM<-:+?=@Q=-.3JLMQ[]L]G(?0II>'HSQ>A3(<[HU8BS6L
MS'BS!7)OM<\7"=<-;^WKYB)A?=O#&E8A95H.JX-YE;Y29K?PJ[5[W6XMZ8ZZ
M[(T>3 WWCR#\TVJ98#0KR%>=RBL_O=7EEL9-I!MZY:S/6>7>) &S0P5)->D"
M(W*2&E[Q21J*!RO.%4)-^4P*WC04W^4=-9T^*C@.5:E\ILI\-_SX</#I_/+[
MQ[/!45_SZ?$-KXSV#OM5CD52MN7PZW%$D"WKD6MI5JJW!_:H53Y)N(P/2:MJ
MS9*E8YG%1<9,$2O"8!/UQV6%>1F0LSHSX]J.LH8VP,;*.!E\K1&X2/%^4\X^
MS2F8+.4H(&0;8% QVV@/#GE;)!\MF\-.#P5I">F#7U_G;V@\GZ1X[\I2E7LB
MC8<EFL'?R&V&''8<+1R%7@Y-0<O^126_:S4X895\Y7N7)4;Y28F*D8R$LQ\Z
MIDDI\T/-PNIH62%(W49 5!9=17K+8VCV#--?/@0:K@US9^[[&Q]]UDFP"\ I
M:.@]%:!^6#??]ET51!.UHA)Q$(U>-8\7DGWG:Y"M]]QLQYE8.!@A45J!56Y[
M_ '!8TD)O'@%#X<1E(=O FJ'6^ /90N >RI^L,;M&F%Q_U+?4M0E *_8A8.:
M<--L9#\3!:7CE1S*5.L!&$HDR"N;[Q6/H1_18J:Y<(#OO',:8U1(NGW(,##"
M;<7K^8M2OI8.:1\QP%<4"R'DDW_ -?$F8!-S03SOYJ0"OEU"_ &^3_UNW.*Y
MP^)P/SSY:NV6OW"AR0&#VR?<E)GY3BWO'WX3;)Y6]C5_^.PHJM.Z/=$2A0KS
MY$FC)W^,YR>W[[P$LV=)\/JI$NPLTQ_X8/=D#ERA:.H9N&LGY1GT+0"Q&+)%
M3KHVVRQEB*BPL$;B9R0ZE]Y;*4Q<29_<=,<:X>.4:N,-27:!]%HQ:M[R>>JV
M,!8UT0W"0M,!: ;A<N[1V-#4E<C(-EOVZ]#CH1,^R@*ADQM_$)OK_&7-1-G.
MW7#/(#1UAY2N4QG!>QMAZ0I0:Y7BX[T6MU EUJ=C8>-[WKS)/6),>8-M2BZ:
MQS_/=L.#>30>S:K!> (]K>'X=%3:/ QM>#Q9^R"BKSFJ7+<QL/^,^V?M#S(J
MZ]J^79.[N!<_=8Y#.H<(\B&QH0@(Q6L^.+AIGEH1^3"_/E=BEY#^+,(;DKF@
MS<?9-HQRZWDC$\65 0.K'H9:.X;IFJ!8-V]\%SWWB1 Q.>RK_!MG'[F^?4J,
M'+7IM+[M^$:]+++S#C6UOAEIZ>B)Y&K]E:5>[\0O2*56ZC_$19=8?9"[PYW.
M+!"+S]S^F%,QGY.(XV_<YS'MQ>C$T?U_]Y?GV;5MO$H30:^#W2;J.[>IEGYX
MY/=LTS5:1&4*W1/P%1-]4<\UJY6YK,Z@@S\9WV#_6>:,.)/2/_Y\['BT+O[O
M&+JE-U91:8YA\W, IU>*M\$6SI>&JY;O>DWKLX#PS-8Q_Z5A1AI8CO@3A1_N
MW!J&.R!@^%3?ZG^]XI2>B]&EO-'5MP"]QTLR]-ZH$/>'&?ZH.N1OH-%;?H%>
MRAT(RV4ZZ@E<N_MF@;YE/22EIGM75W4+!.2PXM:?&K<$^I_R'-9_GU0G#E2K
M-9A%]O-?UC2W1QK%*B53K2KY=NU]F,!6W4%Z;A+#?0U0"Y=RZ51YYE3)KI;+
M<$685#7?:U=]<D+<0JT'!T,EP5[D[$VO&U_\_LI?_%+QT_X KO5),)9UDAM7
M!_1M</75DEY0Z<>?VAA=K'QX-[$<'%:&H8/]8D7M\*J?0<?MMG4J6IXDGXSF
M+T;5!\A7_@/D+I?+]O?)-9/TI7*9H1I%_3=2' ]+V-NV5?BW3_P-&PINL&+Z
M5$I'H\D+FCT?35^,^K[7/V[\G&*CS(I_-$)]IR)W_I<5U=/J=REG_N<8]7#_
MHY9?I%E1@RY32TRE0Z:![\F7-TYO^<<9"^V<WO#E6F%;,30 [Y<:U@HWM$#U
M:YT/_P)02P,$%     @ %$!05@C.];6&#P  O"T  !D   !X;"]W;W)K<VAE
M971S+W-H965T,3@N>&ULO5IM<]LV$OXK&-?MV3.R+%&6[;S..$[2ZUS29.+T
M>C<W]P$B(0D-2:@ :,7]]??L J1(F70\G<Y]L24*6.S[/KO@\ZVQ7]Q:*2^^
M%GGI7ARLO=\\/3UUZ5H5THW-1I7X96EL(3V^VM6IVU@E,]Y4Y*?)9')^6DA=
M'KQ\SL\^VI?/3>5S7:J/5KBJ**2]>Z5RLWUQ,#VH'WS2J[6G!Z<OGV_D2MTH
M_\OFH\6WTX9*I@M5.FU*8=7RQ<'5].FK,UK/"_ZIU=:U/@N29&',%_KR4_;B
M8$(,J5REGBA(_+M5URK/B1#8^#W2/&B.I(WMSS7UMRP[9%E(IZY-_JO._/K%
MP>6!R-125KG_9+9_5U&>.=%+3>[XK]B&M;/9@4@KYTT1-X.#0I?AO_P:]=#:
M<#D9V)#$#0GS'0YB+E]++U\^MV8K+*T&-?K HO)N,*=+,LJ-M_A58Y]_^=//
MUQ_>OQ&?K_[UYN;YJ0=%>GZ:QMVOPNYD8/<T$>]-Z==.O"DSE74)G(*5AI^D
MYN=5\B#%URH=B]ET))))DCQ ;];(-V-ZLR'YRM042GR67\5K[=+<N,HJ\9^K
MA?,6'O'?/ID#Q;-^BA0E3]U&INK% <+ *7NK#E[^\-WT?/+L 7[/&G[/'J+^
M37L\?K>(HGOY53DAO;=Z47FYR/'(B!1FTV6ERY5 @%M)(>+HJ=/."[,4?JW$
MTN0(6EIS) M3E=X)7<(+\YQ6'S\5" Q>^&\E;?0! 0NJ8J%L8T7Z,Z4_$W%=
M6:M*#RHU:T)]17YQZO1HH4JUU)ZHJ@P<Y>)03)-Q@G_)9#S#O[/I^%S<>.F5
MD&4F<I-BT<5X(N98-9W@Q^D3?$KFX[F8T\[7:JEP8/;(\W#,F9C-QT_$49*,
MY\?WSDKPT^7X0AR=C:?'(IF!J[,S''N4G(_/CUL*KT\AID$)_RXFXRE),L?R
MS\:#V'V>H.^@SCM6I^I7YRCHD[ABG6XEK)L3@Q[+\258S?U5-HM2+:TI!KRF
M5\B?2J\0'KX1[F@ROC@6M&("T_QH3+8%4] =/9[A\0_?72;3Y!G':KW)JM18
MXA N*[-,TX'0W4;J[$27)ZG<:-+E%,?7VQLRK&7P1HX!WF;L0^#M4EPQW3+5
MN681R-^=7I5ZJ5,)]\ST$HZCRA2!LU!^JU3)*K-J8RQKF35+VWJL2):AU?0]
M_>9JOY8>E:O*,Y!WJ"5!TW*SR>](ST3IE_'-6"RCESHX9>6-O6M3L^2H.""9
M?D^JBK\L%#Q*M=9!'NU:/O*GO:$CKQ]BD+E*IHC0[_?^[4=6F\61*!5KJR;8
MDC,&K3A"_)&7S4$M0=2^^0I;N?82%_3HUM*J$ZK;&;RW((Z#R8D"I17X'SX=
M3=D-?S;E"310 2I0GE1?55H1:NANG<"%II1HX+2_E.1*<)T_R$G;QQ\E1):H
M[GOF!RC<"NU5$64]FA$O<PH1XF4RD$R09>:DPCFKD'/C]RS'AU)<52N !61!
MMAC^?@0N$:_&XA^50XTRVY&X7FNUA*9JF3XLX>Y@A*QPO98:&*>L,_\K(VU&
M7ZX*E6EW!T:A#)MJTN-\,AE-)A,8VJ1?D A"%D QO-6F<OF=D%M9!^U:%Z*"
M5UEA*@O6)I?B0U&B$CF2$+6 .+EN:_=C+LNQ^#7$/BNVJ_UVLFQS$$YU@CX)
MJNZ$QTZH0A)L@]N;6V5C&/]>:0?]"ZK>T(% +M,F8Y)*IFL\WTAR7LARBQQ&
M<4B1'U,%T>##*+/*E#*4A"Q ;GXMKFZNQ<7T<M01ZBD<GCCM"/I,K,U6@:D1
M4VQY>71!AKTYIW5HLJMMR%,:+UK.AQ2C<Z;4T4IM-I&!T%A<(?QCHAFQO%%K
MG(80*KNLA2-C0B(INWR-\""KBRO](N%DGIA*T1G$.L0Y$$SYNQV;;MB6G$-^
MO+KZ*#:5W1BGW%C\%)3=U8E"K*LLT$^KHH*&R(EV^P>/: PW:LC6"04"F%0S
MZVQ&6=[Q04@JNY,A7TOA5'?+ON2DRV@&D"M4R/R[<CF*:B6G8LW:AG[T+87J
MP\U*D]K'XKW=A?+?W(")-]: %+$F#I]0=HIE?T^!NJQ%PX$/J^T>LX> 6&<-
MW0<R-&45+"=X5*]V@TF_V=5&0 , :#+FU/KVVRN38&8*.C)GRW2'R/8-6ZU*
M4R&,K9<Z: Q.J$.T916#9BERN7&JME,H=/PUUP6 ""\><SI'<LNK#/Y^*RUE
MQ9#NT?LBNTB*W;U"P]JF<H ?<#;#]*"?$?."N +ZP8);F5?!1 3ZMI1X1H-\
MDZZM\I4%47."5&4K2"FSWU KR#,=)P3P?[_D1WPY[>IP+;,NG(!2E;YE=D'F
M\!*EL=8K4<"#I'[ OK0)GIW?C8@.J8BSJ.&2F,;V@+.)XT"DWU XJ#$QN<XX
M0!<RYWS+72]$>'TO$Z'Z MHM@.^\5NYXN*\AGS<E:6((+@_IAR%1S\G806K&
MLXV\LSA(_""+S3.ABDUN[I3: 02T-V>,EZ<S*.E78[\HZQ@C7#SK!F/H;0@A
MW S!F3D<^AQDWJF5K(^D!5 #J:I _P?JXJQ9!A*BUM&=2"Y@./R9[43B? @T
M![A@:4FP-\&-&L><HQWZF:!:R&U0)]IK9'AI[1T".126*35MD/"<<7UPX[TE
MU%91 Q%P430@-0DD\8_6< Z^;^*+"Q"])";>(9<][8L,<836$(@*V/^86>VE
M0P#RDCCLF+/E0$_%1TM"0@ODU 0?-IS8C[CO.[HDV'95$$+XHVDH=.EEN>+P
MKGWR[)*ZRJ-90NPTAP$WJ1()IE8KNLLY)1!"'D7HEN%+UI<PX%IOR :3\>28
M_UT>"YZCG9CE2>7B2<B/%[P @!'P,ZBU)4YLQ?#WR7&??CM+44<N2<19A^=.
M#CC$26B=C_&!$364\9ERQM6G-S>(!D]UZ593I-?I/1P'[ZHK7@@.&^ ZMV/W
MO8^TG7Q_/&K51Z*',.-4QDE:+GT$>:J4:5 ?)0T\LJ9:K?NJR5N]Q $P;QIK
M]8[#5A0'4;=H"_D@V'B?U#0@AX P:1Y*$5$GE8$]R5 "[LF[LD6V3H'8F3T<
ML)25DXMV#E[F > ]+KV.Q':M4;1HS$!M-WECPVR0@$IQJY;7\&W4560_>V3N
M5B'<KE7)QXQ$KN0MB5J:EMP]H%/V)^C!R@:!%/19(\;R?@([HDA,)L]^_O".
M/TV?'>]E+%8JPF<'L&KX+&^ESNLA&R,[>&GE:>C8+>N<20IYAWK Q'4(C]A6
M0$X(3 T(6J&U)G+0)1C:8X2.I#[ 58O?8%4Z%%A"!Z@9#"#+DHH^[8V#"&:6
MY@!M7LUR2=KLYU6[]@D[L#/F0+_/%H>)3)$G;0#*E+]VL(FP*[PD7<L IJY-
MZ9'")45(W<B&*!BCP:;F\28.\6>724V&!TPT#/H4\^>UR9C:],GE^8C1>1%P
MX=%!:_L!$@AD 79#:X+=8*)<*1?0;0RW6(1AYVU,NFPIECOHM)GHW)>=M9NB
M,X!AT6CGH5=@(Z"=_(:F.PU:+>F.B\!L-S5D"GHHT.9FX6C*]FPQ6=:VWQEL
M1'IW%0VYP$E++2-ARL>)%GVV$>TQ$CT<AZ$ON'\<1=GT[*P%U?]DF-48/!S4
M@M/8[65.@7\X:QWS /5 HEW^0@SL9.#QWQ#4X>#DD5G-D]>%>C0,[X,X5 -[
M8$V=M[EG;88(=9O0L$OK$"J'\QU.#\"=QJ6]P#W(2VDS>&/=[K(J!SG\YEB[
MD30,M+FQMBHFB,-I*]=R9[GW^VRHS0C<=O8W&R/CWV)YD&/=-(9U OM;'(#4
M,^4!Q\;!OZ$(NDRGH4]CO^:Q%+E8'#XQ?@^-*P^?"$U ]"W'=R<#&!6F06%V
MPV,WCJN*)GR:4,T]F@/!TE,1_'HP0L=(PNQNSM6C:DB/M%"W%6UXTG;-0I9R
M%68CW)IEU)M L#@8)<T6-+G.]1>:P4$])0O(>G+$:3..LV2U>ZBM!>_YEH$V
M+VKN5!:\@N8:!0D6F:[-UD>%;*TVY G@N=K$9+E"+V>;?0.UDY8"#^V9/,.W
MJ+,P?62W"#$;UGN@8F.EO=N[CV"J.\PT%N_[M,EF2]=8EL<>P[H N(>Q?NC(
M:[8T/"7E2K!S"S;_0J)^DRNVG:&6 N45</^W #&'4S(>G6R ,QG5T;36JY4.
M9;B07P(+?%5!SD6BL:_179 EWUQ65$RC.8=,WZV3P0]4R(/1<$-%(UZ<Q%L<
MO3,QSQP[L;RBL3(5W\5=,U1,@43&XA5WZ=%3ZM%&#D.P%3;HXWFX+RWIH(_9
MADGZ!15>%U71JL_]K).$<6!<;2A*VF'9%J-'87OCX0%DW0G?A<HU1(HI[%NA
MNU5!LK;AFGE(X,L-F#+>"063Z#"3[\G<L1SOM-0O:A,H'!LA9>4 5LU$/N4;
M.4X98:0:BT5)!8$ E]!+05<#E$#<L#E:8=X3+8QEX@D$=>OR3*.2C\T4[U?%
MMPPD$-6EH6%?SV4$ [H*Z<0R_D--6%4Z:RK< *5Q[P5IL-5*AY#E.4B9[5I<
M6E(-7H9U;AW_JIOI5[%1E;[%&(56T.VAH"EO^^]5O$%VH;YWM-<&23%6N?CO
M7][5_Q]):P-6[,.4/M6#^4>3<H.TWM7SZ?[9=+QMW]]UH[S/59BB#%%N*1MV
M[ZBY7M)1]0-3#?@\8\Z](?RP]S1O 323XMR4JQ,.0[/(]2I*%R<:'&P/#HQ#
M4.ZN" :TQ=/^;-0 !2XYA;FM([J)'T =!Z>!4S?5,V9R(,(:#'$O45]IUJ6B
ML?2($@H0=9XK@.HL7II*E&._EY8'[C1D5Z$#5S)0),%C$QBU[3LA&@3=OWIJ
MH' T]P 8[M[8PBLFK>LG;B@FK0XCC$?#^R'2M:?P[5_JJSOP!G.6L5GEQ$:\
MQI>O'LR)K?3[4/>Q>YUFOWMX^RCI[QN%W562U#N3[.X:\4LC<Y_(87RQ-P9X
MQ-U3KXGSNDL*0.";2ALW-Q@-6ZTL-%Q]=K<Y#P<@I9">V2EEA):VN(['3%$:
M(?_O+ 67I@+=&GUU7Z4I=V_GD.(9NY;T7DZF;W56Q7=A:!+*3MM^Q:CU^A2V
MO3/T0@)0U4C<&-1K<2TM.*7O5P#>LL"''Y6Q*XT/[X%@9+JN &-\L/AGA>@
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MP'/TH%DI45$4%2(SK75*F(68MPZL.#<2SI3\9+W2V4HXI;Z(TE2J 4R(7)9
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MK6,=P=>9/,R;MS8H!?^L4L]* G !M](&FQ.,0\N5$OL3;XMQM,V,47EZR**
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M6L0E<B.:1(C*EMI65+BFP0X2OKBC6'O7534A$;C)@;U.ABF]B353ME=A]G9
MMXF1G(WLFR 7RF*OW8%PERUET*H@&:QW9"3Y@9;>-131EV2[?Z[)2J.$=G^'
M5KJQ"N*<X(PN= 2B0SO<+EJO'U1D\T26*Q>UDI=(2AM4ZEBP5=*V"K0PGS9[
MY[P4 3AQ"' E]LF=K8&MMN+6UFAE"T9CB37-'V%I*Z;S(M)-9YC&H_SHW7A
M7\59NA%CH"5WJ<9UJ)FU\Y[O#< RAG)&_Q/_(O]*RI\@WJ*1-U)GTBFA%_S)
M=BF$0%FJE%8'(%:8+O',NTC613*X.?8^[_,,WBGX8*OGP9D.OA9F%5OXPVQ<
M73@DT,9?8(8&+T]<+?,@I99J=82!1P] :@L_G-W Y%T _Q!V@-(U#IK]AO*
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M,O+]1.\7T;5IBN8N8B:GOS4^@MC+ >PO'92M%W+!]K-J]B]02P,$%     @
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M@N"S)@&>4,+9KIF(:J#P<&.U65<U@;(V2P 3?EKZB5(_$:RL-O_=YK3Y .<
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MW4=PY)A+3J0#3B4%:5L_S.A<*V/2K(9>JGG&;2 R;@,A+5)03BT-6L]KV"X
M9XD<*S-?AQB&9D(BXQB( 0T_=9WJWY@A1"H4NQ!\.D.XC$ (!#Z%.;)H3,2A
MDD#MT=)QG^EI\7G"7'_!/G5:/N<"H=OW;NN1RG>IO)A>C4U)8EK>*L/$6\XL
M0Q;54@%MS^G::5@._A++<B!Z*XIESJ9Q*PX2:;KQ1:?(L"J*GB*F-)4%$I+Q
M8I*KI@&J&@-T[JIMOU^/9\>M^C^.E^]UO*"8Z%6NM.I'3 O1FGSR)T4K^949
MM;8Y!.E9,HF(+S+,%,UM<*(*@YH'[.@AY6;CK$@BF%"6>A32&2JIXP4E+RX
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M%D-<Q1 .?8\X^5.OEB@/Y=B;!M0B+1D_S,P&%"O]G0Q]57(4]SB_3B)ZG!Q
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M%T4R4S,QK#5U 6?WR;Y*!A@?UP31S+?RE:@6VK)Z"XN+QA\"I.GF"4GL/B3
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MR>W/9,>&C<)1=\VU\=LRVMTB=3!^W&8XC]I2;\7KD^SW0G/ )M1LT2L:^4,
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M&)5GWT?R\A>$&V$6U)2HT<^)M=WLTX;4E*?R<N%T[D_",^WH7.T?ER@H'9B
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M[-4=IU?^@?6H'9YKOKG$^Y@,+\#\7",438<5="_NLW\ 4$L#!!0    ( !1
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M-IO%TP:^+E;W\/GA$3:SU0*NGMA6H+D>AY9".,,PKN#F)5ST!EPG@F]*VM3
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M% KJT'(@59,H>JKD7'!#M>2DX[!#+OI$7)<X0T/>J#.)Y%4>.]6<3_OML'L
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M+NA?!PT3T/E,TQVZ6K" YN^I_P]02P,$%     @ %$!05N*7B^XZ"0  L!@
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MIQ*1[#(80*=&L:A6["HZRO&MB ,V&O99%$;1$7ZCQM"1YS<Z9*B*=2;8-_[
MWDH;I]H61K!_SQ?6&:3&?_;97'(<[^=(Y7)F<QZ+BP[JP0IS+SJ7KWX9GH9O
MCN@[;O0='^-^>8OR2XI4,+UD+=UOC+Z75!'[]#W*<;^^%6O''X1EW#DC%X6C
M+&!.LQ@AE:J0ZHX!!0RG.K+TUDKK2#&W$FRI4U0VT71YI@OE+),*J9JF1-T[
M8Z@>3_@OP4V5'PS1%=E"F";"]#.DGY!=%\8(Y<"E5HV)!X"0%8/N0BBQE(ZX
MB@0:I>P%&T9!A$L4!B-<QL/@E-TZ[@3C*F&ICD$T#4(V =4PQ,?A:]Q%DV#"
M)K3RK5@*"$R>*0]BQFPT"5ZS;A0%D]X361$^S8(IZXZ#88]%(V@U'D-L-SH-
M3GOLPQ,II#0XX3(-@R%9,@'Y-^W [*E.\'?ISHUWI]COSG[I3]+*^W3-$=V4
M%'0@QT,9-?M7Q:RR:FET=B!K]AKY03F!5'2-<=TPF/88480(S7NMDS64@N_H
M]0BO7_TRBX;1&U\+]2(C8FU(0Z0L3Q)) N&[G,OD1*J3F.>2?#F$^'IYP\9[
M&;I18D"WD<\AZ#9C1VIXTM3PY-DU?*L+$Z/&<$NZOULNT9?LOBH^SG/NS56Q
M3*7W+#&T\D[)I8PYJB:1X(SZ(5D+X=9"*!])(W)M?/!]P&G9GN2BA"%J>H[_
ME-JMN$/7+=($["WZ8)D /,_3#86?.'T/;@.VK(K'HE8*I\VFS<U0_4! -'Q)
M$:R^+ 027;3H8(^TK=3]OY-TQUYW2$&O530$<+Q\='E<\&T5^TP)[ZV:8<O.
M"DM8%[! R3\!MPA@\NX!L;)M$EOZT:ZX$2<T<R0HJHPT+D-.' CM4!:XZPY]
M=7S6Z@0>*##F$'R+!Q$7-/'L+@V1V4/"/]32=T6IA-3Y@VJG+;X;$5OB^KA@
MOL#AADDGLLK6[HATF5#EDB[A 8P#^$W(A1/O0@_9+[T=7Q2;%W<8= #./F+X
MO<%,Q:X"]O?"HDWI=9]=KZ18PE.U35^62'<H0E&X7G&)^4S5#>E*<Y/0PSP3
MB;0;* IGF%B2'R=AV _#$('6\4_@4PE.Z(?W4A<VW3"^YC66K&3&"F258:A=
MJ!;.V)=,H4%:LA MBC2Y;GOW)N4J8#]*2/*.W?5^&\/;&I12 0ZX8S20T"QY
M0J5/(R?27M\+4Y7Q[P7Z/Q*0&CA\P "Q4B>>I>#Q"N]S3LD+6^X!K52'5/D5
M5! /+XP G\<$G!RV8.IT*S:_O6;3X:R_8]09$IXTW3'T#5OIM8!2?<^QE>55
M"OJ1/?7=!I[<]3;L4=JQ5O(!8F3J.>UXI0X;2\ H8'.4?P4T?6]OY34/0RB5
M+6I!9 5(9.6N7GV\2.J>3U\XDLR14C%V-55[]!@(I=QFJZ8]'$N/(>_G\QN6
M%R;75MB ?2B=O>L3@5H72<D_+K("'J(DVJX_**()7+]A6P,*#-"Q]*K[,'*U
M\8( *EO)L*_E<!H'U#YPDJH* ]AEHD3^;1?O5VZEI/*>-0W_*K>$[VMD4PWM
M ?MDMJ7\-WL@Q+G18$6JL1>O"9VJ:>21 Z6J38/ XVY[HNP+3'[CAN\1A"94
M 3E-;36U/0CZS:KV8'9@+@L##ZV__CEE5(:9BH["V0K="Z!]HU:KTQ0H8^.X
M+#V&))1EM26%G^4Y2WEN11VGLM'YQU1FF(\\<>#A'."6%@GR_9X;0L42[K%O
M![IPJMU'C<9[F]H!/D"VWSV4_NE[75!7&,I <,_3H@P1S:)K I[^0;W)UT:X
MPH"I/@%4F0)6\N2_Z!64F38X,J&=-A/:Z;,GM,] @68S0#/:G("A5.2CY M,
M7$Z*O2/;42'[-UYOGT 0VFZZ%=,[O,^B9->*7'!H?)_[\C@P"^V1C!7D7[S+
M^<9 $'O%L_P-$UF>ZHT0V\D VZVQG]^'([3P']K\%,;ZX6#Z9K<*R[T6C0:W
MA^:8"3+Y%&P^BCM>BR0"N(%Z4H;]*+BS<4,&%JSVT89%4PPS^!EM3?) B#$.
M<X(ADG)NI#FC'F!.L3VC2%>@!G>F&F@2<V,VJ."RHPQI$PD+3WT>E/G[B(2V
M>;2A*0>B*H"T:2&+WQOMP?=IB*=3,)V1$A\!8F?[2H)UL57%*(6]2,^KNI</
M38XSTG GG*T$.J.S A@)+U &T]R0>T3O^GUH=T;SVCRCT>"/9B<AE>/JSM=U
MG9/C&>URNZ.(U&F$86 2"LA2NQ6[W0DA!XT<6;E[1RX9IQ# E<PI!F$0]OQE
MUF/^\.]$+T\*6TD",$X] 29%S)VE6UOF5%M#_+[N[?/O#BD:R(Q,'.WHO+.7
M> %)V,KW<$.C]!$LF398,GTVEGQO0,T?VM2@M@\[CC+=CQW[]H $$0MQ)Y6B
MG/815XF_;79PQ<%Y?V=C]5>="5SQU*<SAK.M8E"C&EBQS49=MW_GU=[=EJUT
MIQNTALFX.A_RW?/Q_J2^/I-7#E7,<4Y?Z]GCV:SL05X?ZQ:\O_U6YQR/5]T*
MYU(_C1WFW'(VXK[CYIJD[>I]Z3YHG2)GPMSYLW(:>I$+Y8%R\[8YCI^7I]!;
M\O(L_Q,W"+AEJ5AB*0IWTF&F/!\O'YS._9GT0CNG,W^[$AR##!'@^U)K5S^0
M@.9/BLO_ 5!+ P04    "  40%!6DNOH@BP&  !M$0  &0   'AL+W=O<FMS
M:&5E=',O<VAE970S-RYX;6R]6&U/XS@0_BNC+JQ "FGL)$["0J7RLK?LW4)%
M65:KTWUP&T,CTB3G.!3^_8V=-+R%+,=)]P5LQS-^[.>9&;M[JUS>E LA%-PM
MTZS<'RR4*G:'PW*^$$M>VGDA,OQRE<LE5]B5U\.RD(+'QFB9#JGCL.&2)]E@
MM&?&)G*TEU<J33(QD5!6RR67]P<BS5?[ S)8#YPGUPNE!X:CO8)?BZE0WXN)
MQ-ZP]1(G2Y&529Z!%%?[@S'9/8CT?#/A,A&K\E$;]$YF>7ZC.R?Q_L#1@$0J
MYDI[X/CO5AR*--6.$,;?C<]!NZ0V?-Q>>_]L]HY[F?%2'.;ICR16B_U!.(!8
M7/$J5>?YZHMH]N-K?_,\+<U?6-5S&1W O"I5OFR,$<$RR>K__*XYAT<&H?.*
M 6T,J,%=+V10'G'%1WLR7X'4L]&;;IBM&FL$EV2:E*F2^#5!.S4Z'$].+L9_
MP/3B[/!W&)\>P?3+^/QXYV \/3Z"P[-OD^/3Z?CBY.P4MB[X+!7E]MY0X<+:
M?#AO%CFH%Z&O+$(H?,LSM2CA.(M%_-3!$!&WL.D:]@'M]7@DYC:XQ +J4-KC
MSVV/P37^W%?\31=<BIT#I#>&";]'U2D82\FS:V':?XYGI9(HH;^Z=E_[]KI]
MZ[#:+0L^%_L#C)M2R%LQ&'W\0)CSJ0>YUR+W^KR/IABF<94*R*_@>%FD^;T0
M,%7Y_ 8FE9PO<$LP27D&8ZW_1-UW;:!WB>X-7"P$7.4I!G6274-2 L=@4#Q)
M-1"%'XMF]1)[7,&"WPJ8"9&A>F,!%0I!UO,0W&X_](F021Z#(:F$D[*L-$TR
MF0O-OP,\,]U<@FN1@%ANX,(&D, .(_C*LPJS#=1:(:!R^,;1^5H]!#S+80Y0
MZMM. .-"XA8>3?Y:90)<IQGP+2?RL1G:!%U7Z1._4U$HL9SAOMKY@>4Q!H0R
M._#@;*YR_?61">JXL2"M!6$$B!O8".HI>/H"/ 5FD= #XC';\Y^ I\_!4R".
M%1(/PLAV_<?@:2=XG$\MQPL@I#8-GH&G7>#1@EA>%$) ;(<@%]3U+8;]'IG[
MK<S]-\N\#M;9TV!=<1G#)4\K;K+]&$6R+'2S[!)\_V)&VSR1<(O^4'&-HDLC
MS;RHRXE>L(25D )$J1(L$ BG*G4TJ">QP1^@X*@T)]60K86K%;P+6&*,V4_!
M99,F.\[7&!G)GR?E#7R6&##GN# 0.R*;X-BALPD[V'-]W7/#NN?CM^.[ @LA
M>KW,4SRB%#,!>(X=!9O@1G;HZ9D>L3UT@,/$-WUJ'+:F%T(N@=G4AWL#L[OY
MPU1"G#Z^%1(+.WS61ZFI$;#!$!N!#>($6K ;(08&A2-,3+' L_B9B#2&CQ]"
M2NBGS9>-'B&Q5DCL[4(RA)XUW/0ER'Z?3W.ATF423*;,%(JGDL^4TZS3BF$7
M3BO#,T)J#Z]MG%6J5"@4[3IOH&(^?9X::.!:49WW,'?X'@0V:N4W+&':B>M:
MS,=$Y+F:I^,[(>>)#I\M-["8ZV\#\D)=..39'"],L:6Q78E$FR)(<5<D4L_V
M,;>&=!M3JV?[P6O0.G1+0HOA+0#!:4TQE NB:6"8X^HU)PQS"5JA.:5Z;\QV
MO!XM!*T6@GXMZ$02/\\D#V7?@M,\V[G%\-8\&(16KTQZEWM+'>W03O8 X1TR
M6L?@:;>73BD1&EF>&^GCQMR/8=JMHLO:W1;S,.DS%(7OV$&D,UFCG"T/:0M<
M+1?7)J07PTO2?=]RJ>8<>W9(^HI(V/(=OCGV-9AF!W4:^)XEJI?<7M_O)%?/
MPVM,(\$75%>(J?RO3#=..G@.\4) 3<J(?,WHFF>*==S5MQ!B[D1KHOW(PJ?>
MMKEM!.R7R2)P+(=B:B&19[.P!U='OL" )[Y!AC6)T3[RHY;\Z#WDX]W2/&VS
MEH7O!E>?$GH7>J<2BA<X_G<U,"ORB0DX9KNL58.^4'L1EA77#IQ6#*%O!2S0
M4<]L$OY2#,3!+!&B>"A6)]?Y5VI@H;F':C%@V?$[Q3!\] 1>"GEM'OHES/,J
M4_5KN!UM?TL8UT_HA^GU#Q%XP[Y.,"NEX@I-,:?A95'6C_NZH_+"/*AGN<+G
MN6DN!#YJI)Z WZ_R7*T[>H'V%Y;1/U!+ P04    "  40%!6$?2T%8(#  !&
M!P  &0   'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q]56UOXS8,_BN$[W!H
M@<Y.W*3->DF -.UV 99<<<EV'X9]4&PF%DZR?)+<M/]^I.RDV9#F@V6]D \?
M4B0UW!G[PQ6('EZT*MTH*KRO[I+$905JX6)384DG&V.U\+2TV\15%D4>E+1*
MTD[G)M%"EM%X&/:>['AH:J]DB4\67*VUL*_WJ,QN%'6C_<8WN2T\;R3C826V
MN$3_9_5D:94<4'*IL732E&!Q,XHFW;O['LL'@;\D[MS1'-B3M3$_>#'+1U&'
M":'"S#."H-\S3E$I!B(:/UO,Z&"2%8_G>_3?@N_DRUHXG!KU7>:^&$6#"'+<
MB%KY;V;W!5M_^HR7&>7""+M&MI]&D-7.&]TJ$P,MR^8O7MHX'"D,.N\HI*U"
M&G@WA@++!^'%>&C-#BQ+$QI/@JM!F\C)DB]EZ2V=2M+SX^G7^7RVFC\N5DN8
M+!Y@^G6QFBU^?UQ,9X]+N%B)M4)W.4P\V6*-)&MQ[QO<]!W<;@IS4_K"P6.9
M8_Y?@(1('IBF>Z;WZ5G$!\QBN.Y>0=I)TS-XUP?/KP/>]7N>&ZVEI_SR#D29
MPY3HRG*+92;1P8-TF3*NM@A_3];.6TJ??TZ%H3'2.VV$2^K.52+#440UX] ^
M8S3^]*%[T_E\QH7>P87>.?3QDDHTKQ6"V<"L)+*BS!">K-E:H=TIMF?Q3K-=
M%0@;HZAZ*3K@.2$@G'+@<O1"*L<$3&U!'DA4+8DKVLM4G;.NT*9F)8N9L904
M5X1KP1-^A5::W)%L+C/A,:<J\(7DHLUL34M\H2[DD"6"H<R4SBB9!]FU4,%F
MJ (7 S/>VUISVR&++>.@[(T7"M!YJ8.^DF(ME?2O@0]S>)9Y32*9$E([8B@\
M",H$*H6P:CB4AI7?7,[,,UIJ9'O;5[ K9%9 1O)-$.BB:N\\91N'HT7GW&NG
M)%5;RQ[5GN&9M[%LY6+O#_FOI5+4T-QE#),0>:H,U&NTH3I6K]7_\H'KA8<N
M?$&A?'%$^2-T;^)T__M._1.M^_1AD'9O/Y,_FH,N0O?L=>(!#WU.KPW%@38I
M0F^AZ\<=^E*X26ERTXU_A3](Z@Z4*;>_>+0:V!6&NNC$Z64[?F310?.[A5,E
MD1SU-HUV&SJX(W(4CJ;-'78/C\2DZ8UOXLT+,Q=V2[[3-6Y(M1/?]B.P3==N
M%MY4H5.NC:>^&Z8%/71H68#.-X:NO%VP@</3.?X74$L#!!0    ( !1 4%:A
M"?^,604  %@.   9    >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;+U7VV[C
M-A#]%<(M%@Y@R")ULW<3 TGVDCSD@B1M411]H"4Z%E8279*.-_WZGJ%LQ=TX
MWF"!W8=$%,4Y<V;FS,@Z7&GSV<Z5<NQ+737VJ#=W;O%V.+3Y7-72!GJA&CR9
M:5-+AUMS/[0+HV3AC>IJ*,(P'=:R;'J30[]W;2:'>NFJLE'7AMEE74OS>*(J
MO3KJ\=YFXZ:\GSO:&$X.%_)>W2KWV^+:X&[8H11EK1I;ZH89-3OJ'?.W)S&=
M]P=^+]7*;JT913+5^C/=G!='O9 (J4KECA D+@_J5%45 8'&/VO,7N>2#+?7
M&_2//G;$,I56G>KJC[)P\Z/>J,<*-9/+RMWHU9E:QY,07JXKZ_^S57LV$3V6
M+ZW3]=H8#.JR::_RRSH/6P:C\ 4#L380GG?KR+-\+YV<'!J]8H9. XT6/E1O
M#7)E0T6Y=09/2]BYR>V'3Q<?+N_8^>7'JYN+X[OSJTO6OY/32MF#PZ&#!SHW
MS-=H)RV:> &-"W:A&S>W[$-3J.+_ $-0Z_B)#;\3L1?QO<H#%O$!$Z$0>_"B
M+M[(XT4OQ:ON(2G';M1"&U<V]^ROXZEU!NKX>U>\+5J\&XTZYJU=R%P=]= 2
M5ID'U9N\^86GX;L]7...:[P/?7*+#BR6E6)ZQJX6RDC/][S)=>WWVABH5FP=
MEMT5PEXGNT.XD TZTB=*/<AJ*9VR# S\$&ARQ613,%E5.O=/8*>7)L>*&J1@
MZ#8W!\6.<]EQIGWSQ-NN>0_8:E[F<SI8+0L R6:#3[T+PUP;6,$=4U\PD2R=
M<<Z4TV6+Y+3'M@N5E[,RWR![IAVJ40^J67IXSY]IV!A@6V=941J,BNKQ5;C!
M)N5,6JM@+8UBC7;D I,#29@^>D,$OI#-XYM?1H)G[RS+YZ6:;:6F *Z?<+7\
M#"I$C#@II%IUH$5I\TI3:J<T1EE?UGJ)M"$R#(6J@KT]"!CFE/?YIY*F[4"&
M_E'U%,";'F)G5(DS)2LWQ]HN2I3S6AFK&UFQ4_)XADG&CO-EZ1[;C2N?I3OM
M<.(2+PI2"9FMT\E^97P0)4F08)6-LF"$:\J#F!Z,_*X/7[S#2@R$B +!3I%S
MJNL::X"R4I':E$")>=F6WE>JIE[]M]W(TG$0LEBD ([3(",7HG/ !R(-X?F3
M:I#AJC4O,#A+:G)Z W3Z>;U+KR&4L32^XOE<FGO%HIAB$V$41&P,"E$4<(;6
M![LLB;%^OQ<TQCD!TQ G"8(GP!!Q,&;GSUQMHOOZ&@%C>_TT);HFX0,N.'BF
MD8"C),6I) M2QC/O;Q#& NFZ^KI5^Y";/:!Z1404A41],UP37]9^- XX/>Y[
MG -?Z1"%?X4$^8^38.2EEXUY*\'$,X^>*Y!3>5K(9T,J0RW2K;Q^?>54K.]7
M+RJ00KV4_!@YA 22;?%"1#]'O(+$R\<CN.,<9#CIEJ>DX<QO?$N]$:AG4"],
M:4TJBD*H=Z<&P]$8SU,T+9(;DF<J%1_1S."#<4;7/1K,N-<>S[BO9>S_]T$Y
M:C5(./Y@PL'@%1H,?Y0&14RC !I,J*]Q%?[V27W;.@Q]/"_H4/C4^IF"OV>=
M'R.?WZ]",4:>XC"$%A,:.<]$/J"<_APEAAD%FI$[3BKJ.&3TGDC3T3?%&"$"
MRG.X]2(0U%@0^6C'.*4>HV'U4HO'P-DMXYC2GF3T!DJS[<X=TW3D@]&(VGN/
MDD4[D_@H]KI(_*!ZTD3? _F3?(Q>V?4K<KCU:[]6B(>^:?##@GX1M#_\N]WN
ML^FX_5IX.MY^<UT@'65C6:5F, V#+.DQTW['M#=.+_RWPU0[?(GXY1R??LK0
M 3R?:>TV-^2@^YB<_ =02P,$%     @ %$!05@(NYGI!$   G9D  !D   !X
M;"]W;W)K<VAE971S+W-H965T-# N>&ULO5UM<]LV$OXK&%_OIIUI:O&=S#F>
M<42@\4UB>^RT]Z%S<T-+L,6)1*HD92<W_?$'4K(A$- *C%?NAU22E\^"^X
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MKTBQ6MSRZO+N7V5>-+^+WU85KTG=9 TWW, 8=G?#E\+=2'5GBL/KEIK:NW.
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M4%[PN_>T<.A X_D\3+)?=%>4;360GR:21X6Q:D'$XOR?_"B(6#%0CM8;X,(
MKQE@O,' +0S<-0.GO<&@71BT,V9R5S(>/"))[T3P.R1T:86F#S(R,VOE/HOU
M<[^40MUERD[V+J]'H_[%)W3^%ET.WXV';X>#_O@*]0>#\^OQU7#\#DW./PP'
MPS>7Z!6ZH+<T3JGZ]_E-S+('-R9"$/WLT'./2L+"Y 5ZAEB,1BP,58'DI"E5
M.W5M3;]HTUG>)KRA30Y&(Q[+>8+>Q $-3("F<K#T$B^]/,-61(_ZKY'KO$2X
MA3&ZOO30\V<OT#B-IE1\Y;.O'UG"9%U+!]OC.DO<&AAO>YB6Q5VW?*ANAN=N
MP*MY3B_12(T$M@CIJX"&ZG$),@TIZJN'%]]0-9!E@CY_4#AH*&F4?*E[:GFE
M[?I*=8 Z3A;$IZ<-%8$2*FYIH_?G'TZG]5<=L9!@'A"807:[)+MM0^^-57#6
MF,RG*A#FQ-,%2WA T8+<:VJ1&B&TCE$[<J>% G)?VRVMAKNR!P1FL'=0LG=@
M]7%"A:\84E,,XC,DN22A8I%%TU0D6;?4E[/YBHHEG75,YK5TLUKT7'?;:[UV
M3IJWJZ196[(K:4!@!FF=DK2.E;3W3,T+@OF**Q7_EU.H[F1H)GB$1C10-T5M
ME^O4$-7MKC%EK7Y7IH# #*8.2Z8.[4SQ9*$'YI*1<H1F9!'?YVDL:8!4 H6$
MZF8Z &YB[K".N<,UYK8IY#U0R/#TJ/3TR.KIA79(C15!OZ<TD9E'));,9PNB
M/5R&HB2=1DPN?99SJN9J-4.HKK2@@O% 8VQBP-J"72< 2##OJ(917$]HMR2T
M^V!<ORSB^G)"G>04G<_00'>F2<%IQKV7ZCR(QW7$V6MR-\=YJ^&N) &!&6PZ
MK2K1;-D[:,'A&8W]N=(8W]#G$=4)V!?T$TT$#U)?H@&/]720,XDN6&*4*D?Q
M$FMYKS;'M#9GU]X*BN9!H9F/8B7G=_:1'Q:U0C$.B>9!H9F,XXIQO$V:HX-K
M7.6+23D=+02_94KKH.F]=?8NJC$#W6%[;1*J+W6P-@L]5,ITM=(>CC7;5E-N
M1-%[2D(YMX]/4#D!BN9!H9D45HK":>]E?$*JA@$HF@>%9C)>J1#'+D,>DU$[
M==KCEY3:WH"=Z7H*^>%4^L.Q"Y 5U38BL?H+\H1(3=]J[E;S^$<>IBH,]'4?
MO>*Z(U/]BJ@?!%EO5C07N5/]ZZ$ZD>*N$PHJ4J#03$(KF>)LIU.L =,*L?/P
MA43SH-!,^BKMXQSM)6"""AY0- \*S62\$D>.7;,\*F!VMPJ8H-H'"LU\_5R)
M'VP7/R,ELJ,T6A4SV^9)=N1=.R$HF@>%9K):Z1B\%QV#074,*)H'A68R7ND8
M;-<Q'Y1!*EG(_LT5^O*M$@G^21.I#U_JKU-97X^SSRM:\MQFGU=4G]_BB\M9
MT8+.2G3 :Z'!WLB=*05",RFM]!*VZZ4QCU]%ZZ\G)151%DWK*7+K NC!.DN@
MD@@*S62IDD38_BVD+H"RFSGJ^RF3]WGV:8VBH-H'%,V#0C.IK;0//MA+%(44
M/ -0- \*S62\DD_8+I\>\\GP 6C+NV2[Y<X4/H5@PI5@PG;!-"HFF=])J$!U
M%"B:!X5FLEKI*+P7'85!=10HF@>%9C)>Z2ALUU'_1T+5_26AZJRG"J!:"PK-
M7/M2:2W7KK5^(Z$J$%<3JO7% _9*=UZP\A3"R:V$DVN5";71<Y=LR@Z_\U(@
M4(4$A6926RDD%^]E[16DY!F HGE0:";C*XO='A!0C\BF'H"VK,"R6^Y,X5.H
M*[=25ZY=70W( GVB1"#<<CKH:BYXJJ(!;F'7'@9 114HF@>%9C):B2IW+Z+*
M!155H&@>%)K)>"6J7+OR>9-(%F5+G4BD5W4E*%#\3XG_#4E>+1WYB9[5$IN#
MZX4990K0_N6;D[T).Q/V%!+*K224:Y=0&P<]M@]Z4/D$BN9!H9F,5O+)W8M\
M<D'E$RB:!X5F,E[))]<NGQXYZ"%ESZ! 6PLAZZMNH.K,"6NN[/R(J+C)=M D
M*%O6FF^/**^6NW3ZV=Z4M>MGSK&7[[6I8/*M/R,B;EB<H)#.%*1>(=1 (M]-
MDY](OLCVETRYE#S*#N>4!%3H NK^C'.Y/-$5E'N:>O\!4$L#!!0    ( !1
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MVU,5@)>=7CF1;&-ZGR63JI,RPU0UQ\ U0.VO&)/[B3Z@;K?#'U!+ P04
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MY U_]EE]0(.2%_(DK_XGS_6^O0X)BUSRM Y6+4CC;/,W^%:_$3L!BJ,/L.L
M^VW \#L!_3J@_S;@Y#L!)W7 R:$!@SI@<&B3AG7 \- ,HSI@=&C N X85Y_N
MYN.H/DLGD,'D3/!G(LJ]%:U\4 E11:N/,,Y*=Q=2J%=C%2<G7Z[NZ>]D=G5S
M]65Z/[^Y6Y#KZ1>'7LYGY$-G=G4_=WZU3CL?R0>'R2!.\H_D5W*W<,B'GS^2
MGTF<D=L5+_(@B_*SKE3M*:G=L,Y]L<EM?R>W12YY)E<YH5G$(DW\[)UX^SV
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M1#6%:AK5S*PCV3=L)X/102-4LY16K_0RVC=S1_LZ*[WCLEMGM:,!/53S42U
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MK0LFV62<BC5*\VB%EG\H:E.,5MF$2?YKO)>I^C94X^3DX^WMQ;>KZVLTO;E
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MIBR-LM^NZ>U$[1SH?JF4W1ENGKO7./T#4$L#!!0    ( !1 4%816'@53 0
M !L/   9    >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;*U7WV_B.!#^5ZS<
MZK0K]0@.OWN U%+=;J7V6FVO=P^K?3#) -8Z<=8V4/[['2<A!'!"'XX'B)V9
M\3>?/?/A\5:J'WH%8,A;+!(]\5;&I->^K\,5Q$RW9 H)OEE(%3.#0[7T=:J
M19E3+/R@W>[[,>.)-QUG<\]J.I9K(W@"SXKH=1PSM;L%(;<3CWK[B:]\N3)V
MPI^.4[:$%S"OZ;/"D5]&B7@,B>8R(0H6$^^&7L_HP#ID%O]RV.K*,[&IS*7\
M80?WT<1K6T0@(#0V!,.?#<Q "!L)<?PL@GKEFM:Q^KR/_E>6/"8S9QIF4OS'
M([.:>$./1+!@:V&^RNT7*!+JV7BA%#K[)MO"MNV1<*V-C MG1!#S)/]E;P41
M%0?:K7$("H?@O0Z=PJ&3)9HCR]*Z8X9-QTINB;+6&,T^9-QDWI@-3^PVOAB%
M;SGZF>F-UF T^0(B(L@+>6$"R!^DF&9)1!XXFW/!#0=-/MZ!85Q\0HMG4%HF
M3) 94T"^/4(\!_4=7[R^W)&/'SZ1#X0GY)$+@;NEQ[Y!L'9)/RR W>; @AI@
M=Q"V2(=>D: =! [WV?O=Z;&[CQ25/ 4E3T$6KU,3[SX)90SDQ3 #>(K-%;EE
M@B4A3F759IFZB2)NSR:2<L=U**1>*R1MOK/#5&J<_ZSD.M57!,.)=<23968I
M$\.3-43D*07%; A-OCT@ G*/J^GO+O9RN%TW7%O\USIE(4P\K&X-:@/>]/??
M:+_]IXO+_RG8$;.=DME.4_3I,R:,A&)!AW*=X*%3$ +?L+D 5]YY,-K.HMDF
MM9F.6OVQOZGFXS :MOJCHT_I<H2Z6Z+N-J-6D#(>$7C#AJK!><#S")164+1;
M] 3J!:,C<+T27*\1W)-9@<+NH51&;%;++H"]\[5'M33E<!TNP]:P7?W4@.^7
MX/L7F$6-4F:7E13\7//4UIL+?O\]_#J- C?$00EQT CQN)PO%O/^"0T> "6'
M9&))GA;D%0=%J_U;)L6&N5(=G&<1M'HGJ3J-ANY4AV6JP\94/TL9;;&)NT -
MS]?K=LXVX)+5$:Q1"6O4".L^,2Q9<NP1#<<[#]&O[OP)MM$Y-EK'&&T?)+7=
M".X?:?!LU.,JW(^6[?5:W1-P3K-^:U #KZ+XM!'>S;[1IFQ7UV6+$"=E<X;0
M:=6I 7B06MJH-Z@(.R6%R!M G JY R!S2&#!:P@-7#A.1<%E52VB8[0'^:+-
M^H5T*EON34I0A*@]: 5 AU6M%M"#4M%FJ9H5.I!*E74CN2"R;$@B:TCB\!_/
M"=\I4F?\.JWJCNM!RVBSF.75M!>S2T@=^M0Y/[=.JWX-TH-PT6;E>JIG]0JG
MM"ZS*+;"F8%#L&CK5(9=5D&=K-&#KM%F8<NYOL3QX/S?5:]2]05"I]5I;_4K
M-Q=[;7QD:LGQWZ^ !7KAZ<&=4OE-+!\8F6:7F;DT>#7*'E=X>P5E#?#]0DJS
M']C[47D?GOX"4$L#!!0    ( !1 4%:\RT+8_@4   ,;   9    >&PO=V]R
M:W-H965T<R]S:&5E=#4X+GAM;*V9;6_:.A3'OXK%IFF3MA';A(>.(K6T4ROM
MH6J[.^F^,XD!WR4QLPUMO_UU B4!'QLV]4V;A'-._N?$/C\[&3Y(]4O/.3?H
M,<\*?=J:&[,X:;=U,N<YTQ_E@A?VEZE4.3/V5,W:>J$X2RNG/&N3*.JV<R:*
MUFA87;M1HZ%<FDP4_$8AO<QSII[.>28?3ENX]7SA5LSFIKS0'@T7;,;ON/FQ
MN%'VK+V-DHJ<%UK( BD^/6V=X9,QC4N'RN(?P1]TXQB5J4RD_%6>7*>GK:A4
MQ#.>F#($L_]6?,RSK(QD=?S>!&UM[UDZ-H^?HW^NDK?)3)CF8YG]%*F9G[;Z
M+93R*5MFYE8^7/%-0I7 1&:Z^HL>-K91"R5+;62^<;8*<E&L_[/'32$:#KCC
M<2 ;!W*L ]TXT"K1M;(JK0MFV&BHY -2I;6-5AY4M:F\;3:B*!_CG5'V5V']
MS.CB\O[L^LL=^OX9C2]O[?$W='[VY>S;^!+=75U>WJ.S\?C[CV_W=^@#.F<9
M*Q*NT=L+;IC(]#M[\<?=!7K[^AUZC42![N=RJ5F1ZF';6''E+=K)1LCY6@CQ
M">')1T3Q>T0B0@#W\?'N>->];4NRK0O9UH54\:@GWG<SY\H^ *5X81#3FAM]
M F6U#M.!PY23\$0O6,)/6W:6::Y6O#5Z\PIWHT]0CB\4;"=CNLV8AJ*/;MB3
MDEF&#'M$7"?6&TIW'2.N8I0M8C7J=:-HV%XUTP",!@VC'7F=K;Q.4-YUD<B<
M5^H43[A8L4G&(87K,-W&S?M]1R%@1'P*XZW".*CP8LG15,D<_2>%'3,K.W"6
M]C%!&F/G]M2M(F#DK6)WJ[$;U%@-:TA1U[E9M^,H<HWBKD]1;ZNH=UC1WD2#
M!/:<>Y-N!\=["@&K.![T88G]K<3^$;T@T /Z+]D#7BC83J:#;::#X,/X:9'+
ME7[SJD]P[Q.R,\XN%S2K@)ORA=0"?C@#=Z@Z@R=LLR,71S6]HJ#@*\XR,[?H
MT4M5LBFH<A.K*6'@R#Q@M*NS05E\Q"C/A4[L@H45W&(R+!4[*G#D:@6LL%=L
MC3X<Y(QMM2G/"V&>#G3:39B=VP-][*#9KLR:5S@,K,O?RU)CSLU<IG8(K+@V
M=H'I*2AU1'2BV-4*F/7]):WAA</T&DMMCE7JLLFBR57JFL615VC-,!R&F!<0
M&, 14#_7JN-755,+'X&M !RP2Z;>H$^[^^H ,QH1ZI%7(PSW@H X2Q*UY"GB
MCV6[Y# D<)"#?TJ)EXJVFW%-1!S$D--WP83[[KSO$G?('#+;E5BC#/\URT"U
M+I\Z$=#,(#,OR$@-,A(&V>=,*I$R]._-]1BQ92K,>S134FN4"381F>UTX.[#
MI=6^8L $]SI>Q3722!AI7_B,9<C.2)/QJIDAN_%#<CU3RP3 F4I<9%&"G3(#
M9J07>T4W=G5AM(WG3)702)@"QRP!6.6N$2 K?T5KH)$#0--&Y,S81O*5IZ*4
M:'4N#@P  %CNV@NR\E>SIAH)4^U*ZH6PBRY6]C^6:?162;O_*<?!1#*5VB',
M"Z[L,!'%AX6=>M42_WF4O /S<;&&!\#X "#I7U.0&G\DC+^;AL@%>Y)J6WT!
M[^2("[QNSY4+6'FQ2&HLDC 6G[F3R,*(8E8*MX=:I+;FOCY'7 9B8"$$F/GD
MUI@DX:W>L]SKPG +)0/* W9PKCC7R+]((S742!AJWK4/<1$5N^\4#EGMJJHY
M1L(<VU]<@ )=*F':HP-'(F 71\V%TNZKHQI?-#IBBYS)8O;!/ML<R4DF9M48
MA!=#-$C#/UT,O52TW>1K$M(P"6_7,='4MHNE70PIPT11O:FJ-GAE$< :N(QS
M7J0!M/2"AM84I&$*7O I5ZIJ'(T-_L)N3,.PH2[W@)=_ !R]O8XVWDZ&X?@W
MO8ZZV*-N-P&L?&IK,M(P&;VMA )\<S=W@)47;K2&&SUB;P=/4E!J[+S&[?2C
M_KY4P&K0&^QI;3>^4)2?A[XR-;.;!Y3QJ76+/O:LOUI_<5F?&+FH/EI,I#$R
MKP[GG-F'71K8WZ=2FN>3\CO(]KO7Z']02P,$%     @ %$!05IJ4W)5$ P
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M9,HF]9K*%>,*PUJB9- 98$V79=]7#K0H;.LT%QH;,?NZQEX9I#' [TLA]./
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M32A3;\S8[6R*]O?>H#U$.?I<B;4B?*'R4!L :Q.6W63G[63Q$Y--H3Q$272
M8AS''OGDY?)H5QZ:V'WVN,\>.[_DJ>PVJ$+?SN9*2_,^??<E:BU&?@M[QDY5
M0TH8!^80*9 ;"(K7KZ(,O_/E^T]F.VF3/FWRG'OQ>X.9V^";JUM$E +MW<C6
M*W5>]B;8%!&.C],L#S?#0+ZR*$Z/^K(=U%&/.GH6=;*6$KA&C9#NK(LE$H_H
M&25SRJBFX,5O_;,!5Y*D]J79H?=417&2^.'3'C[]JW4>D!Z8+J7,L=Z)Y^-/
M_R#+3E(\>L3OJTKPB9\_Z_FS?^7WD6:>-R#!&#]"]97A=%#6LH:#F\Q^13X1
MN:)<&92E$>+#(^,@VYNY;6C1N,MM+K2Y*MUC93YF(&V!&5\*H1\:]K[L/X_%
M+U!+ P04    "  40%!6^[(5_> #   1$P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970V,BYX;6RU6%V/VCH0_2M66E6MQ&X^^.P6(E'8ZE:BMVCIWOM0]<&$
M :PZ<6H[R^[]]==.0DB*B4 -+Q G,\=GCF?LD8<[QG^*+8!$SR&-Q,C:2AG?
MV;8(MA!B<<MBB-27->,AEFK(-[:(.>!5ZA12VW.<GAUB$EG^,'TWY_Z0)9*2
M".8<B20,,7_Y")3M1I9K[5\\D,U6ZA>V/XSQ!A8@'^,Y5R.[0%F1$")!6(0X
MK$?6V+V;N'WMD%K\0V G2L](A[)D[*<>?%Z-+$<S @J!U!!8_3W!!"C52(K'
MKQS4*N;4CN7G/?JG-'@5S!(+F##Z+UG)[<@:6&@%:YQ0^<!V?T$>4%?C!8R*
M]!?M<EO'0D$B) MS9\4@)%'VCY]S(4H.G<X)!R]W\,YU:.<.[330C%D:UA1+
M[ \YVR&NK16:?DBU2;U5-"32R[B07'TERD_ZL_OQXGZ!;M G$N$H #0#)8I
M;Z<@,:'BG?KTN)BBMZ_?H=>(1.C;EB4"1RLQM*6:7Z/803[7QVPN[\1<4PAN
M4=MM(<_Q/(/[Y'QWM^INJZB+T+TB="_%:Y\*'80 :&41M] 41,!)G";7]YFR
M19\EA.*'*<X,N&,&UI5W)V(<P,A2I26 /X'EOWGE]IP/IJ@; JMHT"XT:->A
M^_M5IUH#]/#U$6$EBC0N;H;439'T[O#D=US'&=I/Y6 ,1MV2485DIR#9.8MD
MOE":Y5BS;*%Q$"1A0K&$%1J'C$OR']8+:**?S=$K,;MQ!T?\#5;>X%0 W2*
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M%O@D VD .)X+H5\;9H+ND9?\#U!+ P04    "  40%!6D]Y8H)8"  #[!P
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M09@ /;_F7!TZY@%HW_OX#U!+ P04    "  40%!6%&B%2S\$  !J%0  &0
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M+S^1+,WVQI9,2A9GASL@:^!Z@+J_84R^G.CMMG)[=?8O4$L#!!0    ( !1
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M#]+:I-E*#8GU,BXD5W>)RI/#V>/#QYOG/Y_NP>/=;/KQP_/T\6$!;L B6U;
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MM550;=5237>-U+N&+2G9(#VTQ'NU3T*:K$B\49M;*5'=M6-<WS/1;YT3"_S
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M4/?73,W0_$2_S"A>7@W_ U!+ P04    "  40%!6-NIE<D\#  !#"P  &0
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MXHZO_F)UAT@1;\KCO/P+5O6YG@.FRUSPI&XL*TBBM/I/7^J!6&L @XX&J&Z
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M:?'X276 AS3[;7/:%_\!4$L#!!0    ( !1 4%8LE@" %PD  $Y2   9
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MR.NJW+BAW+YLS11-;>DAB=BX$>.T1%KSG6Z;[]38?&\]@&=DFD3K)!:QS,>
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MBF5 MJ!.M[W2TK5-5!)=DK;3?S^24A3;E(1L\XLM4N<<WG,O25R-]XQ_%VL
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M"H1F4A %BVDP'USD8XMW@*\,-GKGF=@DCU+^L(V;<AI$UA!P*(Q5H/CW!%?
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M.AN6F66\5T+_RK2?FEW?7G[]\@D]7/S[Z1[YZ)*G.<\@4Q+Q);J")0@!"_1
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M&N@"A#'0OR\Y5\\GYK-+_9EM]C]02P,$%     @ %$!05F=&.U*3 P  /PP
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M>,H09^)W'RX_7E^13[//5TOREBP@E2)EG%%7%;DFMT*A;2/8/Y"13_2>S$'
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MJ-_G<2S?OB0%%'\;,?P74$L#!!0    ( !1 4%9TLO7E8@,   $+   9
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MR#833W3_"2J' J4OIAG73[2OUCH6BK=<T+P2E@1Y6I@W^5H%XDC PV<$<"6
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MKYVDA!SJ2:@K]:8EP7YM/TX^?Z_Q>!?1G_&:$ 8> S^,3SMKQC8GO5Z\6),
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M=;/R;%6+U<4L1][)8R'DA@$9[V]=5;(?@)3^.J)4S5&E5IS4W.4@N<MY]7Y
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MY$"], 8^67))71OP^$G3PT/I!8LVR7&:><18%"0?UP2[A(H"_/ME%+'G"]'
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M0K48U1)*ZV=H5R;2Y&6B;E;GW>-=QIMO!&D?;@U0M"^$:CJJ&:W6F\TRZ9_
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M$D7S@OKOK_.\>OJA&> A+WYL5OOL_P%02P,$%     @ %$!05HK6RM4V P
M-@D  !D   !X;"]W;W)K<VAE971S+W-H965T.#0N>&ULK99M;]HP$,>_BI55
M52=MY $(T$*D%MB&-"@:;'TQ[85)#K#FV,PVI?OV.R=I1B&P3=H;B.V[OW]W
MML_N[J3ZKM< ACRE7.B>LS9F<^VZ.EY#2G5-;D#@R%*JE!ILJI6K-PIHDCFE
MW T\+W13RH03=;.^J8JZ<FLX$S!51&_3E*J?=\#EKN?XSG/')[9:&]OA1MT-
M7<$,S.?-5&'++542EH+03 JB8-ES;OWK?L?:9P9?&.STWC>QD2RD_&X;HZ3G
M>!8(.,3&*E#\>X0^<&Z%$.-'H>F44UK'_>]G]7=9[!C+@FKH2_[ $K/N.6V'
M)+"D6VX^R=T'*.)I6KU8<IW]DEUAZSDDWFHCT\(9"5(F\G_Z5.1AS\$/3S@$
MA4-PZ- XX5 O'.I9H#E9%M: &AIUE=P19:U1S7YDN<F\,1HF["K.C,)1AGXF
MZM^/QZ/Y>#B9S\CM9$#Z]Y/Y:/)^..F/AC/REHR$WBHJ8B!3)5>*III<#<!0
MQO5K'/X\&Y"KB]?D@C!!QHQS7!K==0V267TW+BCN<HK@!(4?D+$49JW)4"20
MO!1P,:0RKN YKKO@K.( XAJI^V](X 5!!5#_[]W],SCU,LWU3*]^*LTR39G!
MW6\TH2(A?8R6B16(F($F Z9C+C'10+[>+K11N+F_564QGZ11/8D]\-=Z0V/H
M.7BB-:A'<*++5W[HW51EX#^)O<A'H\Q'XYQZ] $H-VO<-,7NJ@HV5_"]3,)6
MH\?(#VNXF(_[4?S)Z@5>L\1KGL5[P-(#2E^^:@=^ZX;$,L6JJ:DM/%6DN9CO
M[S$TO%K[@+3:JEE-&I:DX5E2/)5+T+:F4DXXHPO&F?E9!9GKA'NS-P\ PV/
MYJE,MDJ^UEF^H38,BRTD>Y5D+@WE58BM(\3P<+E;QXRA7^M40[9+R/8_0WZ4
M8D7FH%(RE>K4PK>/:=YZ1UOT3U8OF#LE<^>?F8=/,=\F6%?^CKYS?'0PEX?;
MMMJJ=4#O[EU!*:A5=C-K/#E;8?*J7?:6E_]M=N<=]-_AHR"_PW_+Y"^*,54K
M+!B$PQ(EO5H+#Y3*;^F\8>0FN^@6TN"UF7VN\6$#RAK@^%)*\]RP$Y1/I>@7
M4$L#!!0    ( !1 4%:VT%HO& ,  !8*   9    >&PO=V]R:W-H965T<R]S
M:&5E=#@U+GAM;*U6;6_:,!#^*U8V353:R L!N@XBE89JE4J'RKIIFO;!A(-8
M3>+,-B_=K]\Y"1FP$%$)/A"_W//<W9/8=[TU%\\R!%!D$T>)[!NA4NF5:<H@
MA)C*)D\AP9TY%S%5.!4+4Z8"Z"P#Q9'I6%;'C"E+#*^7K8V%U^-+%;$$QH+(
M91Q3\3* B*_[AFUL%Q[9(E1ZP?1Z*5W !-13.A8X,TN6&8LAD8PG1,"\;US;
M5WY7VV<&WQBLY<Z8Z$RFG#_KR=VL;U@Z((@@4)J!XF,%-Q!%F@C#^%UP&J5+
M#=P=;]EOL]PQERF5<,.C[VRFPKYQ:9 9S.DR4H]\_1F*?-J:+^"1S/[).K?M
M=@P2+*7B<0'&"&*6Y$^Z*738 =C' $X!< X![A% JP"T3@6X!<#-E,E3R73P
MJ:)>3_ U$=H:V?0@$S-#8_HLT:]]H@3N,L0I;S@:WW_Y,1R2P?!A>'OWE8SO
MKQ\FY -YH$)0_4Y(PP=%620O</5IXI/&VXN>J="W9C"#PL\@]^,<\6,[9,03
M%4HR3&8PVR<P,>@R<F<;^<"I9?0A:)*6_9XXEN-4!'1S.MRN@/NGPZV:;%KE
M>VAE?*TC?(^@F  \3XH,(($Y4Y+\O)Y*)?!D_*K2.^=SJ_GT;7$E4QI W\#K
M0()8@>&]>V-WK$]56IV3S#\3V9Z.;JFC6\?N#>,TXB\@\(RH("0TYLM$5<F7
MTUQF-/IN7'E6TW5[YFI7EEI?KY7E3&1[LK1+6=JGR (DP$,HV'297[I'U<G9
MVCOJV ?2U/I[K31G(MN3IE-*TZF59D0W+%[&) 41X/'#6D?XG,!6,$DC+(<$
M(K9@TP@(5MKMYO8C:Q30RFLQ=_YQ[SNS.@=BUD;X6C'/1+8G9K<4LULKIFO9
MC><+ AML2R1@7Q#P1<+^'%[XN33=_S^RRXZE?P?R5!AVK0I#O\+0^;AOF*=E
M[E3,&,0BZSPDG@X\#WD)*E?+YN8ZJ^D'ZP-L>O(>Y1]-WC&-J%BP1)((YDAI
M-;L8ELB[D'RB>)K5Y2E76.6S88B-&PAM@/MSSM5VHAV4K:#W%U!+ P04
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MGPI(ZV#."R'TR; 7]+^IY"]02P,$%     @ %$!05G!E!CC3"   '4(  !D
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MT<:;EHMZ\V_PN-6&HV"ZKIMRN2VLSV"9%]W_V==M(O8*$&DI0+<%Z&$!;BG
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MQMA2 P  KA4   T   !X;"]S='EL97,N>&ULW5A=;]HP%/TK4;I.K30UA(Q
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MN^7V^.OR^R*^+U97G.O[BN'I+U!+ P04    "  40%!6PH ,:SH"  !H,P
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MR<^6/]C<_@102P$"% ,4    "  40%!6!T%-8H$   "Q    $
M    @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( !1 4%:I[B*B
M[0   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+
M 0(4 Q0    ( !1 4%:97)PC$ 8  )PG   3              "  <L!  !X
M;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ %$!05B4.N?\1!P  2RT
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M21D  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( !1 4%9
MA>94*@<  $,@   8              " @2$=  !X;"]W;W)K<VAE971S+W-H
M965T-2YX;6Q02P$"% ,4    "  40%!66[*;KT4#   ;"@  &
M    @(&!)   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @
M%$!05HYV0<>*"P  6W0  !@              ("!_"<  'AL+W=O<FMS:&5E
M=',O<VAE970W+GAM;%!+ 0(4 Q0    ( !1 4%8HAE78U0L  -4Z   8
M          " @;PS  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M    "  40%!6!7J"9I\1  #1,@  &               @(''/P  >&PO=V]R
M:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ %$!05E)5=4<&*   ,H4
M !D              ("!G%$  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q0
M2P$"% ,4    "  40%!6&7[,6M$(  #?%0  &0              @('9>0
M>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( !1 4%88>#/G
M; X  "0Q   9              " @>&"  !X;"]W;W)K<VAE971S+W-H965T
M,3(N>&UL4$L! A0#%     @ %$!05C.[BLD-!P  2A$  !D
M ("!A)$  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  4
M0%!6WDUWZRD$   !"0  &0              @('(F   >&PO=V]R:W-H965T
M<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( !1 4%:J2HW_=00  +T)   9
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M970Q.2YX;6Q02P$"% ,4    "  40%!6'&+,-AL1  #>,@  &0
M    @(%:V@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    (
M !1 4%;HD\H"MP0  ',*   9              " @:SK  !X;"]W;W)K<VAE
M971S+W-H965T,C$N>&UL4$L! A0#%     @ %$!05B4'F%SH!   EPT  !D
M             ("!FO   'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"
M% ,4    "  40%!6&C\%0B<'  !X$@  &0              @(&Y]0  >&PO
M=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( !1 4%9&6#AR%P,
M )8&   9              " @1?]  !X;"]W;W)K<VAE971S+W-H965T,C0N
M>&UL4$L! A0#%     @ %$!05C#%\VIC!   8@D  !D              ("!
M90 ! 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    "  40%!6
M3'FR@PDV  ""NP  &0              @('_! $ >&PO=V]R:W-H965T<R]S
M:&5E=#(V+GAM;%!+ 0(4 Q0    ( !1 4%9UAD\+X ,  #H(   9
M      " @3\[ 0!X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%
M  @ %$!05L['UR"4!@  )A$  !D              ("!5C\! 'AL+W=O<FMS
M:&5E=',O<VAE970R."YX;6Q02P$"% ,4    "  40%!68-3*Q1 #  "Q!@
M&0              @($A1@$ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+
M 0(4 Q0    ( !1 4%8EGC.]I@0  ',,   9              " @6A) 0!X
M;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ %$!05J'.0R-/
M!@  ?0\  !D              ("!14X! 'AL+W=O<FMS:&5E=',O<VAE970S
M,2YX;6Q02P$"% ,4    "  40%!63%+KE=4#  ! "   &0
M@('+5 $ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( !1
M4%;9!1!VZ@0  (<9   9              " @==8 0!X;"]W;W)K<VAE971S
M+W-H965T,S,N>&UL4$L! A0#%     @ %$!05BN41+-)!@  I1,  !D
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M=#,X+GAM;%!+ 0(4 Q0    ( !1 4%:A"?^,604  %@.   9
M  " @9!] 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @
M%$!05@(NYGI!$   G9D  !D              ("!((,! 'AL+W=O<FMS:&5E
M=',O<VAE970T,"YX;6Q02P$"% ,4    "  40%!63$=T&DP'  #?-   &0
M            @(&8DP$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4
M Q0    ( !1 4%8[7ZMLQ 0   LA   9              " @1N; 0!X;"]W
M;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ %$!05O=YT_!! P
M"@X  !D              ("!%J ! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX
M;6Q02P$"% ,4    "  40%!6;U=.-18#  "I"   &0              @(&.
MHP$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( !1 4%;.
M/[]JO 8  ,,I   9              " @=NF 0!X;"]W;W)K<VAE971S+W-H
M965T-#4N>&UL4$L! A0#%     @ %$!05D_$"[T(!   Y!4  !D
M     ("!SJT! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !1 4%;ZNZ\%6B8  ':8 @ 9              "
M@4[% 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ %$!0
M5CF=E/RO!0  -R8  !D              ("!W^L! 'AL+W=O<FMS:&5E=',O
M<VAE970U,BYX;6Q02P$"% ,4    "  40%!6/BO46,X#  ":$P  &0
M        @('%\0$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0
M   ( !1 4%8NO.CB P8  #LC   9              " @<KU 0!X;"]W;W)K
M<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ %$!05DQH_'Z> @  E@8
M !D              ("!!/P! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q0
M2P$"% ,4    "  40%!6EG^M:WT"  "9!0  &0              @('9_@$
M>&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( !1 4%816'@5
M3 0  !L/   9              " @8T! @!X;"]W;W)K<VAE971S+W-H965T
M-3<N>&UL4$L! A0#%     @ %$!05KS+0MC^!0   QL  !D
M ("!$ 8" 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4    "  4
M0%!6FI3<E40#   -#P  &0              @(%%# ( >&PO=V]R:W-H965T
M<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( !1 4%;OH9\M<@,  (D+   9
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M970V-"YX;6Q02P$"% ,4    "  40%!6%&B%2S\$  !J%0  &0
M    @(&B( ( >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    (
M !1 4%;F8LI2'00  ,@2   9              " @1@E @!X;"]W;W)K<VAE
M971S+W-H965T-C8N>&UL4$L! A0#%     @ %$!05C;J97)/ P  0PL  !D
M             ("!;"D" 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"
M% ,4    "  40%!68OF%0K$"  "V"   &0              @('R+ ( >&PO
M=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( !1 4%8M8-T$K04
M .PK   9              " @=HO @!X;"]W;W)K<VAE971S+W-H965T-CDN
M>&UL4$L! A0#%     @ %$!05DM:)=/ $@  ,0L! !D              ("!
MOC4" 'AL+W=O<FMS:&5E=',O<VAE970W,"YX;6Q02P$"% ,4    "  40%!6
M+)8 @!<)  !.4@  &0              @(&U2 ( >&PO=V]R:W-H965T<R]S
M:&5E=#<Q+GAM;%!+ 0(4 Q0    ( !1 4%:Y^.D"=@,  ,$,   9
M      " @0-2 @!X;"]W;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#%
M  @ %$!05DOH;BDW P  WPD  !D              ("!L%4" 'AL+W=O<FMS
M:&5E=',O<VAE970W,RYX;6Q02P$"% ,4    "  40%!6H0SJZZ,#   O#
M&0              @($>60( >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+
M 0(4 Q0    ( !1 4%:6+ %%VP0  '(3   9              " @?A< @!X
M;"]W;W)K<VAE971S+W-H965T-S4N>&UL4$L! A0#%     @ %$!05F=&.U*3
M P  /PP  !D              ("!"F(" 'AL+W=O<FMS:&5E=',O<VAE970W
M-BYX;6Q02P$"% ,4    "  40%!6Q5 T7H0*  #E3P  &0
M@('490( >&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( !1
M4%;;"51]W0,  ,T/   9              " @8]P @!X;"]W;W)K<VAE971S
M+W-H965T-S@N>&UL4$L! A0#%     @ %$!05O8!#-3D P  90\  !D
M         ("!HW0" 'AL+W=O<FMS:&5E=',O<VAE970W.2YX;6Q02P$"% ,4
M    "  40%!6#V5U,?(&   G,0  &0              @(&^> ( >&PO=V]R
M:W-H965T<R]S:&5E=#@P+GAM;%!+ 0(4 Q0    ( !1 4%9TLO7E8@,   $+
M   9              " @>=_ @!X;"]W;W)K<VAE971S+W-H965T.#$N>&UL
M4$L! A0#%     @ %$!05@_GCZLK!@  SB4  !D              ("!@(,"
M 'AL+W=O<FMS:&5E=',O<VAE970X,BYX;6Q02P$"% ,4    "  40%!6=M0Z
M*2,2   2,@$ &0              @('BB0( >&PO=V]R:W-H965T<R]S:&5E
M=#@S+GAM;%!+ 0(4 Q0    ( !1 4%:*ULK5-@,  #8)   9
M  " @3R< @!X;"]W;W)K<VAE971S+W-H965T.#0N>&UL4$L! A0#%     @
M%$!05K;06B\8 P  %@H  !D              ("!J9\" 'AL+W=O<FMS:&5E
M=',O<VAE970X-2YX;6Q02P$"% ,4    "  40%!6/4MJ%VL&  "P1   &0
M            @('XH@( >&PO=V]R:W-H965T<R]S:&5E=#@V+GAM;%!+ 0(4
M Q0    ( !1 4%;6G!&9-P(  +($   9              " @9JI @!X;"]W
M;W)K<VAE971S+W-H965T.#<N>&UL4$L! A0#%     @ %$!05G!E!CC3"
M'4(  !D              ("!"*P" 'AL+W=O<FMS:&5E=',O<VAE970X."YX
M;6Q02P$"% ,4    "  40%!6$@J;/; "  #X!P  &0              @($2
MM0( >&PO=V]R:W-H965T<R]S:&5E=#@Y+GAM;%!+ 0(4 Q0    ( !1 4%:X
M@'#8J (   4'   9              " @?FW @!X;"]W;W)K<VAE971S+W-H
M965T.3 N>&UL4$L! A0#%     @ %$!05EN_QMA2 P  KA4   T
M     ( !V+H" 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  40%!6EXJ[',
M   3 @  "P              @ %5O@( 7W)E;',O+G)E;'-02P$"% ,4
M"  40%!66D9V\L@&  !N.P  #P              @ $^OP( >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ %$!05N;BI-"@ @  !34  !H
M ( !,\8" 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
M%$!05L* #&LZ @  :#,  !,              ( !"\D" %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&     &( 8@#E&@  =LL"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>363</ContextCount>
  <ElementCount>610</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>116</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS</Role>
      <ShortName>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - NOVEL CORONAVIRUS PANDEMIC ("COVID-19")</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19</Role>
      <ShortName>NOVEL CORONAVIRUS PANDEMIC ("COVID-19")</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - ACQUISITIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ACQUISITIONS</Role>
      <ShortName>ACQUISITIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET</Role>
      <ShortName>GOODWILL AND OTHER INTANGIBLE ASSETS, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - ASSETS HELD FOR SALE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ASSETSHELDFORSALE</Role>
      <ShortName>ASSETS HELD FOR SALE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTS</Role>
      <ShortName>DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - LONG-TERM OBLIGATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONS</Role>
      <ShortName>LONG-TERM OBLIGATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATION</Role>
      <ShortName>CAPITAL STOCK AND SHARE-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - EMPLOYEE BENEFIT PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/EMPLOYEEBENEFITPLANS</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - SHARE REPURCHASE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SHAREREPURCHASE</Role>
      <ShortName>SHARE REPURCHASE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SEGMENTINFORMATION</Role>
      <ShortName>SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSTables</Role>
      <ShortName>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - NOVEL CORONAVIRUS PANDEMIC ("COVID-19") (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables</Role>
      <ShortName>NOVEL CORONAVIRUS PANDEMIC ("COVID-19") (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - ACQUISITIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ACQUISITIONSTables</Role>
      <ShortName>ACQUISITIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/ACQUISITIONS</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETTables</Role>
      <ShortName>GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - ASSETS HELD FOR SALE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ASSETSHELDFORSALETables</Role>
      <ShortName>ASSETS HELD FOR SALE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/ASSETSHELDFORSALE</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSTables</Role>
      <ShortName>DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTS</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/LEASES</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - LONG-TERM OBLIGATIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSTables</Role>
      <ShortName>LONG-TERM OBLIGATIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/LONGTERMOBLIGATIONS</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/INCOMETAXES</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables</Role>
      <ShortName>CAPITAL STOCK AND SHARE-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATION</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SEGMENTINFORMATIONTables</Role>
      <ShortName>SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/SEGMENTINFORMATION</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails</Role>
      <ShortName>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition by Payor Class (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition by Payor Class (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Balances Related to Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Balances Related to Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Financial Instruments Where Carrying Value and Fair Value Differ (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Financial Instruments Where Carrying Value and Fair Value Differ (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted Average Shares Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted Average Shares Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - NOVEL CORONAVIRUS PANDEMIC ("COVID-19") (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details</Role>
      <ShortName>NOVEL CORONAVIRUS PANDEMIC ("COVID-19") (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - ACQUISITIONS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails</Role>
      <ShortName>ACQUISITIONS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Activity Related to Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails</Role>
      <ShortName>GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Activity Related to Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Goodwill and Intangibles (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails</Role>
      <ShortName>GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Goodwill and Intangibles (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Activity Related to Other Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails</Role>
      <ShortName>GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Activity Related to Other Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Estimated Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails</Role>
      <ShortName>GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Estimated Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Discontinued Operations and Assets Held For Sale - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DiscontinuedOperationsandAssetsHeldForSaleAdditionalInformationDetail</Role>
      <ShortName>Discontinued Operations and Assets Held For Sale - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Assets Held For Sale - Assets and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/AssetsHeldForSaleAssetsandLiabilitiesDetail</Role>
      <ShortName>Assets Held For Sale - Assets and Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS - Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails</Role>
      <ShortName>DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS - Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - LEASES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LEASESDetails</Role>
      <ShortName>LEASES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/LEASESTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - LEASES - Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LEASESLeaseCostDetails</Role>
      <ShortName>LEASES - Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - LEASES - Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LEASESOperatingLeaseDetails</Role>
      <ShortName>LEASES - Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - LEASES - Finance Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LEASESFinanceLeasesDetails</Role>
      <ShortName>LEASES - Finance Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - LEASES - Supplemental Cashflow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LEASESSupplementalCashflowInformationDetails</Role>
      <ShortName>LEASES - Supplemental Cashflow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - LEASES- Weighted Average Remaining Term and Discount Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LEASESWeightedAverageRemainingTermandDiscountRateDetails</Role>
      <ShortName>LEASES- Weighted Average Remaining Term and Discount Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - LEASES - Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LEASESMaturitiesDetails</Role>
      <ShortName>LEASES - Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - LONG-TERM OBLIGATIONS - Summary of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails</Role>
      <ShortName>LONG-TERM OBLIGATIONS - Summary of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - LONG-TERM OBLIGATIONS - Summary of Long-Term Debt Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails</Role>
      <ShortName>LONG-TERM OBLIGATIONS - Summary of Long-Term Debt Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - LONG-TERM OBLIGATIONS - Maturities of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails</Role>
      <ShortName>LONG-TERM OBLIGATIONS - Maturities of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails</Role>
      <ShortName>LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - LONG-TERM OBLIGATIONS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails</Role>
      <ShortName>LONG-TERM OBLIGATIONS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - INCOME TAXES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/INCOMETAXESNarrativeDetails</Role>
      <ShortName>INCOME TAXES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - INCOME TAXES - Components of Tax Provision by Jurisdiction (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails</Role>
      <ShortName>INCOME TAXES - Components of Tax Provision by Jurisdiction (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - INCOME TAXES - Income Tax Expense Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/INCOMETAXESIncomeTaxExpenseAllocationDetails</Role>
      <ShortName>INCOME TAXES - Income Tax Expense Allocation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000078 - Disclosure - INCOME TAXES - Reconciliation of Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails</Role>
      <ShortName>INCOME TAXES - Reconciliation of Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000079 - Disclosure - INCOME TAXES - Components of Deferred Tax Assets (Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails</Role>
      <ShortName>INCOME TAXES - Components of Deferred Tax Assets (Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0000080 - Disclosure - INCOME TAXES - Reconciliation of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>INCOME TAXES - Reconciliation of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0000081 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>CAPITAL STOCK AND SHARE-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>0000082 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Employee Stock Purchase Plan Purchases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONEmployeeStockPurchasePlanPurchasesDetails</Role>
      <ShortName>CAPITAL STOCK AND SHARE-BASED COMPENSATION - Employee Stock Purchase Plan Purchases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>0000083 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Stock Option Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails</Role>
      <ShortName>CAPITAL STOCK AND SHARE-BASED COMPENSATION - Stock Option Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>0000084 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails</Role>
      <ShortName>CAPITAL STOCK AND SHARE-BASED COMPENSATION - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>0000085 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Non-Vested Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails</Role>
      <ShortName>CAPITAL STOCK AND SHARE-BASED COMPENSATION - Non-Vested Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>0000087 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Non-Vested Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails</Role>
      <ShortName>CAPITAL STOCK AND SHARE-BASED COMPENSATION - Non-Vested Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>0000088 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>0000089 - Disclosure - COMMITMENTS AND CONTINGENCIES - Insurance Programs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Insurance Programs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>0000090 - Disclosure - EMPLOYEE BENEFIT PLANS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>0000091 - Disclosure - SHARE REPURCHASE - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails</Role>
      <ShortName>SHARE REPURCHASE - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>0000092 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails</Role>
      <ShortName>SEGMENT INFORMATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>0000093 - Disclosure - SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails</Role>
      <ShortName>SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>0000094 - Disclosure - RELATED PARTY TRANSACTIONS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="amed-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>0000095 - Disclosure - SUBSEQUENT EVENTS Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUBSEQUENTEVENTSNarrativeDetails</Role>
      <ShortName>SUBSEQUENT EVENTS Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 23 fact(s) appearing in ix:hidden were eligible for transformation: amed:IncreaseDecreaseInAssetsAcquired, amed:IncreaseDecreaseInLiabilitiesAssumed, dei:CurrentFiscalYearEndDate, dei:IcfrAuditorAttestationFlag, us-gaap:DebtInstrumentDescriptionOfVariableRateBasis, us-gaap:DeferredIncomeTaxExpenseBenefit, us-gaap:FiniteLivedIntangibleAssetUsefulLife, us-gaap:GainLossOnSaleOfInvestments, us-gaap:GoodwillOtherIncreaseDecrease, us-gaap:LesseeFinanceLeaseTermOfContract1, us-gaap:LesseeOperatingLeaseOptionToTerminate, us-gaap:LesseeOperatingLeaseRenewalTerm, us-gaap:OperatingIncomeLoss, us-gaap:PropertyPlantAndEquipmentGross, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 -  amed-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="amed-20221231.htm">amed-20221231.htm</File>
    <File>a202210-kexhibit211.htm</File>
    <File>a202210-kexhibit231.htm</File>
    <File>a202210-kexhibit311.htm</File>
    <File>a202210-kexhibit312.htm</File>
    <File>a202210-kexhibit321.htm</File>
    <File>a202210-kexhibit322.htm</File>
    <File>amed-20221231.xsd</File>
    <File>amed-20221231_cal.xml</File>
    <File>amed-20221231_def.xml</File>
    <File>amed-20221231_lab.xml</File>
    <File>amed-20221231_pre.xml</File>
    <File>amedexamendmentno1toexecut.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>amed-20221231_g1.jpg</File>
    <File>amed-20221231_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1317">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="36">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>113
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "amed-20221231.htm": {
   "axisCustom": 6,
   "axisStandard": 29,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 1317,
    "http://xbrl.sec.gov/dei/2022": 36
   },
   "contextCount": 363,
   "dts": {
    "calculationLink": {
     "local": [
      "amed-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "amed-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "amed-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "amed-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "amed-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "amed-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 994,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 25,
    "http://www.amedisys.com/20221231": 3,
    "http://xbrl.sec.gov/dei/2022": 6,
    "total": 34
   },
   "keyCustom": 170,
   "keyStandard": 440,
   "memberCustom": 73,
   "memberStandard": 40,
   "nsprefix": "amed",
   "nsuri": "http://www.amedisys.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.amedisys.com/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:COVID19TextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - NOVEL CORONAVIRUS PANDEMIC (\"COVID-19\")",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19",
     "shortName": "NOVEL CORONAVIRUS PANDEMIC (\"COVID-19\")",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:COVID19TextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - ACQUISITIONS",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.amedisys.com/role/ACQUISITIONS",
     "shortName": "ACQUISITIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET",
     "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - ASSETS HELD FOR SALE",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.amedisys.com/role/ASSETSHELDFORSALE",
     "shortName": "ASSETS HELD FOR SALE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTS",
     "shortName": "DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:LesseeLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - LEASES",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.amedisys.com/role/LEASES",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:LesseeLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - LONG-TERM OBLIGATIONS",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONS",
     "shortName": "LONG-TERM OBLIGATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - INCOME TAXES",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.amedisys.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATION",
     "shortName": "CAPITAL STOCK AND SHARE-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.amedisys.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - EMPLOYEE BENEFIT PLANS",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.amedisys.com/role/EMPLOYEEBENEFITPLANS",
     "shortName": "EMPLOYEE BENEFIT PLANS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - SHARE REPURCHASE",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.amedisys.com/role/SHAREREPURCHASE",
     "shortName": "SHARE REPURCHASE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - SEGMENT INFORMATION",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.amedisys.com/role/SEGMENTINFORMATION",
     "shortName": "SEGMENT INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - RELATED PARTY TRANSACTIONS",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - SUBSEQUENT EVENTS",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.amedisys.com/role/SUBSEQUENTEVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "26",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSTables",
     "shortName": "NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:ScheduleOfCaresActProviderReliefFundsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - NOVEL CORONAVIRUS PANDEMIC (\"COVID-19\") (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables",
     "shortName": "NOVEL CORONAVIRUS PANDEMIC (\"COVID-19\") (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:ScheduleOfCaresActProviderReliefFundsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ieb5d1b02f637456e95eba5e2817a09ea_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ieb5d1b02f637456e95eba5e2817a09ea_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:ScheduleOfBusinessAcquisitionsContessaHealthTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - ACQUISITIONS (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.amedisys.com/role/ACQUISITIONSTables",
     "shortName": "ACQUISITIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:ScheduleOfBusinessAcquisitionsContessaHealthTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETTables",
     "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - ASSETS HELD FOR SALE (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.amedisys.com/role/ASSETSHELDFORSALETables",
     "shortName": "ASSETS HELD FOR SALE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSTables",
     "shortName": "DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - LEASES (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.amedisys.com/role/LEASESTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - LONG-TERM OBLIGATIONS (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSTables",
     "shortName": "LONG-TERM OBLIGATIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:ProvisionforIncomeTaxesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - INCOME TAXES (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.amedisys.com/role/INCOMETAXESTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:ProvisionforIncomeTaxesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables",
     "shortName": "CAPITAL STOCK AND SHARE-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:InsuranceProgramsTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESTables",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:InsuranceProgramsTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - SEGMENT INFORMATION (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://www.amedisys.com/role/SEGMENTINFORMATIONTables",
     "shortName": "SEGMENT INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ieb5d1b02f637456e95eba5e2817a09ea_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesIssued",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ieb5d1b02f637456e95eba5e2817a09ea_I20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ieb5d1b02f637456e95eba5e2817a09ea_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfStatesInWhichEntityOperates",
      "reportCount": 1,
      "unitRef": "state",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
     "shortName": "NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:EquityMethodInvestmentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i0e9dcae6e6af40a2a3ad82452046bbbb_D20220701-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromMinorityShareholders",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:NetServiceRevenueEpisodePaymentRateDuration",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:NetServiceRevenueEpisodePaymentRateDuration",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition by Payor Class (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition by Payor Class (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ieb5d1b02f637456e95eba5e2817a09ea_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash, Cash Equivalents and Restricted Cash (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash, Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ie980f7f172dd4fc384952e9b8c0724f0_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amed:PercentageOfPatientReceivablesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amed:PercentageOfPatientReceivablesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ieb5d1b02f637456e95eba5e2817a09ea_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information Narrative (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i9a008987e83a4ada9f3b12cc812bd0a1_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives of Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i9a008987e83a4ada9f3b12cc812bd0a1_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ieb5d1b02f637456e95eba5e2817a09ea_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Balances Related to Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Balances Related to Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ieb5d1b02f637456e95eba5e2817a09ea_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:FinancialInstrumentDetailsTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ieb5d1b02f637456e95eba5e2817a09ea_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "amed:DebtInstrumentCarryingAmountExcludingFinanceLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Financial Instruments Where Carrying Value and Fair Value Differ (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Financial Instruments Where Carrying Value and Fair Value Differ (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:FinancialInstrumentDetailsTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ieb5d1b02f637456e95eba5e2817a09ea_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "amed:DebtInstrumentCarryingAmountExcludingFinanceLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted Average Shares Outstanding (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted Average Shares Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LaborAndRelatedExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i6711eaed3f0d4ee694ed7955ac3b1e03_I20200327",
      "decimals": "-9",
      "first": true,
      "lang": "en-US",
      "name": "amed:FundingForHealthcareProvidersIncludingHospitals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - NOVEL CORONAVIRUS PANDEMIC (\"COVID-19\") (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
     "shortName": "NOVEL CORONAVIRUS PANDEMIC (\"COVID-19\") (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i6711eaed3f0d4ee694ed7955ac3b1e03_I20200327",
      "decimals": "-9",
      "first": true,
      "lang": "en-US",
      "name": "amed:FundingForHealthcareProvidersIncludingHospitals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - ACQUISITIONS - Narrative (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
     "shortName": "ACQUISITIONS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i361c6850de2f4f6caca843b2cad888d0_D20211018-20211018",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i42b1e865f1ed4b2e8363dfcc39186a91_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Activity Related to Goodwill (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails",
     "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Activity Related to Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i42b1e865f1ed4b2e8363dfcc39186a91_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ieb5d1b02f637456e95eba5e2817a09ea_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Goodwill and Intangibles (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails",
     "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Goodwill and Intangibles (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i6d01709de86048228674a5671c0c2757_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3b13a726ce4740309bdc481148b0ab43_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Activity Related to Other Intangible Assets, Net (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails",
     "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Activity Related to Other Intangible Assets, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "amed:OtherIntangibleAssetsAdditions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ieb5d1b02f637456e95eba5e2817a09ea_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Estimated Future Amortization Expense (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails",
     "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS, NET - Estimated Future Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ieb5d1b02f637456e95eba5e2817a09ea_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i21a308e1f5cd4afdbceafc5966fb3595_I20230210",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Discontinued Operations and Assets Held For Sale - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.amedisys.com/role/DiscontinuedOperationsandAssetsHeldForSaleAdditionalInformationDetail",
     "shortName": "Discontinued Operations and Assets Held For Sale - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i21a308e1f5cd4afdbceafc5966fb3595_I20230210",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i466c99d823de4e3da04d3e6d94ea4feb_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Assets Held For Sale - Assets and Liabilities (Detail)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.amedisys.com/role/AssetsHeldForSaleAssetsandLiabilitiesDetail",
     "shortName": "Assets Held For Sale - Assets and Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i466c99d823de4e3da04d3e6d94ea4feb_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ieb5d1b02f637456e95eba5e2817a09ea_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "amed:PayrollTaxEscrow",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS - Balances (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails",
     "shortName": "DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS - Balances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ieb5d1b02f637456e95eba5e2817a09ea_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "amed:PayrollTaxEscrow",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ieb5d1b02f637456e95eba5e2817a09ea_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - LEASES (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.amedisys.com/role/LEASESDetails",
     "shortName": "LEASES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ieb5d1b02f637456e95eba5e2817a09ea_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - LEASES - Lease Cost (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.amedisys.com/role/LEASESLeaseCostDetails",
     "shortName": "LEASES - Lease Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ieb5d1b02f637456e95eba5e2817a09ea_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - LEASES - Operating Lease (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.amedisys.com/role/LEASESOperatingLeaseDetails",
     "shortName": "LEASES - Operating Lease (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ieb5d1b02f637456e95eba5e2817a09ea_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - LEASES - Finance Leases (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.amedisys.com/role/LEASESFinanceLeasesDetails",
     "shortName": "LEASES - Finance Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ieb5d1b02f637456e95eba5e2817a09ea_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - LEASES - Supplemental Cashflow Information (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.amedisys.com/role/LEASESSupplementalCashflowInformationDetails",
     "shortName": "LEASES - Supplemental Cashflow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ieb5d1b02f637456e95eba5e2817a09ea_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - LEASES- Weighted Average Remaining Term and Discount Rate (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.amedisys.com/role/LEASESWeightedAverageRemainingTermandDiscountRateDetails",
     "shortName": "LEASES- Weighted Average Remaining Term and Discount Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ieb5d1b02f637456e95eba5e2817a09ea_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:LeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ieb5d1b02f637456e95eba5e2817a09ea_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - LEASES - Maturities (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.amedisys.com/role/LEASESMaturitiesDetails",
     "shortName": "LEASES - Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:LeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ieb5d1b02f637456e95eba5e2817a09ea_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ieb5d1b02f637456e95eba5e2817a09ea_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - LONG-TERM OBLIGATIONS - Summary of Long-Term Debt (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails",
     "shortName": "LONG-TERM OBLIGATIONS - Summary of Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ieb5d1b02f637456e95eba5e2817a09ea_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i8f4fcaea6b154a0bbd917fba61d92e52_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - LONG-TERM OBLIGATIONS - Summary of Long-Term Debt Additional Information (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails",
     "shortName": "LONG-TERM OBLIGATIONS - Summary of Long-Term Debt Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i916f340079654056b2571fa1ce003955_I20221231",
      "decimals": "3",
      "lang": "en-US",
      "name": "amed:DebtInstrumentInterestRateatPeriodEnd",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ieb5d1b02f637456e95eba5e2817a09ea_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - LONG-TERM OBLIGATIONS - Maturities of Debt (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails",
     "shortName": "LONG-TERM OBLIGATIONS - Maturities of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ieb5d1b02f637456e95eba5e2817a09ea_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ife65de97c43c4ff38decb113044c4058_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityCommitmentFeePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
     "shortName": "LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ife65de97c43c4ff38decb113044c4058_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityCommitmentFeePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "iab144f7e34ce4a479683c59de399ff42_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "iab144f7e34ce4a479683c59de399ff42_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - LONG-TERM OBLIGATIONS - Narrative (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
     "shortName": "LONG-TERM OBLIGATIONS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ieb5d1b02f637456e95eba5e2817a09ea_I20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "amed:TotalLeverageRatio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - INCOME TAXES - Narrative (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails",
     "shortName": "INCOME TAXES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "amed:BenefitAsComponentOfInterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:ProvisionforIncomeTaxesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - INCOME TAXES - Components of Tax Provision by Jurisdiction (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails",
     "shortName": "INCOME TAXES - Components of Tax Provision by Jurisdiction (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:ProvisionforIncomeTaxesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - INCOME TAXES - Income Tax Expense Allocation (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.amedisys.com/role/INCOMETAXESIncomeTaxExpenseAllocationDetails",
     "shortName": "INCOME TAXES - Income Tax Expense Allocation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:ProvisionforIncomeTaxesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "amed:IncomeTaxEffectsAllocatedToInterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000078 - Disclosure - INCOME TAXES - Reconciliation of Effective Tax Rate (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails",
     "shortName": "INCOME TAXES - Reconciliation of Effective Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ieb5d1b02f637456e95eba5e2817a09ea_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000079 - Disclosure - INCOME TAXES - Components of Deferred Tax Assets (Liabilities) (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails",
     "shortName": "INCOME TAXES - Components of Deferred Tax Assets (Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ieb5d1b02f637456e95eba5e2817a09ea_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3b13a726ce4740309bdc481148b0ab43_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000080 - Disclosure - INCOME TAXES - Reconciliation of Unrecognized Tax Benefits (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.amedisys.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails",
     "shortName": "INCOME TAXES - Reconciliation of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ieb5d1b02f637456e95eba5e2817a09ea_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000081 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Narrative (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
     "shortName": "CAPITAL STOCK AND SHARE-BASED COMPENSATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "amed:Percentageofownershipinsubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i39be0476e53e4678b7f5eebe2f65b0d1_D20221001-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000082 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Employee Stock Purchase Plan Purchases (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONEmployeeStockPurchasePlanPurchasesDetails",
     "shortName": "CAPITAL STOCK AND SHARE-BASED COMPENSATION - Employee Stock Purchase Plan Purchases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i39be0476e53e4678b7f5eebe2f65b0d1_D20221001-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ic8002223ee9342dbb6725f50e35539b6_D20210101-20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000083 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Stock Option Valuation Assumptions (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails",
     "shortName": "CAPITAL STOCK AND SHARE-BASED COMPENSATION - Stock Option Valuation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ic8002223ee9342dbb6725f50e35539b6_D20210101-20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3b13a726ce4740309bdc481148b0ab43_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000084 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails",
     "shortName": "CAPITAL STOCK AND SHARE-BASED COMPENSATION - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:SharedBasedPaymentArrangementNonVestedOptionActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3b13a726ce4740309bdc481148b0ab43_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000085 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Non-Vested Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails",
     "shortName": "CAPITAL STOCK AND SHARE-BASED COMPENSATION - Non-Vested Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:SharedBasedPaymentArrangementNonVestedOptionActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3b13a726ce4740309bdc481148b0ab43_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ifdd8f4e213094cc396d0fcbfc8c7cc13_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000087 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION - Non-Vested Stock Units Activity (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails",
     "shortName": "CAPITAL STOCK AND SHARE-BASED COMPENSATION - Non-Vested Stock Units Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "icd5a663f1bb844bab57b874fbf18534e_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ieb5d1b02f637456e95eba5e2817a09ea_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyReceivableNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000088 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "amed:HealthInsuranceRetentionLimit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "amed:HealthInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000089 - Disclosure - COMMITMENTS AND CONTINGENCIES - Insurance Programs (Details)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Insurance Programs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "amed:HealthInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amed:DefinedContributionPlanEmployerMatchingContribution",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000090 - Disclosure - EMPLOYEE BENEFIT PLANS - Narrative (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://www.amedisys.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails",
     "shortName": "EMPLOYEE BENEFIT PLANS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amed:DefinedContributionPlanEmployerMatchingContribution",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000091 - Disclosure - SHARE REPURCHASE - Narrative (Details)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails",
     "shortName": "SHARE REPURCHASE - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "ib4261a3345d54d03886673d73969d061_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000092 - Disclosure - SEGMENT INFORMATION - Narrative (Details)",
     "menuCat": "Details",
     "order": "87",
     "role": "http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails",
     "shortName": "SEGMENT INFORMATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000093 - Disclosure - SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)",
     "menuCat": "Details",
     "order": "88",
     "role": "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
     "shortName": "SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i65690d26701e4e5ea588f0959375f58b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000094 - Disclosure - RELATED PARTY TRANSACTIONS - Narrative (Details)",
     "menuCat": "Details",
     "order": "89",
     "role": "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
     "shortName": "RELATED PARTY TRANSACTIONS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i65690d26701e4e5ea588f0959375f58b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS",
     "shortName": "NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i3280ba0923f84410aef180ffd57ff732_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20221231.htm",
      "contextRef": "i92bd39f0d2544264b7d724dd1ae6eac3_I20230202",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000095 - Disclosure - SUBSEQUENT EVENTS Narrative (Details)",
     "menuCat": "Details",
     "order": "90",
     "role": "http://www.amedisys.com/role/SUBSEQUENTEVENTSNarrativeDetails",
     "shortName": "SUBSEQUENT EVENTS Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 116,
   "tag": {
    "amed_A2019StockRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Stock Repurchase Program",
        "label": "2019 Stock Repurchase Program [Member]",
        "terseLabel": "2019 Stock Repurchase Program [Member]"
       }
      }
     },
     "localname": "A2019StockRepurchaseProgramMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_A2021ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Share Repurchase Program",
        "label": "2021 Share Repurchase Program [Member]",
        "terseLabel": "2021 Share Repurchase Program [Member]"
       }
      }
     },
     "localname": "A2021ShareRepurchaseProgramMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_A2022NewJointVentureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 New Joint Venture",
        "label": "2022 New Joint Venture [Member]",
        "terseLabel": "2022 New Joint Venture"
       }
      }
     },
     "localname": "A2022NewJointVentureMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_A2023ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2023 Share Repurchase Program",
        "label": "2023 Share Repurchase Program [Member]",
        "terseLabel": "2023 Share Repurchase Program"
       }
      }
     },
     "localname": "A2023ShareRepurchaseProgramMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_A2037ExpirationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2037 Expiration",
        "label": "2037 Expiration [Member]",
        "terseLabel": "2037 Expiration"
       }
      }
     },
     "localname": "A2037ExpirationMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_A30InterestSoldInTwoCareCentersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "30% Interest Sold in Two Care Centers",
        "label": "30% Interest Sold in Two Care Centers [Member]",
        "terseLabel": "30% Interest Sold in Two Care Centers"
       }
      }
     },
     "localname": "A30InterestSoldInTwoCareCentersMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_A49InterestSoldInTwoCareCentersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "49% Interest Sold in Two Care Centers",
        "label": "49% Interest Sold in Two Care Centers [Member]",
        "terseLabel": "49% Interest Sold in Two Care Centers"
       }
      }
     },
     "localname": "A49InterestSoldInTwoCareCentersMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AccruedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Interest",
        "label": "Accrued Interest",
        "terseLabel": "Accrued Interest"
       }
      }
     },
     "localname": "AccruedInterest",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_AcquiredNamesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired Names [Member]",
        "label": "Acquired Names [Member]",
        "terseLabel": "Acquired Names [Member]",
        "verboseLabel": "Acquired Names [Member]"
       }
      }
     },
     "localname": "AcquiredNamesMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ActualClaimsPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Actual Claims Payment",
        "label": "Actual Claims Payment",
        "terseLabel": "Actual claims payment"
       }
      }
     },
     "localname": "ActualClaimsPayment",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_AdditionalPerformanceBasedAwardTargetShareAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional stock units authorized for achievement of targeted performance if target objective is surpassed to the point of achieving the projected maximum payout",
        "label": "Additional Performance Based Award Target share Amount",
        "terseLabel": "Additional Performance Based Award Target share Max Amount"
       }
      }
     },
     "localname": "AdditionalPerformanceBasedAwardTargetShareAmount",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "amed_AlternativeMinimumTaxCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alternative Minimum Tax Credit [Member]",
        "label": "Alternative Minimum Tax Credit [Member]",
        "terseLabel": "Alternative Minimum Tax Credit [Member]"
       }
      }
     },
     "localname": "AlternativeMinimumTaxCreditMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmedisysCIAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amedisys CIA",
        "label": "Amedisys CIA [Member]",
        "terseLabel": "Amedisys CIA [Member]"
       }
      }
     },
     "localname": "AmedisysCIAMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmendedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Credit Agreement [Member]",
        "label": "Amended Credit Agreement [Member]",
        "terseLabel": "Amended Credit Agreement [Member]"
       }
      }
     },
     "localname": "AmendedCreditAgreementMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmortizableAcquiredNameAndNoncompeteAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortizable acquired name and noncompete agreements",
        "label": "Amortizable acquired name and noncompete agreements [Member]",
        "terseLabel": "Amortizable acquired name and noncompete agreements"
       }
      }
     },
     "localname": "AmortizableAcquiredNameAndNoncompeteAgreementsMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmortizableAcquiredNamesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortizable acquired names",
        "label": "Amortizable acquired names [Member]",
        "terseLabel": "Amortizable acquired names [Member]"
       }
      }
     },
     "localname": "AmortizableAcquiredNamesMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization and Impairment of Operating Lease Right Of Use Asset",
        "label": "Amortization and Impairment of Operating Lease Right Of Use Asset",
        "terseLabel": "Amortization and impairment of operating lease right of use assets"
       }
      }
     },
     "localname": "AmortizationAndImpairmentOfOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_AmountReleasedFromEscrow": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount Released From Escrow",
        "label": "Amount Released From Escrow",
        "terseLabel": "Amount Released From Escrow"
       }
      }
     },
     "localname": "AmountReleasedFromEscrow",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_AseraCareHospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AseraCare Hospice Member",
        "label": "AseraCare Hospice [Member]",
        "terseLabel": "AseraCare Hospice [Member]"
       }
      }
     },
     "localname": "AseraCareHospiceMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AssistedCareHomeHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AssistedCare Home Health",
        "label": "AssistedCare Home Health [Member]",
        "terseLabel": "AssistedCare Home Health"
       }
      }
     },
     "localname": "AssistedCareHomeHealthMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_BenefitAsComponentOfInterestExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Benefit as Component of Interest Expense, resulting from the lapse of statute of limitations regarding uncertain tax positions",
        "label": "Benefit as Component of Interest Expense",
        "terseLabel": "Benefit as Component of Interest Expense"
       }
      }
     },
     "localname": "BenefitAsComponentOfInterestExpense",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BuildingAndLeaseholdImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Building And Leasehold Improvements [Member]",
        "label": "Building And Leasehold Improvements [Member]",
        "terseLabel": "Building and Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "BuildingAndLeaseholdImprovementsMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_BusinessAcquisitionClosingPaymentAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition Closing Payment Adjustment",
        "label": "Business Acquisition Closing Payment Adjustment",
        "terseLabel": "Business Acquisition Closing Payment Adjustment"
       }
      }
     },
     "localname": "BusinessAcquisitionClosingPaymentAdjustment",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessAcquisitionProFormaInformationAseraCareTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a the AseraCare acquisition .",
        "label": "Business Acquisition, Pro Forma Information, AseraCare [Table Text Block]",
        "terseLabel": "Schedule of Pro Forma Financial Information, AseraCare"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationAseraCareTableTextBlock",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_BusinessAcquisitionProFormaOperatingIncomeLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma operating income (loss) for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business acquisition pro forma operating income loss",
        "terseLabel": "Business acquisition pro forma operating income loss"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaOperatingIncomeLoss",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessAcquisitionWorkingCapitalAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Working Capital Adjustment",
        "label": "Business Acquisition Working Capital Adjustment",
        "terseLabel": "Business Acquisition Working Capital Adjustment"
       }
      }
     },
     "localname": "BusinessAcquisitionWorkingCapitalAdjustment",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationAcquiredNoncontrollingInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of noncontrolling interest acquired at the acquisition date.",
        "label": "Business Combination Acquired Noncontrolling Interest",
        "terseLabel": "Business Combination Acquired Noncontrolling Interest"
       }
      }
     },
     "localname": "BusinessCombinationAcquiredNoncontrollingInterest",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationAdjustmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination Adjustments",
        "label": "Business Combination Adjustments [Axis]",
        "terseLabel": "Business Combination Adjustments [Axis]"
       }
      }
     },
     "localname": "BusinessCombinationAdjustmentsAxis",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_BusinessCombinationAdjustmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination Adjustments [Domain]",
        "label": "Business Combination Adjustments [Domain]",
        "terseLabel": "Business Combination Adjustments [Domain]"
       }
      }
     },
     "localname": "BusinessCombinationAdjustmentsDomain",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense",
        "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Current Assets Prepaid Expense",
        "terseLabel": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Current Assets Prepaid Expense"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpense",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses",
        "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Current Liabilities Accrued Expenses",
        "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits",
        "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Current Liabilities Payroll and Employee Benefits",
        "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesPayrollAndEmployeeBenefits",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity assumed at the acquisition date",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Equity",
        "negatedTerseLabel": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Equity"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total liabilities and equity assumed at the acquisition date",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities And Equity",
        "negatedTerseLabel": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities And Equity"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities",
        "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Operating Lease Liabilities",
        "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets",
        "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Operating lease right of use assets",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right of Use Assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CARESActDeferralOfEmployerShareSocialSecurityTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The deferral of the employer's share social security tax provided by the CARES Act",
        "label": "CARES Act Deferral Of Employer Share Social Security Tax",
        "terseLabel": "CARES Act Deferral Of Employer Share Social Security Tax"
       }
      }
     },
     "localname": "CARESActDeferralOfEmployerShareSocialSecurityTax",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CARESActInterestRepaidToGovernment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES Act Interest Repaid to Government",
        "label": "CARES Act Interest Repaid to Government",
        "terseLabel": "CARES Act Interest Repaid to Government"
       }
      }
     },
     "localname": "CARESActInterestRepaidToGovernment",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CARESActProviderReliefFundUtilizedByUnconsolidatedJointVentures": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES Act Provider Relief Fund Utilized By Unconsolidated Joint Ventures",
        "label": "CARES Act Provider Relief Fund Utilized By Unconsolidated Joint Ventures",
        "terseLabel": "CARES Act Provider Relief Funds Utilized By Unconsolidated Joint Ventures"
       }
      }
     },
     "localname": "CARESActProviderReliefFundUtilizedByUnconsolidatedJointVentures",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CARESActProviderReliefFundsRepaidByUnconsolidatedJointVentures": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES Act Provider Relief Funds Repaid By Unconsolidated Joint Ventures",
        "label": "CARES Act Provider Relief Funds Repaid By Unconsolidated Joint Ventures",
        "terseLabel": "CARES Act Provider Relief Funds Repaid By Unconsolidated Joint Ventures"
       }
      }
     },
     "localname": "CARESActProviderReliefFundsRepaidByUnconsolidatedJointVentures",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CARESActProviderReliefFundsRepaidToTheGovernment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES Act Provider Relief Funds repaid to the government by consolidated entities",
        "label": "CARES Act Provider Relief Funds repaid to the government",
        "terseLabel": "CARES Act Provider Relief Funds Repaid"
       }
      }
     },
     "localname": "CARESActProviderReliefFundsRepaidToTheGovernment",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CARESActProviderReliefFundsUtilized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES Act Provider Relief Funds Utilized",
        "label": "CARES Act Provider Relief Funds Utilized",
        "terseLabel": "CARES Act Provider Relief Funds Utilized"
       }
      }
     },
     "localname": "CARESActProviderReliefFundsUtilized",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_COVID19DeferralOfSocialSecurityTaxesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 Deferral of Social Security Taxes",
        "label": "COVID-19 Deferral of Social Security Taxes [Member]",
        "terseLabel": "COVID-19 Deferral of Social Security Taxes [Member]"
       }
      }
     },
     "localname": "COVID19DeferralOfSocialSecurityTaxesMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_COVID19TextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for Novel Coronavirus Pandemic \"COVID-19\"",
        "label": "COVID19 [Text Block]",
        "terseLabel": "NOVEL CORONAVIRUS PANDEMIC (\"COVID-19\")"
       }
      }
     },
     "localname": "COVID19TextBlock",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_CapYearAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cap Year [Axis]",
        "label": "Cap Year [Axis]",
        "terseLabel": "Cap Year [Axis]"
       }
      }
     },
     "localname": "CapYearAxis",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_CapYearDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cap Year [Domain]",
        "label": "Cap Year [Domain]",
        "terseLabel": "Cap Year [Domain]"
       }
      }
     },
     "localname": "CapYearDomain",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cap Year Two Thousand Sixteen Through Two Thousand Twenty Three [Member]",
        "label": "Cap Year Two Thousand Sixteen Through Two Thousand Twenty Three [Member]",
        "terseLabel": "Cap Year 2016 Through 2023 [Member]"
       }
      }
     },
     "localname": "CapYearTwoThousandSixteenThroughTwoThousandTwentyThreeMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cap Year Two Thousand Sixteen Through Two Thousand Twenty Two [Member]",
        "label": "Cap Year Two Thousand Sixteen Through Two Thousand Twenty Two [Member]",
        "terseLabel": "Cap Year 2016 Through 2022 [Member]"
       }
      }
     },
     "localname": "CapYearTwoThousandSixteenThroughTwoThousandTwentyTwoMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CashBalanceAssociatedWithProviderReliefFund": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Balance Associated with the CARES Act Provider Relief Fund",
        "label": "Cash Balance Associated With Provider Relief Fund",
        "terseLabel": "Cash Balance Associated With Provider Relief Fund"
       }
      }
     },
     "localname": "CashBalanceAssociatedWithProviderReliefFund",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CashContributionToNoncontrollingInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Contribution To Noncontrolling Interest",
        "label": "Cash Contribution To Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest contributions"
       }
      }
     },
     "localname": "CashContributionToNoncontrollingInterest",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CashDistributionToNoncontrollingInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of dividends or other distributions to noncontrolling interest holders.",
        "label": "Cash Distribution To Noncontrolling Interest",
        "negatedLabel": "Noncontrolling interest distributions"
       }
      }
     },
     "localname": "CashDistributionToNoncontrollingInterest",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CashPaidForInfinityZPICInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Paid For Infinity ZPIC Interest",
        "label": "Cash Paid For Infinity ZPIC Interest",
        "terseLabel": "Cash Paid For Infinity ZPIC Interest"
       }
      }
     },
     "localname": "CashPaidForInfinityZPICInterest",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CertificateOfNeedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificate of Need",
        "label": "Certificate of Need [Member]",
        "terseLabel": "Certificate of Need [Member]"
       }
      }
     },
     "localname": "CertificateOfNeedMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CertificatesOfNeedAndLicensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificates Of Need And Licenses [Member]",
        "label": "Certificates Of Need And Licenses [Member]",
        "terseLabel": "Certificates of Need and Licenses [Member]"
       }
      }
     },
     "localname": "CertificatesOfNeedAndLicensesMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CertificatesOfNeedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificates Of Need [Member]",
        "label": "Certificates Of Need [Member]",
        "terseLabel": "Certificates Of Need [Member]"
       }
      }
     },
     "localname": "CertificatesOfNeedMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CharityCare": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued expenses related to charity care",
        "label": "Charity Care",
        "terseLabel": "Charity care"
       }
      }
     },
     "localname": "CharityCare",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ClearwaterFloridaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clearwater, Florida [Member]",
        "label": "Clearwater, Florida [Member]",
        "terseLabel": "Clearwater, Florida [Member]"
       }
      }
     },
     "localname": "ClearwaterFloridaMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance to the Company's employee stock purchase plan",
        "label": "Common Stock Shares Authorized For Issuance To Employee Stock Purchase Plan",
        "terseLabel": "Common Stock Shares Authorized For Issuance To Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "CommonStockSharesAuthorizedForIssuanceToEmployeeStockPurchasePlan",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "amed_CommonStockSharesAvailableForIssuanceToEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares available for issuance to the Company's employee stock purchase plan",
        "label": "Common Stock Shares Available For Issuance To Employee Stock Purchase Plan",
        "terseLabel": "Common stock available for issuance under Employee Stock Purchase Plan (shares)"
       }
      }
     },
     "localname": "CommonStockSharesAvailableForIssuanceToEmployeeStockPurchasePlan",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "amed_CompassionateCareHospiceCIAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Compassionate Care Hospice CIA",
        "label": "Compassionate Care Hospice CIA [Member]",
        "terseLabel": "Compassionate Care Hospice CIA [Member]"
       }
      }
     },
     "localname": "CompassionateCareHospiceCIAMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ConnectRNMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ConnectRN",
        "label": "ConnectRN [Member]",
        "terseLabel": "ConnectRN [Member]"
       }
      }
     },
     "localname": "ConnectRNMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ConsolidatedInterestCoverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio of adjusted earnings before interest, taxes, depreciation and amortization to cash interest charges",
        "label": "Consolidated Interest Coverage Ratio",
        "terseLabel": "Consolidated interest coverage ratio"
       }
      }
     },
     "localname": "ConsolidatedInterestCoverageRatio",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_ConsolidatedLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Leverage Ratio",
        "label": "Consolidated Leverage Ratio",
        "terseLabel": "Consolidated Leverage Ratio"
       }
      }
     },
     "localname": "ConsolidatedLeverageRatio",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_ContessaHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contessa Health",
        "label": "Contessa Health [Member]",
        "terseLabel": "Contessa Health"
       }
      }
     },
     "localname": "ContessaHealthMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ContributionsAttributableToNoncontrollingInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest related to capital contributions received from noncontrolling interest",
        "label": "Contributions attributable to noncontrolling interest",
        "terseLabel": "Noncontrolling interest contributions"
       }
      }
     },
     "localname": "ContributionsAttributableToNoncontrollingInterest",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CorporateIntegrityAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Integrity Agreement Term",
        "label": "Corporate Integrity Agreement Term",
        "terseLabel": "Corporate integrity agreement term (years)"
       }
      }
     },
     "localname": "CorporateIntegrityAgreementTerm",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Agreement [Member]",
        "label": "Credit Agreement [Member]",
        "terseLabel": "Credit Agreement [Member]"
       }
      }
     },
     "localname": "CreditAgreementMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Facility, Maximum Allowable Consolidated Leverage Ratio Multiple",
        "label": "Credit Facility Maximum Allowable Consolidated Leverage Ratio Multiple",
        "terseLabel": "Credit facility, maximum allowable consolidated leverage ratio multiple"
       }
      }
     },
     "localname": "CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_Creditfacilitymaximumallowableconsolidatedleverageratio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit facility maximum allowable consolidated leverage ratio as defined in the Company's Credit Agreement",
        "label": "Credit facility maximum allowable consolidated leverage ratio",
        "terseLabel": "Credit facility maximum allowable consolidated leverage ratio"
       }
      }
     },
     "localname": "Creditfacilitymaximumallowableconsolidatedleverageratio",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_CurrentAndLongTermObligationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current and Long-Term obligations",
        "label": "Current and Long-Term obligations [Member]",
        "terseLabel": "Current and Long-Term obligations"
       }
      }
     },
     "localname": "CurrentAndLongTermObligationsMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LEASESFinanceLeasesDetails",
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CurrentPortionOfLongTermObligationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current portion of long-term obligations",
        "label": "Current portion of long-term obligations [Member]",
        "terseLabel": "Current portion of long-term obligations"
       }
      }
     },
     "localname": "CurrentPortionOfLongTermObligationsMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LEASESFinanceLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_DebtInstrumentByLeverageRatioTrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, By Leverage Ratio, Tranche Four [Member]",
        "label": "Debt Instrument, By Leverage Ratio, Tranche Four [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Less Than Equal To 0.75 to 1.0"
       }
      }
     },
     "localname": "DebtInstrumentByLeverageRatioTrancheFourMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_DebtInstrumentByLeverageRatioTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, By Leverage Ratio, Tranche One [Member]",
        "label": "Debt Instrument, By Leverage Ratio, Tranche One [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Greater Than 3.00 to 1.0"
       }
      }
     },
     "localname": "DebtInstrumentByLeverageRatioTrancheOneMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_DebtInstrumentByLeverageRatioTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, By Leverage Ratio, Tranche Three [Member]",
        "label": "Debt Instrument, By Leverage Ratio, Tranche Three [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0"
       }
      }
     },
     "localname": "DebtInstrumentByLeverageRatioTrancheThreeMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_DebtInstrumentByLeverageRatioTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, By Leverage Ratio, Tranche Two [Member]",
        "label": "Debt Instrument, By Leverage Ratio, Tranche Two [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Less Than Equal To 3.00 to 1.0 but Greater Than 2.00 to 1.0"
       }
      }
     },
     "localname": "DebtInstrumentByLeverageRatioTrancheTwoMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_DebtInstrumentCarryingAmountExcludingFinanceLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Carrying Amount Excluding Finance Leases",
        "label": "Debt Instrument Carrying Amount Excluding Finance Leases",
        "terseLabel": "Debt Instrument Carrying Amount Excluding Finance Leases"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmountExcludingFinanceLeases",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Interest Additional Interest Above Eurodollar Rate",
        "label": "Debt Instrument Interest Additional Interest Above Eurodollar Rate",
        "terseLabel": "Additional interest rate above Eurodollar Rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestAdditionalInterestAboveEurodollarRate",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Interest Additional Interest Above Federal Fund Rate",
        "label": "Debt Instrument Interest Additional Interest Above Federal Fund Rate",
        "terseLabel": "Additional interest rate above Federal Fund rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestAdditionalInterestAboveFederalFundRate",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_DebtInstrumentInterestRateatPeriodEnd": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Interest Rate at Period End",
        "label": "Debt Instrument Interest Rate at Period End",
        "terseLabel": "Debt Instrument Interest Rate at Period End"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateatPeriodEnd",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_DebtInstrumentPeriodicPaymentPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of the Term Loan that is required as periodic payments including both interest and principal payments",
        "label": "Debt Instrument Periodic Payment Percentage",
        "terseLabel": "Debt Instrument Periodic Payment Percentage"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPercentage",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_DebtIssuanceCostsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for debt issuance costs.",
        "label": "Debt Issuance Costs Policy [Policy Text Block]",
        "terseLabel": "Debt Issuance Costs"
       }
      }
     },
     "localname": "DebtIssuanceCostsPolicyPolicyTextBlock",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_DeferredCompensationPlanLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Compensation Plan Liability",
        "label": "Deferred Compensation Plan Liability",
        "terseLabel": "Deferred compensation plan liability"
       }
      }
     },
     "localname": "DeferredCompensationPlanLiability",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DeferredOperatingIncomeCARESAct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred operating income as a result of the CARES Act in relation to the Novel Coronavirus Pandemic (\"COVID-19\")",
        "label": "Deferred Operating Income (CARES Act)",
        "terseLabel": "Deferred operating income (CARES Act)"
       }
      }
     },
     "localname": "DeferredOperatingIncomeCARESAct",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DeferredTaxAssetDeferredSocialSecurityTaxes": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred social security taxes which are the result of the novel coronavirus pandemic (\"COVID-19\").",
        "label": "Deferred Tax Asset, Deferred Social Security Taxes",
        "terseLabel": "Deferred social security taxes (1)"
       }
      }
     },
     "localname": "DeferredTaxAssetDeferredSocialSecurityTaxes",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DeferredTaxAssetsGoodwillAndIntangibleAssets1": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the estimated future tax effects attributable to the difference between the tax basis of intangible assets and the basis of intangible assets computed in accordance with generally accepted accounting principles. The difference in basis, whether due to amortization or other reasons, will increase future taxable income when such difference reverses.",
        "label": "Deferred Tax Assets Goodwill And Intangible Assets",
        "terseLabel": "Deferred Tax Assets Goodwill And Intangible Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets1",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DeferredTaxAssetsLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.",
        "label": "Deferred Tax Assets, Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiability",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DeferredTaxAssetsLegalAndComplianceMatters": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from legal and compliance matters.",
        "label": "Deferred Tax Assets, Legal and Compliance Matters",
        "terseLabel": "Legal &amp; compliance matters"
       }
      }
     },
     "localname": "DeferredTaxAssetsLegalAndComplianceMatters",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DeferredTaxAssetsProviderReliefFundAdvance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the Provider Relief Fund Advance set up as a result of the novel coronavirus pandemic (\"COVID-19\").",
        "label": "Deferred Tax Assets, Provider Relief Fund Advance",
        "terseLabel": "Deferred Tax Assets, Provider Relief Fund Advance"
       }
      }
     },
     "localname": "DeferredTaxAssetsProviderReliefFundAdvance",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets tax deferred expense compensation and benefits workers compensation",
        "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Workers Compensation",
        "terseLabel": "Workers\u2019 compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsWorkersCompensation",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DeferredTaxLiabilitiesAmortizationOfIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from amortization of intangible assets.",
        "label": "Deferred Tax Liabilities, Amortization of Intangible Assets",
        "negatedTerseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAmortizationOfIntangibleAssets",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DeferredTaxLiabilitiesRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from right-of-use assets.",
        "label": "Deferred Tax Liabilities, Right of Use Assets",
        "negatedTerseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Percentage of Employee Salary Eligible for Employer Match",
        "label": "Defind Contribution Plan Maximum Annual Match Per Employee Salary Percentage",
        "terseLabel": "Maximum percentage of employee salary eligible for employer match (percent)"
       }
      }
     },
     "localname": "DefindContributionPlanMaximumAnnualMatchPerEmployeeSalaryPercentage",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan Employee Contribution For Employer Matching Program",
        "label": "Defined Contribution Plan Employee Contribution For Employee Matching Program",
        "terseLabel": "Employee contribution amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployeeContributionForEmployeeMatchingProgram",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DefinedContributionPlanEmployerMatchingContribution": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined contribution plan employer matching contribution.",
        "label": "Defined Contribution Plan Employer Matching Contribution",
        "terseLabel": "Employer match amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContribution",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DepreciationAndAmortizationForContinuingOperations": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciation And Amortization For Continuing Operations",
        "label": "Depreciation And Amortization For Continuing Operations",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortizationForContinuingOperations",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DetailsOfCertainBalanceSheetAccountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Details Of Certain Balance Sheet Accounts [Abstract]",
        "terseLabel": "Details Of Certain Balance Sheet Accounts [Abstract]"
       }
      }
     },
     "localname": "DetailsOfCertainBalanceSheetAccountsAbstract",
     "nsuri": "http://www.amedisys.com/20221231",
     "xbrltype": "stringItemType"
    },
    "amed_DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Details of Certain Balance Sheet Accounts Disclosure [Text Block]",
        "terseLabel": "DETAILS OF CERTAIN BALANCE SHEET ACCOUNTS"
       }
      }
     },
     "localname": "DetailsOfCertainBalanceSheetAccountsDisclosureTextBlock",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accrued expenses attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group Including Discontinued Operation Accrued Expenses Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedExpensesCurrent",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/AssetsHeldForSaleAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as operating lease liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group Including Discontinued Operation Operating Lease Liabilities Current",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/AssetsHeldForSaleAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as operating lease liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group Including Discontinued Operation Operating Lease Liabilities Noncurrent",
        "terseLabel": "Operating lease liabilities, less current portion"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/AssetsHeldForSaleAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as operating lease right of use asset attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group Including Discontinued Operation Operating Lease Right Of Use Assets Noncurrent",
        "terseLabel": "Disposal Group Including Discontinued Operation Operating Lease Right Of Use Assets Noncurrent"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/AssetsHeldForSaleAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as payroll and employee benefits payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group Including Discontinued Operation Payroll and Employee Benefits Current",
        "terseLabel": "Payroll and employee benefits"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPayrollAndEmployeeBenefitsCurrent",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/AssetsHeldForSaleAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Document And Entity Information [Abstract]",
        "label": "Document And Entity Information [Abstract]",
        "terseLabel": "Document And Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.amedisys.com/20221231",
     "xbrltype": "stringItemType"
    },
    "amed_EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Excess Tax Benefit, Share-based Compensation, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Excess Tax Benefit, Share-based Compensation, Percent",
        "negatedTerseLabel": "Excess tax benefits from share-based compensation (1)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationExcessTaxBenefitSharebasedCompensationPercent",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Non-deductible Executive Compensation, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Non-deductible Executive Compensation, Percent",
        "terseLabel": "Non-deductible executive compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNonDeductibleExecutiveCompensationPercent",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Unrecognized Tax Benefits, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Unrecognized Tax Benefits, Percent",
        "terseLabel": "Unrecognized tax benefits (2)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefitsPercent",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_EpisodeOfCareAsEpisodicBasedRevenueDuration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days in a home health episode of care.",
        "label": "Episode Of Care As Episodic Based Revenue Duration",
        "terseLabel": "Episode of care as episodic-based revenue, days"
       }
      }
     },
     "localname": "EpisodeOfCareAsEpisodicBasedRevenueDuration",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_EquipmentAndFurnitureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment And Furniture [Member]",
        "label": "Equipment And Furniture [Member]",
        "terseLabel": "Equipment and Furniture [Member]"
       }
      }
     },
     "localname": "EquipmentAndFurnitureMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Impact Of Write Off Of Other Comprehensive Income",
        "label": "Equity Impact Of Write Off Of Other Comprehensive Income",
        "negatedTerseLabel": "Write-off of other comprehensive income"
       }
      }
     },
     "localname": "EquityImpactOfWriteOffOfOtherComprehensiveIncome",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ErrorRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Error Rate Percentage",
        "label": "Error Rate Percentage",
        "terseLabel": "Error rate (percent)"
       }
      }
     },
     "localname": "ErrorRatePercentage",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimate of obligations due Medicare upon demand due to overages for the inpatient cap and/or overall payment cap.",
        "label": "Estimated Amount Due Back To Medicare In Other Accrued Liabilities",
        "terseLabel": "Estimated amounts due back to Medicare"
       }
      }
     },
     "localname": "EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_EstimatedInsuranceExcludingLongTermPortion": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated insurance liability, excluding long-term",
        "label": "Estimated Insurance Excluding Long Term Portion",
        "totalLabel": "Estimated Insurance Excluding Long Term Portion"
       }
      }
     },
     "localname": "EstimatedInsuranceExcludingLongTermPortion",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_EstimatedInsuranceLongTermPortion": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails": {
       "order": 2.0,
       "parentTag": "amed_EstimatedInsuranceExcludingLongTermPortion",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term portion of estimated insurance",
        "label": "Estimated Insurance Long Term Portion",
        "negatedTerseLabel": "Estimated Insurance Long Term Portion"
       }
      }
     },
     "localname": "EstimatedInsuranceLongTermPortion",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_EstimatedInsuranceTotal": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails": {
       "order": 1.0,
       "parentTag": "amed_EstimatedInsuranceExcludingLongTermPortion",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated insurance, total",
        "label": "Estimated Insurance Total",
        "totalLabel": "Estimated Insurance Total"
       }
      }
     },
     "localname": "EstimatedInsuranceTotal",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_EstimatedMedicareCapLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued expenses related to the estimated Medicare CAP liability",
        "label": "Estimated Medicare Cap Liability",
        "terseLabel": "Estimated Medicare cap liability"
       }
      }
     },
     "localname": "EstimatedMedicareCapLiability",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "stimated Useful Lives Of Property And Equipment, table",
        "label": "Estimated Useful Lives Of Property And Equipment [Text Block]",
        "terseLabel": "Schedule of Estimated Useful Lives of Property and Equipment"
       }
      }
     },
     "localname": "EstimatedUsefulLivesOfPropertyAndEquipmentTextBlock",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_EvolutionHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evolution Health",
        "label": "Evolution Health [Member]",
        "terseLabel": "Evolution Health"
       }
      }
     },
     "localname": "EvolutionHealthMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ExecutiveStockOptionExerciseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Executive Stock Option Exercise",
        "label": "Executive Stock Option Exercise [Member]",
        "terseLabel": "Executive Stock Option Exercise [Member]"
       }
      }
     },
     "localname": "ExecutiveStockOptionExerciseMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails",
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The impact on revenue due to the extension of the temporary suspension of sequestration as a result of the novel coronavirus pandemic (\"COVID-19\").",
        "label": "Extension Of Temporary Suspension Of Sequestration Revenue Impact",
        "terseLabel": "Extension Of Temporary Suspension Of Sequestration Revenue Impact"
       }
      }
     },
     "localname": "ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ExtrapolatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extrapolated [Member]",
        "label": "Extrapolated [Member]",
        "terseLabel": "Extrapolated [Member]"
       }
      }
     },
     "localname": "ExtrapolatedMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_Fairvalueofshareofcommonstockpercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of a share of common stock, percentage",
        "label": "Fairvalueofshareofcommonstockpercentage",
        "terseLabel": "Fair value of share of common stock (percent)"
       }
      }
     },
     "localname": "Fairvalueofshareofcommonstockpercentage",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_FinanceLeaseCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total amount of finance lease cost including amortization of ROU asset and interest expense",
        "label": "Finance Lease Cost",
        "terseLabel": "Finance Lease Cost"
       }
      }
     },
     "localname": "FinanceLeaseCost",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LEASESLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_FinanceLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance leases Table Text Block",
        "label": "Finance leases [Table Text Block]",
        "terseLabel": "Schedule of Finance Leases"
       }
      }
     },
     "localname": "FinanceLeasesTableTextBlock",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_FinancialInstrumentDetailsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Instrument Details, table",
        "label": "Financial Instrument Details [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FinancialInstrumentDetailsTableTextBlock",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Hundred Fifty Million Revolving Credit Facility [Member]",
        "label": "Five Hundred Fifty Million Revolving Credit Facility [Member]",
        "terseLabel": "Five Hundred Fifty Million Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "FiveHundredFiftyMillionRevolvingCreditFacilityMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_FleetLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fleet Lease Member",
        "label": "Fleet Lease [Member]",
        "terseLabel": "Fleet Lease [Member]"
       }
      }
     },
     "localname": "FleetLeaseMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LEASESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_FloridaZpicRevenueReduction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in revenue as a result of the Florida ZPIC audit",
        "label": "Florida Zpic Revenue Reduction",
        "terseLabel": "Florida Zpic revenue reduction"
       }
      }
     },
     "localname": "FloridaZpicRevenueReduction",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_FourHundredFiftyMillionTermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Hundred Fifty Million Term Loan Facility",
        "label": "Four Hundred Fifty Million Term Loan Facility [Member]",
        "terseLabel": "Four Hundred Fifty Million Term Loan Facility [Member]"
       }
      }
     },
     "localname": "FourHundredFiftyMillionTermLoanFacilityMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_FundingForHealthcareProvidersIncludingHospitals": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding for healthcare providers, including hospitals provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act",
        "label": "Funding For Healthcare Providers Including Hospitals",
        "terseLabel": "Funding For Healthcare Providers Including Hospitals"
       }
      }
     },
     "localname": "FundingForHealthcareProvidersIncludingHospitals",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding immediately distributed to healthcare providers based on their 2019 Medicare Fee-For-Service reimbursements provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act",
        "label": "Funding Immediately Distributed To Healthcare Providers Based On Their 2019 Medicare Fee For Service Reimbursements",
        "terseLabel": "Funding Immediately Distributed To Healthcare Providers Based On Their 2019 Medicare Fee For Service Reimbursements"
       }
      }
     },
     "localname": "FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_FundingReceivedFromCARESAct": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding received by the Company from the Coronavirus Aid Relief and Economic Security (CARES) Act",
        "label": "Funding Received From CARES Act",
        "terseLabel": "Funding Received From CARES Act"
       }
      }
     },
     "localname": "FundingReceivedFromCARESAct",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding Received From Mass Home Care ASAP COVID-19 Provider Sustainability Program",
        "label": "Funding Received From Mass HomeCare ASAP COVID19 Provider Sustainability Program",
        "terseLabel": "Funding Received From Mass HomeCare ASAP COVID19 Provider Sustainability Program"
       }
      }
     },
     "localname": "FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_FundsReceivedFromProviderReliefFundAdvance": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from funds received by the government related to the Novel Coronavirus Pandemic \"COVID-19\"",
        "label": "Funds Received From Provider Relief Fund Advance",
        "terseLabel": "Provider relief fund advance"
       }
      }
     },
     "localname": "FundsReceivedFromProviderReliefFundAdvance",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_GainRelatedToSaleOfNoncontrollingInterestNetOfTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Related To Sale Of Noncontrolling Interest Net Of Tax",
        "label": "Gain Related To Sale Of Noncontrolling Interest Net Of Tax",
        "terseLabel": "Gain Related To Sale Of Noncontrolling Interest Net Of Tax"
       }
      }
     },
     "localname": "GainRelatedToSaleOfNoncontrollingInterestNetOfTax",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_GoodwillDeductibleForIncomeTaxPurposesPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill, Deductible For Income Tax Purposes, Period",
        "label": "Goodwill, Deductible For Income Tax Purposes, Period",
        "terseLabel": "Period of time goodwill is expected to be deductible for income tax purposes"
       }
      }
     },
     "localname": "GoodwillDeductibleForIncomeTaxPurposesPeriod",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_GovernmentGrantsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting policy disclosure text block for government grants",
        "label": "Government Grants [Policy Text Block]",
        "terseLabel": "Government Grants"
       }
      }
     },
     "localname": "GovernmentGrantsPolicyTextBlock",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_HealthInsurance": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails": {
       "order": 1.0,
       "parentTag": "amed_EstimatedInsuranceTotal",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health insurance, estimated liability",
        "label": "Health Insurance",
        "terseLabel": "Health insurance"
       }
      }
     },
     "localname": "HealthInsurance",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_HealthInsuranceDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Insurance Deposits",
        "label": "Health Insurance Deposits",
        "terseLabel": "Health insurance deposits"
       }
      }
     },
     "localname": "HealthInsuranceDeposits",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_HealthInsuranceRetentionLimit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum potential amount of future payments the entity could be required to make related to a specific Health Insurance Claim.",
        "label": "Health Insurance Retention Limit",
        "terseLabel": "Health insurance retention limit"
       }
      }
     },
     "localname": "HealthInsuranceRetentionLimit",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_HeritageHealthcareInnovationFundLPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Heritage Healthcare Innovation Fund LP Member",
        "label": "Heritage Healthcare Innovation Fund LP [Member]",
        "terseLabel": "Heritage Healthcare Innovation Fund LP [Member]"
       }
      }
     },
     "localname": "HeritageHealthcareInnovationFundLPMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HighAcuityCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "High Acuity Care",
        "label": "High Acuity Care [Member]",
        "terseLabel": "High Acuity Care [Member]"
       }
      }
     },
     "localname": "HighAcuityCareMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HistoricalCollectionRateFromMedicare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Historical collection rate from Medicare.",
        "label": "Historical Collection Rate From Medicare",
        "terseLabel": "Historical collection rate from Medicare"
       }
      }
     },
     "localname": "HistoricalCollectionRateFromMedicare",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_HomeHealthAndHospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home Health And Hospice [Member]",
        "label": "Home Health And Hospice [Member]",
        "terseLabel": "Home Health And Hospice [Member]"
       }
      }
     },
     "localname": "HomeHealthAndHospiceMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HomeHealthBenefitManagerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home health benefit manager",
        "label": "Home health benefit manager [Member]",
        "terseLabel": "Home health benefit manager"
       }
      }
     },
     "localname": "HomeHealthBenefitManagerMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HomeHealthMedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home Health Medicare [Member]",
        "label": "Home Health Medicare [Member]",
        "terseLabel": "Home Health Medicare [Member]"
       }
      }
     },
     "localname": "HomeHealthMedicareMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HomeHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home Health [Member]",
        "label": "Home Health [Member]",
        "terseLabel": "Home Health [Member]"
       }
      }
     },
     "localname": "HomeHealthMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/DiscontinuedOperationsandAssetsHeldForSaleAdditionalInformationDetail",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HomeHealthNonMedicareEpisodicBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home Health Non-Medicare - Episodic Based [Member]",
        "label": "Home Health Non-Medicare - Episodic Based [Member]",
        "terseLabel": "Home Health Non-Medicare - Episodic Based [Member]"
       }
      }
     },
     "localname": "HomeHealthNonMedicareEpisodicBasedMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HomeHealthNonMedicareNonEpisodicBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home Health Non-Medicare - Non-Episodic Based [Member]",
        "label": "Home Health Non-Medicare - Non-Episodic Based [Member]",
        "terseLabel": "Home Health Non-Medicare - Non-Episodic Based [Member]"
       }
      }
     },
     "localname": "HomeHealthNonMedicareNonEpisodicBasedMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HospiceAccruals": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued expenses related to Hospice room and board, general in-patient and other expenses",
        "label": "Hospice accruals",
        "terseLabel": "Hospice accruals (room and board, general in-patient and other)"
       }
      }
     },
     "localname": "HospiceAccruals",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_HospiceMedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hospice Medicare [Member]",
        "label": "Hospice Medicare [Member]",
        "terseLabel": "Hospice Medicare [Member]"
       }
      }
     },
     "localname": "HospiceMedicareMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HospiceMedicareRevenueRateAccountedForRoutineCare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage of the entity's Hospice net Medicare service revenue that is derived from routine care.",
        "label": "Hospice Medicare Revenue Rate Accounted For Routine Care",
        "terseLabel": "Hospice Medicare revenue rate accounted for routine care"
       }
      }
     },
     "localname": "HospiceMedicareRevenueRateAccountedForRoutineCare",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_HospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hospice [Member]",
        "label": "Hospice [Member]",
        "terseLabel": "Hospice [Member]"
       }
      }
     },
     "localname": "HospiceMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HospiceNonMedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hospice Non-Medicare [Member]",
        "label": "Hospice Non-Medicare [Member]",
        "terseLabel": "Hospice Non-Medicare [Member]"
       }
      }
     },
     "localname": "HospiceNonMedicareMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ImpactOfChangeInMedicareCollectionRate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impact on Medicare Revenue due to a 0.1% change in our Medicare Collection Rate",
        "label": "Impact of Change in Medicare Collection Rate",
        "terseLabel": "Impact of Change in Medicare Collection Rate"
       }
      }
     },
     "localname": "ImpactOfChangeInMedicareCollectionRate",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/AssetsHeldForSaleAssetsandLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "localname": "IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale",
     "nsuri": "http://www.amedisys.com/20221231",
     "xbrltype": "monetaryItemType"
    },
    "amed_IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/AssetsHeldForSaleAssetsandLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "localname": "IncomeLossBeforeIncomeTaxesForCareCentersRemovedFromAvailableForSale",
     "nsuri": "http://www.amedisys.com/20221231",
     "xbrltype": "monetaryItemType"
    },
    "amed_IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/AssetsHeldForSaleAssetsandLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "amed_IncomeFromContinuingOperationsForCareCentersRemovedFromAvailableForSale",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "localname": "IncomeTaxBenefitExpenseForCareCentersRemovedFromAvailableForSale",
     "nsuri": "http://www.amedisys.com/20221231",
     "xbrltype": "monetaryItemType"
    },
    "amed_IncomeTaxEffectsAllocatedToGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESIncomeTaxExpenseAllocationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Effects Allocated To Goodwill",
        "label": "Income Tax Effects Allocated To Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "IncomeTaxEffectsAllocatedToGoodwill",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESIncomeTaxExpenseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_IncomeTaxEffectsAllocatedToInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESIncomeTaxExpenseAllocationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tax effect of items occuring during the period that have been charged or credited directly to interest expense",
        "label": "Income Tax Effects Allocated to Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "IncomeTaxEffectsAllocatedToInterestExpense",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESIncomeTaxExpenseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_IncreaseDecreaseInAssetsAcquired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase Decrease In Assets Acquired",
        "label": "Increase Decrease In Assets Acquired",
        "terseLabel": "Increase Decrease In Assets Acquired"
       }
      }
     },
     "localname": "IncreaseDecreaseInAssetsAcquired",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_IncreaseDecreaseInLiabilitiesAssumed": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase Decrease In Liabilities Assumed",
        "label": "Increase Decrease In Liabilities Assumed",
        "terseLabel": "Increase Decrease In Liabilities Assumed"
       }
      }
     },
     "localname": "IncreaseDecreaseInLiabilitiesAssumed",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase (decrease) In Operating Lease Right Of Use Asset",
        "label": "Increase Decrease In Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease right of use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_IndemnificationAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount to be reimbursed if and when certain assumed liabilities are paid",
        "label": "Indemnification Amount",
        "terseLabel": "Indemnification amount"
       }
      }
     },
     "localname": "IndemnificationAmount",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_InfinityHomeCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infinity HomeCare [Member]",
        "label": "Infinity HomeCare [Member]",
        "terseLabel": "Infinity HomeCare [Member]"
       }
      }
     },
     "localname": "InfinityHomeCareMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_InsuranceProgramsTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insurance Programs Details, Table",
        "label": "Insurance Programs Table [Table Text Block]",
        "terseLabel": "Schedule of Insurance Programs"
       }
      }
     },
     "localname": "InsuranceProgramsTableTableTextBlock",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_InternallyDevelopedComputerSoftware": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed AMS3 computer software",
        "label": "Internally Developed Computer Software",
        "terseLabel": "Internally developed computer software"
       }
      }
     },
     "localname": "InternallyDevelopedComputerSoftware",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LakelandFloridaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lakeland, Florida [Member]",
        "label": "Lakeland, Florida [Member]",
        "terseLabel": "Lakeland, Florida [Member]"
       }
      }
     },
     "localname": "LakelandFloridaMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_LeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Liability Maturity Table Text Block",
        "label": "Lease Liability Maturity [Table Text Block]",
        "terseLabel": "Schedule of Lease Liability Maturity"
       }
      }
     },
     "localname": "LeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_LeaseTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease type",
        "label": "Lease type [Axis]",
        "terseLabel": "Lease type [Axis]"
       }
      }
     },
     "localname": "LeaseTypeAxis",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LEASESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_LeaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Type",
        "label": "Lease Type [Domain]",
        "terseLabel": "Lease Type [Domain]"
       }
      }
     },
     "localname": "LeaseTypeDomain",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LEASESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_LegalAndOtherSettlements": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued expenses related to legal and other settlements",
        "label": "Legal And Other Settlements",
        "terseLabel": "Legal settlements and other audits"
       }
      }
     },
     "localname": "LegalAndOtherSettlements",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LegalSettlementPaymentLessInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal Settlement Payment Less Interest",
        "label": "Legal Settlement Payment Less Interest",
        "terseLabel": "Legal Settlement Payment Less Interest"
       }
      }
     },
     "localname": "LegalSettlementPaymentLessInterest",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Finance lease, Reduction to ROU assets resulting from reductions to lease obligations",
        "label": "Lessee Finance lease Reduction to ROU assets resulting from reductions to lease obligations",
        "terseLabel": "Lessee Finance lease Reduction to ROU assets resulting from reductions to lease obligations"
       }
      }
     },
     "localname": "LesseeFinanceLeaseReductionToROUAssetsResultingFromReductionsToLeaseObligations",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LEASESSupplementalCashflowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LesseeLeasesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating and finance leases of lessee. Includes, but is not limited to, description of operating and finance lease and maturity analysis of operating and finance lease liability.",
        "label": "Lessee, Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeLeasesTextBlock",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations",
        "label": "Lessee Operating lease Reductions to ROU assets resulting from reductions to lease obligations",
        "terseLabel": "Lessee Operating lease Reductions to ROU assets resulting from reductions to lease obligations"
       }
      }
     },
     "localname": "LesseeOperatingLeaseReductionsToROUAssetsResultingFromReductionsToLeaseObligations",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LEASESSupplementalCashflowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LetterOfCreditFee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the letters of credit, for the letters of credit",
        "label": "Letter Of Credit Fee",
        "terseLabel": "Letter of Credit Fee"
       }
      }
     },
     "localname": "LetterOfCreditFee",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_LettersofCreditmaximumcommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Letters of Credit, maximum commitment",
        "label": "LettersofCreditmaximumcommitment",
        "terseLabel": "Letters of Credit, maximum commitment"
       }
      }
     },
     "localname": "LettersofCreditmaximumcommitment",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LicensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licenses",
        "label": "Licenses [Member]",
        "terseLabel": "Licenses [Member]"
       }
      }
     },
     "localname": "LicensesMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_LineOfCreditFacilityAdditionalBorrowingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility Additional Borrowing Capacity",
        "label": "Line Of Credit Facility Additional Borrowing Capacity",
        "terseLabel": "Credit facility, maximum additional borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LongTermObligationsLessCurrentPortionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term obligations, less current portion",
        "label": "Long-Term obligations, less current portion [Member]",
        "terseLabel": "Long-Term obligations, less current portion"
       }
      }
     },
     "localname": "LongTermObligationsLessCurrentPortionMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LEASESFinanceLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_LowUtilizationPaymentAdjustmentNumberOfVisits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the visit threshold for a low utilization payment adjustment.",
        "label": "Low Utilization Payment Adjustment Number Of Visits",
        "terseLabel": "Low utilization payment adjustment, maximum number of visits"
       }
      }
     },
     "localname": "LowUtilizationPaymentAdjustmentNumberOfVisits",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.",
        "label": "Maximum Days To Submit Final Bill From Date Request For Anticipated Payment Was Paid",
        "terseLabel": "Maximum days to submit final bill from the date the request for anticipated payment was paid"
       }
      }
     },
     "localname": "MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days from the start of the period of care in which the final bill must be submitted to Medicare.",
        "label": "Maximum Days To Submit Final Bill From Start Of Period of Care",
        "terseLabel": "Maximum days to submit final bill from the start of period of care"
       }
      }
     },
     "localname": "MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_MaximumPercentOwnershipForCostMethodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage ownership required in order for an investment to be treated under the cost method of accounting in the entity's financial statements.",
        "label": "Maximum Percent Ownership For Cost Method Percent",
        "terseLabel": "Maximum ownership percentage for cost method investment (percent)"
       }
      }
     },
     "localname": "MaximumPercentOwnershipForCostMethodPercent",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_MaximumPercentOwnershipForEquityMethodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage ownership required in order for an investment to be treated under the equity method of accounting in the entity's financial statements.",
        "label": "Maximum Percent Ownership For Equity Method Percent",
        "terseLabel": "Maximum ownership percentage for equity method investment (percent)"
       }
      }
     },
     "localname": "MaximumPercentOwnershipForEquityMethodPercent",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_MedalogixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medalogix",
        "label": "Medalogix [Member]",
        "terseLabel": "Medalogix [Member]"
       }
      }
     },
     "localname": "MedalogixMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_MedicareRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare Revenue [Member]",
        "label": "Medicare Revenue [Member]",
        "terseLabel": "Medicare Revenue [Member]"
       }
      }
     },
     "localname": "MedicareRevenueMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_MinimumPercentOwnershipForControllingInterestPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage ownership required in order for a variable interest entity (VIE) to be consolidated in the entity's financial statements.",
        "label": "Minimum Percent Ownership For Controlling Interest Percent",
        "terseLabel": "Minimum percent ownership for controlling interest (percent)"
       }
      }
     },
     "localname": "MinimumPercentOwnershipForControllingInterestPercent",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_MorgantownWestVirginiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Morgantown, West Virginia [Member]",
        "label": "Morgantown, West Virginia [Member]",
        "terseLabel": "Morgantown, West Virginia [Member]"
       }
      }
     },
     "localname": "MorgantownWestVirginiaMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_NetOperatingLossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Operating Loss [Member]",
        "label": "Net Operating Loss [Member]",
        "terseLabel": "Net Operating Loss [Member]"
       }
      }
     },
     "localname": "NetOperatingLossMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_NetServiceRevenueEpisodePaymentRateDuration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.",
        "label": "Net Service Revenue, Episode Payment Rate Duration",
        "terseLabel": "Net service revenue episode payment rate"
       }
      }
     },
     "localname": "NetServiceRevenueEpisodePaymentRateDuration",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_NetServiceRevenuePeriodOfCarePaymentRateDuration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.",
        "label": "Net Service Revenue Period Of Care Payment Rate Duration",
        "terseLabel": "Net Service Revenue Period Of Care Payment Rate Duration"
       }
      }
     },
     "localname": "NetServiceRevenuePeriodOfCarePaymentRateDuration",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_NewShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Share Repurchase Program",
        "label": "New Share Repurchase Program [Member]",
        "terseLabel": "New Share Repurchase Program [Member]"
       }
      }
     },
     "localname": "NewShareRepurchaseProgramMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_NonCashAccruedContingentConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Cash Accrued Contingent Consideration",
        "label": "Non Cash Accrued Contingent Consideration",
        "terseLabel": "Accrued contingent consideration"
       }
      }
     },
     "localname": "NonCashAccruedContingentConsideration",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_NonCashNoncontrollingInterestContribution": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Cash Noncontrolling Interest Contribution",
        "label": "Non Cash Noncontrolling Interest Contribution",
        "terseLabel": "Noncontrolling interest contribution"
       }
      }
     },
     "localname": "NonCashNoncontrollingInterestContribution",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_NonMedicareRevenueTermRates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Medicare Revenue Term Rates as a percentage of Medicare Term Rates",
        "label": "Non-Medicare Revenue Term Rates",
        "terseLabel": "Non-medicare revenue term rates"
       }
      }
     },
     "localname": "NonMedicareRevenueTermRates",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_NonVestedStockAndStockUnits": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non vested stock and stock units.",
        "label": "Non Vested Stock And Stock Units",
        "terseLabel": "Non-vested stock and stock units"
       }
      }
     },
     "localname": "NonVestedStockAndStockUnits",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "amed_NonVestedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Vested Stock Units [Member]",
        "label": "Non Vested Stock Units [Member]",
        "terseLabel": "Non-Vested Stock Units [Member]"
       }
      }
     },
     "localname": "NonVestedStockUnitsMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_NonVestedStockUnitsServiceBasedAndPerformanceBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Vested Stock Units - Service-Based and Performance-Based [Member]",
        "terseLabel": "Non-Vested Stock Units - Service-Based and Performance-Based [Member]"
       }
      }
     },
     "localname": "NonVestedStockUnitsServiceBasedAndPerformanceBasedMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_NonVestedStockUnitsServiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Vested Stock Units Service [Member]",
        "terseLabel": "Non-Vested Stock Units - Service-Based [Member]"
       }
      }
     },
     "localname": "NonVestedStockUnitsServiceMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_NoncontrollingInterestRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest Repurchased",
        "label": "Noncontrolling Interest Repurchased",
        "terseLabel": "Noncontrolling Interest Repurchased"
       }
      }
     },
     "localname": "NoncontrollingInterestRepurchased",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_NumberOfAdmittingJointVentures": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Admitting Joint Ventures",
        "label": "Number Of Admitting Joint Ventures",
        "terseLabel": "Number Of Admitting Joint Ventures"
       }
      }
     },
     "localname": "NumberOfAdmittingJointVentures",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_NumberOfBeneficiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of beneficiaries who received services",
        "label": "Number of beneficiaries",
        "terseLabel": "Number of beneficiaries"
       }
      }
     },
     "localname": "NumberOfBeneficiaries",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_NumberOfCareCentersAvailableForSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of care centers that were classified as available for sale during the period.",
        "label": "Number Of Care Centers Available For Sale",
        "terseLabel": "Number of care centers available for sale"
       }
      }
     },
     "localname": "NumberOfCareCentersAvailableForSale",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/DiscontinuedOperationsandAssetsHeldForSaleAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_NumberOfCareCentersClosed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating care centers that were closed during the period.",
        "label": "Number Of Care Centers Closed",
        "terseLabel": "Number of care centers closed"
       }
      }
     },
     "localname": "NumberOfCareCentersClosed",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/DiscontinuedOperationsandAssetsHeldForSaleAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_NumberOfCareCentersConsolidated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating care centers that were consolidated with care centers servicing the same market during the period.",
        "label": "Number Of Care Centers Consolidated",
        "terseLabel": "Number of care centers consolidated"
       }
      }
     },
     "localname": "NumberOfCareCentersConsolidated",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/DiscontinuedOperationsandAssetsHeldForSaleAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_NumberOfCareCentersExited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Care Centers that were exited during the period though closure, consolidation or discontinued start-up process.",
        "label": "Number Of Care Centers Exited",
        "terseLabel": "Number of care centers exited"
       }
      }
     },
     "localname": "NumberOfCareCentersExited",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/DiscontinuedOperationsandAssetsHeldForSaleAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_NumberOfCareCentersIncludedInDiscontinuedOperations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of care centers included in discontinued operations during the period.",
        "label": "Number Of Care Centers Included In Discontinued Operations",
        "terseLabel": "Number of care centers included in discontinued operations"
       }
      }
     },
     "localname": "NumberOfCareCentersIncludedInDiscontinuedOperations",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/DiscontinuedOperationsandAssetsHeldForSaleAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_NumberOfCareCentersIncludedInDivestiturePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of care centers that were included in the divestiture plan during the period.",
        "label": "Number of Care Centers Included in Divestiture Plan",
        "terseLabel": "Number of care centers included in divestiture plan"
       }
      }
     },
     "localname": "NumberOfCareCentersIncludedInDivestiturePlan",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/DiscontinuedOperationsandAssetsHeldForSaleAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_NumberOfCareCentersRemovedFromAvailableForSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of care centers that were removed from available for sale classification during the period.",
        "label": "Number Of Care Centers Removed From Available For Sale",
        "terseLabel": "Number of care centers removed from available for sale"
       }
      }
     },
     "localname": "NumberOfCareCentersRemovedFromAvailableForSale",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/DiscontinuedOperationsandAssetsHeldForSaleAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_NumberOfCareCentersSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of care centers sold during the period.",
        "label": "Number Of Care Centers Sold",
        "terseLabel": "Number of care centers sold"
       }
      }
     },
     "localname": "NumberOfCareCentersSold",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/DiscontinuedOperationsandAssetsHeldForSaleAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_NumberOfClaimsSubmittedBySubsidiary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims submitted by subsidiary.",
        "label": "Number Of Claims Submitted By Subsidiary",
        "terseLabel": "Number of claims submitted by subsidiary"
       }
      }
     },
     "localname": "NumberOfClaimsSubmittedBySubsidiary",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of consolidated entities classified as variable interest entities",
        "label": "Number Of Consolidated Entities Classified As Variable Interest Entities",
        "terseLabel": "Number Of Consolidated Entities Classified As Variable Interest Entities"
       }
      }
     },
     "localname": "NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of prospective unopened care centers for which the start-up process was discontinued during the period",
        "label": "Number Of Prospective Unopened Care Centers Start Up Process Discontinued",
        "terseLabel": "Number of care centers start-up process discontinued"
       }
      }
     },
     "localname": "NumberOfProspectiveUnopenedCareCentersStartUpProcessDiscontinued",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/DiscontinuedOperationsandAssetsHeldForSaleAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_Numberofpatients": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of patients",
        "label": "Number of patients",
        "terseLabel": "Number of patients"
       }
      }
     },
     "localname": "Numberofpatients",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_OneHundredSeventyFiveMillionTermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Hundred Seventy Five Million Term Loan Facility [Member]",
        "label": "One Hundred Seventy Five Million Term Loan Facility [Member]",
        "terseLabel": "One Hundred Seventy Five Million Term Loan Facility [Member]"
       }
      }
     },
     "localname": "OneHundredSeventyFiveMillionTermLoanFacilityMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_OperatingCareCenters": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of care centers owned by the entity as of the balance sheet date.",
        "label": "Operating Care Centers",
        "terseLabel": "Number of owned and operated care centers"
       }
      }
     },
     "localname": "OperatingCareCenters",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_OperatingLeaseTermYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease term, years",
        "label": "Operating Lease Term Years",
        "terseLabel": "Operating lease term (years)"
       }
      }
     },
     "localname": "OperatingLeaseTermYears",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_OperatingLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating leases Table Text Block",
        "label": "Operating leases [Table Text Block]",
        "terseLabel": "Schedule of Operating Leases"
       }
      }
     },
     "localname": "OperatingLeasesTableTextBlock",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_OrganizationAndNatureOfOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization And Nature Of Operations [Line Items]",
        "terseLabel": "Organization And Nature Of Operations [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndNatureOfOperationsLineItems",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_OrganizationAndNatureOfOperationsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization And Nature Of Operations [Table]",
        "terseLabel": "Organization And Nature Of Operations [Table]"
       }
      }
     },
     "localname": "OrganizationAndNatureOfOperationsTable",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_OtherIntangibleAssetsAdditions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions to Other Intangible Assets that occurred during the period",
        "label": "Other Intangible Assets Additions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "OtherIntangibleAssetsAdditions",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_OtherLongTermObligationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Long Term Obligations [Member]",
        "label": "Other Long Term Obligations [Member]",
        "terseLabel": "Other Long Term Obligations [Member]"
       }
      }
     },
     "localname": "OtherLongTermObligationsMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_OtherMiscellaneousDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Miscellaneous Deposits",
        "label": "Other Miscellaneous Deposits",
        "terseLabel": "Other miscellaneous deposits"
       }
      }
     },
     "localname": "OtherMiscellaneousDeposits",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ParkersburgWestVirginiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Parkersburg, West Virginia [Member]",
        "label": "Parkersburg, West Virginia [Member]",
        "terseLabel": "Parkersburg, West Virginia [Member]"
       }
      }
     },
     "localname": "ParkersburgWestVirginiaMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_PatientLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued expenses related to Patient liabilities",
        "label": "Patient Liability",
        "terseLabel": "Patient and payor liabilities"
       }
      }
     },
     "localname": "PatientLiability",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_PaymentOfDeferredSocialSecurityTaxUnderCARESAct": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of Deferred Social Security Tax Under CARES Act",
        "label": "Payment of Deferred Social Security Tax Under CARES Act",
        "terseLabel": "Payment of Deferred Social Security Tax Under CARES Act"
       }
      }
     },
     "localname": "PaymentOfDeferredSocialSecurityTaxUnderCARESAct",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_PaymentsRelatedToTaxAsset": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments related to tax asset",
        "label": "Payments related to tax asset",
        "terseLabel": "Payments related to tax asset"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxAsset",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_PayorClassAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payor Class [Axis]",
        "label": "Payor Class [Axis]",
        "terseLabel": "Payor Class [Axis]"
       }
      }
     },
     "localname": "PayorClassAxis",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_PayorClassDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Payor Class [Axis]",
        "label": "Payor Class [Domain]",
        "terseLabel": "Payor Class [Domain]"
       }
      }
     },
     "localname": "PayorClassDomain",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_PayrollTaxEscrow": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payroll tax escrow",
        "label": "Payroll tax escrow",
        "terseLabel": "Payroll tax escrow"
       }
      }
     },
     "localname": "PayrollTaxEscrow",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of managed care contract volume given opportunity to receive additional payments if certain metrics are met",
        "label": "Percentage Managed Care Contract Volume Able To Receive Additional Payments",
        "terseLabel": "Percentage Managed Care Contract Volume Able To Receive Additional Payments"
       }
      }
     },
     "localname": "PercentageManagedCareContractVolumeAbleToReceiveAdditionalPayments",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of adjusted EBITDA that guarantor subsidiaries represent",
        "label": "Percentage Of Earnings Before Interest Taxes Depreciation And Amortization From Subsidiaries",
        "terseLabel": "Percentage of adjusted EBITDA that guarantor subsidiaries represent"
       }
      }
     },
     "localname": "PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PercentageOfPatientReceivablesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of patient receivables outstanding.",
        "label": "Percentage Of Patient Receivables Outstanding",
        "terseLabel": "Percentage of patient receivables outstanding"
       }
      }
     },
     "localname": "PercentageOfPatientReceivablesOutstanding",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of consolidated net revenues and adjusted EBITDA that guarantor wholly-owned subsidiaries represent",
        "label": "Percentage Of Revenue And Of Earnings Before Interest Taxes Depreciation And Amortization From Wholly Owned Subsidiaries",
        "terseLabel": "Percentage of consolidated revenue and adjusted EBITDA that guarantor wholly-owned subsidiaries represent"
       }
      }
     },
     "localname": "PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PercentageOfTotalReimbursementOfOutlierPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage at which total reimbursement is capped if cost of care is unusually costly.",
        "label": "Percentage Of Total Reimbursement Of Outlier Payment",
        "terseLabel": "Percentage of total reimbursement of outlier payment"
       }
      }
     },
     "localname": "PercentageOfTotalReimbursementOfOutlierPayment",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PercentageofSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Shares Outstanding",
        "label": "Percentage of Shares Outstanding",
        "terseLabel": "Percentage of Shares Outstanding"
       }
      }
     },
     "localname": "PercentageofSharesOutstanding",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_Percentageofownershipinsubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of ownership in subsidiaries",
        "label": "Percentageofownershipinsubsidiaries",
        "terseLabel": "Percentage of ownership in subsidiaries"
       }
      }
     },
     "localname": "Percentageofownershipinsubsidiaries",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of total combined voting power of the Company and our subsidiaries",
        "label": "Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries",
        "terseLabel": "Percentage of total combined voting power of the Company and subsidiaries"
       }
      }
     },
     "localname": "Percentageoftotalcombinedvotingpowerofthecompanyandoursubsidiaries",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_Performancebasedawardtargetshareamount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock units authorized for achievement of targeted performance",
        "label": "Performance Based Award Target Share Amount",
        "terseLabel": "Performance-based award, target number of units to be received (shares)"
       }
      }
     },
     "localname": "Performancebasedawardtargetshareamount",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "amed_PeriodOfCareAsEpisodicBasedRevenueDuration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days in a home health period of care using PDGM",
        "label": "Period Of Care As Episodic Based Revenue Duration",
        "terseLabel": "Period Of Care As Episodic Based Revenue Duration"
       }
      }
     },
     "localname": "PeriodOfCareAsEpisodicBasedRevenueDuration",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_PersonalCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Personal Care [Member]",
        "label": "Personal Care [Member]",
        "terseLabel": "Personal Care [Member]"
       }
      }
     },
     "localname": "PersonalCareMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/AssetsHeldForSaleAssetsandLiabilitiesDetail",
      "http://www.amedisys.com/role/DiscontinuedOperationsandAssetsHeldForSaleAdditionalInformationDetail",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_PortionOfPatientAccountsReceivableDerivedFromMedicare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage of the entity's net patient accounts receivable that is derived from Medicare.",
        "label": "Portion Of Patient Accounts Receivable Derived From Medicare",
        "terseLabel": "Portion of accounts receivable derived from Medicare"
       }
      }
     },
     "localname": "PortionOfPatientAccountsReceivableDerivedFromMedicare",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PotentialClosingPaymentAdjustmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Closing Payment Adjustment",
        "label": "Potential Closing Payment Adjustment [Member]",
        "terseLabel": "Potential Closing Payment Adjustment"
       }
      }
     },
     "localname": "PotentialClosingPaymentAdjustmentMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ProceedsFromBorrowingsUnderTermLoan": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from borrowings under the term loan.",
        "label": "Proceeds From Borrowings Under Term Loan",
        "terseLabel": "Proceeds from borrowings under term loan"
       }
      }
     },
     "localname": "ProceedsFromBorrowingsUnderTermLoan",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ProceedsReceivedFromLoanPartyOfSubsidiary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds Received From Loan Party Of Subsidiary",
        "label": "Proceeds Received From Loan Party Of Subsidiary",
        "terseLabel": "Proceeds Received From Loan Party Of Subsidiary"
       }
      }
     },
     "localname": "ProceedsReceivedFromLoanPartyOfSubsidiary",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ProfessionalLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails": {
       "order": 3.0,
       "parentTag": "amed_EstimatedInsuranceTotal",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Professional liability insurance, estimated liability",
        "label": "Professional Liability",
        "terseLabel": "Professional liability"
       }
      }
     },
     "localname": "ProfessionalLiability",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ProfessionalLiabilityInsuranceRetentionLimit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum potential amount of future payments the entity could be required to make related to a specific Professional Liability Claim.",
        "label": "Professional Liability Insurance Retention Limit",
        "terseLabel": "Professional liability insurance retention limit"
       }
      }
     },
     "localname": "ProfessionalLiabilityInsuranceRetentionLimit",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_PromissoryNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory Notes [Member]",
        "label": "Promissory Notes [Member]",
        "terseLabel": "Promissory Notes [Member]"
       }
      }
     },
     "localname": "PromissoryNotesMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ProviderReliefFundAdvance": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payable related to funds received from the government related to COVID-19",
        "label": "Provider Relief Fund Advance",
        "terseLabel": "Provider Relief Fund Advance"
       }
      }
     },
     "localname": "ProviderReliefFundAdvance",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ProvisionForLiabilityOnRegulatoryAudit": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provision For Liability On Regulatory Audit",
        "label": "Provision For Liability On Regulatory Audit",
        "terseLabel": "Florida ZPIC audit, gross liability"
       }
      }
     },
     "localname": "ProvisionForLiabilityOnRegulatoryAudit",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ProvisionforIncomeTaxesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provision for Income Taxes Table",
        "label": "Provision for Income Taxes [Table Text Block]",
        "terseLabel": "Schedule of Income Tax Provision"
       }
      }
     },
     "localname": "ProvisionforIncomeTaxesTableTextBlock",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_RandolphCountyNorthCarolinaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Randolph County, North Carolina",
        "label": "Randolph County, North Carolina [Member]",
        "terseLabel": "Randolph County, North Carolina"
       }
      }
     },
     "localname": "RandolphCountyNorthCarolinaMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage of estimated payment that is requested at the start of care for an initial period of care.",
        "label": "Rate Of Request For Anticipated Payment Submitted For Initial Period Of Care",
        "terseLabel": "Rate of request for anticipated payment submitted for the initial period of care"
       }
      }
     },
     "localname": "RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage of estimated payment that is requested at the start of care for any subsequent episodes of care.",
        "label": "Rate Of Request For Anticipated Payment Submitted For Subsequent Episodes Of Care",
        "terseLabel": "Rate of request for anticipated payment submitted for subsequent episodes of care"
       }
      }
     },
     "localname": "RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_ReclassToAmortizableIntangible": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification from unamortizable intangible asset to amortizable intangible asset",
        "label": "Reclass to amortizable intangible",
        "terseLabel": "Reclass to amortizable intangible"
       }
      }
     },
     "localname": "ReclassToAmortizableIntangible",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_RecognizedTaxBenefitThatImpactsEffectiveTaxRate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recognized Tax Benefit that Impacts Effective Tax Rate",
        "label": "Recognized Tax Benefit that Impacts Effective Tax Rate",
        "terseLabel": "Recognized Tax Benefit that Impacts Effective Tax Rate"
       }
      }
     },
     "localname": "RecognizedTaxBenefitThatImpactsEffectiveTaxRate",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_RecoveryAmountOfOverpaymentMadeToSubsidiary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recovery amount of the overpayment made to the subsidiary.",
        "label": "Recovery Amount Of Overpayment Made To Subsidiary",
        "terseLabel": "Recovery amount of the overpayment made to the subsidiary"
       }
      }
     },
     "localname": "RecoveryAmountOfOverpaymentMadeToSubsidiary",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recovery amount of overpayment made to subsidiary including interest",
        "label": "Recovery Amount of Overpayment Made To Subsidiary Including Interest",
        "terseLabel": "Recovery amount of overpayment made to subsidiary including interest"
       }
      }
     },
     "localname": "RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recovery amount of over payment made to subsidiary including interest withheld",
        "label": "Recovery Amount Of Over Payment Made To Subsidiary Including Interest Withheld",
        "terseLabel": "Recovery amount of over payment made to subsidiary including interest withheld"
       }
      }
     },
     "localname": "Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ReductionToNetServiceRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction To Net Service Revenue",
        "label": "Reduction To Net Service Revenue",
        "terseLabel": "Reduction To Net Service Revenue"
       }
      }
     },
     "localname": "ReductionToNetServiceRevenue",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue by payor class as a percentage of total net service revenue",
        "label": "Revenue by payor class as a percentage of total net service revenue",
        "terseLabel": "Revenue by payor class as a percentage of total net service revenue"
       }
      }
     },
     "localname": "Revenuebypayorclassasapercentageoftotalnetservicerevenue",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_ReversalOfLossContingencyAccrual": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reversal of Loss Contingency Accrual",
        "label": "Reversal of Loss Contingency Accrual",
        "terseLabel": "Reversal of Loss Contingency Accrual"
       }
      }
     },
     "localname": "ReversalOfLossContingencyAccrual",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_RevolvingCreditFacilityTotal": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revolving Credit Facility Total",
        "terseLabel": "Amount of revolving credit facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityTotal",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_SafeguardZoneProgramIntegrityContractorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Safeguard Zone Program Integrity Contractor [Member]",
        "label": "Safeguard Zone Program Integrity Contractor [Member]",
        "terseLabel": "Safeguard Zone Program Integrity Contractor [Member]"
       }
      }
     },
     "localname": "SafeguardZoneProgramIntegrityContractorMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the Asana business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.",
        "label": "Schedule Of Business Acquisitions Asana Hospice [Table Text Block]",
        "terseLabel": "Schedule Of Business Acquisitions, Asana Hospice"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsAsanaHospiceTableTextBlock",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of AseraCare business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.",
        "label": "Schedule Of Business Acquisitions AseraCare Hospice [Table Text Block]",
        "terseLabel": "Schedule Of Business Acquisitions, AseraCare Hospice"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_ScheduleOfBusinessAcquisitionsContessaHealthTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Business Acquisitions, Contessa Health",
        "label": "Schedule of Business Acquisitions, Contessa Health [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions, Contessa Health"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsContessaHealthTableTextBlock",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Business Acquisitions, Evolution Health",
        "label": "Schedule of Business Acquisitions, Evolution Health [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions, Evolution Health"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsEvolutionHealthTableTextBlock",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Cares Act Provider Relief Funds",
        "label": "Schedule Of Cares Act Provider Relief Funds [Table Text Block]",
        "terseLabel": "Schedule Of Cares Act Provider Relief Funds"
       }
      }
     },
     "localname": "ScheduleOfCaresActProviderReliefFundsTableTextBlock",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Cash Cash Equivalents and Restricted Cash Table Text Block",
        "label": "Schedule of Cash Cash Equivalents and Restricted Cash [Table Text Block]",
        "terseLabel": "Schedule of Cash Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_SecondAmendedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Amended Credit Agreement",
        "label": "Second Amended Credit Agreement [Member]",
        "terseLabel": "Second Amended Credit Agreement"
       }
      }
     },
     "localname": "SecondAmendedCreditAgreementMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ShareBasedAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Awards",
        "label": "Share-Based Awards [Member]",
        "terseLabel": "Share-Based Awards [Member]"
       }
      }
     },
     "localname": "ShareBasedAwardsMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ShareBasedAwardsToMoreThanTenPercentOwnerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based awards to any owner of 10% or more of our total combined voting power of us and our subsidiaries",
        "label": "Share Based Awards To More Than Ten Percent Owner [Member]",
        "terseLabel": "Share Based Awards to More Than Ten Percent Owner [Member]"
       }
      }
     },
     "localname": "ShareBasedAwardsToMoreThanTenPercentOwnerMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The calculated fair value of a stock-based compensation award",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value",
        "terseLabel": "Weighted Average Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValue",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "amed_ShareRepurchaseLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Share Repurchase [Table]",
        "label": "Share Repurchase [Line Items]",
        "terseLabel": "Share Repurchase [Line Items]"
       }
      }
     },
     "localname": "ShareRepurchaseLineItems",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_ShareRepurchaseTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Repurchase [Table]",
        "label": "Share Repurchase [Table]",
        "terseLabel": "Share Repurchase [Table]"
       }
      }
     },
     "localname": "ShareRepurchaseTable",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_SharedBasedPaymentArrangementNonVestedOptionActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for non-vested stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, vestings, forfeitures, and weighted-average grant date fair value.",
        "label": "Shared-based Payment Arrangement, Non-vested Option, Activity [Table Text Block]",
        "terseLabel": "Shared-based Payment Arrangement, Non-vested Option, Activity"
       }
      }
     },
     "localname": "SharedBasedPaymentArrangementNonVestedOptionActivityTableTextBlock",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_SocialSecurityTaxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Social Security Tax",
        "label": "Social Security Tax [Member]",
        "terseLabel": "Social Security Tax [Member]"
       }
      }
     },
     "localname": "SocialSecurityTaxMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_StateTaxCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "State Tax Credit [Member]",
        "label": "State Tax Credit [Member]",
        "terseLabel": "State Tax Credit [Member]"
       }
      }
     },
     "localname": "StateTaxCreditMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period to employees as employer's matching contribution to the company's 401(K) plan",
        "label": "Stock Issued During Period Shares Four Zero One K Employer Match",
        "terseLabel": "Issuance of stock - 401 (k) plan (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued during the period to employees as employer's matching contribution to the company's 401(K) plan",
        "label": "Stock Issued During Period Value Four Zero One K Employer Match",
        "terseLabel": "Issuance of stock - 401 (k) plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental CashFlow Information and NonCash Activity for Leases Table Text Block",
        "label": "Supplemental CashFlow Information and NonCash Activity for Leases [Table Text Block]",
        "terseLabel": "Schedule of Supplemental CashFlow Information and NonCash Activity for Leases"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAndNonCashActivityForLeasesTableTextBlock",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_SurrenderedShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of common stock surrendered by certain employees to satisfy obligations in connection with the vesting of stock. Shares held in Treasury Stock at cost.",
        "label": "Surrendered Shares",
        "terseLabel": "Surrendered shares"
       }
      }
     },
     "localname": "SurrenderedShares",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_SurrenderedSharesInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surrendered Shares In Shares",
        "label": "Surrendered Shares In Shares",
        "terseLabel": "Surrendered Shares In Shares"
       }
      }
     },
     "localname": "SurrenderedSharesInShares",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "amed_SwingLineFacility": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swing Line Facility included within Revolving Credit Facility",
        "label": "Swing Line Facility",
        "terseLabel": "Swing Line Facility"
       }
      }
     },
     "localname": "SwingLineFacility",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_SwingLineLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swing Line Loan [Member]",
        "label": "Swing Line Loan [Member]",
        "terseLabel": "Swing Line Loan [Member]"
       }
      }
     },
     "localname": "SwingLineLoanMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_TaxCreditCarryforwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Credit Carryforward [Member]",
        "label": "Tax Credit Carryforward [Member]",
        "terseLabel": "Tax Credit Carryforward [Member]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_TaxExpenseRecordedToAdditionalPaidInCapital": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESIncomeTaxExpenseAllocationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Expense Recorded to Additional Paid-in-Capital",
        "label": "Tax Expense Recorded to Additional Paid-in-Capital",
        "terseLabel": "Tax expense recorded to additional paid-in-capital"
       }
      }
     },
     "localname": "TaxExpenseRecordedToAdditionalPaidInCapital",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESIncomeTaxExpenseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_TelehealthKitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Telehealth Kits",
        "label": "Telehealth Kits [Member]",
        "terseLabel": "Telehealth Kits"
       }
      }
     },
     "localname": "TelehealthKitsMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LEASESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_TotalCARESActProviderReliefFundsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total CARES Act Provider Relief Funds Received",
        "label": "Total CARES Act Provider Relief Funds Received",
        "terseLabel": "Total CARES Act Provider Relief Funds Received"
       }
      }
     },
     "localname": "TotalCARESActProviderReliefFundsReceived",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_TotalLegalSettlementPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Legal Settlement Payment",
        "label": "Total Legal Settlement Payment",
        "terseLabel": "Total Legal Settlement Payment"
       }
      }
     },
     "localname": "TotalLegalSettlementPayment",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_TotalLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio of debt to earnings before interest, taxes, depreciation and amortization.",
        "label": "Total Leverage Ratio",
        "terseLabel": "Consolidated leverage ratio"
       }
      }
     },
     "localname": "TotalLeverageRatio",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_TypeOfEquityMethodInvestmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of Equity Method Investment",
        "label": "Type of Equity Method Investment [Axis]",
        "terseLabel": "Type of Equity Method Investment [Axis]"
       }
      }
     },
     "localname": "TypeOfEquityMethodInvestmentAxis",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_TypeOfEquityMethodInvestmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of Equity Method Investment [Domain]",
        "label": "Type of Equity Method Investment [Domain]",
        "terseLabel": "Type of Equity Method Investment [Domain]"
       }
      }
     },
     "localname": "TypeOfEquityMethodInvestmentDomain",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_TypeOfIncomeTaxDeferralAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of Income Tax Deferral",
        "label": "Type of Income Tax Deferral [Axis]",
        "terseLabel": "Type of Income Tax Deferral [Axis]"
       }
      }
     },
     "localname": "TypeOfIncomeTaxDeferralAxis",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_TypeOfIncomeTaxDeferralDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of Income Tax Deferral",
        "label": "Type of Income Tax Deferral [Domain]",
        "terseLabel": "Type of Income Tax Deferral [Domain]"
       }
      }
     },
     "localname": "TypeOfIncomeTaxDeferralDomain",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_UnamortizableAcquiredNamesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unamortizable acquired names",
        "label": "Unamortizable acquired names [Member]",
        "terseLabel": "Unamortizable acquired names [Member]"
       }
      }
     },
     "localname": "UnamortizableAcquiredNamesMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_UnamortizedDebtIssuanceCostAmortizationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected amortization period of debt issuance cost",
        "label": "Unamortized Debt Issuance Cost Amortization Period",
        "terseLabel": "Unamortized debt issuance costs, weighted average amortization period, years"
       }
      }
     },
     "localname": "UnamortizedDebtIssuanceCostAmortizationPeriod",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_UncertainTaxBenefitsInLongTermObligations": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Uncertain Tax Benefits In Long Term Obligations",
        "label": "Uncertain Tax Benefits In Long Term Obligations",
        "terseLabel": "Reserve for uncertain tax positions"
       }
      }
     },
     "localname": "UncertainTaxBenefitsInLongTermObligations",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_UnfavorableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unfavorable [Member]",
        "terseLabel": "Unfavorable [Member]"
       }
      }
     },
     "localname": "UnfavorableMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_UnrecognizedTaxBenefitsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits [Axis]",
        "label": "Unrecognized Tax Benefits [Axis]",
        "terseLabel": "Unrecognized Tax Benefits [Axis]"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsAxis",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits Decreases Resulting From Change In Statutory Tax Rate",
        "label": "Unrecognized Tax Benefits Decreases Resulting From Change In Statutory Tax Rate",
        "terseLabel": "Reduction in uncertain tax positions from change in enacted tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromChangeInStatutoryTaxRate",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_UnrecognizedTaxBenefitsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits [Domain]",
        "label": "Unrecognized Tax Benefits [Domain]",
        "terseLabel": "Unrecognized Tax Benefits [Domain]"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDomain",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_UsDepartmentOfJusticeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US Department of Justice",
        "label": "US Department of Justice [Member]",
        "terseLabel": "US Department of Justice [Member]"
       }
      }
     },
     "localname": "UsDepartmentOfJusticeMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_VariousAcquisitionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Various Acquisitions",
        "label": "Various Acquisitions [Member]",
        "terseLabel": "Various Acquisitions [Member]"
       }
      }
     },
     "localname": "VariousAcquisitionsMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_VisitingNurseAssociationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Visiting Nurse Association",
        "label": "Visiting Nurse Association [Member]",
        "terseLabel": "Visiting Nurse Association"
       }
      }
     },
     "localname": "VisitingNurseAssociationMember",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term and discount rate Table Text Block",
        "label": "Weighted average remaining lease term and discount rate [Table Text Block]",
        "terseLabel": "Schedule of Weighted Average Remaining Lease Term and Discount Rate"
       }
      }
     },
     "localname": "WeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_WokersCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails": {
       "order": 2.0,
       "parentTag": "amed_EstimatedInsuranceTotal",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Workers' Compensation insurance, estimated liability",
        "label": "Wokers Compensation",
        "terseLabel": "Workers\u2019 compensation"
       }
      }
     },
     "localname": "WokersCompensation",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESInsuranceProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_WorkersCompensationDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Workers Compensation Deposits",
        "label": "Workers Compensation Deposits",
        "terseLabel": "Workers\u2019 compensation deposits"
       }
      }
     },
     "localname": "WorkersCompensationDeposits",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_WorkersCompensationInsuranceRetentionLimit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum potential amount of future payments the entity could be required to make related to a specific Workers' Compensation Insurance Claim.",
        "label": "Workers Compensation Insurance Retention Limit",
        "terseLabel": "Workers' compensation insurance retention limit"
       }
      }
     },
     "localname": "WorkersCompensationInsuranceRetentionLimit",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_WriteOffOfOtherComprehensiveIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write Off Of Other Comprehensive Income",
        "label": "Write Off Of Other Comprehensive Income",
        "negatedTerseLabel": "Write-off of other comprehensive income"
       }
      }
     },
     "localname": "WriteOffOfOtherComprehensiveIncome",
     "nsuri": "http://www.amedisys.com/20221231",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r784",
      "r785",
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "localname": "AuditorLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r784",
      "r785",
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r784",
      "r785",
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r784",
      "r785",
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r787"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r782"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r782"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r782"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r788"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r782"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r782"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r782"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r782"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r784",
      "r785",
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r783"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.amedisys.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r318",
      "r593",
      "r594",
      "r597",
      "r598",
      "r672",
      "r745",
      "r822",
      "r825",
      "r826"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r318",
      "r593",
      "r594",
      "r597",
      "r598",
      "r672",
      "r745",
      "r822",
      "r825",
      "r826"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r318",
      "r357",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r375",
      "r379",
      "r433",
      "r434",
      "r435",
      "r436",
      "r438",
      "r439",
      "r441",
      "r443",
      "r444",
      "r823",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r318",
      "r357",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r375",
      "r379",
      "r433",
      "r434",
      "r435",
      "r436",
      "r438",
      "r439",
      "r441",
      "r443",
      "r444",
      "r823",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r429",
      "r430",
      "r431",
      "r432",
      "r494",
      "r680",
      "r701",
      "r746",
      "r747",
      "r762",
      "r770",
      "r780",
      "r827",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails",
      "http://www.amedisys.com/role/LEASESDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r429",
      "r430",
      "r431",
      "r432",
      "r494",
      "r680",
      "r701",
      "r746",
      "r747",
      "r762",
      "r770",
      "r780",
      "r827",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails",
      "http://www.amedisys.com/role/LEASESDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r381",
      "r681",
      "r763",
      "r778",
      "r819",
      "r820",
      "r829",
      "r866"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r381",
      "r681",
      "r763",
      "r778",
      "r819",
      "r820",
      "r829",
      "r866"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r429",
      "r430",
      "r431",
      "r432",
      "r477",
      "r494",
      "r526",
      "r527",
      "r528",
      "r679",
      "r680",
      "r701",
      "r746",
      "r747",
      "r762",
      "r770",
      "r780",
      "r816",
      "r827",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails",
      "http://www.amedisys.com/role/LEASESDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r429",
      "r430",
      "r431",
      "r432",
      "r477",
      "r494",
      "r526",
      "r527",
      "r528",
      "r679",
      "r680",
      "r701",
      "r746",
      "r747",
      "r762",
      "r770",
      "r780",
      "r816",
      "r827",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails",
      "http://www.amedisys.com/role/LEASESDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r382",
      "r383",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r764",
      "r779",
      "r829"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r382",
      "r383",
      "r730",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r764",
      "r779",
      "r829"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_AZ": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ARIZONA",
        "terseLabel": "Arizona [Member]"
       }
      }
     },
     "localname": "AZ",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_CT": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONNECTICUT",
        "terseLabel": "Connecticut [Member]"
       }
      }
     },
     "localname": "CT",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_FL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FLORIDA",
        "terseLabel": "Florida [Member]"
       }
      }
     },
     "localname": "FL",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_IL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ILLINOIS",
        "terseLabel": "Illinois [Member]"
       }
      }
     },
     "localname": "IL",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_KY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "KENTUCKY",
        "terseLabel": "KENTUCKY"
       }
      }
     },
     "localname": "KY",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_MA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MASSACHUSETTS",
        "terseLabel": "Massachusetts [Member]"
       }
      }
     },
     "localname": "MA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NC": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NORTH CAROLINA",
        "terseLabel": "NORTH CAROLINA"
       }
      }
     },
     "localname": "NC",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW YORK",
        "terseLabel": "NEW YORK"
       }
      }
     },
     "localname": "NY",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_SC": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SOUTH CAROLINA",
        "terseLabel": "South Carolina [Member]"
       }
      }
     },
     "localname": "SC",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_TN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TENNESSEE",
        "terseLabel": "Tennessee [Member]"
       }
      }
     },
     "localname": "TN",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_WA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WASHINGTON",
        "terseLabel": "WASHINGTON"
       }
      }
     },
     "localname": "WA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "ASU 2016-02 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r36",
      "r777"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r387",
      "r388"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Patient accounts receivable",
        "verboseLabel": "Patient accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r25",
      "r234",
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Accrued Income Taxes, Current"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedInsuranceCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Insurance, Current",
        "terseLabel": "Health insurance"
       }
      }
     },
     "localname": "AccruedInsuranceCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accrued expenses:"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r131",
      "r281"
     ],
     "calculation": {
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation",
        "terseLabel": "Property and equipment, accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r49",
      "r50",
      "r200",
      "r665",
      "r704",
      "r705",
      "r794",
      "r795",
      "r796",
      "r805",
      "r806",
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted-average amortization period"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Acquired Indefinite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "AcquiredIndefiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r536",
      "r537",
      "r538",
      "r805",
      "r806",
      "r807",
      "r844"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r323",
      "r324",
      "r325",
      "r326",
      "r335",
      "r392",
      "r393",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r536",
      "r537",
      "r538",
      "r568",
      "r569",
      "r570",
      "r571",
      "r588",
      "r589",
      "r590",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r631",
      "r632",
      "r637",
      "r638",
      "r639",
      "r640",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r683",
      "r684",
      "r685",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r163",
      "r164",
      "r497"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Non-cash compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising Costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r542"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r530"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r401"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss, Writeoff"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r57",
      "r468",
      "r634",
      "r799"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of deferred debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r468",
      "r634",
      "r760",
      "r761",
      "r799"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of deferred debt issuance costs/debt discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r85",
      "r113",
      "r120"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "negatedLabel": "Amortization"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r85",
      "r127"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment charge"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r232",
      "r248",
      "r285",
      "r315",
      "r365",
      "r371",
      "r377",
      "r394",
      "r433",
      "r434",
      "r436",
      "r437",
      "r438",
      "r440",
      "r442",
      "r444",
      "r445",
      "r593",
      "r597",
      "r614",
      "r777",
      "r823",
      "r824",
      "r856"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Total assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r277",
      "r290",
      "r315",
      "r394",
      "r433",
      "r434",
      "r436",
      "r437",
      "r438",
      "r440",
      "r442",
      "r444",
      "r445",
      "r593",
      "r597",
      "r614",
      "r777",
      "r823",
      "r824",
      "r856"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "terseLabel": "Total current assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsHeldUnderCapitalLeasesMember": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived property, plant or equipment assets held by a lessee through a capital lease arrangement.",
        "label": "Assets Held under Capital Leases [Member]",
        "terseLabel": "Finance Leases [Member]"
       }
      }
     },
     "localname": "AssetsHeldUnderCapitalLeasesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESFinanceLeasesDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r128",
      "r133",
      "r275",
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/AssetsHeldForSaleAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r501",
      "r502",
      "r503",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails",
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails",
      "http://www.amedisys.com/role/LEASESFinanceLeasesDetails",
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r210",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails",
      "http://www.amedisys.com/role/LEASESFinanceLeasesDetails",
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate [Member]",
        "verboseLabel": "Base Rate [Member]"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Building [Member]"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r586",
      "r768",
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r177",
      "r178",
      "r586",
      "r768",
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Schedule of Business Acquisitions, Purchase Price Allocation [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": {
     "auth_ref": [
      "r842",
      "r843"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic",
        "terseLabel": "Business Acquisition, Pro Forma Earnings Per Share, Basic"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": {
     "auth_ref": [
      "r842",
      "r843"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Diluted",
        "terseLabel": "Business Acquisition, Pro Forma Earnings Per Share, Diluted"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "auth_ref": [
      "r189"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "terseLabel": "Goodwill deductible for income tax purposes"
       }
      }
     },
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r584",
      "r585"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Business Acquisition, Pro Forma Net Income (Loss)"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r584",
      "r585"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Business Acquisition, Pro Forma Revenue"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": {
     "auth_ref": [
      "r181"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.",
        "label": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value",
        "negatedTerseLabel": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r185",
      "r186",
      "r188"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Acquisition, total purchase price"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r184",
      "r187"
     ],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Accrued contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r184",
      "r187"
     ],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Accrued contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r190",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "ACQUISITIONS"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationIntegrationRelatedCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.",
        "label": "Business Combination, Integration Related Costs",
        "terseLabel": "Business Combination, Integration Related Costs"
       }
      }
     },
     "localname": "BusinessCombinationIntegrationRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r180"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "auth_ref": [
      "r180"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r180"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r180"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": {
     "auth_ref": [
      "r180"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt",
        "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r180"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r180"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Acquisition, other intangibles recorded"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r180"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r179",
      "r180"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "auth_ref": [
      "r180"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r180"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r179",
      "r180"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest": {
     "auth_ref": [
      "r180"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the assets, including goodwill, in excess of (less than) the aggregate liabilities assumed, less the noncontrolling interest in the acquiree.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r180"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalLeaseObligationsMember": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A borrowing recorded for a lease meeting the criteria for capitalization. A lease is defined as an agreement conveying the right to use property, plant, or equipment (land or depreciable assets) usually for a stated period of time.",
        "label": "Capital Lease Obligations [Member]",
        "terseLabel": "Finance Leases [Member]"
       }
      }
     },
     "localname": "CapitalLeaseObligationsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r67"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired from Acquisition",
        "terseLabel": "Cash Acquired from Acquisition"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r87",
      "r279",
      "r748"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r88",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r81",
      "r87",
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r81",
      "r220"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r45",
      "r240",
      "r256"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r137",
      "r426",
      "r427",
      "r732",
      "r821"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r805",
      "r806",
      "r844"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized (shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r29",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, outstanding (shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common stock, $0.001 par value, 60,000,000 shares authorized; 37,891,186 and 37,674,868 shares issued; and 32,518,278 and 32,509,969 shares outstanding"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r51",
      "r294",
      "r296",
      "r305",
      "r691",
      "r698"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income attributable to Amedisys, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r194",
      "r195",
      "r208",
      "r294",
      "r296",
      "r304",
      "r690",
      "r697"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Comprehensive loss (income) attributable to non-controlling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r193",
      "r208",
      "r294",
      "r296",
      "r303",
      "r689",
      "r696"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r97",
      "r98",
      "r217",
      "r218",
      "r385",
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r97",
      "r98",
      "r217",
      "r218",
      "r385",
      "r714",
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r97",
      "r98",
      "r217",
      "r218",
      "r385",
      "r731",
      "r867"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r97",
      "r98",
      "r217",
      "r218",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percent of net services revenue provided by Medicare"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r97",
      "r98",
      "r217",
      "r218",
      "r385",
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r197",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateMember": {
     "auth_ref": [
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items.",
        "label": "Corporate Segment [Member]",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "CorporateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r105",
      "r370",
      "r371",
      "r372",
      "r373",
      "r379",
      "r811"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Other Segment [Member]"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r60",
      "r681"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of service, excluding depreciation and amortization"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r803",
      "r837",
      "r839"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r174",
      "r565",
      "r575",
      "r803"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Current income tax expense (benefit)"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current income tax expense/(benefit):"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r803",
      "r837",
      "r839"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State and local"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of debt and lease obligation, classified as current.",
        "label": "Debt, Current",
        "terseLabel": "Current portion of long-term obligations"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r142",
      "r314",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r462",
      "r469",
      "r470",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "LONG-TERM OBLIGATIONS"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r233",
      "r236",
      "r247",
      "r318",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r452",
      "r458",
      "r459",
      "r460",
      "r461",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r635",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r801"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Margin on Loans",
        "verboseLabel": "Basis spread on variable rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r26",
      "r236",
      "r247",
      "r473"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Principal amount",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of reference rate used for variable rate of debt instrument.",
        "label": "Debt Instrument, Description of Variable Rate Basis",
        "terseLabel": "Description of variable rate basis"
       }
      }
     },
     "localname": "DebtInstrumentDescriptionOfVariableRateBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r222",
      "r224",
      "r446",
      "r635",
      "r758",
      "r759"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt Instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": {
     "auth_ref": [
      "r43",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual).",
        "label": "Debt Instrument, Frequency of Periodic Payment",
        "terseLabel": "Frequency of periodic payment"
       }
      }
     },
     "localname": "DebtInstrumentFrequencyOfPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r42",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Interest rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r291",
      "r757",
      "r845"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r43",
      "r318",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r452",
      "r458",
      "r459",
      "r460",
      "r461",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r635",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r801"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r43",
      "r144",
      "r145",
      "r146",
      "r147",
      "r221",
      "r222",
      "r224",
      "r246",
      "r318",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r452",
      "r458",
      "r459",
      "r460",
      "r461",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r471",
      "r635",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r801"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross": {
     "auth_ref": [
      "r225"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Line of Credit Arrangements, Gross",
        "terseLabel": "Deferred debt issuance cost"
       }
      }
     },
     "localname": "DebtIssuanceCostsLineOfCreditArrangementsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r803",
      "r838",
      "r839"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r223",
      "r828"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedTerseLabel": "Deferred debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r546",
      "r547"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r85",
      "r174",
      "r566",
      "r574",
      "r575",
      "r803"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes",
        "totalLabel": "Deferred income tax expense (benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails",
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred income tax expense/(benefit):"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r546",
      "r547"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "negatedTotalLabel": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r803",
      "r838",
      "r839"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State and local"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r560"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r835"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r173",
      "r836"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOtherLossCarryforwards": {
     "auth_ref": [
      "r173",
      "r836"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible loss carryforwards, classified as other.",
        "label": "Deferred Tax Assets, Other Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOtherLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r171",
      "r173",
      "r836"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther": {
     "auth_ref": [
      "r173",
      "r836"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from compensation and benefits, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other",
        "terseLabel": "Accrued payroll\u00a0&amp; employee benefits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r173",
      "r836"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
     "auth_ref": [
      "r173",
      "r836"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.",
        "label": "Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r561"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Less: valuation allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails",
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r166",
      "r835"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Gross deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates": {
     "auth_ref": [
      "r173",
      "r836"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from investments in unconsolidated subsidiaries and investments in other affiliates which are not controlled nor consolidated.",
        "label": "Deferred Tax Liabilities, Investment in Noncontrolled Affiliates",
        "negatedTerseLabel": "Investment in partnerships"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r173",
      "r836"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedTerseLabel": "Other liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r173",
      "r836"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedTerseLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome": {
     "auth_ref": [
      "r173",
      "r836"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from tax deferred revenue or income classified as other.",
        "label": "Deferred Tax Liabilities, Tax Deferred Income",
        "negatedTerseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesTaxDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r493"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "401(k) expense recognized"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r85",
      "r129"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r85",
      "r360"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r500",
      "r531",
      "r532",
      "r534",
      "r540",
      "r771"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "CAPITAL SOCK AND SHARE-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operation, Additional Disclosures [Abstract]",
        "terseLabel": "Discontinued Operation, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "auth_ref": [
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r15",
      "r55",
      "r259"
     ],
     "calculation": {
      "http://www.amedisys.com/role/AssetsHeldForSaleAssetsandLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "terseLabel": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DiscontinuedOperationsandAssetsHeldForSaleAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": {
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r8",
      "r15",
      "r18",
      "r548",
      "r573",
      "r579"
     ],
     "calculation": {
      "http://www.amedisys.com/role/AssetsHeldForSaleAssetsandLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Tax Effect of Discontinued Operation",
        "terseLabel": "Discontinued Operation, Tax Effect of Discontinued Operation"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DiscontinuedOperationsandAssetsHeldForSaleAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationsHeldforsaleMember": {
     "auth_ref": [
      "r2",
      "r3",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.",
        "label": "Discontinued Operations, Held-for-sale [Member]",
        "terseLabel": "Assets Held-for-sale [Member]"
       }
      }
     },
     "localname": "DiscontinuedOperationsHeldforsaleMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DiscontinuedOperationsandAssetsHeldForSaleAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r133"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net",
        "terseLabel": "Patient accounts receivable"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/AssetsHeldForSaleAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r128",
      "r133"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/AssetsHeldForSaleAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r126",
      "r133",
      "r275",
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent",
        "terseLabel": "Total assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/AssetsHeldForSaleAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "terseLabel": "Disposal Group, Including Discontinued Operation, Consideration"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DiscontinuedOperationsandAssetsHeldForSaleAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r126",
      "r133"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Goodwill, Noncurrent",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/AssetsHeldForSaleAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r126",
      "r133"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/AssetsHeldForSaleAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r128",
      "r133"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/AssetsHeldForSaleAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r126",
      "r133"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/AssetsHeldForSaleAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r22",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "ASSETS HELD FOR SALE"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ASSETSHELDFORSALE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueFromJointVenturesCurrent": {
     "auth_ref": [
      "r226",
      "r228"
     ],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due from an entity in which the reporting entity shares joint control with another party or group, due within 1 year (or 1 business cycle).",
        "label": "Due from Joint Ventures, Current",
        "terseLabel": "Due from joint ventures"
       }
      }
     },
     "localname": "DueFromJointVenturesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r306",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r336",
      "r338",
      "r343",
      "r344",
      "r345",
      "r347",
      "r608",
      "r609",
      "r692",
      "r699",
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Net income attributable to Amedisys, Inc. common stockholders (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic earnings per common share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r306",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r338",
      "r343",
      "r344",
      "r345",
      "r347",
      "r608",
      "r609",
      "r692",
      "r699",
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Net income attributable to Amedisys, Inc. common stockholders (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Diluted earnings per common share:"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r93",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Weighted-Average Shares Outstanding"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r549"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Income tax expense"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r316",
      "r549",
      "r576"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Income tax expense at U.S. federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "terseLabel": "Other items, net (3)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "auth_ref": [
      "r832",
      "r833"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount",
        "verboseLabel": "Recognized share-based compensation tax benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r833",
      "r840"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State and local income taxes, net of federal income tax benefit (1)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and employee benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r533"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation expense weighted-average period for recognitions (years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r530"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Share-based compensation, tax benefit recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": {
     "auth_ref": [
      "r535"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Exercise of Option, Tax Benefit",
        "terseLabel": "Tax benefit from stock option exercise"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense": {
     "auth_ref": [
      "r165"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of plan compensation cost recognized during the period.",
        "label": "Employee Stock Ownership Plan (ESOP), Compensation Expense",
        "terseLabel": "Employee Stock Purchase Plan expense"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r143",
      "r271",
      "r298",
      "r299",
      "r300",
      "r319",
      "r320",
      "r321",
      "r324",
      "r332",
      "r334",
      "r348",
      "r398",
      "r476",
      "r536",
      "r537",
      "r538",
      "r570",
      "r571",
      "r607",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r629",
      "r665",
      "r704",
      "r705",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Aggregate Cost",
        "terseLabel": "Equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentAggregateCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentDividendsOrDistributions": {
     "auth_ref": [
      "r54",
      "r80",
      "r85",
      "r258"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.",
        "label": "Proceeds from Equity Method Investment, Distribution",
        "terseLabel": "Return on equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsMember": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in the stock of an investee which is adjusted for the investor's share of the earnings or losses of the investee after the date of acquisition.",
        "label": "Equity Method Investments [Member]",
        "terseLabel": "Equity Method Investments [Member]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r80",
      "r110",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EscrowDeposit": {
     "auth_ref": [
      "r239",
      "r733"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.",
        "label": "Escrow Deposit",
        "terseLabel": "Escrow deposit for indemnification purposes and working capital price adjustments"
       }
      }
     },
     "localname": "EscrowDeposit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EurodollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate based on U.S. dollar denominated deposits at foreign banks or foreign branches of U.S. banks.",
        "label": "Eurodollar [Member]",
        "terseLabel": "Eurodollar [Member]"
       }
      }
     },
     "localname": "EurodollarMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtraordinaryAndUnusualItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unusual or Infrequent Items, or Both [Abstract]"
       }
      }
     },
     "localname": "ExtraordinaryAndUnusualItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r611",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r212",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r460",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r612",
      "r676",
      "r677",
      "r678",
      "r758",
      "r759",
      "r765",
      "r766",
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r460",
      "r479",
      "r484",
      "r612",
      "r676",
      "r765",
      "r766",
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r460",
      "r479",
      "r484",
      "r612",
      "r677",
      "r758",
      "r759",
      "r765",
      "r766",
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r460",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r612",
      "r678",
      "r758",
      "r759",
      "r765",
      "r766",
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r460",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r676",
      "r677",
      "r678",
      "r758",
      "r759",
      "r765",
      "r766",
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r215",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r645",
      "r650",
      "r776"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Finance Lease, Interest Expense"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r643",
      "r659"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Total finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESFinanceLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.",
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESFinanceLeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability.",
        "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESFinanceLeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r659"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, to be Paid",
        "terseLabel": "Finance Lease - Total undiscounted lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r659"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Finance Lease - Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r659"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "Finance Lease - 2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r659"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "terseLabel": "Finance Lease - 2027"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r659"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "Finance Lease - 2026"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r659"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "Finance Lease - 2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r659"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "Finance Lease - 2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes finance lease liability.",
        "label": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESFinanceLeasesDetails",
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r659"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Finance Lease - Less: Imputed Interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r646",
      "r654"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Financing cash flow from finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESSupplementalCashflowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": {
     "auth_ref": [
      "r849",
      "r852"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization",
        "negatedTerseLabel": "Finance Lease, ROU Asset, Accumulated Amortization"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESFinanceLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r645",
      "r650",
      "r776"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Finance Lease, Amortization of ROU assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": {
     "auth_ref": [
      "r848"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization",
        "terseLabel": "Finance lease ROU assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESFinanceLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r657",
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Finance Lease, Weighted Average Discount Rate, Percent"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESWeightedAverageRemainingTermandDiscountRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r656",
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance Lease, Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESWeightedAverageRemainingTermandDiscountRateDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Estimated useful life of intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r283",
      "r420"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Intangible assets, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r417",
      "r419",
      "r420",
      "r422",
      "r682",
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r114",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r119",
      "r682"
     ],
     "calculation": {
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r63",
      "r107",
      "r790"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "terseLabel": "Gain (loss) on equity method investments"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfInvestments": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.",
        "label": "Gain (Loss) on Sale of Investments",
        "negatedTerseLabel": "(Gain) loss on equity method investments",
        "verboseLabel": "Gain (Loss) on equity method investments"
       }
      }
     },
     "localname": "GainLossOnSaleOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss (gain) on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnTerminationOfLease": {
     "auth_ref": [
      "r641"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.",
        "label": "Gain (Loss) on Termination of Lease",
        "terseLabel": "Finance Lease, Loss on Termination"
       }
      }
     },
     "localname": "GainLossOnTerminationOfLease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expenses, excluding depreciation and amortization and impairment charge"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Abstract]",
        "terseLabel": "General and administrative expenses:"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r282",
      "r404",
      "r687",
      "r756",
      "r777",
      "r813",
      "r815"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r406",
      "r756"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill recorded during period",
        "verboseLabel": "Additions"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "GOODWILL AND OTHER INTANGIBLE ASSETS, NET"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNET"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r415",
      "r416",
      "r756"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Other Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r405",
      "r412",
      "r756"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Goodwill, Impaired, Accumulated Impairment Loss"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r411"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "negatedTerseLabel": "Reduction in goodwill"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillPurchaseAccountingAdjustments": {
     "auth_ref": [
      "r176",
      "r814"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Purchase Accounting Adjustments",
        "terseLabel": "Adjustments related to acquisitions"
       }
      }
     },
     "localname": "GoodwillPurchaseAccountingAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of patient service revenue recognized, net of contractual allowances and discounts, less the provision for bad debts related to patient service revenue plus all other revenue.",
        "label": "Health Care Organization, Revenue Net of Patient Service Revenue Provisions",
        "terseLabel": "Net service revenue"
       }
      }
     },
     "localname": "HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r85",
      "r123"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "negatedTerseLabel": "Write-off",
        "terseLabel": "Non-cash impairment charge for write-off of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r53",
      "r230",
      "r242",
      "r261",
      "r365",
      "r370",
      "r376",
      "r379",
      "r693",
      "r755"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r18",
      "r259",
      "r276",
      "r580"
     ],
     "calculation": {
      "http://www.amedisys.com/role/AssetsHeldForSaleAssetsandLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r54",
      "r85",
      "r109",
      "r241",
      "r258",
      "r362"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Equity in loss (earnings) from equity method investments",
        "terseLabel": "Equity in (loss) earnings from equity method investments"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/AssetsHeldForSaleAssetsandLiabilitiesDetail",
      "http://www.amedisys.com/role/DiscontinuedOperationsandAssetsHeldForSaleAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r1",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r17",
      "r19",
      "r20",
      "r21",
      "r134",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/AssetsHeldForSaleAssetsandLiabilitiesDetail",
      "http://www.amedisys.com/role/DiscontinuedOperationsandAssetsHeldForSaleAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxCreditsAndAdjustments": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.",
        "label": "Income Tax Credits and Adjustments",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "IncomeTaxCreditsAndAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r316",
      "r550",
      "r558",
      "r564",
      "r572",
      "r577",
      "r581",
      "r582",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Examination [Line Items]",
        "terseLabel": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxExaminationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails",
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExaminationTable": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.",
        "label": "Income Tax Examination [Table]",
        "terseLabel": "Income Tax Examination [Table]"
       }
      }
     },
     "localname": "IncomeTaxExaminationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails",
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r317",
      "r333",
      "r334",
      "r363",
      "r548",
      "r573",
      "r578",
      "r700"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amedisys.com/role/INCOMETAXESIncomeTaxExpenseAllocationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense",
        "totalLabel": "Income tax expense",
        "verboseLabel": "Income from continuing operations"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/INCOMETAXESComponentsofTaxProvisionbyJurisdictionDetails",
      "http://www.amedisys.com/role/INCOMETAXESIncomeTaxExpenseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation": {
     "auth_ref": [
      "r573",
      "r841"
     ],
     "calculation": {
      "http://www.amedisys.com/role/INCOMETAXESIncomeTaxExpenseAllocationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income tax expense (benefit) for continuing operations, discontinued operations, other comprehensive income, and items charged (credited) directly to shareholders' equity.",
        "label": "Income Tax Expense (Benefit), Intraperiod Tax Allocation",
        "totalLabel": "Total income tax expense allocation"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitIntraperiodTaxAllocation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESIncomeTaxExpenseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r297",
      "r544",
      "r545",
      "r558",
      "r559",
      "r563",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes, net of refunds received"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r239",
      "r257",
      "r793"
     ],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Current",
        "terseLabel": "Income tax receivable"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails",
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Patient accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities, net of impact of acquisitions:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r798",
      "r853"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term obligations"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r345",
      "r499"
     ],
     "calculation": {
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r418",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r116",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Indefinite-Lived Intangible Assets [Roll Forward]",
        "terseLabel": "Intangible Assets [Roll Forward]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r112",
      "r117"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Intangible assets, net of accumulated amortization of $14,604 and $19,900",
        "verboseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r223",
      "r244",
      "r301",
      "r359",
      "r633"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r308",
      "r311",
      "r312"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterestAndDividend": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Interest and Dividend",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterestAndDividend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedAtCost": {
     "auth_ref": [
      "r262"
     ],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of the investment.",
        "label": "Investment Owned, at Cost",
        "terseLabel": "Cost method investments"
       }
      }
     },
     "localname": "InvestmentOwnedAtCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Type of Investment [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LaborAndRelatedExpense": {
     "auth_ref": [
      "r797"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.",
        "label": "Labor and Related Expense",
        "terseLabel": "Salaries and benefits"
       }
      }
     },
     "localname": "LaborAndRelatedExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Operating leases rent expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r658",
      "r776"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r854"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Lease Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "auth_ref": [
      "r851"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Term of Contract",
        "terseLabel": "Lessee, Finance Lease, Term of Contract"
       }
      }
     },
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESDetails",
      "http://www.amedisys.com/role/LEASESFinanceLeasesDetails",
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESDetails",
      "http://www.amedisys.com/role/LEASESFinanceLeasesDetails",
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r659"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Operating Lease - Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r659"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Operating Lease - Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r659"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "Operating Lease - 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r659"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "Operating Lease - 2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r659"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "Operating Lease - 2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r659"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "Operating Lease - 2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r659"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "Operating Lease - 2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r659"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Operating Lease - Less: Imputed Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToTerminate": {
     "auth_ref": [
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Terminate",
        "terseLabel": "Lessee, Operating Lease, Option to Terminate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToTerminate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r851"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lessee, Operating Lease, Renewal Term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r851"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lessee, Operating Lease, Term of Contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit [Member]"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Outstanding letters of credit"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r39",
      "r315",
      "r394",
      "r433",
      "r434",
      "r436",
      "r437",
      "r438",
      "r440",
      "r442",
      "r444",
      "r445",
      "r594",
      "r597",
      "r598",
      "r614",
      "r754",
      "r823",
      "r856",
      "r857"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Total liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r34",
      "r238",
      "r254",
      "r777",
      "r802",
      "r812",
      "r846"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r41",
      "r278",
      "r315",
      "r394",
      "r433",
      "r434",
      "r436",
      "r437",
      "r438",
      "r440",
      "r442",
      "r444",
      "r445",
      "r594",
      "r597",
      "r598",
      "r614",
      "r777",
      "r823",
      "r856",
      "r857"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "terseLabel": "Total current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r128",
      "r133",
      "r275",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
        "terseLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/AssetsHeldForSaleAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r16",
      "r126",
      "r133",
      "r275",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent",
        "terseLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/AssetsHeldForSaleAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Commitment Fee"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Credit facility, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Remaining availability under the revolving credit facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r37",
      "r801"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit [Member]"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Settlement awarded to other party"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest expense (income) directly attributable to an award in settlement of litigation.",
        "label": "Litigation Settlement Interest",
        "terseLabel": "Litigation Settlement Interest"
       }
      }
     },
     "localname": "LitigationSettlementInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Term Loan [Member]"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the assets held for sale.",
        "label": "Long-Lived Assets Held-for-sale by Asset Type [Axis]",
        "terseLabel": "Long Lived Assets Held-for-sale by Asset Type [Axis]"
       }
      }
     },
     "localname": "LongLivedAssetsHeldForSaleByAssetTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DiscontinuedOperationsandAssetsHeldForSaleAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongLivedAssetsHeldForSaleNameDomain": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A name of the assets to be disposed.",
        "label": "Long-Lived Assets Held-for-sale, Name [Domain]",
        "terseLabel": "Long Lived Assets Held-for-sale, Name [Domain]"
       }
      }
     },
     "localname": "LongLivedAssetsHeldForSaleNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DiscontinuedOperationsandAssetsHeldForSaleAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r26",
      "r236",
      "r251",
      "r459",
      "r474",
      "r758",
      "r759"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "totalLabel": "Long-term obligations, including current portion"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-Term Debt and Lease Obligation",
        "terseLabel": "Long-term obligations, less current portion"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Long-Term Obligations, Fiscal Year Maturity"
       }
      }
     },
     "localname": "LongTermDebtByMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "negatedLabel": "Current portion of long-term obligations"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-Term Debt, Fair Value",
        "terseLabel": "Long-term obligations, fair value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFinancialInstrumentsWhereCarryingValueandFairValueDifferDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r140",
      "r318",
      "r464"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r140",
      "r318",
      "r464"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r140",
      "r318",
      "r464"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r140",
      "r318",
      "r464"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r140",
      "r318",
      "r464"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSMaturitiesofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r287"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term obligations, less current portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtWeightedAverageInterestRateOverTime": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of long-term debt outstanding calculated over time.",
        "label": "Long-Term Debt, Weighted Average Interest Rate, over Time",
        "terseLabel": "Weighted Average Interest Rate"
       }
      }
     },
     "localname": "LongTermDebtWeightedAverageInterestRateOverTime",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r43",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r138",
      "r139",
      "r428",
      "r429",
      "r430",
      "r817",
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r138",
      "r139",
      "r428",
      "r429",
      "r430",
      "r817",
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r428",
      "r791"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Loss contingency accrual"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r138",
      "r139",
      "r428",
      "r429",
      "r430",
      "r817",
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [
      "r817",
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Number of former employees who filled a putative collective and class action complaint"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyReceivableCurrent": {
     "auth_ref": [
      "r139"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivable related to a loss contingency accrual that is expected to be collected within one year or the normal operating cycle, if longer. For example, an insurance recovery receivable.",
        "label": "Loss Contingency, Receivable, Current",
        "terseLabel": "Settlement amount to be paid by Company's insurance carriers"
       }
      }
     },
     "localname": "LossContingencyReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyReceivableNoncurrent": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivable related to a loss contingency accrual that is expected to be collected after one year or beyond the normal operating cycle, if longer. For example, an insurance recovery receivable.",
        "label": "Loss Contingency, Receivable, Noncurrent",
        "terseLabel": "Indemnity receivable"
       }
      }
     },
     "localname": "LossContingencyReceivableNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r48",
      "r237",
      "r253",
      "r315",
      "r394",
      "r433",
      "r436",
      "r437",
      "r438",
      "r444",
      "r445",
      "r614"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r148"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedTerseLabel": "Noncontrolling interest distributions"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Noncontrolling interest, ownership percentage by noncontrolling owners (percent)"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows from Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r81",
      "r83",
      "r86"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r56",
      "r86",
      "r243",
      "r260",
      "r276",
      "r292",
      "r295",
      "r300",
      "r315",
      "r323",
      "r327",
      "r328",
      "r329",
      "r330",
      "r333",
      "r334",
      "r342",
      "r365",
      "r370",
      "r376",
      "r379",
      "r394",
      "r433",
      "r434",
      "r436",
      "r437",
      "r438",
      "r440",
      "r442",
      "r444",
      "r445",
      "r609",
      "r614",
      "r755",
      "r823"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income attributable to Amedisys, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r198",
      "r207",
      "r292",
      "r295",
      "r333",
      "r334",
      "r796"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Net loss (income) attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r92",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r329",
      "r335",
      "r347",
      "r392",
      "r393",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r536",
      "r537",
      "r538",
      "r568",
      "r569",
      "r570",
      "r571",
      "r588",
      "r589",
      "r590",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r631",
      "r632",
      "r637",
      "r638",
      "r639",
      "r640",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r683",
      "r684",
      "r685",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncompeteAgreementsMember": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.",
        "label": "Noncompete Agreements [Member]",
        "terseLabel": "Noncompete Agreements [Member]"
       }
      }
     },
     "localname": "NoncompeteAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination": {
     "auth_ref": [
      "r149",
      "r181",
      "r199"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from a business combination.",
        "label": "Noncontrolling Interest, Increase from Business Combination",
        "terseLabel": "Acquired noncontrolling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromBusinessCombination",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest": {
     "auth_ref": [
      "r149",
      "r196",
      "r199"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest.",
        "label": "Noncontrolling Interest, Increase from Sale of Parent Equity Interest",
        "terseLabel": "Sale of noncontrolling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r191",
      "r476",
      "r805",
      "r806",
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other (expense) income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r26",
      "r236",
      "r251"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "terseLabel": "Notes payable issued in acquisition"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfBusinessesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of businesses acquired by the entity during the period.",
        "label": "Number of Businesses Acquired",
        "terseLabel": "Acquisition, number of care centers acquired"
       }
      }
     },
     "localname": "NumberOfBusinessesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable business segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfStatesInWhichEntityOperates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of states the entity operates in as of the balance sheet date.",
        "label": "Number of States in which Entity Operates",
        "terseLabel": "Number of states with facilities"
       }
      }
     },
     "localname": "NumberOfStatesInWhichEntityOperates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OpenTaxYear": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format.",
        "label": "Open Tax Year",
        "terseLabel": "Tax years open to examination"
       }
      }
     },
     "localname": "OpenTaxYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r365",
      "r370",
      "r376",
      "r379",
      "r755"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Operating income (loss)",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r651",
      "r776"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Total operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r850"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "auth_ref": [
      "r847"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.",
        "label": "Operating Lease, Impairment Loss",
        "terseLabel": "Impairment of operating lease ROU assets"
       }
      }
     },
     "localname": "OperatingLeaseImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r643"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESMaturitiesDetails",
      "http://www.amedisys.com/role/LEASESOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r643"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/LEASESOperatingLeaseDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r643"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, less current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/LEASESOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r647",
      "r654"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "negatedTerseLabel": "Operating cash flow from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESSupplementalCashflowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r642"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right of use assets",
        "verboseLabel": "Operating lease ROU assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/LEASESOperatingLeaseDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r657",
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESWeightedAverageRemainingTermandDiscountRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r656",
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESWeightedAverageRemainingTermandDiscountRateDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r171"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Reportable Business Segments [Member]"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r23",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r289",
      "r777"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets",
        "totalLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMiscellaneousCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer.",
        "label": "Other Assets, Miscellaneous, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssetsMiscellaneousCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMiscellaneousNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.",
        "label": "Other Assets, Miscellaneous, Noncurrent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssetsMiscellaneousNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r284"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "totalLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent [Abstract]",
        "terseLabel": "Other assets:"
       }
      }
     },
     "localname": "OtherAssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r52",
      "r143",
      "r293",
      "r296",
      "r302",
      "r623",
      "r628",
      "r629",
      "r688",
      "r695",
      "r794",
      "r795"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense classified as other.",
        "label": "Other General and Administrative Expense",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term obligations",
        "totalLabel": "Other long-term obligations"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Other long-term obligations:"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Miscellaneous, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncome": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.",
        "label": "Other Operating Income",
        "terseLabel": "Other operating income"
       }
      }
     },
     "localname": "OtherOperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSundryLiabilitiesNoncurrent": {
     "auth_ref": [
      "r27",
      "r235",
      "r250"
     ],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.",
        "label": "Other Sundry Liabilities, Noncurrent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherSundryLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedTerseLabel": "Payment of accrued contingent consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Payments for legal settlements"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Purchase of company stock",
        "terseLabel": "Purchase of company stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedLabel": "Debt issuance costs",
        "terseLabel": "Payments of Financing Costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r307"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Shares withheld to pay taxes on non-cash compensation",
        "terseLabel": "Payments Related to Tax Withholding for Share-based Compensation"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r70",
      "r591"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Payments to Acquire Businesses, Gross"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisitions of businesses, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "negatedTerseLabel": "Investment in equity method investee"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "terseLabel": "Purchase of investment"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherInvestments": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investments classified as other.",
        "label": "Payments to Acquire Other Investments",
        "negatedTerseLabel": "Purchase of cost method investment"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToDevelopSoftware": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the development or modification of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.",
        "label": "Payments to Develop Software",
        "negatedTerseLabel": "Investments in technology assets"
       }
      }
     },
     "localname": "PaymentsToDevelopSoftware",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r477",
      "r478",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r495",
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "EMPLOYEE BENEFIT PLANS"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/EMPLOYEEBENEFITPLANS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r28",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r28",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, outstanding (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValueOutstanding": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.",
        "label": "Preferred Stock, Value, Outstanding",
        "terseLabel": "Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding"
       }
      }
     },
     "localname": "PreferredStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]",
        "terseLabel": "Other current assets:"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r288",
      "r402",
      "r403",
      "r749"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMinorityShareholders": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.",
        "label": "Proceeds from Noncontrolling Interests",
        "terseLabel": "Proceeds from sale of noncontrolling interest"
       }
      }
     },
     "localname": "ProceedsFromMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Proceeds from Sale of Equity Method Investments",
        "terseLabel": "Proceeds from sale of equity method investment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from the sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfRestrictedInvestments": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period.",
        "label": "Proceeds from Sale of Restricted Investments",
        "terseLabel": "Proceeds from the sale of deferred compensation plan assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfRestrictedInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-Term Debt",
        "terseLabel": "Proceeds from borrowings under revolving line of credit"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r73",
      "r162"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of stock upon exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of stock to employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "Product Concentration Risk [Member]"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r276",
      "r292",
      "r295",
      "r309",
      "r315",
      "r323",
      "r333",
      "r334",
      "r365",
      "r370",
      "r376",
      "r379",
      "r394",
      "r433",
      "r434",
      "r436",
      "r437",
      "r438",
      "r440",
      "r442",
      "r444",
      "r445",
      "r592",
      "r595",
      "r596",
      "r609",
      "r614",
      "r693",
      "r755",
      "r774",
      "r775",
      "r796",
      "r823"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESDetails",
      "http://www.amedisys.com/role/LEASESFinanceLeasesDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Estimated Useful Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r130",
      "r280"
     ],
     "calculation": {
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment [Member]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESFinanceLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r132",
      "r255",
      "r694",
      "r777"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net of accumulated depreciation of $101,364 and $96,937",
        "totalLabel": "Property and equipment, net",
        "verboseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/LEASESFinanceLeasesDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r132",
      "r734",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESDetails",
      "http://www.amedisys.com/role/LEASESFinanceLeasesDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r229",
      "r668"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Related party transaction, amount of transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r266",
      "r668",
      "r669",
      "r855"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r666",
      "r667",
      "r669",
      "r670",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Principal payments of long-term obligations",
        "terseLabel": "Principal payments of long-term obligations"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-Term Debt",
        "negatedLabel": "Repayments of borrowings under revolving line of credit"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r792",
      "r800",
      "r864",
      "r865"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r31",
      "r148",
      "r252",
      "r708",
      "r713",
      "r777"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r271",
      "r319",
      "r320",
      "r321",
      "r324",
      "r332",
      "r334",
      "r398",
      "r536",
      "r537",
      "r538",
      "r570",
      "r571",
      "r607",
      "r704",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition and Deferred Revenue [Abstract]",
        "terseLabel": "Revenue Recognition and Deferred Revenue [Abstract]"
       }
      }
     },
     "localname": "RevenueRecognitionAndDeferredRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]",
        "terseLabel": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the recognition of revenue arrangements under which the entity does or will perform multiple revenue-generating activities, categorized by type of arrangement, including certain revenue arrangements that include software elements. This item does not include multiple-deliverable arrangements for industries that prepare disclosures under specific requirements (for instance, construction-type and production-type contracts) otherwise provided for in the taxonomy.",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements [Table]",
        "terseLabel": "Revenue Recognition, Multiple-deliverable Arrangements [Table]"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r751",
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r655",
      "r776"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESSupplementalCashflowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r655",
      "r776"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESSupplementalCashflowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r385",
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue Benchmark [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of major classes of indefinite-lived intangible assets acquired showing attributes such as amounts and totals. Indefinite-lived intangible assets are assets that have no physical form, but have expected future economic benefit. Indefinite-lived assets are assets that are not subject to amortization. Acquired indefinite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the entity) and in total.",
        "label": "Schedule of Acquired Indefinite-Lived Intangible Assets by Major Class [Table]",
        "terseLabel": "Schedule of Acquired Indefinite-lived Intangible Assets by Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r177",
      "r178",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r43",
      "r144",
      "r145",
      "r146",
      "r147",
      "r221",
      "r222",
      "r224",
      "r246",
      "r758",
      "r760",
      "r804"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long-Term Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Net Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r1",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r17",
      "r19",
      "r20",
      "r21",
      "r134",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Schedule of Carrying Amount of Assets and Liabilities for Disposal Group"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ASSETSHELDFORSALETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Sources of Tax Effects"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r114",
      "r118",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r756"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Goodwill and Other Intangible Assets Net"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Schedule of Line of Credit Facilities [Table Text Block]",
        "terseLabel": "Schedule of Commitment Fee Under Credit Facilities"
       }
      }
     },
     "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Long-Term Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.",
        "label": "Schedule of Nonvested Performance-Based Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Non-Vested Performance-based Units Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Non-Vested Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.",
        "label": "Schedule of Nonvested Share Activity [Table Text Block]",
        "terseLabel": "Schedule of Non-Vested Stock Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedShareActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, classified as other.",
        "label": "Schedule of Other Assets and Other Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Other Long-Term Obligations"
       }
      }
     },
     "localname": "ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.",
        "label": "Schedule of Other Assets [Table Text Block]",
        "terseLabel": "Schedule of Other Assets"
       }
      }
     },
     "localname": "ScheduleOfOtherAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "terseLabel": "Schedule of Other Current Assets"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r227",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of the major payor source of revenue for health care organizations.",
        "label": "Schedule of Revenue Sources, Health Care Organization [Table]",
        "terseLabel": "Schedule of Revenue Sources, Health Care Organization [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenueSourcesHealthCareOrganizationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of patient service revenue (net of contractual allowances and discounts), by major payor source of revenue for health care organizations.",
        "label": "Schedule of Revenue Sources, Health Care Organization [Table Text Block]",
        "terseLabel": "Schedule of Revenue by Payor Class"
       }
      }
     },
     "localname": "ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Operating Income of Reportable Segments"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r496",
      "r498",
      "r501",
      "r502",
      "r503",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of employee stock purchase plan activity.",
        "label": "Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]",
        "terseLabel": "Schedule of Employee Stock Purchase Plan Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r154",
      "r156",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Options Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Award Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r773",
      "r834"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Uncertain Tax Positions"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": {
     "auth_ref": [
      "r201",
      "r202",
      "r203",
      "r204",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table Text Block]",
        "terseLabel": "Schedule of Variable Interest Entities"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Schedule of Weighted-Average Shares Outstanding"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Estimated Aggregate Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r353",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r379",
      "r385",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r424",
      "r425",
      "r756",
      "r866"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails",
      "http://www.amedisys.com/role/AssetsHeldForSaleAssetsandLiabilitiesDetail",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/DiscontinuedOperationsandAssetsHeldForSaleAdditionalInformationDetail",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r353",
      "r354",
      "r355",
      "r365",
      "r368",
      "r373",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r384",
      "r385",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "SEGMENT INFORMATION"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Non-cash compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r771"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period of equity-based awards"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "Percentage of market value for purchases under Employee Stock Purchase Program (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Canceled, forfeited or expired (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Canceled, forfeited or expired (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (usd per share)",
        "verboseLabel": "Non-vested stock granted, weighted average grant date fair value (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r513",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Non-vested, ending balance (shares)",
        "periodStartLabel": "Non-vested, beginning balance (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r513",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Non-vested, ending balance (usd per share)",
        "periodStartLabel": "Non-vested, beginning balance (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected Volatility Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected Volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "verboseLabel": "Expected Volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk Free Interest Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "verboseLabel": "Risk Free Rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "verboseLabel": "Risk Free Rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Equity-based awards, number of shares authorized (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Equity-based awards, shares available for grant (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average\u00a0Contractual Life\u00a0(Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r520"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised during the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r830"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Canceled, forfeited or expired (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r830"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled, forfeited or expired (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r831"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Granted (shares)",
        "verboseLabel": "Options granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r161"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Intrinsic value of options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r505",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, ending balance (shares)",
        "periodStartLabel": "Outstanding, beginning balance (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number\u00a0of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r505",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, ending balance (usd per share)",
        "periodStartLabel": "Outstanding, beginning balance (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average\u00a0Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Per Share Weighted Average Price of Shares Purchased",
        "terseLabel": "Price per Employee Stock Purchase Plan share issued (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONEmployeeStockPurchasePlanPurchasesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award",
        "terseLabel": "Contractual term of share-based award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r501",
      "r502",
      "r503",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockUnitsActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails",
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails",
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r504",
      "r523",
      "r524",
      "r525",
      "r526",
      "r529",
      "r539",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionValuationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r161"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exerciseable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable, weighted average contractual life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "periodEndLabel": "Non-vested stock options ending balance (shares)",
        "periodStartLabel": "Non-vested stock options beginning balance (shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number\u00a0of Shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options forfeited.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares",
        "negatedLabel": "Forfeited (shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (usd per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "Non-vested stock options ending balance (usd per share)",
        "periodStartLabel": "Non-vested stock options beginning balance (usd per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted\u00a0Average Grant Date Fair Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, weighted average contractual life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "negatedLabel": "Vested (shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (usd per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONNonVestedStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r652",
      "r776"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r91",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Computer Software [Member]"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESBalancesRelatedtoPropertyandEquipmentDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r274",
      "r353",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r379",
      "r385",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r423",
      "r424",
      "r425",
      "r756",
      "r866"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaCondensedConsolidatedStatementofIncomeDetails",
      "http://www.amedisys.com/role/AssetsHeldForSaleAssetsandLiabilitiesDetail",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/DiscontinuedOperationsandAssetsHeldForSaleAdditionalInformationDetail",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoGoodwillDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionbyPayorClassDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r47",
      "r143",
      "r271",
      "r298",
      "r299",
      "r300",
      "r319",
      "r320",
      "r321",
      "r324",
      "r332",
      "r334",
      "r348",
      "r398",
      "r476",
      "r536",
      "r537",
      "r538",
      "r570",
      "r571",
      "r607",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r629",
      "r665",
      "r704",
      "r705",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r319",
      "r320",
      "r321",
      "r348",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r28",
      "r29",
      "r143",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Employee Stock Purchase Plan shares issued (shares)",
        "verboseLabel": "Issuance of stock - employee stock purchase plan (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONEmployeeStockPurchasePlanPurchasesDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r28",
      "r29",
      "r143",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance/(cancellation) of non-vested stock (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r28",
      "r29",
      "r143",
      "r148",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "verboseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONStockOptionActivityDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r28",
      "r29",
      "r143",
      "r148"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of stock - employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r143",
      "r148"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance/(cancellation) of non-vested stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r47",
      "r143",
      "r148"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date for the purchase of an entity's own shares under a stock repurchase plan, in the YYYY-MM-DD format.",
        "label": "Stock Repurchase Program Expiration Date",
        "terseLabel": "Stock repurchase program, expiration date"
       }
      }
     },
     "localname": "StockRepurchaseProgramExpirationDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r29",
      "r32",
      "r33",
      "r106",
      "r777",
      "r802",
      "r812",
      "r846"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Amedisys, Inc. stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r191",
      "r192",
      "r206",
      "r271",
      "r272",
      "r299",
      "r319",
      "r320",
      "r321",
      "r324",
      "r332",
      "r398",
      "r476",
      "r536",
      "r537",
      "r538",
      "r570",
      "r571",
      "r607",
      "r623",
      "r624",
      "r629",
      "r665",
      "r705",
      "r706",
      "r802",
      "r812",
      "r846"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance, Stockholders Equity",
        "periodStartLabel": "Balance, Stockholders Equity",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUBSEQUENTEVENTSDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r630",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/DiscontinuedOperationsandAssetsHeldForSaleAdditionalInformationDetail",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTSDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r630",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUBSEQUENTEVENTSDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r630",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/DiscontinuedOperationsandAssetsHeldForSaleAdditionalInformationDetail",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTSDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r630",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/DiscontinuedOperationsandAssetsHeldForSaleAdditionalInformationDetail",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTSDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r673",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUBSEQUENTEVENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Disclosures of Cash Flow Information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.",
        "label": "Technology-Based Intangible Assets [Member]",
        "terseLabel": "Technology-Based Intangible Assets"
       }
      }
     },
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETActivityRelatedtoOtherIntangibleAssetsNetDetails",
      "http://www.amedisys.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNETGoodwillandIntangiblesDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r263",
      "r264",
      "r265",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Patient Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Shares repurchased, weighted average price per share (usd per share)"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r46",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r46",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock at cost (shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r29",
      "r143",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Shares repurchased (shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockTextBlock": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Treasury Stock [Text Block]",
        "terseLabel": "SHARE REPURCHASE"
       }
      }
     },
     "localname": "TreasuryStockTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r46",
      "r150",
      "r151"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock at cost, 5,372,908 and 5,164,899 shares of common stock"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r143",
      "r148",
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedLabel": "Shares repurchased"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r323",
      "r324",
      "r325",
      "r326",
      "r335",
      "r392",
      "r393",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r536",
      "r537",
      "r538",
      "r568",
      "r569",
      "r570",
      "r571",
      "r588",
      "r589",
      "r590",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r631",
      "r632",
      "r637",
      "r638",
      "r639",
      "r640",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r683",
      "r684",
      "r685",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSRecentlyIssuedAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.",
        "label": "Unamortized Debt Issuance Expense",
        "terseLabel": "Unamortized debt issuance costs"
       }
      }
     },
     "localname": "UnamortizedDebtIssuanceExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r543",
      "r553"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Uncertain tax benefits, ending balance",
        "periodStartLabel": "Uncertain tax benefits, beginning balance",
        "terseLabel": "Uncertain tax benefits accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails",
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r554"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Reductions for tax positions related to prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r556"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "negatedTerseLabel": "Settlements"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r551"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Interest and penalties accrued related to uncertain income tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r551"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r555"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions for tax positions related to current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r554"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions for tax positions related to prior year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r557"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedTerseLabel": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails",
      "http://www.amedisys.com/role/INCOMETAXESReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnusualOrInfrequentItemAxis": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by an event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Axis]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Axis]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualOrInfrequentItemDomain": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Domain]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Domain]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnusualOrInfrequentItemLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Unusual or Infrequent Item, or Both [Line Items]",
        "terseLabel": "NOVEL CORONAVIRUS PANDEMIC (\"COVID-19\") [Line Items]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualOrInfrequentItemTable": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the nature and financial statement effect of an event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Table]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Table]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r349",
      "r350",
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r562"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Net change in total valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "auth_ref": [
      "r201",
      "r593",
      "r594",
      "r597",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Primary Beneficiary [Member]"
       }
      }
     },
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r653",
      "r776"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LEASESLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VehiclesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment used primarily for road transportation.",
        "label": "Vehicles [Member]",
        "terseLabel": "Vehicles [Member]"
       }
      }
     },
     "localname": "VehiclesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r337",
      "r345"
     ],
     "calculation": {
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares outstanding (shares)",
        "totalLabel": "Weighted average number of shares outstanding \u2013 diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r336",
      "r345"
     ],
     "calculation": {
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of shares outstanding \u2013 basic",
        "verboseLabel": "Weighted average shares outstanding (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WorkersCompensationLiabilityCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Workers' Compensation Liability, Current",
        "terseLabel": "Workers\u2019 compensation"
       }
      }
     },
     "localname": "WorkersCompensationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.amedisys.com/role/DETAILSOFCERTAINBALANCESHEETACCOUNTSBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    }
   },
   "unitCount": 12
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27405-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=123583895&loc=d3e30768-111565",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2510-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2473-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/subtopic&trid=2208821",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=68176171&loc=SL68176184-208336",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123386454&loc=d3e45280-112737",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123386454&loc=d3e45280-112737",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(21))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123386189&loc=SL77918607-209975",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(d)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r781": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r782": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r783": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r784": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r785": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r786": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r787": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r788": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r789": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123399704&loc=SL77918431-209957",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r862": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r863": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r864": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r865": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r866": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r867": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>114
<FILENAME>0000896262-23-000017-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000896262-23-000017-xbrl.zip
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M1EF8O!#$V7!P*HB2>#3(7DA2%J>C%Y(ABQ.R88P=)8P.<EX.B0/,6)H,H@N
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MVZ>G/'5G^.1=:?,;;F[]'?+I?P!02P,$%     @ %$!05E0.1.#&!P  N!X
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M8V<%"6GF)F)79=J!C5X_.QOU.^PG;J FS%#,V6VI9CF),47!5#K82"BL6"K
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M*!PU36GCXG.5C!XO>RL6GB C:_LXRV.WB8_>HC;/<*?K;Y=/_P102P,$%
M  @ %$!05M]G-?"Z!   80\  !<   !A,C R,C$P+6ME>&AI8FET,S(Q+FAT
M;=5766_;.!!^WU\Q=;!M EBG[Z,!'%E!C69CPU:V[=."%FF;J"1J*3J.]]?O
MD++2'&ML@$4WK1\$2\,YOH\SP^'PS7@:1%]F(6Q4FL#LYN)J$D#-<IQ/C<!Q
MQM$8/D2_74'3=CV(),D*KKC(2.(XX74-:ANE\K[C['8[>]>PA5P[T=S1III.
M(D3!;*IH[7RHO^"3$7K^R_"-9<%8Q-N490IBR8AB%+8%S];PB;+B*UC6854@
M\KWDZXT"W_4;\$G(K_R6E'+%5<+.*SM#IWP?.L;)<"GH_GQ(^2UP^K[&8])Q
M::?7[K6HWVSUNMVXVXKC=L?MQG[<(]T_/ S2P>6E3J'V"7M?2WEF;9CVWV_Z
M=J>5J\&.4[7I>Z[[:\TL/1^N1*;0GT3]\F]IYIDQQ>Z411*^SOH&4JU4K<2Q
M2(3LG[CF-] 2:T52GNS[[R*>L@*NV0[F(B79NWJ!VV 53/)5N;#@?S&,"<,S
MK[LRY [:27C&*@B>KX,.[S9\R14T?-M['/%#X$2N$;L2.6JAV0>QQT@VDZ\4
M?!#.H\GE)!A%D^DU3"]A-I]<!Y/9Z K"SV%P$TU^#_$SK@CGF,OSQ<WH.H)H
M"EX7;NR%'=BP" .C[#5:;OTH 3\*X-$"1N/I+ K'C^!4('IN6[,0?0AA,9I?
MC*[#A37]?!5^@5$0:8GONOY+=_F[0VS^(\1)!K'(,A;KO@([KC:@-@Q&6;8E
M"<Q9+J0"L8)1RB@O]D4=)EELPZE>]/:DZ_ON(!!I3K*]>?,&9X!V+H5,P7.M
MC[ 2TAC<,R*!911[S9C%+%TR^?;$:[N#AE?7[<5_9++T6UE$GW68D6T"%S9\
MW!8(5>SJ$&PX6T%XQ^*MXK<,IJL5CYG4T6I3A[#JL&&2+?> (L57>U "TCU\
MS<0N873-ZI!O9;$E2#U*'F1J24D9I$E7( 40*G+=+Q_J/%JI<^(0P(+()<E8
M84WO$K:'46R(U#E11SE!>*WNX"7IT<:=S FEV**MA*U4W^^\6KZ<>F<0(;A#
M9JRV28+4(M4)1R?W^2/9GULNF3X;"HWZ"9NG!--$@M<ZI6?W=.$^2CS>T$QX
M%V](MF859UZOT42V>@,@&?WI&/-+QGB&M9 24V=8<HK@2HI?#?B*3L(E\IE+
M5FCFZEI,D@10#9UC0:(@1RJ+NM%:\8QDL?Z.!JD9#31#>M4V*8D7.9/&9_&D
M+G0VXQ>]O*I17,H%+2KW3Z.S_XWYI5!*I.69]6-TMS'R9LH,+ME2;HG<'S*P
M72]GFI<D4\N$K\@R895T*21ETD(8"<D+UJ_^#+!'Y@G9]WEF@C%*@\?TZ#GF
M5O>BF"2'0\Z<=Z7X,.(T<.)K-_64HW"T4;1R?!B ;#, .8H^E_6Z=L\]+G9M
M[U[F&-NE?4108%J\KS5JE<*A@/I^?@?>XS%$U]13$&7\__]&&[!O3YJ=P<(\
MRQU^>ES<;_0+@!]VU^1NCE!$PBE4&'Y,5I[-+X:5_T+"SX3SV"2@FUNPP9Z*
M'JKV=R&(I-^1",R:5V+A="8YG@8Y'@?/J#A[CM@QS>E!ZSMZF7K0%I_<QW)1
M7DC[DB5$^WMV0_M64Z;YN=]4R!(+:ZN.JQR[!1R][AV>Y>737(//_P902P,$
M%     @ %$!05C,0M1G'!   F \  !<   !A,C R,C$P+6ME>&AI8FET,S(R
M+FAT;=57;6\:.1#^?K]B2G1M(K&O$,);(E%>6G0Y0+"]7C^=S-H+5A9[ZS4A
MW*^_L9=-0W+1195Z;?F =G=>/,_CF?&X^VHP[4>?9D-8ZTT*LP]OK\=]J#B>
M]['6][Q!-(#WT>_74'?] ")%1,XUEX*DGC><5*"RUCIK>]YNMW-W-5>JE1?-
M/>.J[J52YLREFE:NNN8+_C-"KW[IOG(<&,AXNV%"0ZP8T8S"-N=B!1\IRV_
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M*K*5?KISC_@^Z;,R.'W," ^QM]G/=/(_=+K&]J^P/3G'=8*O;&_P[WKU09#
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MP-R*16%+J62$-1P=QOCPMZ>]XS0^GMB\!VSZZ %;P ?8[Q\?/J#_'&/OP7C
MPY4>['?W]FDTKB/YO_'_^W__E[3B_]3W^1)L,GL/RG$_CZ9GZ!V/'HB_&_&_
MOY[L;P_^.U[ZUM&P>TCG1_,)NTR-83UY79[&(>=HG_*#>#JY[J/,1H3%5S7+
MG_C//4;[;WS._."_TZ43/CD>#O*@U\/A@PK[Q QA_^N9CR:K9NK%JG^9%-B?
MWZ>\=)-_OPV'(4HE0E9.L^OQ,8>88]96!Y]MD;3F\%TY+-CV6,^B#02T0JCU
M.\+Q*U.H14*3#T(XBO#PMPGB.'[P>;^;]B]3(=-15?(CYL&$3"\&_3R8LB)B
M_^.#0QQ^I/&?L^5O#\:?!W^;^BP^<-0].2?0'_FN&U61_<ABDC^K3]Z@0L-A
MK3&OM6/;>/+DY(AC%_J=^E2ZXT84*)^TZW7.67;6/ML\W7G_BJ/3NH @L;=C
MJ_;^Z4'[X-%GCEP_UOO@$$9T3K]$Q+IS6-GT[K"CGG,X\T2TS][*K>VGS,;-
MDZVZ:.6P#5OO.9SY)B).BO_>Y_-IOC>.?%^==;;?FO9[_IT<ZG!4?+I3IY /
M-CDBOE(GHMH'FQ]$E*YH'UOD$"I-L86>=(NR= HUAQTB/?Q-Z;]IYVXUVSL#
M8?MF'X?5A%!^/#BLE)@HLD?#(?;W)G'O[Z=?#WF)I_6M1Y]QF"?_><?#@5W#
M^:)#N7!ZO+H00P>[VWQ,G;EGC;J[\8B_]T3Q<0S9[L?VLU>PN[U_N,L4V/I&
M#'5Z'.=VZXQ_^^#WC^V-5QP1[_ ]?3S9/7S%Y]IG<;7[L295&&K3V4X?E-*Y
ML/AL1>L%1[ YMF*UZTF(+"-A%,">]"7<:I)8\;#WA86K$0F*J5DV\$9920E8
MW[HUM/.%EBW*V:,/11>IZV("'6)L098UK+&ZI7,J6@03P-E;S_^# E],\L;%
MR'J9=4$B8X6K$W2&/UE#.W]H=SYD(2Q[5MU*E.H"@<PA"ZNP%CAME$PILIF^
M]:B=039IMM!^)VR=B).%@YXN/'E-4)ZV-Q+LU!AT8T?L/GN]O[7QR.P^>W[
M7A6JEVT?OC*[7W/;G^N]U#O9FN2T:US;V]\YX-A5\1V>=0[;BA7 L[=G[>YU
M3UX+P>H2MC9,<MH<U[)JZ':V]P]V#]NZK7;..!;^O+O=/KWBR:?)2BU+4*9
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MJ+0F"SD2"X<0ES^%W!#(9I=;-E3J?K]:@51@O8X236"SJ5)1D%T#]L!<NES
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M+K )U>9W&L7;E/;[@]Y@[W32)?'Z%U<1<B&B"BJ49%( RHA:&E2)L0=7;&Y
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M40:$ )P[D&,@@NVMO9,_#_?K[F!KIZ8.#0X<'QM+D</DU.&]%+!CGH2=Q,D
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MJY_!AM#I(98\XO?%E(?'H@C^C6-BA7+!"8,)8D12ZJ2:$2B%DH0.F886Y>,
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MF564!0X#VRB6%>&(R!PL,V$UC60R&GOHWS7..7M?;A"DS '* =+ZV>+8)+C
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MBZ).1%T>2"VSJ0R  K(Z@8.5/-:)EK@<M-WPW8>$"C#HL^2PX\K"14=8;FE
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MTV.NK8<N5<QJ[DE"E=B$VLUIZ*Q9J-TL%N^ZV0!4L.NP:+&8Y/*9_L=ST"]
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MMY1AF+P@")$XBU#'LO'!.%$/"0HE@2KBW18[5&E7E9^8=F(5M_PC5RUG!:9
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MQ(.*=)J:3?0:H2+7\<%2NR7[/<^K]VK:%Z"K8YQ[+M$9^Z+S+<"\B7E>W[G
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M8JK$YBRO-+RN>R,M2UC_T>8(]E*/9XX%TX8))3KB"6U7EW\X*#X4FRW* $H
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MPJ7'2W#QCO&>/)Q9/V\0S!T::ZFC$$_&-6S1:6(%;6%UL]9M?<UAR+5U!>=
M(N[Q0"C7),2($@7L6VVR!7[6G2(VP#FY%HJ7R/09L2G6GE3J?IE[:&<KR+ZY
M)4 ]@Q$#(,1<XSQ;6\"X:\-! 4>]]5I;%N33:W4]JN=?SC+)\,],%UO4ZH?
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M85AO7'/QMW&()M=,/.'[-S<C@?V( M @')T/3BHL]\_KR97S"OIALC\L[ M
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MV1:%]*-+-H21=M/&:,OEF"PY:^'N(GV%]D\B(2+_*0O*#/%]_M(:MA29*3R
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MH_,"_&;NAW,DIUP9;,ZME]:%[B!I%CICR%]9<Q%?JVGID4$%JCM=6OR" N
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MR+J2OX4"S>DML_CR9=F&W)YVE..%Z#:E*R7>%C7GM0(<-&FOC-*AJ^15[+$
MPQY8?'1=+)IRSHLTYTX^V'0C8@HW=([Z"@9)79$6$T4VE?B*S_D*6GLDH5.C
M\WC;MVV9'_SE?<,1*!0XK3D7?$YRI]R.X5*[J%G9*]!.B)-%1J)!:'>1UD>&
MX%.G/LA*QF _)..[JC=TP2^LJ=U ,_N3IF*@/V5]SMUDSP41R_7]10-V1XS
M799NV G/EXO_AM"7&P:+2A^T38K5!I4J"36<E_4.D@IE_8\^%,=P4KT+"P++
MOJR%3C[.;\!'QD"O#OI!3!!^.^R74IP6<3$3^.^RF O\2%ZM6\$=&QC['P@
M''P8QI722Y!0<1<12;W'#J3 0LWD$5Q*L]X%NNMEN>ZEM>/K)''V24[!!,W0
M%#99&Q)BOAK)5PNF3N1/Q,@S0CJ5HP)-LS8AU[H&<6K)RHRKCKOG*W%:7M+$
M<T]>8JLT2N'8F@[UXE<2<'];++199AF6A-5;K-*^LO><+IO(NQ-AH98NBLI+
ML?<(O9H-;^8CZUB1), AS_*F ".LD,2=(S_>3O%:F :4^M=57ZS=-VD="[8Z
MFJ+<S'LZ5!H12FT#_KY[*&#8?;?-M0!"U+?A6_B:CZB4OK7;NSUW,:)U27HH
M!#=6L#*%6)K+Y!?\[V7:&\S@%TE#.6VX$1%)"I_154R1&#.'<E>9G?E>73!*
M)]337D]UOXS_]O+DW][T//G1MU]&V4QKW;=<.D!.DT Y-;+_)TF4O=.&ST7[
M%5POK TU :B-K'=7((DT3)_T6DK,?L=#Y F*"PU9)E]V37IF8A()CT#$";F.
M<$D#MX2)>+K]-I13/3$Y)"I=U06;9I&=>E*+Q1E5Q27K%TM6)-/!,!-0JT<5
MWC4P_.0Z3!?>MVT9[@> 9*.P5]@?6W!CS?($B&$S8K="(= O0BV9;%/;'<3F
M:F)HT_V;)H6BW,Z&DEKO%=$ ,$\Z&D'Q\)M[LB :MO2%8"<X&S]<L\KV25IE
MR[N[Y7/+F8MBU?WP:%HSR9_*BI-$/QP<?;_MOI $(*/]Y-\-!+AB".ER'7U[
M^)C7XKGG8D.'.SJ"6[3J8*^2W1@-*F[S751ERHRVVPI_\J9L)5S%#2'L>ZNZ
MB2CUX/HPX1$8JNK+2O0,,F!1 )]]E!_02<2="/SJ(J"T>QP&,,4CQ195L4X*
MA#)#L;O+PCZ[V\3/O(D_)U1"1J? /6Q#OF,V3G;4#LK(J>@I2^!N*[_ 5H)2
M1W GIG4'+$P1#R>*E*[@F3',>N9 (68!?UWK^K@&\/9)FI ZC50M=QO_!38>
M'9!#*P$K#RH+2^3&_%;/."OR0HHJ^=K=,;Y!NZE43Y54EZ9[FZ)CYUV*'T1.
M6U-8+DSOP#0:RI>[NIVYE&T,(<[KAOQ%UYU>'5I$\95R5BB\2F@!\2D4<1D)
M3B7;+=R@FCIX=B=-G]E((R?XS)J_\?X%F[J.,(3IOO"NLCFX;N&S TLK#WQ3
MK8(5*$="59YZJ/R%]+43;_..8@2((,F35CIN./3KL+4S47DQP.M"->Q;WFFU
MSRR'?\T;QVLR#G$G2DQIP5BEA(B0?0\B%ABW!:UP627!?<MRQGA$R-7'<I[D
M!TI#)#6R MJ4XK,+95,+L(-G+,IWLO-99>=-4QQP VH#-6TY&&5_*/*FXHLL
MP.23VS"$ "TK.)*[B:V_+H';YXYI?Q)34LKS;U>X"]!9HDX VT5*ISZ%35>$
MKT).\C5*7-OSHNA\"LR'C\F:6-,4<(("LMBC=G'(RI4Q@S4I_MC'P;4.J-U'
M":^P<X=FGI*'?SL\^/;UJ$AP-'&R\Z(J5DSMI"T8A +%-A2J=^,*AU-18]03
M+_[:DBAHO[H=)U)*;A?$%8TT+D 6DO)'UKZ@XG2,C-S==P%F<D2#]?>@4G+%
MDB)1HP!X0&#:;6 I"#B_,'7!2B)S-C"56JXSGT?1U@]=8_7DKI-B6D3N^S .
MB:AC*\=(@>_F&BO)&?=VAAY-PT9928,8X8)W!=NQ[V'* %JC_I54GM($QA14
MDK=ROW Y!.V-8-7TN>>=6Y,]MI8:6%?\2E->G(^7#Z=QSUEL[R@?KDQ8BI>X
M+#95K"@$5K@U SOI\A)Z60+<;[AJ48?!ZP?ZO53D!.MQR3,9Q62O1-A#LA;I
M0+Q@]$- R+G(PNU+NIU*PBE1([]L(:W:!;J5CG[16/H"C)ZR?3L0?RG'BB:[
MDM!,$_/O2:9OI.?DQ7PWHHO#I?NH[(#[AI\4+^$P&T>T*K1^:6_)P>!1^K4I
MT2D;1TL'G7Y+;VE'2<)-BCKM19J*+A/^,R8Y=O^YDJ"MO5+X8;A$J54QYD"*
M$K;^ BG.;D0GZ3LD3T#R/+[I2)X;?H$ #QC:^<*V@^&A,#4N;&*[8:,$Z+"'
M6E4Z2KB:-%LV#(98X$-#SYE3MQE\^2[2?@;=/KT8]Z,5V+XG?43'ONH;H?0,
M-1LS8Z<;E"AY5ML1L(C48=F*=KI('_? P:*W'/>5B-@%-X]]7W&4!$KO]/6?
M>4??O#Y!21([?TU"5>WTS_TV%(A+?7AV-#-N L9,O8W6ZA\C#M2J\/=7>+.2
MI''(C&@DH-6;]"%U/E)UI--I1V52D_*5EC;R-7A#&HI\#0;H"^UQ$?OQX J=
M/O[26P.5-XFG*+U-*P:4)8)^^S3#J78?92M(5\::A_B.15+V, %1<ZCU":!A
MH@3\HI$N:KJ#?INN7O8"&COGRCTQZ-Y)*>@[8\H]672FK%KY ECC&<\=&BMJ
MJY7@J=?@\]]PR1ZWL.>T$GV<6_5"49$+NK;FI3RXD"L.:A%<STNV.9<INSWI
MGGG.W83SG@\I ZMAL,TY$"R,*K&%2NA-=RA%^$*5V(7N354M;2U=MCJ,-M14
MD8C,Y:MM8-EF$^_TU;M(,ITOZRT7S-O/^PW/EN<6-7W"D*TC2G'I](WCATQL
MRL\.O2:E!W66;S@^LH0Q&DY2T-;\9%6WCYYDKT@,S[.W_;HP#6N5FJXU#1<G
M3=\?R=G3D;YS+8#4BF>"1VM1R>]/7ASHK;E&>@=Q7(5?[KVW#C3=Y(FC15ZD
M4##L$WK\T+)>"M%%!"ML\O\660RH!3IGEX;&IR%N>(BMWGOJ*7G/[4"[@G,N
MU0CQPFNM9)8[ Y7<9Z(=^U9Q/A)F29>%#S9GUQJNSIG3SF?<6DLZE4@7D0&]
M/)WY^9H)D5B:?*1SL([,D[J 1_2S8(?W*!J)209-(TZ.,1(;6Y+\5LA>K7@M
M%*P:EYCQ'?K5D^:!=@=.79[+@N9N#8Y"6=,@-ACPQ]>] 6_,=<=Y5+I? IA5
M(G#+LC77R:R-JRN19B'B2.*&@)ES,2&@+M!FO"I"ZE:OEZ.LQD33B\]MIMRH
M6_AOKGLR+P_Z:4N9>,@IK\J0( D0=;?HPDS&;,X78$T@^[PZ .&(JQ76C4>F
M8KAAK"?LBJNA6/F- 7CM4NGKO#*Z?%PVB_.RN(ADG2WT#MW*?0-[.2H)TP6)
M=L%X(FZ:SCIIU^HL#5U<HTYNFGLGL2@NE=UJ62R@Y.JL95J;?2N4)QS)EOF)
M>9P8(5K2D^II+GNLH ;;F25F46XE*$;R0V;#IA@&>)AY0/MAH8,=LH?('VB/
M@Q#]\A.P8>?NR$)^\C6 !MUN:SVF'#.\C=8JQ5W",I:EN\9$@IE ;D-^6Z*.
MS/,R+#^N<$1,.5PCTFR94.9F;<]!SBI$U9*_,]:P_(.O;QWD(40JM#\?X'V+
M+LEAZ ?<2%A&P)TJE.I6+(+IID9*=YT$^G;:E0N=*K =:5Q4+0R+C:+IAII&
MJ R0_]ZC35W4U.R3-(FA"4WN+)9NOE1;ARBIVT$TU(BOP%9.GJA?3;W>\'JP
M_S+3XT_1.G\;K9"OP,_]VZA5)AH8MJQ!G$L232]MNJ%FFEJB4R::_MP2A:[^
M,QBPR/!M^>B$G*&V]#(_2^SJ"5?SYA.K[R_0N3'VA/2FB?VT)Z5@W.US:K<]
MU^*O'DJ3%DF3;WUQK=&9[CJO+Z7_@C(,)W+93?8'L;@;9-6,D0%WTK@[!4IZ
MP&<NR!0)+YBB3JC2A;E"^:8^I>SK#GOUKV.OI!^?]8O@_0DIMSLH[^?="FG[
MM!#0BK4@&&1C['C>[<WGW1MLAQV,=K@K0HLMC&VA)NYNB[[ %BGDJ\U7A1P>
M:W 4&&+OMN7S;@M3&@D5;RX\F@"6%14B\MBKT-UO4,EF6R?03V,A1=,A+5NC
ME]UMY^?=SBD*S?-=6]+&51Z[."PIO=NGS[M/$0B/=IQ6*(B#L^28T]V&?-X-
M(6>GX50/XRV++5D-2_CCZ+0H<>S(HG"W93=BR_9L@U(XHSA%?=Y8R+9_CWY[
M$+XG-QG"=W=6?F7G56MGR.;VI,4P\.Y\UB^Q)09Z\'P[=WOPN<UE%^CDC>B9
MV_>? =Y_MR]?9E^6]:('F$6K$Q0$Q#ODZ?5] ]"[RN O<7S0*49WPTK2I+Q7
M@@+1%@N)+S3=^879J1M5NBD@D/WH+RNU\3E$_BA-9VK#ELPA6 ,N9OK9H0_W
MZ-'6Y:'*%YU'@DY!8;]P>C*;[^YR29_WM Z:;@Q:FL38$ IQ[VZ\+[<YW+XH
M_&O#W2OYJ-W9(E\H0IXPE>=SVH^Z<I ZY)5"(Y(BV_#S'/(+<+QMW[1]L;S;
MN\]L1\9S=&?9WX@=8?14/$U-$7F/]W0 &Y%?:K1/RC^>D;:\V\$OX#/'/0P5
M-1X@!30GXY-\O9"$FX1IX[H.P-,;[ "D94:7(Z3B1=Z ,KFI2?E48F)5=75@
M_Y96I>P2],LRT/P!=WRF1K-V_@B5,OP5^4>Y3-=5;+<Q&"Z")/G/9T;=(F!H
MW%)AF#PU\S<XNUM$["]]+#Q!NUB;G!9(@"T&G#^*+K/!U0TH410*S'PH6N2F
MWTC09M)EMM%.LVXM'4DN.3,]+Y?4I:'X2V?]@GY59*>2A.8:NZL6AE:@[=;%
M7#KE\=^ J6;@_UD51AO*X@2IC8(XA<$;,O$P^VM9KQ-*"#A<*;XTH>%O?!W1
MP(U+8:6&(TU[H0.O%P.ZPLPD72CYV0W30H+.A_ZO5#JC[91K!ZLE&+KGO,#,
M&RZH?E_<%-;K ,#Q&KS23N[^H#YGV[?;0BO4T7>P7B0O$B!;T5J=L<'OXPX'
M'U2G(]142DE(3F8L654O17IM@ODC$A\)DG$IJ,5;T?#@Y@.PP<L1>BE#/UQ?
M@\DI55XOU#/HQ7Z5J@J*2F_[\H(_MS:%&ESA,A%YK8]E: !CQ>T>N1H#2FI_
MI8 )Q]< EY[@H(NGVO7NNOHVN>HF2RZ3:VP^_Y3GHCTG Z%6J')NB_06<X6T
MTWAJ:T(^&* .083-1GNEA(77ADZWL2L?=[[CFJ>B.N,6GGP+G[YZYZG%WDJG
M[UUVPB_V]-O9?065OSTY;14^_F"6_9^:CLL;O?%>@N2+0553/_P_;U[Z7_ZE
M*AEL_K$?W_L+_^P>_<"^^"Y?T<KE-*>IM[QYYU\2I.#JH;UR(\.RON.V884*
MQ"M%A+V5%NQ3#WCWZJU_K0'=(YI?A0IES7*/DZK.);ZLC_<H)HDRLQ4J[>1W
MSE  .QT78P4R]F@Q^-IX7JQA+S.G<H+CP:S=C;'=P<D7:@7,0 00MYME*- E
M6F\E;7;O^N:BED^HVGC&A8'GY*I.GF'5\MPZ,]_6H?J'AFJ+M(*!Y=DUHL&0
M"QN@T*GJ6DC==DW3*"OI-7?]$5KWX-:(:]@RD %Q<1KY:SBT'U4.6G[H>2_W
MUS=_OKH9UVB8.YSH>V4^.AW8)GXRPS6_"VU_D3PN^H+WU5*CJ&12-[524>1+
M7DI+BN0;+KB,W1+1>7&+6Y #=;D4I7K7HF[T"DG\&JX83ZV3NWC2Y]UYV93:
M.7AF.8J/Q  +\2>",^3;MD6_@OV%N\W[O)MG_6Z")SKAB$[=UK.)LUA++UZT
M%4Z.)!G^W67=O&^?">7*7<#P<P?AI67]H-64FO:!-)BVVNQVZ[I]Z\B<!1%@
M5L:7-F3NH*X!ZOK=38:ZWH(@T$MF$?%45AS1;8<!76V1'M@:5A\)/P1M+@PI
M[O$AO*8NOO@[2130@IE\1*Q)X<BKNW4,.G_,F:E;.P5Y"J]-WW;)8@>3]Q>L
MN 5A>1<],_"5S\J[5 8<M<BB@(G-O"K,IEFO(D_\+NZ.B^W(]=WVY$[3#8WA
MC&2@8Y:;(&><A2@Y0B]M)YDB#4\2%I]5" <S65:M^0MC4W6#418;F6OXA<0V
M+:L8^JVGH[Q*3*\CC' AO#B3-<K\\7!/@F@?@J5.J1P'E'^.!D;;_.03\P\?
M@AU?72%]F'G_,5JOMP92!QNRH<!!Z/(&#$=CF:1[I9A)$X'(O7=Y7@<9^@1%
M<)C]/,A$.-MM2OCWK^E*LTM*N"]L/CN?@ H=9ZX84$#.I7F5R0VRA,RR;)M^
MVR5Y'>.D34(:'>)1#!GQ6\AO_ 6F@3.8?LV0Q]>1IQC$A/<0@^ 42R!XU./H
M>L63DY3#/CH<8Y!U;/4\!#+<OLOII)5U1(AP2*5R;S^)RCU):99M9KANUK@&
M%::=^C=[+'LE:4]+%B<W0M-]0IMY\")D@4^0!0[<2Q.$2U]B=T+>QO?E\5IY
MG!:A60USVY)SCJ+,6A'3_\]R\7Z>+]YC2?K.B&WIOG@/.FL[*-F[8KTZ>&O"
M3JLDWYS,S9_BWGEE]\Z;$*+!SW(.T'$3I/9*8I_;=XY(>]3]V;EOHA=X)@T/
MM=P'B)I423G]1M1-U#TCY-3XEC;\^J60]P8#;>98LQJA)ET7'T+F5;>=-@E)
M78:(L/77;^:<95AERL,:VUBX[A"2@Y%,154#_"#1U@N * I[,_,])84?N7Y#
M3;PY=\6@AY'Q" I>NKC;$CR&2K?(O/H1\\XJ*80&85X9ZD)E"]R+_F2\-X$W
MJ3.H0YR\YWAU$FK2B3H(OW_SHKOD2/,T9SU2W7%S.2])[J>B;- ,S--5\TXI
M\V!LZ(T1@I)8LT1L-G/"%09 55<N!<N+4"_H=G+X%7QM%/(.AWQB7<086A>Y
MJ!M#GO"]A[.-X*OK+1G-J*ACN.!Z9Z%Y>_M@C6#MA41>VI*%@0 DZ-69-5-9
M%A4= $QFG/&E'Y>;>4\+&9HK,%5E\8&& _R*1/6'?E22^IX87'M3R.TGST,N
MN3OYASU&&)FSL*'L)_#A6"+P>C$$-3FYYPR\N'XXS65'1CBK=^1$Z$+IU_!2
M&'R+8V!DQP[%%73#QV%<[-&TB[YE7$\^IWWX&G US&']YSI[UY,2*ID2T^Y$
M4RCTYX5RS#(? 7NOH$Z%/^+;?03.R_%584WB)?O*/&+7)/>_4;T5_VC]T;+_
MR*N>#06R-X\?'A_+-35<Q9D40!5H,L3GV 3XU!^PD]"M%H<(OZ-G'JG4%NW4
M!GBHHM=@]\L'6<3%1I4.9EO)C8>]".5;JD3@P>=H^<BN+/V%\\IHUJ#C#@V1
MK*>BD,#F9U7-/>E(%):%HUZGP\8]H='[9'%>\&'D!E2%Y$D"@R _Y'Y) S=*
M^73H4 YX(?X>)4F3IW29[>K*^M4?:)(%L "PWZ+F3[[I*YQ594B0I>Z[ Y2H
MR6^=+^7<.&UUY7CQ#[,W5Y\-)2N<E([0)F/<[D%[G7 DPKKKK?*+ND&@R=!K
M0H<\"T35[E&!P9TD-<01C)_Q5SN>T\#HFTY46]+AH&ML=Q.5SR=J[N<TK1WL
M,S-;6 ZD:?+:YLG"3&)S#:#[C7-/7GO#I)3.OJQ/&WH&CNU2%B!$Y9@#G!T8
M/;_QK"N&PCZW0+$MVTI481M_<9C]7*(]Q#*LL2*AS$1:KXM%A _)HK/R ->W
M]KIOS^NF(V.?X8*#C])VH"%>0S/9=JI6:0=X<+[./+YVAFX?%0*%] Z>!!!N
MP%D% OGIUMG#&ND@*],F6UP"T4M8EJ0NWC@-3=T%YT&:2K$:1;%%D,59TNE#
M+'+)D9=MVXN='OAV.];4LLR YRU5Q]E2A$;=D5?]"C T?CS8J%E0CL,=='%2
M1^QCU.TT7Z:7D[Z"=#DP"*N0 !/S-=V^O/'K*GM%<SM^RB;(T??:J8:W9!FS
M*@QH7H@Y7:)/B<65D>\X6.=]Q6(P[EZR4T)\MO\%QD:RM:$CU#6A=R-?MH=T
M5W(?*'2%X7-K.,[SFM__//D-G]V?^$T_R9O>V9F_?^_MZ?-[@@Z5'?(M=_A*
M13A=FKCE\&5.Z'9>FTV7W7]!BTY&VBQ[R2>P+DEL_TQB?IZ=Y@V9;Q5]\OJ\
M%+3AS\6'O'TPTP[$%R6[".GDSF 13+5TL>Q8^GT=67?.=/AB5) [*X;'#^.5
M1)I@';";Z(UN^FWZ*VQ>T',W7)\Q\6U8!GEV_/B;+'["$-/0%X:>Y:<3=>=;
M_EZQ#._=QK*(_"(GIX)U"S]B<C54Z=A:% ZN?4BF\Q"Z70::1_)U6U5RLL/6
MTF8YK#$7S*B@1$VYI=[X<'3A*C%0JNR.,P]'.VC=.?05XB=]HF:ZPTY$[,3W
M-QT[<:-4>0HC9]&R'I,N8B-W*M^?:/AHYUPD%C4."!_%KRP'WY$6,)Q:)+M%
MDRAZ,V<,@%7C3,)WXWI!.DQ&]1X"A(?9<W<FV5 3OT\C;F;L^8(-M!^14-"O
M=+INCQ/@Z%JX]E]SRKM))194K*'$64UC88(YYK^>:D2T=+^%7L2^H,U4'[YP
M=3/*X&!3?O!P[4W1G==+&O793N[Y-^(V'SQO2@[<_JFI^RT\A%<UG0XR0-X\
M_].K>P\.LY!GP6VES>PN\U;3!P.[A,WF"XX_KLG[69X57585?=>(-5I9:VZZ
MY"0VHWX_)]7$*[+H13;/M0!QI<4OSM%0PBI,L9+[L47067(TPS(4P8*02X6^
M>7:?S^N>PR^D(\J:QV>UI&*(^YLXS[X]?/3D&V=!P%AT\D5O7' 1#8UNK>N+
MKHL:]^6E)&4$,U3KYP;MY8((-QQ&[U$HF!7;LJTEC,Q;/IR67N:G^9K<BKS)
M_E[0_Z$O/DI,RA?()'![/UD(]JC6\$'S[-$AVT=%0UN36D@CBR+L!@P%K4E?
M%"$7@Y6U9I"219M86EE4A++-ZPWBD_O%DN:$!X/Q.7'F+'C!DKNT^#M]^2F;
M>^ZU<;O]3V5_2S:XUJO0&KZ7;NM2]IJ6.7QW^/WC;V1$3;%1'_+ZK^.<TQR1
MK[:4F!V;[]++L*%MV>2LU9-^4V:134V]-;]&+@U[K#0&BS"G= J_.Q9/7!Y=
MKU8M'4Q7R"27F0G2C@2IA<AA/SF>>TCZ0M1ROUW">!0MK(WJ !O:TT0*WT;]
MDQ>HN ;R-G[1%\SV_**V-OC&T=&SY+S9.KTMN-[PXYUOOH9KG(_&!?)<H3F!
M KM<XLNB$EAZ.@9E9Q!U5>*RV:ZDGW_UEPIAZW?JZ=(7S];UG'L=T![7FV@/
M[.L]#-^*/(=SY[WA?=PT?BG.G,A-=2:A%';-^&Y 0,A]-M7K3Z)58H;4\*;@
M*"-6'WHD)MVB)4H-2-PZ.VOJR^[\]IDETJSX4GI[269&%JKXA&F+#^SH *#)
M!X=T7C?T91@FL0:>B1'6L*Q5D)2,=^?0M(HA5- &8SM5_LJAG@6DD\M2JXX-
M[B E]&%/JN$OE5KYW<Z$\@I1WI\745&TW_+;T1+2P7#QQNQ^>4@F3 [08R.%
M=W]PT@J%^F#8*!+&F?;OU8I58==(1B#"JI/]%P0V>R&IZ&"$@(^2%[\J<'\&
M30<_2L^5 *OBX6GRLA6D2FRC+7Y7G:"3-5=TQT+QK^II[017S#LEYA^ISHE5
MM-9F>=D,19JLIA6;-Q(#K^=KJTJ^?1KM!$+RG.20X5=2X_8H),B!*V,UAY/;
M=^SMPQ7QJSD3],M2JR6A#=<<P6/973$NK*D_P.TAL?K=MX^>'!Z1"P.K3/N8
M\_[ 4^7O3VS4KV<@603MFD<D5I1_HB"P?F@+.(3 8;E\T4>KN^U [:D>O"L5
MW,N"V848B=R"0C&VA(_)(+T,A,.15BCL].@*!N1B%UH8U@,%,AN0)2 D ^]7
M;M'2VKO%-T!:X"7&.P:5J$UWT&_YB</TEMV8',ACG80L5@1MGA45Q(O\;_9]
M.M!$LA_W\4+D.PG[5R4,L)*A-A";#84P.P'+K+D/=[UX#SOC6AO,\,-Y9YF+
MM)=FW/N[G?X".[U:%Q^L]37#-]9Y56D+AIGBRMEJ13Q]YOTY3_?&<F$7U=WN
M_=MW;Y._QS6 XK"+?LTJTSR.*L*SU*E>^-UQ)5]:^W^-%@%W._9OT:S8QL0[
M8_ /_KB\R"N&Z^!.AW*<)E>^?;B.EP,7DRS(?A!-\Q:)$$LQ<FY9M(NFG!O>
MV2Q8S:M_#0X=!][RLZ;0BS'ERAPX$ +%M/(E)EXC9Z!3Q$*4-@:)-X6O>P[F
MH)F+B8.!&V%<.YI<V/*@-AGKEP;X?P5,A=??_?N\CQK/?LYVU4GX62"B,PFQ
MG+;SXM(R$ZE+$B1*(D2IN^&+I#P8V)[OM\X> ^N!WVD%:EH#E:K!.UZPSWPG
M#14N2]8=R]/GW01RKNG$2BT>N3UD5C/BEYVJ&?@5:0.8?7#9RF%[KWT36)_3
M&9KW8L#=;=IGW33L0P0),=<AE.[=/GS>?9!B)+)RBKOFI1Z5^/0FHQ+OSL"O
MVYL99#MDA-52\F5\[P*57JW(NN+,XIUJ^@)7A'?I[S;@BYV+_Z[I?S*.,]QU
M(O\")X%[QX/S('KX=WOPN5T]ME&!SJL;^C*7Q\W;<EDR0/?N1'SFW<@W19HI
M#:6+=UOQY6X)\^?:RWSKXF]W._(%?6N+%,8:G[O]^,S[ :=BQ9A Y/OK1L!/
MX,3)V[:@';EK+OYE3@D#;G(E71KDXR-J!OVR4=2AW:(J)FY:7Z.WTXU)B#!^
M;I#>D"J)R60JV3=B[0@"M9/L$,IQ"ZO]@^!F;;Z6LGXRAE#E@]P3 "I<7R[4
M8"ZUL2@;NJ9#2> +9L?Z@$8P8\ L",%VEEKSUE9@>D#2'JUF?O?8$(/\G'UC
MKMRPP?H4Z5C1<:5>]Q68 MU' J\=+EZ:T=F"8@Q?9$ANMJ[S*D"O-6&S!YBM
M488UD(T UH\&/\OZ:LW)*EJ48JUUR1_9(Z21/G!E4A-!V= UGMSLEW0HN\D=
M,UVET$P$J34>H= AKEYKAM45D#K9'_(,#S;^,#LAF;2T[GSWD90>[ZOCI;Y&
M9F_PL#Q@1]UCXH]'O9@J/3_"D9WSGY7.N]VZBO;AK 2^(JS=*11=28OR[#*G
M$Z<]:=!Q$41+;7IL&<U;[="%-);WSY+OZ^(O%B3*C1$R;O*N;Q01B4._!TDL
M2V1LV$H$O2$5)J?2@"#&!Z=]OY1X4$_>_9BRG8;G7:.<XH&NF!>&2?K+X5;=
MW+2^L3S=%$JGUY<5K<QYN>5I\?UU2AM-Z_..,WLW$47_"Q J0@%G6&.9G\!!
MF?,"7:.,!\S7$\Y#45F1XHR-)[,M%GR<^*K\O^R]"7/;2+(P^%<JM/8^.99"
M$[Q$RO,Z0BW+;O6T+3_)W1/S;6R\* )%$FT08*, R9Q?OYE9A8.71%('0;"^
M^%Z/3 !UY)U969F^ES41ZT=X6SDN-MTE[:!ZSJ(R"55-.3_4MT_NN)^D9>*\
MJ'!.5Y4D$84 GMY]74 #F.Y8^PZQ4:R64"S /G>][P%<6>Q#0M=1\]J"CJ]Z
M2*TF!*H[FMWE'<'ZZ=JJ?=JUZCVZ#(W5\-25.X9IY/BT6[?L1O[08G^FM9GU
ME7$20^IVBW!K2Q>NGM9TK?L5RROFOW#X=:B4E32)**_KS&#R6F9L(Y+^3G@$
M*L:?+BD4AEJ*ZP+>>.&-1UC8*>#^5,:Z&"0W!RZ[.(S//= <:VFUSC3Q"]D/
M;Z,K)0\6:$'8:R0:Q.T.<<A\&<IJ;)B X8:A@V+>.%X,,#C:'8[R\G\&";M!
M C822&N*%!!3K'M.Y=_S OMI3K_  A&.2.MW%)H,S#5NJ*D 4A F@9,%;739
M_*RN^QAK7)FNJCODQ6+;I4*?<!UIO5-=.F42\6(E,U4Z9:$.%E9*4=70#$)?
M^8@COPVA:]HJ[T4Y#O" JKH$3N$2CK)"=3P+_@S,,?KK'Z//B$<5S0RCF6+C
MZ"UB9+K@\::ERK%ZQ=Q=Y;1.!I;%U^$;^'TV>Z@8DBX$[]X_VFC'(/^9#\"P
M,(NJ);-XH[%X3'!Q_>?5AQ.[9]CS=3&47N#/+I_F@E4CKW #E9G&TZ^,'J7'
MTI!:?J>2K!I/LB.,:;./ZOD1^NE9U1CA2Z&:8J4OGP<!U@:\$51R'5[["!J3
MV?63?^[EO=3\&$Z552[0+#8[4H2=-_SZ<G[[X?Q_V"=5P>Q6G7)^5N\?Z^MY
MZIWL5A[U1\ F2F#P1[6%$*V.[,+X>*H+1N+ Q\9G:?4.:GJ5MT>C>&@XB$6@
MHNY)D(J_D"X*D;-"E4'HV"EDLP;/G(%C[E&DE-"LE_D>1>D89UGCMMPZ3BN/
M]Z.0NZR@OK/2$:DLFFN64"@_H[]Z(* /+C2/7,HWT,^7TKG%SB55UL68<JUP
M?I1V4>@#]^DS9$I[4D=(,V<;G-JCJ2OH=,R0WMZCY<T4_JP5PYR.SZ4\4=<T
MJ*:O7&#@^;.N#(C@-?H^U<W3#29HFX5#'.V3S@-*+3]?A,5N,5DC/UX#& SR
M-M)NX92MMG!,C\DLV-U#G>.F1>LY7E4$HUE?*,^C5/\E"VU^]?7?-9N\[D'2
M!EW6QFO3"KGH;(RH[0A039XP4*!AC1,,(:FL@[1P01906$G>5GK7^U9-P7V1
M%B*EPKG83M!-6SOA4]5N$HFU/Z7&+)K.E091S:GT+VX("T#*#^^Q2<!TXCEI
M.>*4-["AM:KY0].GVF=FR;F^I *Y@ZR0(=(+=0P4- ;UW\+3/:E:I^/1H,C:
MNF%.U")+Y2>=\&RJ*_ FTWQ.XNH'RKWE6QD)S.+0&YGI:CU3S<VV.FEBEAI+
M+WG946=:7UI7801$M-]F,JB0$#*+4"*?##0NH.$^N <)1L4<L>=5FE11C$BX
MB2Y2FK8U+8Z@D]H&A:_PF 4C32E_I]%(;)H"4CK!;I"(7!$,L=((LGA&8,LW
MJZL$T^'[_.JH))F#G%*%4AR8N_%+B!A!PJ+>\:F>P,U3TT^LU()%&HJ=7-.V
M0>E1?$@5. !6"&&>UENGWO24UK5_I141,I@928$5U8\/1)G..R7=IGI[8['-
M) :"@K&ESCA3H$DF^'>G7H.%XO_-\]BLN@4ATD[?9/E+F.^$\1TB_HEJZRO<
ME+\>0)^BWN)Z"J40EF(M:RI12"U+L_)R+@%43.>20_/5%MFGCW5L?=7_4 LZ
M+67'".:L@U6X? ^4UY8G!8+(D621T*+1OE9),"'9/EE'JPB'IJ5P-"$DPE>(
M[_I<8793<S;,BG4494$1FG.X8&@!Q"3X1[!KW0 2EH<* 6.I)'')1)CFQRN%
M*ZUHB(  1X$]-[*ZOC%C![IBK$P-5Z2UVU'-8!HAT&OF8:F]!MJWU=V%-&\6
MD8NX%)&#=6UGP*A(3\69O/%$8#,"EHJ#_7-]41NEF<]$(@6&4"0,C%,KYLJ@
M^Q\,L:Q?3G*"4[D:919BIC$V_,M2?9:ID]21UL2:TVCQ+4TU^P?5M&--L:6&
MSHI]0'L4_I4V[<XR,(.Y+U7^Y4PZ$]8- R3J]F@S99L&%!50[,LP-!<4<BX+
MH-9<"-9!#9N1.\DX4;Y^BJ?B0!A.+TZC.V:ET]QQAZLV+T@#6%16]07).R]D
M Q537///YGI,P'?A'?=U<[.\N7H^"EC$*H>\KRS$1<F5!W"6236>M^JB,(K0
M?Y.U"=A/K=TEWV:5Y@NP),,25LR.\:FV]"D]CF%._X!ZN.D,C(M9K7HUHU5Q
MS;],\<SX7>I2YZ12RXMH:K)9(;2I.Q&V,F$8QZ.X18U^+.B[$-N!2&5I9O<%
MTF0[[&'AK1P>Y?$HQ$1,="EB-"WCM/Y4-FIFW:.326W&/7V)0+^CZ !%:M'E
M!.D_]I)Q&L=:%A/(C>L(VS7H'.ZB%$E+_KMBHMJ-4/9QH9Z>NA@1#C!M6F4O
M;F>R[8-Y2]3$,C-*MX-.5&]H[.4$9MZTT.A<D25VQ+I7W3(I>K#\J\RO),GU
M5Q)YTO6</+B:MC5WZ$O=]!0H*:T0EL]3RSS;4/=ZT%WI[ZAO'U $?IW>U8FG
M$V5QI?4PU)D\73 AY43<H:E MT=.^R[/DLILDG*!/Q!J"7:W*J0DIZ7S"F(1
MB!E($_\"4\0/IT(L2-H]+*Q>()RTLRU!-+_L0U+HWI.J1PZI!,6Q4J1-4NF^
M!.,^=2&(,T362DN!:=>?1\D0C5CJ9*2VI:-]2JUK$LRB?)C<+M*N10G)\&GZ
M!=YZBE1:@NJ1B>]@L)FD)/PX /_=\>C65X(W4.X5$1?NGCU"BKC887K_)#]!
MG^6 !U?$ :(4D4PB-!T)S]J(5VHI15R&KT_Z:/"BH-=^Y_?IW _JOS"C.PWF
ME>M2A1-S"R#K=L$' ^[AH5?H (X#@9K"DX7UWA.K(\W@O25ULXH:E&8X(Y5&
MN5P8^"3(1\SWTNLXJC!5-O-M'OV]_*'UR+FB+;O7;)%DHZ( \$FQIF/QY>SH
M*+U9J/)0:*=4?CN-C,T2M$R[):8T6F2 _;.E%QW2)3*H" 0WY6,-#4V*L_V'
MBFR]C)LQ8JUN4B'DZ9X4WI&;I3D5#!MD]*BY0MW'FJ."'/G-E<B??3U%?_$Z
M92I70=W=XYM9;N#C(G;_,*],W7GL%+PDU.7J0C!U*LB;%"S8?GBQ)2I*"@JE
M_ 4N!^6LJY&)DL@:G?EVX&'KYJRR]D"?L":*C,"&ST5H[HO@#YGHS3N"%VP)
MFNB)!H42X];J ]R5N%QV['C0![_VZH-?7*[G_O>1UW;L>O^TT>*=SFFK=]KK
M#YI.L\V;S=Z@T>MTV__;:!SM\+1X-Q<AK[Y=?F;V+Q9C?WRYN;R]_OW/RP_L
M]MOYQX_LXOKSY\LOWV[WSM3]$JYYE/'@JE?QV)JTU#XJ!VX;@-JO-]=?+V^^
M75WN'R[1;1$_0+.2*E22%$-%?NAPW1;V"Y>C.PQ0U=@W$6!B(?6ZQPN*JF\[
MAL5 [4]5DTZIXNL#UJC73ML])O'R&MH?(GX_5XIC)+BKK[;)N4E_X3$HZQLP
M+F':WT-,2^4!7V?:;KO6:[>+TU*/[/1T]EX''[DKX T,MD^XHX\/*;KJDI4]
MLTX9@X5<7)V^IX _D*I-G22,K0!TE":DMI]5.-*?Z]@:+B,9=;5]&6*IJYBJ
M3D+Q0GWIWM,I_ZKI>9;V7\LZH%-\@@YDN']".33J/Z0'<SN [M!RAX+J],)L
M>K*^V:\=K+3+NFI7E@6/5;C#5]4^@(0&N#'JUUIC_23684E5*R%0"6,B4"_H
M\3^',DY-*SUXVK:6HB_P*KI-NM0!V:&3/ P3P>KN\>1:_:9.P?/,%M4=4(ZP
M0QE264IWZ83-UFEVZ>)$GT *=^8R11%T-69W6LL_4)"?>[GY&!JZU)DZ)@9\
M!!UXZK0\&V&M-FESHC.SB32$4CLK LOT!#O<\XD49^D?[]$N]?GTS N(QNFC
M][-LB!/@D1HF>^A):#[U.#<[K+HR/>((_L]-9]:/+7KT4^PN/NM9W4YKY=.Z
M96_YK-U</>=#7SZTUJ[5;6V[GM=>:\=JUQM[L]9FN[,G:^U:MKW=J*^_5KMA
MG7:[>[+8GF4WFWNR5L-<=:O9W4YL/\)<C?5&_8GTC-(UH,Y04?[W4?,H]Z'I
M/L-98_*#V;,J$J\XS&LTI<R>VYCL/N8SD<:D &.FZO6^']A2'3=TM-:K2W:O
M#(0R[?]7,,J4X?,K668'#0HR-P\8 E^U7:T(X@+,Y0,&QJ_H.9PKS^' 06&$
MI!&21D@:(;FAD'S$2L0*U<,H3 +W1*_6<808#-[K@ F5C)S$C,I3LG0K&]J6
M,,A+0V8A2$F0.?=YGX_Y&K2Q$@Z/$DWC&6%99TL@2HF^NZ&WY5!M]!3;S8/U
M.4F* %%?'PP&M<^"6KMN4%M1U&)NC-UX;_!K\%L!_#[%@MG4?-DE5K^(?L3E
M]_*:,'O(*?8S\T@I&>3 <'IJ<%HYG+Z,1C.8-9A] +,;QTL&]/_V)R02>?\)
M@^WLB;FM;D7-2\"U'S3;W)!:E]/%BTJ;@\;/IE:=P<\^R'R#)<-%6^+G^97V
M;@,!]^Q7/I[(D;?689>A:Z.]#7X,?HSV-EAZ/2QMFVVP/][S=RRU)G<=CM\_
MTMPR0+NGP;K]P\^30G(&2P9+!DO5Q=+S:_!=N]*_84ONJ5'C&^?^58>H*XD?
M8V:5&S^54PT&2R^!I:J?0E_ _(,P"CQS$+TQ[%HF"%=J_%3H"*V2^-EYD-1@
MZ1"Q5+WCZ'^'T7>COC>%7*<Z)%U)_%1.\!@L&2P=GBE<]9/H"]V1RTEB$\5^
MI1M@)OYF\&/P4X;XJ,'2(6*I8L?0U,WN@D<A/-OY!>_](V][TYSA$E-V)1%D
MSJ++C9_*Z0>#)7,6O3F TX9[)I3]TLE@)OQF\&/P8X+8!DOF)/K9T',]\D*C
MNDT26;7PTS;X*35^*J<4#);,*?3F /X(LWBN"5YO'KS>- W,A-W*G:9G\&-2
M! Q^2A2V-H?/#WK-WWT^"G??&F7_"-N<:I8;/T8QE!L_E5,,!DOFU'ES '\2
M830TUY^WB(R:"U3E1M"FW>$,?O9!M!LL&2R94^?<?X[$, R,]MX4;J;.<[GQ
M8XJ7E!L_E5,+!DOFW'ES %_Y\%OHF3K<+YX3; )O^R Z#)8,E@R6*H^E:IU!
M?Q5!(*?^'=^V#.A!$W>W.F1=2?PTZ@9!I490Y;1#);&T0W^EZD?05X'K<=,*
MVES.,?@Q^"F_YC58,E@R)] 9>FY&H2O8E?1YX!H5;LXYJX4?4[JDW/BIG'(P
M6#+GT%NXT.&]"5V;R%LEL60N4I4;/X:+#);,&?03T7,;)J8(]U/\-%,GH]P(
M,FD"Y<9/Y?1#);&T0UNXZJ?0_X1/^7:)W":V8R)P)<>2.6<H-WX,%QDLF:/H
M9W&B/_#O86RRR0QQ5Q)+%5+D^SY&U0\5_RF".'&^3TTT<F,F-<49RXT@$^TR
M6#)8,E@Z@)/%;R((A)1BN[Z"!TW9K4TO<)28J"N)(-L@J.0(,O@I-7YVKKNK
M?JKX>YAXTMQN?8V,D1)'NBJ)'W.[M=SX,?%\@Z5R1_7WPGO^89*"7B$ 7F*"
MKB:"S,76<B.H<GK!8,E<;-T<P)\Y_&0BUYN";=/V!B;N]LHG"P8_I<;/SN.B
M!DN'B*5JG3S_Z45#S]14WL8[,_JAW @RY\[EQD_E-(/!DCE]WL9[CJ:F+J-I
M'EL]_)C^C>7&S\X#HP9+AXBE:AT^_XO+$2PU-@U^3>'>JN&G<J+'8,E@Z5"Q
M5/U3:"FY,TJDB&/3ZW=C\)G:C.7&CVU:!)8<0>8>5;D1M/-(MCF)?M"1%C)F
MYCC:B)^*(L@86.7&3^74@\&2.8[>PHWVG)$WY"::O7\1'H,E@R6#)8.ETE:.
M*3%^*G8H[4DG#*1GM/@ATW0E\6.2RLJ-'Z.Y]P%+.\R\J?PYM"<E_O_)Q#-1
M[$V!9SK0E1L_.P^_&2P9+!DLE1-+%3N/SA*[:^R#=6$99?[2KG2)2;N2^*F<
M #)8,E@Z5"Q5_UQ:RC")MO.I#SK6LVGBD8G%'4PLSN#'1+0-ELJ)I0UU=Z-M
MG;;UTN=P]5<B8V\P+1.VOH4Q]W>MROMAY(KH1,'AK G <\.D[PN&VT^?@L%S
MAB0A0]]SU9/]8XYF:\M:W\\!HK(PE*&(8FRFLVGY.D,1%:>(+3,K#$%4E""V
M[.VT2WJ@(,A/,8?IX']=[^[G?]!_U [ZT4\_9[M)'S+/_>\CK^W8]?YIH\4[
MG=-6[[37'S2=9ILWF[U!H]?IMO^WT3U:&/'9\&'7YQ!R.H^0!B+DZMOE9]:T
M&/O]\M/Y[^SKS?7%Y>6'JR^?;A=WI9<VYGB?CL#=7FH4/C=I+6QE@;9H*[="
ML*\\BMG558U=Q6*L:*U;8U_"6#"[P<B>M]^SBW \]N*Q"&+)>.#"OX,8R$0$
MC@?+&801\P+X[YC'7A@ )P>.B )X@85)Q'PQY#Z;1*$C!!*7M%9":B5HGD8W
M3;LD=-,"NOE\]>62W9Y_O/SV;_;AZO;B]^O;/VXN]X]Z@$88GTQ\D / Z<^(
M4_V=GJS=@M5,0NDA:9U%P@<:NQ/O[STW'FD96?Q*2[QZ_@GO@WQ+XM6?%!;H
M (6+:$< ;39F85'\[P:TWLIH?12E6YCPH3CI1X)_/^$#V.$9]^_Y5![]-$MI
M0&9%J,\#;#7:'D+Z*\%T.==]/;_Y!N)M:\%Q6@[!H01SVV*?SV_^>?F-?;R^
M83>7GZYNO]V<?_E&4OKT_2V[N/[\^?H+N_R?/ZZ^_;L&;_Q^_NWR [O]=GWQ
MSU^O?_]P>0,#?/MV>7/+SK]\8%>WMW_ 3U__N+GX]?SV\I9=?]3?LMO+BS]N
MKKY=K2>7[!99<KN SF<>?1>@P0KJ!Q74KZ$/%HY\;/%:6O1@JL)V>F42L]>@
M01U0OR'.'#K?61QQ%X:'?\<CP;Z<WWXX_Q_VR0_[H&1OA2^<F&F@@%DH(GH+
MOT%U+*?C?NB36F_4WY]_OOQ@T=^@XL]AR '[*/I1PJ.I(CB[7F.->J-9PT$B
MP>[Q/R#SH_"'!\ 6_I2U3K6%.E(0QT$BX8"!B7^%<XNWV+>1)UF0C/NP,GAA
M\2LWA,T%H%LB,8F$!.%!.^!.G, &\R_[(A #S_'@Q_ ^T&/,SP=O.3R1@LD1
MA\$8_(<-(O%W L/"XD?"=\%R2>$AXT@ V (^%BE4^E,FA9-$H$K@<U=P'V="
M"@L1),KVP?6IY<2X""\ 0O/<)%_9_2AD(WXGZ$VRH%D<LCLTLN 7+]++6ZU#
MR\%K'W!; O;^%1P&9[IW%LN_A,("4I<K'!]@#GB,V(2#^\.#*7.X'#%7[Y)8
M;(&@X'5\D["?4ER!0I RW)!F$#\FR(N Z E?&#HE&_A?H'&!%A0;)'$2"8O!
M,F&\2)&H!\H3QH11(A%S3ZU(O<D$)R-;UI@WP%75\+5!@J_#T*ZX$WXX0:.=
ME@5^XGT\2M?<3R3 1TJ+?52# 4 \">)3%LUW' =63V/ A_GZ[SW?AT\FN+9D
MH@$%6TG\6#'B1$0DC6%Q R_@ 3$JC.R2458#>$R\&'Y"*.&/N(2)#\A5(!1]
M<$M%=.<YP## KUXDR/NH,0Z3"Y@<_E<FSDAC8@#R(01.BT<\IK7\$G(E@C[
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MZFY\% DYT45GX#FN8"@"$5&1%J=P5W]FK3Y,G?!AMFBJEJ167F/BAR,F&92
MU+&J =8M@'F\ 7(0W<#/X* +)^0$5ISJ&2N_>.Y_'WEMQZ[W3QLMWNF<MGJG
MO?Z@Z33;O-GL#1J]3K?]OZWZT<^[KD1R]>WRLR++CL7^WYO+V\N;/R\__'^/
ME130M^9[67TH4P-GK@9.:W4-G THI)E1R,X*Y^R.(D\M]OG\R_FGR\^77[Y1
MP:?3][?LP]7MQ1^WMU?77]CYEP_P?^>___OVZI9=?V0?K[Z<?[FX.O^=75Q_
M^7#U+7T'R/J/W[_1*]=?+V_.\<%M&8OM;*Q!BT5)7$\ZB90HUE21&NY/I8=5
MYT(L)B)G!-\]"F_?$R"+24S[XHX')$EA8UR"WI)4(@9'(@4A8_A3E[[#"B0@
MS!,_)G44@OK69?/P]8$7@"('58L5]%0=+E*(>!6R4)\,[\AB"1:8OK!R.0H3
MWT4M!@3NZC)\?R5!H0X?SLX3&%@4YX+UQ6),%< \53V0OD[KAAU]S-Z\S=_$
M==PFDXE/_\;R9Q]XS(LF!O;[9E<U-8Y=2[7]+XD$;$B961-:WYT'00)3W"BU
M!RO^"!!G=OWDGZK:3(ZM##VP/RQ;2(7+L"C@B1^&W_&-PHYX/TQBVK@N(!,!
MXH)$R%H*?'@_Q8@N_@::5B%%%5#3"[]%S0@KO. )0?0B!,T740F[CWK^W_7\
M.9R*9@TO8DO;,9$GO\-2J-+1)"<$[(9.)1G)HN"JXIPJA(0F3F%[$N@1[!?X
MWUEXGV< OX$IV$=.!>\LO9X*</#')1#ENG26)W,(8W4K.5?7*JVDI]AI_M=Z
MC0%98V$[,G"0LX\^ ]$-">;_)=F'67%QGM(C%@/,>.4BXV!\YR;G^>N,YX]F
M^ UI=#439"6[J%K7BNW4&-G2>:&N@EF*J\CLT8MP//8TV()"!<.6+G*X#GW8
MK5<H<;E<T5V#EW?GB?LRDO&#1/LO71DRU2P1$L0(7CCY&_#NQ6ARGXS"L6"C
MO!@78HX,/JR7BAMW5(%6JL0VBL+ <VI ^"?C,.I[+@B3(8J*\[' ZEH!FX03
M[:#5%&'P"<S^PT.W#FS\T];;&CMMOZ5I\'^S4I0!Y9/3M(&(TZE3 0J^4@06
M*"B2*!RSSP)K=45BE;JJL=R%\:=KT==K^^ /(NX:(%)0UEYP%_IW0L,$P3V!
M)R21TZJ=I'*4ND=FIFI;?:W[X+LAR>\S5D!V#?XA)P#B&GKUDFJR902 1,*X
MDR"-X(\6PR45OD['!+SX &20>1S0#9YF1!R/%753VO%443;\F"02%EH#:@0*
M!&TR"L%!G2HSPL&Z?+@[PC'6[O-]7'\-/ODK 8%!H8!H**)INA[:0+:6S("B
M?9#SC4:+D(!1%7'0;Z#@'J3^K@2[ O]6(B\$08RK(NKB!&S.P'@',QW]7[4B
M-?TLV!86D>%(L0'(/S3-8+F9O(21L$(PUJ1#4LW"!B['@G0 5YA=[W0.'^EL
MQ1*T0B+:*?:23\&=OQ-/^60X,JB)&"O>I;7\CH_27X[>%<K39@(^P^[L<H6O
M#0)"I]ZH0D>L*^S)[P KY.4DDH13@"6)G..CVR\?83:%HS 'DZ(33Y$9@/A\
MIE+O;'%(JGH;WB-6<3+%*_"/9NLT$PXG:-1X P]^+A(NS:M<3J LN]-:_H&B
MK+F7FQG.3]23PF-:2)=Q=^S%9#TMX.RO$"PLAL5ODTCQ1?-465>*1C2C_!&0
MQ7RK'J3U(,$*B$'"Q@J+?C+N>[P$BG-#,^J"RCUJ@-TFXS': <=9%?$_@AD]
M\!L![$\-L'=KZM^CUZXVJ-)4ZMN4&VPUK%;G]/FKH<&PO<X+E&YK-U=/:A;[
ME,4VN^M5K]MPL>WZ>@LZT*)X6!=7:1:E$ ^X#-:O2N4=, 2^:MVN" )5U0$#
MXU>T7LZ5]4):>[ZKWOZF$*_9T.8\G@]Y/% P<8W&JE5K8M9L5+PBPB$CUVY6
MO 3102-WR]0_@]ORX_9)+<OWI<*'0D6OU-9#'GB3/UW^@!5(^O.#",*[4&YE
M2.QO<\ MVV27Z'9EQ1'4-A@J.88VU=D&07NA><MWJ7</E.N%'TKA_G11."QX
MBF>^A\1VW%Z_VV[Y;E%4'3GV!KV0#7;V0DX;-!T:FO:W&N76 >X'FN&L8;-5
M+932;&Q9W[$T<;)G-,BKAER[:Y!;7>1N&<TPN"T_;I_D9I<OP+VW/OA+!+CW
MUUK=MCN \2=>#4,&0>5&T,X=/H.F=="T:6W>\GGD>Z!<GRO ;4Y3]LE4WT,T
M'7?6CW0;Y!@>,F@J(9H.,)7[@8[G!Y@TV&R:5.[*(M<^W;30O$'N_B!WR_J&
M!K?EQ^V6GG;Y8MQ[ZX:;).Z9#-3];\M4<0SMW),P:#)HJ@R:=IAQ?SC'R":5
M^]BV3;:PP8[!SE;8,<@QR#%YVPV3MUV(9F_;/[@T03&3_KDZX-DQN;W51>ZF
MG1<-;O<&MYO6$WHMU*[=I0EK@>H)3] @.&O:UO)RW^HG+W!%$)^=V-U7J%R^
MO-QJP0)[_>EG@=6QFE2(]FODA9$J*^\ NF,VXI+UA0BP #27U-E"UZDOU-*=
M*YT;!FM4]=8E7#NPU+ERN&5N-(#&')AW=\(/)U1C>8-MSE)G)]UH"0B1&D%T
MWI>%&.V6186"/V//"_@_H6HL8\5F 23X/[HZ?CA@7W5M:RJ!*&.@6MW$HU#5
M/*TL#7 &8HKHNY;5ZJDJW+U>7N1^IEQTS%K_#U9YCIX!Q>44/R7%^G42ZSYV
M&N\YX@*&[=ET*535V^16Q.SXZ->KVZ-W;"RX) %4:(2" P3BWI_JTOLP9OH]
M$<T5X.$'CG!Q12-@%6^#\%=%^(V@!BLN,:$7\&288#.[R^#.B\* .@KY-78;
M4B<5++C^"3L1!%2L__CH\O83($XU23&(>U7$?<W8U+:M!H-9?6QD<(=G\JNE
MYN'UL&NO[F&W@W9TAB=>DB<H#<75PBR1V'$S:]F#R2DC;Z(,C\_"Y7XX]'[4
MJ ,0-KF@EIXNCWG>> X<(ZGZ6 73&E@R_@2M&S#"!TE$_4/#2>R-8<W*@DFB
M",VAK+4,CI,R#'Z84*^@^S#ZSL;8<=3!XSW0C>F*5-N><Q>;V.'2)WP:&@/H
MU4E(.$E,O5- '0;A'4E&,$^Q"1EV7\56=Q%W8MVZAOF !K!RB,! 11+2#,Y>
M%6?8I\<+$M7&:!B%]\2/63^?"8_B -P*X'YJ/^>I]GW*T28LVC;3?9!FG6F#
MQU?%XZ=(*-05/<=!&,:3B+#B<=7+^0Y-CZSG'S6/$BXY%(663@9YKXP\:H.-
MDO.-W6QF]B@V/^42T.@#6U+SLKQYF\'0JV+H%S&$A8"(%$K'D4L/5H@78  X
M-694:]V)KUX=<D"@& P\QQ.!DW:OS+YQ^(0[7CS=/MY8IN!BD]W&2,+#3?9C
M*//IE/E1V],<;5]'Z%B$#CSY@I/*?C#R*)U0]XTKZ@ZD51=[8[*^D(B $\?G
M8)FG+>S25I]<IN$KE_6GI&06XU2&)G9BU*$4ZHLX%JKI+KACXR3(&^GFG215
M#U"!"$S],R\ LIB$.BQ]>?L)?#UL)ZE:;\+ 2&B9OV84TXY0?5Y@>R?QJ3DX
M]<D4@:1^J7WAA\%0V>VJIZM+K3>)=P-7'8I)96X :9#+9I#XRM9%XODN^L/@
M55&X(\5DBK+[,/+1=$ !C#)=>63,S<_S#,9>.?3O)L!U@*0 8_JH//&$)PI]
M(6N,FD1[\ .(T]!)Z(@ ;'GL84Z6'YF 'G6U-@[7+HTF04%/$IZ%J"48YGUL
M*NPI58='-HA*U3(W[XN=!4*QD3;82(8-=V'H4 0CB $_%+U"+L1OJ<ES;IY$
MX+XA[_FITBO\8G"VBR@Q'FX76GO'ROF8B2$R/HR$[@B.6-/<F@8G_TNFS> !
MUP/5XITL4QQYD09DXF"[=+!Z?=]+(],XB9K:4,'.7)0TIK(\G*).H12_ZI\V
ML%1+%ROYZ&$" &8$Z%-H--_7;$'^J@EF#^[BFL)?Q:;J?0Z2N)8Z@L2*#G*T
M*YQ(94F\.;6ST":%S][T"J%.]18:4H&(,\:.P,(%*K'8+>S9&P!U@'B@L$1$
MW(UN;7'<=#8<9V$I]X),:AP5#3?\7HJ_$U#=RG=EQV\:6?3UG3K++ 3%X7&S
ME3VVV#F0M3JY\J<U=H_'CEXP\'.JY0RL]$%,:YF+S&,8'M%!45TQ\63H>@[R
M0A &)]F_ S$D*@>MY8TGX'T#%"<YU3R:JE@^LID#@Q1#%.\@R36B"6X*. I=
MV;[[4W9Q_>?5AQ.[Q\!-0I $V5%4#2-9@P'B6H[""(^ I2*3( U*X5FTB#V2
M^S[OAQ$#('T'4BMB:A8=*9+N1QZHCJ$.TJMTOBA;\3S29KZJX;Q]R@2DT[*'
MJ \7HE8VB4!AX2%:#;P].ID#9FEVUZ-RH Z:1L-V+2+IE8](5 A1;P)5/PPF
M@.A=W+W2[K![T,K*&)=\C.%,S W ]%Y)!344;D%6(&^Z'):*:9(R ;@JG'HJ
MSVZ,D7HE51 MZ>0:PS7 AP? PL]=A7">+B+E;5\$0US)  D14_8D>/"(%*(H
M?-WG&<6B<H-'\'(6@0/,T4]HOJ2R3^52S(A&_-KUI#.B@W.B1IT#FHZTG^B>
MZ!;IRB)+D>X4SZ;[L[)@&;\G9 )BIO-^0@$%"V@<ZHT^ PB1YN9X0"JS)G)^
MQ(OD,N:NH./X5%7FGBDET/0IT$3B4-M:M3QTJY,48^&,@A =6S3%0*-%'$14
MXM!T@7#0](ZF.)I,)IB\J*@R#T71*(.$WD>?3/$%B?U(.!@NT=N;1.$PXF.I
MK($L#43"O.OIME(9=I= KL#%#FW_*CV!^0@4NT8F4BDUM2:_-+I/$H@3E6)@
M"X0J/J5T'S?]M:AETU,HBWTC D%G#BFA\ XY9JBPYNTC&E*+X9GT]CN0P[#+
M/EF4R00HYWXD5$+9?"9\8=4@+<!E!$(%9R\"I>NAFH 7HY@818G10,"0QT<7
MUU^.WK&0A-+8B_$)GP"IW@%I'A]]O3X_ MOO*E#^I!JXICB4HN@@F\0/3Y+P
MQZ\\E]82,5A5-%4.JM(Y9'W Z^BNYF^"2E(3QQ0UQ!RW$1I"KHCQYT![0%+Q
MNI*$<0ZW) 9YJ$)7M%O.AF0%\3'=BH'-),$8YE7O$[QHW[1F:;$+E8F'%FWG
M]"WAH9'?-%@'1374?A/A*,.U5D0#@/8G *"&VFH6/[Q,VTZ9,VU+IRS/E=GV
M40#' %<.*:U^QF0@;>>*/A(>!X)T07_IE!HT)0/PW-2%"S+^(X$N5>I/9NFD
M<BIC,:[-'JG/S##@9"9ZXWX228I4Y;8[B3W,?%2#BP'\#UEZB>]J Q&7,^9_
M@7  BRX8*I.6KO\H%J-5@.GHD<Y4@9#B7&J!<^J33O]()OBHDVOZVAL=*^E9
M7)!_3IQYE6E2W[+!-Q//%ML[P^M?9#O2*4!Z)(!'IS*WN[5=B0Y(Z%+48=;-
M!_D<:,<M-T9#QR&J*<CZB0_4HI2A@OOL4*%Z]T+E3),>R-P./0Y FN-':C(G
M!(E=(RN,-"_]:Y (7_VM#$+/%^C\S*!6D691!634#;.JP?'< Q3:'2SX7_ J
M.%%%'ZR6QF.!C) /4J90T;STM5H&0R)LBI#0TDA_<AT^F7NKL"J]#0S:3"<Z
M>J^=;]!MP1P:4I@F&C*@Z%QM%HCQQ ^G E-9 C$ G8XI6NNY2F6_UXF(O- &
M#W)J)KP0).H?'EDUG_&BV5<^)=[^8X)!N[6LTN7A[==G5KO]5JT#/.]0.2QG
MA&%\Z^AGG7.T9SNB0.IO"=!UXU057*DQP!2PH4ST)4)P<D&H1XE/S)40XC+9
M.]'XC,B\50>4(@U%XOU )(F!AQZ52MG&3+T:ZB)EG]%S'6^0J1$*_K4 6%$B
MPC5X+U@/1I>#L6AUX%&"8,(9]3KT00R\GY&?XC3'4^;ZO>>#7R=0%S>M[MN9
MF(;> PDEKR!V=6Q&:TJTPEG+LM]FAC.7%+US$7_*[92I;>]JWL?OTWRWKU$8
M"R=/?49U[.+M?/:KTFF4K7;NQ!D8B[_C;Y=@1"AQ<P,D&#@>'2/!/_$C\ R^
MGE^ ;P!:%^^OL+K5?(L0)<OCCK)MLJ7.QXX)Y4$:)R=)/P1O:4AW)O@D-=[!
MV"?H 1V\:39JK>ZIQ7[A.KL@.\.67A89SVFGACE>6EZ3.:.$I8ZK!'1<ED<H
M9W"TEI@L$4\]+"7&*5[W;%<D*5)N3*LS+0B+PO[81T+^#0J.&<50M.-RMQ-?
MP;A+X/(H%Q7S_$XNY9Q4(M[.[5FD_-/E'([DMG3VM5B__C83=UH*'C\L#S)&
MM%<RXKN%("M,5K<:;[,HNIY*.^T#[X=P3]S0]P% ?@CC$XTQ2O'!&+)VTBF6
MF\2^)Z)\]^%@()7'S\G%YP%)K7S!,/=)TVJ_U=&-,(WWXN$VVE.8RWF/)2TX
M8'RL R_ Q@F@HB_ 1O-"=(=2*W\N"!TKN],G$U";G /V]<.GS\H<5%,O71C@
M ] $^L)-X]GP<J^!*\VGI45-E( M2+HK;=:FM/7OE+9 (H-G@Q$-L#MO2$8A
ML0&F)EBZ$R9Y;' "V*G5Z;U5=!J).R\3H/E;@#MXJ]M^FYK1!>(E"/HR5"XB
M15@102/N#]@Q?JCV^8[B_!'IE!",ZM@CV:Q2"F8"KKFK&8=S#A4QAP1\^.K0
M2H$]$GCZ@%A:!M-\%\1F?;I#)Y%I%,'I,"ON9<R_PRAJT.(.<7?T;Y U<H;T
M8"[4+F&0'30638>4C) 39GR_H;K-\#RZ!RWXPFD,\2P9]SA&*GA<)5-T&&D#
MM5063Y,$>,'G2>7),FZ3J517J$OQC13"&7CDF),=3>?8@"*4/PA88$R^:;"^
M/BK$1&TE=S!(DLDBNEI4D/:2NK2K<%^]82M^PA(ZPA=TY!*$A#%.OB8=8BU;
M";J""TKD/9#/O8#9LXT!%GQ_9F?PAB((&1?F*(J@I;2^3S2@(E<@MCTYQ6RD
MOH[QTFF^3\GYJ9)<(3"+VOUK*B9)P6,<R7-/SI-A(I4!BZ=$)"*T8R]C_EV,
M0E_%F .RE(74H1]0ZH@9T&*H"V%\3'DD>3 6\2AT\31HJB)J2K^!*DK<(1!5
M()(XHHL@)IJ;1W-/331W [E("@M,JO">PFS:QBL(1 H!S?JL@CNC5-,H^064
M3B<Y;FX] 4U32?S3][*@CN39FJE^O=D;=Y2V]@\JZ);3*!61<] >G$AQEO[Q
M'GA\XO/IF1?0=NFC][.CXVG??.E7Q(AZK/'<ZUFG]5-$M2X\JR?65& 1%<R5
MO%//L(A<[W3E8S2*5SU[:-B>U6IO-^K#S]K-Y@NLM5/?;M1=K'6?X&K6^E+T
MNMY:'RE%_6B94+N]\.Z26I]*A[Y.L<_NG*8XG=<4I/"6A6]6EU&M,!AF8]W/
M01*%ZK,;5$8M-YS0:%Z#3M;:\*$!;G7E=P.X!P&WN@&LX<8F6]*[P1"6X<A7
MY,C*-Z7^K,Y#?E'G(>JDWS2ESN'3LG;2E'H9D>P4#F_7D2>FK^X&_6$,81G"
M>I&&D5;=$)8A+*,*#6'M"6$UK)TTF3>$57W"VK1-VR$05N5;4]Y08XUSUSVY
M#N!_TI/AIW2GW$/B-_W=]P)-QW5K@PZU!CT&/08]1L@9-!DT51!-E3]N^5J\
M6?)$TW3)WO>$SC93JLMQ_*)BX!E]ZOU$3]N@I[3HV4Y*&S2]/A<U#1>5&3VG
M!CVE1<_.A5SEHZ2_Y!='#S9&>MS<Q-(Q_NA>" &#)H,F@R:#)H,F@Z8*HZGR
ML=*/5#[G@RJ?\SN6S[FA\CD'&S:M6XT7\H<>S%@Q7NL&&-HRD\U@J-1BVV#)
M8,E@R6#)8&ES+%4^D'J9U9W+^GA<4=&ZIP135V8@[R,);FX6;02%?4S"WH&3
M72F2:F[L"QF2,B3U(#1MJV=(RI#4\TJIKB$I0U*[O=YM2,J0U#-?DZP\2;WJ
MX4I6F'=WGJON(W5R.Q$.%J?7'FQ6,OM95S=?BVE%;DXCS\Q1)8JWO]&LJ^@V
M@1+=,,&:O.GR"R2\Y.D>,O.3PCW/"*Y]Y/K=7;D_( +=W',WQ&F(L[0Q $.<
MACA+&TTPQ&F(L[1Q"4.<ACA+&^$PQ)F%07ZBAC0_+S; T;L[P4U0"YE9,M!]
M@M1/V"4NB,].["Z1[2MOC1HM%:J)O_[T[V> U;&:+83#Y2.M=:E_HN[CJ0A8
M]_+$]EJW8A*+<?:D6:^I+IPK&Q;M&[X:I</7-;4+5Z$RF8;*\O;LV%^JV/RP
MT%C1"1/?U=TYF2LF(L#1L>]4WK%3IBTG\[Z*->J!.-%=B1WL.3KV?A0:T ]@
MZC"BQN[875(R/[QG2>SYWG]4U\YE';*.CW[_X^NY/'K'PBCM/"K3OHK8/LL5
MTHF\ONH:.0[IEYA[ONZ4?!%Y)+#8N0/["J@OW&76]K4O8 T66PM6JC'U*CCU
MBRTC<=_PG8:%ZE_](.RJU(KX5C7@4P_V;%_4R_(SCX"VL&UDC5V$P3#"UIT3
M+M,.K'UOPD$+PBSP. H#?N=%B63GGEMC-P((=*"Z:CMA$(Z!D&Z%DT141(7:
M:5^<WUS>XM] TXJ,<QFJ>_/*!*@PD+J3+36,3$#/ D0=UGA;:,4*3[/VQX[/
MO?%L9U9D'UE$!TR9SC$!^(0N;':J>Z#7X6>P*X8C]D$X)*S3=LQUBWU(J)OE
M3"_-1>B@'%+-O]G%]9]7'T[L'HL41'PQ]*2O^%SM&C .DD7#%'8UN^F996<K
M4ZA)NT2_GWOKGAJE>X&,Z:" 8U-8^^ULY]J'P34'G/-)!((DTV-Z$;\E@6!:
MA34(&CCQ(/']Z<+TC8VFSUL!_I;XT[PWO6JGJT=..Z/.[GW$T[[(2A+R62I!
MJ12(.-7;V%%8!$DY6Z#3B&=>#-,Y:^C>+^&=\&<X\2O@1"#G ;-I,CQZ5\:=
M/K@O5$HA$"+A5^D05#Z!XP%[P>_47A6;9X_X'7;0%H%66=@I<IHQ8-XW67VI
MWJ%NQAF/DA[UI)-(F79?CDAESZC2HQNB+_KT.EO84:I$_S7RL&DZD'82@9Z+
M@8#[R/NP.&K$>J]7BI3))2 +O8\[#X"%])F-5U/=R7VEH@M:.%UM#3LE^PG9
M)+KU-[VA5*_O_9UX((6FM<*>01+K]L0(Q2C?1@&^GH1M.N#><$^]1GVIE?F#
M@P.LIZD)HY"ANO:ZL$$_G.@&Q[E=,@)4 @AFQW1X@/V&^R!A(I0$)">P\3PV
MA@?BR6TC4@/86YBV(AU8*8W@BV 8JPZA\'[>MWZ2TCSL%8P<D Q%.$4@?4DL
MRR0:*@,D0SY::A)7<<=!Z"5J(9+ZFZ?R7.$D^R*;:U[HW(,6D[ S[K*A'_9I
M/NIY[(P0 D!B43)1X 99"!+(#:G!:;I,)S76]&=R% +LAKB78BMR)(Q(X55B
M ^6!UBL(GTRK^+@*V@I)=0\$IU3@0NQ@EV OTBHWG.$TBWT-88QX%;-H0DNI
M2*U>H#$KHE2NOB?TP[\E]ZF3-"F)H>H6'DB<WR<E 6#X.^$11YPA$@'7B, (
M*=H!F> !_2)/:%-1[[26-0MW"08$SA'L1],WT9L83_QP*H2B5AB2FK&_IW_E
MGZ<(HE$*JYI!'#:TI@&0Q %0DF@)S)98JRN$)K$ B-RO7R_!S,!9,I#%JB&S
M$D4I3&&2)1HI@V=<;)[[:&?;5'K/^HW+Y7EIO$8\_VYTWI?%<[1;%K4"5I1\
M%_H)3N0"3@!5'O:_TMR;&J4%Z:E-C$B CX-E6B3\RT&^37V@_P))B!(59@O0
M8L26ZXXC)G$>2M"R.8X\1P\:T#OJ;1"]X"G"8(J?4W\L_?J]H9#7II 9XS6E
MD[%'-L2=)[TX50XHVDD!9G('_TE^O=)I*,;[BCBTZ2U)3AF<OC9.4[8"0RU"
ME>."^0=: '16DHD"#C8/ZB;"(G)]^G)NFX"C,BVE;_$@9FZ%8%=@)[!NC7T!
MW<::C%*4[/=L32<#P1-2,"F@#$/2IKD=FOEO2H85W&50[6C.DW0%8XU'9 _E
M!GJ@W.0L=E!*X&[JN(GX/HR^LP\%"[J,VWIP$__*O)H+M"LOPA!1IQ!Y/HR$
M$H[W'O#%+W38=!OS2+V+K.2"+88!PJ$ "A&DZ!#/YV/P#N14YL86!0T"!;'4
MS1@)?R)3Q8C.$G[J%%< K$@?]N%#=!"1-HM17Z2KE.556(+Z7"JQS-/Y*)8Y
MLQ ,@ 7PB\5^#]$-$]&XA@Y>[O!YN*E\^^!*<9_BO;3'?N+Y- $M\P3]AM63
M9<!17I?R3'$G8@!,HRQ)'4++0ZX$<0YF;Y+N3/E%R3B-OB(<T"+UM-V+)L?(
MFZ2+E2'!%Q<,7LY]-@#AC5#N@2]WQ\G^32/7\ [(0JF-(EI#%O$Y=^_ S$<Y
M.?$Y/AV%,+$3@E_S'X6Z.^XGVJ5SPG$?:,TM8JN6HJHV#R#$(M 66$L)QAGI
MQ\RLZE/D3A&6%[$QA?:D=D?)@?5A"^"D@ R*.)A?B8..[6H)H^F_W4+-&TH2
M86<*A'?BO6X'3R=TQ:_TN60]_X3W048F\>I/%OJO[HC'F]VY[-["?T=1?F0U
M%"=],&^^G_ !+/:,^_=\*H]^FI5C(,2* )S?N]KAS__H1_#=DEF7BT2[56Y1
M_PG49Q0@BP#-7@7H>Z<,?04< XL=%L)<U\3AOWOIKX\I!4U:/5A< 2:],JF)
M!=/";F2VQ44X'GOZN(O<9A(T!8VP@461AO&T\,?A$FJ4*PMFA0]_D?ON"($_
M2!T3F$$$2#R4#O!KZ-]1>,>"E8,LE$G$Z13+ 3#V!1L"UP<4LE*Z*_;&=%Q(
MQW4.BB_E+J+5CT&81<'RTBA9:*!,*%D:S5S'_FCOR'5XZ-#MHD >:^ZA/,SQ
MK1CJ893"P60RAN7"('*1_)<'<(_Y& ]X*;@Y1F<2?GRW5N!((53/FVHKRI5Q
ML*+71(JS](_WP%^@OJ=G7D#[H(_>S\HAA.W\Y1D$M7JL)7ZO9YW63U'HZZL[
M>F*M#RS2!W.I/^I9NV.U&ZV5C^N6O?+90\/:#:O=[&PU[,//VLVF66RSN]:P
MC]SE>C2CSFXOO+LDZ:U\S>P_ZG/7?PL.INDE!?#34VB=,F37-KGU]BBD"OF+
M&S10+#<4\;!XG83-=39\:("S#>"V UQ]=Y=1=Y%T^F7QR.K%.K8NS5@N71KN
MFY?;?\DSM6N-QE-O"&[9MO?U>G<88CX88K9;EFV(V1!S%8BY?FI;[9(2<^6K
M3*KXK0[-T-D_A@$/K%_/SHONF]X(:]VB;UI-@Z-RXZC9VK;JDVE>L09X+S#]
MBBX4D%M;8^)'FI#KBDDD'"]/K^7C$%;]G]ECN<,H3FW7&IWZMI=S2V0$5Q]-
MS:9!4_G19'?;NT13Y:WP3Q'V(5)'DR\KTZM8:++7:>R@(&XY3<9J(;;7VD%9
M6H/8ET=LH[YQR.=5$/M,#H3"0F_'*F?]Q#]5HP4=BR77O*KG.VP(F-;F<8=G
MZ7-3CMWOO*Y4-6BHM6T)2$-#AH8R&GHI)VSO:*CZ+J$(!-[.):_/'7N!I^J'
MW&47T^7:GJ+*&1]/N!>IJR\C\#0/[9#GM+WYF;DY/GAM)-GVMAVX#))>"TF=
M3G>72#(^FO'1%L\=F\:^-O;U$VFHL6U2G:$A0T,9#9E8T:'X:!]>ZGBNG*SP
M<![GY@$N8[B_=G)6W>"H[#AJ=+<]RRZ1;U5>D7WU+%&P4ELLCS3[V;*?BDFW
M>BT4/:G5HD'3:Z&IM>UU0I,1M\Z]E&>\D?*TJV+EHSR[6W_V?+<J9D;M*7H;
M[<W;11KT[@]Z[=ZVUYC*=]UQW\S_;R%6M5,]CH[U.?H[K6)J>+#R%'>@:I1Z
MC%F:[S8U;THC@YZ_M6%E,-OH;ANE-M@M/W:/NU:K?&Q;>9?EBK0(B_F/-$/K
MP(X CEN-3?2%"2V_-GY.ZY9M\%->_#3:5F<G^*F"W;_A477>(]?+Y7;$XPH>
M"&P(F49GVW(\U4MA,*'P+6FH_6+G3(:&#H2&[,:+G;#L'0U5WGG"6JWFI&>!
M!>Q3Z[2DL6)S%/ ,1P'U;2]2&/26'[U8-:>LZ'U$H:2M,X(0.Y8\1!'[_&85
MW-Y'M:J/I86.E6Y]QW@<1UX_40U4L*UO&% 3XU!U]*36L4(6FON9>/K/FV?-
MFL.2O4'NL;U)3-0@=I\0NT$PU9R"/;LCMZ!KTDZI-785.-:6)I%NW-4$^+MA
M@B.G>SK8BO#/#Z!R<[9M=ZW.D^SJ9X#1COTJPRV&6]8,,M1[V]8],=QBN.7
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MPIM&+M.ODRCKTWXO@+0F(6[_#I4%[L<A33.E[+AL1M@O/(M #2A.0N(&R'I
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M+0&6:=:5,6>Q?\TH1"+J@HD0$W.K1>;JR6X6+:.5V-$@::-SHT18"&X3#@Z
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M?CIYPV*5(>=VZ<AYO3QP? 'Q/ I!"8P$]^,"I>HOPV#)[6$&R/)<^*$_73U
M]G+^O9M$F"B74^.B2%,P_/D?_>BGGU<2B-Y_&_;Z?A(JJ7D6"9\CE;V_]]QX
MI"WXXE?*=#ZKYY_PO@0-&*_^I$!UR@#9$8FU[%E8%/\[BG*^&8J3?B3X]Q,^
M@,6><?^>3^713S-[&GO!21& \WM?C8$%/(QY-(31*'S66LJD+P<O&O', R7J
M.3,07"AJ2A#\-XAD=AD@T7X DV;<%Y%RZC*I=P%D"G0+HB\D"GWL"WNU -LE
M7!Z2%;0.5SBADN!GX+**"-\JMH6_$3+Q"R&]!S;7*<_>8 >H/WV_1LY7.-?E
M'FPH!QA# C+?-+L,IO=)68(68V\:V;_A97H+?;A Q*#PHCO/R52QQ;X!84R1
M,$*83?T5*7B!.X0^$]"0$^>2<4XG%HP\U*>7:( K70K:\AS,;@G?7J#T/+X?
M>:"3'=AVY/43''+)@G"0-\UVMGY2ND%A]WXHI7HI>T>3-ZU=S)!W9@&\JR%8
M>MDGP!6)$RL +5T&R5[%.@C]JP#<1B^>LO_S]>J"\<1%34)K8T. +X@FUA<!
M^)8Q^A?A,  TNSAV[H_2\F*TD7$;;^Q6OD<I0\>CZ>X]4#B/V#\6N_R!-K96
M/(A;,&CDXV1B-^;(Q*YG/Z2OK8('[ '8!&@<5)Y J/"93Y1J])SL_:)WCS8@
MNN;D'RP9O,9&0/4BRC]VD?'01H-=(33 E?:TC:9]_(OSF\M;=N[$[.O-1S8
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M)>"/N<C/"!4V1:FQ9',K<8KS:"F+O(0)-31_%D<DUM+@>? \80]EXX4&AC;
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M5T9;#A1OYJQKR1!K8VH @)#XHP!^<!4%XFL7YS>7M^S<B=G7FX^:?\C^X'?
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M< E!$L_80W-L%C^!G0#VX\7!1[F2 54@DK,KDH!0RAE@!VQD2M(TX5!E%T"
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M+'K/FJUF)=<#:!6.7X[:/5%+3JXAOXE.YUH1,$;5^3*#A<Z3J8@E7,$WSF;
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M"**==^Y\DG64G:B6<;>HUO:JU?;@0^@[B,Q;\X$!1(_NYO$&$/4;1$_N/QC
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MUAE8@W/YCK5G(#XXQJP:;QCS$95;V;LSYUEFB%(,_ %EG7.!JR0D!<Q*)E.
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MC)K>T=-[B=M[3P!]NMR@T;2JR[QF)H)J!5-9R\W9*U([6N8$:BF!G: -Z(
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M=N(98]<S.%HH,0"HM\!:CJNQ\J[%TL4N1NB$Z )80@Y+-.O7<BWNJE5JQ&O
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M[UP[=6T*22N-C?=&P^AK*T@> EV@>9.4WZ_+-N'F]CHZ=2_24.!$B[DGJQ3
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M&LM. >G"ML6J3<V7W08VG::/\HR+1UK(HMXZO&TR$I8BY%QV@BSSN0:>\[$
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M?U> RV4(AT3NB;/5=V*@X&]RH.G;UD#3+7,'+HP4)"$(S5(4BC8U0ZT_BU[
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M=)2-9.\P<?3;">[-]"#AV) S[E&*UIL3'7Q@4T6%8HCWTIWKS9O)A/]6^V#
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M^$O;&9Z QWS4P%+LK-L^=G&3]U9OXR8GET[CYJ1HT%30.KIBA*QB+6!%0I5
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MWA#PLW%1\/&.82=M:?!-/+ >P2Z=S]$<>-"&>=#Q8N:'9H8Z-2U-=6(##)E
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MQ]+;-J@<F^I'LRVEC0/E/Z:R,E#^ U/^_"Q#S?&IKU%5]XFK6GH,/(#JA@J
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M6M>!F5_MRQA8P\VLX>=BBT_-]CR !HA_Q\:>@*:M^IIIJ5I(J&_Y@>>B-K#
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M3I4"5J)GHB@3S\Y@<:?[TBPK$T')AK\'XS]QB.U$U4PVY)/!<#"9CF?'F*K
M>(?#"4Y^N$XQZS<'3.@]'E$CTI?A.(PO^F/$^NB5 74AO3^%^N\01^.Z[[W
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M.XWR96=L">4/AO)Y$<)*K"I$UAT<DZ\HEZ(=Z X@&5?!NQ"8/M_+]:U+]*B
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M;12L[!Z@EUO>1("^/T#/J8EDF188#>B@.53ID"$(ER F+] $JU*;^T6 7DE
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MX0V_PUPT\+1X>)H_P-XP!E:B3<@0#;3!4H<LMQ@%:HD3%&N?^-HF 70R#SG
MOO%8KJXF+Y4U-)J\-$V>K09+DXV,@!(;KA /+)\U[SGB$1#9<IP(86N;9IWP
MAY2(;!1YA15YF92A4>1E*?(L8Y#$:VJI0%@Z"TNRB\AI[Q Q4A%%B(>IA249
MKU-N5D.37WK0(<O\Y3EVOML?O++J3*MPR,1^>M?JP 3 R+W),]"D4BX$?_Z:
MHP0$9DDXA9$2'O#'"(PLEAH%;/+!.-(9KU<QE;)Q0:XZ,;B;*C?VQ /U>888
M,"M58):BE*0#8F $TDE'L">(L=08CG7>[+"NS(J4:VD4>=5SDIHE>;DJ/'<\
M';41D%BB%$!Q.:,**($-"/B^)UX"75!L%9?DEQ])Z'YIU7E'[59,58*N5#9\
MR3SA=84.GFQW]#L8O?Z'Z&/K2PPY27(\)Q_*E.2OM^H):=!I(>CDKSGYP6-,
MA4>*DNQO3 PY:C12R1BADU R\%6LX] X(%>/,/2AO_#;0E2\(1(/U/,Y(A%9
MS*=086-S-=?$D?7*(IF4#E('E0)>VY1X'3\HDZ'1\)5=NA>[7[K1ZZ?1ZUEV
MD4C2*@F!N# ><<XM,LD09+0FPB;*8H@WZG6SU6%IY&+8\R>V7^]BZ)Y" RZ@
M!5W_^77%'E;BA.MW70"EL]&$[*<WW=/3;N<@3T8#38N#IN-Y:A$33U1%Y -G
MB*>HD9&Y@'STUL :9*0#DX.H=2::<R%>IDXO+0K1Z/0CZ?0,C7#&$8#H@$("
M3>;1YV.KE4*:4D]U3)%JM;9IS+I6S;'5ST>G5R$@<5>5;IQ_/ZS-L^1!6>^Q
MH@1A;!SBSDKD8C#(T$1%8H13L[ACYIK0Q-W90ZT2F3S #/6&,10=A*;G3^'7
M?F;:99?#ZXI4K *? )QZ,YF,-]-S\7O+NE:[-;B81%:WH)5?6H-6;-(DED0U
MH$^'QT<,FV!\%"C:G#4=? "J$0)*)-A '3.1AGQ>A"*\<6X^&VU? :*Q"&5O
M#)8%T(]:S\$J,=%%C&R(8+ PP_,^"8\(EV!]1N:3<$VT\A6H^Y)(2*/N*\)/
M:G6/1CC')4<D8(:XXA'97,9=1T&%PE[Y5WT,]I/QD[T(+,3V3ZJ?AGW@)JW.
MS]59'?X+E;NHTEA%*CO1D8?$/5RW!VJ(H+N_Y!GI=]NM4.5./D.0>V0&,Y.2
M,88[F,!\'.<H9AM^N_@(\[C3:7C+4@'N\_P1%=$GZPA#DEJ)N$D2N2 3$C0Y
M2I,WS)FU38;7.7O(QL][Z=$S<K2^)&!X2K+3P,$3P<%,= 4'HHDD'@FL,.(V
M".2D!XZCDDL6,T8YS[6CU@F=+^CP8^[8!A-6&!,>>0-Y8RRL%#K,1FN\MXQ8
M2Q&.N;*<< 1I3V@^<D\$R;S%1*UM$KYNU/RIN"MF++ST"$YF2*V.[\6< _83
M:$#Y[6?XK!"G]9H^Q?\;MKZ 3N0J5K83JGS$=Z_E!SG> ]^_KMC.4X9V,K[E
M_]]>3LB'R5SD+[8ZX>H'4U>^A^YV 1#K.=X>S?7;K[X]S%, OYS8SG'\8 ?Q
M;4K1-R4X%@>3AUMSG(H1J:@5*6]F<8@K9I&VPB//?<D\TXGAM4V]SN1\+*CQ
M$*\T1#SM?I8&+%X 6,PR+NVQ"IPB&3F 14H:N40%TC1I$@GQBK*U3:;6A7Y(
M/EL#%"L,%$LC3@U0/%^@F"-?+LJD(D="2*!<UD9DC+?(!2]\\HR&2$NM3?(@
M3VT3A+JSCK^Y,X^J[*!R\;C5Z>285#=59T6W7M=6G/O0*T>8553ZR!7'#!L0
M<JX)X=IAZS@[VKF;6_E!^-? V>+@[.U\G3###'5*(FJH!I)D ,X$T4A8K6@@
M0@#%7MOD8EW)^3J%39FPEZ+IG#K@0U(D$@-W-&HF64C>,T.TM(843;]#^DRC
MZ:NCZ3,,1WNP6)R,R,4$AHO! 6DL-%*4TQ2$TUC*M4W-UIF8]QHWFOY2--TZ
MPCD8L(S#JFX!\*5F7I@0F3$I<9HUG9A&TY^1IL_5'N;,,\8\,H1;E)DLLBI8
M1(4.Q'"5]^BM;1JY#B"P0IK^TD-!]^,I$3Z^D:%\;TANC-G=*?Q]W:@]);K]
MU_*Z_U)0/3H1B,,T2::XD-&(Z*R(5&?'MXFVV&_+CG\UJ+XX5-^9/VQ>6^\E
M3HAA;\!^,P$YE_<])"$TERH&ZM8V!;_6\?1C\:P[Z]$3^[ ;.&S@L'%<O7 X
MG*&STB8G@Z (!T(0IX8BS9-%3!@=,:-,J[0HQU4#APT</F<X;+Q[+PX.Y\K_
M64XH$1(I3U,.2TJDM?*($YR<-51:+!;EW7LL.!PY!,8-&4L_+6"W:+_@'9XQ
MU6$&70K=H6O'N1X_Y U-*V]I91&'?PXL7 C_AM:7S?^!'S/2P?&& /@\Z_9;
M6;1_Z<6V';2^Q%_/6V%P,H;.J?MJD?L%7]YB'8CR<'#S+5-2[ '98F_1"P#!
MWUL!:&Z3I!.5+:,Q_?-DHC9G]C@BUXOV,U!%:.POMGUN+_IK_[S2I]-6!UT=
MPMG>UWW<_!_7@SNO>>]W!JC,V^6@E]F'@6K;LW[\9?S+KZ'5/VO;BU]:G=+=
M<M.OI[9W#,T;S51NVZQ++[^O_GK4;&,V%%:YY2.'XNC%HTYME$[- %W]G9 ;
M@O(;O\8;Y,;O;GLLH1N"R1]Z[.W?"<::QC)]I\=^Q\/\75PC8N[::PSD6N2?
MQE14UYJ*[[J]:G 2J[^B[?6KMYV\/7L[^GCJ8J]>^QE9O[+\/W2DIE: >U@)
MJSV*V8-Z8ZK0/3O\V@:.- /W8P.'[Z.6SRA$=GV'#X9G9^V8"[#8=K7=ZOMV
MMS_LP>.[J<ITLGK7[IY7.YV:269C[2YR]2 "\T-&[EUSKE]O(U]#4FIU9F$8
M0%:K5D:6V!\\)*S^PIQQU_7PI?C;%KXM<6<D/^]!H/9BD^&_0%?:'_.!UD@D
MCRDB,(PIXMP(Y"@G2)A\H&Y2VD=7;Z]F+S EMH&D%PE)"R\5TT#2,B%I)MBI
M8-*HD1XEF#C$8X8D[35BUH5<,4IP27-96VKF#]!H$*E!I)5$I$67[FP0:8F(
M-!MO##9GD">-L!$,\9QH;$5,R#H9B)&&RR#6-N4ZQ:NTF>#E^$_NPCIW.JD%
M^G=1_?U^Y\W].>@\M[\E4O<"P??^_7\IT+S8PYU+S3"0R7?=WE@BLT".X;K!
MZ<7A]%]39!;:?7A\9(,F6LN$/+,*<>PDLM8 3AO&*;>>"2*!S-)U)<3B\T*^
MHS#/)T^N0;[7@7P+H\GW1[ZF7/R/@][%5= C@F@B7$0BGTL'IBA#UEO 0,^9
MMT$1YL.BR\4WJ->@WDIU_,E.!&]0[W%0;V_&U(N:!FNSDS!&71^SZQ*8>EX2
MHE44+CGZ_%#OM06*??<T5@/[-?;7JTXL1__U8H+^]>%?'UM?XMUW W\WU_8E
MP_D]._]2L'P)L><LDH=9(AO/ZL)A_.-<^%E[X!Y)!$2I=X@;L%MUR&69B!>6
M1>R4!1BG?!V3!^_SO9^.K'@<J(&Y5P1S2XAG-S"W5)B;"6D;'3GC5B$="4:<
MI("L L"S)B7GK;+1J+5-!C!G%A5!:F"N@;E5Z/73!LD;F%LFS,W&R056"7/K
MD30T(%BI(K(D$B1Y\-1&!PB8J[;@=447E;JS9)A[.3'T^^]!V.MV4"'LHZ..
M+A:U_^"FB5JAQ/Z7TL27[E#:\KXWS(7DNN/SB_.OEP<8-WL07D5ZW6)S. #X
M2GV/6K9N.!J[L2069DE\FJ[4_5E GX^TYMA@IQ$7V"$>>4":,XR(2SQ7=L&Q
M9'*8=6(>G,G1) $W*/6\W#@_BE)-_/'' >KB*D !#B62N$:")8.X$AA9KS%2
MT@=%85*-9 N+/S8(U2#4\_+ - CUZ @U<<9\VN*[G_XX(DQ8"?.'A),V(U1
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M,F]6SN^P+SN]7\?^>G[S_OIFJ_QJ[RW?>ZU;Y:^E9-_=N#NS@A$J)9,2EK"
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MQQT0@'#?2(>)0A&BHC"@3@(;:XFB'$QBIP"ZW;W=S1D&<Y&L_4Z-@8VW^5Z
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MG,>LIC@+.4T08#%0="4(\,<12Y$:H'$HR)0KH0:#'(7!I2D%AJUV.A=F;H(
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M/9I9\ [^^]-?YW]_^OAM=D/GWW_^ >W<A7;N7/P%?=O;/H9G['S;_>;9WX?
MCC]].-W[]-OIWN%>&M<UFSIG4]C %98*.<X3XIP8I).42 <O9*2>)A+6-CE^
MK*IF*X<%_UCJ&88-D*RUO.<B4I"UZ!-G7EGI@L.,64Y(PL$7("%C()G;[]T
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M/-(".Y1< %.>&L6"7]MDS7K;&.[+ A*P[P(66A/G-:_M/Z".+EEC%$G4-AZ
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M[>,XTRHI9$RDP X*@L:DE)(1G5F:QC86J4PW@!DK<8;QVFIJ'D&0<760=T8
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M8%MB*'*('=[P96.7R-JVN9RE$\^B%0'%Q7>*]QI,)$XJ,T-8\O8@:$B^F"F
M%W>A81;GX?*A%[63!*>UK++TYS"6%M^%[]_%9G9NDG\Y'_=F]/??+\!X;+\/
MQJ-W>3BE&.Q&9T$V-^R-U)97G?]R/S@W^V$;\?3/F[L?G@DOW#ZK^H.F26O'
MY&:MR;W='>SE=O6U3O9?N>BLB-=%9^NBLP<QG6\L.KNVB&S!*:"D$7E29(JF
M*>,REZ"ARXS%!@0^-S3];LX?%WT[5*=&3P<&&YO7IPL.GNV1GE<@CM!,_;5#
M<^I8Y#Q-F(P)54D*>D(*>EX,EIO1J2BX-7%J\AN&YAX4,.S1G%O;H[#6TR&"
MFWX)G<$#K-N2N%;.4;7D@@E= >;T@B=-K@/H#$%!JI\^^QH4C99)A*$V,A S
M,0FBKHJSVCQK/ORN^S6H4A?/^B,W=7?3[^'Q07"B1^P3NHM $0XO<>_S/P<Y
MPOE6$1<H2B85_%\W+PY29LM)F=\F>OFWO-PJ67+IS_'6Y;]=]5@P*K.<?M5C
MK_XM2]/O,UAVH\?^YM;7KS'L(A+(_[N1;LQT 8T@"<_B*#F;=)[77LJ7+J5G
MG_'B92):W'6_X7=]#LOKQ(_34"X!/6M/R%TLS>S2<%S<^3J;1 [!,6KF^*C6
M;4Y(7S[A7W5MDML0$**D8;G-2),P0J6,L?:J60^,7>*>WV?.U\LS-^E+0P.+
M5'+=I&],!W'T&-;EO[[?_+OSKO"5#VKBMW&ARTPG,J8V3PN6Y89G1HK,T!(;
MG' C;NI"7QTXW9Z\$%6%"2S_BL'4/';/V^F[X>?!P;#WX>#M^^'[#[OT_8<W
M,(Y_DOT/O5/0G$_?OWV7]G9.OASL;+/]#R=9<P^\:_J>OLG?41CW\/UP_^C]
ML'<T&/9VWESLT]UD_^W+P7L<\\X^V]\YN3C8&=C]?OSY[Z/=R?YAG.SOP+S^
M.;:9B8O,,F(HQV*SC!)I#"=<\C*+2Z42RC:>LW@%8J07K]_M0."OMSP85\FC
MZ[CRHDQ;,[8U8UN$<)8)6*DT5X85+$YC+K5B99*P4L9"LO2F@84U8_L.C.W+
M F/3B6; V["&6V:$\=@2GL>2I$H67"5< 5D!8Z-;RTV='BACN[7>:=W_'I7>
MN9#Y<:E-0F\W[94\^%'SHKM2LA:#G&NF<W.F<[&D3=%,%XDN4B /G1-F$T-$
M61B2)Z46 J@RSI-+,AENR716G^WOJC MO/)2)\ O?S;O2D]8G\UO.9N+"H$1
MU#(6%\0D6A.FM"%@XTB2I/!WS IN5+HZ1>'^CN:OXFJZ6?SC*S6R$*!(80_T
M>(KACF92:QONSA;HIV'>=^F]NJXF8/Z+SI5K7G\+7M][L:2'E3HW)J4)$4P)
MP@PUI-1%3%16&%[$5&5)MO$\8]_.[._\)#T.M]>:IZYYZOTXSM8\]0?QU$9_
MIOM'NQ?[V\<)EXGE14FH%)*PE!:$ S<%=3I/P-*E!K[?>,ZRK?*GX:E._?[-
M9;M<5A+Y?6L+CRJA#1!UTPO-9?^\=K6C.*A?MXCPP[MCDY>2FR(E6B%,HA"&
MB(QKHHLBL:F.P:"[:2K90Z]@?140@AH*B&8D\.B*%5V%N.]8VLRF:F?C,]];
MN*JV)8U'_9KK:[K436H!KKK^FN8S"WBJ34.RSUB!X#/VI)DU9_:@X@$QL<4L
M6YX4)LM/1RZ9#GNM^+Y@+KG"@]$X#*++.C]OAD]8$>Z+#RYI(=; M?GQS 'B
M+-WAYNGA<(:P>&[.B(,$]&.JV@2X6 ?FZ)[O2B[Q22<&Z\3/3CW&.R*YG^$-
M,!WEL/P\<!K,I+JXKILJSL7X.D[$<SIQ2/'PMMDTQ:BS"GX(S>IBI<!P[*8&
M5]VN'?Q7\>696K+7>SF7!?S*5)BT)$[,@0T'=78\ZX/IQ'6.@PG^REWA/V8'
M1[O'H._I5-B84"HR+/ZV1-!2$IDDJ=8@\V,%*D02K^H*[^MH)F,'T#Y;U 7,
M/+?F6& S];B'$C$4/IE ;$C!0&V>OA!]S=4V>QP)W,,&G\I!8+2/\Z1W/IX.
M=-OZ>EK[[M<7\X\!7M6?> 3$ICLYPJ.I!G!C?#6G</@9YU7?M4:TLRL<NH>K
MF88SYZ$]'*A&TY#8?#X54U=ZXU$AVU?"D@*G#=BGQ@Q#6T:'MN.9F>=+QF.S
MN?=WEJQY5(,2X28FZGJL^HX'MPA:,RRN,.2&&0.KKTR-.7WZQYY2.G]&817@
ME>T!75:E=GR3CY? >IO)_,+G]<-VW-O9/V8\C:UF%"-9\$_!L)ML&1.E6895
MTF#*)1O/\^4(^G\[BKO=AN<L%PR=;&7&F"RS,A:@X0F3F%)(DS*WX4FSX4O6
MXGK#OW7#C[:/.:P^9R(FN4@-89Q2PA5\,HFV61+K0F(E=KYLX;4,&E& K]2%
M)I<H!!WLA?F23V!V#?:L]HU.%WJ/=OA=%;K*.MCA>^0W?[6C>]$.#M',U]06
MJ"WI??EXK&*KM*(IL13!&X0$:G,A<V. \]@D811L-LY74-N<BMQ"'UGAFLX"
MC<U:5(/PB]YL'6YU,9B<GGFS%C\/JLH(I+,>.]R39;UF21=9H=(TJ%ZNW=*H
ML07N5KU9I=8\Q(6^)9I<2U"=NNB'.*TK)X&XOXN IRW*]Y-0R>Z1VA:NPA-V
M&79L_=1CRX*F1R16I:%6[C%S9\;X)QQQ@!U$<O-$V_8(<PU>FV:O<V=["16^
MN;^!- \"8=[\;6]O!B0-[$A )!+M\! 6P'5V]4_%YX0; E:V4M/0B]?WI\>1
M3">@#7\1#='#-AH\ ]5XU%>S%ZN!Z _QS/7-N=>K$8&N,ZVV6!"1^4?. '=@
MX-^S8G6IX<8K!U:-!:S5NNO&I0*K=X3C?Y,<[+S[#.]+C_/,EF5>:B(L:L<E
MPI483#.E<:X2D^;&LLM;M'B \*8O$#:'/@-2:AMR@,IC76.\OJDVK^B*$%"N
M ^'_9$RV/NNK&SDW'RB#=>-OF=*:0=Z:0:[P>?Q*1Z'7]=_.8;&$L[$9 >^N
M'4[*BT8'7NS!^A#7X4;G9\Y[??TA.JOZ6&F/A-*AXMF)$DO]0ORY\EXM)*N6
MI%:U40CFPD'3-*>Q;T\%MF0P#D?(]BMLVN-:>LR>[7R0#GJV.8S=9JG=9^'V
MN0-PR;M]4UHX*NY*\TD,INT!FUNM549WRV0$=B81?==CSC_-:>TS;VH+4N :
M>H(5WO?-+&L$C?4O='B\5[E+0VP$XZK3@6A[KR(,+H85ZDY<P:UV#=8]7H?2
M#WNU5-@.0'V=V_4: -OO&ZU]56&/@\G%*UC#R?9(8_+!&7+L-2Q_;^?=,8N-
ME5PS I3-"6,Q)Z6.%<E%QBA/69SD?!'@)4V*TJB"9TIE+-:V%+(TI<AU%N?B
M)PKP!LKQ8,\-V3RZV.[<-$PS#?3! (.9^#BN&M>3$(\ 5AX""1Z^'!@*/HPX
MS/(0YFCZA\T"O]/:V.D@&K@&20'U6]2UF7@\V;XUS;<#X[J4@39=GXXK8"Q;
MT7:++C:XV&SC)WT/<^\BFF 7#6 6VH5&IQ,,%(WMY+S1M% $C<]'#EBV?9IG
ME_TA,OF ^_;$\USDJ>[I,'XW=:_%($<%@FT=)_\[A>WSLFHP'IV0@<,&][-Z
MZA0M(')'35\0'W=?./QUA]/O\Z3/! ;'&SAW=T/HL(T:G/\>$?-@5-.JPF<<
M.>^-#SZ?K=ZW>@RL=URY*.^XB1$'5UL#8H,*X'#J/[<[ZJ WO?;JFA<US=-#
MZ^U5[_+3N.Z9;73) 1"#&#C!%D:X[1A\QGBV$P7&#;NS C[B=V)&&'[W-X<N
M6)5#A6N7[AKYL<:=F\.=2]:X<VO<N0<QG6_$G;L61VY!+6&@*'+0!DMM!9.9
M$2PN\BR.4YERR;BY#)/]6G5FE9@/' *[]CQ4N^VM%\$A 0@$H4!S:!2ZJRV*
MM)!>A*COQO5\_>2A4JNV5QYBL_8KD *^!0M^H1T*O3<*6I'?VG,JE,Y':!AA
MX[N+$"9IFEWZ](J78%\XN\.T1@V.%I0#M"/<LY4S."95_^0$^]".NK,)-E.#
MCB^GDY!2,FE#E,&L:]V[UZ*S=78WI*P23()_EJ[NTN2_0I#:T>0924J7O'\?
M6XY+3_,VJ??'#V%^N1*VE>%:;,];AKX9: A6P<HYFJR:IG!M9SO?_&8EE6(_
M;(.4-<76!-]ENOR&"SZ71+TFI_LFI[;)A!HXTZ3+/X2U1GE&Y3E28Y*L)+)K
M'9;K7?UANPHK_A'V96[7@GD9^'[;)OPV._C@1/:>12G8-BJ>"=8%40I+L&22
M7B)?-[U<!7E9F4L>M;!LC;B<CC#ZA;9="X$.XG,I\]H;<)-95^7N#D1[=M5+
MS6=EC*ZO>LWF@ICWAF/4GZD=8"]O7W))I]-RF$P0,U<LZ.(J-&/$EJD6+7EW
MY0)-?<>P\&[C7'GC?"M_HVOEP#;>G*XG\Y?V87YX<YPRRU.L>LIS['.0\(R(
M0FN2T+PP+&<\SLUCQ"]^VQPN]($UL0KT5,WY7UIOW"Q[8<DO%P(<WC]W([;H
M6/(/!B).XG@K]LZ%VR(1LW*KR.X>W)?QK9@5/P3<=_G21P'$^LZ(:AY_] ?!
M8P"1WE.-[1_3_@!'N@2[>IO9/@8HWMO5'*\4@ES$<<G+PI2I8$(+;E.94*7*
MA$H=B^1; GB-7+1F94;4!5#FXQ2(H:CXGQC><_X>GTW?L-[.Z^'^SLO3WM'[
M_KNC/S[N_PGCHV_HP=O7P\6BXO<[KV%.?PQQ'N^/3N+>G^_.]]_N)KWA?T[W
M__SG_/W;W2_OC]YE[_]\;_</EX :F$J-LH4B66H*PC(EL7^;))I3)GF9I#K+
M-YZG_-(>C3\0&._^V,#?&,@ZQ6A,-\;T53SA^JD_LF,O39E+4'PI*Q1+X[RT
MA:69C7-.,ZKE-\7M5^G%ZW-^_3E?AAEF0FI5V)QD5E#"9,J)C&-*="X-8TS%
MVEBD<S"*@@]_;/U_71 W0BLU?!]^;TQ#_Y=7/L,=P*;OEE\\-K5A=RZL:J?5
MJ#^9=M+!O@$OYK:8+0\K;'DM-U$)TRPMA,[B@A4QYV6I)"@1(N5@^65VK43<
M.W-91-T\Y/'[_W,:J^&_(_&63P\^;)_#&)/>V][IP=$?IS!V>O#G;K;_H3?L
MT7WV_NA-TH/9OWO[_N/_^?+/,4WC)*>));#%P)DX=B[$AM1Y(0L-QGZ<"P$:
MR")#06?/580$)%Q0D$")32F+)>-)7N2<%S*Q,BO2-2']9(2T>WYL,BFI9H+$
M92* DF1*./ 18B07&<^UE33;>%Y<W6[\UU!H_S6G?34PWTN%_9DD$DU0^&#S
MVJ1DW%I1I(76.C4\*VW"OTF_73.2NV D2_B#2XSDW7GOP^GINR_XSI?#=Q]>
MPU,'I_L?WB7[7[;A_[N?WW]X.3PX&GSX/U_>X'HDO:.3S_M?3K+]DV.9%BI%
MH%HI:$:8%0D!TR8E.35E6212V[SX"@%E@::844872<P$,[S0.<BEQ% EXBQ>
MNTM^:KHZ^.<X+WB>@60B9682PLK<@DEF*5&IDL(6+%8IW7B>?0]Q]=CLJ1>+
MJ<!K2^I:N94KEK&LR!)E)&.IXJDM:9G'L8Q+$9?%FK_<.W]9=,<N\I?AFW@?
M^,F[HUVV?_0:U@;GL _K= )S>/,%UNWBW?#?#[T_7SM+2M*<IX;&&!95\$]A
M2,E31D#US7*FI98(L$YO*ZB82)E5H/ P)1@8X;PHBUC24EB:%)SR-2']7(0$
MEA3-I.:99L26,9!3KG,B&&A .1-@2HM2 R]96U*.!;_L^S(0YR:]B3WU\WC^
M$Y58902WG!4L2;40.DNER34O$BJ3-6.X?\:P' @00MDD35)BTI@31E5)I(HI
MG'0;9P;T3\Y7N=N6_?=7P_)^1<K-\_^1U6_/?T3.U;74]RMG6>U_V#Y.6):K
M/.%$YBD0B5"*"*]8Y-8PG0C.LJNRK!Y,6M4WM(6_I$X.<[+FX-*^H2G\(TN\
MRLLM4/>^2U?UY.L>>UT+^,M?^BV#I3?K5[]N ;]N 7_W+>!O-.%?;>'NI3_\
M \A*=$)H<*/DI#M+4ORYV\;\2EUA:,GS."\I-WD)ACT522J9HAH, Z-RD=ZT
MT]:E:O2?"$G_<[1]^?!/<K #QA;]#XQ1?P2#;7#P%L9W]&\?%&OZ_L,?_7<?
M_O/Q_7#O?-%@Z^V\80?PCG?#_<\]^@\8;&^R]SL?D][;O?C]T?OA_I__Z>\/
M7P_???AC5>863U*;4\4(F->&,)4)PGE>D!@[;I0Y2Q.=;3SGCZ>-\KH__)JA
M?1^&IC0O8D4S:Q+.C"FEI&EJT/5MC&1<WK3-U9JAW25#6^P#FTI;BHQ+HE)=
M$*:+C)36ID18SE/T0"5%C@SMCEL#/OJ^\(\GG?67;T"=&:M ITHI2RC+RU0F
M0/!)G%!E*1 \6VM6/YX1+3>+3VR>Y2+)"<L2!II5+DB9VXS86$@J=9FF)38I
MS;>6 ?#7S>)_FK-:9$J5IK1IS$K&N1&9MI:EA0:J2$"?6"L-]W%6%Y4&FE-9
MVD*20JL4SRHG0BE+)"T2IE.>)7GI&@I_LQGT^+K'/_C@]U4\9L64?SX>DTLJ
M,L,2PXUA699(4?"<@FJ@LB2E9;'6!WXXCUG1M%RF&9.:,5(6L28L+DO"I1 D
MD[%27*8JSN3&\[OK6?Z G"GKH]KZ$+C)0?_+"AIG+$ES65!6@K5:Z+@0O*1K
M=> ^CNJB.B!4K'@N<E+0U!*6)S'A&2])R6EL<U6";J#QJ&8/Z*C^]&Z"FV=I
M__)&1PE::V:5*(J\8(4LRYQF>8Z)3#9)M"C7"L&/YS++X!B&EI07RI"4&@5<
M)@8N$Q>&T%1;4<8\5K$ +I,_**-C[2"XX[/*LEB5L4BS,F>,BE*JHM2@$<BB
MM'FIS%HCN(^SNJ@12,O3G$M.E+6,,%T*4.-90@QE7":F9*#8PUDMMI:;6S]>
M!\&WJ/'?%A]]U"?:R$PG,J8V3PN6Y89G1H)]3DOL?LR-6$O?'W^BEQ,?$L%4
M3N$(RYP7A)4I)8(7J.B7M-14V#+!9O5)L<4>2Z1P?<R_^9@G2;:5/M#M_>DM
M/,2'>A9M7](>YA<S]Y[<@\3I+/U.9^7A\\#@!Q!"V\,QK)'O_GBI@%K+IMO(
MIN70,?J9\D(D)-$E%D@6C(C4:&)2V-#"<IO2&'A5G*R034_75N'/<*13F:2B
MH+DRK&!Q&G.I%2N3A)4R%I*E-S4+UT?Z?H[TH@&9*,P D)9DL(NH;G+"6<F)
M+$Q1"JMCHY*-YWQ5-LB]G.B[MAUOJ#V%6K,41JW'4ZQ<:X[E.N'VSA;H87/)
MAV1I]\R:\=V&\1TLA[U%IC.;:TJH*<#.%D81:41)LJS,N1 4]!D%NDS^[9ZS
M.S\HCZ,$8<TRURSSQ^N5:Y9Y=RQS*=@@<H0[4<18#N9?G I24L6)UE:QU)2"
MBP)89GG7GLE[9)E?A?D1QLL?<.?,KLW5-FIN0!XV/<)#@'J(HW-11_]UF[/\
M-1@E5QWJ[FCG@'&>C:9#HL<3$NY^["?\ZR%,/OP3[W_YB&63><E+02A/#6&@
M@!*9R9(DI4ZYE3)-\A2]R2M2A!H4C\U;[77.<L%0K2TSQF29E;'(2RE, NQ
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M8_L/K'G<K\/CXEA23KE5F>+,:"'2)!-4<<E987,=WS1"BS(6LX&0W;7AF/G
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MU^5=]*MZ$DW.QQ[-;(;&,_/2MCD:#EQGVO'?;OJRPZ&XP.S*:>VSC .H?6>
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M!6K;_S:TF @ E$$-</$D&$.%*<=NE*MD-RHZ*S8"Y6N_ ;7T[3%<+&,T>V)
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M3:FDI3'2\8><T35_6/.'U?SA&^/>:_[P8/C#(BQEGJ59JI@@66)+PD2>@/Y
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MU,O4H-DJ:':Q])+'1"5&,:(>\UP>12 31$0*.TP-B=3"ZCTCWP]F#[47S^,
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M2M[*:+BW;'EZ44.R[DA3-Z^JD=,PKD<5[IJLY9[]TJ#6MZ+6NXNHY8PR0H&
M<^(19R8@$XA"6&$L%$N)!K\\L;MA6G>DJ;5[T3KI#R9UE;K]WB$:Q<%QJ^]@
M@':^V6]#NQX#@%WT&E_"JN[!HFY&UQQ060W(]B\ &?<N.9442C$?_-7.YD;
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MZK%@URU54*X0QSS@;8D-&.^WMRU?\M3W7;']UN&&**\<$TE83#A5SGA&+25
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M1<I%3#E'$6,O<*(J8ETW6ZMX4&HJ00JX5PSN.5D"8D0(&3TBT8)-0J-$VH!
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M#\?M*N7^*LSTIFOJ/NLBW_PFEQ3?.C[/,S5>$--*:B/[-8NS0?_L+H$[*S[
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M4F+H?/?"5D;A< +?_"3#>&*KV_OYUXRU&> &4-K_[M=[PDOPKRE0 QA]IST
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MG^TF,?.W,95^&CQ_Z9AO>VQ"UBAN_G8&U"1N_OS@PS[9_P#W<?3^_.#H+3Z
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M@<5!7%<'\?W >UQ_!.[SZ^AEZGR- 7V+@WZ!_8UA/R=?A!&&"6*1S7YD[DA
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MXT*XQIV%MD"X)L$RP"OH.%=HSM]'P9ZALVA[*'8J<7M\<?L)XI9D+(X_LLA
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M3;^\]GOM]+#E#VLGO>[W5KX*,*N:K?5CIP6_]*,?YGOUSKM7^?(":=2]*F>
MP+RT /5:N2K?5[CPUZ+SU)Q*?<.3&@QYD:YK1&DJF6-2&\^#BXX3S2QQU.J$
M92KZ'Q*-)36+0.9+Z;IV]_2G#V?U#[GL"S:!:21CC@?*Z)%CG"(CB%5:4*]-
MNK'O62EV5W8_6_M]H]:$3USY@2G![&2Y]^UA?N&T-3@$\6L-^I5,/0.9^GS6
M^'J@&94*"XND-]G L!'I$"**TDF=,W5%\#?*5+MU#!)B%UIUBGE223/"*>.2
M:2N4MA2DV";,&4XWK3K\"*\^G8*$_@DP?2Z^U5K/7^N?C=,#*IWB02NP'GV
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M3F(GVP-YS.7R ZORA161>MWCZT5LXU920>AJL_M/V0T>ED/OY8J(.Q'CQ#/
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M<UT]DNO\ -L >Y,@S(B2!%,6E;OBC.;+1(F[9JD_L_C!O5+1JP#"J@40@ N
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M-XM,C<J(O4*81&-K\\!B')US"DF:$X QRZE]C"%AL.#1^GRZ<^VU$'AC3HW
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M%R<T7\_J1]_ VDM182%1="$@CCE8>R%X)&W$FGH9$O?3'"M@8G5P(6J5>'0
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M^5Q9=W2,0F^(JKL_>\/U^7^/L#_^NVL_F='.E]^//N]MB/TO?W? B!WM['T
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MZ!X"M@ "VS$A+$Z J]] G4^KTXS%2A7O7<YI.9'PL-EW+V;7 ZK!PHZ&[0X
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MMKH@:K^X7TNIO&18)[9CQR==SB$SLY*;/6>ML5V,<D*J)T<!!C[GOA>N7'[
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MYIDJ_&(2XR364B?J2-!<".7 /><@'M@R$[3$%8DQ-8EYELH_O<L4"1 5(E'
MUB N  &T%0H%;9@&MR4&IE?6"95KBB^1]K_X*,R.'_;.V<H$CYF;*5_'8JZB
M,5YX*4V(EG+*"5=61<5UU%81;ZBJ: S<>7Y_\IK&+".2?9RA,8[JJ!* F,0Q
M( [8!>Z84H@&3JS0F/J2QA"YJ+UY'8MY=@J_F,;<KH5P36.>B?)/T1AP0AD
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MG[\=6-('A,HQBZ@(Q)AA%>2JQLB;8N14 -\;)9S5&GE!*.)88N1@R9$+)HE
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M2TAQ*Q&7#IB!CAA%G[SGTD3P3L$?69L]_7(A?S<1H3N6OJ]%:-E$Z/V!M0S
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M$)T0]\XBZQ1%/A#OM"%*\1S_:;EJQ()[=+^4HP4_^<F!G_!@P,- M#T8\"(
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M8!\V8_W:&!V!QD]N  ,&/KO4)4!@=A!K_ZJ$X42^?/Q[8P>?P)]VH\'1#P/
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MEO_..-M5_) J9SF<<#1L9VCS9MN-'7X=B T(5![@3'Y;6NP-3PQ#Y!654]9
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MK+8!WS?;?;]?3 +(3QLG'GW=V_QT&(7QUI"(L) !EI]%E"L6$:&.L*0UE8&
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MC;GM<H7Z]^WIHPGUMG.5<9NSWW9+3B#O*<$SC'R5N+P7RU_0.BC)M;**6S!
MSEK,0%0A)(C>AWOM-[<.XR-P8W=_FQ^*#,DZ2J0$%PA60R.;'#B,1$C-A69*
MI-PYY:;\47/<]B8YNL:;?(0@11N]94:!0%F.HS?&P'C!LR$"$VQ<*TA/)D@?
M(2*ECA"7=$")@=F!.!3\S9#[.>5D'S<N")ERC>\</K*)/:W+]']5X]7@U_4
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MRI'W.()$* ADA25($$ <R@TE4LPF1NA,8B077X$$Q'S(:W36KXJG\MYE;UR
ME5_)NW_@:/[W\!:/KLJS9)3\ 6D6 S/":=X) ',0\W08K "XM 1CP3B^>WEA
MFV9YL'C^E<=#=O>/ONYM;O-<@)S +C,LD?*"@Z12C2R3$>%HJ78\6>5R78;
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MW][;?0##S>UWO3I*K D87D,"EXQ;RS6UP<80G,)P&8.7AA'G5E*1"2:M[BF
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MC(5XN\CPGR#!+9;?"\N/9KE]<-*,6(&HY *@W#MD9*Y<%@:#'^>YC!J@G"V
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M:5A5IHC8GB9B#8E8M9K%T?$#/1OUX4'^)/GJFJ-X1'$U/70,0U4(#55'"</
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M13![(\A&&#:@UTD>X3V1X#DD[3/SMOU;)L5T<)WWFK-0^QS\,A>PO!3+NQN
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MQ9%^H20#=@7-+T!K,=PFM@-9PIV%&0MD@W' D^)1J1SF-PE[4X*1<309(B'
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M/MH7QH4P[NW8+)?8NT:EBA4^+SYVG"AE\40I-$*F+&8:-<'1 !3@F <_)V.
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M42 ]D$S 4Q]*DQ KP5ZF/$PF,90/+V=1RV4HDR,6Z )=SY)HOA/X:=J*=+B
M%:FX:3:_:6\6)0B4)%#2%@W='92TY/C YR:X"*#TZD!)U71+<ZR#0'4M0[=K
M0&D<%(R2_R(FK&'I*4VO,<SWGG.J$%[JE*FH!I+B@!F+2GM/]0EBB21(T@E;
M$##F+"/29TKBO%>:?IBWC+NS4)RF-,-43=8UITO37X#!,AYZ ^]O/&(DDC!
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M,C R,C$R,S$N>'-D[7UK<R(YLNCW_15U_>7.C1A/M]W3VX_8GA-E#&UV;>
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M(0/ V;_7Z3 F[B]S^OC&([X*X^\VQS]T6'T+29RL(IU.\_;LKXING3"D"<.
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M#5 ]5XD!M)279-LP>-'N$V7E61KD._51Q!.0R*ZH+][C90N7P6&H[C7SHEV
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MK^XP^.(NQ,A3*O='I:_.A=L/ZFE@VQ4!-I9Q-UJ_[DDRR<,X.H;<6B)^N\A
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M1:F%[94OKHP45BG?MO3]=C3W7*VCSA2WBHRZS,R:N8T+?U%H'DLM'1%$Z;
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MSX0:[HP#&I2K'2;Q-)I79;AOKLBF$RW43N>=GQ^F,LL%'LX%9U0YDJU$8].
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MA*0VF_PPS&A?8LC6UG@M<7:P0<S*<_P*@_3;$)]X-T+A-B[!9>#"9&(@(,*
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M"SL*=\8)"G(6!_L%/[T8^:N>9(9)KSE!\SD3:94FEBM*DK$Y*QU<=NW<G$J
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M%+@%95?Y &UME19R/92[_D<"3TJBC=&"L2Q5\CN@5\%"2#&'@E9:P9]7F'Z
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ME4JE"$Y@/7=SIM,@6B@V8"!KVBJ7N]@J/0(\'6 =RVDYEB9&B )NA'CSS>@
M<:0,I [P]I.7U%RU7:DS4"\C7$QU@2II W6"K5I9TY;(!3D*C!E@+"KZ1=*T
M)QX+=1[);SH$YO111VN#XA.>XI?58,#_-5TN+H],HRTOCBE@/@=:L*8%!T]?
M,;3!L*3XW6ZM&XR*=9^^^VNEYCJ8M13@+O.B;EZH+P8G2:W]M&894X]CO9,^
MY;A(F4 JKH0J3+KB=33<D1Z+CYQ-'OC<<7.I&.-:!)_ *96K,4MTT"J B2XR
M7H3V<9RTHM%RJ6X*\4X_O=^PS.;X(J7SK^>G88GYQ=?9?#G][U6R^"1KVBUE
M\J"SD?0^! ,./0?)@TJ:7@V76S=!VA;KX=U_]^'1W8-H)QH;P7]Z /<FQ%K*
MD OMY2':7#O1!'"61;#:U3[3GO'<>HY!?Y3/AETMM+1+.[EVW;>"+#ME2IVN
M2Q:?00;>(H(F*0BG0\YWP\_C&<A[&;8P)E>:27Z$+*V;/+XJ2/UQ6?Q_70IQ
M4B[^;!I.W\\6*TV\KJ;(HG8L?#M=+"?:V)(-N0@V<DWV'RW V3K,T <R4'*Q
M+HVY VV/_+B8M@=MCA 46KN*GU7//192'&VY]()!<KXN1#IR<BP'-%D9':2S
MOG53U6;@GP$S1]?I""VKURZD!WQ6BG;!2C!D3H)248$7T8%TV7AE K?8NDQW
M(.1G0,21]#="L^FU\"<ZI5)<( GH51OWPD@@K.[:L>08D1=L[6^O!?(,J-)+
MUB,T9'[HLLBXDC/2ULAXO4,L3A,TF2&AL#P8[DL:)Z7^H/.FAU"@E;3WG3=]
MM9Z;W1#>UK^N^J@A_U""\3);8(*;.M_$0'!% [(2>4UDP]RZY]LF+(=X#=M+
MU[,19#Y"0& =KLO+@2[(1KIRW8QJ/S>M;;37@1(#1+];<L@<.&-%@O"<+"!'
M6ZGC)4'A7"LG#+T+K3NB[YH4C]RA[IH3?22^R\CAY>6?PBB3=@D8K;V6DR$$
M%@LXC][4_O_1=2K#:1$\W->5:ROM=0T=;B'ZAG<5JXO@R[C2^QKBGIV=E+>S
ML\^KHN5X.OU\T2GI$F60,1>=/42)-?*="D24=88)2JO1"%?NN"<;KM<[/_+)
M$V!$"3?/I[V/JII2M\%?54L$*4M) F(V@;SGP,F.LAZ2\H*IF'@NW1(M>CST
M.+@PEI1;Y\9? EH-=][$5BQ:N.PE:%\'X(HLZ)@,"4QF4:#A5B339S]XZ&''
MH?W64MUE*N>-Q#*O,/!04XVLK<0L#H*JL=N8N?:"L](\'O]$\WZ'.)RM-3'"
MM6.7#+4N$'_E_0Y4[1;9F]OH95]YOQAJ\Q,+TM1V;2I+B+S:R,IP*;6/++1.
MOGK*>;]C,Z>/.D9@S,5PNG_@:?[CC#[Q9?@V78;3B[S(RS-4)X%.()()'22H
MS!QX9<F!%[84I@0OIO4!]3BJ TT@[J/,M0/HFVEBEQG%_PS+\_FJ:?O@=.+[
M']4LE_@1E'<2B84A2Y0L4B;K.(\80R9GLD1DY#\H@W&RZ4/'S2*6I.IDB@&3
MI >%M;M]\0YD+!RETYSGUE?E>^C(>'VS^#[\6#6:?76.[TA!G_[$T^_XS]G9
M\LMB8F2DUXS,P9QD J63A& T0O2H7!%8&+8NF-L6Z^'= ??A49<N6LTU-EI/
MQ\=Q_V\,\T]_SB:Z9$O0 J2L#*@0/#AG(J!CB2FF<BFM+:6>$)\GK[;1SXZZ
M/VZ$2_S 2='>BZ(S2"OK=%3ZRB=R9;/V-M;&IB6VSBCN#?(94ZJWCG;4(7(3
MX-]GY_,)<G1.I@R<R]KT)27P0400Z#,*%2V+S0?3]<3X?"G56T.C-97LB'?Z
M'2="<\F+DE "\[5]5X 8%'U5RUQ1F12;!PCZ8GS&C.JKH1'2?;OB?5&6.+\&
M;4QRR9-PDN2LAN(3N&@M;:S)^>QD]'NCU2V@SY-;V^MJA(3>KJ GJ09$M&'
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M;+V/5'=4Z'7R[N^?7G_XY\EO;]_\_<6G-R?O/GX\__HUS'_,KEMPO,*X'%(
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M"$!#AJ\*GH'GB'3^9>T$"H.F-8<>@71,A&DI_37L&!S07;?RBSHA'J+-SCA
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M$3"]A+]AA,@VDAMQ! PY?5Y:03["*IU#9ZP.H0'F@LC)1MH;.O73W+<".XV
M::&_/@(;=02,*S&6*"3X6./J2D=RZH4B5]XKZW(Q EMH[D!&P/02^\81,'UD
M-NH(&%]$%M8BG<=L-727K+DHR+BC4[K6GA.H3IWAGL8(F*V5M[7,1G!;7M1
MR_4,@\S))$O&0 RU[9:0$;Q/"&@3HM<AI^8E+;< '(=M,URV(W1:6]^O^,5\
M7AF]:D;ZVX^??W-9WKE:P<]EG.7W9./?N%/MLJ:QIL2,L)[]!$P&T.1N-N.A
MZ'B,221CK$WP8HIE!61Q!12SM#91>+6D#'FES-C0?)#)D^'M(S&= Z=M']6V
M#@&]_@O3>4T%NE'8>E77>C6V3QG'R32'@)+@%6WHV/>\&FX6LRRB^$?GIW1\
MUAZFY.Q=H;/QM-'\ I'^J#:OO+1 KOIM7%2YB)"-S &,2X0K\#H"R"D(DCP^
M*4K NX.6-ET@;G[(<=A<345Y7\5;]RAX"-=5_4('9+VR>1Y\W!ZR>9JII8.N
M!\BT]2GP,$*BM@\N:D@\J!J[MN"9KW-\34E2^7QO7.KA:/NA;)X]*+N/*%LK
M^5[;FZMLW^)\B+1]\=H2266AP&FCP5KGN./(D^F61+WA 3M.^VBH@%ECZ8U0
MCK=J=E?;DUR,V#8$)R-9 W0J@>*2OI*T6.,*]R@]+;+U<*9; ([C@!XNVQ%Z
M=%^#N;(Q.\ 9KX3J)I2]E4QMJYQ-:AX@V7'*HF[!TD'8G'($5FI1AL::7\I3
MG<?M+:?_8O/>R3M1].-E3R/IN8] FY<V"2;MZ[^^3>?A1@EOQ,2%BW261+(\
M5 SDY95$ED?FI42AM+<=RYG6??Q>ZERVE_BLJ;A&.'K_.#M?G(?3D_F;LS*_
MF(E;>PA=F(](=H0AES_951NA+" ZJ:#P0C) 9\BZ;/RR/@#GN([E5G(?873"
M!FA7].\ ;J0C^T%@^SG FZFQ&ST&Z&"$P_T1D)PY61R]8ZX. +$J@K=8R/G,
MV@43Z0C<T>ZQQX-_3_SH(?K61L'+D_]X\XK[GVV,[_F<>)5.Z*RU108&,A0/
M*C$&3JE"FZC@9 ^Q:&4W2Z'[,W=O/C34U&Q\,6^T,,:::W][R.^L;)RRUF+J
M?<^'_>WG^FZO^_*)MW@RZDKQKR6>9<S_^B_3_.__.B6;,PKA/":3E0_**ZDT
MT[:X$+,*:K+]8]LWZ7Q[W9;2RN@8&<Q0Y[" $C4M62*#&#ACUFE58NO;WP<!
MC=B2-)DD2I)0A)4UR4A!<.3K.<18I#2)E=%&/1]F2](^NN_1DK2'G-NV)&VZ
M'[Y\\?[-IQ=O/WXZ>?F_7KQ[]?$?+SZ\_NW%Q]>OZ"U^__K=QQ>?WIR\>Q?F
M\U6_BP%[X78/:K /-ECAG3W02J.SYT7($%2*.F8GL<A8@@ZA&#?9[I$C)\UL
MNH?_^:)$KD2@O1U*" X4)D%LCAHP>O2*IYSN=L@?/T7F4=1#=U)Z[M?9V2I?
MX*)#^67/.3JC)FB<-XI,)*-1@U(\TSO.%>3"C2\)9;:M3XT'X!Q@<D=;3MW=
M?%NI9H38U0UH[\/\9+YJ')/KO#A\?SDV9:)*0!M] -HLR,GB*8!G/ )307-O
M0K"Z=3O7#K">,XN:J&J$:,;[^=5DE;5<)TH[5=L=>'+*B.O!0JQ5\8@>%9DV
MP?G6;6$?1O3L.-1002-TB[R-;B/) W.HHC3 72W 58:#)_,%K,TY!L85F:VC
MTNC7EC2>PAIVI=IX_%[,=)FDI%(@]P=44A:4)??'8\W.M%@R0>4QC6X574!Y
M=L1IH9(1NF7<@W5ROEPLPUF>GGV>^)@UJ],$Q6HVNPD97**51R6T\XE;G5OW
M3GD(SR_.;*N<AM78#YVKEY0FGSI&=!:2*+D._9$01"G M<JJCAH+/N_ Z'FF
M&TTCQ30L;KL83(?S1 L-GW%69G^>X7SQ9?IM>K8XCXMIGH;Y%!<3QYGQ2FN(
M(=?N5)'PN:)!6,N9TQA2Q]YY'1[V;'@QBO0;YMX/%L^[\RKWDW+?M@^.84U-
M]8DL>F62 I>K:QC)-S31Q=RM2GT70;%-BW@V-#T,&HR0O=IJ0=_#]+1>7_P^
MF_^=_MWE1!>9O38>8BGTOBK:R)UC-1O,.72TFSO1NF'56&OYQ?)]D*)A%MCJ
MD/D]3.??JQL\*XL*;U;2RH!=5$/DV_4)-,D1<]%90^W!#<KQ.@I&2XAT_G"'
M4DG/.QWS'1_X;-@UFA;6!$Z'E5/>M$>6LV4X)8R1UIZ_SVK7V&^S/W%.O_F"
M]/-OX>P'^3RS\_DM<T6GE$0F<X6EFJ#"-4+P6I"\M-!:2<94M]K<X5B>%\%V
MK+LUW!N_3<$F\=4.=XN3LOIZDB5/6@NR*71BM>TUF1@E)+#(G%5"Q8*M;XF:
M '\V=-V?NM>0=O!=P=:K>#5=I#I'[W?2RS_#_/_B\OU\FO#]^3Q]H;]]%98X
M42ZK8-! ,*FV<*>#P'MNP$H>;?&"<]<Z]VC,]?RB^+[(L8;YPX9LW$\EN&'T
MUL!6[6?Z:?;ZZ[?3V0^\:!]QA;XVIY@$IA6+*4&)@0P=6S@$[0JD9#BK7==L
MUIT,A:%(G@TI=Z^W-:P;?#5R"]G)5="L0GO]\>3]38%>#KV?)!^"R!;!J=K\
M1$M/9HVB]\2FHAA)3&'K:]K>()\-"7>CQC7$&WRULK7 +KKF+%:1@,6;LXL"
MQ$D)7*ED'(2@JK$M-=DMO !#6EI2T1D\F*-][0J>'67W2( U?![<U/#%Z>IO
M,*]?U]5KIR(A*U$!JZ-AE(@1HF0*E+32ENPXXZW=J6[(GAW_1E#8&EX-OC&Z
MWMEQ_GU:>]JO _NS6J5:N%<=Q4[*C39CBXDO)>DB!(C"25A.>_#"21*6T8F,
M7\WNFHCM#NZAX)\=._>C]C4$WM_5T.4";J2#O#E;SJ=GBVE:Y:%-,K(8I;?@
M> VPQ?IJ_O_M?5MS6SF2YOO^BHEYSVG<+Q&[&Z%RN;J]X;)K;5=W]+PP<$G8
MC)9%#TFYRO/K)T%1LB23U#DD#B^2(CI\D:L/$OE] #*!O##E0*1(+EM,(LFC
M>1MZ:#)/CN#'08L5A-^Y2,!"[/CPS.*:F2W7<74B[\Z,CXHPK@CK0,82:6J&
M05#.058IEQHD+IO'J@TWFZ=)^<,38T6$]\[Y)KNNYNNSZ\:>_U#?7.XM; RR
M:"8=N""6#RH>A244G)%)UU.MM0&SCWD]S75P3&19L2)V?GWK9,"]F5Q\Q1GY
M((OIS1;SN/WO+R:S^9O)_)\X?W>3F3[23"BE<@&K:LP#PT0&'7FZQ@5CO7(^
M^=9FSV"3>7+</PY:K"#\SB]W@\WL:HW_,IDN?U3_.SZR0@1T7H,NM;\K]X;L
M/2; %A]2LM;;PDYE%:R<X?/2.!X"K5@O.Z<O;:WME_]U.9Y_>W4QFT\O%Q7L
M%ZT)/WP*%RMO1O^!XX^?JL*^XC1\Q,4_U@?/&D)U=51:YGG0=$H:6[L'6:?!
M6Y[!2UUDD+;H>#1WYZTG_^16V=%HOA?M5BS G9\^M];$XI>_TRXTOOAX-5ER
MP&Q*SF4!R6A-D.1:22HR,(:Q^OR0,VN= ]U2_N=EL"_P5S!YZ[?4ZTC%,IE^
MKH$&BXN#4 6<A^E'G"]"8\/G&ODR\K+D*((")FI!BBP+.&DE9*^])-EU4O?L
MI?61I!W&>S*$&@J#%3S9+3=M0[62KK$J1IJDN03A:MA]5!Q\3311*F"H1=<4
MQDX4VEF4I\6N_2*W@GB[I[VE3Y@OSW&9TK%)CVO[,5V5-;-1:"-U36PB32IA
M$P3#:X=9SV,P2K'2_,VGE?#[*C=WZ*/U(&"WK6'7JHNI"R))2T:!UJZ&4Y=
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M-=%@%#PIW[>[.D8VJ8#T/S"T.]9F7[5L;O8@::]4UJD@^-$4ZF\X[Q-:>\=
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ML:\9X.2A;::]%9!N?;%W,]<JSME%?E<-A/.7?]987AQ):Y)AFDQUK6K]I>#
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MVF-??#AE#+?15$L+N [_ZO7(8H@V60$IUTJ5R20((0LZXJWF3HK Q:9+Y4Y
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MWQ:R7AV&R_?D/&)D7'/' G!5 JB,HCHXOG8;RH%L9)I\:DR-#>(\!D:TTO8
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M[ZJJ/WYJ;/K<_*6EM;NGMZ^?^G6 1A\;GYB<FO[.F&$M+:^LKJVS-S;WN$
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MGNI444__YW=0_2@A[WLQE+8J"]FG5 V*Q$"7W0XR.K)T$KDB.[-2%:AI^XO
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MA3+RT@BOY>R&S)-D']N/%,0HO?V1]AWF]_1<23-V3XGQ/34#9!:L5M 2271
M%YP$7<?4-L:K4R)OKZV\%0.FVQ;!UNSYDTI2]7"J?N8T4U2@#QXZ'%,0LV#^
M),V7LCH57E\'9Y=3NU&;K"IJ#]W=NU$NKY1Z2>H\^E-XW0$IEM=0^WT+YP.
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M4,&/IA7>+\_?;#ZK.4K?%B5\8G&GV*[)_(T-)S:X4M_NVA,&GI8WCQG6)IG
M4@"SW(Q_VY-;ET(RQ[-&5/P[,'NL$=QN/<[0G#1:W&V/)GN- 8L$]CPT\CA_
M":D?.,C\MYPY"HYFB+^\[:2+ZV^$1@HLP.G"PV9DTO&X9!5Z+$\2?S7IV7&6
M%:5;-F5$;+3^>O]J.,.W\/A;+"KYW@L)O =@H+8T8":C_1JA@N+OL5Z4PD)S
M;0IM3HUM>2M:H9A-"K0YM)-9@3@*0D0-OR^:C++Y+W)%].<E"]>31Y_$G<ZW
MOK.9)C6BGWPZ??Z+9@F&<LJWR*,>3+X/ZK[WSH8;KZ#>]*P@N.V+[QI/FLR
MI!#UNQ$=)]P&13H? .5"Z@V&G%^!:X<$=D7_ <-CS9Z&VGUQQ]U_ '!*L97Q
MF'IK!6;/T<*.N/?6,N-FC_S?V.7D!;+\NNXM:BQFWTAXUQRI0!15+V].Q>?0
MWM5Q)'=6-C6\FZ9YD/VE(;R%G_2S%Q1S%[M36RW:K0]"\.6F8OD@BTO;3';:
MON[N!;OTZ]3AH->Q4EJRJ%C1Q<D6=$'%\3* T=^#E)0?_GUC5OK[,2H6'V::
M/FP[@I^0INCB$!-Y\@\M7S;HAOXV$O VBN7;)[ (]1F1UDY<R#Z#%+'7@1<
MI!R_ R?;L!"FELL8[(;P6RDP=5$F&!1E4<@8O6,9*1L]\MS\I;RYJ-J7^<G;
M61A"2;&N(:18+4Q_AL['3QR5P*;)/A\[:X80]_ !<,==V/%W;)X:_T\N:$.V
M,.6EB#*E54[LC@F^69&LM R_:LG^3\$YGR4?@/?OH6=O1-)8GE2FE^C97ML+
M7KL-B4%W&ZD#Z-% 03A2J/%2*!7:W"5S!I>N:NF&/U:\]HO UUGI>(-)TY"P
MVS/$0\[C]W<KO.TF 7:E-D?+-J>%O=!?-,_-A+&P 9V_-6I?')^E+'6MVD&P
M>\9[QJB>UG\FPPH9L\_BU=!X%N' OAXR%)*@6!WSG0O)+/0-FOA*$ OB]UN$
MM2I22$.W'C3..8^CRLHEBA]:/X,ID"5H^39QUO= 4PH]E'(63_Z%*]$R,?\#
ML,=2N5KW\^?JF%RVUJ1::(*%3O%)RY>+;]S"&#UA"VIP>48JQU_+&!50B".C
M*H%=7(G!$&6,FDJ4"*,+;REMJGE@*GA^JL%!F)KKRI_ 6M6*"MWS2V\3^;O6
M!,8XCURJF@AS79</OF-)']$D31& U< 7V\MXYY3+I%+X09/6,WHM,!!W^/P^
M.J.35YN=^%VA E;SRW4LZOX$0\^(@XK]QU6G@;"74,GNA2QU5RHX['U6,:P6
M[$^[K97%?#\7:E=1YO:[>I9$M;;7Z3@<IDGIZ? "E[(^J"<0?<3N\E\N=H#U
M^'_JW19#4U_T0:>FK&Y$!^)T($GD9L%Q:^9D#&HHV $D)9)86"YY\O@DU8GB
MTU)W,'W;5KX?/.:H':TK>Y;DL&@/C36(D_WFG'T#5[OY@9)5O:K,('4R\[8M
MEMSB =!TR!GD:S^0S6GV!Z:M+HHCZK+XP,_$Z.?:-TZUKPH8IL _MNYOW"3V
MIHOBX",,4J<XR694!$KW]:ZI*<:>"1%6XNMI$SFX0K18[A8SA_P*OM)F):U3
MWPV1ILZ*/YLEF\4@(L6N"M6 ZCKGO@'BIK*J)O 8"C],Z1OJC07/5%QW5W>V
M\9<FLC;%7N%OV7H \XXAFN2J_R(K/+UKH4$9KU/6T)KL#W$7WIPZ)YX\:U71
M-ZZ3JS]YERB]F1'\E84[$1$+3^IF6?)Q[Q;6U:K5_^;2&#[YM2G2L^[G_KM,
M_#;KC)<Y93@Y=]ZQ<BA-U[W3OIPVI8M,MP1#Q;;56#)?]/!J$.YFJ!E5+PSP
MMX-'U%0)C7[Q,#7$F,22S07)E>L_OV$+NT]#3$)X "#)9_;'DM3*1)'?=\C1
M+$SBI0;H4_YV7O:OL^+XOTZ:.=@4_ZM[GZ-C%%0#"(FJMEO/CNNSV<; \$L.
M_IMD45VW#6P"P?QA^1B_OOU%"!_"3RV'JE5J9JE7(G6W B//>]0)/S.)AP>S
M;<U)\2??9:[&V&7J:T2]JG.\<O_9[L5-$R,:C7OYY(EPMU9* CR30=HS5:5&
M\UN\J7Z)SA"H_?#[>K/_LT#>@'I?N?(--VHRFWB:5-@ 7;9[@T;+'76^^&3)
M2KK^'(DCD9'![DEP O4<IGTQ#+F+UK0S?:G)E@6ANB]!MKHG,CP'69,,\$90
M^9L/1+XL[^IYI'J9V 6XQ8]]>?VN3A;U=RQ1O=!VQXX3C^2.)!UI264$&Y@J
MLC(:H^;K -TYDL:7'!S-%N$ ^.9I"SF;'3AC,&^1FV3=^^7")]ROR!)SU'9R
M,L?\6=6\<S5*9B5=S<43E1VZ^33Y7]P? +""L?=<^:*5Y$3=+P9E60+S]PWS
M"[*]3 V^9FX.PAIGNS_6U5"2B;\'6-OY$W?9V3RK*^1$?%,?)8C'67[,<A5V
MXQQ7BE/W4V<99NO!;;0]PVVH-]R<GT:*52DF180@]E^BLV^UM=7F=$?<W6Z>
M!@DDRG:*:LHJ=&SEY*!;5U)VMQ/"CVG#BJ;*6_@K:R+,E*S-ZK4%E1C <MJ+
M7]^YW'RRIU;A4E0XMI..[6--KIDLH'D[L22;T-_4)61Q8N[E<MGA&Q??^%0G
M4#('9^??'A75L+<$%!I"<JS'I=WK*HU&14\(]TX6&$VU(E3VYX.2!M4*2H!$
M;KW[_\3.D#A]5<SX'O\!P-AI&DNXB-O;?5[9DGD#&F/'!"\&1Z^1=Q;;7A]\
MSIDOA]6MZD?@S":E)&K=[] -"5^H*;N*3+6'W[KG+&][_& .XVO>M6%?6KWF
M%-F1<7_AC/:.@>K<DCT.KC$""!H<US? K2L<?!4*K3TN:@VE'7QC''0MZ14T
M,1EEIWR[<AN(4850H $-[G=6B-U-3Z'OVS=N]+#1^DL[)"#+<B>[3V;@1254
M7^L.J@L6!B^&[,K2)PJ&'9E/K!2"O,;<;J2>1R- GS@A>_,#K@R=SL9?DWJ]
M0T9;YL;FMGH\@K>?W)9+[!:='AI2<?6",:0=*60(L.CI0S1I G$^7O\G%N5:
M?D>"7TV$LFE]9396C/G<O6PYH.R#*JU;9+F"R[0A_2;NQ\6_!HGS(J+<(I1A
M8(7W"Y;7?M9'A"H9DQU2(Q;!$^D"&V_K>@-P<TN;DWZL,X&LS_$03K*C?)1N
MI+!*JY>9*X. &8E6%4;.F6B!2_]R7"$@MXKM>$,PBA(YK33?W#@-^SDM@&$1
M'^2D<Y3SHI9P]OE*!J*^PLRAU;2Q_(Q;W4152[ K;I+K1;A5-)?6BYNW!V^&
MXM_Z;72"UE@-+FW,*F'(S5/G-@[Y'Y4=0;]CMPFC'X ANI=X4A8@*SL\M%T-
MZRSDV.YAL.S.\X@Z.R'ZB1P!KOE7P]2W=7)LY)^>L[=+L/0)#Z#JR[@:'X5>
MT9Y@'].&L[5*3+1-Q-VBZ?)>3M?GHWRY]GX6YP=&_IG09#>DP?.MGZY4Y%U6
M(VJ<(M NXSP!B=,;#UJP\Z2A\$'.?)<&YS1OL![<>4+D-!+K<4!^3IQ;"FG>
MH\C0TDI#:2A-C1JQV:M 30PF!P897E2+1WV[7@T4H6"-JSTN*BZ+J]UN(V^K
MGL0*^ZTWR:O?N_$^\=[->2"DMF^D(UNO0;P5B^995M_O7CWVO'!)"@]-AWQ+
M1!S=@D[J_H/C\QR<E'3&""(P8^67<$Q>[@XUD40[8I!X0]-KC^N4NI(=H8_?
M.<R:;E@;R.;3 SA9]Z\V*SF""RK+G$MB1&;V9[BO- S(WGN^1H!FOT;H5V%Y
MTGQ9*TWB9*B_7+%'2O#)++&3XA=O;/YOJ>K8J^TW]15.C@[[X#.?&8%C4H5E
M4VG>%1/B*"MF,8^UX!$;>C9K GZ,4BXB+ 0E27(:QW ',#N-J)]XEZ6+@UF:
M7+:I56#ARXWP6X3[<Z_1Z@> L!T/DG ^/4,'Z:P>3^/$7ARNSZ5FO'G9]$J:
M\,5S,H=7UCXKWOM$"-\O[8R.4?+ABP2';\;)QCP*'2_*].IJ0UF;!].Q-**W
M1,/7GP\05]M5;?]V,92M&<2$R=-_=C"!</7$<[=@=ZP%\>":Z6EB;R17YMHP
M5=Q!!;5.L$"\?=14WL0@"B M<E@9 XVS@H/-@0-,#PW4+\S@,5WH0\# \D/A
MG7*"( J1E6ZN]8A8IHRYV^ T.]6N<&25V?>QN<^SA7@BWL^BSA<"X!EA/[@&
M]EE:=DAE:-(7^?DMR?2*RK$[_CB&[(L9.^]$H0KNBMD .X4B!5893RHC&P53
M<V0N]!?K8'NKS(*U=L4?J ST@<+[HKV2RS*%EY&3OZ[+P^R=!VYRFB3.N@R
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M[<<8(XWVQ\$&:S7==(A]PGNHBUW5L5B-*KSYPN,CV;Z%Q1PK';/)#@)E6/7
M?W"D7&+;-)J9.W=7IMT2^I.Z4UIQ=J$_[\M.SP4BXS3=9(O,*@V?ONJ>*,D#
MD+HOR[8@=!Z[?.E?@R?W&QL V\*6TG/UHF+T3D2M9_<EM]@9 MS?NO3//K$C
MW6]C/,:E,*P^N@L.&%H\,SG(\"X0(]Q]IGI#'*!P5)E>L$BYH.17P@6[#MF]
MJOUZACV.>L-"[%=F&<A]%H>YW236;=B7:&A+P#'G>$@U)!JGO)7S %@XY7^M
M^'>C\[Q&/K[//'F:STB)NX,V!A")[(GJ,Z+Z-IFD"IVV/SB8Z_(2J(GXK'!_
M]'K_UEG#%E:4;\'G;-.$/5UDZ&(1"S&+P?'F]L3.SDL#TM_,N,60YU'TE5F\
MLQ0*-S1@-#(YHPP?@VMW8N64#(""1&?2],?*;<3YIPYO]>&Y_&W%3] 8)W)3
MU2TTU?(6$LAF>:A'-S!>MT+X\^'9*#MV\%UK=S%'K8G<(:B><GFU;$H";RVC
MN&GQ)\6GFO C[GZR1VKQU>'6&9XN&NSXK,Z&_7L&I8_5Z<98<2J-_ED93#;"
M)D^:T</1D_F3M.BBD9+3L)^G_+ <O%>_H3[HIP3'-!K\]9:]-9'_RT!6N9*[
M*IG['Q/[')9L(7D-*0R.#/'.034AK!D!)&)V= N7/T_O5-+S;:+F#CC6&YW/
M7[VBO;QS@ZHA8ZNJ9&M4RQ-J-$\L<%FE]+^S6@EJ%ZE'&(5TKKC."%_X8_VL
M<*1O3CX\K#1]M\U^D<MW:?+C@R6+!,#J7V*K-_TYGU&YS)9D^J45?N_6]Y)-
M;B%8XXX7%0;04(WU_GOE$1<EU6JFKFI%[<*ROLYVZ@PA3%;',;";:*0/G]&7
MU4I,5@XUS<%7RI/Z0]0%-=_AH@]6Y S;6QIB,B(@83+>.2LTD'\G<[JJ:'9I
M7G=IAZ3^M[9R_1*ZI:977%Z)L&-7:39N^>H=/_O+ZWO*Z4UR<[2OE7L?5-F>
M(^8,,L8+/ZO4M4D1<</K-K/!0D?R?RN%AQUQ]\./!3%KIL7:_E;"S[7 )K6!
M=)!'%R;E:G^QNKHJ.YOKVX') DJA B.=E3NBS^T:X1]C9X<Y.)@D#JDU"&XJ
MQ?R4GZ'CA)EID1D9MBS)B:YW=*PU3+D9LAK5Z8-=7]=.5HSW1!%O- U'=N"1
MH2!9(47?I.477[)VP61N/9NT0Z$^E-]J-Q;T=62H(N*ENE\$\:#32DMB\!DJ
MKBFGS:L?(T\H,+[_,.W,B!5UU]GM?#BS5,[Q_AT_J]]+F32[9DC+I_443WLL
M/)6?'@=T&?4\=HJ10%GQM@>%3,/<61FE'1EO]@L8<8SK;@B@6?KXA.0TU=2U
M1WUOJP_=%&]^%BUT&Z,J UC9^-..0Q6>^5$J5$_ UFB<H0WR+<-6E/7OLXIJ
M#T"T5$E#_%F-E;.#K*3B6GDGI8DN3C6':F*!'7O(;GQJR)BLK//L[/OK4Y;M
MC5<MS64#9@.,SHVF:&BH$^3GY?%+0O6(W)  =89*IJPQ\0? P]Y/^+[NY[@D
M$8?CP3Z?B<>UP6]M*:+6S(_A>^@[Q!DY0K>\L:BVI]F7RG5@S3K1];:I,]4:
M@R'DND\_C#81-C((7>D9$A+110V?E%!E%4_9H:H?R86=ZU]5'I9C#CH'.T6!
M(HA'45#3*;XJ" &^*T? MB0Z:J3TI9G"U/K/PPV1&*CK%4G*IF64"TJW61%O
MK,V%.&/:];40:IA[NIMKL+,SEG5$?T"V9P,PO8+P%ID,,1#5E@6166NJCI7R
M8Y3JT?EF47EZ](\Q).MB1K#HNM:8/P+5/9&-2$J%C\MNB;5J41<A*\.BW%/+
M@37T#,\ML3*]2*!CLA*D\IMP7M=:1&PJ"3OWX%R!X90HUB5HL?]+G[+F^*VP
M#_8'K3'B]C"SNO3A(&R,=>@KPA0M[7 .L:#CI&AM#1G >2;@J#K7;A"\<;1W
ME,,.)M![;>$/T6BR,%AKD[QW]Q@S^!;WNKIVYO#IU^ES)&<@<;CG_8E3L^\<
MT=>U]T\7YRO</JJA8OJLL)L^ &_BWHJSV2DK<H<T5T^L17SV85W/Y@Z8LX_K
M3TO<TID\VT4[:R<S&BL4)7IUC).5<,6;<'?TJPO% 1ZZY/_8RY8E\NK0Z1,Q
M6O\H]O4@7>:)+@:OSZ/[A8H$"L+?,[8R)H8IOK5$HNM]OWEM%\#ARO,Q,QN)
M,!"#RX&'Z]O@[L] EFZX;LO 1E*OWGX'$A<V2+%<8@4_.K)J317#T.ZWB$-N
MX2)(,"T@+4M[_EF=[FJ2PSI/EV?)L+54-PY:OS!9T*HJ^G8[3,^T[;UI[16/
M==I"9,K*FD1C,GD*GH^+F1A7JYW!K<K173-[6P$_);ODRPGE=V[;Q6E(!@X>
M>&4QV5S=06\OF%$!TA;>/%L2P=2TE#HV=B]W(H%=(@)0"1;7P6R;&;S U-S%
MX'U&K-#@+SO,;G_>'[?Z6P$F!B."250N#9E6?.1R',2IPS(+Z#%]LEX:^M#_
MU-^VM3S# ]9UIR1V1XWO@.F8?_TJZ*^G8YKNU"K]\M4^(V\.*)7,;WX.P]_Z
MF/^^**?=KW UOO+E-[G %'@ /F65$#XWV25NQUKJ_8YKF8.]J*KY=;Q<[U3S
M<?U>E$=1R&!A/$.<S.IPL4.],>ZA>7KE*V9QEV2Z?$HP12]N%J=3<>F0N<X:
M=_"U+,WJ0[E]5:IZ:R)8^RWBD^NKX":K+S&2F'@7DF*G^E"$L()+)=4)3I1<
M4>62G68G=\K?!*\1=@@#JTON=Y!IIAK_R3^KW;2I[+ S_1%5M7@V@7C07G.@
M)49A./F.BE .-@9K:-.Q42M\UU!4^UAD.Z9H>8P(U]&$JHJ_5NDWUYQX@!#2
MB^?K"1GO]O4@)768 WE??_"7//7$^,VK%V4>3;M*;RG'<#?U+%#P5WFKH?LV
M8P3?<[==R("X_4Q"2SDN^$MYXZV.!E\%KW9=DR!%?3O3O5K5W%I=+)G4P%5@
MI^]QK#'5V:$DQ>@N!6E"4&ET"C.@J4^MKS()LYAPW'> /2%1=^09W$CZ(8!+
M&Z/6>N09=BZF4%6GS(&Y/1M\G_HYV0D@DV72+G['J@6;7AK%)\[ ER+[E4"G
M21N8@X5Z;+APPN>M&E*7WM6";AG#;O8 #)17Q.6E386<*U4001/FMV%1N5TI
M@MP]BQ%]7=VY_;1&Y_Z1P&8[G'3*(=;=D=36I>3FQYP<<;G5+\W7P?<W%5%W
ME*^G*DP;ILK9Z]!RG1EM/#&&B3LZ3+[1IB.=SB1I6^>@K0116FNQ6B>239J\
MX<?(_X6LH#;B";8_+NSM4><K)^#WQ#",D^2=G/:!%,O.^YNTZ1=-?&)?\+">
M(7@U'[G_G(Q-10H)(2'6&E$O\O0!(-E-JVSU*[86Q[OQJQBNQGZY>CC(36E.
M^8'U1:.VIHW&IH%YGE#G&,4][73=&#'$5FDVMWJ\**'^I2YL/]_"I:8\(KRK
M)IDU<!AAS, %87)*3%5[ FK'ZUYFK#_W/\KYJJ@ZEV[+#PD6/-B&8 $"00/!
M78*%H,$W[K!QW[@$=P@0)(3@A.!L7(([!'=WV;@&:_[Q/_1_SKCCG-M];]^^
MH_NA7E?5FC7G^KZU:E6)U=*G"/HC&(](>23L3&;JOI!NKFJL'S^DC9^E"F98
M/_D65R;F*KFKX($ONH9$P\6:G&7IP:PBG3,-GF4N;=9G?(T9=;<II'F3"AA,
MJLC+,L-_'-(O$:>RJN-3 9$QBQ3HPH%"T$XUXU7P'3-)LN*([<!\&))>#!.Y
M.[O?-3P)B?P4[*R$ MF^=\T5FACZYLG\X:W1#>5G(@)D0 8#R60Y/5ZFMXM1
MET=ZK"J"M]BYG]?F6VA\>,2OC'PA1\^,O)*1_[W3U<>! "+A6O4E\^)#;GXY
MPD9]U%5< %Z2<,(N=/JF!2I1,ILO\G5S8N2$VBV;[?DQS3%DXM!>*0J&=.M1
MFXP(*N;/+&J!!=E*=EK,[M;M7GU&S#;3W>(P,$[R IYX+/Q=4Q&AQ@=_UJJT
M!JAA_ J=_\BW,#]+!!6, !D@(Y 6QT&4T#GFV;;''6RP*Z)(6U\"0B,M&/L>
M9&PX15^VQK<M31/NO$C["[Y2GK2F-;8:HTRE);#PHGC2(88YX72+)L\C_%@Q
M9!&4K'84$EZE5067N"&D>6K.-9A2V9Q@&/M4-MS/5*TMP3]JJ#_A%_^-Z&3V
MD6VB]6_N;-J:#%3=EVBC(_.M[GIO*D11#WP_)EGC+*2G^XM2S-=/)OWNWT$O
MU*K.)X7&F-!_X,BG9']_@!0W)!#>?9P<SHE%*=-2/G$^R-UU  &1"G@6U:[&
MM:H#04;HR '"F5/HV=NI \*",%AM>2,QT2)M_?A6DX5^KZ=YU<EX6#DLC$[#
MS,VKT0\%\OEJJ6B'W[>3QO)'/U:6[C9NG!M=T9!4;XGF6\184;>32XJ/U*@!
M%DCSAL?Z(27.4!C$QDW^JT*-4?Q"IVL,@34@(!?H9R]-#J6 I=TU_=A[ -B"
MJAZ BEF>VTX7F1F"&,W,E:7IZDXA,:X5WR>W;/1AS"Z0&$SW[TR>Q3RJ+WEJ
M1Y.,-SBM\$VCI9B>57>1E6G"UU,O&XJ)M9N"/<F^F%+T_"0"J?!1U9^*DK@E
MO<+%E:']J+J\%@[X?%DA8P*OC[OPF4URO=VP8PLUQGL \BP F>Z;3$H5B*+2
M1!7\)1YKD2_$F.PY:EV*\8>K<L)NMO9>HJ&%#7[OS<SX@R2Y0]B\5/^<5:]]
MQ^MSVIA<Y\H9*S?^G&&1"YUJ2] -5?Q,JN8ZE>, F&3(X]$P)P)A2)0@S_>E
M;O-<B'KR6)^,,H0^-1](.&457:;(RYWP$N5L@%7+,ZFVQ"6XWY 7FNQ%$M,R
M"#J__/RA8R^O#5^>:A$:,CB@$GKA.G?Z[&LIH6E+=5>V4^4^2G^?B/G0,7V*
M?]1=]980WXXHW@Y_TT&N0/%4R#D6*YW.CYIX4;?TLZ?/HZ77PDL]Z2/T3E3'
M;*HT;0)]#K0.Z.*F/3ZA?5.L7CLO1#_F'5MNLWQY."#LJJ<,4IAS'_)I5-V
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M%N)HBM>=GCD'2^1#J%Z.;@X'CA*RO6229<:]X#BJ,=K'+&U8MO>@_7*(E7]
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MFMLFU.&'^YY_Y4^\J%YNY/A6YQF[_/LB?5)+1AW:.Z,XC*CG(QA&1&Z6_)C
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M>AY$#B(0.PZ"1$1A0ED21?3T2/,='4]ME=B(J080R.D86H@XWP6Y'D$- >3
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ME<_JJ1$=%"O9U\LI&Y"'_CAH$/ @Z [,Q6O 7@O02@W6Q-:JKGS2!-<GZ$$
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M!+TW[]^?TE _U_9:/-VU^)"63WF)Y[\4^>+I*J/SA2H7KUQD3>8YSI:)YY1
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M8-9 W4I0Y65KQ 17[H"RN;YT =A8UY?K;UA>FQ7*1MWYKBV?R1+\+O0GE0Z
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M )6,#LOW=$'@JE+/P3[&+<K3I>:[^CN=#_<P"?^:EZ\9$VV0?.L3['.?>TQ
M)*I*.KZOPW@Q#"A#F/(D\7VC0[WC74S-U&N$7&<+Z',/?!A+ UON;(0&GNS#
M@6-ACYT-TDBVESU8=G96)PZ=-M7A-\>SGSHEW[&5NI_L07,' K+^D1?_5%1Z
M15ZS)9E?\O]>E57!K!G!L4<$3:#:_RKRBS"%- T$C!4-ALQ+]?^,R<^BXZE1
MXJ%X1- (#QKIP49\"RZP&0T#^AP(XX%)=1KP6A#P0#"/1,N'HVM[X&W'UCU
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MY8\:DX'YN%4+5'IM71]O:P;6JH'MX6NU6W.X7?YI]\-H<07]4<,YTI5TXR_
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MNS-$ ^@ZCPZ[WA_OQ-! BYV#0I/G^UEG?\ES_GLVG^O<7S0,&(.Q+Q27^CB
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M1T)Z A-B=%[;V<O4]E/;$H+?:AD-#V.[T>QF &<8#3S_[> QGOA&ZG=->]7
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MWPM@$,91X!$>A]2J$-=96(](M^,C;4;#+O ;F(@W(FK(M)"P.CC28KKCXE-
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M_:]*>.CC_V5XGGH83Y,[LC-0&OK,M!:M;^+7=VC87&B=@<I8M:R>!5"]9(4
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M=FIT>2]T$L\Z=-&VIN<YZ!OLZ0?!=& :W%UQUKQWLP!:;J %!UN2#P*MQ>G
M(!"/=&K@"FJ[@P5KQ#H/',Q;&^\@PEK#G0,*^[<_N/+3MY4^1KF5U=/;:]*,
M10DA.O66QY-0V=BA#TEE:'M$(D0]*:15"NCA19[:XE(+6M=U4G9A+>\'U7 Z
M/LZ&5OJD1F]H:WZ8&DVUZF#]50"_;6\(IEB1Z>1@3:T"TW&!_Y@5ETX.P& 5
MED[WW"LW$EW>+,IE45E(=Z+(<IZQ1HSMS"NI0(%4FQ.4, I1%$M(1$!@2(4,
M>.1SA(1%_B.C3J>V>FBQP49NT J^9IJ>>7',1L!@@S( K@/S^L=":I5.R#FT
M(VU+'I_%7E:NY;.H=R-?<Z*VUL]D"3+M4_VO55:H=9.4^OEZ&%YK!4N0+=A\
MQ?5E ]59'=I+I,IOYK50?\U>R7S]N+,L0U:@G\@D9-;6F-F"K+3;RPAD]V[/
M/<V*EG56C^OOZI^OF])8)$RE3'SH>T$*$2<)I"(.H%H*N) D$D%@===ZK*.I
MK0 ;.4$EZ!FEKHYB:VC].T!L:)N]%UCVIO4))%P9Q,>Z&=>,/:'L.^/SU/-]
M_,E"K[V8?,CG_&;Q^'NNB[I<"?UIV;@$Z=0L4>!A11$A@0C'%!+L$<@\)G#"
M$RI\<X/1J,NID47H_5_KJWR@Q=8!-TKPNEI2([J-VY41[@9FHG,T!R82(R![
M.;(9(6KCW.8:V9%LQ/.^JI:><#88=7O'&;4THL><C6:[7G16;_;@['\4V5+<
M2GDKJS*J^B2B$,]B46;?FY0O,Y823$B$(:),_1.E,4QU[&D2R8"F1":I9U,Z
MV;!;H\DP?O'D2G"82ZGW2WE5$)AM"Z_W0TIZ"ZXQ& $#ZG8$Z$AIV+6P0$FK
M_M]45=X1N$E4Y19$"[9V"^9(5'TNJ'9D;0Y1)U,;-#,>39OKM,/1%J_UR+'[
M\^5,ZF(Z)&$PC@,&4:)^(CP@D C!$YXF?HA]XQR[/U].S1S^F90E8<^K4BR7
MMM9:"U$W0_90?& &_/GRX>'RZJ^_/%P_=H3_V:7=W2C8-^VN:F&\M+L;<7?2
M[FY]W/-L2CQIMKT7K[JNX.+I4,0C]@(_H7$,?2ZEFE$I5GM0Y,$D41,MQ:'T
ML57!*H,^IS;K'J[_HF-/P<VW+[?W/U?AJ9;G5 8X&QY9N45OZ-.K6EJP%G?X
MR$\+@%P=:AGT..[YECD$[XZZ+%[M1SEW1?XJBN6;3KZ_O%SPZW^MLE?=YW6Y
MS%[TUN274LC5_*NR",I9A$@0IDD $\XI1$AXD$K$81R@",<$!Y)8>>M8]3XU
M&EK+"&HAP==,6N;NL4/?C)(&PW1@<FKEOJ@*M]2W<&O9+\ !M+]W^#E9$U4O
MV!Q1EEW?HY)7+UCV::Q?(^?&^]RH?>NBJAES62H#O50=_R7/^>_9?+X70L(%
M29,02\A3PB&B400)D01R+A!-TR - CLG1'L9ID9N#ZN7%UUV)Y?@DBVS[SHG
MW[V85Q-PF8-6B6J6UCOVC:J@UA5\$X99$,\9.T,[;=@1&=INVXK[>0^S'H+U
M>(P3[V,-HO- 'W,)/BC"QQJBXZ$]]DWUS&\NI=!S?9,P_5[-]WNA=<_F==W[
MPUE\KW\P498;;_3+%YW1;>93Q&F,$(PYUW5/N8 IPQ@& 468RI@SD<Z^BX+F
MQKG.'8MH,\FW!1UNKM]OHOK*(RG0MS.@6Z8]=SW"9NS[D:,V,#6O5=NJ4 &T
M=F!7O3H5>I/3&OS4J/.GB\/>W=NYU&N5'69/'V@P7.51=RW>N!G5!P+W76[U
MH?KI61A)2%$45>!I6^0V4QM6E%*2D#2 J1"ZSE'$88IC!,.4APP%DI-0KJ]?
M\R69FRT"AWOK<^NZ[G,X@OA+D9<EX(W(%77/-T);EB,Z#+,9"9^!VF@U7&N,
M-%-NB7C1N9&PK_K3B8.K(CZ'.QFW)D^GHN]*['0_W8\7MEI21NO#4MFHS_E<
MO5_J(X#EV[J6("<^QPRGD,7:LRY@$<2I(#!)(QG%/.&^L*J)8]KQU+;=7V\N
M/]U\O7F\N7ZH4G!>_S^_W#P:EO"T!MV,-X: <F FV1)Y?8RX?!ND;*,M.H[X
MQ;C;41G'%HQ]#K)^OQ\K?2%9\7<R7VVVTUL=_RR(OE_AMXM[G?:XR!9/ZH%O
MN4ZO4?^J3*JLK#;>,\)QX!-!84(E@LB/8X@C%$#N)US2R/<YLCHX=";9U'A-
M*P8JS4"C1A53<P'6JE03=5N9YBC+,@3!W=B:L>.'C-C ]+D9K+/&QYI+G6/I
MB&S=R34J&SN'<Y^NW7?0U\I<-@DO'L1R.:^HI=[65C''>I]775'<D6+Y-B.Q
MY$Q@JM-I,F5J^@+2),&0)6JSBGV>XM"HZ%>OWJ?&RQN1 :FEU;<[M7/PJQ;8
MUO2T&0E3^W,@? <W0ENYP4;P]C@/7&[0KJ_/[CK1[F&7]D#-F7%JT_?(%FH/
M6-Z;J7T:.2,%S[M#O/>9%CX=R;3P)2^DR):*B34_7_]XS>K*N.7-HHZP_8?(
MGIZ7@E]^%P5Y$M<_1,&R4MP5&1,S&25")I)#-<2Z0*(G8.J'$F)!&*,)02FQ
MBXG]2&VFQKU71'UEYSIEBZS54G20%T!HK=2//ZU*KH/6ZVL@RPS%'_NU,;R3
M_Z-\&8:^W7>8!V@+D_KD8X.*#G^K<;D +3*@@0:TV( *',<Y@CYZC%VF#_HP
M7?Y?]KZU.6X<R_*O(&8V9EP10@\?X&OGDRS;7=JV+8>EZHZ9^I"!I\2I5%)-
M9LI6__H%0#)?RF0"3)!B;VQ,3)<LD<"]!\3!!7 ?XV<6>NMA.YATZ,V%ZKE%
MX7*+Q)NZ](O[SZKR72W67:'2EN0+O.2S!%,/*5>)%&%]7Q;"S \X1&F"HPAG
M&;<[3C+J=6K+8BVTXK1&;*#E;DE.6<QKV2UW)T:#8+@K<0WMT+L1%ZC:[T)L
M4'*U^S#J<]Q=APT,KW8;5B_WB*.^D^\H)[/&D:"^",3S#\4CSA>S.&911C(/
M>AQ1B%2ZM%0ER.%$9!&-_,3WC>*-3G<U-2)2PM8>EVO'GE9@\'LMLDUBAFZ8
MNUG'+7@#4\VHN%F$1CO#;ZPD9\=Q=!0);81(9Q!T=POCQ3\;:;(3^FSV1@\Z
MO2H6"TZ7W[\VJ5:"($8BHS%,B3IO#L-$FG>A!XG'/9*0. PC84R@>XU/C3+7
MXO7)7+,/G $EG@''P"3H% D+DCL#D9%H;2VA(Q([HG$G;>V_,QY1'9%VAYJ.
M/=-OZ]F65Y<[8G77=K4J2SG(LR +&$,L@H2+!"*4I3#%"8*1)^*(I%DF$J.Z
MZ-W=3(V@6BE55D\EIMT&\@B49CO&\P$:F++6V#027H!&1G?[P6X,'&T CW0R
MZHZO6]']+=Z)I_O-^[5I<[E:/NC2:Y<_\VH6DR BGISRGN^G$"68PBSV8A@R
MY(=9'*=19C7O#W<SM7F_94.OY02_*TDM_8N.H&I& >=C-3 %](')F@2Z47!$
M D<Z&94$NA7=)X$33_<C@3:__OM5E2_405)U2>N4V-( \/PX32.(DS2&B,BU
M/^4\A5F64-^3FY;4,TIF>KJKJ9&!EJNNNW4!%NMR&53EA:1-YDW<R&['#AUP
MFS&$&Q '9HE-A9&-F.#R%&#6/'$:"T=<T='1J'QQ6N%]SC!XH^=]55%5<ANB
M#ISY@KY\YY3GS\HV415:&[,W\S+!$B$@"0,"$0YCB(D@,$$BD<S"<4KL;JM.
M]SDU)KE>,/ZX4(MDN9;6\D[* &C#&RFW\ U]'Z6BXK;$U9[&C<"ZG!%UO?>P
MP,?5391!C^/>0YE#\.H6RN+5?I2S=_N^6QGH9K6LEGC!&K=A.O,8]S@/?1@2
M59LY3!C$?B#D_P@BDBP5F&.[U )6_=O,I''R!JQ=>G#CTE/5U;^*C>3@7?T[
M2U\RNX%)8H$%QG)#&2!I5@:)!S,2,A@@XHN4)H**V&95&&Q8QE@?7@W*QMH\
M,#S_]J]IX/O_"8A29<@Q,EM0!D-^X*7EE7/;JXIX6\)?@/>=:%LO,[U0<[3@
MV/4]ZM+3"Y;]1:A?(^?F$?LK+G.UTK79[#_*55!%N&QR4(G(SQ#.$I@03T"4
M<01)("UA3V4_]E%(J5R,>N4/.]GWU!AO.U55*_RF#$,K?M^T8*>'PHS:!@)X
M8&(SPW:D%&#&P#E/_76ZYS=*^64,R?%47^9-G',I<+O$R]IC%L]5$,+M ^<J
M+^,E8_I4#,\WB6:K]R_R'T]%A>=_+HO54W7=5LU3S^@=P8JSQCVM6#3!LRQ!
M7B@R!A,:!A!YV(-IAAGT?9]E"4]C)"+[6X;!Y9X:F[8:@%J%"[!6 FQK 39J
M](N:'NNSL+DFF=1@#\SL XQSSVN9T5!W>L\SO-1O<'$TVE <OHD:KWLG1]27
ME)8K/+]<7N&R?)&_U)'I,\Y")C(:P9#Y&"(6((@CAF 2(A$C%",BK*Z[C7J=
MVC*B#UOI1FJ :['/.JH^ GBOP^KS81SYN!I<GD#PW./I;D2&.: ^TN=;'E%W
MPW#BD/K$RSU3'6[S7#?-[>?MW;K22;, Q9[O08(R'Z)4A! G60PQC<(D\[ T
MCZWNSIQ(-37:VDIUC;6HEMD2G8R4&9^-CO^H!NEI>_3B=5[R86[QG +M*MFC
M$YG&S0WI$L97J22=-MXC!$.V\E=>+7F=0NZW1;ZL;GGYG-,Z-E@:L=]X*8KR
M4=FU^E>-HWV:15B2,8<)CPA$ 2*2H/T 2FK./!%AR=%&N8'.DF)J-"SU@+4B
M0&L"M"H @D:;)B6!2C>PI5#SVQ[1#[U'KYNJ1QN3@:EYV.&PB[TX%\[.((W>
MC8\7S7&N_CMA'V<WUCL^I)24O)6ZK?$_7^>)#44D,C].H4\2R8HDQ# 5DAH#
MX<61\*,T2JR,U9,]3HT!&X%5:AZ5OK_ZW]9A(R<0-C,RG>(V,$NUD.WD\6[$
M'201KS$X[J),3O0W=L")F?H'8D\,7^QAB'V:<[[4&0N:)=H+>1KB+(+<IP(B
M%GD0\SB",8Y$'"<^S;#1O=#!UJ=&&UJ^.L]&'SOH%7@&]LTYD S,"*[1L B*
M/0>5D:)BM]&IA71DHAW3O=/T>O72>";5,7EW3*6C#SDN@OHY7_#K)7^L9B*0
M)D\DB0NE<:(R?7LP181!FF9I(@+?HS1S4OETW>74V*RS/B?X7<D-M."6=\\&
MX)N91VXA'9@-':#IKL3I*X"&KFNZZ7 :Q4Q? 6!<P?3UFW84I O'WU[-D!\D
M* TY3'RN^47 C$84!F$F/!%X@GI&;M-->U,CC]MBM7P 5UAVF"^PY?K?8M1-
M STT'WB.W][\=O<KN+K\?O/Y^NOE^?-X3\,#D[3B]$_WQ?-_J"?K":I^VDS,
MMH519MV>N.V4VO^UW7QA/)]II[B7O_'Y_"^+XL?B5MH!Q8*SZZI:2;N0HY3X
M"'$84I)"Q ,.,?%"R"@5D1!RI<Z,\NV<[&EJ<ZP6%BAIX1]*7-#*"VJ!S6;;
M:82[YZ%3W :>H?TA,YZTQG!T3&?91CV;Y0^;R7RZY5&FN;&"+0&8O]#CQ.&W
MZ@-7A0O4VGPC_L^J6N:TW3$FOA]1+T%0_D<:\GZ4P8RQ%')&8AQX&4:)49&Q
M4QU-C1A^NP4;697S>"-MGVUX%[X&YQ..4!N8%L8"S.((PQ%P(YUF' /0T9F&
M 1B=QQM=[X]WTF&@Q<ZAA\GS?<NWDF6;S"H,?!9'DAI9&D<JWVL*4R^6AE08
MD)!Z48 2J[0@6VU/C1?;ZXBGHM0YD.5W.B\6]U#V_0@*,F^*?%@7:=V :79P
MT1.B@4E0235 "K #RCJKN;II>>1"JZ]4>EU=]?4C/:P;'>GXG3_),7[ %:^#
M*H@?1JG  B8"AW+&^@'$022D61-S(JDOI:EY@M%#/4QMWFH9P49(NYB7XT :
MV"_GPC/TB<- R%@8*N<B-)*%8HV4G872A4*G:7+PQ?%LDBZY=XR1S@?[6R'7
MBVI9ZO&O/SQ!44@)#R 760P1\JE*HRQ@G"+,<8(8IU8%J [T,3EVVXKR_;PV
M1Y3@8"-YSSB_0Q";VRAG #<T[^UC=M<+LU[&S!%4'!HU^SV,;MP<4?&0D7/L
MT3,K-5\OGE;+ZC-_YO.PV3SSU.=!ZB&8Q8G<GE >PDSX&"8>#ED0,L)YO]K+
MK_N:&D5L%^BMI;T 6EX06AY1F !M1A".X!N8*,Y"KG]!X^.8N"Y1?*"GMRDZ
M?%SEHV6$.U[I':O5!*C>B.V:8=_Y'"]5&;%J6;TJ&;:53"1,TC@*DP"&5"49
M"WP"4RY-$ ]G61@D+,UX8AFE=8X\4Z.AJ\MOUW>7G\'MS=5?P.77#^#VU\OO
M'^'[R]N/'\#5S9=O'[_>7MY=WQS/]#_(J!D:-..-Q1B;OOVZD%NE(W\?)!.,
M(_S<A6"=)<W8P5<NH#L0=N6DV7Y<VZ:@E3T359),'9QN(@A"+\NHBL+/(@Q1
M%C"( R1@@%*6!%GHIZ%5.IBNSJ;&DJVL8%M8$Q=X>YC-F,\5> /36F_<K*G,
M!!!'/-79U:@D9*+T/L,8O=.O9%95S'.F:*K-?'55U$G^OJMN9A[%2!IC,8QB
M'ZE<TQB21*3J?HJG/,X2/S6/&SC9W=0H9%M@D+<)WV@C,M"AM';EI4[ ;7 2
M[A3$@:ED![]UPKQ66O#=.7YV!;O<X3C2X;F62YVU8?8_*QV)RG&YR!?W%2!<
M%"5??Z078(E_JM OQI]*3O.ZL+ER=L:/ZM;U'[BM/DMQ];#U;4L[Y;XC3Z1U
MB3 SC$\5#3O1RJAEQ,PTVB\L9OA6KUBOHI1-__=33K_++?QBQ;]SMJ)Z!F1!
M2'PD^3H.@E@E2(T@H1Z21F" *0FSS"-&Q_BG.IH:<3>B B4K*&MAY7\;::VB
MGXZ#:T#6CB ;^G!N&ZU&3O#=,5I686-.4!N+E%O9)(NNOS5< 2S_4:WFV@UK
M^<#!&N5OUU< KUCNP+G#%*X306?'WQ\S_NRD%GNA:*>?[UF[24I;+)92<OG0
M?<O7S:%\[/L))C&'''')J#C-(&$IAVF8I)P3D4:!45END\ZFQJJ[LJX-.DL_
MK4YXS7;2KD ;F%>/X#7 A8<)(*Z*-G5U-6[9)@.E7Q5N,GFGC_O[0EK9Q?TB
M_P=G=_CG>[[@(E]6ND9AQ"+JDYA +E@(4:0J-Z4I@\+G(J(!02@TRE)_JJ.I
MT<6VJ+JT82NL50'(D_ :F&&.0!N8+D;"R\;YW0UN8SF_]\7/T@G^-"C=3O =
M[X_H!']:BUTG>(/G^SC6JI1+.OJ(?5B5DI*_\3(O6%U9Y)/\-/Z;E\7-@O_E
MX^/3O'CAY1>\I \S:7&E/D\%1"2*)*52'V8>99 GE/$HC3FUH-1^,DR-;94"
M*D&5KG&D\Y-!@#P?O/OC%_ DG[0L0G7.Z!@P\O"8#WWYJR&N-0"U"J#6H2UV
MI+0 2@T@]0!_ :TF0*LR_"C8^ X//AHC+0%?]\M\Y?4 L7J U#;\J1ZD90%X
MK8Q\2N[6FW^4_UZ!1Z6<>EQ;BCE9M4>EZG5:/#[AQ8M\3$ZN=W^IYY8KY^6S
MAJ';O;E?TR,Z0)^E^ZZ+]'E-]5C%FK2JB_LKV<557<EX1KFJ*A=0F/@95A=F
M")(H"R$-,AH23\1^[!NO48=ZF-H*M)E\Q8]%DPFST'++?VP7>;;@OH/(&JPO
MY^(U\.JQ%D^EYN#@R@TN%HQ_+CXC\?D'7M$R?]($K-@8YXN6QX_4#Z\_/?*B
MG^%UF@%)[\T9+*E+:LC5067]4O<Q?W+$W5V =C+SP1?'X]TNN7=8M?/!<TO]
M?>""EZ7>6=3YJ"\7VYD1M4O[QM&09+'GL9!!+XKE%D!(7#/**,0H"E/F"91Z
M5F>P/>68&O]N!V-\E9]WJXS>"]?J:$[>4JAO/4"[\3([U!UA%(;>$VP-@ 'X
M(Q4,[(6F\^*!=E*\42'!7E =+RK8K[E^7/IQ51:LF,]QV=RDA"B)8QS%<E!4
MI1."0TBD)0H925.>,)K$S"I,9[^#J;'?1KZ>H3BO$#2CK7-P&9B/;""Q)IAC
M>CMBCE?-CTH)QY3;G^M'G^LWB?]<%.Q'/I]_ETU^*LH?N&0SSN,D%83!) BQ
M2JM&8)9R C$C+,3"$R*QJNM^H(^I3>561/"[$A(T4EI.YT-8FLWH,Q$:>%+;
M@F,]L3O4=S2W#_4PZO3N4'%_AG<]VN.D2)H$^4+%A&Q.%E5JT^8DBF__7O;6
M_OI+<R+YK2SN2_PX2QBC09(FD(9R%X2H7-:Q1!F&890D/!%^ZIM??S@1:6H4
MTHJY>X:+'XM51TZ=H8;+X+QJ]$$8F*4:?<"VX#KC,EB/S,Z?I%*;O[1J@4:O
MT0?,XB!M]($;[>2M]P"6Y@-H=\;F%.O.0SDW/8UWBN<4F9UC/[<M]S.+KQ>T
MU"&U>'Y5/#X6B_HJYW)9=ZVWT<6K",NM4-QJEF:QQS!CT&>I!Q&*!92_2B"+
M&0JB0/BQG=OF^2)-;<6L+[2+IQZ9]QR,CYEE/B[J R^16\J 6IO6<V!;'W7O
M_"&?RPGVS,%'(3C5#N4G8L\=!/"XQ]Q=Y?ES!1J[J+PC  _4BW?5<L]#QR;Z
M[!LO=3?Z0^5L'1?MQ[&(U#X%\2Q4F4PQS 2)8( 3Q#'Q8QX;E?4T[&]JE-J(
MMPG2>Y*V$:VGNO9/L:QG=PINPP-+=R .?7[9XB9%K1GO K28#A&/;HB,JQ/.
M$[V->^!IIOJK\T_#U_K1RTUYCQ=-J.HFA%+^0Y7DE!]:NPNZ$9_R!5[0',]O
MY6]J:EO/"L2"D/! P"CV,$0,>S#UH@@R'A/)0F'(4ZO$RDZDFAI5;2MU 7;4
MJBO:;BFF[(^U:F"C6^_<&F[&V8S]1A^]@3ERK(&S)E.G0#NB7#<RC4K,3F'<
MIV^WC?>L =CF0RHNZ=]7N;15FV0GO/K*ES?B"E</S5_83'AAP/R0P# E<AN?
M^@+BF*JRR")-,I\D-(UF"WZO7 [-V-RF>Z-IG]73?EN(X6:_EJS*ZQ0]<G:3
MM? 78,&7M7=<]0!PHX%EA4";H3&C7^=PCU0UL!%;[<8;\<#[+:R_UE@KZ=N_
M'\?:OGY@#]!<51*TZ7K<FH(]0'E57;!/&SUN_;YSG3/HY5+?/]V(&_F/I[KO
M+YBI3?J*5#G+<?DR2WB8ABA*H)]Q)/?,L0]QQD)(/41C+_90&%+CNSV+CJ=F
MD;:B-Y=VK0=OL=$ /$H5VKB,:JV(Q6V1S;@87.(-A/; W+8&NA8;W BP)3A0
MDH.[ MP.#;#%I=M 0(^6,*3GE^W*5[T'?)VW93;MC7<GUD/+G9NO/N^?E\)S
MRYK[UM1W^%;FE%_.]8#*7[?>*!]_/G&ZU)ZE'^JL)V3.:T%G889QZ"4IS*(X
M@$B(#&8^QY"$:4PI%C%'O7)^.I%N:JO,VIN*K04%HBA!OJ#%(U=)U,#3JGPJ
M*EM?>;=C:F9<O]E(#;Q"K3.2;BEV 5H=+D"KA?:UW^C1+&CN\Y4ZQ==Q@E,W
MLKU)1E2GL!Y+H>JV$W?5-8+&Z5Q:_820!,$@H *BA$OS'V4$H@!1[&=1D,96
MI]4=?4V-BX_7B @<5M<(SJZNT0.^@0GR+.2<5-<(1JNN$4REND9@7UUC_Y4>
M1PE_*\H_Y%S<SC/_@4O[)%]6,QJ'/"*2,=($2\LO356B3\(A]<*0^#Q#J46=
MY8Z.ID8<C:C_]J]IX"?_J5,TM"*K_+=:9HM-:Q?$!J< CH ;F#(:*<&VF."#
M6[ L=O2.0!MI!]\//+M-N@$BG9ORKO?'VX0;:+&SZ39YOD^:*5T"5C[,FS0@
MLU20*$9)!@.!$42<23O+)PE43DDI)KX*KS#/(+7?_-08<DO )C..3?ZA5^ 9
ML.!9D S,?=MHW)Z/ADVBI7-0&;-"J[Y-;%W5M&=PM04:>0&4ERH;QU82I64!
MU(2MQ,MV#6^5%%D2Q8+7*9)_Y,L'?:KYS"N=_Z3-5O:GUOGU@<]5K05P5W(L
M^WP!M6,R5G47JJ6K(]"C ]&=1>G56R,F2#HF\6[NHZ-/V;$FX_FLJ9O]*:\H
MGO\7Q^7'!?N EWS&?$%8%L20<L0@RJ)8E:J/H"?B.*,T3%%@M$?MZF1J#-K6
MK*\%!4I2($4%2E8S]NB$M)M170$U,*_VPLAXWIJ <&#?67'ZI_OB^3_DZ_66
M4_ZPV6EV-CK*Y#91JYWB1L_V+MDHS2P\_W-9K)ZN%W2^8I*>56FS8B&)>L59
MDP!H<T"F<BG7PLRP%WB$!AXD@?+V1G$("4D"* 2/8LQ(Y*56R2;.DF9JU-%*
M:%V-\8P!,3O=&@WF@8FGU0-H1=096*,*V-8%K)79OCS8*.2T1N/YN+JKT'B&
M+&/79SP?M@/5&1TTVF//^5$:N(]UQ1]IQZJT<ZI"NBJ0_DU58));!1+Q."99
M #&7YB8B*(,92WQ(D,>") SE_V>M-^.=X5;T9*]&TW;7B?%N!))<RPW6@NN*
M\D!7E&]DM]BFG4;?8!/K!LR1@F5&!]!BW^L4R)'VP1J\I0+OJ991[57Y&N6\
MU<31CM08HLX=ZNE6QMNQ&FNTLX,U?\M9O=SOZ\SVUTRE#!6Y"IUL4K8U[I^[
MJ=ODW^0GR!I;O'[R9OG RUD6^3CQ?2Z-8*$JKLF?,C_%T&<J-V7@AQDQROH[
MCKA3,Y4/U9Z] !N%P;;&;5K%5N=7^14;M2] NS&M7[@ 6O>SZ_^Z_&S,[/7I
M? P#+V:3^ Y<U#,>8'B&JXCL4MBWKJD\ / &59F'Z+6GCU&^R)?\<_ZL*X[*
MN96O!?DLI;Y>\L=JYD<I2?TTA'%$"40)P9#XF5RQLH02G_L"^YZ5LY%!IU-;
M<FJ9H18:;*1N2>5W)3C0DMLZ'YF,@!GON\9U8/9V :F]5Y(%1J[<DTRZ'-=/
MR0*$5PY+-N_V3>2TV^Y7OOSXLSF1:0]?9C1A+!(H@+X?J$+S(8,XP1Y$A//(
M3Q,6<\M43:<[G1HI;4T:W-@J33@GIG+SNYKK+>A.*6_YM__EHXO80]K^^5]^
M=I%YGFTB)X/Q27R$TS1,H9>H"JB1W.:DG',H?(]$G'H<$3I[YB4IWFJ$MCL?
M98QJL0? 6K @"U,)<^3A#*(0(17O[$'&0U_^BB"2I+.ZHM'M$I?+M\%[7X !
M]P7\/E_H$B!-)8\AON^8Q$G,(QC$7$"4!C'$)) VDB^0)WA*_! WF']<&$:9
M#X-XV_V AXH+-BS89O:/:_@&MG]>,4,=(/YN+?/Z^NEX,;X>>=K,,7*6B<V@
MRY%SK9F#\#J;FL6[/?.[XWSQN:BJF\4M5@4BOI6J/M;R16747'Z4V\,G=:X]
M2[,P23&3%I"@3#(083#SI!D4AK&(2(2B,$CMLER8==SC:FA@_E$R@W?W4OI?
M@'+F;N]YI;'SU*B@K1W>JF"9(]YL/,Q(RB'&(V625_Y[[Y3(&MSZHC1OC<E6
M?)WT=PD^GD38/M&\%6"N<L^;=3IN.GHK(%YEJ+=[NQ]S7;+_657+-ED&8_HS
MP?-O.)>;Q2O\E"_Q7#L<$I5I<MM]^SNO ^[X+2^?<\KK8HS-09EZ0 ?)S&CF
MQT1M(_Q0R+T>3SV(.5&5TL,@P(R1@(<VN[ZA!9[:CO%KL8 ZU<]V](L=&PX^
MQF8\.J61&YB!+[]=7UV<RN6KW9F4,W0=F7Y55$NPI9,[/AX+>$=,/KBXHZX!
M8X&_OWJ,UF\/#ZJZH.R-J(O-TQR7.:]F7L!X'*NC0>K[*K.P#]. JN*ZOH]Y
ME%&!A7'DSL$N)L?MZU*G9%M,"V>>PTAV\[$;? 9FT*&@L?!M.ANBT6NC[T %
M?CP4H.24Z]N:JI[+KH(8.['I=&0Z_.9XSDN=DN\X+'4_V<_<OE(2+I:U6^KW
MO/KC_<N=;.GR9U[-(L^/T]CWH$\B"E$LS>6,I#XD02APX-$4)U:^]AU]38T(
M=T0%2E:@1 6_*V$MKV>[(#8S5!T!-S!#]L3,VGHT0,.1X=?5TZ@VFX'*^^:6
MR2O]*&/+IZ1Q)IE%(N$1P3$DF;H_101!C!(.T] C/$M]3GP^6Q;2PC-CBM==
M6!'$NJ/A/O8[U0=HG/?!O&^AZP-89IZ'LT!:G5X<2BQ#$4#"DA!RD=$H85D8
M9E;G$V=B.0+9#H>E&;V>A]# K+HEW-JMT!V7'E?=$84>Z&!4YCRNX#YA=CS9
MCR<W]7"V-[-;YRWO7UZ7S%%E/]<)?;3+7ETG2S'XIY+SZX6<D;Q:?L=+_B5?
MY(^KQYD79CC(H@!FE'*(/(_"C(D0^H%'!(JC1+*RG9_$6*)/S]="FRU*6J#$
MO "/M:!V3#3:R)OQVQ1'<V#6W#[IW,F=LZ6U2BYQ\$14J7X!-JG.P);Z%V#S
MA;00-)_*EQ.?BC4YCSUNCBA_-+%'74C&'HS]Y6GT_OO5G.9RY52)++=6T^_Y
M_</R1OQ6->X.,Q3&/$R$!T,:((@H3V"6Q"GT4^2Q6*UE0MA&HYIUW</O8(R0
M5"TF+ 1<58T;IETA8A/0#8Y@'6(X6NUG+;!.Q[MC*&NAU0FD%-O*:=(&4KOB
MS8ZA'>DL]W*=.9ZU8*M4U>TF[07@O1*B\J_UC_SQJ2AQ^0)8+N2;7+)L!12O
M@O+5YUZYRK9DA_.IRLPF38U:>ME"M_W:RC:O]@X$TD&TZ@)YK^GW7!0EO]QX
ME%]N.93/>$0C$J8<LB2,Y'H01S"-$8=91!B-,2(TL(ID[2O(U,Y%&CW 7%_)
M?[_YK9DLUM%!_8;%;',Q!M@#+R,MSEJ'9NU0]+1>.RX T:J +5W MC).@XO.
M@M-=P%$_,<8.0CH+K .!2>>UYR C5M6=.:92OYT7U:KD=_SG\KV$XX]9A&(L
M0I9"DJA*3B0-(4Z2#(:$A%PD:9;X6>^D6#T$FAJ17M[>?KR[!;]^_/P!?+KY
M#FXO/W\\(T=6GR$R(],Q@1_:-M_)E%6=3I5578"-1N!WI1/02CF\.G2%[Q 9
ML_J(\W9)L\X KS-OUCGM]CBQ4&<ITJA2GFA+?H5+_FM1/>647UU?-M4;<!K[
M2<8$]/W(@RA(8YAE*())(E@J&$.4&#E!F'4W->;<$1@HB4$C,I R6Q;+,$3<
MX*3"*8Z#NT6,#Z'%R813*$<ZE.B&U-%1@C$PG:<(IUL9[P#!6*.=LP/SMWKP
M[Z5$+-3GUM_YT[I*4G%?XL?F4T:,^,)G'@P%(1!Y4:B<3+BT<F,/AXCX/#&R
M;<VZFQK_*GGK2RJPD1@T(EM0QFF<#5C7*7H#LVXG<'U(]S2"%J3K%,F12+??
MIVC'N<:X='+NZ5;&XUQCC78XU_RM?B<.7XM%49O4B_MK78!2U:!;5/R25,L2
MT^5,9-1CU$?0PS2$2,0(8IQR:?:R+/8"GT5VOK\G>YP:\^K46&UUSG>\%O:7
M_VUW;' :9[-S :?H#<R\V[*"ZP:_1MQ?P.^MQ YW]<;H.-JVG^YOU'VYL?K[
M&V_S%Z?J (=_:C<HQ$40,Q7-&ZE$*H%(5'D "AF)2<)I1#R23LT!KA;]G\ !
MKA9T:@YPS<B;T><41W-@%GX3![@3G\H$'>!VQ^V?Q@&N$?O_,0>XW<$8WP%N
MK__!R]M<4JJ<:ZJOQ9)7*EEK@:5D.D!2N=!\Y<L99F'(LH3".".^RO2=P(P*
M!M,(9<I3#C-L5:39J713,]F_2;D5?^%&\B;85$D[6$4<@S'L<?4WYLB,>@]H
M4C&G54]5S)$*UDFVE8I@HZ/.<_8F973,P1^_K(Z!;%,MLV,.ZQEE=RPZZ9MV
M5NVB[O#/R]7RH2CSY<N'XA'GBQF.64R]5$5$AABB3!7@H32%89;Q($UH$GC4
M+M7LX8ZF1LG-_E_YYZXE!;_7LEJ&41_%UHQ?72 V,%7V ZM'_L9N))SE;#S2
MS<AY&KN5?9V;\<3SO9P,2N4*O=36YKUJ\_)>VI[*0%759F8L"424A0&,49!
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MP=,MCT);Q@JV/&/^PLA&<-W[C=!_K9JL5__@;)9Y,>:AET#NIQ0B&C)(D!]
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MR>3>(HLB@2CS,#7:3+@09M)+KVZUSC* ?X):.</UU,E V5XH# O_B-<+:T7
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MH6TI;_/>IT:7C?!--0P([AYXR;&2V)I$+8; F#.' 79XBMQ@>K&^S7]1=<D
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MJKE =8B!M.^3#*?0HUX&$8L2F,5J(6))'*8\\A@R\@QV)=#45J3:LSY7$EZ
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MO)JE8<H]BD+(D2H0R0(?9LS/H$!I%J5"!,(WKXIVOCQ38]:-1OI,4^D$6J5
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ML*NO,M>W-=:I9EJ=55KR]IZC41ML]%:,TVI>9ZBI=3_+<7_PS\?,!6!*'\7
M]L9DO@?[/*,C#9*K9*1#BSMNQM*1P'^5UG2L?GL&112R!UX^?N!D^04O59:[
MG,O%MW7HOQ'?RGRALI?,KQ<JX?7=CV(F8H99FH4PI*%*@>JKK-,LA"1):,QY
M$,N5S2I HH<04UNFY/1!EM$/?: W6PZ&!G3H+:44'RKY@5) U236*KPT]46D
ML XC(<Z RE541!\1QHV0. .D5]$2Y[35C^3^+)E4>=?>+%3'^:*A8KV3F'%,
MA,A\!I'GQ1")0!6*#*C\)^$1Y2R*F+ ALZ[.ID9:^Q4L5%%;:5-M"6Y':9U
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MB /HA0F7%BPCD,2)-&,]&H2IB&),S9T[CW8SM27E4.$KT,AJ05G'8358%IR
M-3#W#XZ3!7\[P6LDDOZ&7[338ME4J%@60.C::J7<$.K:HSH3MHJKOB^>>;G0
M1PY;3U_=_/7Z _0S1X1]$KM.5C[^]GC4>U*#'7X]_72_TX"VR/GG?,&OE_RQ
MFO',9WY*(RA8'$K^Y 1F/D=0T,3G//58EAJEPCC:P]2HLQ40_*Y$!%I&RSW_
M:Q3-]OEG83,P4]K!8KV=/ZJZHRW\Z_9'W;8?56]_JW[\P9Y!<FT!K]I9^=.\
M^+$)%<4\37@2!C"FOIS;/&*0))X'$T8H3[G':6*52+.KLZE-\ZOM FAKP:NU
MY[X6WC)NK@MK,P9PA># 9+ 6<Q>N0<H@F4#B*IBNJZMQ(^H,E'X55F?R3C\6
M^83S4J?:NUX\K9;59_[,YWY;_<$/XL3'$8P]'D/DH1!B&C)($>4AR@+?$U;A
MMAU]38U#E*AMVLA:V@N@Y05^S]N"+J#-&,01?$.?N9V#G#6%&&#BB$&Z>AJ5
M0 Q4WN</DU?.S:GT-Y[?/\@5]U+N"?$];[.&UTEL]\((4228[TOKA 1,Q2K%
M5.X\,(5ADL0>2WR1!E8^#KVDF!KE;$<8MFK 1@_0Y *^D:.WQ N6+^[[)EFR
M&2=#RV9H](<V>0X #UK@-\4%FB$8)^=2#R2=)UZRD>&-LB_U@.EX"J8^C?7*
MP[0;V-3^^[90=9EO.55YH%[D7WDU"P*U7?,)])CP((I(!#')$A@0GX0(I<1#
MV"(-DW''4^/&=6A@5=3%JQMAP5))"][Y-@7C;0; X#!\(%@')KW749@7FP#,
M6G30R@ZT\ ,A;'&,/A#2(QVL7SZJ%$F <%&H?+MSO1RHNT^YMCQ+XZR)<I6_
M_Z&.>_5Y!6M'1'[G "N=7^7N9G7E0/TO_OA4E+A\ 2P7\D6NF]'']:Q[ OUX
MR.D#4%$1ZER_U"4(5?\Z>VJAC'=:E,4"/^?EJ@)/T@+ACSD%[_ZE/>S_EU]<
M94WM,<@GTG&9MS=F-BYK+?>2<=F_WR=D0M6=5U^;<BK:SH5^5WR56KZN2C\C
M(??C,(E@$'C*?3F.("'2R!<>R7#,B!_%H7E8A6WW4UNW=J4$>>N02[<5LXE$
ML!X/@P5L4)0'7L9V9'_%C8O#\ \*N$UXR)# C[NJR;4B7]!2>X?FBV/ ;U\3
MT\:C=&<J[%TRVXZ?991*7_B[(UFL6QTQVJ6OQKL1,;U;Z5NSY4>37U*V^4V:
M(?)'6M_IW)17#_)KY->+[2?DEY@_S?GZHFT6T#0-@L2#4:86)2P7I2SQ$TB2
M5-V 9W[F61UDGRW1Y-8I_@-LY 6[*LG! K52:FKO/-;H=<:%^OF#:W9(->J0
M#;SHC3):/4K9.$+86?F;<^49N62.(_A>E]EQU7#ODEOJTK+Q:V+O7WZK.+M>
MW#QQ5=5A<7\I=Z_/.O/Y3/A)$"$N(,9854*F%&8H"2&6FXDL\*A/5-9QJWI<
MAEU;$?)(Q;JHNGU_:F0'Y 44K=P KP6W+M9E.A:FM#H$PH/SY[)V;?BV!>X[
M);FDS%_ 6GAP>1KF/A6_+!%S5P[,M..Q:X59 G*@D)AM"_VH3/8@VUR^?).?
MDPK45,DAGQ23-O?X) M8S$DLK<M4\E>:4(@9\2#':8RH("G'1A[IAOU-S8IL
MQ=7QQFM9[1CJ%,1FM.00N(&YJ)7T FA9=Z$;P&'"$!E'G'.JMU&)QE#U?78Q
M?:T?I7RO3T2^8=G#78D7E5K:BT6;=I &8<2S"$9!YD/D\1"F5 A(?4]$ 2<\
MI%85J#I[FQJ=-,("+2W8$K=G3L)NJ,V(Q1F  ]/*&=A94XH1)HX(I;NO4>G$
M2.U],C%[J4^\-LY+=8O("U$IAX5"T.+QL5A4JI:RY"^JCH+O^8R@((M\'*M3
M, R1B+@T42B!81P$-$JQ3WVCHS";3J=&+-I%4<NMSJVUY+KVHY8=:.'!NT9\
M&\<"TS$PN),9 -F!&<=0X@'@M FD=@_K6+'3.]\L/OS57@ #H"WCI>T0ZPZ1
M-FQKQ*AH.^UV Z$MW^U!ZM<+D2_RY8M*D*C*HS9[H)2EH4"A#XD7(L7A F)!
M.&0Q\U.<^7'J&26C[NAC:I3=2@E:,?ND:3@"IP$=GP_2P.P[)#X6_'H^3B/1
M:0^\['BS&XE.FCSRZGBLV"W[#@F>>-2.\QC/9Q^:\;]<+%9X_IT_%>5RAK*(
M1AD+84Q3 A'%<AOLQQGTDI@B/_(][AGE*CO6P=38KI41U$*"6DJSF7P4Q&Z:
M<P'-P!QGB8KQ?#VE^H&M:\7IG^Z+Y_^0K]:[5OG#9K-ZM,%1IO I==KY>_*Y
M'@;+S:+-#7.K2K<O7U2VF"9#C*IH_+G B[TT2'Z<H#@@$4PC=<1%,D_=^24P
M%0&+6.HA818+U+/_J4U]J<$Z15*C ]!YD]I,2;KZM]+CK(Q5/0;*P$P:%OZ!
MZ66ZR%L88,..P$C&V2 C86>^]<>QT[3KT>QX9E]_G7=,PC.:.3<&5=T"7R[8
M7MT^';HURR+BR\&(H:H2#1%+Y::9!2&D+$0H(U&0";N,&":]3FUU>57%4ETW
MOJID68<XVI:6-AH%LUL6Y]@.O'2X@?6,<%$#F)R'AW;U^4;AH 8P' __-'FY
MATG\F2_5S"Y$G1CQ$?_,'U>/ZJ@PU]F_9Q[C B=I!/TD2B *N =Q&@>2F%*)
M1L+"")D7(CG5V]0(J9%73QPM\05H9 8;H2VLJY-H&UBQ+C$<F'A.B>H2.0LK
MU"6"(]F<YWV(=L:E*3R=IN3)1L8S'$WUV3$3C5^RX]RJ7&[2)?V9%_<E?GK(
M*9Y?_LRK69!X ><)@VE*0XAB',*,!RG$*/6)QUF6"J/HQ,Y>IL:QV_*!WY6$
MAJ9=-Y;=3.H,H8$9U 8<XUENI'R7028;V#+&Y+\VAEAWVZ-,>B/UVLEN]G"_
MQ-"4<U9]DG*]+\JR^)$O[JO?%O+U=ILY\V+!B<J R -U4\K\#&:(QY GB8A\
M+#+$,IL4T:<ZG-K4;T6NPRG)6FBP4E*#I3I'F4NY[1(BGX3=P,AR#.; ++'&
M48D+-O("+?#F/,HQCG8IIO\O>>_:W#B.K G_%41L[)Z>"*,/+R )SGYRW?IX
MH[KLJ/;TQ(G^H,#5YK8L>D2IJCR__@5 4C=+%$"!-'O?,W&JJVP2R'Q /$@D
M$ID^\1S)ZKI_%/4UEV(AY^7W4Y_IH]A^JK[R3#@ =B[#]-EV1LTU;:O58=9I
MZ_=ZY3RBJYM%M5J:C^K=B\Y IW,L?=7?EXZ#5+OP3^JK:AS>"$<)2KF H4@Q
M1%C]02D6D,4\%*':(:=9Y)#VR*7OJ3'X7C+;5G1@9/^[^G=5@?M'LM!^)F6_
MW)<@^#E+]/7Z\.? *6&/T_A8\/MPJ ]]RJP$!UO)K\"[EP/<KT C/] *]#D#
M<H3;*4724+"/M"+XA]\U_5 ? ,]D(')J<LPD1'UT/<A#U*N)?@<]]X(]+LIY
M^?!B*D+?J(]Q\: S7YD42-4FH( 0S$.J;'X2093K#$0\XC!+,H2SD.09MBI"
MYM3KU):-K="P+FR^%;O.]N9X<=@.>KO3'>^ #KPBG,=R@'MZ3B!Y.MNQZW/4
MLQTG& [/=MQ>]GPE>)M%-^(LS65 (&(\4'\(!O.$)U 7FD])A'+"G+(=G^]R
M:FRT>SXZZ"5AU]3%?J$<W@G1=55XP+S$]C -?6_XC3(.VP-@?7OXTES"VP[:
MU(_ZWDF=K/BFJM;*.%.V3L!E&,*0$@I1E%)(T@3!G 09SJF,!7$*>3G=U=0(
M9R-I>R^J,&*"G\Q-G<KR4I\%Q+8TXP.XP>EED_ZWQJQ)>%X+ZI-,SH'AC41.
M=C0R>9Q3^#5IG'VC9ZB<;LH80^_+IV>QJ,QN_GJYU%F@ZAW<]I$[\F)BP[^3
MI:&MU<MVIU?=KA[%4KN>;I]-'L OI:EG+_C7<C[_5"[U2[.(R)3$,H&)L7QB
M'L,\SX@:*A0P1G'*L=5%M;<1?VJD9E2#U&Q!=O4'.P#H3$:[SS4@ (/"%:AQ
MV/&O5, @ 5;:B=A@<04V:%P=J7^@$0(-1*XQ@N-^?G;D/-V/:F#"K[^3=Y;?
MT[NW_9[<@R/?9%A]15F.*_RXX9IO,C"OXC[?1HI^R_:'HGHN*S+_95FNGV\6
M;+[6%8#43W6RW6*A[((FUYG2P+@V=![>M3(@%JM9%A&.@SB$/,<Y1)PC'5Z*
M(:."X20A89Q9W9WT(,O4%M1[G<BQ+JO@Z Z]9$#L5J618![Z,*W1 A@U=$&X
M1A&PJPG8J'+5.%3-DM&HXV])\("I)WZ_1))1R=H#9(?,ZZ/)?C3Z7NN\6-5M
M?RVJ/]^)!7M\(LL_FQQ@F:X_EX0<(AJ&$*6,Z10;!,:!9%F4I#*PNV=NV^'4
M"'%/7J %!AN)>R9=.XNY'1WZ1')@SKL,1&=2LT7&$W.=[6Y4>K)5_I"#K-_K
M$Y>Z2?WS*UFH/[G.BV%J)A"V^KV<*ZOQVA1+^%K7NKCFO-!BD'EC9E8SGB =
MC,ZA#!,$$1($$A9(*'(4YQ$)2)XZA*U>+,_4:&JK$6A4 B:%2ZL4J+4"U^9
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MUQ\!64/CB7K.]S<JZ5BK?T@W]B]><E-+<'-ZU&21?%]6J^OFNH(VONH=]RS
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M,9BE/$TI"V.6.466G>YJ:K1E;LRWTH)YJ>M6[LKK1E$=$-OQD1_@!B:?C9!
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M5D$'C)K@4%9K 8I&#9T/B^]6C2PWFKAXA'H,E(VS;5CXAW:]U<C?RCK&H5$
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MA)!J4TL[;+'^&Y<AQ%F2!#B-,A(IIY)VKX:8&GG4H4PM9D^N. *B'3]<!LW
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MV:>VQFS.QJT+8;Y 4)V1\WU$SN/<VQG%$YW1@=<YF\-U1?_3=2T*H($!M#B
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M(FA <,:Y5?V!RT69&L?6]0=Y<W:D3UG'"Z;%DE%' 7M@/FV%!Y7TNV<9=Q4
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MU58KD3"((I@#P6(=P0,SD G*@< A3$)":4Y#XVN\B8E;VFE)PU[P]NA29\^
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M(HS6[?P)#ET+Y9J)  2Z2>[?@G</7Q]W38L=H68S++3B)ARS'?WT6,_6L>B
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M/_CN3]$[^[HYG?>+C^W_H2BHFV<HDB:I'MLO.'F)I+ & 1D U9(__486>"=
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MB7;3YV";"A8IK=+6/G=Y9AN\/*6BF]:P[8%E1SGW "D/B3?61FU\25%)]+^
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ME/D^"W>KA27IT;,0Q'%T(B4ME^YYC$0IX07G('6NG8]<3TUO L 6[5<=5?0
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M0AO%D^8L0?W#R-=2V7T'\:XQ6DN%O6C&LY?^WZOKT23GTS5UD W#X?$,[U-
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MGT>3Z:PI5UG2?R/1,GOGXVA^Q_PZAG]?RGQ(08!+*&)%A<.-7SKBF54D,:5
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M?9CA5Y,/?ERN8)]]!;C)8MZA%.,"EZ0J5\/*T*9L,$8H5[@$=9IZYI65F_6
M?,U;=\I!;?*B54M"LI05-9) 4Q07.">6@L3E&:CU#'S2]3CMC0%K%Q$/TEIO
MH9B^VJH2Q&UWC'?]+ZO8FU545'+%FHGH]W(6$6*D7A%A76G0IADIPZT)Y[C5
M& ^65Q^V\I""G4S(89E$ LL'WN%08Y0@@4>272PW 21;)DET3D;$+"D/:B,#
ML?+QW?HO.ZCOP1K?77*]7<''1[^=#TX_'W\X//AM;^LT]JK'U%G;+]%7*^:"
ML%@1NUL!!@PZE#3R4AB2#?%&91*#IHXQ:3/4GH*]FI*=8Z<'3[W#,*<Y^T!9
M.1=&=UT;=-<E EEHHSGS,2G5+H,]L105]/\DFJD@\KZ:C8.C_>//Z,W_QW:[
M__U_7L5,K*6GDGFXO3NP B,A< ,\&0QQA<)=Q9?T6V9$QTR#,X$+WMKUC?J&
M8L6C[^479=)<T40L8V7,+=<D*-S[-$-0BQCPC]KM$9^CIUN340L3:^^I[*J!
MOAJ/_;V3@_-2Z7R\_[>]HX]GO^^=#CZ@"_\1U_#)X.BLV>:W,2N;/;B*P=F"
MAXK9X24JFI9?M^,ZKL=[-)T-F_[DH0STN.D5=HM,R8QW3AABN"FC/")"R5))
MO N46^6U]+4KZ7:CN$+6>+.W?[C_]GM5*HIBR,"!J!QP*3-+B<\8/HBD8L 8
MGM:O:-B1Y.YSQF^$SQ7YXS=3=6^-Z_'GSP?GS042M$O[QTVI\N!HVW+KYQY7
MQY!N2F\E\UFZ)(Z6XX'W)G=W^DIEZXI]/'-F(E.4T(!QOK3&$5>:>$J4D 6I
MO!"U?;M7$;AS9YA-7G:W0)(Q.FH:"/C2,!>$(U8[04($SK-QU,I.Q-$3T]<>
MMIXT@VE/;WTU;(//)X?'_SD8?!@<#3X=G)\<[FV7JEKYG"JF[&4*Z]FPV[VM
MZ?JS&,V:^T0K4":#C]QK03($5+TW"E%F&3& VYG++EM:VWUY!7D[MXW%]RS?
MTLQ^/\$=?G;[N@\P@3Q:<\E*"XT.1B2!.B!21D&\C9(XBU(1'#^4M=W@;6GM
MW*:U@K4G36+?0I-]M6U-^'@Z./ERNO\[!I';F+7'CZAS >XYNFK=*OF?J]'B
MY]V])9KQ?T"),MJ5R8"!!"\#R3J'H$)PV5>_/_* @EU-TGGI>GDU^]DTXKZ#
MJ0TZQFB!^.0MD3E:XAE$##4T&.:"U*9VZFPU)1U?,=E>VX\M1@5!]]8>#'XK
M$='!T:?CT\];I\-6/*6.57B!NDJ&X0PNBNT_A6_367%O[THU,#!7UB0"Y?*1
M])J3X!0ZMRHFKID"!$#EI;2.EIVOOSYZ[LH-3M*D4YDAP9PFTH!&=A,E.:@H
M7"BEQ;4MQP9D==R;K@8VGEQ[K:R,OEJ7T\'AWOG@X\G>Z?E_GI]BD+*WO_7!
M_]IG5;$TFU%:R=Y<9PE/_&SQ\WSFT>>-#V\L10& 6TCI#2%P9V$4 W9;HNC$
MC%',4TUKGY6_1-/N@]!6/W\5]"U3TG*7$.NN\>X-<2Q&XD#S%,JM+5:[5\DK
MR.O6'E7%SM/9:.THJ:_VZ>S+A[/!OW]!%V/PQ[:-H)X\HU)#D.<HJ^7W7(4Y
M_,\54CCX_O!H),N,VBT%]0XQA*$U<5YHHB%BC&MCLJ+V);5UM.S>V_GA<^^7
MQ=)D%$8$U&1%)"X/XC)&!%0JR<%QH7SM$LNUQ'3=?[<"#I[V;JXA^+Y:CK6]
MF/S#7DS35;V8;AJ<;&-NZKRXBHUJ00:]ZCV7A<R49HI;FJ<$EX$@3F1/E LL
M(U9-YK5G2U?L/==)GZU=D/W*-[QAWZU6L?I,9R6;M36*&Q*3H65HC2$6T&Y*
M;A&#EG$%M4]4VNN_=01_WGOX#,W"U23>LP4_EW_>;1,!=P?G%!#O33E*3!@
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M:RCMYARR!\:QK@[[&F>4 Y-=KHP_^/=U6KRLI:B=9BY<!F1&NE+8P(ED4I+
MC2#1.\YMZ4M6O3'OJF8N._)3^A4]KMB(G+F<$V%EPH"4Y=)OMIP$09$UI7%Y
MU,ZFK"&EVXS'#OI^;"AJB+KKTH3K),OD8BF7QYSHS"!G1I2F%'U &DAP.1 F
MD_$)N/;*OF037GY-MR<0%0!169)=8V)YDPU6\D%U]C0I#$-#P(V5(\I#D)H8
M)D.,R5OKW4:(>.8EW5;;U<)#+2EVC8:SJV^X\Y>\JQ^7^_R?QM,_[]=G3=+1
M=-*,N8F+T??1XN>GZ6PUTXY:$TO*P@I;VC!J$I23A*$;3Q/C+%"^$71J4=1M
M45TMG'6BGZY!^>A>XRE<8D1P8WO/87:);#=G"1@5G/K%X^/;,EB))H];<I*&
M2,<I<59X8I*P,4>,,MEF=[=VHZ/;NKI: 'Q#770-NX:EFQ#PYV>_N)KAWX]+
M\ZFT3#A'HI,,W;]2"V.L(1"<28$&F?EF%<.;O*W;^\NU(%1=KKT-L(^/?CL?
MG'X^_G!X\-O>CG?]UC^L3NB]&:VU*B\@+%94_)CDA4T81@FG$T+*46*9"J7L
MQWMFK/:Z>G7%2DHJ5E"442)W QWNQXW",:L,R3:4OEQ>E,(F1ZA4FF7A,C>U
M&\F^3%7']0F[H^*9&H0:BNA5TOG:<HY*DZ3#Z>2B[+Z%RT>6%(27D'P@'D0D
M4E-+G"JQ*6,6LO9.>-4:T#:CL=N<0*NP:T%)O0(A[C+E\CZ2,%I\\O$F6WZO
M_6 (&LIF)LI0-P^..(0+B9Q%;Y656;;7/_(%XKI-/;0*NYIJZ:M[=7"T?_QY
M<+[W'[L<8CQ]2!5WZ@7:*KE1M^-^5N"(,@RQ( 8,K<H<#!'+!'6G26+ N#7)
M4E[[W/L9<G8*Q)J6('/409[.;M_Q)*.1&'<IXIIQ'@-*R0,0[Z@@3#LI5/#9
M;YAQVNAUW7I*M13_("ZK+^9>[52#G*$DQ>"6MY*?.(4XG13[N*IW+J?&&<X#
M09;+K"R>2) Z$\^D0EDJH5U[-4NOI[=;-ZHV)M]<@[U"Z\=K I#)VYJ$]>4(
M7/N$#/G2C@2=AH![>A 1B+'6&A\X0&BOI.15I';K<[6/T?;TUBMX?IG,<-E=
M3$;_V[#Z 2:01XOYZ70\_C2=_>EGZ7$^SVG#(:5RP(#2#5218',D/C-*/4\N
MI?;B@-=2V^U94?L@;55[?0T7]O=.#L[+E)[C_;_M'7T\^WWO=/!A[VSP$3WU
MD\'169/TW#Z0>,WCJX086_-3\?;<$IT8:-Z;^G@*X]+#NYFBUK0>#64NY(G_
M^7#X"]?*^N" 1%GB7,X<\8([$A5C/$.FQM8N4=J-XGK&<_6TS &B;/H3X&R!
M*^[D:A:_XF^4UM0W1[F/UF2(VD,V*+92^EANQ!)O?2)6<R&!)QU4>Q:U"@O=
MWX9[(_RNM\1O#X5>N1%W[%_+=Z]L/@W;R^&Q\S(<^[HUT/SJ<OG9X]QIR%$&
M)X@WRA"I#3+NK2%9<,YC-C:YVB,RZW+0<?J[7^O@C8#0TV5P7P'WN5^S\ 4W
M,E'6E):50L.$?AD )S0"L*!-9KYVD]3=J>XX[=XON+>H\*[K9QHFTX-%/9OY
MR453OG8TG?P!\T6Y^-UH?C6[*%#&-/<DA=+PBP==9H1G0L$'ZY@4 ?)F580[
MT])M3-@!:KO08:^L,K+WO6&O$<(:[I3.IN08"1/+ 3$4(V/K"?4RLA@4#:8]
M"[P)A=V6'?;"VE979#]A>C>)K=E(ODQ&BW7;B$.A1L<"8:Y<]^4N$_R>$B52
M IU%N6W9/FHW)[C;PL=^@;@E-?<3TR<P:XK;)W'I+CW';=(R,6XB,3J79#K3
M)+#$"5#)9=8"E[!H']2OH'@C5)O_?Z"Z+47W-AM]_/GSP7DS+7[OZ./^<3/T
M>'"TVQ#GEQ]:)_/\.MHKY9L1HY>CQ1*$D[3?-(ZZ@$F9H[7BH"1H$61RKO3J
M+5ZGBL0Y_,,"35KSK&2L75[[*@)WBJP.)OBHLE1.9M.+F;^\3H0\-OY2)$\%
M,;RT+HP(%A>C(RE)C!)-$I)NUDM_D[=UF\IM#QH/@J'J8N^K<3H;_%96]\'1
MI^/3SSN>BZU]5ITA\AM16LD"G<%%P=@I?"L=0R<7MXB2WK$4N"&A-,A#_0=B
MO91$E/N_X#,&$]4]CS6T5$Q*/GK#O6N&'WY>__!>^&23M8)%HE6Y#>2,)8XK
M09P":E,9QFM:3,*_AM1N3545##V36&Q-:7VU54=[YU].!\>?CD\&I\M[2^B0
MG!T?'GQLOD,'Y>1T<(8VHOGV^-.G _QL_Z <G.^=#QHGYLC/RF7^[W#==68;
M,]<&&74&3+8MGTK&]7AVX2?7;9AQ!Y]/QZ-T<Z?YY![WQ_EV]NYMC]![40E5
MVN$F7B::XA]:2^(QTB4B6"> L:AT[2:'50C?K:W'/0K*#?!RY:0T-+IMJ=KL
MB4-#G<'_T*0X4.B9,$L\8R5B@\BRR4JQS69Z;?:^;NWLV\/I87^0^BKI08+F
MH G6FST$_\7>C]%\F&@ YKT@8!EN6R92XICQ)$6:HE/.0*J=_WY*18?=0]M0
M]+2JU'N'FWU<9A?3V;70/D.94CWDTI=18HP((<MR*RT"/,9H5$4.P(S*O'8U
MT\M4=7W)8S>]/PNCG970]>GR[S ;+?P%+&<V193HP60R_=ZP4Z8&'YY<,Y6L
MLC0WHSI]Z5. @G.)!Z*8XA&R4YIMUL1HTS?V"36[JWG:MLR[!M)G2'X\O1C]
MN*9=0Q \@T4$0"8R<335G HB\$_ILHA6;I8W>_3@KF_GM >+7238M?;1-YQ
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M-9O.!_>5AI ^C>>+EG^+\V8<RV"C)%R45R&4>A)091/+6 @)!)6ZD;F$BSQ
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MJW^C9?M<)5+C-FU-!#VX1M=SC,XGJ\C??:9J-L@ 1FCT@IDVH;06L*45OB0
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MX4<^V,9#9]((;GWD1-KRAXF1!)<#R4X$ISQW/M:^MUZGIMG3^,,.6M<111]
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M S_++A>31[T+,9G23XM:160,DH00-(DQ4RL\52":U91NN' S)!U4N+Q-UO=
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MZS?.W8C GN886D;?SJ(Z[(*X#WY4IC_,OL&H,&$^Z:06;B,J]E@&MSUWVJ^
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M@Y)12U-<<U4L[D2L$9H '@//0@XY-W-Q=^RIM*?..A7DOQ,+NT;""PV"0-I
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MLBM1>+.HS46:G58ZRE+!+=ZR!!L)^?RT&W>@)2%OR+6NA?SYR\ ",\9;32B
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M3HWZ^;PC\D>+=BST;40VJ<&_'AB.)^,$>9,Z(FZIC9F3*-"-DS$DXAQ^97(
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M/I P'4[20 #31D9#-*>&2('>B\]HP?@D,S#JDK2UF_N\14\SA!Y.DKBZ#'J
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MC=!'34OM0I45&90RJ]H0G1R%$C(PZ4B(P68>6N<#CB1QWJ-O,J@,A^3>>NL
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M_:['Y^42_W1;<YKC<P?U= BR5W^&Y6FUQ:]"O(N@I:;S'\GC%+%V@G 0>9'
M8A2YH,[R^RCXL7"[O]C<_5B.$WA[J:Q#"'Y8G>:%+9*.8P)2R(),79\#N&P=
MX<H(27^%DN5=85<7F+L3RW%";;1J.H37I>!J]<+/9$%LSI>U6N)W4L#"&>V<
M"1HLKT.W:Y W^.2ACCC,NHZE9<.RI<:L.@B(]K^ .(42.T?G8^)<:*Z+E\%
MU$K61N:T#WE28 /SW!4FG!WGL8Q8?!!6W7]A=4*5=@C9]_AE]2?F7TAA#TP1
M[F-F"CE$5H,)/C*(00J0,:H8HY&F[(S69]8=!%3_7T"=1I$=/#P]*K9+O;Q=
M;3:5Q4=_Y2<LJS5>_N+'\/?".IE+4+65, ^76],A^771:UZXTRK=GQXY34[0
M>-*'A=O9C[H'Y@1*K_N#^'A3"J;SD_+HOR^<YQB1+"J#6">8I5![DF7 8H1'
M*4QR!]D-+Q$Z#/L_[%O3X4#0!]*_R_5YL=:WMF6^YI-VKG%>,?"&MK6R9)8X
MGC)(P5E$R4N,K;L5[TKK,+S_L ]>!X5",\@W;FKPL&Y_^Q>A3FT.<7E*.L+-
M[JT+QGR^28."G?F9KPV!8#:I(BT@<PF4+ )"0G+[F,Y2<EMB:ITN]\]M0Q!R
MUH%9"S*D" KI-(B)_ABR+T5C9(*U+L7^KS8$^^-ZKC8$8^#2@=7R?'5SSDH:
M+Q6P+3/9(S@O'2 F%V4)/#<?.OE?;0C&06A4&X(Q^NP!G'?*<3%Z+"Q$2$)7
ML8@$7KDZ,I@ED771SK4NFSJ:-@2C%/ML&X(Q4IX[1OQ(G764T16G.%2#$53)
M#KR7"-:Y%'*(T8AA3VL[EJ8?J!7!*"V]4)H^1F0=' J'= *M3<D:<@(9CQF4
M-D@2#K5_G6*(2A536L>A>DOU/V)G?O_;M%>L=; -1\0X7J6TNJ";ZMWJG(QY
M\IM7X6SS'A,N_ZP:JMT<0]391<_!U:<?Y8V#B"P!&H:L!)MC\RX231GXIQNF
M.\)T][A88\P<UX;Y?8U?PS(3V]L!I)<!I]<7ZXJ%A2Z>JTC,&F<5J"@RQ,PX
M()=.1I^XC*W;(C8B_9]^WQQ\DS3#20?;XY+X[5O0X-CY-:=9VQBE(6.8V%58
M$EWN]),.,F=G=2(#H/&.V)W:'Z?^8I]-<" T=(#[4=M]13^>?ZOIAU5=;_[/
MQ?)K5>.[U5FZXEY*62\^"9)7QY!5GS G"UIIP:.Q-BLWY^WP(@<_3DW(P2Z)
MMJB9.^@S@O6K'\X^O<6PP??+3Y_/3\H?F^LN\M_Y#XG)J-%#*2;1F>$5>(R%
MSHR,25M=XL#VE1,0]^/4JNRR(;J Q'%=(]?C(6\QBT&6Z 2"]W4J?7!U$(W0
MD'(1O!#'7LQX:SPD^,<IJCG0);$G)HYK SP8)_*=:>N8]\XQX*Y65KI,XJ8;
M$(KSG-E4>&D^SKL)X3].<<^!-D0CC!S7QGC JB"A^J(%!)2ZCB7S$ N=!E%9
M3#8H5M@$\TQV)??'J1HZ5!!V'SP<&?2OXLV_AV\UOGP=3 @Z6E$X UTT[762
M.CB-L:9F:I9K-96=,3?W<:)_G)JD []%[(&-(W*:B4M:N0Z/?_/EZ^GJ&^)/
M>(9E^3VR' 0K2OH,3-2^STIL6_A$8*0&YIFWF0_KJ]22JA^H#.D0?G);%!P1
M_&FSK^G/5Y,,OW.KD4>/"4JLF?DH:[4W_2<5@49$X[(;5E^Z-RD_4,W1(8#>
M0-]'A.Z[X:];!0S7?#/'/7/U/I.\CM6D#1TR\2V%=H'II 7&UCA_B:@?J.KH
M\"'0/3'0@95_BX.='@P5%^2[6 L"=9WCI10XE1GD)!&E,R1VV=C&WY/D81OB
MAW]$/B0P_@EWP"U'/^N8,2L)66+MPL ">&,LE%S'TC.C%>J#70,C(SS\AWT=
MGAL)1WP9W YRY11#Y!RLCK3MBV;@I<H0)?TM>3U:^.93H?:F>MC.^&&?B6>"
M1Z\UVC^_^?CJU[<?3GYY_>8]_?3NIU=O7[U[_>;#O][0/[Q^??+'NX\?KG1X
M5=J\V:56>Y=EV@R5WY>_/6NW+P_BRP^?E->XII_.[FR*JY#B36DK(_.";(H
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MFBA!H:]-1J2&*+*/(25O2OL _;,DS?N0.M6=UE(/W<#J[B3,;8)5J5D)VR<
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M 9"'5,S;^[,A0O84< <0N77V6:]E4>3=2Y% F5@@%B6!UP1:[KV0NG6Y^CA
M3-?NLR$B=I-GW_'YNV[_WD'ZQS_7,%(_@-YIPO4J1::\SI TU@X624!,S(,K
M*.2VG#2WCFM/&:Z_YU0M>$8;9?; D\7JJB?B+!&BK6:!2R]RF3:8=H^@KL+W
M8W3_?%QM'['O?)#\B>NXFB0.^Z!EK$G1D.\=0"1#?I14&J*CTY'8*<&'4K1I
MWKSB68JZ"N:WP]%>@N_ -'F"FUL=.()++'-32#BE-O:@/>+K@(6(2>>"F3'=
MO&'K2T1U%>R? $P[BK]?/"TB>74FT8$J2]T67MKZ3,I :,>Y#\Y%WMHE>H*4
MKB+^$V!GE*C[MHEOAXXV>YO$CWZMH47\,K73&,3<Y\*T).^7%TNF2RYT0@15
M9S@F)@S9+Z;O_)7G,NV-*SEC0&"\EB(6IR%H2?L%A>7!<$]NY"3)</UWUAFC
M]S&==<:(O(,;YW87XK?UMZLV:C58*,%XF2TPP0THY@P$5S0@*Y'7QA&8!W5?
M& &=IVB9&S>-E'V_$V4+R7>*H)N*L< 9*Q*$YPJ44P$<+PD*YUHY84@\K<V6
MIZF9%T5MM#T 0CN(O@,0/5E_>%4MJ##*I%T"1K*JZ<0(@9%?Z#QZXQ7ST;6.
M_+Y 4G]PVD7S0\MX=U##W"_-5R&%WVN:Q3:7YV'O\BNN@HRY:'(-HZS-]FTJ
MY!_*",6AM!J-<,6]9"2/6W+><$YC\$PH[;DQ] @7U1RXR^QUGZT@92G5!<TF
M@%*!DRU@/23EZY#FQ',95AT^8M%Y(SE3X&@JB<^-I.LI,F?YZ9V!10N7O03M
MK:HNB2!3("0PF46!AEN1S)ASZ+G%YHWC3'@"-9-PSU;1K:X=7F'@=?*&L[9N
M@N(@*,L!8^;:"\Z*']01LX5E-+*ASBR]UO9QV5KKHV>(W6[\@:'6AEJ01G)B
M*4N(O)I^RG IM8\LM'X-^T<TU!D%A5T:ZHS02P=0VSX5;_Z%I_F/,U+.Z_!U
M61O';\-R5^>S3@*=0(0Z6*].U'/@E25G6-A2F!*\F-:'V<M4=0JT78%P?R1=
M6ZUT@+.7*IX9XUH$G\"1I&I_ODPW )D9)KK(>!$DKVD:JNS7JF>6]G/[W)8M
M]= !K)ZIY?@)RVJ-KU*Z^')Q&LXQWRGNR-HJ)Y,'G0UM'Q8,./0<) \J:<.2
MRZVOSUUI[3'2OB-@AE?BM-->WRA]BD,M9<B%)0C1UH ,DL=E602KG8K&><:;
MIP2.I[)'AV)R9+;0V'A,^DM,GN&GNO#'Z5V-=WB^L"(@F2L%G,D&E$$&WI+)
MH>M4-:=#SO=;?D_G8[P;F+<Y6U.@?>#63 M=Y''>WCSWDPD_D,*P<G92+G]M
M&4Y_7VV6599O:B[)9EDK9Y:;\X4VMF03+=C(=2V:0=I0)(;@R7WCN5B7ICP"
M=Z=\[G2LPQR+!])L9]?W(_F,(QBO \4S;6=(SE?&I0/':O#!9&5TD,XVCPLV
M(W[N^N\#HWIR_?8*[!'LLE*T"U:"(;L;E(H*O(@.I,O&*Q.X17$(.#<&\82E
MYP<&\42Z[!6Z"YU2*2Z0Q+1)H+ P$B"KMTLL.4;D!5M'D1XE9.XR]P/#;)3<
M^\[/_G#Q]>OI=LN$T]=A\[F<KO[Z]:RLUE\NWT/WS=@>^/V&.=R[<#1-5G>)
M7C')+4C,A7 7"8%,&# A<:\Y<Z&TMGZF+'/\/7RK4MTLD!$# CW(Z'P=)63(
MDA49:$^AS-%JJ:>M;[RF9.Y(X<[:?KX.9"=!]Q-BN7UD_KY>TB7\E6[A:YYT
M]$XDGZ'([0BJ4$=]E 0QHV*":VYR:_ \2]#<,;UF&&HG]GZ@="\4>1+I[#[#
M_"L9<^ESG57XRVK]5 V5QB!]8 )J]G+M^TO^MDT:A#,^Z$S;2K<.YNU![MRQ
MOF8P/)3*.K#)A[#ZN/T8+5<VA0+22D;VH]'@7>)DD4I+;C/QBJTSR7<F=N[H
MWD&1N;^ZYL[Q?+P=>KY(VQ3$CZOW)W]<9EN\Q\W%:?V57TCHMW]C^S^YE;:X
MR,&48K,#+T/-OR#7*:(S8&52(=L@O!R85-R<MKF#='N#LP>=]0'9.T^0UZSM
MQ+N0BGB,#G36 52($J+!4-O^2Q0AT?^3(_#:C+"Y@W$MP3J/MOJ.I?P'UAL&
M\ZL_:2-_HO]YS8M;7J:!A[/\\W*35A=GY^_)1MX[KK+#6@UC+/MR.DV\11MI
M4 D'LB8&*E6;RWD"M^-,)IN9M*5UM?"4\9:GA+S]QRIIOB@E<"N#!<%]S8S3
M EP, J*B(YYY5:R(C3D>2V-7,9HQ"'D^1M-8.1UX,[=/] '<2:]R\<R ]ZRV
M/2&;V'$NP0MRWH00J)J/.!I'85>!G7V -Z%B.H#=L]OJ]D7R.ZY3[:94@DE*
MD#.6!"-[ 34'IVR .JVN3@N+6;5^\QI+8U?!G,G.O'V5TP'XGME:CW$GD+'(
ME((H9=U:Q4$4=:=%'0U3&G7S=B3C*.PJ5C/1F;>O8OKV(7X+YQ?KY?FR0;.L
MAY]JZ &\0.<T!KXIS#E&OF'RJ:8;95)X4 F0)5&DXD9T_J#Z[$#J9&-4CKQ?
M1;ZX2J5 J$-7ZXCR;!/6I\"#5 3UUR9KC-['M,D:(_(.;JLGV_=P:;TR&D&4
M.L9>,U6-/P8H>;&<[EV\7[/_ [;)&J7LH6VRQDB^4P1=E6\:'8RRD4$LMN8:
M1 =!%@4EH)8!@W2L]9/4T;7)&J7MX6VRQHA^[EC]D 87'DUP*C$R_)RKXQ S
M<59/;R&4\44RS_U+)DS3%B)S=, :I=2Q+43&2+B#8^>E!$TI;$F&_ .3JOF.
MFH$O=#3+6#A*ISG/AS%]WHXJAIZE=<@^UUA+/70#JR>22:XSGWZ^P'?DC7S\
M"T__Q-]69^>?-PLCHS3U730G23+424*HQWKTJ%P16!BVGOZT*ZT]VE,[ F;
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MJ;;MTX8!-T&#DE&#UT:#3.2R"1><$M,,?WF9MKZ+E@\!P5':Z1UU?YSEJ\P
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M_]MZM=DL+!/&)1E!HB'72(4,7ED'PI"G;J3FR":I.!E,X3"$'M\#Q30JZ@6
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M_Z/24P&D!U=I#V4^!8L=)#OW+?)*,&G?_/UUN1VZ>%UG$C%QX2*=?+&6[\9
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M^)8+=X/6L<6F^^3^X,B:3;^-<?,?TN4XY5?7Y1'ZV]('CX$;%T,$SXLAB<
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M/7V"5J%NXT-FGA+PRFD0W*&BMSP!"39&5D*4LJ_!!H]LI\F<M,,HM.W%T3K
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M#[C+CD)B7@>FT?]AS=P$3U)RU%5<VZ"YQS;NNP+CF&VFG[FP&JL],L'X&&V
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M@:AFXV=H0-B<P"WT]\=TB!;$>2<<9.W04%#1@4G*(TM,E(S;%$DO'1DKT]%
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MCI.8!">UZ^R?VL_ *JB2S#M!:0<!#!U=/$-9TL>IN1FL2+072E)P7I;>$YF
M=2&5JLR@%+=E&GLG[^G9I5I$RBXBG?;&WZ'1\B[]YTE:7,B:44*!,UJRU)%#
ME@8+04C) W%$VXY#")]>:-B'CGZ04I.W0^,$44_MQ\4T_&L3-6BD,1NR!6]"
MQ'N<<K#$*]!4DYB-$*GC@)QGEQKVO:$WK5*1OPV@A?$GL4\#1\?2&^!>*A"H
M+\%(AS=W5IJ08*P0W>^@)Y<:]B6@OSNH'G^'1LL#0M[<ED@1GSPO[J3*$CU
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MU+!JJ(KH.\!I=SD,'8@^_S:]7 ZZO]< !^_P1*WCD&B9I&-E:?06&-AD16D
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M3#I1'LQ!@+;#<+-#!1#[1-D>XCB6I(R*N1B]IF ,DGE!A8I16PZ,+=M1EK!
M0EA)25E@+#A#J@\7/&3F!=[YEJAD(9@":$\M.,/Q )' @DJH3?,OG'FQC?0[
M95YLP^X6KJ@-K\,ZZ$"4)2"#*+6YWH/QA$+,1B:6B RYYU/1<.;%5C+NF'FQ
M#</;Q,W:2[6">+^L"Y!XF 2U:*UY9$[,Z+5:YG*,/;M@K6=>;"7JSID7V_"]
M/0"MXQ 4]XXZ-P%/IK12]!E,, 2HUI:BV4=,_=%.QY1YL960.V5>;,/Q]F#S
MPS$P1! 778*0D2F"Z8@7N=&HF$7D! ^6\]6'.NX3^3EL[D7%&VLWEO?O*JW_
MHOSBT;O[__ZO_P-02P,$%     @ %$!05H;2+X_3/0  'VD! !X   !A;65D
M97AA;65N9&UE;G1N;S%T;V5X96-U="YH=&WM?6E7VUBV]O?W5^BFU]L-:PF'
M(7/JUEH$G I]4\ "JG/K4Y8L'6-59,FM(<3]Z^^>SB3)X*02;"C2U0G8&LZP
MSY[WLW_ZK\.3@XO?3X?!I)YFP>EO;]X?'02/MAX__K!W\/CQX<5A\.[BU_?!
MD\'V3G!11GF5UFF11]GCQ\/C1\&C25W/7CU^?'5U-;C:&Q3EY>.+L\?XJ">/
MLZ*HU""IDT<__X2?P-\J2G[^?S_]U]96<%C$S53E=1"7*JI5$C15FE\&'Q)5
M?0JVMN2J@V(V+]/+21WL;N_N!1^*\E/Z.>+OZ[3.U,_Z.3\]YM]_>DPO^6E4
M)/.??TK2ST&:_/>C=.]I-'[Q/!H]VXO'3W;WME\^>_8\'BOU/-YYMOWTZ?;'
M'1CD8[B<[ZGJ>:;^^]$TS;<F"M__ZOGNK'Y]E2;UY-7.]O;_?T37_?S3N,AK
M>%D)-_./_(S.DVKUI=Z*LO0R?T7S><2WZJ_C(BO*5W_;IC^O\9NM<31-L_FK
M?URD4U4%Q^HJ."NF4?Z/L((]V*I4F8[YPBK]CWJU@\.C7Z]XO$_@.5F:*SU^
M'O3PRR0=I76PLSW8?>X/N7^P,2RM*G_X:)_WCG;_U^'Q(?S_(C@^&00[P=H/
M^.)D_<<(BWIX=/[[>?#NY/WAT?$O8?!^\'YP,+@3(S\^'!X&^\>'P=GP_&+_
M GXY'_YK>+9_?# ,3M_O'P=O3\Z"X?\.#WZ[./K7,#AY^_;H8'AVOLS4_FBJ
M.AW/'RT\TS_PMMMF W__&W"]U]V_+]X=G0?M4P=$O9!FOGU+@HUZDE;!W__V
M8G=W^_4^L/ $V3C]OO-Z,X#OIE&B@J@*BG%03U2PNU/501+-\??CXK.:CE09
MHES8Q6<I_:CA>*SB.OVL@D.0*_IY83":!_"6)*WF5?"NR!*0-GH:81 %[XLF
MK=(HCX(LG:8HD+(T&J596L^#N)C.HGRN]W45M!_<SLO[R<5=W@->"[VN@_4[
M6BOD4:]I&(F*BS)"+>E5DR>JQ*L>_?PA. K@2 7#X!S^-X2?WZV2H/[^MZ<O
M7J_?YJTG7_SP;G@VW#\/B0_)"0A454>C+*TFP"OP\T7<)2#F!A=%>1*<X5W(
M7<[59P7:=*R"TRS*@W%1!L,O*FZ(<YV,QVFLRLIC;'B=88_*<+E_-MD\V'V*
MG'#G)>SJR]?XHH<MPBVZPMVI@KH((MP#^@Z7,42Q,E,E,'K<BUE35DT$<X$+
MSW%9BSS8V=5RAV](\P!VI([@WU)5,[BJPH=4JL:]JR?!2&7%U</ZF_57>44\
M$'^A=59Z0=\449G@+X=I">M8E"3B]?$)@Z,\'O!SFJQ.IW!<@EE4DJTH^RH/
MDFT.@PGL1#2;E: 5\"9'6I]P=VBB2I7FMR>QUF5KCD\^!!>X/:")#4-#TZAB
MX9* 8A1I#E7!4F5 Q[ +EL-8%:RM6_U8$;*F@GS?TA;P"[V:]Y:J=@:+Z.H@
MFJ4U#/$_>.B F59!4\&/P"%)M3?K1((O+^J@@,4J@2>K(%%C>%$B1Q+.+Y 4
MKJ2P5J2PJ8IRD*+(92M8!7Q'$51-/)%WT6MX[>_OD=X=K%9'[-_X5=HB6CX_
M<<5S#RO#'Q-4P\"VR^'553.JY-:->-/A=-=SL1D_9"M3X_K5WC,8XC>25/=!
M^A/R!RYZ-G^4PI1RON;V"7'O)9J L&:W9(-V:)$&<*&F,V#&Y1S4Y!EZH6$C
M@0(.HFKBZ-(;YU&&UR#'>5/D3;5Y2P>H?]4"^'-<U%=I/0&U/R=R- 2\$0$9
MC@H4L#EQS2Q5#<X)-9Q9-"?6B1Q3D? )@VI2-%GB*;C("M,<-:0(/H-5 ,HW
M9@0:"SO/7U<!+%U6\/-P*$53P[H!KP[ Z)"']MSN/'SI1P>_% 4:.5$%,X0I
MJ10G$,01OBS']XT4*&.@/ZB8'#C!W@[Y</9(+\F]R563*,MP)9#S=X>WD<+Z
MY7#@BP;>KO[=1!D)Y*LBV-C=#&K:2'Q>U4QQ63?V-^7QBR8SPF%61$%D(> $
M2./!L>.M"2X&/&IH9WTABT2,!>8G8@DH$@4?"+2DX?V&+YSG(\>*\(.T(MLO
M,JN-U[:7TED<[QEF?.D4M6<8'=B"LS*%!VIA:0:P262V\887X9*B+B6MRY?^
M=82K8CQ=(SQ'@8K*G-EJ[QK2)/";6:D^IP7<,$ZK&)XTAQMQWS?F"]^R>$.
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MC6DEE4C\9>Q\DKW/MK<P&X7/(H=5_/=IHH8[3NDBDS01'/'^ZPM3S0]$Z(
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M2PP$L2>BGJQ2T=G$=-7HLHQF$S?PLK-]J^[F[T>N=\;AW"_4+IP53_.:T\.
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MIG0H+^'>,LK00:S0+RQ>:!VOHQ2N %C198KFN=DWC,G!8\QNF-0NWR50-;1
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MT5M_?>"Y"ZKV\:/6!C%:.D-!RRV4,P\G+.R@B+' &"' .HB<&V#$TKPI;8Y
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M0K.73@1IR^2#?2[2A$(6[0P-M_\[TU9E2EZGT9=TVDP%]9EEA\Q6,(6\R^1
M8T2 3R@M;NFN'V8/Z/U0[*!)*$E*]^RU"[%BB+D/;KQ7RP?QR@O4*E5,%Z4B
MJ',GO: '%#T4K<E+]#"Y&>@!$0G(S]22TR 8+10#WQM]:&=[=0U*-]);,DR6
M (=\,GCV$A?"16=/)<R+!0"'#.J./FB@!*_! 398Y1HTQ/A*[(4BV[WGV8W%
MOA53=%^SL"1W5Y-I87"*,.V8FQGL+G(,H@3<Y)1$K<+!C:!F 6?#@!FK!4E3
MD\=CBMZU2/M;6Z,203O3@RC==%-^A2)/-\E5!-YUOG9R+#EPGQ3X,N2X4T5]
M@ZP+*0HP! (/(![<&D397D!7<'S/[/?5$OT:4?W.@/U57.*"(M'!D=9Z][*$
MNC>(#,@#D:8NNNC1=1;>]8"2_!  71%*\HJYPOJPA9T7@^T]S1;.T;+5I>1P
M4-]HA-KEV<+HF]C":#FV<-?V^?,Z;3/K/'W;K+/(OF:?XV_:Y_A>[O/Z;+,!
M;Q$UEAL 25<T4%U[^AI,HT\<:M/]@L@VP=WCXD]0)Z5()]0E.FS>F,9#6G>(
M85^**951:2\7)<>#$IQP1\S^!II!JX69[N''GAP*72)LDTVE("V@\HURR3F(
M1FC7.1IT2"XRVU S('@6MS,G4VY:]M0BV;'X@]7G!;5N![*7IIWFC4 WU1/L
M)[&QMTF86TX(U7=,41T8.@L2G4GO^+\J?9#H5.HL,@*:LMTL=@09]]Z<I[42
MC\PW]YV$(5W"JZT[S=-:?B_<,"8IWJ]9%L5D*(:2QI"6VEVK;;IN1(SJ<3 S
MRHWGD">=26T!<!'6V3'AT!ON37AS[7"R;@)7=XWX8]74Z \^T[[TA_IBW<2
M^2N=KGJ2E@F[)Z@E B(A2;<]XP2>!UGZB1H_%W*%$M;_=2UKX7;TFV =1G#<
M$*8GG-P7V]M;>\^>;^V^>/&$$K6OK@9P%[;BR^FB 3#B8$/4II(J$EB^[CS=
M?KZS.< *+D$D4,:3*C,AL'4I&AY)O$.GTKE#DU.N*W2Q$9(TNN[ ,B4LV,;M
M8&D65;7M%X5%/=TBY*_A"_)17<S6/3WFY9U)CVGY(/^Z'.&^2*C;2L!9RA@@
MF/W^"G<W QK=L$TE,6"$=-/M7C(54?Q<-V3NA$\YG)7-/0>OEP!M:WMKLC2\
M!CF8KEV4;&60<E^:IA!=I_4R Y70K[2U$ Z)*1<$!-N3<D'\7W=;Y2I8@BN@
ML#*[NBOEOQ>FW1_[Y# 7B"&.G_7,@4QDYUGRD=?#PAG</3D2MZ6T?85]K".
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M?4=N[E8D=C?"E%Z&O)[:,X08@GF2)H*#48*"@Y!0;%&%_ 8,!8KKD,F]Y@I
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MSN-1D<SAGTD]S7[^/U!+ 0(4 Q0    ( !1 4%;%(24_90P  &VI   7
M          "  0    !A,C R,C$P+6ME>&AI8FET,C$Q+FAT;5!+ 0(4 Q0
M   ( !1 4%8%,0H7$0,  'T(   7              "  9H,  !A,C R,C$P
M+6ME>&AI8FET,C,Q+FAT;5!+ 0(4 Q0    ( !1 4%9:G:\:N@<  )X>   7
M              "  > /  !A,C R,C$P+6ME>&AI8FET,S$Q+FAT;5!+ 0(4
M Q0    ( !1 4%94#D3@Q@<  +@>   7              "  <\7  !A,C R
M,C$P+6ME>&AI8FET,S$R+FAT;5!+ 0(4 Q0    ( !1 4%;?9S7PN@0  &$/
M   7              "  <H?  !A,C R,C$P+6ME>&AI8FET,S(Q+FAT;5!+
M 0(4 Q0    ( !1 4%8S$+49QP0  )@/   7              "  ;DD  !A
M,C R,C$P+6ME>&AI8FET,S(R+FAT;5!+ 0(4 Q0    ( !1 4%:!8-J:#;T$
M )M+,@ 1              "  ;4I  !A;65D+3(P,C(Q,C,Q+FAT;5!+ 0(4
M Q0    ( !1 4%;#8A(I4BH  $[J 0 1              "  ?'F! !A;65D
M+3(P,C(Q,C,Q+GAS9%!+ 0(4 Q0    ( !1 4%;;A'6TNS$  +SJ 0 5
M          "  7(1!0!A;65D+3(P,C(Q,C,Q7V-A;"YX;6Q02P$"% ,4
M"  40%!6ZRR#+^'+  "&W @ %0              @ %@0P4 86UE9"TR,#(R
M,3(S,5]D968N>&UL4$L! A0#%     @ %$!05D3^V3XA"P  +PP  !0
M         ( != \& &%M960M,C R,C$R,S%?9S$N:G!G4$L! A0#%     @
M%$!05G]"O"_48P  6H\  !0              ( !QQH& &%M960M,C R,C$R
M,S%?9S(N:G!G4$L! A0#%     @ %$!05L1C#&!L\ $ +4 4 !4
M     ( !S7X& &%M960M,C R,C$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( !1
M4%8-^M5,0C@! !H*#@ 5              "  6QO" !A;65D+3(P,C(Q,C,Q
M7W!R92YX;6Q02P$"% ,4    "  40%!6AM(OC],]   ?:0$ '@
M    @ 'AIPD 86UE9&5X86UE;F1M96YT;F\Q=&]E>&5C=70N:'1M4$L%!@
0   /  \ ^ ,  /#E"0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
